PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DAJ	Prossin, AR; Zalcman, SS; Heitzeg, MM; Koch, AE; Campbell, PL; Phan, KL; Stohler, CS; Zubieta, JK				Prossin, Alan R.; Zalcman, Steven S.; Heitzeg, Mary M.; Koch, Alisa E.; Campbell, Phillip L.; Phan, K. Luan; Stohler, Christian S.; Zubieta, Jon-Kar			Dynamic Interactions Between Plasma IL-I Family Cytokines and Central Endogenous Opioid Neurotransmitter Function in Humans	NEUROPSYCHOPHARMACOLOGY			English	Article							INTERLEUKIN-1 RECEPTOR ANTAGONIST; RHEUMATOID-ARTHRITIS; MAJOR DEPRESSION; PAIN SENSITIVITY; NEGATIVE AFFECT; MESSENGER-RNA; RAT-BRAIN; RESPONSES; FIBROMYALGIA; INFLAMMATION	Evidence in animal models suggests IL-I family cytokines interact with central endogenous opioid neurotransmitter systems, inducing or perpetuating pathological states such as persistent pain syndromes, depression, substance use disorders, and their comorbidity. Understanding these interactions in humans is particularly relevant to understanding pathological states wherein this neurotransmitter system is implicated (ie, persistent pain, mood disorders, substance use disorders, etc). Here, we examined relationships between IL-I beta, IL-Ira, and functional measures of the endogenous opioid system in 34 healthy volunteers, in the absence and presence of a standardized sustained muscular pain challenge, a psychophysical challenge with emotionally and physically stressful components. Mu-opioid receptor availability in vivo was examined with [(11) C]carfentanil positron emission tomography (PET) scanning. Sex and neuroticism impacted IL-I family cytokines; higher baseline IL-1 beta and IL-1ra was identified in females with lower neuroticism. Higher baseline IL-I beta was also associated with reduced mu-opioid receptor availability (amygdala) and greater pain sensitivity. The pain challenge increased IL-1 beta in females with high neuroticism. Strong associations between IL-Ira (an anti-nociceptive cytokine) and ft-opioid receptor activation (VP/NAcc) were identified during the pain challenge and the resulting analgesic effect of it-opioid receptor activation was moderated by changes in IL-1 beta whereby volunteers with greater pain induced increase in IL-1 beta experienced less endogenous opioid analgesia. This study demonstrates the presence of relationships between inflammatory factors and a specific central neurotransmitter system and circuitry, of relevance to understanding interindividual variations in regulation of responses to pain and other physical and emotional stressors.	[Prossin, Alan R.; Heitzeg, Mary M.; Phan, K. Luan; Zubieta, Jon-Kar] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat, Houston, TX 77054 USA; [Prossin, Alan R.] Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA; [Zalcman, Steven S.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Psychiat, Newark, NJ 07103 USA; [Koch, Alisa E.] Vet Adm Ann Arbor, Med Serv, Ann Arbor, MI USA; [Koch, Alisa E.; Campbell, Phillip L.] Univ Michigan, Sch Med, Dept Internal Med, Div Rheumatol, Ann Arbor, MI USA; [Phan, K. Luan] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA; [Stohler, Christian S.] Columbia Coll Dent Med, New York, NY USA; [Zubieta, Jon-Kar] Univ Michigan, Sch Med, Mol & Behav Neurosci Inst, Ann Arbor, MI USA; [Zubieta, Jon-Kar] Univ Michigan, Dept Radiol, Sch Med, Ann Arbor, MI 48109 USA	Prossin, AR (reprint author), Univ Texas Hlth Sci Ctr Houston, Dept Psychiat, 1941 East Rd,Suite 2308, Houston, TX 77054 USA.	alan.prossin@uth.tmc.edu	STOHLER, CHRISTIAN/AAQ-7539-2020; Heitzeg, Mary/M-7154-2017; Prossin, Alan/K-2967-2015	Prossin, Alan/0000-0003-1262-522X; Heitzeg, Mary/0000-0002-6737-2971	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA 027492, K99 DA 033454, R01 DA 022520, K99 DA033454, R00 DA033454]		AHMED MS, 1985, PEPTIDES, V6, P1149, DOI 10.1016/0196-9781(85)90442-5; ANGST J, 1986, COMPR PSYCHIAT, V27, P511, DOI 10.1016/0010-440X(86)90055-6; Anisman H, 1993, Rev Neurosci, V4, P147; Berkley KJ, 2006, AM J PHYSIOL-REG I, V291, pR241, DOI 10.1152/ajpregu.00287.2006; Buller KM, 2005, NEUROPHARMACOLOGY, V49, P230, DOI 10.1016/j.neuropharm.2005.03.014; Carrasquillo Y, 2007, J NEUROSCI, V27, P1543, DOI 10.1523/JNEUROSCI.3536-06.2007; Cawthorne C, 2011, BRIT J PHARMACOL, V162, P659, DOI 10.1111/j.1476-5381.2010.01068.x; Costa P.T., 1992, REVISED NEO PERSONAL; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Day HEW, 1999, J COMP NEUROL, V413, P113; Day HEW, 1996, NEUROENDOCRINOLOGY, V63, P207, DOI 10.1159/000126959; Day HEW, 1999, J NEUROENDOCRINOL, V11, P561; First M.B., 1995, STRUCTURED CLIN INTE; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; GEAR RW, 1995, J NEUROSCI, V15, P3154; Gear RW, 1999, J NEUROSCI, V19, P7175, DOI 10.1523/JNEUROSCI.19-16-07175.1999; Goadsby PJ, 2005, NAT REV DRUG DISCOV, V4, P741, DOI 10.1038/nrd1822; Gur A, 2008, CURR PAIN HEADACHE R, V12, P175, DOI 10.1007/s11916-008-0031-4; Harris RE, 2007, J NEUROSCI, V27, P10000, DOI 10.1523/JNEUROSCI.2849-07.2007; Hayes A. F., 2012, PROCESS VERSATILE CO; Hutchinson MR, 2008, BRAIN BEHAV IMMUN, V22, P1178, DOI 10.1016/j.bbi.2008.05.004; Hutchinson MR, 2011, PHARMACOL REV, V63, P772, DOI 10.1124/pr.110.004135; JONES AKP, 1994, BRIT J RHEUMATOL, V33, P909; Kennedy SE, 2006, ARCH GEN PSYCHIAT, V63, P1199, DOI 10.1001/archpsyc.63.11.1199; Liberzon I, 2002, P NATL ACAD SCI USA, V99, P7084, DOI 10.1073/pnas.102174799; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Meyer C R, 1997, Med Image Anal, V1, P195, DOI 10.1016/S1361-8415(97)85010-4; Miller AH, 2009, BIOL PSYCHIAT, V65, P732, DOI 10.1016/j.biopsych.2008.11.029; Narendran R, 2008, SYNAPSE, V62, P851, DOI 10.1002/syn.20566; Neugebauer V, 2004, NEUROSCIENTIST, V10, P221, DOI 10.1177/1073858403261077; Paine P, 2009, PAIN, V144, P236, DOI 10.1016/j.pain.2009.02.022; Pauli P, 1999, PAIN, V80, P359, DOI 10.1016/S0304-3959(98)00231-0; Peterson PK, 1998, J NEUROIMMUNOL, V83, P63, DOI 10.1016/S0165-5728(97)00222-1; Prossin AR, 2011, BIOL PSYCHIAT, V69, P808, DOI 10.1016/j.biopsych.2010.10.014; Prossin AR, 2010, AM J PSYCHIAT, V167, P925, DOI 10.1176/appi.ajp.2010.09091348; Raghavendra V, 2002, J NEUROSCI, V22, P9980, DOI 10.1523/jneurosci.22-22-09980.2002; Ray R, 2011, P NATL ACAD SCI USA, V108, P9268, DOI 10.1073/pnas.1018699108; Renner F, 2013, J AFFECT DISORDERS, V150, P201, DOI 10.1016/j.jad.2013.03.022; Resendez SL, 2013, J NEUROSCI, V33, P9140, DOI 10.1523/JNEUROSCI.4123-12.2013; Rohleder N, 2006, LIFE SCI, V78, P3082, DOI 10.1016/j.lfs.2005.12.016; Ruzicka BB, 1997, NEUROSCIENCE, V79, P517, DOI 10.1016/S0306-4522(96)00669-0; Salemi S, 2003, J RHEUMATOL, V30, P146; Shavit Y, 2005, PAIN, V115, P50, DOI 10.1016/j.pain.2005.02.003; Uceyler N, 2006, ARTHRITIS RHEUM-US, V54, P2656, DOI 10.1002/art.22026; Uceyler N, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-245; Vallejo Ricardo, 2004, Am J Ther, V11, P354, DOI 10.1097/01.mjt.0000132250.95650.85; Vassend O, 2013, PAIN, V154, P722, DOI 10.1016/j.pain.2013.01.010; WATKINS LR, 1994, BRAIN RES, V654, P15, DOI 10.1016/0006-8993(94)91566-0; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; WORSLEY KJ, 1995, NEUROIMAGE, V2, P183, DOI 10.1006/nimg.1995.1024; Yamakawa K, 2009, BIOL PSYCHOL, V82, P25, DOI 10.1016/j.biopsycho.2009.05.001; Yasuno F, 2007, SYNAPSE, V61, P242, DOI 10.1002/syn.20361; Zautra AJ, 2007, J BEHAV MED, V30, P187, DOI 10.1007/s10865-007-9097-4; Zubieta JK, 2002, J NEUROSCI, V22, P5100, DOI 10.1523/JNEUROSCI.22-12-05100.2002; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952; Zubieta JK, 2009, ANN NY ACAD SCI, V1156, P198, DOI 10.1111/j.1749-6632.2009.04424.x	57	10	10	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	FEB	2015	40	3					554	565		10.1038/npp.2014.202			12	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	AY6ET	WOS:000347660900004	25139063	Green Published, Bronze			2020-06-30	J	Robleda, G; Roche-Campo, F; Urrutia, G; Navarro, M; Sendra, MA; Castillo, A; Rodriguez-Arias, A; Juanes-Borrejo, E; Gich, I; Mancebo, J; Banos, JE				Robleda, Gemma; Roche-Campo, Ferran; Urrutia, Gerard; Navarro, Marta; Sendra, Maria-Angels; Castillo, Ana; Rodriguez-Arias, Ainhoa; Juanes-Borrejo, Elena; Gich, Ignasi; Mancebo, Jordi; Banos, Josep-E.			A randomized controlled trial of fentanyl in the pre-emptive treatment of pain associated with turning in patients under mechanical ventilation: research protocol	JOURNAL OF ADVANCED NURSING			English	Article						analgesia; behavioral pain scale; critical care; mechanical ventilation; nurse procedures; nursing; pain	AGITATION-SEDATION SCALE; CRITICALLY-ILL PATIENTS; CARE; INDEX; TOOL; RELIABILITY; ANALGESICS; VALIDATION; INDICATORS; VALIDITY	Aim. To compare the effectiveness and safety of fentanyl with placebo as pre-emptive treatment for pain associated with turning in patients in intensive care units. Background. Turning is frequently a painful procedure in this setting. Pre-emptive administration of supplementary analgesia may help decrease this pain. However, medical literature on pre-emptive analgesia in these patients is scarce. Design. A randomized, double-blind, controlled clinical trial. Methods. This study will assess the benefits and risks of pre-emptive analgesia with fentanyl compared with placebo on turning-associated pain. Eighty patients will be recruited from among those older than 18 years and needing mechanical ventilation for at least 24 hours. Pain intensity will be assessed using the Behavioral Pain Scale. Primary outcome will be pain intensity between the baseline and 30 minutes after turning, measured by the area under the curve of the pain scale scores. Secondary outcomes will be the usefulness of physiological parameters and the Bispectral Index to measure pain and the safety of pre-emptive fentanyl in turning. The study protocol was approved in February 2011. Discussion. If pre-emptive fentanyl is more effective than placebo and reasonably safe, the results of the current study may change nursing attitude in managing turning in critically ill patients. As a consequence, pain may be decreased during this nursing procedure.	[Robleda, Gemma] Hosp Santa Creu & Sant Pau, Dept Methodol Clin Management & Res, Barcelona, Spain; [Robleda, Gemma] Univ Barcelona, Sch Med, E-08007 Barcelona, Spain; [Roche-Campo, Ferran; Navarro, Marta; Sendra, Maria-Angels; Castillo, Ana; Mancebo, Jordi] Hosp Santa Creu & Sant Pau, Intens Care Unit, Barcelona, Spain; [Urrutia, Gerard; Gich, Ignasi] IIB Hosp Santa Creu & St Pau, Dept Clin Epidemiol & Publ Hlth, Barcelona, Spain; [Urrutia, Gerard; Gich, Ignasi] Univ Autonoma Barcelona, CIBERESP, E-08193 Barcelona, Spain; [Rodriguez-Arias, Ainhoa; Juanes-Borrejo, Elena] IIB Hosp Santa Creu & St Pau, Intens Care Unit, Barcelona, Spain; [Banos, Josep-E.] Univ Pompeu Fabra, Dept Expt & Hlth Sci, Barcelona, Spain	Robleda, G (reprint author), Hosp Santa Creu & Sant Pau, Dept Methodol Clin Management & Res, Barcelona, Spain.	grobleda@santpau.cat	Robleda, Gemma/AAG-4467-2020; Banos, Josep-E/D-8118-2014	Robleda, Gemma/0000-0003-3301-1171; Urrutia, Gerard/0000-0002-8850-0960; banos, josep-e/0000-0001-8202-6893; Gich, Ignasi/0000-0003-3975-6588			Adesanya AO, 2009, J CRIT CARE, V24, P322, DOI 10.1016/j.jcrc.2008.11.004; Aissaoui Y, 2005, ANESTH ANALG, V101, P1470, DOI 10.1213/01.ANE.0000182331.68722.FF; Arbour C, 2010, INTENS CRIT CARE NUR, V26, P83, DOI 10.1016/j.iccn.2009.11.003; Arroyo-Novoa Carmen Mabel, 2008, Intensive Crit Care Nurs, V24, P20, DOI 10.1016/j.iccn.2007.05.002; Bergeron N, 2001, INTENS CARE MED, V27, P859, DOI 10.1007/s001340100909; Brocas E, 2002, INTENS CARE MED, V28, P211, DOI 10.1007/s00134-001-1189-y; BRUSTER S, 1994, BRIT MED J, V309, P1542, DOI 10.1136/bmj.309.6968.1542; Celis-Rodriguez E, 2007, Med Intensiva, V31, P428; Chanques G, 2011, BRIT J ANAESTH, V106, P336, DOI 10.1093/bja/aeq375; Chanques G, 2007, ANESTHESIOLOGY, V107, P858, DOI 10.1097/01.anes.0000287211.98642.51; Chanques G, 2007, INTENS CARE MED, V33, P554, DOI 10.1007/s00134-006-0510-1; Cobos-Carbo A, 2011, MED CLIN-BARCELONA, V137, P213, DOI 10.1016/j.medcli.2010.09.034; Desbiens NA, 1996, CRIT CARE MED, V24, P1953, DOI 10.1097/00003246-199612000-00005; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Fulton T R, 2000, Am J Crit Care, V9, P125; Gelinas C, 2007, CLIN J PAIN, V23, P497, DOI 10.1097/ajp.0b013e31806a23fb; Gelinas Celine, 2011, Intensive Crit Care Nurs, V27, P46, DOI 10.1016/j.iccn.2010.11.002; Gelinas C, 2009, J CRIT CARE, V24, DOI 10.1016/j.jcrc.2009.01.013; Herr K, 2006, PAIN MANAG NURS, V7, P44, DOI 10.1016/j.pmn.2006.02.003; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Lennmarken C., 2006, ANESTHESIOLOGY, V105, pA1042; Li D, 2009, J CRIT CARE, V24, DOI 10.1016/j.jcrc.2008.07.005; Mancebo J, 2006, AM J RESP CRIT CARE, V173, P1233, DOI 10.1164/rccm.200503-353OC; Pardo C, 2006, Med Intensiva, V30, P379; Payen JF, 2007, ANESTHESIOLOGY, V106, P687, DOI 10.1097/01.anes.0000264747.09017.da; Payen JF, 2001, CRIT CARE MED, V29, P2258, DOI 10.1097/00003246-200112000-00004; Puntillo K, 2004, AM J CRIT CARE, V13, P292, DOI 10.4037/ajcc2004.13.4.292; PUNTILLO KA, 1990, HEART LUNG, V19, P526; Puntillo KA, 2002, AM J CRIT CARE, V11, P415, DOI 10.4037/ajcc2002.11.5.415; Puntillo KA, 2002, HEART LUNG, V31, P303, DOI 10.1067/mhl.2002.125652; Puntillo KA, 1997, CRIT CARE MED, V25, P1159, DOI 10.1097/00003246-199707000-00017; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P671, DOI 10.1097/00000542-199809000-00017; Rosow C, 2001, Anesthesiol Clin North Am, V19, P947; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c332; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Siffleet J, 2007, J CLIN NURS, V16, P2142, DOI 10.1111/j.1365-2702.2006.01840.x; Vazquez M, 2011, NURS CRIT CARE, V16, P178, DOI 10.1111/j.1478-5153.2011.00436.x; Virani Tazim, 2007, Adv Skin Wound Care, V20, P528, DOI 10.1097/01.ASW.0000294765.20296.38; Young Jeanne, 2006, Intensive Crit Care Nurs, V22, P32, DOI 10.1016/j.iccn.2005.04.004	39	5	6	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0309-2402	1365-2648		J ADV NURS	J. Adv. Nurs.	FEB	2015	71	2					441	450		10.1111/jan.12513			10	Nursing	Nursing	AY7GL	WOS:000347729100019	25168967				2020-06-30	J	Ingelmo, PM; Frawley, G; Bortone, L				Ingelmo, Pablo M.; Frawley, Geoff; Bortone, Luciano			We can't tell emergence agitation from pain, yet. Reply to: Stucke and Weisman 'Can we tell emergence agitation from pain?'	PEDIATRIC ANESTHESIA			English	Letter									[Ingelmo, Pablo M.] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Dept Anesthesia, Montreal, PQ, Canada; [Frawley, Geoff] Royal Childrens Hosp, Dept Anaesthesia & Pain Management, Melbourne, Vic, Australia; [Bortone, Luciano] Azienda Osped Parma, Serv Anaesthesia & Intens Care 1, Parma, Italy	Ingelmo, PM (reprint author), McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Dept Anesthesia, Montreal, PQ, Canada.	pablo.ingelmo@mcgill.ca					Shah GS, 2014, PEDIATR ANESTH, V24, P994, DOI 10.1111/pan.12436	1	1	1	0	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	FEB	2015	25	2					218	220		10.1111/pan.12597			3	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	AY8FP	WOS:000347790200020	25580659				2020-06-30	J	Parker, JA; Grange, C				Parker, J. A.; Grange, C.			Anaesthetic management of a parturient with uncorrected tetralogy of Fallot undergoing caesarean section	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Letter							PREGNANCY; WOMEN		[Parker, J. A.; Grange, C.] John Radcliffe Hosp, Nuffield Dept Anaesthet, Oxford OX3 9DU, England	Parker, JA (reprint author), John Radcliffe Hosp, Nuffield Dept Anaesthet, Oxford OX3 9DU, England.	jacquismail@gmail.com					Dabrowski W, 2004, ANESTEZJOL INTENS TE, V36, P191; Drenthen W, 2010, EUR HEART J, V31, P2124, DOI 10.1093/eurheartj/ehq200; Gal R, 2000, ANEST NEODKL PECE, V11, P144; Hamlyn EL, 2005, INT J OBSTET ANESTH, V14, P355, DOI 10.1016/j.ijoa.2005.01.001; HOFFMAN JIE, 1995, PEDIATR CARDIOL, V16, P103, DOI 10.1007/BF00801907; Solanki SL, 2011, SAUDI J ANAESTH, V5, P320, DOI 10.4103/1658-354X.84111; Srivastava A, 2009, INTERNET J ANESTH, V21, P1; Veldtman GR, 2004, J AM COLL CARDIOL, V44, P174, DOI 10.1016/j.jacc.2003.11.067	8	3	4	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	FEB	2015	24	1					88	90		10.1016/j.ijoa.2014.10.002			3	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	CB6GP	WOS:000349725800019	25499812				2020-06-30	J	Hsu, DT; Sanford, BJ; Meyers, KK; Love, TM; Hazlett, KE; Walker, SJ; Mickey, BJ; Koeppe, RA; Langenecker, SA; Zubieta, JK				Hsu, D. T.; Sanford, B. J.; Meyers, K. K.; Love, T. M.; Hazlett, K. E.; Walker, S. J.; Mickey, B. J.; Koeppe, R. A.; Langenecker, S. A.; Zubieta, J-K			It still hurts: altered endogenous opioid activity in the brain during social rejection and acceptance in major depressive disorder	MOLECULAR PSYCHIATRY			English	Article							POSITRON-EMISSION-TOMOGRAPHY; ANTERIOR CINGULATE; SELF-ESTEEM; LIFE EVENTS; SYSTEM; PAIN; MECHANISMS; RELEASE; REWARD; STRESS	The mu-opioid receptor (MOR) system, well known for dampening physical pain, is also hypothesized to dampen 'social pain.' We used positron emission tomography scanning with the selective MOR radioligand [C-11] carfentanil to test the hypothesis that MOR system activation (reflecting endogenous opioid release) in response to social rejection and acceptance is altered in medication-free patients diagnosed with current major depressive disorder (MDD, n = 17) compared with healthy controls (HCs, n = 18). During rejection, MDD patients showed reduced endogenous opioid release in brain regions regulating stress, mood and motivation, and slower emotional recovery compared with HCs. During acceptance, only HCs showed increased social motivation, which was positively correlated with endogenous opioid release in the nucleus accumbens, a reward structure. Altered endogenous opioid activity in MDD may hinder emotional recovery from negative social interactions and decrease pleasure derived from positive interactions. Both effects may reinforce depression, trigger relapse and contribute to poor treatment outcomes.	[Hsu, D. T.] SUNY Stony Brook, Dept Psychiat, Stony Brook, NY 11794 USA; [Hsu, D. T.; Sanford, B. J.; Love, T. M.; Mickey, B. J.; Zubieta, J-K] Univ Michigan, Dept Psychiat, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA; [Meyers, K. K.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Hazlett, K. E.] Marquette Univ, Dept Psychol, Milwaukee, WI 53233 USA; [Walker, S. J.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA; [Koeppe, R. A.; Zubieta, J-K] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA; [Langenecker, S. A.] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA	Hsu, DT (reprint author), SUNY Stony Brook, Dept Psychiat, Hlth Sci Ctr, T10-040C, Stony Brook, NY 11794 USA.	David.Hsu@stonybrookmedicine.edu	Hsu, David/J-5814-2014; Love, Tiffany/W-8427-2019; Mickey, Brian/J-1756-2014; Langenecker, Scott/F-3548-2012	Love, Tiffany/0000-0001-9299-3190; Mickey, Brian/0000-0002-7847-7680; Langenecker, Scott/0000-0002-7932-5494	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K01 MH085035, K23 MH074459, R01 DA022520, R01 DA027494]; Brain & Behavior Research FoundationNARSAD; Rachel Upjohn Clinical Scholars Award; Michigan Institute for Clinical & Health Research; Phil F Jenkins Foundation	This research was supported by National Institute of Health grants K01 MH085035 (DTH), K23 MH074459 (SAL), R01 DA022520 and R01 DA027494 (JKZ), a Brain & Behavior Research Foundation Young Investigator Award (DTH), Rachel Upjohn Clinical Scholars Award (DTH), pilot grants from the Michigan Institute for Clinical & Health Research (DTH), and the Phil F Jenkins Foundation (JKZ). We thank the Nuclear Medicine technologists for performing the PET scans, Ramin Ranjbar for performing the cortisol assays, and Dr Audrey Seasholtz for analysis support of cortisol assays (University of Michigan).	BEATTY WW, 1982, PHARMACOL BIOCHEM BE, V17, P905, DOI 10.1016/0091-3057(82)90470-1; BECK AT, 1967, DEPRESSION CAUSES TR; Block J., 1965, CHALLENGE RESPONSE S; BROWN GW, 1995, PSYCHOL MED, V25, P7, DOI 10.1017/S003329170002804X; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; CARR KD, 1988, BRAIN RES, V441, P173, DOI 10.1016/0006-8993(88)91396-0; Chelnokova O, 2014, MOL PSYCHIATR, V19, P746, DOI 10.1038/mp.2014.1; Colasanti A, 2012, BIOL PSYCHIAT, V72, P371, DOI 10.1016/j.biopsych.2012.01.027; Danese A, 2009, ARCH PEDIAT ADOL MED, V163, P1135, DOI 10.1001/archpediatrics.2009.214; Davey CG, 2010, HUM BRAIN MAPP, V31, P660, DOI 10.1002/hbm.20895; DeWall CN, 2010, PSYCHOL SCI, V21, P931, DOI 10.1177/0956797610374741; Drolet G, 2001, PROG NEURO-PSYCHOPH, V25, P729, DOI 10.1016/S0278-5846(01)00161-0; Ehnvall A, 2009, ACTA PSYCHIAT SCAND, V119, P375, DOI 10.1111/j.1600-0447.2008.01316.x; Eisenberger NI, 2012, NAT REV NEUROSCI, V13, P421, DOI 10.1038/nrn3231; Eisenberger NI, 2011, J COGNITIVE NEUROSCI, V23, P3448, DOI 10.1162/jocn_a_00027; Eisenberger NI, 2003, SCIENCE, V302, P290, DOI 10.1126/science.1089134; Ferry AT, 2000, J COMP NEUROL, V425, P447, DOI 10.1002/1096-9861(20000925)425:3<447::AID-CNE9>3.0.CO;2-V; Fisher HE, 2010, J NEUROPHYSIOL, V104, P51, DOI 10.1152/jn.00784.2009; FREDMAN L, 1988, J AFFECT DISORDERS, V15, P103, DOI 10.1016/0165-0327(88)90077-8; Hammen C, 2009, CURR DIR PSYCHOL SCI, V18, P200, DOI 10.1111/j.1467-8721.2009.01636.x; HERMAN BH, 1981, SCIENCE, V211, P1060, DOI 10.1126/science.7466377; Herman JP, 2005, PROG NEURO-PSYCHOPH, V29, P1201, DOI 10.1016/j.pnpbp.2005.08.006; Horner MS, 2014, DEPRESS ANXIETY, V31, P952, DOI 10.1002/da.22244; Hsu DT, 2013, MOL PSYCHIATR, V18, P1211, DOI [10.1038/mp.2013.96, 10.1038/mp.2013.139]; Hsu DT, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00073; JOHNSON EO, 1992, NEUROSCI BIOBEHAV R, V16, P115, DOI 10.1016/S0149-7634(05)80175-7; Joiner T, 1999, INTERACTIONAL NATURE OF DEPRESSION, P3, DOI 10.1037/10311-013; Joiner TE, 2002, J PERS ASSESS, V79, P472, DOI 10.1207/S15327752JPA7903_05; Kalin NH, 1995, PSYCHONEUROENDOCRINO, V20, P735, DOI 10.1016/0306-4530(95)00023-2; KALIN NH, 1988, BRAIN RES, V440, P285, DOI 10.1016/0006-8993(88)90997-3; Keller MC, 2007, AM J PSYCHIAT, V164, P1521, DOI 10.1176/appi.ajp.2007.06091564; Kendler KS, 2003, ARCH GEN PSYCHIAT, V60, P789, DOI 10.1001/archpsyc.60.8.789; Kennedy SE, 2006, ARCH GEN PSYCHIAT, V63, P1199, DOI 10.1001/archpsyc.63.11.1199; Koepp MJ, 2009, NEUROIMAGE, V44, P252, DOI 10.1016/j.neuroimage.2008.08.032; Kross E, 2011, P NATL ACAD SCI USA, V108, P6270, DOI 10.1073/pnas.1102693108; Lara ME, 1999, CLIN PSYCHOL REV, V19, P553, DOI 10.1016/S0272-7358(98)00066-X; LEARY MR, 1995, J PERS SOC PSYCHOL, V68, P518, DOI 10.1037/0022-3514.68.3.518; MacDonald Geoff, 2011, SOCIAL PAIN NEUROPSY; Mayberg HS, 1999, AM J PSYCHIAT, V156, P675; Monroe SM, 1999, J ABNORM PSYCHOL, V108, P606, DOI 10.1037/0021-843X.108.4.606; Najib A, 2004, AM J PSYCHIAT, V161, P2245, DOI 10.1176/appi.ajp.161.12.2245; Narendran R, 2009, SYNAPSE, V63, P447, DOI 10.1002/syn.20628; Nelson EE, 1998, NEUROSCI BIOBEHAV R, V22, P437, DOI 10.1016/S0149-7634(97)00052-3; Nolan SA, 2003, J PERS SOC PSYCHOL, V85, P745, DOI 10.1037/0022-3514.85.4.745; PANKSEPP J, 1980, NEUROSCI BIOBEHAV R, V4, P473, DOI 10.1016/0149-7634(80)90036-6; PANKSEPP J, 1981, BRAIN RES BULL, V7, P405, DOI 10.1016/0361-9230(81)90038-1; Pecina M, 2013, NEUROPSYCHOPHARMACOL, V38, P639, DOI 10.1038/npp.2012.227; Pizzagalli DA, 2004, MOL PSYCHIATR, V9, P393, DOI 10.1038/sj.mp.4001469; Pizzagalli DA, 2009, AM J PSYCHIAT, V166, P702, DOI 10.1176/appi.ajp.2008.08081201; Prince-Embury S, 1996, RESILIENCE CHILDREN, P135; Rosenberg M., 1965, SOC ADOLESCENT SELF; SIEGEL MA, 1985, BEHAV NEURAL BIOL, V44, P509, DOI 10.1016/S0163-1047(85)91024-6; Silk JS, 2014, SOC COGN AFFECT NEUR, V9, P1798, DOI 10.1093/scan/nst175; Slavich GM, 2009, J SOC CLIN PSYCHOL, V28, P223, DOI 10.1521/jscp.2009.28.2.223; Smith YR, 1998, J CLIN ENDOCR METAB, V83, P4498, DOI 10.1210/jc.83.12.4498; Sowislo JF, 2013, PSYCHOL BULL, V139, P213, DOI 10.1037/a0028931; Trezza V, 2011, J NEUROSCI, V31, P6362, DOI 10.1523/JNEUROSCI.5492-10.2011; Trezza V, 2010, TRENDS PHARMACOL SCI, V31, P463, DOI 10.1016/j.tips.2010.06.008; VANDERSCHUREN LJMJ, 1995, EUR J PHARMACOL, V276, P257, DOI 10.1016/0014-2999(95)00040-R; Way BM, 2009, P NATL ACAD SCI USA, V106, P15079, DOI 10.1073/pnas.0812612106; Widom CS, 2007, ARCH GEN PSYCHIAT, V64, P49; Witvliet M, 2010, J ABNORM CHILD PSYCH, V38, P1045, DOI 10.1007/s10802-010-9426-x; Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005; Zubieta JK, 2003, ARCH GEN PSYCHIAT, V60, P1145, DOI 10.1001/archpsyc.60.11.1145; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	65	69	72	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1359-4184	1476-5578		MOL PSYCHIATR	Mol. Psychiatr.	FEB	2015	20	2					193	200		10.1038/mp.2014.185			8	Biochemistry & Molecular Biology; Neurosciences; Psychiatry	Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry	CB9XE	WOS:000349986700008	25600108	Green Accepted			2020-06-30	J	Yoshida, K; Nishizawa, D; Ichinomiya, T; Ichinohe, T; Hayashida, M; Fukuda, K; Ikeda, K				Yoshida, Kaori; Nishizawa, Daisuke; Ichinomiya, Takashi; Ichinohe, Tatsuya; Hayashida, Masakazu; Fukuda, Ken-ichi; Ikeda, Kazutaka			Prediction Formulas for Individual Opioid Analgesic Requirements Based on Genetic Polymorphism Analyses	PLOS ONE			English	Article							MAJOR ABDOMINAL-SURGERY; GENOME-WIDE ASSOCIATION; PAIN; SENSITIVITY; MORPHINE; PHARMACOGENETICS; EQUIVALENT; GENOTYPE; DRUGS; TRIAL	Background The analgesic efficacy of opioids is well known to vary widely among individuals, and various factors related to individual differences in opioid sensitivity have been identified. However, a prediction model to calculate appropriate opioid analgesic requirements has not yet been established. The present study sought to construct prediction formulas for individual opioid analgesic requirements based on genetic polymorphisms and clinical data from patients who underwent cosmetic orthognathic surgery and validate the utility of the prediction formulas in patients who underwent major open abdominal surgery. Methods To construct the prediction formulas, we performed multiple linear regression analyses using data from subjects who underwent cosmetic orthognathic surgery. The dependent variable was 24-h postoperative or perioperative fentanyl use, and the independent variables were age, gender, height, weight, pain perception latencies (PPL), and genotype data of five single-nucleotide polymorphisms (SNPs). To examine the utility of the prediction formulas, we performed simple linear regression analyses using subjects who underwent major open abdominal surgery. Actual 24-h postoperative or perioperative analgesic use and the predicted values that were calculated using the multiple regression equations were incorporated as dependent and independent variables, respectively. Results Multiple linear regression analyses showed that the four SNPs, PPL, and weight were retained as independent predictors of 24-h postoperative fentanyl use (R-2 = 0.145, P = 5.66 x 10(-10)) and the two SNPs and weight were retained as independent predictors of perioperative fentanyl use (R-2 = 0.185, P = 1.99 x 10(-15)). Simple linear regression analyses showed that the predicted values were retained as an independent predictor of actual 24-h postoperative analgesic use (R-2 = 0.033, P = 0.030) and perioperative analgesic use (R-2 = 0.100, P = 1.09 x 10(-4)), respectively. Conclusions We constructed prediction formulas, and the possible utility of these prediction formulas was found in another type of surgery.	[Yoshida, Kaori; Nishizawa, Daisuke; Ikeda, Kazutaka] Tokyo Metropolitan Inst Med Sci, Addict Substance Project, Tokyo 113, Japan; [Yoshida, Kaori; Fukuda, Ken-ichi] Tokyo Dent Coll, Dept Dent Anesthesiol, Tokyo, Japan; [Ichinomiya, Takashi] Gifu Univ, Grad Sch Med, Dept Biomed Informat, Gifu, Japan; [Hayashida, Masakazu] Juntendo Univ, Sch Med, Dept Anesthesiol & Pain Med, Tokyo 113, Japan	Ikeda, K (reprint author), Tokyo Metropolitan Inst Med Sci, Addict Substance Project, Tokyo 113, Japan.	ikeda-kz@igakuken.or.jp	Ichinomiya, Takashi/W-2784-2018	Ichinomiya, Takashi/0000-0002-9173-4514	Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (Tokyo, Japan)Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [22790518, 23390377, 24659549, 24790544, 25116532, 26293347, 26860360]; Ministry of Health, Labour and Welfare (MHLW) of Japan (Tokyo, Japan)Ministry of Health, Labour and Welfare, Japan [H21-3jigan-ippan-011, H22-Iyaku-015, H25-Iyaku-020, H26-Kakushintekigan-ippan-060, 14524680]; Smoking Research Foundation (Tokyo, Japan); Astellas Foundation for Research on Metabolic Disorders (Tokyo, Japan)	The Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (Tokyo, Japan; no. 22790518, 23390377, 24659549, 24790544, 25116532, 26293347, and 26860360), Ministry of Health, Labour and Welfare (MHLW) of Japan (Tokyo, Japan; no. H21-3jigan-ippan-011, H22-Iyaku-015, H25-Iyaku-020, H26-Kakushintekigan-ippan-060, and 14524680), Smoking Research Foundation (Tokyo, Japan), and Astellas Foundation for Research on Metabolic Disorders (Tokyo, Japan). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson JL, 2007, CIRCULATION, V116, P2563, DOI 10.1161/CIRCULATIONAHA.107.737312; Aoki Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098548; BAHAR M, 1985, ANAESTHESIA, V40, P529; Basar H, 2003, J ENDOUROL, V17, P3, DOI 10.1089/089277903321196706; Bisgaard T, 2001, PAIN, V90, P261, DOI 10.1016/S0304-3959(00)00406-1; BUCHANAN WW, 1986, AM J MED, V80, P145, DOI 10.1016/0002-9343(86)90134-8; Cha PC, 2010, HUM MOL GENET, V19, P4735, DOI 10.1093/hmg/ddq389; Coulbault L, 2006, CLIN PHARMACOL THER, V79, P316, DOI 10.1016/j.clpt.2006.01.007; Fukuda K, 2009, PAIN, V147, P194, DOI 10.1016/j.pain.2009.09.004; Goldstein Frederick J., 2002, Journal of the American Osteopathic Association, V102, pS15; GUINARD JP, 1995, ANESTHESIOLOGY, V82, P377, DOI 10.1097/00000542-199502000-00008; Hayashida M, 2008, PHARMACOGENOMICS, V9, P1605, DOI 10.2217/14622416.9.11.1605; HOSKIN PJ, 1991, DRUGS, V41, P326, DOI 10.2165/00003495-199141030-00002; Ide S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070694; Ikeda K, 2005, TRENDS PHARMACOL SCI, V26, P311, DOI 10.1016/j.tips.2005.04.001; Ip HYV, 2009, ANESTHESIOLOGY, V111, P657, DOI 10.1097/ALN.0b013e3181aae87a; Kasai S, 2008, N-S ARCH PHARMACOL, V377, P269, DOI 10.1007/s00210-007-0205-3; Klepstad P, 2004, ACTA ANAESTH SCAND, V48, P1232, DOI 10.1111/j.1399-6576.2004.00517.x; KLINCK JR, 1982, ANAESTHESIA, V37, P907, DOI 10.1111/j.1365-2044.1982.tb01852.x; Kobayashi D, 2009, PAIN ORIG DIAGN TREA, P101; LOPER KA, 1990, ANESTH ANALG, V70, P72; Maliepaard M, 2013, NAT REV DRUG DISCOV, V12, P103, DOI 10.1038/nrd3931; Martikainen IK, 2004, NEUROSCI LETT, V361, P140, DOI 10.1016/j.neulet.2003.12.060; Nielsen CS, 2008, PAIN, V136, P21, DOI 10.1016/j.pain.2007.06.008; Nishizawa D, 2014, MOL PSYCHIATR, V19, P55, DOI 10.1038/mp.2012.164; Nishizawa D, 2010, METHODS MOL BIOL, V617, P395, DOI 10.1007/978-1-60327-323-7_29; Nishizawa D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007060; Ozcan S, 2002, SCAND J UROL NEPHROL, V36, P281, DOI 10.1080/003655902320248254; PATHAK KS, 1983, ANESTH ANALG, V62, P841; Rogers JF, 2002, AM J MED, V113, P746, DOI 10.1016/S0002-9343(02)01363-3; SUNSHINE S, 1994, [No title captured], P923; Zineh I, 2011, PHARMACOTHERAPY, V31, P729, DOI 10.1592/phco.31.8.729	32	5	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2015	10	1							e0116885	10.1371/journal.pone.0116885			13	Multidisciplinary Sciences	Science & Technology - Other Topics	CA7UF	WOS:000349122100048	25615449	DOAJ Gold, Green Published			2020-06-30	J	Didwaniya, N; Reddy, A; Gottumukkala, RS; Bruera, E				Didwaniya, Neha; Reddy, Akhila; Gottumukkala, Raju S.; Bruera, Eduardo			What Is Your Gut Feeling About Opioid Rotation?	JOURNAL OF CLINICAL ONCOLOGY			English	Article									[Didwaniya, Neha; Reddy, Akhila; Gottumukkala, Raju S.; Bruera, Eduardo] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	Didwaniya, N (reprint author), Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.						Cruciani RA, 2012, J PAIN, V13, P379, DOI 10.1016/j.jpain.2012.01.007; Mallinckrodt Brand Pharmaceuticals, 2010, EX HYDR HCI EXT REL; Purdue Pharma, 2009, MS CONT MORPH SULF C; Purdue Plarma, 2010, OXYCONTIN OX HYDR CO; Reddy A, 2013, ONCOLOGIST, V18, P212, DOI 10.1634/theoncologist.2012-0269	5	2	2	0	1	AMER SOC CLINICAL ONCOLOGY	ALEXANDRIA	2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA	0732-183X	1527-7755		J CLIN ONCOL	J. Clin. Oncol.	JAN 20	2015	33	3					E11	E12		10.1200/JCO.2013.49.8204			2	Oncology	Oncology	CF3BC	WOS:000352421400001	24590650				2020-06-30	J	Sharma, A; Subramaniam, R; Misra, M; Joshiraj, B; Krishnan, G; Varma, P; Kishore, S				Sharma, Ankur; Subramaniam, Rajeshwari; Misra, Mahesh; Joshiraj, Bandi; Krishnan, Gopi; Varma, Prerna; Kishore, Shyam			Anesthetic Management of Emergent Laparoscopic Bilateral Adrenalectomy in a Patient with a Life-Threatening Cortisol Crisis	A & A CASE REPORTS			English	Article							DEPENDENT CUSHINGS-SYNDROME; METABOLIC ALKALOSIS; HYPERTENSION; HYPOKALEMIA; ETOMIDATE; INFUSION	Cushing syndrome may rarely present with life-threatening hypercortisolism, manifested by hypertension, hypokalemia, hyperglycemia, and edema. If medical treatment proves ineffective in ameliorating the symptoms, emergent rescue adrenalectomy may be the only way to relieve the crisis. We describe the anesthetic management of a patient with an ectopic adrenocorticotropic hormone-secreting tumor, whose condition was rapidly deteriorating due to severe cortisol excess, and emergent adrenalectomy was the only available therapeutic modality. Despite severe metabolic derangement, edema, and incipient respiratory failure, emergent bilateral laparoscopic adrenalectomy was performed and the patient improved sufficiently to undergo surgery for the ectopic lesion without incident.	[Sharma, Ankur; Subramaniam, Rajeshwari; Joshiraj, Bandi; Krishnan, Gopi] All India Inst Med Sci, Dept Anesthesia, New Delhi, India; [Misra, Mahesh] All India Inst Med Sci, Dept Surg Disciplines, New Delhi, India; [Varma, Prerna] All India Inst Med Sci, Dept Anesthesiol, New Delhi, India; [Kishore, Shyam] All India Inst Med Sci, Dept Endocrinol, New Delhi, India	Subramaniam, R (reprint author), All India Inst Med Sci, Dept Anesthesia, Room 5010-D,5th Floor Teaching Block, New Delhi, India.	drsrajeshwari@gmail.com					Dabbagh A, 2009, ANESTH ANALG, V108, P238, DOI 10.1213/ane.0b013e318187ed37; Fernandez-Rodriguez E, 2008, ARQ BRAS ENDOCRINOL, V52, P1066, DOI 10.1590/S0004-27302008000600019; Galla JH, 2000, J AM SOC NEPHROL, V11, P369; Han Jennifer Y, 2012, Endocr Pract, V18, pe85, DOI 10.4158/EP11315.CR; Isidori AM, 2007, ARQ BRAS ENDOCRINOL, V51, P1217, DOI 10.1590/S0004-27302007000800007; Izzedine H, 2009, KIDNEY INT, V76, P115, DOI 10.1038/ki.2008.427; Kamenicky P, 2011, J CLIN ENDOCR METAB, V96, P2796, DOI 10.1210/jc.2011-0536; Lutgers HL, 2010, CRIT CARE MED, V38, P1598, DOI 10.1097/CCM.0b013e3181e47b7a; Manickam A, 2012, INDIAN J ANAESTH, V56, P401, DOI 10.4103/0019-5049.100838; Martinez-Valles Miguel Angel, 2009, Cases J, V2, P6174, DOI 10.4076/1757-1626-2-6174; Nemergut EC, 2005, ANESTH ANALG, V101, P1170, DOI 10.1213/01.ane.0000166976.61650.ae; Salameh RR, 2008, J LAPAROENDOSC ADV S, V18, P52, DOI 10.1089/lap.2007.0016; SCHULTE HM, 1990, J CLIN ENDOCR METAB, V70, P1426, DOI 10.1210/jcem-70-5-1426; TANAKA M, 1992, INTERNAL MED, V31, P385, DOI 10.2169/internalmedicine.31.385; Tiyadatah BN, 2012, J ENDOUROL, V26, P157, DOI 10.1089/end.2011.0295; Torpy DJ, 2002, ANN NY ACAD SCI, V970, P134, DOI 10.1111/j.1749-6632.2002.tb04419.x; Vella A, 2001, J CLIN ENDOCR METAB, V86, P1596, DOI 10.1210/jc.86.4.1596; Young WF, 2007, ARQ BRAS ENDOCRINOL, V51, P1349, DOI 10.1590/S0004-27302007000800021	18	0	0	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2325-7237	2575-3126		A A CASE REP	A A Case Rep.	JAN 15	2015	4	2					15	18		10.1213/XAA.0000000000000110			4	Anesthesiology	Anesthesiology	CM3EX	WOS:000357565800001	25611000				2020-06-30	J	Bendel, S; Springe, D; Pereira, A; Grandgirard, D; Leib, SL; Putzu, A; Schlickeiser, J; Jakob, SM; Takala, J; Haenggi, M				Bendel, Stepani; Springe, Dirk; Pereira, Adriano; Grandgirard, Denis; Leib, Stephen L.; Putzu, Alessandro; Schlickeiser, Jannis; Jakob, Stephan M.; Takala, Jukka; Haenggi, Matthias			Do different anesthesia regimes affect hippocampal apoptosis and neurologic deficits in a rodent cardiac arrest model?	BMC ANESTHESIOLOGY			English	Article						Cardiac arrest; Rats; Sevoflurane; Fentanyl; Ketamine; Medetomidine; Neuroprotection	CEREBRAL-ISCHEMIA; CARDIOPULMONARY-RESUSCITATION; THERAPEUTIC HYPOTHERMIA; CEREBROSPINAL-FLUID; TERM RECOVERY; RATS; BRAIN; SEVOFLURANE; NEUROPROTECTION; DEXMEDETOMIDINE	Background: Different anesthesia regimes are commonly used in experimental models of cardiac arrest, but the effects of various anesthetics on clinical outcome parameters are unknown. We conducted a study in which we subjected rats to cardiac arrest under medetomidine/ketamine or sevoflurane/fentanyl anesthesia. Methods: Asystolic cardiac arrest for 8 minutes was induced in 73 rats with a mixture of potassium chloride and esmolol. Daily behavioral and neurological examination included the open field test (OFT), the tape removal test (TRT) and a neurodeficit score (NDS). Animals were randomized for sacrifice on day 2 or day 5 and brains were harvested for histology in the hippocampus cornus ammonis segment CA1. The inflammatory markers IL-6, TNF-alpha, MCP-1 and MIP-1 alpha were assessed in cerebrospinal fluid (CSF). Proportions of survival were tested with the Fisher's exact test, repeated measurements were assessed with the Friedman's test; the baseline values were tested using Mann-Whitney U test and the difference of results of repeated measures were compared. Results: In 31 animals that survived beyond 24 hours neither OFT, TRT nor NDS differed between the groups; histology was similar on day 2. On day 5, significantly more apoptosis in the CA1 segment of the hippocampus was found in the sevoflurane/fentanyl group. MCP-1 was higher on day 5 in the sevoflurane/fentanyl group (p = 0.04). All other cyto- and chemokines were below detection threshold. Conclusion: In our cardiac arrest model neurological function was not influenced by different anesthetic regimes; in contrast, anesthesia with sevoflurane/fentanyl results in increased CSF inflammation and histologic damage at day 5 post cardiac arrest.	[Bendel, Stepani; Springe, Dirk; Pereira, Adriano; Putzu, Alessandro; Schlickeiser, Jannis; Jakob, Stephan M.; Takala, Jukka; Haenggi, Matthias] Univ Hosp Bern, Inselspital, Dept Intens Care Med, CH-3010 Bern, Switzerland; [Bendel, Stepani; Springe, Dirk; Pereira, Adriano; Putzu, Alessandro; Schlickeiser, Jannis; Jakob, Stephan M.; Takala, Jukka; Haenggi, Matthias] Univ Bern, Bern, Switzerland; [Bendel, Stepani] Kuopio Univ Hosp, Dept Intens Care Med, SF-70210 Kuopio, Finland; [Grandgirard, Denis; Leib, Stephen L.] Univ Bern, Inst Infect Dis, Neuroinfect Lab, Bern, Switzerland; [Leib, Stephen L.] Fed Off Civil Protect, Spiez Lab, Div Biol, Spiez, Switzerland	Haenggi, M (reprint author), Univ Hosp Bern, Inselspital, Dept Intens Care Med, CH-3010 Bern, Switzerland.	matthias.haenggi@insel.ch	Leib, Stephen/M-3786-2019; Haenggi, Matthias/A-8073-2008; Pereira, Adriano/F-9342-2014; Haenggi, Matthias/O-2642-2019; Leib, Stephen L/A-7866-2011; Grandgirard, Denis/AAB-8786-2020	Leib, Stephen/0000-0002-1106-6123; Haenggi, Matthias/0000-0001-5845-031X; Pereira, Adriano/0000-0002-3528-3800; Haenggi, Matthias/0000-0001-5845-031X; Leib, Stephen L/0000-0002-1106-6123; Grandgirard, Denis/0000-0002-4151-5196; Putzu, Alessandro/0000-0002-4943-450X	Stiftung fur die Forschung in Anasthesiogie und Intensivmedizin Bern; Swiss National Science FoundationSwiss National Science Foundation (SNSF) [31003A-138094]	The study was supported by the Stiftung fur die Forschung in Anasthesiogie und Intensivmedizin Bern. DG and SL receive support from the Swiss National Science Foundation (31003A-138094). The funding agencies had no role in design, in the collection, analysis, and interpretation of data; writing the manuscript; and in the decision to submit the manuscript. The authors would like to thank Aurelien Frobert, Department of Cardiac Surgery, University Hospital Bern and Roland Galmbacher, Department of Anesthesiology, University of Heidelberg for their valuable technical assistance.	Adamczyk S, 2010, BRIT J ANAESTH, V104, P191, DOI 10.1093/bja/aep365; Albertsmeier M, 2007, RESUSCITATION, V74, P552, DOI 10.1016/j.resuscitation.2007.01.040; Becker Daniel E, 2008, Anesth Prog, V55, P124, DOI 10.2344/0003-3006-55.4.124; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BLOMQVIST P, 1985, J CEREBR BLOOD F MET, V5, P420, DOI 10.1038/jcbfm.1985.57; Bottiger BW, 1997, RESUSCITATION, V34, P79, DOI 10.1016/S0300-9572(96)01029-5; Grandgirard D, 2010, ANTIMICROB AGENTS CH, V54, P1323, DOI 10.1128/AAC.00812-09; Haenggi M, 2010, ANESTH ANALG, V110, P1259, DOI 10.1213/ANE.0b013e3181d77357; Head BP, 2007, CURR OPIN ANESTHESIO, V20, P395, DOI 10.1097/ACO.0b013e3282efa69d; Hellstrom J, 2014, CRIT CARE MED, V42, pE161, DOI 10.1097/CCM.0b013e3182a643d7; HENDRICKX HHL, 1984, RESUSCITATION, V12, P97, DOI 10.1016/0300-9572(84)90062-5; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hossmann KA, 2008, NEUROPHARMACOLOGY, V55, P257, DOI 10.1016/j.neuropharm.2007.12.004; HSU WH, 1981, ENDOCRINOLOGY, V109, P825, DOI 10.1210/endo-109-3-825; Hudetz JA, 2010, J CARDIOTHOR VASC AN, V24, P131, DOI 10.1053/j.jvca.2009.05.008; Ivacko J, 1997, J CEREBR BLOOD F MET, V17, P759; Jolkkonen J, 1999, EUR J PHARMACOL, V372, P31, DOI 10.1016/S0014-2999(99)00186-7; KATZ L, 1995, J CEREBR BLOOD F MET, V15, P1032, DOI 10.1038/jcbfm.1995.129; Kiryk A, 2011, BEHAV BRAIN RES, V219, P1, DOI 10.1016/j.bbr.2010.12.004; Knapp J, 2013, RESUSCITATION, V84, P1450, DOI 10.1016/j.resuscitation.2013.04.012; Landoni G, 2013, BRIT J ANAESTH, V111, P886, DOI 10.1093/bja/aet231; Langdon KD, 2008, EUR J NEUROSCI, V28, P2310, DOI 10.1111/j.1460-9568.2008.06513.x; Liu H, 2012, RESUSCITATION, V83, P1491, DOI 10.1016/j.resuscitation.2012.04.009; Madl Christian, 2004, Curr Opin Crit Care, V10, P213, DOI 10.1097/01.ccx.0000127542.32890.fa; MAIER C, 1993, ANESTHESIOLOGY, V79, P306, DOI 10.1097/00000542-199308000-00016; Manwani B, 2011, BRAIN BEHAV IMMUN, V25, P1689, DOI 10.1016/j.bbi.2011.06.015; Meybohm P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007588; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Nurmi J, 2012, DIABETES CARE, V35, P510, DOI 10.2337/dc11-1478; Rogers P, 1972, Resuscitation, V1, P25, DOI 10.1016/0300-9572(72)90060-3; Rosen C, 2014, RESUSCITATION, V85, P227, DOI 10.1016/j.resuscitation.2013.10.032; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; Teschendorf P, 2008, NEUROSCI LETT, V448, P194, DOI 10.1016/j.neulet.2008.10.030; VONPLANTA I, 1988, J APPL PHYSIOL, V65, P2641; WALSH RN, 1976, PSYCHOL BULL, V83, P482, DOI 10.1037/0033-2909.83.3.482; Zhu JC, 2009, EUR J ANAESTH, V26, P961, DOI 10.1097/EJA.0b013e328330e968; Zitta K, 2010, EUR J PHARMACOL, V645, P39, DOI 10.1016/j.ejphar.2010.07.017	37	10	10	0	8	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	JAN 15	2015	15								2	10.1186/1471-2253-15-2			13	Anesthesiology	Anesthesiology	CB7FI	WOS:000349791800001	25972075	DOAJ Gold, Green Published			2020-06-30	J	Serghini, I; Qamouss, Y; Zoubir, M; Lalaoui, JS; Boughalem, M				Serghini, Issam; Qamouss, Youssef; Zoubir, Mohamed; Lalaoui, Jaafar Salim; Boughalem, Mohamed			Fatal intoxication caused by the application of the multiple transdermals patchs of fentanyl	PAN AFRICAN MEDICAL JOURNAL			English	Article						Fentanyl; transdermal patch; respiratory insufficiency; fatal intoxication	ABUSE; PAIN	Fentanyl (N-phenyl-N-(1-2-phenylethyl-4-piperidyl)propanamide) is a potent synthetic narcotic analgesic. He has an analgesic effect 100 times greater than that of morphine. The use of transdermal fentanyl delivrery systems has increased over recent years especially in patients with chronic pain who are already treated with high doses of morphine or it is derivate. However, many cases of fentanyl intoxication through a variety of transderrmal systems have been reported. This paper reports a fatality due to excessive administered Fentanyl Sandoz(R) Matrix 50 mu g/h transdermal therapeutic systems.	[Serghini, Issam; Qamouss, Youssef; Zoubir, Mohamed; Lalaoui, Jaafar Salim; Boughalem, Mohamed] Univ Cadi Ayyad, Fac Med & Pharm, Hop Mil Avicenne, Pole Anesthesie Reanimat, Marrakech 40010, Morocco	Serghini, I (reprint author), Univ Cadi Ayyad, Fac Med & Pharm, Hop Mil Avicenne, Pole Anesthesie Reanimat, Marrakech 40010, Morocco.						Arvanitis ML, 2002, AM J EMERG MED, V20, P58, DOI 10.1053/ajem.2002.29562; BULLINGHAM RES, 1983, OPIATE ANALGESIA; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; DESIO JM, 1993, ANESTHESIOLOGY, V79, P1139, DOI 10.1097/00000542-199311000-00036; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; Inturrisi CE, 2002, CLIN J PAIN, V18, pS3, DOI 10.1097/00002508-200207001-00002; Kramer Christopher, 1998, Journal of the American Osteopathic Association, V98, P385; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; Moon JM, 2011, J EMERG MED, V40, P37, DOI 10.1016/j.jemermed.2007.10.075; Purucker M, 2000, ANN EMERG MED, V35, P314, DOI 10.1016/S0196-0644(00)70091-6; ROY SD, 1989, PHARM RES-DORDR, V6, P825, DOI 10.1023/A:1015944018555	12	3	3	0	6	AFRICAN FIELD EPIDEMIOLOGY NETWORK-AFENET	KAMPALA	PO BOX 12874, KAMPALA, 00000, UGANDA	1937-8688			PAN AFR MED J	Pan Afr. Med. J.	JAN 7	2015	20								21	10.11604/pamj.2015.20.21.5886			4	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	DM6RE	WOS:000376479300005	26015841	DOAJ Gold, Green Published			2020-06-30	J	Zhang, N; Cai, YR; Yi, XW; Xiao, YN; Chen, B; Li, WX				Zhang, N.; Cai, Y. R.; Yi, X. W.; Xiao, Y. N.; Chen, B.; Li, W. X.			Effects of prolonged anesthesia with dexmedetomidine, fentanyl, or remifentanil on the self-renewal of mouse embryonic stem cells	GENETICS AND MOLECULAR RESEARCH			English	Article						Dexmedetomidine; Remifentanil; Mouse embryonic stem cells; Fentanyl; Self-renewal	FETAL; DIFFERENTIATION; CYCLE; INHIBITION; EXPOSURE; INTERNALIZATION; NEUROTOXICITY; APOPTOSIS; PATHWAYS; SURVIVAL	Previous study has indicated that exposure to anesthesia in early development leads to neuro-apoptosis and is followed by longterm cognitive dysfunction. Given that larger numbers of pregnant women currently receive anesthesia during the first trimester, we wanted to mimic this process in vitro using mouse embryonic stem cells (mESCs) and to explore how different anesthetics affect the self-renewal of mESCs. In the present study, mESCs were exposed to dexmedetomidine, fentanyl, or remifentanil at clinical concentrations for 48 h. The mESCs were then analyzed for cell proliferation and apoptosis. Furthermore, we used flow cytometry to analyze the cell cycle and quantitative real-time polymerase chain reaction to detect the gene expression during the cell cycle as well as the relevant stemness markers. We found that prolonged anesthesia with dexmedetomidine or fentanyl significantly inhibited mESC proliferation, with fewer cell numbers as well as decreased expression of cyclin B and cyclin E mRNA compared to that in the control group; meanwhile, p21 and RB2 gene expression was increased. Additionally, increases or decreases in the proportion of cells in the G1 and S phases, respectively, were observed in the dexmedetomidine-and fentanyl-treated groups. These anesthetics also repressed the gene expression of mESC stemness makers such as Oct4 and Sox2. However, remifentanil seemed to have no significant influence on the self-renewal of mESCs. These results demonstrated that prolonged anesthesia with dexmedetomidine or fentanyl, but not remifentanil, inhibited mESC proliferation by blocking the G1 to S transition, and repressed the maintenance of mESC stemness.	[Zhang, N.; Cai, Y. R.; Xiao, Y. N.; Chen, B.; Li, W. X.] Fudan Univ, Eye Ear Nose & Throat Hosp, Dept Anesthesiol, Shanghai 200433, Peoples R China; [Yi, X. W.] Fudan Univ, Zhong Shan Hosp, Dept Anesthesiol, Shanghai 200433, Peoples R China	Li, WX (reprint author), Fudan Univ, Eye Ear Nose & Throat Hosp, Dept Anesthesiol, Shanghai 200433, Peoples R China.	wenxianli66@gmail.com			Laboratory of the Eye, Ear, Nose, and Throat Hospital, Fudan University, China	Research supported by the Laboratory of the Eye, Ear, Nose, and Throat Hospital, Fudan University, China.	Abdelalim EM, 2013, STEM CELL REV REP, V9, P764, DOI 10.1007/s12015-013-9469-9; Akeju O, 2014, NEUROTOXICOL TERATOL, V43, P59, DOI 10.1016/j.ntt.2014.04.001; Allaert SEG, 2007, ACTA ANAESTH BELG, V58, P119; Andang M, 2008, NATURE, V451, P460, DOI 10.1038/nature06488; Anselmi L, 2013, J NEUROSCI RES, V91, P854, DOI 10.1002/jnr.23214; Conklin JF, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2254; Demirel N, 2014, AM J PERINAT, V31, P983, DOI 10.1055/s-0034-1370348; Filipczyk AA, 2007, STEM CELL RES, V1, P45, DOI 10.1016/j.scr.2007.09.002; Griffioen KJS, 2004, BRAIN RES, V1007, P109, DOI 10.1016/j.brainres.2004.02.010; Hu XW, 2013, NEUROL SCI, V34, P1955, DOI 10.1007/s10072-013-1419-4; Kim E, 2006, J BIOL CHEM, V281, P33749, DOI 10.1074/jbc.M603862200; Kim HS, 2010, PHYSIOL RES, V59, P347; Kim MO, 2008, J CELL BIOCHEM, V104, P1407, DOI 10.1002/jcb.21716; Koo E, 2014, J TOXICOL SCI, V39, P251, DOI 10.2131/jts.39.251; Kouvaras E, 2008, NEUROPHARMACOLOGY, V55, P1172, DOI 10.1016/j.neuropharm.2008.07.025; Lang C, 2002, ANAESTHESIST, V51, P409, DOI 10.1007/s00101-002-0293-x; Lei SY, 2014, J NEUROSURG ANESTH, V26, P349, DOI 10.1097/ANA.0000000000000117; Lin H, 2009, NEUROPSYCHOPHARMACOL, V34, P2097, DOI 10.1038/npp.2009.34; Liou SF, 2009, TOXICOLOGY, V256, P13, DOI 10.1016/j.tox.2008.10.025; Liu QD, 2014, STEM CELL REP, V3, P1103, DOI 10.1016/j.stemcr.2014.10.006; Malk K, 2014, BRAIN DEV-JPN, V36, P116, DOI 10.1016/j.braindev.2013.01.009; Palanisamy A, 2012, INT J OBSTET ANESTH, V21, P152, DOI 10.1016/j.ijoa.2012.01.005; Paris A, 2006, ANESTH ANALG, V102, P456, DOI 10.1213/01.ane.0000194301.79118.e9; Peng M, 2013, J SURG RES, V179, pE219, DOI 10.1016/j.jss.2012.05.047; Re A, 2014, STEM CELL RES, V13, P316, DOI 10.1016/j.scr.2014.07.008; Rogliani P, 2013, PULM PHARMACOL THER, V26, P325, DOI 10.1016/j.pupt.2013.01.002; Ruiz S, 2011, CURR BIOL, V21, P45, DOI 10.1016/j.cub.2010.11.049; Schoeftner S, 2013, STEM CELLS, V31, P717, DOI 10.1002/stem.1315; Schwirtlich M, 2010, FASEB J, V24, P1218, DOI 10.1096/fj.09-143586; Spann MN, 2015, MAGN RESON IMAGING, V33, P213, DOI 10.1016/j.mri.2014.08.033; Thaete LG, 2013, LAB ANIM-UK, V47, P175, DOI 10.1177/0023677213480769; van Dartel DAM, 2014, TOXICOLOGY, V324, P76, DOI 10.1016/j.tox.2014.07.009; Wang RX, 2012, EXP CELL RES, V318, P2094, DOI 10.1016/j.yexcr.2012.05.017; Wang Y, 2008, NAT GENET, V40, P1478, DOI 10.1038/ng.250; Xu J, 2013, CELL MOL BIOL LETT, V18, P494, DOI 10.2478/s11658-013-0102-3; Yu YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078769; Zheng H, 2013, ANESTHESIOLOGY, V118, P516, DOI 10.1097/ALN.0b013e3182834d5d; Zheng H, 2010, J NEUROSCI, V30, P8102, DOI 10.1523/JNEUROSCI.6069-09.2010	38	0	0	0	2	FUNPEC-EDITORA	RIBEIRAO PRETO	RUA FLORIANO PEIXOTO 2444, ALTO DA BOA VISTA, RIBEIRAO PRETO, SP 00000, BRAZIL	1676-5680			GENET MOL RES	Genet. Mol. Res.		2015	14	4					17809	17819		10.4238/2015.December.22.5			11	Biochemistry & Molecular Biology; Genetics & Heredity	Biochemistry & Molecular Biology; Genetics & Heredity	DF8DN	WOS:000371587400054	26782426	Bronze			2020-06-30	J	Genc, M; Sahin, N; Maral, J; Celik, E; Kar, AA; Usar, P; Korkut, B; Guclu, S				Genc, M.; Sahin, N.; Maral, J.; Celik, E.; Kar, A. A.; Usar, P.; Korkut, B.; Guclu, S.			Does bupivacaine and fentanyl combination for epidural analgesia shorten the duration of labour?	JOURNAL OF OBSTETRICS AND GYNAECOLOGY			English	Article						bupivacaine; epidural analgesia; fentanyl; labour	DROTAVERINE HYDROCHLORIDE; PROGRESS; ANESTHESIA; CORTISOL; DELIVERY	In this study we aimed to explore the effects of epidural analgesia achieved by a combination of low-dose bupivacaine and fentanyl infused through an epidural catheter on mother, foetus and labour process in nulliparous at-term pregnant women during vaginal delivery. This study was designed in a prospective, randomised controlled manner. Epidural analgesia was achieved in 50 nulliparous women. Fifty nulliparous women did not undergo epidural analgesia procedure. The duration of the first stage of labour was significantly shortened, while the second stage was significantly lengthened in pregnant women who underwent epidural analgesia (p < 0.05). In conclusion, starting epidural analgesia application during the active phase of the first stage of labour may shorten the duration of the first stage compared with the group of nulliparous women not undergoing epidural analgesia. The factor that has an impact on this may be the addition of fentanyl to bupivacaine used for epidural analgesia.	[Genc, M.; Sahin, N.; Celik, E.; Korkut, B.; Guclu, S.] Sifa Univ, Fac Med, Dept Obstet & Gynecol, Izmir, Turkey; [Maral, J.; Kar, A. A.; Usar, P.] Sifa Univ, Fac Med, Dept Anaesthesia & Intens Care, Izmir, Turkey	Genc, M (reprint author), Sifa Univ, Fac Med, Dept Obstet & Gynecol, Izmir, Turkey.	doktorminegenc@gmail.com					ACOG Committee Opinion, 2002, OBSTET GYNECOLOGY, V99, P369; Anim-Somuah M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000331.pub3; Bodner-Adler Barbara, 2003, Archives of Gynecology and Obstetrics, V267, P130, DOI 10.1007/s00404-002-0294-7; Cheng YW, 2014, OBSTET GYNECOL, V123, P527, DOI 10.1097/AOG.0000000000000134; Gomar C, 2000, EUR J ANAESTH, V17, P542, DOI 10.1046/j.1365-2346.2000.00733.x; Halpern SH, 1998, JAMA-J AM MED ASSOC, V280, P2105, DOI 10.1001/jama.280.24.2105; Jeschke E, 2012, J OBSTET GYNAECOL, V32, P342, DOI 10.3109/01443615.2012.661491; Lacassie HJ, 2003, ANESTH ANALG, V97, P1509, DOI 10.1213/01.ANE.0000083375.48151.FF; Leighton BL, 2005, EVIDENCE-BASED OBSTETRIC ANESTHESIA, P10; Leighton BL, 2002, SEMIN PERINATOL, V26, P122, DOI 10.1053/sper.2002.32201; Littleford J, 2004, CAN J ANAESTH, V51, P586, DOI 10.1007/BF03018403; Lurie S, 2000, EUROPEAN J OBSTETRIC, V89, P153; Lurie S, 1991, ASIA OCEANIA J OBSTE, V17, P944; Mousa WF, 2012, SAUDI J ANAESTH, V6, P36, DOI 10.4103/1658-354X.93055; NEUMARK J, 1985, ACTA ANAESTH SCAND, V29, P555, DOI 10.1111/j.1399-6576.1985.tb02253.x; ONUR E, 1989, ARCH GYNECOL OBSTET, V244, P227, DOI 10.1007/BF01560086; Pirbudak L, 2002, EUR J ANAESTH, V19, P271, DOI 10.1017/S0265021502000431; Rzepka R, 2012, GINEKOL POL, V83, P92; Sharma JB, 2001, INT J GYNECOL OBSTET, V74, P255, DOI 10.1016/S0020-7292(01)00448-9; Singh KC, 2004, INT J GYNECOL OBSTET, V84, P17, DOI 10.1016/S0020-7292(03)00276-5; Skrablin S, 2011, J OBSTET GYNAECOL, V31, P134, DOI 10.3109/01443615.2010.542840; THORP JA, 1989, AM J OBSTET GYNECOL, V161, P670, DOI 10.1016/0002-9378(89)90377-3; Throp JA, 1994, OBSTET GYNECOL SURV, V49, P362; Torvaldsen Siranda, 2012, Evid Based Med, V17, P21, DOI 10.1136/ebm-2011-100092; Weigl W, 2010, GINEKOL POL, V81, P41; Worstell T, 2014, OBSTET GYNECOL, V123, p84S, DOI 10.1097/01.AOG.0000447412.62293.82; Yilmaz B, 2009, INT J GYNECOL OBSTET, V107, P126, DOI 10.1016/j.ijgo.2009.06.021; Zhang J, 1999, AM J OBSTET GYNECOL, V180, P970, DOI 10.1016/S0002-9378(99)70669-1	28	5	5	1	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0144-3615	1364-6893		J OBSTET GYNAECOL	J. Obstet. Gynaecol.		2015	35	7					672	675		10.3109/01443615.2014.991299			4	Obstetrics & Gynecology	Obstetrics & Gynecology	DD4BS	WOS:000369868100004	25546524				2020-06-30	J	Karsli, ND; Subasi, D; Terzioglu, B; Turan, G; Ekinci, O				Karsli, N. D.; Subasi, D.; Terzioglu, B.; Turan, G.; Ekinci, O.			ED50 and ED95 of Intrathecal Isobaric Levobupivacaine Coadministered with Fentanyl for Transurethral Resections: Randomized, Double-blind Trial	DRUG RESEARCH			English	Article						levobupivacaine; effective dose 50%; effective dose 95%; transurethral resection	RACEMIC BUPIVACAINE; SPINAL-ANESTHESIA; HYPERBARIC ROPIVACAINE; OPIOIDS; S(-)-BUPIVACAINE; 0.75-PERCENT; 0.5-PERCENT	Background: Levobupivacaine use is progressively increased for intrathecal anesthesia in transurethral resections. The aim was to determine ED50 and ED95 of intrathecal isobaric levobupivacaine by addition of 25mcg fentanyl for patients undergoing transurethral resections. Methods: A total of 100 patients undergoing transurethral resections with ASA I-III, were randomized to groups receiving intrathecal 0.5% isobaric levobupivacaine in doses of 6, 8, 10, 12 or 14mg in equal volumes with 25mcg intrathecal fentanyl addition. Sensorial block level was determined by pinprick and motor block by Bromage scale. Results: Mean onset time of sensorial block in 6mg group was significantly longer than that of sensorial block in 10mg, 12mg and 14mg groups (p<0.01), 8mg was longer than 12mg and 14mg (p<0.01), and 10mg onset time of sensorial block was significantly longer than 12mg and 14mg (p<0.01). Mean onset time of T10 sensory level in 6mg group was significantly longer than mean onset time of T10 sensory level in 10mg, 12mg and 14mg (p<0.01), the mean onset time of T10 sensory level in 8mg group was also significantly longer than that of 12mg, 14mg groups (p<0.01). ED50 and ED95 of levobupivacaine coadministered with 25 mcg fentanyl were 7.32mg and 10.88mg, respectively. Conclusion: Levobupivacaine with opioid co-administration can be used in doses considerably lower than doses proposed for routine use as it is a safe drug depending on its hemodynamic effects, side effects.	[Karsli, N. D.; Subasi, D.; Turan, G.; Ekinci, O.] Haydarpasa Numune Training & Res Hosp, Dept Anaesthesiol & Intens Care, Istanbul, Turkey; [Terzioglu, B.] Haydarpasa Numune Training & Res Hosp, Pharmacol & Toxicol Unit, Istanbul, Turkey	Ekinci, O (reprint author), Haydarpasa Numune Res & Training Hosp, Dept Anesthesiol & Intens Care, Tibbiye Cad, TR-34668 Istanbul, Turkey.	droekinci@gmail.com	BEBITOGLU, BERNA TERZIOGLU/E-1533-2019	BEBITOGLU, BERNA TERZIOGLU/0000-0003-4601-7871			Alley EA, 2002, ANESTH ANALG, V94, P188, DOI 10.1097/00000539-200201000-00036; Atallah MM, 2006, ACTA ANAESTH SCAND, V50, P798, DOI 10.1111/j.1399-6576.2006.01063.x; Bouvet L, 2011, BRIT J ANAESTH, V106, P215, DOI 10.1093/bja/aeq296; Burke D, 1999, REGION ANESTH PAIN M, V24, P519, DOI 10.1016/S1098-7339(99)90042-1; Burlacu Crina L, 2008, Ther Clin Risk Manag, V4, P381; Camorcia M, 2004, BRIT J ANAESTH, V92, P850, DOI 10.1093/bja/aeh155; Carvalho B, 2005, ANESTHESIOLOGY, V103, P606, DOI 10.1097/00000542-200509000-00025; Casati A, 2003, J CLIN ANESTH, V15, P126, DOI 10.1016/S0952-8180(02)00513-5; Chang S Y, 2004, MED SCI MONITOR, V10, P110; Cox CR, 1998, BRIT J ANAESTH, V80, P289; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; Foster RH, 2000, DRUGS, V59, P551, DOI 10.2165/00003495-200059030-00013; Ginosar Y, 2004, ANESTHESIOLOGY, V100, P676, DOI 10.1097/00000542-200403000-00031; Gravenstein D, 1997, ANESTH ANALG, V84, P438, DOI 10.1097/00000539-199702000-00037; Hallworth SP, 2005, ANESTH ANALG, V100, P1159, DOI 10.1213/01.ANE.0000149548.88029.A2; Kallio H, 2005, REGION ANESTH PAIN M, V30, P48, DOI 10.1016/j.rapm.2004.11.002; Kopacz DJ, 2000, ANESTH ANALG, V90, P642, DOI 10.1097/00000539-200003000-00026; Lee YY, 2005, EUR J ANAESTH, V22, P899, DOI 10.1017/S0265021505001523; Malhotra V, 1996, ANESTHESIA RENAL GEN, P303; Manullang TR, 2000, ANESTH ANALG, V90, P1162, DOI 10.1097/00000539-200005000-00030; Mather LE, 1998, ANESTH ANALG, V86, P805, DOI 10.1097/00000539-199804000-00024; McLeod GA, 2001, ANAESTHESIA, V56, P331, DOI 10.1046/j.1365-2044.2001.01964.x; Morrison SG, 2000, ANESTH ANALG, V90, P1308, DOI 10.1097/00000539-200006000-00009; Mulroy MF, 2000, ANESTH ANALG, V91, P860, DOI 10.1097/00000539-200010000-00017; Murphy PM, 2003, ANESTH ANALG, V97, P1709, DOI 10.1213/01.ANE.0000089965.75585.0D; Parpaglioni P, 2005, ANESTHESIOLOGY, V103, P1233; Peduto VA, 2003, EUR J ANAESTH, V20, P979, DOI 10.1097/00003643-200312000-00008; van de Velde M, 2007, ANESTHESIOLOGY, V106, P149, DOI 10.1097/00000542-200701000-00024; Yegin A, 2005, ACTA ANAESTH SCAND, V49, P401, DOI 10.1111/j.1399-6576.2005.00607.x	29	1	1	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	2194-9379	2194-9387		DRUG RES	Drug Res.	JAN	2015	65	1					24	29		10.1055/s-0034-1370940			6	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	AY6ZY	WOS:000347712200005	24668575				2020-06-30	J	Kasture, S; Saraf, H				Kasture, Sarang; Saraf, Hrushikesh			Epidural versus intra-articular infusion analgesia following total knee replacement	JOURNAL OF ORTHOPAEDIC SURGERY			English	Article						analgesia, epidural; arthroplasty, replacement, knee; pain management	LOCAL INFILTRATION ANALGESIA; PAIN MANAGEMENT; CONTROLLED-TRIAL; DOUBLE-BLIND; ARTHROPLASTY; MORPHINE; INJECTION	Purpose. To compare the efficacy of epidural versus intra-articular infusion analgesia following total knee replacement (TKR). Methods. 25 men and 50 women aged 55 to 75 (mean, 67) years who underwent primary TKR by a single surgeon were randomised and consented to receive either epidural (n=35) or intra-articular (n=40) infusion analgesia for 48 hours at 5 ml/hr. All patients also received intravenous aqueous diclofenac 50 mg twice a day. Patients were assessed 6 hourly for visual analogue score (VAS) for pain to determine the analgesic effect. Complications such as paraesthesia in the lower limbs, hypotension, urinary retention, and abdominal distension were recorded, as was the rehabilitation progress with respect to the time to stand, climb stairs, use of commode chair, and discharge. Results. The epidural and intra-articular infusion groups were comparable with respect to age, sex, weight, and operating time, as was the analgesic efficacy within 48 hours of TKR. Patients with epidural infusion analgesia had a higher complication rate in terms of hypotension (51.4% vs. 22.5%, p=0.015) and troublesome paraesthesia in the lower limbs (45.7% vs. 12.5%, p=0.028), and a trend of higher abdominal distension rate (20% vs. 5%, p=0.073). Patients with intra-articular infusion analgesia were able to stand/walk earlier (2.08 vs. 2.54 days, p<0.001). The 2 groups did not differ significantly in the time needed to climb stairs, use of commode chair, and discharge. Conclusion. The efficacy of epidural and intra-articular infusion analgesia was comparable. Intra-articular infusion was associated with fewer complications and earlier rehabilitation.	[Kasture, Sarang] MIMER Med Coll, Pune, Maharashtra, India; [Saraf, Hrushikesh] Shashwat Multispecialty Hosp, Pune, Maharashtra, India	Kasture, S (reprint author), MIMER Med Coll, Pune, Maharashtra, India.	sarangkasture@gmail.com	Kasture, Sarang/AAM-9808-2020				Affas F, 2011, ACTA ORTHOP, V82, P441, DOI 10.3109/17453674.2011.581264; Andersen KV, 2010, ACTA ORTHOP, V81, P606, DOI 10.3109/17453674.2010.519165; Dalury DF, 2011, J BONE JOINT SURG AM, V93A, P1938, DOI 10.2106/JBJS.9320icl; Essving P, 2011, ANESTH ANALG, V113, P926, DOI 10.1213/ANE.0b013e3182288deb; Essving P, 2010, ACTA ORTHOP, V81, P354, DOI 10.3109/17453674.2010.487241; Fajardo Marc, 2011, Orthopedics, V34, P354, DOI 10.3928/01477447-20110317-11; Gomez-Cardero P, 2010, CLIN ORTHOP RELAT R, V468, P1242, DOI 10.1007/s11999-009-1202-2; Ikeuchi M, 2013, KNEE SURG SPORT TR A, V21, P2680, DOI 10.1007/s00167-012-2004-8; Joo JH, 2011, J ARTHROPLASTY, V26, P1095, DOI 10.1016/j.arth.2011.03.052; Shanthanna H, 2012, INDIAN J ANAESTH, V56, P270, DOI 10.4103/0019-5049.98776; Spreng UJ, 2010, BRIT J ANAESTH, V105, P675, DOI 10.1093/bja/aeq232; Tripuraneni KR, 2011, ORTHOPEDICS, V34, DOI 10.3928/01477447-20110124-11; Zhang S, 2011, J INT MED RES, V39, P1369, DOI 10.1177/147323001103900423	13	6	8	0	2	HONG KONG ACAD MEDICINE PRESS	HONG KONG	9/F/, ROOM 901, 99 WONG CHUK HANG RD, ABERDEEN, HONG KONG, 00000, PEOPLES R CHINA	1022-5536	2309-4990		J ORTHOP SURG-HONG K	J. Orthop. Surg.		2015	23	3					287	289		10.1177/230949901502300304			3	Orthopedics; Surgery	Orthopedics; Surgery	CZ9YT	WOS:000367454500004	26715701	DOAJ Gold			2020-06-30	J	Kapoor, M; Herrick, D				Kapoor, Mukesh; Herrick, Daniel			A 27-Year-Old Female on Chronic Opioid Therapy	JOURNAL OF CLINICAL SLEEP MEDICINE			English	Editorial Material							CENTRAL SLEEP-APNEA; UNITED-STATES; ADAPTIVE SERVOVENTILATION; PAIN RELIEVERS		[Kapoor, Mukesh; Herrick, Daniel] Dartmouth Hitchcock Med Ctr, Sleep Disorders Ctr, Lebanon, NH 03766 USA	Kapoor, M (reprint author), 18 Old Etna Rd, Lebanon, NH 03766 USA.	mukeshkapoor2011@u.northwestern.edu					Cao M, 2014, J CLIN SLEEP MED, V10, P855, DOI 10.5664/jcsm.3954; Davis MJ, 2012, J CLIN SLEEP MED, V8, P579, DOI 10.5664/jcsm.2164; Farney RJ, 2013, EUR RESPIR J, V42, P394, DOI 10.1183/09031936.00120012; Javaheri S, 2014, SLEEP MED CLIN, V9, P49, DOI 10.1016/j.jsmc.2013.10.003; Javaheri S, 2014, J CLIN SLEEP MED, V10, P637, DOI 10.5664/jcsm.3788; Javaheri S, 2008, J CLIN SLEEP MED, V4, P305; Mogri M, 2008, CHEST, V133, P1484, DOI 10.1378/chest.07-1891; Mogri M, 2009, SLEEP BREATH, V13, P49, DOI 10.1007/s11325-008-0208-4; Paulozzi LJ, 2014, MMWR-MORBID MORTAL W, V63, P563; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Rose AR, 2014, J CLIN SLEEP MED, V10, P847, DOI 10.5664/jcsm.3950; Sharkey KM, 2010, DRUG ALCOHOL DEPEN, V108, P77, DOI 10.1016/j.drugalcdep.2009.11.019; Walker JM, 2007, J CLIN SLEEP MED, V3, P455; Wang D, 2005, CHEST, V128, P1348, DOI 10.1378/chest.128.3.1348; Webster LR, 2008, PAIN MED, V9, P425, DOI 10.1111/j.1526-4637.2007.00343.x; Webster LR, 2013, PAIN MED, V14, P959, DOI 10.1111/pme.12194; Webster LR, 2011, PAIN MED, V12, pS26, DOI 10.1111/j.1526-4637.2011.01134.x	17	1	1	0	0	AMER ACAD SLEEP MEDICINE	WESTCHESTER	ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA	1550-9389	1550-9397		J CLIN SLEEP MED	J. Clin. Sleep Med.		2015	11	6					683	687		10.5664/jcsm.4786			5	Clinical Neurology	Neurosciences & Neurology	CY3BZ	WOS:000366284500015	25845899	Green Published			2020-06-30	J	Szczeklik, W; Andrychiewicz, A; Gorka, K; Konarska, K; Soja, J; Sladek, K				Szczeklik, Wojciech; Andrychiewicz, Anna; Gorka, Karolina; Konarska, Katarzyna; Soja, Jerzy; Sladek, Krzysztof			Flexible bronchoscopy under conscious sedation with midazolam and fentanyl can be safely performed by nonanesthesiologists	POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE			English	Letter							GASTROINTESTINAL ENDOSCOPY; FIBEROPTIC BRONCHOSCOPY; NON-ANESTHESIOLOGISTS; MODERATE SEDATION; EUROPEAN-SOCIETY; GASTROENTEROLOGY; GUIDELINE; PROPOFOL; NURSES		[Szczeklik, Wojciech; Gorka, Karolina; Konarska, Katarzyna; Soja, Jerzy; Sladek, Krzysztof] Jagiellonian Univ, Coll Med, Krakow, Poland; [Andrychiewicz, Anna; Gorka, Karolina; Soja, Jerzy; Sladek, Krzysztof] Univ Hosp Krakow, Dept Pulmonol, Krakow, Poland; [Szczeklik, Wojciech] Univ Hosp Krakow, Dept Allergy & Immunol, Div Anaesthesiol & Intens Therapy, Krakow, Poland	Szczeklik, W (reprint author), Univ Jagiellonski, Coll Med, Katedra Chorob Wewnetrznych 2, Ul Skawinska 8, PL-31066 Krakow, Poland.	wojciech.szczeklik@uj.edu.pl	Konarska, Katarzyna/AAL-3761-2020; Szczeklik, Wojciech/N-8096-2014	Szczeklik, Wojciech/0000-0002-1349-1123; Konarska, Katarzyna/0000-0002-3887-4104			Andrychiewicz A, 2017, CLIN RESPIR J, V11, P566, DOI 10.1111/crj.12384; Andrychiewicz A, 2015, J ASTHMA, V52, P920, DOI 10.3109/02770903.2015.1005842; CLARKSON K, 1993, CHEST, V104, P1029, DOI 10.1378/chest.104.4.1029; Dang D, 2012, INTERN MED J, V42, P300, DOI 10.1111/j.1445-5994.2010.02261.x; Du Rand IA, 2013, THORAX, V68, P786, DOI 10.1136/thoraxjnl-2013-203629; Dumonceau JM, 2013, ENDOSCOPY, V45, P496, DOI 10.1055/s-0033-1344142; Dumonceau JM, 2010, ENDOSCOPY, V42, P960, DOI 10.1055/s-0030-1255728; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Jose RJ, 2013, EUR RESPIR REV, V22, P106, DOI 10.1183/09059180.00006412; Perel A, 2011, EUR J ANAESTH, V28, P580, DOI 10.1097/EJA.0b013e328348a977; Putinati S, 1999, CHEST, V115, P1437, DOI 10.1378/chest.115.5.1437; Rex DK, 2006, ALIMENT PHARM THER, V24, P163, DOI 10.1111/j.1365-2036.2006.02986.x; Soja J, 2015, POL ARCH MED WEWN, V125, P659, DOI 10.20452/pamw.3047; Tobin CD, 2013, SIMUL HEALTHC, V8, P114, DOI 10.1097/SIH.0b013e3182786209	14	5	5	1	1	MEDYCYNA PRAKTYCZNA	KRAKOW	UL KRAKOWSKA 41, KRAKOW, 31-066, POLAND	0032-3772			POL ARCH MED WEWN	Pol. Arch. Med. Wewn.		2015	125	11					869	871		10.20452/pamw.3172			3	Medicine, General & Internal	General & Internal Medicine	CY0IH	WOS:000366089300012	26447141	Other Gold			2020-06-30	J	Haytural, C; Aydinli, B; Demir, B; Bozkurt, E; Parlak, E; Disibeyaz, S; Sarac, A; Ozgok, A; Kazanci, D				Haytural, Candan; Aydinli, Bahar; Demir, Berna; Bozkurt, Elif; Parlak, Erkan; Disibeyaz, Selcuk; Sarac, Ahmet; Ozgok, Aysegul; Kazanci, Dilek			Comparison of Propofol, Propofol-Remifentanil, and Propofol-Fentanyl Administrations with Each Other Used for the Sedation of Patients to Undergo ERCP	BIOMED RESEARCH INTERNATIONAL			English	Article							UPPER GASTROINTESTINAL ENDOSCOPY; MIDAZOLAM; PETHIDINE; ETOMIDATE	Introduction. Using single anesthetic agent in endoscopic retrograde cholangiopancreatography (ERCP) may lead to inadequate analgesia and sedation. To achieve the adequate analgesia and sedation the single anesthetic agent doses must be increased which causes undesirable side effects. For avoiding high doses of single anesthetic agent nowadays combination with sedative agents is mostly a choice for analgesia and sedation for ERCP. Aim. The aim of this study is to investigate the effects of propofol alone, propofol + remifentanil, and propofol + fentanyl combinations on the total dose of propofol to be administered during ERCP and on the pain scores after the process. Materials and Method. This randomized study was performed with 90 patients (ASA I-II-III) ranging between 18 and 70 years of age who underwent sedation/analgesia for elective ERCP. The patients were administered only propofol (1.5mg/kg) in Group., remifentanil (0.05 mu g/kg) + propofol (1.5mg/kg) combination in Group II, and fentanyl (1 mu g/kg) + propofol (1.5mg/kg) combination in Group III. All the patients' sedation levels were assessed with the Ramsey Sedation Scale (RSS). Their recovery was assessed with the Aldrete and Numerical Rating Scale Score (NRS) at 10 min intervals. Results. The total doses of propofol administered to the patients in the three groups in this study were as follows: 375mg in Group I, 150mg in Group II, and 245mg in Group III. Conclusion. It was observed that, in the patients undergoing ERCP, administration of propofol in combination with an opioid provided effective and reliable sedation, reduced the total dose of propofol, increased the practitioner satisfaction, decreased the pain level, and provided hemodynamic stability compared to the administration of propofol alone.	[Haytural, Candan; Aydinli, Bahar; Demir, Berna; Sarac, Ahmet; Ozgok, Aysegul; Kazanci, Dilek] Turkiye Yuksek Ihtisas Educ & Res Hosp, Anesthesia Clin, TR-06810 Ankara, Turkey; [Bozkurt, Elif] Caycuma State Hosp, Anesthesia Clin, Zonguldak, Turkey; [Parlak, Erkan] Sakarya Univ, Fac Med, Gastroenterol Clin, Sakarya, Turkey; [Disibeyaz, Selcuk] Turkiye Yuksek Ihtisas Hosp, Gastroenterol Clin, TR-06810 Ankara, Turkey	Kazanci, D (reprint author), Turkiye Yuksek Ihtisas Educ & Res Hosp, Anesthesia Clin, Kizilay S 4, TR-06810 Ankara, Turkey.	dilekkazanci@gmail.com	disibeyaz, selcuk/I-2890-2014; ozgok, Aysegul/AAG-4356-2019	disibeyaz, selcuk/0000-0002-1637-7684; 			Agostoni M, 2007, DIGEST LIVER DIS, V39, P1024, DOI 10.1016/j.dld.2007.08.004; Amornyotin S, 2011, GASTROENT RES PRACT, DOI 10.1155/2011/134819; Falk J, 2004, ANN PHARMACOTHER, V38, P1272, DOI 10.1345/aph.1E008; Fredman B., 1999, ANESTHESIA ANALGESIA, V82, P355; Gazdag G, 2004, J ECT, V20, P225, DOI 10.1097/00124509-200412000-00007; Gillham MJ, 2001, GASTROINTEST ENDOSC, V54, P14, DOI 10.1067/mge.2001.116358; Ince IE, 2013, J PEDIAT HEMATOL ONC, V35, P112, DOI 10.1097/MPH.0b013e318279cbda; Iyilikci L, 2004, J CLIN ANESTH, V16, P499, DOI 10.1016/j.jclinane.2004.01.005; Karaman S., 2005, TURK ANESTEZIYOLOJI, V33, P313; Kramer Kyle J, 2012, Anesth Prog, V59, P107, DOI 10.2344/12-00001.1; Lee TH, 2012, DIGEST DIS SCI, V57, P2113, DOI 10.1007/s10620-012-2234-0; Marik PE, 2004, CURR PHARM DESIGN, V10, P3639, DOI 10.2174/1381612043382846; Mazanikov M, 2012, ENDOSCOPY, V44, P487, DOI 10.1055/s-0031-1291655; Michalodimitrakis M, 1999, AM J FOREN MED PATH, V20, P93, DOI 10.1097/00000433-199903000-00022; MURRAY AW, 1990, GUT, V31, P270, DOI 10.1136/gut.31.3.270; Thompson AM, 2004, SURG ENDOSC, V18, P22, DOI 10.1007/s00464-003-9069-x; Turan M., 2003, CUKUROVA U TIP FAKUL, V25, P171; Yuceyar L., 1994, THESIS ISTANBUL U IS	18	11	12	0	2	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2314-6133	2314-6141		BIOMED RES INT	Biomed Res. Int.		2015									465465	10.1155/2015/465465			5	Biotechnology & Applied Microbiology; Medicine, Research & Experimental	Biotechnology & Applied Microbiology; Research & Experimental Medicine	CV2DE	WOS:000364066300001	26576424	DOAJ Gold, Green Published			2020-06-30	J	Minkowitz, HS; Danesi, H; Ding, L; Jones, JB				Minkowitz, Harold S.; Danesi, Hassan; Ding, Li; Jones, James B.			Development of the fentanyl iontophoretic transdermal system (ITS) for patient-controlled analgesia of postoperative pain management	PAIN MANAGEMENT			English	Article						fentanyl; iontophoretic transdermal system; morphine; patient-controlled analgesia; postoperative pain	DELIVERY-SYSTEM; IV-PCA; MORPHINE; PHARMACOKINETICS; MODALITIES; EFFICACY; SAFETY; CARE	The fentanyl iontophoretic transdermal system (ITS) is a needle-free, patient-activated drug delivery system used for patient-controlled analgesia in adult hospitalized patients with postoperative pain. The system design has been updated to a separated system consisting of a Controller and a Drug Unit, and has had regulatory submissions in USA and Europe in 2014. Fentanyl ITS has been shown to be therapeutically equivalent to morphine intravenous (iv.) patient-controlled analgesia. One of the advantages of fentanyl ITS is that patients have better mobility as there is no need for an iv. pump, iv. lines and pole. The introduction of the updated fentanyl ITS will add a versatile tool to the postoperative pain management armamentarium.	[Minkowitz, Harold S.] Mem Hermann Mem City Med Ctr, Dept Anesthesiol, Houston, TX 77024 USA; [Danesi, Hassan; Ding, Li; Jones, James B.] The Med Co, Parsippany, NJ 07054 USA	Minkowitz, HS (reprint author), Mem Hermann Mem City Med Ctr, Dept Anesthesiol, Houston, TX 77024 USA.	harold@minkowitzmd.com			Medicines Company; AcelRX Pharma; Malincrodt	HS Minkowitz reports the following relevant disclosures: The Medicines Company-Research Funding, Consultant, AcelRX Pharma-Research Funding, Consultant, Malincrodt-Research Funding, Speaker. H Danesi, L Ding and JB Jones are employees of The Medicines Company. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.	[Anonymous], 2015, IONSYS FENT IONT TRA; Bonnet F, 2009, CURR MED RES OPIN, V25, P293, DOI 10.1185/03007990802631321 ; Bourne MH, 2010, PHYS THER, V90, P707, DOI 10.2522/ptj.20080323; Camu F, 1998, ANESTH ANALG, V87, P890, DOI 10.1097/00000539-199810000-00027; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Evans C, 2007, PAIN MANAG NURS, V8, P86, DOI 10.1016/j.pmn.2007.03.004; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Gupta SK, 2005, CLIN PHARMACOKINET, V44, P25, DOI 10.2165/00003088-200544001-00005; Gupta SK, 1998, J PHARM SCI, V87, P976, DOI 10.1021/js970437d; Harding G, 2007, J ADV NURS, V59, P530, DOI 10.1111/j.1365-2648.2007.04284.x; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Herndon CM, 2007, PHARMACOTHERAPY, V27, P745, DOI 10.1592/phco.27.5.745; Langford RM, 2014, BR J PAIN S2, V8, P7; Lindley P, 2009, J ADV NURS, V65, P1370, DOI 10.1111/j.1365-2648.2009.04991.x; Markey DW, 2002, J NURS CARE QUAL, V16, P1, DOI 10.1097/00001786-200207000-00002; Minkowitz H, 2014, ANESTH ANALG, V118, pS209; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Morris BA, 2010, ORTHOP NURS, V29, P290, DOI 10.1097/NOR.0b013e3181ef7a5d; Oderda GM, 2003, J PAIN SYMPTOM MANAG, V25, P276, DOI 10.1016/S0885-3924(02)00691-7; Pennington P, 2009, PAIN MANAG NURS, V10, P124, DOI 10.1016/j.pmn.2007.09.001; Phipps JB, 2015, EXPERT OPIN DRUG MET, V11, P481, DOI 10.1517/17425255.2015.1020296; Rothman M, 2009, CURR MED RES OPIN, V25, P1433, DOI 10.1185/03007990902862032; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; The Medicines Company, 2015, DAT FIL; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; US Department of Health and Human Services, GUID IND FO IN PRESS; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333	29	4	5	0	6	FUTURE MEDICINE LTD	LONDON	UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND	1758-1869	1758-1877		PAIN MANAG	Pain Manag.		2015	5	5					327	337		10.2217/PMT.15.26			11	Clinical Neurology	Neurosciences & Neurology	CV3LF	WOS:000364160000003	26023880				2020-06-30	J	Saffer, CS; Minkowitz, HS; Ding, L; Danesi, H; Jones, JB				Saffer, Craig S.; Minkowitz, Harold S.; Ding, Li; Danesi, Hassan; Jones, James B.			Fentanyl iontophoretic transdermal system versus morphine intravenous patient-controlled analgesia for pain management following gynecological surgery: a meta-analysis of randomized, controlled trials	PAIN MANAGEMENT			English	Article						fentanyl; gynecologic surgery; intravenous; iontophoretic transdermal system; morphine; patient-controlled analgesia; postoperative pain	PLACEBO-CONTROLLED TRIAL; POSTOPERATIVE PAIN; MEDICATION ERRORS; NATIONAL-SURVEY; DERIVATIVES; EFFICACY; SAFETY	Aim: To compare the efficacy and safety of patient-controlled fentanyl iontophoretic transdermal system (ITS) with morphine intravenous (iv.) patient-controlled analgesia (PCA) for pain management following gynecological surgery. Methods: Two-open-label, multicenter, randomized, active-controlled, parallel-group studies (n = 1142) were conducted that compared fentanyl ITS with morphine iv. PCA for postoperative pain. The subgroup of gynecological surgery patients from each trial was utilized for this meta-analysis (n = 604). Of these patients, 295 received fentanyl ITS (40 mu g/dose) and 309 received morphine iv. PCA (1 mg/dose) for up to 72 h. Efficacy measures included the patient global assessment (PGA) and the investigator global assessment (IGA) of the method of pain control. Results: Gynecological surgery patients (n = 604) included in this meta-analysis had a mean age of 45 years, were predominantly Caucasian (65%) and had a mean body mass index of 29 mg/kg(2). There were statistically significantly more patients treated with fentanyl ITS and more investigators who rated their pain control method as 'excellent' on the PGA at 24h (49.3 vs 37.4%, respectively; p = 0.0029) and IGA at the last assessment (59.5 vs 38.0%, respectively; p < 0.0001), respectively, compared with morphine iv. PCA at the last assessment. Conclusion: Following gynecological surgery, patients and investigators were more satisfied (had a higher percent of an 'excellent' rating on the PGA and IGA, respectively) with fentanyl ITS than morphine iv. PCA as a method of pain control.	[Saffer, Craig S.] West Coast Ob Gyn Inc, San Diego, CA 92123 USA; [Minkowitz, Harold S.] Mem Hermann Mem City Med Ctr, Dept Anesthesiol, Houston, TX 77024 USA; [Ding, Li; Danesi, Hassan; Jones, James B.] The Med Co, Parsippany, NJ 07054 USA	Danesi, H (reprint author), The Med Co, Parsippany, NJ 07054 USA.	hassan.danesi@themedco.com			Medicines Company; AcelRX Pharma; Mallinckrodt	This research has been funded by The Medicines Company, AcelRX Pharma and Mallinckrodt. L Ding, JB Jones and H Danesi are employees of The Medicines Company. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.	Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Gan TJ, 2014, CURR MED RES OPIN, V30, P149, DOI 10.1185/03007995.2013.860019; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Harding G, 2007, J ADV NURS, V59, P530, DOI 10.1111/j.1365-2648.2007.04284.x; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Hicks RW, 2008, AM J HEALTH-SYST PH, V65, P429, DOI 10.2146/ajhp070194; Hudcova J, 2006, COCHRANE DB SYST REV, DOI 10.1002/146518583.CD003348.pub2; Institute for Safe Medication Practices, MISPR PCA CONC LEADS; Institute for Safe Medication Practices, HIGH AL MED FEAT RED; Lindley P, 2009, J ADV NURS, V65, P1370, DOI 10.1111/j.1365-2648.2009.04991.x; Markey DW, 2002, J NURS CARE QUAL, V16, P1, DOI 10.1097/00001786-200207000-00002; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Mayes S, 2006, ANN PHARMACOTHER, V40, P2178, DOI 10.1345/aph.1H135; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Morris BA, 2010, ORTHOP NURS, V29, P290, DOI 10.1097/NOR.0b013e3181ef7a5d; ROSOW CE, 1982, ANESTHESIOLOGY, V56, P93, DOI 10.1097/00000542-198202000-00003; Rothman M, 2009, CURR MED RES OPIN, V25, P1433, DOI 10.1185/03007990902862032; Schein JR, 2009, DRUG SAFETY, V32, P549, DOI 10.2165/00002018-200932070-00002; SMYTHE M, 1992, PHARMACOTHERAPY, V12, P132; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Wells N, 2008, PATIENT SAFETY QUALI	26	5	5	0	3	FUTURE MEDICINE LTD	LONDON	UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND	1758-1869	1758-1877		PAIN MANAG	Pain Manag.		2015	5	5					339	348		10.2217/PMT.15.29			10	Clinical Neurology	Neurosciences & Neurology	CV3LF	WOS:000364160000004	26088721	Bronze			2020-06-30	J	Sayin, P; Dobrucali, H; Turk, HS; Totoz, T; Isil, CT; Hanci, A				Sayin, Pinar; Dobrucali, Hale; Turk, Hacer Sebnem; Totoz, Tolga; Isil, Canan Tulay; Hanci, Ayse			Effects of intra-articular levobupivacaine, fentanyl-levobupivacaine and tramadol-levobupivacaine for postoperative pain in arthroscopic knee surgery	ACTA ORTHOPAEDICA ET TRAUMATOLOGICA TURCICA			English	Article						Analgesic need; fentanyl; intra-articular; knee surgery; levobupivacaine; postoperative pain; tramadol	BUPIVACAINE PROVIDES; ANALGESIA; MORPHINE; DURATION	Objective: The aim of this study was to compare the postoperative analgesic efficacy of intra-articularly injected levobupivacaine, levobupivacaine-fentanyl, and levobupivacaine-tramadol combinations. Methods: Eighty patients scheduled for elective knee arthroscopy were divided randomly into 4 groups of 20 patients each. Group 1 (the control group) received intra-articular saline, Group 2 received levobupivacaine 2.5 mg/ml, Group 3 received levobupivacaine 2.5 mg/ml + tramadol 50 mg, and Group 4 received levobupivacaine 2.5 mg/ml + fentanyl 150 mcg. All patients were operated on under general anesthesia, and a total of 20 ml study solution was injected: 7 ml subcutaneously before surgery and 13 ml intra-articularly upon completion of surgery. For postoperative, pain visual analogue scale (VAS) was assessed at the 1st, 2nd, 4th, 8th, 12th, and 24th hours postoperatively. Patients with a VAS score over 5 received diclofenac sodium, and the need for rescue analgesics was recorded. Results: At the 1st, 2nd, 4th, 8th, 12th, and 24th postoperative hours, Group 3 and Group 4 had statistically significant lower VAS scores of pain (p<0.01). Postoperative rescue analgesic requirements were different among the groups. The postoperative 1st hour analgesic requirement was statistically significantly lower in Group 3 and Group 4 when compared to the other groups (p<0.01). At the postoperative 2nd and 4th hours, analgesic requirements were statistically significantly lower in Group 3 than in the other groups (p<0.01). Analgesic requirements were statistically significantly lower in Group 3 and Group 4 than in the other groups (p<0.01). Analgesic requirements at the 12th and 24th postoperative hours did not show any statistically significant difference (p>0.05). Conclusion: The results indicated that levobupivacaine combined with either fentanyl or tramadol decreased rescue analgesic requirements when compared to levobupivacaine alone.	[Sayin, Pinar; Dobrucali, Hale; Turk, Hacer Sebnem; Isil, Canan Tulay; Hanci, Ayse] Sisli Hamidiye Etfal Training & Res Hosp, Dept Anesthesiol & Reanimat, Istanbul, Turkey; [Totoz, Tolga] Bagcilar Training & Res Hosp, Dept Anesthesiol & Reanimat, Istanbul, Turkey	Sayin, P (reprint author), Sisli Hamidiye Etfal Egitim & Arastirma Hastanesi, Anesteziyol & Reanimasyon Klin, TR-34377 Istanbul, Turkey.	drpinaray@yahoo.com		TURK, HACER SEBNEM/0000-0003-0225-1965			Alagol A, 2004, KNEE SURG SPORT TR A, V12, P184, DOI 10.1007/s00167-003-0454-8; Bengisun ZK, 2010, J ANESTH, V24, P694, DOI 10.1007/s00540-010-0970-x; Beyzadeoglu T, 2007, KNEE SURG SPORT TR A, V15, P564, DOI 10.1007/s00167-006-0221-8; Brill S, 2004, CAN J ANAESTH, V51, P975, DOI 10.1007/BF03018482; De Andres J, 1998, EUR J ANAESTH, V15, P10, DOI 10.1097/00003643-199801000-00003; Eren M, 2008, AGRI, V20, P17; GEUTJENS G, 1994, ARTHROSCOPY, V10, P299, DOI 10.1016/S0749-8063(05)80116-1; Gristwood RW, 2002, DRUG SAFETY, V25, P153, DOI 10.2165/00002018-200225030-00002; Hosseini H, 2012, KNEE SURG SPORT TR A, V20, P1839, DOI 10.1007/s00167-011-1791-7; Ivani G, 2001, Minerva Anestesiol, V67, P20; Jacobson E, 2006, KNEE SURG SPORT TR A, V14, P120, DOI 10.1007/s00167-005-0655-4; Jacobson E, 2000, ARTHROSCOPY, V16, P183, DOI 10.1016/S0749-8063(00)90034-3; Jawish D, 1996, Cah Anesthesiol, V44, P415; Karaman Y, 2009, SAUDI MED J, V30, P629; LAWRENCE AJ, 1992, EUR J CLIN PHARMACOL, V43, P351, DOI 10.1007/BF02220608; Mandal P, 2002, INDIAN J ANESTHESIA, V46, P107; Morgan GE, 2004, KLIN ANESTEZIYOLOJI, V3, P233; Ozok U, 1996, TURK KLIN TIP BILIM, V16, P374; Raj N, 2004, EUR J ANAESTH, V21, P932, DOI 10.1017/S0265021504000304; STEIN C, 1991, NEW ENGL J MED, V325, P1123, DOI 10.1056/NEJM199110173251602; Turk HS, 2012, TURKIYE KLIN J ANEST, V10, P7; Tverskoy M, 1998, ANESTH ANALG, V87, P1121, DOI 10.1097/00000539-199811000-00026; Varkel V, 1999, CAN J ANAESTH, V46, P867, DOI 10.1007/BF03012977; Zeidan A, 2008, ANESTH ANALG, V107, P292, DOI 10.1213/ane.0b013e31816ba364	24	4	4	0	2	TURKISH ASSOC ORTHOPAEDICS TRAUMATOLOGY	ISTANBUL	TIP FAKULTESI ORTOPEDI VE TRAVMATOLOJI KLINIGI, ISTANBUL, TOPKAPI 34390, TURKEY	1017-995X			ACTA ORTHOP TRAUMATO	Acta Orthop. Traumatol. Turc.		2015	49	3					267	273		10.3944/AOTT.2015.14.0107			7	Orthopedics	Orthopedics	CO3OQ	WOS:000359068200008	26200405	DOAJ Gold			2020-06-30	J	Tian, X; Yang, YH; Wei, HY; Lao, JQ; Wang, HP; Tian, YY				Tian, X.; Yang, Y. -H.; Wei, H. -Y.; Lao, J. -Q.; Wang, H. -P.; Tian, Y. -Y.			Rapid sedation induced by fentanyl combined with propofol via an intrathecal chemotherapy injection for leukemia in children	GENETICS AND MOLECULAR RESEARCH			English	Article						Children; Propofol; Fentanyl; Intrathecal injection	PEDIATRIC ONCOLOGY; SPINAL-ANESTHESIA; TRIAL; MANAGEMENT; ANALGESIA; MIDAZOLAM; MORPHINE	This study explored the sedative and analgesic effects of fentanyl combined with propofol via an intrathecal chemotherapy injection for acute leukemia (acute lymphocytic leukemia or acute myelocytic leukemia) among children, to relieve pain and difficulty during intrathecal injection, improve treatment compliance, increase the success rate of single puncture, and reduce procedure failure, with the aim of developing a painless procedure for children with acute leukemia. Fifty person-times received fentanyl combined with propofol via an intrathecal chemotherapy injection among the hospitalized children with leukemia. The patients' cooperation with the procedure, response to the medication, dosages of fentanyl and propofol, reaction to the procedures, wake-up time, and changes in oxygen saturation (SpO(2)), heart rate (HR), respiration, and blood pressure (BP) before, during,and after the procedures were observed. The doctors who performed the procedures assessed the quality of sedation and analgesia. In the treatment group, the patients were quiet during the lumbar puncture and intrathecal injection, showing good sedation and analgesia. HR and respiration decreased slightly. There were no changes in SpO(2) and BP. No obvious respiratory depression occurred with proper dosages. Only a few patients showed stertorous respiration, which stopped soon after the procedures. In the control group, the patients were agitated, crying, and not cooperative before and during the procedures, which made the procedures very difficult. During intrathecal injection, pain obviously reduced and the success rate of single lumbar puncture increased. It is safe and effective to apply fentanyl combined with propofol for sedation and analgesia.	[Tian, X.; Yang, Y. -H.; Wang, H. -P.] Kunming Childrens Hosp, Dept Hematol, Kunming, Yunnan Province, Peoples R China; [Wei, H. -Y.; Lao, J. -Q.] Guangxi Med Univ, Affiliated Hosp 4, Dept Pediat, Nanning, Guangxi Provinc, Peoples R China; [Tian, Y. -Y.] Sichuan Univ, West China Hosp, Dept Urol, Chengdu, Sichuan Provinc, Peoples R China	Yang, YH (reprint author), Kunming Childrens Hosp, Dept Hematol, Kunming, Yunnan Province, Peoples R China.	XinTiandoc@126.com			Scientific Research Foundation of Yunnan Province, China [2010EZ246]	Research supported by the Scientific Research Foundation of Yunnan Province, China (#2010EZ246).	Baniadam A, 2010, AM J VET RES, V71, P720, DOI 10.2460/ajvr.71.7.720; Barbi E, 2005, J PEDIAT HEMATOL ONC, V27, P639, DOI 10.1097/01.mph.0000193474.06870.9c; Batra YK, 2010, PEDIATR ANESTH, V20, P625, DOI 10.1111/j.1460-9592.2010.03326.x; Draisci Gaetano, 2009, J Opioid Manag, V5, P197; Gorman R, 2002, PEDIATRICS, V110, P836; Gottschling S, 2005, J PEDIAT HEMATOL ONC, V27, P471, DOI 10.1097/01.mph.0000179238.37647.91; Kearns RJ, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-51; Leino T, 2009, N-S ARCH PHARMACOL, V380, P539, DOI 10.1007/s00210-009-0460-6; Lundeberg S, 2011, PEDIATR ANESTH, V21, P274, DOI 10.1111/j.1460-9592.2010.03411.x; Mantadakis E, 2009, J PEDIATR ONCOL NURS, V26, P217, DOI 10.1177/1043454209339733; Masala S, 2011, CARDIOVASC INTER RAD, V34, P1014, DOI 10.1007/s00270-010-9985-9; Nagel K, 2008, PEDIATR BLOOD CANCER, V51, P634, DOI 10.1002/pbc.21669; Nguyen M, 2010, REGION ANESTH PAIN M, V35, P261, DOI 10.1097/AAP.0b013e3181de12e4; Rebel A, 2011, PAIN RES MANAG, V16, P19, DOI 10.1155/2011/691712; Reeves ST, 2004, PEDIATRICS, V114, pE74, DOI 10.1542/peds.114.1.e74; Shadangi BK, 2011, SINGAP MED J, V52, P432; Wodlin NB, 2011, BJOG-INT J OBSTET GY, V118, P299, DOI 10.1111/j.1471-0528.2010.02697.x; Yaster Myron, 2001, Indian Journal of Pediatrics, V68, P749, DOI 10.1007/BF02752416; Yousef AA, 2010, INT J OBSTET ANESTH, V19, P401, DOI 10.1016/j.ijoa.2010.07.019	19	1	1	0	3	FUNPEC-EDITORA	RIBEIRAO PRETO	RUA FLORIANO PEIXOTO 2444, ALTO DA BOA VISTA, RIBEIRAO PRETO, SP 00000, BRAZIL	1676-5680			GENET MOL RES	Genet. Mol. Res.		2015	14	2					3687	3693		10.4238/2015.April.17.18			7	Biochemistry & Molecular Biology; Genetics & Heredity	Biochemistry & Molecular Biology; Genetics & Heredity	CL7WT	WOS:000357183700083	25966137	Bronze			2020-06-30	J	Xu, L; Ren, LJ; Wang, ZH; Tian, XT; Qi, LH; Fan, QP; Xiang, YL				Xu, Lin; Ren, Lijun; Wang, Zhihua; Tian, Xingtao; Qi, Lihong; Fan, Qiping; Xiang, Yulian			Oxidative treatment of fentanyl compounds in water by sodium bromate combined with sodium sulphite	WATER SCIENCE AND TECHNOLOGY			English	Article						fentanyl compounds; NaBrO3/NaHSO3/Na2SO3; oxidative degradation; product analysis	NABRO3/NAHSO3 REAGENT; ESTERIFICATION; IDENTIFICATION; DEGRADATION; ACIDS	As narcotic analgesics, fentanyl compounds have been commonly produced and widely used during surgical procedures. The residual and waste of fentanyl compounds have potential harmful impacts on the environment and human health. The oxidative degradation of fentanyl compounds by sodium bromate mixed systems was studied. Factors influencing the oxidation reaction, including molar ratio of NaBrO3/H+/SO32-, molar ratio of NaBrO3/fentanyl and pH, were investigated. Fentanyl, carfentanil and 3-methylfentanyl were able to be completely degraded in 30 minutes by a NaBrO3 mixed system under optimum conditions, the molar ratio of NaBrO3/H+/SO32- equal to 20:3:10, the molar ratio of NaBrO3:fentanyl compounds 50:1 and pH = 4. Sufentanil was only able to be degraded by 74% under the same conditions. The degradation products of the fentanyl compounds detected and identified by gas chromatography/mass spectrometry suggested several possible degradation pathways.	[Xu, Lin; Ren, Lijun; Wang, Zhihua; Tian, Xingtao; Qi, Lihong; Fan, Qiping; Xiang, Yulian] Beijing Univ Chem Technol, State Key Lab Chem Resource Engn, Beijing 100029, Peoples R China	Wang, ZH (reprint author), Beijing Univ Chem Technol, State Key Lab Chem Resource Engn, Beijing 100029, Peoples R China.	zhwang@mail.buct.edu.cn	Qi, LI/AAF-3389-2019				Beckwith RC, 1996, INORG CHEM, V35, P995, DOI 10.1021/ic950909w; Bierenstiel M, 2005, TETRAHEDRON, V61, P4911, DOI 10.1016/j.tet.2005.03.056; Garg A, 2010, J PHARMACEUT BIOMED, V53, P325, DOI 10.1016/j.jpba.2010.04.004; GOROMARU T, 1984, ANESTHESIOLOGY, V61, P73, DOI 10.1097/00000542-198461010-00013; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; JANSSEN PAJ, 1962, BRIT J ANAESTH, V34, P260, DOI 10.1093/bja/34.4.260; Khan KM, 2003, TETRAHEDRON, V59, P5549, DOI 10.1016/S0040-4020(03)00812-3; dos Santos MEL, 2013, WORLD J GASTROENTERO, V19, P3439, DOI 10.3748/wjg.v19.i22.3439; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; MASUDA H, 1994, J ORG CHEM, V59, P5550, DOI 10.1021/jo00098a012; Metsger L, 2000, TETRAHEDRON, V56, P1905, DOI 10.1016/S0040-4020(00)00098-3; Newshan G, 1998, J PAIN SYMPTOM MANAG, V16, P277; OHTA H, 1990, CHEM LETT, P733, DOI 10.1246/cl.1990.733; Qi LH, 2011, DEFENCE SCI J, V61, P30, DOI 10.14429/dsj.61.68; Raikos N, 2009, J SEP SCI, V32, P1018, DOI 10.1002/jssc.200800447; Sachs H, 1996, INT J LEGAL MED, V109, P213, DOI 10.1007/BF01225521; STANLEY TH, 1978, ANESTH ANALG, V57, P411; TAKASE K, 1995, CHEM LETT, P871, DOI 10.1246/cl.1995.871; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x	19	1	1	1	25	IWA PUBLISHING	LONDON	ALLIANCE HOUSE, 12 CAXTON ST, LONDON SW1H0QS, ENGLAND	0273-1223	1996-9732		WATER SCI TECHNOL	Water Sci. Technol.		2015	72	1					38	44		10.2166/wst.2015.185			7	Engineering, Environmental; Environmental Sciences; Water Resources	Engineering; Environmental Sciences & Ecology; Water Resources	CL7FH	WOS:000357137400005	26114269	Bronze			2020-06-30	J	Kao, SC; Lee, HC; Cheng, CW; Lin, CF; Tsai, H				Kao, Shengchin; Lee, Hungchen; Cheng, Chihwen; Lin, Chingfeng; Tsai, Hsini			Pain Control after Total Knee Arthroplasty: Comparing Intra-Articular Local Anesthetic Injection with Femoral Nerve Block	BIOMED RESEARCH INTERNATIONAL			English	Article							MORPHINE AND/OR BUPIVACAINE; INFILTRATION ANALGESIA; HIP; MANAGEMENT; EFFICACY; PROTOCOL; SURGERY; PLACEBO	Background. Direct intra-articular injection of low doses of local anesthetic (IALA) after closure of the joint capsule remains controversial for pain control after total knee arthroplasty (TKA). Methods. A retrospective study comparing patients receiving IALA with high doses (0.5% bupivacaine 60 mL) of local anesthetics or FNB in addition to intravenous patient-controlled analgesia with opioids for pain management after TKA was conducted. The primary end point was to compare the analgesic efficacy and early ambulation between the two groups. Results. No significant differences between the two groups in pain intensity, cumulative opioid consumption, incidences of opioid-related side effects, the time interval from the end of operation to the first time the patient could walk assisted with a walker postoperatively, and postoperative hospital stay were identified. Three patients in the IALA group but none in the FNB group walked within 12 hours after the end of operation. Summary. IALA with high doses of local anesthetics provides comparable analgesic efficacy as single-shot FNB after TKA and might be associated with earlier ambulation than FNB postoperatively.	[Kao, Shengchin; Cheng, Chihwen; Tsai, Hsini] Chang Gung Mem Hosp, Dept Anesthesiol, Taoyuan 333, Taiwan; [Lee, Hungchen; Lin, Chingfeng] Chang Gung Univ, Grad Inst Clin Med Sci, Taoyuan 333, Taiwan	Kao, SC (reprint author), Chang Gung Mem Hosp, Dept Anesthesiol, Taoyuan 333, Taiwan.	sckao1974@gmail.com			 [CLRPG3D0041]	The authors thank Tseng Hsiao-Jung, Biostatistical Center for Clinical Research, Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan (supported by Grant no. CLRPG3D0041), for statistical assistance.	Affas F, 2011, ACTA ORTHOP, V82, P441, DOI 10.3109/17453674.2011.581264; Andersen LO, 2014, BRIT J ANAESTH, V113, P360, DOI 10.1093/bja/aeu155; Badner NH, 1996, J BONE JOINT SURG AM, V78A, P734, DOI 10.2106/00004623-199605000-00013; Browne C, 2004, J ARTHROPLASTY, V19, P377, DOI 10.1016/j.arth.2003.10.012; Brydone A. S., 2015, ANAESTHESIA; Carli F, 2010, BRIT J ANAESTH, V105, P185, DOI 10.1093/bja/aeq112; Chan EY, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009941.pub2; Choi P. T., 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003071; Chung KC, 2014, PAIN MED, V15, P225, DOI 10.1111/pme.12299; Essving P, 2010, ACTA ORTHOP, V81, P354, DOI 10.3109/17453674.2010.487241; Fischer HBJ, 2008, ANAESTHESIA, V63, P1105, DOI 10.1111/j.1365-2044.2008.05565.x; Fowler SJ, 2008, BRIT J ANAESTH, V100, P154, DOI 10.1093/bja/aem373; Goyal N, 2013, CLIN ORTHOP RELAT R, V471, P64, DOI 10.1007/s11999-012-2596-9; Husted H, 2011, ACTA ORTHOP, V82, P679, DOI 10.3109/17453674.2011.636682; Ilfeld BM, 2010, ANESTH ANALG, V111, P1552, DOI 10.1213/ANE.0b013e3181fb9507; Kerr DR, 2008, ACTA ORTHOP, V79, P174, DOI 10.1080/17453670710014950; Mauerhan DR, 1997, J ARTHROPLASTY, V12, P546, DOI 10.1016/S0883-5403(97)90178-9; Parvataneni HK, 2007, J ARTHROPLASTY, V22, P33, DOI 10.1016/j.arth.2007.03.034; Ritter MA, 1999, J BONE JOINT SURG BR, V81B, P301, DOI 10.1302/0301-620X.81B2.9110; Rosen Adam S, 2010, HSS J, V6, P155, DOI 10.1007/s11420-010-9155-2; Ryu Junnosuke, 1993, Bulletin Hospital for Joint Diseases, V53, P35; Shaheen PE, 2009, J PAIN SYMPTOM MANAG, V38, P409, DOI 10.1016/j.jpainsymman.2009.06.004; Tanaka N, 2001, J ARTHROPLASTY, V16, P306, DOI 10.1054/arth.2001.21496; Toftdahl K, 2007, ACTA ORTHOP, V78, P172, DOI 10.1080/17453670710013645; Vendittoli PA, 2006, J BONE JOINT SURG AM, V88A, P282, DOI 10.2106/JBJS.E.00173; Wang H, 2002, REGION ANESTH PAIN M, V27, P139, DOI 10.1053/rapm.2002.29253	26	8	8	0	6	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2314-6133	2314-6141		BIOMED RES INT	Biomed Res. Int.		2015	2015								649140	10.1155/2015/649140			6	Biotechnology & Applied Microbiology; Medicine, Research & Experimental	Biotechnology & Applied Microbiology; Research & Experimental Medicine	CI3TN	WOS:000354670400001	26064937	DOAJ Gold, Green Published			2020-06-30	J	Uno, K; Nishizawa, D; Seo, S; Takayama, K; Matsumura, S; Sakai, N; Ohi, K; Nabeshima, T; Hashimoto, R; Ozaki, N; Hasegawa, J; Sato, N; Tanioka, F; Sugimura, H; Fukuda, KI; Higuchi, S; Ujike, H; Inada, T; Iwata, N; Sora, I; Iyo, M; Kondo, N; Won, MJ; Naruse, N; Uehara-Aoyama, K; Itokawa, M; Yamada, M; Ikeda, K; Miyamoto, Y; Nitta, A				Uno, K.; Nishizawa, D.; Seo, S.; Takayama, K.; Matsumura, S.; Sakai, N.; Ohi, K.; Nabeshima, T.; Hashimoto, R.; Ozaki, N.; Hasegawa, J.; Sato, N.; Tanioka, F.; Sugimura, H.; Fukuda, K. -I.; Higuchi, S.; Ujike, H.; Inada, T.; Iwata, N.; Sora, I.; Iyo, M.; Kondo, N.; Won, M. -J.; Naruse, N.; Uehara-Aoyama, K.; Itokawa, M.; Yamada, M.; Ikeda, K.; Miyamoto, Y.; Nitta, A.			The Piccolo Intronic Single Nucleotide Polymorphism rs13438494 Regulates Dopamine and Serotonin Uptake and Shows Associations with Dependence-Like Behavior in Genomic Association Study	CURRENT MOLECULAR MEDICINE			English	Article						Dependence-like behavior; dopamine; Piccolo; serotonin; single nucleotide polymorphism	GENE POLYMORPHISM; VNTR POLYMORPHISM; RECEPTOR GENE; DISORDERS; DISC1; ALPHA	Piccolo (PCLO) inhibits methamphetamine-induced neuropharmacological effects via modulation of dopamine (DA) uptake and regulation of the transport of synaptic vesicles in neuronal cells. Clinical studies have recently suggested that the single nucleotide polymorphism (SNP) rs13438494 in the intron 24 of the PCLO gene is associated with psychiatric disorder, in the meta-analysis of GWAS. Therefore, in this study, we attempted to evaluate the possible role of the PCLO SNP in the mechanisms of uptake of monoamines. To characterize rs13438494 in the PCLO gene, we constructed plasmids carrying either the C or A allele of the SNP and transiently transfected them into SH-SY5Y cells to analyze genetic effects on the splicing of PCLO mRNA. The C and A allele constructs produced different composition of the transcripts, indicating that the intronic SNP does affect the splicing pattern. We also transfected DA and serotonin (5-hydroxytryptamine; 5-HT) transporters into cells and analyzed their uptakes to elucidate the association to psychiatric disorders. In the cells transfected with the C allele, both the DA and 5-HT uptake were enhanced compared to the A allele. We also conducted a clinical study, in order to clarify the genetic associations. PCLO rs13438494 exhibits a relationship with the symptoms of drug dependence or related parameters, such as the age of first exposure to methamphetamine, eating disorders, tobacco dependence and fentanyl requirement. Our findings suggest that rs13438494 is associated with drug abuse and contributes to the pathogenesis of psychiatric disorders via modulation of neurotransmitter turnover.	[Uno, K.; Seo, S.; Takayama, K.; Matsumura, S.; Miyamoto, Y.; Nitta, A.] Toyama Univ, Fac Pharmaceut Sci, Dept Pharmaceut Therapy & Neuropharmacol, Toyama 9300194, Japan; [Nishizawa, D.; Hasegawa, J.; Sora, I.; Ikeda, K.] Tokyo Metropolitan Inst Med Sci, Addict Subst Project, Tokyo 113, Japan; [Seo, S.] Toyama Univ, Fac Pharmaceut Sci, Dept Pharmaceut Educ, Toyama 9300194, Japan; [Sakai, N.] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Mol & Pharmacol Neurosci, Hiroshima, Japan; [Ohi, K.; Hashimoto, R.] Osaka Univ, Grad Sch Med, Dept Psychiat, Osaka, Japan; [Nabeshima, T.] Meijo Univ, Dept Reg Pharmaceut Care & Sci, Nagoya, Aichi, Japan; [Hashimoto, R.] Osaka Univ, United Grad Sch Child Dev, Mol Res Ctr Childrens Mental Dev, Osaka, Japan; [Ozaki, N.] Nagoya Univ, Grad Sch Med, Dept Psychiat, Nagoya, Aichi 4648601, Japan; [Ozaki, N.; Ujike, H.; Inada, T.; Iwata, N.; Sora, I.; Iyo, M.; Kondo, N.; Won, M. -J.; Naruse, N.; Uehara-Aoyama, K.; Itokawa, M.; Yamada, M.; Ikeda, K.] Japanese Genet Initiat Drug Abuse, Hamamatsu, Shizuoka, Japan; [Sato, N.] Hamamatsu Univ, Sch Med, Dept Clin Nursing, Hamamatsu, Shizuoka, Japan; [Sato, N.; Sugimura, H.] Hamamatsu Univ, Sch Med, Dept Tumor Pathol, Hamamatsu, Shizuoka, Japan; [Tanioka, F.] Iwata City Hosp, Dept Pathol, Iwata, Japan; [Fukuda, K. -I.] Tokyo Dent Coll, Dept Dent Anesthesiol, Tokyo, Japan; [Higuchi, S.] Natl Hosp Org, Kurihama Med & Addict Ctr, Yokosuka, Kanagawa, Japan; [Ujike, H.] Ujike Nishiguchi Clin, Okayama, Japan; [Inada, T.] Seiwa Hosp, Inst Neuropsychiat, Dept Psychiat, Tokyo, Japan; [Iwata, N.] Fujita Hlth Univ, Sch Med, Dept Psychiat, Toyoake, Aichi 47011, Japan; [Sora, I.] Tohoku Univ, Grad Sch Med, Dept Psychobiol, Sendai, Miyagi 980, Japan; [Iyo, M.] Chiba Univ, Grad Sch Med, Dept Psychiat, Chiba, Japan; [Kondo, N.] Seimei Hosp, Fuji, Shizuoka, Japan; [Won, M. -J.] Koujin Hosp, Nagoya, Aichi, Japan; [Naruse, N.] Saitama Seishin Iryo Ctr, Saitama, Japan; [Uehara-Aoyama, K.] Serigaya Hosp, Kanagawa Psychiat Ctr, Yokohama, Kanagawa, Japan; [Itokawa, M.] Tokyo Metropolitan Inst Med Sci, Schizophrenia & Depress Project, Tokyo 113, Japan; [Yamada, M.] Natl Ctr Neurol & Psychiat, Dept Neuropsychopharmacol, Kodaira, Tokyo, Japan	Nitta, A (reprint author), Toyama Univ, Fac Pharmaceut Sci, Dept Pharmaceut Therapy & Neuropharmacol, 2630 Sugitani, Toyama 9300194, Japan.	nitta@pha.u-toyama.ac.jp	Ozaki, Norio/M-8908-2014; Hashimoto, Ryota/AAE-3200-2019; Yamada, Mitsuhiko/AAO-1107-2020; Ohi, Kazutaka/J-7851-2019; Nitta, Atsumi/AAF-4211-2019; Hashimoto, Ryota/P-8572-2014	Ozaki, Norio/0000-0002-7360-4898; Hashimoto, Ryota/0000-0002-5941-4238; Yamada, Mitsuhiko/0000-0002-5649-2310; Ohi, Kazutaka/0000-0001-9577-9640; Hashimoto, Ryota/0000-0002-5941-4238; Inada, Toshiya/0000-0002-8427-5639; IWATA, Nakao/0000-0003-3189-6076	Program for Next Generation World-Leading Researchers [LS047]; Japan Society for the Promotion of SciencMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; Ministry of Health, Labor and Welfare of JapanMinistry of Health, Labour and Welfare, Japan; Ministry of Education, Science, Sports, Culture and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); SRF Grant for Biomedical Research	We thank Jyunko Tsuda for technical assistance with the cell culture. This study was supported by a Program for Next Generation World-Leading Researchers (LS047); grants-in-aid for Scientific Research from Japan Society for the Promotion of Science; a grant-in-aid for Research on Regulatory Science of Pharmaceuticals, Health and Labour Science; Research Grants from the Ministry of Health, Labor and Welfare of Japan; a grant-in-aid for Scientific Research in Innovative Areas (Comprehensive Brain Science Network) from the Ministry of Education, Science, Sports, Culture and Technology of Japan; and a SRF Grant for Biomedical Research.	Becker S, 2012, NEUROSCI LETT, V520, P182, DOI 10.1016/j.neulet.2012.03.013; Cen X, 2008, MOL PSYCHIATR, V13, P451, DOI 10.1038/sj.mp.4002132; Choi KH, 2011, BIOL PSYCHIAT, V69, P353, DOI 10.1016/j.biopsych.2010.09.042; Craddock N, 2006, MOL PSYCHIATR, V11, P446, DOI 10.1038/sj.mp.4001808; Dick O, 2001, J COMP NEUROL, V439, P224, DOI 10.1002/cne.1344; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; GARNER DM, 1982, PSYCHOL MED, V12, P871, DOI 10.1017/S0033291700049163; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; Ibi D, 2010, NEUROCHEM INT, V56, P77, DOI 10.1016/j.neuint.2009.09.004; Illi A, 2010, PSYCHIAT RES, V176, P85, DOI 10.1016/j.psychres.2009.03.010; Kawakami N, 1999, ADDICT BEHAV, V24, P155, DOI 10.1016/S0306-4603(98)00127-0; Kishi T, 2011, CURR NEUROPHARMACOL, V9, P133, DOI 10.2174/157015911795016994; Kishi T, 2011, CURR NEUROPHARMACOL, V9, P129, DOI 10.2174/157015911795017065; Lin SH, 2012, EUR NEUROPSYCHOPHARM, V22, P647, DOI 10.1016/j.euroneuro.2012.01.002; Matsui A, 2011, J NEUROSCI, V31, P17729, DOI 10.1523/JNEUROSCI.4570-11.2011; Matsushita S, 2002, MOL PSYCHIATR, V7, P538, DOI 10.1038/sj.mp.4001028; Melikian HE, 1999, J NEUROSCI, V19, P7699; Miyasaka K, 2006, J NEURAL TRANSM, V113, P1279, DOI 10.1007/s00702-005-0393-2; Nishizawa D, 2014, MOL PSYCHIATR, V19, P55, DOI 10.1038/mp.2012.164; Niwa M, 2008, J NEUROCHEM, V107, P1697, DOI 10.1111/j.1471-4159.2008.05738.x; Palo OM, 2007, HUM MOL GENET, V16, P2517, DOI 10.1093/hmg/ddm207; Pedersen NP, 2011, J NEUROPHYSIOL, V106, P731, DOI 10.1152/jn.01062.2010; Sears C, 2011, BIPOLAR DISORD, V13, P630, DOI 10.1111/j.1399-5618.2011.00955.x; Seo S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076960; Shinohara M, 2004, J PSYCHIATR NEUROSCI, V29, P134; Stapleton JA, 2007, ADDICT BIOL, V12, P221, DOI 10.1111/j.1369-1600.2007.00058.x; Ujike H, 2003, PHARMACOGENOMICS J, V3, P242, DOI 10.1038/sj.tpj.6500189; Ujike H, 2011, CURR NEUROPHARMACOL, V9, P163, DOI 10.2174/157015911795017137; Ujike Hiroshi, 2004, Nihon Shinkei Seishin Yakurigaku Zasshi, V24, P299; Wang Z, 2012, GENES BRAIN BEHAV, V11, P524, DOI 10.1111/j.1601-183X.2012.00797.x; Yammamoto H, 2013, J PHARMACOL SCI, V121, P25, DOI 10.1254/jphs.12229FP; Zhang F, 2006, AM J MED GENET B, V141B, P155, DOI 10.1002/ajmg.b.30274	32	4	4	0	7	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1566-5240	1875-5666		CURR MOL MED	Curr. Mol. Med.		2015	15	3					265	274		10.2174/1566524015666150330145722			10	Medicine, Research & Experimental	Research & Experimental Medicine	CH3HM	WOS:000353920400008	25817861				2020-06-30	J	Rorick-Kehn, LM; Witcher, JW; Lowe, SL; Gonzales, CR; Weller, MA; Bell, RL; Hart, JC; Need, AB; McKinzie, JH; Statnick, MA; Suico, JG; McKinzie, DL; Tauscher-Wisniewski, S; Mitch, CH; Stoltz, RR; Wong, CJ				Rorick-Kehn, Linda M.; Witcher, Jennifer W.; Lowe, Stephen L.; Gonzales, Celedon R.; Weller, Mary Ann; Bell, Robert L.; Hart, John C.; Need, Anne B.; McKinzie, Jamie H.; Statnick, Michael A.; Suico, Jeffrey G.; McKinzie, David L.; Tauscher-Wisniewski, Sitra; Mitch, Charles H.; Stoltz, Randall R.; Wong, Conrad J.			Determining Pharmacological Selectivity of the Kappa Opioid Receptor Antagonist LY2456302 Using Pupillometry as a Translational Biomarker in Rat and Human	INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY			English	Article						translational biomarker; pupillometry; kappa opioid receptor; dynorphin; LY2456302	IN-VIVO; OCULAR HYDRODYNAMICS; NALTREXONE; MODULATION; DYNORPHIN; DISCOVERY; TRAMADOL; MORPHINE; AGONIST; BINDING	Background: Selective kappa opioid receptor antagonism is a promising experimental strategy for the treatment of depression. The kappa opioid receptor antagonist, LY2456302, exhibits similar to 30-fold higher affinity for kappa opioid receptors over mu opioid receptors, which is the next closest identified pharmacology. Methods: Here, we determined kappa opioid receptor pharmacological selectivity of LY2456302 by assessing mu opioid receptor antagonism using translational pupillometry in rats and humans. Results: In rats, morphine-induced mydriasis was completely blocked by the nonselective opioid receptor antagonist naloxone (3 mg/kg, which produced 90% mu opioid receptor occupancy), while 100 and 300 mg/kg LY2456302 (which produced 56% and 87% mu opioid receptor occupancy, respectively) only partially blocked morphine-induced mydriasis. In humans, fentanyl-induced miosis was completely blocked by 50 mg naltrexone, and LY2456302 dose-dependently blocked miosis at 25 and 60 mg (minimal-to-no blockade at 4-10 mg). Conclusions: We demonstrate, for the first time, the use of translational pupillometry in the context of receptor occupancy to identify a clinical dose of LY2456302 achieving maximal kappa opioid receptor occupancy without evidence of significant mu receptor antagonism.	[Rorick-Kehn, Linda M.; Witcher, Jennifer W.; Lowe, Stephen L.; Gonzales, Celedon R.; Bell, Robert L.; Hart, John C.; Need, Anne B.; McKinzie, Jamie H.; Statnick, Michael A.; Suico, Jeffrey G.; McKinzie, David L.; Tauscher-Wisniewski, Sitra; Mitch, Charles H.; Wong, Conrad J.] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA; [Weller, Mary Ann] inVentiv Hlth Clin, Ann Arbor, MI USA; [Stoltz, Randall R.] Covance Clin Res Unit Inc, Evansville, IN USA	Rorick-Kehn, LM (reprint author), Lilly Corp Ctr, Lilly Res Labs, DC0510, Indianapolis, IN 46285 USA.	rorickkehnlm@lilly.com			Eli Lilly and Company, Indianapolis, INEli Lilly	Studies were sponsored and funded by Eli Lilly and Company, Indianapolis, IN. Portions of this manuscript were written by MaryAnn Weller, a technical writer employed by inVentiv Health Clinical and co-author of the paper. All other authors declare responsibility for the scientific content of the manuscript.	Berton O, 2006, NAT REV NEUROSCI, V7, P137, DOI 10.1038/nrn1846; Carr GV, 2011, PSYCHOPHARMACOLOGY, V213, P265, DOI [10.1007/s00213-010-1832-9, 10.1007/s00213-010-2097-z]; Diaz Buezo N., 2009, US Patent, Patent No. [US20090186873, 20090186873]; Divin MF, 2009, BRIT J PHARMACOL, V156, P1044, DOI 10.1111/j.1476-5381.2008.00035.x; Greenwald MK, 1996, J PHARMACOL EXP THER, V277, P1228; Harrison C, 2013, NAT REV DRUG DISCOV, V12, P415, DOI 10.1038/nrd4028; Insel TR, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004873; Jones HE, 2000, DRUG ALCOHOL DEPEN, V60, P29, DOI 10.1016/S0376-8716(99)00138-6; KLEMFUSS H, 1979, J PHARMACOL EXP THER, V208, P91; Knaggs RD, 2004, ANESTH ANALG, V99, P108, DOI 10.1213/01.ANE.0000116924.16535.BA; Knoll AT, 2010, BRAIN RES, V1314, P56, DOI 10.1016/j.brainres.2009.09.074; Lotsch JR, 2005, J PAIN SYMPTOM MANAG, V29, pS90, DOI 10.1016/j.jpainsymman.2005.01.012; Lowe SL, 2014, J CLIN PHARMACOL, V54, P968, DOI 10.1002/jcph.286; MANSOUR A, 1994, J COMP NEUROL, V350, P412, DOI 10.1002/cne.903500307; Margolis EB, 2003, J NEUROSCI, V23, P9981; Matouskova O, 2011, J CLIN PHARM THER, V36, P513, DOI 10.1111/j.1365-2710.2010.01203.x; Melichar JK, 2003, EUR J PHARMACOL, V459, P217, DOI 10.1016/S0014-2999(02)02872-8; MENDELSON JH, 1978, PSYCHONEUROENDOCRINO, V3, P231, DOI 10.1016/0306-4530(78)90013-6; Mitch CH, 2011, J MED CHEM, V54, P8000, DOI 10.1021/jm200789r; Need AB, 2007, LIFE SCI, V81, P1389, DOI 10.1016/j.lfs.2007.09.005; PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896; Rasmussen CA, 2007, T AM OPHTHAL SOC, V105, P238; Rasmussen Carol A, 2007, Trans Am Ophthalmol Soc, V105, P225; Rorick-Kehn LM, 2014, NEUROPHARMACOLOGY, V77, P131, DOI 10.1016/j.neuropharm.2013.09.021; Russell KRM, 2000, EXP EYE RES, V70, P675, DOI 10.1006/exer.2000.0832; Russell KRM, 2002, EXP EYE RES, V75, P259, DOI 10.1006/exer.2002.2024; SPANAGEL R, 1992, P NATL ACAD SCI USA, V89, P2046, DOI 10.1073/pnas.89.6.2046; Szekeres PG, 1997, J PHARMACOL EXP THER, V283, P1276; Tauscher J, 2012, 4 DEC 2012 ANN M AM, P253; Tomasi G, 2013, J NUCL MED, V54, P600, DOI 10.2967/jnumed.112.112672; VACCARINO AL, 1988, NEUROSCI LETT, V84, P103, DOI 10.1016/0304-3940(88)90345-X; Wadenberg MLG, 2000, PSYCHOPHARMACOLOGY, V150, P422, DOI 10.1007/s002130000466; WEINHOLD LL, 1993, DRUG ALCOHOL DEPEN, V31, P177, DOI 10.1016/0376-8716(93)90070-7; WEST TEG, 1988, BRAIN RES, V462, P126, DOI 10.1016/0006-8993(88)90594-X	34	10	10	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1461-1457	1469-5111		INT J NEUROPSYCHOPH	Int. J. Neuropsychopharmacol.	JAN	2015	18	2								10.1093/ijnp/pyu036			11	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	CF4OS	WOS:000352530300014	25637376	DOAJ Gold, Green Published			2020-06-30	J	Craig, MG; Grant, EN; Tao, WK; McIntire, DD; Leveno, KJ				Craig, Margaret G.; Grant, Erica N.; Tao, Weike; McIntire, Donald D.; Leveno, Kenneth J.			A Randomized Control Trial of Bupivacaine and Fentanyl versus Fentanyl-only for Epidural Analgesia during the Second Stage of Labor	ANESTHESIOLOGY			English	Article							CESAREAN DELIVERY; INTRAVENOUS MEPERIDINE; ANESTHESIA; PAIN	Background: The purpose of this prospective, double-blinded, parallel-arm, randomized trial was to examine the effects of epidural bupivacaine on the length of the second stage of labor in nulliparous women. Methods: The authors assessed length of second-stage labor, degree of motor blockade, mode of delivery, and visual analog scores in 310 nulliparous women with labor epidurals randomized to receive either: (1) 0.125% bupivacaine and fentanyl 2 g/ml or (2) fentanyl 10 g/ml alone via epidural using double blinding. Results: The median duration of the second stage was 75 min (41, 128) in the bupivacaine/fentanyl group versus 73 min (42, 120) in the fentanyl-only group (P = 0.17) with a median difference of 6.0 (95% CI, -6.0 to 18.0). Furthermore, there was no difference in degree of motor blockade, incidence of operative delivery, visual analog scores, or neonatal outcomes between the two groups. No adverse events were reported. Conclusions: Use of epidural bupivacaine/fentanyl or a fentanyl-only infusion during the second stage of labor did not affect the duration of the second stage of labor, degree of motor blockade, mode of delivery, pain relief, and maternal or neonatal outcomes. However, in the fentanyl-only infusion group, there was a fivefold increase in opioid exposure to the fetus with unknown effects on neurobehavior, an outcome not assessed beyond the immediate postnatal period in this study.	[Craig, Margaret G.; Grant, Erica N.; Tao, Weike] Univ Texas SW Med Ctr Dallas, Dept Anesthesiol & Pain Management, Dallas, TX 75390 USA; [McIntire, Donald D.; Leveno, Kenneth J.] Univ Texas SW Med Ctr Dallas, Dept Obstet & Gynecol, Dallas, TX 75390 USA	Grant, EN (reprint author), Univ Texas SW Med Ctr Dallas, Dept Anesthesiol & Pain Management, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	erica.grant@utsouthwestern.edu			Center for Translational Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas; National Institutes of Health/National Center for Advancing Translational Sciences, Bethesda, Maryland [KL2TR000453]	Dr. Grant's contribution to this work was conducted with support from the Center for Translational Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas, and the National Institutes of Health/National Center for Advancing Translational Sciences, Bethesda, Maryland (grant no. KL2TR000453). The University of Texas Southwestern IRB number and approval date: 052009-049 and November 12, 2009.	Abenhaim HA, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2007.11.061; Alexander JM, 2002, OBSTET GYNECOL, V100, P46, DOI 10.1016/S0029-7844(02)02009-4; Alexander JM, 2001, ANESTH ANALG, V92, P1524; Anim-Somuah M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000331.pub3; BREEN TW, 1993, ANESTH ANALG, V77, P919; CHESTNUT DH, 1987, ANESTHESIOLOGY, V66, P774, DOI 10.1097/00000542-198706000-00011; CHESTNUT DH, 1990, ANESTHESIOLOGY, V72, P613, DOI 10.1097/00000542-199004000-00006; Cunningham F, 2010, WILLIAMS OBSTET, P374; Gambling DR, 1998, ANESTHESIOLOGY, V89, P1336, DOI 10.1097/00000542-199812000-00010; Lieberman E, 2002, AM J OBSTET GYNECOL, V186, pS31, DOI 10.1067/mob.2002.122522; Lindow SW, 2004, BJOG-INT J OBSTET GY, V111, P1075, DOI 10.1111/j.1471-0528.2004.00267.x; MacArthur C, 2001, LANCET, V358, P19; Moises ECD, 2005, EUR J CLIN PHARMACOL, V61, P517, DOI 10.1007/s00228-005-0967-9; Osterman Michelle J K, 2011, Natl Vital Stat Rep, V59, P1; RAMIN SM, 1995, OBSTET GYNECOL, V86, P783, DOI 10.1016/0029-7844(95)00269-W; Sharma SK, 2004, ANESTHESIOLOGY, V100, P142, DOI 10.1097/00000542-200401000-00023; Sharma SK, 2002, ANESTHESIOLOGY, V96, P546, DOI 10.1097/00000542-200203000-00007; Sharma SK, 1997, ANESTHESIOLOGY, V87, P487, DOI 10.1097/00000542-199709000-00006; Torvaldsen S, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004457.PUB2	19	8	10	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	JAN	2015	122	1					172	177		10.1097/ALN.0000000000000454			6	Anesthesiology	Anesthesiology	CE3OT	WOS:000351737100024	25254902				2020-06-30	J	Parate, LH; Manjrekar, SP; Anandaswamy, TC; Manjunath, B				Parate, L. H.; Manjrekar, S. P.; Anandaswamy, T. C.; Manjunath, B.			The effect of addition of low dose fentanyl to epidural bupivacaine (0.5%) in patients undergoing elective caesarean section: A randomized, parallel group, double blind, placebo controlled study	JOURNAL OF POSTGRADUATE MEDICINE			English	Article						Elective caesarean section; epidural 0.5% bupivacaine; fentanyl	VISCERAL PAIN; ANALGESIA; ANESTHESIA; BLOCK; ROPIVACAINE; SURGERY; LABOR; ONSET	Background: Opioids have synergistic action with local anesthetics which may alter characteristics of epidural block. Giving opioids to mother before delivery of baby is still fully not accepted with some fearing risk of neonatal depression. Aims: Our primary aim was to evaluate the analgesic effect of addition of 50 mu g fentanyl to epidural 0.5% bupivacaine in patients undergoing elective caesarean section using visual analog scale. The secondary aim was to assess onset of analgesia, volume of drug required to achieve T6 level, grade and duration of motor block and Apgar score. Materials and Methods: In this prospective, randomized, double blind, placebo controlled study 64 patients scheduled for elective caesarean section under epidural anesthesia were randomly divided into two groups of 32 each. The fentanyl group received 1ml of 50 mu g fentanyl and the saline group received 1ml of normal saline mixed with 10ml of 0.5% bupivacaine for epidural anesthesia. VAS score, time to achieve T6 level, dose of bupivacaine, intraoperative analgesic consumption and duration of analgesia, grade and duration of motor block and any adverse maternal and neonatal effects were noted. Statistical Analysis: Data was analyzed using Students t test, chi-square test and Mann-Whitney U-test. The values of P < 0.05 were considered statistically significant. Results: Fentanyl improved the VAS score significantly (1.6 +/- 1.32) compared to the saline group (3.77 +/- 1.0, P < 0.0001). It also reduced the intraoperaitve analgesic supplementation compared to the saline group. (P = 0.031). The postoperative duration of analgesia was prolonged in the fentanyl group (275.80 +/- 13.61 min) compared to the saline group (191.47 +/- 12.16 min, P < 0.0001). The other characteristics of epidural block were unaltered. Conclusion: Addition of 50 mu g fentanyl to epidural 0.5% bupivacaine significantly reduces the VAS score. It also reduces intra-operative analgesia supplementation and prolongs the duration of postoperative analgesia without altering the other characteristics of block. The neonatal outcome is not affected with addition of fentanyl before delivery of baby.	[Parate, L. H.; Anandaswamy, T. C.] MS Ramaiah Med Coll, Dept Anaesthesia, Bangalore, Karnataka, India; [Manjrekar, S. P.] Indira Gandhi Med Coll, Dept Anaesthesia, Nagpur, Maharashtra, India; [Manjunath, B.] MS Ramaiah Med Coll, Dept Community Med, Bangalore, Karnataka, India	Parate, LH (reprint author), MS Ramaiah Med Coll, Dept Anaesthesia, Bangalore, Karnataka, India.	dr_leenag@yahoo.co.in		, Tejesh/0000-0002-0553-5405			ALAHUHTA S, 1990, ACTA ANAESTH SCAND, V34, P95, DOI 10.1111/j.1399-6576.1990.tb03050.x; Bauer M, 2012, ANESTHESIOL RES PRAC, V2012, DOI 10.1155/2012/309219; Behera BK, 2008, J POSTGRAD MED, V54, P86; Bogra J, 2005, BMC ANESTHESIOL, V5, P5, DOI DOI 10.1186/1471-2253-5-5; Bromage PR, 1978, EPIDURAL ANALGESIA, P144; Cherng CH, 2005, ANESTH ANALG, V101, P1834, DOI 10.1213/01.ANE.0000184131.06529.35; Cherng CH, 2001, REGION ANESTH PAIN M, V26, P523, DOI 10.1053/rapm.2001.27852; Ginosar Y, 2003, ANESTH ANALG, V97, P1439, DOI 10.1213/01.ANE.0000081792.84877.A2; Guilfoyle MR, 2012, SPINE J, V12, P646, DOI 10.1016/j.spinee.2012.07.007; Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543; Hillyard SG, 2011, BRIT J ANAESTH, V107, P668, DOI 10.1093/bja/aer300; HIRABAYASHI Y, 1995, BRIT J ANAESTH, V75, P266, DOI 10.1093/bja/75.3.266; Hong JY, 2010, J KOREAN MED SCI, V25, P287, DOI 10.3346/jkms.2010.25.2.287; Jagatia K, 2013, INT J MED SCI PUBLIC, V2, P707; Kasaba T, 1996, CAN J ANAESTH, V43, P1211, DOI 10.1007/BF03013426; KING MJ, 1990, ANAESTHESIA, V45, P285, DOI 10.1111/j.1365-2044.1990.tb14733.x; Kumar Manoj, 2003, J Perinatol, V23, P425; McGlade DP, 1997, ANAESTH INTENS CARE, V25, P262, DOI 10.1177/0310057X9702500310; Ngan Kee WD, 2014, ANESTHESIOLOGY, V120, P1126, DOI 10.1097/ALN.0000000000000118; Rastogi Bhawna, 2013, Saudi J Anaesth, V7, P142, DOI 10.4103/1658-354X.114058; Russell IF, 2004, INT J OBSTET ANESTH, V13, P146, DOI 10.1016/j.ijoa.2003.12.007; Sadurni M, 2010, EUR J ANAESTH, V27, P131, DOI 10.1097/00003643-201006121-00422; Sadurni M, 2013, ACTA ANAESTH SCAND, V57, P1103, DOI 10.1111/aas.12118; Shapiro A, 1998, INT J OBSTET ANESTH, V7, P23, DOI 10.1016/S0959-289X(98)80024-1; Wee MYK, 2005, INT J OBSTET ANESTH, V14, P147, DOI 10.1016/j.ijoa.2004.09.008	25	0	0	0	4	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0022-3859			J POSTGRAD MED	J. Postgrad. Med.	JAN-MAR	2015	61	1					27	31		10.4103/0022-3859.147032			5	Medicine, General & Internal	General & Internal Medicine	CE3PL	WOS:000351740000006	25511214	DOAJ Gold, Green Published			2020-06-30	J	Takigawa, C; Goto, F; Tanda, S; Shima, Y; Yomiya, K; Matoba, M; Adachi, I; Yoshimoto, T; Eguchi, K				Takigawa, Chizuko; Goto, Fumio; Tanda, Shigeru; Shima, Yasuo; Yomiya, Kinomi; Matoba, Motohiro; Adachi, Isamu; Yoshimoto, Tetsusuke; Eguchi, Kenji			Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese cancer patients with detailed evaluation	JAPANESE JOURNAL OF CLINICAL ONCOLOGY			English	Article						fentanyl buccal tablet; breakthrough pain; cancer pain; rapid-onset opioids; pain management	TOLERANT PATIENTS; DOUBLE-BLIND; LONG-TERM; RECOMMENDATIONS; TOLERABILITY; CITRATE; EAPC	Objective: Rapid analgesic onset opioids, particularly fentanyl buccal tablet, is preferable for managing breakthrough pain. The efficacy and safety of fentanyl buccal tablet and its association with around-the-clock opioids needs to be explored with an option of dose adjustments, more closely reflecting administration in clinical practice. The aim of the study was to assess the safety and efficacy of fentanyl buccal tablet in breakthrough pain management in combination with around-the-clock opioids with the dose adjustment option, and explore the dose adjustment's influence on breakthrough pain management using detailed evaluation. Methods: The 12-week open-label, multi-center study was conducted throughout Japan. Cancer patients aged 20 years or older, experiencing persistent pain controlled with around-the-clock opioids and breakthrough pain with supplemental medications were enrolled. Fentanyl buccal tablet and around-the-clock opioid doses could be adjusted under protocol-specified conditions. Efficacy variables were assessed at each fentanyl buccal tablet administration. Safety was assessed mainly by adverse events. Results: All efficacy variables showed sustained analgesic effect. Nearly half the patients stayed on the same dose; most fentanyl buccal tablet administrations did not require additional supplemental medications. Dose increase of fentanyl buccal tablet and around-the-clock opioids seemed to improve breakthrough pain intensity and frequency, respectively. Fentanyl buccal tablet and around-the-clock opioid doses were not strongly associated. Treatment-related adverse events were all common with opioid treatment and did not increase over time. Conclusions: Fentanyl buccal tablet can stably and safely manage breakthrough pain in cancer patients with independent dose adjustment based on detailed evaluation of each patient's condition. Breakthrough pain management using fentanyl buccal tablet with around-the-clock opioids at optimal doses may be an important factor in palliative care for cancer patients with breakthrough pain.	[Takigawa, Chizuko] KKR Sapporo Med Ctr, Dept Palliat Med, Sapporo, Hokkaido 0620931, Japan; [Goto, Fumio] Int Univ Hlth & Welf Hosp, Nasushiobara, Japan; [Tanda, Shigeru] Tohoku Rosai Hosp, Dept Med Oncol, Sendai, Miyagi, Japan; [Shima, Yasuo] Tsukuba Med Ctr Hosp, Dept Palliat Med, Tsukuba, Ibaraki, Japan; [Yomiya, Kinomi] Saitama Canc Ctr, Dept Palliat Care, Saitama, Japan; [Matoba, Motohiro] Aomori Prefectural Cent Hosp, Dept Palliat Med, Aomori, Japan; [Adachi, Isamu] Shizuoka Canc Ctr, Div Palliat Med, Shizuoka, Japan; [Yoshimoto, Tetsusuke] Chukyo Hosp, Dept Palliat & Support Care, Nagoya, Aichi, Japan; [Eguchi, Kenji] Teikyo Univ, Sch Med, Dept Internal Med & Med Oncol, Itabashi Ku, Tokyo, Japan	Takigawa, C (reprint author), KKR Sapporo Med Ctr, Dept Palliat Med, Toyohira Ku, Hiragishi 1-6, Sapporo, Hokkaido 0620931, Japan.	chizuko-takigawa@kkr-smc.com			Taiho Pharmaceuticals, Co., Ltd., Tokyo, Japan; Taiho Pharmaceuticals, Co., Ltd, Tokyo, Japan	This clinical research was supported by Taiho Pharmaceuticals, Co., Ltd., Tokyo, Japan. Funding to pay the Open Access publication charges for this article was provided by Taiho Pharmaceuticals, Co., Ltd, Tokyo, Japan.	Ashburn MA, 2011, ANESTH ANALG, V112, P693, DOI 10.1213/ANE.0b013e318209d320; BENNETT D, 2005, [No title captured], V30, P354; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Davies A, 2013, J PAIN SYMPTOM MANAG, V46, P619, DOI 10.1016/j.jpainsymman.2012.12.009; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Fine PG, 2010, J PAIN SYMPTOM MANAG, V40, P747, DOI 10.1016/j.jpainsymman.2010.02.009; Foley KM, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P981; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; Kosugi T, 2014, J PAIN SYMPTOM MANAG, V47, P990, DOI 10.1016/j.jpainsymman.2013.07.006; Mercadante S, 1998, CANCER TREAT REV, V24, P425, DOI 10.1016/S0305-7372(98)90005-6; Nalamachu S, 2011, CURR MED RES OPIN, V27, P519, DOI 10.1185/03007995.2010.545380; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy Russell K, 2010, J Opioid Manag, V6, P109; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Slatkin Neal E, 2007, J Support Oncol, V5, P327; TWYCROSS RG, 1982, PAIN, V14, P303, DOI 10.1016/0304-3959(82)90137-3; Uberall MA, 2011, CURR MED RES OPIN, V27, P1385, DOI 10.1185/03007995.2011.583231; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279	24	3	4	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0368-2811	1465-3621		JPN J CLIN ONCOL	Jpn. J. Clin. Oncol.	JAN	2015	45	1					67	74		10.1093/jjco/hyu167			8	Oncology	Oncology	CC3DE	WOS:000350224200011	25381384	Bronze, Green Published			2020-06-30	J	Prathanvanich, P; Chand, B				Prathanvanich, Pornthep; Chand, Bipan			The role of capnography during upper endoscopy in morbidly obese patients: a prospective study	SURGERY FOR OBESITY AND RELATED DISEASES			English	Article						Obesity; Bariatric; Anesthesia; GI Endoscopy; CO2; Capnography; Complications		Background: Pulmonary depression remains a major concern when performing upper endoscopy in the morbidly obese patient. The aim of this prospective study is to determine the effects of sedation and role of capnography during preoperative upper endoscopy in obese patients. Methods: Eighty-two consecutive diagnostic upper gastrointestinal endoscopies were performed in morbidly obese patients in an outpatient setting. Data on amount of drug administration and cardiorespiratory change were recorded. Results: Mean body mass index and duration of procedure was 46.4 +/- 8.2 kg/m(2) and 9.4 +/- 2.5 minutes, respectively. The mean dose of propofol was 139.5 +/- 45.1 mg. No clinically significant cardiorespiratory complications occurred. Respiratory depression (RD) was seen in 33/82 (40.2%) patients and included a mean absolute change in end-tidal carbon dioxide (EtCO2) of 7.1 +/- 8.5 mm Hg from baseline (P = .001). 54/82 (65.9%) patients had subclinical RD with 27/54 (50%) having RD. Abnormal EtCO2 detected all episodes of RD. The sensitivity and negative predictive value in determining RD by a change in EtCO2 > 10 mm Hg or an absent EtCO2 waveform during any point of the procedure was 81% and 78%, respectively. The relative risk was 2.3. Conclusion: Capnography provided a real time assessment of changes in ventilation and can detect early phases of respiratory depression. Utilization of propofol as a means for sedation, with extended advanced monitoring technique, can allow for reduced adverse outcomes in morbidly obese patients undergoing upper endoscopy. (C) 2015 American Society for Metabolic and Bariatric Surgery. All rights reserved.	[Prathanvanich, Pornthep; Chand, Bipan] Loyola Univ Chicago, Stritch Sch Med, Dept Surg, Div GI Minimally Invas Surg, Maywood, IL 60153 USA	Chand, B (reprint author), Loyola Univ Chicago, Stritch Sch Med, Dept Surg, 2160 S First Ave, Maywood, IL 60153 USA.	bchand@LUMC.edu		PRATHANVANICH, PORNTHEP/0000-0003-3442-1017			Beitz A, 2012, AM J GASTROENTEROL, V107, P1205, DOI 10.1038/ajg.2012.136; Frey WC, 2003, OBES SURG, V13, P676, DOI 10.1381/096089203322509228; Lichtenstein DR, 2008, GASTROINTEST ENDOSC, V68, P815, DOI 10.1016/j.gie.2008.09.029; Qadeer MA, 2009, DIGEST DIS SCI, V54, P1035, DOI 10.1007/s10620-008-0452-2; Radaelli Franco, 2004, Gastrointest Endosc Clin N Am, V14, P335, DOI 10.1016/j.giec.2004.01.008	6	1	1	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1550-7289	1878-7533		SURG OBES RELAT DIS	Surg. Obes. Relat. Dis.	JAN-FEB	2015	11	1					193	200		10.1016/j.soard.2014.05.018			8	Surgery	Surgery	CC7FY	WOS:000350534300032	25264331				2020-06-30	J	Mercadante, S				Mercadante, Sebastiano			Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain	EXPERT REVIEW OF CLINICAL PHARMACOLOGY			English	Article						breakthrough cancer pain; cancer pain; fentanyl buccal tablet; opioids	OPIOID-TOLERANT PATIENTS; IMMEDIATE-RELEASE OXYCODONE; OPEN-LABEL; INTRAVENOUS MORPHINE; DOUBLE-BLIND; MU-G; MANAGEMENT; SAFETY; PHARMACOKINETICS; BIOAVAILABILITY	Fentanyl buccal tablet (FBT) (FENTORA) is indicated for the management of breakthrough pain (BTP) in patients with cancer pain and who are tolerant to >= 60 mg of oral morphine equivalents, at least with the current availability of the minimal strength of 100 mg. FBT uses the OraVescent technology to further increase the rate and extent of absorption of fentanyl. Short-term, randomized, controlled, clinical studies of FBT in patients with cancer pain have shown the efficacy of FBT in the management of breakthrough cancer pain. The efficacy was also confirmed in long-term studies on the safety and tolerability of FBT. It has been recommended that administration should be tailored to the patient's individual requirement, through dose titration starting from the lowest dose to find the effective dose. However, recent studies have demonstrated that predictable doses calculated from the basal opioid regimen are safe and more effective than doses achieved after dose titration.	[Mercadante, Sebastiano] La Maddalena Canc Ctr, Pain Relief & Support Care Unit, I-90146 Palermo, Italy; [Mercadante, Sebastiano] Univ Palermo, Dept Anesthesia & Intens Care, Palermo, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Pain Relief & Support Care Unit, Via San Lorenzo 312, I-90146 Palermo, Italy.	terapiadeldolore@lamaddalenanet.it					Ashburn MA, 2011, ANESTH ANALG, V112, P693, DOI 10.1213/ANE.0b013e318209d320; Blick SKA, 2006, DRUGS, V66, P2387, DOI 10.2165/00003495-200666180-00013; Darwish M, 2007, EXPERT OPIN PHARMACO, V8, P2011, DOI 10.1517/14656566.8.13.2011; Darwish M, 2006, CLIN THER, V28, P715, DOI 10.1016/j.clinthera.2006.05.016; Darwish M, 2008, CLIN DRUG INVEST, V28, P1, DOI 10.2165/00044011-200828010-00001; Darwish M, 2007, CLIN DRUG INVEST, V27, P605, DOI 10.2165/00044011-200727090-00002; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Darwish M, 2007, J CLIN PHARMACOL, V47, P56, DOI 10.1177/0091270006294129; Davies AN, 2008, J PAIN SYMPTOM MANAG, V35, P406, DOI 10.1016/j.jpainsymman.2007.05.010; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Haugen DF, 2010, PAIN, V149, P476, DOI 10.1016/j.pain.2010.02.035; Kleeberg UR, 2011, PAIN PRACT, V11, P185, DOI 10.1111/j.1533-2500.2010.00414.x; Kosugi T, 2014, J PAIN SYMPTOM MANAG, V47, P990, DOI 10.1016/j.jpainsymman.2013.07.006; Mercadante S, 2004, J PAIN, V5, P2, DOI 10.1016/j.jpain.2003.09.007; Mercadante S, 2008, J PAIN SYMPTOM MANAG, V35, P307, DOI 10.1016/j.jpainsymman.2007.04.018; Mercadante S, 2013, SUPPORT CARE CANCER, V21, P2335, DOI 10.1007/s00520-013-1799-2; Mercadante S, 2013, CURR MED RES OPIN, V29, P667, DOI 10.1185/03007995.2013.792247; Mercadante S, 2012, CURR MED RES OPIN, V28, P963, DOI 10.1185/03007995.2012.683112; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; Mercadante S, 2011, CRIT REV ONCOL HEMAT, V80, P460, DOI 10.1016/j.critrevonc.2010.12.002; Mercadante S, 2011, J PAIN SYMPTOM MANAG, V42, P464, DOI 10.1016/j.jpainsymman.2010.12.010; Mercadante S, 2010, LANCET ONCOL, V11, P484, DOI 10.1016/S1470-2045(09)70350-X; Mercadante S, 2009, EUR J PAIN, V13, P329, DOI 10.1016/j.ejpain.2008.11.021; Osborne V, 2014, EUR J PAIN, V18, P506, DOI 10.1002/j.1532-2149.2013.00389.x; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Webster LR, 2013, PAIN MED, V14, P1332, DOI 10.1111/pme.12184; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279; Zeppetella G, 2009, EUR J CANCER CARE, V18, P331, DOI 10.1111/j.1365-2354.2008.01009.x	31	2	2	0	4	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1751-2433	1751-2441		EXPERT REV CLIN PHAR	Expert Rev. Clin. Pharmacol.	JAN	2015	8	1					9	13		10.1586/17512433.2015.977254			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CC0JV	WOS:000350022500003	25359295				2020-06-30	J	Moore, PW; Palmer, RB; Donovan, JW				Moore, Philip W.; Palmer, Robert B.; Donovan, Joseph Ward			Fatal Fentanyl Patch Misuse in a Hospitalized Patient with a Postmortem Increase in Fentanyl Blood Concentration	JOURNAL OF FORENSIC SCIENCES			English	Article						forensic science; forensic toxicology; humans; analgesics; opioid; fentanyl; pharmacokinetics; transdermal; postmortem; necrokinetic	TRANSDERMALLY ADMINISTERED FENTANYL; PHARMACOKINETICS; REDISTRIBUTION; DURAGESIC(R); SUFENTANIL; ALFENTANIL; ABSORPTION; INTERVAL	Opioid-related mortality happens, even in healthcare settings. We describe serial postmortem fentanyl blood concentrations in a hospital inpatient who fatally abused transdermal fentanyl. This is a single-patient case report. A 42-year-old man with lymphoma was started on transdermal fentanyl therapy while hospitalized for chronic abdominal pain. The patient was last seen awake 1.3h prior to being found apneic and cyanotic. During the resuscitation attempt, a small square-shaped film was removed from the patient's oropharynx. Femoral blood was collected 0.5 and 2h postmortem, and the measured fentanyl concentration increased from 1.6 to 14ng/mL. Study limitations include potential laboratory or collection errors and missing data. (i) Providers must be vigilant for signs of fentanyl patch abuse. (ii) Postmortem blood concentrations are not static postmortem, likely secondary to decreasing pH, increased aqueous solubility, and tissue redistribution, and are therefore unlikely to accurately represent antemortem blood concentrations.	[Moore, Philip W.] PinnacleHlth Hospitalists, Dept Internal Med, Harrisburg, PA 17101 USA; [Moore, Philip W.; Donovan, Joseph Ward] PinnacleHlth Toxicol Ctr, Dept Internal Med, Harrisburg, PA 17101 USA; [Moore, Philip W.; Donovan, Joseph Ward] Penn State Univ, Dept Emergency Med, Coll Med, Hershey, PA 17033 USA; [Palmer, Robert B.] Toxicol Associates PLLC, Denver, CO 80210 USA; [Palmer, Robert B.] Rocky Mt Poison & Drug Ctr, Denver, CO 80204 USA	Moore, PW (reprint author), PinnacleHlth Hospitalists, Dept Internal Med, 111 S Front St, Harrisburg, PA 17101 USA.	pwmoore@pinnaclehealth.org					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Bjorkman S, 1998, ANESTHESIOLOGY, V88, P657, DOI 10.1097/00000542-199803000-00016; Bronstein AC, 2011, CLIN TOXICOL, V49, P910, DOI 10.3109/15563650.2011.635149; CALIS KA, 1992, CLIN PHARMACY, V11, P22; Ceelen L, 2012, AM J FOREN MED PATH, V33, P119, DOI 10.1097/PAF.0b013e3181fbbb49; CHRISTIAN CM, 1983, ANESTHESIOLOGY, V58, P275, DOI 10.1097/00000542-198303000-00015; Gill JR, 2013, J MED TOXICOL, V9, P34, DOI 10.1007/s13181-012-0253-z; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; Ibrahim AE, 2003, ANESTHESIOLOGY, V98, P853, DOI 10.1097/00000542-200304000-00011; Janssen Biotech, 1997, JANS BIOT RIA KITS, P1; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; Olson KN, 2010, AM J CLIN PATHOL, V133, P447, DOI 10.1309/AJCP4X5VHFSOERFT; Palamalai V, 2013, CLIN BIOCHEM, V46, P598, DOI 10.1016/j.clinbiochem.2013.02.001; Palmer RB, 2010, CLIN TOXICOL, V48, P771, DOI 10.3109/15563650.2010.525514; PLEZIA PM, 1989, PHARMACOTHERAPY, V9, P2; Prosser JM, 2010, J MED TOXICOL, V6, P443, DOI 10.1007/s13181-010-0092-8; ROY SD, 1989, PHARMACEUT RES, V6, P147, DOI 10.1023/A:1015932610010; SAWYER WR, 1988, J FORENSIC SCI, V33, P1439; SEBEL PS, 1987, EUR J CLIN PHARMACOL, V32, P529, DOI 10.1007/BF00637682; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Warner Margaret, 2011, NCHS Data Brief, P1; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x	28	10	10	1	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-1198	1556-4029		J FORENSIC SCI	J. Forensic Sci.	JAN	2015	60	1					243	246		10.1111/1556-4029.12559			4	Medicine, Legal	Legal Medicine	AZ8AR	WOS:000348437700038	25041753				2020-06-30	J	Yang, CH; Tian, X; Yin, HB; Gao, XH; Li, N				Yang, Chun-Hui; Tian, Xin; Yin, Hai-Bin; Gao, Xiao-Hui; Li, Na			Sedation and Analgesia With Fentanyl and Etomidate for Intrathecal Injection in Childhood Leukemia Patients	MEDICINE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; DOUBLE-BLIND; ANESTHETIC INDUCTION; PROCEDURAL-SEDATION; PROPOFOL; CHILDREN; MYOCLONUS; MIDAZOLAM; EFFICACY; SAFETY	In this study, we tried to find a safe as well as fast effective treatment for sedation and analgesia for intrathecal injection in childhood leukemia patients, relieving treatment difficulties and pain, increasing the success rate of single intrathecal injection. The patients were divided into the experimental group (fentanyl combined with etomidate) and the control group (lidocaine only) randomly. The experimental group was given fentanyl 1 to 2 mu g/kg intravenously first, then etomidate 0.1 to 0.3 mg/kg intravenously after the pipe washed. The patients younger than 1.5 years or who did not achieve satisfied sedative and analgesic situation received an additional time of etomidate (0.1-0.3 mg/kg). The patients were given oxygen at the rate of 4-5 L/min during the whole operation, and the finger pulse oximeter was used simultaneously to detect the changes in heart rate (HR) and blood oxygen saturation (SpO(2)). The doctors who performed the procedures assessed the quality of sedation and analgesia. In the experimental group, the patients' HR increased slightly after given fentanyl combined with etomidate. The patients' SpO(2) was stable. Most patients achieved a good sedative and analgesic state within 1 to 2 minutes, and no case of respiration depression or cardiac arrhythmias occurred during the whole operation. The wake-up time was 55.42 +/- 20.62 min. In the control group, the patients were not very cooperative during the intrathecal injection, which made the procedures very difficult. During intrathecal injection, pain obviously reduced and the success rate of single lumbar puncture increased. It is safe and effective to apply fentanyl combined with etomidate for sedation and analgesia.	[Yang, Chun-Hui; Gao, Xiao-Hui] Dali Univ, Dali, Peoples R China; [Tian, Xin; Li, Na] Kunming Med Univ, Dept Hematol & Oncol, Childrens Hosp, Kunming 650000, Yunnan, Peoples R China; [Yin, Hai-Bin] Kunming Med Univ, Kunming 650000, Yunnan, Peoples R China	Tian, X (reprint author), Kunming Med Univ, Dept Hematol & Oncol, Childrens Hosp, 288 Qianxing Rd, Kunming 650000, Yunnan, Peoples R China.	2021148542@qq.com			Scientific Research Foundation of Yunnan Province, China [2013EZ246]	Research supported by the Scientific Research Foundation of Yunnan Province, China (#2013EZ246).	Barbi E, 2005, J PEDIAT HEMATOL ONC, V27, P639, DOI 10.1097/01.mph.0000193474.06870.9c; Bartkowska-Sniatkowska A, 2014, ANAESTH INTENSIVE TH, V46, P109, DOI [10.5603/AIT.2014.021, 10.5603/AIT.2014.0021]; Cechvala MM, 2008, J PEDIAT HEMATOL ONC, V30, P142, DOI 10.1097/MPH.0b013e31815d8953; Chiaretti A, 2010, EUR J CANCER CARE, V19, P212, DOI 10.1111/j.1365-2354.2008.01006.x; Forman SA, 2011, ANESTHESIOLOGY, V114, P695, DOI 10.1097/ALN.0b013e3181ff72b5; Golzari SEJ, 2014, NEW ENGL J MED, V371, P90, DOI 10.1056/NEJMc1405676; Gu WJ, 2014, CHEST; Hueter L, 2003, ACTA ANAESTH SCAND, V47, P482, DOI 10.1034/j.1399-6576.2003.00081.x; Isitemiz I, 2014, MED SCI MONITOR, V20, P262, DOI 10.12659/MSM.889833; Jian L, 2013, JILIN MED J, V34, P1688; Ko BJ, 2013, KOREAN J ANESTHESIOL, V64, P12, DOI 10.4097/kjae.2013.64.1.12; Komatsu R, 2013, ANESTH ANALG, V117, P1329, DOI 10.1213/ANE.0b013e318299a516; Kukanich B, 2012, J VET PHARMACOL THER, V35, P3, DOI 10.1111/j.1365-2885.2012.01416.x; Lee-Jayaram JJ, 2010, PEDIATR EMERG CARE, V26, P408, DOI 10.1097/PEC.0b013e3181e057cd; Mantadakis E, 2009, J PEDIATR ONCOL NURS, V26, P217, DOI 10.1177/1043454209339733; Nagel K, 2008, PEDIATR BLOOD CANCER, V51, P634, DOI 10.1002/pbc.21669; Nguyen M, 2010, REGION ANESTH PAIN M, V35, P261, DOI 10.1097/AAP.0b013e3181de12e4; Ray NP, 2008, J PEDIAT HEMATOL ONC, V30, P117, DOI 10.1097/MPH.0b013e31815d892a; Setty S, 2012, MINERVA ANESTESIOL, V78, P258; van den Broek WW, 2004, J ECT, V20, P107, DOI 10.1097/00124509-200406000-00006; van der Linde HJ, 2011, J PHARMACOL TOXICOL, V63, P96, DOI 10.1016/j.vascn.2010.06.002; Winterhalter M, 2010, EUR J MED RES, V15, P47; Wu J, 2013, CONTRACEPTION, V87, P55, DOI 10.1016/j.contraception.2012.08.014; Xin T, 2010, CLIN MED ENG, V17, P43; Zhang GH, 2009, CHINESE MED J-PEKING, V122, P2330, DOI 10.3760/cma.j.issn.0366-6999.2009.19.026	25	5	5	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	JAN	2015	94	1							e361	10.1097/MD.0000000000000361			5	Medicine, General & Internal	General & Internal Medicine	AY5TF	WOS:000347633800018	25569654	DOAJ Gold, Green Published			2020-06-30	J	Hillman, AD; Witenko, CJ; Sultan, SM; Gala, G				Hillman, Ashley D.; Witenko, Corey J.; Sultan, Said M.; Gala, Gary			Serotonin Syndrome Caused by Fentanyl and Methadone in a Burn Injury	PHARMACOTHERAPY			English	Article						serotonin syndrome; narcotics; drug interaction; fentanyl; methadone	TOXICITY; VORICONAZOLE; DIAGNOSIS	Serotonin syndrome is a syndrome identified by a triad of altered mental status, neuromuscular overactivity, and autonomic instability caused by the overstimulation of serotonin in the central nervous system and periphery. Serotonin syndrome may be provoked with the addition or increase in serotonergic agents such as selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, tricyclic antidepressants, and monoamine oxidase inhibitors as well as other agents with serotonergic properties. Some narcotics, including fentanyl and methadone, have these properties and may be associated with the development of serotonin syndrome when used in conjunction with other agents. Currently, there are no identified case reports of narcotics as the sole agent causing serotonin syndrome. This report provides a brief overview of serotonin syndrome, particularly with cases involving administration of narcotics such as fentanyl and methadone. The case described is the first report associated with fentanyl and methadone without the coadministration of other serotonergic agents, and a possible drug interaction with voriconazole is discussed. This raises awareness of using multiple serotonergic narcotics and the potential precipitation of serotonin syndrome.	[Hillman, Ashley D.; Witenko, Corey J.; Sultan, Said M.] Univ North Carolina Hosp & Clin, Dept Pharm, Chapel Hill, NC USA; [Gala, Gary] Univ North Carolina Hosp & Clin, Dept Psychiat, Chapel Hill, NC USA	Hillman, AD (reprint author), UNC Hosp, 101 Mannind Dr,Campus Box 7600, Chapel Hill, NC 27514 USA.	said.sultan@unchealth.unc.edu		Hillman, Ashley/0000-0003-3878-8414			Ables AZ, 2010, AM FAM PHYSICIAN, V81, P1139; Ailawadhi S, 2007, J CLIN PHARM THER, V32, P199, DOI 10.1111/j.1365-2710.2007.00813.x; Boyer EW, 2005, NEW ENGL J MED, V352, P1112, DOI 10.1056/NEJMra041867; Bush E, 2006, J PALLIAT MED, V9, P1257, DOI 10.1089/jpm.2006.9.1257; Dunkley EJC, 2003, QJM-INT J MED, V96, P635, DOI 10.1093/qjmed/hcg109; Ener RA, 2003, PAIN MED, V4, P63, DOI 10.1046/j.1526-4637.2003.03005.x; Gillman PK, 2005, BRIT J ANAESTH, V95, P434, DOI 10.1093/bja/aei210; Graudins A, 1998, J Emerg Med, V16, P615, DOI 10.1016/S0736-4679(98)00057-2; GUZE BH, 1985, NEW ENGL J MED, V313, P163, DOI 10.1056/NEJM198507183130306; Isbister GK, 2005, CLIN NEUROPHARMACOL, V28, P205, DOI 10.1097/01.wnf.0000177642.89888.85; Kapur S, 1997, AM J PSYCHIAT, V154, P884; Liu P, 2007, ANTIMICROB AGENTS CH, V51, P110, DOI 10.1128/AAC.00559-06; Martin TG, 1996, ANN EMERG MED, V28, P520, DOI 10.1016/S0196-0644(96)70116-6; Martinez Terry T, 2008, Proc West Pharmacol Soc, V51, P42; Mason PJ, 2000, MEDICINE, V79, P201, DOI 10.1097/00005792-200007000-00001; Pilgrim JL, 2011, FORENSIC SCI MED PAT, V7, P162, DOI 10.1007/s12024-010-9188-3; Rang ST, 2008, CAN J ANAESTH, V55, P521, DOI 10.1007/BF03016672; Rastogi R, 2011, ANESTHESIOLOGY, V115, P1291, DOI 10.1097/ALN.0b013e31823940c0; Saari TI, 2008, EUR J CLIN PHARMACOL, V64, P25, DOI 10.1007/s00228-007-0398-x; Saper CB, 2000, PRINCIPLES NEURAL SC, P896; Sun-Edelstein C, 2008, EXPERT OPIN DRUG SAF, V7, P587, DOI [10.1517/14740338.7.5.587, 10.1517/14740338.7.5.587 ]	21	11	11	1	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0277-0008	1875-9114		PHARMACOTHERAPY	Pharmacotherapy	JAN	2015	35	1					112	117		10.1002/phar.1528			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CA8IV	WOS:000349163100016	25615513				2020-06-30	J	Loflin, R; Koyfman, A				Loflin, Rob; Koyfman, Alex			When Used for Sedation, Does Ketamine Increase Intracranial Pressure More Than Fentanyl or Sufentanil?	ANNALS OF EMERGENCY MEDICINE			English	Editorial Material							TRAUMATIC BRAIN-INJURY		[Loflin, Rob] Caril Roanoke Mem Hosp, Caril Clin Virginia Tech Caril Emergency Med Res, Roanoke, VA 24014 USA; [Koyfman, Alex] UT Southwestern Med Ctr Parkland Mem Hosp, Dept Emergency Med, Dallas, TX USA	Loflin, R (reprint author), Caril Roanoke Mem Hosp, Caril Clin Virginia Tech Caril Emergency Med Res, Roanoke, VA 24014 USA.						Bowles Eric D, 2012, AANA J, V80, P445; EVANS J, 1971, LANCET, V1, P40; Filanovsky Y, 2010, CAN J EMERG MED, V12, P154; Green SM, 2011, ANN EMERG MED, V57, P449, DOI 10.1016/j.annemergmed.2010.11.030; Roberts DJ, 2011, CRIT CARE MED, V39, P2743, DOI 10.1097/CCM.0b013e318228236f; Sehdev Rajesh S, 2006, Emerg Med Australas, V18, P37; SHAPIRO HM, 1972, BRIT J ANAESTH, V44, P1200, DOI 10.1093/bja/44.11.1200; Zeiler FA, 2014, NEUROCRIT CARE, V21, P163, DOI 10.1007/s12028-013-9950-y	8	7	7	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	JAN	2015	65	1					55	56		10.1016/j.annemergmed.2014.08.017			2	Emergency Medicine	Emergency Medicine	AY6GC	WOS:000347664200013	25233812				2020-06-30	J	Kang, JH; Oh, SY; Song, SY; Lee, HY; Kim, JH; Lee, KE; Lee, HR; Hwang, IG; Park, SH; Kim, WS; Park, YS; Park, K				Kang, Jung Hun; Oh, Sung Yong; Song, Seo-Young; Lee, Hui-Young; Kim, Jung Han; Lee, Kyoung Eun; Lee, Hye Ran; Hwang, In Gyu; Park, Se Hoon; Kim, Won Seok; Park, Young Suk; Park, Keunchil			The efficacy of low-dose transdermal fentanyl in opioid-naive cancer patients with moderate-to-severe pain	KOREAN JOURNAL OF INTERNAL MEDICINE			English	Article						Transdermal patch; Fentanyl; Neoplasms; Pain; Opioids	RELEASE ORAL MORPHINE; PALLIATIVE CARE; MANAGEMENT; TRIAL; GUIDELINES; RELIEF; SAFETY	Background/Aims: Little is known about the efficacy of low-dose transdermal fentanyl (TDF) patches in opioid-naive patients with moderate-to-severe cancer pain. Methods: This study had an open-label, prospective design, and was conducted between April 2007 and February 2009 in seven tertiary cancer hospitals; 98 patients were enrolled. TDF was started using a low-dose formulation (12.5 mu g/ hr), and the dose was adjusted according to the clinical situation of individual patients. Pain intensity, the TDF doses used, and adverse events (AEs) were monitored over 4 weeks. Data were analyzed using the intent-to-treat and per-protocol principles. Results: Of the 98 patients enrolled, 64 (65%) completed the study. The median pain intensity decreased from 6.0 to 3.0 (p < 0.001.) at the follow-up visit. The efficacy of low-dose TDF on pain relief was consistent across groups separated according to gender (p < 0.004 age (p < 0.001.), metastasis (p < 0.001), previous treatment (p < 0.001), and baseline pain intensity (p < 0.001.). The decrease in pain intensity was significantly greater in the severe group compared with the moderate group (mean +/- SD, 5.10 +/- 2.48 vs. 2.48 +/- 1.56; p < 0.001). TDF dose (27.8 mu g/ hr vs. 24.8 mu g/hr, p = 0.423) and the mean treatment time (7.5 days vs. 7.9 days, p = 0.740) required for pain control were not different between the two pain-intensity groups. Patients had AEs of only mild or moderate intensity; among these, nausea (38%) was the most common, followed by vomiting (22%) and somnolence (22%). Conclusions: Low-dose TDF was an effective treatment for patients with cancer pain of moderate-to-severe intensity. Further randomized trials assessing the efficacy of TDF for severe pain and/or optimal starting doses are warranted.	[Kang, Jung Hun] Gyeongsang Natl Univ, Sch Med, Dept Internal Med, Jinju, South Korea; [Oh, Sung Yong] Dong A Univ, Coll Med, Dept Internal Med, Pusan, South Korea; [Song, Seo-Young; Lee, Hui-Young] Kangwon Natl Univ, Sch Med, Dept Internal Med, Chunchon, South Korea; [Kim, Jung Han] Hallym Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Lee, Kyoung Eun] Ewha Womans Univ, Sch Med, Dept Internal Med, Seoul, South Korea; [Lee, Hye Ran] Inje Univ, Ilsan Paik Hosp, Dept Internal Med, Goyang, South Korea; [Hwang, In Gyu] Chung Ang Univ, Coll Med, Dept Internal Med, Seoul 156756, South Korea; [Park, Se Hoon; Kim, Won Seok; Park, Young Suk; Park, Keunchil] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul 135710, South Korea	Park, K (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol & Oncol, 81 Irwon Ro, Seoul 135710, South Korea.	kpark@skku.edu			Janssen KoreaJohnson & Johnson USAJanssen Biotech Inc	This study was sponsored by Janssen Korea.	Allan L, 2005, SPINE, V30, P2484, DOI 10.1097/01.brs.0000186860.23078.a8; [Anonymous], 1990, World Health Organ Tech Rep Ser, V804, P1; Barber A, 1997, Expert Opin Investig Drugs, V6, P1351, DOI 10.1517/13543784.6.10.1351; Burton AW, 2007, EXPERT REV ANTICANC, V7, P1501, DOI 10.1586/14737140.7.11.1501; Coller J, 2009, EUR J CLIN PHARMACOL, V65, P121, DOI 10.1007/s00228-008-0570-y; Dahan A., 2009, THERAPY, V6, P633; DREXEL H, 1989, PAIN, V36, P169, DOI 10.1016/0304-3959(89)90020-1; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Goldfarb NM, 2012, J CLIN RES BEST PRAC, V8, P1; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Hoya Y, 2010, SUPPORT CARE CANCER, V18, P761, DOI 10.1007/s00520-010-0869-y; Hui D, 2013, CANCER-AM CANCER SOC, V119, P1098, DOI 10.1002/cncr.27854; Iconomou G, 2000, ANTICANCER RES, V20, P4821; JAGOX A, 1994, NEW ENGL J MED, V330, P651, DOI 10.1056/NEJM199403033300926; Komurcu S, 2007, EUR J CANCER CARE, V16, P67, DOI 10.1111/j.1365-2354.2006.00707.x; Kress HG, 2008, J PAIN SYMPTOM MANAG, V36, P268, DOI 10.1016/j.jpainsymman.2007.10.023; Likert R, 1932, ARCH PSYCHOL, V22, P1, DOI DOI 10.1111/J.1540; Mercadante S, 2006, J PAIN SYMPTOM MANAG, V31, P242, DOI 10.1016/j.jpainsymman.2006.01.001; Mercadante S, 2008, EUR J PAIN, V12, P1040, DOI 10.1016/j.ejpain.2008.01.013; Mercadante S, 2006, CANCER TREAT REV, V32, P304, DOI 10.1016/j.ctrv.2006.03.001; Mercadante S, 2009, CLIN THER, V31, P2134, DOI 10.1016/j.clinthera.2009.10.013; Meuser T, 2001, PAIN, V93, P247, DOI 10.1016/S0304-3959(01)00324-4; Mystakidou K, 2003, INT J CANCER, V107, P486, DOI 10.1002/ijc.11416; Prommer E, 2009, J PALLIAT MED, V12, P947, DOI 10.1089/jpm.2009.0051; Riley J, 2006, SUPPORT CARE CANCER, V14, P56, DOI 10.1007/s00520-005-0843-2; Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; Swarm R, 2010, J NATL COMPR CANC NE, V8, P1046, DOI 10.6004/jnccn.2010.0076; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; van Seventer R, 2003, CURR MED RES OPIN, V19, P457, DOI 10.1185/030079903125002045; VENTAFRIDDA V, 1987, CANCER, V59, P850, DOI 10.1002/1097-0142(19870215)59:4<850::AID-CNCR2820590432>3.0.CO;2-1; Vielvoye-Kerkmeer APE, 2000, J PAIN SYMPTOM MANAG, V19, P185, DOI 10.1016/S0885-3924(99)00152-9; Yang QO, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-67; Yennurajalingam S, 2012, J PAIN SYMPTOM MANAG, V44, P340, DOI 10.1016/j.jpainsymman.2011.09.014	34	4	4	0	4	KOREAN ASSOC INTERNAL MEDICINE	SEOUL	101-2501 LOTTE CASTLE PRESIDENT, 109 MAPO-DAERO, MAPO-GU, SEOUL, 121-916, SOUTH KOREA	1226-3303	2005-6648		KOREAN J INTERN MED	Korean J. Intern. Med.	JAN	2015	30	1					88	95		10.3904/kjim.2015.30.1.88			8	Medicine, General & Internal	General & Internal Medicine	AY7NN	WOS:000347746800014	25589840	DOAJ Gold, Green Published			2020-06-30	J	Drees, R; Johnson, RA; Pinkerton, M; Del Rio, AM; Saunders, JH; Francois, CJ				Drees, Randi; Johnson, Rebecca A.; Pinkerton, Marie; Del Rio, Alejandro Munoz; Saunders, Jimmy H.; Francois, Christopher J.			EFFECTS OF TWO DIFFERENT ANESTHETIC PROTOCOLS ON 64-MDCT CORONARY ANGIOGRAPHY IN DOGS	VETERINARY RADIOLOGY & ULTRASOUND			English	Article						computed tomography; dexmedetomidine; fentanyl; heart; midazolam	COMPUTED-TOMOGRAPHY ANGIOGRAPHY; MINIMUM ALVEOLAR CONCENTRATION; CONTINUOUS RATE INFUSION; CONSTANT RATE INFUSION; ISOFLURANE ANESTHESIA; DIAGNOSTIC-ACCURACY; LIDOCAINE-KETAMINE; PULMONIC STENOSIS; IMAGE QUALITY; HEART-RATE	Heart rate is a major factor influencing diagnostic image quality in computed tomographic coronary artery angiography (MDCT-CA), with an ideal heart rate of 60-65 beats/min in humans. The purpose of this prospective study was to compare effects of two different clinically applicable anesthetic protocols on cardiovascular parameters and 64-MDCT-CA quality in 10 healthy dogs. Scan protocols and bolus volumes were standardized. Image evaluations were performed in random order by a board-certified veterinary radiologist who was unaware of anesthetic protocols used. Heart rate during image acquisition did not differ between protocols (P = 1), with 80.6 +/- 7.5 bpm for protocol A and 79.2 +/- 14.2 bpm for protocol B. Mean blood pressure was significantly higher (P > 0.05) using protocol B (protocol A 62.9 +/- 9.1 vs. protocol B 72.4 +/- 15.9 mmHg). The R-R intervals allowing for best depiction of individual coronary artery segments were found in the end diastolic period and varied between the 70% and 95% interval. Diagnostic quality was rated excellent, good, and moderate in the majority of the segments evaluated, with higher scores given for more proximal segments and lower for more distal segments, respectively. Blur was the most commonly observed artifact and mainly affected the distal segments. No significant differences were identified between the two protocols for optimal reconstruction interval, diagnostic quality and measured length individual segments, or proximal diameter of the coronary arteries (P = 1). Findings indicated that, when used with a standardized bolus volume, both of these anesthetic protocols yielded diagnostic quality coronary 64-MDCT-CA exams in healthy dogs. (C) 2014 American College of Veterinary Radiology.	[Drees, Randi; Johnson, Rebecca A.] UW Madison VMTH, Dept Surg Sci, Madison, WI 53706 USA; [Pinkerton, Marie] UW Madison VMTH, Dept Pathobiol Sci, Madison, WI 53706 USA; [Del Rio, Alejandro Munoz; Francois, Christopher J.] UW Madison, Dept Med Phys, Madison, WI 53792 USA; [Del Rio, Alejandro Munoz; Francois, Christopher J.] UW Madison, Dept Radiol, Sch Med & Publ Hlth, Madison, WI 53792 USA; [Saunders, Jimmy H.] UGent, Fac Vet Med, B-9820 Merelbeke, Belgium	Drees, R (reprint author), Univ London, Royal Vet Coll, Dept Clin Sci & Serv, London AL9 7TA, Herts, England.	rdrees@rvc.ac.uk		Francois, Christopher/0000-0001-5254-1181	Clinical and Translational Science Award (CTSA) programUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [1UL1RR025011]; National Center for Advancing Translational Sciences (NCATS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [9U54TR000021]; Clinical and Translational Science Award (CTSA) program through NIH National Center for Advancing Translational Sciences (NCATS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000427]	Funding sources: The project was supported by the Clinical and Translational Science Award (CTSA) program, previously through the National Center for Research Resources (NCRR) grant 1UL1RR025011, and now by the National Center for Advancing Translational Sciences (NCATS), grant 9U54TR000021. Additionally the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS), supported Dr. Johnson grant UL1TR000427.	Aguado D, 2011, VET J, V189, P63, DOI 10.1016/j.tvjl.2010.05.029; Austen W G, 1975, Circulation, V51, P5; Braz LG, 2008, J INVEST SURG, V21, P360, DOI 10.1080/08941930802440803; BUCHANAN JW, 1990, J AM VET MED ASSOC, V196, P115; Buchanan JW, 2001, J VET INTERN MED, V15, P101, DOI 10.1892/0891-6640(2001)015&lt;0101:POSRCA&gt;2.3.CO;2; Chun EJ, 2008, J COMPUT ASSIST TOMO, V32, P86, DOI 10.1097/rct.0b013e318059befa; de Graaf FR, 2010, HEART LUNG CIRC, V19, P107, DOI 10.1016/j.hlc.2009.11.004; de Graaf FR, 2010, AM J CARDIOL, V105, P767, DOI 10.1016/j.amjcard.2009.10.058; Drees R, 2011, VET RADIOL ULTRASOUN, V52, P507, DOI 10.1111/j.1740-8261.2011.01826.x; Ebner LS, 2013, AM J VET RES, V74, P963, DOI 10.2460/ajvr.74.7.963; EVANS HE, 1993, [No title captured], P598; Ferasin L, 2010, J SMALL ANIM PRACT, V51, P412, DOI 10.1111/j.1748-5827.2010.00954.x; Grimm KA, 2005, AM J VET RES, V66, P1222, DOI 10.2460/ajvr.2005.66.1222; Heniff MS, 1997, ACAD EMERG MED, V4, P1115, DOI 10.1111/j.1553-2712.1997.tb03692.x; Holm S, 1979, SCAND J STAT, V17, P571; JONES DJ, 1979, ANESTHESIOLOGY, V51, P430, DOI 10.1097/00000542-197911000-00012; Keating SCJ, 2013, AM J VET RES, V74, P672, DOI 10.2460/ajvr.74.5.672; Kerl JM, 2008, RADIOLOGY, V247, P356, DOI 10.1148/radiol.2472070856; Kimura F, 2010, JPN J RADIOL, V28, P437, DOI 10.1007/s11604-010-0448-7; KOCH T, 1993, [No title captured], P45; KONIG H, 2005, [No title captured], P445; Leschka S, 2006, EUR RADIOL, V16, P1964, DOI 10.1007/s00330-006-0262-x; Lin GY, 2008, VET ANAESTH ANALG, V35, P141, DOI 10.1111/j.1467-2995.2007.00365.x; Liu S, 1986, J AM VET MED ASSOC, P227; Menke J, 2013, AM HEART J, V165, P154, DOI 10.1016/j.ahj.2012.10.026; Pan CJ, 2013, EXP THER MED, V5, P636, DOI 10.3892/etm.2012.828; Pascoe PJ, 2006, VET ANAESTH ANALG, V33, P97, DOI 10.1111/j.1467-2995.2005.00236.x; Pollard R., 2011, Veterinary computed tomography, P57; Pollard RE, 2008, AM J VET RES, V69, P1268, DOI 10.2460/ajvr.69.10.1268; R Development Core Team, 2012, R LANG ENV STAT COMP; Rahmani N, 2009, ACAD RADIOL, V16, P604, DOI 10.1016/j.acra.2008.11.008; Rosset A, 2004, J DIGIT IMAGING, V17, P205, DOI 10.1007/s10278-004-1014-6; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; Seddighi Reza, 2011, Vet Anaesth Analg, V38, P195, DOI 10.1111/j.1467-2995.2011.00615.x; Sieslack AK, 2013, AM J VET RES, V74, P990, DOI 10.2460/ajvr.74.7.990; Steagall PVM, 2006, JAVMA-J AM VET MED A, V229, P522, DOI 10.2460/javma.229.4.522; Uilenreef JJ, 2008, VET ANAESTH ANALG, V35, P1, DOI 10.1111/j.1467-2995.2007.00344.x; Utsunomiya D, 2006, AM J ROENTGENOL, V187, P638, DOI 10.2214/AJR.05.0612	38	8	8	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1058-8183	1740-8261		VET RADIOL ULTRASOUN	Vet. Radiol. Ultrasound	JAN-FEB	2015	56	1					46	54		10.1111/vru.12185			9	Veterinary Sciences	Veterinary Sciences	AY9ED	WOS:000347851700010	25065815	Green Accepted			2020-06-30	J	Barann, M; Stamer, UM; Lyutenska, M; Stuber, F; Bonisch, H; Urban, B				Barann, M.; Stamer, U. M.; Lyutenska, M.; Stueber, F.; Boenisch, H.; Urban, B.			Effects of opioids on human serotonin transporters	NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY			English	Article						Fentanyl; Morphine; Tramadol; Meperidine; Ketamine; Serotonin (5-hydroxtryptamine)	PATIENT-CONTROLLED ANALGESIA; HUMAN 5-HT3A RECEPTORS; SURGICAL PATIENTS; TRAMADOL; FENTANYL; MEPERIDINE; PAROXETINE; TOXICITY; EMESIS; CELLS	The serotonin (5-hydroxtryptamine, 5-HT) system plays a role in analgesia and emesis. The aim of this study was to test whether opioids or ketamine inhibit the human 5-HT transporter and whether this increases free plasma 5-HT concentrations. HEK293 cells, stably transfected with the human 5-HT transporter cDNA, were incubated with morphine, hydromorphone, fentanyl, alfentanil, pethidine (meperidine), tramadol, ketamine, and the reference substance citalopram (specific 5-HT transporter inhibitor). The uptake of [H-3]5-HT was measured by liquid scintillation counting. In a second series of experiments, study drugs were incubated with plasma of ten healthy blood donors and change of 5-HT plasma-concentrations were measured (ELISA). The end point was the inhibition of the 5-HT transporter by different analgesics either in HEK293 cells or in human platelets ex vivo. Tramadol, pethidine, and ketamine suppressed [H-3]5-HT uptake dose-dependently with an IC50 of 1, 20.9, and 230 mu M, respectively. These drugs also prevented 5-HT uptake in platelets with an increase in free plasma 5-HT. Free 5-HT concentrations in human plasma were increased by citalopram 1 mu M, tramadol 20 mu M, pethidine 30 mu M, and ketamine 100 mu M to 280 [248/312]%, 269 [188/349]%, and 149 [122/174]%, respectively, compared to controls without any co-incubation (means [95 % CI]; all p < 0.005). No change in both experimental settings was observed for the other opioids. Tramadol and pethidine inhibited the 5-HT transporter in HEK293 cells and platelets. This inhibition may contribute to serotonergic effects when these opioids are given in combination, e.g., with monoamine oxidase inhibitors or selective serotonin reuptake inhibitors.	[Barann, M.; Lyutenska, M.; Urban, B.] Univ Bonn, Dept Anaesthesiol & Intens Care Med, D-53127 Bonn, Germany; [Stamer, U. M.; Stueber, F.] Univ Bern, Dept Anaesthesiol & Pain Med, Inselspital, CH-3010 Bern, Switzerland; [Stamer, U. M.; Stueber, F.] Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland; [Boenisch, H.] Univ Bonn, Inst Pharmacol & Toxicol, D-53127 Bonn, Germany	Stamer, UM (reprint author), Univ Bern, Dept Anaesthesiol & Pain Med, Inselspital, Freiburgstr, CH-3010 Bern, Switzerland.	ulrike.stamer@dkf.unibe.ch			Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG) [BA 1454]	This study was funded by a grant of the Deutsche Forschungsgemeinschaft (DFG; BA 1454).	Ailawadhi S, 2007, J CLIN PHARM THER, V32, P199, DOI 10.1111/j.1365-2710.2007.00813.x; Alkhatib AA, 2010, DIGEST DIS SCI, V55, P215, DOI 10.1007/s10620-009-0711-x; Barann M, 2000, N-S ARCH PHARMACOL, V362, P255, DOI 10.1007/s002100000288; Barann M, 2006, EUR J PHARMACOL, V531, P54, DOI 10.1016/j.ejphar.2005.11.054; Barann M, 2006, PHARMACOL REP, V58, P253; Bijl D, 2004, NETH J MED, V62, P309; Boyer EW, 2005, NEW ENGL J MED, V352, P1112, DOI 10.1056/NEJMra041867; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Fisar Z, 2010, NEUROENDOCRINOL LETT, V31, P645; Gillman PK, 2005, BRIT J ANAESTH, V95, P434, DOI 10.1093/bja/aei210; Gillman PK, 2014, MONOAMINE OXYDASE IN, DOI 10.1093/bja/aei210; Gollapudy S, 2012, J CLIN ANESTH, V24, P251, DOI 10.1016/j.jclinane.2011.04.017; Grond S, 1999, BRIT J CLIN PHARMACO, V48, P254, DOI 10.1046/j.1365-2125.1999.00986.x; Jeleazcov C, 2014, ANESTHESIOLOGY, V120, P378, DOI 10.1097/ALN.0b013e3182a76d05; JELLINEK H, 1990, ANAESTHESIST, V39, P513; KOSKA AJ, 1981, ANESTH ANALG, V60, P8; LEHMANN KA, 1990, CLIN J PAIN, V6, P212, DOI 10.1097/00002508-199009000-00008; Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6; Niesler B, 2003, GENE, V310, P101, DOI 10.1016/S0378-1119(03)00503-1; OSULLIVAN JF, 1962, BRIT MED J, P151; PAECH MJ, 1994, ANESTHESIOLOGY, V80, P1268, DOI 10.1097/00000542-199406000-00014; Pedavally S, 2014, NEUROCRIT CARE, V21, P108, DOI 10.1007/s12028-013-9914-2; Rang ST, 2008, CAN J ANAESTH, V55, P521, DOI 10.1007/BF03016672; Rastogi R, 2011, ANESTHESIOLOGY, V115, P1291, DOI 10.1097/ALN.0b013e31823940c0; Reves JG, 2011, ANESTHESIA, P282; Schloss P, 1998, J PSYCHOPHARMACOL, V12, P115, DOI 10.1177/026988119801200201; Sommer Claudia, 2006, Curr Pain Headache Rep, V10, P101, DOI 10.1007/s11916-006-0020-4; Stamer UM, 2007, CLIN PHARMACOL THER, V82, P41, DOI 10.1038/sj.clpt.6100152; Sun-Edelstein C, 2008, EXPERT OPIN DRUG SAF, V7, P587, DOI [10.1517/14740338.7.5.587, 10.1517/14740338.7.5.587 ]; Urban BW, 2006, PHARMACOL THERAPEUT, V111, P729, DOI 10.1016/j.pharmthera.2005.12.005; WHITE PF, 1980, ANESTHESIOLOGY, V52, P231, DOI 10.1097/00000542-198003000-00008; Wittmann M, 2008, ANESTH ANALG, V107, P107, DOI 10.1213/ane.0b013e31817342c2; Wittmann M, 2006, ANESTH ANALG, V103, P747, DOI 10.1213/01.ane.0000229706.84471.4d	33	14	15	0	14	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-1298	1432-1912		N-S ARCH PHARMACOL	Naunyn-Schmiedebergs Arch. Pharmacol.	JAN	2015	388	1					43	49		10.1007/s00210-014-1056-3			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AY2GE	WOS:000347406000006	25332055				2020-06-30	J	Keszler, M; Abubakar, K				Keszler, Martin; Abubakar, Kabir			Volume Guarantee Ventilation during Surgical Closure of Patent Ductus Arteriosus	AMERICAN JOURNAL OF PERINATOLOGY			English	Article						patent ductus arteriosus; surgical closure; volume guarantee ventilation	INFANTS	BackgroundSurgical closure of patent ductus arteriosus (PDA) is associated with adverse outcomes. Surgical exposure requires retraction of the lung, resulting in decreased aeration and compliance. Optimal respiratory support for PDA surgery is unknown. Experience with volume guarantee (VG) ventilation at our institution led us to hypothesize that surgery would be better tolerated with automatic adjustment of pressure by VG to maintain tidal volume (V-T) during retraction. ObjectiveThe objective of this study was to describe ventilator support, V-T, and oxygenation of infants supported with VG during PDA surgery. Design/MethodsVentilator variables, oxygen saturation, and heart rate were recorded during PDA surgery in a convenience sample of infants during PDA closure on VG. Pressure limit increased 11% and set V-T was 26% lower during lung retraction. Fentanyl and pancuronium/vecuronium were used for anesthesia/muscle relaxation. Longitudinal data were analyzed by analysis of variance for repeated measures. ResultsSeven infants, 25.41.5 weeks and 723 +/- 141g, underwent closure of PDA on VG at a mean age 29.9 days. No air leak, bradycardia, or death occurred. Target V-T was maintained with a modest increase in inflation pressure. Oxygenation remained adequate. ConclusionsVG avoided hypoxemia and maintained adequate V-T with only a modest increase in peak inflation pressure and thus may be a useful mode during PDA surgery.	[Keszler, Martin] Brown Univ, Dept Pediat, Women & Infants Hosp Rhode Isl, Providence, RI 02912 USA; [Abubakar, Kabir] Georgetown Univ Hosp, Dept Pediat, Washington, DC 20007 USA	Keszler, M (reprint author), Women & Infants Hosp Rhode Isl, Dept Pediat, 101 Dudley St, Providence, RI 02905 USA.	mkeszler@wihri.org	Abubakar, Kabir M/AAC-9972-2020; Keszler, Martin/H-7260-2019	Keszler, Martin/0000-0002-9964-664X			Abubakar KM, 2001, PEDIATR PULM, V32, P71, DOI 10.1002/ppul.1091; BHUTANI VK, 1986, AM J DIS CHILD, V140, P449, DOI 10.1001/archpedi.1986.02140190059026; Chorne N, 2007, PEDIATRICS, V119, P1165, DOI 10.1542/peds.2006-3124; Clyman R, 2009, J PEDIATR-US, V154, P873, DOI 10.1016/j.jpeds.2009.01.005; Gould DS, 2003, PEDIATRICS, V112, P1298, DOI 10.1542/peds.112.6.1298; Kabra NS, 2007, J PEDIATR-US, V150, P229, DOI 10.1016/j.jpeds.2006.11.039; Keszler M, 2004, PEDIATR PULM, V38, P240, DOI 10.1002/ppul.20063; Keszler M, 2009, ARCH DIS CHILD-FETAL, V94, pF279, DOI 10.1136/adc.2008.147157; Keszler M, 2007, CLIN PERINATOL, V34, P107, DOI 10.1016/j.clp.2006.12.011; Laughon M, 2007, J PERINATOL, V27, P164, DOI 10.1038/sj.jp.7211662; Muralidhar K, 2001, PAEDIATR ANAESTH, V11, P45, DOI 10.1046/j.1460-9592.2001.00614.x; SHENASSA H, 1986, Canadian Journal of Cardiology, V2, P353; TAYLOR RL, 1986, AM J SURG, V152, P704, DOI 10.1016/0002-9610(86)90453-8; Tobias JD, 2001, PAEDIATR ANAESTH, V11, P483, DOI 10.1046/j.1460-9592.2001.00695.x; Wheeler K, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003666.pub3	15	1	1	0	1	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0735-1631	1098-8785		AM J PERINAT	Am. J. Perinatol.	JAN	2015	32	1					23	26		10.1055/s-0034-1371713			4	Obstetrics & Gynecology; Pediatrics	Obstetrics & Gynecology; Pediatrics	AX4OC	WOS:000346910600004	24705968				2020-06-30	J	Fauno, P; Lund, B; Christiansen, SE; Gjoderum, O; Lind, M				Fauno, Peter; Lund, Bent; Christiansen, Svend Erik; Gjoderum, Ole; Lind, Martin			Analgesic Effect of Hamstring Block After Anterior Cruciate Ligament Reconstruction Compared With Placebo: A Prospective Randomized Trial	ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY			English	Article							FEMORAL NERVE BLOCK; PAIN-CONTROL; INTRAARTICULAR MORPHINE; POSTOPERATIVE PAIN; ACL RECONSTRUCTION; SITE MORBIDITY; DOUBLE-BLIND; BUPIVACAINE; INFILTRATION; MANAGEMENT	Purpose: To evaluate the effect of a hamstring block for postoperative pain management using 20 mL of 0.25% bupivacaine compared with placebo after anterior cruciate ligament (ACL) reconstruction with a hamstring autograft. Methods: In a 3-month period, 45 patients undergoing ACL reconstruction with a hamstring autograft who all received a femoral nerve block were randomized to receive either 20 mL of 0.25% bupivacaine or 20 mL of saline water administered through a catheter into the donor-site space. The patients and recovery staff were blinded to the treatment. Postoperative donor-site pain was evaluated subjectively by the patients using a pain score (Likert scale from 0 to 10). The pain was registered for each hour in the first 6 hours and thereafter once daily for 8 days. Furthermore, the requirement for postoperative analgesic medicine was registered. Results: The hamstring block group (n = 23) had significantly less pain for each of the first 6 postoperative hours. The pain score was reduced from 4.2 to 2.3 (95% confidence interval, 1.3 to 3.3) (P = .01) in the first hour and from 2.8 to 1.3 (95% confidence interval, 0.6 to 1.9) in the sixth hour, and there was a significantly lower overall requirement for early postoperative fentanyl, reduced from a mean of 58 to 35 mg (P = .02), and morphine, reduced from a mean of 10 to 6 mg (P = .04). After 6 hours, there was no difference in the pain level and use of analgesics between the 2 groups. Conclusions: With the use of a donor-site block in hamstring ACL reconstruction, the donor-site pain level, as well as the overall requirement for fentanyl and morphine, was significantly reduced in the first 6 postoperative hours. No effect of the donor-site block was seen after 6 hours.	[Fauno, Peter; Lund, Bent; Christiansen, Svend Erik; Lind, Martin] Aarhus Univ Hosp, Dept Sports Traumatol, DK-8000 Aarhus, Denmark; [Gjoderum, Ole] Aarhus Univ Hosp, Dept Anesthesiol, DK-8000 Aarhus, Denmark	Fauno, P (reprint author), Aarhus Univ Hosp, Dept Sports Traumatol, Tage Hansens Gade 2, DK-8000 Aarhus, Denmark.	petefaun@rm.dk					Akinci SB, 2005, ARTHROSCOPY, V21, P1060, DOI 10.1016/j.arthro.2005.05.012; Beynnon BD, 2005, AM J SPORT MED, V33, P1751, DOI 10.1177/0363546505279922; Brandsson S, 1996, Knee Surg Sports Traumatol Arthrosc, V4, P200, DOI 10.1007/BF01567963; Brandsson S, 2000, ACTA ORTHOP SCAND, V71, P280, DOI 10.1080/000164700317411889; Bushnell BD, 2010, ARTHROSCOPY, V26, P894, DOI 10.1016/j.arthro.2009.11.022; Chew HF, 2003, ARTHROSCOPY, V19, P500, DOI 10.1053/jars.2003.50110; Denson DD, 1991, CLIN PRACTICE REGION, P73; Feller JA, 2001, KNEE SURG SPORT TR A, V9, P260, DOI 10.1007/s001670100216; Frost S, 2000, ARTHROSCOPY, V16, P243, DOI 10.1016/S0749-8063(00)90047-1; Hoher J, 1997, ARTHROSCOPY, V13, P210, DOI 10.1016/S0749-8063(97)90156-0; Hsu LP, 2013, J BONE JOINT SURG AM, V95A, P1465, DOI [10.2106/JBJS.L.01534, 10.2106/JBJS.L.00246]; Joshi GP, 2013, ANESTHESIOLOGY, V118, P780, DOI 10.1097/ALN.0b013e31828866e1; Kartus J, 2001, ARTHROSCOPY, V17, P971, DOI 10.1053/jars.2001.28979; Kristensen PK, 2014, KNEE SURG SPORT TR A, V22, P317, DOI 10.1007/s00167-013-2399-x; Oderda GM, 2003, J PAIN SYMPTOM MANAG, V25, P276, DOI 10.1016/S0885-3924(02)00691-7; Philip BK, 2002, J CLIN ANESTH, V14, P354, DOI 10.1016/S0952-8180(02)00372-0; Rosenberg PH, 2004, REGION ANESTH PAIN M, V29, P564, DOI 10.1016/j.rapm.2004.08.003; Shaw AD, 2005, KNEE, V12, P271, DOI 10.1016/j.knee.2004.05.010; Tetzlaff JE, 1997, J CLIN ANESTH, V9, P542, DOI 10.1016/S0952-8180(97)00141-4; Tetzlaff JE, 1999, REGION ANESTH PAIN M, V24, P220, DOI 10.1016/S1098-7339(99)90131-1; Woods GW, 2006, AM J SPORT MED, V34, P1328, DOI 10.1177/0363546505286145; YASUDA K, 1995, AM J SPORT MED, V23, P706, DOI 10.1177/036354659502300613	22	13	14	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0749-8063	1526-3231		ARTHROSCOPY	Arthroscopy	JAN	2015	31	1					63	68		10.1016/j.arthro.2014.07.024			6	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	AX6KY	WOS:000347032400017	25239172				2020-06-30	J	Unal, SS; Aksoy, M; Ahiskalioglu, A; Erdem, AF; Adanur, S				Unal, S. S.; Aksoy, M.; Ahiskalioglu, A.; Erdem, A. F.; Adanur, S.			The effect of intravenous preemptive paracetamol on postoperative fentanyl consumption in patients undergoing open nephrectomy: A prospective randomized study	NIGERIAN JOURNAL OF CLINICAL PRACTICE			English	Article						Fentanyl; intravenous paracetamol; open nephrectomy; preemptive analgesia	ORTHOPEDIC-SURGERY; ANALGESIC EFFICACY; PAIN MANAGEMENT; ACETAMINOPHEN; PROPACETAMOL; METAANALYSIS; SINGLE; NAUSEA; TRIALS; SAFETY	Aim: We investigated the efficacy of intravenous (IV) preemptive paracetamol on postoperative total fentanyl consumption and fentanyl-related side effects in patients undergoing open nephrectomy. Materials and Methods: A total of 60 patients scheduled for elective open nephrectomy under general anesthesia were included. All patients received Patient-controlled IV analgesia with fentanyl postoperatively. Patients were randomly allocated into three equal groups: The fentanyl group received 100 mL of IV normal saline as a placebo, with the first dose ending 30 min before intubation. In paracetamol group, IV 1 g paracetamol was given to the patients 30 min after extubation with repeated doses every 6 h totally 4 times a day. In preemptive paracetamol group, patients received IV 1 g paracetamol every 6 h, with the first dose ending 30 min before intubation. Results: Postoperative cumulative fentanyl consumption for 24 h was significantly higher in the fentanyl group (1009 +/- 139.361 mu g) than those of paracetamol (752.25 +/- 112.665 mu g) and preemptive paracetamol groups (761.10 +/- 226.625 mu g) (P = 0.001 for both). In early postoperative period (0-4 h); whereas total fentanyl consumption showed no statistically significant difference among groups (P = 0.186), the nausea-vomiting scores were significantly higher in the fentanyl group compared with other groups (P = 0.012). Conclusion: In patients undergoing open nephrectomy, use of preemptive or postoperative paracetamol reduces fentanyl related nausea-vomiting without a decrease in total fentanyl consumption in the early postoperative period. Furthermore, use of preemptive or postoperative paracetamol reduces total fentanyl requirements in the first 24 h postoperatively providing a safe and effective postoperative analgesia.	[Unal, S. S.] Kecioren Training & Res Hosp, Dept Anesthesiol & Reanimat, Ankara, Turkey; [Aksoy, M.; Ahiskalioglu, A.] Ataturk Univ, Fac Med, Dept Anesthesiol & Reanimat, Erzurum, Turkey; [Erdem, A. F.] Sakarya Univ, Fac Med, Dept Anesthesiol & Reanimat, Sakarya, Turkey; [Adanur, S.] Ataturk Univ, Fac Med, Dept Urol, Erzurum, Turkey	Aksoy, M (reprint author), Ataturk Univ, Fac Med, Dept Anesthesiol & Reanimat, Erzurum, Turkey.	drmaksoy@hotmail.com	Ahiskalioglu, Ali/K-5343-2019; Ahiskalioglu, Ali/B-7473-2016; ADANUR, SENOL/N-5139-2019	Ahiskalioglu, Ali/0000-0002-8467-8171; Ahiskalioglu, Ali/0000-0002-8467-8171; 			Alhashemi JA, 2006, CAN J ANAESTH, V53, P1200, DOI 10.1007/BF03021581; Apfel CC, 2013, PAIN, V154, P677, DOI 10.1016/j.pain.2012.12.025; Arici S, 2009, AGRI, V21, P54; Berry FA, 1998, PAEDIATR ANAESTH, V8, P187, DOI 10.1046/j.1460-9592.1998.00247.x; Cattabriga I, 2007, EUR J CARDIO-THORAC, V32, P527, DOI 10.1016/j.ejcts.2007.05.017; Cok OY, 2011, EUR J ANAESTH, V28, P836, DOI 10.1097/EJA.0b013e32834c580b; DELBOS A, 1995, J PAIN SYMPTOM MANAG, V10, P279, DOI 10.1016/0885-3924(95)00004-I; Elvir-Lazo OL, 2010, CURR OPIN ANESTHESIO, V23, P697, DOI 10.1097/ACO.0b013e32833fad0a; Gianesello L, 2012, J NEUROSURG ANESTH, V24, P121, DOI 10.1097/ANA.0b013e31823a885b; Hernandez-Palazon J, 2001, ANESTH ANALG, V92, P1473, DOI 10.1097/00000539-200106000-00024; Juhl GI, 2006, EUR J PAIN, V10, P371, DOI 10.1016/j.ejpain.2005.06.004; Kashefi Parviz, 2012, Adv Biomed Res, V1, P66, DOI 10.4103/2277-9175.100197; Kesimci E, 2011, AGRI, V23, P153, DOI 10.5505/agri.2011.86548; Khalili G, 2013, J CLIN ANESTH, V25, P188, DOI 10.1016/j.jclinane.2012.09.004; Kilicaslan A, 2010, AGRI, V22, P7; Ko MJ, 2010, KOREAN J ANESTHESIOL, V58, P357, DOI 10.4097/kjae.2010.58.4.357; LENTH RV, 2006, JAVA APPLETS POWER S; Marret E, 2005, ANESTHESIOLOGY, V102, P1249, DOI 10.1097/00000542-200506000-00027; McNicol ED, 2011, BRIT J ANAESTH, V106, P764, DOI 10.1093/bja/aer107; Murat I, 2005, PEDIATR ANESTH, V15, P663, DOI 10.1111/j.1460-9592.2004.01518.x; Peduto VA, 1998, ACTA ANAESTH SCAND, V42, P293, DOI 10.1111/j.1399-6576.1998.tb04919.x; Pickering G, 2006, CLIN PHARMACOL THER, V79, P371, DOI 10.1016/j.clpt.2005.12.307; Remy C, 2006, CURR OPIN ANESTHESIO, V19, P562, DOI 10.1097/01.aco.0000245285.30282.70; Schulz KF, 2011, INT J SURG, V9, P672, DOI 10.1016/j.ijsu.2011.09.004; Sinatra RS, 2005, ANESTHESIOLOGY, V102, P822, DOI 10.1097/00000542-200504000-00019; Trabulsi EJ, 2010, UROLOGY, V76, P1122, DOI 10.1016/j.urology.2010.03.052; Wang Y, 2012, CHINESE MED J-PEKING, V125, P579, DOI 10.3760/cma.j.issn.0366-6999.2012.04.004	27	7	7	0	6	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	1119-3077			NIGER J CLIN PRACT	Niger. J. Clin. Pract.	JAN-FEB	2015	18	1					68	74		10.4103/1119-3077.146982			7	Medicine, General & Internal	General & Internal Medicine	AX6WM	WOS:000347059000013	25511347				2020-06-30	J	Knych, HK; Steffey, EP; Mitchell, MM; Casbeer, HC				Knych, H. K.; Steffey, E. P.; Mitchell, M. M.; Casbeer, H. C.			Effects of age on the pharmacokinetics and selected pharmacodynamics of intravenously administered fentanyl in foals	EQUINE VETERINARY JOURNAL			English	Article						horse; fentanyl; foal; opioid; pharmacokinetics; behaviour	HEPATIC BLOOD-FLOW; NARCOTIC ANALGESICS; RESPONSES; SITES	Reasons for performing studyThe use of fentanyl is limited in adult horses, in part due to potential for central nervous system excitation. The pharmacokinetics and the plasma concentration-related behavioural actions of fentanyl have not been described for young foals. ObjectivesThe goal of the present study was to describe the pharmacokinetics and behavioural effects of fentanyl following administration to the same group of foals at 3 different ages. Study designExperimental study in healthy foals. MethodsFentanyl was administered i.v. (4g/kg bwt) to a group of 9 foals on 3 separate occasions at 6-8, 20-22 and 41-42 days of age. Blood samples were collected prior to administration and at multiple times until 24h post administration. Blood samples were analysed for fentanyl concentrations and pharmacokinetics determined at each age. Behavioural and physiological effects were also assessed. ResultsThe average volume of distribution was 3.55, 1.53 and 1.82l/kg bwt and clearance 50.2, 40.7 and 35.7ml/min/kg bwt when foals were 6-8, 20-22 and 41-42 days of age, respectively. The elimination half-life was slightly prolonged (49.3min) at 6-8 days relative to 20-22 and 41-42 days of age (25.8 and 33.7min, respectively). The primary metabolite detected in blood samples was the same as for adult horses. While the onset and duration varied widely between foals, sedation was observed at all ages studied. ConclusionsFentanyl appears to be consistently well tolerated following i.v. administration of 4g/kg bwt to foals ranging in age from 1 to 6 weeks. The results of this study support further study of fentanyl for clinical use in foals.	[Knych, H. K.; Steffey, E. P.; Mitchell, M. M.; Casbeer, H. C.] Univ Calif Davis, Sch Vet Med, KL Maddy Equine Analyt Chem Lab, Davis, CA 95616 USA; [Knych, H. K.] Univ Calif Davis, Sch Vet Med, Dept Vet Mol Biosci, Davis, CA 95616 USA; [Steffey, E. P.] Univ Calif Davis, Sch Vet Med, Dept Vet Surg & Radiol, Davis, CA 95616 USA	Knych, HK (reprint author), Univ Calif Davis, Sch Vet Med, KL Maddy Equine Analyt Chem Lab, Davis, CA 95616 USA.	hkknych@ucdavis.edu					ACLAND HM, 1984, VET PATHOL, V21, P3, DOI 10.1177/030098588402100102; BAGGOT JD, 1984, EQUINE VET J, V16, P364, DOI 10.1111/j.2042-3306.1984.tb01945.x; BOXENBAUM H, 1980, J PHARMACOKINET BIOP, V8, P165, DOI 10.1007/BF01065191; BRUMBAUGH GW, 1983, J VET PHARMACOL THER, V6, P219, DOI 10.1111/j.1365-2885.1983.tb00467.x; COMBIE J, 1981, AM J VET RES, V42, P716; Crisman MV, 1996, AM J VET RES, V57, P1759; Dyke TM, 1998, AM J VET RES, V59, P1476; Eberspacher E, 2008, VET ANAESTH ANALG, V35, P249, DOI 10.1111/j.1467-2987.2007.00378.x; EDWARDS DJ, 1990, AUST VET J, V67, P251, DOI 10.1111/j.1751-0813.1990.tb07779.x; FRINCKE JM, 1980, DRUG METAB DISPOS, V8, P425; Gurkan Aydin, 2005, Ann Card Anaesth, V8, P140; Haechler S, 2000, VET PATHOL, V37, P669, DOI 10.1354/vp.37-6-669; JOHNSON K L, 1984, Anesthesiology (Hagerstown), V61, pA441, DOI 10.1097/00000542-198409001-00441; KAMERLING SG, 1985, GEN PHARMACOL, V16, P253, DOI 10.1016/0306-3623(85)90078-3; KOEHNTOP DE, 1986, ANESTH ANALG, V65, P227; LAUBIE M, 1977, N-S ARCH PHARMACOL, V296, P255, DOI 10.1007/BF00498691; LAUBIE M, 1974, EUR J PHARMACOL, V28, P66, DOI 10.1016/0014-2999(74)90113-7; Mama KR, 2005, AM J VET RES, V66, P1002, DOI 10.2460/ajvr.2005.66.1002; MAMA KR, 1993, CAN J VET RES, V57, P106; Maxwell LK, 2003, EQUINE VET J, V35, P484, DOI 10.2746/042516403775600415; NOUWS JFM, 1992, J ANIM SCI, V70, P3627; PRESCOTT JF, 1983, J VET PHARMACOL THER, V6, P67, DOI 10.1111/j.1365-2885.1983.tb00456.x; RUCQUOI M, 1983, BRIT J ANAESTH, V55, pS223; Russo C. I., 2002, P 14 INT C RAC AN VE, P413; STEFFEY EP, 1987, AM J VET RES, V48, P7; Thomas W P, 1987, J Reprod Fertil Suppl, V35, P623; Thomasy SM, 2007, EQUINE VET J, V39, P54, DOI 10.2746/042516407X153011; WECKMAN TJ, 1989, AM J VET RES, V50, P502; Zhou RL, 2012, ANESTH ANALG, V114, P122, DOI 10.1213/ANE.0b013e318232e922	29	3	3	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0425-1644	2042-3306		EQUINE VET J	Equine Vet. J.	JAN	2015	47	1					72	77		10.1111/evj.12246			6	Veterinary Sciences	Veterinary Sciences	AX2IT	WOS:000346767600013	25263971				2020-06-30	J	Okushima, S; Vettorato, E; Corletto, F				Okushima, Sayaka; Vettorato, Enzo; Corletto, Federico			Chronotropic effect of propofol or alfaxalone following fentanyl administration in healthy dogs	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						alfaxalone; dogs; fentanyl; heart rate; propofol	BRADYCARDIA; ANESTHESIA; INDUCTION	ObjectiveTo compare the effect of alfaxalone and propofol on heart rate (HR) and blood pressure (BP) after fentanyl administration in healthy dogs. Study designProspective, randomised clinical study. AnimalsFifty healthy client owned dogs (ASA I/II) requiring general anaesthesia for elective magnetic resonance imaging for neurological conditions. MethodsAll dogs received fentanyl 7gkg(-1) IV and were allocated randomly to receive either alfaxalone (n=25) or propofol (n=25) to effect until endotracheal (ET) intubation was possible. Heart rate and oscillometric BP were measured before fentanyl (baseline), after fentanyl (Time F) and after ET intubation (Time GA). Post-induction apnoea were recorded. Data were analysed using Fisher's exact test, Mann Whitney U test and one-way anova for repeated measures as appropriate; p value <0.05 was considered significant. ResultsDogs receiving propofol showed a greater decrease in HR (-14 beat minute(-1), range -47 to 10) compared to alfaxalone (1beatminute(-1), range -33 to 26) (p=0.0116). Blood pressure decreased over the three time periods with no difference between groups. Incidence of post-induction apnoea was not different between groups. ConclusionFollowing fentanyl administration, anaesthetic induction with propofol resulted in a greater negative chronotropic effect while alfaxalone preserved or increased HR. Clinical relevanceFollowing fentanyl administration, HR decreases more frequently when propofol rather than alfaxalone is used as induction agent. However, given the high individual variability and the small change in predicted HR (-7.7beats per minute after propofol), the clinical impact arising from choosing propofol or alfaxalone is likely to be small in healthy animals. Further studies in dogs with myocardial disease and altered haemodynamics are warranted.	[Okushima, Sayaka; Vettorato, Enzo; Corletto, Federico] Dick White Referrals, Six Mile Bottom, Cambs, England	Okushima, S (reprint author), Dick White Referrals, Six Mile Bottom, Cambs, England.	so@dickwhitereferrals.com					Acierno MJ, 2013, J VET EMERG CRIT CAR, V23, P37, DOI 10.1111/vec.12011; Amengual M, 2013, VET ANAESTH ANALG, V40, P115, DOI 10.1111/j.1467-2995.2012.00747.x; BILLARD V, 1994, ANESTHESIOLOGY, V81, P1384, DOI 10.1097/00000542-199412000-00013; COLSON P, 1988, ANESTH ANALG, V67, P906; Covey-Crump GL, 2008, VET ANAESTH ANALG, V35, P463, DOI 10.1111/j.1467-2995.2008.00408.x; CULLEN PM, 1987, ANESTH ANALG, V66, P1115; Hashiba E, 2003, ACTA ANAESTH SCAND, V47, P1059, DOI 10.1034/j.1399-6576.2003.00228.x; Maney JK, 2013, VET ANAESTH ANALG, V40, P237, DOI 10.1111/vaa.12006; Muir W, 2008, VET ANAESTH ANALG, V35, P451, DOI 10.1111/j.1467-2995.2008.00406.x; Nolan AM, 1991, VET ANAESTH ANALG, V18, P30	10	9	9	0	13	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	JAN	2015	42	1					88	92		10.1111/vaa.12166			5	Veterinary Sciences	Veterinary Sciences	AX2IS	WOS:000346767500011	24735086				2020-06-30	J	Cattai, A; Rabozzi, R; Natale, V; Franci, P				Cattai, Andrea; Rabozzi, Roberto; Natale, Valentina; Franci, Paolo			The incidence of spontaneous movements (myoclonus) in dogs undergoing total intravenous anaesthesia with propofol	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						anaesthesia; dogs; myoclonus; Propofol; TIVA	TRIAL	ObjectiveTo evaluate the incidence of myoclonus (involuntary movements during anaesthesia, unrelated to inadequate hypnosis or analgesia, and of sufficient severity to require treatment) in dogs anaesthetized with a TIVA of propofol with or without the use of fentanyl. Study designRetrospective clinical study. AnimalsDogs, undergoing general anaesthesia for clinical procedures between January 2012 and January 2013 and subject to TIVA with propofol. MethodsA retrospective analysis reviewed the medical and anaesthetic records. Animals with existing or potential neurological or neuromuscular pathology in the anamnesis or upon clinical examination and cases with incomplete clinical records were excluded. Myoclonus was considered as involuntary muscle contractions which did not cease following a bolus administration of propofol or fentanyl and, due to their intensity and duration, made continuation of the procedure impracticable without other drug administration. Tremors, paddling or muscle spasms, explicable as insufficient hypnosis or analgesia, and transient excitatory phenomena only present during the awakening phase, were not considered as myoclonus. ResultsOut of a total of 492 dogs undergoing anaesthesia, six mixed breed dogs (1.2%), one male and five females, American Society of Anaesthesiologists (ASA) physical status I, median (range) weight 20.5 (7-37)kg and age 1.5 (1-5)years had myoclonus according to the aforementioned definition. In all subjects, myoclonus appeared within 20minutes after induction of anaesthesia, and mainly involved the limb muscles. All subjects appeared to be in an adequate plane of anaesthesia before and during myoclonus. Conclusions and clinical relevanceThis study shows that 1.2% of dogs, undergoing TIVA with propofol with or without fentanyl administration, developed myoclonus, which required to be, and were treated successfully pharmacologically. The cause of this phenomenon is yet to be determined.	[Cattai, Andrea; Franci, Paolo] Univ Padua, Dept Anim Med Prod & Hlth, Agripolis, Padua, Italy; [Rabozzi, Roberto; Natale, Valentina] Clin Vet Adriat, Vasto, Italy	Franci, P (reprint author), Univ Padua, Dept Anim Med Prod & Hlth, Agripolis, Viale Univ, Padua, Italy.	paolo.franci@unipd.it		Cattai, Andrea/0000-0002-4721-3711			Bilotta F, 2006, PEDIATR ANESTH, V16, P1232, DOI 10.1111/j.1460-9592.2006.01970.x; BORGEAT A, 1991, ANESTHESIOLOGY, V74, P24, DOI 10.1097/00000542-199101000-00005; Davies C., 1991, Journal of Veterinary Anaesthesia, V18, P48; HALL LW, 1987, J SMALL ANIM PRACT, V28, P623, DOI 10.1111/j.1748-5827.1987.tb01277.x; Kerz T, 2001, ANESTHESIOLOGY, V94, P32, DOI 10.1097/00000542-200101000-00010; REDDY RV, 1993, ANESTH ANALG, V77, P1008; ROBERTSON SA, 1992, AM J VET RES, V53, P1027; San-juan D, 2010, CLIN NEUROPHYSIOL, V121, P998, DOI 10.1016/j.clinph.2009.12.016; Tsai YC, 2007, J VET MED SCI, V69, P1179, DOI 10.1292/jvms.69.1179; Voss LJ, 2008, ANESTH ANALG, V107, P1689, DOI 10.1213/ane.0b013e3181852595	10	6	6	0	8	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	JAN	2015	42	1					93	98		10.1111/vaa.12160			6	Veterinary Sciences	Veterinary Sciences	AX2IS	WOS:000346767500012	24961940				2020-06-30	J	White, PF; Elvir-Lazo, OL; Zaentz, AS; Kariger, R; Yumul, R; Khany, MM; Stern, A; Vuong, M; Wender, RH				White, P. F.; Elvir-Lazo, O. L.; Zaentz, A. S.; Kariger, R.; Yumul, R.; Khany, M. M.; Stern, A.; Vuong, M.; Wender, R. H.			Does small-dose fentanyl improve perioperative outcomes in the ambulatory setting? A randomized, double-blind, placebo-controlled study	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							INDUCED COUGH; ANESTHESIA; SURGERY; PAIN; INDUCTION; MIDAZOLAM; RECOVERY	BackgroundDespite its widespread use, the beneficial effect of low-dose fentanyl administered at induction of anesthesia on perioperative outcomes has not been studied in the ambulatory setting. Therefore, this study was designed to test the hypothesis that administration of small-dose fentanyl vs. saline during induction reduces coughing and movements without adversely affecting recovery after day-surgery. MethodsOne hundred consenting outpatients scheduled to undergo superficial surgical procedures under general anesthesia with a laryngeal mask airway (LMA) device for airway management were randomly assigned to one of two treatment groups: control (n=50) or fentanyl (n=50). After administration of 2ml of the unlabelled study medication containing either fentanyl (100g) or saline, anesthesia was induced with lidocaine 30-50mg and propofol 2mg/kg IV followed by the insertion of an LMA device. General anesthesia was maintained using a propofol infusion, 75g/kg/min, and desflurane (2-5% end-tidal) in 100% oxygen. ResultsCoughing was observed in six (12%) and ten (20%) in the fentanyl and control group, respectively (P=0.41). The incidence of movements during surgery was lower in the fentanyl group (18% vs. 31%, P<0001). There were no significant differences in early and late recovery times or pain scores between the two groups. ConclusionAdministration of a small-dose of fentanyl at induction of anesthesia significantly reduced purposeful movements during day-surgery under propofol-desflurane anesthesia. No significant difference was found in coughing or recovery times.	[White, P. F.; Elvir-Lazo, O. L.; Zaentz, A. S.; Kariger, R.; Yumul, R.; Khany, M. M.; Stern, A.; Vuong, M.; Wender, R. H.] Cedars Sinai Med Ctr, Dept Anesthesiol, Los Angeles, CA 90048 USA; [White, P. F.] Univ Bologna, Ist Ortoped Rizzoli, Bologna, Italy; [White, P. F.] White Mt Inst, Sea Ranch, CA 95497 USA	White, PF (reprint author), White Mt Inst, 41299 Tallgrass, Sea Ranch, CA 95497 USA.	paul.white@cshs.org			Baxter Healthcare [219942]; White Mountain Institute, a private non-for-profit education and research foundation; General Anesthesia Specialty Practice (GASP), Los Angeles, CA	Baxter Healthcare provided an investigator-sponsored clinical research grant (#219942) to Cedars Sinai Medical Center in Los Angeles. Dr White also receives support from the White Mountain Institute, a private non-for-profit education and research foundation, and the General Anesthesia Specialty Practice (GASP), Los Angeles, CA.	Ambesh SP, 2010, BRIT J ANAESTH, V104, P40, DOI 10.1093/bja/aep333; Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Bauer KP, 2004, J CLIN ANESTH, V16, P177, DOI 10.1016/j.jclinane.2003.07.003; Hung KC, 2010, ANAESTHESIA, V65, P4, DOI 10.1111/j.1365-2044.2009.06109.x; Lenz H, 2008, ACTA ANAESTH SCAND, V52, P149, DOI 10.1111/j.1399-6576.2007.01471.x; Lesage S, 2009, CAN J ANAESTH, V56, P733, DOI 10.1007/s12630-009-9150-6; Lida K, 2009, MASUI, V58, P962; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; Pavlin DJ, 2002, ANESTH ANALG, V95, P627, DOI 10.1097/00000539-200209000-00025; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; SHAFER A, 1989, ANESTHESIOLOGY, V71, P495, DOI 10.1097/00000542-198910000-00004; Smith I, 2008, EUR J ANAESTH, V25, P790, DOI 10.1017/S026502150800464X; Tang QF, 2010, UPSALA J MED SCI, V115, P121, DOI 10.3109/03009730903291034; White PF, 1999, J CLIN ANESTH, V11, P78; White PF, 2003, ANESTH ANALG, V97, P1633, DOI 10.1213/01.ANE.0000085296.07006.BA; Zarate E, 1999, ANESTHESIOLOGY, V90, P956, DOI 10.1097/00000542-199904000-00005	16	3	3	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JAN	2015	59	1					56	64		10.1111/aas.12424			9	Anesthesiology	Anesthesiology	AW9NA	WOS:000346583000006	25329822				2020-06-30	J	Werther, T; Olischar, M; Giordano, V; Czaba, C; Waldhoer, T; Berger, A; Pollak, A; Deindl, P				Werther, Tobias; Olischar, Monika; Giordano, Vito; Czaba, Christine; Waldhoer, Thomas; Berger, Angelika; Pollak, Arnold; Deindl, Philipp			Bispectral Index and Lower Margin Amplitude of the Amplitude-Integrated Electroencephalogram in Neonates	NEONATOLOGY			English	Article						Amplitude-integrated electroencephalogram; Bispectral index; Cerebral function monitoring; Neonates; Sedation	FULL-TERM NEWBORN; PRETERM INFANTS; EEG SIGNALS; SEDATION; CHILDREN; BRAIN; AGE; MATURATION; ANESTHESIA; ARTIFACTS	Background: The lower margin amplitude (LMA) of the amplitude-integrated electroencephalogram (aEEG) is suppressed in neonates during deep sedation, a feature that is attributed to the bispectral index (BIS) in adults. Objective: We compare the BIS and the LMA of the aEEG in neonates. Methods: Thirty neurologically healthy neonates between 37 and 44 weeks postmenstrual age were included in this study. Twenty patients received sedoanalgesic therapy for various reasons. BIS and aEEG recordings were performed simultaneously. The digital data were imported in the numerical software environment Matlab (R). The LMA of the aEEG was computed on a 1-min time scale and synchronized with the BIS data. The correlation between the time-dependent variables BIS and LMA was estimated using the Spearman rank correlation index. Results: The median correlation between BIS and LMA was 0.3. Inclusion of recordings of high signal quality only into analysis improved the median correlation index to 0.6. Conclusions: We found a light-to-moderate correlation between BIS and LMA in our study cohort and a good correlation in the subgroup with high signal quality. (C) 2014 S. Karger AG, Basel	[Werther, Tobias; Olischar, Monika; Giordano, Vito; Czaba, Christine; Berger, Angelika; Pollak, Arnold; Deindl, Philipp] Med Univ Vienna, Ctr Publ Hlth, Dept Pediat & Adolescent Med, Div Neonatol Intens Care & Neuropediat, Vienna, Austria; [Waldhoer, Thomas] Med Univ Vienna, Ctr Publ Hlth, Dept Epidemiol, Vienna, Austria; [Deindl, Philipp] Univ Med Ctr Hamburg Eppendorf, Dept Neonatol & Pediat Intens Care Med, DE-20246 Hamburg, Germany	Deindl, P (reprint author), Univ Med Ctr Hamburg Eppendorf, Dept Neonatol & Pediat Intens Care Med, Martinistr 52, DE-20246 Hamburg, Germany.	p.deindl@uke.de	Werther, Tobias/A-6608-2018	Werther, Tobias/0000-0003-2442-8557; Waldhoer, Thomas/0000-0003-2043-8299; Berger, Angelika/0000-0001-8775-2405	Janssen-Cilag Award 'Nachwuchs-Forderpreis Schmerz'	This study was partially founded by the Janssen-Cilag Award 'Nachwuchs-Forderpreis Schmerz'.	Bernet V, 2010, PEDIATR RES, V67, P650, DOI 10.1203/PDR.0b013e3181da44ba; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; de Vries LS, 2006, CLIN PERINATOL, V33, P619, DOI 10.1016/j.clp.2006.06.002; Dubowitz L, 2005, MENT RETARD DEV D R, V11, P52, DOI 10.1002/mrdd.20048; Griesmaier E, 2014, NEONATOLOGY, V105, P175, DOI 10.1159/000356782; Griesmaier E, 2013, PEDIATR RES, V73, P226, DOI 10.1038/pr.2012.171; Hagmann CF, 2006, PEDIATRICS, V118, P2552, DOI 10.1542/peds.2006-2519; Hellstrom-Westas L, 2006, SEMIN FETAL NEONAT M, V11, P503, DOI 10.1016/j.siny.2006.07.011; Johansen JW, 2006, BEST PRACT RES-CLIN, V20, P81, DOI 10.1016/j.bpa.2005.08.004; Kostovic I, 2006, SEMIN FETAL NEONAT M, V11, P415, DOI 10.1016/j.siny.2006.07.001; Lamas A, 2008, INTENS CARE MED, V34, P2092, DOI 10.1007/s00134-008-1198-1; Lee HJ, 2010, NEONATOLOGY, V98, P245, DOI 10.1159/000277936; Lehmann A, 2003, ANESTH ANALG, V96, P336, DOI 10.1097/00000539-200302000-00008; Malviya S, 2007, PEDIATRICS, V120, pE461, DOI 10.1542/peds.2006-2577; Massaro AN, 2012, NEONATOLOGY, V102, P197, DOI 10.1159/000339570; MAYNARD D, 1969, BRIT MED J, V4, P545, DOI 10.1136/bmj.4.5682.545-a; Natalucci G, 2013, NEONATOLOGY, V103, P134, DOI 10.1159/000345202; Olischar M, 2007, ACTA PAEDIATR, V96, P1743, DOI 10.1111/j.1651-2227.2007.00462.x; Olischar M, 2012, NEONATOLOGY, V102, P203, DOI 10.1159/000339567; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; Rosen I, 2006, CLIN PERINATOL, V33, P593, DOI 10.1016/j.clp.2006.06.013; Sadhasivam S, 2006, ANESTH ANALG, V102, P383, DOI 10.1213/01.ANE.0000184115.57837.30; Scraggs Terri L, 2012, Neurodiagn J, V52, P176; Toet MC, 2008, CLIN PERINATOL, V35, P665, DOI 10.1016/j.clp.2008.07.017; WEBSTER JG, 1984, IEEE T BIO-MED ENG, V31, P823, DOI 10.1109/TBME.1984.325244; Young GB, 2000, CLIN NEUROPHYSIOL, V111, P1955, DOI 10.1016/S1388-2457(00)00433-8	26	4	5	0	7	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1661-7800	1661-7819		NEONATOLOGY	Neonatology		2015	107	1					34	41		10.1159/000365277			8	Pediatrics	Pediatrics	AW4JD	WOS:000346246300006	25323947				2020-06-30	J	Longhini, F; Ferrero, F; De Luca, D; Cosi, G; Alemani, M; Colombo, D; Cammarota, G; Berni, P; Conti, G; Bona, G; Della Corte, F; Navalesi, P				Longhini, Federico; Ferrero, Federica; De Luca, Daniele; Cosi, Gianluca; Alemani, Moreno; Colombo, Davide; Cammarota, Gianmaria; Berni, Paola; Conti, Giorgio; Bona, Gianni; Della Corte, Francesco; Navalesi, Paolo			Neurally Adjusted Ventilatory Assist in Preterm Neonates with Acute Respiratory Failure	NEONATOLOGY			English	Article						Mechanical ventilation; Premature infant; Respiratory insufficiency; Neurally adjusted ventilatory assist	DISTRESS-SYNDROME; RANDOMIZED CROSSOVER; PRESSURE-SUPPORT; INFANTS; VARIABILITY; ASYNCHRONY; CHILDREN; NAVA	Background: Neurally adjusted ventilatory assist (NAVA) is a novel mode of ventilation that has been demonstrated to improve infant-ventilator interaction, compared to the conventional modes in retrospective and short-term studies. Objectives: To prospectively evaluate the physiologic effects of NAVA in comparison with pressure-regulated volume control (PRVC) in two nonrandomized 12-hour periods. Methods: We studied 14 consecutive intubated preterm neonates receiving mechanical ventilation for acute respiratory failure. Peak airway pressure (Paw(peak)), diaphragm electrical activity (EAdi), tidal volume (V-T), mechanical (RRmec) and neural (RRneu) respiratory rates, neural apneas, and the capillary arterialized blood gases were measured. The RRmec-to-RRneu ratio (MNR) and the asynchrony index were also calculated. The amount of fentanyl administered was recorded. Results: Paw(peak) and V-T were greater in PRVC (p < 0.01). Blood gases and RRmec were not different between modes, while RRneu and the EAdi swings were greater in NAVA (p = 0.02 and p < 0.001, respectively). MNR and the asynchrony index were remarkably lower in NAVA than in PRVC (p = 0.03 and p < 0.001, respectively). 1,841 neural apneas were observed during PRVC, with none in NAVA. Less fentanyl was administered during NAVA, as opposed to PRVC (p < 0.01). Conclusions: In acutely ill preterm neonates, NAVA can be safely and efficiently applied for 12 consecutive hours. Compared to PRVC, NAVA is well tolerated with fewer sedatives. (C) 2014 S. Karger AG, Basel	[Longhini, Federico; Alemani, Moreno; Della Corte, Francesco; Navalesi, Paolo] Eastern Piedmont Univ A Avogadro, Dept Translat Med, IT-28100 Novara, Italy; [Bona, Gianni] Eastern Piedmont Univ A Avogadro, Dept Hlth Sci, Div Pediat, IT-28100 Novara, Italy; [Ferrero, Federica; Cosi, Gianluca; Colombo, Davide; Cammarota, Gianmaria; Berni, Paola; Della Corte, Francesco] Maggiore Carita Hosp, Novara, Italy; [De Luca, Daniele; Conti, Giorgio] Univ Cattolica Sacro Cuore, Dept Intens Care & Anesthesia, Rome, Italy; [Navalesi, Paolo] ASL VC, St Andrea Hosp, Vercelli, Italy; [Navalesi, Paolo] CRRF Mons L Novarese, Moncrivello, Italy; [De Luca, Daniele] South Paris Univ Hosp, Med Ctr A Beclere, AP HP, Div Pediat & Neonatal Crit Care, Paris, France	Navalesi, P (reprint author), Eastern Piedmont Univ A Avogadro, Dept Translat Med, Via Solaroli 17, IT-28100 Novara, Italy.	paolo.navalesi@med.unipmn.it	Longhini, Federico/I-8501-2019; Navalesi, Paolo/F-9559-2010; Navalesi, Paolo/I-9584-2019; Cammarota, Gianmaria/AAF-5146-2020; Colombo, Davide/I-8140-2019	Longhini, Federico/0000-0002-6970-7202; Navalesi, Paolo/0000-0002-3733-3453; Navalesi, Paolo/0000-0002-3733-3453; Colombo, Davide/0000-0003-0756-6632; Della Corte, Francesco/0000-0003-1736-2318; De Luca, Daniele/0000-0002-3846-4834			Amer Acad Pediat, 2006, PEDIATRICS, V118, P2231, DOI 10.1542/peds.2006-2277; Beck J, 2009, PEDIATR RES, V65, P663, DOI 10.1203/PDR.0b013e31819e72ab; Bengtsson JA, 2010, PEDIATR CRIT CARE ME, V11, P253, DOI 10.1097/PCC.0b013e3181b0655e; Bordessoule A, 2012, PEDIATR RES, V72, P194, DOI 10.1038/pr.2012.64; Brander L, 2009, INTENS CARE MED, V35, P1979, DOI 10.1007/s00134-009-1626-x; Breatnach C, 2010, PEDIATR CRIT CARE ME, V11, P7, DOI 10.1097/PCC.0b013e3181b0630f; Colombo D, 2008, INTENS CARE MED, V34, P2010, DOI 10.1007/s00134-008-1208-3; de la Oliva P, 2012, INTENS CARE MED, V38, P838, DOI 10.1007/s00134-012-2535-y; De Luca D, 2013, INTENS CARE MED, V39, P2083, DOI 10.1007/s00134-013-3110-x; Delisle S, 2013, RESP CARE, V58, P745, DOI 10.4187/respcare.01456; Kallio M, 2014, PEDIAT PULMONOL, DOI 10.1002/ppul.22995; Lee J, 2012, J PEDIATR-US, V161, P808, DOI 10.1016/j.jpeds.2012.04.040; Mauri T, 2013, INTENS CARE MED, V39, P282, DOI 10.1007/s00134-012-2755-1; Nock ML, 2004, J PEDIATR-US, V144, P291, DOI 10.1016/j.jpeds.2003.11.035; Piastra M, 2014, J CRIT CARE, V29, DOI 10.1016/j.jcrc.2013.08.006; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Schulze A, 2007, NEONATOLOGY, V92, P1, DOI 10.1159/000098376; Sinderby C, 1999, NAT MED, V5, P1433, DOI 10.1038/71012; Stein H, 2013, J PERINATOL, V33, P452, DOI 10.1038/jp.2012.136; Stein H, 2012, J PEDIATR-US, V160, P786, DOI 10.1016/j.jpeds.2011.10.014; Sweet DG, 2013, NEONATOLOGY, V103, P353, DOI 10.1159/000349928; Thille AW, 2006, INTENS CARE MED, V32, P1515, DOI 10.1007/s00134-006-0301-8; van Kaam AH, 2010, J PEDIATR, V157; Vignaux L, 2013, PEDIATR CRIT CARE ME, V14, pE316, DOI 10.1097/PCC.0b013e31828a8606; Wheeler KI, 2011, NEONATOLOGY, V100, P219, DOI 10.1159/000326080	25	23	25	0	9	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1661-7800	1661-7819		NEONATOLOGY	Neonatology		2015	107	1					60	67		10.1159/000367886			8	Pediatrics	Pediatrics	AW4JD	WOS:000346246300011	25401284				2020-06-30	J	Wade, CL; Vendruscolo, LF; Schlosburg, JE; Hernandez, DO; Koob, GF				Wade, Carrie L.; Vendruscolo, Leandro F.; Schlosburg, Joel E.; Hernandez, Daniel O.; Koob, George F.			Compulsive-Like Responding for Opioid Analgesics in Rats with Extended Access	NEUROPSYCHOPHARMACOLOGY			English	Article							DISCRIMINATIVE STIMULUS; DRUG-USE; HEROIN; BUPRENORPHINE; COCAINE; RECEPTOR; ESCALATION; DEPENDENCE; AGONIST; MODELS	The abuse of prescription opioids that are used for the treatment of chronic pain is a major public health concern, costing similar to$ 53.4 billion annually in lost wages, health-care costs, and criminal costs. Although opioids remain a first-line therapy for the treatment of severe chronic pain, practitioners remain cautious because of the potential for abuse and addiction. Opioids such as heroin are considered very rewarding and reinforcing, but direct and systematic comparisons of compulsive intake between commonly prescribed opioids and heroin in animal models have not yet been performed. In the present study, we evaluated the potential for compulsive-like drug seeking and taking, using intravenous self-administration of oxycodone, fentanyl, and buprenorphine in rats allowed long access sessions (12 h). We measured compulsive-like intake using an established escalation model and responding on a progressive ratio schedule of reinforcement. We compared the potential for compulsive-like self-administration of these prescription opioids and heroin, which has been previously established to induce increasing intake that models the transition to addiction in humans. We found that animals that self-administered oxycodone, fentanyl, or heroin, but not buprenorphine had similar profiles of escalation and increases in breakpoints. The use of extended access models of prescription opioid intake will help better understand the biological factors that underlie opioid dependence.	[Wade, Carrie L.; Vendruscolo, Leandro F.; Schlosburg, Joel E.; Hernandez, Daniel O.; Koob, George F.] Scripps Res Inst, Comm Neurobiol Addict Disorders, La Jolla, CA 92037 USA	Wade, CL (reprint author), Scripps Res Inst, Comm Neurobiol Addict Disorders, 10550 North Torrey Pines Rd,SP30-2400, La Jolla, CA 92037 USA.	clwade@scripps.edu			National Institutes of Health from the National Institute on Drug Abuse [DA004043]; Pearson Center for Alcoholism and Addiction Research	This research was financially supported by National Institutes of Health grants DA004043 from the National Institute on Drug Abuse and the Pearson Center for Alcoholism and Addiction Research. The authors declare no conflict of interest.	Ahmed SH, 2002, NAT NEUROSCI, V5, P625, DOI 10.1038/nn872; Ahmed SH, 2000, NEUROPSYCHOPHARMACOL, V22, P413, DOI 10.1016/S0893-133X(99)00133-5; American Psychiatric Association, 2013, DIAGN STAT MAN MENT; Barbier E, 2013, NEUROPSYCHOPHARMACOL, V38, P976, DOI 10.1038/npp.2012.261; Beardsley PM, 2004, EXP CLIN PSYCHOPHARM, V12, P163, DOI 10.1037/1064-1297.12.3.163; BOZARTH MA, 1985, JAMA-J AM MED ASSOC, V254, P81, DOI 10.1001/jama.254.1.81; Calipari ES, 2014, J NEUROCHEM, V128, P224, DOI 10.1111/jnc.12452; Cashman JR, 2014, J PHARMACOL EXP THER, V350, P171, DOI 10.1124/jpet.114.214262; Chen SA, 2006, NEUROPSYCHOPHARMACOL, V31, P2692, DOI 10.1038/sj.npp.1301008; COLPAERT FC, 1978, PHARMACOL BIOCHEM BE, V9, P863, DOI 10.1016/0091-3057(78)90370-2; Edwards S, 2012, METHODS MOL BIOL, V829, P31, DOI 10.1007/978-1-61779-458-2_2; FRANCES B, 1992, J PHARMACOL EXP THER, V262, P25; HODOS W, 1961, SCIENCE, V134, P943, DOI 10.1126/science.134.3483.943; Huang P, 2001, J PHARMACOL EXP THER, V297, P688; KAJIWARA M, 1986, JPN J PHARMACOL, V40, P95, DOI 10.1254/jjp.40.95; Ko MC, 2002, J PHARMACOL EXP THER, V301, P698, DOI 10.1124/jpet.301.2.698; Koob GF, 2014, NEUROPHARMACOLOGY, V76, P370, DOI 10.1016/j.neuropharm.2013.05.024; Koob GF, 2009, NEUROPHARMACOLOGY, V56, P18, DOI 10.1016/j.neuropharm.2008.07.043; Koob GF, 2004, NEUROSCI BIOBEHAV R, V27, P739, DOI 10.1016/j.neubiorev.2003.11.007; KOOB GF, 2006, NEUR ADD, pR9; Margolis EB, 2003, J NEUROSCI, V23, P9981; Martin TJ, 2008, EXP CLIN PSYCHOPHARM, V16, P357, DOI 10.1037/a0013597; Martin TJ, 2007, ANESTHESIOLOGY, V106, P312, DOI 10.1097/00000542-200702000-00020; Mello NK, 2007, NEUROPSYCHOPHARMACOL, V32, P1985, DOI 10.1038/sj.npp.1301319; MELLO NK, 1988, DRUG ALCOHOL DEPEN, V21, P81, DOI 10.1016/0376-8716(88)90053-1; Murphy NP, 1996, NEUROSCIENCE, V75, P1, DOI 10.1016/0306-4522(96)00322-3; Negus SS, 2006, J PHARMACOL EXP THER, V317, P711, DOI 10.1124/jpet.105.095380; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Piazza PV, 2000, J NEUROSCI, V20, P4226; Prus AJ, 2009, FRONT NEUROSCI, P59; ROBERTS DCS, 1989, PSYCHOPHARMACOLOGY, V97, P535, DOI 10.1007/BF00439560; Sante AB, 2000, BEHAV PHARMACOL, V11, P583, DOI 10.1097/00008877-200011000-00005; SHANNON HE, 1984, J PHARMACOL EXP THER, V229, P768; Substance Abuse and Mental Health Services Administration, 2012, TREATM EP DAT SET; Vendruscolo LF, 2011, PHARMACOL BIOCHEM BE, V98, P570, DOI 10.1016/j.pbb.2011.03.004; Volpe DA, 2011, REGUL TOXICOL PHARM, V59, P385, DOI 10.1016/j.yrtph.2010.12.007; Wee S, 2009, PSYCHOPHARMACOLOGY, V205, P565, DOI 10.1007/s00213-009-1563-y; World Health Organization, 1992, INT STAT CLASS DIS R; Zernig G, 2007, PHARMACOLOGY, V80, P65, DOI 10.1159/000103923	39	49	49	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	JAN	2015	40	2					421	428		10.1038/npp.2014.188			8	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	AW2WQ	WOS:000346147800018	25060491	Bronze, Green Published			2020-06-30	J	Kuo, A; Wyse, BD; Meutermans, W; Smith, MT				Kuo, A.; Wyse, B. D.; Meutermans, W.; Smith, M. T.			In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile	BRITISH JOURNAL OF PHARMACOLOGY			English	Article						morphine; morphine-6-glucuronide (M6G); oxycodone; buprenorphine; fentanyl; antinociception; constipation; respiratory depression; intracerebroventricular; rat	INTRACEREBROVENTRICULAR MORPHINE; CEREBROSPINAL-FLUID; ARRIVE GUIDELINES; RECEPTOR; MU; RATS; OXYCODONE; DELTA; BINDING; PAIN	Background and PurposeFor patients experiencing inadequate analgesia and intolerable opioid-related side effects on one strong opioid analgesic, pain relief with acceptable tolerability is often achieved by rotation to a second strong opioid. These observations suggest subtle pharmacodynamic differences between opioids in vivo. This study in rats was designed to assess differences between opioids in their in vivo profiles. Experimental ApproachMale Sprague Dawley rats were given single i.c.v. bolus doses of morphine, morphine-6-glucuronide (M6G), fentanyl, oxycodone, buprenorphine, DPDPE ([D-penicillamine(2,5)]-enkephalin) or U69,593. Antinociception, constipation and respiratory depression were assessed using the warm water tail-flick test, the castor oil-induced diarrhoea test and whole body plethysmography respectively. Key ResultsThese opioid agonists produced dose-dependent antinociception, constipation and respiratory depression. For antinociception, morphine, fentanyl and oxycodone were full agonists, buprenorphine and M6G were partial agonists, whereas DPDPE and U69,593 had low potency. For constipation, M6G, fentanyl and buprenorphine were full agonists, oxycodone was a partial agonist, morphine produced a bell-shaped dose-response curve, whereas DPDPE and U69,593 were inactive. For respiratory depression, morphine, M6G, fentanyl and buprenorphine were full agonists, oxycodone was a partial agonist, whereas DPDPE and U69,593 were inactive. The respiratory depressant effects of fentanyl and oxycodone were of short duration, whereas morphine, M6G and buprenorphine evoked prolonged respiratory depression. Conclusion and ImplicationsFor the seven opioids we assessed, no two had the same profile for evoking antinociception, constipation and respiratory depression, suggesting that these effects are differentially regulated. Our findings may explain the clinical success of opioid rotation'. Linked ArticlesThis article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit	[Kuo, A.; Wyse, B. D.; Smith, M. T.] Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia; [Kuo, A.; Wyse, B. D.; Smith, M. T.] Univ Queensland, Ctr Integrated Preclin Drug Dev, Brisbane, Qld 4072, Australia; [Meutermans, W.] Alchemia Ltd, Brisbane, Qld, Australia	Smith, MT (reprint author), Univ Queensland, Ctr Integrated Preclin Drug Dev, Level 3,Steele Bldg, Brisbane, Qld 4072, Australia.	maree.smith@uq.edu.au	Smith, Maree T/I-4005-2015; Kuo, Andy/I-4007-2015	Smith, Maree T/0000-0003-2281-3734; 	Australian Research Council Linkage GrantAustralian Research Council [LP0668324]; Alchemia Ltd.; Australian Postgraduate Award (Industry) PhD stipend; Queensland Government Smart State Research Facilities Fund	This work was supported financially by an Australian Research Council Linkage Grant (LP0668324) in collaboration with Alchemia Ltd. A. K. was supported by an Australian Postgraduate Award (Industry) PhD stipend. This project utilized infrastructure purchased with funds from the Queensland Government Smart State Research Facilities Fund. The authors thank Dr Samantha South and Dr Warinkarn Hemstapat for the technical assistance to A. K. in the initial stages of this work.	ABBOTT FV, 1988, LIFE SCI, V43, P1685, DOI 10.1016/0024-3205(88)90479-1; Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1459, DOI 10.1111/bph.12445; Backlund M, 1997, J CLIN ANESTH, V9, P30, DOI 10.1016/S0952-8180(96)00212-7; BLOND S, 1994, LANCET, V343, P857, DOI 10.1016/S0140-6736(94)92060-5; Bourasset F, 2003, J NEUROCHEM, V86, P1564, DOI 10.1046/j.1471-4159.2003.01990.x; BROCCARDO M, 1992, EUR J PHARMACOL, V218, P69, DOI 10.1016/0014-2999(92)90148-W; Brown SM, 2011, ANESTHESIOLOGY, V115, P1251, DOI 10.1097/ALN.0b013e318238fea0; Bui JD, 1999, NEUROSCIENCE, V90, P1115, DOI 10.1016/S0306-4522(98)00519-3; BURKS TF, 1988, LIFE SCI, V43, P2177, DOI 10.1016/0024-3205(88)90410-9; BUTELMAN ER, 1993, J PHARMACOL EXP THER, V264, P145; CARRUPT PA, 1991, J MED CHEM, V34, P1272, DOI 10.1021/jm00108a005; Chung SJ, 2006, J PHARMACOL EXP THER, V318, P262, DOI 10.1124/jpet.106.103960; Cox BM, 2015, BRIT J PHARMACOL, V172, P317, DOI 10.1111/bph.12612; Dahan A, 2006, PALLIATIVE MED, V20, pS3, DOI 10.1191/0269216306pm1126oa; Dietis N, 2011, BRIT J ANAESTH, V107, P8, DOI 10.1093/bja/aer115; Ferrante FM, 1996, J PAIN SYMPTOM MANAG, V11, P265, DOI 10.1016/0885-3924(95)00201-4; Francisco NA, 2007, EUR J PAIN, P61; Furst S, 2005, J PHARMACOL EXP THER, V312, P609, DOI 10.1124/jpet.104.075176; GALLIGAN JJ, 1983, J PHARMACOL EXP THER, V226, P356; Goineau S, 2010, TOXICOL APPL PHARM, V247, P191, DOI 10.1016/j.taap.2010.06.012; GREER JJ, 1991, J PHYSIOL-LONDON, V437, P727, DOI 10.1113/jphysiol.1991.sp018622; Hindle A, 2008, BJA EDUC, V8, P81, DOI 10.1093/bjaceaccp/mkn016; Hjelmstad GO, 2003, J NEUROPHYSIOL, V89, P2389, DOI 10.1152/jn.01115.2002; Jaffe JH, 1991, PHARMACOL BASIS THER, P485; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Katsumata S, 1995, EUR J PHARM-MOLEC PH, V291, P367, DOI 10.1016/0922-4106(95)90078-0; Kelly E, 2013, BRIT J PHARMACOL, V169, P1430, DOI 10.1111/bph.12222; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI 10.1111/j.1476-5381.2010.00872.x; Koo CY, 2011, OPEN ANESTHESIOL J, V5, P23; LAHTI RA, 1985, EUR J PHARMACOL, V109, P281, DOI 10.1016/0014-2999(85)90431-5; Lalovic B, 2006, CLIN PHARMACOL THER, V79, P461, DOI 10.1016/j.clpt.2006.01.009; LAREGINA A, 1988, LIFE SCI, V42, P293, DOI 10.1016/0024-3205(88)90638-8; Law PY, 2013, TRENDS BIOCHEM SCI, V38, P275, DOI 10.1016/j.tibs.2013.03.003; Lee KO, 1999, EUR J PHARMACOL, V378, P323, DOI 10.1016/S0014-2999(99)00460-4; Lemberg KK, 2006, ANESTHESIOLOGY, V105, P801, DOI 10.1097/00000542-200610000-00027; LEOW KP, 1994, LIFE SCI, V54, P1229; LEVINGER IM, 1971, J ANAT, V108, P447; LING GSF, 1985, J PHARMACOL EXP THER, V232, P149; Luger TJ, 2005, EUR J ANAESTH, V22, P236, DOI 10.1017/S0265021505230405; MASSI P, 1994, EUR J PHARMACOL, V253, P269, DOI 10.1016/0014-2999(94)90201-1; Mather L.E., 1999, OPIOIDS PAIN CONTROL, P188; McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x; McPherson J, 2010, MOL PHARMACOL, V78, P756, DOI 10.1124/mol.110.066613; Meert TF, 2005, PHARMACOL BIOCHEM BE, V80, P309, DOI 10.1016/j.pbb.2004.12.002; Misra A, 2003, J PHARM PHARM SCI, V6, P252; Molinari P, 2010, J BIOL CHEM, V285, P12522, DOI 10.1074/jbc.M109.059410; Mutolo D, 2007, NEUROSCIENCE, V150, P720, DOI 10.1016/j.neuroscience.2007.09.028; Nielsen CK, 2007, PAIN, V132, P289, DOI 10.1016/j.pain.2007.03.022; Nielsen CK, 2000, J PHARMACOL EXP THER, V295, P91; OHTANI M, 1995, J PHARMACOL EXP THER, V272, P505; Ohtani M, 1997, J PHARMACOL EXP THER, V281, P428; Osinski MA, 1999, AM J PHYSIOL-GASTR L, V276, pG125; Otis JA, 1999, CONSULT PHARM SA, V14, P19; PAZOS A, 1983, EUR J PHARMACOL, V87, P309, DOI 10.1016/0014-2999(83)90343-6; PETRILLO P, 1984, LIFE SCI, V35, P917, DOI 10.1016/0024-3205(84)90657-X; Pham T, 2003, ANESTHESIOLOGY, V98, P459, DOI 10.1097/00000542-200302000-00027; PLUMMER JL, 1990, PAIN, V40, P339, DOI 10.1016/0304-3959(90)91131-2; PORRECA F, 1984, J PHARMACOL EXP THER, V230, P341; POYHIA R, 1994, PHARMACOL TOXICOL, V74, P23; Raehal KM, 2005, J PHARMACOL EXP THER, V314, P1195, DOI 10.1124/jpet.105.087254; REISINE T, 1996, [No title captured], P521; Riviere PJM, 2004, BRIT J PHARMACOL, V141, P1331, DOI 10.1038/sj.bjp.0705763; Romberg R, 2003, BRIT J ANAESTH, V91, P862, DOI 10.1093/bja/aeg279; ROMER D, 1980, LIFE SCI, V27, P971, DOI 10.1016/0024-3205(80)90107-1; Ross FB, 1997, PAIN, V73, P151, DOI 10.1016/S0304-3959(97)00093-6; SCHUG SA, 1992, DRUG SAFETY, V7, P200, DOI 10.2165/00002018-199207030-00005; SHOOK JE, 1989, J PHARMACOL EXP THER, V249, P83; Smith MT, 2008, CURR OPIN ANESTHESIO, V21, P596, DOI 10.1097/ACO.0b013e32830a4c4a; Smith MT, 1999, ANESTH ANALG, V88, P109, DOI 10.1097/00000539-199901000-00021; South SM, 2001, J PHARMACOL EXP THER, V297, P446; Taniguchi H, 1998, EUR J PHARMACOL, V353, P265, DOI 10.1016/S0014-2999(98)00411-7; Thorpe D M, 2001, Curr Pain Headache Rep, V5, P237, DOI 10.1007/s11916-001-0037-7; Toll L, 1998, NIDA Res Monogr, V178, P440; VANDENHOOGEN RHWM, 1986, J PHARMACOL EXP THER, V237, P252; Varamini P, 2012, J MED CHEM, V55, P5859, DOI 10.1021/jm300418d; WRIGHT AWE, 1994, THER DRUG MONIT, V16, P200, DOI 10.1097/00007691-199404000-00016; YAMADA KA, 1981, J APPL PHYSIOL, V51, P1278	77	28	28	0	16	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	JAN	2015	172	2			SI		532	548		10.1111/bph.12696			17	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AX3FU	WOS:000346826500026	24641546	Green Published			2020-06-30	J	Sclar, DA				Sclar, David Alexander			Remifentanil, Fentanyl, or the Combination in Surgical Procedures in the United States: Predictors of Use in Patients with Organ Impairment or Obesity	CLINICAL DRUG INVESTIGATION			English	Article							MAJOR METABOLITE; LIVER-DISEASE; RENAL-FAILURE; PHARMACOKINETICS; ANESTHESIA; PHARMACODYNAMICS; SURGERY; RECOVERY; GI87084B; PROPOFOL	Introduction Remifentanil has a rapid onset and short duration of action, predictable pharmacokinetic/pharmacodynamic profile, and unlike fentanyl, does not accumulate with repeated or prolonged administration. This study evaluated predictors of remifentanil use in surgical patients with renal or hepatic impairment, or obesity in the United States who received remifentanil, fentanyl, or the combination. Methods Data (2010) from the US Healthcare National Inpatient Database, State Inpatient Database, State Ambulatory Surgery Database, and private hospital and Medicaid databases were used in this analysis. Patients included had presence of hepatic or renal disease, and/or obesity and were > 5 and a parts per thousand currency sign80 years of age. Results In 2010, 9,274 patients with renal impairment, 1,896 with hepatic impairment, and 6,278 with obesity were identified. The percentage of surgical patients diagnosed with renal disease, hepatic disease, or obesity who received remifentanil was 41, 28, and 35 %, respectively; 29, 17, and 22 % received both remifentanil and fentanyl, and 30, 55, and 43 % received fentanyl alone, respectively. In patients with renal or hepatic disease the probability of remifentanil use was greater for persons aged > 50 years, with Medicare as primary payer, or who were diagnosed with obesity (p < 0.05 all comparisons). In obese patients, the probability of remifentanil use was greater for persons aged > 50 years or female (both p < 0.05). For all 3 disease states, the probability of remifentanil use was lower for those receiving epidural anesthesia or with Medicaid as primary payer (p < 0.05 all comparisons). Conclusion Remifentanil in combination with fentanyl is used less than fentanyl in surgical patients with hepatic impairment or obesity. This is inconsistent with the fact that the pharmacokinetic/pharmacodynamic features of remifentanil suggest it is the preferred intraoperative opioid in these patients. Predictors of remifentanil use in patients with renal or hepatic impairment, or obesity include older age, obesity, and Medicare as primary payer. Remifentanil in combination with fentanyl was significantly less utilized than fentanyl in persons with Medicaid as primary payer even though there was a disproportionate enrollment of beneficiaries with renal or hepatic disease, or obesity in state Medicaid programs.	Midwestern Univ, Coll Pharm, Glendale, AZ 85308 USA	Sclar, DA (reprint author), Midwestern Univ, Coll Pharm, Glendale, AZ 85308 USA.	dsclar@midwestern.edu			Mylan Specialty L.P. (Canonsburg, PA); Mylan Specialty, L.P.	This research was supported by Mylan Specialty L.P. (Canonsburg, PA). The author acknowledges Stem Scientific (Lyndhurst, NJ) for writing assistance funded by Mylan Specialty, L.P. Dr. Sclar has served as a consultant to Mylan Specialty, L.P.	[Anonymous], SUBL FENT CITR; [Anonymous], ULT REM; Bekker AY, 2000, ANESTH ANALG, V91, P117, DOI 10.1097/00000539-200007000-00022; Bellamy MC, 2013, PERIOPER MED, V2, DOI 10.1186/2047-0525-2-12; Bergland A, 2008, ACTA ANAESTH SCAND, V52, P1394, DOI 10.1111/j.1399-6576.2008.01782.x; Dahaba AA, 1999, CAN J ANAESTH, V46, P696, DOI 10.1007/BF03013962; De Baerdemaeker LEC, 2007, BRIT J ANAESTH, V99, P404, DOI 10.1093/bja/aem164; Dershwitz M, 1996, ANESTHESIOLOGY, V84, P812, DOI 10.1097/00000542-199604000-00008; Duke J., 2011, ANESTHESIA SECRETS; Dumont L, 1998, BRIT J ANAESTH, V81, P265; Egan TD, 1998, ANESTHESIOLOGY, V89, P562, DOI 10.1097/00000542-199809000-00004; EGAN TD, 1995, CLIN PHARMACOKINET, V29, P80, DOI 10.2165/00003088-199529020-00003; EGAN TD, 1993, ANESTHESIOLOGY, V79, P881, DOI 10.1097/00000542-199311000-00004; Engoren M, 2001, ANESTH ANALG, V93, P859, DOI 10.1097/00000539-200110000-00011; Gaszynski TM, 2004, OBES SURG, V14, P498, DOI 10.1381/096089204323013488; GLASS PSA, 1993, ANESTH ANALG, V77, P1031; Hogue S, 1999, AM J HEALTH-SYST PH, V56, P55; Hoke JF, 1997, J PHARMACOL EXP THER, V281, P226; Jellish WS, 2000, OTOLARYNG HEAD NECK, V122, P222, DOI 10.1016/S0194-5998(00)70243-9; Navapurkar VU, 1998, BRIT J ANAESTH, V81, P881; Patel T, 1999, MAYO CLIN PROC, V74, P593, DOI 10.4065/74.6.593; Pitsiu M, 2004, BRIT J ANAESTH, V92, P493, DOI 10.1093/bja/aeh086; Reddy P, 2002, J CLIN PHARM THER, V27, P127, DOI 10.1046/j.1365-2710.2002.00401.x; Sclar DA, 2013, P 67 ANN POSTGR ASS; Scott LJ, 2005, DRUGS, V65, P1793, DOI 10.2165/00003495-200565130-00007; Sieber F, 2010, MILLERS ANESTHESIA, P2261; Sinha AC, 2010, MILLERS ANESTHESIA, P2089; Song DJ, 2000, ANESTH ANALG, V90, P1111, DOI 10.1097/00000539-200005000-00020; US Department of Health and Human Services Agency for Healthcare Research and Quality, US HEALTHC COST UT P; Vaja R, 2010, BJA EDUC, V10, P15, DOI 10.1093/bjaceaccp/mkp040; Wagener Gebhard, 2010, Anesthesiol Clin, V28, P39, DOI 10.1016/j.anclin.2010.01.006; WESTMORELAND CL, 1993, ANESTHESIOLOGY, V79, P893, DOI 10.1097/00000542-199311000-00005	32	4	4	0	4	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1173-2563	1179-1918		CLIN DRUG INVEST	Clin. Drug Invest.	JAN	2015	35	1					53	59		10.1007/s40261-014-0251-9			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AX8GB	WOS:000347147000006	25471739	Other Gold, Green Published			2020-06-30	J	Lewis, SR; Nicholson, A; Reed, SS; Kenth, JJ; Alderson, P; Smith, AF				Lewis, Sharon R.; Nicholson, Amanda; Reed, Stephanie S.; Kenth, Johnny J.; Alderson, Phil; Smith, Andrew F.			Anaesthetic and sedative agents used for electrical cardioversion	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Review						Anesthetics; Apnea; Diazepam; Electric Countershock; Etomidate; Fentanyl; Hypnotics and Sedatives; Hypotension; Mental Recall; Methyl Ethers; Midazolam; Piperidines; Propofol; Randomized Controlled Trials as Topic; Thiopental; Humans	ASSOCIATION TASK-FORCE; PROCEDURAL SEDATION; ATRIAL-FIBRILLATION; ACC/AHA/ESC GUIDELINES; CARDIOLOGY COMMITTEE; EMERGENCY-DEPARTMENT; DEVELOP GUIDELINES; AMERICAN-COLLEGE; EUROPEAN-SOCIETY; PROPOFOL	Background Electrical cardioversion is an effective procedure for restoring normal sinus rhythmin the hearts of patients with irregular heart rhythms. It is important that the patient is not fully conscious during the procedure, as it can be painful and distressing. The drug used to make patients unaware of the procedure should rapidly achieve the desired level of sedation, should wear off quickly and should not cause cardiovascular or respiratory side effects. Objectives We aimed to compare the safety, effectiveness and adverse events associated with various anaesthetic or sedative agents used in direct current cardioversion for cardiac arrhythmia in both elective and emergency settings. We sought answers to the following specific questions. Which drugs deliver the best outcomes for patients undergoing electrical cardioversion? Does using a particular agent confer advantages or disadvantages? Is additional analgesic necessary to prevent pain? Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) on 27 March 2014. Our search terms were relevant to the review question and were not limited by outcomes. We also carried out searches of clinical trials registers and forward and backward citation tracking. Selection criteria We considered all randomized controlled trials and quasi-randomized and cluster-randomized studies with adult participants undergoing electrical cardioversion procedures in the elective or emergency setting. Data collection and analysis Two review authors independently assessed trial quality and extracted data, consulting with a third review author for disagreements. We used standard Cochrane methodological procedures, including assessment of risk of bias for all studies. Main results We included 23 studies with 1250 participants that compared one drug with one or more other drugs. Of these comparisons, 19 studies compared propofol with another drug. Seven of these compared propofol with etomidate (four of which combined the drugs with remifentanil or fentanyl), five midazolam, six thiopentone and two sevoflurane. Three studies compared etomidate with thiopentone, and three etomidate with midazolam. Two studies compared thiopentone with midazolam, one thiopentone with diazepam and one midazolam with diazepam. Drug doses and the time over which the drugs were given varied between studies. Although all studies were described as randomized, limited information was provided about the methods used for selection and group allocation. A high level of performance bias was observed across studies, as study authors had not attempted to blind the anaesthetist to group allocation. Similarly, study authors had rarely provided sufficient information on whether outcome assessors had been blinded. Included studies presented outcome data for hypotension, apnoea, participant recall, success of cardioversion, minor adverse events of nausea and vomiting, pain at injection site and myoclonus, additional analgesia and participant satisfaction. We did not pool the data from different studies in view of the multiple drug comparisons, differences in definitions and reporting of outcomes, variability of endpoints and high or unclear risk of bias across studies. Authors' conclusions Few studies reported statistically significant results for our relevant outcomes, and most study authors concluded that both, or all, agents compared in individual studies were adequate for cardioversion procedures. It is our opinion that at present, there is no evidence to suggest that current anaesthetic practice for cardioversion should change.	[Lewis, Sharon R.] Royal Lancaster Infirm, Patient Safety Res, Pointer Court 1,Ashton Rd, Lancaster LA1 1RP, England; [Nicholson, Amanda] Univ Liverpool, Liverpool Reviews & Implementat Grp, Liverpool L69 3BX, Merseyside, England; [Reed, Stephanie S.; Kenth, Johnny J.; Smith, Andrew F.] Royal Lancaster Infirm, Dept Anaesthesia, Lancaster LA1 1RP, England; [Alderson, Phil] Natl Inst Hlth & Care Excellence, Manchester, Lancs, England	Lewis, SR (reprint author), Royal Lancaster Infirm, Patient Safety Res, Pointer Court 1,Ashton Rd, Lancaster LA1 1RP, England.	Sharon.Lewis@mbht.nhs.uk	Smith, Andrew F/C-5384-2012; Kenth, Johnny/J-3985-2013	Kenth, Johnny/0000-0002-0348-6865	NIHR Cochrane Collaboration Programme Grant: Enhancing the safety, quality and productivity of perioperative care, UK., UK [10/4001/04]; National Institute for Health ResearchNational Institute for Health Research (NIHR) [10/4001/04]	NIHR Cochrane Collaboration Programme Grant: Enhancing the safety, quality and productivity of perioperative care. Project Ref: 10/4001/04, UK., UK.	Academy of Medical Royal Colleges, 2013, SAF SED PRACT HEALTH; Akcaboy ZN, 2007, SAUDI MED J, V28, P1550; Akcaboy ZN, 2008, GENEL TIP DERGISI, V18; Altinoren B, 2005, EUR J ANAESTH, V22, P131; Blomstrom-Lundqvist C, 2003, CIRCULATION, V108, P1871, DOI 10.1161/01.CIR.0000091380.04100.84; Broch Porcar MJ, 1999, MED INTENSIVA, V23, P209; Camm AJ, 2012, EUR HEART J, V33; Canessa R, 1991, J Cardiothorac Vasc Anesth, V5, P566, DOI 10.1016/1053-0770(91)90007-G; Coll-Vinent B, 2003, ANN EMERG MED, V42, P767, DOI 10.1016/S0196-0644(03)00510-9; DELLINGER A, 1988, Annales Francaises d'Anesthesie et de Reanimation, V7, P128, DOI 10.1016/S0750-7658(88)80140-0; European Heart Rhythm Association, 2006, J Am Coll Cardiol, V48, pe247, DOI 10.1016/j.jacc.2006.07.010; Ford S R, 1991, J Cardiothorac Vasc Anesth, V5, P563, DOI 10.1016/1053-0770(91)90006-F; Fuster V, 2001, J AM COLL CARDIOL, V38, P1231, DOI 10.1016/S0735-1097(01)01587-X; Fuster V, 2006, J AM COLL CARDIOL, V48, P854, DOI 10.1016/j.jacc.2006.07.009; GALE DW, 1993, CRIT CARE MED, V21, P1509, DOI 10.1097/00003246-199310000-00019; GUPTA A, 1990, ANAESTHESIA, V45, P872, DOI 10.1111/j.1365-2044.1990.tb14576.x; Herregods LL, 2003, J CLIN ANESTH, V15, P91, DOI 10.1016/S0952-8180(02)00520-2; Higgins JPT, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184; Hohl CM, 2008, ACAD EMERG MED, V15, P1, DOI 10.1111/j.1553-2712.2007.00022.x; Huter L, 2007, ANESTH ANALG, V105, P1298, DOI 10.1213/01.ane.0000287248.25610.c0; HULLANDER RM, 1993, ANESTH ANALG, V77, P690; James S, 2003, ANAESTHESIA, V58, P291, DOI 10.1046/j.1365-2044.2003.306519.x; Jan KT, 1995, ACTA ANAESSIOLOGI, V33, P35; Kalogridaki M, 2011, HELL J CARDIOL, V52, P483; Karthikeyan S, 2002, ANAESTHESIA, V57, P1114, DOI 10.1046/j.1365-2044.2002.02782_3.x; Kick O, 1996, Anasthesiol Intensivmed Notfallmed Schmerzther, V31, P288, DOI 10.1055/s-2007-995922; KOWEY PR, 1988, AM J CARDIOL, V61, P1106, DOI 10.1016/0002-9149(88)90135-X; Link MS, 2010, CIRCULATION, V122, pS706, DOI 10.1161/CIRCULATIONAHA.110.970954; Maltepe F, 2006, ANAESTH INTENS CARE, V34, P353, DOI 10.1177/0310057X0603400309; Mitchell ARJ, 2003, EUROPACE, V5, P391, DOI 10.1016/S1099-5129(03)00077-1; Morao S, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009491, DOI 10.1002/14651858.CD009491]; Munoz Martinez T, 2002, MED INTENSIVA, V26, P98; National Institute for Health and Clinical Excellence, 2006, CG36 NAT I HLTH CLIN, VCG36; Nordic Cochrane Centre, 2011, REV MAN REVMAN VERS; ORKO R, 1976, ANN CLIN RES, V8, P248; ORKO R, 1976, BRIT J ANAESTH, V48, P257, DOI 10.1093/bja/48.3.257; Parlak M, 2006, ACAD EMERG MED, V13, P493, DOI 10.1197/j.aem.2005.12.013; Prieto MJ, 1995, MED INTENSIVA S1, P40; Reed SS, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD010824, DOI 10.1002/14651858.CD010824]; Reiffel JA, 2009, PACE, V32, P1073, DOI 10.1111/j.1540-8159.2009.02441.x; Resuscitation Council, 2010, RESUSCITATION GUIDEL, P81; Sharafudeen S, 2010, ANAESTHESIA, V65, P94, DOI 10.1111/j.1365-2044.2009.06184_1.x; Siedy J, 2010, KARDIOL POL, V68, P1249; Smith AF, 2011, BRIT J ANAESTH, V106, P38, DOI 10.1093/bja/aeq308; Smith AF, 2009, BRIT J ANAESTH, V103, P623, DOI 10.1093/bja/aep273; Smith A, 2009, ANESTHESIOLOGY, V110, P4, DOI 10.1097/ALN.0b013e318190b263; STERNLO JE, 1991, ACTA ANAESTH SCAND, V35, P606, DOI 10.1111/j.1399-6576.1991.tb03357.x; Symington L, 2006, EMERG MED J, V23, P89, DOI 10.1136/emj.2005.023713; Thomson Reuters, 2011, X5 THOMS REUT; TIONGSON JG, 1978, DEL MED J, V50, P601; VALTONEN M, 1988, CAN J ANAESTH, V35, P479, DOI 10.1007/BF03026895; Wakai A, 2008, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007399, DOI 10.1002/14651858.CD007399]; Wall BF, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010698; Wilmott AR, 2014, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD010898, DOI 10.1002/14651858.CD010898]; Wood J, 2006, EMERG MED J, V23, P932, DOI 10.1136/emj.2006.043067; Yidirim V, 2007, ADV THER, V24, P662	56	5	5	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1469-493X	1361-6137		COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2015		3							CD010824	10.1002/14651858.CD010824.pub2			84	Medicine, General & Internal	General & Internal Medicine	DL3OC	WOS:000375542100035	25803543	Green Published			2020-06-30	J	Schnabel, A; Reichl, SU; Meyer-Friessem, C; Zahn, PK; Pogatzki-Zahn, E				Schnabel, Alexander; Reichl, Sylvia U.; Meyer-Friessem, Christine; Zahn, Peter K.; Pogatzki-Zahn, Esther			Tramadol for postoperative pain treatment in children	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Review							ANALGESIC EFFICACY; INTRAVENOUS TRAMADOL; ADENO-TONSILLECTOMY; RELIEF; MORPHINE; SURGERY; ADENOTONSILLECTOMY; PHARMACOKINETICS; INFILTRATION; PHARMACOLOGY	Background According to current recommendations a multimodal approach is believed to be the gold standard for postoperative pain treatment in children. However, several surveys in the last few years demonstrated that postoperative pain in children is still a serious problem, mainly because opioids are avoided. One of the reasons for this is the fear of severe adverse events following opioid administration. Tramadol is a weak mu-opioid agonist and inhibits reuptake of noradrenaline and serotonin (5HT). Because of a relatively wide therapeutic window and a ceiling effect with a lower risk for severe adverse events (for example respiratory depression) tramadol is a widely used opioid in children. However, the exact efficacy and occurrence of adverse events following tramadol (in comparison with placebo or other opioids) for postoperative pain treatment in children and adolescents are currently not clear. Objectives To assess the effectiveness and side effect profile of tramadol for postoperative pain relief in children and adolescents undergoing different surgical procedures. Search methods We searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2014, Issue 6), MEDLINE via PubMed (January 1966 to July 2014) and EMBASE via Ovid (January 1947 to July 2014). There were no restrictions regarding language or date of publication. The reference lists of all included trials were checked for additional studies. Selection criteria All randomised controlled clinical trials investigating the perioperative administration of tramadol compared to placebo or other opioids for postoperative pain treatment in children and adolescents were included. Data collection and analysis Three review authors independently assessed the study eligibility, performed the data extraction and assessed the risk of bias of included trials. Main results Twenty randomised controlled trials involving 1170 patients were included in this systematic review. The overall risk of bias in included trials was assessed as unclear, because concealment of allocation processes and blinding of outcome assessors were poorly described. Due to inconsistent outcome reporting, data from 17 included trials could be pooled for some endpoints only. Eight trials compared tramadol administration with placebo and five trials found that the need for rescue analgesia in the postoperative care unit (PACU) was reduced in children receiving tramadol (RR 0.40; 95% CI 0.20 to 0.78; low quality evidence). Only one trial investigated the number of patients with moderate to severe pain, but a non-validated pain scale was used (very low quality evidence). Four trials compared morphine with tramadol administration. There was no clear evidence of difference in the need for rescue analgesia in the PACU (RR 1.25; 95% CI 0.83 to 1.89; low quality evidence) with tramadol compared with morphine. No trials could be pooled for the outcome ' number of patients with moderate to severe pain'. Three trials were included for the comparison of tramadol with nalbuphine. There was no clear evidence for the need for rescue analgesia in the PACU (RR 0,63; 95% CI 0.16 to 2.45; low quality evidence). Only one trial reported the number of patients with moderate to severe pain, but used a non-validated pain scale (very low quality evidence). Two out of six included trials, which compared pethidine with tramadol, reported the number of children with a need for rescue analgesia within the PACU and showed no clear evidence (RR 0.93; 95% CI 0.43 to 2.02; very low quality evidence). Two trials reported the number of patients with moderate to severe pain and showed a lower RR in patients treated with tramadol (RR 0.64; 95% CI 0.36 to 1.16; low quality evidence). Only one trial was included, which compared tramadol with fentanyl, reporting the number of patients with the need for rescue analgesia (very low quality evidence). Generally, adverse events were poorly reported. Most data could be pooled for the comparison with placebo focusing on the RR for postoperative nausea and vomiting (PONV) in the postoperative care unit and 24 h postoperation. Children treated with tramadol, compared to placebo, did not show clear evidence of benefit for PONV in the postoperative care unit (RR 0.84; 95% CI 0.28 to 2.52; moderate quality evidence) and 24 h postoperation (RR 0.78; 95% CI 0.54 to 1.12; moderate quality evidence). Authors' conclusions The overall evidence regarding tramadol for postoperative pain in children is currently low or very low and should be interpreted with caution due to small studies and methodological problems (different validated and non-validated pain scales with different pain triggers, missing sample size calculations and missing intention-to-treat analysis). Nevertheless, we demonstrated that tramadol administration might provide appropriate analgesia when compared to placebo; this is based on results showing reduced rescue analgesia in children treated with tramadol compared to placebo. In contrast, the evidence regarding the comparison with other opioids (for example morphine) was uncertain. Adverse events were only poorly reported, so an accurate risk-benefit analysis was not possible.	[Schnabel, Alexander] Univ Wurzburg, Dept Anaesthesia & Crit Care, D-97070 Wurzburg, Germany; [Reichl, Sylvia U.] Paracelsus Med Univ, Dept Anesthesiol Perioperat & Intens Care Med, Salzburg, Austria; [Meyer-Friessem, Christine; Zahn, Peter K.] Univ Klinikum Bergmannsheil GmbH Bochum, Dept Anaesthesiol Intens Care Med Palliat Care Me, Bochum, Germany; [Pogatzki-Zahn, Esther] Univ Hosp Munster, Dept Anesthesiol Intens Care & Pain Med, Munster, Germany	Schnabel, A (reprint author), Univ Wurzburg, Dept Anaesthesia & Crit Care, Oberduerrbacher Str 6, D-97070 Wurzburg, Germany.	alexander_schnabel@gmx.de		Meyer-Friessem, Christine/0000-0001-8743-2065	editorial office of the Cochrane Pain, Palliative and Supportive Group; National Institute for Health Research (NIHR)National Institute for Health Research (NIHR)	We would like to thank the peer reviewers for their valuable comments and the editorial office of the Cochrane Pain, Palliative and Supportive Group for the support. The present review was not sponsored by any drug company or any institutional organisation.; Cochrane Review Group funding acknowledgement: The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane PaPaS Group. Disclaimer: The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, National Health Service (NHS) or the Department of Health.	Aguirre Corcoles E, 2003, Cir Pediatr, V16, P30; Akkaya T, 2009, EUR J ANAESTH, V26, P333, DOI 10.1097/EJA.0b013e32831c8988; Ali SM, 2008, LARYNGOSCOPE, V118, P1547, DOI 10.1097/MLG.0b013e318178272e; Allegaert K, 2011, PEDIATR ANESTH, V21, P266, DOI 10.1111/j.1460-9592.2010.03389.x; Altunkaya H, 2003, BRIT J ANAESTH, V90, P320, DOI 10.1093/bja/aeg079; Andrews K, 2002, PAIN, V99, P185, DOI 10.1016/S0304-3959(02)00100-8; Antila H, 2006, PEDIATR ANESTH, V16, P548, DOI 10.1111/j.1460-9592.2005.01819.x; Apiliogullari S, 2011, REGIONAL ANESTHESIA; Awad IT, 2004, EUR J ANAESTH, V21, P379, DOI 10.1017/S0265021504005058; Bamigbade TA, 1998, HOSP MED, V59, P373; BARSOUM MW, 1995, CLIN DRUG INVEST, V9, P183, DOI 10.2165/00044011-199509040-00001; Bedirli N, 2011, REGIONAL ANESTHESIA; Borazan H, 2012, INT J MED SCI, V9, P492, DOI 10.7150/ijms.4793; Bosenberg AT, 1998, ANAESTHESIA, V53, P960, DOI 10.1046/j.1365-2044.1998.00526.x; Bozkurt P, 2005, PEDIATR ANESTH, V15, P1041, DOI 10.1111/j.1460-9592.2005.01738.x; Chiaretti A, 2000, CHILD NERV SYST, V16, P93, DOI 10.1007/s003810050019; Chu Y, 2006, ANESTH ANALG, V102, P1668, DOI 10.1213/01.ANE.0000219587.02263.A0; Cocelli LP, 2012, INT J PEDIATR OTORHI, V76, P653, DOI 10.1016/j.ijporl.2012.01.031; Courtney MJ, 2001, ARCH OTOLARYNGOL, V127, P385, DOI 10.1001/archotol.127.4.385; de Alencar AJC, 2012, ARCH DIS CHILD-FETAL, V97, pF24, DOI 10.1136/adc.2010.203851; Dadure C, 2009, CAN J ANAESTH, V56, P843, DOI 10.1007/s12630-009-9169-8; DAYER P, 1994, DRUGS, V47, P3, DOI 10.2165/00003495-199400471-00003; Demiraran Y, 2005, BRIT J ANAESTH, V95, P510, DOI 10.1093/bja/aei214; Ekemen S, 2008, PEDIATR SURG INT, V24, P695, DOI 10.1007/s00383-008-2147-3; Engelhardt T, 2003, PAEDIATR ANAESTH, V13, P249, DOI 10.1046/j.1460-9592.2003.00983.x; Ertugrul F, 2006, J INT MED RES, V34, P648, DOI 10.1177/147323000603400610; Finkel JC, 2002, ANESTH ANALG, V94, P1469, DOI 10.1097/00000539-200206000-00017; Franck LS, 2004, ARCH DIS CHILD-FETAL, V89, pF71, DOI 10.1136/fn.89.1.F71; Glaser R, 1999, ARCH GEN PSYCHIAT, V56, P450, DOI 10.1001/archpsyc.56.5.450; Griessinger N, 1997, UROLOGE A, V36, P552, DOI 10.1007/s001200050136; Groenewald CB, 2012, PEDIATR ANESTH, V22, P661, DOI 10.1111/j.1460-9592.2012.03807.x; Gunes Y, 2004, PEDIATR ANESTH, V14, P324, DOI 10.1046/j.1460-9592.2003.01214.x; HENNIES HH, 1988, ARZNEIMITTEL-FORSCH, V38-2, P877; Higgins JP, COCHRANE HDB SYSTEMA; Hirschfeld G, 2013, PAIN, V154, P154, DOI 10.1016/j.pain.2012.10.008; Hullett BJ, 2006, PEDIATR ANESTH, V16, P648, DOI 10.1111/j.1460-9592.2005.01827.x; Kharasch S, 2003, ARCH PEDIAT ADOL MED, V157, P1054, DOI 10.1001/archpedi.157.11.1054; Khosravi MB, 2006, PEDIATR ANESTH, V16, P54, DOI 10.1111/j.1460-9592.2005.01740.x; Lintz W, 1998, ARZNEIMITTEL-FORSCH, V48, P889; Macarone Palmieri A, 1998, Minerva Anestesiol, V64, P545; Metodiev Y, 2011, REGIONAL ANESTHESIA; Michelet D, 2012, ANESTH ANALG, V114, P393, DOI 10.1213/ANE.0b013e31823d0b45; Mikhel'son VA, 2003, ANESTEZIOL REANIMAT, V1, P24; Moyao-Garcia Diana, 2009, Acta Biomed, V80, P124; Murthy BVS, 2000, BRIT J ANAESTH, V84, P346; Niesters M, 2013, BRIT J ANAESTH, V110, P175, DOI 10.1093/bja/aes447; Oliveira EDS, 2000, PEDIAT ANESTHESIA, V413, P89; Orliaguet G, 2015, PEDIATRICS; Osifo OD, 2008, AM J PERINAT, V25, P617, DOI 10.1055/s-0028-1090582; Ostrei kov IF, 1993, ANESTEZID REANIMATOL, V3, P28; Ozalevli M, 2005, PEDIATR ANESTH, V15, P979, DOI 10.1111/j.1460-9592.2005.01591.x; Ozer Z, 2003, EUR J ANAESTH, V20, P920; Ozkose Z, 2000, INT J PEDIATR OTORHI, V53, P207, DOI 10.1016/S0165-5876(00)82008-X; Page MG, 2013, J PAIN RES, V6, P167, DOI 10.2147/JPR.S40846; Payne K A, 2002, Anesth Prog, V49, P109; Payne K A, 1999, Anesth Prog, V46, P91; Pendeville PE, 2000, EUR J ANAESTH, V17, P576, DOI 10.1046/j.1365-2346.2000.00729.x; RevMan, 2014, REV MAN REVMAN 5 3; Roelofse JA, 1999, EUR J ANAESTH, V16, P441, DOI 10.1046/j.1365-2346.1999.00505.x; Romsing J, 1996, PAEDIATR ANAESTH, V6, P215, DOI 10.1111/j.1460-9592.1996.tb00431.x; Russell P, 2013, CURR OPIN ANESTHESIO, V26, P420, DOI 10.1097/ACO.0b013e3283625cc8; SCAIFE JM, 1988, J CHILD PSYCHOL PSYC, V29, P185, DOI 10.1111/j.1469-7610.1988.tb00703.x; SCHAFFER J, 1986, ANAESTHESIST, V35, P408; Schnabel A, 2014, COCHRANE DB SYST REV, V7; Schunemann Holger J, 2008, Evid Based Med, V13, P162, DOI 10.1136/ebm.13.6.162-a; Scott LJ, 2000, DRUGS, V60, P139, DOI 10.2165/00003495-200060010-00008; Segerdahl M, 2008, ACTA ANAESTH SCAND, V52, P821, DOI 10.1111/j.1399-6576.2008.01669.x; Standing JF, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005538.pub2; Stanko D, 2013, PEDIATR ANESTH, V23, P690, DOI 10.1111/pan.12170; Subramanyam R, 2014, PEDIATR ANESTH, V24, P412, DOI 10.1111/pan.12342; Sun Y, 2010, J SHANGHAI JIAOTONG, V1; Tarkkila P, 1998, EUR J ANAESTH, V15, P64, DOI 10.1097/00003643-199801000-00013; Taylor EM, 2008, PAIN RES MANAG, V13, P25, DOI 10.1155/2008/478102; Umuroglu T, 2004, PEDIATR ANESTH, V14, P568, DOI 10.1111/j.1460-9592.2004.01223.x; van den Berg AA, 1999, EUR J ANAESTH, V16, P186, DOI 10.1046/j.1365-2346.1999.00451.x; VICKERS MD, 1992, ANAESTHESIA, V47, P291, DOI 10.1111/j.1365-2044.1992.tb02166.x; Viitanen H, 2001, BRIT J ANAESTH, V86, P572, DOI 10.1093/bja/86.4.572; Walker SM, 2009, PAIN, V141, P79, DOI 10.1016/j.pain.2008.10.012; Weisman SJ, 1998, ARCH PEDIAT ADOL MED, V152, P147	79	24	25	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1469-493X	1361-6137		COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2015		3							CD009574	10.1002/14651858.CD009574.pub2			72	Medicine, General & Internal	General & Internal Medicine	CF5PI	WOS:000352608900032	25785365	Green Published			2020-06-30	J	Wakai, A; Blackburn, C; McCabe, A; Reece, E; O'Connor, G; Glasheen, J; Staunton, P; Cronin, J; Sampson, C; McCoy, SC; O'Sullivan, R; Cummins, F				Wakai, Abel; Blackburn, Carol; McCabe, Aileen; Reece, Emilia; O'Connor, Ger; Glasheen, John; Staunton, Paul; Cronin, John; Sampson, Christopher; McCoy, Siobhan C.; O'Sullivan, Ronan; Cummins, Fergal			The use of propofol for procedural sedation in emergency departments	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Review							RANDOMIZED CLINICAL-TRIAL; MIDAZOLAM; REDUCTION; CARDIOVERSION; ANALGESIA; FENTANYL; KETAMINE	Background There is increasing evidence that propofol is efficacious and safe for procedural sedation (PS) in the emergency department (ED) setting. However, propofol has a narrow therapeutic window and lacks of a reversal agent. The aim of this review was to cohere the evidence base regarding the efficacy and safety profile of propofol when used in the ED setting for PS. Objectives To identify and evaluate all randomized controlled trials (RCTs) comparing propofol with alternative drugs (benzodiazepines, barbiturates, etomidate and ketamine) used in the ED setting for PS. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2013, Issue 9), MEDLINE (1950 to September week 2 2013) and EMBASE (1980 to week 2 2013). We searched the Current Controlled Trials metaRegister of Clinical Trials (compiled by Current Science) (September 2013). We checked the reference lists of trials and contacted trial authors. We imposed no language restriction. We re-ran the search in February 2015. We will deal with the one study awaiting classification when we update the review. Selection criteria RCTs comparing propofol to alternative drugs (benzodiazepines, barbiturates, etomidate and ketamine) used in the ED setting for PS in participants of all ages. Data collection and analysis Two authors independently performed data extraction. Two authors performed trial quality assessment. We used mean difference (MD), odds ratio (OR) and 95% confidence intervals (CI) to measure effect sizes. Two authors independently assessed and rated the methodological quality of each trial using The Cochrane Collaboration tool for assessing risk of bias. Main results Ten studies (813 participants) met the inclusion criteria. Two studies only included participants 18 years and younger; six studies only included participants 18 years and older; one study included participants between 16 and 65 years of age and one study included only adults but did not specify the age range. Eight of the included studies had a high risk of bias. The included studies were clinically heterogeneous. We undertook no meta-analysis. The primary outcome measures of this review were: adverse effects (as defined by the study authors) and participant satisfaction (as defined by the study authors). In one study comparing propofol/fentanyl with ketamine/midazolam, delayed adverse reactions (nightmares and behavioural change) were noted in 10% of the ketamine/midazolam group and none in the propofol/fentanyl group. Seven individual studies reported no evidence of a difference in adverse effects between intravenous propofol, with and without adjunctive analgesic agents, and alternative interventions. Three individual studies reported no evidence of a difference in pain at the injection site between intravenous propofol and alternative interventions. Four individual studies reported no evidence of a difference in participant satisfaction between intravenous propofol, with and without adjunctive analgesic agents, and alternative interventions (ketamine, etomidate, midazolam). All the studies employed propofol without the use of an adjunctive analgesic and all, except one, were small (fewer than 100 participants) studies. The quality of evidence for the adverse effects and participant satisfaction outcomes was very low. Nine included studies (eight comparisons) reported all the secondary outcome measures of the review except mortality. It was not possible to pool the results of the included studies for any of the secondary outcome measures because the comparator interventions were different and the measures were reported in different ways. Seven individual studies reported no evidence of difference in incidence of hypoxia between intravenous propofol, with and without adjunctive analgesic agents, and alternative interventions. Authors' conclusions No firm conclusions can be drawn concerning the comparative effects of administering intravenous propofol, with or without an adjunctive analgesic agent, with alternative interventions in participants undergoing PS in the ED setting on adverse effects (including pain at the injection site) and participant satisfaction. The review was limited because no two included studies employed the same comparator interventions, and because the number of participants in eight of the included studies were small (fewer than 100 participants).	[Wakai, Abel; McCabe, Aileen] Royal Coll Surgeons Ireland, Emergency Care Res Unit, Div Populat Hlth Sci PHS, Dublin 2, Ireland; [Blackburn, Carol] Our Ladys Childrens Hosp Crumlin, Dept Emergency Med, Dublin, Ireland; [Reece, Emilia] Princess Alexandra Hosp, Dept Anaesthesia, Woolloongabba, Qld, Australia; [O'Connor, Ger] Mater Misericordiae Univ Hosp, Dept Emergency Med, Dublin, Ireland; [Glasheen, John; McCoy, Siobhan C.] Cork Univ Hosp, Dept Emergency Med, Cork, Ireland; [Staunton, Paul] St James Hosp, Dept Emergency Med, Dublin 8, Ireland; [Cronin, John] Our Ladys Childrens Hosp Crumlin, Natl Childrens Res Ctr, Dept Emergency Med, Paediat Emergency Res Unit, Dublin, Ireland; [Cronin, John] Univ Coll Dublin, Dublin 2, Ireland; [Sampson, Christopher] Univ Missouri, Dept Emergency Med M562, Columbia, MO USA; [O'Sullivan, Ronan] Our Ladys Childrens Hosp Crumlin, Natl Childrens Res Ctr, Dublin, Ireland; [O'Sullivan, Ronan] Cork Univ Hosp, Cork, Ireland; [Cummins, Fergal] Natl Ambulance, Dept Clin Serv, Abu Dhabi, U Arab Emirates; [Cummins, Fergal] Charles Sturt Univ, Port Macquarie, Australia; [Cummins, Fergal] Univ Limerick, Grad Entry Med Sch 1, Limerick, Ireland; [Cummins, Fergal] REDSPoT Retrieval Emergency Disaster Med Res & De, Limerick, Ireland	Wakai, A (reprint author), Royal Coll Surgeons Ireland, Emergency Care Res Unit, Div Populat Hlth Sci PHS, 123 St Stephens Green, Dublin 2, Ireland.	awakai@rcsi.ie	; McCabe, Aileen/E-7569-2013	Wakai, Abel/0000-0003-2021-2388; O'Connor, Gerard/0000-0002-4584-3760; McCabe, Aileen/0000-0002-9462-5874			Ab-Rahman NH, 2008, ANN EMERG MED, V51, P479, DOI 10.1016/j.annemergmed.2008.01.297; [Anonymous], 2002, PHYS DESK REFERENCE, P667; Bahn EL, 2005, EMERG MED CLIN N AM, V23, P503, DOI 10.1016/j.emc.2004.12.013; Caro DA, 2012, MANUAL EMERGENCY AIR, P241; Coll-Vinent B, 2003, ANN EMERG MED, V42, P767, DOI 10.1016/S0196-0644(03)00510-9; Cook D, 1998, SYSTEMATIC REV SYNTH, V1, P91; Dunn MJG, 2011, EMERG MED J, V28, P6, DOI 10.1136/emj.2008.067652; Glasziou P, 2001, SYSTEMATIC REV HLTH; Godambe SA, 2003, PEDIATRICS, V112, P116, DOI 10.1542/peds.112.1.116; Godwin SA, 2014, ANN EMERG MED, V63, P247, DOI 10.1016/j.annemergmed.2013.10.015; Green SM, 2003, ANN EMERG MED, V42, P792, DOI 10.1016/S0196-0644(03)00746-7; Havel CJ, 1999, ACAD EMERG MED, V6, P989, DOI 10.1111/j.1553-2712.1999.tb01180.x; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184; Holger JS, 2005, AM J EMERG MED, V23, P248, DOI 10.1016/j.ajem.2005.01.001; Kaye P, 2014, EMERG MED J, V31, P904, DOI 10.1136/emermed-2013-202742; Langendam MW, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-81; LEFEBVRE C, 1996, 4 INT COCHR C AD AUS; McMaster University, 2014, GRADEPRO COMP PROGR; Miner JR, 2007, ANN EMERG MED, V49, P15, DOI 10.1016/j.annemergmed.2006.06.042; Miner JR, 2010, ACAD EMERG MED, V17, P604, DOI 10.1111/j.1553-2712.2010.00776.x; Miner JR, 2009, ACAD EMERG MED, V16, P825, DOI 10.1111/j.1553-2712.2009.00487.x; Miner JR, 2005, ACAD EMERG MED, V12, P190, DOI 10.1197/j.aem.2004.10.004; Mittal N, 2013, J CLIN PEDIATR DENT, V37, P415, DOI 10.17796/jcpd.37.4.thv8372410714342; Ozturk TC, 2014, HONG KONG J EMERG ME, V21, P346; Parlak M, 2006, ACAD EMERG MED, V13, P493, DOI 10.1197/j.aem.2005.12.013; Rahman NH, 2010, INT J EMERGENCY MED, V28, P861; Reed SS, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD010824, DOI 10.1002/14651858.CD010824]; RevMan, 2014, REV MAN REVMAN 5 3; Tang YY, 2010, J MINIM INVAS GYN, V17, P325, DOI 10.1016/j.jmig.2010.01.017; Taylor DM, 2005, ACAD EMERG MED, V12, P13, DOI 10.1197/j.aem.2004.08.039; The Joint Commission, MOD SED MED PAT MON; The Joint Commission, 2005, COMPR ACCR MAN HOSP; Wakai A, 2008, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007399, DOI 10.1002/14651858.CD007399]	34	4	7	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1469-493X	1361-6137		COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2015		7							CD007399	10.1002/14651858.CD007399.pub2			56	Medicine, General & Internal	General & Internal Medicine	CQ5MF	WOS:000360647800031	26222247	Green Published			2020-06-30	J	Zeppetella, G; Davies, AN				Zeppetella, G.; Davies, A. N.			Opioids for the management of breakthrough pain in cancer patients (Withdrawn paper. 2015. art. no. CD004311)	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Correction																Zeppetella G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub4	1	5	5	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1469-493X	1361-6137		COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2015		8							CD004311	10.1002/14651858.CD004311.pub4			4	Medicine, General & Internal	General & Internal Medicine	CQ5MB	WOS:000360647400051	26275024				2020-06-30	J	Duan, GY; Guo, SN; Zhan, HM; Qi, DM; Zhang, YH; Zhang, XW				Duan, Guangyou; Guo, Shanna; Zhan, Huiming; Qi, Dongmei; Zhang, Yuhao; Zhang, Xianwei			A New Real-time Method for Detecting the Effect of Fentanyl Using the Preoperative Pressure Pain Threshold and Narcotrend Index A Randomized Study in Female Surgery Patients	MEDICINE			English	Article							POSTOPERATIVE PAIN; CONTROLLED ANALGESIA; SENSITIVITY; SEDATION; MORPHINE; OPIOIDS	Individual variability in the effects of opioid analgesics such as fentanyl remains a major challenge for tailored pharmacological treatment including postoperative analgesia. This study aimed to establish a new real-time method for detecting the effects of fentanyl and their individual differences in the preoperative period, using the pressure pain threshold (PPT) and Narcotrend index (NTI) test. Eighty women undergoing elective surgery under general anesthesia were enrolled in this randomized, double-blinded, placebo-controlled study to receive either intravenous fentanyl (Group F) or saline (Group S). Before (T1) and 5 (T2) and 10 min (T3) after intravenous injection, the PPT, NTI, respiratory rate, heart rate, blood pressure, and pulse oxygen saturation were measured. The initial time at which the Narcotrend index showed a decline was also recorded. In total, 40 patients in Group S and 38 patients in Group F were included in the final analysis. At 5 min and 10 min after intravenous fentanyl administration, the analgesic effect was determined by measuring the PPT, which was significantly increased (P < 0.001), and the sedative effect was detected using the NTI, which was significantly decreased (P < 0.001). The distribution of percentage changes of the PPT and NTI showed individual differences. At T2 and T3, the absolute changes in NTI and PPT were positively correlated (r = 0.444 at T2, P = 0.005; r = 0.332 at T3, P = 0.042). Through the PPT and NTI, it was feasible to easily detect the effects of fentanyl and their individual differences in real time before induction of anesthesia in the operation room. This method could potentially be applied to preoperatively determine patients' sensitivity to fentanyl.	[Duan, Guangyou; Guo, Shanna; Zhan, Huiming; Qi, Dongmei; Zhang, Yuhao; Zhang, Xianwei] Huazhong Univ Sci & Technol, Dept Anesthesiol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Peoples R China	Zhang, XW (reprint author), Huazhong Univ Sci & Technol, Dept Anesthesiol, Tongji Hosp, Tongji Med Coll, 1095 Jie Fang Rd, Wuhan 430030, Peoples R China.	ourpain@163.com			Ministry of Health of the People's Republic of China	This study was partially supported by a 2010 Clinical Key Disciplines Construction Grant from the Ministry of Health of the People's Republic of China. The authors have no conflicts of interest to disclose.	Abrishami A, 2011, ANESTHESIOLOGY, V114, P445, DOI 10.1097/ALN.0b013e3181f85ed2; Alabas OA, 2012, EUR J PAIN, V16, P1211, DOI 10.1002/j.1532-2149.2012.00121.x; Amornyotin S, 2011, MED DEVICES-EVID RES, V4, P43, DOI 10.2147/MDER.S17236; Carrasco G, 2000, CRIT CARE, V4, P217, DOI 10.1186/cc697; David HJ, 2007, J PAIN, V8, P650; Doufas AG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054807; Duan Guang-You, 2012, Zhonghua Yi Xue Za Zhi, V92, P448, DOI 10.3760/cma.j.issn.00376-2491-2012.07.005; Duan GY, 2013, ANESTHESIOLOGY, V118, P436, DOI 10.1097/ALN.0b013e31827dde74; Fillingim RB, 2004, ANESTHESIOLOGY, V100, P1263, DOI 10.1097/00000542-200405000-00031; Geppetti P, 2009, CLIN DRUG INVEST, V29, P3, DOI 10.2165/0044011-200929001-00002; Hagle Mary E, 2004, Orthop Nurs, V23, P18, DOI 10.1097/00006416-200401000-00007; Hooten WM, 2010, PAIN MED, V11, P1587, DOI 10.1111/j.1526-4637.2010.00962.x; Hsu YW, 2005, ANESTHESIOLOGY, V103, P613, DOI 10.1097/00000542-200509000-00026; Ip HYV, 2009, ANESTHESIOLOGY, V111, P657, DOI 10.1097/ALN.0b013e3181aae87a; Kinser AM, 2009, J STRENGTH COND RES, V23, P312, DOI 10.1519/JSC.0b013e31818f051c; Overdyk FJ, 2007, ANESTH ANALG, V105, P412, DOI 10.1213/01.ane.0000269489.26048.63; Paech MJ, 2012, DRUG TODAY, V48, P119, DOI 10.1358/dot.2012.48.2.1745275; Palmer Pamela P, 2010, Anesthesiol Clin, V28, P587, DOI 10.1016/j.anclin.2010.08.010; Riley JL, 2010, PAIN MED, V11, P195, DOI 10.1111/j.1526-4637.2009.00680.x; Rolke R, 2006, PAIN, V123, P231, DOI 10.1016/j.pain.2006.01.041; Ruiz-Ruiz B, 2011, J PAIN, V12, P1040, DOI 10.1016/j.jpain.2011.04.001; Sayed-Noor AS, 2008, CLIN J PAIN, V24, P232, DOI 10.1097/AJP.0b013e3181602159; Sibille KT, 2011, PAIN MED, V12, P1076, DOI 10.1111/j.1526-4637.2011.01157.x; Staahl C, 2007, SCAND J GASTROENTERO, V42, P383, DOI 10.1080/00365520601014414; Wang HL, 2011, PAIN MED, V12, P1720, DOI 10.1111/j.1526-4637.2011.01276.x; Weber F, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507001329; Weber F, 2008, PEDIATR ANESTH, V18, P823, DOI 10.1111/j.1460-9592.2008.02692.x; Wu CL, 2011, LANCET, V377, P2215, DOI 10.1016/S0140-6736(11)60245-6	28	6	8	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	JAN	2015	94	1							e316	10.1097/MD.0000000000000316			6	Medicine, General & Internal	General & Internal Medicine	AY5TF	WOS:000347633800011	25569647	DOAJ Gold, Green Published			2020-06-30	J	Yuan, JJ; Hou, JK; Zhang, W; Chang, YZ; Li, ZS; Wang, ZY; Du, YY; Ma, XJ; Zhang, LR; Kan, QC; Candiotti, KA				Yuan, Jing-Jing; Hou, Jun-Kai; Zhang, Wei; Chang, Yan-Zi; Li, Zhi-Song; Wang, Zong-Yu; Du, Ying-Ying; Ma, Xiao-Jing; Zhang, Li-Rong; Kan, Quan-Cheng; Candiotti, Keith A.			CYP3A4*1G Genetic Polymorphism Influences Metabolism of Fentanyl in Human Liver Microsomes in Chinese Patients	PHARMACOLOGY			English	Article						Fentanyl; Metabolism in vitro; Microsome; CYP3A4; Polymorphisms	CYP3A4; PHARMACOKINETICS; EFFICACY; 3A4	Purpose:This study aimed to investigate whether CYP3A4*1G genetic polymorphism influences the metabolism of fentanyl in human liver microsomes in Chinese patients. Methods: The human liver microsomes were obtained from 88 hepatobiliary surgery patients who accepted liver resection surgery in this study. A normal liver sample (confirmed by the Department of Pathology) was taken from the outer edge of the resected tissue. The metabolism of fentanyl in human liver microsomes was studied. The concentration of fentanyl was measured by high performance liquid chromatography. The CYP3A4*1G variant allele was genotyped using the PCR restriction fragment length polymorphism method. Results: The frequency of the CYP3A4* 1G variant allele was 0.188 in the 88 Chinese patients who had received hepatobiliary surgery. The metabolic rate of fentanyl in patients homozygous for the * 1G/*1G variant (0.85 +/- 0.37) was significantly lower than that in patients bearing the wild-type allele * 1/*1 (1.89 +/- 0.58) or in patients heterozygous for the *1/*1G variant (1.82 +/- 0.65; p < 0.05). There were no gender-related differences in the metabolic rate of fentanyl (p > 0.05) nor was there any correlation between age and metabolic rate of fentanyl (p > 0.05). Results from different hepatobiliary diseases showed no significant difference in the metabolic rate of fentanyl (p > 0.05). The difference of CYP3A4 mRNA among different CYP3A4*1G variant alleles was significant (p < 0.05). There was positive correlation between CYP3A4 mRNA and metabolic rate offentanyl (p < 0.01). Conclusions: CYP3A4*1G genetic polymorphism decreases the metabolism of fentanyl. There is a positive correlation between CYP3A4 mRNA level and metabolism of fentanyl. (C) 2015 S. Karger AG, Basel	[Yuan, Jing-Jing; Hou, Jun-Kai; Zhang, Wei; Chang, Yan-Zi; Li, Zhi-Song; Wang, Zong-Yu; Du, Ying-Ying; Ma, Xiao-Jing] Zhengzhou Univ, Affiliated Hosp 1, Dept Anesthesiol, Zhengzhou 450052, Peoples R China; [Zhang, Li-Rong] Zhengzhou Univ, Sch Med, Dept Pharmacol, Zhengzhou 450052, Peoples R China; [Kan, Quan-Cheng] Key Lab Pharmacogen, Zhengzhou, Henan Province, Peoples R China; [Candiotti, Keith A.] Dept Anesthesiol Perioperat Med & Pain Management, Miami, FL USA	Zhang, W (reprint author), Zhengzhou Univ, Affiliated Hosp 1, Dept Anesthesiol, 1 East JianShe Rd, Zhengzhou 450052, Peoples R China.	zhangw571012@126.com; lrzhang@zzu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81171060, 81173127, 81273581]	This work was supported by the National Natural Science Foundation of China (Grant Nos. 81171060, 81173127 and 81273581). The work was completed in the Henan Key Laboratory of Molecular Medicine, PR China. The authors thank the staff of the hepatobiliary surgery for their assistance and Mr. Yuanxiang Tao (Department of Anesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey) for his critical reading of the manuscript.	Anderson GD, 2005, J WOMENS HEALTH, V14, P19, DOI 10.1089/jwh.2005.14.19; Dai D, 2001, J PHARMACOL EXP THER, V299, P825; Du J, 2007, CLIN CHIM ACTA, V383, P172, DOI 10.1016/j.cca.2007.04.027; Du J, 2006, PHARMACOGENOMICS, V7, P831, DOI 10.2217/14622416.7.6.831; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Gaedigk A, 2006, DRUG METAB DISPOS, V34, P504, DOI 10.1121/dmd.105.007799; Gao Y, 2008, EUR J CLIN PHARMACOL, V64, P877, DOI 10.1007/s00228-008-0502-x; Gibson GG, 2002, XENOBIOTICA, V32, P165, DOI 10.1080/00498250110102674; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; Hsieh KP, 2001, DRUG METAB DISPOS, V29, P268; KOBAYASHI K, 1994, J PHARMACEUT BIOMED, V12, P839, DOI 10.1016/S0731-7085(94)80025-1; KREMERS P, 1981, EUR J BIOCHEM, V118, P599, DOI 10.1111/j.1432-1033.1981.tb05561.x; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Parkinson A, 2004, TOXICOL APPL PHARM, V199, P193, DOI 10.1016/j.taap.2004.01.010; Thummel KE, 1998, ANNU REV PHARMACOL, V38, P389, DOI 10.1146/annurev.pharmtox.38.1.389; Zhang W., 2012, INT J PHOTOENERGY, V2012, P1, DOI DOI 10.1109/JSTSP.2013.2285520; Zhang W, 2011, EUR J ANAESTH, V28, P245, DOI 10.1097/EJA.0b013e3283438b39; Zhang W, 2010, EUR J CLIN PHARMACOL, V66, P61, DOI 10.1007/s00228-009-0726-4	20	15	17	0	11	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0031-7012	1423-0313		PHARMACOLOGY	Pharmacology		2015	96	1-2					55	60		10.1159/000433441			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CO9PI	WOS:000359507300009	26088794				2020-06-30	J	Albrecht, M; Henke, J; Tacke, S; Markert, M; Guth, B				Albrecht, Maike; Henke, Julia; Tacke, Sabine; Markert, Michael; Guth, Brian			Influence of repeated anaesthesia on physiological parameters in male Wistar rats: a telemetric study about isoflurane, ketamine-xylazine and a combination of medetomidine, midazolam and fentanyl	BMC VETERINARY RESEARCH			English	Article						Rat; Repeated anaesthesia; Isoflurane; Ketamine xylazine; Medetomidine midazolam fentanyl; Telemetry; Heart rate; Blood pressure; Body temperature; Body weight	INTRAPERITONEAL INJECTION; LABORATORY-ANIMALS; LOCOMOTOR-ACTIVITY; HEART-RATE; DEXMEDETOMIDINE; RADIOTELEMETRY; TEMPERATURE; INDUCTION; TOLERANCE; RESTRAINT	Background: This study evaluated the influence of repeated anaesthesia using isoflurane (ISO, 2-3 Vol%), ketamine-xylazine (KX, 100 mg.kg(-1) + 5 mg.kg(-1), i.m.) or a combination of medetomidine-midazolam-fentanyl (MMF, 0.15 mg.kg(-1) + 2.0 mg.kg(-1) + 0.005 mg.kg(-1), i.m.) on heart rate (HR), arterial blood pressure (BP), body temperature (BT), duration of anaesthetic intervals and body weight (BW) in Wistar rats. Rats were instrumented with a telemetric system for the measurement of systolic, diastolic and mean arterial pressure (SAP, DAP, MAP), pulse pressure (PP), HR and BT during induction, maintenance and recovery of anaesthesia. Each anaesthesia was performed six times within three weeks. KX was not antagonized, but ISO delivery was terminated 40 minutes after induction and MMF was reversed with atipamezole-flumazenil-naloxone (AFN, 0.75 mg.kg(-1) + 0.2 mg.kg(-1) + 0.12 mg.kg(-1), s.c.). Results: With repeated anaesthesia, ISO showed a decrease of HR and BP. A significant decrease of PP could be observed with repeated anaesthesia using MMF. HR and BP were not affected by repeated KX anaesthesia, but we noted a reduction of sleeping time and BW. Neither MMF nor ISO showed significant differences in the duration of anaesthetic intervals and BW. With KX we observed tissue necrosis at the injection site and surgical tolerance was not achieved in 25% of the anaesthesias performed. Conclusion: HR, BP values, BT, duration of anaesthetic intervals and BW were affected differently by repeated anaesthesia performed with ISO, KX or MMF. ISO produced a reproducible anaesthesia, thereby being suitable for repeated use, but with a decrease of HR and BP throughout the six anaesthesias. The use of ISO in cases where these parameters should be unaffected is therefore not advised. The inability to produce a surgical tolerance, the reduction of sleeping time and BW, as well as the tissue necrosis are significant contraindications for a repeated use of KX. Only mild changes of BP were found with repeated MMF anaesthesia, so it seems suitable for serial use, unless the high BP and the low HR during the surgical plane of anaesthesia are undesirable for a special procedure.	[Albrecht, Maike; Henke, Julia] Boehringer Ingelheim Pharma GmbH & Co KG, Dept Nonclin Drug Safety, Biol Lab Serv, D-88397 Biberach, Germany; [Tacke, Sabine] Univ Giessen, Dept Vet Clin Sci, Clin Small Anim Surg, D-35392 Giessen, Germany; [Markert, Michael; Guth, Brian] Boehringer Ingelheim Pharma GmbH & Co KG, Dept Drug Discovery Support Gen Pharmacol, D-88397 Biberach, Germany	Henke, J (reprint author), Boehringer Ingelheim Pharma GmbH & Co KG, Dept Nonclin Drug Safety, Biol Lab Serv, Birkendorfer Str 65, D-88397 Biberach, Germany.	julia.henke@boehringer-ingelheim.com	Tacke, Sabine/A-3213-2019				Albrecht M, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0198-3; Altholtz LY, 2006, J AM ASSOC LAB ANIM, V45, P17; Arras M, 2001, COMPARATIVE MED, V51, P443; Baker HJ, 1980, LAB RAT; Becker Daniel E, 2006, Anesth Prog, V53, P98, DOI 10.2344/0003-3006(2006)53[98:EOLAP]2.0.CO;2; BRAGA VA, 2011, MODERN TELEMETRY, P183; Burnside WM, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-48; Chassagne MC, 2000, COMP HAEMATOL INT, V10, P126, DOI 10.1007/s005800070003; Coria-Avila GA, 2007, LAB ANIMAL, V36, P25, DOI 10.1038/laban0707-25; Das RG, 2007, LAB ANIM-UK, V41, P312; Diehl KH, 2001, J APPL TOXICOL, V21, P15, DOI 10.1002/jat.727; EGER EI, 1987, ANESTH ANALG, V66, P1230; Erhardt W, 2012, ANASTHESIE ANALGESIE; Flecknell P.A., 1987, LAB ANIMAL ANAESTHES; Franco NH, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002399; GREEN CJ, 1981, LAB ANIM, V15, P163, DOI 10.1258/002367781780959107; Greene Adrianne N., 2007, Journal of Pharmacological and Toxicological Methods, V56, P218, DOI 10.1016/j.vascn.2007.04.006; Hedenqvist P, 2000, LAB ANIM, V34, P207, DOI 10.1258/002367700780457536; Hildebrandt IJ, 2008, ILAR J, V49, P17, DOI 10.1093/ilar.49.1.17; Kosanke Y, 2012, THESIS ZENTRUM KLIN; Kramer K, 2003, PHYSIOL GENOMICS, V13, P197, DOI 10.1152/physiolgenomics.00164.2002; KRINKE GJ, 2000, LAB RAT; Kroiss M, 2013, KLEINTIERPRAXIS, V58, P644, DOI 10.2377/0023-2076-58-644; LIVINGSTON A, 1978, BRIT J PHARMACOL, V64, P63, DOI 10.1111/j.1476-5381.1978.tb08641.x; LIVINGSTON A, 1977, BRIT J PHARMACOL, V59, pP491; Livingston A, 1977, Br J Pharmacol, V60, p296P; LIVINGSTON A, 1976, BRIT J PHARMACOL, V57, pP457; Lukasik VM, 2003, NMR BIOMED, V16, P459, DOI 10.1002/nbm.836; MARIETTA MP, 1976, J PHARMACOL EXP THER, V196, P536; Meijer MK, 2006, LAB ANIM-UK, V40, P382, DOI 10.1258/002367706778476370; Mihara T, 2012, ANESTH ANALG, V115, P805, DOI 10.1213/ANE.0b013e3182632bcb; Morton D B, 2000, ILAR J, V41, P80; Morton DB, 2003, LAB ANIM-UK, V37, P261, DOI 10.1258/002367703322389861; Ozturk A, 2007, B VET I PULAWY, V51, P635; Prudian F, 1997, N-S ARCH PHARMACOL, V355, P774, DOI 10.1007/PL00005012; Rahmanian-Schwarz A, 2012, J INVEST SURG, V25, P123, DOI 10.3109/08941939.2011.611582; Schierok H, 2000, J PHARMACOL TOXICOL, V43, P211, DOI 10.1016/S1056-8719(00)00101-5; Schmaljohann D, 2006, ADV DRUG DELIVER REV, V58, P1655, DOI 10.1016/j.addr.2006.09.020; Settle TL, 2010, J MED PRIMATOL, V39, P50, DOI 10.1111/j.1600-0684.2009.00393.x; SMITH W, 1993, LAB ANIM, V27, P30, DOI 10.1258/002367793781082377; STEWARD JP, 1968, APPL MICROBIOL, V16, P1418, DOI 10.1128/AEM.16.9.1418-1419.1968; Tremoleda JL, 2012, EJNMMI RES, V2, DOI 10.1186/2191-219X-2-44; Veilleux-Lemieux D, 2013, J AM ASSOC LAB ANIM, V52, P567; Vyskocilova E, 2013, BIOMED RES INT, DOI 10.1155/2013/408573; Wellington D, 2013, J AM ASSOC LAB ANIM, V52, P481; Wenger S, 2012, J EXOT PET MED, V21, P7, DOI 10.1053/j.jepm.2011.11.010	46	15	15	1	13	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1746-6148		BMC VET RES	BMC Vet. Res.	DEC 31	2014	10								310	10.1186/s12917-014-0310-8			15	Veterinary Sciences	Veterinary Sciences	CA3QW	WOS:000348822300002	25551200	DOAJ Gold, Green Published			2020-06-30	J	She, YJ; Wang, HZ; Huang, JX; Tan, YH; Wang, ZX; Tian, H; Song, XR				She, Ying-Jun; Wang, Huai-Zhen; Huang, Jun-Xiang; Tan, Yong-Hong; Wang, Zi-Xing; Tian, Hang; Song, Xing-Rong			Effect of a Bolus Dose of Fentanyl on the ED50 and ED95 of Sevoflurane in Neonates	MEDICAL SCIENCE MONITOR			English	Article						Anesthesia; Inhalation; Fentanyl; Infant; Newborn	MINIMUM ALVEOLAR CONCENTRATION; LARYNGEAL MASK AIRWAY; INFANTS; MAC; ANESTHESIA; HALOTHANE; INSERTION; PRETERM	Background: The minimum alveolar concentration (MAC) of sevoflurane in neonates is 3.3%, but this value has not been verified in Chinese neonates and the effect of different doses of fentanyl on MAC in neonates has not been investigated. This study was designed to determine the ED 50 and ED 95 values of sevoflurane in Chinese neonates with and without fentanyl. Material/Methods: Ninety-three neonates were randomly assigned to receive sevoflurane alone (control group, n= 30), 1 mu g/kg sevoflurane (group fent 1, n= 29), or 2 mu g/kg fentanyl (group fent 2, n= 32). Following inhalational induction and tracheal intubation, the end-tidal concentration of sevoflurane was adjusted to achieve the designated concentration, which was determined using the modified Dixon's up-and-down method starting with 3.0% in each group, with a 0.25% step size. Success was defined as no motor response within 60 s of skin incision. Results: The MAC (standard deviation) values of sevoflurane were 2.91% (0.27) in the control group, 2.53% (0.31) in the fent 1 group, and 2.34% (0.33) in the fent 2 group according to Dixon's up-and-down method. Logistic probit regression analysis revealed that the ED50 and ED95 (95% CI) of sevoflurane in neonates were 2.82% (2.66-2.98) and 3.39% (2.89-3.89), respectively, in the control group; 2.44% (2.19-2.68) and 3.30% (2.51-4.09), respectively, in the fent 1 group; and 2.21% (1.97-2.45) and 3.11% (2.35-3.88), respectively, in the fent 2 group. Conclusions: The MAC value of sevoflurane in Chinese neonates was lower than previously reported and was reduced by the addition of fentanyl.	[She, Ying-Jun; Wang, Huai-Zhen; Huang, Jun-Xiang; Tan, Yong-Hong; Wang, Zi-Xing; Tian, Hang; Song, Xing-Rong] Guangzhou Med Univ, Affiliated Women & Children Med Ctr, Guangzhou Women & Children Med Ctr, Dept Anesthesiol, Guangzhou, Guangdong, Peoples R China; [She, Ying-Jun] Jinan Univ, Affiliated Hosp 1, Dept Anesthesiol, Guangzhou, Guangdong, Peoples R China	Song, XR (reprint author), Guangzhou Med Univ, Affiliated Women & Children Med Ctr, Guangzhou Women & Children Med Ctr, Dept Anesthesiol, Guangzhou, Guangdong, Peoples R China.	songxr1966@yeah.net					Aantaa R, 2001, BRIT J ANAESTH, V86, P213, DOI 10.1093/bja/86.2.213; Bai WY, 2010, J CLIN ANESTH, V22, P592, DOI 10.1016/j.jclinane.2010.05.002; Casati A, 2001, Minerva Anestesiol, V67, P621; COLLINS C, 1985, ANESTH ANALG, V64, P1078; CRAWFORD MW, 1992, ANESTH ANALG, V75, P1000; Davidson AJ, 2008, PEDIATR ANESTH, V18, P702, DOI 10.1111/j.1460-9592.2008.02664.x; Davis PJ, 2000, ANESTH ANALG, V90, P863, DOI 10.1213/00000539-200004000-00017; Ezri T, 2007, ANESTHESIOLOGY, V107, P9, DOI 10.1097/01.anes.0000267534.31668.62; Feuerecker M, 2011, BRIT J ANAESTH, V107, P726, DOI 10.1093/bja/aer226; LANDAIS A, 1995, PAEDIATR ANAESTH, V5, P297, DOI 10.1111/j.1460-9592.1995.tb00309.x; Lee JR, 2008, ANESTH ANALG, V106, P1122, DOI 10.1213/01.ane.0000286174.07844.e9; LERMAN J, 1994, ANESTHESIOLOGY, V80, P814, DOI 10.1097/00000542-199404000-00014; Longnecher D E, 2008, ANESTHESIOLOGY, P1520; Lu W, 2000, ANESTHESIOLOGY, V92, P985, DOI 10.1097/00000542-200004000-00015; Mapleson WW, 1996, BRIT J ANAESTH, V76, P179; Michel F, 2010, PEDIATR ANESTH, V20, P712, DOI 10.1111/j.1460-9592.2010.03334.x; Miller R. D., 2009, MILLERS ANESTHESIA; MURRAY DJ, 1992, ANESTH ANALG, V74, P329; Nishina K, 2006, PEDIATR ANESTH, V16, P834, DOI 10.1111/j.1460-9592.2006.01874.x; Paul M, 2001, ANESTHESIOLOGY, V95, P1362, DOI 10.1097/00000542-200112000-00014; Prakash YS, 2000, ANESTHESIOLOGY, V92, P1114, DOI 10.1097/00000542-200004000-00030; Prakash YS, 2002, ANESTHESIOLOGY, V96, P893, DOI 10.1097/00000542-200204000-00017; WEBB AI, 1987, AM J VET RES, V48, P1733; Wilson AS, 1997, ANESTH ANALG, V84, P315, DOI 10.1097/00000539-199702000-00013; YASTER M, 1987, ANESTHESIOLOGY, V66, P524, DOI 10.1097/00000542-198704000-00013; YASTER M, 1987, ANESTHESIOLOGY, V66, P433, DOI 10.1097/00000542-198703000-00035	26	3	3	0	3	INT SCIENTIFIC INFORMATION, INC	MELVILLE	150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA	1643-3750			MED SCI MONITOR	Med. Sci. Monitor	DEC 14	2014	20						2658	2665		10.12659/MSM.891276			8	Medicine, Research & Experimental	Research & Experimental Medicine	CC2ER	WOS:000350158500001	25503557	Green Published			2020-06-30	J	Morgan, MM; Reid, RA; Saville, KA				Morgan, Michael M.; Reid, Rachel A.; Saville, Kimber A.			Functionally Selective Signaling for Morphine and Fentanyl Antinociception and Tolerance Mediated by the Rat Periaqueductal Gray	PLOS ONE			English	Article							MU-OPIOID RECEPTOR; N-TERMINAL KINASE; DESENSITIZATION; AGONIST; PROTEIN; PHOSPHORYLATION; MICROINJECTION; ACTIVATION; DEPENDENCE; EFFICACY	Functionally selective signaling appears to contribute to the variability in mechanisms that underlie tolerance to the antinociceptive effects of opioids. The present study tested this hypothesis by examining the contribution of G protein-coupled receptor kinase (GRK)/Protein kinase C (PKC) and C-Jun N-terminal kinase (JNK) activation on both the expression and development of tolerance to morphine and fentanyl microinjected into the ventrolateral periaqueductal gray of the rat. Microinjection of morphine or fentanyl into the periaqueductal gray produced a dose-dependent increase in hot plate latency. Microinjection of the nonspecific GRK/PKC inhibitor Ro 32-0432 into the periaqueductal gray to block muopioid receptor phosphorylation enhanced the antinociceptive effect of morphine but had no effect on fentanyl antinociception. Microinjection of the JNK inhibitor SP600125 had no effect on morphine or fentanyl antinociception, but blocked the expression of tolerance to repeated morphine microinjections. In contrast, a microinjection of Ro 32-0432 blocked the expression of fentanyl, but not morphine tolerance. Repeated microinjections of Ro 32-0432 blocked the development of morphine tolerance and inhibited fentanyl antinociception whether rats were tolerant or not. Repeated microinjections of SP600125 into the periaqueductal gray blocked the development of tolerance to both morphine and fentanyl microinjections. These data demonstrate that the signaling molecules that contribute to tolerance vary depending on the opioid and methodology used to assess tolerance (expression vs. development of tolerance). This signaling difference is especially clear for the expression of tolerance in which JNK contributes to morphine tolerance and GRK/PKC contributes to fentanyl tolerance.	[Morgan, Michael M.; Reid, Rachel A.; Saville, Kimber A.] Washington State Univ, Dept Psychol, Vancouver, WA 98686 USA	Morgan, MM (reprint author), Washington State Univ, Dept Psychol, Vancouver, WA 98686 USA.	mmmorgan@vancouver.wsu.edu			National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA015498]	Funded by the National Institute on Drug Abuse (http://www.drugabuse.gov/) grant # DA015498. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aiyar N, 2000, EUR J PHARMACOL, V403, P1, DOI 10.1016/S0014-2999(00)00419-2; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bobeck EN, 2012, J PAIN, V13, P799, DOI 10.1016/j.jpain.2012.05.005; Bobeck EN, 2009, PAIN, V147, P210, DOI 10.1016/j.pain.2009.09.008; BODNAR RJ, 1990, BRAIN RES, V529, P324, DOI 10.1016/0006-8993(90)90845-3; Buntin-Mushock C, 2005, ANESTH ANALG, V100, P1740, DOI 10.1213/01.ANE.0000152191.29311.9B; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; do K Kim, 2011, J NEUROCHEM, V116, P1077; Doll C, 2012, BRIT J PHARMACOL, V167, P1259, DOI 10.1111/j.1476-5381.2012.02080.x; Eidson LN, 2013, J NEUROSCI, V33, P15952, DOI 10.1523/JNEUROSCI.1609-13.2013; Eidson LN, 2013, J PAIN, V14, P393, DOI 10.1016/j.jpain.2012.12.010; Fan XL, 2003, NEUROSCIENCE, V122, P997, DOI 10.1016/j.neuroscience.2003.08.062; Fossum EN, 2008, BRAIN RES, V1204, P53, DOI 10.1016/j.brainres.2008.02.022; Gunn A, 2011, J PAIN, V12, P222, DOI 10.1016/j.jpain.2010.06.011; Hull LC, 2010, J PHARMACOL EXP THER, V332, P1127, DOI 10.1124/jpet.109.161455; JACQUET YF, 1974, SCIENCE, V185, P1055, DOI 10.1126/science.185.4156.1055; Johnson EA, 2006, MOL PHARMACOL, V70, P676, DOI 10.1124/mol.106.022376; Kelly E, 2008, BRIT J PHARMACOL, V153, pS379, DOI 10.1038/sj.bjp.0707604; Kim JA, 2008, CURR BIOL, V18, P129, DOI 10.1016/j.cub.2007.12.057; Lamberts JT, 2013, J NEUROSCI, V33, P4369, DOI 10.1523/JNEUROSCI.5470-12.2013; Lane DA, 2005, BRAIN RES, V1047, P65, DOI 10.1016/j.brainres.2005.04.001; Ma WY, 2001, EUR J NEUROSCI, V14, P1091, DOI 10.1046/j.0953-816x.2001.01731.x; McPherson J, 2010, MOL PHARMACOL, V78, P756, DOI 10.1124/mol.110.066613; Melief EJ, 2010, P NATL ACAD SCI USA, V107, P11608, DOI 10.1073/pnas.1000751107; Morgan MM, 2006, PHARMACOL BIOCHEM BE, V85, P214, DOI 10.1016/j.pbb.2006.08.003; Morgan MM, 2009, BRAIN RES, V1295, P59, DOI 10.1016/j.brainres.2009.07.100; Paxinos G, 2005, RAT BRAIN STEREOTAXI; Rivero G, 2012, MOL PHARMACOL, V82, P178, DOI 10.1124/mol.112.078659; Smith FL, 2002, BRAIN RES, V958, P28, DOI 10.1016/S0006-8993(02)03394-2; Smith FL, 2006, PHARMACOL RES, V54, P474, DOI 10.1016/j.phrs.2006.09.007; TALLARIDA R, 2000, DRUG SYNERGISM DOSE; Tortorici V, 1999, BEHAV NEUROSCI, V113, P833, DOI 10.1037/0735-7044.113.4.833; TRUJILLO KA, 1995, NEUROPSYCHOPHARMACOL, V13, P301, DOI 10.1016/0893-133X(95)00088-U; Wagley Y, 2013, BBA-MOL CELL RES, V1833, P1476, DOI 10.1016/j.bbamcr.2013.02.017; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449	35	10	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2014	9	12							e114269	10.1371/journal.pone.0114269			17	Multidisciplinary Sciences	Science & Technology - Other Topics	AX8FY	WOS:000347146700019	25503060	DOAJ Gold, Green Published			2020-06-30	J	Kuwabara, H; Heishman, SJ; Brasic, JR; Contoreggi, C; Cascella, N; Mackowick, KM; Taylor, R; Rousset, O; Willis, W; Huestis, MA; Concheiro, M; Wand, G; Wong, DF; Volkow, ND				Kuwabara, Hiroto; Heishman, Stephen J.; Brasic, James R.; Contoreggi, Carlo; Cascella, Nicola; Mackowick, Kristen M.; Taylor, Richard; Rousset, Olivier; Willis, William; Huestis, Marilyn A.; Concheiro, Marta; Wand, Gary; Wong, Dean F.; Volkow, Nora D.			Mu Opioid Receptor Binding Correlates with Nicotine Dependence and Reward in Smokers	PLOS ONE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; STRIATAL DOPAMINE RELEASE; WITHDRAWAL SYMPTOMS; SMOKING; FMRI; QUANTIFICATION; REPLACEMENT; MODULATION; OCCUPANCY; RESPONSES	The rewarding effects of nicotine are associated with activation of nicotine receptors. However, there is increasing evidence that the endogenous opioid system is involved in nicotine's rewarding effects. We employed PET imaging with [C-11] carfentanil to test the hypotheses that acute cigarette smoking increases release of endogenous opioids in the human brain and that smokers have an upregulation of mu opioid receptors (MORs) when compared to nonsmokers. We found no significant changes in binding potential (BPND) of [C-11] carfentanil between the placebo and the active cigarette sessions, nor did we observe differences in MOR binding between smokers and nonsmokers. Interestingly, we showed that in smokers MOR availability in bilateral superior temporal cortices during the placebo condition was negatively correlated with scores on the Fagerstrom Test for Nicotine Dependence (FTND). Also in smokers, smoking-induced decreases in [C-11] carfentanil binding in frontal cortical regions were associated with self-reports of cigarette liking and wanting. Although we did not show differences between smokers and nonsmokers, the negative correlation with FTND corroborates the role of MORs in superior temporal cortices in nicotine addiction and provides preliminary evidence of a role of endogenous opioid signaling in frontal cortex in nicotine reward.	[Kuwabara, Hiroto; Brasic, James R.; Rousset, Olivier; Willis, William; Wong, Dean F.] Johns Hopkins Univ, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21218 USA; [Heishman, Stephen J.; Cascella, Nicola; Wong, Dean F.] Johns Hopkins Univ, Dept Psychiat, Baltimore, MD USA; [Wand, Gary] Johns Hopkins Univ, Dept Med, Baltimore, MD USA; [Wong, Dean F.] Johns Hopkins Univ, Dept Neurosci, Baltimore, MD USA; [Heishman, Stephen J.; Contoreggi, Carlo; Mackowick, Kristen M.; Taylor, Richard; Huestis, Marilyn A.; Concheiro, Marta] NIDA, Intramural Res Program, Baltimore, MD USA; [Volkow, Nora D.] NIDA, Rockville, MD USA	Kuwabara, H (reprint author), Johns Hopkins Univ, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21218 USA.	hkuwaba1@jhmi.edu			NIH, National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA); NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K24 DA000412]; Radiology Internal Funds; National Center for Advancing Translational Sciences (NCATS) a component of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR 001079]; NIH Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	Financial support was provided by the Intramural Research Program of NIH, National Institute on Drug Abuse (SH, CC, KM, RT), and an award from NIDA, K24 DA000412 (DFW), as well as Radiology Internal Funds (DFW). All authors declare no conflicts of interest. Additionally, resources were provided by the Johns Hopkins Institute for Clinical and Translational Research (ICTR), which is funded in part by grant number UL1 TR 001079 from the National Center for Advancing Translational Sciences (NCATS) a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the Johns Hopkins ICTR, NCATS or NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; ASHBURNER J, 2003, HUMAN BRAIN FUNCTION, P635, DOI DOI 10.1016/B978-012264841-0/50034-2; Balfour DJK, 1996, PHARMACOL THERAPEUT, V72, P51, DOI 10.1016/S0163-7258(96)00099-X; Barrett SP, 2004, SYNAPSE, V54, P65, DOI 10.1002/syn.20066; Baumann B, 1999, J NEUROPSYCH CLIN N, V11, P71, DOI 10.1176/jnp.11.1.71; Berrendero F, 2002, J NEUROSCI, V22, P10935; Brody AL, 2009, INT J NEUROPSYCHOPH, V12, P305, DOI 10.1017/S146114570800922X; Brody AL, 2009, NEUROPSYCHOPHARMACOL, V34, P282, DOI 10.1038/npp.2008.87; Buchhalter AR, 2005, ADDICTION, V100, P550, DOI 10.1111/j.1360-0443.2005.01030.x; Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P1124; Champtiaux N, 2003, J NEUROSCI, V23, P7820; Colasanti A, 2012, BIOL PSYCHIAT, V72, P371, DOI 10.1016/j.biopsych.2012.01.027; Cole DM, 2010, NEUROIMAGE, V52, P590, DOI 10.1016/j.neuroimage.2010.04.251; DANNALS RF, 1985, INT J APPL RADIAT IS, V36, P303, DOI 10.1016/0020-708X(85)90089-4; DHATT RK, 1995, J NEUROCHEM, V64, P1878; Donny EC, 2007, ADDICTION, V102, P324, DOI 10.1111/j.1360-0443.2006.01670.x; Endres CJ, 2003, NUCL MED BIOL, V30, P177, DOI 10.1016/S0969-8051(02)00411-0; Esterlis I, 2010, J NUCL MED, V51, P1226, DOI 10.2967/jnumed.109.072447; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Hadjiconstantinou M, 2011, NEUROPHARMACOLOGY, V60, P1209, DOI 10.1016/j.neuropharm.2010.11.010; Hahn B, 2013, BIOL PSYCHIAT, V74, P436, DOI 10.1016/j.biopsych.2013.03.017; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; Heishman SJ, 2008, NICOTINE TOB RES, V10, P643, DOI 10.1080/14622200801908174; Hughes J, 1998, TOB CONTROL, V7, P92, DOI 10.1136/tc.7.1.92a; Hughes JR, 2006, NICOTINE TOB RES, V8, P153, DOI 10.1080/14622200500494856; Ichise M, 2003, J CEREBR BLOOD F MET, V23, P1096, DOI 10.1097/01.WCB.0000085441.37552.CA; Innis RB, 2007, J CEREBR BLOOD F MET, V27, P1533, DOI 10.1038/sj.jcbfm.9600493; Krishnan-Sarin S, 1999, ARCH GEN PSYCHIAT, V56, P663, DOI 10.1001/archpsyc.56.7.663; Kuwabara H, 2012, J NUCL MED, V53, P805, DOI 10.2967/jnumed.111.098186; Lee JH, 2005, APPL PSYCHOPHYS BIOF, V30, P195, DOI 10.1007/s10484-005-6377-z; Lerman C, 2004, PHARMACOGENOMICS J, V4, P184, DOI 10.1038/sj.tpj.6500238; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; Maes F, 1997, IEEE T MED IMAGING, V16, P187, DOI 10.1109/42.563664; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; MALIN DH, 1993, PSYCHOPHARMACOLOGY, V112, P339, DOI 10.1007/BF02244930; Martin-Soelch C, 2003, EUR J NEUROSCI, V18, P680, DOI 10.1046/j.1460-9568.2003.02791.x; Mawlawi O, 2001, J CEREBR BLOOD F MET, V21, P1034, DOI 10.1097/00004647-200109000-00002; McClernon FJ, 2008, NEUROPSYCHOPHARMACOL, V33, P2148, DOI 10.1038/sj.npp.1301618; Oswald LM, 2005, NEUROPSYCHOPHARMACOL, V30, P821, DOI 10.1038/sj.npp.1300667; Patenaude B, 2011, NEUROIMAGE, V56, P907, DOI 10.1016/j.neuroimage.2011.02.046; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; Rahmim A, 2005, PHYS MED BIOL, V50, P4887, DOI 10.1088/0031-9155/50/20/010; Ray R, 2011, P NATL ACAD SCI USA, V108, P9268, DOI 10.1073/pnas.1018699108; Scott DJ, 2007, NEUROPSYCHOPHARMACOL, V32, P450, DOI 10.1038/sj.npp.1301238; Sossi V, 2005, IEEE NUCL SCI CONF R, P2195; Walters CL, 2005, NEURON, V46, P933, DOI 10.1016/j.neuron.2005.05.005; Weerts EM, 2013, INT J NEUROPSYCHOPH, V16, P47, DOI 10.1017/S146114571200017X; Weerts EM, 2011, ALCOHOL CLIN EXP RES, V35, P2162, DOI 10.1111/j.1530-0277.2011.01565.x; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	49	18	18	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2014	9	12							e113694	10.1371/journal.pone.0113694			15	Multidisciplinary Sciences	Science & Technology - Other Topics	AW9YP	WOS:000346611400017	25493427	DOAJ Gold, Green Published			2020-06-30	J	Ide, S; Nishizawa, D; Fukuda, K; Kasai, S; Hasegawa, J; Hayashida, M; Minami, M; Ikeda, K				Ide, Soichiro; Nishizawa, Daisuke; Fukuda, Ken-ichi; Kasai, Shinya; Hasegawa, Junko; Hayashida, Masakazu; Minami, Masabumi; Ikeda, Kazutaka			Haplotypes of P2RX7 gene polymorphisms are associated with both cold pain sensitivity and analgesic effect of fentanyl	MOLECULAR PAIN			English	Article						P2X7 receptor; ATP; Purinergic receptor; Single-nucleotide polymorphism; Pain; Fentanyl; Cold pain; Haplotype analysis; Perioperative analgesia	P2X(7) RECEPTOR; P2X7 RECEPTOR; SPLICE VARIANTS; INFLAMMATION; NOCICEPTION; TOLERANCE; RELEASE; ROLES; POWER	Background: The P2X7 receptor is a member of the P2X family of adenosine 5'-triphosphate- gated cation channels. Several recent studies have demonstrated that this receptor is involved in mechanisms related to pain and inflammation. However, unknown is whether polymorphisms of the P2RX7 gene that encodes the human P2X7 receptor influence pain sensitivity and analgesic effects of opioids. The P2RX7 gene is known to be highly polymorphic. Thus, the present study examined associations between fentanyl sensitivity and polymorphisms in the P2RX7 gene in 355 Japanese patients who underwent painful orofacial cosmetic surgery. Results: We first conducted linkage disequilibrium (LD) analyses for 55 reported single-nucleotide polymorphisms (SNPs) in the region within and around the P2RX7 gene using genomic samples from 100 patients. In our samples, 42 SNPs were polymorphic, and a total of five LD blocks with six Tag SNPs (rs2708092, rs1180012, rs1718125, rs208293, rs1718136, and rs7132846) were observed. Thus, we further analyzed associations between genotypes/haplotypes of these Tag SNPs and clinical data using a total of 355 samples. In the genotype-based association study, only the rs1718125 G > A SNP tended to be associated with higher pain scores on a visual analog scale 24 h after surgery (VAS24). The haplotype-based association study showed that subjects with homozygous haplotype No. 3 (GTAAAC; estimated frequency: 15.0%) exhibited significantly higher cold pain sensitivity and lower analgesic effects of fentanyl for acute cold pain in the cold pressor test. Conversely, subjects who carried haplotype No. 1 (ACGGAC; estimated frequency: 24.5%) tended to exhibit lower cold pain sensitivity and higher analgesic effects of fentanyl. Furthermore, subjects with homozygous haplotype No. 2 (GCGGAC; estimated frequency: 22.9%) exhibited significantly lower VAS24 scores. Conclusions: Cold pain sensitivity and analgesic effects of fentanyl were related to the SNP and haplotypes of the P2RX7 gene. The patients with the rs1718125 G>A SNP tended to show higher VAS24 scores. Moreover, the combination of polymorphisms from the 5'-flanking region to exon 5 recessively affected cold pain sensitivity and analgesic effects of opioids for acute cold pain. The present findings shed light on the involvement of P2RX7 gene polymorphisms in naive cold pain sensitivity and analgesic effects of fentanyl.	[Ide, Soichiro; Nishizawa, Daisuke; Kasai, Shinya; Hasegawa, Junko; Ikeda, Kazutaka] Tokyo Metropolitan Inst Med Sci, Addict Subst Project, Setagaya Ku, Tokyo 1568506, Japan; [Ide, Soichiro; Minami, Masabumi] Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sapporo, Hokkaido, Japan; [Fukuda, Ken-ichi] Tokyo Dent Coll, Dept Dent Anesthesiol, Tokyo, Japan; [Hayashida, Masakazu] Juntendo Univ, Sch Med, Dept Anesthesiol & Pain Med, Tokyo 113, Japan	Ikeda, K (reprint author), Tokyo Metropolitan Inst Med Sci, Addict Subst Project, Setagaya Ku, 2-1-6 Kamikitazawa, Tokyo 1568506, Japan.	ikeda-kz@igakuken.or.jp	Minami, Masabumi/A-3883-2012	Minami, Masabumi/0000-0002-0144-0679	Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (Tokyo, Japan)Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [22790518, 23390377, 24659549, 24790544, 25116532, 26293347, 26860360]; Ministry of Health, Labour and Welfare (MHLW) of Japan (Tokyo, Japan)Ministry of Health, Labour and Welfare, Japan [H21-3jigan-ippan-011, H22-Iyaku-015, H25-Iyaku-020]; Smoking Research Foundation (Tokyo, Japan); Astellas Foundation for Research on Metabolic Disorders (Tokyo, Japan)	We acknowledge Mr. Michael Arends for his assistance with editing the manuscript. We are grateful to the volunteers for their participation in this study and the anesthesiologists and surgeons at Tokyo Dental College Suidoubashi Hospital for collecting the clinical data. This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (Tokyo, Japan; no. 22790518, 23390377, 24659549, 24790544, 25116532, 26293347, and 26860360), the Ministry of Health, Labour and Welfare (MHLW) of Japan (Tokyo, Japan; no. H21-3jigan-ippan-011, H22-Iyaku-015, and H25-Iyaku-020), Smoking Research Foundation (Tokyo, Japan), and Astellas Foundation for Research on Metabolic Disorders (Tokyo, Japan).	Alves LA, 2013, MOLECULES, V18, P10953, DOI 10.3390/molecules180910953; Aoki Y, 2013, NEUROSCI LETT, V542, P1, DOI 10.1016/j.neulet.2013.02.039; Banke TG, 2010, AM J PHYSIOL-CELL PH, V298, pC1457, DOI 10.1152/ajpcell.00489.2009; Barabas ME, 2013, MOL PAIN, V9, DOI 10.1186/1744-8069-9-9; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bisgaard T, 2001, PAIN, V90, P261, DOI 10.1016/S0304-3959(00)00406-1; Bradley HJ, 2011, J BIOL CHEM, V286, P8176, DOI 10.1074/jbc.M110.211284; Burnstock G, 2004, INT REV CYTOL, V240, P31, DOI 10.1016/S0074-7696(04)40002-3; Burnstock G, 2013, EUR J PHARMACOL, V716, P24, DOI 10.1016/j.ejphar.2013.01.078; Cabrini G, 2005, J IMMUNOL, V175, P82, DOI 10.4049/jimmunol.175.1.82; Carlson CS, 2003, NAT GENET, V33, P518, DOI 10.1038/ng1128; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Carroll WA, 2009, PURINERG SIGNAL, V5, P63, DOI 10.1007/s11302-008-9110-6; Cheewatrakoolpong B, 2005, BIOCHEM BIOPH RES CO, V332, P17, DOI 10.1016/j.bbrc.2005.04.087; Chen ML, 2012, J PAIN, V13, P945, DOI 10.1016/j.jpain.2012.06.007; Chessell IP, 2005, PAIN, V114, P386, DOI 10.1016/j.pain.2005.01.002; Clark AK, 2010, J NEUROSCI, V30, P573, DOI 10.1523/JNEUROSCI.3295-09.2010; Coulbault L, 2006, CLIN PHARMACOL THER, V79, P316, DOI 10.1016/j.clpt.2006.01.007; de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669; Falk S, 2012, J OSTEOPOROS, V2012, DOI 10.1155/2012/758181; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Feng YH, 2006, J BIOL CHEM, V281, P17228, DOI 10.1074/jbc.M602999200; Fukuda K, 2009, PAIN, V147, P194, DOI 10.1016/j.pain.2009.09.004; Fuller SJ, 2009, PURINERG SIGNAL, V5, P257, DOI 10.1007/s11302-009-9136-4; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Georgiou JG, 2005, J INVEST DERMATOL, V125, P482, DOI 10.1111/j.0022-202X.2005.23835.x; Honore P, 2006, J PHARMACOL EXP THER, V319, P1376, DOI 10.1124/jpet.106.111559; Hughes JP, 2007, PURINERG SIGNAL, V3, P163, DOI 10.1007/s11302-006-9031-1; Ide S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070694; Ikeda K, 2005, TRENDS PHARMACOL SCI, V26, P311, DOI 10.1016/j.tips.2005.04.001; Inoue K, 2007, PURINERG SIGNAL, V3, P135, DOI 10.1007/s11302-006-9045-8; Kasai S, 2011, PHARMACOGENOMICS, V12, P1305, DOI [10.2217/pgs.11.68, 10.2217/PGS.11.68]; Li SSY, 2003, BIOSTATISTICS, V4, P513, DOI 10.1093/biostatistics/4.4.513; Locovei S, 2007, FEBS LETT, V581, P483, DOI 10.1016/j.febslet.2006.12.056; Loh HH, 1998, MOL BRAIN RES, V54, P321, DOI 10.1016/S0169-328X(97)00353-7; McGaraughty S, 2007, NEUROSCIENCE, V146, P1817, DOI 10.1016/j.neuroscience.2007.03.035; Moriyama A, 2013, J PHARMACOL SCI, V121, P48, DOI 10.1254/jphs.12159FP; Nishizawa D, 2014, MOL PSYCHIATR, V19, P55, DOI 10.1038/mp.2012.164; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Sawada Y, 2007, BRAIN RES, V1160, P39, DOI 10.1016/j.brainres.2007.05.047; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; Sora I, 2001, NEUROPSYCHOPHARMACOL, V25, P41, DOI 10.1016/S0893-133X(00)00252-9; Sorge RE, 2012, NAT MED, V18, P595, DOI 10.1038/nm.2710; Suzuki T, 2004, J NEUROSCI, V24, P1, DOI 10.1523/JNEUROSCI.3792-03.2004; Tsuda M, 2010, BRAIN RES REV, V63, P222, DOI 10.1016/j.brainresrev.2009.11.003; Xu XJ, 2012, J CELL SCI, V125, P3776, DOI 10.1242/jcs.099374; Zhou D, 2010, J NEUROSCI, V30, P8042, DOI 10.1523/JNEUROSCI.5377-09.2010; Zwisler ST, 2010, FUND CLIN PHARMACOL, V24, P517, DOI 10.1111/j.1472-8206.2009.00781.x	48	18	18	0	12	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1744-8069			MOL PAIN	Mol. Pain	DEC 3	2014	10								75	10.1186/1744-8069-10-75			11	Neurosciences	Neurosciences & Neurology	AY4SG	WOS:000347567800001	25472448	DOAJ Gold, Green Published			2020-06-30	J	Heapy, A; Dziura, J; Buta, E; Goulet, J; Kulas, JF; Kerns, RD				Heapy, Alicia; Dziura, James; Buta, Eugenia; Goulet, Joseph; Kulas, Joseph F.; Kerns, Robert D.			Using Multiple Daily Pain Ratings to Improve Reliability and Assay Sensitivity: How Many Is Enough?	JOURNAL OF PAIN			English	Article						Interactive voice response; assay sensitivity; chronic pain; self-report assessment; reliability	CLINICAL-TRIALS; INTENSITY	The Initiative for Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) has reported diminished assay sensitivity in pain treatment trials and recommended investigation of the causes. Specific recommendations included examination of outcome measure reliability and lengthening the baseline measurement period to allow more measurements to be collected. This secondary data analysis evaluated the minimum number of daily pain intensity ratings required to obtain a reliability of at least .90 and whether a composite of this smaller number of ratings was interchangeable with the composite of all ratings. Veterans Affairs medical center patients made 14 daily calls to an automated telephone system to report their average daily pain intensity rating. A single daily rating produced less than adequate reliability (intraclass correlation coefficient = .65), but a composite of the average of 5 ratings resulted in reliability above .90. A Bland-Altman analysis revealed that the differences between a 5-day composite and the composite of all ratings were small (mean .09 points, standard deviation = .45; 95% confidence interval = -.05 to .23) and below the threshold for a clinically meaningful difference, indicating that the 2 measurements are interchangeable. Our results support the IMMPACT recommendations for improving assay sensitivity by collecting a multiple-day baseline of pain intensity ratings. Perspective: This study examined the minimum number of pain ratings required to achieve reliability of .90 and examined whether this smaller subset of ratings could be used interchangeably with a composite of all available ratings. Attention to measure reliability could enhance the assay sensitivity, power, and statistical precision of pain treatment trials. Published by Elsevier Inc.	[Heapy, Alicia; Goulet, Joseph; Kulas, Joseph F.; Kerns, Robert D.] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA; [Heapy, Alicia; Dziura, James; Buta, Eugenia; Goulet, Joseph; Kulas, Joseph F.; Kerns, Robert D.] Yale Univ, Sch Med, New Haven, CT USA	Heapy, A (reprint author), VA Connecticut Healthcare Syst 11ACLGS, 950 Campbell Ave, West Haven, CT 06516 USA.	alicia.heapy@va.gov		Goulet, Joseph/0000-0002-0842-804X	Jansen Pharmaceutical; Veterans Health Administration Health Services Research and Development Service Center of Innovation [CIN 13-407]	This material is based on work supported by Jansen Pharmaceutical. A.H., J.G., and R.D.K. were supported by the Veterans Health Administration Health Services Research and Development Service Center of Innovation (CIN 13-407).	BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bolton JE, 1999, PAIN, V83, P533, DOI 10.1016/S0304-3959(99)00161-X; Dworkin RH, 2012, PAIN, V153, P1148, DOI 10.1016/j.pain.2012.03.003; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Heapy A, 2007, PAIN MED, V8, pS145, DOI 10.1111/j.1526-4637.2007.00378.x; Higgins DH, 2006, ANN M AM PSYCH ASS N; *INT C HARM, E10 CHOIC CONTR GROU; Jamison RN, 2001, PAIN, V91, P277, DOI 10.1016/S0304-3959(00)00450-4; JENSEN MP, 1993, PAIN, V55, P195, DOI 10.1016/0304-3959(93)90148-I; Jensen MP, 2011, HDB PAIN ASSESSMENT, V3, P19; Katz J, 1999, SURG CLIN N AM, V79, P231, DOI 10.1016/S0039-6109(05)70381-9; KERNS RD, 1988, J BEHAV MED, V11, P71, DOI 10.1007/BF00846170; Lachin John M, 2004, Clin Trials, V1, P553, DOI 10.1191/1740774504cn057oa; McDonald C J, 1983, Stat Med, V2, P417; Nunnally J.C., 1978, PSYCHOMETRIC THEORY; Perkins DO, 2000, BIOL PSYCHIAT, V47, P762, DOI 10.1016/S0006-3223(00)00837-4; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Spearman C, 1910, BRIT J PSYCHOL, V3, P271, DOI 10.1111/j.2044-8295.1910.tb00206.x; TURNER JA, 1994, JAMA-J AM MED ASSOC, V271, P1609, DOI 10.1001/jama.271.20.1609	20	14	14	0	2	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1526-5900			J PAIN	J. Pain	DEC	2014	15	12					1360	1365		10.1016/j.jpain.2014.09.012			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AX4HC	WOS:000346893100014	25283469				2020-06-30	J	Wager, TT; Chandrasekaran, RY; Bradley, J; Rubitski, D; Berke, H; Mente, S; Butler, T; Doran, A; Chang, C; Fisher, K; Knafels, J; Liu, SP; Ohren, J; Marconi, M; DeMarco, G; Sneed, B; Walton, K; Horton, D; Rosado, A; Mead, A				Wager, Travis T.; Chandrasekaran, Ramalakshmi Y.; Bradley, Jenifer; Rubitski, David; Berke, Helen; Mente, Scot; Butler, Todd; Doran, Angela; Chang, Cheng; Fisher, Katherine; Knafels, John; Liu, Shenping; Ohren, Jeff; Marconi, Michael; DeMarco, George; Sneed, Blossom; Walton, Kevin; Horton, David; Rosado, Amy; Mead, Andy			Casein Kinase 1 delta/epsilon Inhibitor PF-5006739 Attenuates Opioid Drug-Seeking Behavior	ACS CHEMICAL NEUROSCIENCE			English	Article						Casein kinase 1; CK1 delta; CK1 epsilon; PF-5006739; dual inhibitor; circadian rhythm; phase-delaying; opioid reinstatement; drug addiction	CIRCADIAN GENES; SYSTEM; DARPP-32; MUTATION; DETERMINANTS; ALIGNMENT; EPSILON	Casein kinase 1 delta (CK1 delta) and casein kinase 1 epsilon (CK1 epsilon) inhibitors are potential therapeutic agents for a range of psychiatric disorders. The feasibility of developing a CNS kinase inhibitor has been limited by an inability to identify safe brain-penetrant compounds with high kinome selectivity. Guided by structure-based drug design, potent and selective CK1 delta/epsilon inhibitors have now been identified that address this gap, through the design and synthesis of novel 4-[4-(4-fluoropheny1)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine derivatives. PF-5006739 (6) possesses a desirable profile, with low nanomolar in vitro potency for CK1 delta/epsilon (IC50 = 3.9 and 17.0 nM, respectively) and high kinome selectivity. In vivo, 6 demonstrated robust centrally mediated circadian rhythm phase-delaying effects in both nocturnal and diurnal animal models. Further, 6 dose-dependently attenuated opioid drug-seeking behavior in a rodent operant reinstatement model in animals trained to self-administer fentanyl. Collectively, our data supports further development of 6 as a promising candidate to test the hypothesis of CK1 delta/epsilon inhibition in treating multiple indications in the clinic.	[Wager, Travis T.; Rubitski, David; Mente, Scot; Fisher, Katherine; Marconi, Michael; DeMarco, George] Pfizer Worldwide Res & Dev, Cambridge, MA 02139 USA; [Chandrasekaran, Ramalakshmi Y.; Bradley, Jenifer; Berke, Helen; Butler, Todd; Doran, Angela; Chang, Cheng; Knafels, John; Liu, Shenping; Ohren, Jeff; Sneed, Blossom; Horton, David; Rosado, Amy; Mead, Andy] Pfizer Worldwide Res & Dev, Groton, CT 06340 USA; [Walton, Kevin] NIAID, Div Pharmacotherapies & Med Consequences Drug Abu, NIH, Rockville, MD 20852 USA	Wager, TT (reprint author), Pfizer Worldwide Res & Dev, 610 Main St, Cambridge, MA 02139 USA.	travis.t.wager@pfizer.com	Stevens, David/F-4683-2015	Stevens, David/0000-0002-8412-2202; Ohren, Jeffrey/0000-0002-2669-9353			Abarca C, 2002, P NATL ACAD SCI USA, V99, P9026, DOI 10.1073/pnas.142039099; Badura L, 2007, J PHARMACOL EXP THER, V322, P730, DOI 10.1124/jpet.107.122846; Bryant CD, 2012, NEUROPSYCHOPHARMACOL, V37, P1026, DOI 10.1038/npp.2011.287; Bryant CD, 2009, PSYCHOPHARMACOLOGY, V203, P703, DOI 10.1007/s00213-008-1417-z; Chergui K, 2005, J NEUROSCI, V25, P6601, DOI 10.1523/JNEUROSCI.1082-05.2005; Degenhardt L, 2013, LANCET, V382, P1564, DOI 10.1016/S0140-6736(13)61530-5; Ertl P, 2008, METHODS PRINC MED CH, P111; Falcon E, 2009, NEUROPHARMACOLOGY, V56, P91, DOI 10.1016/j.neuropharm.2008.06.054; Feng B, 2008, DRUG METAB DISPOS, V36, P268, DOI 10.1124/dmd.107.017434; Fernandez E, 2006, PLOS COMPUT BIOL, V2, P1619, DOI 10.1371/journal.pcbi.0020176; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Gallego M, 2007, NAT REV MOL CELL BIO, V8, P139, DOI 10.1038/nrm2106; Gao H, 2008, DRUG METAB DISPOS, V36, P2130, DOI 10.1124/dmd.107.020131; Hosea NA, 2009, J CLIN PHARMACOL, V49, P513, DOI 10.1177/0091270009333209; Jones CR, 1999, NAT MED, V5, P1062; Li DD, 2011, J NEUROCHEM, V118, P237, DOI 10.1111/j.1471-4159.2011.07308.x; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; LU Y, 2008, Patent No. 2008043019; Mahajan SD, 2009, INT REV NEUROBIOL, V88, P199, DOI 10.1016/S0074-7742(09)88008-2; Marchant NJ, 2013, CURR OPIN NEUROBIOL, V23, P675, DOI 10.1016/j.conb.2013.01.003; Meng QJ, 2010, P NATL ACAD SCI USA, V107, P15240, DOI 10.1073/pnas.1005101107; Mente S, 2013, J MED CHEM, V56, P6819, DOI 10.1021/jm4006324; Mente S, 2012, ACS MED CHEM LETT, V3, P515, DOI 10.1021/ml300029a; Morgan P, 2012, DRUG DISCOV TODAY, V17, P419, DOI 10.1016/j.drudis.2011.12.020; Nairn AC, 2004, NEUROPHARMACOLOGY, V47, P14, DOI 10.1016/j.neuropharm.2004.05.010; Newman AH, 2012, J MED CHEM, V55, P6689, DOI 10.1021/jm300482h; O'Connor EC, 2010, PSYCHOPHARMACOLOGY, V208, P365, DOI 10.1007/s00213-009-1739-5; Perreau-Lenz S, 2012, NEUROPSYCHOPHARMACOL, V37, P2121, DOI 10.1038/npp.2012.62; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; Spanagel R, 2005, NAT MED, V11, P35, DOI 10.1038/nm1163; Svenningsson P, 2005, AAPS J, V7, DOI 10.1208/aapsj070235; Svenningsson P, 2004, ANNU REV PHARMACOL, V44, P269, DOI 10.1146/annurev.pharmtox.44.101802.121415; Wager TT, 2013, J MED CHEM, V56, P9771, DOI 10.1021/jm401485p; Wager TT, 2010, ACS CHEM NEUROSCI, V1, P435, DOI 10.1021/cn100008c; Wager TT, 2010, ACS CHEM NEUROSCI, V1, P420, DOI 10.1021/cn100007x; Walton KM, 2009, J PHARMACOL EXP THER, V330, P430, DOI 10.1124/jpet.109.151415; Xu Y, 2005, NATURE, V434, P640, DOI 10.1038/nature03453	37	12	12	0	3	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	DEC	2014	5	12					1253	1265		10.1021/cn500201x			13	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	AX1AY	WOS:000346682000015	25299732				2020-06-30	J	Abu-Halaweh, SA; Aloweidi, AK; Qudaisat, IY; Al-Hussami, MO; Al Zaben, KR; Abu-Halaweh, AS				Abu-Halaweh, S. A.; Aloweidi, A. K.; Qudaisat, I. Y.; Al-Hussami, M. O.; Al Zaben, K. R.; Abu-Halaweh, A. S.			Pretreatment with remifentanil, fentanyl, or lidocaine to prevent withdrawal after rocuronium using venous occlusion technique in children and adolescents: a prospective randomized placebo-controlled double-blind study	JOURNAL OF ANESTHESIA			English	Article						Anesthesia; Fentanyl; Lidocaine; Pain; Remifentanil; Rocuronium bromide	INJECTION PAIN; SUFENTANIL	Pain caused by intravenous injection of the muscle relaxant rocuronium bromide is common in children and adolescents. The cause of this unwanted effect is still unclear, and different pretreatment drugs have been administered in attempts to alleviate this side effect, with varying degrees of success. This study used a 60-s venous occlusion technique to evaluate the effectiveness of pretreatment with lidocaine, fentanyl, or remifentanil in preventing pain-induced withdrawal caused by intravenous injection of rocuronium bromide during the induction of general anesthesia. One hundred and one child and adolescent patients, ASA I (TM)-I (TM) I (TM), requiring various surgical procedures under general anesthesia with muscle relaxation and mechanical ventilation, were enrolled. Patients were allocated randomly using computer-generated randomization into one of four pretreatment groups: a remifentanil group (1 A mu g/kg, n = 25), fentanyl group (1 A mu g/kg, n = 26), lidocaine 1 % group (0.5 mg/kg, n = 25), and normal saline group (n = 25). Drug doses were prepared in normal saline to a total volume of 5 ml. Venous occlusion was applied 10 cm above the venous access site. Pretreatment drugs were injected and retained for 60 s at the site of injection by an anesthetist blinded to group allocation. After release of the tourniquet, rocuronium (0.5 mg/kg) was then injected over 5 s, and withdrawal was recorded by another anesthetist blinded to group allocation. Descriptive statistics, analysis of variance, and a chi-squared test were used to statistically analyze the results as appropriate. Compared to normal saline, all other pretreatment groups scored a significantly lower mean of withdrawal response (P < 0.001). Lidocaine was superior to both remifentanil (P < 0.05) and fentanyl (P < 0.05) in suppressing the withdrawal response to rocuronium injection. Remifentanil was superior to fentanyl in suppressing the withdrawal response caused by rocuronium injection (P < 0.001). Using a venous occlusion technique for 60 s, lidocaine was found to be most effective in preventing the withdrawal effect caused by rocuronium injection in children and adolescents. Lidocaine was superior to remifentanil which, in turn, was more effective than fentanyl.	[Abu-Halaweh, S. A.; Aloweidi, A. K.; Qudaisat, I. Y.; Al Zaben, K. R.] Univ Jordan, Fac Med, Dept Anesthesia, Amman 11942, Jordan; [Abu-Halaweh, S. A.; Aloweidi, A. K.; Qudaisat, I. Y.; Al Zaben, K. R.] Univ Jordan, Fac Med, ICU, Amman 11942, Jordan; [Al-Hussami, M. O.] Univ Jordan, Fac Nursing, Amman 11942, Jordan; [Abu-Halaweh, A. S.] Univ Jordan, Fac Med, Amman 11942, Jordan	Abu-Halaweh, SA (reprint author), Univ Jordan, Fac Med, Dept Anesthesia, Queen Rania St, Amman 11942, Jordan.	s.halaweh@ju.edu.jo	Al-zaben, khaled/E-9992-2015; QUDAISAT, Ibraheem/D-7838-2015	Al-zaben, khaled/0000-0002-0283-5613; Al-Hussami, Mahmoud/0000-0002-4947-8887; QUDAISAT, Ibraheem/0000-0001-6907-5164			Abdusoglu MN, 2011, EUR J ANAESTH, V28, P229, DOI 10.1097/EJA.0b013e3283425603; Ahmad N, 2005, ANESTH ANALG, V100, P987, DOI 10.1213/01.ANE.0000147790.76114.3A; Blunk JA, 2003, EUR J ANAESTH, V20, P245, DOI 10.1097/00003643-200303000-00011; Borgeat A, 1997, BRIT J ANAESTH, V79, P382, DOI 10.1093/bja/79.3.382; Chaudhary K, 2013, J ANESTH, V27, P402, DOI 10.1007/s00540-012-1533-0; Cheong KF, 2000, BRIT J ANAESTH, V84, P106; Dalgleish DJ, 2000, ANAESTHESIA, V55, P828, DOI 10.1046/j.1365-2044.2000.01629-34.x; GISSEN AJ, 1987, ANESTH ANALG, V66, P1272; HAGENOUW RRPM, 1986, ANESTH ANALG, V65, P1175; Jaffe RA, 1996, ANESTH ANALG, V83, P776, DOI 10.1097/00000539-199610000-00021; Jeon Y, 2013, KOREAN J ANESTHESIOL, V64, P25, DOI 10.4097/kjae.2013.64.1.25; Kelment W, 1991, BRIT J ANAESTH, V66, P189; Kim JY, 2007, BRIT J ANAESTH, V98, P120, DOI 10.1093/bja/ael285; Lesniak A, 2011, ACTA NEUROBIOL EXP, V71, P129; Lui Jiin-Tarng, 2002, Chang Gung Med J, V25, P617; Massad IM, 2006, SAUDI MED J, V27, P997; Memis D, 2002, ANESTH ANALG, V94, P1517, DOI 10.1097/00000539-200206000-00026; Oh AY, 2007, ACTA ANAESTH SCAND, V51, P1190, DOI 10.1111/j.1399-6576.2007.01371.x; Sari M, 2008, SAUDI MED J, V29, P374; Shevchenko Y, 1999, ANESTH ANALG, V88, P746, DOI 10.1097/00000539-199904000-00011; Shin YH, 2011, KOREAN J ANESTHESIOL, V60, P329, DOI 10.4097/kjae.2011.60.5.329; Solomowitz B H, 1993, Anesth Prog, V40, P20; Steegers MAH, 1996, ANESTH ANALG, V83, P203, DOI 10.1097/00000539-199607000-00065	23	5	6	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	DEC	2014	28	6					886	890		10.1007/s00540-014-1836-4			5	Anesthesiology	Anesthesiology	AW4GX	WOS:000346240300014	24816536				2020-06-30	J	Stogner, JM				Stogner, John M.			The Potential Threat of Acetyl Fentanyl: Legal Issues, Contaminated Heroin, and Acetyl Fentanyl "Disguised" as Other Opioids	ANNALS OF EMERGENCY MEDICINE			English	Editorial Material									Univ N Carolina, Dept Criminal Justice & Criminol, Charlotte, NC 28223 USA	Stogner, JM (reprint author), Univ N Carolina, Dept Criminal Justice & Criminol, Charlotte, NC 28223 USA.	johnstogner@uncc.edu					Drug Enforcement Administration, 2013, AC FENT N 1 PHEN 4 Y; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Khey Dave N, 2014, EMERGING TRENDS DRUG; Lank PM, 2013, WEST J EMERG MED, V14, P467, DOI 10.5811/westjem.2013.1.14496; North Carolina Department of Health and Human Services, DHHS ISS HLTH ADV DE; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Roberts JR, 2013, EMERG MED NEWS, V35, P1	7	50	51	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	DEC	2014	64	6					637	639		10.1016/j.annemergmed.2014.07.017			3	Emergency Medicine	Emergency Medicine	AW3YZ	WOS:000346220200015	25153008				2020-06-30	J	Hayashi, T; Ikehata, S; Matsuzaki, H; Yasuda, K; Makihara, T; Futamura, A; Arakawa, Y; Kuki, R; Fukuura, K; Takahashi, H; Mori, N; Higashiguchi, T; Yamada, S				Hayashi, Takahiro; Ikehata, Saori; Matsuzaki, Haruna; Yasuda, Kimio; Makihara, Toshiyasu; Futamura, Akihiko; Arakawa, Yuki; Kuki, Rika; Fukuura, Kumiko; Takahashi, Hiroshi; Mori, Naoharu; Higashiguchi, Takashi; Yamada, Shigeki			Influence of Serum Albumin Levels during Opioid Rotation from Morphine or Oxycodone to Fentanyl for Cancer Pain	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						serum albumin level; opioid rotation; fentanyl; cancer pain; numerical rating scale	TRANSDERMAL FENTANYL; ORAL MORPHINE; BINDING; CONVERSION; PROFILES; SUPPORT; HEAT; RAT	Morphine, oxycodone, and fentanyl are commonly used to control cancer pain. Because these drugs have differences in receptor affinity or pharmacokinetic parameters, changing the opioid formulation may result in an unexpected outcome, depending on the patient's condition. This study investigated whether low serum protein levels influence the effectiveness of opioid rotation by determining the impact of serum albumin levels on the analgesic effect before and after opioid rotation from morphine or oxycodone to fentanyl in cancer patients. The patients were classified into 3 groups according to their serum albumin levels before opioid rotation: group 1, <2.5g/dL; group 2, from 2.5g/dL to <3.0g/dL; and group 3, >= 3.0g/dL. There was no significant change in the percentage of patients with good pain control after rotation in group 1 or group 2; however, the percentage of patients with good pain control increased significantly in group 3. When the percentage of patients whose numerical rating scale scores increased, were unchanged, or decreased after rotation were compared, a significant difference in the percentage of those showing improvement was noted among the 3 groups and between groups 1 and 3. These findings suggest that monitoring serum albumin levels during fentanyl therapy is useful for pain management, and that the effectiveness of opioid rotation to fentanyl in patients with serum albumin levels of <2.5 g/dL should be carefully evaluated after rotation.	[Hayashi, Takahiro; Makihara, Toshiyasu; Arakawa, Yuki; Kuki, Rika; Fukuura, Kumiko; Yamada, Shigeki] Fujita Hlth Univ Hosp, Dept Pharm, Toyoake, Aichi 4701192, Japan; [Futamura, Akihiko; Mori, Naoharu; Higashiguchi, Takashi] Fujita Hlth Univ, Sch Med, Dept Surg & Palliat Med, Toyoake, Aichi 4701192, Japan; [Takahashi, Hiroshi] Fujita Hlth Univ, Div Med Stat, Toyoake, Aichi 4701192, Japan; [Ikehata, Saori; Matsuzaki, Haruna; Yasuda, Kimio] Kinjo Gakuin Univ, Coll Pharm, Moriyama Ku, Nagoya, Aichi 4638521, Japan; [Hayashi, Takahiro] Meijo Univ, Fac Pharm, Tempaku Ku, Nagoya, Aichi 4688503, Japan	Hayashi, T (reprint author), Fujita Hlth Univ Hosp, Dept Pharm, 1-98 Dengakugakubo, Toyoake, Aichi 4701192, Japan.	taka-h@fujita-hu.ac.jp	Mori, Naoharu/AAL-3230-2020	Mori, Naoharu/0000-0002-0357-8604			Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; [Anonymous], 2013, NCCN CLIN PRACT GUID; Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; CHEN JC, 1993, LIFE SCI, V52, P389, DOI 10.1016/0024-3205(93)90152-S; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Gallego AO, 2007, CLIN TRANSL ONCOL, V9, P298, DOI 10.1007/s12094-007-0057-9; Heiskanen T, 1997, PAIN, V73, P37, DOI 10.1016/S0304-3959(97)00072-9; Higashiguchi Takashi, 2011, Gan To Kagaku Ryoho, V38, P1235; Hohenberger P, 1999, CHIRURG, V70, P1422, DOI 10.1007/PL00002578; Ishizaki T., 1985, CLIN PHARM LECT, P89; Kokubun H, 2004, JPN HOSPICE PALLIATI, V14, P464; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; MEULDERMANS WEG, 1982, ARCH INT PHARMACOD T, V257, P4; Monory K, 1999, LIFE SCI, V64, P2011, DOI 10.1016/S0024-3205(99)00148-4; Moore KT, 2012, J CLIN PHARMACOL, V52, P1174, DOI 10.1177/0091270011411710; Mortimer J, 2011, PALLIATIVE CARE FORM, P345; Nielsen CK, 2007, PAIN, V132, P289, DOI 10.1016/j.pain.2007.03.022; Nomura M, 2013, CLIN J PAIN, V29, P487, DOI 10.1097/AJP.0b013e318266f6a5; Okazawa M, 2008, JPN J PHARM PALLIAT, V1, P53; Rivadeneira DE, 1998, CA-CANCER J CLIN, V48, P69, DOI 10.3322/canjclin.48.2.69; Tomibayashi A, 2011, JPN J CANC CLIN, V57, P135; Twycross R, 2001, SYMPTOM MANAGEMENT A, P17; World Health Organization, 1996, CANC PAIN REL; Yang YR, 1998, EUR J PHARMACOL, V351, P23, DOI 10.1016/S0014-2999(98)00296-9	25	6	6	0	6	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	DEC	2014	37	12					1860	1865		10.1248/bpb.b14-00119			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AU3EO	WOS:000345495600002	25590058	Bronze			2020-06-30	J	Yokoyama, K; Ikeda, O; Kawanaka, K; Nakasone, Y; Inoue, S; Tamura, Y; Yamashita, Y				Yokoyama, Koichi; Ikeda, Osamu; Kawanaka, Koichi; Nakasone, Yutaka; Inoue, Seijiro; Tamura, Yoshitaka; Yamashita, Yasuyuki			Pain control in patients with hepatocellular carcinoma treated by percutaneous radiofrequency ablation: comparison of the efficacy of one-shot and continuous intravenous fentanyl delivery	ACTA RADIOLOGICA			English	Article						Pain control; hepatocellular carcinoma; percutaneous radiofrequency ablation; intravenous fentanyl delivery	COAGULATION NECROSIS; HEPATIC RESECTION; TISSUE ABLATION; LIVER; REMIFENTANIL; MODEL; COMPLICATIONS; EMBOLIZATION; MANAGEMENT; INJECTION	Background Hepatic percutaneous radiofrequency ablation (RFA) is usually performed with the patient under deep intravenous (i.v.) sedation or general anesthesia. Nonetheless, many patients report pain during and/or after the procedure. Purpose To perform a prospective study of pain control obtained by the i.v. one-shot delivery and the continuous i.v. infusion of fentanyl in patients with hepatocellular carcinoma (HCC) treated by RFA. Material and Methods Between April 2007 and March 2010, 83 patients with 106 HCCs underwent percutaneous RFA. All HCCs were addressed by computed tomography (CT)-guided percutaneous RFA performed within 5h of embolization of the tumor vessels with iodized oil and gelatin sponges. Standard anesthesia consisted of 10mL of 1% lidocaine injected locally. For conscious sedation, group one patients (n=41) were injected i.v. with 100 mu g of fentanyl before and 100 mu g of fentanyl 30min after percutaneous RFA. In group two (n=42) we delivered fentanyl by continuous i.v. infusion at 100 mu g/h during RFA. Upon request, patients in both groups also received 5mg of diazepam i.v. for pain during the RFA procedure. The severity of pain experienced by all patients was evaluated on a visual analogue scale (VAS) and complications elicited by the anesthesia regimens were recorded. We also assessed the effectiveness of the treatment on sequential follow-up CT and/or magnetic resonance imaging (MRI) at 3-month intervals. Results Percutaneous RFA was technically successful in all 83 patients. Two patients in group one (4.8%) and one patient in group two (2.4%) manifested residual enhancement 3 months post RFA. There was no significant difference in the local recurrence rate between the two groups. At 4.01.8 for group one and 3.4 +/- 1.9 for group two, the VAS score was not significantly different. Major fentanyl or diazepam toxicity was recorded in 11 patients (24.4%) in group one and two patients (4.8%) in group two; the difference was statistically significant (P<0.01). Conclusion The continuous infusion of fentanyl provided effective and safe analgesia in HCC patients undergoing percutaneous RFA.	[Yokoyama, Koichi; Ikeda, Osamu; Kawanaka, Koichi; Nakasone, Yutaka; Inoue, Seijiro; Tamura, Yoshitaka; Yamashita, Yasuyuki] Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Diagnost Radiol, Kumamoto 8608556, Japan	Ikeda, O (reprint author), Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Diagnost Radiol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	osamu-3643ik@do9.enjoy.ne.jp					Arima K, 2007, INT J UROL, V14, P585, DOI 10.1111/j.1442-2042.2007.01740.x; Bruix J, 2001, J HEPATOL, V35, P421, DOI 10.1016/S0168-8278(01)00130-1; Child III CG, 1964, LIVER PORTAL HYPERTE, P49; Chinn SB, 2001, AM J ROENTGENOL, V176, P789, DOI 10.2214/ajr.176.3.1760789; Cho YK, 2010, HEPATOLOGY, V51, P1284, DOI 10.1002/hep.23466; Egan TD, 2004, BRIT J ANAESTH, V92, P335, DOI 10.1093/bja/aeh075; Gandhi S, 2006, CLIN RADIOL, V61, P888, DOI 10.1016/j.crad.2006.05.011; Gillams AR, 2003, EUR J SURG ONCOL, V29, P9, DOI 10.1053/ejso.2002.1346; GLASS PSA, 1993, ANESTH ANALG, V77, P1031; Goldberg SN, 2005, RADIOLOGY, V235, P728, DOI 10.1148/radiol.2353042205; Goldberg SN, 1998, J VASC INTERV RADIOL, V9, P101, DOI 10.1016/S1051-0443(98)70491-9; Goldberg SN, 2001, HEPATO-GASTROENTEROL, V48, P359; Groban L, 2009, ANESTH ANALG, V109, P301, DOI 10.1213/ane.0b013e3181a91944; Koda M, 2004, AM J ROENTGENOL, V183, P583, DOI 10.2214/ajr.183.3.1830583; Krucker J, 2007, J VASC INTERV RADIOL, V18, P1141, DOI 10.1016/j.jvir.2007.06.014; Kurokohchi K, 2007, WORLD J GASTROENTERO, V13, P4398, DOI 10.3748/wjg.v13.i32.4398; Lee WS, 2008, J CLIN GASTROENTEROL, V42, P945, DOI 10.1097/MCG.0b013e318064e752; Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104; Minami Y, 2010, WORLD J RADIOL, V2, P417, DOI 10.4329/wjr.v2.i11.417; Miyamoto N, 2009, JPN J RADIOL, V27, P185, DOI 10.1007/s11604-009-0317-4; Mulier S, 2008, DIGEST SURG, V25, P445, DOI 10.1159/000184736; Nimmaanrat S, 2007, MINERVA ANESTESIOL, V73, P333; Patterson EJ, 1998, ANN SURG, V227, P559, DOI 10.1097/00000658-199804000-00018; Rama-Maceiras P, 2005, ACTA ANAESTH SCAND, V49, P305, DOI 10.1111/j.1399-6576.2005.00650.x; Rhim H, 2005, ABDOM IMAGING, V30, P409, DOI 10.1007/s00261-004-0255-7; Rhim H, 2008, AM J ROENTGENOL, V190, P91, DOI 10.2214/AJR.07.2384; Roy JD, 2006, ANESTH ANALG, V103, P990, DOI 10.1213/01.ane.0000238040.41872.7e; Rust C, 2001, Clin Liver Dis, V5, P161, DOI 10.1016/S1089-3261(05)70159-8; Sugimori K, 2002, HEPATOL RES, V24, P164, DOI 10.1016/S1386-6346(02)00030-X; WEWERS ME, 1990, RES NURS HEALTH, V13, P227, DOI 10.1002/nur.4770130405	30	9	11	0	9	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0284-1851	1600-0455		ACTA RADIOL	Acta Radiol.	DEC	2014	55	10					1219	1225		10.1177/0284185113519623			7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	AT9CI	WOS:000345225200010	24413224				2020-06-30	J	Kukanich, B; Allen, P				Kukanich, B.; Allen, P.			Comparative pharmacokinetics of intravenous fentanyl and buprenorphine in healthy greyhound dogs	JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS			English	Article							PROTEIN-BINDING; MORPHINE; SURROGATES	The purpose of this study was to compare the pharmacokinetics of two highly protein-bound, lipophilic opioid drugs. Fentanyl (10g/kg) and buprenorphine (20g/kg) were administered intravenously (IV) to six healthy greyhound dogs (three males and three females). The doses were based on clinically administered doses for dogs. Plasma drug concentrations were determined using liquid chromatography with mass spectrometry, and noncompartmental pharmacokinetics were estimated with computer software. The volume of distribution (area) was larger for fentanyl (7.42L/kg) compared to buprenorphine (3.54L/kg). The plasma clearance of fentanyl (38.6mLmin/kg) was faster than buprenorphine (10.3mLmin/kg). The terminal half-life of fentanyl (2.22h) was shorter than buprenorphine (3.96h). Despite similar physicochemical properties including octanol-water partition coefficient and pKa, the pharmacokinetics of fentanyl and buprenorphine were not similar. Both fentanyl (84%) and buprenorphine (95-98%) are considered highly protein bound, but the differences in protein binding may contribute to the lack of similarity of pharmacokinetics in healthy dogs.	[Kukanich, B.; Allen, P.] Kansas State Univ, Coll Vet Med, Dept Anat & Physiol, Manhattan, KS 66506 USA	Kukanich, B (reprint author), Kansas State Univ, Coll Vet Med, Dept Anat & Physiol, Manhattan, KS 66506 USA.	Kukanich@ksu.edu	KuKanich, Butch/A-7911-2008		COBRE program at Kansas State University [NIH P20-RR017686S1]	The authors would like to thank the COBRE program at Kansas State University for providing funding (NIH P20-RR017686S1).	GARRETT ER, 1990, BIOPHARM DRUG DISPOS, V11, P311, DOI 10.1002/bdd.2510110403; GARRETT ER, 1985, J PHARM SCI, V74, P515, DOI 10.1002/jps.2600740505; KuKanich B, 2010, J VET PHARMACOL THER, V33, P15, DOI 10.1111/j.1365-2885.2009.01098.x; KuKanich Butch, 2011, Vet J, V190, pe140, DOI 10.1016/j.tvjl.2011.02.008; MEULDERMANS WEG, 1982, ARCH INT PHARMACOD T, V257, P4; MURPHY MR, 1983, ANESTHESIOLOGY, V59, P537, DOI 10.1097/00000542-198312000-00009; MURPHY MR, 1979, ANESTHESIOLOGY, V50, P13, DOI 10.1097/00000542-197901000-00004; RIOND JL, 1990, J VET PHARMACOL THER, V13, P415, DOI 10.1111/j.1365-2885.1990.tb00797.x; ROY SD, 1994, J PHARM SCI, V83, P126, DOI 10.1002/jps.2600830204; Shott S, 2011, JAVMA-J AM VET MED A, V238, P55, DOI 10.2460/javma.238.1.55; 2008, DURAGESIC PACKAGE IN	11	4	4	1	16	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0140-7783	1365-2885		J VET PHARMACOL THER	J. Vet. Pharmacol. Ther.	DEC	2014	37	6					595	597		10.1111/jvp.12129			3	Pharmacology & Pharmacy; Veterinary Sciences	Pharmacology & Pharmacy; Veterinary Sciences	AU0ES	WOS:000345297000010	24684621	Green Accepted			2020-06-30	J	Ramos-Zepeda, GA; Herrero-Zorita, C; Herrero, JF				Ramos-Zepeda, Guillermo A.; Herrero-Zorita, Carlos; Herrero, Juan F.			Interaction of the adenosine A(1) receptor agonist N6-cyclopentyladenosine and kappa-opioid receptors in rat spinal cord nociceptive reflexes	BEHAVIOURAL PHARMACOLOGY			English	Article						adenosine; inflammation; opioids; pain; rat; single motor unit; spinal cord; wind-up	DEXKETOPROFEN TROMETAMOL ENHANCE; MORPHINE-INDUCED ANALGESIA; FENTANYL ANTINOCICEPTION; NITROPARACETAMOL NCX-701; WIND-UP; MU; TOLERANCE; RELEASE; PAIN; MICE	Antinociception induced by the adenosine A(1) receptor agonist N6-cyclopentyladenosine (CPA) is linked to opioid receptors. We studied the subtype of receptors to which CPA action is related, as well as a possible enhancement of antinociception when CPA is coadministered with opioid receptor agonists. Spinal cord neuronal nociceptive responses of male Wistar rats with inflammation were recorded using the single motor unit technique. CPA antinociception was challenged with naloxone or norbinaltorphimine. The antinociceptive activity of fentanyl and U-50488H was studied alone and combined with CPA. Reversal of CPA antinociception was observed with norbinaltorphimine (82.9 +/- 13% of control) but not with low doses of naloxone (27 +/- 8% of control), indicating an involvement of kappa-opioid but not mu-opioid receptors. Low doses of CPA did not modify fentanyl antinociception. However, a significant enhancement of the duration of antinociception was seen when U-50488H was coadministered with CPA. We conclude that antinociception mediated by CPA in the spinal cord is associated with activation of kappa-opioid but not mu-opioid receptors in inflammation. In addition, coadministration of CPA and kappa-opioid receptor agonists is followed by significantly longer antinociception, opening new perspectives in the treatment of chronic inflammatory pain. (C) 2014 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.	[Ramos-Zepeda, Guillermo A.; Herrero-Zorita, Carlos; Herrero, Juan F.] Univ Alcala De Henares, Dept Syst Biol, Unit Physiol, Fac Med, Madrid 28871, Spain	Herrero, JF (reprint author), Univ Alcala De Henares, Dept Syst Biol, Unidad Fisiol, Campus Univ, Madrid 28871, Spain.	juanf.herrero@uah.es	Herrero-Zorita, Carlos/H-7492-2015	Herrero-Zorita, Carlos/0000-0002-9637-6496	Spanish Ministry of Science and TechnologySpanish Government [SAF2001-1048-C03-03]	This work was supported by the Spanish Ministry of Science and Technology (grant SAF2001-1048-C03-03). The authors thank Dr E.J. Taylor for the English and scientific revisions of the manuscript.	AHLIJANIAN MK, 1985, EUR J PHARMACOL, V112, P171, DOI 10.1016/0014-2999(85)90493-5; Aley KO, 1997, J NEUROSCI, V17, P735; Borghi V, 2002, BRAIN RES, V956, P339, DOI 10.1016/S0006-8993(02)03568-0; CAHILL CM, 1995, J PHARMACOL EXP THER, V275, P84; CONTRERAS E, 1990, GEN PHARMACOL-VASC S, V21, P763, DOI 10.1016/0306-3623(90)91031-L; DELANDER GE, 1986, J PHARMACOL EXP THER, V239, P88; Gaitan G, 2005, LIFE SCI, V77, P85, DOI 10.1016/j.lfs.2004.12.022; Gaitan G, 2005, PHARMACOL BIOCHEM BE, V80, P327, DOI 10.1016/j.pbb.2004.12.004; Gaitan G, 2003, EUR J PHARMACOL, V481, P181, DOI 10.1016/j.ejphar.2003.09.024; Gaitan G, 2002, BRIT J PHARMACOL, V135, P393, DOI 10.1038/sj.bjp.0704491; HARTELL NA, 1991, J PHYSIOL-LONDON, V442, P513, DOI 10.1113/jphysiol.1991.sp018806; Herrero JF, 2000, PROG NEUROBIOL, V61, P169, DOI 10.1016/S0301-0082(99)00051-9; Herrero JF, 1996, BRIT J PHARMACOL, V118, P968, DOI 10.1111/j.1476-5381.1996.tb15494.x; Herrero JF, 1996, BRAIN RES, V717, P62, DOI 10.1016/0006-8993(95)01585-X; Herrero JF, 1996, NEUROSCI LETT, V209, P21, DOI 10.1016/0304-3940(96)12588-X; HERRERO JF, 1991, BRIT J PHARMACOL, V104, P166, DOI 10.1111/j.1476-5381.1991.tb12402.x; HERRERO JF, 1993, BRIT J PHARMACOL, V110, P303, DOI 10.1111/j.1476-5381.1993.tb13809.x; JACOBSON KA, 1992, J MED CHEM, V35, P407, DOI 10.1021/jm00081a001; KARLSTEN R, 1991, NEUROSCI LETT, V121, P267, DOI 10.1016/0304-3940(91)90701-T; Lee YW, 1996, J PHARMACOL EXP THER, V277, P1642; MALEC D, 1990, POL J PHARMACOL PHAR, V42, P1; Curros-Criado MM, 2009, BRIT J PHARMACOL, V158, P601, DOI 10.1111/j.1476-5381.2009.00343.x; Molina C, 2011, PHARMACOL BIOCHEM BE, V99, P385, DOI 10.1016/j.pbb.2011.05.022; PORTOGHESE PS, 1994, J MED CHEM, V37, P1495, DOI 10.1021/jm00036a015; Ralevic V, 1998, PHARMACOL REV, V50, P413; Ramos-Zepeda G, 2005, NEUROSCI LETT, V384, P177, DOI 10.1016/j.neulet.2005.04.073; Ramos-Zepeda G, 2004, EUR J PHARMACOL, V499, P247, DOI 10.1016/j.ejphar.2004.07.083; Ramos-Zepeda G, 2013, LIFE SCI, V93, P233, DOI 10.1016/j.lfs.2013.06.017; REEVE AJ, 1995, BRIT J PHARMACOL, V116, P2221, DOI 10.1111/j.1476-5381.1995.tb15057.x; SAWYNOK J, 1989, TRENDS PHARMACOL SCI, V10, P186, DOI 10.1016/0165-6147(89)90235-6; Sawynok J, 2003, PROG NEUROBIOL, V69, P313, DOI 10.1016/S0301-0082(03)00050-9; Sawynok J, 1998, EUR J PHARMACOL, V347, P1, DOI 10.1016/S0014-2999(97)01605-1; Solano R, 1997, J NEUROSCI METH, V73, P135, DOI 10.1016/S0165-0270(96)02220-0; SWEENEY MI, 1987, J PHARMACOL EXP THER, V243, P657; SWEENEY MI, 1987, EUR J PHARMACOL, V141, P169, DOI 10.1016/0014-2999(87)90428-6; THORN SA, 1994, BRAIN RES, V663, P352, DOI 10.1016/0006-8993(94)91286-6	36	1	1	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0955-8810	1473-5849		BEHAV PHARMACOL	Behav. Pharmacol.	DEC	2014	25	8					741	749		10.1097/FBP.0000000000000091			9	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	AT3ZW	WOS:000344876900005	25325292				2020-06-30	J	Molgat-Seon, Y; Daboval, T; Chou, S; Jay, O				Molgat-Seon, Yannick; Daboval, Thierry; Chou, Shirley; Jay, Ollie			Assessing neonatal heat balance and physiological strain in newborn infants nursed under radiant warmers in intensive care with fentanyl sedation	EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY			English	Article						Radiant warmer; Neonate; Heat balance; Thermoregulation	PREMATURE-INFANTS; WATER-LOSS; THERMAL ENVIRONMENT; PRETERM INFANTS; BABIES; HYPOTHERMIA; TERM; TEMPERATURE; INCUBATOR; SKIN	To assess heat balance status of newborn infants nursed under radiant warmers (RWs) during intensive care. Heat balance, thermal status and primary indicators of physiological strain were concurrently measured in 14 newborns nursed under RWs for 105 min. Metabolic heat production (M), evaporative heat loss (E), convective (C) and conductive heat flow (K), rectal temperature (T (re)) and mean skin temperatures (T (sk)) were measured continuously. The rate of radiant heat required for heat balance (R (req)) and the rate of radiant heat provided (R (prov)) were derived. The rate of body heat storage (S) was calculated using a two-compartment model of 'core' (T (re)) and 'shell' (T (sk)) temperatures. Mean M, E, C and K were 10.5 +/- A 2.7 W, 5.8 +/- A 1.1 W, 6.2 +/- A 0.8 W and 0.1 +/- A 0.1 W, respectively. Mean R (prov) (1.7 +/- A 2.6 W) and R (req) (1.7 +/- A 2.7 W) were similar (p > 0.05). However, while the resultant mean change in body heat content after 105 min was negligible (-0.1 +/- A 3.7 kJ), acute time-dependent changes in S were evidenced by a mean positive heat storage component of +6.4 +/- A 2.6 kJ and a mean negative heat storage component of -6.5 +/- A 3.7 kJ. Accordingly, large fluctuations in both T (re) and T (sk) occurred that were actively induced by changes in RW output. Nonetheless, no active physiological responses (heart rate, breathing frequency and mean arterial pressure) to these bouts of heating and cooling were observed. RWs maintain net heat balance over a prolonged period, but actively induce acute bouts of heat imbalance that cause rapid changes in T (re) and T (sk). Transient bouts of heat storage do not exacerbate physiological strain, but could in the longer term.	[Molgat-Seon, Yannick; Jay, Ollie] Univ Ottawa, Fac Hlth Sci, Thermal Ergon Lab, Ottawa, ON, Canada; [Molgat-Seon, Yannick] Univ British Columbia, Hlth & Integrated Physiol Lab, Sch Kinesiol, Vancouver, BC V5Z 1M9, Canada; [Daboval, Thierry; Chou, Shirley; Jay, Ollie] Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON K1H 8L1, Canada; [Daboval, Thierry] Childrens Hosp Eastern Ontario, Div Neonatol, Ottawa, ON K1H 8L1, Canada; [Daboval, Thierry; Chou, Shirley] Univ Ottawa, Fac Med, Ottawa, ON, Canada; [Chou, Shirley] Childrens Hosp Eastern Ontario, Dept Gen Surg, Ottawa, ON K1H 8L1, Canada; [Jay, Ollie] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2006, Australia	Jay, O (reprint author), Univ Sydney, Fac Hlth Sci, Sydney, NSW 2006, Australia.	ollie.jay@sydney.edu.au	Jay, Ollie/AAD-8009-2020; Molgat-Seon, Yannick/L-8481-2017	Molgat-Seon, Yannick/0000-0003-4021-4540; Jay, Ollie/0000-0002-6076-6337; Daboval, Thierry/0000-0002-5321-6193	Natural Sciences and Engineering Research Council (NSERC) of CanadaNatural Sciences and Engineering Research Council of Canada; Children's Hospital of Eastern Ontario Department of Pediatric Surgery Seed Fund Grant; University of Ottawa Master's Scholarship	This research was supported by a Natural Sciences and Engineering Research Council (NSERC) of Canada Discovery Grant (Grant Holder: OJ) as well as by a Children's Hospital of Eastern Ontario Department of Pediatric Surgery Seed Fund Grant (Grant Holder: SC). YMS was supported by a University of Ottawa Master's Scholarship. The authors wish to thank the volunteers for their co-operation and the CHEO NICU Nursing staff for their assistance during data collection.	Agourram B, 2010, J APPL PHYSIOL, V108, P1674, DOI 10.1152/japplphysiol.00799.2009; Bauer J, 2009, AM J CLIN NUTR, V90, P1517, DOI 10.3945/ajcn.2009.28304; BAUMGART S, 1985, PEDIATRICS, V75, P89; BAUMGART S, 1980, CRIT CARE MED, V8, P721, DOI 10.1097/00003246-198012000-00004; Baumgart S, 2008, CLIN PERINATOL, V35, P183, DOI 10.1016/j.clp.2007.11.002; BELL EF, 1980, J PEDIATR-US, V96, P460, DOI 10.1016/S0022-3476(80)80698-6; Bolton DPG, 1996, J APPL PHYSIOL, V80, P2234; BUNTAIN WL, 1977, J LOUISIANA ST MED S, V129, P5; Charkoudian N, 2014, COMPR PHYSIOL, V4, P793, DOI 10.1002/cphy.c130029; FLENADY VJ, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000435; FORSYTH JS, 1995, ARCH DIS CHILD-FETAL, V73, pF4, DOI 10.1136/fn.73.1.F4; Gagnon D, 2013, J APPL PHYSIOL, V114, P394, DOI 10.1152/japplphysiol.00877.2012; Ginalski MK, 2008, BIOMED MATER, V3, DOI 10.1088/1748-6041/3/3/034113; HAYCOCK GB, 1978, J PEDIATR-US, V93, P62, DOI 10.1016/S0022-3476(78)80601-5; HAZAN J, 1991, AM J OBSTET GYNECOL, V164, P111, DOI 10.1016/0002-9378(91)90638-8; HEY EN, 1970, ARCH DIS CHILD, V45, P328, DOI 10.1136/adc.45.241.328; HILL JUNE R., 1965, J PHYSIOL [LONDON], V180, P239, DOI 10.1113/jphysiol.1965.sp007701; Kalia YN, 1998, J INVEST DERMATOL, V111, P320, DOI 10.1046/j.1523-1747.1998.00289.x; KJARTANSSON S, 1995, PEDIATR RES, V37, P233, DOI 10.1203/00006450-199502000-00018; LEBLANC MH, 1982, PEDIATRICS, V69, P439; Lyon AJ, 2011, ARCH DIS CHILD-FETAL, V96, pF71, DOI 10.1136/adc.2009.161158; Magnarelli Frank, 2006, Biomed Instrum Technol, V40, P215, DOI 10.2345/i0899-8205-40-3-215.1; Mann DR, 2003, J CLIN ENDOCR METAB, V88, P3339, DOI 10.1210/jc.2002-022030; MARKS KH, 1980, PEDIATRICS, V66, P228; MAYFIELD SR, 1984, J PEDIATR-US, V104, P271, DOI 10.1016/S0022-3476(84)81011-2; Meyer MP, 2001, PEDIATRICS, V108, P395, DOI 10.1542/peds.108.2.395; Molgat-Seon Y, 2013, J PERINATOL, V33, P738, DOI 10.1038/jp.2013.32; Museux N, 2008, MED PHYS, V35, P89, DOI 10.1118/1.2815966; Okada Y, 1998, PEDIATR SURG INT, V13, P508, DOI 10.1007/s003830050385; Parsons K., 2002, HUMAN THERMAL ENV EF; RUTTER N, 1979, ARCH DIS CHILD, V54, P858, DOI 10.1136/adc.54.11.858; RUTTER N, 1979, ARCH DIS CHILD, V54, P178, DOI 10.1136/adc.54.3.178; Seguin JH, 1996, ARCH DIS CHILD-FETAL, V74, pF137, DOI 10.1136/fn.74.2.F137; Sherman TI, 2006, NEONATAL NETW, V25, P251, DOI 10.1891/0730-0832.25.4.251; SILVERMAN WA, 1958, PEDIATRICS, V22, P876; Sinclair JC, 2013, NEONATOLOGY, V103, P224, DOI 10.1159/000346066; SINCLAIR JC, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001074; Steward D K, 2001, Biol Res Nurs, V2, P198, DOI 10.1177/109980040100200305; Thomas Karen A, 2010, Adv Neonatal Care, V10, pS2, DOI 10.1097/ANC.0b013e3181f1c4b1; Tourneux P, 2009, ARCH PEDIATRIE, V16, P1057, DOI 10.1016/j.arcped.2009.03.014; Trevisanuto D, 2011, RESUSCITATION, V82, P720, DOI 10.1016/j.resuscitation.2011.02.019; WENGER CB, 1972, J APPL PHYSIOL, V32, P456; WHELDON AE, 1982, EARLY HUM DEV, V6, P131, DOI 10.1016/0378-3782(82)90100-1; Witt Catherine L, 2010, Adv Neonatal Care, V10, pS1, DOI 10.1097/ANC.0b013e3181efed30; World health organisation, 1997, WHORHTMSM972	45	4	4	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-6319	1439-6327		EUR J APPL PHYSIOL	Eur. J. Appl. Physiol.	DEC	2014	114	12					2539	2549		10.1007/s00421-014-2964-0			11	Physiology; Sport Sciences	Physiology; Sport Sciences	AT2DC	WOS:000344740500009	25115506				2020-06-30	J	Draskovic, B; Stanic, D; Uram-Benka, A; Fabri, I				Draskovic, Biljana; Stanic, Danica; Uram-Benka, Anna; Fabri, Izabella			Stress indicators during general anesthesia with opioid analgesics in children	TURKISH JOURNAL OF MEDICAL SCIENCES			English	Article						Children; stress response; opioid analgesics; surgical intervention	REMIFENTANIL; LEPTIN; ALFENTANIL	Background/aim: To determine which of the applied opioid analgesics brings the most powerful blockade of the stress response with the fewest side effects in children. Materials and methods: This was a prospective, observational clinical study. The study included 150 boys, aged 2-5 years, ASA I, who underwent herniectomy or orchidopexy in day case surgery. The introduction and maintenance of anesthesia was intravenous (propofol, rocuronium, and opioids); airway was maintained by laryngeal mask and ventilation by mixture of oxygen/air. Subjects were divided into 3 groups depending on the applied opioid analgesics (fentanyl, alfentanil, remifentanil). Results: The fentanyl group had the highest blood glucose values (AS = 5.14; SD = 0.47) and the highest increase in cortisone level at the moment of incision and at awakening (AS = 536.09; SD = 198.56). The lowest increase in cortisone was recorded in the remifentanil group. A significant decrease in leptin was registered at awakening in the fentanyl group and at the moment of incision in the remifentanil group (P = 0.939). Conclusion: Remifentanil is the opioid analgesic with the highest suppressing effect on the stress response to surgical intervention in children.	[Draskovic, Biljana; Stanic, Danica; Uram-Benka, Anna; Fabri, Izabella] Univ Novi Sad, Fac Med, Inst Child & Adolescent Hlth Care Vojvodina, Clin Pediat Surg, Novi Sad 21000, Serbia	Fabri, I (reprint author), Univ Novi Sad, Fac Med, Inst Child & Adolescent Hlth Care Vojvodina, Clin Pediat Surg, Novi Sad 21000, Serbia.	izabellafabri@gmail.com					Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Aosasa S, 2000, WORLD J SURG, V24, P10, DOI 10.1007/s002689910003; Bell G, 2004, PEDIATR ANESTH, V14, P856, DOI 10.1111/j.1460-9592.2004.01326.x; Buyukkocak U, 2006, MEDIAT INFLAMM, V1, P1; Chanavaz C, 2005, BRIT J ANAESTH, V94, P74, DOI 10.1093/bja/aeh293; Charmandari E, 2003, HORM RES, V59, P161, DOI 10.1159/000069325; Cicek M, 2005, EUR J ANAESTH, V22, P683, DOI 10.1017/S0265021505001134; Demirbilek S, 2004, J CLIN ANESTH, V16, P358, DOI 10.1016/j.jclinane.2003.10.002; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; Ghizzoni L, 2003, ANN NY ACAD SCI, V997, P56, DOI 10.1196/annals.1290.007; Gommers D, 2008, CRIT CARE, V12, DOI 10.1186/cc6150; Karayiannakis AJ, 2005, EUR CYTOKINE NETW, V16, P91; Marana E, 2008, ACTA ANAESTH SCAND, V52, P541, DOI 10.1111/j.1399-6576.2008.01589.x; Michalaki M, 2009, OBES SURG, V19, P1424, DOI 10.1007/s11695-009-9852-4; Modan-Moses D, 2001, CRIT CARE MED, V29, P2377, DOI 10.1097/00003246-200112000-00022; Sammartino M, 2010, PEDIATR ANESTH, V20, P246, DOI 10.1111/j.1460-9592.2009.03241.x; Srinivas R, 2010, CHILD NERV SYST, V26, P647, DOI 10.1007/s00381-009-1038-9; Tomic V., 2004, PRIRUCNIK VASKULARNE, P145; Weale NK, 2004, BRIT J ANAESTH, V92, P187, DOI 10.1093/bja/aeh038; Wilhelm W, 2008, CRIT CARE, V12, DOI 10.1186/cc6152	20	2	3	0	4	TUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY	ANKARA	ATATURK BULVARI NO 221, KAVAKLIDERE, ANKARA, 00000, TURKEY	1300-0144	1303-6165		TURK J MED SCI	Turk. J. Med. Sci.	DEC	2014	44	6					1095	1102		10.3906/sag-1305-36			8	Medicine, General & Internal	General & Internal Medicine	AS3DH	WOS:000344155900028	25552167	Bronze			2020-06-30	J	Mercadante, S; Caruselliy, A; Meliz, MR; Bellavia, G; Tuttolomondo, A; Casuccio, A				Mercadante, S.; Caruselliy, A.; Meliz, M. R.; Bellavia, G.; Tuttolomondo, A.; Casuccio, A.			Patients' Acceptability of Different Fentanyl Products for Breakthrough Cancer Pain	CLINICAL ONCOLOGY			English	Letter									[Mercadante, S.] La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, Palermo, Italy; [Meliz, M. R.] Univ Palermo, Fac Pharm, Palermo, Italy; [Tuttolomondo, A.] Univ Palermo, Dipartimento Biomed Med Interna & Specialist DIBI, Palermo, Italy; [Casuccio, A.] Univ Palermo, Dept Sci Hlth Promot & Mother Child Care G DAless, Palermo, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, Palermo, Italy.		casuccio, alessandra/B-1730-2013	casuccio, alessandra/0000-0002-5676-9535; Tuttolomondo, Antonino/0000-0001-6440-7318			Bedard G, 2013, SUPPORT CARE CANCER, V21, P2557, DOI 10.1007/s00520-013-1817-4; England Ruth, 2011, BMJ Support Palliat Care, V1, P349, DOI 10.1136/bmjspcare-2011-000037; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; Webber K, 2011, SUPPORT CARE CANCER, V19, P2041, DOI 10.1007/s00520-010-1062-z	4	4	5	0	0	ELSEVIER SCIENCE LONDON	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0936-6555	1433-2981		CLIN ONCOL-UK	Clin. Oncol.	DEC	2014	26	12					806	806		10.1016/j.clon.2014.09.003			1	Oncology	Oncology	AU2JM	WOS:000345444500014	25439311	Green Published			2020-06-30	J	Mick, I; Myers, J; Stokes, PRA; Erritzoe, D; Colasanti, A; Bowden-Jones, H; Clark, L; Gunn, RN; Rabiner, EA; Searle, GE; Waldman, AD; Parkin, MC; Brailsford, AD; Nutt, DJ; Lingford-Hughes, AR				Mick, Inge; Myers, Jim; Stokes, Paul R. A.; Erritzoe, David; Colasanti, Alessandro; Bowden-Jones, Henrietta; Clark, Luke; Gunn, Roger N.; Rabiner, Eugenii A.; Searle, Graham E.; Waldman, Adam D.; Parkin, Mark C.; Brailsford, Alan D.; Nutt, David J.; Lingford-Hughes, Anne R.			Amphetamine induced endogenous opioid release in the human brain detected with [C-11]carfentanil PET: replication in an independent cohort	INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY			English	Article						Amphetamine; [C-11]carfentanil; opioid system; PET	POSITRON-EMISSION-TOMOGRAPHY; RECEPTOR; SYSTEM; ANATOMY; CORTEX	This study aimed to replicate a previous study which showed that endogenous opioid release, following an oral dose of amphetamine, can be detected in the living human brain using [C-11]carfentanil positron emission tomography (PET) imaging. Nine healthy volunteers underwent two [C-11]carfentanil PET scans, one before and one 3 h following oral amphetamine administration (0.5 mg/kg). Regional changes in [C-11]carfentanil BPND from pre- to post-amphetamine were assessed. The amphetamine challenge led to significant reductions in [C-11]carfentanil BPND in the putamen, thalamus, frontal lobe, nucleus accumbens, anterior cingulate, cerebellum and insula cortices, replicating our earlier findings. None of the participants experienced significant euphoria/'high', supporting the use of oral amphetamine to characterize in vivo endogenous opioid release following a pharmacological challenge. [C-11]carfentanil PET is able to detect changes in binding following an oral amphetamine challenge that reflects endogenous opioid release and is suitable to characterize the opioid system in neuropsychiatric disorders.	[Mick, Inge; Myers, Jim; Stokes, Paul R. A.; Erritzoe, David; Colasanti, Alessandro; Gunn, Roger N.; Nutt, David J.; Lingford-Hughes, Anne R.] Univ London Imperial Coll Sci Technol & Med, Ctr Neuropsychopharmacol, Fac Med, Div Brain Sci, London W12 0NN, England; [Stokes, Paul R. A.; Colasanti, Alessandro; Rabiner, Eugenii A.] Kings Coll London, Inst Psychiat, Dept Psychol Med, Ctr Affect Disorders, London WC2R 2LS, England; [Colasanti, Alessandro; Gunn, Roger N.; Rabiner, Eugenii A.; Searle, Graham E.] Imanova Ltd, Ctr Imaging Sci, London, England; [Bowden-Jones, Henrietta] Univ London Imperial Coll Sci Technol & Med, CNWL NHS Fdn Trust, Natl Problem Gambling Clin, London W12 0NN, England; [Clark, Luke] Univ Cambridge, Dept Psychol, Lab Affect Risk & Gambling Experiments, Cambridge CB2 1TN, England; [Waldman, Adam D.] Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Expt Med, Dept Imaging, London W12 0NN, England; [Parkin, Mark C.] Kings Coll London, Drug Control Ctr, London WC2R 2LS, England	Lingford-Hughes, AR (reprint author), Univ London Imperial Coll Sci Technol & Med, Ctr Neuropsychopharmacol, Fac Med, Div Brain Sci, 160 Du Cane Rd, London W12 0NN, England.	anne.lingford-hughes@imperial.ac.uk	Rabiner, Eugenii A./G-6263-2012	Rabiner, Eugenii A./0000-0003-3612-6687; Waldman, Adam D/0000-0003-4398-6431; Myers, James/0000-0001-6382-4275; Erritzoe, David/0000-0002-7022-6211; Stokes, Paul/0000-0002-2274-8330; Brailsford, Alan/0000-0001-6198-4910; Clark, Luke/0000-0003-1103-2422; Mick, Inge Maria/0000-0002-0142-6156; Gunn, Roger/0000-0003-1181-5769; Colasanti, Alessandro/0000-0001-6017-801X	Medical Research CouncilMedical Research Council UK (MRC) [MRC G1002226]; Medical Research CouncilMedical Research Council UK (MRC) [G1000183B, G0001354B, G0001354, G1002226]; National Institute for Health ResearchNational Institute for Health Research (NIHR) [2160]	This study was funded by the Medical Research Council - MRC G1002226. The authors wish to thank the study participants and the clinical team at Imanova Ltd, Centre for Imaging Sciences. This report presents independent research partly carried out at the NIHR/Wellcome Trust Imperial Clinical Research Facility. The views expressed are those of the authors and not necessarily those of the Imperial College Healthcare NHS Trust, the NIHR or the Department of Health.	Colasanti A, 2012, BIOL PSYCHIAT, V72, P371, DOI 10.1016/j.biopsych.2012.01.027; Guterstam J, 2013, INT J NEUROPSYCHOPH, V16, P763, DOI 10.1017/S1461145712000818; Hiller JM, 1996, NEUROCHEM RES, V21, P1333, DOI 10.1007/BF02532374; Hsu DT, 2013, MOL PSYCHIATR, V18, P1211, DOI [10.1038/mp.2013.96, 10.1038/mp.2013.139]; Koepp MJ, 2009, NEUROIMAGE, V44, P252, DOI 10.1016/j.neuroimage.2008.08.032; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Love TM, 2009, ARCH GEN PSYCHIAT, V66, P1124, DOI 10.1001/archgenpsychiatry.2009.134; Maarrawi J, 2013, PAIN, V154, P2563, DOI 10.1016/j.pain.2013.07.042; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; Paterson LM, 2010, J CEREBR BLOOD F MET, V30, P1682, DOI 10.1038/jcbfm.2010.104; Petrovic P, 2008, J NEUROSCI, V28, P10509, DOI 10.1523/JNEUROSCI.2807-08.2008; Rabiner EA, 2011, MOL PSYCHIATR, V16, P826, DOI 10.1038/mp.2011.29; Shotbolt P, 2012, J CEREBR BLOOD F MET, V32, P127, DOI 10.1038/jcbfm.2011.115; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Tziortzi AC, 2011, NEUROIMAGE, V54, P264, DOI 10.1016/j.neuroimage.2010.06.044; VANKAMMEN DP, 1975, PSYCHOPHARMACOLOGIA, V44, P215, DOI 10.1007/BF00428897; Williams TM, 2009, EUR NEUROPSYCHOPHARM, V19, P740, DOI 10.1016/j.euroneuro.2009.06.007; Zubieta JK, 2009, ANN NY ACAD SCI, V1156, P198, DOI 10.1111/j.1749-6632.2009.04424.x	18	27	27	0	4	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1461-1457	1469-5111		INT J NEUROPSYCHOPH	Int. J. Neuropsychopharmacol.	DEC	2014	17	12					2069	2074		10.1017/S1461145714000704			6	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	AT5TX	WOS:000345006100015	24807268	Bronze			2020-06-30	J	Stanley, TH				Stanley, Theodore H.			The Fentanyl Story	JOURNAL OF PAIN			English	Article						Fentanyl; rapid-acting opioids; sublingual; patch; nasal; oral transmucosal	BREAKTHROUGH CANCER PAIN; RESPIRATORY DEPRESSION; TRANSDERMAL FENTANYL; OXYGEN ANESTHESIA; SUBLINGUAL SPRAY; BUCCAL TABLET; CITRATE OTFC; DOUBLE-BLIND; IMMOBILIZATION; DEATHS	Fentanyl, introduced more than 50 years ago, has become the most often used opioid for intraoperative analgesia. Since the early 1990s the fentanyl patch has been available for management of chronic pain of all forms of cancer as well as the persistent, intense pain from many noncancerous maladies. More than a half dozen rapid-onset transmucosal fentanyl preparations have been developed, approved, launched, and popularized for "breakthrough" pain syndromes in the past 20 years. The purpose of this article is to describe why this opioid has become so important in the treatment of pain in modern clinical practice. The data indicate that fentanyl's popularity has occurred because it has minimal cardiovascular effects, does not result in increases in plasma histamine, is relatively short in onset of action and duration of effect, is easy and inexpensive to synthesize and prepare for the marketplace, and is now familiar to clinicians working in pain and perioperative medicine throughout the world. Perspective: Fentanyl has become one of the most important opioids in the management of pain because it is available for administration intravenously, transdermally, and transmucosally. Its flexibility, potency, familiarity, and physical characteristics explain why it has become so valuable to clinicians managing pain throughout the world. (C) 2014 by the American Pain Society	Univ Utah, Sch Med, Dept Anesthesiol, Salt Lake City, UT 84132 USA	Stanley, TH (reprint author), Univ Utah, Sch Med, Dept Anesthesiol, 30 North 1900 East 3C444, Salt Lake City, UT 84132 USA.	Theodore.stanley@hsc.utah.edu					ADAMS AP, 1978, BRIT MED J, V1, P278, DOI 10.1136/bmj.1.6108.278; Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; [Anonymous], 1999, PHYS DESK REF, P1418; ASHBURN M A, 1988, Anesthesiology (Hagerstown), V69, pA348, DOI 10.1097/00000542-198809010-00347; ASHBURN MA, 1989, ANESTHESIOLOGY, V71, P615, DOI 10.1097/00000542-198910000-00026; ASHBURN MA, 1993, ANESTH ANALG, V76, P377; BAILEY PL, 1985, J WILDLIFE MANAGE, V49, P931, DOI 10.2307/3801373; Bailey PL, 1994, ANESTHESIA; BECKER LD, 1976, ANESTHESIOLOGY, V44, P291, DOI 10.1097/00000542-197604000-00003; BOVILL JG, 1984, ANESTHESIOLOGY, V61, P731; BROWN DL, 1985, CHEST, V88, P779, DOI 10.1378/chest.88.5.779; BULOW HH, 1995, ACTA ANAESTH SCAND, V39, P835; Darwish M, 2008, CLIN DRUG INVEST, V28, P1, DOI 10.2165/00044011-200828010-00001; de Castro J, 1976, 6 WORLD C AN MEX, P214; DECASTRO J, 1969, ANESTH ANALG REANIM, V26, P145; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; DUTHIE DJR, 1988, BRIT J ANAESTH, V60, P614, DOI 10.1093/bja/60.6.614; EDMONDSSEAL J, 1970, BRIT J ANAESTH, V42, P207, DOI 10.1093/bja/42.3.207; Ellenhorn J, 1997, ELLENHORNS MED TOXIC, P319; FINE PG, 1991, PAIN, V45, P149, DOI 10.1016/0304-3959(91)90181-V; FREYE E, 1977, ARZNEIMITTEL-FORSCH, V27, P1037; Freyer FJ, 2014, PROVIDENCE J; GARRIOTT JC, 1984, J ANAL TOXICOL, V8, P288, DOI 10.1093/jat/8.6.288; Hasbrouck J D, 1970, Ann Thorac Surg, V10, P364; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; JANSSEN DL, 1993, J ZOO WILDLIFE MED, V24, P11; Krinsky CS, 2011, AM J FOREN MED PATH, V32, P347, DOI 10.1097/PAF.0b013e31822ad269; LIU WS, 1976, ANESTH ANALG, V55, P168; LOWENSTEIN E, 1969, NEW ENGL J MED, V281, P1389, DOI 10.1056/NEJM196912182812503; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Mayes S, 2006, ANN PHARMACOTHER, V40, P2178, DOI 10.1345/aph.1H135; McLoughlin R, 1997, PALLIATIVE MED, V11, P419; MEULEMAN T, 1984, J WILDLIFE MANAGE, V48, P258, DOI 10.2307/3808484; NILSSON C, 1982, ACTA ANAESTH SCAND, V26, P240, DOI 10.1111/j.1399-6576.1982.tb01762.x; Parikh N, 2013, CLIN THER, V35, P236, DOI 10.1016/j.clinthera.2013.02.017; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Rauck R, 2012, CURR MED RES OPIN, V28, P859, DOI 10.1185/03007995.2012.683111; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Regnard C, 2003, PALLIATIVE MED, V17, P714, DOI 10.1191/0269216303pm838cr; Reves J, 1988, INTRAVENOUS ANESTHES; ROWBOTHAM DJ, 1989, BRIT J ANAESTH, V63, P56, DOI 10.1093/bja/63.1.56; Smydo J, 1979, Anesth Prog, V26, P47; STANLEY TH, 1978, ANESTH ANALG, V57, P411; STANLEY TH, 1979, CAN ANAESTH SOC J, V26, P168, DOI 10.1007/BF03006976; Stanley TH, 1989, ANESTH ANALG, V69, P31; Stanley TH, 2014, WOUNDROUS STORY ANES; Stanley TH, 1980, INT S INT AN CHIC GR, P367; Stanley TH, 2008, ANESTH ANALG, V106, P451, DOI 10.1213/ane.0b013e3181605add; STREISAND JB, 1989, ANESTH ANALG, V69, P28; VANLEEUWEN L, 1981, ANAESTHESIST, V30, P397	52	81	84	5	27	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1526-5900			J PAIN	J. Pain	DEC	2014	15	12					1215	1226		10.1016/j.jpain.2014.08.010			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AX4HC	WOS:000346893100002	25441689				2020-06-30	J	de Hoogd, S; Ahlers, SJGM; van Dongen, EPA; Tibboel, D; Dahan, A; Knibbe, CAJ				de Hoogd, Sjoerd; Ahlers, Sabine J. G. M.; van Dongen, Eric P. A.; Tibboel, Dick; Dahan, Albert; Knibbe, Catherijne A. J.			Remifentanil versus fentanyl during cardiac surgery on the incidence of chronic thoracic pain (REFLECT): study protocol for a randomized controlled trial	TRIALS			English	Article						Chronic pain; Sternotomy; Remifentanil; Fentanyl; Postoperative pain	OPIOID-INDUCED HYPERALGESIA; POST-STERNOTOMY PAIN; D-ASPARTATE RECEPTOR; SHORT-TERM INFUSION; RISK-FACTORS; POSTINFUSION HYPERALGESIA; POSTOPERATIVE PAIN; INDUCED ANALGESIA; PREVALENCE; HUMANS	Background: Chronic thoracic pain after cardiac surgery is prevalent (11 to 56%) and may affect patients' physical and mental health status. Despite its favorable pharmacokinetic and pharmacodynamic properties, high doses of remifentanil administered during surgery are reported to cause acute postoperative pain and increased requirements for analgesics. Recently, an association between remifentanil use and the incidence of chronic thoracic pain in the long term was also reported. Our objective is to investigate the influence of the intraoperative remifentanil on chronic postoperative pain in a prospective randomized controlled trial. Methods/design: In this prospective, randomized, single-blind clinical trial, all patients (N = 126) between 18 and 85 years undergoing cardiac surgery via sternotomy receive a continuous infusion of propofol together with intermittent intravenous fentanyl at predetermined times perioperatively. Patients are randomized to receive either an additional continuous infusion of remifentanil (0.15 mu g(-1)kgIBW(-1) min(-1)) or additional fentanyl (200 to 500 mu g) as needed during surgery. The primary end point is the prevalence of chronic thoracic pain 12 months after surgery. Secondary end points include acute postoperative pain; postoperative analgesic use; chronic thoracic pain 3 and 6 months after surgery; quality of life (SF-12) at 3, 6 and 12 months after surgery; work productivity; and use of health care. In addition, thermal detection and pain thresholds are measured preoperatively, 3 days after surgery and 12 months after surgery using quantitative sensory testing (QST). Finally, the influence of several genetic variances on the different outcomes will be measured. Discussion: Chronic thoracic pain is prevalent after cardiac surgery, and research is needed to minimize the risk of chronic persistent postoperative pain, which is an invalidating, long-term complication of surgery. The objective of this trial is to determine the influence of perioperative remifentanil on long-term pain outcomes for cardiac patients in a prospective randomized trial. The results may be used to optimize perioperative analgesia techniques and, thereby, improve quality of life after cardiac surgery.	[de Hoogd, Sjoerd; Ahlers, Sabine J. G. M.; Knibbe, Catherijne A. J.] St Antonius Hosp, Dept Clin Pharm, NL-3435 CM Nieuwegein, Netherlands; [van Dongen, Eric P. A.] St Antonius Hosp, Dept Anesthesiol & Intens Care, NL-3435 CM Nieuwegein, Netherlands; [Tibboel, Dick; Knibbe, Catherijne A. J.] Sophia Childrens Univ Hosp, Erasmus MC, NL-3015 CN Rotterdam, Netherlands; [Tibboel, Dick; Knibbe, Catherijne A. J.] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Surg, NL-3015 CN Rotterdam, Netherlands; [Dahan, Albert] Leiden Univ, Med Ctr, Dept Anesthesiol, NL-2333 ZA Leiden, Netherlands; [Knibbe, Catherijne A. J.] Leiden Univ, Leiden Acad Ctr Drug Res, Div Pharmacol, Leiden, Netherlands	Knibbe, CAJ (reprint author), St Antonius Hosp, Dept Clin Pharm, Koekoeklaan 1, NL-3435 CM Nieuwegein, Netherlands.	c.knibbe@antoniusziekenhuis.nl		Knibbe, Catherijne Annette Jantine/0000-0001-9893-4415			Ahlers SJGM, 2012, ANAESTH INTENS CARE, V40, P417, DOI 10.1177/0310057X1204000306; Angst MS, 2003, PAIN, V106, P49, DOI 10.1016/S0304-3959(03)00276-8; Bruce J, 2003, PAIN, V104, P265, DOI 10.1016/S0304-3959(03)00017-4; Cho AR, 2013, ANESTH ANALG, V116, P685, DOI 10.1213/ANE.0b013e31827ee372; Choiniere M, 2014, CAN MED ASSOC J, V186, pE213, DOI 10.1503/cmaj.131012; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Derrode N, 2003, BRIT J ANAESTH, V91, P842, DOI 10.1093/bja/aeg263; Edwards FH, 2001, J AM COLL CARDIOL, V37, P885, DOI 10.1016/S0735-1097(00)01202-X; Eisenberg E, 2001, PAIN, V92, P11, DOI 10.1016/S0304-3959(00)00466-8; Fletcher D, 2014, BRIT J ANAESTH, V112, P991, DOI 10.1093/bja/aeu137; Gjeilo KH, 2010, ACTA ANAESTH SCAND, V54, P70, DOI 10.1111/j.1399-6576.2009.02097.x; Greco M, 2012, J CARDIOTHOR VASC AN, V26, P110, DOI 10.1053/j.jvca.2011.05.007; Guntz E, 2005, ANESTHESIOLOGY, V102, P1235, DOI 10.1097/00000542-200506000-00025; Kalso E, 2001, ACTA ANAESTH SCAND, V45, P935, DOI 10.1034/j.1399-6576.2001.450803.x; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Kim SH, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00108; Koppert W, 2003, ANESTHESIOLOGY, V99, P152, DOI 10.1097/00000542-200307000-00025; Koppert W, 2003, PAIN, V106, P91, DOI 10.1016/S0304-3959(03)00294-X; Lahtinen P, 2006, ANESTHESIOLOGY, V105, P794, DOI 10.1097/00000542-200610000-00026; Lenz H, 2011, PAIN, V152, P1289, DOI 10.1016/j.pain.2011.02.007; Meyerson J, 2001, ACTA ANAESTH SCAND, V45, P940, DOI 10.1034/j.1399-6576.2001.450804.x; Noordzij PG, 2010, ANESTHESIOLOGY, V112, P1105, DOI 10.1097/ALN.0b013e3181d5f95c; Raffa Robert B, 2013, Pain Manag Nurs, V14, pe67, DOI 10.1016/j.pmn.2011.04.002; Rivosecchi RM, 2014, EXPERT OPIN DRUG SAF, V13, P587, DOI 10.1517/14740338.2014.902931; Rolke R, 2006, PAIN, V123, P231, DOI 10.1016/j.pain.2006.01.041; Rolke R, 2006, EUR J PAIN, V10, P77, DOI 10.1016/j.ejpain.2005.02.003; Salengros JC, 2010, J CARDIOTHOR VASC AN, V24, P608, DOI 10.1053/j.jvca.2009.10.006; Taillefer MC, 2006, J THORAC CARDIOV SUR, V131, P1274, DOI 10.1016/j.jtcvs.2006.02.001; Troster A, 2006, ANESTHESIOLOGY, V105, P1016; van Gulik L, 2012, BRIT J ANAESTH, V109, P616, DOI 10.1093/bja/aes247; van Gulik L, 2011, EUR J CARDIO-THORAC, V40, P1309, DOI 10.1016/j.ejcts.2011.03.039; Wong GTC, 2010, J CARDIOTHOR VASC AN, V24, P790, DOI 10.1053/j.jvca.2009.09.012; Zhao M, 2008, ANESTHESIOLOGY, V109, P308, DOI 10.1097/ALN.0b013e31817f4c5d	33	4	4	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1745-6215			TRIALS	Trials	NOV 27	2014	15								466	10.1186/1745-6215-15-466			6	Medicine, Research & Experimental	Research & Experimental Medicine	AX4AI	WOS:000346876200001	25429720	DOAJ Gold, Green Published			2020-06-30	J	Gluck, L; Loktev, A; Mouledous, L; Mollereau, C; Law, PY; Schulz, S				Glueck, Laura; Loktev, Anastasia; Mouledous, Lionel; Mollereau, Catherine; Law, Ping-Yee; Schulz, Stefan			Loss of Morphine Reward and Dependence in Mice Lacking G Protein-Coupled Receptor Kinase 5	BIOLOGICAL PSYCHIATRY			English	Article						Bar code; conditioned place preference; dependence; G protein-coupled receptor kinase; mu opioid receptor; phosphorylation	BETA-ARRESTIN; ANALGESIC TOLERANCE; NUCLEUS-ACCUMBENS; ARRIVE GUIDELINES; OPIOID INHIBITION; ERK ACTIVATION; PHOSPHORYLATION; DESENSITIZATION; COCAINE; DRUGS	Background: The clinical benefits of opioid drugs are counteracted by the development of tolerance and addiction. We provide in vivo evidence for the involvement of G protein-coupled receptor kinases (GRKs) in opioid dependence in addition to their roles in agonist-selective mu-opioid receptor (MOR) phosphorylation. Methods: In vivo MOR phosphorylation was examined by immunoprecipitation and nanoflow liquid chromatography-tandem mass spectrometry analysis. Using the hot-plate and conditioned place preference test, we investigated opioid-related antinociception and reward effects in mice lacking GRK3 or GRK5. Results: Etonitazene and fentanyl stimulated the in vivo phosphorylation of multiple carboxyl-terminal phosphate acceptor sites, including threonine 370, serine 375, and threonine 379, which was predominantly mediated by GRK3. By contrast, morphine promoted a selective phosphorylation of serine 375 that was predominantly mediated by GRK5. In contrast to GRK3 knockout mice, GRK5 knockout mice exhibited reduced antinociceptive responses after morphine administration and developed morphine tolerance similar to wild-type mice but fewer signs of physical dependence. Also, morphine was ineffective in inducing conditioned place preference in GRK5 knockout mice, whereas cocaine conditioned place preference was retained. However, the reward properties of morphine were evident in knock-in mice expressing a phosphorylation-deficient S375A mutation of the MOR. Conclusions: These findings show for the first time that MOR phosphorylation is regulated by agonist-selective recruitment of distinct GRK isoforms that influence different opioid-related behaviors. Modulation of GRK5 function could serve as a new approach for preventing addiction to opioids, while maintaining the analgesic properties of opioid drugs at an effective level.	[Glueck, Laura; Loktev, Anastasia; Schulz, Stefan] Univ Jena, Jena Univ Hosp, Inst Pharmacol & Toxicol, D-07747 Jena, Germany; [Mouledous, Lionel; Mollereau, Catherine] Univ Toulouse, CNRS, Inst Pharmacol & Biol Struct, Toulouse, France; [Law, Ping-Yee] Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	Schulz, S (reprint author), Univ Jena, Jena Univ Hosp, Inst Pharmacol & Toxicol, Drackendorfer Str 1, D-07747 Jena, Germany.	Stefan.Schulz@med.uni-jena.de	Schulz, Stefan/A-6928-2017	Schulz, Stefan/0000-0002-5997-8885; Law, Ping-Yee/0000-0002-5364-1093; Mollereau, Catherine/0000-0003-1543-5624; Mouledous, Lionel/0000-0002-7675-3493	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [SCHU924/11-2, SCHU924/15-1]; National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [1R01DA031442-01A1]; Region Midi-Pyrenees and European funds (FEDER, Fonds Europeen de Developpement Economique et Regional)Region Occitanie	This work was supported by Deutsche Forschungsgemeinschaft Grant Nos. SCHU924/11-2 and SCHU924/15-1 to SS and National Institute on Drug Abuse Grant No. 1R01DA031442-01A1 to P-YL and SS. We thank Odile Burlet-Schiltz and Carine Froment for the mass spectrometry analyses (Proteomics and Mass Spectrometry of Biomolecules, Institut de Pharmacologie et de Biologie Structurale, Toulouse, France), which are supported by Region Midi-Pyrenees and European funds (FEDER, Fonds Europeen de Developpement Economique et Regional). We thank Heidrun Guder and Heike Stadler for excellent technical assistance.	Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Bohn LM, 2003, J NEUROSCI, V23, P10265; BOUTON ME, 1993, PSYCHOL BULL, V114, P80, DOI 10.1037/0033-2909.114.1.80; Busillo JM, 2010, J BIOL CHEM, V285, P7805, DOI 10.1074/jbc.M109.091173; Butcher AJ, 2011, J BIOL CHEM, V286, P11506, DOI 10.1074/jbc.M110.154526; Chen YJ, 2011, J CELL BIOL, V194, P905, DOI 10.1083/jcb.201104114; Connor M, 2004, BRIT J PHARMACOL, V143, P685, DOI 10.1038/sj.bjp.0705938; Doll C, 2012, BRIT J PHARMACOL, V167, P1259, DOI 10.1111/j.1476-5381.2012.02080.x; Doll C, 2011, BRIT J PHARMACOL, V164, P298, DOI 10.1111/j.1476-5381.2011.01382.x; Eitan S, 2003, J NEUROSCI, V23, P8360; Ford CP, 2006, J NEUROSCI, V26, P2788, DOI 10.1523/JNEUROSCI.4331-05.2006; FUNADA M, 1993, NEUROPHARMACOLOGY, V32, P1315; Gainetdinov RR, 1999, NEURON, V24, P1029, DOI 10.1016/S0896-6273(00)81048-X; Gainetdinov RR, 2000, TRENDS PHARMACOL SCI, V21, P366, DOI 10.1016/S0165-6147(00)01538-8; GLICK SD, 1995, BRAIN RES, V681, P147, DOI 10.1016/0006-8993(95)00306-B; Gong YX, 2010, NEUROSCI LETT, V468, P115, DOI 10.1016/j.neulet.2009.10.079; Grecksch G, 2011, J NEUROSCI, V31, P13890, DOI 10.1523/JNEUROSCI.2304-11.2011; Haberstock-Debic H, 2003, J NEUROSCI, V23, P4324; Heitzler D, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.22; Just S, 2013, MOL PHARMACOL, V83, P633, DOI 10.1124/mol.112.082875; Kara E, 2006, MOL ENDOCRINOL, V20, P3014, DOI 10.1210/me.2006-0098; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI 10.1111/j.1476-5381.2010.00872.x; Kim J, 2005, P NATL ACAD SCI USA, V102, P1442, DOI 10.1073/pnas.0409532102; Koch T, 2008, PHARMACOL THERAPEUT, V117, P199, DOI 10.1016/j.pharmthera.2007.10.003; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; Kuzmin AV, 1997, EUR J PHARMACOL, V321, P265, DOI 10.1016/S0014-2999(96)00961-2; Lintas A, 2011, J NEUROSCI, V31, P11172, DOI 10.1523/JNEUROSCI.1781-11.2011; Loudon RP, 1996, BLOOD, V88, P4547, DOI 10.1182/blood.V88.12.4547.bloodjournal88124547; Lupp A, 2011, REGUL PEPTIDES, V167, P9, DOI 10.1016/j.regpep.2010.09.004; Macey TA, 2006, J BIOL CHEM, V281, P34515, DOI 10.1074/jbc.M604278200; Maldonado R, 1997, NATURE, V388, P586, DOI 10.1038/41567; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x; McPherson J, 2010, MOL PHARMACOL, V78, P756, DOI 10.1124/mol.110.066613; Melief EJ, 2010, P NATL ACAD SCI USA, V107, P11608, DOI 10.1073/pnas.1000751107; Miller CA, 2005, NEURON, V47, P873, DOI 10.1016/j.neuron.2005.08.006; Nobles KN, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001707; Premont RT, 2007, ANNU REV PHYSIOL, V69, P511, DOI 10.1146/annurev.physiol.69.022405.154731; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; Raehal KM, 2011, NEUROPHARMACOLOGY, V60, P58, DOI 10.1016/j.neuropharm.2010.08.003; Raehal KM, 2009, DRUG ALCOHOL DEPEN, V104, P187, DOI 10.1016/j.drugalcdep.2009.04.011; Reiter E, 2006, TRENDS ENDOCRIN MET, V17, P159, DOI 10.1016/j.tem.2006.03.008; Reiter E, 2012, ANNU REV PHARMACOL, V52, P179, DOI 10.1146/annurev.pharmtox.010909.105800; Ren XR, 2005, P NATL ACAD SCI USA, V102, P1448, DOI 10.1073/pnas.0409534102; Sallese M, 1997, J BIOL CHEM, V272, P10188; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; Schulz S, 2004, EMBO J, V23, P3282, DOI 10.1038/sj.emboj.7600334; Shenoy SK, 2006, J BIOL CHEM, V281, P1261, DOI 10.1074/jbc.M506576200; STEKETEE JD, 1992, PROG NEURO-PSYCHOPH, V16, P237, DOI 10.1016/0278-5846(92)90075-P; Terman GW, 2004, BRIT J PHARMACOL, V141, P55, DOI 10.1038/sj.bjp.0705595; Valjent E, 2004, EUR J NEUROSCI, V19, P1826, DOI 10.1111/j.1460-9568.2004.03278.x; Valjent E, 2006, P NATL ACAD SCI USA, V103, P2932, DOI 10.1073/pnas.0511030103; Wang WS, 2012, J NEUROSCI, V32, P13763, DOI 10.1523/JNEUROSCI.1991-12.2012; Wee S, 2010, PSYCHOPHARMACOLOGY, V210, P121, DOI 10.1007/s00213-010-1825-8; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298	56	19	20	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0006-3223	1873-2402		BIOL PSYCHIAT	Biol. Psychiatry	NOV 15	2014	76	10					767	774		10.1016/j.biopsych.2014.01.021			8	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	AT2AN	WOS:000344733100004	24629717	Green Accepted			2020-06-30	J	Li, W; He, SW; Zhou, YY; Li, Y; Hao, JB; Zhou, XR; Wang, F; Zhang, Y; Huang, ZH; Li, ZY; Loh, HH; Law, PY; Zheng, H				Li, Wen; He, Songwei; Zhou, Yuye; Li, Yuan; Hao, Jianbang; Zhou, Xingru; Wang, Feng; Zhang, Yang; Huang, Zhenhua; Li, Zhiyuan; Loh, Horace H.; Law, Ping-Yee; Zheng, Hui			Neurod1 Modulates Opioid Antinociceptive Tolerance via Two Distinct Mechanisms	BIOLOGICAL PSYCHIATRY			English	Article						Analgesia; learning; Neurod1; opioid; tolerance; water maze	ADULT HIPPOCAMPAL NEUROGENESIS; NERVOUS-SYSTEM; RECEPTOR INTERNALIZATION; PATTERN SEPARATION; RAT HIPPOCAMPUS; DOWN METHOD; MORPHINE; MEMORY; EXPRESSION; INHIBITION	Background: The activity of neurogenic differentiation 1 (Neurod1) decreases after morphine administration, which leads to impairments of the stability of dendritic spines in primary hippocampal neurons, adult neurogenesis in mouse hippocampi, and drug-associated contextual memory. The current study examined whether Neurod1 could affect the development of opioid tolerance. Methods: Lentivirus encoding Neurod1, microRNA-190 (miR-190), or short hairpin RNA against Neurod1 was injected into mouse hippocampi separately or combined (more than eight mice for each treatment) to modulate NeuroD1 activity. The antinociceptive median effective dose values of morphine and fentanyl were determined with tail-flick assay and used to calculate development of tolerance. Contextual learning and memory were assayed using the Morris water maze. Results: Decrease in NeuroD1 activity increased the initial antinociceptive median effective dose values of both morphine and fentanyl, which was reversed by restoring NeuroD1 activity. In contrast, decrease in NeuroD1 activity inhibited development of tolerance in a time-dependent manner, paralleling its effects on the acquisition and extinction of contextual memory. In addition, only development of tolerance, but not antinociceptive median effective dose values, was modulated by the expression of miR-190 and Neurod1 driven by Nestin promoter. Conclusions: Neurod1 regulates the developments of opioid tolerance via a time-dependent pathway through contextual learning and a short-response pathway through antinociception.	[Li, Wen; He, Songwei; Zhou, Yuye; Li, Yuan; Hao, Jianbang; Zhou, Xingru; Li, Zhiyuan; Zheng, Hui] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Guangdong Prov Key Lab Stem Cell & Regenerat Med, CAS Key Lab Regenerat Biol, Guangzhou 510530, Guangdong, Peoples R China; [Wang, Feng] Jinan Univ, Guangdong Prov Key Lab Pharmacodynam Constituents, Coll Pharm, Guangzhou, Guangdong, Peoples R China; [Zhang, Yang] Guangdong Acad Med Sci, Dept Lab, Guangzhou, Guangdong, Peoples R China; [Zhang, Yang] Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China; [Huang, Zhenhua] Nanfang Hosp, Ctr Canc, Guangzhou, Guangdong, Peoples R China; [Loh, Horace H.; Law, Ping-Yee] Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	Zheng, H (reprint author), 190 Kaiyuan Ave, Guangzhou 510530, Guangdong, Peoples R China.	zheng_hui@gibh.ac.cn	Wang, Feng/I-8263-2019	Law, Ping-Yee/0000-0002-5364-1093; Zheng, Hui/0000-0001-6801-0529	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [31100773]; National Basic Research Program of ChinaNational Basic Research Program of China [2010CB945402]; Guangzhou International Science and Technology Cooperation Projects from Bureau of Science and Information Technology of Guangzhou Municipal Government [2012J5100007]; Guangdong Natural Science FoundationNational Natural Science Foundation of Guangdong Province [S2012010010087]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA031442-A1]	This work was supported by the National Natural Science Foundation of China Grant No. 31100773, National Basic Research Program of China Grant No. 2010CB945402, Guangzhou International Science and Technology Cooperation Projects from Bureau of Science and Information Technology of Guangzhou Municipal Government Grant No. 2012J5100007, Guangdong Natural Science Foundation Grant No. S2012010010087, and National Institutes of Health Grant No. DA031442-A1.	Aimone JB, 2011, NEURON, V70, P589, DOI 10.1016/j.neuron.2011.05.010; ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; Chae JH, 2004, MOL CELLS, V18, P271; Cho JH, 2004, MOL NEUROBIOL, V30, P35, DOI 10.1385/MN:30:1:035; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; DIXON WJ, 1991, NEUROSCI BIOBEHAV R, V15, P47, DOI 10.1016/S0149-7634(05)80090-9; DIXON WJ, 1965, J AM STAT ASSOC, V60, P967, DOI 10.2307/2283398; DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018; Eisch AJ, 2006, HIPPOCAMPUS, V16, P271, DOI 10.1002/hipo.20161; Eisch AJ, 2000, P NATL ACAD SCI USA, V97, P7579, DOI 10.1073/pnas.120552597; Mendes LAF, 2008, LIFE SCI, V83, P644, DOI 10.1016/j.lfs.2008.09.006; Gaudilliere B, 2004, NEURON, V41, P229, DOI 10.1016/S0896-6273(03)00841-9; Hashemi M, 2010, BRAIN RES, V1313, P79, DOI 10.1016/j.brainres.2009.11.020; Hernandez-Rabaza V, 2009, NEUROSCIENCE, V159, P59, DOI 10.1016/j.neuroscience.2008.11.054; Kalyuzhny AE, 1998, J COMP NEUROL, V392, P528; Khahlzadeh E, 2010, PHARMACOL BIOCHEM BE, V97, P325, DOI 10.1016/j.pbb.2010.08.018; KHANNA S, 1989, PAIN, V39, P337, DOI 10.1016/0304-3959(89)90047-X; Koch T, 2005, MOL PHARMACOL, V67, P280, DOI 10.1124/mol.104.004994; Lee JK, 2000, DEV DYNAM, V217, P361, DOI 10.1002/(SICI)1097-0177(200004)217:4<361::AID-DVDY3>3.0.CO;2-8; Leuner B, 2006, HIPPOCAMPUS, V16, P216, DOI 10.1002/hipo.20153; Liao D, 2005, P NATL ACAD SCI USA, V102, P1725, DOI 10.1073/pnas.0406797102; Narita M, 2006, NEUROSCIENCE, V138, P609, DOI 10.1016/j.neuroscience.2005.11.046; Pearse D, 2001, BRAIN RES, V894, P193, DOI 10.1016/S0006-8993(01)01993-X; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Seo S, 2007, EMBO J, V26, P5093, DOI 10.1038/sj.emboj.7601923; SIEGEL S, 1978, J EXP PSYCHOL ANIM B, V4, P188; SIEGEL S, 1977, J EXP PSYCHOL ANIM B, V3, P1, DOI 10.1037/0097-7403.3.1.1; Snyder JS, 2009, J NEUROSCI, V29, P14484, DOI 10.1523/JNEUROSCI.1768-09.2009; Snyder JS, 2005, NEUROSCIENCE, V130, P843, DOI 10.1016/j.neuroscience.2004.10.009; Svoboda KR, 1998, J NEUROSCI, V18, P7084; SWEARENGEN E, 1989, NEUROPHARMACOLOGY, V28, P689, DOI 10.1016/0028-3908(89)90152-4; Tamaddonfard E, 2011, PHARMACOL REP, V63, P423, DOI 10.1016/S1734-1140(11)70508-4; von Bohlen und Halbach O, 2007, CELL TISSUE RES, V329, P409, DOI 10.1007/s00441-007-0432-4; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Zheng H, 2008, MOL PHARMACOL, V73, P178, DOI 10.1124/mol.107.039842; Zheng H, 2013, NEUROPSYCHOPHARMACOL, V38, P770, DOI 10.1038/npp.2012.242; Zheng H, 2012, BMC CELL BIOL, V13, DOI 10.1186/1471-2121-13-6; Zheng H, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.177089; Zheng H, 2010, J BIOL CHEM, V285, P21994, DOI 10.1074/jbc.M110.112607; Zheng H, 2010, J NEUROSCI, V30, P8102, DOI 10.1523/JNEUROSCI.6069-09.2010; Zheng H, 2010, MOL PHARMACOL, V77, P102, DOI 10.1124/mol.109.060848; Zuo ZY, 2005, ANESTH ANALG, V101, P728, DOI 10.1213/01.ANE.0000160588.32007.AD	42	10	10	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0006-3223	1873-2402		BIOL PSYCHIAT	Biol. Psychiatry	NOV 15	2014	76	10					775	784		10.1016/j.biopsych.2014.05.013			10	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	AT2AN	WOS:000344733100005	24993058	Green Accepted			2020-06-30	J	Sidhu, SK; Weavil, JC; Venturelli, M; Garten, RS; Rossman, MJ; Richardson, RS; Gmelch, BS; Morgan, DE; Amann, M				Sidhu, Simranjit K.; Weavil, Joshua C.; Venturelli, Massimo; Garten, Ryan S.; Rossman, Matthew J.; Richardson, Russell S.; Gmelch, Benjamin S.; Morgan, David E.; Amann, Markus			Spinal mu-opioid receptor-sensitive lower limb muscle afferents determine corticospinal responsiveness and promote central fatigue in upper limb muscle	JOURNAL OF PHYSIOLOGY-LONDON			English	Article							REDUCES VOLUNTARY ACTIVATION; MOTOR CORTEX; INTRACORTICAL INHIBITION; GROUP-III; ENDURANCE EXERCISE; LEG MOVEMENT; HUMANS; CONTRACTIONS; STRENGTH; OUTPUT	We investigated the influence of group III/IV lower limb muscle afferents on the development of supraspinal fatigue and the responsiveness of corticospinal projections to an arm muscle. Eight males performed constant-load leg cycling exercise (80% peak power output) for 30 s (non-fatiguing) and to exhaustion (similar to 9 min; fatiguing) both under control conditions and with lumbar intrathecal fentanyl impairing feedback from mu-opioid receptor-sensitive lower limb muscle afferents. Voluntary activation (VA) of elbow flexors was assessed via transcranial magnetic stimulation (TMS) during maximum voluntary contraction (MVC) and corticospinal responsiveness was monitored via TMS-evoked potentials (MEPs) during a 25% MVC. Accompanied by a significant 5 +/- 1% reduction in VA from pre- to post-exercise, elbow flexor MVC progressively decreased during the fatiguing trial (P < 0.05). By contrast, with attenuated feedback from locomotor muscle afferents, MVC and VA remained unchanged during fatiguing exercise (P>0.3). MEPs decreased by 36 +/- 6% (P < 0.05) from the start of exercise to exhaustion under control conditions, but this reduction was prevented with fentanyl blockade. Furthermore, fentanyl blockade prevented the significant increase in elbow flexor MEP observed from rest to non-fatiguing exercise under control conditions and resulted in a 14% lower corticospinal responsiveness during this short bout (P < 0.05). Taken together, in the absence of locomotor muscle fatigue, group III/IV-mediated leg muscle afferents facilitate responsiveness of the motor pathway to upper limb flexor muscles. By contrast, in the presence of cycling-induced leg fatigue, group III/IV locomotor muscle afferents facilitate supraspinal fatigue in remote muscle not involved in the exercise and disfacilitate, or inhibit, the responsiveness of corticospinal projections to upper limb muscles.	[Sidhu, Simranjit K.; Venturelli, Massimo; Richardson, Russell S.; Amann, Markus] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; [Weavil, Joshua C.; Rossman, Matthew J.; Richardson, Russell S.; Amann, Markus] Univ Utah, Dept Exercise & Sport Sci, Salt Lake City, UT USA; [Garten, Ryan S.; Richardson, Russell S.; Amann, Markus] Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Salt Lake City, UT 84148 USA; [Gmelch, Benjamin S.; Morgan, David E.; Amann, Markus] Univ Utah, Dept Anaesthesiol, Salt Lake City, UT USA	Sidhu, SK (reprint author), VA Med Ctr, 500 Foothill Dr,GRECC 182, Salt Lake City, UT 84148 USA.	Simran.Sidhu@utah.edu	Venturelli, Massimo/F-3235-2014; Venturelli, Massimo/AAQ-4613-2020; Sidhu, Simranjit/A-5478-2012	Venturelli, Massimo/0000-0002-2469-8787; Venturelli, Massimo/0000-0002-2469-8787; Sidhu, Simranjit/0000-0002-4797-8298; Weavil, Joshua/0000-0002-2032-8498; Amann, Markus/0000-0002-4012-8880	National Heart, Lung and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL-103786, HL-116579]; Veterans Affairs Merit GrantUS Department of Veterans Affairs [E6910R]	This study was supported by the National Heart, Lung and Blood Institute (HL-103786 and HL-116579) and a Veterans Affairs Merit Grant (E6910R).	Amann M, 2014, INT J CARDIOL, V174, P368, DOI 10.1016/j.ijcard.2014.04.157; Amann M, 2013, J APPL PHYSIOL, V115, P355, DOI 10.1152/japplphysiol.00049.2013; Amann M, 2011, J PHYSIOL-LONDON, V589, P5299, DOI 10.1113/jphysiol.2011.213769; Amann M, 2009, J PHYSIOL-LONDON, V587, P271, DOI 10.1113/jphysiol.2008.163303; Balter JE, 2007, J NEUROPHYSIOL, V97, P1809, DOI 10.1152/jn.01038.2006; BIGLANDRITCHIE BR, 1986, J PHYSIOL-LONDON, V379, P451, DOI 10.1113/jphysiol.1986.sp016263; Birdsong WT, 2010, NEURON, V68, P739, DOI 10.1016/j.neuron.2010.09.029; Bruijnzeel AW, 2009, BRAIN RES REV, V62, P127, DOI 10.1016/j.brainresrev.2009.09.008; FUGLEVAND AJ, 1993, J NEUROPHYSIOL, V70, P2470; Gandevia SC, 1996, J PHYSIOL-LONDON, V490, P529, DOI 10.1113/jphysiol.1996.sp021164; Graven-Nielsen T, 2003, EUR J PAIN, V7, P93, DOI 10.1016/S1090-3801(02)00069-1; Hilty L, 2011, EXP PHYSIOL, V96, P505, DOI 10.1113/expphysiol.2010.056226; Jankowski MP, 2013, J NEUROPHYSIOL, V109, P2374, DOI 10.1152/jn.01067.2012; Kennedy DS, 2014, J APPL PHYSIOL, V116, P385, DOI 10.1152/japplphysiol.01166.2013; Kennedy DS, 2013, J PHYSIOL-LONDON, V591, P3591, DOI 10.1113/jphysiol.2012.248559; Lalley PM, 2008, RESP PHYSIOL NEUROBI, V164, P160, DOI 10.1016/j.resp.2008.02.004; Light AR, 2008, J NEUROPHYSIOL, V100, P1184, DOI 10.1152/jn.01344.2007; Martin PG, 2008, J PHYSIOL-LONDON, V586, P1277, DOI 10.1113/jphysiol.2007.140426; McNeil CJ, 2011, J PHYSIOL-LONDON, V589, P3533, DOI 10.1113/jphysiol.2011.207191; Millet GY, 2003, J APPL PHYSIOL, V94, P193, DOI 10.1152/japplphysiol.00600.2002; Racinais S, 2007, MED SCI SPORT EXER, V39, P268, DOI 10.1249/01.mss.0000251775.46460.cb; Rasmussen P, 2010, J PHYSIOL-LONDON, V588, P1985, DOI 10.1113/jphysiol.2009.186767; Schabrun SM, 2012, J PAIN, V13, P187, DOI 10.1016/j.jpain.2011.10.013; Sidhu SK, 2013, MED SCI SPORT EXER, V45, P654, DOI 10.1249/MSS.0b013e31827b119c; Sidhu SK, 2009, J APPL PHYSIOL, V106, P556, DOI 10.1152/japplphysiol.90911.2008; Todd G, 2004, MUSCLE NERVE, V29, P834, DOI 10.1002/mus.20027; Todd G, 2003, J PHYSIOL-LONDON, V551, P661, DOI 10.1113/jphysiol.2003.044099; Yoon T, 2012, J APPL PHYSIOL, V112, P849, DOI 10.1152/japplphysiol.00799.2011; Zehr EP, 2007, J PHYSIOL-LONDON, V582, P209, DOI 10.1113/jphysiol.2007.133843; Zehr EP, 2007, NEUROSCI LETT, V419, P10, DOI 10.1016/j.neulet.2007.03.045; Zehr EP, 2004, NEUROSCIENTIST, V10, P347, DOI 10.1177/1073858404264680	31	56	56	1	13	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3751	1469-7793		J PHYSIOL-LONDON	J. Physiol.-London	NOV 15	2014	592	22					5011	5024		10.1113/jphysiol.2014.275438			14	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	AU7IC	WOS:000345773100015	25172953	Green Published			2020-06-30	J	Nakama-Kitamura, M				Nakama-Kitamura, Mototaka			The distinctive significance of analgesic drugs and olfactory stimulants on learned pain in mice	BRAIN RESEARCH			English	Article						Conditioned nociceptive response; Learned pain; Analgesia; Odor olfactory stimulation; Mouse	ANTERIOR CINGULATE CORTEX; MECHANISM; ODOR; GABAPENTIN; PERCEPTION; EMOTION; ROLES	Chronic pain is often intractable to analgesics, and in animals it involves a conditioned nociceptive response (CR)-learned pain. The neural pathways of nociception and olfactory function in the brain overlap. The influence of olfactory stimuli on acute pain has been studied in some depth in animal and human models, but the influence of olfactory stimuli on learned pain has not been understood. We examined the effects of analgesic drugs and olfactory stimulants (preferred or repellent odor) on acute pain, the unconditioned nociceptive response (UCR) and the CR in mice. The CR was provoked by repeated injection of formalin into the hind-paw in animals in the same context, which elicited the typical pain behaviors of paw licking (including biting). The analgesic drugs acetaminophen, fentanyl, gabapentin and fluvoxamine diminished the UCR but did not affect the CR. In contrast, the preferred odor reduced both the UCR and the CR. Our findings suggest that, like chronic pain, the CR is resistant to analgesic drugs and that preferred odor suppress the neural pathways that mediate the CR of pain perception. (C) 2014 Elsevier B.V. All rights reserved.	Kwansei Gakuin Univ, Dept Integrated Psychol Sci, Nishinomiya, Hyogo 6628501, Japan	Nakama-Kitamura, M (reprint author), Kwansei Gakuin Univ, Dept Integrated Psychol Sci, Nishinomiya, Hyogo 6628501, Japan.	m-k@jttk.zaq.ne.jp					Ahn HS, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-32; Bartolo M, 2013, PAIN, V154, P2054, DOI 10.1016/j.pain.2013.06.032; Bonnefont J, 2003, DRUGS, V63, P1, DOI 10.2165/00003495-200363992-00002; Clarke H, 2013, CAN J ANESTH, V60, P432, DOI 10.1007/s12630-013-9890-1; Dewilde S, 2009, CURR MED RES OPIN, V25, P2007, DOI 10.1185/03007990903090849; Furudono Y, 2009, CHEM SENSES, V34, P151, DOI 10.1093/chemse/bjn071; Gabbott PLA, 2006, NEUROSCIENCE, V139, P1039, DOI 10.1016/j.neuroscience.2006.01.026; Gauriau Bernard, 2004, CURR MED RES OPIN, V25, P2007; Gregoire S, 2013, MOL PAIN, V9, DOI 10.1186/1744-8069-9-41; Gustavsson A, 2013, PAIN MED, V14, P1072, DOI 10.1111/pme.12095; Gustin SM, 2010, CEREB CORTEX, V20, P1409, DOI 10.1093/cercor/bhp205; Heimann D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068654; Ikeda H, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-14; Jahangeer AC, 1997, PHYSIOL BEHAV, V62, P359, DOI 10.1016/S0031-9384(97)00024-3; Kilic FS, 2012, INDIAN J MED RES, V135, P630; Kim SS, 2010, CURR GENOMICS, V11, P70, DOI 10.2174/138920210790217990; Kobayakawa K, 2007, NATURE, V450, P503, DOI 10.1038/nature06281; Kukkar A, 2013, ARCH PHARM RES, V36, P237, DOI 10.1007/s12272-013-0057-y; Low LA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034316; Martin GN, 2006, PSYCHOSOM MED, V68, P613, DOI 10.1097/01.psy.0000227753.35200.3e; Mico JA, 2006, TRENDS PHARMACOL SCI, V27, P348, DOI 10.1016/j.tips.2006.05.004; Miranda HF, 2012, INFLAMMATION, V35, P1132, DOI 10.1007/s10753-011-9420-7; Nakama-Kitamura M, 2011, BRAIN RES, V1406, P8, DOI 10.1016/j.brainres.2011.06.028; Nanji KC, 2013, SIMUL HEALTHC, V8, P143, DOI 10.1097/SIH.0b013e31827d27f9; Neugebauer V, 2009, BRAIN RES REV, V60, P226, DOI 10.1016/j.brainresrev.2008.12.014; Prescott J, 2007, PSYCHOL SCI, V18, P308, DOI 10.1111/j.1467-9280.2007.01894.x; Renner B, 2012, EXP BRAIN RES, V219, P13, DOI 10.1007/s00221-012-3063-2; Rosland J.H., 1990, BEHAV BRAIN RES, V5, P177; Sikandar S, 2013, PAIN, V154, P1263, DOI 10.1016/j.pain.2013.03.041; Snedecor SJ, 2013, J PAIN RES, V6, P539, DOI 10.2147/JPR.S45966; Stankewitz A, 2011, NEUROLOGY, V77, P476, DOI 10.1212/WNL.0b013e318227e4a8; Todd AJ, 2010, NAT REV NEUROSCI, V11, P823, DOI 10.1038/nrn2947; Villemure C, 2003, PAIN, V106, P101, DOI 10.1016/S0304-3959(03)00297-5; Villemure C, 2010, NEUROSCIENTIST, V16, P276, DOI 10.1177/1073858409359200; Vranken Jan H., 2009, Central Nervous System Agents in Medicinal Chemistry, V9, P71; Weiss J, 2011, NATURE, V472, P186, DOI 10.1038/nature09975; Zhuo M, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-14; Zhuo M, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0146; Zufall F, 2012, ARCH NEUROL-CHICAGO, V69, P1119, DOI 10.1001/archneurol.2012.21	39	1	1	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	NOV 7	2014	1588						104	112		10.1016/j.brainres.2014.09.026			9	Neurosciences	Neurosciences & Neurology	AU2SX	WOS:000345468900011	25242616	Bronze			2020-06-30	J	Gombert-Handoko, KB				Gombert-Handoko, K. B.			A Randomized, Placebo-controlled Study of a New Sublingual Formulation of Fentanyl Citrate (Fentanyl Ethypharm) for Breakthrough Pain in Opioid-treated Patients With Cancer	CLINICAL THERAPEUTICS			English	Letter							DOUBLE-BLIND; CROSSOVER		Onze Lieve Vrouw Hosp, Dept Pharm, Amsterdam, Netherlands	Gombert-Handoko, KB (reprint author), Onze Lieve Vrouw Hosp, Dept Pharm, Amsterdam, Netherlands.						Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Novotna S, 2014, CLIN THER, V36, P357, DOI 10.1016/j.clinthera.2014.01.006; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310	5	0	0	1	1	ELSEVIER	BRIDGEWATER	685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA	0149-2918	1879-114X		CLIN THER	Clin. Ther.	NOV	2014	36	11					1704	1704		10.1016/j.clinthera.2014.06.023			1	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AU9YX	WOS:000345948900021	25048312				2020-06-30	J	Saleh, AJ; Zhang, LB; Hadi, SM; Ouyang, W				Saleh, Amin J.; Zhang, Liangbin; Hadi, Sally M.; Ouyang, Wen			A priming dose of intravenous ketamine-dexmedetomidine suppresses fentanyl-induced coughing: A double-blind, randomized, controlled study	UPSALA JOURNAL OF MEDICAL SCIENCES			English	Article						Anesthesia; fentanyl-induced coughing; dexmedetomidine; ketamine	ANESTHESIA INDUCTION; LIDOCAINE; PROPOFOL; PREMEDICATION; INTUBATION	Objective. This study was designed to investigate whether a priming dose of ketamine-dexmedetomidine can effectively suppress fentanyl-induced coughing (FIC). Methods. Altogether 400 patients of ASA I and II, aged 18-70 years, undergoing various elective surgical procedures, were randomly allocated into four groups of 100 patients each. Patients in the placebo group received volume-matched normal saline 0.15 ml/kg + normal saline 0.05 mL/kg. One group of patients was given ketamine 0.15 mg/kg + normal saline 0.05 ml/ kg (KET), and another group dexmedetomidine 0.5 mu g/kg + normal saline 0.05 ml/kg (DEX). Finally, one group of patients received ketamine 0.15 mg/kg + dexmedetomidine 0.5 mu g/kg (KETODEX). After fentanyl administration, the onset time and severity of cough for 1 min were recorded. Cough severity was graded as mild (grade 1-2), moderate (grade 3-5), or severe (grade >5). Result. The incidence of FTC was 53%, 34%, 20%, and 9% in the placebo, DEX, KET, and KETODEX groups, respectively. The incidence of cough was significantly lower in the KETODEX group. Likewise, the onset time of cough was significantly delayed in the KETODEX group. Only nine patients in the KETODEX group had either mild (6%) or moderate (3%) cough, with none suffering from severe cough. Conclusion. A priming dose of KETODEX effectively suppressed the cough reflex induced by fentanyl and delayed the onset time of cough. Therefore, treatment with KETODEX may be a clinically useful method for preventing FIC.	[Saleh, Amin J.; Zhang, Liangbin; Hadi, Sally M.; Ouyang, Wen] Cent S Univ, Xiangya Hosp 3, Dept Anesthesiol, Changsha 410013, Hunan, Peoples R China	Ouyang, W (reprint author), Cent S Univ, Xiangya Hosp 3, Dept Anesthesiol, Changsha 410013, Hunan, Peoples R China.	ouyangwen133@vip.sina.com					Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; Ai Q, 2010, PHARMACOL REP, V62, P747, DOI 10.1016/S1734-1140(10)70333-9; Ambesh SP, 2009, INT J ANESTHESIOL, V20, P7; Bailey PL, 1999, ANESTHESIOLOGY, V90, P335, DOI 10.1097/00000542-199901000-00067; Bollucuoglu K, 2013, BRATISL MED J, V114, P514, DOI 10.4149/BLL_2013_107; BOVILL JG, 1984, ANESTHESIOLOGY, V61, P731; GRELL FL, 1970, ANESTH ANAL CURR RES, V49, P523; Guler G, 2010, CURR THER RES CLIN E, V71, P289, DOI 10.1016/j.curtheres.2010.10.004; He L, 2012, UPSALA J MED SCI, V117, P18, DOI 10.3109/03009734.2011.629749; Hirota K, 1996, BRIT J ANAESTH, V76, P266; Horng HC, 2007, ACTA ANAESTH SCAND, V51, P862, DOI 10.1111/j.1399-6576.2007.01335.x; Horng Huei-Chi, 2012, Acta Anaesthesiol Taiwan, V50, P147, DOI 10.1016/j.aat.2012.12.003; Hung KC, 2010, ANAESTHESIA, V65, P4, DOI 10.1111/j.1365-2044.2009.06109.x; Kamei Junzo, 2013, Cough, V9, P3, DOI 10.1186/1745-9974-9-3; Kim JE, 2014, J ANESTH, V28, P257, DOI 10.1007/s00540-013-1695-4; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; Lui PW, 1996, CAN J ANAESTH, V43, P1216; Mathewson HS, 1997, RESP CARE, V42, P292; Nehama J, 1996, PEDIATR EMERG CARE, V12, P294, DOI 10.1097/00006565-199608000-00015; Pabelick CM, 1997, ANESTHESIOLOGY, V86, P1104, DOI 10.1097/00000542-199705000-00014; Pandey CK, 2004, ANESTH ANALG, V99, P1696, DOI 10.1213/01.ANE.0000136967.82197.82; Patel Chirag Ramanlal, 2013, J Anaesthesiol Clin Pharmacol, V29, P318, DOI 10.4103/0970-9185.117066; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; Pipanmekaporn T, 2013, ANESTHESIOL RES PRAC, V2013, DOI 10.1155/2013/236089; SAID SI, 1995, NEUROSCIENCE, V65, P943, DOI 10.1016/0306-4522(95)00021-A; Sato T, 1998, ANESTH ANALG, V87, P1383, DOI 10.1097/00000539-199812000-00033; Shin HW, 2013, KOREAN J ANESTHESIOL, V65, P114, DOI 10.4097/kjae.2013.65.2.114; Sun ZT, 2011, J ANESTH, V25, P860, DOI 10.1007/s00540-011-1237-x; Tang QF, 2010, UPSALA J MED SCI, V115, P121, DOI 10.3109/03009730903291034; Tweed WA, 2001, ANESTH ANALG, V92, P1442; Wang SS, 2014, PEDIATR ANESTH, V24, P275, DOI 10.1111/pan.12284; YASUDA I, 1978, ANESTHESIOLOGY, V49, P117, DOI 10.1097/00000542-197808000-00012; Yeh CC, 2007, J CLIN ANESTH, V19, P53, DOI 10.1016/j.jclinane.2006.05.021; Yu J, 2012, IRISH J MED SCI, V181, P517, DOI 10.1007/s11845-012-0807-8; Zhu Min Min, 2007, J Inflamm (Lond), V4, P10, DOI 10.1186/1476-9255-4-10	36	6	6	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-9734	2000-1967		UPSALA J MED SCI	Ups. J. Med. Sci.	NOV	2014	119	4					333	337		10.3109/03009734.2014.968270			5	Medicine, General & Internal	General & Internal Medicine	AU6OQ	WOS:000345722500006	25367551	DOAJ Gold, Green Published			2020-06-30	J	Braga, ADD; Braga, FSD; Hirata, ES; Pereira, RIC; Frias, JA; Antunes, IF				de Assunao Braga, Angelica de Fatima; da Silva Braga, Franklin Sarmento; Hirata, Eunice Sizue; Costa Pereira, Rosa Ines; Frias, Jose Aristeu; Antunes, Isadora Fregonese			Association of lipophilic opioids and hyperbaric bupivacaine in spinal anesthesia for elective cesarean section. Randomized controlled study	ACTA CIRURGICA BRASILEIRA			English	Article						Anesthetics; Combined Subarachnoid Space; Analgesics, Opioid; Fentanyl, Sufentanil; Anesthetics, Local; Bupivacaine; Cesarean Section	PERIOPERATIVE ANALGESIA; INTRATHECAL MORPHINE; INDUCED PRURITUS; 10 MG; SUFENTANIL; FENTANYL; CLONIDINE; EFFICACY; DELIVERY; TRIALS	PURPOSE: To evaluate the efficacy and side-effects of fentanyl and sufentanil combined with hyperbaric spinal bupivacaine in elective cesarean section. METHODS: A prospective, randomized, double-blind study with 64 term parturients, distributed into 2 groups according to the opioid combined with hyperbaric bupivacaine 0.5% (10mg): GF - fentanyl (25 mu g) and GS - sufentanil (5.0 mu g). The latency and maximum sensory block level; degree and duration of motor block; duration and quality of analgesia; maternal-fetal repercussions were evaluated. This was an intention-to-treat analysis with a 5% significance level. RESULTS: The latency period, maximum sensory block level, motor block degree and perioperative analgesia were similar in both groups. Motor block and analgesia had a longer duration in the sufentanil group. Maternal adverse effects and neonatal repercussions were similar. The incidence of hypotension was higher in the fentanyl group. In both groups, there was a predominance of patients who were awake and either calm or sleepy. CONCLUSIONS: The addition of fentanyl and sufentanil to hyperbaric subarachnoid bupivacaine was shown to be effective for the performance of cesarean section, and safe for the mother and fetus. Analgesia was more prolonged with sufentanil.	[de Assunao Braga, Angelica de Fatima; da Silva Braga, Franklin Sarmento; Hirata, Eunice Sizue; Costa Pereira, Rosa Ines; Frias, Jose Aristeu; Antunes, Isadora Fregonese] Univ Estadual Campinas, Sch Med, Dept Anesthesiol, Campinas, SP, Brazil	Braga, FSD (reprint author), Rua Dr Jose Bonifacio Coutinho Nogueira, BR-13091611 Campinas, SP, Brazil.	franklinbraga@terra.com.br	COSTA PEREIRA, Rosa Ines/E-9871-2015	COSTA PEREIRA, Rosa Ines/0000-0001-8905-5662			ABOULEISH E, 1988, ANESTH ANALG, V67, P370; ABOULEISH E, 1988, BRIT J ANAESTH, V60, P592, DOI 10.1093/bja/60.5.592; Akkamahadevi P, 2012, INDIAN J ANAESTH, V56, P365, DOI 10.4103/0019-5049.100819; Arzola C, 2011, BRIT J ANAESTH, V107, P308, DOI 10.1093/bja/aer200; Bang YS, 2012, KOREAN J ANESTHESIOL, V63, P321, DOI 10.4097/kjae.2012.63.4.321; BELZARENA SD, 1992, ANESTH ANALG, V74, P653; Braga ADFD, 2003, EUR J ANAESTH, V20, P631; Braga AA, 2012, REV BRAS ANESTESIOL, V62, P775, DOI 10.1016/S0034-7094(12)70178-2; Braz José Reinaldo Cerqueira, 2003, Rev. Bras. Anestesiol., V53, P561, DOI 10.1590/S0034-70942003000500002; Chu C C, 1995, Acta Anaesthesiol Sin, V33, P149; COURTNEY MA, 1992, REGION ANESTH, V17, P274; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; Dahlgren G, 1997, ANESTH ANALG, V85, P1288, DOI 10.1097/00000539-199712000-00020; Braga ADD, 2013, ACTA CIR BRAS, V28, P26, DOI 10.1590/S0102-86502013000100005; Braga ADD, 2010, REV BRAS ANESTESIOL, V60, P121, DOI 10.1590/S0034-70942010000200003; Dyer Robert A, 2004, Curr Opin Anaesthesiol, V17, P301, DOI 10.1097/01.aco.0000137088.29861.64; FILOS KS, 1992, ANESTHESIOLOGY, V77, P267, DOI 10.1097/00000542-199208000-00008; Grass JA, 1997, ANESTH ANALG, V85, P365, DOI 10.1097/00000539-199708000-00022; Hamber EA, 1999, REGION ANESTH PAIN M, V24, P255; HUNT CO, 1989, ANESTHESIOLOGY, V71, P535, DOI 10.1097/00000542-198910000-00009; Idowu O A, 2011, Afr J Med Med Sci, V40, P213; Karaman S, 2006, EUR J ANAESTH, V23, P285, DOI 10.1017/S0265021505001869; Karaman S, 2011, AGRI, V23, P57, DOI 10.5505/agri.2011.44127; Kjellberg F, 2001, EUR J ANAESTH, V18, P346, DOI 10.1046/j.0265-0215.2000.00826.x; Lee JH, 2011, KOREAN J ANESTHESIOL, V60, P103, DOI 10.4097/kjae.2011.60.2.103; Nelson KE, 2002, ANESTHESIOLOGY, V96, P1070, DOI 10.1097/00000542-200205000-00007; SCOTT PV, 1982, POSTGRAD MED J, V58, P531, DOI 10.1136/pgmj.58.683.531; Sibilla C, 1997, INT J OBSTET ANESTH, V6, P43, DOI 10.1016/S0959-289X(97)80051-9; Szarvas S, 2003, J CLIN ANESTH, V15, P234, DOI 10.1016/S0952-8180(02)00501-9; Trivedi V, 2008, INDIAN J PAIN, V22, P157; Vyas Nitika, 2010, J Anaesthesiol Clin Pharmacol, V26, P488	31	2	2	3	10	ACTA CIRURGICA BRASILEIRA	SAO PAULO	ALAMEDA RIO CLARO, 179-41, SAO PAULO, SP 01332-010, BRAZIL	0102-8650	1678-2674		ACTA CIR BRAS	Acta Cir. Bras.	NOV	2014	29	11					752	758		10.1590/S0102-86502014001800010			7	Surgery	Surgery	AU2DO	WOS:000345426500010	25424297	DOAJ Gold, Green Published			2020-06-30	J	Kanbara, T; Nakamura, A; Takasu, K; Ogawa, K; Shibasaki, M; Mori, T; Suzuki, T; Hasegawa, M; Sakaguchi, G; Kanemasa, T				Kanbara, Tomoe; Nakamura, Atsushi; Takasu, Keiko; Ogawa, Koichi; Shibasaki, Masahiro; Mori, Tomohisa; Suzuki, Tsutomu; Hasegawa, Minoru; Sakaguchi, Gaku; Kanemasa, Toshiyuki			The Contribution of Gi/o Protein to Opioid Antinociception in an Oxaliplatin-Induced Neuropathy Rat Model	JOURNAL OF PHARMACOLOGICAL SCIENCES			English	Article						opioid; antinociception; oxaliplatin; neuropathy; Gi/o protein	PAINFUL PERIPHERAL NEUROPATHY; ADVANCED COLORECTAL-CANCER; DIFFERENTIAL ACTIVATION; RECEPTOR AGONISTS; SPINAL-CORD; MORPHINE; OXYCODONE; NEUROTOXICITY; CHEMOTHERAPY; MOUSE	Oxaliplatin is a chemotherapeutic agent that induces chronic refractory neuropathy. To determine whether opioids effectively relieve this chronic neuropathy, we investigated the efficacies of morphine, oxycodone, and fentanyl, and the mechanisms underlying opioid antinociception, in oxaliplatin-induced neuropathy in rats. Rats exhibited significant mechanical allodynia following 2 weeks of chronic oxaliplatin administration. Within the range of doses that did not induce sedation and/or muscle rigidity, morphine (3 mg/kg, subcutaneously, s.c.) and oxycodone (0.3 - 0.56 mg/kg, s.c.) completely reversed oxaliplatin-induced mechanical allodynia, whereas fentanyl (0.017 - 0.03 mg/kg, s.c.) showed partial antinociception. The antinociception of the optimal doses of morphine and oxycodone were completely inhibited by pertussis toxin (PTX; 0.5 mu g/rat, i.c.v.), a Gi/o protein inhibitor, while the partial effect of fentanyl was not affected in the oxaliplatin model. In the [S-35]-GTP gamma S binding assay, activation of mu-opioid receptor by fentanyl, but not by morphine or oxycodone, in the mediodorsal thalamus was significantly reduced in oxaliplatin-treated rats. These results indicate that the lower antinociceptive potency of fentanyl in the oxaliplatin model might in part result from the loss of PTX-sensitive Gi/o protein activation, and the degree of Gi/o protein activation might be related to the potency of antinociception by opioids in this model.	[Kanbara, Tomoe; Nakamura, Atsushi; Takasu, Keiko; Ogawa, Koichi; Hasegawa, Minoru; Sakaguchi, Gaku; Kanemasa, Toshiyuki] Shionogi & Co Ltd, Discovery Res Labs, Pain & Neurol, Toyonaka, Osaka 5610825, Japan; [Kanbara, Tomoe; Nakamura, Atsushi; Shibasaki, Masahiro; Mori, Tomohisa; Suzuki, Tsutomu] Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Toxicol, Shinagawa Ku, Tokyo 1428501, Japan	Kanemasa, T (reprint author), Shionogi & Co Ltd, Discovery Res Labs, Pain & Neurol, 1-1,3 Chome,Futaba Cho, Toyonaka, Osaka 5610825, Japan.	toshiyuki.kanemasa@shionogi.co.jp					Ali BH, 2010, BASIC CLIN PHARMACOL, V106, P272, DOI 10.1111/j.1742-7843.2009.00512.x; Argyriou AA, 2008, CANCER TREAT REV, V34, P368, DOI 10.1016/j.ctrv.2008.01.003; Argyriou AA, 2007, ACTA ONCOL, V46, P1131, DOI 10.1080/02841860701355055; Argyriou AA, 2013, CANCER-AM CANCER SOC, V119, P438, DOI 10.1002/cncr.27732; Cascinu S, 2002, J CLIN ONCOL, V20, P3478, DOI 10.1200/JCO.2002.07.061; Cavaletti G, 2001, EUR J CANCER, V37, P2457, DOI 10.1016/S0959-8049(01)00300-8; Ding Z, 2009, BRIT J PHARMACOL, V157, P831, DOI 10.1111/j.1476-5381.2009.00209.x; Extra JM, 1998, SEMIN ONCOL, V25, P13; Goode TL, 1997, LIFE SCI, V60, pPL107, DOI 10.1016/S0024-3205(96)00684-4; Hartmann JT, 2003, EXPERT OPIN PHARMACO, V4, P889, DOI 10.1517/eoph.4.6.889.22200; Kanbara T, 2014, NEUROSCI LETT, V580, P119, DOI 10.1016/j.neulet.2014.08.005; Krishnan AV, 2005, MUSCLE NERVE, V32, P51, DOI 10.1002/mus.20340; Ling B, 2007, PAIN, V128, P225, DOI 10.1016/j.pain.2006.09.016; Madia PA, 2012, PHARMACOL BIOCHEM BE, V101, P155, DOI 10.1016/j.pbb.2011.11.001; Meyer L, 2011, PAIN, V152, P170, DOI 10.1016/j.pain.2010.10.015; Minami K, 2009, J PHARMACOL SCI, V111, P60, DOI 10.1254/jphs.09139FP; Nagashima M, 2014, SUPPORT CARE CANCER, V22, P1579, DOI 10.1007/s00520-014-2132-4; Nakamura A, 2014, BRIT J PHARMACOL, V171, P253, DOI 10.1111/bph.12441; Nakamura A, 2013, BRIT J PHARMACOL, V168, P375, DOI 10.1111/j.1476-5381.2012.02139.x; Nakamura Atsushi, 2011, J Pain Palliat Care Pharmacother, V25, P318, DOI 10.3109/15360288.2011.620689; Narita M, 1999, BRIT J PHARMACOL, V126, P451, DOI 10.1038/sj.bjp.0702330; Narita M, 2001, J NEUROSCI, V21, P3715, DOI 10.1523/JNEUROSCI.21-11-03715.2001; Ozaki S, 2003, NEUROSCIENCE, V116, P89, DOI 10.1016/S0306-4522(02)00699-1; Pasetto LM, 2006, CRIT REV ONCOL HEMAT, V59, P159, DOI 10.1016/j.critrevonc.2006.01.001; Paxinos G, 2006, RAT BRAIN STEREOTAXI; Quasthoff S, 2002, J NEUROL, V249, P9, DOI 10.1007/PL00007853; Rajagopal S, 2011, MOL PHARMACOL, V80, P367, DOI 10.1124/mol.111.072801; Renn CL, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-29; Saidak Z, 2006, BRIT J PHARMACOL, V147, P671, DOI 10.1038/sj.bjp.0706661; Saif MW, 2010, ANTICANCER RES, V30, P2927; Sakurai M, 2009, PAIN, V147, P165, DOI 10.1016/j.pain.2009.09.003; Sanchez-Blazquez P, 1999, J PHARMACOL EXP THER, V291, P12; Sanchez-Blazquez P, 2001, BRAIN RES BULL, V54, P229, DOI 10.1016/S0361-9230(00)00448-2; Tseng LF, 1996, J PHARMACOL EXP THER, V279, P39; Xiao WH, 2012, NEUROSCIENCE, V203, P194, DOI 10.1016/j.neuroscience.2011.12.023; Zheng H, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.177089	36	8	8	0	1	JAPANESE PHARMACOLOGICAL SOC	KYOTO	EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604, JAPAN	1347-8613	1347-8648		J PHARMACOL SCI	J. Pharmacol. Sci.	NOV	2014	126	3					264	273		10.1254/jphs.14133FP			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AU4AQ	WOS:000345551900009	25346041	Bronze			2020-06-30	J	Manchikanti, L; Benyamin, RM; Candido, KD; Hirsch, JA				Manchikanti, Laxmaiah; Benyamin, Ramsin M.; Candido, Kenneth D.; Hirsch, Joshua A.			Cohen et al. Reach Inappropriate Conclusions on the Effect of Sedation on the Accuracy and Treatment Outcomes for Diagnostic Injections	PAIN MEDICINE			English	Letter							2-YEAR FOLLOW-UP; LOW-BACK-PAIN; RADIOFREQUENCY DENERVATION; EPIDURAL INJECTIONS; COST-EFFECTIVENESS; CONTROLLED-TRIAL; DOUBLE-BLIND		[Manchikanti, Laxmaiah] Univ Louisville, Dept Anesthesiol & Perioperat Med, Louisville, KY 40292 USA; [Manchikanti, Laxmaiah] Pain Management Ctr, Paducah, KY USA; [Benyamin, Ramsin M.] Millennium Pain Ctr, Bloomington, IL USA; [Benyamin, Ramsin M.] Univ Illinois, Coll Med, Dept Surg, Urbana, IL 61801 USA; [Candido, Kenneth D.] Advocate Illinois Mason Med Ctr, Dept Anesthesiol, Chicago, IL USA; [Hirsch, Joshua A.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Hirsch, Joshua A.] Harvard Univ, Sch Med, Boston, MA USA	Manchikanti, L (reprint author), Univ Louisville, Dept Anesthesiol & Perioperat Med, Louisville, KY 40292 USA.						Cohen SP, 2014, PAIN MED, V15, P588, DOI 10.1111/pme.12389; Cohen SP, 2013, NAT REV RHEUMATOL, V9, P101, DOI 10.1038/nrrheum.2012.198; Cohen SP, 2010, ANESTHESIOLOGY, V113, P395, DOI 10.1097/ALN.0b013e3181e33ae5; DePalma MJ, 2011, PAIN MED, V12, P224, DOI 10.1111/j.1526-4637.2010.01045.x; HINGORANI K, 1966, Annals of Physical Medicine, V8, P303; Howick J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062599; Louhiala P, 2008, Med Humanit, V34, P107, DOI 10.1136/jmh.2008.000307; Manchikanti Laxmaiah, 2004, Pain Physician, V7, P301; Manchikanti Laxmaiah, 2004, Pain Physician, V7, P411; Manchikanti Laxmaiah, 2006, Pain Physician, V9, P47; Manchikanti Laxmaiah, 2005, Pain Physician, V8, P349; Manchikanti L, 2014, INT J MED SCI, V11, P309, DOI 10.7150/ijms.8069; Manchikanti L, 2013, PAIN PHYSICIAN, V16, pE491; Manchikanti Laxmaiah, 2013, Pain Physician, V16, pS49; Manchikanti L, 2013, PAIN PHYSICIAN, V16, pE1; Manchikanti Laxmaiah, 2012, J Pain Res, V5, P381, DOI 10.2147/JPR.S35924; Novak S, 2008, SPINE J, V8, P412, DOI 10.1016/j.spinee.2007.11.002; Smith HS, 2009, PAIN PHYSICIAN, V12, P195	18	2	2	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	NOV	2014	15	11					1978	1980		10.1111/pme.12561			3	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	AU4EI	WOS:000345561700019	25288045	Bronze			2020-06-30	J	Cohen, SP; Hameed, H; Pasquina, PF; Hurley, RW				Cohen, Steven P.; Hameed, Haroon; Pasquina, Paul F.; Hurley, Robert W.			Sedation for Diagnostic Injections: Prioritizing Patient Interests	PAIN MEDICINE			English	Letter							CLINICAL-TRIALS; PAIN		[Cohen, Steven P.] Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; [Cohen, Steven P.] Johns Hopkins Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; [Cohen, Steven P.; Pasquina, Paul F.] Uniformed Serv Univ Hlth Sci, Dept Phys Med & Rehabil, Bethesda, MD 20814 USA; [Cohen, Steven P.] Uniformed Serv Univ Hlth Sci, Dept Anesthesiol, Bethesda, MD 20814 USA; [Hameed, Haroon] KURE Pain Management, Annapolis, MD USA; [Hurley, Robert W.] Med Coll Wisconsin, Dept Anesthesiol, Milwaukee, WI 53226 USA	Cohen, SP (reprint author), Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA.		MD/PhD, Robert W. Hurley/V-6619-2019	Hurley, Robert/0000-0001-6591-9390			Chou R, 2010, DRUGS, V70, P387, DOI 10.2165/11318690-000000000-00000; Cohen SP, 2004, ANESTHESIOLOGY, V101, P495, DOI 10.1097/00000542-200408000-00032; Cohen SP, 2014, PAIN MED, V15, P588, DOI 10.1111/pme.12389; HINGORANI K, 1966, Annals of Physical Medicine, V8, P303; Hsieh FY, 2003, EVAL HEALTH PROF, V26, P239, DOI 10.1177/0163278703255230; Koshi Edvin B, 2007, Pain Pract, V7, P4, DOI 10.1111/j.1533-2500.2007.00104.x; Manchikanti Laxmaiah, 2006, Pain Physician, V9, P47; Moll W, 1973, Med Welt, V24, P1747; Morton DL, 2009, PAIN, V146, P194, DOI 10.1016/j.pain.2009.07.026; Rudolph U, 2011, NAT REV DRUG DISCOV, V10, P685, DOI 10.1038/nrd3502; Schweizer E, 1997, J CLIN PSYCHIAT, V58, P30; Umscheid CA, 2011, POSTGRAD MED, V123, P194, DOI 10.3810/pgm.2011.09.2475; Wikipedia, COMP EFF RES	13	0	0	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1526-2375	1526-4637		PAIN MED	Pain Med.	NOV	2014	15	11					1980	1981		10.1111/pme.12559			2	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	AU4EI	WOS:000345561700020	25287941	Bronze			2020-06-30	J	Cohen, S; Glatstein, MM; Scolnik, D; Rom, L; Yaron, A; Otremski, S; Ben-Tov, A; Reif, S				Cohen, Shlomi; Glatstein, Miguel M.; Scolnik, Dennis; Rom, Liat; Yaron, Ayala; Otremski, Sorina; Ben-Tov, Amir; Reif, Shimon			Propofol for Pediatric Colonoscopy: The Experience of a Large, Tertiary Care Pediatric Hospital	AMERICAN JOURNAL OF THERAPEUTICS			English	Article						propofol; colonoscopy; pediatrics; ileal intubation	SEDATION; ILEOSCOPY; MIDAZOLAM; CHILDREN; TRIAL	Successful colonoscopy includes full visualization of the terminal ileum, especially in inflammatory bowel disease when ileal biopsy is essential. In children, higher levels of anxiety and lack of cooperation often necessitate a deeper level of sedation. The aim of this study was to evaluate the effectiveness of propofol compared with midazolam and fentanyl for colonoscopy, and in accomplishing ileal and cecal intubation in particular. This was a retrospective cohort study comparing the rates of successful colonoscopy in patients receiving propofol with those receiving midazolam/fentanyl. Complete, successful, colonoscopy to the terminal ileum was achieved in 78% of propofol patients compared with 66% of the midazolam/ fentanyl group (P = 0.004). Endoscopy reaching the cecum, but not the terminal ileum, was achieved in 78% of propofol patients and 66% of midazolam/ fentanyl patients. The use of propofol was associated with a statistically significant increase in the rate of successful colonoscopy reaching the terminal ileum.	[Cohen, Shlomi; Rom, Liat; Yaron, Ayala; Ben-Tov, Amir; Reif, Shimon] Tel Aviv Univ, Sackler Sch Med, Dana Dwek Children Hosp, Div Pediat,Gastroenterol Unit, IL-64239 Tel Aviv, Israel; [Glatstein, Miguel M.] Tel Aviv Univ, Sackler Sch Med, Dana Dwek Children Hosp, Div Pediat Emergency Med,Dept Pediat, IL-64239 Tel Aviv, Israel; [Glatstein, Miguel M.] Tel Aviv Univ, Sackler Sch Med, Dana Dwek Children Hosp, Div Clin Pharmacol & Toxicol, IL-64239 Tel Aviv, Israel; [Scolnik, Dennis] Univ Toronto, Hosp Sick Children, Dept Pediat, Div Pediat Emergency Med, Toronto, ON M5G 1X8, Canada; [Scolnik, Dennis] Univ Toronto, Hosp Sick Children, Div Clin Pharmacol & Toxicol, Toronto, ON M5G 1X8, Canada; [Otremski, Sorina] Tel Aviv Univ, Sackler Sch Med, Tel Aviv Sourasky Med Ctr, Dept Anesthesiol, IL-64239 Tel Aviv, Israel	Glatstein, MM (reprint author), Tel Aviv Univ, Sackler Sch Med, Dana Dwek Children Hosp, Div Pediat Emergency Med, 6 Weizmann St, IL-64239 Tel Aviv, Israel.	Nopasara73@hotmail.com					Agudelo SC, 2012, MED INTENSIVA, V36, P410, DOI 10.1016/j.medin.2011.11.018; Bright E, 2003, ENDOSCOPY, V35, P683; Geboes K, 1998, AM J GASTROENTEROL, V93, P201, DOI 10.1111/j.1572-0241.1998.00201.x; Havel CJ, 1999, ACAD EMERG MED, V6, P989, DOI 10.1111/j.1553-2712.1999.tb01180.x; ISRAEL DM, 1994, J PEDIATR GASTR NUTR, V19, P283, DOI 10.1097/00005176-199410000-00004; Khutia SK, 2012, INDIAN J ANAESTH, V56, P145, DOI 10.4103/0019-5049.96313; Lightdale JR, 2007, J PEDIATR GASTR NUTR, V45, P500, DOI 10.1097/MPG.0b013e3180691168; Mahoney Lisa B, 2007, Curr Treat Options Gastroenterol, V10, P412, DOI 10.1007/s11938-007-0041-z; Rigby-Jones AE, 2011, PEDIATR ANESTH, V21, P247, DOI 10.1111/j.1460-9592.2010.03454.x; Short CE, 1999, VET CLIN N AM-SMALL, V29, P747, DOI 10.1016/S0195-5616(99)50059-4; Singh H, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006268.pub2; VanNatta ME, 2006, AM J GASTROENTEROL, V101, P2209, DOI 10.1111/j.1572-0241.2006.00760.x	12	5	6	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1075-2765	1536-3686		AM J THER	Am. J. Ther.	NOV-DEC	2014	21	6					509	511		10.1097/MJT.0b013e31826a94e9			3	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AT5XG	WOS:000345012600026	23567786				2020-06-30	J	Molina-Martinez, LM; Gonzalez-Espinosa, C; Cruz, SL				Molina-Martinez, Luz M.; Gonzalez-Espinosa, Claudia; Cruz, Silvia L.			Dissociation of immunosuppressive and nociceptive effects of fentanyl, but not morphine, after repeated administration in mice: Fentanyl-induced sensitization to LPS	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Neurodepression; Innate immunity; Nociception; Analgesia; Opiate tolerance; LPS sensitization; TNF alpha release; Mast cells	MU-OPIOID RECEPTOR; IMMUNE FUNCTION; TOLERANCE; MODULATION; TNF; BUPRENORPHINE; ACTIVATION; MECHANISMS; INFECTION; SYSTEM	Immunosuppressive morphine actions are well characterized, but other opiates are less studied. The objectives of this work were: (a) to compare the acute effects of morphine and fentanyl to inhibit early peritoneal LPS-induced TNF alpha release; (b) to find if, as in the case of morphine, intraperitoneal mast cells (MCs) are the target of fentanyl's immunosuppressive actions; and (c) to analyze if repeated opiate administration induces tolerance to opiate immunosuppressive effects. Independent groups of mice received a single i.p. injection of morphine (0.1-10 mg/kg) or fentanyl (0.001-0.1 mg/kg) 10 min prior to LPS (1 mg/kg). Peritoneal TNF alpha levels were determined 1 h later. The effects of fentanyl were analyzed in MC-deficient mice (W-sh) and in W-sh mice reconstituted with bone marrow-derived MCs. Other animals received 6 or 10 doses of morphine (10 mg/kg, 3 x /day) or fentanyl (0.1 mg/kg 3 x /day) and were then challenged with LPS. Fentanyl was equally effective and 1000x more potent than morphine to inhibit i.p. LPS-induced TNF alpha release and this was dependent on intraperitoneal MCs. Repeated morphine administration induced tolerance to both antinociception and inhibition of response to endotoxin. Repeated fentanyl injection did not induce significant antinociceptive tolerance, but, interestingly, produced sensitization to LPS. In conclusion: (1) opiates with different analgesic potency also differ in their potency to induce immunosuppression; (2) MCs are the cellular target of the immunosuppressive actions of fentanyl here studied; (3) in contrast with morphine, tolerance to fentanyl's immunosuppressive actions can be dissociated from tolerance to its antinociceptive effects. (C) 2014 Elsevier Inc. All rights reserved.	[Molina-Martinez, Luz M.; Gonzalez-Espinosa, Claudia; Cruz, Silvia L.] CINVESTAV, Dept Farmacobiol, Mexico City 14330, DF, Mexico	Cruz, SL (reprint author), CINVESTAV, Dept Farmacobiol, Mexico City 14330, DF, Mexico.	slcruzm@cinvestav.mx	; Gonzalez-Espinosa, Claudia/C-4417-2019	Cruz, Silvia/0000-0002-8617-3556; Molina-Martinez, Luz M./0000-0002-5064-9647; Gonzalez-Espinosa, Claudia/0000-0001-7332-3829	ConacytConsejo Nacional de Ciencia y Tecnologia (CONACyT) [188565, 219851]	This work is derived from Luz Maria Molina-Martinez's doctoral dissertation and was supported by grant 188565 (CGE) and fellowship 219851 (LMMM) from Conacyt.	Bastami S, 2013, ACTA ONCOL, V52, P1022, DOI 10.3109/0284186X.2012.737932; Bilfinger TV, 1998, INT J CARDIOL, V64, pS61, DOI 10.1016/S0167-5273(98)00037-0; Eisenstein TK, 2006, J NEUROIMMUNE PHARM, V1, P237, DOI 10.1007/s11481-006-9019-1; Fukagawa H, 2013, J ANESTH, V27, P93, DOI 10.1007/s00540-012-1469-4; Hutchinson MR, 2011, PHARMACOL REV, V63, P772, DOI 10.1124/pr.110.004135; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Madera-Salcedo IK, 2013, J IMMUNOL, V191, P3400, DOI 10.4049/jimmunol.1202658; Madera-Salcedo IK, 2011, J NEUROIMMUNOL, V232, P101, DOI 10.1016/j.jneuroim.2010.10.017; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Martucci C, 2004, PAIN, V110, P385, DOI 10.1016/j.pain.2004.04.020; Michel A, 2013, J IMMUNOL, V190, P5534, DOI 10.4049/jimmunol.1203355; Ninkovic J, 2013, AMINO ACIDS, V45, P9, DOI 10.1007/s00726-011-1163-0; Pradhan AA, 2012, BRIT J PHARMACOL, V167, P960, DOI 10.1111/j.1476-5381.2012.02075.x; Raehal KM, 2011, NEUROPHARMACOLOGY, V60, P58, DOI 10.1016/j.neuropharm.2010.08.003; Roy S, 2006, J NEUROIMMUNE PHARM, V1, P77, DOI 10.1007/s11481-005-9009-8; Roy S, 2011, J NEUROIMMUNE PHARM, V6, P442, DOI 10.1007/s11481-011-9292-5; Sacerdote P, 2006, PALLIATIVE MED, V20, pS9, DOI 10.1191/0269216306pm1124oa; Stevens CW, 2013, BRIT J PHARMACOL, V168, P1421, DOI 10.1111/bph.12028; STEVENS CW, 1989, J PHARMACOL EXP THER, V251, P216; Vallejo R, 2011, PAIN PHYSICIAN, V14, pE343; Waldhoer M, 2004, ANNU REV BIOCHEM, V73, P953, DOI 10.1146/annurev.biochem.73.011303.073940; Walker EA, 2001, PSYCHOPHARMACOLOGY, V154, P131, DOI 10.1007/s002130000620; Wang J, 2008, ARCH IMMUNOL THER EX, V56, P299, DOI 10.1007/s00005-008-0035-0; Wang XH, 2012, P NATL ACAD SCI USA, V109, P6325, DOI 10.1073/pnas.1200130109; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Zuo ZY, 2005, ANESTH ANALG, V101, P728, DOI 10.1213/01.ANE.0000160588.32007.AD	26	10	10	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	NOV	2014	42						60	64		10.1016/j.bbi.2014.06.011			5	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	AS7IK	WOS:000344429900009	24975593				2020-06-30	J	Plasencia, AMA; Mowry, J; Smith, J; Quigley, K				Plasencia, A. M. Arroyo; Mowry, J.; Smith, J.; Quigley, K.			In vitro release of fentanyl from transdermal patches in gastric and intestinal fluid	CLINICAL TOXICOLOGY			English	Article						Simulated; Release; Pharmacokinetics; Fentanyl; Transdermal; Patch		Context. Fentanyl patches are intended for transdermal use to treat pain. However, these patches have been abused by ingestion, offering a unique mode of drug delivery with unknown drug release characteristics. Objectives. In vitro fentanyl release from patches in simulated gastric and intestinal fluid was evaluated. Materials and methods. Ten 75 mcg/hr fentanyl transdermal patches (Mylan Pharmaceuticals Inc., Morgantown, WV), simulated gastric fluid without enzymes, and USP simulated intestinal fluid (Ricca Chemical Company, Arlington, TX) were obtained. Each fentanyl patch was placed into either 100 mL of simulated gastric fluid or 100 mL of simulated intestinal fluid. Flasks were agitated at 24 rpm while incubated at 36.8 degrees C. Fluid was sampled at time zero and 5, 15, 30, 60, 120, and 180 min after submersion. Fentanyl was assayed using ultra performance liquid chromatography coupled with tandem mass spectrometry (AIT Laboratories, Indianapolis, IN). Results. An average of 239 mcg and 1,962 mcg of fentanyl was released into gastric fluid and 338 mcg and 3,139 mcg into intestinal fluid in 5 min and 3 h, respectively. An average of 26% and 41% of 7.65 mg of fentanyl contained within the 75 mcg/hr patch was released into gastric and intestinal fluid in 3 h, respectively (p = 0.169, Student's t-test). Discussion. Our results demonstrate fentanyl release within 5 min of submersion. Conclusion. These results help support the potential rapid onset of clinical compromise reported and are relevant to the design of future pharmacokinetic studies of fentanyl release from transdermal patches.	[Plasencia, A. M. Arroyo] Washington Univ, Dept Med, Sch Med, St Louis, MO 63110 USA; [Mowry, J.; Smith, J.] Indiana Univ Hlth, Indiana Poison Ctr, Indianapolis, IN USA; [Quigley, K.] AIT Labs, Indianapolis, IN USA	Plasencia, AMA (reprint author), Washington Univ, Sch Med, Dept Internal Med, 660 South Euclid Ave,Campus Box 8058, St Louis, MO 63110 USA.	aarroyo@dom.wustl.edu		Arroyo Plasencia, Anna/0000-0002-0943-998X			*AM ASS POIS CONTR, NAT POIS DAT SYST TA; Chapman E, 2012, CHEST, V141, P1321, DOI 10.1378/chest.11-1462; Firestone M, 2009, INT J DRUG POLICY, V20, P90, DOI 10.1016/j.drugpo.2008.02.016; Mowry JB, 2013, CLIN TOXICOL, V51, P949, DOI 10.3109/15563650.2013.863906; Mrvos R, 2012, J EMERG MED, V42, P549, DOI 10.1016/j.jemermed.2011.05.017; *MYL PHARM INC, 2012, PROD INF FENT TRANSD; Prosser JM, 2010, J MED TOXICOL, V6, P443, DOI 10.1007/s13181-010-0092-8; Reid BO, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-45; ROY SD, 1989, PHARMACEUT RES, V6, P147, DOI 10.1023/A:1015932610010; *WATS PHARM INC, 2012, PROD INF FENT TRANSD	10	4	4	1	6	INFORMA HEALTHCARE	NEW YORK	52 VANDERBILT AVE, NEW YORK, NY 10017 USA	1556-3650	1556-9519		CLIN TOXICOL	Clin. Toxicol.	NOV	2014	52	9					945	947		10.3109/15563650.2014.967399			3	Toxicology	Toxicology	AS6FH	WOS:000344359400004	25345435				2020-06-30	J	Lee, YW; Kim, YJ; Kim, JM; Bae, JH; Choi, CY				Lee, Yong Woo; Kim, Yang Jae; Kim, Joon Mo; Bae, Jeong Hun; Choi, Chul Young			Efficacy and Safety of Transdermal Fentanyl in the Control of Postoperative Pain After Photorefractive Keratectomy	JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS			English	Article							PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; CLINICAL PAIN; MANAGEMENT; ANALGESIA; MULTICENTER; DICLOFENAC; INTENSITY; MODERATE; SURGERY	Purpose: To evaluate the efficacy and safety of transdermal fentanyl (TDF) in the control of postoperative pain following photorefractive keratectomy (PRK). Methods: One hundred ninety-nine consecutive PRK cases (398 eyes) were retrospectively reviewed. For postoperative pain control, 96 patients (63 females) were treated with tramadol 37.5 mg/acetaminophen 325 mg combination tablets (2 tablets bid), 103 patients (73 females) were treated with TDF (12 mu g/h). Postoperative pain intensity using the visual analog scale (VAS) during postoperative 3 days including the evening of the day of the operation and peak pain intensity, rated using the verbal descriptor scale (VDS) at postoperative 4 days, were compared between 2 groups. Overall adverse events in the 2 treatment groups were also compared. Results: The differences in mean pain intensity scores were significant between the control group and the fentanyl group (P=0.001, Repeated-measures analysis of variance). The proportion of severe pain (VAS>54 mm) was significantly lower in the fentanyl group than the control group by morning of postoperative 2 days (P<0.007). The proportion of patients who rated their peak pain intensity as "intolerable pain" was significantly higher (P=0.001) in the control group (30/96, 31.3%) than the fentanyl group (13/103, 12.6%). Total number of patients who reported adverse events was significantly higher in the fentanyl group (P=0.013) than the control group. However, there were no irreversible or severe adverse events in both treatment groups and nausea was the most common (14/103, 13.6%) complaint reported in the fentanyl group. Conclusion: TDF was more effective in the control of postoperative pain after PRK than tramadol/acetaminophen and no irreversible or severe adverse effect was reported with 12 mu g/h concentration. TDF could be considered as alternative regimen of analgesic method after PRK.	[Lee, Yong Woo; Kim, Yang Jae; Kim, Joon Mo; Bae, Jeong Hun; Choi, Chul Young] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Med Ctr, Dept Ophthalmol, Seoul 110746, South Korea	Choi, CY (reprint author), Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Med Ctr, Dept Ophthalmol, Seoul 110746, South Korea.	sashimi0@naver.com					Boom M, 2013, ANESTHESIOLOGY, V119, P663, DOI 10.1097/ALN.0b013e31829ce4cb; Boyd S., 2007, REFRACTIVE SURG NIGH, P55; BULOW HH, 1995, ACTA ANAESTH SCAND, V39, P835; CAPLAN RA, 1989, JAMA-J AM MED ASSOC, V261, P1036, DOI 10.1001/jama.261.7.1036; Caporossi A., 2007, REFRACTIVE SURFACE A, P229; CARLSSON AM, 1983, PAIN, V16, P87, DOI 10.1016/0304-3959(83)90088-X; Chang JTC, 2010, JPN J CLIN ONCOL, V40, P307, DOI 10.1093/jjco/hyp166; CHAPMAN CR, 1985, PAIN, V22, P1, DOI 10.1016/0304-3959(85)90145-9; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Collins SL, 1997, PAIN, V72, P95, DOI 10.1016/S0304-3959(97)00005-5; Correll D., 2007, PAIN MANAGEMENT, P197; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; DUTHIE DJR, 1988, BRIT J ANAESTH, V60, P614, DOI 10.1093/bja/60.6.614; EIFERMAN RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P1022, DOI 10.1001/archopht.1993.01090080016002; Hersh PS, 1998, OPHTHALMOLOGY, V105, P1512, DOI 10.1016/S0161-6420(98)98038-1; Hoy SM, 2008, DRUGS, V68, P1711, DOI 10.2165/00003495-200868120-00008; Ishihara M, 2010, SUPPORT CARE CANCER, V18, P1531, DOI 10.1007/s00520-009-0775-3; Jachiet M, 2013, DERMATOLOGY, V226, P347, DOI 10.1159/000350939; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; JOYCE CRB, 1975, EUR J CLIN PHARMACOL, V8, P415, DOI 10.1007/BF00562315; Kim SJ, 2010, SURV OPHTHALMOL, V55, P108, DOI 10.1016/j.survophthal.2009.07.005; Koyyalagunta K., 2007, PAIN MANAGEMENT, V2, P939, DOI [DOI 10.1016/B978-0-7216-0334-6.50117-5, 10.1016/B978-0-7216-0334-6.50117-5]; Melki SA, 2001, SURV OPHTHALMOL, V46, P95, DOI 10.1016/S0039-6257(01)00254-5; Myotoku M, 2010, J PALLIAT MED, V13, P401, DOI 10.1089/jpm.2009.0355; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; O'Doherty M, 2007, J REFRACT SURG, V23, P133; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; PLEZIA PM, 1989, PHARMACOTHERAPY, V9, P2; PRICE DD, 1986, PAIN, V24, P197, DOI 10.1016/0304-3959(86)90042-4; Rajan MS, 2004, OPHTHALMOLOGY, V111, P1813, DOI 10.1016/j.ophtha.2004.05.019; Sachs CJ, 2005, AM FAM PHYSICIAN, V71, P913; SANDLER AN, 1994, ANESTHESIOLOGY, V81, P1169, DOI 10.1097/00000542-199411000-00010; SEVARINO FB, 1992, ANESTHESIOLOGY, V77, P463, DOI 10.1097/00000542-199209000-00010; Siafaka I, 2004, Pain Pract, V4, P98, DOI 10.1111/j.1533-2500.2004.04206.x; VANBASTELAERE M, 1995, J CLIN ANESTH, V7, P26, DOI 10.1016/0952-8180(94)00000-T; Waldman SD., 2007, PAIN MANAGEMENT, P225; Weinstock VM, 1996, J REFRACT SURG, V12, P792; Woreta FA, 2013, SURV OPHTHALMOL, V58, P529, DOI 10.1016/j.survophthal.2012.11.004	38	3	3	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1080-7683	1557-7732		J OCUL PHARMACOL TH	J. Ocular Pharmacol. Ther.	NOV 1	2014	30	9					783	789		10.1089/jop.2013.0125			7	Ophthalmology; Pharmacology & Pharmacy	Ophthalmology; Pharmacology & Pharmacy	AS6PZ	WOS:000344386300012	25029377				2020-06-30	J	Juebner, M; Fietzke, M; Beike, J; Rothschild, MA; Bender, K				Juebner, Martin; Fietzke, Mathias; Beike, Justus; Rothschild, Markus A.; Bender, Katja			Assisted suicide by fentanyl intoxication due to excessive transdermal application	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						Assisted suicide; Fentanyl; Organ distribution; Transdermal therapeutic system	POSTMORTEM REDISTRIBUTION; RESIDUAL FENTANYL; METABOLISM; PHARMACOKINETICS; DURAGESIC(R); NORFENTANYL; PATCHES; MATRIX; URINE; BLOOD	Herein, we report a case of an assisted suicide committed by application of 34 matrix-based fentanyl-containing transdermal therapeutic systems (TTS) with different release rates. The TTS were supplied by the husband but administered by the deceased herself. Besides routine systematic toxicological analysis (STA), the concentrations of fentanyl and norfentanyl were determined in the blood (femoral and heart), urine, stomach content, brain, lung tissue, musculus iliopsoas, liver, kidney, bile and in some of the used TTS by LC-MS/MS. Blood levels of fentanyl were 60.6 mu g/L in femoral blood and 94.1 mu g/L in heart blood. These concentrations are in good concordance with levels described in cases with accidental or lethal suicidal fentanyl patch application. The organ distribution indicates an influence of post-mortem redistribution. The levels of residual fentanyl in the TTS were also determined. STA furthermore revealed supratherapeutic levels of bromazepam. Thus, the cause of death was a combination of fentanyl and bromazepam intoxication. However, considering the determined levels of fentanyl and norfentanyl in the entire set of specimens and the high toxicity in comparison to bromazepam, fentanyl was the leading toxic noxa.	[Juebner, Martin; Fietzke, Mathias; Beike, Justus; Rothschild, Markus A.; Bender, Katja] Univ Hosp Cologne, Inst Legal Med, D-50823 Cologne, Germany	Juebner, M (reprint author), Univ Hosp Cologne, Inst Legal Med, Melatengurtel 60-62, D-50823 Cologne, Germany.	martin.juebner@uk-koeln.de		Mercer-Chalmers-Bender, Katja/0000-0002-3843-9065			Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Andresen H, 2012, J ANAL TOXICOL, V36, P182, DOI 10.1093/jat/bks005; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Dumas EO, 2008, AAPS J, V10, P537, DOI 10.1208/s12248-008-9056-1; DVORCHIK BH, 1976, CLIN CHEM, V22, P868; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; Feierman DE, 1996, ANESTH ANALG, V82, P936, DOI 10.1097/00000539-199605000-00008; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Jumbelic MI, 2010, AM J FOREN MED PATH, V31, P18, DOI 10.1097/PAF.0b013e31818738b8; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Lo Vecchio F., 2011, AM J EMERG MED, V29; Luckenbill K, 2008, J ANAL TOXICOL, V32, P639, DOI 10.1093/jat/32.8.639; Michaud K, 2001, FORENSIC SCI INT, V124, P112, DOI 10.1016/S0379-0738(01)00584-9; Moriya F, 1999, J FORENSIC SCI, V44, P10; Naito T, 2012, CHEM PHARM BULL, V60, P56, DOI 10.1248/cpb.60.56; Oda M, 2003, EUR J CLIN PHARMACOL, V59, P615, DOI 10.1007/s00228-003-0681-4; Olson KN, 2010, AM J CLIN PATHOL, V133, P447, DOI 10.1309/AJCP4X5VHFSOERFT; Palmer RB, 2010, CLIN TOXICOL, V48, P771, DOI 10.3109/15563650.2010.525514; Peer CJ, 2007, J ANAL TOXICOL, V31, P515, DOI 10.1093/jat/31.8.515; Pohland RC, 1997, J FORENSIC SCI, V42, P812; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; POUNDER DJ, 1994, AM J FOREN MED PATH, V15, P231, DOI 10.1097/00000433-199409000-00010; Prodduturi S, 2010, J PHARM SCI-US, V99, P2357, DOI 10.1002/jps.22004; Rendic S, 2002, DRUG METAB REV, V34, P83, DOI 10.1081/DMR-120001392; Schulz M, 2012, CRIT CARE, V16, DOI 10.1186/cc11441; STOECKEL H, 1979, BRIT J ANAESTH, V51, P741, DOI 10.1093/bja/51.8.741; Strano-Rossi S, 2011, J APPL TOXICOL, V31, P649, DOI 10.1002/jat.1613; Van Nimmen NFJ, 2007, J CHROMATOGR B, V846, P264, DOI 10.1016/j.jchromb.2006.09.002; Werner U, 2003, CLIN PHARMACOL THER, V74, P130, DOI 10.1016/S0009-9236(03)00120-6; Wiesbrock Urs O., 2008, Archiv fuer Kriminologie, V222, P23; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x	32	10	10	0	19	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0937-9827	1437-1596		INT J LEGAL MED	Int. J. Legal Med.	NOV	2014	128	6					949	956		10.1007/s00414-014-0982-4			8	Medicine, Legal	Legal Medicine	AR8HA	WOS:000343815100008	24577713				2020-06-30	J	Candiotti, KA; Yang, Z; Buric, D; Arheart, K; Zhang, YP; Rodriguez, Y; Gitlin, MC; Carvalho, E; Jaraba, I; Wang, LY				Candiotti, Keith A.; Yang, Zhe; Buric, David; Arheart, Kris; Zhang, Yanping; Rodriguez, Yiliam; Gitlin, Melvin C.; Carvalho, Enisa; Jaraba, Isabel; Wang, Liyong			Catechol-O-Methyltransferase Polymorphisms Predict Opioid Consumption in Postoperative Pain	ANESTHESIA AND ANALGESIA			English	Article							MORPHINE REQUIREMENTS; GENE POLYMORPHISMS; CANCER-PATIENTS; COMT GENE; MICE; ANALGESIA; RESPONSES	BACKGROUND: Previous studies have associated the catechol-O-methyltransferase (COMT) enzyme rs4680 polymorphism with opioid consumption in the treatment of chronic cancer pain. In this study, we evaluated the association between COMT rs4680 and rs4818 polymorphisms and opioid consumption in the acute postoperative period after a nephrectomy. METHODS: Opioid consumption and pain scores were evaluated in 152 patients for 48 hours after nephrectomy. The genotype of each patient was determined using polymerase chain reaction on DNA extracted from blood samples. The association between rs4680 and rs4818 genotypes and opioid consumption was evaluated using general linear model regression analysis. All P values and confidence intervals were Bonferroni corrected for the 3 comparisons among genotypes. RESULTS: In the 24-hour period after surgery (COMT rs4680), patients homozygous for the variant Val/Val consumed 36% (95% confidence interval, 31%-41%) more opioids than patients homozygous for the Met/Met group (P = 0.009). No statistically significant differences among the 3 genotype groups were noted for pain scores or emesis medication use in the first 24 hours after surgery. There was a statistically significant increase in emesis medication use in patients possessing the CC genotype of rs4818 when compared to patients carrying the GG genotypes (P = 0.035). In the 6- to 48-hour postsurgery period, there was significantly higher opioid consumption in the high-activity homozygotes Val/Val than in the homozygous Met/Met group for COMT rs4680 (0-6 h: P = 0.005; 0-12 h: P = 0.015; 0-24 h: P = 0.015; and 0-48 h: P = 0.023). Patients in the homozygous GG group COMT rs4818 single nucleotide polymorphism showed statistically significant differences in opioid consumption in the first 6 hours after nephrectomy compared with heterozygous CG patients (P = 0.02). CONCLUSIONS: The genetic variant of the COMT rs4680 single nucleotide polymorphism is associated with variability in opioid consumption in postoperative nephrectomy patients. The COMT rs4818 polymorphism may prove useful in predicting emesis medication use postoperatively.	[Candiotti, Keith A.; Yang, Zhe; Buric, David; Arheart, Kris; Zhang, Yanping; Rodriguez, Yiliam; Gitlin, Melvin C.; Carvalho, Enisa; Jaraba, Isabel; Wang, Liyong] Univ Miami, Sch Med, Dept Anesthesiol Perioperat Med & Pain Management, Miami, FL 33101 USA	Candiotti, KA (reprint author), Univ Miami, Sch Med, Jackson Mem Hosp, Dept Anesthesiol Perioperat Med & Pain Management, 1611 NW 12th Ave,Cent 130 R-370, Miami, FL 33101 USA.	kcandiotti@med.miami.edu			Department of Anesthesiology, Perioperative Management and Pain Medicine, University of Miami, Miller School of Medicine	This work was supported by the Department of Anesthesiology, Perioperative Management and Pain Medicine, University of Miami, Miller School of Medicine.	Candiotti KA, 2011, ANESTHESIOLOGY, V114, P1162, DOI 10.1097/ALN.0b013e318216e9cb; Coulbault L, 2006, CLIN PHARMACOL THER, V79, P316, DOI 10.1016/j.clpt.2006.01.007; Diatchenko L, 2005, HUM MOL GENET, V14, P135, DOI 10.1093/hmg/ddi013; Gogos JA, 1998, P NATL ACAD SCI USA, V95, P9991, DOI 10.1073/pnas.95.17.9991; Henker RA, 2013, BIOL RES NURS, V15, P309, DOI 10.1177/1099800411436171; Kambur O, 2008, BASIC CLIN PHARMACOL, V103, P367, DOI 10.1111/j.1742-7843.2008.00289.x; Kim H, 2006, MOL PAIN, V2, DOI 10.1186/1744-8069-2-24; Kolesnikov Y, 2011, ANESTH ANALG, V112, P448, DOI 10.1213/ANE.0b013e318202cc8d; Lachman HM, 1996, PHARMACOGENETICS, V6, P243, DOI 10.1097/00008571-199606000-00007; Lee PJ, 2011, CLIN J PAIN, V27, P93, DOI 10.1097/AJP.0b013e3181f15885; LOTTA T, 1995, BIOCHEMISTRY-US, V34, P4202, DOI 10.1021/bi00013a008; Papaleo F, 2008, J NEUROSCI, V28, P8709, DOI 10.1523/JNEUROSCI.2077-08.2008; Rakvag TT, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-64; Rakvag TT, 2005, PAIN, V116, P73, DOI 10.1016/j.pain.2005.03.032; Ross JR, 2008, CANCER-AM CANCER SOC, V112, P1390, DOI 10.1002/cncr.23292; Rut M, 2014, ACTA NEUROCHIR, V156, P245, DOI 10.1007/s00701-013-1895-6; Tammimaki A, 2012, PHARMACOGENET GENOM, V22, P673, DOI 10.1097/FPC.0b013e3283560c46; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546	18	30	33	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999	1526-7598		ANESTH ANALG	Anesth. Analg.	NOV	2014	119	5					1194	1200		10.1213/ANE.0000000000000411			7	Anesthesiology	Anesthesiology	AR5OK	WOS:000343633500028	25185591				2020-06-30	J	Wang, BT; Colby, JM; Wu, AHB; Lynch, KL				Wang, Bei-Tzu; Colby, Jennifer M.; Wu, Alan H. B.; Lynch, Kara L.			Cross-Reactivity of Acetylfentanyl and Risperidone With a Fentanyl Immunoassay	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article								Fentanyl and its analogs, such as acetylfentanyl, have become a concern for potential abuse. Fentanyl compliance monitoring and urine drug testing are becoming increasingly necessary; however, a limited number of fentanyl immunoassays have been validated for clinical use. The purpose of this study was to validate the use of the DRIA (R) fentanyl immunoassay, determine the potential cross-reactivity of acetylfentanyl and other pharmaceuticals, and investigate acetylfentanyl use in San Francisco. All urine toxicology samples from patients presenting to the emergency department were analyzed using the fentanyl immunoassay for 4 months. Positive samples were analyzed qualitatively using liquid chromatography-high resolution mass spectrometry (LC-HRMS) for fentanyl, fentanyl metabolites, fentanyl analogs and greater than 200 common drugs and metabolites. Subsequently, quantitative analysis was performed using LC-tandem mass spectrometry (LC-MS-MS). Acetylfentanyl, risperidone and 9-hydroxyrisperidone were found to cross-react with the fentanyl immunoassay. No acetylfentanyl was detected in our emergency department patient population. The fentanyl immunoassay demonstrated 100% diagnostic sensitivity in a subset of urines tested; however, the specificity was only 86% due to seven false-positive samples observed. Five of the seven samples were positive for risperidone and 9-hydroxyrisperidone. The DRIA (R) fentanyl immunoassay can be used to screen for fentanyl or acetylfentanyl; however, confirmatory testing should be performed for all samples that screen positive.	[Wang, Bei-Tzu; Colby, Jennifer M.; Wu, Alan H. B.; Lynch, Kara L.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Lab Med, San Francisco, CA 94110 USA	Lynch, KL (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Lab Med, 1001 Potrero Ave NH2M16, San Francisco, CA 94110 USA.	kara.lynch@ucsf.edu					Bishop Jeffrey R, 2008, Neuropsychiatr Dis Treat, V4, P55; CDC Health Alert Network, 2013, REC LAB TEST AC PAT; CDC. MMWR, 2013, MMWR-MORBID MORTAL W, V62, P703; CDC. MMWR, 2005, MMWR-MORBID MORTAL W, V57, P793; Gardner DM, 2005, CAN MED ASSOC J, V172, P1703, DOI 10.1503/cmaj.1041064; JAFFE JH, 1985, PHARMACOL BASIS THER, P491; Krinsky CS, 2011, AM J FOREN MED PATH, V32, P347, DOI 10.1097/PAF.0b013e31822ad269; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; North Carolina Department of Health and Human Services, 2014, DHHS ISS HLTH ADV DE; Pennsylvania Department of Drug and Alcohol Programs, 2013, DRUG CAUS LEAST 50 F; Randall C.B., 2004, DISPOSITION TOXIC DR, P451; RUNAGYUTTIKARN W, 1990, J ANAL TOXICOL, V14, P160, DOI 10.1093/jat/14.3.160; Snyder ML, 2011, CLIN CHIM ACTA, V412, P946, DOI 10.1016/j.cca.2011.01.029; Springfield AC, 1996, J ANAL TOXICOL, V20, P202, DOI 10.1093/jat/20.3.202; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L	16	20	20	2	15	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	NOV-DEC	2014	38	9					672	675		10.1093/jat/bku103			4	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	AT0DA	WOS:000344606000008	25248490	Bronze			2020-06-30	J	Zwicker, JD; Zhang, Y; Ren, J; Hutchinson, MR; Rice, KC; Watkins, LR; Greer, JJ; Funk, GD				Zwicker, Jennifer D.; Zhang, Yong; Ren, Jun; Hutchinson, Mark R.; Rice, Kenner C.; Watkins, Linda R.; Greer, John J.; Funk, Gregory D.			Glial TLR4 signaling does not contribute to opioid-induced depression of respiration	JOURNAL OF APPLIED PHYSIOLOGY			English	Article						opioid; pre-Botzinger complex; rat; respiratory depression; toll-like receptor	PRE-BOTZINGER COMPLEX; LONG-TERM POTENTIATION; UNDERLYING NEUROPATHIC PAIN; EVOKED FIELD POTENTIALS; NECROSIS-FACTOR-ALPHA; TOLL-LIKE RECEPTORS; SPINAL DORSAL-HORN; BRAIN-STEM SLICES; IN-VITRO; PREBOTZINGER COMPLEX	Opioids activate glia in the central nervous system in part by activating the toll-like receptor 4 (TLR4)/myeloid differentiation 2 (MD2) complex. TLR4/MD2-mediated activation of glia by opioids compromises their analgesic actions. Glial activation is also hypothesized as pivotal in opioid-mediated reward and tolerance and as a contributor to opioid-mediated respiratory depression. We tested the contribution of TLR4 to opioid-induced respiratory depression using rhythmically active medullary slices that contain the pre-Botzinger Complex (preBotC, an important site of respiratory rhythm generation) and adult rats in vivo. Injection with DAMGO (mu-opioid receptor agonist; 50 mu M) or bath application of DAMGO (500 nM) or fentanyl (1 mu M) slowed frequency recorded from XII nerves to 40%, 40%, or 50% of control, respectively. This DAMGO-mediated frequency inhibition was unaffected by preapplication of lipopolysaccharides from Rhodobacter sphaeroides (a TLR4 antagonist, 2,000 ng/ml) or (+) naloxone (1-10 mu M, a TLR4-antagonist). Bath application of (-) naloxone (500 nM; a TLR4 and mu-opioid antagonist), however, rapidly reversed the opioid-mediated frequency decrease. We also compared the opioid-induced respiratory depression in slices in vitro in the absence and presence of bath-applied minocycline (an inhibitor of microglial activation) and in slices prepared from mice injected (ip) 18 h earlier with minocycline or saline. Minocycline had no effect on respiratory depression in vitro. Finally, the respiratory depression evoked in anesthetized rats by tail vein infusion of fentanyl was unaffected by subsequent injection of (+) naloxone, but completely reversed by (-) naloxone. These data indicate that neither activation of microglia in preBotC nor TLR4/MD2-activation contribute to opioid-induced respiratory depression.	[Zwicker, Jennifer D.; Zhang, Yong; Ren, Jun; Greer, John J.; Funk, Gregory D.] Univ Alberta, Fac Med & Dent, Women & Childrens Hlth Res Inst, Dept Physiol,Neurosci & Mental Hlth Inst, Edmonton, AB T6G 2E1, Canada; [Hutchinson, Mark R.] Univ Adelaide, Sch Med Sci, Discipline Physiol, Adelaide, SA, Australia; [Rice, Kenner C.] NIDA, Chem Biol Res Branch, Rockville, MD USA; [Rice, Kenner C.] NIAAA, Rockville, MD 20852 USA; [Watkins, Linda R.] Univ Colorado, Dept Psychol, Boulder, CO 80309 USA; [Watkins, Linda R.] Univ Colorado, Ctr Neurosci, Boulder, CO 80309 USA	Funk, GD (reprint author), Univ Alberta, Dept Physiol, 3-020G Katz Grp Ctr, Edmonton, AB T6G 2E1, Canada.	gf@ualberta.ca	Hutchinson, Mark R/G-4147-2014; Hutchinson, Mark/N-1815-2019	Hutchinson, Mark R/0000-0003-2154-5950; Hutchinson, Mark/0000-0003-2154-5950; Funk, Gregory/0000-0001-5848-0631	Canadian Institutes for Health Research GrantCanadian Institutes of Health Research (CIHR) [RES0006842]; Alberta Innovates Health Solutions (AIHS); Canadian Foundation for Innovation (CFI)Canada Foundation for Innovation; Alberta Science and Research Authority; AIHS studentship; Women and Children's Health Research Institute studentship; Australian Research Council Research FellowshipAustralian Research Council [DP110100297]; intramural research programs of the National Institute on Drug Abuse; National Institute of Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Support for this study was supported by Canadian Institutes for Health Research Grant RES0006842, Alberta Innovates Health Solutions (AIHS), Canadian Foundation for Innovation (CFI), and Alberta Science and Research Authority. J. Zwicker was supported by an AIHS studentship. G.D. Funk and J.J. Greer are AIHS Scientists. Y. Zhang was supported by a Women and Children's Health Research Institute studentship. M. Hutchinson is the recipient of Australian Research Council Research Fellowship DP110100297. The work of the Drug Design and Synthesis Section, CBRB, NIDA, and NIAAA was supported by the intramural research programs of the National Institute on Drug Abuse and the National Institute of Alcohol Abuse and Alcoholism.	Abate W, 2010, J LIPID RES, V51, P334, DOI 10.1194/jlr.M000513; Balan KV, 2011, RESP PHYSIOL NEUROBI, V178, P458, DOI 10.1016/j.resp.2011.03.003; Ballanyi K, 1997, J PHYSIOL-LONDON, V504, P127, DOI 10.1111/j.1469-7793.1997.127bf.x; Baumgartner U, 2006, NEUROIMAGE, V30, P692, DOI 10.1016/j.neuroimage.2005.10.033; BENVENGA MJ, 1992, J PHARMACOL TOXICOL, V27, P45, DOI 10.1016/1056-8719(92)90020-2; Burns Lindsay H, 2010, Recent Pat CNS Drug Discov, V5, P210; Caso JR, 2007, CIRCULATION, V115, P1599, DOI 10.1161/CIRCULATIONAHA.106.603431; Choi JI, 2010, PAIN, V149, P243, DOI 10.1016/j.pain.2010.02.008; Coller JK, 2012, PHARMACOL THERAPEUT, V134, P219, DOI 10.1016/j.pharmthera.2012.01.008; Colman AS, 2001, RESP PHYSIOL, V127, P157, DOI 10.1016/S0034-5687(01)00240-7; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; Curran B, 2001, NEUROSCIENCE, V108, P83, DOI 10.1016/S0306-4522(01)00405-5; Ferrini F, 2013, NAT NEUROSCI, V16, P183, DOI 10.1038/nn.3295; Gaveriaux-Ruff C, 2001, J PHARMACOL EXP THER, V298, P1193; Grace PM, 2011, BRAIN BEHAV IMMUN, V25, P1322, DOI 10.1016/j.bbi.2011.04.003; Gray PA, 1999, SCIENCE, V286, P1566, DOI 10.1126/science.286.5444.1566; GREER JJ, 1995, J PHYSIOL-LONDON, V485, P845, DOI 10.1113/jphysiol.1995.sp020774; Greer JJ, 2006, J PHYSIOL-LONDON, V570, P437, DOI 10.1113/jphysiol.2005.097238; GUTTERIDGE JMC, 1992, ANN NEUROL, V32, pS16, DOI 10.1002/ana.410320705; Hajiha M, 2009, J PHYSIOL-LONDON, V587, P2677, DOI 10.1113/jphysiol.2009.171678; Hanke ML, 2011, CLIN SCI, V121, P367, DOI 10.1042/CS20110164; Howard RF, 2003, JAMA-J AM MED ASSOC, V290, P2464, DOI 10.1001/jama.290.18.2464; Hutchinson MR, 2008, BRAIN BEHAV IMMUN, V22, P1248, DOI 10.1016/j.bbi.2008.07.008; Hutchinson MR, 2008, EUR J NEUROSCI, V28, P20, DOI 10.1111/j.1460-9568.2008.06321.x; Hutchinson MR, 2010, BRAIN BEHAV IMMUN, V24, P83, DOI 10.1016/j.bbi.2009.08.004; Hutchinson MR, 2005, INT IMMUNOPHARMACOL, V5, P1713, DOI 10.1016/j.intimp.2005.05.006; Huxtable AG, 2011, RESP PHYSIOL NEUROBI, V178, P482, DOI 10.1016/j.resp.2011.06.017; Huxtable AG, 2010, J NEUROSCI, V30, P3947, DOI 10.1523/JNEUROSCI.6027-09.2010; Huxtable AG, 2009, J NEUROSCI, V29, P14713, DOI 10.1523/JNEUROSCI.2660-09.2009; Johnson SM, 1996, J APPL PHYSIOL, V80, P2120; Johnston IN, 2004, J NEUROSCI, V24, P7353, DOI 10.1523/JNEUROSCI.1850-04.2004; Kalish RS, 2004, CLIN IMMUNOL, V113, P270, DOI 10.1016/j.clim.2004.07.012; Kawasaki Y, 2008, J NEUROSCI, V28, P5189, DOI 10.1523/JNEUROSCI.3338-07.2008; Kloppenburg M, 1996, ANTIMICROB AGENTS CH, V40, P934, DOI 10.1128/AAC.40.4.934; Krause KL, 2009, J APPL PHYSIOL, V107, P1591, DOI 10.1152/japplphysiol.90548.2008; Laferriere A, 2005, DEV BRAIN RES, V156, P210, DOI 10.1016/j.devbrainres.2005.03.002; Laferriere A, 1999, DEV BRAIN RES, V112, P1, DOI 10.1016/S0165-3806(98)00149-7; Lalley PM, 2006, AM J PHYSIOL-REG I, V290, pR1387, DOI 10.1152/ajpregu.00530.2005; Li J, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-10; LIU GS, 1990, J NEUROPHYSIOL, V64, P423; Liu L, 2011, BRAIN BEHAV IMMUN, V25, P1223, DOI 10.1016/j.bbi.2011.03.016; Liu YL, 2007, NEUROPHARMACOLOGY, V52, P708, DOI 10.1016/j.neuropharm.2006.09.011; Lorier AR, 2008, J PHYSIOL-LONDON, V586, P1429, DOI 10.1113/jphysiol.2007.143024; Lorier AR, 2007, J NEUROSCI, V27, P993, DOI 10.1523/JNEUROSCI.3948-06.2007; Lorier AR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008766; Maier K, 2007, NEUROBIOL DIS, V25, P514, DOI 10.1016/j.nbd.2006.10.022; Mansson R, 2007, NEUROBIOL DIS, V25, P198, DOI 10.1016/j.nbd.2006.09.008; Manzke T, 2003, SCIENCE, V301, P226, DOI 10.1126/science.1084674; Minoretti P, 2006, NEUROSCI LETT, V391, P147, DOI 10.1016/j.neulet.2005.08.047; Montandon G, 2011, J NEUROSCI, V31, P1292, DOI 10.1523/JNEUROSCI.4611-10.2011; Morin-Surun MP, 2001, EUR J NEUROSCI, V13, P1703, DOI 10.1046/j.0953-816x.2001.01547.x; Moss IR, 2006, ANESTHESIOLOGY, V105, P715, DOI 10.1097/00000542-200610000-00017; Mustapic S, 2010, J NEUROPHYSIOL, V103, P409, DOI 10.1152/jn.00188.2009; Narita M, 2006, NEUROPSYCHOPHARMACOL, V31, P2476, DOI 10.1038/sj.npp.1301007; Nicotra L, 2012, EXP NEUROL, V234, P316, DOI 10.1016/j.expneurol.2011.09.038; Nikodemova M, 2007, J BIOL CHEM, V282, P15208, DOI 10.1074/jbc.M611907200; Nutile-McMenemy N, 2007, J NEUROCHEM, V103, P2035, DOI 10.1111/j.1471-4159.2007.04889.x; Oertel BG, 2010, CLIN PHARMACOL THER, V87, P204, DOI 10.1038/clpt.2009.194; Osikowicz M, 2009, PAIN, V147, P175, DOI 10.1016/j.pain.2009.09.002; Pattinson KTS, 2009, J NEUROSCI, V29, P8177, DOI 10.1523/JNEUROSCI.1375-09.2009; Raghavendra V, 2004, EUR J NEUROSCI, V20, P467, DOI 10.1111/j.1460-9568.2004.03514.x; Ren J, 2006, AM J RESP CRIT CARE, V174, P1384, DOI 10.1164/rccm.200606-778OC; Ren J, 2009, ANESTHESIOLOGY, V110, P1364, DOI 10.1097/ALN.0b013e31819faa2a; Romberg R, 2003, BRIT J ANAESTH, V91, P862, DOI 10.1093/bja/aeg279; Ruangkittisakul A, 2006, J NEUROSCI, V26, P11870, DOI 10.1523/JNEUROSCI.3357-06.2006; Ruangkittisakul A, 2010, ADV EXP MED BIOL, V669, P123, DOI 10.1007/978-1-4419-5692-7_25; SCAMMAN FL, 1983, ANESTH ANALG, V62, P332; Schwarz JM, 2012, J NEUROCHEM, V120, P948, DOI 10.1111/j.1471-4159.2011.07630.x; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; Song P, 2001, NEUROSCI RES, V39, P281, DOI 10.1016/S0168-0102(00)00226-1; Stucke AG, 2008, J NEUROPHYSIOL, V100, P2878, DOI 10.1152/jn.90620.2008; Tadmouri A, 2014, J NEUROSCI RES, V92, P627, DOI 10.1002/jnr.23336; Takeda S, 2001, ANESTHESIOLOGY, V95, P740, DOI 10.1097/00000542-200109000-00029; Tan LH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003966; Telgkamp P, 1999, J NEUROPHYSIOL, V82, P2163; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Terashvili M, 2008, EUR J PHARMACOL, V587, P147, DOI 10.1016/j.ejphar.2008.03.020; Tibboel D, 2005, SEMIN FETAL NEONAT M, V10, P195, DOI 10.1016/j.siny.2004.11.002; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; WAMSLEY JK, 1983, PHARMACOL REV, V35, P69; Wang HF, 2008, BIORESOURCES, V3, P3; Watkins LR, 2009, TRENDS PHARMACOL SCI, V30, P581, DOI 10.1016/j.tips.2009.08.002; Wei F, 2008, J NEUROSCI, V28, P10482, DOI 10.1523/JNEUROSCI.3593-08.2008; Wilkins A, 2004, NEURON GLIA BIOL, V1, P297, DOI 10.1017/S1740925X05000104; XIA Y, 1991, BRAIN RES, V549, P181, DOI 10.1016/0006-8993(91)90457-7; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Zhou LJ, 2008, EXP NEUROL, V212, P507, DOI 10.1016/j.expneurol.2008.04.034; Zhou LJ, 2011, BRAIN BEHAV IMMUN, V25, P322, DOI 10.1016/j.bbi.2010.09.025	88	7	8	0	8	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587	1522-1601		J APPL PHYSIOL	J. Appl. Physiol.	OCT 15	2014	117	8					857	868		10.1152/japplphysiol.00534.2014			12	Physiology; Sport Sciences	Physiology; Sport Sciences	AR0DX	WOS:000343238500005	25103966	Green Published			2020-06-30	J	Zhang, LF; Bao, Y; Shi, DP				Zhang, Lifeng; Bao, Yang; Shi, Dongping			Comparing the pain of propofol via different combinations of fentanyl, sufentanil or remifentanil in gastrointestinal endoscopy	ACTA CIRURGICA BRASILEIRA			English	Article						Gastrointestinal Endoscopy; Propofol; Fentanyl; Sufentanil; Remifentanil	TOTAL INTRAVENOUS ANESTHESIA; INJECTION PAIN; SURGICAL-PATIENTS; DOUBLE-BLIND; SEDATION; SURGERY; PRETREATMENT; LIDOCAINE; EFFICACY; ALFENTANIL	PURPOSE: To evaluate the pain on injection of propofol via different combinations of fentanyl, sufentanil or remifentanil in gastrointestinal endoscopy. METHODS: Total 439 patients were randomly allocated into 6 groups. Propofol & fentanil (PF) group received 1 mu g/kg fentanyl, propofol & sufentanil (PS) group received 0.1 mu g/kg sufentanil and propofol & remifentanyl (PR) group received 1 mu g/kg remifentanyl prior to administration of 1-2 mg/kg of propofol. The propofol & half-fentanil (Pf) group, propofol & half-sufentanil (Ps) group and propofol & half-remifentanyl (Pr) group were given 0.5 mu g/kg fentanyl, 0.05 mu g/kg sufentanil and 0.5 mu g/kg remifentanyl, respectively and later administrated 1-2 mg/kg propofol. All patients were monitored for the blood pressure (MAP), heart rate (HR), and oxygen saturation (SpO(2)). Additionally, the pain intensity was assessed using a 4-point verbal rating scale (VRS) by professional doctors. RESULTS: The incidence of pain due to propofol injection in Ps group (33.8%) was significantly lower than other 5 groups. The heart rate (HR) and mean arterial pressure (MAP) were maintained within the normal limits in all six groups and there was no hypotension or bradycardia encountered during the study period. CONCLUSION: Propofol and sufentanil group was the most suitable program for painless gastroscopy.	[Zhang, Lifeng; Bao, Yang; Shi, Dongping] Shanghai Jiading Cent Hosp, Shanghai 201800, Peoples R China	Shi, DP (reprint author), Shanghai Jiading Cent Hosp, Dept Anesthesiol, 1 North Rd,Juyuan St, Shanghai 201800, Peoples R China.	dongpingshi001@hotmail.com			Science and Technology Development Fund Project, Jiading District, Shanghai [201115]	Science and Technology Development Fund Project, Jiading District, Shanghai (No 201115).	Agarwal A, 2004, ANESTH ANALG, V98, P683, DOI 10.1213/01.ANE.0000103266.73568.18; Ahonen J, 2000, BRIT J ANAESTH, V85, P533, DOI 10.1093/bja/85.4.533; Amornyotin S, 2011, HEPATOB PANCREAT DIS, V10, P313, DOI 10.1016/S1499-3872(11)60052-0; [Anonymous], 1996, PHARMACOL REV, P48567, DOI [10.1046/j.1365-2044.1998.00405.x, DOI 10.1046/J.1365-2044.1998.00405.X]; Basaranoglu G, 2005, EUR J ANAESTH, V22, P890, DOI 10.1017/S0265021505231502; BRESLOW N, 1970, BIOMETRIKA, V57, P579, DOI 10.1093/biomet/57.3.579; Ellett MLC, 2010, GASTROENTEROL NURS, V33, P111, DOI 10.1097/SGA.0b013e3181d601fb; Fujii Y, 2009, CLIN THER, V31, P2107, DOI 10.1016/j.clinthera.2009.10.012; Gerlach K, 2003, EUR J ANAESTH, V20, P813, DOI 10.1097/00003643-200310000-00007; Haeseler G, 2008, BRIT J PHARMACOL, V155, P265, DOI 10.1038/bjp.2008.255; HALL RI, 1991, CAN J ANAESTH, V38, P996, DOI 10.1007/BF03008618; Han YK, 2010, KOREAN J ANESTHESIOL, V58, P435, DOI 10.4097/kjae.2010.58.5.435; Iyilikci L, 2004, J CLIN ANESTH, V16, P499, DOI 10.1016/j.jclinane.2004.01.005; Jung M, 2000, ENDOSCOPY, V32, P233, DOI 10.1055/s-2000-96; Kwak KH, 2008, CLIN THER, V30, P1113, DOI 10.1016/j.clinthera.2008.05.019; Liljeroth E, 2001, ACTA ANAESTH SCAND, V45, P839, DOI 10.1034/j.1399-6576.2001.045007839.x; Lindholm EE, 2013, ANESTHESIOLOGY, V119, P802, DOI 10.1097/ALN.0b013e31829bd883; Macario A, 1999, ANESTH ANALG, V88, P1085, DOI 10.1097/00000539-199905000-00023; Martorano PP, 2008, MINERVA ANESTESIOL, V74, P233; Mayes S, 2006, ANN PHARMACOTHER, V40, P2178, DOI 10.1345/aph.1H135; MCCRIRRICK A, 1990, ANAESTHESIA, V45, P443, DOI 10.1111/j.1365-2044.1990.tb14329.x; Meaudre E, 2004, EUR J ANAESTH, V21, P793, DOI 10.1017/S0265021504000079; Mehta CR, 1983, J AM STAT ASSOC, V78, P427, DOI [10.1080/01621459.1983.10477989, DOI 10.1080/01621459.1983.10477989]; Mertens MJ, 2003, ANESTHESIOLOGY, V99, P347, DOI 10.1097/00000542-200308000-00016; Miner JR, 2007, ANN EMERG MED, V50, P182, DOI 10.1016/j.annemergmed.2006.12.017; Roehm KD, 2003, ANAESTHESIA, V58, P165, DOI 10.1046/j.1365-2044.2003.02964_2.x; Savoia G, 2001, Minerva Anestesiol, V67, P206; SHAFER A, 1988, ANESTHESIOLOGY, V69, P348, DOI 10.1097/00000542-198809000-00011; Stevens JB, 1998, ANESTH ANALG, V86, P45, DOI 10.1097/00000539-199801000-00009; STOKES DN, 1989, BRIT J ANAESTH, V62, P202, DOI 10.1093/bja/62.2.202; Tan CH, 1998, ANAESTHESIA, V53, P468, DOI 10.1046/j.1365-2044.1998.00405.x; Trapani G, 1998, J MED CHEM, V41, P1846, DOI 10.1021/jm970681h; Weale NK, 2004, BRIT J ANAESTH, V92, P187, DOI 10.1093/bja/aeh038; Wehrmann T, 1999, GASTROINTEST ENDOSC, V49, P677, DOI 10.1016/S0016-5107(99)70281-6	34	8	12	0	9	ACTA CIRURGICA BRASILEIRA	SAO PAULO	ALAMEDA RIO CLARO, 179-41, SAO PAULO, SP 01332-010, BRAZIL	0102-8650	1678-2674		ACTA CIR BRAS	Acta Cir. Bras.	OCT	2014	29	10					675	680		10.1590/S0102-8650201400160008			6	Surgery	Surgery	AS0QI	WOS:000343982100008	25318000	DOAJ Gold			2020-06-30	J	Kang, H; Chung, YS; Choe, JW; Woo, YC; Kim, SW; Park, SJ; Hong, J				Kang, Hyun; Chung, Yoon Sang; Choe, Ju Won; Woo, Young Cheol; Kim, Sang Wook; Park, Soon J.; Hong, Joonhwa			Application of Lidocaine Jelly on Chest Tubes to Reduce Pain Caused by Drainage Catheter after Coronary Artery Bypass Surgery	JOURNAL OF KOREAN MEDICAL SCIENCE			English	Article						Coronary Artery Bypass; Pain; Postoperative; Analgesia	CARDIAC-SURGERY; LAPAROSCOPIC APPENDECTOMY; INTENSITY; RELIEF	The objective of this study was to assess the effect of lidocaine jelly application to chest tubes on the intensity and duration of overall pain, chest tube site pain and the required analgesics for postoperative pain relief in coronary artery bypass graft (CABG) patients. For patients in group L, we applied sterile 2% lidocaine jelly on the chest tubes just before insertion, and for patients in group C, we applied normal saline. Overall visual analogue scale (VAS), maximal pain area with their VAS were documented postoperatively, and the frequency that button of patient-controlled analgesia was pressed (FPB) and total fentanyl consumption were assessed. The number of patients who complained that tube site was the most painful site was significantly higher in group C than in group L (85% vs. 30% at extubation, P < 0.001). The overall VAS score was significantly higher in group C than in group L (39.14 +/- 12.49 vs. 27.74 +/- 13.76 at extubation, P = 0.006). After all of the tubes were removed, the VAS score decreased more in group C (5.74 +/- 4.77, P < 0.001) than in group L (3.05 +/- 2.48, P < 0.001). FPB and total fentanyl consumption were significantly higher in group C than in group L (73.00, 59.00-78.00 vs. 34.00, 31.00-39.25, P < 0.001; 2,214.65 +/- 37.01 vs. 1,720.19 +/- 361.63, P < 0.001, respectively). Lidocaine jelly application is a very simple way to reduce postoperative pain by reducing chest tube site pain after CABG.	[Kang, Hyun; Chung, Yoon Sang; Kim, Sang Wook; Hong, Joonhwa] Chung Ang Univ, Coll Med, Heart Res Inst, Seoul 156755, South Korea; [Kang, Hyun; Woo, Young Cheol] Chung Ang Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul 156755, South Korea; [Chung, Yoon Sang; Choe, Ju Won; Hong, Joonhwa] Chung Ang Univ, Coll Med, Dept Thorac & Cardiovasc Surg, Seoul 156755, South Korea; [Kim, Sang Wook] Chung Ang Univ, Coll Med, Dept Cardiol, Seoul 156755, South Korea; [Park, Soon J.] Case Western Reserve Univ, Sch Med, Dept Surg, Cleveland, OH 44106 USA	Hong, J (reprint author), Chung Ang Univ, Coll Med, Dept Thorac & Cardiovasc Surg, 102 Heukseok Ro, Seoul 156755, South Korea.	Joonhwa.hong@gmail.com	Kang, Hyun/AAE-7872-2020	Kang, Hyun/0000-0003-2844-5880; Chung, Yoon Sang/0000-0002-6901-0245			Cervini P, 2002, SURG ENDOSC, V16, P1579, DOI 10.1007/s00464-002-8803-0; Hollmann MW, 2000, ANESTHESIOLOGY, V93, P858, DOI 10.1097/00000542-200009000-00038; Kim TH, 2011, SURG ENDOSC, V25, P3183, DOI 10.1007/s00464-011-1684-3; Kissin I, 2000, ANESTHESIOLOGY, V93, P1138, DOI 10.1097/00000542-200010000-00040; Koppert W, 2000, PAIN, V85, P217, DOI 10.1016/S0304-3959(99)00268-7; Lahtinen P, 2006, ANESTHESIOLOGY, V105, P794, DOI 10.1097/00000542-200610000-00026; Mueller XM, 2000, EUR J CARDIO-THORAC, V18, P570, DOI 10.1016/S1010-7940(00)00515-7; Mueller XM, 2000, CHEST, V118, P391, DOI 10.1378/chest.118.2.391; O'Connor CJ, 1999, CRIT CARE MED, V27, P2314, DOI 10.1097/00003246-199910000-00055; Petrenko AB, 2003, ANESTH ANALG, V97, P1108, DOI 10.1213/01.ANE.0000081061.12235.55; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; ROWLAND M, 1971, ANN NY ACAD SCI, V179, P383, DOI 10.1111/j.1749-6632.1971.tb46915.x; Sasseron AB, 2009, REV BRAS CIR CARDIOV, V24, P490, DOI 10.1590/S0102-76382009000500010; Watkins LR, 1995, PAIN, V63, P289, DOI 10.1016/0304-3959(95)00186-7; Weissman C, 1999, ANESTH ANALG, V88, P1272, DOI 10.1097/00000539-199906000-00014	15	0	0	0	0	KOREAN ACAD MEDICAL SCIENCES	SEOUL	302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA	1011-8934	1598-6357		J KOREAN MED SCI	J. Korean Med. Sci.	OCT	2014	29	10					1398	1403		10.3346/jkms.2014.29.10.1398			6	Medicine, General & Internal	General & Internal Medicine	AS5PN	WOS:000344322500011	25368494	DOAJ Gold, Green Published			2020-06-30	J	Marinetti, LJ; Ehlers, BJ				Marinetti, Laureen J.; Ehlers, Brooke J.			A Series of Forensic Toxicology and Drug Seizure Cases Involving Illicit Fentanyl Alone and in Combination with Heroin, Cocaine or Heroin and Cocaine	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							COOK COUNTY; DEATHS; ILLINOIS; EPIDEMIC	The Montgomery County Coroner's Office Toxicology Section and the Miami Valley Regional Crime Lab (MVRCL) Drug Chemistry Section have been receiving case work in drug seizures, death cases and human performance cases involving products marketed as heroin or as illicit fentanyl. Upon analysis by the Drug Chemistry Section, these products were found to contain various drug(s) including illicit fentanyl only, illicit fentanyl and heroin, illicit fentanyl and cocaine and illicit fentanyl, heroin and cocaine. Both the Chemistry and Toxicology Sections began seeing these combinations starting in late October 2013. The percentage of the combinations encountered by the MVRCL as well as the physical appearance of the product, and the results of presumptive screening tests will be discussed. The demographics of the users and the results of toxicology and autopsy findings on the decedents will also be discussed. According to regional drug task force undercover agents, there is evidence that some of the products are being sold as illicit fentanyl and not just as a heroin product. Also, there is no evidence to support that the fentanyl source is being diverted from pharmaceutical grade fentanyl. The chemistry section currently has over 109 confirmed cases, and the toxicology section currently has 81 confirmed drug deaths, 8 driving under the influence of drugs and 1 suicidal hanging. Both sections are continuing to see these cases at the present time.	[Marinetti, Laureen J.; Ehlers, Brooke J.] MCCO, MVRCL, Dayton, OH 45402 USA	Marinetti, LJ (reprint author), MCCO, MVRCL, Dayton, OH 45402 USA.	LMarinetti@redwoodtoxicology.com					Algren DA, 2013, J MED TOXICOL, V9, P106, DOI 10.1007/s13181-012-0285-4; Denton JS, 2008, J FORENSIC SCI, V53, P452, DOI 10.1111/j.1556-4029.2008.00669.x; Hull MJ, 2007, J FORENSIC SCI, V52, P1383, DOI 10.1111/j.1556-4029.2007.00564.x; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; Wong SC, 2008, J FORENSIC SCI, V53, P495, DOI 10.1111/j.1556-4029.2007.00648.x	6	36	38	0	44	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	OCT	2014	38	8			SI		592	598		10.1093/jat/bku086			7	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	AR1DY	WOS:000343324100021	25217552	Bronze			2020-06-30	J	Soares, JHN; Brosnan, RJ; Smith, A; Mayhew, PD				Soares, Joao Henrique Neves; Brosnan, Robert J.; Smith, Andrea; Mayhew, Philipp D.			Rabbit model of chest wall rigidity induced by fentanyl and the effects of apomorphine	RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY			English	Article						Fentanyl; Rigidity; Apomorphine; Dopaminergic; Rabbit	INDUCED MUSCLE RIGIDITY; MORPHINE; RATS	A rabbit model for fentanyl-induced chest wall rigidity and the effect of apomorphine was evaluated. Eleven New Zealand adult rabbits were anesthetized and mechanically ventilated. An esophageal balloon catheter was used to estimate pleural pressure (P-pl). Chest wall compliance (C-cw) at baseline was calculated during pentobarbital anesthesia. A loading dose of 0.1 mg kg(-1) of fentanyl followed by infusion of 0.01 mg kg(-1) min(-1) was started in all animals, and C-cw reassessed. In the rabbits that developed decreased C-cw apomorphine 0.4 mg kg(-1) followed by a 0.004 mg kg(-1) min(-1) was administered and C-cw was reassessed. C-cw at baseline and after fentanyl and fentanyl + apomorphine were compared with one-way ANOVA followed by Bonferroni-Holm test (P < 0.05). In 5 rabbits, C-cw decreased significantly after fentanyl administration and apomorphine was able to restore C-cw to baseline values. Rabbits can be used as a model for fentanyl-induced chest wall rigidity. Results from this study support central dopaminergic pathways as being at least partially responsible for the opioid-induced chest wall rigidity. (C) 2014 Elsevier B.V. All rights reserved.	[Soares, Joao Henrique Neves; Smith, Andrea] Univ Calif Davis, Sch Vet Med, William R Pritchard Vet Med Teaching Hosp, Davis, CA 95616 USA; [Brosnan, Robert J.; Mayhew, Philipp D.] Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA	Soares, JHN (reprint author), Univ Calif Davis, Sch Vet Med, William R Pritchard Vet Med Teaching Hosp, One Garrod Dr, Davis, CA 95616 USA.	jhsoares@ucdavis.edu; rjbrosnan@ucdavis.edu; smith.aalsmith@gmail.com; philmayhew@gmail.com	Soares, Joao/AAD-7928-2019; Soares, Joao Henrique Neves/G-8519-2016	Soares, Joao Henrique Neves/0000-0001-9044-3208	Department of Surgical and Radiological Sciences in the School of Veterinary Medicine, University of California, Davis	This project was supported by funds from the Department of Surgical and Radiological Sciences in the School of Veterinary Medicine, University of California, Davis.	COMSTOCK MK, 1981, ANESTH ANALG, V60, P362; Coruh B, 2013, CHEST, V143, P1145, DOI 10.1378/chest.12-2131; GENC E, 1983, NEUROPHARMACOLOGY, V22, P471, DOI 10.1016/0028-3908(83)90165-X; Koller W, 2004, NEUROLOGY, V62, pS22, DOI 10.1212/WNL.62.6_suppl_4.S22; Lalley PM, 2008, RESP PHYSIOL NEUROBI, V164, P160, DOI 10.1016/j.resp.2008.02.004; MARTY J, 1981, ACTA ANAESTH SCAND, V25, P293, DOI 10.1111/j.1399-6576.1981.tb01654.x; SCAMMAN FL, 1983, ANESTH ANALG, V62, P332; VACANTI CA, 1992, J CLIN ANESTH, V4, P282, DOI 10.1016/0952-8180(92)90129-O; Vankova ME, 1996, ANESTHESIOLOGY, V85, P574, DOI 10.1097/00000542-199609000-00017; WAND P, 1973, EUR J PHARMACOL, V24, P189, DOI 10.1016/0014-2999(73)90071-X	10	5	5	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1569-9048	1878-1519		RESP PHYSIOL NEUROBI	Respir. Physiol. Neuro.	OCT 1	2014	202						50	52		10.1016/j.resp.2014.07.017			3	Physiology; Respiratory System	Physiology; Respiratory System	AR1WU	WOS:000343376100008	25093961				2020-06-30	J	Subramanian, A; Wanta, BT; Fogelson, JL; Curry, TB; Hannon, JD				Subramanian, Arun; Wanta, Brendan T.; Fogelson, Jeremy L.; Curry, Timothy B.; Hannon, James D.			Time to Extubation During Propofol Anesthesia for Spine Surgery With Sufentanil Compared With Fentanyl	SPINE			English	Article						adult; anesthetics; intravenous; evoked potentials; motor evoked potentials; somatosensory; female; fentanyl; humans; male; monitoring; intraoperative; neurological examination; neurosurgical procedures; postoperative period; propofol; sufentanil	RATIONAL OPIOID SELECTION; EVOKED-POTENTIALS; BISPECTRAL INDEX; CARDIAC-SURGERY; REMIFENTANIL; PHARMACOKINETICS; ALFENTANIL; EMERGENCE; MORPHINE; FASTER	Study Design. Retrospective cohort study. Objective. This study compares time to extubation between major spine surgery patients anesthetized with fentanyl versus sufentanil infusions in combination with propofol. Summary of Background Data. In patients undergoing spinal fusion with intraoperative electrophysiological monitoring of the spinal cord, total intravenous anesthesia with a propofol/opioid combination results in better electrophysiological signals compared with volatile anesthetics. Pharmacokinetic data suggest that total intravenous anesthesia with sufentanil should lead to more rapid emergence from anesthesia than with fentanyl. However, this has never been tested in the spine surgery patient population. Methods. With institutional review board approval, all major spine patients receiving a propofol-based total intravenous anesthesia with fentanyl were compared with those receiving sufentanil. Time to extubation, defined as the time from surgical closure to tracheal extubation, was the study outcome. Relevant demographic, anthropomorphic, anesthetic, and surgical data were collected. Association between type of opioid and time to extubation was tested for statistical significance. Multiple linear regression analysis was used to control for confounders. Results. A total of 167 patients met inclusion criteria (fentanyl = 72, sufentanil = 95). There was no statistically significant difference between the 2 groups in terms of baseline characteristics. Time from surgical closure to extubation in the fentanyl versus sufentanil groups was not statistically different (mean [SD]: 40.2 [26.7] min vs. 45.0 [36.9] min; P = 0.36). On multivariate analysis, total dose of propofol and male sex were associated with increased time to extubation. Conclusion. The use of sufentanil may not reduce time to extubation compared with fentanyl despite its favorable pharmacokinetic profile. Higher doses of propofol and male sex were associated with longer time to extubation and seem to play a greater role than choice of opioid.	[Subramanian, Arun; Wanta, Brendan T.; Curry, Timothy B.; Hannon, James D.] Mayo Clin, Dept Anesthesiol, Rochester, MN 55905 USA; [Fogelson, Jeremy L.] Mayo Clin, Dept Neurosurg, Rochester, MN 55905 USA	Subramanian, A (reprint author), Mayo Clin, Dept Anesthesiol, 200 1st St SW, Rochester, MN 55905 USA.	Subramanian.Arun@mayo.edu	Hannon, James/P-8409-2019				Ahonen J, 2000, BRIT J ANAESTH, V85, P533, DOI 10.1093/bja/85.4.533; [Anonymous], NEUROMODULATION; APFELBAUM JL, 1993, ANESTH ANALG, V77, pS10; Bouillon TW, 2004, ANESTHESIOLOGY, V100, P1353, DOI 10.1097/00000542-200406000-00006; BOVILL JG, 1984, ANESTHESIOLOGY, V61, P502, DOI 10.1097/00000542-198411000-00004; Gan TJ, 1999, ANESTHESIOLOGY, V90, P1283, DOI 10.1097/00000542-199905000-00010; Hellstrom J, 2012, SCAND CARDIOVASC J, V46, P262, DOI 10.3109/14017431.2012.676209; Hentgen E, 2002, ANESTH ANALG, V95, P597, DOI 10.1097/00000539-200209000-00019; Hoymork SC, 2005, BRIT J ANAESTH, V95, P627, DOI 10.1093/bja/aei245; Hoymork SC, 2003, BRIT J ANAESTH, V91, P773, DOI 10.1093/bja/aeg258; Kazama T, 1997, ANESTHESIOLOGY, V87, P213, DOI 10.1097/00000542-199708000-00007; MEULDERMANS WEG, 1982, ARCH INT PHARMACOD T, V257, P4; NIEMEGEERS CJE, 1976, ARZNEIMITTEL-FORSCH, V26, P1551; Nitzschke R, 2012, ANAESTHESIST, V61, P320, DOI 10.1007/s00101-012-2015-3; Samra SK, 2001, ANESTH ANALG, V92, P1510; SANFORD TJ, 1986, ANESTH ANALG, V65, P259; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; Vuyk J, 1997, ANESTHESIOLOGY, V87, P1549, DOI 10.1097/00000542-199712000-00033; Wachtel RE, 2011, CAN J ANESTH, V58, P714, DOI 10.1007/s12630-011-9519-1	19	4	4	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0362-2436	1528-1159		SPINE	SPINE	OCT 1	2014	39	21					1758	1764		10.1097/BRS.0000000000000509			7	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	AQ8YG	WOS:000343125700011	25010093				2020-06-30	J	Stucke, AG; Weisman, SJ				Stucke, Astrid G.; Weisman, Steven J.			Can we tell emergence agitation frompain? Comment on Bortone et al.: the effect of fentanyl and clonidine on early postoperative negative behavior in children	PEDIATRIC ANESTHESIA			English	Letter							SEVOFLURANE		[Stucke, Astrid G.] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA	Stucke, AG (reprint author), Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA.	astucke@mcw.edu					Bock M, 2002, BRIT J ANAESTH, V88, P790, DOI 10.1093/bja/88.6.790; Bortone L, 2014, PEDIATR ANESTH, V24, P614, DOI 10.1111/pan.12388; Kulka PJ, 2001, ANESTH ANALG, V93, P335, DOI 10.1097/00000539-200108000-00019	3	2	2	0	5	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	OCT	2014	24	10					1114	1114		10.1111/pan.12507			1	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	AQ6CW	WOS:000342896800017	25196292				2020-06-30	J	Torres, LM; Revnic, J; Knight, AD; Perelman, M				Torres, Luis M.; Revnic, Julia; Knight, Alastair D.; Perelman, Michael			Relationship between Onset of Pain Relief and Patient Satisfaction with Fentanyl Pectin Nasal Spray for Breakthrough Pain in Cancer	JOURNAL OF PALLIATIVE MEDICINE			English	Article							ONCOLOGY PATIENTS; PREVALENCE; MANAGEMENT; PHARMACOKINETICS; RECOMMENDATIONS; EFFICACY; OPIOIDS	Background: Satisfaction with pain relief in patients with breakthrough pain in cancer (BTPc) has typically been assessed by overall efficacy without consideration of the rapidity of that response. Objective: To determine the relationship between speed of onset of pain relief and patient satisfaction for treated BTPc episodes overall and for individual treatments. Design: Pooled data from two randomized, double-blinded crossover studies. Setting/Subjects: Patients having 1-4 BTPc episodes per day on >= 60 mg/day oral morphine or equivalent. Episodes treated with fentanyl pectin nasal spray (FPNS; 100-800 mu g), immediate-release morphine sulfate (IRMS), or placebo. Measurements: Pain intensity was measured on an 11-point scale (5-60 minutes posttreatment); satisfaction was measured on a 4-point scale (30 and 60 minutes). The primary analysis assessed the overall relationship of time to onset of pain relief (pain intensity difference [PID]>= 1) or time to clinically meaningfully reduction in pain (PID >= 2) versus patient satisfaction and overall pain intensity (summed pain intensity difference at 30 [SPID30] and 60 minutes [SPID60]) assessed by analysis of variance (ANOVA). A secondary analysis assessed whether satisfaction was different between treatments using a within-patient comparison. Results: Eight hundred thirty-one FPNS-treated, 368 IRMS-treated, and 200 placebo-treated episodes were analyzed. Overall, within the pool there was a statistically significant relationship between time to onset of pain relief (PID >= 1 and PID >= 2) and patient satisfaction (both speed of relief and overall) at 30 and 60 minutes (p<0.001); this relationship was also true within individual treatment groups (p<0.01). Similar results were found for overall pain intensity reduction. When treatment groups were compared using within-patient data, FPNS provided earlier onset of pain relief than IRMS or placebo (p<0.05), which translated into better satisfaction at 60 minutes (p<0.01). Conclusions: Earlier onset of pain relief resulted in greater patient satisfaction and overall relief of pain; between-treatment comparisons showed that FPNS provided earlier pain relief and greater satisfaction than IRMS or placebo.	[Torres, Luis M.] Hosp Univ Puerta Mar, Cadiz 11009, Spain; [Revnic, Julia] Hop Jean Jaures, Paris, France; [Knight, Alastair D.] Evicom Ltd, Teddington, Middx, England; [Perelman, Michael] Archimedes Dev Ltd, Nottingham, England	Torres, LM (reprint author), Hosp Univ Puerta Mar, Av Ana Viya 21, Cadiz 11009, Spain.	lm.torres@me.com	Torres, Luis M/Q-6983-2019; Torres, Luis Miguel/O-1720-2015	Torres, Luis Miguel/0000-0002-0194-7875	Archimedes	Luis M. Torres is a consultant for Ferrer and ProStrakan, and is on the speakers' bureaus of Archimedes and Cephalon. Julia Revnic had been paid by Archimedes for educational presentations; her previous institution received research support from Archimedes. Alastair D. Knight serves as a statistical consultant to Archimedes Development Ltd. Michael Perelman is employed by Archimedes Development Ltd.	Abernethy Amy P, 2008, Am J Manag Care, V14, pS129; [Anonymous], 2012, NCCN CLIN PRACT GUID; BENNETT D, 2005, [No title captured], V30, P296; BENNETT D, 2005, [No title captured], V30, P354; Caraceni A, 2012, J PAIN SYMPTOM MANAG, V43, P833, DOI 10.1016/j.jpainsymman.2011.05.018; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Davies A, 2013, J PAIN SYMPTOM MANAG, V46, P619, DOI 10.1016/j.jpainsymman.2012.12.009; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Davies AN, 2008, J PAIN SYMPTOM MANAG, V35, P406, DOI 10.1016/j.jpainsymman.2007.05.010; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Davies GM, 2000, CEPHALALGIA, V20, P554, DOI 10.1046/j.1468-2982.2000.00082.x; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; Hirsh AT, 2005, CLIN J PAIN, V21, P302, DOI 10.1097/01.ajp.0000113057.92184.90; Kress HG, 2010, EUR J PAIN S, V4, P191; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; Miaskowski C, 2001, J CLIN ONCOL, V19, P4275, DOI 10.1200/JCO.2001.19.23.4275; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Stahmer SA, 1998, ACAD EMERG MED, V5, P851, DOI 10.1111/j.1553-2712.1998.tb02811.x; Vissers D, 2010, CURR MED RES OPIN, V26, P1037, DOI 10.1185/03007991003694340; Zeppetella G, 2009, EUR J CANCER CARE, V18, P331, DOI 10.1111/j.1365-2354.2008.01009.x; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012	29	8	9	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1096-6218	1557-7740		J PALLIAT MED	J. Palliat. Med.	OCT 1	2014	17	10					1150	1157		10.1089/jpm.2014.0089			8	Health Care Sciences & Services	Health Care Sciences & Services	AQ4DS	WOS:000342743200014	25211772				2020-06-30	J	Fredheim, OM				Fredheim, O. M.			Increasing use of opioids for pain	EUROPEAN JOURNAL OF PAIN			English	Editorial Material									[Fredheim, O. M.] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, N-7034 Trondheim, Norway; [Fredheim, O. M.] Akershus Univ Hosp, Div Surg, Ctr Palliat Med, Lorenskog, Norway	Fredheim, OM (reprint author), Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, N-7034 Trondheim, Norway.	olav.m.fredheim@ntnu.no		Fredheim, Olav/0000-0002-0931-0027			Fredheim OMS, 2010, EUR J PAIN, V14, P289, DOI 10.1016/j.ejpain.2009.05.006; Mellbye A, 2012, ACTA ANAESTH SCAND, V56, P1267, DOI 10.1111/j.1399-6576.2012.02766.x; Zin CS, 2014, EUR J PAIN, V18, P1343, DOI 10.1002/j.1532-2149.2014.496.x	3	3	3	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	OCT	2014	18	9					1219	1220		10.1002/ejp.505			2	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	AP3MJ	WOS:000341979800001	25195682				2020-06-30	J	Zuckerman, M; Weisberg, SN; Boyer, EW				Zuckerman, Matthew; Weisberg, Stacy N.; Boyer, Edward W.			PITFALLS OF INTRANASAL NALOXONE	PREHOSPITAL EMERGENCY CARE			English	Article						prescription opioids; overdose; intranasal naloxone	INJECTION-DRUG USERS; OPIOID OVERDOSE; HEROIN OVERDOSE; UNITED-STATES; HOME NALOXONE; DEATHS; FENTANYL; PREVENTION; TRANSPORT; EPIDEMIC	We present a case of failed prehospital treatment of fentanyl induced apnea with intranasal (IN) naloxone. While IN administration of naloxone is becoming more common in both lay and pre-hospital settings, older EMS protocols utilized intravenous (IV) administration. Longer-acting, higher potency opioids, such as fentanyl, may not be as easily reversed as heroin, and studies evaluating IN administration in this population are lacking. In order to contribute to our understanding of the strengths and limitations of IN administration of naloxone, we present a case where it failed to restore ventilation. We also describe peer reviewed literature that supports the use of IV naloxone following heroin overdose and explore possible limitations of generalizing this literature to opioids other than heroin and to IN routes of administration.	[Zuckerman, Matthew; Weisberg, Stacy N.; Boyer, Edward W.] Univ Massachusetts, Dept Emergency Med, Sch Med, Worcester, MA 01655 USA	Weisberg, SN (reprint author), Univ Massachusetts, Dept Emergency Med, Sch Med, 55 Lake Ave North, Worcester, MA 01655 USA.	Stacy.Weisberg@umassmemorial.org	Zuckerman, Matthew/V-3419-2018; Zuckerman, Matthew/T-9036-2018; Boyer, Edward/AAF-3609-2020	Zuckerman, Matthew/0000-0001-9576-4203; Zuckerman, Matthew/0000-0001-9576-4203; 	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K24 DA037109]		Administration SAaMHS, 2011, NSDUH SER H, P11; Baca CT, 2005, ADDICTION, V100, P1823, DOI 10.1111/j.1360-0443.2005.01259.x; Barton ED, 2005, J EMERG MED, V29, P265, DOI 10.1016/j.jemermed.2005.03.007; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Boyer EW, 2012, NEW ENGL J MED, V367, P146, DOI 10.1056/NEJMra1202561; Cai R., 2010, Morbidity and Mortality Weekly Report, V59, P705; Castillo T, 2013, HUFFINGTON POST; Centers for Disease C, 2011, PRESCR PAINK OV US V; Coffin PO, 2007, ACAD EMERG MED, V14, P616, DOI 10.1111/j.1553-2712.2007.tb01846.x; Dettmer K, 2001, BRIT MED J, V322, P895, DOI 10.1136/bmj.322.7291.895; Jones CM, 2013, JAMA-J AM MED ASSOC, V309, P657, DOI 10.1001/jama.2013.272; Kerr D, 2008, ADDICTION, V103, P379, DOI 10.1111/j.1360-0443.2007.02097.x; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Madadi P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060600; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pES9; McDonald DC, 2012, J PAIN, V13, P988, DOI 10.1016/j.jpain.2012.07.007; Mrvos R, 2012, J EMERG MED, V42, P549, DOI 10.1016/j.jemermed.2011.05.017; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Paulozzi Leonard, 2012, Morbidity and Mortality Weekly Report, V61, P10; Robertson TM, 2009, PREHOSP EMERG CARE, V13, P512, DOI 10.1080/10903120903144866; Sporer KA, 2007, ANN EMERG MED, V49, P172, DOI 10.1016/j.annemergmed.2006.05.025; Stoove MA, 2009, DRUG ALCOHOL REV, V28, P347, DOI 10.1111/j.1465-3362.2009.00057.x; Thomas S, 2008, AM J FOREN MED PATH, V29, P162, DOI 10.1097/PAF.0b013e3181651b66; Vilke GM, 2003, ACAD EMERG MED, V10, P893, DOI 10.1111/j.1553-2712.2003.tb00636.x; Walley AY, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f174; Wampler DA, 2011, PREHOSP EMERG CARE, V15, P320, DOI 10.3109/10903127.2011.569854; WOODY GE, 1993, NEW ENGL J MED, V329, P1661, DOI 10.1056/NEJM199311253292220; Worthington Nancy, 2006, Harm Reduct J, V3, P19	28	23	23	0	6	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1090-3127	1545-0066		PREHOSP EMERG CARE	Prehosp. Emerg. Care	OCT-DEC	2014	18	4					550	554		10.3109/10903127.2014.896961			5	Emergency Medicine; Public, Environmental & Occupational Health	Emergency Medicine; Public, Environmental & Occupational Health	AP7AR	WOS:000342230400013	24830404	Green Accepted			2020-06-30	J	Sprung, J; Scavonetto, F; Yeoh, TY; Kramer, JM; Karnes, RJ; Eisenach, JH; Schroeder, DR; Weingarten, TN				Sprung, Juraj; Scavonetto, Federica; Yeoh, Tze Yeng; Kramer, Jessica M.; Karnes, R. Jeffrey; Eisenach, John H.; Schroeder, Darrell R.; Weingarten, Toby N.			Outcomes After Radical Prostatectomy for Cancer: A Comparison Between General Anesthesia and Epidural Anesthesia with Fentanyl Analgesia: A Matched Cohort Study	ANESTHESIA AND ANALGESIA			English	Article							KILLER-CELL-ACTIVITY; RETROSPECTIVE ANALYSIS; REGIONAL-ANESTHESIA; RECURRENCE RATES; PAIN RELIEF; SURGERY; REDUCE; CYTOTOXICITY; METHODOLOGY; SUPPRESSION	BACKGROUND: The use of regional anesthesia for cancer surgery has been associated with improved oncologic outcomes. One of the proposed mechanisms is a reduction in the use of systemic opioids that may cause immunosuppression. We used a retrospective matched cohort design to compare long-term oncologic outcomes after prostatectomy for cancer performed under general anesthesia with systemic opioids or with epidural anesthesia with epidural fentanyl analgesia. Since epidural fentanyl is quickly reabsorbed systemically, we hypothesized that there would be no difference in long-term oncological outcomes between the 2 groups. METHODS: There were 486 men who underwent prostatectomy performed under epidural anesthesia between January 1, 1991, and January 31, 1996. They were 1: 1 matched based on age (+/- 5 years), surgical year (+/- 1 year), and baseline prostate cancer pathology to patients who had general anesthesia with systemic opioids. Long-term cancer outcomes and all-cause mortality were examined. Analyses were performed using stratified proportional hazards regression models, with hazard ratios >1 indicating worse outcome for general anesthesia only compared with epidural anesthesia and fentanyl analgesia. RESULTS: After adjusting for positive surgical margins and adjuvant therapies, patients in the general anesthesia group were found not to be at increased risk of prostate cancer recurrence (hazard ratio [HR] = 0.79, 95% confidence interval [CI], 0.60-1.04], systemic tumor progression (HR = 0.92, 95% CI, 0.46-1.84), cancer-specific mortality (HR = 0.53, 95% CI, 0.18-1.58), or overall mortality (HR = 1.23, 95% CI 0.93-1.63) when compared with patients who received epidural anesthesia. CONCLUSIONS: Compared with general anesthesia with systemic opioids, epidural anesthesia and analgesia with fentanyl were not associated with improvement in oncologic outcomes in patients undergoing radical prostatectomy for cancer.	[Sprung, Juraj; Scavonetto, Federica; Yeoh, Tze Yeng; Kramer, Jessica M.; Eisenach, John H.; Weingarten, Toby N.] Mayo Clin, Coll Med, Dept Anesthesiol, Rochester, MN 55905 USA; [Yeoh, Tze Yeng] Natl Univ Hlth Syst, Natl Univ Hosp, Dept Anesthesiol, Singapore, Singapore; [Kramer, Jessica M.] Midwest Anesthesiologists PA, Plymouth, MN USA; [Karnes, R. Jeffrey] Mayo Clin, Coll Med, Dept Urol, Rochester, MN 55905 USA; [Schroeder, Darrell R.] Mayo Clin, Coll Med, Dept Hlth Sci Res, Rochester, MN 55905 USA	Sprung, J (reprint author), Mayo Clin, Coll Med, Dept Anesthesiol, 200 First St SW, Rochester, MN 55905 USA.	sprung.juraj@mayo.edu			Center for Translational Science Activities [UL1 TR000135]	Research Electronic Data Capture (REDCap (R)) system is supported by Center for Translational Science Activities grant support (UL1 TR000135). This research was carried out with departmental Small Grant. The funders played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.	*AM PAIN SOC, 1999, PRINC AN US TREATM A; Amling CL, 2001, J UROLOGY, V165, P1146, DOI 10.1016/S0022-5347(05)66452-X; Bar-Yosef S, 2001, ANESTHESIOLOGY, V94, P1066, DOI 10.1097/00000542-200106000-00022; Beilin B, 1996, ANESTH ANALG, V82, P492, DOI 10.1097/00000539-199603000-00011; Ben-Eliyahu S, 1999, INT J CANCER, V80, P880; Biki B, 2008, ANESTHESIOLOGY, V109, P180, DOI 10.1097/ALN.0b013e31817f5b73; Brand JM, 1997, CLIN IMMUNOL IMMUNOP, V83, P190, DOI 10.1006/clin.1997.4351; Christopherson R, 2008, ANESTH ANALG, V107, P325, DOI 10.1213/ane.0b013e3181770f55; de Oliveira GS, 2011, REGION ANESTH PAIN M, V36, P271, DOI 10.1097/AAP.0b013e318217aada; Denis MG, 1997, INT J CANCER, V74, P540, DOI 10.1002/(SICI)1097-0215(19971021)74:5<540::AID-IJC11>3.0.CO;2-A; Fleming ID, 1997, AM JOINT COMMITTEE C; Forget P, 2011, EUR J ANAESTH, V28, P830, DOI 10.1097/EJA.0b013e32834b7d9a; Gupta A, 2011, BRIT J ANAESTH, V107, P164, DOI 10.1093/bja/aer100; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; MARKOVIC SN, 1993, ANESTHESIOLOGY, V78, P700, DOI 10.1097/00000542-199304000-00013; McCarthy L, 2001, DRUG ALCOHOL DEPEN, V62, P111, DOI 10.1016/S0376-8716(00)00181-2; McPherson ML, 2009, DEMYSTIFYING OPIOID, P161; Menigaux C, 2001, ANESTH ANALG, V93, P472, DOI 10.1097/00000539-200108000-00046; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; POLLOCK RE, 1987, NAT IMMUN CELL GROW, V6, P269; Sakaguchi M, 2006, ANESTH ANALG, V102, P1103, DOI 10.1213/01.ane.0000198330.84341.35; SANDLER AN, 1992, ANESTHESIOLOGY, V77, P626, DOI 10.1097/00000542-199210000-00003; Scavonetto F, 2013, BR J ANAESTH; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Sessler DI, 2008, CONTEMP CLIN TRIALS, V29, P517, DOI 10.1016/j.cct.2008.01.002; Sessler DI, 2008, EUR J CANCER PREV, V17, P269, DOI 10.1097/CEJ.0b013e3282f0c005; Sessler DI, 2010, CAN J ANAESTH, V57, P99, DOI 10.1007/s12630-009-9222-7; Sessler DI, 2009, ANESTHESIOLOGY, V111, P1, DOI 10.1097/ALN.0b013e3181a913e1; Shakhar G, 2003, ANN SURG ONCOL, V10, P972, DOI 10.1245/ASO.2003.02.007; SHAPIRO J, 1981, J CLIN INVEST, V68, P678, DOI 10.1172/JCI110303; Snyder GL, 2010, BRIT J ANAESTH, V105, P106, DOI 10.1093/bja/aeq164; Tsui BCH, 2010, CAN J ANAESTH, V57, P107, DOI 10.1007/s12630-009-9214-7; Vallejo Ricardo, 2004, Am J Ther, V11, P354, DOI 10.1097/01.mjt.0000132250.95650.85; Welters ID, 2003, CURR OPIN ANESTHESIO, V16, P509, DOI 10.1097/00001503-200310000-00011; Wuethrich PY, 2010, ANESTHESIOLOGY, V113, P570, DOI 10.1097/ALN.0b013e3181e4f6ec; Yamaguchi K, 2000, ANN SURG, V232, P58, DOI 10.1097/00000658-200007000-00009; Yeager MP, 2010, REGION ANESTH PAIN M, V35, P483, DOI 10.1097/AAP.0b013e3181fa11a9; YEAGER MP, 1995, ANESTHESIOLOGY, V83, P500, DOI 10.1097/00000542-199509000-00008; Zincke H, 2001, J UROLOGY, V166, P2208, DOI 10.1016/S0022-5347(05)65536-X	40	21	21	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999	1526-7598		ANESTH ANALG	Anesth. Analg.	OCT	2014	119	4					859	866		10.1213/ANE.0000000000000320			8	Anesthesiology	Anesthesiology	AP1KL	WOS:000341828200013	24977632				2020-06-30	J	Zin, CS; Chen, LC; Knaggs, RD				Zin, C. S.; Chen, L. -C.; Knaggs, R. D.			Changes in trends and pattern of strong opioid prescribing in primary care	EUROPEAN JOURNAL OF PAIN			English	Article							CHRONIC NONCANCER PAIN; PRACTICE RESEARCH DATABASE; LAST 3 MONTHS; NONMALIGNANT PAIN; CONSUMPTION; MORPHINE; ANALGESICS; PRESCRIPTIONS; GUIDELINE; DIVERSION	BackgroundThis study evaluated the prescribing trends of four commonly prescribed strong opioids in primary care and explored utilization in non-cancer and cancer users. MethodsThis cross-sectional study was conducted from 2000 to 2010 using the UK Clinical Practice Research Datalink. Prescriptions of buprenorphine, fentanyl, morphine and oxycodone issued to adult patients were included in this study. Opioid prescriptions issued after patients had cancer medical codes were defined as cancer-related use; otherwise, they were considered non-cancer use. Annual number of prescriptions and patients, defined daily dose (DDD/1000 inhabitants/day) and oral morphine equivalent (OMEQ) dose were measured in repeat cross-sectional estimates. ResultsIn total, there were 2,672,022 prescriptions (87.8% for non-cancer) of strong opioids for 178,692 users (59.9% female, 83.9% non-cancer, mean age 67.117.0 years) during the study period. The mean annual (DDD/1000 inhabitants/day) was higher in the non-cancer group than in the cancer group for all four opioids; morphine (0.73 +/- 0.28 vs. 0.12 +/- 0.04), fentanyl (0.46 +/- 0.29 vs. 0.06 +/- 0.24), oxycodone (0.24 +/- 0.19 vs. 0.038 +/- 0.028) and buprenorphine (0.23 +/- 0.15 vs. 0.008 +/- 0.006). The highest proportion of patients were prescribed low opioid doses (OMEQ50mg/day) in both non-cancer (50.3%) and cancer (39.9%) groups, followed by the dose ranks of 51-100mg/day (26.2% vs. 28.7%), 101-200mg/day (15.1% vs. 19.2%) and >200mg/day (8.25% vs. 12.1%). ConclusionsThere has been a huge increase in strong opioid prescribing in the United Kingdom, with the majority of prescriptions for non-cancer pain. Morphine was the most frequently prescribed, but the utilization of oxycodone, buprenorphine and fentanyl increased markedly over time.	[Zin, C. S.; Chen, L. -C.; Knaggs, R. D.] Univ Nottingham, Sch Pharm, Div Social Res Med & Hlth, Nottingham NG7 2RD, England; [Zin, C. S.] Int Islamic Univ Malaysia, Kulliyyah Pharm, Kuantan 25200, Pahang Darul Ma, Malaysia; [Knaggs, R. D.] Nottingham Univ Hosp NHS Trust, Pain Management Serv, Nottingham, England; [Knaggs, R. D.] Nottingham Univ Hosp NHS Trust, Dept Pharm, Nottingham, England	Chen, LC (reprint author), Univ Nottingham, Sch Pharm, Div Social Res Med & Hlth, East Dr,Univ Pk, Nottingham NG7 2RD, England.	chia.chen@nottingham.ac.uk		Chen, Li-Chia/0000-0002-6158-6645; Knaggs, Roger/0000-0003-1646-8321	University of Nottingham; Ministry of Higher Education, MalaysiaMinistry of Education, Malaysia	L.-C.C. was granted an Early Career Research and Knowledge Transfer Award from the University of Nottingham from 2010 to 2012, which supported accessing the CPRD dataset. C.S.Z. was funded by a postdoctoral scholarship from the Ministry of Higher Education, Malaysia.	Bekkering GE, 2011, CURR MED RES OPIN, V27, P1477, DOI 10.1185/03007995.2011.586332; Boggon R, 2013, PHARMACOEPIDEM DR S, V22, P168, DOI 10.1002/pds.3374; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Caudill-Slosberg MA, 2004, PAIN, V109, P514, DOI 10.1016/j.pain.2004.03.006; Chapman CR, 2010, J PAIN, V11, P807, DOI 10.1016/j.jpain.2010.02.019; Chou R, 2003, J PAIN SYMPTOM MANAG, V26, P1026, DOI 10.1016/j.jpainsymman.2003.03.003; Chou R, 2009, J PAIN, V10, P147, DOI 10.1016/j.jpain.2008.10.007; Clausen TG, 1997, ACTA ANAESTH SCAND, V41, P162, DOI 10.1111/j.1399-6576.1997.tb04632.x; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Fischer B, 2011, PHARMACOEPIDEM DR S, V20, P1269, DOI 10.1002/pds.2190; Fredheim OMS, 2010, EUR J PAIN, V14, P289, DOI 10.1016/j.ejpain.2009.05.006; Gao W, 2011, BRIT J CANCER, V104, P1704, DOI 10.1038/bjc.2011.150; Gilson AM, 2007, J PAIN, V8, P682, DOI 10.1016/j.jpain.2007.05.012; Gilson AM, 2004, J PAIN SYMPTOM MANAG, V28, P176, DOI 10.1016/j.jpainsymman.2004.01.003; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Gordon D B, 1999, J Palliat Med, V2, P209, DOI 10.1089/jpm.1999.2.209; Hall GC, 2006, PAIN, V122, P156, DOI 10.1016/j.pain.2006.01.030; Hamunen K, 2008, EUR J PAIN, V12, P705, DOI 10.1016/j.ejpain.2007.10.012; Hamunen K, 2009, EUR J PAIN, V13, P954, DOI 10.1016/j.ejpain.2008.11.006; Higginson IJ, 2012, J CLIN ONCOL, V30, P4373, DOI 10.1200/JCO.2012.42.0919; Hurley RW, 2008, ANESTH ANALG, V107, P309, DOI 10.1213/01.ane.0b013e31816ba437; Kelly JP, 2008, PAIN, V138, P507, DOI 10.1016/j.pain.2008.01.027; Lawrenson R, 1999, J PUBLIC HEALTH MED, V21, P299, DOI 10.1093/pubmed/21.3.299; Leong M, 2009, INTERN MED J, V39, P676, DOI 10.1111/j.1445-5994.2009.01982.x; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; National Health Service, 2013, PRESCR COST AN ENGL; National Health Service, 2011, ADD MED INV CONF COM; Noble M, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006605.pub2; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; Ponizovsky AM, 2012, EUR J CLIN PHARMACOL, V68, P89, DOI 10.1007/s00228-011-1099-z; Portenoy RK, 2004, LANCET, V364, P739, DOI 10.1016/S0140-6736(04)16951-1; Poulsen KK, 2013, BASIC CLIN PHARMACOL, V112, P110, DOI 10.1111/j.1742-7843.2012.00927.x; Scholten W, 2007, ANESTH ANALG, V105, P1, DOI 10.1213/01.ane.0000267542.72315.34; Sullivan M, 2005, J PAIN, V6, P2, DOI 10.1016/j.jpain.2004.10.006; Sullivan MD, 2008, PAIN, V138, P440, DOI 10.1016/j.pain.2008.04.027; Svendsen K, 2011, PALLIATIVE MED, V25, P725, DOI 10.1177/0269216311398300; Trescot A, 2008, PAIN PHYSICIAN, V11, pS181; Unruh AM, 1996, PAIN, V65, P123, DOI 10.1016/0304-3959(95)00214-6; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7; WHO Collaborating Centre for Drug Statistics Methodology,, 2013, GUID ATC CLASS DDD A; [WHO International Working Group for Drug Statistics Methodology WHO Collaborating Centre for Drug Statistics Methodology WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services], 2003, INTR DRUG UT RES; Williams T, 2012, THER ADV DRUG SAF, V3, P89, DOI 10.1177/2042098611435911; Zerzan JT, 2006, MED CARE, V44, P1005, DOI 10.1097/01.mlr.0000228025.04535.25	43	102	103	2	20	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	OCT	2014	18	9					1343	1351		10.1002/j.1532-2149.2014.496.x			9	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	AP3MJ	WOS:000341979800016	24756859	Green Published, Green Accepted			2020-06-30	J	Quelch, DR; Katsouri, L; Nutt, DJ; Parker, CA; Tyacke, RJ				Quelch, Darren R.; Katsouri, Loukia; Nutt, David J.; Parker, Christine A.; Tyacke, Robin J.			Imaging endogenous opioid peptide release with [C-11]carfentanil and [H-3]diprenorphine: influence of agonist-induced internalization	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						[C-11]carfentanil; [H-3]diprenorphine; immunofluoresence; internalization; PET; mu receptor	POSITRON-EMISSION-TOMOGRAPHY; RECEPTOR-BINDING; GUANINE-NUCLEOTIDE; NUCLEUS-ACCUMBENS; BRAIN; AMPHETAMINE; PAIN; RAT; METHADONE; SYSTEM	Understanding the cellular processes underpinning the changes in binding observed during positron emission tomography neurotransmitter release studies may aid translation of these methodologies to other neurotransmitter systems. We compared the sensitivities of opioid receptor radioligands, carfentanil, and diprenorphine, to amphetamine-induced endogenous opioid peptide (EOP) release and methadone administration in the rat. We also investigated whether agonist-induced internalization was involved in reductions in observed binding using subcellular fractionation and confocal microscopy. After radioligand administration, Significant reductions in [C-11]carfentanil, but not [H-3]diprenorphine, uptake were observed after methadone and amphetamine pretreatment. Subcellular fractionation and in vitro radioligand binding studies showed that amphetamine pretreatment only decreased total [C-11]carfentanil binding. In vitro saturation binding studies conducted in buffers representative of the internalization pathway suggested that mu-receptors are significantly less able to bind the radioligands in endosomal compared with extracellular compartments. Finally, a significant increase in mu-receptor-early endosome co-localization in the hypothalamus was observed after amphetamine and methadone treatment using double-labeling confocal microscopy, with no changes in delta- or kappa-receptor co-localization. These data indicate carfentanil may be superior to diprenorphine when imaging EOP release in vivo, and that alterations in the ability to bind internalized receptors may be a predictor of ligand sensitivity to endogenous neurotransmitter release.	[Quelch, Darren R.; Nutt, David J.; Parker, Christine A.; Tyacke, Robin J.] Univ London Imperial Coll Sci Technol & Med, Ctr Neuropsychopharmacol, Div Brain Sci, London W12 0NN, England; [Katsouri, Loukia] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Ctr Neuroinflammat & Neurodegenerat, Div Brain Sci, London W12 0NN, England; [Parker, Christine A.] GlaxoSmithKline, Global Imaging Unit, Stevenage, Herts, England	Quelch, DR (reprint author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Ctr Neuropsychopharmacol, Div Brain Sci, London W12 0NN, England.	d.quelch09@imperial.ac.uk			Biotechnology and Biological Science Research Council CASE award studentship; GlaxoSmithKline Global Imaging Unit; Medical Research CouncilMedical Research Council UK (MRC) [G0400575, G1002226]	This work was supported by a Biotechnology and Biological Science Research Council CASE award studentship in collaboration with the GlaxoSmithKline Global Imaging Unit.	Bencherif B, 2002, PAIN, V99, P589, DOI 10.1016/S0304-3959(02)00266-X; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; CHANG KJ, 1981, MOL PHARMACOL, V20, P1; CHILDERS SR, 1983, LIFE SCI, V33, P215, DOI 10.1016/0024-3205(83)90481-2; Colasanti A, 2012, BIOL PSYCHIAT, V72, P371, DOI 10.1016/j.biopsych.2012.01.027; Garrido MJ, 1999, J PHARMACOL EXP THER, V288, P179; Gorelick DA, 2005, BIOL PSYCHIAT, V57, P1573, DOI 10.1016/j.biopsych.2005.02.026; Guo NN, 2010, NEUROPSYCHOPHARMACOL, V35, P806, DOI 10.1038/npp.2009.189; Guterstam J, 2013, INT J NEUROPSYCHOPH, V16, P763, DOI 10.1017/S1461145712000818; Hammers A, 2007, BRAIN, V130, P1009, DOI 10.1093/brain/awm012; Hammers A, 2006, NEUROIMAG CLIN N AM, V16, P529, DOI 10.1016/j.nic.2006.06.004; Heinz A, 2005, ARCH GEN PSYCHIAT, V62, P57, DOI 10.1001/archpsyc.62.1.57; Hume SP, 2007, J PHARMACOL EXP THER, V322, P661, DOI 10.1124/jpet.107.121749; JABER M, 1995, NEUROSCIENCE, V65, P1041, DOI 10.1016/0306-4522(94)00537-F; Jones AKP, 2004, EUR J PAIN, V8, P479, DOI 10.1016/j.ejpain.2003.11.017; KHACHATURIAN H, 1984, BRAIN RES BULL, V13, P785, DOI 10.1016/0361-9230(84)90237-5; KINEMAN RD, 1989, BIOL REPROD, V40, P1119, DOI 10.1095/biolreprod40.5.1119; Kling MA, 2000, J PHARMACOL EXP THER, V295, P1070; Koepp MJ, 1998, LANCET, V352, P952, DOI 10.1016/S0140-6736(97)09077-6; Laduron P, 1977, Int Rev Neurobiol, V20, P251, DOI 10.1016/S0074-7742(08)60655-8; Lam M, 2008, PSYCHOPHARMACOLOGY, V201, P261, DOI 10.1007/s00213-008-1267-8; Laruelle M, 2000, J CEREBR BLOOD F MET, V20, P423, DOI 10.1097/00004647-200003000-00001; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; Marinell PW, 2004, NEUROSCIENCE, V127, P777, DOI 10.1016/j.neuroscience.2004.05.047; Melichar JK, 2005, J PHARMACOL EXP THER, V312, P309, DOI 10.1124/jpet.104.072686; MINTUN MA, 1984, ANN NEUROL, V15, P217, DOI 10.1002/ana.410150302; Mitchell J, 2012, TLS-TIMES LIT SUPPL, P6; NEUMAIER JF, 1989, BRAIN RES, V493, P292, DOI 10.1016/0006-8993(89)91164-5; Olive MF, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-23-j0002.2001; PFEIFFER A, 1982, J NEUROSCI, V2, P912; Quelch DR, 2012, SYNAPSE, V66, P1035, DOI 10.1002/syn.21605; RUIZGAYO M, 1992, BRAIN RES, V571, P306, DOI 10.1016/0006-8993(92)90669-Z; Sood P, 2009, J NEUROSCI METH, V185, P39, DOI 10.1016/j.jneumeth.2009.09.004; Sprenger T, 2006, PAIN, V122, P63, DOI 10.1016/j.pain.2006.01.003; STEIN EA, 1990, BRAIN RES, V533, P213, DOI 10.1016/0006-8993(90)91342-E; TEMPEL A, 1987, P NATL ACAD SCI USA, V84, P4308, DOI 10.1073/pnas.84.12.4308; von Zastrow M, 2010, DRUG ALCOHOL DEPEN, V108, P166, DOI 10.1016/j.drugalcdep.2010.02.014; Wang YL, 2008, LIFE SCI, V83, P693, DOI 10.1016/j.lfs.2008.09.023; Willoch F, 2004, PAIN, V108, P213, DOI 10.1016/j.pain.2003.08.014; Zubieta JK, 2000, NEUROPSYCHOPHARMACOL, V23, P326, DOI 10.1016/S0893-133X(00)00110-X	40	16	17	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2014	34	10					1604	1612		10.1038/jcbfm.2014.117			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AQ1IV	WOS:000342536000004	25005876	Green Published, Bronze			2020-06-30	J	Bartkowska-Sniatkowska, A; Bienert, A; Wiczling, P; Owczarek, M; Rosada-Kurasinska, J; Grzeskowiak, M; Matysiak, J; Kokot, ZJ; Kaliszan, R; Grzeskowiak, E				Bartkowska-Sniatkowska, Alicja; Bienert, Agnieszka; Wiczling, Pawel; Owczarek, Marcin; Rosada-Kurasinska, Jowita; Grzeskowiak, Malgorzata; Matysiak, Jan; Kokot, Zenon J.; Kaliszan, Roman; Grzeskowiak, Edmund			Pharmacokinetics and pharmacodynamics of propofol in children undergoing different types of surgeries	PHARMACOLOGICAL REPORTS			English	Article						Propofol; Bispectral index; Pharmacokinetic and pharmacodynamics modeling; Children; Total intravenous anesthesia	BISPECTRAL INDEX MONITOR; CONTROLLED INFUSION; HUMAN PLASMA; MODEL; ANESTHESIA; MIDAZOLAM; SEDATION; REMIFENTANIL; VALIDATION; PAEDFUSOR	Background: Propofol is a commonly used agent in total intravenous anesthesia (TIVA). However, the link between its pharmacokinetics and pharmacodynamics has not been fully characterized in children yet. Our aim was to determine the quantitative relationship between the venous plasma concentration and bispectral index (BIS) effect in a heterogeneous group of pediatric patients undergoing various surgical procedures (ASA status I-III) Methods: Nine male and nine female patients were anesthetized with propofol-fentanyl TIVA. Sparse venous samples for propofol concentrations assay and dense BIS measurements were collected during and after the end of infusion. Nonlinear mixed-effect modeling in NONMEM was used for data analysis. Results: A three-compartment model was linked with a classical E-max model through a biophase compartment to describe the available data. All clearance and volume terms were allometrically scaled to account for the body mass difference among the patients under study. A typical patient had their PK parameters observed within the range of literature values for children. The pharmacodynamic parameters were highly variable. The EC50 of 2.80 mg/L and the biophase distribution rate constant of 3.33 min(-1) were found for a typical patient. Conclusions: The BIS values in children are highly correlated with the propofol effect compartment concentrations according to the classical E-max. concentration-response relationship. Children had slightly lower sensitivity to propofol and slightly higher clearance, as compared with the adult data available in literature. The intra-patient variations in the BIS require the anesthesiologist's attention in using BIS values alone to evaluate the depth of anesthesia in children. (C) 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.	[Bartkowska-Sniatkowska, Alicja; Rosada-Kurasinska, Jowita] Poznan Univ Med Sci, Dept Pediat Anesthesiol & Intens Therapy, Poznan, Poland; [Bienert, Agnieszka; Grzeskowiak, Edmund] Poznan Univ Med Sci, Dept Clin Pharm & Biopharm, Poznan, Poland; [Wiczling, Pawel; Kaliszan, Roman] Med Univ Gdansk, Dept Biopharmaceut & Pharmacodynam, Gdansk, Poland; [Owczarek, Marcin] Coll Med Bydgoszcz, Dept Anaesthesiol & Intens Therapy, Bydgoszcz, Poland; [Grzeskowiak, Malgorzata] Poznan Univ Med Sci, Dept Teaching Anesthesiol & Intens Therapy, Poznan, Poland; [Matysiak, Jan; Kokot, Zenon J.] Poznan Univ Med Sci, Dept Analyt Chem, Poznan, Poland	Wiczling, P (reprint author), Med Univ Gdansk, Dept Biopharmaceut & Pharmacodynam, Gdansk, Poland.	wiczling@gumed.edu.pl	Matysiak, Jan/R-6498-2016; Wiczling, Pawel/T-3987-2018	Matysiak, Jan/0000-0002-9993-1504; Wiczling, Pawel/0000-0002-2878-3161; Rosada-Kurasinska, Jowita/0000-0002-8116-4028; Bartkowska-Sniatkowska, Alicja/0000-0003-4950-2346; Kokot, Zenon/0000-0003-4950-9759; Kaliszan, Roman/0000-0001-7977-9878; Grzeskowiak, Malgorzata/0000-0003-4215-8730; Grzeskowiak, Edmund/0000-0002-9938-6729; Bienert, Agnieszka/0000-0001-7272-5738			Absalom A, 2005, BRIT J ANAESTH, V95, P110, DOI 10.1093/bja/aei567; Absalom A, 2003, BRIT J ANAESTH, V91, P507, DOI 10.1093/bja/aeg220; Absalom AR, 2009, BRIT J ANAESTH, V103, P26, DOI 10.1093/bja/aep143; Amigoni A, 2012, MINERVA ANESTESIOL, V78, P322; Anderson BJ, 2008, ANNU REV PHARMACOL, V48, P303, DOI 10.1146/annurev.pharmtox.48.113006.094708; Anderson BJ, 2000, BRIT J CLIN PHARMACO, V50, P125, DOI 10.1046/j.1365-2125.2000.00231.x; Anderson BJ, 2010, CURR OPIN ANESTHESIO, V23, P356, DOI 10.1097/ACO.0b013e32833938db; Bergstrand M, 2011, AAPS J, V13, P143, DOI 10.1208/s12248-011-9255-z; Bienert A, 2012, PHARMACOL REP, V64, P782, DOI 10.1016/S1734-1140(12)70874-5; Bienert Agnieszka, 2005, Acta Pol Pharm, V62, P95; Bjornsson MA, 2010, J PHARMACOKINET PHAR, V37, P243, DOI 10.1007/s10928-010-9157-1; Brosius KK, 2002, ANESTH ANALG, V94, P31, DOI 10.1097/00000539-200201000-00006; Chidambaran V, 2013, BMC ANESTHESIOL, V13, DOI 10.1186/1471-2253-13-8; Constant I, 2013, ANN FR ANESTH, V32, P37; Constant I, 2010, PEDIATR ANESTH, V20, P233, DOI 10.1111/j.1460-9592.2010.03269.x; Cortinez L I, 2006, Rev Esp Anestesiol Reanim, V53, P289; Dawidowicz AL, 2003, BIOMED CHROMATOGR, V17, P447, DOI 10.1002/bmc.269; Dawidowicz AL, 2000, BIOMED CHROMATOGR, V14, P249, DOI 10.1002/1099-0801(200006)14:4<249::AID-BMC981>3.0.CO;2-H; Jeleazcov C, 2008, BRIT J ANAESTH, V100, P509, DOI 10.1093/bja/aem408; Johnson TN, 2002, BRIT J ANAESTH, V89, P428, DOI 10.1093/bja/aef213; KATARIA BK, 1994, ANESTHESIOLOGY, V80, P104, DOI 10.1097/00000542-199401000-00018; Knibbe CAJ, 2005, BRIT J CLIN PHARMACO, V59, P705, DOI 10.1111/j.1365-2125.2005.02239.x; Lerman J, 2010, PEDIATR ANESTH, V20, P273, DOI 10.1111/j.1460-9592.2009.03238.x; MARSH B, 1991, BRIT J ANAESTH, V67, P41, DOI 10.1093/bja/67.1.41; Minto CF, 2000, ANESTHESIOLOGY, V92, P1603, DOI 10.1097/00000542-200006000-00017; Munoz HR, 2006, ACTA ANAESTH SCAND, V50, P882, DOI 10.1111/j.1399-6576.2006.01062.x; Munoz HR, 2004, ANESTHESIOLOGY, V101, P1269; Overly FL, 2005, J ORAL MAXIL SURG, V63, P215, DOI 10.1016/j.joms.2004.07.013; Park HJ, 2007, PEDIATR ANESTH, V17, P353, DOI 10.1111/j.1460-9592.2006.02096.x; Parke J, 1999, COMPUT METH PROG BIO, V59, P19, DOI 10.1016/S0169-2607(98)00098-4; Peeters MMM, 2008, CLIN PHARMACOL THER, V83, P443, DOI 10.1038/sj.clpt.6100309; Playfor SD, 2005, CRIT CARE, V9, P25, DOI 10.1186/cc3001; Restrepo JG, 2009, CURR DRUG METAB, V10, P236, DOI 10.2174/138920009787846305; Rigby-Jones AE, 2007, PAEDIATR ANAESTH, V17, P610; Rigby-Jones AE, 2011, PEDIATR ANESTH, V21, P247, DOI 10.1111/j.1460-9592.2010.03454.x; Rigouzzo A, 2008, ANESTH ANALG, V106, P1109, DOI 10.1213/ane.0b013e318164f388; Sadhasivam S, 2006, ANESTH ANALG, V102, P383, DOI 10.1213/01.ANE.0000184115.57837.30; Savic RM, 2009, AAPS J, V11, P558, DOI 10.1208/s12248-009-9133-0; Schnider TW, 1998, ANESTHESIOLOGY, V88, P1170, DOI 10.1097/00000542-199805000-00006; Schuttler J, 2000, ANESTHESIOLOGY, V92, P727, DOI 10.1097/00000542-200003000-00017; SHORT TG, 1992, BRIT J ANAESTH, V69, P162, DOI 10.1093/bja/69.2.162; SHORT TG, 1991, BRIT J ANAESTH, V67, P539, DOI 10.1093/bja/67.5.539; SHORT TG, 1994, BRIT J ANAESTH, V72, P302, DOI 10.1093/bja/72.3.302; Standing JF, 2010, PEDIATR ANESTH, V20, P7, DOI 10.1111/j.1460-9592.2009.03174.x; Takata K, 2008, BRIT J ANAESTH, V101, P648, DOI 10.1093/bja/aen249; Tirel O, 2008, BRIT J ANAESTH, V100, P82, DOI 10.1093/bja/aem339; Watcha MF, 2001, ANESTH ANALG, V92, P805; Wiczling P, 2012, PHARMACOL REP, V64, P113, DOI 10.1016/S1734-1140(12)70737-5	48	4	6	1	17	POLISH ACAD SCIENCES INST PHARMACOLOGY	KRAKOW	SMETNA 12, 31-343 KRAKOW, POLAND	1734-1140			PHARMACOL REP	Pharmacol. Rep.	OCT	2014	66	5					821	829		10.1016/j.pharep.2014.04.012			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AO1GW	WOS:000341061600013	25149986				2020-06-30	J	Lin, YQ; Kwong, KS; Cheung, SH; Poon, WY				Lin, Yueqiong; Kwong, Koon Shing; Cheung, Siu Hung; Poon, Wai-Yin			Step-up testing procedure for multiple comparisons with a control for a latent variable model with ordered categorical responses	STATISTICS IN MEDICINE			English	Article						ordered categorical response; latent normal variable model; familywise error rate; sample size determination	SAMPLE-SIZE DETERMINATION; ORDINAL DATA; TRIAL; PRETREATMENT; TOXICITIES; PROPOFOL; PAIN	In clinical studies, multiple comparisons of several treatments to a control with ordered categorical responses are often encountered. A popular statistical approach to analyzing the data is to use the logistic regression model with the proportional odds assumption. As discussed in several recent research papers, if the proportional odds assumption fails to hold, the undesirable consequence of an inflated familywise type I error rate may affect the validity of the clinical findings. To remedy the problem, a more flexible approach that uses the latent normal model with single-step and stepwise testing procedures has been recently proposed. In this paper, we introduce a step-up procedure that uses the correlation structure of test statistics under the latent normal model. A simulation study demonstrates the superiority of the proposed procedure to all existing testing procedures. Based on the proposed step-up procedure, we derive an algorithm that enables the determination of the total sample size and the sample size allocation scheme with a pre-determined level of test power before the onset of a clinical trial. A clinical example is presented to illustrate our proposed method. Copyright (c) 2014 John Wiley & Sons, Ltd.	[Lin, Yueqiong] Fuzhou Univ, Sch Econ & Management, Fuzhou 350002, Peoples R China; [Kwong, Koon Shing] Singapore Management Univ, Sch Econ, Singapore 178903, Singapore; [Cheung, Siu Hung; Poon, Wai-Yin] Chinese Univ Hong Kong, Dept Stat, Shatin, Hong Kong, Peoples R China	Kwong, KS (reprint author), Singapore Management Univ, Sch Econ, 90 Stamford Rd, Singapore 178903, Singapore.	kskwong@smu.edu.sg		Cheung, Siu Hung/0000-0001-7121-4047; Poon, Wai Yin/0000-0002-1940-8925	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [11326180]; Singapore Management University from the Ministry of Education Academic Research Tier 1 [C244/MSS12E002]; Research Grants Council of the Hong Kong Special Administrative RegionHong Kong Research Grants Council [CUHK403112]	The authors are grateful to the referees for providing helpful comments that have significantly improved this paper. Lin's research was funded by the National Natural Science Foundation of China (Grant No. 11326180). Kwong's research was funded by the Singapore Management University through a research grant (C244/MSS12E002) from the Ministry of Education Academic Research Tier 1. Poon's research was funded by the Research Grants Council of the Hong Kong Special Administrative Region (CUHK403112).	Bekele BN, 2004, J AM STAT ASSOC, V99, P26, DOI 10.1198/016214504000000043; DUNNETT CW, 1989, APPL STAT-J ROY ST C, V38, P564, DOI 10.2307/2347754; DUNNETT CW, 1991, STAT MED, V10, P939, DOI 10.1002/sim.4780100614; DUNNETT CW, 1992, J AM STAT ASSOC, V87, P162, DOI 10.2307/2290465; Fagerland MW, 2009, STAT MED, V28, P1487, DOI 10.1002/sim.3561; Fujii Y, 2009, CLIN THER, V31, P2107, DOI 10.1016/j.clinthera.2009.10.012; HAYTER AJ, 1991, J STAT PLAN INFER, V27, P271, DOI 10.1016/0378-3758(91)90042-D; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; Horn M, 1998, BIOMETRICAL J, V40, P589, DOI 10.1002/(SICI)1521-4036(199809)40:5<589::AID-BIMJ589>3.0.CO;2-8; Horn M, 2004, LECT NOTES MONOGRAPH, V47, P48; Kwong KS, 2008, COMPUT STAT DATA AN, V52, P5091, DOI 10.1016/j.csda.2008.05.005; Kwong KS, 2000, STAT PROBABIL LETT, V49, P411, DOI 10.1016/S0167-7152(00)00076-6; Leon-Novelo LG, 2010, BIOMETRICS, V66, P966, DOI 10.1111/j.1541-0420.2009.01359.x; Lin YQ, 2013, STAT MED, V32, P3192, DOI 10.1002/sim.5751; Liu W, 1997, J STAT PLAN INFER, V62, P255, DOI 10.1016/S0378-3758(96)00193-0; Lu TY, 2015, STAT METHODS MED RES, V24, P949, DOI 10.1177/0962280211434425; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; Poon WY, 2004, STAT MED, V23, P2155, DOI 10.1002/SIM.1814; QU YS, 1995, BIOMETRICS, V51, P268, DOI 10.2307/2533332; WHITEHEAD J, 1993, STAT MED, V12, P2257, DOI 10.1002/sim.4780122404; Whitehead J, 2009, STAT MED, V28, P828, DOI 10.1002/sim.3508; WILCOXON F, 1945, BIOMETRICS BULL, V1, P80, DOI 10.2307/3001968; Young S., 1993, RESAMPLING BASED MUL; Zhao GY, 2012, J CLIN ANESTH, V24, P284, DOI 10.1016/j.jclinane.2011.08.013	24	3	3	0	10	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0277-6715	1097-0258		STAT MED	Stat. Med.	SEP 20	2014	33	21					3629	3638		10.1002/sim.6190			10	Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability	Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics	AN2NX	WOS:000340423700002	24757077				2020-06-30	J	Kanbara, T; Nakamura, A; Shibasaki, M; Mori, T; Suzuki, T; Sakaguchi, G; Kanemasa, T				Kanbara, Tomoe; Nakamura, Atsushi; Shibasaki, Masahiro; Mori, Tomohisa; Suzuki, Tsutomu; Sakaguchi, Gaku; Kanemasa, Toshiyuki			Morphine and oxycodone, but not fentanyl, exhibit antinociceptive effects mediated by G-protein inwardly rectifying potassium (GIRK) channels in an oxaliplatin-induced neuropathy rat model	NEUROSCIENCE LETTERS			English	Article						MOR agonists; Antinociception; Oxaliplatin; Neuropathy; G-protein inwardly rectifying K+ channel	MU-OPIOID RECEPTOR; NEURONS	It has begun to be understood that mu-opioid receptor (MOR) produces ligand-biased agonism, which contributes to differential physiological functions of MOR agonists. We previously demonstrated that in oxaliplatin-induced neuropathy in rats, morphine and oxycodone exhibited antinociceptive effects while antinociception of fentanyl was partial, and such different efficacies might result from the different level of Gi/o protein activation. Based on our background, to reveal further mechanism, we focused on the role of Gi/o protein-related downstream signaling, the G-protein inwardly rectifying K(+)1 (GIRK1) channel. The GIRK1 channel blocker tertiapin-Q (30 pmol) was intracerebroventricularly (i.c.v.) or intrathecally (i.t.) administered to rats with oxaliplatin-induced neuropathy. The antinociception of systemic morphine (3 mg/kg, subcutaneously (s.c.)) was suppressed only by pretreatment of i.t. tertiapin-Q while supraspinal tertiapin-Q suppressed only the antinociception of systemic oxycodone (0.56 mg/kg, s.c.). Partial antinocicpetion of fentanyl (0.017 mg/kg, s.c.) was neither affected by i.c.v nor i.t. tertiapin-Q These results demonstrated that GIRK1 channels differentially contribute to antinociceptive effects of MOR agonists, and that action site of GIRK1 channels is also different between morphine and oxycodone in oxaliplatin model. This study suggests the possibility that GIRK1 channels have a crucial role for antinociception of MOR agonists in oxaliplatin-induced neuropathy. (C) 2014 Elsevier Ireland Ltd. All rights reserved.	[Kanbara, Tomoe; Nakamura, Atsushi; Sakaguchi, Gaku; Kanemasa, Toshiyuki] Shionogi & Co Ltd, Pain & Neurol Discovery Res Labs, Toyonaka, Osaka 5610825, Japan; [Kanbara, Tomoe; Nakamura, Atsushi; Shibasaki, Masahiro; Mori, Tomohisa; Suzuki, Tsutomu] Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Toxicol, Shinagawa Ku, Tokyo 1428501, Japan	Kanemasa, T (reprint author), Shionogi & Co Ltd, Pain & Neurol Discovery Res Labs, 1-1 3-chome,Futaba Cho, Toyonaka, Osaka 5610825, Japan.	toshiyuki.kanemasa@shionogi.co.jp					Ali BH, 2010, BASIC CLIN PHARMACOL, V106, P272, DOI 10.1111/j.1742-7843.2009.00512.x; BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; BHARGAVA HN, 1993, BRAIN RES, V607, P1, DOI 10.1016/0006-8993(93)91482-8; Celver J, 2004, MOL PHARMACOL, V65, P528, DOI 10.1124/mol.65.3.528; Chen SR, 2006, BRAIN RES, V1081, P119, DOI 10.1016/j.brainres.2006.01.053; Chen YP, 2005, J PHARMACOL EXP THER, V314, P611, DOI 10.1124/jpet.105.085563; Gonzalez-Rodriguez S, 2010, N-S ARCH PHARMACOL, V381, P59, DOI 10.1007/s00210-009-0471-3; Hahm ET, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-41; Han MH, 2010, BIOL PSYCHIAT, V67, P761, DOI 10.1016/j.biopsych.2009.08.041; Hoekman J.D., ANESTH ANALG, V113; Imai Satoshi, 2006, JAPANESE JOURNAL OF NEUROPSYCHOPHARMACOLOGY, V26, P183; Jin WL, 1998, BIOCHEMISTRY-US, V37, P13291, DOI 10.1021/bi981178p; Kanbara T, CONTRIBUTION G UNPUB; Koch T, 2005, MOL PHARMACOL, V67, P280, DOI 10.1124/mol.104.004994; Koyyalagunta D, 2012, PAIN PHYSICIAN, V15, pES39; Kuo A., 2014, BR J PHARM IN PRESS; LEVY RA, 1979, EUR J PHARMACOL, V57, P43, DOI 10.1016/0014-2999(79)90102-X; Marker CL, 2005, J NEUROSCI, V25, P3551, DOI 10.1523/JNEUROSCI.4899-04.2005; Minami K., J PHARM SCI, V111; Moulin DE, 1996, LANCET, V347, P143, DOI 10.1016/S0140-6736(96)90339-6; Nagashima M, 2014, SUPPORT CARE CANCER, V22, P1579, DOI 10.1007/s00520-014-2132-4; Nakamura A., 2013, BRIT J PHARMACOL, V168, P75; Nakamura A., 2014, BRIT J PHARMACOL, V171, P53; Nakamura Atsushi, 2011, J Pain Palliat Care Pharmacother, V25, P318, DOI 10.3109/15360288.2011.620689; Narita M, 2002, NEUROSCIENCE, V111, P127, DOI 10.1016/S0306-4522(01)00515-2; Narita M, 2008, NEUROPSYCHOPHARMACOL, V33, P1097, DOI 10.1038/sj.npp.1301471; Narita M, 2013, ADDICT BIOL, V18, P614, DOI 10.1111/j.1369-1600.2011.00354.x; Nelson KA, 1997, J PAIN SYMPTOM MANAG, V13, P262, DOI 10.1016/S0885-3924(96)00329-6; Paxinos G, 2007, RAT BRAIN STEREOTAXI; Poyhia R., 1992, PHARMACOL TOXICOL, V70, P25; Psigfogeorgou K, 2011, J NEUROSCI, V31, P5617, DOI 10.1523/JNEUROSCI.4146-10.2011; REICHLING DB, 1988, PROG BRAIN RES, V77, P31; Saif MW, 2010, ANTICANCER RES, V30, P2927; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; Takasu K, ENHANCED GABAE UNPUB; URBAN MO, 1994, BRAIN RES, V652, P9, DOI 10.1016/0006-8993(94)90311-5; Zheng H, 2008, MOL PHARMACOL, V73, P178, DOI 10.1124/mol.107.039842	38	10	10	0	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	SEP 19	2014	580						119	124		10.1016/j.neulet.2014.08.005			6	Neurosciences	Neurosciences & Neurology	AQ0NC	WOS:000342479000024	25128218				2020-06-30	J	Valdez, CA; Leif, RN; Mayer, BP				Valdez, Carlos A.; Leif, Roald N.; Mayer, Brian P.			An Efficient, Optimized Synthesis of Fentanyl and Related Analogs	PLOS ONE			English	Article							EPIDURAL INTRATHECAL ROUTE; MOSCOW THEATER SIEGE; OPIOID-RECEPTOR; CLINICAL USE; TOLERANCE; EFFICACY; COMPLEX	The alternate and optimized syntheses of the parent opioid fentanyl and its analogs are described. The routes presented exhibit high-yielding transformations leading to these powerful analgesics after optimization studies were carried out for each synthetic step. The general three-step strategy produced a panel of four fentanyls in excellent yields (73-78%) along with their more commonly encountered hydrochloride and citric acid salts. The following strategy offers the opportunity for the gram-scale, efficient production of this interesting class of opioid alkaloids.	[Valdez, Carlos A.; Leif, Roald N.; Mayer, Brian P.] Lawrence Livermore Natl Lab, Phys & Life Sci Directorate, Livermore, CA 94550 USA; [Valdez, Carlos A.; Leif, Roald N.; Mayer, Brian P.] Lawrence Livermore Natl Lab, Forens Sci Ctr, Livermore, CA USA	Mayer, BP (reprint author), Lawrence Livermore Natl Lab, Phys & Life Sci Directorate, Livermore, CA 94550 USA.	mayer22@llnl.gov			Lawrence Livermore National Laboratory (llnl.gov) under the Laboratory Directed Research and Development (LDRD) program [14-ERD-048]	The authors (CAV, BPM, and RNL) received funding from Lawrence Livermore National Laboratory (llnl.gov) under the Laboratory Directed Research and Development (LDRD) program, project number 14-ERD-048. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albanese D, 2008, ORG PROCESS RES DEV, V12, P736, DOI 10.1021/op800001d; Balannik V, 2009, BIOCHEMISTRY-US, V48, P11872, DOI 10.1021/bi9014488; Burova SA, 2007, SYNTHETIC COMMUN, V37, P3029, DOI 10.1080/00397910701542996; Chauhan S, 2008, ENVIRON TOXICOL PHAR, V26, P113, DOI 10.1016/j.etap.2008.03.003; Coupland RM, 2003, LANCET, V362, P1346, DOI 10.1016/S0140-6736(03)14684-3; DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018; Friedrichsdorf SJ, 2014, J PAIN RES, V7, P117, DOI 10.2147/JPR.S58862; Gant T. G., 2010, [No title captured], Patent No. [20100016365, US 20100016365A1]; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; Ghaffarzadeh M, 2012, TETRAHEDRON LETT, V53, P203, DOI 10.1016/j.tetlet.2011.11.018; Gordon DB, 2006, ONCOL NURS FORUM, V33, P257, DOI 10.1188/06.ONF.257-264; Granier S, 2012, NATURE, V485, P400, DOI 10.1038/nature11111; Grass J A, 2000, Anesthesiol Clin North Am, V18, P407, DOI 10.1016/S0889-8537(05)70170-X; GRASS JA, 1992, J PAIN SYMPTOM MANAG, V7, P271, DOI 10.1016/0885-3924(92)90061-L; GRASS JA, 1992, J PAIN SYMPTOM MANAG, V7, P419, DOI 10.1016/0885-3924(92)90022-A; Gupta PK, 2005, J CHEM RES, P452; JANSSEN PA, 1961, J PHARM PHARMACOL, V13, P513, DOI 10.1111/j.2042-7158.1961.tb11864.x; JANSSEN PAJ, 1960, J MED PHARMACEUT CH, V2, P31; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; Lee SK, 2014, INT J GEN MED, V7, P49, DOI 10.2147/IJGM.S42187; Lehmann KA, 2005, J PAIN SYMPTOM MANAG, V29, pS72, DOI 10.1016/j.jpainsymman.2005.01.005; Maciejewski D, 2012, ANAESTH INTENSIVE TH, V44, P35; Manglik A, 2012, NATURE, V485, P321, DOI 10.1038/nature10954; Mercadante S, 2011, CURR PAIN HEADACHE R, V15, P244, DOI 10.1007/s11916-011-0191-5; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Rieder J, 2003, LANCET, V361, P1131, DOI 10.1016/S0140-6736(03)12869-3; Sirohi S, 2008, PHARMACOL BIOCHEM BE, V91, P115, DOI 10.1016/j.pbb.2008.06.019; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Stanley TH, 2005, J PAIN SYMPTOM MANAG, V29, pS67, DOI 10.1016/j.jpainsymman.2005.01.009; Thompson AA, 2012, NATURE, V485, P395, DOI 10.1038/nature11085; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Watson AJA, 2011, J ORG CHEM, V76, P2328, DOI 10.1021/jo102521a; Wax PM, 2003, ANN EMERG MED, V41, P700, DOI 10.1067/mem.2003.148; Wu HX, 2012, NATURE, V485, P327, DOI 10.1038/nature10939	34	28	28	2	46	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2014	9	9							e108250	10.1371/journal.pone.0108250			8	Multidisciplinary Sciences	Science & Technology - Other Topics	AQ6KR	WOS:000342921200089	25233364	DOAJ Gold, Green Published			2020-06-30	J	Yong, Z; Gao, X; Ma, WT; Dong, HJ; Gong, ZH; Su, RB				Yong, Zheng; Gao, Xiang; Ma, Wentao; Dong, Huajing; Gong, Zehui; Su, Ruibin			Nalmefene reverses carfentanil-induced loss of righting reflex and respiratory depression in rats	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Nalmefene; Carfentanil; Loss of righting reflex; Respiratory depression	CERVUS-ELAPHUS-NELSONI; ALCOHOL DEPENDENCE; NALOXONE; CITRATE; MU; IMMOBILIZATION; ANESTHESIA; HYDROCHLORIDE; NALTREXONE; OCCUPANCY	Reversing the respiratory depression induced by carfentanil involves intravenous administration of naloxone or naltrexone, but this treatment has disadvantages. Hence, finding a more appropriate treatment to counter the depressive actions of carfentanil is needed. In the present study, with the naloxone as a control, we investigated the efficacy of nalmefene for countering the depressive actions of carfentanil. Rats were treated successively with carfentanil (10 mu g/kg, i.v.) and nalmefene (9.4-150.0 mu g/kg, i.m.), and the duration of loss of righting reflex (LORR) recorded. Respiratory parameters were measured in free-moving rats using a whole-body plethysmograph after rats were administered carfentanil (20 mu g/kg, iv,) and nalmefene (9.4-150.0 mu g/kg, i.m.) sequentially. The parameters of arterial blood gases were also examined. Nalmefene (9.4-150.0 mu g/kg, i.m.) treatment dose-dependently decreased the duration of carfentanil-induced LORR. The respiratory rate after 60 min of nalmefene (150.0 mu g/kg, i.m.) treatment increased from 343 +/- 5.3 bursts/min to 117.8 +/- 18.9 bursts/min, and enhanced pause decreased from 1.1 +/- 0.1 to 0.4 +/- 0.1, and was close to those of normal rats. Furthermore, nalmefene (37.5-150.0 mu g/kg) treatment could enable the PaO2, SaO(2) and PaCO2 to approach normal levels 10 min (15 min after carfentanil injection) or 30 min (25 min after carfentanil injection) after injection. While, a single injection of naloxone (150.0 mu g/kg, i.m.) only achieved partial remission of respiratory depression. These data suggest that nalmefene more effectively counters the depressive actions induced by carfentanil and is a more appropriate treatment to antagonize carfentanil toxicity compared with naloxone. (C) 2014 Elsevier B.V. All rights reserved.	[Yong, Zheng; Gao, Xiang; Ma, Wentao; Dong, Huajing; Gong, Zehui; Su, Ruibin] Beijing Inst Pharmacol & Toxicol, Beijing 100850, Peoples R China	Su, RB (reprint author), Beijing Inst Pharmacol & Toxicol, 27 Taiping Rd, Beijing 100850, Peoples R China.	ruibinsu@126.com			National Science and Technology Major Projects for "Major New Drugs Innovation and Development " in China [2013ZX09J13104-01A]	Funding for this study was provided by National Science and Technology Major Projects for "Major New Drugs Innovation and Development (2013ZX09J13104-01A)" in China.	Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; DIXON R, 1987, J CLIN PHARMACOL, V27, P233, DOI 10.1002/j.1552-4604.1987.tb02191.x; Franks NP, 2008, NAT REV NEUROSCI, V9, P370, DOI 10.1038/nrn2372; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; Goodman AJ, 2007, CHEMMEDCHEM, V2, P1552, DOI 10.1002/cmdc.200700143; Hagelberg N, 2012, NEUROSCI LETT, V521, P11, DOI 10.1016/j.neulet.2012.05.042; HURLE MA, 1985, NEUROPHARMACOLOGY, V24, P597, DOI 10.1016/0028-3908(85)90100-5; Ingman K, 2005, NEUROPSYCHOPHARMACOL, V30, P2245, DOI 10.1038/sj.npp.1300790; JOHNSTONE RE, 1974, ANESTHESIOLOGY, V41, P361, DOI 10.1097/00000542-197410000-00010; Keating GM, 2013, CNS DRUGS, V27, P761, DOI 10.1007/s40263-013-0101-y; Kim S, 1997, J NUCL MED, V38, P1726; LONGNECKER DE, 1973, ANESTH ANALG, V52, P447, DOI 10.1213/00000539-197352030-00033; Lust EB, 2011, J EMERG MED, V40, P198, DOI 10.1016/j.jemermed.2009.09.026; Ly HG, 2013, PAIN, V154, P2072, DOI 10.1016/j.pain.2013.06.026; Mason BJ, 1999, ARCH GEN PSYCHIAT, V56, P719, DOI 10.1001/archpsyc.56.8.719; MEYER MC, 1984, J CLIN PSYCHIAT, V45, P15; Miller MW, 1996, J WILDLIFE DIS, V32, P234, DOI 10.7589/0090-3558-32.2.234; Moresco A, 2001, J ZOO WILDLIFE MED, V32, P81, DOI 10.1638/1042-7260(2001)032[0081:UONTRC]2.0.CO;2; MORINSURUN MP, 1984, EUR J PHARMACOL, V98, P235, DOI 10.1016/0014-2999(84)90594-6; NEUMANN G, 1980, RES EXP MED, V177, P135, DOI 10.1007/BF01851842; RAMSAY EC, 1995, J WILDLIFE DIS, V31, P391, DOI 10.7589/0090-3558-31.3.391; Sarton E, 2008, ADV EXP MED BIOL, V605, P486; SHAW ML, 1995, J AM VET MED ASSOC, V206, P833; Soyka M, 2010, EXPERT OPIN INV DRUG, V19, P1451, DOI 10.1517/13543784.2010.522990; SRISURAPANONT M, 2002, [No title captured], V2, P1867; Storms TN, 2006, J ZOO WILDLIFE MED, V37, P347, DOI 10.1638/05-079.1	26	12	12	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	SEP 5	2014	738						153	157		10.1016/j.ejphar.2014.05.044			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AM6TM	WOS:000339998000019	24886878				2020-06-30	J	Netherton, SJ; Wang, DM; McRae, A; Lang, E				Netherton, Stuart J.; Wang, Dongmei; McRae, Andrew; Lang, Eddy			Computerized physician order entry and decision support improves ED analgesic ordering for renal colic	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							EMERGENCY-DEPARTMENT; CONTROLLED-TRIAL; KETOROLAC; PAIN; MORPHINE; MEDICINE; SYSTEMS; DRUG	Objectives: Computerized physician order entry (CPOE) offers the potential for safer, faster patient care, as well as greater use of evidence-based therapy via built-in decision support. However, the effectiveness of CPOE in yielding these benefits has shown mixed results in the emergency department (ED) setting. Our objective was to evaluate the impact of CPOE implementation on analgesic prescribing and dosing practices for renal colic presentations. Methods: This retrospective pre/post comparative study was conducted in 3 tertiary hospitals that implemented CPOE in 2010. Two patient groups were compared: prior to (pre-CPOE) and after (post-CPOE) CPOE implementation. Each group consisted of 230 randomly selected, high-acuity patients presenting to the ED with renal colic. The primary outcome was the proportion of patients receiving ketorolac in the ED. Secondary outcomes included choice of analgesic and average morphine dose. Results: The proportion of patients receiving ketorolac significantly increased after CPOE implementation (65.6% pre-CPOE vs 76.5% post-CPOE, P=.015), as did the proportion of patients receiving fentanyl (pre, 9.7%; post, 16.7%; P=.047). Differences in morphine use (pre, 66.0%; post, 69.1%) and average morphine dose (pre, 10.09 mg; post, 12.28 mg) did not reach statistical significance. Conclusions: The introduction of CPOE is associated with an increase in ketorolac use for ED renal colic visits. This may reflect the inclusion of ketorolac in the renal colic order set. Computerized physician order entry implementation with condition-specific electronic order sets and decision support may improve evidence-based practice. (C) 2014 Elsevier Inc. All rights reserved.	[Netherton, Stuart J.; Wang, Dongmei; McRae, Andrew; Lang, Eddy] Univ Calgary, Dept Emergency Med, Calgary, AB, Canada	Lang, E (reprint author), Dept Emergency Med, Rm C231 Foothills Med Ctr,1403 29th St NW, Calgary, AB T2N 2T9, Canada.	eddy.lang@albertahealthservices.ca	Lang, Eddy/I-4759-2014	Lang, Eddy/0000-0003-0850-4337			Adam Terrence J, 2011, AMIA Annu Symp Proc, V2011, P38; Alberta Innovates Health Solutions, PROJ ETH COMM CONS I; Asaro PV, 2008, ACAD EMERG MED, V15, P908, DOI 10.1111/j.1553-2712.2008.00235.x; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; Beveridge R, 1999, CJEM S, V1, pS2; Bullard MJ, 2008, CAN J EMERG MED, V10, P136; Di Trolio Robert N., 1999, Journal of the American Osteopathic Association, V99, P589; Fosnocht DE, 2005, EMERG MED CLIN N AM, V23, P297, DOI 10.1016/j.emc.2004.12.003; Georgiou A, 2013, ANN EMERG MED, V61, P644, DOI 10.1016/j.annemergmed.2013.01.028; Griffey RT, 2009, ANN EMERG MED, V53, P469, DOI 10.1016/j.annemergmed.2008.05.035; Holdgate A., 2005, COCHRANE DB SYST REV, V2, DOI [10.1002/14651858.CD004137.pub2, DOI 10.1002/14651858.CD004137.PUB2]; Jelinek GA, 2000, BRIT MED J, V321, P1236, DOI 10.1136/bmj.321.7271.1236; Nam HS, 2007, CEREBROVASC DIS, V23, P289, DOI 10.1159/000098329; Piasecki Jill K, 2005, AMIA Annu Symp Proc, P1081; Radley DC, 2013, J AM MED INFORM ASSN, V20, P470, DOI 10.1136/amiajnl-2012-001241; Rainer TH, 2000, BMJ-BRIT MED J, V321, P1247, DOI 10.1136/bmj.321.7271.1247; Rupp T, 2004, ANN EMERG MED, V43, P494, DOI 10.1016/j.annemergmed.2003.11.019; Safdar B, 2006, ANN EMERG MED, V48, P173, DOI 10.1016/j.annemergmed.2006.03.013; Teichman JMH, 2004, NEW ENGL J MED, V350, P684, DOI 10.1056/NEJMcp030813; Terrell KM, 2009, J AM GERIATR SOC, V57, P1388, DOI 10.1111/j.1532-5415.2009.02352.x; Venkat A, 2010, VACCINE, V28, P6058, DOI 10.1016/j.vaccine.2010.06.090; YEALY DM, 1992, ANN EMERG MED, V21, P985, DOI 10.1016/S0196-0644(05)82941-5	22	7	7	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	SEP	2014	32	9					958	961		10.1016/j.ajem.2014.05.002			4	Emergency Medicine	Emergency Medicine	AR1AY	WOS:000343312600002	24997107				2020-06-30	J	Shervin, F; Said, S; Mohammad-Taghi, T; Shahram, BH; Mona, A; Hamed, B; Morteza, S; Mojtaba, S; Habibolla, M				Shervin, Farahmand; Said, Shiralizadeh; Mohammad-Taghi, Talebian; Shahram, Bagheri-Hariri; Mona, Arbab; Hamed, Basirghafouri; Morteza, Saeedi; Mojtaba, Sedaghat; Habibolla, Mirzababai			Nebulized fentanyl vs intravenous morphine for ED patients with acute limb pain: a randomized clinical trial	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							EMERGENCY-DEPARTMENT; ANALGESIA; CHILDREN	Objective: Intravenous morphine has been used as a common method of pain control in emergency care. Nebulized fentanyl is also an effective temporary substitute. This study was designed to compare the effectiveness of nebulized fentanyl with intravenous (IV) morphine on management of acute limb pain. Methods: This was a placebo-controlled, double-blind randomized clinical trial. Ninety emergency department patients with moderate to severe pain aged 15 to 50 years were blocked randomized and enrolled in this study. Forty-seven patients in the experimental group received nebulized fentanyl (4 mu g/kg) and IV normal saline as placebo, and the remaining 43 patients in the control group received IV morphine (0.1 mg/kg) and nebulized normal saline as placebo. All participants' pain scores were assessed by Numerical Rating Scale before and after intervention at 5-, 10-, 15-, 30-, 45-, and 60-minute intervals. Patients' vital sign and possible adverse effects were recorded respectively. Finally, all participants were assessed for their satisfaction. Results: The mean initial pain score in the experimental group was 8.7 and 8.4 in the control group (P=.1). Pain relief in both groups after 5 and 10 minutes were similar (P=.72). Although the pain relief was significantly greater with fentanyl at 15 minutes, this difference is not clinically significant. Pain management in both groups was successful and was more than 3 scores reduction in Numerical Rating Scale. Patient satisfaction in both groups was similar. No adverse effects were reported in the experimental group. Conclusion: This study suggests that nebulized fentanyl is a rapid, safe, and effective method for temporary control of acute limb pain in emergency department patients. (C) 2014 Elsevier Inc. All rights reserved	[Shervin, Farahmand; Mohammad-Taghi, Talebian; Shahram, Bagheri-Hariri; Mona, Arbab; Morteza, Saeedi; Mojtaba, Sedaghat] Univ Tehran Med Sci, Tehran, Iran; [Said, Shiralizadeh; Habibolla, Mirzababai] AJA Univ Med Sci, Tehran, Iran; [Hamed, Basirghafouri] Iran Univ Med Sci, Tehran, Iran	Shahram, BH (reprint author), Imam Khomeini Complex Hosp, Emergency Dept, Keshavarz Blvd, Tehran 1419733141, Iran.	hariri@sina.tums.ac.ir	Farahmand, Shervin/J-9637-2017; Talebian, Mohammad Taghi/K-3884-2017; Basir Ghafouri, Hamed/P-4984-2018; Sedaghat, Mohammad/H-3514-2017; Saeedi, Morteza/J-1605-2017	Farahmand, Shervin/0000-0002-6588-9125; Talebian, Mohammad Taghi/0000-0001-9071-7846; Basir Ghafouri, Hamed/0000-0001-8792-7906; Bagheri-Hariri, Shahram/0000-0002-9818-0411; Sedaghat, Mohammad/0000-0001-8381-2482; Saeedi, Morteza/0000-0001-8416-6048			Bartfield JM, 2003, ACAD EMERG MED, V10, P215, DOI 10.1197/aemj.10.3.215; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Crellin D, 2010, EMERG MED AUSTRALAS, V22, P62, DOI 10.1111/j.1742-6723.2010.01257.x; Fink R, 2000, BUMC P, V13, P236; Furyk JS, 2009, EMERG MED AUSTRALAS, V21, P203, DOI 10.1111/j.1742-6723.2009.01183.x; HIGGINS MJ, 1991, ANAESTHESIA, V46, P973, DOI 10.1111/j.1365-2044.1991.tb09862.x; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; Miner J, 2010, PAIN MANAGEMENT ROSE, P2410; Miner JR, 2007, ACAD EMERG MED, V14, P895, DOI 10.1197/j.aem.2007.06.036; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Sabri A, 2013, BIO-MED MATER ENG, V23, P93, DOI 10.3233/BME-120735; Saubermann AJ, 2012, MT SINAI J MED, V79, P46, DOI 10.1002/msj.21295; van Dishoeck AM, 2009, EUR J CARDIOVASC NUR, V8, P125, DOI 10.1016/j.ejcnurse.2008.10.004; WORSLEY MH, 1990, ANAESTHESIA, V45, P449, DOI 10.1111/j.1365-2044.1990.tb14331.x	14	12	13	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	SEP	2014	32	9					1011	1015		10.1016/j.ajem.2014.05.051			5	Emergency Medicine	Emergency Medicine	AR1AY	WOS:000343312600012	25027194				2020-06-30	J	Ramachandran, R; Rewari, V; Chandralekha; Sinha, R; Trikha, A; Sharma, P				Ramachandran, Rashmi; Rewari, Vimi; Chandralekha; Sinha, Renu; Trikha, Anjan; Sharma, Pradeep			Sub-Tenon block does not provide superior postoperative analgesia vs intravenous fentanyl in pediatric squint surgery	EUROPEAN JOURNAL OF OPHTHALMOLOGY			English	Article						Oculocardiac reflex; Pain; Pediatric anesthesia; Postoperative nausea and vomiting; Squint surgery; Sub-Tenon block	RANDOMIZED CONTROLLED-TRIAL; STRABISMUS SURGERY; GENERAL-ANESTHESIA; PERIOPERATIVE ANALGESIA; PERIBULBAR BLOCK; PAIN RELIEF; CHILDREN; ONDANSETRON; COMPLICATIONS; PREVENTION	Purpose: We evaluated the efficacy of sub-Tenon block in decreasing per/operative pain, incidence of intraoperative oculocardiac reflex (OCR), and postoperative nausea and vomiting (PONV) in pediatric squint surgery. Methods:A total of 67 children age 2-12 years, American Society of Anesthesiologists Physical Status 1 and 2, were randomized to receive either sub-Tenon block (ST) in the operative eye or 2 mcg/kg of intravenous fentanyl (F) for squint surgery after induction of general anesthesia in this double-blind study. Postoperative pain was measured by either modified Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) or Visual Analogue Scale (VAS). Pain in the postoperative period (up to 2 hours) was measured as the primary endpoint. Other parameters measured in the groups were intraoperative hemodynamics, postoperative modified CHEOPS or VAS at shifting, 1, 2, 6, 12, and 24 hours after surgery, incidence of intraoperative OCR, and PONV at shifting, 30 minutes, 1, 2, 6, 12, and 24 hours after surgery. Results: There was no statistical difference in the postoperative pain scores in the recovery room up to 2 hours after surgery. The VAS and CHEOPS scores were not different in the groups up to 24 hours after surgery. The incidence of OCR was significantly higher in group F than group ST The incidence of PONV was significantly higher in group F than group ST at 30 minutes and 1 hour after the surgery (41%, 47% vs 19%, 9%, respectively, p<0.05). However, there was no statistically significant difference in intraoperative hemodynamics and PONV scores after 2 hours in the postanesthesia care unit. Conclusions: Use of sub-Tenon block does not decrease the incidence of postoperative pain significantly in children undergoing squint surgery, However, it leads to a statistically significant decrease in the incidence of intraoperative OCR and PONV in the early recovery period in these patients.	[Ramachandran, Rashmi; Rewari, Vimi; Chandralekha; Sinha, Renu; Trikha, Anjan] All India Inst Med Sci, Dept Anaesthesiol, Delhi, India; [Sharma, Pradeep] All India Inst Med Sci, Dept Ophthalmol, Dr Rajendra Prasad Ctr Ophthalm Sci, Delhi, India	Rewari, V (reprint author), K-25, Delhi 110017, India.	vimirewari@gmail.com					[Anonymous], 2012, ANESTHESIOLOGY, V116, P248, DOI DOI 10.1097/ALN.0B013E31823C1030; Arencibia ZB, 2012, DRUG SAFETY, V35, P1119, DOI 10.2165/11633620-000000000-00000; Bhardwaj N, 2004, J PEDIAT OPHTH STRAB, V41, P100, DOI 10.3928/0191-3913-20040301-10; Bowhay AR, 2001, PAEDIATR ANAESTH, V11, P215, DOI 10.1046/j.1460-9592.2001.00631.x; Chandler JR, 2013, PEDIATR ANESTH, V23, P309, DOI 10.1111/pan.12090; Crellin D, 2007, PEDIATR ANESTH, V17, P720, DOI 10.1111/j.1460-9592.2007.02218.x; Deb K, 2001, PAEDIATR ANAESTH, V11, P161, DOI 10.1046/j.1460-9592.2001.00623.x; Fry RA, 1999, REGION ANESTH PAIN M, V24, P582, DOI 10.1016/S1098-7339(99)90055-X; Gayer S, 2008, MINERVA ANESTESIOL, V74, P23; Ghai B, 2009, ANESTH ANALG, V108, P1132, DOI 10.1213/ane.0b013e318198a3fd; Gupta N, 2007, ANAESTHESIA, V62, P1110, DOI 10.1111/j.1365-2044.2007.05220.x; Kumar CM, 2011, EYE, V25, P694, DOI 10.1038/eye.2011.69; Kumar Chandra M, 2006, Ophthalmol Clin North Am, V19, P209; Mavrakanas NA, 2011, CURR OPIN OPHTHALMOL, V22, P58, DOI 10.1097/ICU.0b013e328341426f; Morris B, 2009, BRIT J OPHTHALMOL, V93, P329, DOI 10.1136/bjo.2008.145268; Rodgers A, 2010, CAN J ANAESTH, V57, P602, DOI 10.1007/s12630-010-9300-x; Sadhasivam S, 2000, ANESTHESIOLOGY, V92, P1035, DOI 10.1097/00000542-200004000-00021; Samol NB, 2012, INT ANESTHESIOL CLIN, V50, P83, DOI 10.1097/AIA.0b013e31826df81a; Sheard RM, 2004, J AAPOS, V8, P314, DOI 10.1016/j.jaapos.2004.01.017; Shende D, 1999, ACTA ANAESTH SCAND, V43, P265, DOI 10.1034/j.1399-6576.1999.430305.x; Splinter WM, 1997, ANESTHESIOLOGY, V87, P542, DOI 10.1097/00000542-199709000-00013; Steib A, 2005, REGION ANESTH PAIN M, V30, P478, DOI 10.1016/j.rapm.2005.04.011; Zink W, 2004, REGION ANESTH PAIN M, V29, P333, DOI 10.1016/j.rapm.2004.02.008	23	8	8	0	1	WICHTIG PUBLISHING	MILAN	72/74 VIA FRIULI, 20135 MILAN, ITALY	1120-6721	1724-6016		EUR J OPHTHALMOL	Eur. J. Ophthalmol.	SEP-OCT	2014	24	5					643	649		10.5301/ejo.5000438			7	Ophthalmology	Ophthalmology	AR0OH	WOS:000343270700001	24619855				2020-06-30	J	Tian, X; Xiang, Y; Fan, Y; Bu, H; Yang, H; Manyande, A; Gao, F; Tian, Y				Tian, X.; Xiang, Y.; Fan, Y.; Bu, H.; Yang, H.; Manyande, A.; Gao, F.; Tian, Y.			Impact of malnutrition on propofol consumption and recovery time among patients undergoing laparoscopic gastrointestinal surgery	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							PROTEIN-ENERGY MALNUTRITION; SUBJECTIVE GLOBAL ASSESSMENT; NEURONAL SODIUM-CHANNELS; NUTRITIONAL RISK; HOSPITAL STAY; HIPPOCAMPAL-FORMATION; ABDOMINAL-SURGERY; SURGICAL-PATIENTS; GABA(A) RECEPTOR; DRUG DISPOSITION	Background: Malnutrition is a major health problem, especially in hospitalized patients as it can be closely related to many post-operative complications. However, research on malnutrition and its effect on the outcome of general anesthesia have been largely neglected. Here we investigated malnutrition status on propofol consumption and recovery time among patients undergoing laparoscopic gastrointestinal surgery under general anesthesia. Methods: One hundred and one patients were recruited between January and June 2012 at Tongji Hospital and assigned into three groups according to Nutritional Risk Screening Tool 2002 score. A standard combined general anesthesia procedure was performed under regular monitoring. The dosage of propofol needed for induction, consumption during maintenance and recovery time were recorded. Results: When compared with normal nutritional status individuals, the propofol dosage at induction was significantly decreased about 4.3% in moderate malnutritional status patients (P < 0.01) and about 16.8% in severely malnutritional status patients (P < 0.01). The average consumption of propofol was also significantly lower in malnourished individuals; for moderate malnutritional, the decrease was about 20% (P < 0.01) while for the severely malnutritional, it was 30% (P < 0.01) when compared with normal nutritional status individuals. For the recovery time of propofol anesthesia, the patients with severe malnutritional status awoke average 6.8 min later than those normally nourished (P < 0.01), but those patients with moderate malnutrition status did not (P = 0.885). Conclusion: The present results indicate that the dosage and recovery time of propofol does change in malnourished individuals. Therefore, malnutrition may somehow affect the outcome of general anesthesia. (C) 2014 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd	[Tian, X.; Bu, H.; Yang, H.; Gao, F.; Tian, Y.] Huazhong Univ Sci & Technol, Dept Anesthesiol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China; [Xiang, Y.] Huazhong Univ Sci & Technol, Dept Ophthalmol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China; [Fan, Y.] Huazhong Univ Sci & Technol, Dept Nutr & Food Hyg, Sch Publ Hlth, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China; [Manyande, A.] Univ West London, Sch Psychol Social Work & Human Sci, London, England	Gao, F (reprint author), Huazhong Univ Sci & Technol, Dept Anesthesiol, Tongji Hosp, Tongji Med Coll, Jiefang Rd 1095, Wuhan 430030, Hubei, Peoples R China.	13971587381@163.com			Natural Science Foundation of ChinaNational Natural Science Foundation of China [30901395]; Ministry of Education of ChinaMinistry of Education, China [20090142120012, 20110142120021]	This work was supported by Natural Science Foundation of China (30901395 to X. Tian) and the Doctoral Fund of Ministry of Education of China (20090142120012 to X. Tian, 20110142120021 to Y. Xiang).	Beau P, 2001, GASTROEN CLIN BIOL, V25, P891; Boitano LT, 2012, AM J SURG, V204, pE27, DOI 10.1016/j.amjsurg.2012.07.023; Boullata JI, 2010, P NUTR SOC, V69, P543, DOI 10.1017/S0029665110001990; Bozzetti F, 2007, CLIN NUTR, V26, P698, DOI 10.1016/j.clnu.2007.06.009; BUCHANAN N, 1977, S AFR MED J, V52, P733; Correia MITD, 2003, CLIN NUTR, V22, P235, DOI 10.1016/S0261-5614(02)00215-7; DETSKY AS, 1987, JPEN-PARENTER ENTER, V11, P8, DOI 10.1177/014860718701100108; Fowler CJ, 2004, TRENDS PHARMACOL SCI, V25, P59, DOI 10.1016/j.tips.2003.12.001; Gheorghe C, 2013, CHIRURGIA-BUCHAREST, V108, P535; Giner M, 1996, NUTRITION, V12, P23, DOI 10.1016/0899-9007(95)00015-1; Haeseler G, 2008, BRIT J PHARMACOL, V155, P265, DOI 10.1038/bjp.2008.255; Haeseler G, 2003, EUR J ANAESTH, V20, P220, DOI 10.1097/00003643-200303000-00007; Idoipe Tomas A, 1990, NUTRICION HOSPITALAR, V5, P77; Johansen N, 2004, CLIN NUTR, V23, P539, DOI 10.1016/j.clnu.2003.10.008; JUNG D, 1989, DRUG METAB DISPOS, V17, P365; Karateke F, 2013, J PAK MED ASSOC, V63, P1405; Karl A, 2011, EUR J MED RES, V16, P469, DOI 10.1186/2047-783X-16-10-469; Kingston S, 2006, ANESTHESIOLOGY, V104, P763, DOI 10.1097/00000542-200604000-00021; Kondrup J, 2003, CLIN NUTR, V22, P321, DOI 10.1016/S0261-5614(02)00214-5; Krasowski MD, 2002, J MED CHEM, V45, P3210, DOI 10.1021/jm010461a; KRISHNASWAMY K, 1981, CLIN PHARMACOKINET, V6, P152, DOI 10.2165/00003088-198106020-00005; KRISHNASWAMY K, 1989, CLIN PHARMACOKINET, V17, P68, DOI 10.2165/00003088-198900171-00006; Kuppinger D, 2012, BRIT J SURG, V99, P728, DOI 10.1002/bjs.8710; Kuppinger D, 2013, NUTRITION, V29, P399, DOI 10.1016/j.nut.2012.06.013; Kuzu MA, 2006, WORLD J SURG, V30, P378, DOI 10.1007/s00268-005-0163-1; Leandro-Merhi VA, 2011, JPEN-PARENTER ENTER, V35, P241, DOI 10.1177/0148607110374477; Lin SJ, 2012, J NURS RES, V20, P110, DOI 10.1097/jnr.0b013e318254eac9; Lister JP, 2005, HIPPOCAMPUS, V15, P393, DOI 10.1002/hipo.20065; Ljungqvist O, 2003, BRIT J SURG, V90, P400, DOI 10.1002/bjs.4066; MCWHIRTER JP, 1994, BRIT MED J, V308, P945, DOI 10.1136/bmj.308.6934.945; Medvedev D I, 2000, Morfologiia, V118, P17; MEHTA S, 1983, J PEDIATR GASTR NUTR, V2, P407, DOI 10.1097/00005176-198302030-00004; Miller KR, 2013, JPEN-PARENTER ENTER, V37, p39S, DOI 10.1177/0148607113493928; Motawi TK, 2013, FOOD CHEM TOXICOL, V56, P467, DOI 10.1016/j.fct.2013.02.042; ORSER BA, 1995, BRIT J PHARMACOL, V116, P1761, DOI 10.1111/j.1476-5381.1995.tb16660.x; Oshikoya KA, 2010, EUR J CLIN PHARMACOL, V66, P1025, DOI 10.1007/s00228-010-0851-0; PAULABARBOSA MM, 1989, EXP NEUROL, V103, P186, DOI 10.1016/0014-4886(89)90081-2; Pronio A, 2008, CLIN TER, V159, P13; Reen RK, 1999, J NUTR BIOCHEM, V10, P615, DOI 10.1016/S0955-2863(99)00045-5; Sorensen J, 2008, CLIN NUTR, V27, P340, DOI 10.1016/j.clnu.2008.03.012; Stratton RJ, 2004, BRIT J NUTR, V92, P799, DOI 10.1079/BJN20041258; Studley HO, 1936, J AMER MED ASSOC, V106, P458, DOI 10.1001/jama.1936.02770060032009; Trapani G, 1998, J MED CHEM, V41, P1846, DOI 10.1021/jm970681h; van Bokhorst-de van der Schueren MAE, 2014, CLIN NUTR, V33, P39, DOI 10.1016/j.clnu.2013.04.008; WILLIFORD WO, 1991, NEW ENGL J MED, V325, P525; Zhang W, 1999, EUR J DRUG METAB PH, V24, P141, DOI 10.1007/BF03190359	46	2	2	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	SEP	2014	58	8					942	947		10.1111/aas.12373			6	Anesthesiology	Anesthesiology	AQ7MD	WOS:000343001000005	25060045				2020-06-30	J	Krinsky, CS; Lathrop, SL; Zumwalt, R				Krinsky, Clarissa S.; Lathrop, Sarah L.; Zumwalt, Ross			An Examination of the Postmortem Redistribution of Fentanyl and Interlaboratory Variability	JOURNAL OF FORENSIC SCIENCES			English	Article						forensic science; forensic pathology; toxicology; fentanyl; postmortem redistribution; interlaboratory variability	TRANSDERMAL FENTANYL; PAIN; PHARMACOKINETICS; TOXICOLOGY; DEATHS	Fentanyl is a synthetic opioid agonist used for pain control. Often administered as a transdermal patch, it is an interesting drug for study of postmortem redistribution. We hypothesized that fentanyl concentrations would increase over time after death, as measured in blood drawn on the day prior to autopsy and in blood drawn at the time of autopsy in ten cases where fentanyl patches were identified at the scene. Concentrations were compared, and heart blood to femoral blood ratios were calculated as markers of postmortem redistribution. Fentanyl concentrations measured in peripheral blood drawn the day of autopsy (peripheral blood 2 [PB2]) were higher than those drawn the day prior to autopsy (peripheral blood 1 [PB1]) with a mean ratio (PB2/PB1) of 1.80. The ratio of heart blood concentrations (HB) to femoral blood concentrations drawn at autopsy (PB2) had a mean ratio (HB/PB2) of 1.08. Some cases had blood from the same source analyzed at two different laboratories, and concentrations of fentanyl in those samples showed inter- and intralaboratory differences up to 25ng/mL. Postmortem fentanyl concentrations may be affected by antemortem factors, postmortem redistribution, and laboratory variability. Forensic pathologists must use caution in interpreting fentanyl levels as part of death investigation.	[Krinsky, Clarissa S.; Lathrop, Sarah L.; Zumwalt, Ross] Univ New Mexico, New Mexico Off Med Investigator, Hlth Sci Ctr, Albuquerque, NM 87131 USA	Krinsky, CS (reprint author), Univ New Mexico, Dept Pathol, Hlth Sci Ctr, New Mexico Off Med Investigator, MSC07 4040, Albuquerque, NM 87131 USA.	ckrinsky@salud.unm.edu			Johnson and JohnsonJohnson & Johnson USA	Co-authors Krinsky and Zumwalt have received financial support from Johnson and Johnson and other manufacturers of the fentanyl patch, or their legal representation, as a paid consultant.	Baselt R.C., 2014, DISPOSITION TOXIC DR; CALIS KA, 1992, CLIN PHARMACY, V11, P22; Ceelen L, 2012, AM J FOREN MED PATH, V33, P119, DOI 10.1097/PAF.0b013e3181fbbb49; Drummer OH, 2004, FORENSIC SCI INT, V142, P101, DOI 10.1016/j.forsciint.2004.02.013; GOURLAY GK, 1989, PAIN, V37, P193, DOI 10.1016/0304-3959(89)90130-9; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; KLAUSNER JM, 1988, ARCH SURG-CHICAGO, V123, P66; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Krinsky CS, 2011, AM J FOREN MED PATH, V32, P347, DOI 10.1097/PAF.0b013e31822ad269; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Luckenbill K, 2008, J ANAL TOXICOL, V32, P639, DOI 10.1093/jat/32.8.639; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Olson KN, 2010, AM J CLIN PATHOL, V133, P447, DOI 10.1309/AJCP4X5VHFSOERFT; Palmer RB, 2010, CLIN TOXICOL, V48, P771, DOI 10.3109/15563650.2010.525514; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; Van Nimmen NFJ, 2010, J CLIN PHARMACOL, V50, P667, DOI 10.1177/0091270009347872	18	10	10	2	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-1198	1556-4029		J FORENSIC SCI	J. Forensic Sci.	SEP	2014	59	5					1275	1279		10.1111/1556-4029.12381			5	Medicine, Legal	Legal Medicine	AQ3GO	WOS:000342679300014	25065851				2020-06-30	J	Mori, T; Kanbara, T; Harumiya, M; Iwase, Y; Masumoto, A; Komiya, S; Nakamura, A; Shibasaki, M; Kanemasa, T; Sakaguchi, G; Suzuki, T				Mori, Tomohisa; Kanbara, Tomoe; Harumiya, Masato; Iwase, Yoshiyuki; Masumoto, Aki; Komiya, Sachiko; Nakamura, Atsushi; Shibasaki, Masahiro; Kanemasa, Toshiyuki; Sakaguchi, Gaku; Suzuki, Tsutomu			Establishment of Opioid-Induced Rewarding Effects Under Oxaliplatin- and Paclitaxel-Induced Neuropathy in Rats	JOURNAL OF PHARMACOLOGICAL SCIENCES			English	Article						rewarding effect; oxaliplatin; paclitaxel; neuropathic pain; mu-opioid receptor agonist	INDUCED PERIPHERAL NEUROPATHY; NUCLEUS-ACCUMBENS; PLACE PREFERENCE; QUANTITATIVE ASSESSMENT; DIABETIC NEUROPATHY; MORPHINE; PAIN; MODEL; INHIBITION; NEUROMETER	The rewarding effects of mu-receptor agonists can be suppressed under several pain conditions. We recently showed that clinically used mu-receptor agonists possess efficacies for relieving the neuropathic pain induced by chemotherapeutic drug in rats; however, it is possible that the use of mu-receptor agonists may trigger the rewarding effects even under chemotherapeutic drug induced neuropathic pain. Nevertheless, no information is available regarding whether mu-receptor agonists produce psychological dependence under chemotherapeutic drug induced neuropathic pain. Therefore, we examined the effects of neuropathy induced by chemotherapeutic drugs on the rewarding effects of morphine, oxycodone, and fentanyl in rats. Repeated treatment with oxaliplatin or paclitaxel produced neuropathy as measured by the von Frey test. Rewarding effects produced by antinociceptive doses of mu-receptor agonists were not suppressed under oxaliplatin- or paclitaxel-induced neuropathy. Furthermore, the morphine-induced increase in the release of dopamine from the nucleus accumbens, which is a critical step in the rewarding effects of mu-receptor agonists, was not altered in paclitaxel-treated rats. These results suggest that the rewarding effects of mu-receptor agonists can still be established under oxaliplatin- or paclitaxel-induced neuropathic pain. Therefore, patients should be carefully monitored for psychological dependence on mu-receptor agonists when they are used to control chemotherapeutic drug-induced neuropathic pain.	[Mori, Tomohisa; Kanbara, Tomoe; Harumiya, Masato; Iwase, Yoshiyuki; Masumoto, Aki; Komiya, Sachiko; Nakamura, Atsushi; Shibasaki, Masahiro; Suzuki, Tsutomu] Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Toxicol, Shinagawa Ku, Tokyo 1428501, Japan; [Kanbara, Tomoe; Nakamura, Atsushi; Kanemasa, Toshiyuki; Sakaguchi, Gaku] Shionogi & Co Ltd, Discovery Res Labs, Pain & Neurol, Toyonaka, Osaka 5610825, Japan	Suzuki, T (reprint author), Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Toxicol, Shinagawa Ku, 2-4-41 Ebara, Tokyo 1428501, Japan.	suzuki@hoshi.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Shionogi Co., Ltd.	This work was supported in part by Ministry of Education, Culture, Sports, Science and Technology of Japan and also supported by Shionogi & Co., Ltd.	Argyriou AA, 2013, CANCER-AM CANCER SOC, V119, P438, DOI 10.1002/cncr.27732; Baron R, 2009, PAIN, V146, P34, DOI 10.1016/j.pain.2009.06.001; Benturquia N, 2008, NEUROSCIENCE, V155, P341, DOI 10.1016/j.neuroscience.2008.05.015; Dina OA, 2001, NEUROSCIENCE, V108, P507, DOI 10.1016/S0306-4522(01)00425-0; Eisenberg E, 2005, JAMA-J AM MED ASSOC, V293, P3043, DOI 10.1001/jama.293.24.3043; Inoue Kenichi, 2011, Gan To Kagaku Ryoho, V38, P1137; Kautio AL, 2008, J PAIN SYMPTOM MANAG, V35, P31, DOI 10.1016/j.jpainsymman.2007.02.043; KOOB GF, 1992, ANN NY ACAD SCI, V654, P171, DOI 10.1111/j.1749-6632.1992.tb25966.x; LIU S, 1995, ANESTHESIOLOGY, V82, P60, DOI 10.1097/00000542-199501000-00009; Liu SB, 2012, CNS NEUROSCI THER, V18, P652, DOI 10.1111/j.1755-5949.2012.00338.x; Liu YL, 2009, EUR J PHARMACOL, V602, P321, DOI 10.1016/j.ejphar.2008.11.031; MASSON EA, 1991, DIABETIC MED, V8, pS63, DOI 10.1111/j.1464-5491.1991.tb02159.x; Miller DK, 1997, BRAIN RES, V776, P162, DOI 10.1016/S0006-8993(97)01013-5; Nagashima M, 2014, SUPPORT CARE CANCER, V22, P1579, DOI 10.1007/s00520-014-2132-4; Narita M, 2005, NEUROPSYCHOPHARMACOL, V30, P111, DOI 10.1038/sj.npp.1300527; Nestler EJ, 1996, NEURON, V16, P897, DOI 10.1016/S0896-6273(00)80110-5; Niikura K, 2010, TRENDS PHARMACOL SCI, V31, P299, DOI 10.1016/j.tips.2010.04.003; Ozaki S, 2002, J NEUROCHEM, V82, P1192, DOI 10.1046/j.1471-4159.2002.01071.x; Passik SD, 2009, MAYO CLIN PROC, V84, P593, DOI 10.1016/S0025-6196(11)60748-9; PITEI DL, 1994, DIABETIC MED, V11, P872, DOI 10.1111/j.1464-5491.1994.tb00371.x; Popik P, 1998, NEUROPHARMACOLOGY, V37, P1033, DOI 10.1016/S0028-3908(98)00105-1; POTHOS E, 1991, BRAIN RES, V566, P348, DOI 10.1016/0006-8993(91)91724-F; SELTZER Z, 1990, PAIN, V43, P205, DOI 10.1016/0304-3959(90)91074-S; Suzuki R, 1999, PAIN, V80, P215, DOI 10.1016/S0304-3959(98)00208-5; SUZUKI T, 1991, EUR J PHARMACOL, V205, P85; Suzuki T, 1996, LIFE SCI, V59, P1667, DOI 10.1016/0024-3205(96)00498-5; Tay B, 1997, ANESTH ANALG, V84, P1071, DOI 10.1097/00000539-199705000-00021; Valjent E, 2006, P NATL ACAD SCI USA, V103, P2932, DOI 10.1073/pnas.0511030103; Wolf S, 2008, EUR J CANCER, V44, P1507, DOI 10.1016/j.ejca.2008.04.018; Woodcock J, 2009, NEW ENGL J MED, V361, P2105, DOI 10.1056/NEJMp0908913	30	9	9	1	1	JAPANESE PHARMACOLOGICAL SOC	KYOTO	EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604, JAPAN	1347-8613	1347-8648		J PHARMACOL SCI	J. Pharmacol. Sci.	SEP	2014	126	1					47	55		10.1254/jphs.14134FP			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AP7MS	WOS:000342262000006	25141998	Bronze			2020-06-30	J	Feltracco, P; Carollo, C; Barbieri, S; Milevoj, M; Pettenuzzo, T; Gringeri, E; Boetto, R; Ori, C				Feltracco, P.; Carollo, C.; Barbieri, S.; Milevoj, M.; Pettenuzzo, T.; Gringeri, E.; Boetto, R.; Ori, C.			Pain Control After Liver Transplantation Surgery	TRANSPLANTATION PROCEEDINGS			English	Article; Proceedings Paper	37th Congress of the Italian-Transplantation-Society (SITO)	OCT 24-26, 2013	Bari, ITALY	Italian Tranplantat Soc			INDUCED RESPIRATORY DEPRESSION; POSTOPERATIVE ANALGESIA; EPIDURAL-ANESTHESIA; HEPATIC RESECTION; SUFENTANIL; MORPHINE; PHARMACOKINETICS; REMIFENTANIL; SAFETY; METABOLISM	Background. Although post liver transplantation pain is not as severe as expected from the size of the surgical incision, optimal pain control becomes crucial to aid compliance with the ventilator, improve respiratory function, and facilitate an early weaning from mechanical ventilation. Methods. Because the majority of analgesics are primarily metabolized and excreted by the hepatobiliary system, a poor recovery of graft function will result in a decrease in clearance and reduced elimination of the drug. On the other hand, if the liver is working well, the metabolism of analgesics improves significantly with minimal accumulation. Morphine-based analgesia has been associated with a higher risk of sedation and respiratory depression compared with major abdominal surgical procedures. Fentanyl and sufentanil in continuous intravenous infusion may be preferred in the presence of hemodynamic instability or bronchospasm. Sufentanil produces shorter-lasting respiratory depression and long-lasting analgesia than does fentanyl. Results. The provision of potent continuous analgesia, independent of the duration of infusion, and the unique pharmacokinetics, not significantly affected by the functional status of the graft, make remifentanil appropriate for the majority of liver-transplanted patients. Unlike for patients with very severe pain after major abdominal surgery, liver transplant recipients usually benefit from tramadol, either in repeated intravenous boluses or continuous intravenous infusion. Paracetamol has been included as adjuvant (or sole agent, rarely) in the analgesic treatment of mild to moderate postoperative pain. The combination treatment (paracetamol plus tramadol) is a reasonable, safe option with improved analgesia and concurrent reduction in the incidence of some opioid-related side effects. Conclusions. Frequent review of the patient's response is mandatory when potent opioids are used because dose-dependent respiratory depression is a serious and potentially life-threatening adverse effect. The benefits provided by epidural analgesia in this particular setting should be weighed against the risks because in the presence of markedly deranged perioperative blood clotting, the development of epidural hematoma represents a disastrous complication.	[Feltracco, P.; Carollo, C.; Barbieri, S.; Milevoj, M.; Pettenuzzo, T.; Ori, C.] Univ Padua, Dipartimento Med, UOC Anestesia & Terapia Intens, Padua, Italy; [Gringeri, E.; Boetto, R.] Univ Padua, Unita Chirurg Epatobiliare, Padua, Italy; [Gringeri, E.; Boetto, R.] Univ Padua, Dipartimento Chirurg Gen & Trapianti Organo, Ctr Trapianto Epat, Padua, Italy	Feltracco, P (reprint author), Univ Padua, Dipartimento Med, UOC Anestesia & Terapia Intens, Via Cesare Battisti 257, Padua, Italy.	paolofeltracco@inwind.it	Gringeri, Enrico/K-4199-2018; GRINGERI, ENRICO/AAB-9315-2019	GRINGERI, ENRICO/0000-0002-3459-7306; Pettenuzzo, Tommaso/0000-0002-6745-8919			BAILEY PL, 1990, ANESTH ANALG, V70, P8; Barilaro C, 2001, Minerva Anestesiol, V67, P171; Benson Gordon D, 2005, Am J Ther, V12, P133, DOI 10.1097/01.mjt.0000140216.40700.95; CANEPA G, 1993, INT J CLIN PHARM RES, V13, P43; Clemente A, 2008, MINERVA ANESTESIOL, V74, P549; CROTTY B, 1989, EUR J CLIN PHARMACOL, V36, P501, DOI 10.1007/BF00558076; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; Della Rocca G, 2010, TRANSPL P, V42, P2229, DOI 10.1016/j.transproceed.2010.05.043; Dershwitz M, 1996, ANESTHESIOLOGY, V84, P812, DOI 10.1097/00000542-199604000-00008; Donovan KL, 1997, TRANSPLANTATION, V63, P1423, DOI 10.1097/00007890-199705270-00010; EISENACH JC, 1989, MAYO CLIN PROC, V64, P356, DOI 10.1016/S0025-6196(12)65257-4; Feltracco P, 2008, TRANSPL P, V40, P1979, DOI 10.1016/j.transproceed.2008.05.006; Glanemann M, 2007, TRANSPL P, V39, P535, DOI 10.1016/j.transproceed.2006.12.013; HASSELSTROM J, 1993, CLIN PHARMACOKINET, V24, P344, DOI 10.2165/00003088-199324040-00007; Hortnagl H, 1994, LANCET, V3, P480; HOUMES RJM, 1992, ANESTH ANALG, V74, P510; Hwang GS, 2010, CURR OPIN ORGAN TRAN, V15, P377, DOI 10.1097/MOT.0b013e3283387f75; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Lane M, 2002, CARE CRIT ILL, V18, P146; Larson AM, 2005, HEPATOLOGY, V42, P1364, DOI 10.1002/hep.20948; Latta Kenneth S, 2002, Am J Ther, V9, P53, DOI 10.1097/00045391-200201000-00010; LEHMANN KA, 1993, ACTA ANAESTH SCAND, V37, P176, DOI 10.1111/j.1399-6576.1993.tb03696.x; LIU S, 1995, ANESTHESIOLOGY, V82, P1474, DOI 10.1097/00000542-199506000-00019; Liu SS, 2007, ANESTH ANALG, V104, P689, DOI 10.1213/01.ane.0000255040.71600.41; Mandell MS, 2007, LIVER TRANSPLANT, V13, P1557, DOI 10.1002/lt.21263; Miecznikowski R, 2005, ANESTH ANALG, V101, P1891; Mimoz O, 2001, ANAESTHESIA, V56, P520, DOI 10.1046/j.1365-2044.2001.01980.x; Mizrak A, 2012, J CLIN ANAL MED, V3, P7, DOI 10.4328/JCAM.438; Moretti EW, 2002, J CLIN ANESTH, V14, P416, DOI 10.1016/S0952-8180(02)00390-2; Navapurkar VU, 1998, BRIT J ANAESTH, V81, P881; OURAHMA S, 1993, ANN FR ANESTH, V12, P357, DOI 10.1016/S0750-7658(05)80101-7; Ozier Y, 2008, CURR OPIN ANESTHESIO, V21, P391, DOI 10.1097/ACO.0b013e3282ff85f4; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; RABINOVITZ M, 1992, AM J GASTROENTEROL, V87, P1696; RaucoulesAime M, 1997, ANESTH ANALG, V84, P1019, DOI 10.1097/00000539-199705000-00012; Robertson KM, 1996, ANESTH ANALG, V82, pS381; Rudin A, 2007, ANESTH ANALG, V104, P1409, DOI 10.1213/01.ane.0000261847.26044.1d; SCHAFER M, 1994, P NATL ACAD SCI USA, V91, P4219, DOI 10.1073/pnas.91.10.4219; Skurzak S, 2010, ACTA ANAESTH SCAND, V54, P970, DOI 10.1111/j.1399-6576.2010.02274.x; Soltesz S, 2001, BRIT J ANAESTH, V86, P763, DOI 10.1093/bja/86.6.763; Strassels SA, 2005, AM J HEALTH-SYST PH, V62, P2019, DOI 10.2146/ajhp040490.p2; Tolman Keith G., 1998, American Journal of Medicine, V105, p13S, DOI 10.1016/S0002-9343(98)00070-9; Trzebicki J, 2010, ANN TRANSPL, V15, P35; Vidhya Malar HL, 2012, J CLIN TOXICOL, V2, P7; WESTMORELAND CL, 1993, ANESTHESIOLOGY, V79, P893, DOI 10.1097/00000542-199311000-00005	46	10	11	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0041-1345	1873-2623		TRANSPL P	Transplant. Proc.	SEP	2014	46	7					2300	2307		10.1016/j.transproceed.2014.07.023			8	Immunology; Surgery; Transplantation	Immunology; Surgery; Transplantation	AP9KA	WOS:000342397500029	25242774				2020-06-30	J	Jirapinyo, P; Abu Dayyeh, B; Thompson, CC				Jirapinyo, Pichamol; Abu Dayyeh, Barham K.; Thompson, Christopher C.			Conscious Sedation for Upper Endoscopy in the Gastric Bypass Patient: Prevalence of Cardiopulmonary Adverse Events and Predictors of Sedation Requirement	DIGESTIVE DISEASES AND SCIENCES			English	Article						Endoscopic sedation; Conscious sedation; Gastric bypass; Cardiopulmonary adverse events	MONITORED ANESTHESIA CARE; GASTROINTESTINAL-ENDOSCOPY; GI ENDOSCOPY; GUIDELINES	Safety of conscious sedation for performing esophagoduodenoscopy (EGD) in obese and Roux-en-Y gastric bypass (RYGB) patients remains controversial. Additionally, it has been suggested that patients with higher body mass index (BMI) require higher sedation doses, imparting greater risk. The aim of this study is to assess the prevalence of sedation-related adverse events and the independent predictors of sedation requirements in RYGB patients. This study is a retrospective database review of RYGB patients who underwent EGD under conscious sedation. Database analysis was performed and linear regression applied to identify significant predictors of sedation requirement. Primary outcomes are sedation-related adverse events and predictors of sedation requirement. Data on 1,385 consecutive procedures (diagnostic 967; therapeutic 418) performed under conscious sedation were analyzed. Unplanned events were reported in 1.6 %, with 0.6 % being cardiopulmonary in nature and 0.7 % requiring early termination. Multivariable linear regression revealed procedural time was the only significant predictor of fentanyl (standardized beta 0.34; P value < 0.001) and midazolam (standardized beta 0.30; P value < 0.001) doses. Post-RYGB BMI was not significantly associated with the dose of fentanyl (standardized beta 0.08; P value 0.29) or midazolam administered (standardized beta 0.01; P value 0.88). Upper endoscopy can be safely performed in RYGB patients under conscious sedation with a similar cardiopulmonary risk profile to that of standard EGD. The non-cardiopulmonary adverse events were procedure-specific and unrelated to sedation. Procedure length, and not absolute BMI, was the only predictor of sedation requirement in this patient population.	[Jirapinyo, Pichamol] Yale New Haven Med Ctr, New Haven, CT 06504 USA; [Jirapinyo, Pichamol; Abu Dayyeh, Barham K.; Thompson, Christopher C.] Brigham & Womens Hosp, Boston, MA 02215 USA; [Abu Dayyeh, Barham K.] Mayo Clin Hosp, Rochester, MN USA	Thompson, CC (reprint author), Brigham & Womens Hosp, 75 Francis St Thorn 1404, Boston, MA 02215 USA.	ccthompson@partners.org			NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [T32 DK007533, P30 DK034854]		Agostoni M, 2011, GASTROINTEST ENDOSC, V74, P266, DOI 10.1016/j.gie.2011.04.028; Aisenberg J, 2005, AM J GASTROENTEROL, V100, P996, DOI 10.1111/j.1572-0241.2005.50034.x; DANESHMEND TK, 1991, GUT, V32, P12, DOI 10.1136/gut.32.1.12; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Keefe EB, 1989, GASTROINTEST ENDOSC, V36, pS13; Kumar N, 2012, CLIN GASTROENTEROL H; Lichtenstein DR, 2008, GASTROINTEST ENDOSC, V68, P815, DOI 10.1016/j.gie.2008.09.029; Madan AK, 2008, OBES SURG, V18, P545, DOI 10.1007/s11695-007-9338-1; Santry HP, 2005, JAMA-J AM MED ASSOC, V294, P1909, DOI 10.1001/jama.294.15.1909; Schirmer B, 2002, OBES SURG, V12, P634, DOI 10.1381/096089202321019594; Sharma VK, 2007, GASTROINTEST ENDOSC, V66, P27, DOI 10.1016/j.gie.2006.12.040; SILVIS SE, 1976, JAMA-J AM MED ASSOC, V235, P928, DOI 10.1001/jama.235.9.928; Vargo John J, 2011, Gastrointest Endosc Clin N Am, V21, P257, DOI 10.1016/j.giec.2011.02.011; Waring JP, 2003, GASTROINTEST ENDOSC, V58, P317, DOI 10.1067/S0016-5107(03)00001-4	14	6	6	0	3	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0163-2116	1573-2568		DIGEST DIS SCI	Dig. Dis. Sci.	SEP	2014	59	9					2173	2177		10.1007/s10620-014-3140-4			5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	AP4ZA	WOS:000342088300041	24723069	Green Accepted			2020-06-30	J	Paparella, SF				Paparella, Susan F.			INTRAVENOUS FENTANYL: UNDERSTANDING AND MANAGING THE RISK	JOURNAL OF EMERGENCY NURSING			English	Editorial Material							ANALGESIA		ISMP, Horsham, PA 19044 USA	Paparella, SF (reprint author), ISMP, Horsham, PA 19044 USA.	spaparella@ismp.org					Asseri M, 2012, PA PATIENT SAF ADVIS, V9, P122; Conti G, 2005, CURR DRUG TARGETS, V6, P767, DOI 10.2174/138945005774574407; Grissinger M, 2013, PA PATIENT SAF ADVIS, V10, P59; Institute for Safe Medication Practices, 2007, ISMP MED SAF ALERT A, V12, P2; Institute for Safe Medication Practices, 2003, ISMP MED SAFETY ALER, V8, P1; Pasero Chris, 2005, J Perianesth Nurs, V20, P279, DOI 10.1016/j.jopan.2005.03.007; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034	7	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0099-1767	1527-2966		J EMERG NURS	J. Emerg. Nurs.	SEP	2014	40	5					488	490		10.1016/j.jen.2014.05.017			3	Emergency Medicine; Nursing	Emergency Medicine; Nursing	AP3HI	WOS:000341965800020	25194654				2020-06-30	J	Borle, AP; Chhabra, A; Subramaniam, R; Rewari, V; Sinha, R; Ramachandran, R; Kumar, R; Seth, A				Borle, Anuradha P.; Chhabra, Anjolie; Subramaniam, Rajeshwari; Rewari, Vimi; Sinha, Renu; Ramachandran, Rashmi; Kumar, Rajeev; Seth, Amlesh			Analgesic Efficacy of Paravertebral Bupivacaine During Percutaneous Nephrolithotomy: An Observer Blinded, Randomized Controlled Trial	JOURNAL OF ENDOUROLOGY			English	Article							POSTOPERATIVE PAIN; NERVE BLOCKADE; ROPIVACAINE; ANESTHESIA; SURGERY	Background and Purpose: A unilateral paravertebral (PVB) block with catheter can provide extendable analgesia without physiological changes. The objective of this study was to assess the efficacy of PVB bupivacaine for providing perioperative pain relief in adults undergoing percutaneous nephrolithotomy (PCNL) under general anesthesia. Methods: Fifty American Society of Anesthesiologists Grade I, II patients, aged 18 to 65 years, were included in this prospective, randomized, controlled, observer blinded trial. PVB group patients received preinduction 20mL of 0.5% bupivacaine in the T9-10 paravertebral space and a catheter in addition to general anesthesia. Control group patients received only general anesthesia. All patients received intravenous fentanyl (2 mu g/kg on induction, 0.5 mu g/kg on 20% increase in heart rate or mean blood pressure) and paracetamol every 6 hours. Postoperative pain was assessed using the visual analog scale (VAS) (0-10 cm) at rest and movement by a blinded observer at 0, 1, 2, 4, 6, 12, and 24 hours postoperatively. Results: Data of 48 patients were analyzed. Intraoperative fentanyl requirement was higher in the control group (2.74 +/- 0.75 mu g/kg [95 % confidence interval (CI) 2.42, 3.05]) than the PVB group (2.07 +/- 0.26 mu g/kg [95 % CI 1.96, 2.18]), (P = 0.0001). Time to first postoperative analgesic requirement was longer in the PVB group (120 min [30-570]) than the control group (30 min [0-180]), (P = 0.0000). The VAS on rest (0, 1, 2, and 12 h) and movement (all time points) were significantly lower in the PVB group. Postoperative fentanyl consumption was lower in this group (175 mu g [25-475]) compared with the control group (525 mu g[(150-1275]), (P = 0.0000). Conclusions: Unilateral PVB block with catheter provided effective perioperative analgesia for PCNL.	[Borle, Anuradha P.; Chhabra, Anjolie; Subramaniam, Rajeshwari; Rewari, Vimi; Sinha, Renu; Ramachandran, Rashmi] All India Inst Med Sci, Dept Anaesthesiol, New Delhi, India; [Kumar, Rajeev; Seth, Amlesh] All India Inst Med Sci, Dept Urol, New Delhi, India	Chhabra, A (reprint author), House 13,Rd 61, New Delhi 110026, India.	anjolie5@hotmail.com	Kumar, Rajeev/I-2338-2016	Kumar, Rajeev/0000-0002-0783-1101			Aar MK, 2001, ANESTHESIOLOGY, V95, P771; Ak K, 2013, MED PRIN PRACT, V22, P229, DOI 10.1159/000345381; Akin S, 2005, UROL INT, V75, P345, DOI 10.1159/000089172; Amer T, 2012, UROL INT, V88, P373, DOI 10.1159/000336145; Dalela D, 2004, J ENDOUROL, V18, P544, DOI 10.1089/0892779041783401; Elbealy E, 2008, J MED SCI, V8, P170; Jonnavithula N, 2009, J ENDOUROL, V23, P857, DOI 10.1089/end.2008.0634; Luyet C, 2012, ANAESTHESIA, V67, P1321, DOI 10.1111/j.1365-2044.2012.07234.x; McGuirk S, 2011, ANAESTHESIA, V66, P84, DOI 10.1111/j.1365-2044.2010.06560.x; Myles PS, 1999, ANESTH ANALG, V88, P83, DOI 10.1097/00000539-199901000-00016; Naja MZ, 2004, ANAESTHESIA, V59, P459, DOI 10.1111/j.1365-2044.2004.03705.x; Naja Z, 2001, ANAESTHESIA, V56, P1184; Pietrow PK, 2003, J ENDOUROL, V17, P411, DOI 10.1089/089277903767923218; Preminger Glenn M, 2010, Arch Ital Urol Androl, V82, P23; Pusch F, 2000, BRIT J ANAESTH, V85, P841, DOI 10.1093/bja/85.6.841; Radecka E, 2003, ACTA RADIOL, V44, P447, DOI 10.1034/j.1600-0455.2003.00083.x; Richardson J, 1998, BRIT J ANAESTH, V81, P230; Ugras MY, 2007, J ENDOUROL, V21, P499, DOI 10.1089/end.2006.0335; Vogt A, 2005, BRIT J ANAESTH, V95, P816, DOI 10.1093/bja/aei250	19	19	21	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0892-7790	1557-900X		J ENDOUROL	J. Endourol.	SEP	2014	28	9					1085	1090		10.1089/end.2014.0179			6	Urology & Nephrology	Urology & Nephrology	AO9GI	WOS:000341663700012	24828850				2020-06-30	J	Yu, C; Li, S; Deng, F; Yao, Y; Qian, L				Yu, C.; Li, S.; Deng, F.; Yao, Y.; Qian, L.			Comparison of dexmedetomidine/fentanyl with midazolam/fentanyl combination for sedation and analgesia during tooth extraction	INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article						dexmedetomidine; midazolam; fentanyl; dental surgery; day surgery; analgesia	3RD MOLAR SURGERY; CONSCIOUS SEDATION; AMERICAN-SOCIETY; LITHOTRIPSY; RECOVERY; AGONISTS; ALPHA-2; HUMANS; RATS; CARE	Dexmedetomidine is an alpha 2-adrenergic receptor agonist that causes minimal respiratory depression compared with alternative drugs. This study investigated whether combined dexmedetomidine/fentanyl offered better sedation and analgesia than midazolam/fentanyl in dental surgery. Sixty patients scheduled for unilateral impacted tooth extraction were randomly assigned to receive either dexmedetomidine and fentanyl (D/F) or midazolam and fentanyl (M/F). Recorded variables were patient preoperative anxiety scores, vital signs, visual analogue scale (VAS) pain scores, Observer's Assessment of Alertness/Sedation Scale (OAAS) scores after drug administration, surgeon and patient degree of satisfaction, and the duration of analgesia after surgery. The OAAS scores were significantly lower for patients administered D/F compared to those who received M/F. The duration of analgesia after the surgical procedure was significantly longer in patients who received D/F (5.3 h) than in those who received M/F (4.1 h; P = 0.017). The number of surgeons satisfied with the level of sedation/analgesia provided by D/F was significantly higher than for M/F (P = 0.001). Therefore, dexmedetomidine/fentanyl appears to provide better sedation, stable haemodynamics, surgeon satisfaction, and postoperative analgesia than midazolam/fentanyl during office-based unilateral impacted tooth extraction.	[Yu, C.; Li, S.; Deng, F.; Yao, Y.] Chongqing Med Univ, Dept Anesthesia, Stomatol Hosp, Chongqing 401146, Peoples R China; [Qian, L.] Duke NUS Grad Med Sch Singapore, Singapore, Singapore	Yu, C (reprint author), Chongqing Med Univ, Dept Anesthesia, Stomatol Hosp, 426 Songshibeilu, Chongqing 401146, Peoples R China.	yucongab@sina.com			Research Project of Health Bureau of Chongqing, Chongqing, China [2013-1-031]	This study was supported by the Research Project of Health Bureau of Chongqing (2013-1-031, Chongqing, China). The authors thank the surgeons of the Oral-maxillofacial Department of the Stomatology Hospital of Chongqing Medical University, China, and their peers who have previously published papers on this topic.	Abdalla Mahmoud I M, 2006, J Anesth, V20, P54, DOI 10.1007/s00540-005-0351-z; ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Alhashemi JA, 2004, CAN J ANAESTH, V51, P342, DOI 10.1007/BF03018237; ARROWSMITH JB, 1991, GASTROINTEST ENDOSC, V37, P421, DOI 10.1016/S0016-5107(91)70773-6; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Bergese SD, 2010, J CLIN ANESTH, V22, P35, DOI 10.1016/j.jclinane.2009.02.016; BLOOR BC, 1992, ANESTHESIOLOGY, V77, P1134, DOI 10.1097/00000542-199212000-00014; Candiotti KA, 2010, ANESTH ANALG, V110, P47, DOI 10.1213/ane.0b013e3181ae0856; Chen C, 2014, J SURG RES, V187, P211, DOI 10.1016/j.jss.2013.09.018; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Cheung CW, 2007, ANAESTHESIA, V62, P1132, DOI 10.1111/j.1365-2044.2007.05230.x; CORREASALES C, 1992, ANESTHESIOLOGY, V76, P948, DOI 10.1097/00000542-199206000-00013; Dere K, 2010, EUR J ANAESTH, V27, P648, DOI 10.1097/EJA.0b013e3283347bfe; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Elbaradie Samia, 2004, J Egypt Natl Canc Inst, V16, P153; FROEHLICH F, 1995, GASTROENTEROLOGY, V108, P697, DOI 10.1016/0016-5085(95)90441-7; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; Hsu YW, 2004, ANESTHESIOLOGY, V101, P1066, DOI 10.1097/00000542-200411000-00005; Huupponen E, 2008, ACTA ANAESTH SCAND, V52, P289, DOI 10.1111/j.1399-6576.2007.01537.x; Kayhan GE, 2013, J SURG RES, V183, P733, DOI 10.1016/j.jss.2013.03.028; Khan ZP, 1999, ANAESTHESIA, V54, P146, DOI 10.1046/j.1365-2044.1999.00659.x; Koroglu A, 2005, BRIT J ANAESTH, V94, P821, DOI 10.1093/bja/aei119; Maksimow A, 2007, ACTA ANAESTH SCAND, V51, P22, DOI 10.1111/j.1399-6576.2006.01174.x; Mukhtar AM, 2006, ANESTH ANALG, V103, P52, DOI 10.1213/01.ane.0000217204.92904.76; Ogawa Sachie, 2008, Anesth Prog, V55, P82, DOI 10.2344/0003-3006-55.3.82; Parikh Devangi A, 2013, J Anaesthesiol Clin Pharmacol, V29, P173, DOI 10.4103/0970-9185.111671; Reich DL, 2002, ANESTH ANALG, V95, P273, DOI 10.1097/00000539-200208000-00003; Sakaguchi Yoshiro, 2006, Masui, V55, P856; Sanders RD, 2009, ANESTHESIOLOGY, V110, P1077, DOI 10.1097/ALN.0b013e31819daedd; Taghinia AH, 2008, PLAST RECONSTR SURG, V121, P269, DOI 10.1097/01.prs.0000293867.05857.90; Ustun Y, 2006, J ORAL MAXIL SURG, V64, P1353, DOI 10.1016/j.joms.2006.05.020; Venn RM, 2000, CRIT CARE, V4, P302, DOI 10.1186/cc712; Wijeysundera DN, 2003, AM J MED, V114, P742, DOI 10.1016/S0002-9343(03)00165-7; Zeyneloglu P, 2008, EUR J ANAESTH, V25, P961, DOI 10.1017/S0265021508004699	35	12	12	0	11	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0901-5027	1399-0020		INT J ORAL MAX SURG	Int. J. Oral Maxillofac. Surg.	SEP	2014	43	9					1148	1153		10.1016/j.ijom.2014.03.019			6	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	AO6NW	WOS:000341469800020	24794760				2020-06-30	J	Diakomi, M; Papaioannou, M; Mela, A; Kouskouni, E; Makris, A				Diakomi, Maria; Papaioannou, Marianna; Mela, Argyro; Kouskouni, Evangelia; Makris, Alexandros			Preoperative Fascia Iliaca Compartment Block for Positioning Patients With Hip Fractures for Central Nervous Blockade A Randomized Trial	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article							PLACEBO-CONTROLLED-TRIAL; FEMORAL-NECK FRACTURE; SPINAL-BLOCK; OLDER-ADULTS; PAIN; ANALGESIA; SCALES	Background and Objectives: Appropriate pain management may positively affect outcome following hip fractures. Positioning patients for spinal anesthesia (SA) can be extremely painful. Peripheral nerve blockades are gaining popularity in this setting. This prospective, randomized study compares the efficacy of fascia iliaca compartment block (FICB) to intravenous (IV) fentanyl for positioning hip fracture patients for SA. Methods: Forty-one patients scheduled for hip fracture surgery were randomized to receive a bolus dose of IV fentanyl (IVFE) 1.5 g/kg (IVFE group) or an FICB using 40 mL ropivacaine 0.5% (FICB group) 5 or 20 minutes before positioning for SA, respectively. Numeric rating pain scale scores before and following the analgesic intervention, time needed and quality of patient position for SA performance, postoperative analgesia in terms of time to first IV morphine dose demand and morphine consumption during the first 24 hours, and patient satisfaction were documented. Results: Compared with the IVFE group, the FICB group showed significantly lower numeric rating pain scale scores in all instances following the analgesic intervention (P < 0.001), shorter spinal performance time (P = 0.001), and better quality of position (P = 0.001). Postoperative morphine consumption was lower (P = 0.026), the time to first dose demand was longer (P = 0.001), and patient satisfaction rates were higher (P < 0.001) in the FICB group. Conclusions: Performing an FICB before positioning for SA provides superior pain management compared with IVFE administration, facilitates spinal performance, and yields satisfactory postoperative analgesia and wide patient acceptance, hence improving overall quality and efficiency of care.	[Diakomi, Maria; Papaioannou, Marianna; Mela, Argyro; Makris, Alexandros] Asklepie Hosp Voula, Dept Anesthesiol, Athens 16673, Greece; [Kouskouni, Evangelia] Univ Athens, Sch Med, Dept Microbiol, Aretaieio Hosp, GR-11527 Athens, Greece	Makris, A (reprint author), Asklepie Hosp Voula, Dept Anesthesiol, Vas Pavlou 1, Athens 16673, Greece.	makrisalexandros@hotmail.com					Abou-Setta AM, 2011, ANN INTERN MED, V155, P234, DOI 10.7326/0003-4819-155-4-201108160-00346; Atchabahian A, 2001, ANESTHESIOLOGY, V94, P534, DOI 10.1097/00000542-200103000-00029; Bouaziz H, 2002, ANESTH ANALG, V94, P445, DOI 10.1097/00000539-200202000-00041; Candal-Couto JJ, 2005, INJURY, V36, P505, DOI 10.1016/j.injury.2004.10.015; Capdevila X, 1998, ANESTH ANALG, V86, P1039, DOI 10.1097/00000539-199805000-00025; Chibnall JT, 2001, PAIN, V92, P173, DOI 10.1016/S0304-3959(00)00485-1; Cornell Charles, 2013, J Bone Joint Surg Am, V95, pe211, DOI 10.2106/JBJS.L.01519; DALENS B, 1989, ANESTH ANALG, V69, P705; Dolan J, 2008, REGION ANESTH PAIN M, V33, P526, DOI 10.1016/j.rapm.2008.03.008; Foss NB, 2007, ANESTHESIOLOGY, V106, P773, DOI 10.1097/01.anes.0000264764.56544.d2; Monzon DG, 2010, INT J EMERG MED, V3, P321, DOI 10.1007/s12245-010-0234-4; Haentjens P, 2010, ANN INTERN MED, V152, P380, DOI 10.7326/0003-4819-152-6-201003160-00008; Haslam L, 2013, CAN GERIATR J, V16, P16, DOI 10.5770/cgj.16.52; Herr KA, 2004, CLIN J PAIN, V20, P207, DOI 10.1097/00002508-200407000-00002; Hung WW, 2012, JAMA-J AM MED ASSOC, V307, P2185, DOI 10.1001/jama.2012.4842; Iamaroon A, 2010, LOCAL REG ANESTH, V3, P21; Kanis JA, 2012, OSTEOPOROSIS INT, V23, P2239, DOI 10.1007/s00198-012-1964-3; Lyritis GP, 2013, OSTEOPOROSIS INT, V24, P1579, DOI 10.1007/s00198-012-2154-z; Morrison RS, 2003, J GERONTOL A-BIOL, V58, P76; Mouzopoulos G, 2009, J ORTHOP TRAUMATOL, V10, P127, DOI 10.1007/s10195-009-0062-6; Neuman MD, 2012, ANESTHESIOLOGY, V117, P72, DOI 10.1097/ALN.0b013e3182545e7c; Newman B, 2013, ANAESTHESIA, V68, P899, DOI 10.1111/anae.12321; Shariat AN, 2013, REGION ANESTH PAIN M, V38, P201, DOI 10.1097/AAP.0b013e31828a3c7c; Sia S, 2004, ANESTH ANALG, V99, P1221, DOI 10.1213/01.ANE.0000134812.00471.44; Yun MJ, 2009, ACTA ANAESTH SCAND, V53, P1282, DOI 10.1111/j.1399-6576.2009.02052.x	25	22	24	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1098-7339	1532-8651		REGION ANESTH PAIN M	Region. Anesth. Pain Med.	SEP-OCT	2014	39	5					394	398		10.1097/AAP.0000000000000133			5	Anesthesiology	Anesthesiology	AO7BM	WOS:000341507000007	25068412				2020-06-30	J	Maino, P; Koetsier, E; Perez, RSGM				Maino, Paolo; Koetsier, Eva; Perez, Roberto S. G. M.			Fentanyl Overdose Caused by Malfunction of SynchroMed II Intrathecal Pump Two Case Reports	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article							DRUG-DELIVERY; BACLOFEN THERAPY; PAIN; RECOMMENDATIONS; MANAGEMENT	Objective: Intrathecal drug delivery systems (intrathecal pumps) are used to treat patients with chronic refractory pain syndromes and spasticity. The objective of our case report was to demonstrate that intrathecal pump malfunction can lead to intrathecal overdosing of drugs. Case Report: We present 2 cases of intrathecal pump malfunction leading to overinfusion. The first case concerns a patient with an intrathecal pump that was implanted almost 5 years before the reported incident. During a refill procedure, 12.5 mL was aspirated instead of the expected 21.8 mL. Analysis of the pump revealed that the pump was overinfusing. The second case concerns a patient with an intrathecal pump that was implanted more than 5 years before the reported incident. Ten hours after a regular refill of the pump, she was found in a comatose state, and when the intrathecal pump was emptied, only 16 mL was aspirated instead of the 19.6 mL expected. Analysis of the pump revealed that the inner tubing was not running smoothly over the roller arms, possibly causing spurts, which could have caused an overinfusion. Conclusions: We present 2 cases of intrathecal pump malfunction, which most likely led to overinfusion of fentanyl intrathecally. To reduce the risk of this complication, particular attention should be paid to drug reservoir volume discrepancies and overdose symptoms reported by patients.	[Maino, Paolo; Koetsier, Eva] Neuroctr Svizzera Italiana, Ctr Terapia Dolore EOC, Lugano, Switzerland; [Perez, Roberto S. G. M.] Vrije Univ Amsterdam, Med Ctr, Dept Anesthesiol, Amsterdam, Netherlands	Koetsier, E (reprint author), Osped Italiano, Ctr Terapia Dolore EOC, Via Capelli, CH-6962 Viganello, Switzerland.	evakoetsier6@gmail.com		Koetsier, Eva/0000-0002-8786-0665			Deer TR, 2012, NEUROMODULATION, V15, P467, DOI 10.1111/j.1525-1403.2012.00486.x; Deer TR, 2012, NEUROMODULATION, V15, P436, DOI 10.1111/j.1525-1403.2012.00476.x; Francisco GE, 2009, PM&R, V1, P852, DOI 10.1016/j.pmrj.2009.07.015; Medtronic, 2012, ADD MEDTR NEUR INTR; Medtronic, SUMM APPR DRUGS SYNC; Medtronic, URG MED DEV SAF NOT; Medtronic, INCR RISK MOT STALL; Medtronic for healthcare professionals, TARG DRUGS DEL PROD; Perruchoud C, NEUROMODULATION; Prager J, 2014, NEUROMODULATION, V17, P354, DOI 10.1111/ner.12146; Reig E, 2009, NEUROMODULATION, V12, P122, DOI 10.1111/j.1525-1403.2009.00206.x; Rezai A, 2013, PAIN PHYSICIAN, V16, P415; Sgouros S, 2010, PEDIATR NEUROSURG, V46, P62, DOI 10.1159/000315319; Watve SV, 2012, SPINAL CORD, V50, P107, DOI 10.1038/sc.2011.112	14	11	11	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1098-7339	1532-8651		REGION ANESTH PAIN M	Region. Anesth. Pain Med.	SEP-OCT	2014	39	5					434	437		10.1097/AAP.0000000000000132			4	Anesthesiology	Anesthesiology	AO7BM	WOS:000341507000014	25075457				2020-06-30	J	Weltrowska, G; Lemieux, C; Chung, NN; Guo, JJ; Wilkes, BC; Schiller, PW				Weltrowska, Grazyna; Lemieux, Carole; Chung, Nga N.; Guo, Jason J.; Wilkes, Brian C.; Schiller, Peter W.			'Carba'-carfentanil (trans isomer): A mu opioid receptor (MOR) partial agonist with a distinct binding mode	BIOORGANIC & MEDICINAL CHEMISTRY			English	Article						Carfentanil; 'Carba'-carfentanil; Opioid activity profiles; mu opioid receptor binding mode	TRANSMEMBRANE DOMAIN; PEPTIDE AGONISTS; OPIATE RECEPTOR; ANALOGS; ANTAGONISTS; MORPHINE; SALVINORIN; CONVERSION; ENKEPHALIN; FENTANYL	There is strong evidence to indicate that a positively charged nitrogen of endogenous and exogenous opioid ligands forms a salt bridge with the Asp residue in the third transmembrane helix of opioid receptors. To further examine the role of this electrostatic interaction in opioid receptor binding and activation, we synthesized 'carba'-analogues of the highly potent mu opioid analgesic carfentanil (3), in which the piperidine nitrogen was replaced with a carbon. The resulting trans isomer (8b) showed reduced, but still significant MOR binding affinity (K-i(mu) = 95.2 nM) with no MOR versus DOR binding selectivity and was a MOR partial agonist. The cis isomer (8a) was essentially inactive. A MOR docking study indicated that 8b bound to the same binding pocket as parent 3, but its binding mode was somewhat different. A re-evaluation of the uncharged morphine derivative N-formylnormorphine (9) indicated that it was a weak MOR antagonist showing no preference for MOR over KOR. Taken together, the results indicate that deletion of the positively charged nitrogen in mu opioid analgesics reduces MOR binding affinity by 2-3 orders of magnitude and may have pronounced effects on the intrinsic efficacy and on the opioid receptor selectivity profile. (C) 2014 Elsevier Ltd. All rights reserved.	[Weltrowska, Grazyna; Lemieux, Carole; Chung, Nga N.; Wilkes, Brian C.; Schiller, Peter W.] Clin Res Inst Montreal, Lab Chem Biol & Peptide Res, Montreal, PQ H2W 1R7, Canada; [Schiller, Peter W.] Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada; [Guo, Jason J.] Northeastern Univ, Ctr Drug Discovery, Boston, MA 02115 USA	Schiller, PW (reprint author), Clin Res Inst Montreal, Lab Chem Biol & Peptide Res, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	schillp@ircm.qc.ca			U.S. National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA004443]; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP-89716]	The work was supported by grants from the U.S. National Institutes of Health (DA004443) and the Canadian Institutes of Health Research (MOP-89716).	Anand JP, 2012, CHEM BIOL DRUG DES, V80, P763, DOI 10.1111/cbdd.12014; [Anonymous], 2012, ECONOMIST, V401, P1; Befort K, 1996, MOL PHARMACOL, V49, P216; Berezowska I, 2009, CHEM BIOL DRUG DES, V74, P329, DOI 10.1111/j.1747-0285.2009.00867.x; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; Cardillo G, 2004, J MED CHEM, V47, P5198, DOI 10.1021/jm0498811; Casy A. F., 1986, OPIOID ANALGESICS CH, P287; Cavalli A, 1999, NEUROSCIENCE, V93, P1025, DOI 10.1016/S0306-4522(99)00280-8; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Decaillot F.M., 2004, DELTA RECEPTOR, P41; DIMAIO J, 1982, J MED CHEM, V25, P1432, DOI 10.1021/jm00354a008; FELDMAN PL, 1990, J ORG CHEM, V55, P4207, DOI 10.1021/jo00300a047; Granier S, 2012, NATURE, V485, P400, DOI 10.1038/nature11111; Harding WW, 2005, J MED CHEM, V48, P4765, DOI 10.1021/jm048963m; HENDERSON G, 1972, BRIT J PHARMACOL, V46, P764, DOI 10.1111/j.1476-5381.1972.tb06901.x; Kane BE, 2008, J MED CHEM, V51, P1824, DOI 10.1021/jm701040v; KATRITZKY AR, 1989, SYNTHESIS-STUTTGART, P949; Li JG, 1999, LIFE SCI, V65, P175, DOI 10.1016/S0024-3205(99)00234-9; Lu YX, 2001, J MED CHEM, V44, P3048, DOI 10.1021/jm0101186; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; PATON WDM, 1957, BRIT J PHARM CHEMOTH, V12, P119, DOI 10.1111/j.1476-5381.1957.tb01373.x; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; Ross NC, 2010, TETRAHEDRON LETT, V51, P5020, DOI 10.1016/j.tetlet.2010.07.086; Roth BL, 2002, P NATL ACAD SCI USA, V99, P11934, DOI 10.1073/pnas.182234399; Saito T, 2002, J ANTIBIOT, V55, P847, DOI 10.7164/antibiotics.55.847; Schiller PW, 2003, LIFE SCI, V73, P691, DOI 10.1016/S0024-3205(03)00389-8; SCHILLER PW, 1978, BIOCHEM BIOPH RES CO, V85, P1332, DOI 10.1016/0006-291X(78)91149-X; Traber D. F., 1992, J ORG CHEM, V57, P4037; WATERFIELD AA, 1979, EUR J PHARMACOL, V58, P11, DOI 10.1016/0014-2999(79)90334-0; Weltrowska G, 2010, J MED CHEM, V53, P2875, DOI 10.1021/jm9019068; WILKES BC, 1990, BIOPOLYMERS, V29, P89, DOI 10.1002/bip.360290113; Wu HX, 2012, NATURE, V485, P327, DOI 10.1038/nature10939	32	6	7	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0968-0896	1464-3391		BIOORGAN MED CHEM	Bioorg. Med. Chem.	SEP 1	2014	22	17					4581	4586		10.1016/j.bmc.2014.07.033			6	Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry, Organic	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry	AO4GC	WOS:000341293300006	25129170	Green Accepted			2020-06-30	J	Skorga, P; Young, CF				Skorga, Phyllis; Young, Charlotte F.			Transdermal Fentanyl for Cancer Pain	CLINICAL NURSE SPECIALIST			English	Article									[Skorga, Phyllis; Young, Charlotte F.] Arkansas State Univ Jonesboro, Coll Nursing & Hlth Profess, Jonesboro, AR USA	Skorga, P (reprint author), Care of Fowler SB, Walden Univ, 165 Essex Ave,Unit 106, Metuchen, NJ 08840 USA.	njfowlers761@msn.com					Hadley G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010270.pub2	1	0	0	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0887-6274	1538-9782		CLIN NURSE SPEC	Clin. Nurse Spec.	SEP-OCT	2014	28	5					264	265		10.1097/NUR.0000000000000067			2	Nursing	Nursing	AN7XN	WOS:000340814400005	25111404				2020-06-30	J	Bausewein, C; Simon, ST				Bausewein, Claudia; Simon, Steffen T.			Inhaled nebulized and intranasal opioids for the relief of breathlessness	CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE			English	Review						dyspnea; inhalation; intranasal; nebulized; opioids	FENTANYL CITRATE; DIFFERENT ROUTES; DOUBLE-BLIND; DYSPNEA; MORPHINE; CANCER; DISEASE; LUNG; PHARMACOKINETICS; BIOAVAILABILITY	Purpose of review Inhaled nebulized and intranasal opioid administration is available with a proven short onset of action for the relief of pain. As breathlessness episodes are short, these routes of administration seem to be attractive for breathlessness management. This review describes the recent studies evaluating the effectiveness of inhaled nebulized and intranasal application of opioids for patients suffering from refractory breathlessness. Recent findings Since 2012, one systematic review and three primary studies have been identified. The systematic review summarized five studies including seventy patients testing nebulized fentanyl and two studies including five patients evaluating intranasal application. Two randomized controlled trials tested inhaled fentanyl or morphine and one retrospective chart review described the application of intranasal fentanyl in newborn babies. Inhaled fentanyl did not improve the intensity or unpleasantness of perceived dyspnea, but the rate of increase in dyspnea intensity and unpleasantness ratings between isotime and peak exercise was less after treatment with fentanyl. Inhaled morphine improved breathlessness in chronic obstructive pulmonary disease patients. Summary There is currently not enough evidence to support the use of inhaled application of opioids for the relief of breathlessness. There are no controlled trials assessing the efficacy and effectiveness of intranasal opioid application, but a pilot trial is underway to provide preliminary data.	[Bausewein, Claudia] Munich Univ Hosp, Dept Palliat Med, D-81377 Munich, Germany; [Simon, Steffen T.] Uniklin Koln, Zentrum Palliativmed, D-50924 Cologne, Germany	Bausewein, C (reprint author), Munich Univ Hosp, Dept Palliat Med, Marchioninistr 15, D-81377 Munich, Germany.	Claudia.bausewein@med.uni-muenchen.de		Bausewein, Claudia/0000-0002-0958-3041	German Federal Ministry of Education and ResearchFederal Ministry of Education & Research (BMBF); TEVA Ltd.	C.B. receives research funding from the German Federal Ministry of Education and Research.; S.T.S. received research funding for a clinical trial (IIT) evaluation of buccal fentanyl for episodic breathlessness from TEVA Ltd.	Abernethy AP, 2003, BRIT MED J, V327, P523, DOI 10.1136/bmj.327.7414.523; Benson Heather A. E., 1998, Australian Journal of Hospital Pharmacy, V28, P236; Bruera E, 2005, J PAIN SYMPTOM MANAG, V29, P613, DOI 10.1016/j.jpainsymman.2004.08.016; Burburan M, 2009, EUR J PALLIAT CARE, V39; Charles MA, 2008, J PAIN SYMPTOM MANAG, V36, P29, DOI 10.1016/j.jpainsymman.2007.08.016; CHRUBASIK J, 1988, BRIT J ANAESTH, V61, P228, DOI 10.1093/bja/61.2.228; Coyne PJ, 2002, J PAIN SYMPTOM MANAG, V23, P157, DOI 10.1016/S0885-3924(01)00391-8; Crellin D, 2010, EMERG MED AUSTRALAS, V22, P62, DOI 10.1111/j.1742-6723.2010.01257.x; Currow DC, 2011, J PAIN SYMPTOM MANAG, V42, P388, DOI 10.1016/j.jpainsymman.2010.11.021; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Freye Enno, 2007, Pain Pract, V7, P324, DOI 10.1111/j.1533-2500.2007.00157.x; Ghanei M, 2007, INHAL TOXICOL, V19, P451, DOI 10.1080/08958370601174990; Graff GR, 2004, RESPIRATION, V71, P646, DOI 10.1159/000081769; Grassin-Delyle S, 2012, PHARMACOL THERAPEUT, V134, P366, DOI 10.1016/j.pharmthera.2012.03.003; Harlos MS, 2013, J PAIN SYMPTOM MANAG, V46, P265, DOI 10.1016/j.jpainsymman.2012.07.009; JENNINGS AL, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002066; Jensen D, 2012, J PAIN SYMPTOM MANAG, V43, P706, DOI 10.1016/j.jpainsymman.2011.05.007; Kallet RH, 2007, RESP CARE, V52, P900; Krajnik M, 2009, J PAIN SYMPTOM MANAG, V38, P747, DOI 10.1016/j.jpainsymman.2009.03.008; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Mahler DA, 2010, CHEST, V137, P674, DOI 10.1378/chest.09-1543; Nave R, 2013, DRUG DELIV, V20, P216, DOI 10.3109/10717544.2012.762435; OSBORNE R, 1990, CLIN PHARMACOL THER, V47, P12, DOI 10.1038/clpt.1990.2; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Reddy SK, 2009, J PALLIAT MED, V12, P29, DOI 10.1089/jpm.2008.0158; SATO H, 1988, BIOCHEM PHARMACOL, V37, P2273; Scharnagel R, 2013, SCHMERZ, V27, P7, DOI 10.1007/s00482-012-1278-6; Shohrati M, 2012, PULM MED, V2012, DOI 10.1155/2012/610921; Simon ST, 2013, J PAIN SYMPTOM MANAG, V46, P874, DOI 10.1016/j.jpainsymman.2013.02.019; Simon ST, 2012, J PALLIAT MED, V15, P1374, DOI 10.1089/jpm.2012.0249; Sitte T, 2009, WIEN MED WOCHENSCHR, V159, P566, DOI 10.1007/s10354-009-0724-2; Sitte Thomas, 2008, J Pain Symptom Manage, V36, pe3, DOI 10.1016/j.jpainsymman.2008.08.002; Smith TJ, 2009, J PALLIAT MED, V12, P771, DOI 10.1089/jpm.2009.0113; Striebel H W, 1993, Schmerz, V7, P122, DOI 10.1007/BF02527870; Thronas M, 2014, J Opioid Manag, V10, P21, DOI 10.5055/jom.2014.0188; Weingartner V, 2013, J PALLIAT MED, V16, P1275, DOI 10.1089/jpm.2013.0087; Zebraski SE, 2000, LIFE SCI, V66, P2221, DOI 10.1016/S0024-3205(00)00434-3	37	11	11	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1751-4258	1751-4266		CURR OPIN SUPPORT PA	Curr. Opin Support Palliat. Car.	SEP	2014	8	3					208	212		10.1097/SPC.0000000000000071			5	Health Care Sciences & Services	Health Care Sciences & Services	AN3TT	WOS:000340512300004	25004175				2020-06-30	J	Bossi, P; Locati, L; Bergamini, C; Mirabile, A; Granata, R; Imbimbo, M; Resteghini, C; Licitra, L				Bossi, Paolo; Locati, Laura; Bergamini, Cristiana; Mirabile, Aurora; Granata, Roberta; Imbimbo, Martina; Resteghini, Carlo; Licitra, Lisa			Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer	ORAL ONCOLOGY			English	Article						Fentanyl pectin nasal spray; Breakthrough pain (BTP); Oral mucositis; Chemo radiotherapy; Head and neck cancer	CLINICAL-PRACTICE GUIDELINES; RECEIVING RADIOTHERAPY; SEVERITY; RECOMMENDATIONS; CHEMOTHERAPY; ASSOCIATION; PREVALENCE; MANAGEMENT; EFFICACY; MORPHINE	Background: Painful mucositis is one of the most distressing toxicities of chemoradiotherapy (CRT) for head and neck cancer (HNC), with the characteristics of incidental predictable breakthrough pain (BTP) during swallowing. Fentanyl pectin nasal spray (FPNS) could be a good therapeutic option. Methods: Patients were prospectively considered if receiving basal analgesic therapy with opiates for painful mucositis of grade >= 4 on a numerical rating scale from 0 to 10. They were offered FPNS 100 mcg before oral intake. When patients reached the effective dose, they evaluated the basal pain intensity before FPNS use and after 10, 20, 30 and 40 min. Results: Seventeen HNC patients were offered FPNS before oral intake, with 15 patients completing treatment. Mean reduction of incidental BTP intensity after FPNS was 3.1 points (range 1.2-5.8). Mean time elapsed since FPNS use and highest pain reduction was 26 min. Conclusions: FPNS demonstrated activity against BTP when swallowing in HNC patients. These data should be considered as hypothesis-generating. (C) 2014 Elsevier Ltd. All rights reserved.	[Bossi, Paolo; Locati, Laura; Bergamini, Cristiana; Mirabile, Aurora; Granata, Roberta; Imbimbo, Martina; Resteghini, Carlo; Licitra, Lisa] Fdn IRCCS Ist Nazl Tumori, I-20133 Milan, Italy	Bossi, P (reprint author), Fdn IRCCS Ist Nazl Tumori, Via Venezian 1, I-20133 Milan, Italy.	paolo.bossi@istitutotumori.mi.it	Resteghini, Carlo/H-9405-2017; Locati, Laura D/B-8163-2017; Granata, Roberta/B-8649-2017; Bossi, Paolo/I-2376-2019; Bossi, Paolo/D-1807-2017; Licitra, Lisa F/C-6271-2017; Bergamini, Cristiana/H-9431-2017; Imbimbo, Martina/K-4510-2016	Resteghini, Carlo/0000-0002-0188-9759; Locati, Laura D/0000-0003-3315-2580; Granata, Roberta/0000-0001-6584-3138; Bossi, Paolo/0000-0003-0135-0224; Bossi, Paolo/0000-0003-0135-0224; Licitra, Lisa F/0000-0003-0623-4118; Bergamini, Cristiana/0000-0001-7616-5125; Imbimbo, Martina/0000-0003-2521-7540			Argiris A, 2008, LANCET, V371, P1695, DOI 10.1016/S0140-6736(08)60728-X; Bar V, 2010, CANCER-AM CANCER SOC, V116, P4206, DOI 10.1002/cncr.25274; Bhatnagar S, 2010, J PALLIAT MED, V13, P291, DOI 10.1089/jpm.2009.0266; Bradley PJ, 2012, EUR ARCH OTO-RHINO-L, V269, P2451, DOI 10.1007/s00405-012-2209-y; Caraceni A, 2002, J PAIN SYMPTOM MANAG, V23, P239, DOI 10.1016/S0885-3924(01)00409-2; Cerchietti LCA, 2002, CANCER, V95, P2230, DOI 10.1002/cncr.10938; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Elting LS, 2008, CANCER-AM CANCER SOC, V113, P2704, DOI 10.1002/cncr.23898; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Jandhyala R, 2013, J PAIN SYMPTOM MANAG; Keefe DM, 2007, CANCER-AM CANCER SOC, V109, P820, DOI 10.1002/cncr.22484; Ling IS, 2011, SUPPORT CARE CANCER, V19, P1343, DOI 10.1007/s00520-010-0955-1; Murphy Barbara A, 2007, J Support Oncol, V5, P13; Pignon JP, 2009, RADIOTHER ONCOL, V92, P4, DOI 10.1016/j.radonc.2009.04.014; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233; Russi EG, 2012, CANCER TREAT REV, V38, P1033, DOI 10.1016/j.ctrv.2012.04.002; Scully C, 2006, ORAL DIS, V12, P229, DOI 10.1111/j.1601-0825.2006.01258.x; Trotti A, 2003, RADIOTHER ONCOL, V66, P253, DOI 10.1016/S0167-8140(02)00404-8; Vissers D, 2010, CURR MED RES OPIN, V26, P1037, DOI 10.1185/03007991003694340; Wong PC, 2006, J PAIN SYMPTOM MANAG, V32, P27, DOI 10.1016/j.jpainsymman.2005.12.020; Zeppetella G, 2011, CLIN ONCOL-UK, V23, P393, DOI 10.1016/j.clon.2010.12.002	23	10	11	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1368-8375	1879-0593		ORAL ONCOL	Oral Oncol.	SEP	2014	50	9					884	887		10.1016/j.oraloncology.2014.06.013			4	Oncology; Dentistry, Oral Surgery & Medicine	Oncology; Dentistry, Oral Surgery & Medicine	AN0IF	WOS:000340267300018	25001894				2020-06-30	J	Fernandez, MA; Karthikeyan, S; Wyse, M; Foguet, P				Fernandez, M. A.; Karthikeyan, S.; Wyse, M.; Foguet, P.			The incidence of postoperative urinary retention in patients undergoing elective hip and knee arthroplasty	ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND			English	Article						Urinary retention; Arthroplasty; Urethral catheterisation	LOWER-LIMB ARTHROPLASTY; INTRATHECAL MORPHINE; EPIDURAL-ANESTHESIA; RISK-FACTORS; REPLACEMENT; ANALGESIA; CATHETERIZATION; METAANALYSIS; PREVENTION; MANAGEMENT	INTRODUCTION Postoperative urinary retention requiring urethral catheterisation increases the risk of joint sepsis following arthroplasty. Spinal anaesthesia with opiate administration is used widely in lower limb arthroplasty. We sought to establish whether the choice of opiate agent had any effect on the incidence of postoperative retention and therefore the risk of joint sepsis. METHODS A total of 445 consecutive patients who underwent primary elective lower limb arthroplasty were reviewed retrospectively. Patients had general anaesthesia and femoral nerve block (GA+FNB), spinal anaesthesia and intrathecal fentanyl (SA+ITF) or spinal anaesthesia and intrathecal morphine (SA+ITM). RESULTS Urinary retention was observed in 14% of male and 2% of female patients with GA+FNB, 9% of male and 3% of female patients with SA+ITF, and 60% of male (p=0.0005) and 5% of female patients with SA+ITM. Men who experienced retention were older (68 vs 64 years, p=0.013) and had longer inpatient stays (6.7 vs 4.6 days, p=0.043). Fewer patients in the SA+ITM group required breakthrough analgesia (28% vs 58%, p=0.004). CONCUSIONS The use of ITM in men significantly increases the incidence of urinary retention requiring urethral catheterisation and subsequently increases the risk of deep joint sepsis. Its use should be rationalised against the intended benefits and alternatives sought where possible.	[Fernandez, M. A.; Karthikeyan, S.; Wyse, M.; Foguet, P.] Univ Hosp Coventry & Warwickshire NHS Trust, Coventry, W Midlands, England	Fernandez, MA (reprint author), Univ Hosp Coventry & Warwickshire NHS Trust, Coventry, W Midlands, England.	miguel.fernandez@warwick.ac.uk			National Institute for Health ResearchNational Institute for Health Research (NIHR) [1809]		Bachmann M, 1997, BRIT J ANAESTH, V78, P666, DOI 10.1093/bja/78.6.666; Balderi T, 2011, MINERVA ANESTESIOL, V77, P1050; Balderi T, 2010, MINERVA ANESTESIOL, V76, P120; Baldini G, 2009, ANESTHESIOLOGY, V110, P1139, DOI 10.1097/ALN.0b013e31819f7aea; Cumming D, 2007, INT ORTHOP, V31, P483, DOI 10.1007/s00264-006-0227-3; FITZGERALD RH, 1992, ORTHOP CLIN N AM, V23, P259; FOGARTY DJ, 1995, J ROY SOC MED, V88, P70; Gehling M, 2009, ANAESTHESIA, V64, P643, DOI 10.1111/j.1365-2044.2008.05817.x; Griesdale DEG, 2011, CAN J ANESTH, V58, P1097, DOI 10.1007/s12630-011-9595-2; Hassett Patrick, 2008, BMC Anesthesiol, V8, P5, DOI 10.1186/1471-2253-8-5; Izard Jason P, 2006, Can J Urol, V13, P3158; Kieffer WKM, 2012, ANN ROY COLL SURG, V94, P356, DOI 10.1308/003588412X13171221591691; Kotwal R, 2008, ACTA ORTHOP BELG, V74, P332; Kumar P., 2006, Int. braz j urol., V32, P31, DOI 10.1590/S1677-55382006000100005; Lingaraj K., 2007, SMJ Singapore Medical Journal, V48, P213; Macdowell AD, 2004, J BONE JOINT SURG BR, V86B, P1115, DOI 10.1302/0301-620X.86B8.14240; Mendieta Sanchez J M, 1999, Rev Esp Anestesiol Reanim, V46, P433; Meylan N, 2009, BRIT J ANAESTH, V102, P156, DOI 10.1093/bja/aen368; Murphy PM, 2003, ANESTH ANALG, V97, P1709, DOI 10.1213/01.ANE.0000089965.75585.0D; O'Riordan JA, 2000, EUR J ANAESTH, V17, P431, DOI 10.1046/j.1365-2346.2000.00720.x; Oishi CS, 1995, J ARTHROPLASTY, V10, P732, DOI 10.1016/S0883-5403(05)80067-1; Rathmell JP, 2003, ANESTH ANALG, V97, P1452, DOI 10.1213/01.ANE.0000083374.44039.9E; Souron V, 2003, CAN J ANAESTH, V50, P574, DOI 10.1007/BF03018643; STAMM WE, 1991, AM J MED, V91, pS65, DOI 10.1016/0002-9343(91)90345-X; WATERHOUSE N, 1987, J BONE JOINT SURG BR, V69, P64; Williams A, 1995, J ROY SOC MED, V88, pP699; WROBLEWSKI BM, 1980, CLIN ORTHOP RELAT R, P209	27	16	18	0	9	ROYAL COLL SURGEONS ENGLAND	LONDON	35-43 LINCOLN'S INN FIELDS, LONDON WC2A 3PN, ENGLAND	0035-8843	1478-7083		ANN ROY COLL SURG	Ann. R. Coll. Surg. Engl.	SEP	2014	96	6					462	465		10.1308/003588414X13946184902523			4	Surgery	Surgery	AP8NN	WOS:000342335800012	25198980	Green Published			2020-06-30	J	Mahlke, NS; Ziesenitz, V; Mikus, G; Skopp, G				Mahlke, Nina Sophia; Ziesenitz, Victoria; Mikus, Gerd; Skopp, Gisela			Quantitative low-volume assay for simultaneous determination of fentanyl, norfentanyl, and minor metabolites in human plasma and urine by liquid chromatography-tandem mass spectrometry (LC-MS/MS)	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						Fentanyl; Metabolites; Human plasma; Urine; LC-MS/MS	HUMAN LIVER-MICROSOMES; TRANSDERMAL FENTANYL; GAS-CHROMATOGRAPHY; MAJOR METABOLITES; PERFORMANCE; IDENTIFICATION; POSTMORTEM; BLOOD; PHARMACOKINETICS; QUANTIFICATION	A rapid and sensitive liquid chromatography/tandem mass spectrometric (LC-MS/MS) method for simultaneous quantification of fentanyl (F), norfentanyl (NF), despropionylfentanyl (DPF), and hydroxynorfentanyl (OHNF) in human plasma and urine specimens has been developed and validated according to international guidelines. Analytes were extracted from 250-mu L plasma or urine by liquid-liquid extraction. OHNF in urine affords a second extraction step and analysis with a different column. Calibration curves in plasma were linear from 0.05-10 ng/mL for F, 0.07-0.5 ng/mL for NF, 0.02-1.0 ng/ml for DPF, and 0.67-3.0 ng/mL for OHNF; in urine, from 0.09-10.0, 0.17-50, 0.08-1.0, and 1.0-5.0 ng/mL for F, NF, DPF, and OHNF, respectively. Analytical bias and intra- and inter-assay imprecision were within +/- 15 % of target, except for OHNF in plasma and DPF in urine at the respective lower quality control level. All analytes were stable in processed samples when stored for 24 h at room temperature. Recoveries and process efficiencies were above 82.9 and 75.1 % for all analytes in plasma and urine. The low level of DPF in plasma indicated with a matrix effect of 71.3 % moderate ion suppression, all other analytes in plasma and urine showed no matrix effects. The lower limit of quantification (LOQ) in plasma was 0.05, 0.07, 0.02 and 0.67 ng/mL for F, NF, DPF, and OHNF, respectively. In urine, the LOQ of F, NF, DPF, and OHNF were 0.09, 0.17, 0.08, and 1.28 ng/mL, respectively. This assay has been applied to human specimens collected during a clinical drug-drug interaction study.	[Mahlke, Nina Sophia; Skopp, Gisela] Univ Hosp, Inst Legal Med & Traff Med, D-69115 Heidelberg, Germany; [Ziesenitz, Victoria; Mikus, Gerd] Univ Hosp, Dept Clin Pharmacol & Pharmacoepidemiol, D-69120 Heidelberg, Germany	Skopp, G (reprint author), Univ Hosp, Inst Legal Med & Traff Med, Voss Str 2, D-69115 Heidelberg, Germany.	gisela.skopp@med.uni-heidelberg.de	Mikus, Gerd/D-4152-2013; Ziesenitz, Victoria/J-2945-2019	Mikus, Gerd/0000-0003-1783-133X; Ziesenitz, Victoria/0000-0003-2836-4212			Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Andresen H, 2012, J ANAL TOXICOL, V36, P182, DOI 10.1093/jat/bks005; [Anonymous], 2001, GUID IND BIOAN METH; Arvanitis ML, 2002, AM J EMERG MED, V20, P58, DOI 10.1053/ajem.2002.29562; Bansal R, 1996, J LIQ CHROMATOGR R T, V19, P353, DOI 10.1080/10826079608001220; Baselt R.C., 2014, DISPOSITION TOXIC DR; Clavijo CF, 2011, J SEP SCI, V34, P3568, DOI 10.1002/jssc.201100422; CLOTZ MA, 1991, CLIN PHARMACY, V10, P581; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Cooreman S, 2010, J SEP SCI, V33, P2654, DOI 10.1002/jssc.201000330; Dale Eric, 2009, BMJ Case Rep, V2009, DOI 10.1136/bcr.01.2009.1454; Day J, 2003, J ANAL TOXICOL, V27, P513, DOI 10.1093/jat/27.7.513; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; GOROMARU T, 1984, ANESTHESIOLOGY, V61, P73, DOI 10.1097/00000542-198461010-00013; Guitton J, 1997, J CHROMATOGR B, V693, P59, DOI 10.1016/S0378-4347(97)00050-9; Heishman SJ, 2007, DRUG ABUSE HDB; Hull MJ, 2007, J FORENSIC SCI, V52, P1383, DOI 10.1111/j.1556-4029.2007.00564.x; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Jenkins A. J., 2007, DRUG ABUSE HDB; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lu CA, 2010, BIOMED CHROMATOGR, V24, P711, DOI 10.1002/bmc.1351; Marier JF, 2006, J CLIN PHARMACOL, V46, P642, DOI 10.1177/0091270006286901; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; Maruyama Y, 1969, Keio J Med, V18, P59; Matuszewski BK, 2003, ANAL CHEM, V75, P3019, DOI 10.1021/ac020361s; Musshoff F, 2006, J MASS SPECTROM, V41, P633, DOI 10.1002/jms.1021; Peer CJ, 2007, J ANAL TOXICOL, V31, P515, DOI 10.1093/jat/31.8.515; Peters F. T., 2009, TOXICHEM KRIMTECH, V76, P185; Pihlainen K, 2005, J MASS SPECTROM, V40, P539, DOI 10.1002/jms.831; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; Portier EJG, 1999, J CHROMATOGR B, V723, P313, DOI 10.1016/S0378-4347(98)00518-0; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; Scarth JP, 2010, DRUG TEST ANAL, V2, P1, DOI 10.1002/dta.88; SCHNEIDER E, 1986, N-S ARCH PHARMACOL, V334, P267, DOI 10.1007/BF00508781; SILVERSTEIN JH, 1993, ANESTH ANALG, V76, P618; Strano-Rossi S, 2011, J APPL TOXICOL, V31, P649, DOI 10.1002/jat.1613; Tateishi T, 1995, BIOCHEM PHARMACOL, V50, P1921, DOI 10.1016/0006-2952(95)02088-8; Teske J, 2007, INT J LEGAL MED, V121, P147, DOI 10.1007/s00414-006-0137-3; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; VANROOY HH, 1981, J CHROMATOGR, V223, P85, DOI 10.1016/S0378-4347(00)80070-5; Verplaetse R, 2010, J CHROMATOGR B, V878, P1987, DOI 10.1016/j.jchromb.2010.05.033; Ziesenitz VC, 2013, BASIC CLIN PHARMACOL, V113, P43, DOI 10.1111/bcpt.12066	43	19	19	1	34	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0937-9827	1437-1596		INT J LEGAL MED	Int. J. Legal Med.	SEP	2014	128	5					771	778		10.1007/s00414-014-1040-y			8	Medicine, Legal	Legal Medicine	AN3WV	WOS:000340520300009	24997532				2020-06-30	J	Kim, W; Song, IH; Lim, YH; Kim, MR; Kim, YE; Hwang, JH; Kim, IK; Song, SW; Kim, JW; Lee, WW; Kim, HJ; Kim, C; Kim, HC; Kim, IY; Park, HP; Kim, DG; Jeon, BS; Paek, SH				Kim, Wonki; Song, In Ho; Lim, Yong Hoon; Kim, Mi-Ryoung; Kim, Young Eun; Hwang, Jae Ha; Kim, In Keyoung; Song, Sang Woo; Kim, Jin Wook; Lee, Woong-Woo; Kim, Han-Joon; Kim, Cheolyoung; Kim, Hee Chan; Kim, In Young; Park, Hee Pyoung; Kim, Dong Gyu; Jeon, Beom Seok; Paek, Sun Ha			Influence of Propofol and Fentanyl on Deep Brain Stimulation of the Subthalamic Nucleus	JOURNAL OF KOREAN MEDICAL SCIENCE			English	Article						Parkinson Disease; Microelectrodes; Propofol; Fentanyl; Subthalamic Nucleus; Deep Brain Stimulation	PARKINSONS-DISEASE; GENERAL-ANESTHESIA; STEREOTACTIC SURGERY; NEURONAL-ACTIVITY; DYSTONIA; SHIFT	We investigated the effect of propofol and fentanyl on microelectrode recording (MER) and its clinical applicability during subthalamic nucleus (STN) deep brain stimulation (DBS) surgery. We analyzed 8 patients with Parkinson's disease, underwent bilateral STN DBS with MER. Their left sides were done under awake and then their right sides were done with a continuous infusion of propofol and fentanyl under local anesthesia. The electrode position was evaluated by preoperative MRI and postoperative CT. The clinical outcomes were assessed at six months after surgery. We isolated single unit activities from the left and the right side MERs. There was no significant difference in the mean firing rate between the left side MERs (38.7 +/- 16.8 spikes/sec, n = 78) and the right side MERs (35.5 +/- 17.2 spikes/sec, n = 66). The bursting pattern of spikes was more frequently observed in the right STN than in the left STN. All the electrode positions were within the STNs on both sides and the off-time Unified Parkinson's Disease Rating Scale part III scores at six months after surgery decreased by 67% of the preoperative level. In this study, a continuous infusion of propofol and fentanyl did not significantly interfere with the MER signals from the STN. The results of this study suggest that propofol and fentanyl can be used for STN DBS in patients with advanced Parkinson's disease improving the overall experience of the patients.	[Kim, Wonki; Lim, Yong Hoon; Kim, Mi-Ryoung; Hwang, Jae Ha; Kim, In Keyoung; Song, Sang Woo; Kim, Jin Wook; Kim, Dong Gyu; Paek, Sun Ha] Seoul Natl Univ, Coll Med, Dept Neurosurg, Seoul, South Korea; [Song, In Ho] Osong Med Innovat Fdn, Med Device Dev Ctr, Cheongwon, South Korea; [Kim, Young Eun; Lee, Woong-Woo; Kim, Han-Joon; Jeon, Beom Seok] Seoul Natl Univ, Coll Med, Dept Neurol, Seoul, South Korea; [Kim, Cheolyoung] Med Imaging Lab, Seoul, South Korea; [Kim, Cheolyoung] CyberMed Inc, Seoul, South Korea; [Kim, Hee Chan] Seoul Natl Univ, Coll Med, Dept Med Engn, Seoul, South Korea; [Kim, In Young] Hanyang Univ, Dept Biomed Engn, Seoul 133791, South Korea; [Park, Hee Pyoung] Seoul Natl Univ, Coll Med, Dept Anaesthesiol & Pain Med, Seoul, South Korea; [Jeon, Beom Seok; Paek, Sun Ha] Seoul Natl Univ, Coll Med, Ischem Hypox Dis Inst, Seoul, South Korea; [Paek, Sun Ha] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea; [Paek, Sun Ha] Seoul Natl Univ Hosp, Clin Res Inst, Seoul 110744, South Korea	Paek, SH (reprint author), Seoul Natl Univ Hosp, Dept Neurosurg, 101 Daehak Ro, Seoul 110744, South Korea.	paeksh@snu.ac.kr		Lim, Yong Hoon/0000-0002-0346-2345; Kim, Han-Joon/0000-0001-8219-9663; Park, Hee-Pyoung/0000-0002-4772-0780; Lee, Woong-Woo/0000-0002-8767-7967	Korea Institute of Planning & Evaluation for Technology in Food, Agriculture, Forestry, and Fisheries, Republic of Korea [311011-05-3-SB020]; Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea [HI09C13540100, HI10C14110400, HI12C02050101]	This work was supported by a grant from the Korea Institute of Planning & Evaluation for Technology in Food, Agriculture, Forestry, and Fisheries, Republic of Korea (No. 311011-05-3-SB020) and a grant from the Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (No. HI09C13540100, HI10C14110400 and HI12C02050101).	ANDERSON BJ, 1994, BRIT J NEUROSURG, V8, P387, DOI 10.3109/02688699409029633; BENABID AL, 1987, APPL NEUROPHYSIOL, V50, P344; Benabid AL, 2003, CURR OPIN NEUROBIOL, V13, P696, DOI 10.1016/j.conb.2003.11.001; Benarroch EE, 2008, NEUROLOGY, V70, P1991, DOI 10.1212/01.wnl.0000313022.39329.65; Benazzouz A, 2002, MOVEMENT DISORD, V17, pS145, DOI 10.1002/mds.10156; Bohmdorfer W, 2003, ANAESTHESIST, V52, P795, DOI 10.1007/s00101-003-0522-y; Deiner Stacie, 2009, Anesthesiol Clin, V27, P391, DOI 10.1016/j.anclin.2009.07.005; Duque P, 2008, EUR J NEUROL, V15, P76, DOI 10.1111/j.1468-1331.2008.02166.x; Harries AM, 2012, J NEUROSURG, V116, P107, DOI 10.3171/2011.7.JNS11319; Hertel Frank, 2006, Neurosurgery, V59, pE1138; Hutchison WD, 2003, ANN NEUROL, V53, P480, DOI 10.1002/ana.10474; Hutchison WD, 1998, ANN NEUROL, V44, P622, DOI 10.1002/ana.410440407; Khan MF, 2008, STEREOT FUNCT NEUROS, V86, P44, DOI 10.1159/000108588; Lefaucheur JP, 2008, EUR NEUROL, V60, P186, DOI 10.1159/000148246; Lin SH, 2008, J NEUROSURG, V109, P238, DOI 10.3171/JNS/2008/109/8/0238; MacIver MB, 2011, ANESTHESIOLOGY, V115, P254, DOI 10.1097/ALN.0b013e3182217126; Magnin M, 2000, NEUROSCIENCE, V96, P549, DOI 10.1016/S0306-4522(99)00583-7; Maltete D, 2004, ARCH NEUROL-CHICAGO, V61, P390, DOI 10.1001/archneur.61.3.390; Martinez-Santiesteban FM, 2007, PHYS MED BIOL, V52, P2073, DOI 10.1088/0031-9155/52/8/003; Miyagi Y, 2007, J NEUROSURG, V107, P989, DOI 10.3171/JNS-07/11/0989; Obeso JA, 2001, NEW ENGL J MED, V345, P956, DOI 10.1056/nejmoa000827; Paek SH, 2011, WORLD NEUROSURG, V75, P517, DOI 10.1016/j.wneu.2010.12.003; Rodriguez-Oroz MC, 2001, BRAIN, V124, P1777, DOI 10.1093/brain/124.9.1777; SCHALTENBRAND G, 1998, [No title captured]; Schrock LE, 2009, J NEUROPHYSIOL, V102, P3740, DOI 10.1152/jn.00544.2009; Steigerwald F, 2008, J NEUROPHYSIOL, V100, P2515, DOI 10.1152/jn.90574.2008; Velly LJ, 2007, ANESTHESIOLOGY, V107, P202, DOI 10.1097/01.anes.0000270734.99298.b4; Venkatraghavan L, 2010, ANESTH ANALG, V110, P1138, DOI 10.1213/ANE.0b013e3181d2a782; Weinberger M, 2006, J NEUROPHYSIOL, V96, P3248, DOI 10.1152/jn.00697.2006; Yamada K, 2007, PARKINSONISM RELAT D, V13, P101, DOI 10.1016/j.parkreldis.2006.07.008	30	13	16	0	2	KOREAN ACAD MEDICAL SCIENCES	SEOUL	302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA	1011-8934	1598-6357		J KOREAN MED SCI	J. Korean Med. Sci.	SEP	2014	29	9					1278	1286		10.3346/jkms.2014.29.9.1278			9	Medicine, General & Internal	General & Internal Medicine	AS5PG	WOS:000344321800016	25246748	DOAJ Gold, Green Published			2020-06-30	J	Choi, JB; Shim, YH; Lee, YW; Lee, JS; Choi, JR; Chang, CH				Choi, Jong Bum; Shim, Yon Hee; Lee, Youn-Woo; Lee, Jeong Soo; Choi, Jong-Rim; Chang, Chul Ho			Incidence and Risk Factors of Postoperative Nausea and Vomiting in Patients with Fentanyl-Based Intravenous Patient-Controlled Analgesia and Single Andemetic Prophylaxis	YONSEI MEDICAL JOURNAL			English	Article						Analgesia; antiemetics; fentanyl; patient-controlled; postoperative nausea and vomiting	RANDOMIZED CONTROLLED-TRIAL; SEVOFLURANE; ONDANSETRON; ANESTHESIA; THYROIDECTOMY; MANAGEMENT; OUTCOMES; SURGERY; SCORE	Purpose: We evaluated the incidence and risk factors of postoperative nausea and vomiting (PONY) in patients with fentanyl-based intravenous patient-controlled analgesia (IV-PCA) and single antiemetic prophylaxis of 5-hydroxytryptamine type 3 (5 HT3)-receptor antagonist after the general anesthesia. Materials and Methods: In this retrospective study, incidence and risk factors for PONY were evaluated with fentanyl IV-PCA during postoperative 48 hours after various surgeries. Results: Four hundred-forty patients (23%) Of 1878 had showed PONY. PCA was discontinued temporarily in 268 patients (14%), mostly due to PONY (88% of 268 patients). In multivariate analysis, female, non-smoker, history of motion sickness or PONY long duration of anesthesia (>180 min), use of desflurane and intraoperative remifentanil infusion were independent risk factors for PONY If one, two, three, four, five, or six of these risk factors were present, the incidences of PONY were 18%, 19%, 22%, 31%, 42%, or 50%. Laparoscopic surgery and higher dose of fentanyl were not risk factors for PONY Conclusion: Despite antiemetic prophylaxis with 5 HT3-receptor antagonist, 23% of patients with fentanyl-based 1V-PCA after general anesthesia showed PONV. Long duration of anesthesia and use of desflurane were identified as risk factors, in addition to risk factors of Apfel's score (female, non-smoker, history of motion, sickness or PONY). Also, intraoperative remifentanil infusion was risk factor independent of postoperative opioid use. As the incidence of PONY was up to 50% according to the number of risk factors, risk-adapted, multimodal or combination therapy should be applied.	[Choi, Jong Bum; Shim, Yon Hee; Lee, Youn-Woo; Lee, Jeong Soo; Choi, Jong-Rim; Chang, Chul Ho] Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Anesthesia & Pain Res Inst, Seoul 120752, South Korea	Chang, CH (reprint author), Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Anesthesia & Pain Res Inst, 50-1 Yonsei Ro, Seoul 120752, South Korea.	anezzang@yuhs.ac		Lee, Jeong Soo/0000-0002-8947-3706; Chang, Chulho/0000-0001-5647-8298; Shim, Yon Hee/0000-0003-1921-3391			Anderson BJ, 2000, ANAESTH INTENS CARE, V28, P155, DOI 10.1177/0310057X0002800205; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Apfel CC, 2004, NEW ENGL J MED, V350, P2441, DOI 10.1056/NEJMoa032196; Apfel CC, 2002, BRIT J ANAESTH, V88, P659, DOI 10.1093/bja/88.5.659; Apfel Christian C, 2003, Int Anesthesiol Clin, V41, P13, DOI 10.1097/00004311-200341040-00004; Choi DH, 2005, J KOREAN MED SCI, V20, P811, DOI 10.3346/jkms.2005.20.5.811; Choi YS, 2008, SPINE, V33, pE602, DOI 10.1097/BRS.0b013e31817c6bde; East JM, 2009, W INDIAN MED J, V58, P130; Eberhart LHJ, 2011, EUR J ANAESTH, V28, P155, DOI 10.1097/EJA.0b013e3283427f4f; Fero KE, 2011, EXPERT OPIN PHARMACO, V12, P2283, DOI 10.1517/14656566.2011.598856; Gan TJ, 2002, JAMA-J AM MED ASSOC, V287, P1233, DOI 10.1001/jama.287.10.1233; Hocker J, 2006, ANAESTHESIA, V61, P752, DOI 10.1111/j.1365-2044.2006.04715.x; Kim SH, 2013, YONSEI MED J, V54, P1273, DOI 10.3349/ymj.2013.54.5.1273; Koivuranta M, 1997, ANAESTHESIA, V52, P443, DOI 10.1111/j.1365-2044.1997.117-az0113.x; Kranke P, 2011, EUR J ANAESTH, V28, P152, DOI 10.1097/EJA.0b013e3283435e51; Lauta E, 2010, J NEUROSURG ANESTH, V22, P110, DOI 10.1097/ANA.0b013e3181c959da; Macario A, 1999, ANESTH ANALG, V89, P652, DOI 10.1097/00000539-199909000-00022; Macario A, 2005, AM J HEALTH-SYST PH, V62, P63, DOI 10.1093/ajhp/62.1.63; Moon YE, 2012, BRIT J ANAESTH, V108, P417, DOI 10.1093/bja/aer423; Morad AH, 2009, J NEUROSURG, V111, P343, DOI 10.3171/2008.11.JNS08797; Pierre S, 2011, EUR J ANAESTH, V28, P160, DOI 10.1097/EJA.0b013e328342fd86; Roberts GW, 2005, ANESTH ANALG, V101, P1343, DOI 10.1213/01.ANE.0000180204.64588.EC; Sinclair DR, 1999, ANESTHESIOLOGY, V91, P109, DOI 10.1097/00000542-199907000-00018; Song JW, 2011, ANAESTHESIA, V66, P263, DOI 10.1111/j.1365-2044.2011.06648.x; Stadler M, 2003, ANESTHESIOLOGY, V98, P46, DOI 10.1097/00000542-200301000-00011; Tan T, 2010, ANESTH ANALG, V111, P83, DOI 10.1213/ANE.0b013e3181c0ee9e; Tramer Martin R, 2004, Best Pract Res Clin Anaesthesiol, V18, P693, DOI 10.1016/j.bpa.2004.05.003; White PF, 2008, ANESTH ANALG, V107, P452, DOI 10.1213/ane.0b013e31817b842c; White PF, 2008, ANESTH ANALG, V107, P459, DOI 10.1213/ane.0b013e31817aa6e4; Won YJ, 2011, J INT MED RES, V39, P1834, DOI 10.1177/147323001103900526	30	20	23	0	0	YONSEI UNIV COLL MEDICINE	SEOUL	50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA	0513-5796	1976-2437		YONSEI MED J	Yonsei Med. J.	SEP 1	2014	55	5					1430	1435		10.3349/YMJ.2014.55.5.1430			6	Medicine, General & Internal	General & Internal Medicine	AM4XY	WOS:000339860700036	25048507	DOAJ Gold, Green Published			2020-06-30	J	Fujii, T; Takana, K; Orita, S; Inoue, G; Ochiai, N; Kuniyoshi, K; Aoki, Y; Ishikawa, T; Miyagi, M; Kamoda, H; Suzuki, M; Sakuma, Y; Kubota, G; Oikawa, Y; Inage, K; Sainoh, T; Sato, J; Yamauchi, K; Toyone, T; Nakamura, J; Kishida, S; Takahashi, K; Ohtori, S				Fujii, Tatsuya; Takana, Koshi; Orita, Sumihisa; Inoue, Gen; Ochiai, Nobuyasu; Kuniyoshi, Kazuki; Aoki, Yasuchika; Ishikawa, Tetsuhiro; Miyagi, Masayuki; Kamoda, Hiroto; Suzuki, Miyako; Sakuma, Yoshihiro; Kubota, Gou; Oikawa, Yasuhiro; Inage, Kazuhide; Sainoh, Takeshi; Sato, Jun; Yamauchi, Kazuyo; Toyone, Tomoaki; Nakamura, Junichi; Kishida, Shunji; Takahashi, Kazuhisa; Ohtori, Seiji			Progressive Change in Joint Degeneration in Patients with Knee or Hip Osteoarthritis Treated with Fentanyl in a Randomized Trial	YONSEI MEDICAL JOURNAL			English	Article						Opioid; knee; hip; osteoarthritis	CHRONIC NONCANCER PAIN; RISK-FACTORS; DOUBLE-BLIND; MANAGEMENT; EFFICACY; RELEASE; SAFETY; WOMEN	Purpose: Opioids improve pain from knee and hip osteoarthritis (OA) and decrease the functional impairment of patients. However, there is a possibility that opioids induce analgesia and suppress the physiological pain of OA in patients, thereby inducing the progression of OA changes in these patients. The purpose of the current study was to investigate the possibility of progressive changes in OA among patients using opioids. Materials and Methods: Two hundred knee or hip OA patients were evaluated in the current prospective, randomized, active-controlled study. Patients were randomized 1:1:1 into three parallel treatment groups: loxoprofen, tramadol/acetaminophen, and transdermal fentanyl groups. Medication was administered for 12 weeks. Pain scores and progressive OA changes on X-ray films were evaluated. Results: Overall, pain relief was obtained by all three groups. Most patients did not show progressive OA changes; however, 3 patients in the transdermal fentanyl group showed progressive OA changes during the 12 weeks of treatment. These 3 patients used significantly higher doses than others in the transdermal fentanyl group. Additionally, the average pain score for these 3 patients was significantly lower than the average pain score for the other patients in the transdermal fentanyl group. Conclusion: Fentanyl may induce progressive changes in knee or hip OA during a relatively short period, compared with oral Non-Steroidal Anti-Inflammatory Drugs or tramadol.	[Fujii, Tatsuya; Takana, Koshi; Orita, Sumihisa; Inoue, Gen; Ochiai, Nobuyasu; Kuniyoshi, Kazuki; Aoki, Yasuchika; Ishikawa, Tetsuhiro; Miyagi, Masayuki; Kamoda, Hiroto; Suzuki, Miyako; Sakuma, Yoshihiro; Kubota, Gou; Oikawa, Yasuhiro; Inage, Kazuhide; Sainoh, Takeshi; Sato, Jun; Yamauchi, Kazuyo; Toyone, Tomoaki; Nakamura, Junichi; Kishida, Shunji; Takahashi, Kazuhisa; Ohtori, Seiji] Chiba Univ, Grad Sch Med, Dept Orthopaed Surg, Chiba 2608670, Japan	Ohtori, S (reprint author), Chiba Univ, Grad Sch Med, Dept Orthopaed Surg, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	sohtori@faculty.chiba-u.jp					Abdulla A, 2013, AGE AGEING, V42, pI1, DOI 10.1093/ageing/afs200; Ackermann PW, 2001, J ORTHOPAED RES, V19, P372, DOI 10.1016/S0736-0266(00)90029-9; Afilalo M, 2010, CLIN DRUG INVEST, V30, P489, DOI 10.2165/11533440-000000000-00000; Centers for Disease Control and Prevention, 2008, ARTHR TYP OV; Cooper C, 2000, ARTHRITIS RHEUM, V43, P995, DOI 10.1002/1529-0131(200005)43:5<995::AID-ANR6>3.0.CO;2-1; Dougados M, 1996, ANN RHEUM DIS, V55, P356, DOI 10.1136/ard.55.6.356; FELSON DT, 1995, ARTHRITIS RHEUM-US, V38, P1500, DOI 10.1002/art.1780381017; Hale M, 2009, CURR MED RES OPIN, V25, P1095, DOI [10.1185/03007990902816970, 10.1185/03007990902816970 ]; Kalso E, 2004, PAIN, V112, P372, DOI 10.1016/j.pain.2004.09.019; Karlsson M, 2009, CLIN THER, V31, P503, DOI 10.1016/j.clinthera.2009.03.001; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; Lane NE, 2004, ARTHRITIS RHEUM-US, V50, P1477, DOI 10.1002/art.20213; Mabilleau G, 2010, J MUSCULOSKEL NEURON, V10, P84; Manchikanti L, 2011, PAIN PHYSICIAN, V14, P91; Muraki S, 2012, ARTHRITIS RHEUM-US, V64, P1447, DOI 10.1002/art.33508; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Schenk I, 1996, ANN ANAT, V178, P515, DOI 10.1016/S0940-9602(96)80108-7; Zhang W, 2010, OSTEOARTHR CARTILAGE, V18, P476, DOI 10.1016/j.joca.2010.01.013	18	3	3	0	6	YONSEI UNIV COLL MEDICINE	SEOUL	50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA	0513-5796	1976-2437		YONSEI MED J	Yonsei Med. J.	SEP 1	2014	55	5					1379	1385		10.3349/ymj.2014.55.5.1379			7	Medicine, General & Internal	General & Internal Medicine	AM4XY	WOS:000339860700029	25048500	DOAJ Gold, Green Published			2020-06-30	J	Albrecht, M; Henke, J; Tacke, S; Markert, M; Guth, B				Albrecht, Maike; Henke, Julia; Tacke, Sabine; Markert, Michael; Guth, Brian			Effects of isoflurane, ketamine-xylazine and a combination of medetomidine, midazolam and fentanyl on physiological variables continuously measured by telemetry in Wistar rats	BMC VETERINARY RESEARCH			English	Article						Rat; Anaesthesia; Isoflurane; Ketamine-xylazine; Medetomidine-midazolam-fentanyl; Telemetry; Heart rate; Blood pressure; Core body temperature	LOCOMOTOR-ACTIVITY; CIRCADIAN-RHYTHMS; HEART-RATE; INTRAPERITONEAL INJECTIONS; LABORATORY-ANIMALS; BODY-TEMPERATURE; ANESTHESIA; MICE; RADIOTELEMETRY; BUTORPHANOL	Background: This study investigated effects on cardiovascular parameters during anaesthesia with isoflurane (ISO, 2 3 Vol%), ketamine-xylazine (MK, 100 + 5 mg.kg(-1)) or a combination of medetomidine-midazolamfentanyl (MMF, 0.15 mg.kg(-1) + 2.0 mg.kg(-1) + 0.005 mg.kg(-1)) in rats throughout induction, maintenance and recovery from anaesthesia. Rats were instrumented with a telemetric system for the measurement of systolic, diastolic and mean arterial pressure (SAP, DAP, MAP), pulse pressure (PP), heart rate (HR) and core body temperature (BT). The parameters were continuously measured before, during and after each type of anaesthesia. Forty minutes after induction, ISO delivery was terminated and IVIIVIF was antagonized with atipamezole-flumazenilnaloxone (AFN, 0.75 mg.kg(-1) + 0.2 mg.kg(-1)+ 0.12 mg.kg(-1)) whereas KX was not antagonized. Results: Differences were observed between anaesthesias with KX (301 min) lasting much longer than MMF (45 min) and ISO (43 min). HR in ISO (T< = 404 25 bpm) increased during the time of surgical tolerance whereas a HR decrease was observed in KX = 255 26 bpm) and MMF (7.\c = 209 24 bpm). In ISO (MAP during time of surgical tolerance: 7,c = 89 12.3 mmHg) and KX (MAP during wake up period: 7v = 84 8.5 mmHg) mild hypotensive values were observed, whereas blood pressure (BP) in MMF (MAP during time of surgical tolerance: 7 = 138 9.9 mmHg) increased. Despite keeping animals on a warming pad, a loss of BT of about VC was seen in all groups. Additionally, we observed a peaked increase of HR = 445 20 bpm) during the wake-up period with ISO and an increase of PP (7 = 59 8.5 mmHg) in IV11V1F during the time of surgical tolerance. Conclusion: The anaesthesias influenced very differently the cardiovascular parameters measured in Ws ar rats. ISO caused mild hypotension and increased HR whereas IVIIVIF produced a marked hypertension and a significant decrease of HR. The slightest alterations of BP, HR and BT were observed using KX, but the long wake-up and recovery period suggest the need for prolonged monitoring.	[Albrecht, Maike; Henke, Julia] Boehringer Ingelheim Pharma GmbH & Co KG, Biol Lab Serv, Dept Nonclin Drug Safety, D-88397 Biberach, Germany; [Tacke, Sabine] Univ Giessen, Clin Small Anim Surg, Dept Vet Clin Sci, D-35392 Giessen, Germany; [Markert, Michael; Guth, Brian] Boehringer Ingelheim Pharma GmbH & Co KG, Dept Drug Discovery Support, Gen Pharmacol, D-88397 Biberach, Germany	Henke, J (reprint author), Boehringer Ingelheim Pharma GmbH & Co KG, Biol Lab Serv, Dept Nonclin Drug Safety, Birkendorfer Str 65, D-88397 Biberach, Germany.	julia.henke@boehringer-ingelheim.com	Tacke, Sabine/A-3213-2019				Arnold M, 2010, PHYSIOL BEHAV, V99, P592, DOI 10.1016/j.physbeh.2010.01.021; Astner S, 1998, THESIS TU MUNCHEN MU; Avsaroglu H, 2007, LAB ANIM-UK, V41, P337, DOI 10.1258/002367707781282811; Bahrami S, 2011, SHOCK, V35, P573, DOI 10.1097/SHK.0b013e318212266b; Baker NJ, 2011, J AM ASSOC LAB ANIM, V50, P916; Bourque SL, 2010, J AM ASSOC LAB ANIM, V49, P617; BRAGA VA, 2011, MODERN TELEMETRY, P183; Coria-Avila GA, 2007, LAB ANIMAL, V36, P25, DOI 10.1038/laban0707-25; Dang V, 2008, J AM ASSOC LAB ANIM, V47, P56; Das RG, 2007, LAB ANIM-UK, V41, P312; Dispersyn G, 2009, ANESTHESIOLOGY, V110, P1305, DOI 10.1097/ALN.0b013e3181a10225; Dittmar MS, 2004, COMPARATIVE MED, V54, P652; EGER EI, 1984, BRIT J ANAESTH, V56, pS71; Erhardt W, 2012, ANASTHESIE ANALGESIE; Flecknell P.A., 1987, LAB ANIMAL ANAESTHES; GAERTNER DJ, 1987, LAB ANIM SCI, V37, P80; GREEN CJ, 1981, LAB ANIM, V15, P163, DOI 10.1258/002367781780959107; Greene Adrianne N., 2007, Journal of Pharmacological and Toxicological Methods, V56, P218, DOI 10.1016/j.vascn.2007.04.006; Hedenqvist P, 2000, LAB ANIM-UK, V34, P244, DOI 10.1258/002367700780384762; Heitz A, 2005, THESIS TU MUNCHEN MU; Henke J, 2005, VET ANAESTH ANALG, V32, P261, DOI 10.1111/j.1467-2995.2005.00242.x; Henke J, 2004, J VET MED A, V51, P259, DOI 10.1111/j.1439-0442.2004.00632.x; Henke J, 1996, Tierarztl Prax, V24, P85; HENKE J, 2000, P 7 WCVA BERN, P99; Henke J, 1998, ED P SPRING M AVA, P70; Hildebrandt IJ, 2008, ILAR J, V49, P17, DOI 10.1093/ilar.49.1.17; Hjalmarsdottir B, 2005, THESIS TU MUNCHEN MU; HU C, 1992, LAB ANIM-UK, V26, P15, DOI 10.1258/002367792780809075; Janssen BJA, 2004, AM J PHYSIOL-HEART C, V287, pH1618, DOI 10.1152/ajpheart.01192.2003; KARI HP, 1978, RES COMMUN CHEM PATH, V20, P475; Karwacki Z, 2001, Folia Morphol (Warsz), V60, P235; Kikuchi T, 2013, NEUROSCIENCE, V237, P151, DOI 10.1016/j.neuroscience.2013.01.062; Kosanke Y, 2012, THESIS LUDWIG MAXIMI; Kramer K, 2003, PHYSIOL GENOMICS, V13, P197, DOI 10.1152/physiolgenomics.00164.2002; Kraus AL, 1980, LABORATORY RAT, VII, P22; KRINKE GJ, 2000, LAB RAT; Mantel R, 1999, THESIS TU MUNCHEN MU; Meijer MK, 2006, LAB ANIM-UK, V40, P382, DOI 10.1258/002367706778476370; Mihara T, 2012, ANESTH ANALG, V115, P805, DOI 10.1213/ANE.0b013e3182632bcb; Morton DB, 2003, LAB ANIM-UK, V37, P261, DOI 10.1258/002367703322389861; Murphy KL, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00087; Neff U, 2000, THESIS TU MUNCHEN MU; Pelissier AL, 1998, SCI TECH ANIM LAB, V23, P91; Perantoni D, 2000, THESIS TU MUNCHEN MU; Picollo C, 2012, ARQ BRAS MED VET ZOO, V64, P860, DOI 10.1590/S0102-09352012000400011; Prudian F, 1997, N-S ARCH PHARMACOL, V355, P774, DOI 10.1007/PL00005012; Pypendop B, 1996, AM J VET RES, V57, P724; Roltgen I, 2002, THESIS TU MUNCHEN MU; Salice VS, 2013, CRIT CARE, V17, P144; Schierok H, 2000, J PHARMACOL TOXICOL, V43, P211, DOI 10.1016/S1056-8719(00)00101-5; Schulte am Esch J, 2000, ANASTHESIE INTENSIVM, P147; SMILER KL, 1990, LAB ANIM SCI, V40, P60; STEWARD JP, 1968, APPL MICROBIOL, V16, P1418, DOI 10.1128/AEM.16.9.1418-1419.1968; Stokes EL, 2009, LAB ANIM-UK, V43, P149, DOI 10.1258/la.2008.008020; Sun FJ, 2003, CONTEMP TOP LAB ANIM, V42, P32; Toft MF, 2006, LAB ANIM-UK, V40, P261, DOI 10.1258/002367706777611433; Tremoleda JL, 2012, EJNMMI RES, V2, DOI 10.1186/2191-219X-2-44; Wellington D, 2013, J AM ASSOC LAB ANIM, V52, P481; Wenger S, 2012, J EXOT PET MED, V21, P7, DOI 10.1053/j.jepm.2011.11.010; Whitesall SE, 2004, AM J PHYSIOL-HEART C, V286, pH2408, DOI 10.1152/ajpheart.01089.2003	60	42	46	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-6148			BMC VET RES	BMC Vet. Res.	AUG 23	2014	10								198	10.1186/s12917-014-0198-3			14	Veterinary Sciences	Veterinary Sciences	AO3AY	WOS:000341201600001	25149627	DOAJ Gold, Green Published			2020-06-30	J	Altwegg-Boussac, T; Chavez, M; Mahon, S; Charpier, S				Altwegg-Boussac, Tristan; Chavez, Mario; Mahon, Severine; Charpier, Stephane			Excitability and responsiveness of rat barrel cortex neurons in the presence and absence of spontaneous synaptic activity in vivo	JOURNAL OF PHYSIOLOGY-LONDON			English	Article							NEOCORTICAL PYRAMIDAL NEURONS; CORTICAL-NEURONS; INTRINSIC EXCITABILITY; INTRACELLULAR ACTIVITY; BACKGROUND ACTIVITY; NETWORK ACTIVITY; GAIN MODULATION; MECHANISMS; RESPONSES; SLEEP	The amplitude and temporal dynamics of spontaneous synaptic activity in the cerebral cortex vary as a function of brain states. To directly assess the impact of different ongoing synaptic activities on neocortical function, we performed in vivo intracellular recordings from barrel cortex neurons in rats under two pharmacological conditions generating either oscillatory or tonic synaptic drive. Cortical neurons membrane excitability and firing responses were compared, in the same neurons, before and after complete suppression of background synaptic drive following systemic injection of a high dose of anaesthetic. Compared to the oscillatory state, the tonic pattern resulted in a more depolarized and less fluctuating membrane potential (V-m), a lower input resistance (R-m) and steeper relations of firing frequency versus injected current (F-I). Whatever their temporal dynamics, suppression of background synaptic activities increased mean V-m, without affecting R-m, and induced a rightward shift of F-I curves. Both types of synaptic drive generated a high variability in current-induced firing rate and patterns in cortical neurons, which was much reduced after removal of spontaneous activity. These findings suggest that oscillatory and tonic synaptic patterns differentially facilitate the input-output function of cortical neurons but result in a similar moment-to-moment variability in spike responses to incoming depolarizing inputs.	[Altwegg-Boussac, Tristan; Chavez, Mario; Mahon, Severine; Charpier, Stephane] UPMC, Inst Cerveau & Moelle Epiniere, Ctr Rech, F-75013 Paris, France; [Altwegg-Boussac, Tristan; Chavez, Mario; Mahon, Severine; Charpier, Stephane] Univ Paris 06, INSERM, U1127, F-75013 Paris, France; [Altwegg-Boussac, Tristan; Chavez, Mario; Mahon, Severine; Charpier, Stephane] Hop La Pitie Salpetriere, CNRS, UMR 7225, F-75013 Paris, France; [Charpier, Stephane] Univ Paris 06, F-75005 Paris, France	Charpier, S (reprint author), Hop La Pitie Salpetriere, Inst Cerveau & Moelle Epiniere, Ctr Rech, 47 Blvd Hop, F-75013 Paris, France.	stephane.charpier@upmc.fr	Mahon, Severine/E-7195-2017; Chavez, Mario/D-8495-2011	Chavez, Mario/0000-0003-0390-4833	Fondation de FranceFondation de France; Institut National de la Sante Et de la Recherche MedicaleInstitut National de la Sante et de la Recherche Medicale (Inserm); Pierre & Marie Curie University; program 'Investissements d'avenir'French National Research Agency (ANR) [ANR-10-IAIHU-06]	This work was supported by grants from the Fondation de France, the Institut National de la Sante Et de la Recherche Medicale, the Pierre & Marie Curie University and the program 'Investissements d'avenir' ANR-10-IAIHU-06.	Arieli A, 1996, SCIENCE, V273, P1868, DOI 10.1126/science.273.5283.1868; Azouz R, 2005, J NEUROPHYSIOL, V94, P2785, DOI 10.1152/jn.00542.2005; Azouz R, 1999, J NEUROSCI, V19, P2209; BARANYI A, 1993, J NEUROPHYSIOL, V69, P1865; BARRETT JN, 1975, FED PROC, V34, P1398; BRAITENBERG V, 1998, CORTEX STAT GEOMETRY; Brillinger DR, 2001, TIME SERIES DATA ANA; Bruno RM, 2006, SCIENCE, V312, P1622, DOI 10.1126/science.1124593; Burns D, 1968, UNCERTAIN NERVOUS SY; Cardin JA, 2008, NEURON, V59, P150, DOI 10.1016/j.neuron.2008.05.002; CATON R, 1875, BRIT MED J, V2, P278; Chance FS, 2002, NEURON, V35, P773, DOI 10.1016/S0896-6273(02)00820-6; Charpier S, 1999, NEUROSCIENCE, V91, P1209, DOI 10.1016/S0306-4522(98)00719-2; Chipaux M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058180; Civillico EF, 2012, FRONT SYST NEUROSCI, V6, DOI 10.3389/fnsys.2012.00025; Constantinople CM, 2011, NEURON, V69, P1061, DOI 10.1016/j.neuron.2011.02.040; Contreras D, 1996, J PHYSIOL-LONDON, V490, P159, DOI 10.1113/jphysiol.1996.sp021133; Daoudal G, 2003, LEARN MEMORY, V10, P456, DOI 10.1101/lm.64103; Destexhe A, 2003, NAT REV NEUROSCI, V4, P739, DOI 10.1038/nrn1198; Destexhe A, 1999, J NEUROPHYSIOL, V81, P1531; Destexhe A, 2001, NEUROSCIENCE, V107, P13, DOI 10.1016/S0306-4522(01)00344-X; Destexhe Alain, 2010, Front Cell Neurosci, V4, P9, DOI 10.3389/fncel.2010.00009; Drummond GB, 2009, J PHYSIOL-LONDON, V587, P713, DOI 10.1113/jphysiol.2008.167387; Ermentrout GB, 2008, TRENDS NEUROSCI, V31, P428, DOI 10.1016/j.tins.2008.06.002; Ferron JF, 2009, J NEUROSCI, V29, P9850, DOI 10.1523/JNEUROSCI.5176-08.2009; Fricker D, 1999, J PHYSIOL-LONDON, V517, P791, DOI 10.1111/j.1469-7793.1999.0791s.x; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; GOTTESMANN C, 1992, NEUROSCI BIOBEHAV R, V16, P31, DOI 10.1016/S0149-7634(05)80048-X; Gutnick Michael J., 1995, P33; Haider B, 2007, J NEUROPHYSIOL, V97, P4186, DOI 10.1152/jn.01114.2006; Haider B, 2009, NEURON, V62, P171, DOI 10.1016/j.neuron.2009.04.008; HALL RD, 1974, BRAIN RES, V66, P23, DOI 10.1016/0006-8993(74)90076-6; Hasenstaub A, 2007, J NEUROSCI, V27, P9607, DOI 10.1523/JNEUROSCI.2184-07.2007; Ho N, 2000, J NEUROPHYSIOL, V84, P1488; Holt GR, 1996, J NEUROPHYSIOL, V75, P1806; Husain AM, 2006, J CLIN NEUROPHYSIOL, V23, P208, DOI 10.1097/01.wnp.0000220094.60482.b5; Kroeger D, 2007, J NEUROSCI, V27, P10597, DOI 10.1523/JNEUROSCI.3440-07.2007; Laureys S, 2005, NAT REV NEUROSCI, V6, P899, DOI 10.1038/nrn1789; Lukatch HS, 2005, CEREB CORTEX, V15, P1322, DOI 10.1093/cercor/bhi015; Lukatch HS, 1996, ANESTHESIOLOGY, V84, P1425, DOI 10.1097/00000542-199606000-00019; Mahon S, 2001, CEREB CORTEX, V11, P360, DOI 10.1093/cercor/11.4.360; Mahon S, 2006, J NEUROSCI, V26, P12587, DOI 10.1523/JNEUROSCI.3987-06.2006; Mahon S, 2012, J NEUROSCI, V32, P11377, DOI 10.1523/JNEUROSCI.0415-12.2012; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; McCormick DA, 2003, CEREB CORTEX, V13, P1219, DOI 10.1093/cercor/bhg104; Muroi Y, 2009, BIOPHYS J, V96, P499, DOI 10.1016/j.bpj.2008.09.037; Nowak LG, 1997, CEREB CORTEX, V7, P487, DOI 10.1093/cercor/7.6.487; Pantazis D, 2005, NEUROIMAGE, V25, P383, DOI 10.1016/j.neuroimage.2004.09.040; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.physiol.58.1.299; Pare D, 1998, J NEUROPHYSIOL, V79, P1450; Paxinos G. T., 1986, RAT BRAIN STEREOTAXI; Paz JT, 2009, J PHYSIOL-LONDON, V587, P3189, DOI 10.1113/jphysiol.2009.169334; Petersen CCH, 2003, P NATL ACAD SCI USA, V100, P13638, DOI 10.1073/pnas.2235811100; Polack PO, 2006, J PHYSIOL-LONDON, V571, P461, DOI 10.1113/jphysiol.2005.100925; Rudolph M, 2003, J COMPUT NEUROSCI, V14, P239, DOI 10.1023/A:1023245625896; Rudolph M, 2007, J NEUROSCI, V27, P5280, DOI 10.1523/JNEUROSCI.4652-06.2007; Sachdev RNS, 2004, J NEUROPHYSIOL, V92, P3511, DOI 10.1152/jn.00347.2004; Sanchez-Vives MV, 2000, J NEUROSCI, V20, P4267; Shu YS, 2003, J NEUROSCI, V23, P10388; Silver RA, 2010, NAT REV NEUROSCI, V11, P474, DOI 10.1038/nrn2864; SIMONS DJ, 1992, EXP BRAIN RES, V91, P259; Steriade M, 2006, NEUROSCIENCE, V137, P1087, DOI 10.1016/j.neuroscience.2005.10.029; STERIADE M, 1993, J NEUROSCI, V13, P3266; Steriade M, 2004, NAT REV NEUROSCI, V5, P121, DOI 10.1038/nrn1325; Steriade M, 2001, J NEUROPHYSIOL, V85, P1969; TEICH MC, 1992, SINGLE NEURON COMPUT, P589; TIMOIARIA C, 1970, PHYSIOL BEHAV, V5, P1057, DOI 10.1016/0031-9384(70)90162-9; Waters J, 2006, J NEUROSCI, V26, P8267, DOI 10.1523/JNEUROSCI.2152-06.2006; Wilent WB, 2004, J NEUROSCI, V24, P3985, DOI 10.1523/JNEUROSCI.5782-03.2004; Wolfensohn S, 1998, HDB LAB ANIMAL MANAG; Zou Q, 2005, NEUROCOMPUTING, V65, P673, DOI 10.1016/j.neucom.2004.10.096	71	14	14	0	18	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3751	1469-7793		J PHYSIOL-LONDON	J. Physiol.-London	AUG 15	2014	592	16					3577	3595		10.1113/jphysiol.2013.270561			19	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	AN4ZS	WOS:000340599200020	24732430	Green Published			2020-06-30	J	Ambros, B; Alcorn, J; Duke-Novakovski, T; Livingston, A; Dowling, PM				Ambros, Barbara; Alcorn, Jane; Duke-Novakovski, Tanya; Livingston, Alexander; Dowling, Patricia M.			Pharmacokinetics and pharmacodynamics of a constant rate infusion of fentanyl (5 mu g/kg/h) in awake cats	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article							INTRAVENOUS FENTANYL; ISOFLURANE-FENTANYL; DOGS; ANESTHESIA; PROPOFOL; ANALGESICS; SUFENTANIL; MANAGEMENT; ALFENTANIL; PAIN	Objective-To evaluate the pharmacokinetics and thermal and mechanical antinociceptive effects of a fentanyl constant rate infusion (CRI) in conscious cats. Animals-8 healthy adult cats. Procedures-At a >= 14-day interval, 7 cats received a loading dose (LD) of fentanyl (5 mu g/kg, IV [administered at 0 hours]) followed by fentanyl infusion (5 mu g/kg/h, IV) for 2 hours or similar administrations of equivalent volumes of 0.9% saline (NaCl) solution. One cat received only the fentanyl treatment. For both treatments, sedation and adverse events were evaluated and mechanical threshold (MT) and thermal threshold (TT) testing was performed prior to (baseline) and at predetermined times up to 26 hours after LD administration; plasma fentanyl concentrations were determined at similar times when the cats received fentanyl. Results-Fentanyl induced mild sedation during the infusion. The only adverse effect associated with fentanyl LD administration was profuse salivation (1 cat). Saline solution administration did not significantly change MT or TT over time. For the duration of the CRI, MT and TT differed significantly between treatments, except for TT 1 hour after LD administration. For the fentanyl treatment, MT and TT were significantly higher than baseline at 0.25 to 0.75 hours and at 0.25 to 1 hour, respectively. During the fentanyl CRI, mean +/- SD plasma fentanyl concentration decreased from 4.41 +/- 1.86 ng/mL to 2.99 +/- 1.28 ng/mL and was correlated with antinociception; plasma concentrations < 1.33 +/- 0.30 ng/mL were not associated with antinociception. Conclusions and Clinical Relevance-Fentanyl CRI (5 mu g/kg/h) induced mechanical and thermal antinociception in cats.	[Ambros, Barbara; Duke-Novakovski, Tanya] Univ Saskatchewan, Dept Small Anim Clin Sci, Saskatoon, SK S7N 5B4, Canada; [Livingston, Alexander; Dowling, Patricia M.] Univ Saskatchewan, Dept Vet Biomed Sci, Saskatoon, SK S7N 5B4, Canada; [Alcorn, Jane] Univ Saskatchewan, Western Coll Vet Med, Saskatoon, SK S7N 5B4, Canada; [Alcorn, Jane] Univ Saskatchewan, Div Pharm, Coll Pharm & Nutr, Saskatoon, SK S7N 5B4, Canada	Ambros, B (reprint author), Univ Saskatchewan, Dept Small Anim Clin Sci, Saskatoon, SK S7N 5B4, Canada.	barbara.ambros@usask.ca			Companion Animal Health Fund, Western College of Veterinary Medicine	Supported by the Companion Animal Health Fund, Western College of Veterinary Medicine.	Dixon MJ, 2010, LAB ANIM-UK, V44, P247, DOI 10.1258/la.2010.009080; Dixon MJ, 2002, RES VET SCI, V72, P205, DOI 10.1053/rvsc.2001.0543; Dohoo SE, 1998, CAN VET J, V39, P491; HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003; Iizuka T, 2013, VET J, V198, P289, DOI 10.1016/j.tvjl.2013.06.021; Kamata M, 2012, J VET MED SCI, V74, P231, DOI 10.1292/jvms.10-0565; Keating SCJ, 2013, AM J VET RES, V74, P672, DOI 10.2460/ajvr.74.5.672; Lee DD, 2000, AM J VET RES, V61, P672, DOI 10.2460/ajvr.2000.61.672; Liehmann L, 2006, VET ANAESTH ANALG, V33, P158, DOI 10.1111/j.1467-2995.2005.00251.x; Lotsch J, 2004, CLIN PHARMACOKINET, V43, P983; Mendes GM, 2003, J AM VET MED ASSOC, V223, P1608, DOI 10.2460/javma.2003.223.1608; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Pypendop BH, 2014, J VET PHARMACOL THER, V37, P13, DOI 10.1111/jvp.12047; Robertson SA, 2005, J VET PHARMACOL THER, V28, P87, DOI 10.1111/j.1365-2885.2004.00628.x; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; Shilo Y, 2011, VET ANAESTH ANALG, V38, P603, DOI 10.1111/j.1467-2995.2011.00648.x; SPINK RR, 1966, AM J VET RES, V27, P1041	18	7	7	0	10	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0002-9645	1943-5681		AM J VET RES	Am. J. Vet. Res.	AUG	2014	75	8					716	721		10.2460/ajvr.75.8.716			6	Veterinary Sciences	Veterinary Sciences	CA6EA	WOS:000349000500003	25061702				2020-06-30	J	Cata, JP; Keerty, V; Keerty, D; Feng, L; Norman, PH; Gottumukkala, V; Mehran, JR; Engle, M				Cata, Juan P.; Keerty, Visesh; Keerty, Dinesh; Feng, Lei; Norman, Peter H.; Gottumukkala, Vijaya; Mehran, John R.; Engle, Mitchel			A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection	CANCER MEDICINE			English	Article						Neoplasms; opioids; recurrence; surgery	PERIOPERATIVE EPIDURAL ANALGESIA; BREAST-CANCER; RADICAL PROSTATECTOMY; ANESTHETIC TECHNIQUE; RECEPTOR GENE; TUMOR-GROWTH; SURGERY; SURVIVAL; POLYMORPHISM; ASSOCIATION	Preclinical studies have demonstrated that opioid receptor agonists increase the rate of non-small cell lung cancer (NSCLC) growth and metastasis. Following institutional review board approval, we retrieved data on 901 patients who underwent surgery for NSCLC at MD Anderson Cancer Center. Comprehensive demographics, intraoperative data, and recurrence-free survival (RFS) and overall survival (OS) at 3 and 5 years were obtained. Cox proportional analyses were conducted to assess the association between intraoperative opioid exposure and RFS and OS. The median intraoperative fentanyl equivalents dosage was 10.15 mu g/kg. The multivariate analysis by stage indicated that a trend toward significance for opioid consumption as a risk factor in stage I patients (P = 0.053). No effect was found on RFS for stage II or III patients. Alternatively, opioid consumption was a risk factor for OS for stage I patients (P = 0.036), whereas no effect was noted for stage II or III patients. Intraoperative opioid use is associated with decreased OS in stage I but not stage II-III NSCLC patients. Until randomized controlled studies explore this association further, opioids should continue to be a key component of balanced anesthesia.	[Cata, Juan P.; Keerty, Visesh; Norman, Peter H.; Gottumukkala, Vijaya] Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Perioperat Med, Houston, TX 77030 USA; [Keerty, Dinesh] Wright Ctr Grad Med Educ, Dept Internal Med, Scranton, PA USA; [Feng, Lei] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Mehran, John R.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Surg, Houston, TX 77030 USA; [Engle, Mitchel] Univ Texas MD Anderson Canc Ctr, Dept Pain Med, Houston, TX 77030 USA	Cata, JP (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Perioperat Med, Unit 409,1515 Holcombe Blvd, Houston, TX 77030 USA.	jcata@mdanderson.org		Keerty, Dinesh/0000-0002-0287-8664	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA016672]		Baltayiannis N, 2013, J THORAC DIS, V5, pS425, DOI 10.3978/j.issn.2072-1439.2013.09.17; Biki B, 2008, ANESTHESIOLOGY, V109, P180, DOI 10.1097/ALN.0b013e31817f5b73; Bortsov AV, 2012, ANESTHESIOLOGY, V116, P896, DOI 10.1097/ALN.0b013e31824b96a1; Cata JP, 2011, EUR J PAIN S, V5, P345, DOI DOI 10.1016/J.EUJPS.2011.08.017; Cata JP, 2014, J CLIN ANESTH, V26, P3, DOI 10.1016/j.jclinane.2013.06.007; Cata JP, 2013, J CLIN ANESTH, V25, P255, DOI 10.1016/j.jclinane.2012.12.007; Chen WK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056540; Exadaktylos AK, 2006, ANESTHESIOLOGY, V105, P660, DOI 10.1097/00000542-200610000-00008; Farooqui M, 2007, BRIT J CANCER, V97, P1523, DOI 10.1038/sj.bjc.6604057; Forget P, 2011, EUR J ANAESTH, V28, P830, DOI 10.1097/EJA.0b013e32834b7d9a; Forget P, 2010, ANESTH ANALG, V110, P1630, DOI 10.1213/ANE.0b013e3181d2ad07; Fujioka N, 2011, ANESTH ANALG, V113, P1353, DOI 10.1213/ANE.0b013e318232b35a; Gottschalk A, 2010, ANESTHESIOLOGY, V113, P27, DOI 10.1097/ALN.0b013e3181de6d0d; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Lennon FE, 2012, ANESTHESIOLOGY, V116, P857, DOI 10.1097/ALN.0b013e31824babe2; Lennon FE, 2012, ANESTHESIOLOGY, V116, P940, DOI 10.1097/ALN.0b013e31824b9512; LILLEMOE KD, 1993, ANN SURG, V217, P447, DOI 10.1097/00000658-199305010-00004; LISSONI P, 1993, TUMORI, V79, P198; Madar I, 2007, J NUCL MED, V48, P207; MANECKJEE R, 1990, P NATL ACAD SCI USA, V87, P3294, DOI 10.1073/pnas.87.9.3294; Mathew B, 2011, ANESTH ANALG, V112, P558, DOI 10.1213/ANE.0b013e31820568af; Myles PS, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1491; Na II, 2012, J CANCER RES THER, V8, P373, DOI 10.4103/0973-1482.103515; Nosotti M, 2003, CHEST, V124, P102, DOI 10.1378/chest.124.1.102; Sessler DI, 2008, CONTEMP CLIN TRIALS, V29, P517, DOI 10.1016/j.cct.2008.01.002; Smith TJ, 2002, J CLIN ONCOL, V20, P4040, DOI 10.1200/JCO.2002.02.118; Wang S, 2013, INT J CLIN ONCOL, V18, P666, DOI 10.1007/s10147-012-0441-5; Yardeni Israel Z, 2008, J Opioid Manag, V4, P27; Zylla D, 2013, CANCER-AM CANCER SOC, V119, P4103, DOI 10.1002/cncr.28345	29	51	55	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2045-7634			CANCER MED-US	Cancer Med.	AUG	2014	3	4					900	908		10.1002/cam4.236			9	Oncology	Oncology	AZ4WW	WOS:000348222300015	24692226	DOAJ Gold, Green Published			2020-06-30	J	Layton, D; Osborne, V; Al-Shukri, M; Shakir, SAW				Layton, Deborah; Osborne, Vicki; Al-Shukri, Mohammad; Shakir, Saad A. W.			Indicators of Drug-Seeking Aberrant Behaviours: The Feasibility of Use in Observational Post-Marketing Cohort Studies for Risk Management	DRUG SAFETY			English	Article							CHRONIC NONCANCER PAIN; PHYSICIANS ASIPP GUIDELINES; AMERICAN SOCIETY; GENERAL-PRACTICE; CLINICAL-TRIALS; OPIOID ABUSE; PREDICTORS; DEPENDENCE; ADDICTION; THERAPY	Problematic prescription drug use is reflected by or associated with drug-seeking aberrant behaviours. Research gaps include lack of post-marketing evidence and instruments. As part of the pharmacovigilance requirements, a risk management plan was developed for fentanyl buccal tablets (FEBT) by the manufacturer, with an additional pharmacovigilance activity requested by the regulatory authority, to investigate the risks of misuse, abuse, criminal use, off-label use and accidental exposure to FEBT after the product became commercially available. A Modified Prescription-Event Monitoring (M-PEM), observational, post-authorisation safety surveillance (PASS) study was conducted, with an overall aim to examine the use of FEBT in relation to their safety as prescribed in primary care in England. One of the exploratory objectives included estimating the prevalence of aberrant behaviours during FEBT treatment. To determine the feasibility of estimating the prevalence of risk factors associated with dependence on starting treatment and aberrant behaviours in patients during treatment with a prototypical abuse liable substance (fentanyl), as based on the application of an existing index (the Chabal criteria). Data were collected as part of the M-PEM PASS study; exposure and outcome data (including risk factors for dependence and aberrant behaviours based on behavioural not clinical manifestations) were derived from questionnaires sent to primary care physicians in England during April 2008 to June 2011. For the exploratory objective of interest, descriptive statistics and simple (non-weighted) risk scores were constructed on aggregate counts (score a parts per thousand yen3 considered 'high-risk'). Supplementary analyses explored the relationship between the two indices and the characteristics of patients with aberrant behaviours and those without (crude odds ratios plus 95 % confidence interval (CI) were calculated). In a cohort of 551 patients, the prevalence of at least one pre-existing risk factor for dependence was 26 % (n = 145), whilst the frequency of aberrant behaviours observed during treatment was 8 % (n = 46). Patients with aberrant behaviours had several different characteristics to patients without. The two indices were associated (chi (2) df (20) = 58.72, p < 0.001), but a high-dependence risk-factor score provided a poor indication of high aberrant behaviour risk; the area under the receiver operating characteristic curve was 0.58 (95 % CI 0.41, 0.74). Study limitations included subjectivity in relation to physicians identifying aberrant behaviours, and under-reporting thereof in PASS observational study designs. The presence of these criteria does not confirm misuse, but should be considered as a signal of problematic opioid misuse, which requires investigation. Further research is needed to develop a more robust analytical construct. In this PASS study, the prevalence of at least one pre-existing risk factor for dependence was 26 %, whilst the frequency of aberrant behaviours observed during treatment was 8 %. Patients with aberrant behaviours had several different characteristics to patients without. This study demonstrates the feasibility of the systematic collection of physician reports of risk factors for dependence and aberrant behaviours to facilitate the development of risk scores, using these reports to support the post-marketing risk management of products with misuse potential.	[Layton, Deborah; Osborne, Vicki; Al-Shukri, Mohammad; Shakir, Saad A. W.] Drug Safety Res Unit, Southampton SO31 1AA, Hants, England; [Layton, Deborah; Osborne, Vicki; Shakir, Saad A. W.] Univ Portsmouth, Portsmouth, Hants, England	Layton, D (reprint author), Drug Safety Res Unit, Bursledon Hall,Blundell Lane, Southampton SO31 1AA, Hants, England.	deborah.layton@dsru.org		Osborne, Vicki/0000-0002-3669-6084	manufacturer of FEBT (Cephalon)	All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: Saad AW Shakir, Deborah Layton and Vicki Osborne are all employees of the DSRU. The DSRU is an independent charity (No. 327206) that works in association with the University of Portsmouth. It receives unconditional donations from pharmaceutical companies. The companies have no control on the conduct or the publication of the studies conducted by the DSRU. The DSRU has received such funds from the manufacturer of FEBT (Cephalon). The DSRU retained its full academic independence in respect of the conduct of the study and external communications of the results of the study. In addition, Saad Shakir has received money for providing training in pharmacovigilance to pharmaceutical companies. Deborah Layton has received money for the development of an educational module on adverse drug reaction reporting for the Centre for Pharmacy Postgraduate Education at the University of Manchester and as a guest lecturer to undergraduate pharmacy students. Vicki Osborne has received money as a guest lecturer to postgraduate pharmacovigilance students. Mohammad Al-Shukri is now an employee of GlaxoSmithKline.	American Academy of Pain Medicine the American Pain Society and the American Society of Addition Medicine, 2001, WMJ, V100, P28; American Psychiatric Association, 2013, DIAGN STAT MAN MENT; American Psychological Assocation, 2007, DIAGN STAT MAN MENT; Arfken CL, 2003, DRUG ALCOHOL DEPEN, V70, pS97, DOI 10.1016/S0376-8716(03)00102-9; Atluri Sairam L, 2004, Pain Physician, V7, P333; Ballantyne JC, 2007, PAIN, V129, P235, DOI 10.1016/j.pain.2007.03.028; British Medical Association Board of Science British Medical Association Science and Education, 2006, REP ADV DRUG RACT GU; British Pain Society, 2010, OP PERS PAIN GOOD PR; Chabal C, 1997, CLIN J PAIN, V13, P150, DOI 10.1097/00002508-199706000-00009; Chou R, 2009, J PAIN, V10, P131, DOI 10.1016/j.jpain.2008.10.009; *CIOMS, 2002, INT ETH GUID BIOM RE; Collett BJ, 2001, BRIT J ANAESTH, V87, P133, DOI 10.1093/bja/87.1.133; Cone EJ, 2006, DRUG ALCOHOL DEPEN, V83, pS31, DOI 10.1016/j.drugalcdep.2005.11.027; Edlund MJ, 2007, PAIN, V129, P355, DOI 10.1016/j.pain.2007.02.014; European Medicines Agency, 2008, EMEAHC833 EFFENTORA; European Medicines Agency, 2012, EMA8731382011; European Medicines Agency, EMEA347162008; European Medicines Agency, EMA8731382011; European Medicines Agency, EMA8276612011; Fine Robert L, 2007, Proc (Bayl Univ Med Cent), V20, P5; Fishbain DA, 2008, PAIN MED, V9, P444, DOI 10.1111/j.1526-4637.2007.00370.x; Food and Drug Administration, 2008, CTR DRUG EV RES CDER; Food and Drug Administration, GUID IND DEV US RISK; General Medical Council, 2009, CONF DISCL INF ED TR; General Medical Council, 2009, CONF; Griffiths RR, 2003, DRUG ALCOHOL DEPEN, V70, pS41, DOI 10.1016/S0376-8716(03)00098-X; Hedden SL, 2006, SUBST ABUSE TREAT PR, V1, DOI 10.1186/1747-597X-1-6; Heeley E, 2001, LANCET, V358, P1872, DOI 10.1016/S0140-6736(01)06898-2; ICH Harmonised Tripartite Guideline, 2003, ICH HARM TRIP GUID P; Katz NP, 2007, CLIN J PAIN, V23, P103, DOI 10.1097/01.ajp.0000210953.86255.8f; Layton D, 2011, PHARMACOEPIDEM DR S, P301; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pS1; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pS67; Martin RM, 1998, BRIT MED J, V317, P119, DOI 10.1136/bmj.317.7151.119; McAvoy BR, 1996, BRIT MED J, V313, P732; Meltzer EC, 2011, PAIN, V152, P397, DOI 10.1016/j.pain.2010.11.006; National Institutes of Health, 2011, NAT I DRUG AB NIDA R; Nicholson B, 2007, SOUTH MED J, V100, P1028, DOI 10.1097/SMJ.0b013e3180f626ff; Savage SR, 2002, CLIN J PAIN, V18, pS28, DOI 10.1097/00002508-200207001-00004; Sehgal N, 2012, PAIN PHYSICIAN, V15, pES67; Smith SM, 2013, PAIN, V154, P2287, DOI 10.1016/j.pain.2013.05.053; Solanki DR, 2011, PAIN PHYSICIAN, V14, pE119; The American College of Occupational and Environmental Medicine, GUID CHRON US OP; World Health Organisation, MAN SUBST AB AB DRUG	44	5	5	0	5	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0114-5916	1179-1942		DRUG SAFETY	Drug Saf.	AUG	2014	37	8					639	650		10.1007/s40264-014-0193-4			12	Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology	Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology	AT0GI	WOS:000344614700008	24969120	Green Published, Other Gold			2020-06-30	J	Passik, SD; Narayana, A; Yang, RH				Passik, Steven D.; Narayana, Arvind; Yang, Ronghua			Aberrant Drug-Related Behavior Observed During a 12-Week Open-Label Extension Period of a Study Involving Patients Taking Chronic Opioid Therapy for Persistent Pain and Fentanyl Buccal Tablet or Traditional Short-Acting Opioid for Breakthrough Pain	PAIN MEDICINE			English	Article						Aberrant Behavior; Breakthrough Pain; Chronic Pain; Fentanyl Buccal Tablet; Opioid; Risk Assessment	CHRONIC NONCANCER PAIN; TOLERANT PATIENTS; VALIDATION; ADDICTION; PREDICTORS; MANAGEMENT; CANCER; ISSUES; MISUSE; TOOL	Objective. Evaluate aberrant drug-related behaviors in patients administering fentanyl buccal tablet or traditional short-acting opioids for breakthrough pain. Design. Twelve-week open-label extension. Setting. Forty-two US sites. Subjects. Opioid-tolerant patients with chronic pain who completed the previous randomized, double-blind, crossover portion of a study comparing fentanyl buccal tablet and immediate-release oxycodone for treatment of breakthrough pain. Methods. Patients were rerandomized to continue treatment with fentanyl buccal tablet or begin any traditional short-acting opioid. Assessments included Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R) at baseline and Addiction Behaviors Checklist and Current Opioid Misuse Measure at baseline and final visit. Case report forms were reviewed retrospectively to identify aberrant drug-related behaviors. Results. One hundred thirty patients entered the open-label extension (fentanyl buccal tablet, N = 65; traditional short-acting opioid, N = 65). SOAPP-R scores were <18 (low risk of aberrant drug-related behavior) in 74% of patients; no significant differences in SOAPP-R scores were observed between treatment groups. At the final visit, <= 14% of patients in each treatment group had scores indicating potential aberrant drug-related behavior (Addiction Behaviors Checklist >= 3, Current Opioid Misuse Measure >= 9); no significant differences in scores were observed between treatment groups. Baseline SOAPP-R score >= 18 was not predictive of Addiction Behaviors Checklist >= 3 but was predictive of Current Opioid Misuse Measure >= 9. Aberrant behaviors were identified in 12 (18%) fentanyl buccal tablet patients and 13 (20%) traditional short-acting opioid patients. Conclusions. Incidence of aberrant drug-related behaviors was similar between patients taking fentanyl buccal tablet and traditional short-acting opioids over 12 weeks.	[Passik, Steven D.] Millennium Res Inst, San Diego, CA 92127 USA; [Narayana, Arvind; Yang, Ronghua] Teva Pharmaceut, Frazer, PA USA	Passik, SD (reprint author), Millennium Res Inst, 16980 Via Tazon, San Diego, CA 92127 USA.	Steven.passik@millenniumlabs.com			Cephalon, Inc. (Frazer, Pennsylvania, USA); Teva Pharmaceuticals	This study was sponsored by Cephalon, Inc. (Frazer, Pennsylvania, USA), now a wholly owned subsidiary of Teva Pharmaceuticals. The authors thank Craig Q. Earl, PhD, formerly of Teva Pharmaceuticals, for contributions to study design and data analysis. Writing support was provided by Peloton Advantage, LLC, funded by Teva Pharmaceuticals.	[Anonymous], 2011, FENT PACK INS; [Anonymous], 2011, EFF BUCC TABL PACK I; Ballantyne JC, 2003, ONCOLOGIST, V8, P567, DOI 10.1634/theoncologist.8-6-567; Bhamb B, 2006, CURR MED RES OPIN, V22, P1859, DOI 10.1185/030079906X132398; Butler SF, 2008, J PAIN, V9, P360, DOI 10.1016/j.jpain.2007.11.014; Butler SF, 2007, PAIN, V130, P144, DOI 10.1016/j.pain.2007.01.014; Chou R, 2009, J PAIN, V10, P131, DOI 10.1016/j.jpain.2008.10.009; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Compton P, 1998, J PAIN SYMPTOM MANAG, V16, P355, DOI 10.1016/S0885-3924(98)00110-9; Fine PG, 2010, PAIN MED, V11, P1024, DOI 10.1111/j.1526-4637.2010.00891.x; International Conference on Harmonisation Working Group, 1996, INT C HARM WORK GROU; Ives TJ, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-46; Janka L, 2011, J PAIN, V12, pP62; Marsch LA, 2001, J PHARMACOL EXP THER, V299, P1056; Michna E, 2004, J PAIN SYMPTOM MANAG, V28, P250, DOI 10.1016/j.jpainsymman.2004.04.007; Passik SD, 2003, PAIN MED, V4, P186, DOI 10.1046/j.1526-4637.2003.03018.x; Passik SD, 2011, J PAIN SYMPTOM MANAG, V41, P116, DOI 10.1016/j.jpainsymman.2010.03.012; Passik SD, 2009, MAYO CLIN PROC, V84, P593, DOI 10.1016/S0025-6196(11)60748-9; Passik Steven D, 2002, J Pain Palliat Care Pharmacother, V16, P39; Portenoy RK, 1996, J PAIN SYMPTOM MANAG, V11, P203, DOI 10.1016/0885-3924(95)00187-5; Trescot Andrea M, 2006, Pain Physician, V9, P1; Webster LR, 2005, PAIN MED, V6, P432, DOI 10.1111/j.1526-4637.2005.00072.x; Webster LR, 2013, PAIN MED, V14, P1332, DOI 10.1111/pme.12184; Wu SM, 2006, J PAIN SYMPTOM MANAG, V32, P342, DOI 10.1016/j.jpainsymman.2006.05.010	24	17	18	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1526-2375	1526-4637		PAIN MED	Pain Med.	AUG	2014	15	8					1365	1372		10.1111/pme.12431			8	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	AQ2PW	WOS:000342630800020	24666664	Bronze			2020-06-30	J	Kim, KT; Cho, DC; Sung, JK; Kim, YB; Kang, H; Song, KS; Choi, GJ				Kim, Kyoung-Tae; Cho, Dae-Chul; Sung, Joo-Kyung; Kim, Young-Baeg; Kang, Hyun; Song, Kwang-Sup; Choi, Geun-Joo			Intraoperative systemic infusion of lidocaine reduces postoperative pain after lumbar surgery: a double-blinded, randomized, placebo-controlled clinical trial	SPINE JOURNAL			English	Article						Inflammation; Lidocaine; Microdiscectomy; Muscle injury; Opioid consumption; Postoperative pain	BACK MUSCLE INJURY; INTRAVENOUS LIDOCAINE; SPINE SURGERY; HOSPITAL STAY; DISKECTOMY; ISCHEMIA; REPERFUSION; INHIBITION; NEUTROPHIL; MECHANISMS	BACKGROUND CONTEXT: Analgesic effect of lidocaine infusion on postoperative pain. PURPOSE: The aim of this study was to evaluate the analgesic effect of lidocaine infusion on postoperative pain after lumbar microdiscectomy. STUDY DESIGN: This study used a prospective, randomized, double-blinded, and placebo-controlled clinical trial. PATIENT SAMPLE: Fifty-one patients participated in this randomized, double-blinded study. OUTCOME MEASURES: The primary outcome was the visual analog scale (VAS) (0 100 mm) pain score at 4 hours after surgery. The secondary outcomes were the VAS pain score at 2, 8, 12, 24, and 48 hours after surgery, the frequency with which patients pushed the button (FPB) of the patient-controlled analgesia system, and the fentanyl consumption at 2, 4, 8, 12, 24, and 48 hours after surgery. Other outcomes were satisfaction scores regarding pain control and the overall recovery process, incidence of postoperative nausea and vomiting (PONV), and length of hospital stay (HS). METHODS: Preoperatively and throughout the surgery, Group L received intravenous lidocaine infusion (a 1.5-mg/kg bolus followed by a 2-mg/kg/h infusion until the end of the surgical procedure) and Group C received normal saline infusion as a placebo. RESULTS: The VAS scores and fentanyl consumption were significantly lower in Group L compared with Group C except at 48 h after surgery (p<.05). Total fentanyl consumption, total FPB, length of HS, and satisfaction scores were also significantly lower in Group L compared with Group C (p<.05). CONCLUSIONS: Intraoperative systemic infusion of lidocaine decreases pain perception during microdiscectomy, thus reducing the consumption of opioid and the severity of postoperative pain. This effect contributes to reduce the length of HS. (C) 2014 Elsevier Inc. All rights reserved.	[Kim, Kyoung-Tae; Cho, Dae-Chul; Sung, Joo-Kyung] Kyungpook Natl Univ Hosp, Dept Neurosurg, Taegu 700720, South Korea; [Kim, Young-Baeg] Chung Ang Univ Hosp, Coll Med, Dept Neurosurg, Seoul 156755, South Korea; [Kang, Hyun; Choi, Geun-Joo] Chung Ang Univ Hosp, Coll Med, Dept Anaesthesiol & Pain Med, Seoul 156755, South Korea; [Song, Kwang-Sup] Chung Ang Univ Hosp, Coll Med, Dept Orthoped Surg, Seoul 156755, South Korea	Kang, H (reprint author), Chung Ang Univ Hosp, Dept Anaesthesiol & Pain Med, 224-1 Heukseok Dong, Seoul 156755, South Korea.	roman00@cau.ac.kr	Song, Kwang-Sup/AAC-3891-2020; Kang, Hyun/AAE-7872-2020	Kang, Hyun/0000-0003-2844-5880			Aono H, 2007, J BONE JOINT SURG BR, V89B, P1478, DOI 10.1302/0301-620X.89B11.19478; BARTLETT E E, 1962, J Am Med Womens Assoc, V17, P809; Blankesteijn WM, 2001, ACTA PHYSIOL SCAND, V173, P75, DOI 10.1046/j.1365-201X.2001.00887.x; BUTWELL NB, 1993, AM J PHYSIOL, V264, pH1884; CASSUTO J, 1985, ANESTH ANALG, V64, P971; Cook VL, 2008, EQUINE VET J, V40, P353, DOI 10.2746/042516408X293574; DAHL JB, 1993, BRIT J ANAESTH, V70, P434, DOI 10.1093/bja/70.4.434; Ersayli DT, 2006, SPINE, V31, P2221, DOI 10.1097/01.brs.0000232801.19965.a0; Fischer LG, 2001, ANESTH ANALG, V92, P1041; Gallos G, 2004, ANESTHESIOLOGY, V101, P902, DOI 10.1097/00000542-200410000-00015; GILBERT C R A, 1951, Curr Res Anesth Analg, V30, P301; Groudine SB, 1998, ANESTH ANALG, V86, P235, DOI 10.1097/00000539-199802000-00003; Herroeder S, 2007, ANN SURG, V246, P192, DOI 10.1097/SLA.0b013e31805dac11; INSLER SR, 1995, J CARDIOTHOR VASC AN, V9, P541, DOI 10.1016/S1053-0770(05)80138-7; Janig W, 2008, PAIN, V137, P5, DOI 10.1016/j.pain.2008.04.001; Kaba A, 2007, ANESTHESIOLOGY, V106, P11, DOI 10.1097/00000542-200701000-00007; Kaczmarek DJ, 2009, ANESTHESIOLOGY, V110, P1041, DOI 10.1097/ALN.0b013e31819dabda; Kawaguchi Y, 1998, SPINE, V23, P2282, DOI 10.1097/00007632-199811010-00006; Kawaguchi Y, 1997, SPINE, V22, P1018, DOI 10.1097/00007632-199705010-00015; Kawaguchi Y, 1996, SPINE, V21, P941, DOI 10.1097/00007632-199604150-00007; Kim KT, 2009, SPINE, V34, P2674, DOI 10.1097/BRS.0b013e3181b4aaac; Kirillova I, 2011, PAIN, V152, P1562, DOI 10.1016/j.pain.2011.02.046; Koppert W, 2004, ANESTH ANALG, V98, P1050, DOI 10.1213/01.ANE.0000104582.71710.EE; Kotil K, 2007, J NEUROSURG-SPINE, V6, P121, DOI 10.3171/spi.2007.6.2.121; Lan W, 2004, EUR J ANAESTH, V21, P892, DOI 10.1017/S0265021504000249; Lan W, 2004, EUR J ANAESTH, V21, P967, DOI 10.1017/S0265021504000353; Li CY, 2003, ANESTH ANALG, V97, P1312, DOI 10.1213/01.ANE.0000081795.96158.3E; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; NAESH O, 1995, ACTA ANAESTH SCAND, V39, P1053, DOI 10.1111/j.1399-6576.1995.tb04228.x; Ready LB, 1996, REGIONAL ANESTHESIA, P632; Shin DA, 2008, J NEUROSURG-SPINE, V8, P39, DOI 10.3171/SPI-08/01/039; THELANDER U, 1992, SPINE, V17, P400, DOI 10.1097/00007632-199204000-00004; THOMSON PD, 1973, ANN INTERN MED, V78, P499, DOI 10.7326/0003-4819-78-4-499; THOREN P, 1981, ACTA PHYSIOL SCAND, V111, P51, DOI 10.1111/j.1748-1716.1981.tb06704.x; Vigneault L, 2011, CAN J ANESTH, V58, P22, DOI 10.1007/s12630-010-9407-0; WALL PD, 1988, PAIN, V33, P289, DOI 10.1016/0304-3959(88)90286-2; Werdehausen R, 2012, ANESTHESIOLOGY, V116, P147, DOI 10.1097/ALN.0b013e31823cf233; Zhang XW, 2000, EUR J PHARMACOL, V392, pR1, DOI 10.1016/S0014-2999(00)00108-4	38	31	33	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1529-9430	1878-1632		SPINE J	Spine Journal	AUG	2014	14	8					1559	1566		10.1016/j.spinee.2013.09.031			8	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	AO4JT	WOS:000341304300025	24216403				2020-06-30	J	Perniola, A; Magnuson, A; Axelsson, K; Gupta, A				Perniola, Andrea; Magnuson, Anders; Axelsson, Kjell; Gupta, Anil			Intraperitoneal Local Anesthetics Have Predominant Local Analgesic Effect A Randomized, Double-blind Study	ANESTHESIOLOGY			English	Article							PERIOPERATIVE INTRAVENOUS LIDOCAINE; MANAGING POSTOPERATIVE NAUSEA; ABDOMINAL HYSTERECTOMY; SYSTEMIC LIDOCAINE; HOSPITAL STAY; CONSENSUS GUIDELINES; CONTINUOUS-INFUSION; WOUND INFUSION; PAIN; RECOVERY	Background: It remains unclear whether analgesia from intraperitoneal local anesthetics is via local or central mechanisms. This double-blind clinical trial tests the hypothesis that intraperitoneal local anesthetic is superior to continuous IV infusion for pain management. Primary outcome was morphine consumption during 0 to 24 h. Methods: Informed consent was obtained from 60 patients, age 30 to 75 yr, American Society of Anesthesiologists physical status I to II, undergoing abdominal hysterectomy. A computer-generated program randomized patients in parallel arms to group IV: continuous infusion of lidocaine 50 mg/h (10 ml) IV and saline 10 ml/h intermittently intraperitoneal; group IP: injection of lidocaine 50 mg/h (10 ml) once every hour intraperitoneally and continuous infusion of saline 10 ml/h intravenously; and group P (placebo): saline 10 ml/h both intravenously and intermittent intraperitoneal injection. Postoperative morphine consumption, pain intensity, recovery, home discharge, and lidocaine concentrations were measured. Results: Morphine consumption during 0 to 24 h was lower in group IP versus group IV, mean difference -22.6 mg (95% CI, 11.4 to 33.8; P < 0.01). No difference was seen between group IV and group P. The total mean plasma concentration of lidocaine in group IP was significantly lower than group IV, 0 to 4.5 h postoperatively (P = 0.03) with no evidence of systemic toxicity. Pain intensity and other recovery parameters were similar between the groups. Conclusion: The lower supplemental morphine consumption and plasma lidocaine concentration in group IP would confirm that the effects of local anesthetics are likely to be predominant via local intraperitoneal receptors or anti-inflammatory effects and not via central mechanisms alone.	[Perniola, Andrea; Axelsson, Kjell; Gupta, Anil] Univ Orebro, Sch Hlth & Med Sci, Orebro Univ Hosp, Dept Anesthesiol & Intens Care, SE-70182 Orebro, Sweden; [Magnuson, Anders] Univ Orebro, Sch Hlth & Med Sci, Orebro Univ Hosp, Clin Epidemiol & Biostat Unit,Clin Res Ctr, SE-70182 Orebro, Sweden	Perniola, A (reprint author), Univ Hosp, Dept Anesthesiol & Intens Care, SE-70185 Orebro, Sweden.	perniola.d@gmail.com			Research Committee, Orebro County Council, Orebro, Sweden	This study was supported partly by funds obtained from the Research Committee, Orebro County Council, Orebro, Sweden.	Ali PB, 1998, BRIT J ANAESTH, V80, P245, DOI 10.1093/bja/80.2.245; Beaussier M, 2007, ANESTHESIOLOGY, V107, P461, DOI 10.1097/01.anes.0000278903.91986.19; Bertoglio S, 2012, ANESTH ANALG, V115, P1442, DOI 10.1213/ANE.0b013e31826b4694; Brandsborg B, 2008, ACTA ANAESTH SCAND, V52, P327, DOI 10.1111/j.1399-6576.2007.01552.x; Brandsborg B, 2011, BRIT J ANAESTH, V107, P940, DOI 10.1093/bja/aer264; Bryson GL, 2010, CAN J ANESTH, V57, P759, DOI 10.1007/s12630-010-9332-2; CASSUTO J, 1985, ANESTH ANALG, V64, P971; De Oliveira GS, 2012, ANESTH ANALG, V115, P262, DOI 10.1213/ANE.0b013e318257a380; Fant F, 2011, BRIT J ANAESTH, V107, P782, DOI 10.1093/bja/aer296; Fuhrer Y, 1996, ANN FR ANESTH, V15, P128, DOI 10.1016/0750-7658(96)85033-7; Gan TJ, 2003, ANESTH ANALG, V97, P62, DOI 10.1213/01.ANE.0000068580.00245.95; Gerbershagen HJ, 2013, ANESTHESIOLOGY, V118, P934, DOI 10.1097/ALN.0b013e31828866b3; Glass PSA, 2007, ANESTH ANALG, V105, P1528, DOI 10.1213/01.ane.0000295854.53423.8A; Grady MV, 2012, ANESTH ANALG, V115, P1078, DOI 10.1213/ANE.0b013e3182662e01; Gupta A, 2004, ANESTH ANALG, V99, P1173, DOI 10.1213/01.ANE.0000130260.24433.A2; Harvey KP, 2009, AM J SURG, V198, P231, DOI 10.1016/j.amjsurg.2008.10.015; Herroeder S, 2007, ANN SURG, V246, P192, DOI 10.1097/SLA.0b013e31805dac11; Kaba A, 2007, ANESTHESIOLOGY, V106, P11, DOI 10.1097/00000542-200701000-00007; Kahokehr A, 2011, BRIT J SURG, V98, P29, DOI 10.1002/bjs.7293; Kahokehr A, 2011, ANN SURG, V254, P28, DOI 10.1097/SLA.0b013e318221f0cf; Kahokehr A, 2011, ANZ J SURG, V81, P237, DOI 10.1111/j.1445-2197.2010.05573.x; Kehlet H, 2007, ANESTHESIOLOGY, V107, P369, DOI 10.1097/01.anes.0000278901.96504.49; Koppert W, 2004, ANESTH ANALG, V98, P1050, DOI 10.1213/01.ANE.0000104582.71710.EE; Liu SS, 2006, J AM COLL SURGEONS, V203, P914, DOI 10.1016/j.jamcollsurg.2006.08.007; Marret E, 2008, BRIT J SURG, V95, P1331, DOI 10.1002/bjs.6375; Martin F, 2008, ANESTHESIOLOGY, V109, P118, DOI 10.1097/ALN.0b013e31817b5a9b; McCarthy GC, 2010, DRUGS, V70, P1149, DOI 10.2165/10898560-000000000-00000; McKay A, 2009, ANESTH ANALG, V109, P1805, DOI 10.1213/ANE.0b013e3181be371b; Ng A, 2002, ANESTH ANALG, V95, P158, DOI 10.1097/00000539-200207000-00028; Omote K, 2007, ANESTHESIOLOGY, V106, P5, DOI 10.1097/00000542-200701000-00004; Perniola A, 2014, BRIT J ANAESTH, V112, P328, DOI 10.1093/bja/aet345; Perniola A, 2009, EUR J ANAESTH, V26, P421, DOI 10.1097/EJA.0b013e3283261b53; White PF, 2004, ANESTH ANALG, V98, P550, DOI 10.1213/01.ANE.0000077703.55461.EC; Woodhouse A, 1998, BRIT J CLIN PHARMACO, V45, P57, DOI 10.1046/j.1365-2125.1998.00635.x; Wu CL, 2011, LANCET, V377, P2215, DOI 10.1016/S0140-6736(11)60245-6; Zohar E, 2001, ANESTH ANALG, V93, P482, DOI 10.1097/00000539-200108000-00048	36	10	10	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	AUG	2014	121	2					352	361		10.1097/ALN.0000000000000267			10	Anesthesiology	Anesthesiology	AM7EW	WOS:000340028500018	24758776				2020-06-30	J	Schreiber, JA				Schreiber, Judith A.			Understanding the Cancer Pain Experience	CURRENT PAIN AND HEADACHE REPORTS			English	Review						Cancer pain; Management; Survivorship; Treatment options; Intervention	BREAKTHROUGH PAIN; DOUBLE-BLIND; MANAGEMENT; FENTANYL; EFFICACY; KETAMINE; PARACETAMOL; ADHERENCE; KNOWLEDGE; BARRIERS	Cancer pain management is a major element of successful cancer survivorship. Regardless of where someone is along the cancer experience, from a newly diagnosed patient to long-term survivor, pain is a potential treatment-related effect that can have a significant impact on a survivor's life. Quality pain management for cancer survivors is complicated by the fact that cancer-related pain can be due to the tumor, surgery, radiation, and/or chemotherapy. Additionally, the pain experience is related to many psychosocial/spiritual factors. Despite almost 40 years of attention devoted to improving cancer pain management, many cancer survivors are less than optimally treated, often owing to survivor and healthcare provider knowledge barriers. This article reviews some of the latest research related to cancer pain management treatment options, measurement/assessment, and interventions. Progress has been made in understanding new aspects of the pain experience, but more work is yet to be done.	Univ Louisville, Sch Nursing, Louisville, KY 40592 USA	Schreiber, JA (reprint author), Univ Louisville, Sch Nursing, 555 S Floyd St,Room 4057, Louisville, KY 40592 USA.	judy.schreiber@louisville.edu					Al Khalaileh M, 2012, INT J PALLIAT NURS, V18, P535, DOI 10.12968/ijpn.2012.18.11.535; [Anonymous], 2012, CANC TREATM SURV FAC; Bell RF, 2012, COCHRANE DB SYST REV, V11, DOI DOI 10.1002/14651858; Bredlau AL, 2013, PAIN MED, V14, P1505, DOI 10.1111/pme.12182; Doorenbos AZ, 2008, ONCOL NURS FORUM, V35, P891, DOI [10.1188/08.ONF.E100-E107, 10.1188/08.ONF. E100-E107]; Dunham M, 2013, J CLIN NURS, V22, P2100, DOI 10.1111/jocn.12106; Guitart J, 2013, CLIN DRUG INVEST, V33, P675, DOI 10.1007/s40261-013-0111-z; Hadley G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010270.pub2; Hardy J, 2012, J CLIN ONCOL, V30, P3611, DOI 10.1200/JCO.2012.42.1081; Hovind IL, 2013, J CLIN NURS, V22, P1044, DOI 10.1111/jocn.12167; Institute of Medicine, 2011, REL PAIN AM BLUEPR T; Jablonski K, 2012, J HOSP PALLIAT NURS, V14, P533, DOI 10.1097/NJH.0b013e31825c7b50; Jandhyala R, 2013, J PAIN SYMPTOM MANAG, V46, P573, DOI 10.1016/j.jpainsymman.2012.09.009; Knudsen AK, 2012, SUPPORT CARE CANCER, V20, P2491, DOI 10.1007/s00520-011-1361-z; Koller A, 2013, EUR J ONCOL NURS, V17, P1, DOI 10.1016/j.ejon.2012.02.006; Kongsgaard U, 2014, SUPPORT CARE CANCER, P1; Ling CC, 2012, J ADV NURS, V68, P511, DOI 10.1111/j.1365-2648.2011.05841.x; Macario A, 2011, PAIN PRACT, V11, P290, DOI 10.1111/j.1533-2500.2010.00426.x; Mercadante S, 2014, J PAIN, V15, P602, DOI 10.1016/j.jpain.2014.02.002; Mercadante S, 2013, SUPPORT CARE CANCER, V21, P2335, DOI 10.1007/s00520-013-1799-2; Modesto-Lowe Vania, 2012, J Opioid Manag, V8, P167, DOI 10.5055/jom.2012.0113; Nabal M, 2012, PALLIATIVE MED, V26, P305, DOI 10.1177/0269216311428528; National Cancer Institute, 2013, PAIN PDQ HLTH PROF V; Ngamkham S, 2012, PAIN MANAG NURS, V13, P27, DOI 10.1016/j.pmn.2010.12.003; Pizzo PA, 2012, NEW ENGL J MED, V366, P197, DOI 10.1056/NEJMp1109084; Prommer EE, 2012, J PALLIAT MED, V15, P474, DOI 10.1089/jpm.2011.0244; Rhee YO, 2012, J IMMIGR MINOR HEALT, V14, P1045, DOI 10.1007/s10903-012-9582-x; Rustoen T, 2014, CANCER NURS, V37, P34, DOI 10.1097/NCC.0b013e3182948418; Rustoen T, 2013, EUR J ONCOL NURS, V17, P95, DOI 10.1016/j.ejon.2012.05.005; Rustoen T, 2012, J PAIN SYMPTOM MANAG, V44, P321, DOI 10.1016/j.jpainsymman.2011.09.015; Salas S, 2012, J PALLIAT MED, V15, P287, DOI 10.1089/jpm.2011.0353; Samuels JG, 2012, APPL NURS RES, V25, P89, DOI 10.1016/j.apnr.2010.05.001; Schreiber JA, 2014, PAIN MANAG NURS, V15, P474, DOI 10.1016/j.pmn.2012.12.006; Schreiber JA, 2013, ONCOL NURS FORUM, V40, P106, DOI 10.1188/13.ONF.106-108; Sessle BJ, 2011, PAIN RES MANAG, V16, P416, DOI 10.1155/2011/513423; Soto E, 2012, AM J HOSP PALLIAT ME, V29, P308, DOI 10.1177/1049909111416345; Taylor DR, 2013, CLIN PHARMACOL-ADV A, V5, P131, DOI 10.2147/CPAA.S26649; Tse MMY, 2012, CANCER NURS, V35, P438, DOI 10.1097/NCC.0b013e3182360730; Rivera IV, 2014, ADV THER, V31, P107, DOI 10.1007/s12325-013-0086-4; Webster LR, 2013, PAIN MED, V14, P1332, DOI 10.1111/pme.12184; Yoong J, 2013, J PALLIAT MED, V16, P391, DOI 10.1089/jpm.2012.0400; Zeppetella G, 2014, J PAIN SYMPTOM MANAG, V47, P772, DOI 10.1016/j.jpainsymman.2013.05.020; Zhu JY, 2012, CANCER-AM CANCER SOC, V118, P6278, DOI 10.1002/cncr.27673	43	2	2	1	17	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1531-3433	1534-3081		CURR PAIN HEADACHE R	Curr. Pain Headache Rep.	AUG	2014	18	8							440	10.1007/s11916-014-0440-5			6	Clinical Neurology	Neurosciences & Neurology	AM8AT	WOS:000340092100007	24925442				2020-06-30	J	Hoekman, JD; Srivastava, P; Ho, RJY				Hoekman, John D.; Srivastava, Pramod; Ho, Rodney J. Y.			Aerosol-Stable Peptide-Coated Liposome Nanoparticles: A Proof-of-Concept Study with Opioid Fentanyl in Enhancing Analgesic Effects and Reducing Plasma Drug Exposure	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						aerosols; liposomes; fentanyl; targeted drug delivery; integrin; aerosolized liposomes; CNS; aerosolized nanoparticles	INTRACELLULAR DELIVERY; OLFACTORY EPITHELIUM; RGD PEPTIDE; CELLS; RATS; 1-(2-CHLOROETHYL)-3-CYCLOHEXYL-1-NITROSOUREA; NEBULIZATION; DOXORUBICIN; DEXTRAN; LIPIDS	Previously, we reported a novel pressurized olfactory drug (POD) delivery device that deposits aerosolized drug preferentially to upper nasal cavity. This POD device provided sustained central nervous system (CNS) levels of soluble morphine analgesic effects. However, analgesic onset of less soluble fentanyl was more rapid but brief, likely because of hydrophobic fentanyl redistribution readily back to blood. To determine whether fentanyl incorporated into an aerosol-stable liposome that binds to nasal epithelial cells will enhance CNS drug exposure and analgesic effects and reduce plasma exposure, we constructed Arg-Gly-Asp (RGD) liposomes anchored with acylated integrin-binding peptides (palmitoyl-Gly-Arg-Gly-Asp-Ser). The RGD liposomes, which assume gel phase membrane structure at 25 degrees C, were stable under the stress of aerosolization as only 2.2 +/- 0.5% calcein leakage was detected. The RGD-mediated integrin binding of liposome is also verified to be unaffected by aerosolization. Rats treated with fentanyl in RGD liposome and POD device exhibited greater analgesic effect, as compared with the free drug counterpart (AUC(effect) = 1387.1% vs. 760.1% MPE*min), whereas approximately 20% reduced plasma drug exposure was noted (AUC(0-120) = 208.2 vs. 284.8 ng min/mL). Collectively, fentanyl incorporated in RGD liposomes is physically and biologically stable under aerosolization, enhanced the overall analgesic effects, and reduced plasma drug exposure for the first 2 h. (c) 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:2231-2239, 2014	[Hoekman, John D.; Srivastava, Pramod; Ho, Rodney J. Y.] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA	Ho, RJY (reprint author), Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA.	rodneyho@u.washington.edu			NIH grantsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AI 077390, MH086351]; University of Washington Technology Innovation grant [TGIF-1001]; Milo Gibaldi Endowment	This work was supported in part by NIH grants AI 077390 and MH086351, and University of Washington Technology Innovation grant TGIF-1001. R.Y.J.H. is also supported by Milo Gibaldi Endowment.	Aggarwal R, 2004, CLIN OTOLARYNGOL, V29, P201, DOI 10.1111/j.1365-2273.2004.00797.x; Bethune C, 1999, PHARMACEUT RES, V16, P896, DOI 10.1023/A:1018886321917; Bethune CR, 2001, CANCER RES, V61, P3669; Bridges PA, 2000, INT J PHARM, V204, P69, DOI 10.1016/S0378-5173(00)00477-4; Charlton S, 2007, EUR J PHARM SCI, V30, P295, DOI 10.1016/j.ejps.2006.11.018; Choi SU, 2008, J PHARM SCI-US, V97, P931, DOI 10.1002/jps.21020; DE LORENZO A J, 1960, Trans Am Laryngol Assoc, V81, P39; DELORENZO AJ, 1957, J BIOPHYS BIOCHEM CY, V3, P839, DOI 10.1083/jcb.3.6.839; Dhuria SV, 2010, J PHARM SCI-US, V99, P1654, DOI 10.1002/jps.21924; Dubey PK, 2004, J DRUG TARGET, V12, P257, DOI 10.1080/10611860410001728040; Garanger E, 2007, ANTI-CANCER AGENT ME, V7, P552, DOI 10.2174/187152007781668706; Hoekman JD, 2011, ANESTH ANALG, V113, P641, DOI 10.1213/ANE.0b013e3182239b8c; Hoekman JD, 2011, AAPS PHARMSCITECH, V12, P534, DOI 10.1208/s12249-011-9614-1; HU LR, 1986, BIOCHEM BIOPH RES CO, V141, P973; Huang Y, 1998, ADV DRUG DELIV REV, V29, P147; Illum L, 2003, J CONTROL RELEASE, V87, P187, DOI 10.1016/S0168-3659(02)00363-2; Jansson B, 2002, J DRUG TARGET, V10, P379, DOI 10.1080/1061186021000001823; Kraft JC, 2014, J PHARM SCI-US, V103, P29, DOI 10.1002/jps.23773; Kurohane K, 2000, LIFE SCI, V68, P273, DOI 10.1016/S0024-3205(00)00938-3; Miyamoto M, 2001, INT J PHARM, V226, P127, DOI 10.1016/S0378-5173(01)00797-9; NIVEN RW, 1990, PHARM RES-DORDR, V7, P1127, DOI 10.1023/A:1015924124180; Piperoudi S, 2006, CHEM PHYS LIPIDS, V139, P96, DOI 10.1016/j.chemphyslip.2005.11.003; Willis M, 1998, ADV DRUG DELIV REV, V29, P249, DOI DOI 10.1016/S0169-409X(97)00083-5; Xiong XB, 2005, J CONTROL RELEASE, V107, P262, DOI 10.1016/j.jconrel.2005.03.030; Xiong XB, 2008, PHARM RES-DORDR, V25, P2555, DOI 10.1007/s11095-008-9673-5	25	12	13	0	32	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	AUG	2014	103	8					2231	2239		10.1002/jps.24022			9	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	AN0MC	WOS:000340277700002	24909764	Green Accepted			2020-06-30	J	Wang, K; Cao, L; Deng, Q; Sun, LQ; Gu, TY; Song, J; Qi, DY				Wang, Kai; Cao, Liang; Deng, Qian; Sun, Li-Qiang; Gu, Tian-Yu; Song, Jie; Qi, Dun-Yi			The effects of epidural/spinal opioids in labour analgesia on neonatal outcomes: a meta-analysis of randomized controlled trials	CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							HEART-RATE-VARIABILITY; FENTANYL; BUPIVACAINE; SUFENTANIL; 0.125-PERCENT; MEPERIDINE; REMIFENTANIL; 0.25-PERCENT; ROPIVACAINE; ANESTHESIA	Epidural/spinal opioids are increasingly used to relieve parturients' pain in labour. Some studies indicate that opioids can induce side effects in neonates, such as respiratory depression and neurobehavioural changes. This meta-analysis aimed to clarify the effects of opioids in labour analgesia on neonates. PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and EMBASE (TM) were searched for relevant randomized controlled trials (RCTs). The neonatal data of Apgar scores, Neurological and Adaptive Capacity Scores (NACS), and umbilical cord pH values were extracted. Statistical analyses were carried out using Review Manager 5.2 and Stata(A (R)) 10. Twenty-one trials with 2,859 participants were included in our meta-analysis. No difference in the incidence of Apgar scores < 7 was shown between the opioid and control groups at one minute (risk difference [RD] 0.0%, 95% confidence interval [CI]: -3.0 to 2.0, P = 0.78; I (2) = 0%, 95% CI: 0 to 50) and at five minutes (RD -1.0%, 95% CI: -2.0 to 1.0, P = 0.31; I (2) = 0%, 95% CI: 0 to 50). No significant differences were found in the NACS at two hours (mean difference [MD] -0.35, 95% CI: -1.70 to 1.01, P = 0.62; I (2) = 0%, 95% CI: 0 to 79) and at 24 hr (MD -0.45, 95% CI: -1.36 to 0.46, P = 0.33; I (2) = 3%, 95% CI: 0 to 26). Also, no significant differences were found in umbilical cord artery pH (MD -0.02, 95% CI: -0.06 to 0.03, P = 0.48; I (2) = 80%, 95% CI: 46 to 92) and vein pH (MD -0.03, 95% CI: -0.07 to 0.00, P = 0.08; I (2) = 77%, 95% CI: 36 to 91). No significant publication bias was found. The common doses of fentanyl and sufentanil used with an epidural/spinal technique in labour analgesia are safe for neonates up to 24 hr after delivery. In future studies, more attention should be paid to the long-term side effects in neonates.	[Wang, Kai; Qi, Dun-Yi] Xuzhou Med Coll, Dept Anesthesiol, Jiangsu Prov Key Lab Anesthesiol, Affiliated Hosp, Xuzhou 221006, Peoples R China; [Cao, Liang] Nantong Univ, Affiliated Hosp 2, Dept Intens Care Unit, Nantong, Peoples R China; [Deng, Qian] Xuzhou Med Coll, Xuzhou Stomatol Hosp, Dept Nursing, Xuzhou 221006, Peoples R China; [Sun, Li-Qiang] Xuzhou Med Coll, Dept Gynecol & Obstet, Affiliated Hosp, Xuzhou 221006, Peoples R China; [Gu, Tian-Yu; Song, Jie] Nantong Univ, Affiliated Hosp 2, Dept Anesthesiol, Nantong 226001, Peoples R China	Qi, DY (reprint author), Xuzhou Med Coll, Dept Anesthesiol, Jiangsu Prov Key Lab Anesthesiol, Affiliated Hosp, 99 West Huaihai Rd, Xuzhou 221006, Peoples R China.	songjie1004@sina.com; qdy6808@163.com					Akkamahadevi P, 2012, INDIAN J ANAESTH, V56, P365, DOI 10.4103/0019-5049.100819; AMIELTISON C, 1982, ANESTHESIOLOGY, V56, P340, DOI 10.1097/00000542-198205000-00003; Anim-Somuah M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000331.pub3; APGAR V, 1953, Curr Res Anesth Analg, V32, P260; Bauer ME, 2012, INT J OBSTET ANESTH, V21, P294, DOI 10.1016/j.ijoa.2012.05.007; Beilin Y, 2005, ANESTHESIOLOGY, V103, P1211, DOI 10.1097/00000542-200512010-00016; Capogna G, 2011, ANESTH ANALG, V113, P826, DOI 10.1213/ANE.0b013e31822827b8; Chong DSY, 2004, ACTA PAEDIATR, V93, P53, DOI 10.1080/08035250310007295; Claes B, 1998, REGION ANESTH PAIN M, V23, P540, DOI 10.1016/S1098-7339(98)90078-5; DESPRATS R, 1983, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V12, P901; Douma MR, 2011, INT J OBSTET ANESTH, V20, P118, DOI 10.1016/j.ijoa.2010.11.009; Evron S, 2007, CURR OPIN ANESTHESIO, V20, P181, DOI 10.1097/ACO.0b013e328136c1d1; Fahey J, 2005, J MIDWIFERY WOM HEAL, V50, P498, DOI 10.1016/j.jmwh.2005.08.007; Ferrari J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000964.pub3; Fleet J, 2011, MIDWIFERY, V27, pE106, DOI 10.1016/j.midw.2009.11.002; Friedrich JO, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-5; Gambling D, 2013, ANESTH ANALG, V116, P636, DOI 10.1213/ANE.0b013e31827e4e29; George RB, 2013, ANESTH ANALG, V116, P133, DOI 10.1213/ANE.0b013e3182713b26; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HAMZA J, 1992, PEDIATR RES, V32, P412, DOI 10.1203/00006450-199210000-00009; HODGKINSON R, 1978, CAN ANAESTH SOC J, V25, P405, DOI 10.1007/BF03006570; Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13; Jaskot B, 2011, GINEKOL POL, V82, P767; JONES G, 1989, BRIT J ANAESTH, V63, P254, DOI 10.1093/bja/63.3.254; Jones L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009234.pub2; JORROT JC, 1989, ANN FR ANESTH, V8, P321, DOI 10.1016/S0750-7658(89)80073-5; Kalra S, 2010, SAUDI J ANAESTH, V4, P178, DOI 10.4103/1658-354X.71569; KARINIEMI V, 1981, BRIT J OBSTET GYNAEC, V88, P718, DOI 10.1111/j.1471-0528.1981.tb01271.x; KOCH G, 1968, ACTA OBSTET GYN SCAN, V47, P27, DOI 10.3109/00016346809157463; Landau R, 2013, ANESTH ANALG, V116, P386, DOI 10.1213/ANE.0b013e318273f2c7; Lavand'homme P, 2010, INT J OBSTET ANESTH, V19, P1, DOI 10.1016/j.ijoa.2009.09.003; Lee BB, 2002, REGION ANESTH PAIN M, V27, P31, DOI 10.1053/rapm.2002.27836; Leong WL, 2011, ANESTH ANALG, V113, P818, DOI 10.1213/ANE.0b013e3182289fe9; Lilker S, 2009, J CLIN ANESTH, V21, P108, DOI 10.1016/j.jclinane.2008.06.027; LOFTUS JR, 1995, ANESTHESIOLOGY, V83, P300, DOI 10.1097/00000542-199508000-00010; Malin GL, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1471; Malvasi A, 2010, EUR REV MED PHARMACO, V14, P799; Vidal JMM, 2008, REV ESP ANEST REANIM, V55, P341, DOI 10.1016/S0034-9356(08)70589-9; Melchor J C, 1991, Rev Esp Anestesiol Reanim, V38, P80; MELZACK R, 1984, PAIN, V19, P321, DOI 10.1016/0304-3959(84)90079-4; MILON D, 1986, Annales Francaises d'Anesthesie et de Reanimation, V5, P18, DOI 10.1016/S0750-7658(86)80117-4; MURPHY JD, 1991, BRIT MED J, V302, P564, DOI 10.1136/bmj.302.6776.564; Nakamura G, 2009, REV ASSOC MED BRAS, V55, P405, DOI 10.1590/S0104-42302009000400014; Nikkola E M, 2000, J Clin Monit Comput, V16, P597, DOI 10.1023/A:1012268617009; O'Sullivan G, 2005, CURR OBSTET GYNAECOL, V15, P9; Olofsson C, 1998, ACTA ANAESTH SCAND, V42, P284, DOI 10.1111/j.1399-6576.1998.tb04918.x; Pace MC, 2004, ANN NY ACAD SCI, V1034, P356, DOI 10.1196/annals.1335.037; Porter J, 1998, ANESTHESIOLOGY, V89, P79, DOI 10.1097/00000542-199807000-00014; RAYBURN WF, 1989, OBSTET GYNECOL, V74, P604; ROBERTS H, 1957, LANCET, V1, P128; Ruban P, 2000, ANAESTH INTENS CARE, V28, P517, DOI 10.1177/0310057X0002800505; Salim R, 2005, OBSTET GYNECOL, V106, P301, DOI 10.1097/01.AOG.0000171109.53832.8d; SCANLON JW, 1974, ANESTHESIOLOGY, V40, P121, DOI 10.1097/00000542-197402000-00005; Schnabel A, 2012, EUR J ANAESTH, V29, P177, DOI 10.1097/EJA.0b013e32834fc260; STEINBERG RB, 1992, REGION ANESTH, V17, P131; Tian FB, 2013, INT J CLIN EXP MED, V6, P334; VANSTEENBERGE A, 1987, BRIT J ANAESTH, V59, P1518; VERTOMMEN JD, 1991, ANESTHESIOLOGY, V74, P809, DOI 10.1097/00000542-199105000-00002; Vettermann J, 1996, ANAESTHESIST, V45, P428, DOI 10.1007/s001010050277; VISCOMI CM, 1990, ANESTH ANALG, V71, P679	60	9	11	0	19	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X	1496-8975		CAN J ANESTH	Can. J. Anesth.	AUG	2014	61	8					695	709		10.1007/s12630-014-0185-y			15	Anesthesiology	Anesthesiology	AM3CH	WOS:000339728900002	25011701				2020-06-30	J	Eberl, S; Polderman, JAW; Preckel, B; Kalkman, CJ; Fockens, P; Hollmann, MW				Eberl, S.; Polderman, J. A. W.; Preckel, B.; Kalkman, C. J.; Fockens, P.; Hollmann, M. W.			Is "really conscious" sedation with solely an opioid an alternative to every day used sedation regimes for colonoscopies in a teaching hospital? Midazolam/fentanyl, propofol/alfentanil, or alfentanil only for colonoscopy: a randomized trial	TECHNIQUES IN COLOPROCTOLOGY			English	Article						Alfentanil; Colonoscopy; Conscious sedation; Safety; Satisfaction	PROPOFOL; SATISFACTION; RECOVERY; PATIENT	We investigated the satisfaction of patients and endoscopists and concurrently safety aspects of an "alfentanil only" and two clinically routinely used sedation regimes in patients undergoing colonoscopy in a teaching hospital. One hundred and eighty patients were prospectively randomized in three groups: M (midazolam/fentanyl), A (alfentanil), and P (propofol/alfentanil); M and A were administered by an endoscopy nurse, P by an anesthesia nurse. Interventions, heart rate, saturation, electrocardiogram, noninvasive blood pressure, and expiratory CO2 were monitored using video assistance. After endoscopy, patients and gastroenterologists completed questionnaires about satisfaction. A high level of satisfaction was found in all groups, with patients in group P being more satisfied with their sedation experience (median 1.75, p < 0.001). Gastroenterologist satisfaction varied not significantly between the three alternatives. Patients in group A felt less drowsy, could communicate more rapidly than patients in both other groups, and met discharge criteria immediately after the end of the procedure. Respiratory events associated with sedation were observed in 43 % patients in group M, 47 % in group P, but only 13 % in group A (p < 0.001). These results suggest that alfentanil could be an alternative for sedation in colonoscopy even in the setting of a teaching hospital. It results in satisfied patients easily taking up information, and recovering rapidly. Although one might expect to observe more respiratory depression with an "opioid only" sedation technique without involvement of anesthesia partners, respiratory events were less frequent than when other methods were used.	[Eberl, S.; Polderman, J. A. W.; Preckel, B.; Hollmann, M. W.] Univ Amsterdam, Acad Med Ctr, Dept Anesthesiol, NL-1105 AZ Amsterdam, Netherlands; [Kalkman, C. J.] Univ Utrecht, Univ Med Ctr, Div Anesthesiol Intens Care & Emergency Med, Utrecht, Netherlands; [Fockens, P.] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands	Eberl, S (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Anesthesiol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	S.Eberl@amc.uva.nl	Eberl, Susanne/X-2637-2019; Kalkman, Cor/O-3215-2019	Eberl, Susanne/0000-0002-6609-5888; Kalkman, Cor/0000-0002-8372-6960			ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Chartier L, 2009, CAN J GASTROENTEROL, V23, P203, DOI 10.1155/2009/903545; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Cote GA, 2010, CLIN GASTROENTEROL H, V8, P137, DOI 10.1016/j.cgh.2009.07.008; DIPALMA JA, 1995, SOUTHERN MED J, V88, P630, DOI 10.1097/00007611-199506000-00006; Eberl S, 2012, TECH COLOPROCTOL, V16, P271, DOI 10.1007/s10151-012-0834-5; Froehlich F, 2006, ENDOSCOPY, V38, P461, DOI 10.1055/s-2006-925368; Heuss LT, 2012, ENDOSCOPY, V44, P504, DOI 10.1055/s-0031-1291668; Inadomi JM, 2010, GASTROINTEST ENDOSC, V72, P580, DOI 10.1016/j.gie.2010.04.040; McQuaid KR, 2008, GASTROINTEST ENDOSC, V67, P910, DOI 10.1016/j.gie.2007.12.046; NEWMAN MG, 1969, ANESTH ANAL CURR RES, V48, P136, DOI 10.1213/00000539-196948010-00028; Rex DK, 1999, GASTROINTEST ENDOSC, V49, P554, DOI 10.1016/S0016-5107(99)70381-0; Singh H, 2008, COCHRANE DB SYST REV, V8; Ulmer BJ, 2003, CLIN GASTROENTEROL H, V1, P425, DOI 10.1016/S1542-3565(03)00226-X; Usta B, 2011, J CLIN GASTROENTEROL, V45, pE72, DOI 10.1097/MCG.0b013e318201fbce; van Turenhout ST, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-46; Vargo J, 2009, CLIN GASTROENTEROL H, V7, P156, DOI 10.1016/j.cgh.2008.09.004; Vargo JJ, 2010, CLIN GASTROENTEROL H, V8, P103, DOI 10.1016/j.cgh.2009.11.001; Vijan S, 2004, ALIMENT PHARM THERAP, V20, P507, DOI 10.1111/j.1365-2036.2004.01960.x; von Deliusa S, 2007, EUR J GASTROEN HEPAT, V19, P465, DOI 10.1097/MEG.0b013e3280ad4425; Wehrmann T, 2008, SCAND J GASTROENTERO, V43, P368, DOI 10.1080/00365520701679181	21	12	13	0	1	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1123-6337	1128-045X		TECH COLOPROCTOL	Tech. Coloproctology	AUG	2014	18	8					745	752		10.1007/s10151-014-1188-y			8	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	AM5JZ	WOS:000339895500010	24973875				2020-06-30	J	Kwon, SY; Lee, G; Kim, YS				Kwon, So-Young; Lee, Guisera; Kim, Yong-Shin			Management of severely painful uterine leiomyoma in a pregnant woman with epidural block using a subcutaneous injection port	ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA			English	Letter							MYOMAS		[Kwon, So-Young; Kim, Yong-Shin] Catholic Univ Korea, Dept Anesthesiol & Pain Med, St Vincent Hosp, Suwon, South Korea; [Lee, Guisera] Catholic Univ Korea, Dept Obstet & Gynecol, St Vincent Hosp, Suwon, South Korea	Kim, YS (reprint author), Catholic Univ Korea, Dept Anesthesiol & Pain Med, St Vincent Hosp, Suwon, South Korea.	aneskim@catholic.ac.kr					Baloniak Barbara, 2002, Ginekol Pol, V73, P260; EXACOUSTOS C, 1993, OBSTET GYNECOL, V82, P97; Phelan JP, 1995, OBSTET GYN CLIN N AM, V22, P801; TREISSMAN DA, 1982, CAN MED ASSOC J, V126, P505	4	2	2	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6349	1600-0412		ACTA OBSTET GYN SCAN	Acta Obstet. Gynecol. Scand.	AUG	2014	93	8					839	839		10.1111/aogs.12399			1	Obstetrics & Gynecology	Obstetrics & Gynecology	AM1OI	WOS:000339616100016	24766600				2020-06-30	J	Kasivisvanathan, R; Abbassi-Ghadi, N; Prout, J; Clevenger, B; Fusai, GK; Mallett, SV				Kasivisvanathan, Ramanathan; Abbassi-Ghadi, Nima; Prout, Jeremy; Clevenger, Ben; Fusai, Giuseppe K.; Mallett, Susan V.			A prospective cohort study of intrathecal versus epidural analgesia for patients undergoing hepatic resection	HPB			English	Article							LAPAROSCOPIC COLORECTAL SURGERY; RANDOMIZED CLINICAL-TRIAL; POSTOPERATIVE PAIN RELIEF; OPEN LIVER RESECTION; ENHANCED RECOVERY; METASTASES; OUTCOMES; ANESTHESIA; PROGRAM; CANCER	Background: The aim of this prospective observational study was to compare peri/post-operative outcomes of thoracic epidural analgesia (TEA) versus intrathecal morphine and fentanyl patient-controlled analgesia (ITM+fPCA) for patients undergoing a hepatic resection (HR). Method: Patients undergoing elective, one-stage, open HR for benign and malignant liver lesions, receiving central neuraxial block as part of the anaesthetic, in a high-volume hepato-pancreato-biliary unit, were included in the study. The primary outcome measure was post-operative length of stay (LoS). Results: A total of 73 patients (36 TEA and 37 ITM+fPCA) were included in the study. The median (IQR) post-operative LoS was 13 (11-15) and 11 (9-13) days in the TEA and ITM+fPCA groups, respectively (P = 0.011). There was significantly lower median intra-operative central venous pressure (P < 0.001) and blood loss (P = 0.017) in the TEA group, and a significant reduction in the time until mobilization (P < 0.001), post-operative intra-venous fluid/vasopressor requirement (P < 0.001/P = 0.004) in the ITM+fPCA group. Pain scores were lower at a clinically significant level 12 h post-operatively in the TEA group (P < 0.001); otherwise there were no differences out to day five. There were no differences in quality of recovery or postoperative morbidity/mortality between the two groups. Conclusion: ITM+fPCA provides acceptable post-operative outcomes for HR, but may also increase the incidence of intra-operative blood loss in comparison to TEA.	[Kasivisvanathan, Ramanathan; Prout, Jeremy; Clevenger, Ben; Mallett, Susan V.] Royal Free London NHS Fdn Trust, Dept Anaesthesia, London, England; [Abbassi-Ghadi, Nima] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, St Marys Hosp, London, England; [Fusai, Giuseppe K.] UCL, Dept Hepatobiliary Surg, London NW3 2QG, England; [Fusai, Giuseppe K.] UCL, Liver Transplant Unit, London NW3 2QG, England	Kasivisvanathan, R (reprint author), UCL, Royal Free Hosp Campus,Pond St, London NW3 2QG, England.	drramanathankasi@googlemail.com	Mallett, Susan V/A-1842-2012; Clevenger, Ben/O-2467-2015	Mallett, Susan V/0000-0003-0715-3213; Clevenger, Ben/0000-0001-5659-6323			Abdalla EK, 2004, ANN SURG, V239, P818, DOI 10.1097/01.sla.0000128305.90650.71; Adam R, 2007, SEMIN ONCOL, V34, pS7, DOI 10.1053/j.seminoncol.2007.01.003; Bodian CA, 2001, ANESTHESIOLOGY, V95, P1356, DOI 10.1097/00000542-200112000-00013; Clavien PA, 2009, ANN SURG, V250, P187, DOI 10.1097/SLA.0b013e3181b13ca2; De Pietri L, 2006, ANESTH ANALG, V102, P1157, DOI 10.1213/01.ane.0000198567.85040.ce; Gurusamy KS, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007338.pub3; Gustafsson UO, 2011, ARCH SURG-CHICAGO, V146, P571, DOI 10.1001/archsurg.2010.309; Hermanides J, 2012, BRIT J ANAESTH, V109, P144, DOI 10.1093/bja/aes214; Jones C, 2013, BRIT J SURG, V100, P1015, DOI 10.1002/bjs.9165; Jones RM, 1998, BRIT J SURG, V85, P1058; Kehlet H, 2001, BRIT J ANAESTH, V87, P62, DOI 10.1093/bja/87.1.62; Kehlet H, 2009, CURR OPIN CRIT CARE, V15, P355, DOI 10.1097/MCC.0b013e32832fbbe7; Koea Jonathan B, 2009, HPB Surg, V2009, P271986, DOI 10.1155/2009/271986; Lee SG, 2005, J HEPATO-BILIARY-PAN, V12, P38, DOI 10.1007/s00534-004-0949-9; Levy BF, 2011, BRIT J SURG, V98, P1068, DOI 10.1002/bjs.7545; McLeod GA, 2001, ANAESTHESIA, V56, P75, DOI 10.1046/j.1365-2044.2001.01763-7.x; Page A, 2008, J AM COLL SURGEONS, V206, P1184, DOI 10.1016/j.jamcollsurg.2007.12.041; Prytherch DR, 1998, BRIT J SURG, V85, P1217; Revie EJ, 2011, HPB, V13, P206, DOI 10.1111/j.1477-2574.2010.00274.x; Rigg JRA, 2002, LANCET, V359, P1276, DOI 10.1016/S0140-6736(02)08266-1; Sakowska M, 2009, WORLD J SURG, V33, P1802, DOI 10.1007/s00268-009-0131-2; Schultz NA, 2013, BRIT J SURG, V100, P138, DOI 10.1002/bjs.8996; Stark PA, 2013, ANESTHESIOLOGY, V118, P1332, DOI 10.1097/ALN.0b013e318289b84b; Tomlinson JS, 2007, J CLIN ONCOL, V25, P4575, DOI 10.1200/JCO.2007.11.0833; Turk DC, 1957, HDB PAIN ASSESSMENT, P1; Tzimas P, 2013, ANAESTHESIA, V68, P628, DOI 10.1111/anae.12191; van Dam RM, 2008, BRIT J SURG, V95, P969, DOI 10.1002/bjs.6227; Virlos I, 2010, BRIT J SURG, V97, P1401, DOI 10.1002/bjs.7127; Wu CL, 2005, ANESTHESIOLOGY, V103, P1079, DOI 10.1097/00000542-200511000-00023	29	15	16	0	8	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1365-182X	1477-2574		HPB	HPB	AUG	2014	16	8					768	775		10.1111/hpb.12222			8	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	AM2FQ	WOS:000339665600011	24467320	Green Published, Bronze			2020-06-30	J	Visoiu, M				Visoiu, Mihaela			Outpatient analgesia via paravertebral peripheral nerve block catheter and On-Q pump-a case series	PEDIATRIC ANESTHESIA			English	Article						child; acute postoperative pain; outpatient analgesia; regional; local anesthetic; lumbar paravertebral catheter	ABDOMINIS PLANE BLOCK; POSTOPERATIVE PAIN-CONTROL; CREST BONE-GRAFT; CHILDREN; EFFICACY	Outpatient pain management after iliac crest bone harvesting can be challenging. We report the use of home L2 paravertebral nerve block catheter (L2PVBC) in a series of five children. The pain scores were low, and analgesic medication consumption was minimal. No complications were reported related with these catheters, and the patients reported very high pain control satisfaction scores. Outpatient L2PVBC can be beneficial as part of a multi-modal analgesia strategy in selected pediatric patients.	[Visoiu, Mihaela] Univ Pittsburgh, Childrens Hosp Pittsburgh, Acute Intervent Pediat Perioperat Pain Serv, Dept Anesthesiol,Med Ctr, Pittsburgh, PA 15213 USA	Visoiu, M (reprint author), Childrens Hosp Pittsburgh, Dept Anesthesiol, Childrens Hosp Dr,4401 Penn Ave, Pittsburgh, PA 15224 USA.	visoium@upmc.edu					Buckenmaier CC, 2010, PAIN MED, V11, P790, DOI 10.1111/j.1526-4637.2010.00842.x; Chiono J, 2010, REGION ANESTH PAIN M, V35, P520, DOI 10.1097/AAP.0b013e3181fa117a; Dadure C, 2012, PEDIATR ANESTH, V22, P93, DOI 10.1111/j.1460-9592.2011.03730.x; Dadure C, 2009, CAN J ANAESTH, V56, P843, DOI 10.1007/s12630-009-9169-8; Ganesh A, 2007, ANESTH ANALG, V105, P1234, DOI 10.1213/01.ane.0000284670.17412.b6; Gurnaney H, 2014, ANESTH ANALG, V118, P621, DOI 10.1213/ANE.0b013e3182a08fd4; Howard R, 2008, PEDIATR ANESTH, V18, P36, DOI 10.1111/j.1460-9592.2008.02431.x; Isyanov A, 2009, PEDIATR ANESTH, V19, P282, DOI 10.1111/j.1460-9592.2008.02879.x; Johr M, 2012, PEDIATR ANESTH, V22, P44, DOI 10.1111/j.1460-9592.2011.03669.x; Jonnavithula N, 2010, PEDIATR ANESTH, V20, P727, DOI 10.1111/j.1460-9592.2010.03347.x; Klaassen Z, 2011, CLIN ANAT, V24, P454, DOI 10.1002/ca.21098; Lipp AK, 2004, BRIT J ANAESTH, V92, P273, DOI 10.1093/bja/aeh045; Ludot H, 2008, REGION ANESTH PAIN M, V33, P52, DOI 10.1016/j.rapm.2007.07.014; Mai CL, 2012, PEDIATR ANESTH, V22, P831, DOI 10.1111/j.1460-9592.2012.03916.x; Murata H, 2013, ANESTH ANALG, V116, P255, DOI 10.1213/ANE.0b013e31826f5e25; Ouaki J, 2009, PEDIATR ANESTH, V19, P887, DOI 10.1111/j.1460-9592.2009.03095.x; Tran TMN, 2009, BRIT J ANAESTH, V102, P123, DOI 10.1093/bja/aen344	17	8	8	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	AUG	2014	24	8					875	878		10.1111/pan.12427			4	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	AL8LQ	WOS:000339390700013	24815589				2020-06-30	J	Gupta, B; Ayub, A; Bindra, A; Gupta, S; Mishra, B				Gupta, Babita; Ayub, Arshad; Bindra, Ashish; Gupta, Surendra; Mishra, Biplab			Distal tracheoesophageal fistula in pediatric patient - an anesthetic challenge	PEDIATRIC ANESTHESIA			English	Letter									[Gupta, Babita; Ayub, Arshad; Gupta, Surendra] All India Inst Med Sci, Dept Anesthesiol & Intens Care, New Delhi, India; [Bindra, Ashish] All India Inst Med Sci, Dept Neuroanesthesiol & Intens Care, New Delhi, India; [Mishra, Biplab] All India Inst Med Sci, Dept Surg, New Delhi 110029, India	Gupta, B (reprint author), All India Inst Med Sci, Dept Anesthesiol & Intens Care, New Delhi, India.	drbabitagupta@yahoo.co.in					Au CL, 1999, CAN J ANAESTH, V46, P688, DOI 10.1007/BF03013960; Hammer GB, 1999, ANESTH ANALG, V89, P1426, DOI 10.1097/00000539-199912000-00019; Ho AMH, 2008, BRIT J ANAESTH, V101, P690, DOI 10.1093/bja/aen264; Horishita T, 2003, ANESTH ANALG, V97, P1856, DOI 10.1213/01.ANE.0000077680.55641.20; Magnusson L, 1997, CAN J ANAESTH, V44, P1282, DOI 10.1007/BF03012777	5	1	1	0	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	AUG	2014	24	8					886	888		10.1111/pan.12449			4	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	AL8LQ	WOS:000339390700019	25039876				2020-06-30	J	Xiang, K; Cai, HW; Song, ZB				Xiang, Kai; Cai, Hongwei; Song, Zongbin			Comparison of Analgesic Effects of Remifentanil and Fentanyl NCA after Pediatric Cardiac Surgery	JOURNAL OF INVESTIGATIVE SURGERY			English	Article						pediatric; postoperative analgesia; cardiac surgery; fentanyl; remifentanil	PAIN; MANAGEMENT	The purpose of this study was to compare the analgesic effects of remifentanil with fentanyl following pediatric cardiac surgery. Fifty patients were included in the study and were randomized into two groups. Patients in group R were given remifentanil (50 mu g/ml) at an infusion rate of 0.07 mu g/kg/min and with bolus doses of 0.25 mu g/kg with a 5-min lockout time; group F patients received fentanyl (50 mu g/ml) at an infusion rate of 0.1 mu g/kg/min and with bolus doses of 1 mu g/kg with a 5-min lockout time. Pain was assessed using the Face, Legs, Activity, Cry, Consolability scale (FLACC scale), and sedation was assessed using the Ramsay sedation score. The number of boluses and demands, time to extubation, and side effects were analyzed. The FLACC scale, Ramsay sedation score, and mean extubation times were similar in the two groups. The total number of boluses and demands were significantly greater for group R than for group F. Itching as a side-effect was more severe in group F (p < .05). NCA remifentanil and fentanyl offer similarly effective pain control after pediatric cardiac surgery, but remifentanil has fewer side effects than fentanyl, indicating the suitability of remifentanil for use in NCA systems.	[Xiang, Kai] Xiangtan Cent Hosp, Dept Anesthesiol, Xiangtan, Hunan, Peoples R China; [Cai, Hongwei; Song, Zongbin] Cent S Univ, Xiangya Hosp, Dept Anesthesiol, Changsha, Hunan, Peoples R China	Cai, HW (reprint author), Xiangya Hosp, Dept Anesthesiol, 87 Xiangya Rd, Changsha, Hunan, Peoples R China.	hongweicai666@outlook.com		song, zongbin/0000-0002-0447-8648			Akca T, 2004, J INVEST SURG, V17, P333, DOI 10.1080/08941930490524390; Dere K, 2009, J INVEST SURG, V22, P112, DOI 10.1080/08941930802713019; Douma MR, 2010, BRIT J ANAESTH, V104, P209, DOI 10.1093/bja/aep359; Fernandez EF, 2010, J PERINATOL, V30, P814, DOI 10.1038/jp.2010.44; Gurbet A, 2004, J CARDIOTHOR VASC AN, V18, P755, DOI 10.1053/j.jvca.2004.08.014; Hong JY, 2009, J ENDOUROL, V23, P1843, DOI 10.1089/end.2009.0059; Hue JP, 2010, KOREAN J PAIN, V23, P99; Marsh DF, 2009, ANAESTHESIA, V64, P301, DOI 10.1111/j.1365-2044.2008.05731.x; Masood E, 2012, SAUDI J ANAESTH, V6, P323; Popping DM, 2013, ANN SURG IN PRESS; Stroumpos C, 2010, EXPERT OPIN DRUG SAF, V9, P355, DOI 10.1517/14740331003672579; Taylor EM, 2008, PAIN RES MANAG, V13, P25, DOI 10.1155/2008/478102; van Valen R, 2012, EUR J CARDIOVASC NUR, V11, P62, DOI 10.1177/1474515111430879; Viviand X, 2003, INT J OBSTET ANESTH, V12, P83, DOI 10.1016/S0959-289X(02)00155-3; Wildgaard K, 2009, EUR J CARDIO-THORAC, V36, P170, DOI 10.1016/j.ejcts.2009.02.005; Wolf AR, 2012, PEDIATR ANESTH, V22, P19, DOI 10.1111/j.1460-9592.2011.03714.x; Wolf AR, 2011, PEDIATR ANESTH, V21, P567, DOI 10.1111/j.1460-9592.2010.03460.x; Wynne R, 2004, AM J CRIT CARE, V13, P384, DOI 10.4037/ajcc2004.13.5.384	18	3	3	0	4	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0894-1939	1521-0553		J INVEST SURG	J. Invest. Surg.	AUG	2014	27	4					214	218		10.3109/08941939.2013.879968			5	Surgery	Surgery	AL3EY	WOS:000339010200004	24564266				2020-06-30	J	Martinez, SA; Wilson, MG; Linton, DD; Newbound, GC; Freise, KJ; Lin, TL; Clark, TP				Martinez, S. A.; Wilson, M. G.; Linton, D. D.; Newbound, G. C.; Freise, K. J.; Lin, T. -L.; Clark, T. P.			The safety and effectiveness of a long-acting transdermal fentanyl solution compared with oxymorphone for the control of postoperative pain in dogs: a randomized, multicentered clinical study	JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS			English	Article							ADMINISTERED FENTANYL; ORTHOPEDIC-SURGERY; LABORATORY BEAGLES; PHARMACOKINETICS; PATCHES; MANAGEMENT; EFFICACY; BEHAVIOR; MORPHINE; OVARIOHYSTERECTOMY	A prospective, double-blinded, positive-controlled, multicenter, noninferiority study was conducted to evaluate the safety and effectiveness of transdermal fentanyl solution (TFS) compared with oxymorphone for the control of postoperative pain in dogs. Five hundred and two (502) client-owned dogs were assigned to a single dose of TFS (2.7 mg/kg) applied 2-4 h prior to surgery or oxymorphone hydrochloride (0.22 mg/kg) administered subcutaneously 2-4 h prior to surgery and q6h through 90 h. Pain was evaluated over 4 days by blinded observers using a modified Glasgow composite pain scale, and the a priori criteria for treatment failure was a pain score >= 8 or adverse event necessitating withdrawal. Four TFS- and eight oxymorphone-treated dogs were withdrawn due to lack of pain control. Eighteen oxymorphone-treated, but no TFS-treated dogs were withdrawn due to severe adverse events. The one-sided upper 95% confidence interval of the difference between TFS and oxymorphone treatment failure rates was -5.3%. Adverse events associated with oxymorphone were greater in number and severity compared with TFS. It was concluded that a single administration of TFS was safe and noninferior to repeated injections of oxymorphone for the control of postoperative pain over 4 days at the dose rates of both formulations used in this study.	[Martinez, S. A.] Washington State Univ, Coll Vet Med, Pullman, WA 99164 USA; [Wilson, M. G.] Indiana Univ Sch Med, Div Clin Pharmacol, Indianapolis, IN 46202 USA; [Linton, D. D.; Newbound, G. C.; Freise, K. J.; Lin, T. -L.; Clark, T. P.] Nexcyon Pharmaceut Inc, Madison, WI 53703 USA	Clark, TP (reprint author), Nexcyon Pharmaceut Inc, 644 W Washington Ave, Madison, WI 53703 USA.	clarktp@nexcyon.com		Lin, Ting-Li/0000-0002-7578-3367			BAILEY PL, 1987, ANESTH ANALG, V66, P542; Bateman SW, 2008, VET ANAESTH ANALG, V35, P341, DOI 10.1111/j.1467-2995.2007.00387.x; Branson K. R., 2001, Veterinary pharmacology and therapeutics, P268; Carson HJ, 2010, LEGAL MED, V12, P157, DOI 10.1016/j.legalmed.2010.03.001; Clark T.P, 2001, EFFECT PERIOPERATIVE; Egger CM, 2007, VET ANAESTH ANALG, V34, P200, DOI 10.1111/j.1467-2995.2006.00310.x; Egger CM, 1998, VET SURG, V27, P159, DOI 10.1111/j.1532-950X.1998.tb00114.x; FDA-CVM, 2012, GUID IND ACT CONTR S; FDA-CVM, 2007, 141230 FDACVM NADA U; FDA-CVM, 2001, GUID IND 85 GOOD CLI; Freise KJ, 2012, J VET PHARMACOL THER, V35, P65, DOI 10.1111/j.1365-2885.2012.01407.x; Freise KJ, 2012, J VET PHARMACOL THER, V35, P45, DOI 10.1111/j.1365-2885.2012.01409.x; Freise KJ, 2012, J VET PHARMACOL THER, V35, P27, DOI 10.1111/j.1365-2885.2012.01411.x; Freise K.J., 2012, J VET PHARM THERA S2, V35, P3; GARRETT ER, 1990, BIOPHARM DRUG DISPOS, V11, P311, DOI 10.1002/bdd.2510110403; Gilberto DB, 2003, CONTEMP TOP LAB ANIM, V42, P21; Gimbel JS, 2005, ARCH PHYS MED REHAB, V86, P2284, DOI 10.1016/j.apmr.2005.07.303; GUTSTEIN HB, 2006, GOODMAN GILMANS PHAR, P547; Hardie EM, 1997, APPL ANIM BEHAV SCI, V51, P111, DOI 10.1016/S0168-1591(96)01078-7; Hofmeister EH, 2004, J AM ANIM HOSP ASSOC, V40, P468, DOI 10.5326/0400468; Holton L, 2001, VET REC, V148, P525, DOI 10.1136/vr.148.17.525; Janssen Pharmaceutica Products L.P., 2005, DUR FENT TRANSD SYST; Kukanich B, 2008, J VET PHARMACOL THER, V31, P580, DOI 10.1111/j.1365-2885.2008.00987.x; Kukanich B, 2005, J VET PHARMACOL THER, V28, P371, DOI 10.1111/j.1365-2885.2005.00661.x; Kyles AE, 1998, RES VET SCI, V65, P245, DOI 10.1016/S0034-5288(98)90151-5; Kyles AE, 1996, AM J VET RES, V57, P715; Lafuente MP, 2005, JAVMA-J AM VET MED A, V227, P1768, DOI 10.2460/javma.2005.227.1768; Linton DD, 2012, J VET PHARMACOL THER, V35, P53, DOI 10.1111/j.1365-2885.2012.01408.x; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; Martinez S.A., 2001, EFFECT PERIOPERATIVE; Mathews KA, 2000, VET CLIN N AM-SMALL, V30, P729, DOI 10.1016/S0195-5616(08)70004-4; Mills PC, 2004, AM J VET RES, V65, P1697, DOI 10.2460/ajvr.2004.65.1697; Murrell JC, 2008, VET REC, V162, P405, DOI 10.1136/vr.162.13.403; Neugebauer EAM, 2007, SURG ENDOSC, V21, P1047, DOI 10.1007/s00464-006-9186-4; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6; Pettifer GR, 2004, VET ANAESTH ANALG, V31, P109, DOI 10.1111/j.1467-2987.2004.00158.x; Pickel P.J., 2001, MATH STAT BASIC IDEA; Riviere JE, 2001, ADV DRUG DELIVER REV, V50, P175, DOI 10.1016/S0169-409X(01)00157-0; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; Savides MC, 2012, J VET PHARMACOL THER, V35, P35, DOI 10.1111/j.1365-2885.2012.01410.x; Schmiedt CW, 2007, VET ANAESTH ANALG, V34, P70, DOI 10.1111/j.1467-2995.2006.00302.x; Urquhart J, 2000, J INTERN MED, V248, P357, DOI 10.1046/j.1365-2796.2000.00758.x; VENGPEDERSEN P, 1995, J PHARM SCI, V84, P1101, DOI 10.1002/jps.2600840913; Weintraub WS, 2010, INT J CLIN PRACT, V64, P1359, DOI 10.1111/j.1742-1241.2010.02481.x; Welch JA, 2002, J VET EMERG CRIT CAR, V12, P81, DOI 10.1046/j.1435-6935.2002.00021.x	46	13	13	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0140-7783	1365-2885		J VET PHARMACOL THER	J. Vet. Pharmacol. Ther.	AUG	2014	37	4					394	405		10.1111/jvp.12096			12	Pharmacology & Pharmacy; Veterinary Sciences	Pharmacology & Pharmacy; Veterinary Sciences	AL4HX	WOS:000339094800011	24344787	Green Published			2020-06-30	J	DosSantos, MF; Martikainen, IK; Nascimento, TD; Love, TM; DeBoer, MD; Schambra, HM; Bikson, M; Zubieta, JK; DaSilva, AF				DosSantos, Marcos F.; Martikainen, Ilkka K.; Nascimento, Thiago D.; Love, Tiffany M.; DeBoer, Misty D.; Schambra, Heidi M.; Bikson, Marom; Zubieta, Jon-Kar; DaSilva, Alexandre F.			Building up Analgesia in Humans via the Endogenous mu-Opioid System by Combining Placebo and Active tDCS: A Preliminary Report	PLOS ONE			English	Article							DIRECT-CURRENT STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; MEDIAL PREFRONTAL CORTEX; MOTOR CORTEX; PERIAQUEDUCTAL GRAY; NEUROPATHIC PAIN; BACK-PAIN; BRAIN; MODULATION; ANTICIPATION	Transcranial Direct Current Stimulation (tDCS) is a method of non-invasive brain stimulation that has been frequently used in experimental and clinical pain studies. However, the molecular mechanisms underlying tDCS-mediated pain control, and most important its placebo component, are not completely established. In this pilot study, we investigated in vivo the involvement of the endogenous mu-opioid system in the global tDCS-analgesia experience. Nine healthy volunteers went through positron emission tomography (PET) scans with [C-11] carfentanil, a selective m-opioid receptor (MOR) radiotracer, to measure the central MOR activity during tDCS in vivo (non-displaceable binding potential, BPND) - one of the main analgesic mechanisms in the brain. Placebo and real anodal primary motor cortex (M1/2mA) tDCS were delivered sequentially for 20 minutes each during the PET scan. The initial placebo tDCS phase induced a decrease in MOR BPND in the periaqueductal gray matter (PAG), precuneus, and thalamus, indicating activation of endogenous mu-opioid neurotransmission, even before the active tDCS. The subsequent real tDCS also induced MOR activation in the PAG and precuneus, which were positively correlated to the changes observed with placebo tDCS. Nonetheless, real tDCS had an additional MOR activation in the left prefrontal cortex. Although significant changes in the MOR BPND occurred with both placebo and real tDCS, significant analgesic effects, measured by improvements in the heat and cold pain thresholds, were only observed after real tDCS, not the placebo tDCS. This study gives preliminary evidence that the analgesic effects reported with M1-tDCS, can be in part related to the recruitment of the same endogenous MOR mechanisms induced by placebo, and that such effects can be purposely optimized by real tDCS.	[DosSantos, Marcos F.; Martikainen, Ilkka K.; Nascimento, Thiago D.; DeBoer, Misty D.; DaSilva, Alexandre F.] Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; [DosSantos, Marcos F.; Martikainen, Ilkka K.; Nascimento, Thiago D.; DeBoer, Misty D.; DaSilva, Alexandre F.] Univ Michigan, Sch Dent, MCOHR, Ann Arbor, MI 48109 USA; [Martikainen, Ilkka K.; Love, Tiffany M.; Zubieta, Jon-Kar; DaSilva, Alexandre F.] Univ Michigan, Translat Neuroimaging Lab, MBNI, Ann Arbor, MI 48109 USA; [Schambra, Heidi M.] Columbia Univ, Dept Neurol, New York, NY USA; [Schambra, Heidi M.] Columbia Univ, Dept Rehabil & Regenerat Med, New York, NY USA; [Bikson, Marom] CUNY City Coll, Dept Biomed Engn, New York, NY 10031 USA	DaSilva, AF (reprint author), Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.	adasilva@umich.edu	Love, Tiffany/W-8427-2019; DosSantos, Marcos/E-8913-2014	Love, Tiffany/0000-0001-9299-3190; DosSantos, Marcos/0000-0002-5997-9693	Michigan Institute for Clinical & Health Research Clinical Trial Planning Program/CTSA, University of Michigan [UL1RR024986]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), BrazilCAPES; University of Michigan, Ann Arbor, United States of America; Swedish Cultural Foundation in Finland, Helsinki, Finland	This work was supported by the following grants: Dr. DaSilva, the principal investigator of the study, was supported by Michigan Institute for Clinical & Health Research Clinical Trial Planning Program/CTSA high-tech funding UL1RR024986, University of Michigan. Dr. Santos was also supported by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazil, and by the University of Michigan, Ann Arbor, United States of America. Dr. Martikainen was supported by the Swedish Cultural Foundation in Finland, Helsinki, Finland. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amanzio M, 1999, J NEUROSCI, V19, P484; Amer Assoc Electrodiagnost Med, 2004, MUSCLE NERVE, V29, P734, DOI 10.1002/mus.20053; Antal A, 2011, NEUROIMAGE, V55, P590, DOI 10.1016/j.neuroimage.2010.11.085; Apkarian AV, 2004, J NEUROSCI, V24, P10410, DOI 10.1523/JNEUROSCI.2541-04.2004; Bachmann CG, 2010, CLIN NEUROPHYSIOL, V121, P2083, DOI 10.1016/j.clinph.2010.05.005; Bingel U, 2006, PAIN, V120, P8, DOI 10.1016/j.pain.2005.08.027; Boggio PS, 2009, NEUROPSYCHOLOGIA, V47, P212, DOI 10.1016/j.neuropsychologia.2008.07.022; DANNALS RF, 1985, INT J APPL RADIAT IS, V36, P303, DOI 10.1016/0020-708X(85)90089-4; DaSilva AF, 2012, HEADACHE; DaSilva AF, 2011, JOVE-J VIS EXP, DOI 10.3791/2744; DaSilva AF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003396; DaSilva AFM, 2007, NEUROREPORT, V18, P301, DOI 10.1097/WNR.0b013e32801776bb; de Andrade DC, 2011, PAIN, V152, P320, DOI 10.1016/j.pain.2010.10.032; DosSantos Marcos Fabio, 2012, Front Psychiatry, V3, P93, DOI 10.3389/fpsyt.2012.00093; Essick GK, 2004, J OROFAC PAIN, V18, P345; Fregni F, 2006, ARTHRITIS RHEUM-US, V54, P3988, DOI 10.1002/art.22195; Fregni F, 2006, PAIN, V122, P197, DOI 10.1016/j.pain.2006.02.023; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Garcia-Larrea L, 1999, PAIN, V83, P259, DOI 10.1016/S0304-3959(99)00114-1; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Hansson P, 2007, PAIN, V129, P256, DOI 10.1016/j.pain.2007.03.030; Harris RE, 2009, NEUROIMAGE, V47, P1077, DOI 10.1016/j.neuroimage.2009.05.083; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; Jin CW, 2013, NMR BIOMED, V26, P58, DOI 10.1002/nbm.2819; Johnson S, 2006, PAIN, V123, P187, DOI 10.1016/j.pain.2006.02.030; Jurgens TP, 2012, EUR J PAIN, V16, P1251, DOI 10.1002/j.1532-2149.2012.00135.x; Kano M, 2013, AM J PHYSL GASTROINT; Kuchinad A, 2007, J NEUROSCI, V27, P4004, DOI 10.1523/JNEUROSCI.0098-07.2007; Leppa M, 2006, NEUROIMAGE, V31, P661, DOI 10.1016/j.neuroimage.2005.12.019; LEVINE JD, 1978, LANCET, V2, P654, DOI 10.1016/S0140-6736(78)92762-9; Linnman C, 2012, NEUROIMAGE, V60, P505, DOI 10.1016/j.neuroimage.2011.11.095; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; Lorenz J, 2002, NEURON, V35, P383, DOI 10.1016/S0896-6273(02)00767-5; Luedtke K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048857; Maarrawi J, 2007, NEUROLOGY, V69, P827, DOI 10.1212/01.wnl.0000269783.86997.37; Mainero C, 2011, ANN NEUROL, V70, P838, DOI 10.1002/ana.22537; Maleki N, 2013, NMR BIOMED; Metz AE, 2009, P NATL ACAD SCI USA, V106, P2423, DOI 10.1073/pnas.0809897106; MINOSHIMA S, 1993, J NUCL MED, V34, P322; Moloney TM, 2013, NEUROSCI LETT, V534, P289, DOI 10.1016/j.neulet.2012.11.049; Mylius V, 2012, PAIN, V153, P1350, DOI 10.1016/j.pain.2012.04.009; Nahmias F, 2009, PAIN, V147, P224, DOI 10.1016/j.pain.2009.09.016; Nitsche MA, 2003, SUPPL CLIN NEUROPHYS, V56, P255; O'Connell NE, 2013, CLIN J PAIN, V29, P26, DOI 10.1097/AJP.0b013e318247ec09; O'Connell NE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047514; O'Connell NE, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008208.pub2; Ossipov MH, 2010, J CLIN INVEST, V120, P3779, DOI 10.1172/JCI43766; Phelps EA, 2004, NEURON, V43, P897, DOI 10.1016/j.neuron.2004.08.042; Porro CA, 2002, J NEUROSCI, V22, P3206, DOI 10.1523/JNEUROSCI.22-08-03206.2002; Rolke R, 2006, PAIN, V123, P231, DOI 10.1016/j.pain.2006.01.041; Schestatsky P, 2011, ARQ NEURO-PSIQUIAT, V69, P943, DOI 10.1590/S0004-282X2011000700019; Scott DJ, 2008, ARCH GEN PSYCHIAT, V65, P220, DOI 10.1001/archgenpsychiatry.2007.34; Stagg CJ, 2013, J NEUROSCI, V33, P11425, DOI 10.1523/JNEUROSCI.3887-12.2013; Summers J, 2004, NEUROSCI LETT, V368, P197, DOI 10.1016/j.neulet.2004.07.008; Taylor JJ, 2013, NEUROPSYCHOPHARMACOL; Taylor JJ, 2012, PAIN, V153, P1219, DOI 10.1016/j.pain.2012.02.030; Villamar MF, 2013, JOVE-J VIS EXP, DOI 10.3791/50309; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; Wager TD, 2007, P NATL ACAD SCI USA, V104, P11056, DOI 10.1073/pnas.0702413104; Wagner T, 2007, NEUROIMAGE, V35, P1113, DOI 10.1016/j.neuroimage.2007.01.027; Watson A, 2009, PAIN, V145, P24, DOI 10.1016/j.pain.2009.04.003; Wrigley PJ, 2013, PAIN, V154, P2178, DOI 10.1016/j.pain.2013.06.045; Wu D, 2013, EXP BRAIN RES; YARNITSKY D, 1994, J NEUROL SCI, V125, P39, DOI 10.1016/0022-510X(94)90239-9; Youssef AM, 2013, PAIN; Zheng X, 2011, NEUROIMAGE, V58, P26, DOI 10.1016/j.neuroimage.2011.06.018; Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005; Zubieta JK, 2009, ANN NY ACAD SCI, V1156, P198, DOI 10.1111/j.1749-6632.2009.04424.x; Zyloney CE, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-80	69	37	37	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2014	9	7							e102350	10.1371/journal.pone.0102350			9	Multidisciplinary Sciences	Science & Technology - Other Topics	AO4KM	WOS:000341306600068	25029273	DOAJ Gold, Green Published			2020-06-30	J	Miranda, HF; Noriega, V; Zanetta, P; Prieto, JC; Prieto-Rayo, JC; Aranda, N; Sierralta, F				Miranda, Hugo F.; Noriega, Viviana; Zanetta, Pilar; Carlos Prieto, Juan; Carlos Prieto-Rayo, Juan; Aranda, Nicolas; Sierralta, Fernando			Isobolographic analysis of the opioid-opioid interactions in a tonic and a phasic mouse model of induced nociceptive pain	JOURNAL OF BIOMEDICAL SCIENCE			English	Article						Interaction opioid-opioid; Acetic acid writhing test; Hot plate assay; Isobolographic analysis; Synergism	ACETIC-ACID; NOR-BINALTORPHIMINE; MORPHINE; SYNERGISM; TRAMADOL; FENTANYL; COMBINATION; TOLERANCE; ENANTIOMERS; MECHANISM	Background: Opioids have been used for the management of pain and coadministration of two opioids may induce synergism. In a model of tonic pain, the acetic acid writhing test and in a phasic model, the hot plate, the antinociceptive interaction between fentanyl, methadone, morphine, and tramadol was evaluated. Results: The potency of opioids in the writhing test compared to the hot plate assay was from 2.5 (fentanyl) to 15.5 (morphine) times, respectively. The ED50 was used in a fixed ratio for each of the six pairs of opioid combinations, which, resulted in a synergistic antinociception except for methadone/tramadol and fentanyl/tramadol which were additive, in the hot plate. The opioid antagonists naltrexone, naltrindole and nor-binaltorphimine, suggests that the synergism of morphine combinations are due to the activation of MOR subtypes with partially contribution of DOR and KOR, however fentanyl and methadone combinations are partially due to the activation of MOR and DOR subtypes and KOR lack of participation. The antinociceptive effects of tramadol combinations, are partially due to the activation of MOR, DOR and KOR opioid subtypes. Conclusion: These results suggets that effectiveness and magnitude of the interactions between opioids are dependent on pain stimulus intensity.	[Miranda, Hugo F.; Zanetta, Pilar; Carlos Prieto, Juan; Carlos Prieto-Rayo, Juan; Aranda, Nicolas; Sierralta, Fernando] Univ Chile, Fac Med, Pharmacol Program, ICBM, Santiago 7, Chile; [Miranda, Hugo F.; Noriega, Viviana] Univ Andres Bello, Fac Med, Sch Pharm, Santiago, Chile; [Noriega, Viviana; Carlos Prieto, Juan] Univ Chile, Cardiovasc Dept, Hosp Clin, Santiago, Chile; [Sierralta, Fernando] Univ Finis Terrae, Fac Odontol, Santiago, Chile	Miranda, HF (reprint author), Univ Chile, Fac Med, Pharmacol Program, ICBM, Independencia 1027, Santiago 7, Chile.	hmiranda@med.chile.cl			Universidad Andres Bello [DI-02-11/CB]	This work was partially supported by project DI-02-11/CB from Universidad Andres Bello.	Barrera NP, 2005, TRENDS PHARMACOL SCI, V26, P526, DOI 10.1016/j.tips.2005.08.003; COLLIER HOJ, 1968, BRIT J PHARMACOL, V32, P295, DOI 10.1111/j.1476-5381.1968.tb00973.x; EDDY NB, 1953, J PHARMACOL EXP THER, V107, P385; Hojo M, 2008, J PHARMACOL SCI, V108, P308, DOI 10.1254/jphs.08244FP; Kolesnikov YA, 2010, EUR J PHARMACOL, V638, P61, DOI 10.1016/j.ejphar.2010.04.020; KOSTER R, 1959, FED PROC, V18, P412; Kurihara T, 2003, PHARMACOL BIOCHEM BE, V74, P841, DOI 10.1016/S0091-3057(03)00014-5; Lashbrook JM, 1999, PAIN, V82, P65, DOI 10.1016/S0304-3959(99)00031-7; Le Bars D, 2001, PHARMACOL REV, V53, P597; Lemberg K, 2006, ANESTH ANALG, V102, P1768, DOI 10.1213/01.ane.0000205751.88422.41; Loscalzo LM, 2008, EUR J PHARMACOL, V580, P306, DOI 10.1016/j.ejphar.2007.11.011; Mao JR, 2011, J PAIN, V12, P157, DOI 10.1016/j.jpain.2010.07.006; Mary F, 2008, EUR J PHARMACOL, V583, P48; MCQUAY HJ, 1989, PAIN, V36, P111, DOI 10.1016/0304-3959(89)90118-8; Miranda HF, 2009, FUND CLIN PHARMACOL, V23, P81, DOI 10.1111/j.1472-8206.2008.00636.x; Miranda HF, 2006, PAIN, V121, P22, DOI 10.1016/j.pain.2005.11.012; Miranda HF, 2004, CAN J PHYSIOL PHARM, V82, P331, DOI 10.1139/Y04-027; Miranda HF, 2012, INFLAMMATION, V35, P1132, DOI 10.1007/s10753-011-9420-7; Naidu PS, 2007, EUR J PHARMACOL, V566, P132, DOI 10.1016/j.ejphar.2007.03.031; Neelakantan H, 2012, EUR J PHARMACOL, V686, P55, DOI 10.1016/j.ejphar.2012.04.042; Pan YX, 2005, MOL PHARMACOL, V68, P866, DOI 10.1124/mol.105.011858; Pavao-de-Souza GF, 2012, PHARMACOL BIOCHEM BE, V101, P320, DOI 10.1016/j.pbb.2012.01.018; RAFFA RB, 1993, J PHARMACOL EXP THER, V267, P331; Ramiro S, 2012, J RHEUMATOL, V39, P47, DOI 10.3899/jrheum.120342; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; Reichert JA, 2001, PAIN, V89, P221, DOI 10.1016/S0304-3959(00)00365-1; Romero A, 2010, PHARMACOL BIOCHEM BE, V97, P363, DOI 10.1016/j.pbb.2010.09.005; Satyanarayana PSV, 2004, PROG NEURO-PSYCHOPH, V28, P641, DOI 10.1016/j.pnpbp.2004.01.015; Silva-Moreno A, 2012, EUR J PHARMACOL, V674, P239, DOI 10.1016/j.ejphar.2011.10.034; Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3; Sirohi S, 2008, PHARMACOL BIOCHEM BE, V91, P115, DOI 10.1016/j.pbb.2008.06.019; SUZUKI T, 1992, EUR J PHARMACOL, V213, P91, DOI 10.1016/0014-2999(92)90237-X; TAKEMORI AE, 1988, J PHARMACOL EXP THER, V246, P255; Tallarida RJ, 2000, DRUG SYNERGISM DOSE, P26; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; Waldhoer M, 2004, ANNU REV BIOCHEM, V73, P953, DOI 10.1146/annurev.biochem.73.011303.073940; Whittle SL, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003113.pub3; Zhang Z, 2010, J NEUROSCI, V30, P4735, DOI 10.1523/JNEUROSCI.5968-09.2010	38	12	12	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1021-7770	1423-0127		J BIOMED SCI	J. Biomed. Sci.	JUL 15	2014	21								62	10.1186/s12929-014-0062-6			9	Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	AM7TT	WOS:000340072300001	25017386	DOAJ Gold, Green Published			2020-06-30	J	Desai, SN; Santhosh, MCB				Desai, Sameer N.; Santhosh, M. C. B.			A randomized, double blind comparison of pethidine and ketoprofen as adjuvants for lignocaine in intravenous regional anaesthesia	REVISTA BRASILEIRA DE ANESTESIOLOGIA			English	Article						Intravenous regional anaesthesia; Pethidine; Ketoprofen	POSTOPERATIVE PAIN; DOSE-RESPONSE; BIER BLOCK; LIDOCAINE; ANALGESIA; SURGERY	Background and objectives: A review of all the adjuncts for intravenous regional anaesthesia concluded that there is good evidence to recommend NonSteroidal Anti-Inflammatory agents and pethidine in the dose of 30 mg dose as adjuncts to intravenous regional anaesthesia. But there are no studies to compare pethidine of 30 mg dose to any of the NonSteroidal Anti-Inflammatory agents. Methods: In a prospective, randomized, double blind study, 45 patients were given intravenous regional anaesthesia with either lignocaine alone or lignocaine with pethidine 30 mg or lignocaine with ketprofen 100 mg. Fentanyl was used as rescue analgesic during surgery. For the first 6 h of postoperative period analgesia was provided by fentanyl injection and between 6 and 24 h analgesia was provided by diclofenac tablets. Visual analogue scores for pain and consumption of fentanyl and diclofenac were compared. Results: The block was inadequate for one case each in lignocaine group and pethidine group, so general anaesthesia was provided. Time for the first dose of fentanyl required for post-operative analgesia was significantly more in pethidine and ketoprofen groups compared to lignocaine group (156.7 +/- 148.8 and 153.0 +/- 106.0 vs. 52.1 +/- 52.4 min respectively). Total fentanyl consumption in first 6 h of postoperative period was less in pethidine and ketoprofen groups compared to lignocaine group (37.5 +/- 29.0 mcg, 38.3 +/- 20.8 mcg vs. 64.2 +/- 27.2 mcg respectively). Consumption of diclofenac tablets was 2.4 +/- 0.7, 2.5 +/- 0.5 and 2.0 +/- 0.7 in the control, pethidine and ketoprofen group respectively, which was statistically not significant. Side effects were not significantly different between the groups. Conclusion: Both pethidine and ketoprofen are equally effective in providing postoperative analgesia up to 6 h, without significant difference in the side effects and none of the adjuncts provide significant analgesia after 6 h. (C) 2013 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. All rights reserved..	[Desai, Sameer N.; Santhosh, M. C. B.] Shri Dharmasthala Manjunatheshwara Med Coll, Dept Anaesthesiol, Dharwad, Karnataka, India; All India Inst Med Sci, Dept Anesthesiol & Crit Care, New Delhi, India	Desai, SN (reprint author), Shri Dharmasthala Manjunatheshwara Med Coll, Dept Anaesthesiol, Dharwad, Karnataka, India.	sameeranaes@gmail.com					Basto ER, 2001, ANESTH ANALG, V92, P1052; Brill S, 2004, ACTA ANAESTH SCAND, V48, P117, DOI 10.1111/j.1399-6576.2004.00280.x; BROWN EM, 1989, CAN J ANAESTH, V36, P307, DOI 10.1007/BF03010770; Choyce A, 2002, CAN J ANAESTH, V49, P32, DOI 10.1007/BF03020416; ELHAKIM M, 1991, ACTA ANAESTH SCAND, V35, P279, DOI 10.1111/j.1399-6576.1991.tb03289.x; Foedt Weser J, 1980, NEW ENGL J MED, V302, P1179; HOLLINGWORTH A, 1982, INJURY, V13, P331, DOI 10.1016/0020-1383(82)90331-X; Priya V, 2002, J Postgrad Med, V48, P109; Reuben SS, 1999, ANESTH ANALG, V88, P831, DOI 10.1097/00000539-199904000-00028; Sen S, 2006, BRIT J ANAESTH, V97, P408, DOI 10.1093/bja/ael170; Stein C, 1997, PAIN, V71, P119, DOI 10.1097/00006396-199706000-00001; Steinberg RB, 1998, ANESTH ANALG, V86, P791, DOI 10.1097/00000539-199804000-00021; Subramaniam R, 2003, J Postgrad Med, V49, P123; Terse T, 2001, CLIN ANAESTHESIA, P1114; Tuomilehto H, 2000, BRIT J ANAESTH, V85, P224, DOI 10.1093/bja/85.2.224; WOOLF CJ, 1989, BRIT J ANAESTH, V63, P139, DOI 10.1093/bja/63.2.139; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026; Yurtlu S, 2011, J INT MED RES, V39, P1923, DOI 10.1177/147323001103900537	18	0	0	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0034-7094	1806-907X		REV BRAS ANESTESIOL	Rev. Bras. Anestesiol.	JUL-AUG	2014	64	4					221	226		10.1016/j.bjane.2013.03.016			6	Anesthesiology	Anesthesiology	AO2PR	WOS:000341168200001	25096765	DOAJ Gold, Green Published			2020-06-30	J	Laboureyras, E; Aubrun, F; Monsaingeon, M; Corcuff, JB; Laulin, JP; Simonnet, G				Laboureyras, Emilie; Aubrun, Frederic; Monsaingeon, Maud; Corcuff, Jean-Benoit; Laulin, Jean-Paul; Simonnet, Guy			Exogenous and endogenous opioid-induced pain hypersensitivity in different rat strains	PAIN RESEARCH & MANAGEMENT			English	Article						Genetic factors; Individual history; Pain hypersensitivity; Rat strains	RECEPTOR-EXPRESSING NEURONS; LONG-LASTING HYPERALGESIA; EXCITATORY AMINO-ACID; POSTOPERATIVE PAIN; MORPHINE-TOLERANCE; ABNORMAL PAIN; SENSITIZATION; MECHANISMS; WITHDRAWAL; ANALGESIA	BACKGROUND: Opioid-induced hyperalgesia (OIH) is a recognized complication of opioid use that may facilitate the development of exaggerated postoperative pain. OBJECTIVE: To examine the role of genetic factors on OIH by comparing four rat strains. Because the authors previously reported that the endogenous opioids released during non-nociceptive environmental stress induce latent pain sensitization, genetic and environmental factor interactions were also evaluated. METHODS: First, the propensity of Sprague Dawley, Wistar, Lewis and Fischer rats to develop OIH following single or repeated fentanyl exposures was compared by measuring the nociceptive threshold using the paw pressure vocalization test. Second, Sprague Dawley and Fischer rats were exposed to a series of three non-nociceptive environmental stress sessions to evaluate the ability of endogenous opioids to enhance hyperalgesia associated with a carrageenan-induced hind-paw inflammation test performed two weeks later. RESULTS : Sprague Dawley, Wistar and Lewis rats exhibited OIH, although differences were observed. OIH was not observed in Fischer rats. Inflammatory hyperalgesia enhancement induced through previous stress in Sprague Dawley rats was not observed in Fischer rats. CONCLUSIONS: The pain level not only reflects nociceptive inputs but also depends on both the history and genetic factors of the individual. Genetic and environmental models may provide new insights into the mechanisms that underlie individual differences observed in postoperative pain.	[Laboureyras, Emilie; Monsaingeon, Maud; Corcuff, Jean-Benoit; Laulin, Jean-Paul; Simonnet, Guy] Univ Bordeaux Segalen, Team Homeostasie Allostasie Pathol Rehabil, UMR CNRS 5287, F-33076 Bordeaux, France; [Aubrun, Frederic] Univ Lyon 1, Dept Anesthesiol & Crit Care, Grp Hosp Nord, Hop Croix Rousse, F-69365 Lyon, France; [Aubrun, Frederic] CHU Pitie Salpetriere, Dept Anesthesiol & Crit Care, Paris, France	Simonnet, G (reprint author), Univ Bordeaux Segalen, Team Homeostasie Allostasie Pathol Rehabil, UMR CNRS INCIA 5287, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	gsimonnet@yahoo.com			Universite Bordeaux Segalen; Universite Bordeaux 1, Bordeaux, France; CNRS, Paris, FranceCentre National de la Recherche Scientifique (CNRS); Assistance Publique - Hopitaux de Paris - CNRS; Universite Bordeaux Segalen (Postes d'accueil)	This work was supported by the Universite Bordeaux Segalen, the Universite Bordeaux 1, Bordeaux, France and the CNRS, Paris, France. Dr Aubrun was the recipient of a joined research grant from Assistance Publique - Hopitaux de Paris - CNRS and Universite Bordeaux Segalen (Postes d'accueil).	Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; BASBAUM AI, 1995, PAIN, V61, P349, DOI 10.1016/0304-3959(95)00009-H; Celerier E, 2006, ANESTHESIOLOGY, V104, P546; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Celerier E, 2001, J NEUROSCI, V21, P4074, DOI 10.1523/JNEUROSCI.21-11-04074.2001; Celerier E, 1999, BRAIN RES, V847, P18, DOI 10.1016/S0006-8993(99)01998-8; Chu LF, 2009, PHARMACOGENET GENOM, V19, P193, DOI 10.1097/FPC.0b013e328322e73d; Crofford LJ, 2010, NAT REV RHEUMATOL, V6, P191, DOI 10.1038/nrrheum.2010.24; De Felice M, 2010, ANN NEUROL, V67, P325, DOI 10.1002/ana.21897; Drdla R, 2009, SCIENCE, V325, P207, DOI 10.1126/science.1171759; FRY JP, 1980, BRIT J PHARMACOL, V68, P585, DOI 10.1111/j.1476-5381.1980.tb14574.x; Grosu Irina, 2011, Anesthesiol Clin, V29, P311, DOI 10.1016/j.anclin.2011.04.001; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Heinl C, 2011, J NEUROSCI, V31, P16748, DOI 10.1523/JNEUROSCI.3491-11.2011; Ip HYV, 2009, ANESTHESIOLOGY, V111, P657, DOI 10.1097/ALN.0b013e3181aae87a; Joly V, 2005, ANESTHESIOLOGY, V103, P147, DOI 10.1097/00000542-200507000-00022; Kest B, 2004, MAMM GENOME, V15, P610, DOI 10.1007/s00335-004-2367-3; Kest B, 2002, NEUROSCIENCE, V115, P463, DOI 10.1016/S0306-4522(02)00458-X; Kest B, 2002, PHARMACOL BIOCHEM BE, V73, P821, DOI 10.1016/S0091-3057(02)00908-5; King T, 2005, PAIN, V116, P276, DOI 10.1016/j.pain.2005.04.014; Koetzner L, 2004, J NEUROSCI, V24, P1451, DOI 10.1523/JNEUROSCI.1517-03.2004; Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0; Laulin JP, 1998, EUR J NEUROSCI, V10, P782, DOI 10.1046/j.1460-9568.1998.00083.x; Le Roy C, 2011, J PAIN, V12, P1069, DOI 10.1016/j.jpain.2011.04.011; Lee M, 2011, PAIN PHYSICIAN, V14, P145; Lenz H, 2011, PAIN, V152, P1289, DOI 10.1016/j.pain.2011.02.007; Liang DY, 2006, PHARMACOGENET GENOM, V16, P825, DOI 10.1097/01.fpc.0000236321.94271.f8; Liang DY, 2011, ANESTHESIOLOGY, V114, P1180, DOI 10.1097/ALN.0b013e31820efb19; Liang DY, 2006, ANESTHESIOLOGY, V104, P1054, DOI 10.1097/00000542-200605000-00023; Liang DY, 2006, PAIN, V121, P232, DOI 10.1016/j.pain.2005.12.026; MAO J, 1994, J NEUROSCI, V14, P2301; Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; McEwen BS, 2000, NEUROCHEM RES, V25, P1219, DOI 10.1023/A:1007687911139; Neeley EW, 2011, PHYSIOL BEHAV, V104, P334, DOI 10.1016/j.physbeh.2011.02.032; Quartilho A, 2004, ANESTHESIOLOGY, V100, P1538, DOI 10.1097/00000542-200406000-00029; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025; Rivat C, 2007, NEUROPSYCHOPHARMACOL, V32, P2217, DOI 10.1038/sj.npp.1301340; Rivat C, 2009, EUR J NEUROSCI, V29, P727, DOI 10.1111/j.1460-9568.2009.06616.x; Simonin F, 2006, P NATL ACAD SCI USA, V103, P466, DOI 10.1073/pnas.0502090103; Simonnet G, 2003, NEUROREPORT, V14, P1, DOI 10.1097/00001756-200301200-00001; SOLOMON RL, 1980, AM PSYCHOL, V35, P691, DOI 10.1037/0003-066X.35.8.691; Stubhaug A, 1997, ACTA ANAESTH SCAND, V41, P1124, DOI 10.1111/j.1399-6576.1997.tb04854.x; Vanderah TW, 2000, J NEUROSCI, V20, P7074, DOI 10.1523/JNEUROSCI.20-18-07074.2000; Vardanyan A, 2009, J PAIN, V10, P243, DOI 10.1016/j.jpain.2008.07.004; Vera-Portocarrero LP, 2007, PAIN, V129, P35, DOI 10.1016/j.pain.2006.09.033; Wilder-Smith OHG, 2006, ANESTHESIOLOGY, V104, P601, DOI 10.1097/00000542-200603000-00028; WISE RA, 1988, J ABNORM PSYCHOL, V97, P118, DOI 10.1037/0021-843X.97.2.118; ZHOU Y, 1992, NEUROREPORT, V3, P1121	49	7	11	1	5	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1203-6765	1918-1523		PAIN RES MANAG	Pain Res. Manag.	JUL-AUG	2014	19	4					191	197		10.1155/2014/285308			7	Clinical Neurology	Neurosciences & Neurology	AN3CW	WOS:000340463500007	24839623	DOAJ Gold, Green Published			2020-06-30	J	Zucco, F; Bonezzi, C; Fornasari, D				Zucco, Furio; Bonezzi, Cesare; Fornasari, Diego			Breakthrough Cancer Pain (BTcP): a Synthesis of Taxonomy, Pathogenesis, Therapy, and Good Clinical Practice in Adult Patients in Italy	ADVANCES IN THERAPY			English	Review						Breakthrough cancer pain (BTcP); Cancer; Fentanyl; Pain; Pain exacerbation; Palliative care	TRANSMUCOSAL FENTANYL CITRATE; DOUBLE-BLIND; INTRAVENOUS MORPHINE; BUCCAL TABLETS; DRUG-DELIVERY; MU-G; PREVALENCE; MANAGEMENT; SPRAY; PHARMACOKINETICS	Pain presents in 80% of patients with advanced cancer, and 30% have periods of increased pain due to fluctuating intensity, known as breakthrough cancer pain (BTcP). BTcP is high-intensity, short-duration pain occurring in several episodes per day and is non-responsive to treatment. The clinical approach to BTcP is variable. A review of the literature was performed to provide clinicians and practitioners with a rational synthesis of the ongoing scientific debate on BTcP and to provide a basis for optimal clinical approach to BTcP in adult Italian patients. Data show that circadian exacerbations of pain should be carefully monitored, differentiating, if possible, between fluctuations of background pain (BP), end-of-dose effect, and BTcP. BTcP should be monitored in all care contexts in clinical practice and each care facility must have all the medications and products approved for use in BTcP at their disposal. Data show that knowledge about medications for BTcP is lacking: medications for BTcP treatment are not interchangeable, although containing the same active substance; each physician must know the specific characteristics of each medication, its pharmacological properties, limitations in clinical practice, specifics relating to titration and repeatability of administration, and technical specifics relating to the accessibility and delivery. Importantly, before choosing a rapid-onset opioid (ROO), it is essential to deeply understand the status of patient and the characteristics of their family unit/caregivers, taking into account the patient's progressive loss of autonomy and/or cognitive-relational functionality. When BTcP therapy is initiated or changed, special attention must be paid to training the patient and family members/caregivers, providing clear instructions regarding the timing of drug administration. The patient must already be treated effectively with opioids before introducing ROOs for control of BTcP.	[Zucco, Furio] Presenza Amica Assoc, I-20145 Milan, Italy; [Bonezzi, Cesare] Salvatore Maugeri Fdn, Pain Therapy Ctr, Pavia, Italy; [Bonezzi, Cesare] Hospitalisat & Hlth Care, Sci Inst Res, Pavia, Italy; [Fornasari, Diego] CNR Natl Res Council Italy, Inst Neurosci, Dept Med Biotechnol & Translat Med, Cellular & Mol Pharmacol Sect, Milan, Italy	Zucco, F (reprint author), Presenza Amica Assoc, Piazza Piemonte 4, I-20145 Milan, Italy.	fzucco_1951@libero.it	Bonezzi, Cesare/AAB-9991-2020	CESARE, BONEZZI/0000-0001-9330-2531; Fornasari, Diego/0000-0002-9668-3103	ProStrakan Srl	Editorial assistance in the preparation of this manuscript was provided by Brunilde Iovene, an independent medical writer, and by Mary Hines of Springer Healthcare Communications. Support for this assistance was funded by ProStrakan Srl. No other funding or sponsorship was received for this study or publication of this article. All named authors meet the ICMJE criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.	Agency for Healthcare Research and Quality, 2001, AHRQ PUBL; [Anonymous], 2012, OP PALL CAR SAF EFF; Bartlett JA, 2012, AAPS PHARMSCITECH, V13, P1110, DOI 10.1208/s12249-012-9839-7; Bhala N, 2013, LANCET, V382, P769, DOI 10.1016/S0140-6736(13)60900-9; Bornemann-Cimenti H, 2013, DTSCH ARZTEBL INT, V110, P271, DOI 10.3238/arztebl.2013.0271; Bredenberg S, 2003, EUR J PHARM SCI, V20, P327, DOI 10.1016/j.ejps.2003.07.002; Campisi G, 2010, CURR PHARM DESIGN, V16, P641, DOI 10.2174/138161210790883778; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Caraceni A, 2012, J PAIN SYMPTOM MANAG, V43, P833, DOI 10.1016/j.jpainsymman.2011.05.018; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; CERVERO F, 1994, PAIN, V58, P21, DOI 10.1016/0304-3959(94)90181-3; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Corli C, 2011, QUALCHE DOLORE MENO; Darwish M, 2008, CLIN DRUG INVEST, V28, P1, DOI 10.2165/00044011-200828010-00001; Darwish M, 2006, CLIN PHARMACOKINET, V45, P843, DOI 10.2165/00003088-200645080-00006; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Davis M.P., 2009, OPIOIDS CANC PAIN; Dickenson A, 2013, ANAEST INTENS CARE M, V14, P484; England Ruth, 2011, BMJ Support Palliat Care, V1, P349, DOI 10.1136/bmjspcare-2011-000037; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Fanelli C, 2010, DOLORE CRONICO MED G; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Gomez-Batiste X, 2002, J PAIN SYMPTOM MANAG, V24, P45, DOI 10.1016/S0885-3924(02)00421-9; Grassin-Delyle S, 2012, PHARMACOL THERAPEUT, V134, P366, DOI 10.1016/j.pharmthera.2012.03.003; Hagen NA, 2008, CURR PAIN HEADACHE R, V12, P241, DOI 10.1007/s11916-008-0042-1; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Madhav NVS, 2009, J CONTROL RELEASE, V140, P2, DOI 10.1016/j.jconrel.2009.07.016; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V27, P352, DOI 10.1016/j.jpainsymman.2003.09.006; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; Mercadante S, 2011, J PAIN SYMPTOM MANAG, V42, P464, DOI 10.1016/j.jpainsymman.2010.12.010; Moore N, 2012, CURR MED RES OPIN, V28, P1781, DOI 10.1185/03007995.2012.735227; Narang N, 2011, INT J PHARM PHARM S2, V3, P18; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Rauck R, 2012, CURR MED RES OPIN, V28, P859, DOI 10.1185/03007995.2012.683111; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Shojaei A H, 1998, J Pharm Pharm Sci, V1, P15; Smith HS, 2013, J PAIN RES, V6, P189, DOI 10.2147/JPR.S40745; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; Vissers D, 2010, CURR MED RES OPIN, V26, P1037, DOI 10.1185/03007991003694340; Walsh D, 2000, SEMIN ONCOL, V27, P45; Walsh Declan, 2004, Support Cancer Ther, V1, P157, DOI 10.3816/SCT.2004.n.007; Woodcock J, 2012, NEW ENGL J MED, V367, P2463, DOI 10.1056/NEJMp1212969; Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030; Wordliczek J, 2013, CANC PAIN; Zeppetella G, 2011, CLIN ONCOL-UK, V23, P393, DOI 10.1016/j.clon.2010.12.002; Zeppetella G, 2009, EUR J CANCER CARE, V18, P331, DOI 10.1111/j.1365-2354.2008.01009.x; Zeppetella G, 2010, 5 BRIST OP C; Zucco F, 2010, HOSPICE ITALIA 2010, P1	54	11	12	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0741-238X	1865-8652		ADV THER	Adv. Ther.	JUL	2014	31	7					657	682		10.1007/s12325-014-0130-z			26	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	AM3ET	WOS:000339736200001	25005168	Green Published, Other Gold			2020-06-30	J	Samala, RV; Bloise, R; Davis, MP				Samala, Renato V.; Bloise, Rafael; Davis, Mellar P.			Efficacy and Safety of a Six-Hour Continuous Overlap Method for Converting Intravenous to Transdermal Fentanyl in Cancer Pain	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Fentanyl; fentanyl conversion; transdermal fentanyl	QUALITY-OF-LIFE; ORAL MORPHINE	Context. Managing cancer pain often requires opioid medications, such as fentanyl, which is frequently initiated parenterally, and then converted to transdermal form. Little evidence exists to guide this conversion. Objectives. To observe the efficacy and safety of a six-hour continuous overlap method for converting intravenous fentanyl (IVF) to transdermal fentanyl (TF) in patients with cancer pain. Methods. We switched from IVF to TF using a 1: 1 (IVF: TF) conversion ratio and overlapped a continuous, nontapered dose of IVF until six hours after TF placement. Pain intensity by Numeric Rating Scale, number of rescue analgesic doses, and presence and severity of opioid-related adverse events were recorded immediately before TF placement, and at six, 12, 18, and 24 hours thereafter. Results. A total of 17 consecutive patients with cancer pain controlled on IVF were converted to TF. Median age was 65 years, 10 were female, and all had Stage IV cancer. Pain intensity at six and 24 hours remained stable; a slight but statistically significant increase in Numeric Rating Scale was noted at 12 and 18 hours (P = 0.01 and 0.02, respectively); however, there was no significant increase in number of rescue doses throughout the observation period. Only one patient experienced opioid-related adverse events. Conclusion. A continuous six-hour overlap method is a safe and effective strategy when converting from IVF to TF in patients with cancer pain. A slight increase in pain intensity may occur, but does not lead to increased rescue doses. (C) 2014 U. S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.	[Samala, Renato V.] Cleveland Clin Fdn, Ctr Connected Care, Cleveland, OH 44195 USA; [Davis, Mellar P.] Cleveland Clin Fdn, Harry R Horvitz Ctr Palliat Med, Cleveland, OH 44195 USA; [Bloise, Rafael] Lawrence Gen Hosp, Palliat & Support Care Serv, Lawrence, MA USA	Samala, RV (reprint author), Cleveland Clin Fdn, Ctr Connected Care, 9500 Euclid Ave,S31, Cleveland, OH 44195 USA.	samalar@ccf.org					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Chiou TJ, 2010, AM J HOSP PALLIAT ME, V27, P31, DOI 10.1177/1049909109346427; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; Fainsinger RL, 1996, J PALLIATIVE CARE, V12, P48, DOI 10.1177/082585979601200110; Kornick CA, 2001, CANCER, V92, P3056, DOI 10.1002/1097-0142(20011215)92:12<3056::AID-CNCR10166>3.0.CO;2-H; MISER AW, 1989, PAIN, V37, P15, DOI 10.1016/0304-3959(89)90148-6; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Nomura M, 2013, CLIN J PAIN, V29, P487, DOI 10.1097/AJP.0b013e318266f6a5; Nomura M, 2011, SUPPORT CARE CANCER, V19, P691, DOI 10.1007/s00520-010-0890-1; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; Prommer E, 2009, J PALLIAT MED, V12, P947, DOI 10.1089/jpm.2009.0051; Radbruch L, 2000, PALLIATIVE MED, V14, P111, DOI 10.1191/026921600671594561; SIMMONDS MA, 1992, J PAIN SYMPTOM MANAG, V7, pS36, DOI 10.1016/0885-3924(92)90051-I; World Health Organization Expert Committee, 1990, CANC PAIN REL PALL C	16	2	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	JUL	2014	48	1					132	136		10.1016/j.jpainsymman.2013.09.001			5	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	AL0ZH	WOS:000338855100020	24291296	Bronze			2020-06-30	J	Davis, MP				Davis, Mellar P.			Efficacy of Rapid-Onset Oral Fentanyl: What Does It Mean?	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter							METAANALYSIS; PAIN		Cleveland Clin, Dept Hosp & Palliat Med, Taussig Canc Inst, Cleveland, OH 44106 USA	Davis, MP (reprint author), Cleveland Clin, Dept Hosp & Palliat Med, Taussig Canc Inst, Cleveland, OH 44106 USA.						Egger M, 1997, BMJ-BRIT MED J, V315, P1533, DOI 10.1136/bmj.315.7121.1533; Egger M, 1997, BMJ-BRIT MED J, V315, P1371, DOI 10.1136/bmj.315.7119.1371; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Farrar JT, 2010, NAT MED, V16, P1284, DOI 10.1038/nm.2249; Farrar JT, 2010, ANESTHESIOLOGY, V112, P1464, DOI 10.1097/ALN.0b013e3181de0e6d; Farrar JT, 2010, J PAIN, V11, P109, DOI 10.1016/j.jpain.2009.06.007; Farrar JT, 2010, PAIN, V149, P163, DOI 10.1016/j.pain.2010.03.013; Jandhyala R, 2013, J PAIN SYMPTOM MANAG, V46, P573, DOI 10.1016/j.jpainsymman.2012.09.009	8	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	JUL	2014	48	1					E2	E3		10.1016/j.jpainsymman.2014.03.003			2	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	AL0ZH	WOS:000338855100002	24704798	Bronze			2020-06-30	J	Tsze, DS; Vitberg, YM; Berezow, J; Starc, TJ; Dayan, PS				Tsze, Daniel S.; Vitberg, Yaffa M.; Berezow, Joel; Starc, Thomas J.; Dayan, Peter S.			Treatment of Tetralogy of Fallot Hypoxic Spell With Intranasal Fentanyl	PEDIATRICS			English	Article						Tetralogy of Fallot; congenital heart disease; tet spell; hypoxic spell; hypercyanotic spell; intranasal; fentanyl	CHEST-WALL RIGIDITY; BREAKTHROUGH CANCER PAIN; CHILDREN; PHARMACOKINETICS; MANAGEMENT; CROSSOVER; DELIVERY; MORPHINE; INFANTS; OPIOIDS	We present the case of a 3-month-old girl who had unrepaired Tetralogy of Fallot who presented to the emergency department with an acute hypoxic episode. The patient was hyperpneic and cyanotic, with an initial oxygen saturation of 56%. She did not respond to knee-to-chest positioning. A single dose of intranasal fentanyl was administered with subsequent resolution of her symptoms and improvement of her oxygen saturation to 78% within 10 minutes. To our knowledge, this is the first report of the successful treatment of a hypoxic episode of Tetralogy of Fallot using intranasal fentanyl.	[Tsze, Daniel S.; Vitberg, Yaffa M.; Berezow, Joel; Starc, Thomas J.; Dayan, Peter S.] Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA	Tsze, DS (reprint author), Div Pediat Emergency Med, 3959 Broadway,CHN 1-116, New York, NY 10032 USA.	dst2141@columbia.edu		Tsze, Daniel/0000-0002-7567-8743			Apitz C, 2009, LANCET, V374, P1462, DOI 10.1016/S0140-6736(09)60657-7; Benthuysen J L, 1988, J Cardiothorac Anesth, V2, P749, DOI 10.1016/0888-6296(88)90098-1; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849; CHIEN YW, 1989, [No title captured]; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Coruh B, 2013, CHEST, V143, P1145, DOI 10.1378/chest.12-2131; Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI [10.1586/ERN.11.63, 10.1586/ern.11.63]; Dewhirst E, 2012, PEDIATR EMERG CARE, V28, P465, DOI 10.1097/PEC.0b013e3182535a2a; Dietrich E, 2012, ANN PHARMACOTHER, V46, P1382, DOI 10.1345/aph.1R069; Ellerton JA, 2013, EMERG MED J, V30, P501, DOI 10.1136/emermed-2012-202291; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; Grassin-Delyle S, 2012, PHARMACOL THERAPEUT, V134, P366, DOI 10.1016/j.pharmthera.2012.03.003; Hansen MS, 2012, ACTA ANAESTH SCAND, V56, P407, DOI 10.1111/j.1399-6576.2011.02613.x; Hansen MS, 2013, DAN MED J, V60; Illum L, 2004, J PHARM PHARMACOL, V56, P3, DOI 10.1211/0022357022539; Lahat E, 2000, BRIT MED J, V321, P83, DOI 10.1136/bmj.321.7253.83; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Mudd S, 2011, J PEDIATR HEALTH CAR, V25, P316, DOI 10.1016/j.pedhc.2010.04.011; Park MK, 2007, PEDIAT CARDIOLOGY PR, P235; Rao PS, 2009, INDIAN J PEDIATR, V76, P57, DOI 10.1007/s12098-009-0030-4; SANFORD TJ, 1986, ANESTH ANALG, V65, P259; Smith H, 2012, CNS DRUGS, V26, P509, DOI 10.2165/11630580-000000000-00000; Vaughn R L, 1981, Anesth Prog, V28, P50; Wolfe TR, 2010, PEDIATRICS, V126, P532, DOI 10.1542/peds.2010-0616; Zeppetella G, 2013, J PAIN SYMPTOM MANAG	28	2	2	0	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUL	2014	134	1					E266	E269		10.1542/peds.2013-3183			4	Pediatrics	Pediatrics	AK9UZ	WOS:000338774800033	24936003				2020-06-30	J	Dewhirst, E; Fedel, G; Raman, V; Rice, J; Barry, N; Jatana, KR; Elmaraghy, C; Merz, M; Tobias, JD				Dewhirst, Elisabeth; Fedel, Gina; Raman, Vidya; Rice, Julie; Barry, N'Diris; Jatana, Kris R.; Elmaraghy, Charles; Merz, Meredith; Tobias, Joseph D.			Pain management following myringotomy and tube placement: Intranasal dexmedetomidine versus intranasal fentanyl	INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY			English	Article						Intranasal dexmedetomidine; Intranasal fentanyl; Myringotomy; Post-operative analgesia; Recovery	POSTOPERATIVE ANALGESIA; BILATERAL MYRINGOTOMY; EQUALIZATION TUBES; CHILDREN; PREMEDICATION; MIDAZOLAM; ACETAMINOPHEN; ANESTHESIA	Purpose: Despite the brevity of the procedure, bilateral myringotomy and tympanostomy tube placement (BMT) can result in significant postoperative pain and discomfort. As the procedure is frequently performed without intravenous access, non-parenteral routes of administration are frequently used for analgesia. The current study prospectively compares the efficacy of intranasal (IN) dexmedetomidine with IN fentanyl for children Undergoing BMT. Methods: This prospective, double-blinded, randomized clinical trial included pediatric patients undergoing BMT. The patients were randomized to receive either IN dexmedetomidine (1 mu g/kg) or fentanyl (2 mu g/kg) after the induction of general anesthesia with sevoflurane. All patients received rectal acetaminophen (40 mg/kg) and the first 50 patients also received premedication with oral midazolam. Postoperative pain and recovery were assessed using pediatric pain and recovery scales, and any adverse effects were monitored for. Results: The study cohort included 100 patients who ranged in age from 1 to 7.7 years and in weight from 8.6 to 37.4 kg. They were divided into 4 groups with 25 patients in each group: (1) midazolam premedication + IN dexmedetomidine; (2) midazolam premedication + IN fentanyl; (3) no premedication + IN dexmedetomidine; and (4) no premedication + IN fentanyl. Pain scores were comparable when comparing groups 2, 3 and 4, but were higher in group I (midazolam premedication with IN dexmedetomidine). There was no difference in total time in the post-anesthesia care unit (PACU) or time from arrival in the PACU until hospital discharge between the 4 groups. The heart rate (HR) was significantly lower in group 3 when compared to the other groups at several different times after arrival to the PACU. No clinically significant difference was noted in blood pressure. Conclusion: Following BMT, when no premedication is administered, there was no clinical advantage when comparing IN dexmedetomidine (1 mu g/kg) to IN fentanyl (2 mu g/kg). The addition of oral midazolam as a premedication worsened the outcome measures particularly for children receiving IN dexmedetomidine. (C) 2014 Elsevier Ireland Ltd. All rights reserved.	[Dewhirst, Elisabeth] Ohio State Univ, Dept Anesthesiol & Pain Med, Wexner Med Ctr, Columbus, OH 43210 USA; [Fedel, Gina; Raman, Vidya; Rice, Julie; Barry, N'Diris; Tobias, Joseph D.] Nationwide Childrens Hosp, Dept Anesthesiol & Pain Med, Columbus, OH USA; [Jatana, Kris R.; Elmaraghy, Charles; Merz, Meredith] Nationwide Childrens Hosp, Dept Otolaryngol Head & Neck Surg, Columbus, OH USA; [Jatana, Kris R.; Elmaraghy, Charles; Merz, Meredith; Tobias, Joseph D.] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA; [Tobias, Joseph D.] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH USA	Dewhirst, E (reprint author), Ohio State Univ, Dept Anesthesiol & Pain Med, Wexner Med Ctr, 410 W 10th Ave, Columbus, OH 43210 USA.	elisabeth.dewhirst@osumc.edu; joseph.tobias@nationwidechildrens.org	Jatana, Kris/E-3309-2011; Merz, Meredith/E-3669-2011		Nationwide Children's Hospital (NCH) [275911]	Internal grant from Nationwide Children's Hospital (NCH grant 275911).	ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Anttila M, 2003, BRIT J CLIN PHARMACO, V56, P691, DOI 10.1046/j.1365-2125.2003.01944.x; BELLEVILLE JP, 1992, ANESTHESIOLOGY, V77, P1125, DOI 10.1097/00000542-199212000-00013; Bennie RE, 1998, ANESTHESIOLOGY, V89, P385, DOI 10.1097/00000542-199808000-00015; CASEY WF, 1990, ANESTHESIOLOGY, V72, P637, DOI 10.1097/00000542-199004000-00011; Finkel JC, 2001, ANESTH ANALG, V92, P1164; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Ghali AM, 2011, SAUDI J ANAESTH, V5, P387, DOI 10.4103/1658-354X.87268; Golparvar M, 2004, PEDIATR ANESTH, V14, P924, DOI 10.1111/j.1460-9592.2004.01349.x; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; HANNALLAH RS, 1987, ANESTHESIOLOGY, V66, P832, DOI 10.1097/00000542-198706000-00023; Iirola T, 2011, EUR J CLIN PHARMACOL, V67, P825, DOI 10.1007/s00228-011-1002-y; Manworren Renee C B, 2003, Pediatr Nurs, V29, P140; Massanari M, 1997, CLIN PEDIATR, V36, P681, DOI 10.1177/000992289703601202; Menon DV, 2007, J AM COLL CARDIOL, V50, P626, DOI 10.1016/j.jacc.2007.03.060; Pappas AL, 2003, ANESTH ANALG, V96, P1621, DOI 10.1213/01.ANE.0000064206.51296.1D; Pestieau SR, 2011, PEDIATR ANESTH, V21, P1128, DOI 10.1111/j.1460-9592.2011.03615.x; Rampersad S, 2010, PEDIATR ANESTH, V20, P1028, DOI 10.1111/j.1460-9592.2010.03427.x; STEWARD DJ, 1975, CAN ANAESTH SOC J, V22, P111, DOI 10.1007/BF03004827; Talon MD, 2009, J BURN CARE RES, V30, P599, DOI 10.1097/BCR.0b013e3181abff90; TOBIAS JD, 1995, ANESTH ANALG, V81, P496, DOI 10.1097/00000539-199509000-00012; Tobias JD, 2007, PEDIATR CRIT CARE ME, V8, P115, DOI 10.1097/01.PCC.0000257100.31779.41; Virtanen R., 1998, EUR J PHARMACOL, V150, P9; WATCHA MF, 1992, CAN J ANAESTH, V39, P649, DOI 10.1007/BF03008224; Yuen VM, 2012, ANAESTHESIA, V67, P1210, DOI 10.1111/j.1365-2044.2012.07309.x; Yuen VM, 2010, ANAESTHESIA, V65, P922, DOI 10.1111/j.1365-2044.2010.06453.x; Yuen VM, 2008, ANESTH ANALG, V106, P1715, DOI 10.1213/ane.0b013e31816c8929; Yuen VM, 2007, ANESTH ANALG, V105, P374, DOI 10.1213/01.ane.0000269488.06546.7c	28	7	7	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-5876	1872-8464		INT J PEDIATR OTORHI	Int. J. Pediatr. Otorhinolaryngol.	JUL	2014	78	7					1090	1094		10.1016/j.ijporl.2014.04.014			5	Otorhinolaryngology; Pediatrics	Otorhinolaryngology; Pediatrics	AK7KV	WOS:000338608100024	24814231	Green Accepted			2020-06-30	J	Hunseler, C; Balling, G; Rohlig, C; Blickheuser, R; Trieschmann, U; Lieser, U; Dohna-Schwake, C; Gebauer, C; Moller, O; Hering, F; Hoehn, T; Schubert, S; Hentschel, R; Huth, RG; Muller, A; Muller, C; Wassmer, G; Hahn, M; Harnischmacher, U; Behr, J; Roth, B				Huenseler, Christoph; Balling, Gunter; Roehlig, Christoph; Blickheuser, Rainer; Trieschmann, Uwe; Lieser, Ulla; Dohna-Schwake, Christian; Gebauer, Corinna; Moeller, Oliver; Hering, Fritz; Hoehn, Thomas; Schubert, Stephan; Hentschel, Roland; Huth, Ralf G.; Mueller, Andreas; Mueller, Carsten; Wassmer, Gernot; Hahn, Moritz; Harnischmacher, Urs; Behr, Julie; Roth, Bernhard		Clonidine Study Grp	Continuous Infusion of Clonidine in Ventilated Newborns and Infants: A Randomized Controlled Trial	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						analgesia; clonidine; infant; intravenous infusion; newborn; sedation	NEONATAL ABSTINENCE SYNDROME; CRITICALLY-ILL CHILDREN; INTENSIVE-CARE-UNIT; ORAL CLONIDINE; INTRAVENOUS CLONIDINE; PEDIATRIC-PATIENTS; MECHANICAL VENTILATION; POSTOPERATIVE PAIN; NORWOOD PROCEDURE; SEDATION	Objectives: To assess the influence of an infusion of clonidine 1 mu g/kg/hr on fentanyl and midazolam requirement in ventilated newborns and infants. Design: Prospective, double-blind, randomized controlled multicenter trial. Controlled trials. com/ISRCTN77772144. Setting: Twenty-eight level 3 German PICUs/neonatal ICUs. Patients: Ventilated newborns and infants: stratum I (1-28 d), stratum II, (29-120 d), and stratum III (121 d to 2 yr). Interventions: Patients received clonidine 1 mu g/kg/hr or placebo on day 4 after intubation. Fentanyl and midazolam were adjusted to achieve a defined level of analgesia and sedation according to Hartwig score. Measurements and Main Results: Two hundred nineteen infants were randomized; 212 received study medication, 69.7% were ventilated in the postoperative care and 30.3% for other reasons. Primary endpoint: consumption of fentanyl and midazolam in the 72 hours following the onset of study medication (main observation period) in the overall study population. The confirmatory analysis of the overall population showed no difference in the consumption of fentanyl and midazolam. Explorative age-stratified analysis demonstrated that in stratum I (n = 112) the clonidine group had a significantly lower consumption of fentanyl (clonidine: 2.1 +/- 1.8 mu g/kg/hr, placebo: 3.2 +/- 3.1 mu g/kg/hr; p = 0.032) and midazolam (clonidine: 113.0 +/- 100.1 mu g/kg/hr, placebo: 180.2 +/- 204.0 mu g/kg/hr; p = 0.030). Strata II (n = 43) and III (n = 46) showed no statistical difference. Sedation and withdrawal-scores were significantly lower in the clonidine group of stratum I (p < 0.001). Frequency of severe adverse events did not differ between groups. Conclusions: Clonidine 1 mu g/kg/hr in ventilated newborns reduced fentanyl and midazolam demand with deeper levels of analgesia and sedation without substantial side effects. This was not demonstrated in older infants, possibly due to lower clonidine serum levels.	[Huenseler, Christoph; Roth, Bernhard] Univ Cologne, Childrens Hosp, Dept Neonatol & Pediat Intens Care, D-50931 Cologne, Germany; [Balling, Gunter; Roehlig, Christoph] TUM, Dept Pediat Cardiol & Congenital Heart Dis, German Heart Ctr Munich, Munich, Germany; [Blickheuser, Rainer] DRK Childrens Hosp, Dept Pediat Anesthesia, Siegen, Germany; [Trieschmann, Uwe] Univ Cologne, Dept Anaesthesiol & Postoperat Intens Care Med, D-50931 Cologne, Germany; [Lieser, Ulla] Univ Hosp Halle, Dept Neonatol, Halle, Germany; [Dohna-Schwake, Christian] Univ Essen Gesamthsch, Childrens Hosp, Dept Pediat Intens Care, Essen, Germany; [Gebauer, Corinna] Hosp Univ Leipzig, Dept Pediat, Leipzig, Germany; [Moeller, Oliver] Univ Gottingen, Dept Pediat 3, D-37073 Gottingen, Germany; [Hering, Fritz] City Cologne, Childrens Hosp, Dept Pediat Anaesthesia, Cologne, Germany; [Hoehn, Thomas] Univ Dusseldorf, Dept Pediat Neonatol & Intens Care, Dusseldorf, Germany; [Schubert, Stephan] German Heart Ctr Berlin, Dept Pediat Cardiol, Berlin, Germany; [Hentschel, Roland] Hosp Univ Freiburg, Dept Pediat, Freiburg, Germany; [Huth, Ralf G.] Johannes Gutenberg Univ Mainz, Dept Pediat, Mainz, Germany; [Mueller, Andreas] Univ Hosp Bonn, Dept Neonatol, Bonn, Germany; [Mueller, Carsten] Univ Cologne, Inst Pharmacol, Dept Therapeut Drug Monitoring, D-50931 Cologne, Germany; [Wassmer, Gernot; Hahn, Moritz] Univ Cologne, Inst Med Stat Informat & Epidemiol, D-50931 Cologne, Germany; [Harnischmacher, Urs; Behr, Julie] Univ Cologne, Ctr Clin Studies, D-50931 Cologne, Germany	Hunseler, C (reprint author), Univ Cologne, Childrens Hosp, Kerpener Str 62, D-50931 Cologne, Germany.	christoph.huenseler@uk-koeln.de	Schubert, Stephan/K-1490-2019	Trieschmann, Uwe/0000-0003-2529-9005	German Ministry of Education and Research (BMBF)Federal Ministry of Education & Research (BMBF) [01KN1106]; Koln Fortune Program of the Medical Faculty of the University of Cologne; Boehringer Ingelheim, Ingelheim, GermanyBoehringer Ingelheim; Germany Ministry of Education and Research; Boehringer Ingleheim; NovartisNovartis	Supported, in part, by German Ministry of Education and Research (BMBF), Koln Fortune Program of the Medical Faculty of the University of Cologne, and Boehringer Ingelheim, Ingelheim, Germany.; Dr. Hunseler's institution received grant support, support for travel, support for participation in review activities, and provision of assistance/equipment/administrative support from the Germany Ministry of Education and Research, Koln Fortune Program of the Medical Faculty of the University of Cologne, and Boehringer Ingleheim. Dr. Blickheuser received support for travel. His institution received grant support (Stephanie Wied). Dr. Lieser received support for travel from Fahrtkosten fur Studientreffen erhalten. Dr. Dohna-Schwake's institution received a consulting fee/honorarium. Dr. Hering consulted for and received support for travel from Studienleitung. Dr. Hoehn's institution received a consulting fee/honorarium. Dr. Schubert received grant support from and lectured for Novartis. Dr. Hentschel received support for travel to investigator meetings, disclosed receiving other support (fee per included case), and employed by the University Children's Hospital Freiburg. Dr. Wassmer disclosed past employment with the Institute for Medical Statistics. Dr. Behr received support for travel from the University of Cologne. Dr. Roth received support for travel. His institution received grant support. Dr. Harnischmacher received grant support from the German Ministry of Education and Research, Koln Fortune Program of the Medical Faculty of the University of Cologne, and Boehringer Ingleheim (Ingleheim, Germany) and received support for article research (CTCC is supported by the German Ministry of Education and Research - BMBF grant 01KN1106). The remaining authors have disclosed that they do not have any potential conflicts of interest.	Agthe AG, 2009, PEDIATRICS, V123, pE849, DOI 10.1542/peds.2008-0978; Algra SO, 2011, NETH HEART J, V19, P369, DOI 10.1007/s12471-011-0171-8; Ambrose C, 2000, BRIT J ANAESTH, V84, P794; Anand KJS, 2013, PEDIATR CRIT CARE ME, V14, P27, DOI 10.1097/PCC.0b013e318253c80e; Anand KJS, 2010, PEDIATRICS, V125, pE1208, DOI 10.1542/peds.2009-0489; Aranda JV, 2005, CLIN THER, V27, P877, DOI 10.1016/j.clinthera.2005.06.019; Arenas-Lopez S, 2004, INTENS CARE MED, V30, P1625, DOI 10.1007/s00134-004-2319-0; Aretz S, 2004, BIOL NEONATE, V85, P243, DOI 10.1159/000076238; Batra YK, 2010, PEDIATR ANESTH, V20, P625, DOI 10.1111/j.1460-9592.2010.03326.x; Bergendahl HTG, 1997, ACTA ANAESTH SCAND, V41, P381, DOI 10.1111/j.1399-6576.1997.tb04703.x; Dahmani S, 2010, ACTA ANAESTH SCAND, V54, P397, DOI 10.1111/j.1399-6576.2009.02207.x; DAVIES DS, 1977, CLIN PHARMACOL THER, V21, P593; Dominguez KD, 2003, ANN PHARMACOTHER, V37, P473, DOI 10.1345/aph.1C324; FARRINGTON CP, 1990, STAT MED, V9, P1447, DOI 10.1002/sim.4780091208; FINNEGAN LP, 1975, ADDICT DIS, V2, P141; Franck LS, 2008, PEDIATR CRIT CARE ME, V9, P573, DOI 10.1097/PCC.0b013e31818c8328; Gamble C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051787; HARTWIG S, 1991, EUR J PEDIATR, V150, P784, DOI 10.1007/BF02026712; Hunseler C, 2011, EUR J PEDIATR, V170, P837, DOI 10.1007/s00431-010-1354-9; Ista E, 2009, INTENS CARE MED, V35, P1075, DOI 10.1007/s00134-009-1487-3; Karamichalis JM, 2011, ANN THORAC SURG, V92, P660, DOI 10.1016/j.athoracsur.2011.03.086; Lehmacher W, 1999, BIOMETRICS, V55, P1286, DOI 10.1111/j.0006-341X.1999.01286.x; Lowery R, 2005, PEDIATR ANESTH, V15, P694, DOI 10.1111/j.1460-9592.2004.01515.x; MARCUS R, 1976, BIOMETRIKA, V63, P655, DOI 10.1093/biomet/63.3.655; Mikawa K, 1996, ANESTH ANALG, V82, P225, DOI 10.1097/00000539-199602000-00001; Miranda DR, 1996, CRIT CARE MED, V24, P64, DOI 10.1097/00003246-199601000-00012; Muller C, 2007, J CHROMATOGR A, V1139, P221, DOI 10.1016/j.chroma.2006.11.020; Nishina K, 1997, ANESTHESIOLOGY, V87, P1324, DOI 10.1097/00000542-199712000-00010; Nishina K, 1996, ACTA ANAESTH SCAND, V40, P746, DOI 10.1111/j.1399-6576.1996.tb04522.x; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Pichot C, J INTENSIVE CARE MED, V27, P219; Pichot C, 2012, J INTENSIVE CARE MED; Playfor S, 2006, INTENS CARE MED, V32, P1125, DOI 10.1007/s00134-006-0190-x; Pohl-Schickinger A, 2008, PEDIATR ANESTH, V18, P217, DOI 10.1111/j.1460-9592.2008.02413.x; Potts AL, 2007, PEDIATR ANESTH, V17, P924, DOI 10.1111/j.1460-9592.2007.02251.x; Shi SS, 2008, CHEST, V134, P768, DOI 10.1378/chest.07-2573; Tobias JD, 2000, CRIT CARE MED, V28, P2122, DOI 10.1097/00003246-200006000-00079; van Dijk M, 2000, PAIN, V84, P367, DOI 10.1016/S0304-3959(99)00239-0; Vetter TR, 2007, ANESTH ANALG, V104, P1356, DOI 10.1213/01.ane.0000261521.52562.de; Voituron N, 2012, RESP PHYSIOL NEUROBI, V180, P132, DOI 10.1016/j.resp.2011.11.003; WING LMH, 1977, EUR J CLIN PHARMACOL, V12, P463, DOI 10.1007/BF00561067; Xie HG, 2011, J CLIN PHARMACOL, V51, P502, DOI 10.1177/0091270010370587	43	33	33	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JUL	2014	15	6					511	522		10.1097/PCC.0000000000000151			12	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	AK8WK	WOS:000338709100007	24751788				2020-06-30	J	Colton, K; Yang, SM; Hu, PF; Chen, HH; Bonds, B; Scalea, TM; Stein, DM				Colton, Katharine; Yang, Shiming; Hu, Peter F.; Chen, Hegang H.; Bonds, Brandon; Scalea, Thomas M.; Stein, Deborah M.			Intracranial pressure response after pharmacologic treatment of intracranial hypertension	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; secondary insults; intracranial pressure; critical care documentation; automated documentation	7.2-PERCENT HYPERTONIC SALINE; CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; INTENSIVE-CARE; MANNITOL; PROPOFOL; FENTANYL; SUFENTANIL; METABOLISM; SEDATION	BACKGROUND: The accepted treatment of increased intracranial pressure (ICP) in patients experiencing severe traumatic brain injury is multimodal and algorithmic, obscuring individual effects of treatment. Using continuous vital signs monitoring, we sought to measure treatment effect and ascertain the accuracy of manual data recording. METHODS: Patients older than 17 years, admitted and requiring ICP monitoring between 2008 and 2010 at a high-volume urban trauma center, were retrospectively evaluated. Timing and dose of ICP-directed therapy were recorded from paper and electronic medical records. ICP data were collected automatically at 6-second intervals and from manual charts. A statistical mixed model was applied to all data to account for multiple sampling. RESULTS: A total of 117 patients met inclusion criteria; 450 treatments were administered when nursing records indicate an ICP greater than 20 mm Hg, While 968 treatments were given when ICP was greater than 20 mm Hg by automated data. Pharmacologic treatments identified include hypertonic saline (HTS), mannitol, barbiturates, and dose escalations of propofol or fentanyl infusions. Treatment with HTS resulted in the largest ICP decrease of the treatments examined, with a 1-hour ICP reduction of 8.8/9.9 mm Hg (for a small/large dose) according to manual data and a reduction of 3.0/2.4 mm Hg according to automated data. Propofol and fentanyl escalations resulted in smaller but significant ICP reductions. Mannitol (n = 8) resulted in statistically insignificant trends down in the first hour but rebounded by the second hour after administration. The average ICP in the hour before medication administration was higher for barbiturates (27 mm Hg) and mannitol (32 mm Hg) than for the other interventions (18-19 mm Hg). CONCLUSION: ICP fell after administration of HTS, mannitol, or barbiturates and showed continued improvement after 2 hours. ICP fell initially after treatment with short-acting propofol and fentanyl but trended back up after 2 hours. Manually recorded data consistently overestimated treatment effectiveness. Automated data collection gives a more accurate assessment of patient status and responsiveness to treatment. Copyright (C) 2014 by Lippincott Williams & Wilkins	[Colton, Katharine; Yang, Shiming; Hu, Peter F.; Chen, Hegang H.; Bonds, Brandon; Scalea, Thomas M.; Stein, Deborah M.] Univ Maryland, Sch Med, Shock Trauma Anesthesia Res Organized Res Ctr, Baltimore, MD USA; [Colton, Katharine; Yang, Shiming; Hu, Peter F.; Chen, Hegang H.; Bonds, Brandon; Scalea, Thomas M.; Stein, Deborah M.] R Adams Cowley Shock Trauma Ctr, Baltimore, MD USA; [Colton, Katharine] Duke Univ, Sch Med, Durham, NC USA	Colton, K (reprint author), Duke Univ, Sch Med, 804 Remington Circle, Durham, NC 27705 USA.	krcolton@gmail.com	Yang, Shiming/I-3695-2015	Yang, Shiming/0000-0003-0338-4268; Stein, Deborah/0000-0003-3683-3963	 [FA8650-11-2-6D06];  [FA8650-12-2-6D09];  [FA8650-13-2-6D15]	This study was funded in part by the grants FA8650-11-2-6D06, FA8650-12-2-6D09, and FA8650-13-2-6D15.	Albanese J, 1999, CRIT CARE MED, V27, P407, DOI 10.1097/00003246-199902000-00050; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Becker DP, 1972, INTRACRANIAL PRESSUR, P309; Brain Trauma Foundation American Association of Neurological Surgeons Congress of Neurological Surgeons, 2008, J NEUROTRAUM, V25, P276; Bratton S.L., 2007, J NEUROTRAUMA S1, V24, pS55, DOI DOI 10.1089/NEU.2007.9988; Cottenceau V, 2011, J NEUROTRAUM, V28, P2003, DOI 10.1089/neu.2011.1929; de Nadal M, 2000, ANESTHESIOLOGY, V92, P11, DOI 10.1097/00000542-200001000-00008; FARLING PA, 1989, ANAESTHESIA, V44, P222, DOI 10.1111/j.1365-2044.1989.tb11228.x; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gugerty B, 2007, CHALLENGES OPPORTUNI; Hartl R, 1997, J TRAUMA, V42, pS41, DOI 10.1097/00005373-199705001-00008; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Hravnak M, 2008, ARCH INTERN MED, V168, P1300, DOI 10.1001/archinte.168.12.1300; Hravnak M, 2011, CRIT CARE MED, V39, P65, DOI 10.1097/CCM.0b013e3181fb7b1c; Kahraman S, 2011, J TRAUMA, V70, P547, DOI 10.1097/TA.0b013e31820c768a; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; Lauer KK, 1997, CAN J ANAESTH, V44, P929, DOI 10.1007/BF03011963; LOUGHHEAD MG, 1988, MED J AUSTRALIA, V148, P458, DOI 10.5694/j.1326-5377.1988.tb139571.x; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MCGRAW CP, 1983, NEUROSURGERY, V13, P269, DOI 10.1227/00006123-198309000-00009; Mulligan Alison, 2010, Intensive Crit Care Nurs, V26, P196, DOI 10.1016/j.iccn.2010.03.002; Munar F, 2000, J NEUROTRAUM, V17, P41, DOI 10.1089/neu.2000.17.41; PINAUD M, 1990, ANESTHESIOLOGY, V73, P404, DOI 10.1097/00000542-199009000-00007; Schatzmann C, 1998, ACT NEUR S, V71, P31; Schrot RJ, 2002, LANCET, V359, P1633, DOI 10.1016/S0140-6736(02)08545-8; SPERRY RJ, 1992, ANESTHESIOLOGY, V77, P416, DOI 10.1097/00000542-199209000-00002; Subbe CP, 2007, INTENS CARE MED, V33, P619, DOI 10.1007/s00134-006-0516-8; The Brain Trauma Foundation The American Association of Neurological Surgeons The Joint Section on Neurotrauma and Critical Care, 2000, J NEUROTRAUM, V17, P537; Turner H B, 1988, J Neurosci Nurs, V20, P236; Venkatesh B, 2004, INTENS CARE MED, V30, P510, DOI 10.1007/s00134-003-2102-7; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; WHITE PF, 1982, ANESTHESIOLOGY, V57, P242, DOI 10.1097/00000542-198209000-00019; Wilson SJ, 2013, EMERG MED J, V30, P186, DOI 10.1136/emermed-2011-200499; Zanier ER, 2007, CRIT CARE, V11, DOI 10.1186/cc5155; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021	38	17	19	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2014	77	1					47	53		10.1097/TA.0000000000000270			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AK4IY	WOS:000338389600012	24977754				2020-06-30	J	Neto, AS; Simonis, FD; Barbas, CSV; Biehl, M; Determann, RM; Elmer, J; Friedman, G; Gajic, O; Goldstein, JN; Horn, J; Juffermans, NP; Linko, R; de Oliveira, RP; Sundar, S; Talmor, D; Wolthuis, EK; de Abreu, MG; Pelosi, P; Schultz, MJ				Serpa Neto, Ary; Simonis, Fabienne D.; Barbas, Carmen S. V.; Biehl, Michelle; Determann, Rogier M.; Elmer, Jonathan; Friedman, Gilberto; Gajic, Ognjen; Goldstein, Joshua N.; Horn, Janneke; Juffermans, Nicole P.; Linko, Rita; de Oliveira, Roselaine Pinheiro; Sundar, Sugantha; Talmor, Daniel; Wolthuis, Esther K.; de Abreu, Marcelo Gama; Pelosi, Paolo; Schultz, Marcus J.			Association between tidal volume size, duration of ventilation, and sedation needs in patients without acute respiratory distress syndrome: an individual patient data meta-analysis	INTENSIVE CARE MEDICINE			English	Article						Mechanical ventilation; Sedation; Analgesia; Meta-analysis	CRITICALLY-ILL PATIENTS; ACUTE LUNG INJURY; MECHANICAL VENTILATION; OUTCOMES; DELIRIUM; ICU	Mechanical ventilation with lower tidal volumes (a parts per thousand currency sign6 ml/kg of predicted body weight, PBW) could benefit patients without acute respiratory distress syndrome (ARDS). However, tidal volume reduction could be associated with increased patient discomfort and sedation needs, and consequent longer duration of ventilation. The aim of this individual patient data meta-analysis was to assess the associations between tidal volume size, duration of mechanical ventilation, and sedation needs in patients without ARDS. Studies comparing ventilation with different tidal volume sizes in patients without ARDS were screened for inclusion. Corresponding authors were asked to provide individual participant data. Patients were assigned to three groups based on tidal volume size (a parts per thousand currency sign6 ml/kg PBW, 6-10 ml/kg PBW, or a parts per thousand yen10 ml/kg PBW). Ventilator-free days, alive at day 28, and dose and duration of sedation (propofol and midazolam), analgesia (fentanyl and morphine), and neuromuscular blockade (NMB) were compared. Seven investigations (2,184 patients) were included in the analysis. The number of patients breathing without assistance by day 28 was higher in the group ventilated with tidal volume a parts per thousand currency sign6 ml/kg PBW compared to those ventilated with tidal volume a parts per thousand yen10 ml/kg PBW (93.1 vs. 88.6 %; p = 0.027, respectively). Only two investigations (187 patients) could be included in the meta-analysis of sedation needs. There were neither differences in the percentage of study days that patients received sedatives, opioids, or NMBA nor in the total dose of benzodiazepines, propofol, opioids, and NMBA. This meta-analysis suggests that use of lower tidal volumes in patients without ARDS at the onset of mechanical ventilation could be associated with shorter duration of ventilation. Use of lower tidal volumes seems not to affect sedation or analgesia needs, but this must be confirmed in a robust, well-powered randomized controlled trial.	[Serpa Neto, Ary; Simonis, Fabienne D.; Barbas, Carmen S. V.; Determann, Rogier M.; Horn, Janneke; Juffermans, Nicole P.; Wolthuis, Esther K.; Schultz, Marcus J.] Univ Amsterdam, Acad Med Ctr, Dept Intens Care, NL-1105 AZ Amsterdam, Netherlands; [Serpa Neto, Ary] ABC Med Sch FMABC, Med Intens Care Unit, Santo Andre, Brazil; [Serpa Neto, Ary] Hosp Israelita Albert Einstein, Dept Crit Care Med, Sao Paulo, Brazil; [Biehl, Michelle; Gajic, Ognjen] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN USA; [Elmer, Jonathan; Goldstein, Joshua N.] Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Pittsburgh, PA USA; [Friedman, Gilberto] Univ Fed Rio Grande do Sul, Sch Med, Porto Alegre, RS, Brazil; [Linko, Rita] Helsinki Univ Hosp, Dept Anaesthesia & Intens Care Med, Vantaa, Finland; [de Oliveira, Roselaine Pinheiro] Univ Fed Ciencias Saude Porto Alegre, Sch Med, Porto Alegre, RS, Brazil; [Sundar, Sugantha; Talmor, Daniel] Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02215 USA; [Sundar, Sugantha; Talmor, Daniel] Harvard Univ, Sch Med, Boston, MA USA; [de Abreu, Marcelo Gama] Univ Hosp Carl Gustav Carus, Dept Anesthesiol & Intens Care Med, Dresden, Germany; [Pelosi, Paolo] Univ Genoa, IRCCS San Martino IST, Dept Surg Sci & Integrated Diagnost, Genoa, Italy; [Schultz, Marcus J.] Univ Amsterdam, Acad Med Ctr, Lab Expt Intens Care & Anesthesiol, NL-1105 AZ Amsterdam, Netherlands	Neto, AS (reprint author), Hosp Israelita Albert Einstein, Dept Crit Care Med, Albert Einstein Ave 700, Sao Paulo, Brazil.	aryserpa@terra.com.br	Barbas, Carmen Silvia Valente/H-1048-2013; Friedman, Gilberto/F-7208-2015; Friedman, Gilberto/F-7212-2015; Goldstein, Joshua N/H-8953-2016; Neto, Ary Serpa/D-1927-2012	Barbas, Carmen Silvia Valente/0000-0002-3922-6256; Friedman, Gilberto/0000-0001-9369-2488; Neto, Ary Serpa/0000-0003-1520-9387; Pelosi, Paolo/0000-0001-5055-3023			Antonelli M, 2013, INTENS CARE MED, V39, P543, DOI 10.1007/s00134-012-2807-6; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Brummel NE, 2014, INTENS CARE MED, V40, P370, DOI 10.1007/s00134-013-3136-0; Cheng IW, 2005, CRIT CARE MED, V33, P63, DOI 10.1097/01.CCM.0000149836.76063.71; de Oliveira RP, 2010, CRIT CARE, V14, DOI 10.1186/cc8919; Determann RM, 2010, CRIT CARE, V14, DOI 10.1186/cc8230; Elmer J, 2013, CRIT CARE MED, V41, P1992, DOI 10.1097/CCM.0b013e31828a3f4d; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Ferguson ND, 2012, JAMA-J AM MED ASSOC, V308, P1689, DOI 10.1001/jama.2012.14509; Haenggi M, 2013, INTENS CARE MED, V39, P2171, DOI 10.1007/s00134-013-3034-5; Kahn JM, 2005, CRIT CARE MED, V33, P766, DOI 10.1097/01.CCM.0000157786.41506.24; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; LEE PC, 1990, CHEST, V97, P430, DOI 10.1378/chest.97.2.430; Linko R, 2009, INTENS CARE MED, V35, P1352, DOI 10.1007/s00134-009-1519-z; Neto AS, 2012, JAMA-J AM MED ASSOC, V308, P1651, DOI 10.1001/jama.2012.13730; Putensen C, 2009, ANN INTERN MED, V151, P566, DOI 10.7326/0003-4819-151-8-200910200-00011; REISINE T, 1996, [No title captured], P521; Neto AS, 2014, CURR OPIN CRIT CARE, V20, P25, DOI 10.1097/MCC.0000000000000044; Sharshar T, 2014, INTENS CARE MED, V40, P484, DOI 10.1007/s00134-014-3214-y; Shehabi Y, 2013, INTENS CARE MED, V39, P910, DOI 10.1007/s00134-013-2830-2; Sundar S, 2011, ANESTHESIOLOGY, V114, P1102, DOI 10.1097/ALN.0b013e318215e254; Vinayak AG, 2006, CRIT CARE MED, V34, P1668, DOI 10.1097/01.CCM.0000218412.86977.40; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949; Wolthuis EK, 2007, CRIT CARE, V11, DOI 10.1186/cc5969; Yilmaz M, 2007, CRIT CARE MED, V35, P1660, DOI 10.1097/01.CCM.0000269037.66955.F0	26	63	67	0	19	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	JUL	2014	40	7					950	957		10.1007/s00134-014-3318-4			8	Critical Care Medicine	General & Internal Medicine	AK1UI	WOS:000338202000004	24811940				2020-06-30	J	Shaner, RL; Kaplan, P; Hamelin, EI; Bragg, WA; Johnson, RC				Shaner, Rebecca L.; Kaplan, Pearl; Hamelin, Elizabeth I.; Bragg, William A.; Johnson, Rudolph C.			Comparison of two automated solid phase extractions for the detection of ten fentanyl analogs and metabolites in human urine using liquid chromatography tandem mass spectrometry	JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES			English	Article						Fentanyls; Fentanyl; Solid phase extraction; Liquid chromatography; Mass spectrometry; Method development; Automation	SIMULTANEOUS QUANTIFICATION; MAJOR METABOLITES; PLASMA; DRUG; SPE; CARFENTANIL; SUFENTANIL	Two types of automated solid phase extraction (SPE) were assessed for the determination of human exposure to fentanyls in urine. High sensitivity is required to detect these compounds following exposure because of the low dose required for therapeutic effect and the rapid clearance from the body for these compounds. To achieve this sensitivity, two acceptable methods for the detection of human exposure to seven fentanyl analogs and three metabolites were developed using either off-line 96-well plate SPE or on-line SPE. Each system offers different advantages: off-line 96-well plate SPE allows for high throughput analysis of many samples, which is needed for large sample numbers, while on-line SPE removes almost all analyst manipulation of the samples, minimizing the analyst time needed for sample preparation. Both sample preparations were coupled with reversed phase liquid chromatography and isotope dilution tandem mass spectrometry (LC-MS/MS) for analyte detection. For both methods, the resulting precision was within 15%, the accuracy within 25%, and the sensitivity was comparable with the limits of detection ranging from 0.002 ng/mL to 0.041 ng/mL. Additionally, matrix effects were substantially decreased from previous reports for both extraction protocols. The results of this comparison showed that both methods were acceptable for the detection of exposures to fentanyl analogs and metabolites in urine. Published by Elsevier B.V.	[Shaner, Rebecca L.; Hamelin, Elizabeth I.; Bragg, William A.; Johnson, Rudolph C.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA; [Kaplan, Pearl] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA	Johnson, RC (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,MS F44, Atlanta, GA 30341 USA.	rmj6@cdc.gov		Shaner, Rebecca/0000-0002-5257-1329	Intramural CDC HHS [CC999999]		Allanson JP, 1996, RAPID COMMUN MASS SP, V10, P811, DOI 10.1002/(SICI)1097-0231(199605)10:7<811::AID-RCM561>3.0.CO;2-Q; AYRES WA, 1981, J PSYCHOACTIVE DRUGS, V13, P91, DOI 10.1080/02791072.1981.10471455; Bonfiglio R, 1999, RAPID COMMUN MASS SP, V13, P1175, DOI 10.1002/(SICI)1097-0231(19990630)13:12<1175::AID-RCM639>3.0.CO;2-0; Cooreman S, 2010, J SEP SCI, V33, P2654, DOI 10.1002/jssc.201000330; de Boer T, 2012, BIOMED CHROMATOGR, V26, P1461, DOI 10.1002/bmc.2722; Ghassabian S, 2012, J CHROMATOGR B, V903, P126, DOI 10.1016/j.jchromb.2012.07.005; Harrison AC, 1998, J PHARMACEUT BIOMED, V16, P777, DOI 10.1016/S0731-7085(97)00110-6; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Jagerdeo E, 2008, J CHROMATOGR B, V874, P15, DOI 10.1016/j.jchromb.2008.08.026; KRAM TC, 1981, ANAL CHEM, V53, P1379, DOI 10.1021/ac00235a003; Meert TF, 1996, PHARM WORLD SCI, V18, P1, DOI 10.1007/BF00449683; Nadine H.A.F.V., 2004, J CHROMATOGR A, V1035, P249; National Research Council Chemical and Biological Terrorism, 1999, CHEM BIOL TERR RES D; Poklis A., 1995, CLIN TOXICOL, V33, P439; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; Shou WZ, 2001, RAPID COMMUN MASS SP, V15, P466, DOI 10.1002/rcm.255; SILVERSTEIN JH, 1993, ANESTH ANALG, V76, P618; Simpson H, 1998, RAPID COMMUN MASS SP, V12, P75, DOI 10.1002/(SICI)1097-0231(19980131)12:2<75::AID-RCM112>3.0.CO;2-C; Skulska Agnieszka, 2005, Przegl Lek, V62, P581; Snyder ML, 2011, CLIN CHIM ACTA, V412, P946, DOI 10.1016/j.cca.2011.01.029; Strano-Rossi S, 2011, J APPL TOXICOL, V31, P649, DOI 10.1002/jat.1613; Taylor J. K., 1987, QUALITY ASSURANCE CH; Valaer AK, 1997, J CHROMATOGR SCI, V35, P461, DOI 10.1093/chromsci/35.10.461; Wang GH, 2011, FORENSIC SCI INT, V206, P127, DOI 10.1016/j.forsciint.2010.07.022; Wang LQ, 2006, J ANAL TOXICOL, V30, P335, DOI 10.1093/jat/30.5.335; Wang Y, 2012, BIOANALYSIS, V4, P2141, DOI 10.4155/BIO.12.184; Zhang HW, 1999, ANAL CHEM, V71, P3955, DOI 10.1021/ac990162h	29	14	15	2	49	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1570-0232	1873-376X		J CHROMATOGR B	J. Chromatogr. B	JUL 1	2014	962						52	58		10.1016/j.jchromb.2014.05.025			7	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	AK4PO	WOS:000338406800008	24893271	Green Accepted			2020-06-30	J	Abrisham, SMJ; Ghahramani, R; Heiranizadeh, N; Kermani-Alghoraishi, M; Ayatollahi, V; Pahlavanhosseini, H				Abrisham, Seyyed Mohammad Jalil; Ghahramani, Rahil; Heiranizadeh, Najmeh; Kermani-Alghoraishi, Mohammad; Ayatollahi, Vida; Pahlavanhosseini, Hamid			Reduced morphine consumption and pain severity with transdermal fentanyl patches following total knee arthroplasty	KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY			English	Article						Transdermal fentanyl patch; Patient control analgesia; Morphine; Postoperative analgesia	POSTOPERATIVE PAIN; DOUBLE-BLIND; CONTROLLED-TRIAL; ANALGESIA; INFILTRATION; MANAGEMENT; SYSTEM	To determine the effects of transdermal fentanyl patches (TFPs) for postoperative analgesia in patients undergoing total knee arthroplasty (TKA) surgery. A randomized, double-blind, controlled trial study of 40 ASA I-III patients undergoing TKA surgery was performed under general anaesthesia. Patients were randomly divided into two groups. Group I (n = 20) received two 25 mu g TFPs placed on the laterals of chest wall approximately 12 h before induction of general anaesthesia. Group II, the control group (n = 20), received placebo patches of identical size. Postoperative pain at rest was assessed with visual analogue scale (VAS) at 0, 30 min and 2, 4, 6, 12, 24, 48 and 72 h. Total rescue consumption of morphine was estimated with patient control analgesia during the first 72 h after operation. The degree of active knee flexion and incidence of side effects were also evaluated. The VAS scores at 2, 4, 6, 12, 24, 48 and 72 h were significantly less in the group I compared to the group II (p < 0.05). Total morphine consumption was significantly less in group I than in group II (p < 0.05). No significant differences were found between the groups in the postoperative active knee flexion (n.s.). Side effects were similar between the groups. Transdermal fentanyl patches provide effective pain relief and decrease total rescue morphine consumption during the first 72 h after operation without additive side effects in patients undergoing TKA surgery. I.	[Abrisham, Seyyed Mohammad Jalil; Pahlavanhosseini, Hamid] Shahid Sadoughi Univ Med Sci, Dept Orthoped, Safaeeie, Yazd, Iran; [Ghahramani, Rahil] Shahid Sadoughi Univ Med Sci, Student Res Comm, Shahid Sadoughi Hosp, Safaeeie, Yazd, Iran; [Heiranizadeh, Najmeh; Ayatollahi, Vida] Shahid Sadoughi Univ Med Sci, Dept Anesthesiol, Safaeeie, Yazd, Iran; [Kermani-Alghoraishi, Mohammad] Isfahan Univ Med Sci, Dept Cardiol, Esfahan, Iran	Ghahramani, R (reprint author), Shahid Sadoughi Univ Med Sci, Student Res Comm, Shahid Sadoughi Hosp, Ebne Sina Blvd,Shahid Ghandi Blvd, Safaeeie, Yazd, Iran.	rahil.ghahramani@gmail.com	jarahzadeh, Mohammad Hossein/S-6882-2017; pahlavanhosseini, hamid/R-7309-2017; abrisham, seyed mohammad jalil/G-1128-2017	jarahzadeh, Mohammad Hossein/0000-0002-4511-3389; pahlavanhosseini, hamid/0000-0001-5833-9902; abrisham, seyed mohammad jalil/0000-0002-9742-1762; Kermani-Alghoraishi, Mohammad/0000-0003-1215-4077; Kermani-Alghoraishi, Mohammad/0000-0002-3701-3572			Amr SA, 2012, J AM SCI, V8, P417; Andersen KV, 2010, ACTA ORTHOP, V81, P606, DOI 10.3109/17453674.2010.519165; Barrera E, 2009, EUR J PAIN, V13, pS191; BONICA JJ, 1990, MANAGEMENT PAIN, V1, P461; CAPLAN RA, 1989, JAMA-J AM MED ASSOC, V261, P1036, DOI 10.1001/jama.261.7.1036; Carli F, 2010, BRIT J ANAESTH, V105, P185, DOI 10.1093/bja/aeq112; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; Fischer HBJ, 2008, ANAESTHESIA, V63, P1105, DOI 10.1111/j.1365-2044.2008.05565.x; Fu PL, 2009, KNEE, V16, P280, DOI 10.1016/j.knee.2008.12.012; Fukuda K, 2010, MILLERS ANESTHESIA, P769; Gourlay G K, 2001, Lancet Oncol, V2, P165, DOI 10.1016/S1470-2045(00)00258-8; GOURLAY GK, 1989, PAIN, V37, P193, DOI 10.1016/0304-3959(89)90130-9; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Horlocker TT, 2002, REGION ANESTH PAIN M, V27, P105, DOI 10.1053/rapm.2002.27177; Lauretti Gabriela Rocha, 2009, Coluna/Columna, V8, P412, DOI 10.1590/S1808-18512009000400012; Lehmann LJ, 1997, REGION ANESTH, V22, P24, DOI 10.1016/S1098-7339(06)80052-0; Lombardi AV, 2004, CLIN ORTHOP RELAT R, P125, DOI 10.1097/01.blo.000147701.24029.cc; Maheshwari AV, 2009, CLIN ORTHOP RELAT R, V467, P1418, DOI 10.1007/s11999-009-0728-7; MIGUEL R, 1995, ANESTHESIOLOGY, V83, P470, DOI 10.1097/00000542-199509000-00005; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Parvataneni Hari K, 2007, Instr Course Lect, V56, P125; Pechevis M, 2000, LETT PHARM, V14, P10; SANDLER AN, 1994, ANESTHESIOLOGY, V81, P1169, DOI 10.1097/00000542-199411000-00010; SEVARINO FB, 1992, ANESTHESIOLOGY, V77, P463, DOI 10.1097/00000542-199209000-00010; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; VANBASTELAERE M, 1995, J CLIN ANESTH, V7, P26, DOI 10.1016/0952-8180(94)00000-T; WEWERS ME, 1990, RES NURS HEALTH, V13, P227, DOI 10.1002/nur.4770130405	27	8	8	0	8	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0942-2056	1433-7347		KNEE SURG SPORT TR A	Knee Surg. Sports Traumatol. Arthrosc.	JUL	2014	22	7					1580	1584		10.1007/s00167-012-2287-9			5	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	AK1TZ	WOS:000338200800015	23212185				2020-06-30	J	Bjelland, TW; Klepstad, P; Haugen, BO; Nilsen, T; Salvesen, O; Dale, O				Bjelland, T. W.; Klepstad, P.; Haugen, B. O.; Nilsen, T.; Salvesen, O.; Dale, O.			Concentrations of remifentanil, propofol, fentanyl, and midazolam during rewarming from therapeutic hypothermia	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							EUROPEAN-RESUSCITATION-COUNCIL; CARDIAC-ARREST; PHARMACOKINETICS; DISPOSITION; GUIDELINES; BYPASS; BLOOD	Background The clearance of sedatives and analgesics may be reduced by therapeutic hypothermia. However, little is known about the concentrations of such drugs during rewarming. The aim of this study was to describe the serum concentrations of sedatives and analgesics during rewarming from therapeutic hypothermia. Methods Blood samples were collected for quantification of drug concentrations in 22 patients given analgesia/sedation with either remifentanil/propofol or fentanyl/midazolam during rewarming from therapeutic hypothermia (33-34 degrees C) after cardiac arrest. Samples for were drawn before (-2h) and during rewarming (0-8h). Linear mixed effects models were used to describe serum concentrations and adjust for rates of infusion during rewarming from therapeutic hypothermia. Results Subjects with samples analyzed were remifentanil (n=8), propofol (n=14), fentanyl (n=8), and midazolam (n=8). Age, body mass index, and simplified acute physiology score II [mean (standard deviation)] were 64 (14.2) years, 27.3 (3.7) kg/m2, and 69 (13.2), respectively. While the concentration of fentanyl was not significantly affected by temperature, concentrations of remifentanil, propofol, and midazolam decreased with core temperature by 16%, 12%, and 11% (mean values) from 33 degrees C to 37 degrees C after adjusting for rates of infusion, respectively. Conclusion Concentrations of remifentanil, propofol, and midazolam decreased during rewarming from therapeutic hypothermia when adjusting for rates of infusion. No changes were demonstrated for fentanyl.	[Bjelland, T. W.; Klepstad, P.; Haugen, B. O.; Nilsen, T.; Dale, O.] Norwegian Univ Sci & Technol NTNU, Fac Med, Dept Circulat & Med Imaging, Trondheim, Norway; [Salvesen, O.] Norwegian Univ Sci & Technol NTNU, Fac Med, Unit Appl Clin Res, Trondheim, Norway; [Klepstad, P.; Dale, O.] St Olavs Univ Hosp, Clin Anaesthesia & Intens Care, Trondheim, Norway; [Haugen, B. O.] St Olavs Univ Hosp, Clin Cardiol, Trondheim, Norway	Dale, O (reprint author), Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, N-7491 Trondheim, Norway.	ola.dale@ntnu.no			Norwegian University of Science and Technology; St. Olav's University Hospital; Royal Norwegian Society of Sciences and Letters	Funding: This study was funded by the Norwegian University of Science and Technology and St. Olav's University Hospital. A grant was received from the Royal Norwegian Society of Sciences and Letters.	Bastiaans DET, 2013, INT J CLIN PHARM-NET, V35, P210, DOI 10.1007/s11096-012-9725-0; Bender J, 1999, J PHARMACEUT BIOMED, V21, P559, DOI 10.1016/S0731-7085(99)00151-X; Bjelland TW, 2012, INTENS CARE MED, V38, P959, DOI 10.1007/s00134-012-2540-1; Bjelland TW, 2013, DRUG METAB DISPOS, V41, P214, DOI 10.1124/dmd.112.045567; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; Deakin CD, 2010, RESUSCITATION, V81, P1305, DOI 10.1016/j.resuscitation.2010.08.017; Fukuoka N, 2004, RESUSCITATION, V60, P225, DOI 10.1016/j.resuscitation.2003.09.017; GROSSE CM, 1994, J PHARMACEUT BIOMED, V12, P195, DOI 10.1016/0731-7085(94)90030-2; Hiraoka H, 2004, CLIN PHARMACOL THER, V75, P324, DOI 10.1016/j.clpt.2003.12.004; Hostler D, 2010, DRUG METAB DISPOS, V38, P781, DOI 10.1124/dmd.109.031377; JENNETT B, 1975, LANCET, V1, P480; KELSEY SF, 1986, AM J EMERG MED, V4, P72; KOREN G, 1987, EUR J CLIN PHARMACOL, V32, P373, DOI 10.1007/BF00543972; Kurita T, 2013, ACTA ANAESTH SCAND, V57, P754, DOI 10.1111/aas.12076; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LESLIE K, 1995, ANESTH ANALG, V80, P1007, DOI 10.1097/00000539-199505000-00027; Michelsen LG, 2001, ANESTH ANALG, V93, P1100, DOI 10.1097/00000539-200111000-00006; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; Russell D, 1997, BRIT J ANAESTH, V79, P456, DOI 10.1093/bja/79.4.456; RUSSELL GN, 1989, ANAESTHESIA, V44, P205, DOI 10.1111/j.1365-2044.1989.tb11223.x; van den Broek MPH, 2010, CLIN PHARMACOKINET, V49, P277, DOI 10.2165/11319360-000000000-00000	21	16	17	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JUL	2014	58	6					709	715		10.1111/aas.12300			7	Anesthesiology	Anesthesiology	AJ8PD	WOS:000337967300010	24611449				2020-06-30	J	Anaraki, AN; Mirzaei, K				Anaraki, Abdolreza Najafi; Mirzaei, Kamran			The effect of gabapentin versus intrathecal fentanyl on postoperative pain and morphine consumption in cesarean delivery: a prospective, randomized, double-blind study	ARCHIVES OF GYNECOLOGY AND OBSTETRICS			English	Article						Cesarean section; Gabapentin; Intrathecal fentanyl; Pain; Postoperative	PLACEBO; MANAGEMENT	Pain after cesarean delivery is a leading cause of chronic pain and there are many attempts to reduce it without total success. Gabapentin is effective in reducing acute and chronic pain with little experience in parturient. The purpose of this study is to compare the effect of pre-emptive gabapentin with intrathecal fentanyl on reducing postoperative pain and morphine consumption in cesarean surgery. Seventy-eight primiparous women who scheduled for non-emergency cesarean delivery were enrolled in the study and separated into two groups. The control group received 12.5 mg of heavy bupivacaine 0.5 % plus 10 mu g of fentanyl intrathecally and the case group received 300 mg of gabapentin orally 2 h before surgery and 12.5 mg of heavy bupivacaine 0.5 % intrathecally. Data collection including blood pressure, heart rate, neonate sedation, Apgar score, visual analogous scale at several hours, at first, need to analgesic postoperatively. In the fentanyl group, the need for analgesic drug was earlier, total dose of morphine in 24 h and patient satisfaction was higher than the gabapentin group. The mean visual analogous scale at several hours postoperatively in the fentanyl groups was significantly higher than the gabapentin groups (P = 0.001). Preemptive use of gabapentin is a safe and effective way to reduce postoperative pain and morphine consumption in parturients after cesarean surgery.	[Anaraki, Abdolreza Najafi] Bushehr Univ Med Sci, Dept Anaesthesiol & Intens Care Unit, Fac Med, Bushehr, Iran; [Mirzaei, Kamran] Bushehr Univ Med Sci, Dept Community Med, Fac Med, Bushehr, Iran	Mirzaei, K (reprint author), Bushehr Univ Med Sci, Dept Community Med, Fac Med, Bushehr, Iran.	kamran.mirzaei@yahoo.com	mirzaei, kamran/K-2419-2017	mirzaei, kamran/0000-0003-3551-1866; mirzaei, Kamran/0000-0003-0434-2852			Ajori L, 2012, ARCH GYNECOL OBSTET, V285, P677, DOI 10.1007/s00404-011-2023-6; CHANEY MA, 1995, CAN J ANAESTH, V42, P891, DOI 10.1007/BF03011037; Christensen M, 2008, AM J PREV MED, V35, P594, DOI 10.1016/j.amepre.2008.09.007; Dahlgren G, 1997, ANESTH ANALG, V85, P1288, DOI 10.1097/00000539-199712000-00020; Dirks J, 2002, ANESTHESIOLOGY, V97, P560, DOI 10.1097/00000542-200209000-00007; Eckhardt K, 2000, ANESTH ANALG, V91, P185, DOI 10.1097/00000539-200007000-00035; Eltzschig HK, 2003, NEW ENGL J MED, V348, P319, DOI 10.1056/NEJMra021276; ETCHES RC, 1989, CAN J ANAESTH, V36, P165, DOI 10.1007/BF03011441; Fukushima S, 2011, PAIN MED, V12, P717, DOI 10.1111/j.1526-4637.2011.01084.x; Halpern SH, 2001, REGION ANESTH PAIN M, V26, P298; Kainu JP, 2010, INT J OBSTET ANESTH, V19, P4, DOI 10.1016/j.ijoa.2009.03.013; Miovech S M, 1994, J Obstet Gynecol Neonatal Nurs, V23, P53, DOI 10.1111/j.1552-6909.1994.tb01850.x; Montouris G, 2003, EPILEPSY BEHAV, V4, P310, DOI 10.1016/S1525-5050(03)00110-0; Moore A, 2011, ANESTH ANALG, V112, P167, DOI 10.1213/ANE.0b013e3181fdf5ee; Ohman I, 2005, EPILEPSIA, V46, P1621, DOI 10.1111/j.1528-1167.2005.00251.x; Rorarius MGF, 2004, PAIN, V110, P175, DOI 10.1016/j.pain.2004.03.023; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Short J, 2012, ANESTH ANALG, V115, P1336, DOI 10.1213/ANE.0b013e31826ac3b9; WILSON E, 1990, BRIT J ANAESTH, V64, P48, DOI 10.1093/bja/64.1.48	19	6	6	0	7	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0932-0067	1432-0711		ARCH GYNECOL OBSTET	Arch. Gynecol. Obstet.	JUL	2014	290	1					47	52		10.1007/s00404-014-3152-5			6	Obstetrics & Gynecology	Obstetrics & Gynecology	AJ6GB	WOS:000337787600009	24518937	Green Accepted			2020-06-30	J	Perez-Protto, S; Geube, M; Ontaneda, D; Dalton, JE; Kurz, A; Sessler, DI				Perez-Protto, Silvia; Geube, Mariya; Ontaneda, Daniel; Dalton, Jarrod E.; Kurz, Andrea; Sessler, Daniel I.			Sensitivity to volatile anesthetics in patients with dementia: a case-control analysis	CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							MINIMUM ALVEOLAR CONCENTRATION; BISPECTRAL INDEX; NOXIOUS-STIMULATION; ISOFLURANE; PROPOFOL; ELECTROENCEPHALOGRAM; CONSCIOUSNESS; RESPONSES; FENTANYL; POTENCY	Patients with dementia are thought to be more sensitive to anesthesia, although volatile anesthetic requirement has not specifically been evaluated in this population. We tested the hypothesis that patients with dementia having non-cardiac surgery have a lower ratio of bispectral index (BIS) to minimal alveolar concentration (MAC) during the five minutes immediately preceding incision, thus exhibiting deeper hypnotic levels at a given MAC fraction. We obtained records from our database registry on patients who had volatile general anesthesia during their most recent operation. We excluded patients premedicated with midazolam. Patients with dementia were identified and their diagnosis was confirmed by chart review. Each patient with dementia was successfully matched with a maximum of five patients without dementia using a multivariate nearest-neighbor distance-matching algorithm restricted to the following criteria: American Society of Anesthesiologists physical status, age, five-minute pre-incision time-weighted average (TWA) estimated effect-site concentration of propofol and fentanyl, and use of remifentanil. Our primary outcome was the TWA BIS-to-MAC ratio during the five minutes immediately preceding incision. We analyzed 31 patients with dementia matched with 151 patients without dementia. Median [quartiles] TWA BIS-to-MAC ratios for the matched patients were 85 [73, 100] for the patients with dementia and 78 [73, 84] for the patients without dementia. The percent difference in mean BIS-to-MAC ratios between patients with dementia and patients without dementia was 9% (95% confidence interval: -9% to 29%) (P = 0.35, Wald test). Our results do not support the hypothesis that patients with dementia are more sensitive to volatile anesthetics than patients without dementia.	[Perez-Protto, Silvia; Geube, Mariya] Cleveland Clin Fdn, Inst Anesthesiol, Cleveland, OH 44195 USA; [Ontaneda, Daniel] Cleveland Clin Fdn, Neurol Inst, Cleveland, OH 44195 USA; [Dalton, Jarrod E.] Cleveland Clin Fdn, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA; [Dalton, Jarrod E.; Kurz, Andrea; Sessler, Daniel I.] Cleveland Clin Fdn, Dept Outcomes Res, Cleveland, OH 44195 USA	Sessler, DI (reprint author), Cleveland Clin Fdn, Dept Outcomes Res, 9500 Euclid Ave, Cleveland, OH 44195 USA.	ds@or.org	Sessler, Daniel/D-3504-2011	Sessler, Daniel/0000-0001-9932-3077; Ontaneda, Daniel/0000-0002-2838-9148			Antognini JF, 2000, ANESTH ANALG, V91, P1282, DOI 10.1097/00000539-200011000-00043; Antognini JF, 2000, ANESTHESIOLOGY, V92, P559, DOI 10.1097/00000542-200002000-00040; ANTOGNINI JF, 1993, ANESTHESIOLOGY, V79, P1244, DOI 10.1097/00000542-199312000-00015; Bharmal MF, 2007, ALZ DIS ASSOC DIS, V21, P92, DOI 10.1097/WAD.0b013e31805c0835; Bianchi SL, 2010, ANESTH ANALG, V110, P427, DOI 10.1213/ANE.0b013e3181b5a292; Bolla LR, 2000, GERIATRICS, V55, P34; Bonferroni C.E., 1935, STUDI ONORE PROFESSO, P13; Burton DA, 2004, DRUG AGING, V21, P229, DOI 10.2165/00002512-200421040-00002; Di Nino G, 2010, J ALZHEIMERS DIS, V22, pS121, DOI 10.3233/JAD-2010-101299; Eckel B, 2010, ANESTH ANALG, V110, P438, DOI 10.1213/ANE.0b013e3181b76383; Eger EI, 2002, ANESTHESIOLOGY, V96, P238, DOI 10.1097/00000542-200201000-00037; Erdogan MA, 2012, EUR J ANAESTH, V29, P326, DOI 10.1097/EJA.0b013e32835475c6; Faraway J. J., 2006, C&H TEXT STAT SCI; Funder KS, 2010, J ALZHEIMERS DIS, V22, pS129, DOI 10.3233/JAD-2010-100810; Funder KS, 2009, CURR OPIN ANESTHESIO, V22, P712, DOI 10.1097/ACO.0b013e328331a4eb; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Gyulai FE, 2001, ANESTHESIOLOGY, V95, P585, DOI 10.1097/00000542-200109000-00008; Hu CJ, 2012, WORLD J SURG, V36, P2051, DOI 10.1007/s00268-012-1609-x; Katoh T, 1998, ANESTHESIOLOGY, V88, P18, DOI 10.1097/00000542-199801000-00006; Katoh T, 1998, ANESTHESIOLOGY, V88, P642, DOI 10.1097/00000542-199803000-00014; Katzan Irene, 2011, AMIA Annu Symp Proc, V2011, P683; Kazama T, 1997, ANESTHESIOLOGY, V87, P213, DOI 10.1097/00000542-199708000-00007; KOCHS E, 1994, ANESTHESIOLOGY, V80, P1026, DOI 10.1097/00000542-199405000-00012; Kox WJ, 2006, ANESTH ANALG, V102, P825, DOI 10.1213/01.ane.0000197776.26307.fa; Leslie K, 2010, ANESTH ANALG, V110, P816, DOI 10.1213/ANE.0b013e3181c3bfb2; Mathews DM, 2012, ANESTH ANALG, V114, P759, DOI 10.1213/ANE.0b013e3182455ac2; Matthews FE, 2013, LANCET, V382, P1405, DOI 10.1016/S0140-6736(13)61570-6; MERKEL G, 1963, ANESTHESIOLOGY, V24, P346, DOI 10.1097/00000542-196305000-00016; Monk TG, 2005, ANESTH ANALG, V100, P4, DOI 10.1213/01.ANE.0000147519.82841.5E; Morimoto Y, 2004, ANESTH ANALG, V98, P1336, DOI 10.1213/01.ANE.0000105867.17108.B6; National Center for Health Statistics, 2012, DISCH LEAST ON PROC; Nickalls RWD, 2003, BRIT J ANAESTH, V91, P170, DOI 10.1093/bja/aeg132; Pinheiro J. C., 2000, MIXED EFFECTS MODELS; Qiu CX, 2007, CURR OPIN PSYCHIATR, V20, P380, DOI 10.1097/YCO.0b013e32816ebc7b; QUASHA AL, 1980, ANESTHESIOLOGY, V53, P315, DOI 10.1097/00000542-198010000-00008; RAMPIL IJ, 1993, ANESTHESIOLOGY, V78, P707, DOI 10.1097/00000542-199304000-00014; RAMPIL IJ, 1994, ANESTHESIOLOGY, V80, P606, DOI 10.1097/00000542-199403000-00017; Renna M, 2003, ANESTH ANALG, V96, P1380, DOI 10.1213/01.ANE.0000059223.78879.0F; Schnider TW, 1998, ANESTHESIOLOGY, V88, P1170, DOI 10.1097/00000542-199805000-00006; Schraag S, 1999, ANESTH ANALG, V89, P1311, DOI 10.1213/00000539-199911000-00045; Sebel PS, 1997, ANESTH ANALG, V84, P891, DOI 10.1097/00000539-199704000-00035; Sessler DI, 2012, ANESTHESIOLOGY, V116, P1195, DOI 10.1097/ALN.0b013e31825683dc; Sleigh JW, 2010, J CLIN MONIT COMPUT, V24, P307, DOI 10.1007/s10877-010-9251-3; SMITH C, 1994, ANESTHESIOLOGY, V81, P820, DOI 10.1097/00000542-199410000-00008; St Germaine-Smith C, 2012, NEUROLOGY, V79, P1049, DOI 10.1212/WNL.0b013e3182684707; Stoelting R.K., 2006, PHARM PHYSL ANESTHET	46	8	8	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X	1496-8975		CAN J ANESTH	Can. J. Anesth.	JUL	2014	61	7					611	618		10.1007/s12630-014-0165-2			8	Anesthesiology	Anesthesiology	AI7OW	WOS:000337084200003	24764187				2020-06-30	J	Hui, D; Bruera, E				Hui, David; Bruera, Eduardo			The Essential Role of Feasibility Studies in Supportive Care: Reply to Sanz Rubiales and del Valle	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter							DOUBLE-BLIND; CONTROLLED-TRIAL; CANCER; PLACEBO; FATIGUE		[Hui, David; Bruera, Eduardo] Univ Texas Houston, MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Houston, TX 77030 USA	Hui, D (reprint author), Univ Texas Houston, MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dhui@mdanderson.org		Sanz Rubiales, Alvaro/0000-0003-0594-3844			Bruera E, 2006, J CLIN ONCOL, V24, P2073, DOI 10.1200/JCO.2005.02.8506; de la Cruz M, 2010, CANCER-AM CANCER SOC, V116, P766, DOI 10.1002/cncr.24751; Hui D, 2014, J PAIN SYMPTOM MANAG, V47, P209, DOI 10.1016/j.jpainsymman.2013.03.017; Hui D, 2011, ONCOLOGIST, V16, P694, DOI 10.1634/theoncologist.2010-0397; Miller M, 2000, HASTINGS CENT REP, V30, P34, DOI 10.2307/3527646	5	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	JUL	2014	48	1					E5	E6		10.1016/j.jpainsymman.2014.05.001			2	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	AL0ZH	WOS:000338855100005	24819085	Bronze			2020-06-30	J	Jandhyala, R; Fullarton, JR; Bennett, MI				Jandhyala, Ravi; Fullarton, John R.; Bennett, Michael I.			Efficacy of Rapid-Onset Oral Fentanyl: What Does It Mean? Reply	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter									[Jandhyala, Ravi] Latralis Ltd, Banbury, England; [Fullarton, John R.] Strategen Ltd, Basingstoke, Hants, England; [Bennett, Michael I.] Univ Leeds, Leeds, W Yorkshire, England	Jandhyala, R (reprint author), Latralis Ltd, Banbury, England.	rjandhyala@latralis.com	Bennett, Michael I/A-1620-2009	Bennett, Michael I/0000-0002-8369-8349			Vissers D, 2010, CURR MED RES OPIN, V26, P1037, DOI 10.1185/03007991003694340	1	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	JUL	2014	48	1					E3	E4		10.1016/j.jpainsymman.2014.04.002			2	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	AL0ZH	WOS:000338855100003	24809763	Bronze			2020-06-30	J	Rubiales, AS; del Valle, ML				Sanz Rubiales, Alvaro; Luisa del Valle, Maria			Placebo-Controlled Feasibility Randomized Trial?	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter							CANCER		[Sanz Rubiales, Alvaro] Hosp Univ Rio Hortega, Med Oncol Sect, Valladolid, Spain; [Luisa del Valle, Maria] Hosp Clin Univ Valladolid, Radiotherapy Serv, Valladolid, Spain	Rubiales, AS (reprint author), Hosp Univ Rio Hortega, Med Oncol Sect, Valladolid, Spain.	asrubiales@gmail.com		del Valle, Maria Luisa/0000-0001-9727-5788; Sanz Rubiales, Alvaro/0000-0003-0594-3844			Arain M, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-67; Hui D, 2014, J PAIN SYMPTOM MANAG, V47, P209, DOI 10.1016/j.jpainsymman.2013.03.017; Rubiales AS, 1996, ANN ONCOL, V7, P755	3	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	JUL	2014	48	1					E4	E5		10.1016/j.jpainsymman.2014.03.011			2	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	AL0ZH	WOS:000338855100004	24819084	Bronze			2020-06-30	J	Tanaka, K; Nakanishi, Y; Sekino, S; Ikegami, M; Ikeda, H; Kamei, J				Tanaka, Ken-ichiro; Nakanishi, Yuki; Sekino, Shyota; Ikegami, Megumi; Ikeda, Hiroko; Kamei, Junzo			Fentanyl produces an anti-hyperalgesic effect through the suppression of sodium channels in mice with painful diabetic neuropathy	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Fentanyl; Painful diabetic neuropathy; Voltage-gated sodium channel; Opioid receptor; Mouse	ROOT GANGLION NEURONS; PROTEIN-KINASE-C; OPIOID RECEPTOR AGONIST; GATED NA+ CHANNELS; SENSORY NEURONS; POSSIBLE INVOLVEMENT; SPINAL-CORD; MECHANICAL HYPERALGESIA; MU(1)-OPIOID RECEPTORS; PERIPHERAL NEUROPATHY	Diabetic neuropathy is one of the most frequent complications of diabetes mellitus. Therefore, the present study was designed to investigate the anti-hyperalgesic mechanism of fentanyl in a mouse model of streptozotocin-induced diabetic neuropathy. The antinociceptive response was assessed by recording the latency in a tail-flick test. The tail flick latency in diabetic mice was significantly shorter than that in non diabetic mice. Fentanyl, at doses of 3 and 10 mu g/kg, s.c., produced a dose dependent increase in the tail flick latencies in diabetic mice. While fentanyl (3 mu g/kg, s.c.) did not produce a significant inhibition of the tail flick response in non diabetic mice, it significantly prolonged the tail flick latency in diabetic mice to the same level as the baseline latency in non diabetic mice. Although pretreatment with naloxone (3 mg/kg, s.c.) completely antagonized fentanyl-induced antinociception in non diabetic mice, it had no effect on the antinociceptive effect of fentanyl in diabetic mice. Pretreatment with either of the voltage gated sodium channel openers fenvarelarte and veratridine practically abolished the antinociceptive effects of fentanyl in diabetic mice. However, neither fenvarelate nor veratridine affected the antinociceptive effect of fentanyl in non diabetic mice. These results suggest that the anti-hyperalgesic effect of fentanyl is mediated through the blockade of sodium channels in diabetic mice, whereas opioid receptors mediate the antinociceptive effect of fentanyl in non-diabetic mice. (C) 2014 Elsevier B.V. All rights reserved.	[Tanaka, Ken-ichiro; Nakanishi, Yuki; Sekino, Shyota; Ikegami, Megumi; Ikeda, Hiroko; Kamei, Junzo] Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Pathophysiol & Therapeut, Shinagawa Ku, Tokyo 1428501, Japan; [Tanaka, Ken-ichiro] Yokohama City Univ, Grad Sch Med, Dept Endocrinol & Metab, Yokohama, Kanagawa, Japan	Kamei, J (reprint author), Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Pathophysiol & Therapeut, Shinagawa Ku, 4-41,Ebara 2 Chome, Tokyo 1428501, Japan.	kamei@hoshi.ac.jp					Adriaensen H, 2005, DIABETES-METAB RES, V21, P231, DOI 10.1002/dmrr.552; Ahlgren SC, 1997, NEUROSCIENCE, V76, P285; AHLGREN SC, 1993, NEUROSCIENCE, V52, P1049, DOI 10.1016/0306-4522(93)90551-P; AHLGREN SC, 1994, J NEUROPHYSIOL, V72, P684; Akopian AN, 1996, NATURE, V379, P257, DOI 10.1038/379257a0; Baron R, 2009, PAIN, V146, P34, DOI 10.1016/j.pain.2009.06.001; Boulton AJM, 1998, DIABETIC MED, V15, P508, DOI 10.1002/(SICI)1096-9136(199806)15:6<508::AID-DIA613>3.3.CO;2-C; CAFFREY JM, 1992, BRAIN RES, V592, P283, DOI 10.1016/0006-8993(92)91687-A; Calcutt NA, 1996, PAIN, V68, P293, DOI 10.1016/S0304-3959(96)03201-0; Chen SR, 2003, ANESTHESIOLOGY, V99, P1409, DOI 10.1097/00000542-200312000-00026; Chen SR, 2002, ANESTHESIOLOGY, V97, P1602, DOI 10.1097/00000542-200212000-00037; Coward K, 2000, PAIN, V85, P41, DOI 10.1016/S0304-3959(99)00251-1; DEJGARD A, 1988, LANCET, V1, P9; Dib-Hajj SD, 1998, P NATL ACAD SCI USA, V95, P8963, DOI 10.1073/pnas.95.15.8963; Dyck PJ, 2000, DIABETES CARE, V23, P510, DOI 10.2337/diacare.23.4.510; Fox A, 1999, PAIN, V81, P307, DOI 10.1016/S0304-3959(99)00024-X; Haeseler G, 2006, PAIN, V126, P234, DOI 10.1016/j.pain.2006.07.003; Hashimoto K, 2009, NEUROSCI LETT, V453, P62, DOI 10.1016/j.neulet.2009.01.066; Hirade M, 1999, NEUROSCIENCE, V90, P933, DOI 10.1016/S0306-4522(98)00486-2; Hong SS, 2006, BIOCHEM BIOPH RES CO, V339, P652, DOI 10.1016/j.bbrc.2005.11.057; Hong SS, 2004, J BIOL CHEM, V279, P29341, DOI 10.1074/jbc.M404167200; HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4; KAMEI J, 1995, NEUROSCI LETT, V196, P169, DOI 10.1016/0304-3940(95)11867-V; KAMEI J, 1992, BRAIN RES, V571, P199, DOI 10.1016/0006-8993(92)90655-S; Kamei J, 2000, EUR J PHARMACOL, V391, P91, DOI 10.1016/S0014-2999(00)00049-2; KAMEI J, 1994, NEUROSCI LETT, V165, P141, DOI 10.1016/0304-3940(94)90729-3; KAMEI J, 1992, BRAIN RES, V576, P139, DOI 10.1016/0006-8993(92)90619-K; Kohno T, 2005, PAIN, V117, P77, DOI 10.1016/j.pain.2005.05.035; KOSTYUK PG, 1981, NEUROSCIENCE, V6, P2423, DOI 10.1016/0306-4522(81)90088-9; LAUBIE M, 1974, EUR J PHARMACOL, V28, P66, DOI 10.1016/0014-2999(74)90113-7; Laubie M., 1975, ARCH PHARM, V296, P255; Leffler A, 2012, ANESTHESIOLOGY, V116, P1335, DOI 10.1097/ALN.0b013e3182557917; Malcangio M, 1998, PAIN, V76, P151, DOI 10.1016/S0304-3959(98)00037-2; Narita M, 2002, LIFE SCI, V70, P2341, DOI 10.1016/S0024-3205(01)01550-8; Novakovic SD, 1998, J NEUROSCI, V18, P2174; Ogata N, 2002, JPN J PHARMACOL, V88, P365, DOI 10.1254/jjp.88.365; Ohsawa M, 1999, EUR J PHARMACOL, V372, P221, DOI 10.1016/S0014-2999(99)00228-9; Ohsawa M, 1997, EUR J PHARMACOL, V339, P27, DOI 10.1016/S0014-2999(97)01365-4; Ohsawa M, 2000, EUR J PHARMACOL, V401, P55, DOI 10.1016/S0014-2999(00)00408-8; Ohsawa M, 2008, EUR J PHARMACOL, V588, P213, DOI 10.1016/j.ejphar.2008.04.029; Oskarsson P, 1997, DIABETES CARE, V20, P1594, DOI 10.2337/diacare.20.10.1594; OSSIPOV MH, 1995, NEUROSCI LETT, V199, P83, DOI 10.1016/0304-3940(95)12026-Z; ROY ML, 1992, J NEUROSCI, V12, P2104; Said G, 1996, J NEUROL, V243, P431, DOI 10.1007/BF00900495; Suzuki N, 2011, ANESTH ANALG, V113, P941, DOI 10.1213/ANE.0b013e31822827a2; Suzuki T, 2005, NEUROPHARMACOLOGY, V49, P1121, DOI 10.1016/j.neuropharm.2005.06.009; Tate S, 1998, NAT NEUROSCI, V1, P653, DOI 10.1038/3652; Veves A, 2008, PAIN MED, V9, P660, DOI 10.1111/j.1526-4637.2007.00347.x; Viola V, 2006, J DIABETES COMPLICAT, V20, P34, DOI 10.1016/j.jdiacomp.2005.05.007; Waxman SG, 1999, PAIN, pS133; Wolff RF, 2010, SWISS MED WKLY, V140, P297, DOI smw-12995; WRIGHT JM, 1994, PHARMACOTHERAPY, V14, P689	52	3	4	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	JUN 15	2014	733						68	74		10.1016/j.ejphar.2014.03.042			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AH1YU	WOS:000335918600008	24704555				2020-06-30	J	Lovborg, H; Holmlund, M; Hagg, S				Lovborg, Henrik; Holmlund, Mikael; Hagg, Staffan			Medication errors related to transdermal opioid patches: lessons from a regional incident reporting system	BMC PHARMACOLOGY & TOXICOLOGY			English	Article						Transdermal patch; Opioids; Fentanyl; Buprenorphine; Medication errors; Incident reporting system	PRESCRIBER ORDER ENTRY; FENTANYL	Objective: A few cases of adverse reactions linked to erroneous use of transdermal opioid patches have been reported in the literature. The aim of this study was to describe and characterize medication errors (MEs) associated with use of transdermal fentanyl and buprenorphine. Methods: All events concerning transdermal opioid patches reported between 2004 and 2011 to a regional incident reporting system and assessed as MEs were scrutinized and characterized. MEs were defined as "a failure in the treatment process that leads to, or has the potential to lead to, harm to the patient". Results: In the study 151 MEs were identified. The three most common error types were wrong administration time 67 (44%), wrong dose 34 (23%), and omission of dose 20 (13%). Of all MEs, 118 (78%) occurred in the administration stage of the medication process. Harm was reported in 26 (17%) of the included cases, of which 2 (1%) were regarded as serious harm (nausea/vomiting and respiratory depression). Pain was the most common adverse reaction reported. Conclusions: Of the reported MEs related to transdermal fentanyl and buprenorphine, most occurred during administration. Improved routines to ascertain correct and timely administration and educational interventions to reduce MEs for these drugs are warranted.	[Lovborg, Henrik; Holmlund, Mikael; Hagg, Staffan] Linkoping Univ, Dept Clin Pharmacol, Linkoping, Sweden; [Lovborg, Henrik; Holmlund, Mikael; Hagg, Staffan] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden; [Lovborg, Henrik] Linkoping Univ Hosp, S-58185 Linkoping, Sweden	Lovborg, H (reprint author), Linkoping Univ, Dept Clin Pharmacol, Linkoping, Sweden.	Henrik.Lovborg@lio.se	Hagg, Staffan/G-5612-2013	Hagg, Staffan/0000-0002-5137-8420	County Council of Ostergotland	The authors would like to thank the County Council of Ostergotland for providing data and Ingela Jakobsson for assistance with data handling. Research and preparation of manuscript funded by the County Council of Ostergotland.	[Anonymous], 2003, SWEDISH CODE STATUTE, P460; [Anonymous], 2010, PRESCRIRE INT, V19, P22; Clemens KE, 2007, JPN J CLIN ONCOL, V37, P302, DOI 10.1093/jjco/hym017; Durand C, 2012, AM J HEALTH-SYST PH, V69, P116, DOI 10.2146/ajhp110158; Dy Sydney Morss, 2007, J Opioid Manag, V3, P189; Ferner RE, 2006, DRUG SAFETY, V29, P1011, DOI 10.2165/00002018-200629110-00001; Grissinger Matthew, 2009, Consult Pharm, V24, P864, DOI 10.4140/TCP.n.2009.864; Hoffman RS, 2009, HUM EXP TOXICOL, V28, P599, DOI 10.1177/0960327109107044; Jozefczyk Kenneth G, 2013, J Pharm Pract, V26, P434, DOI 10.1177/0897190012465982; Kim HK, 2012, PEDIATRICS, V130, pE1700, DOI 10.1542/peds.2012-1342; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Kress HG, 2010, EUR J PHARM BIOPHARM, V75, P225, DOI 10.1016/j.ejpb.2010.02.005; Lee M, 2002, DRUG TOPICS     0401, P54; Lisby M, 2012, SCAND J PUBLIC HEALT, V40, P203, DOI 10.1177/1403494811435489; Lovborg H, 2012, CURR DRUG SAF, V7, P30, DOI 10.2174/157488612800492717; Mrvos R, 2012, J EMERG MED, V42, P549, DOI 10.1016/j.jemermed.2011.05.017; Pintor-Marmol A, 2012, PHARMACOEPIDEM DR S, V21, P799, DOI 10.1002/pds.3296; Reason J, 2000, BRIT MED J, V320, P768, DOI 10.1136/bmj.320.7237.768; Sindali Katia, 2012, J Med Case Rep, V6, P220, DOI 10.1186/1752-1947-6-220; Tanner T, 2008, SKIN RES TECHNOL, V14, P249, DOI 10.1111/j.1600-0846.2008.00316.x; Villamanan E, 2013, INT J CLIN PHARM-NET, V35, P577, DOI 10.1007/s11096-013-9771-2; Wohlrab J, 2011, EXPERT OPIN DRUG DEL, V8, P939, DOI 10.1517/17425247.2011.574689	22	6	6	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		2050-6511		BMC PHARMACOL TOXICO	BMC Pharmacol. Toxicol.	JUN 9	2014	15								31	10.1186/2050-6511-15-31			6	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	AJ2GN	WOS:000337473900002	24912424	DOAJ Gold, Green Published			2020-06-30	J	Aoki, Y; Yoshida, K; Nishizawa, D; Kasai, S; Ichinohe, T; Ikeda, K; Fukuda, K				Aoki, Yoshinori; Yoshida, Kaori; Nishizawa, Daisuke; Kasai, Shinya; Ichinohe, Tatsuya; Ikeda, Kazutaka; Fukuda, Ken-ichi			Factors that Affect Intravenous Patient-Controlled Analgesia for Postoperative Pain Following Orthognathic Surgery for Mandibular Prognathism	PLOS ONE			English	Article							ASSOCIATION; GENE	The predictors of postoperative pain and analgesic consumption were previously found to include preoperative pain, anxiety, age, type of surgery, and genotype, but remaining unclear was whether intraoperative factors could predict postoperative pain. In the present study, we investigated the time-course of fentanyl consumption using intravenous patient-controlled analgesia records from patients who underwent orthognathic surgery for mandibular prognathism and analyzed the influence of anesthesia methods and surgical methods together with sex on the time course. A significant difference in the time course of fentanyl administration was found (P<0.001). No significant difference in the time course of fentanyl administration was found between males and females (P = 0.653), with no interaction between time course and sex (P = 0.567). No significant difference in the time course of fentanyl administration was found among anesthesia methods, such as fentanyl induction followed by fentanyl maintenance, fentanyl induction followed by remifentanil maintenance, and remifentanil induction followed by remifentanil maintenance (P = 0.512), but an interaction between time course and anesthesia method was observed (P = 0.004). A significant difference in the time course of fentanyl administration was found between surgical methods, such as bilateral mandibular sagittal split ramus osteotomy (BSSRO) and BSSRO combined with Le Fort I osteotomy (bimaxillary; P = 0.008), with no interaction between time course and surgical method (P = 0.535). Total postoperative 24 h consumption associated with the bimaxillary procedure was significantly higher than with BSSRO (P = 0.008). The present results indicate that administration patterns and total 24 h consumption were different among the three groups of anesthesia methods and between the two groups of surgical methods, respectively. Although more research on patient-controlled analgesia patterns and consumption is necessary, the present study will contribute to adequately relieving individual patients from postoperative pain.	[Aoki, Yoshinori; Yoshida, Kaori; Nishizawa, Daisuke; Kasai, Shinya; Ikeda, Kazutaka] Tokyo Metropolitan Inst Med Sci, Addict Subst Project, Tokyo 113, Japan; [Aoki, Yoshinori; Yoshida, Kaori; Ichinohe, Tatsuya; Fukuda, Ken-ichi] Tokyo Dent Coll, Dept Dent Anesthesiol, Tokyo, Japan	Ikeda, K (reprint author), Tokyo Metropolitan Inst Med Sci, Addict Subst Project, Tokyo 113, Japan.	ikeda-kz@igakuken.or.jp			Ministry of Health, Labour and Welfare (MHLW) of JapanMinistry of Health, Labour and Welfare, Japan [H21-3jigan-ippan-011, H22-Iyaku-015, H25-Iyaku-020]; JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [20602020, 20390162, 23390377, 24790544, 24659549, 26293347]; MEXT KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [25116532]; Smoking Research Foundation; Naito FoundationNaito Memorial Foundation; Astellas Foundation for Research on Metabolic Disorders	This work was supported by grants from the Ministry of Health, Labour and Welfare (MHLW) of Japan (H21-3jigan-ippan-011, H22-Iyaku-015, and H25-Iyaku-020), JSPS KAKENHI grant no. 20602020, 20390162, 23390377, 24790544, 24659549, and 26293347, MEXT KAKENHI grant no. 25116532, the Smoking Research Foundation, the Naito Foundation, and the Astellas Foundation for Research on Metabolic Disorders. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aoki Y, 2013, NEUROSCI LETT, V542, P1, DOI 10.1016/j.neulet.2013.02.039; BELL WH, 1975, J ORAL SURG, V33, P412; Burkle H, 1996, ANESTH ANALG, V83, P646, DOI 10.1097/00000539-199609000-00038; Chegini Soudeh, 2012, Anesth Prog, V59, P69, DOI 10.2344/11-10.1; de Santana-Santos T, 2013, MED ORAL PATOL ORAL, V18, pE65, DOI 10.4317/medoral.18039; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fukuda K, 2009, PAIN, V147, P194, DOI 10.1016/j.pain.2009.09.004; Haerle F, 1997, ATLAS CRANIOMAXILLOF, p[90, 100]; Ip HYV, 2009, ANESTHESIOLOGY, V111, P657, DOI 10.1097/ALN.0b013e3181aae87a; Kehlet H, 2001, BRIT J ANAESTH, V87, P62, DOI 10.1093/bja/87.1.62; Nagatsuka C, 2000, Anesth Prog, V47, P119; Nishizawa D, 2014, MOL PSYCHIATR, V19, P55, DOI 10.1038/mp.2012.164; Nishizawa D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007060; OBWEGESER H, 1965, SSO Schweiz Monatsschr Zahnheilkd, V75, P365; TRAUNER R, 1957, Oral Surg Oral Med Oral Pathol, V10, P677, DOI 10.1016/S0030-4220(57)80063-2; United Nations, 2011, REP INT NARC CONTR B, P59; Warltier DC, 2000, ANESTHESIOLOGY, V92, P253, DOI 10.1097/00000542-200001000-00038; Wassmund M, 1935, LEHRBUCH PRAKTISCHEN, VI, P282; Weiser TG, 2008, LANCET, V372, P139, DOI 10.1016/S0140-6736(08)60878-8	19	4	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2014	9	6							e98548	10.1371/journal.pone.0098548			5	Multidisciplinary Sciences	Science & Technology - Other Topics	AI5ML	WOS:000336911400063	24893040	DOAJ Gold, Green Published			2020-06-30	J	Kim, K; Kim, WJ; Choi, DK; Lee, YK; Choi, IC; Sim, JY				Kim, Kyungmi; Kim, Wook-Jong; Choi, Dae-Kee; Lee, Yoon Kyung; Choi, In-Cheol; Sim, Ji-Yeon			The analgesic efficacy and safety of nefopam in patient-controlled analgesia after cardiac surgery: A randomized, double-blind, prospective study	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						Nefopam; patient-controlled analgesia; adult cardiac surgery	PAIN; REMIFENTANIL; INVOLVEMENT; MANAGEMENT; MORPHINE	Objective: The efficacy and side-effects of nefopam were prospectively compared with those of fentanyl for patient-controlled analgesia (PCA) following cardiac surgery. Methods: Patients scheduled to undergo cardiac surgery were randomly assigned between three PCA groups (nefopam, fentanyl or nefopam + fentanyl). Pain was assessed at rest and during movement at 12, 24, 36, 48 and 72 h after surgery using a visual analogue scale (VAS). Total infused PCA volume, number of rescue drug injections, duration of intubation and length of stay in the intensive care unit were recorded. The incidence of adverse effects was noted at 48 h postoperatively. Results: There were no significant between-group differences in VAS score, total PCA infusion volume or number of rescue injections (n = 92 per group). Nausea was significantly more common in the fentanyl group compared with both other groups. Conclusions: PCA with nefopam alone provides suitable postoperative analgesia after cardiac surgery.	[Kim, Kyungmi; Kim, Wook-Jong; Choi, Dae-Kee; Choi, In-Cheol; Sim, Ji-Yeon] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Anaesthesia & Pain Med, Seoul 138736, South Korea; [Lee, Yoon Kyung] Hallym Univ, Coll Med, Hangang Sacred Heart Hosp, Dept Anaesthesia & Pain Med, Seoul, South Korea	Sim, JY (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Anaesthesia & Pain Med, 388-1 Pungnap 2Dong, Seoul 138736, South Korea.	jysim@amc.seoul.kr			Asan Medical Center Hospital [2011-0271-0002]	This study was supported by a grant from Asan Medical Center Hospital in 2011 (2011-0271-0002, Commissioned by Pharmbio Pharmaceutical, Co, Ltd).	Beloeil H, 2007, BRIT J CLIN PHARMACO, V64, P686, DOI 10.1111/j.0306-5251.2007.02960.x; Bonnet F, 2005, BRIT J ANAESTH, V95, P52, DOI 10.1093/bja/aei038; Daabiss M, 2011, INDIAN J ANAESTH, V55, P111, DOI 10.4103/0019-5049.79879; DORDONI PL, 1994, ANAESTHESIA, V49, P1046, DOI 10.1111/j.1365-2044.1994.tb04352.x; ESPOSITO E, 1986, EUR J PHARMACOL, V128, P157, DOI 10.1016/0014-2999(86)90762-4; Evans MS, 2008, BRIT J ANAESTH, V101, P610, DOI 10.1093/bja/aen267; GASSER JC, 1975, CLIN PHARMACOL THER, V18, P175; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; Guindon J, 2007, DRUGS, V67, P2121, DOI 10.2165/00003495-200767150-00002; Ho SC, 2002, ANESTH ANALG, V95, P820, DOI 10.1097/00000539-200210000-00006; HUNSKAAR S, 1987, EUR J PHARMACOL, V138, P77, DOI 10.1016/0014-2999(87)90339-6; KEHLET H, 1993, ANESTH ANALG, V77, P1048; Kruger M, 1999, SURG CLIN N AM, V79, P387, DOI 10.1016/S0039-6109(05)70388-1; MCLINTOCK TTC, 1988, BRIT J SURG, V75, P779, DOI 10.1002/bjs.1800750818; Mimoz O, 2001, ANAESTHESIA, V56, P520, DOI 10.1046/j.1365-2044.2001.01980.x; Minto CF, 1997, ANESTHESIOLOGY, V86, P10, DOI 10.1097/00000542-199701000-00004; Ould-Ahmed M, 2007, ANN FR ANESTH, V26, P74, DOI 10.1016/j.annfar.2006.07.080; Reimer-Kent J, 2003, AM J CRIT CARE, V12, P136, DOI 10.4037/ajcc2003.12.2.136; Richebe P, 2013, J CARDIOTHOR VASC AN, V27, P427, DOI 10.1053/j.jvca.2012.08.015; SUNSHINE A, 1975, CLIN PHARMACOL THER, V18, P530; Swarm RA, 2001, CURR PROB SURG, V38, P845, DOI 10.1067/msg.20011.118495; TIGERSTEDT I, 1979, ACTA ANAESTH SCAND, V23, P555, DOI 10.1111/j.1399-6576.1979.tb01486.x; Tirault M, 2006, ANESTH ANALG, V102, P110, DOI 10.1213/01.ANE.0000181103.07170.15; Tracqui A, 2002, J ANAL TOXICOL, V26, P239, DOI 10.1093/jat/26.4.239; Urwin SC, 1999, BRIT J ANAESTH, V83, P501; Verleye M, 2004, BRAIN RES, V1013, P249, DOI 10.1016/j.brainres.2004.04.035; Watt-Watson J, 1998, J Cardiovasc Nurs, V12, P39	28	13	15	0	4	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0300-0605	1473-2300		J INT MED RES	J. Int. Med. Res.	JUN	2014	42	3					684	692		10.1177/0300060514525351			9	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	AM9JI	WOS:000340197300009	24691459	DOAJ Gold			2020-06-30	J	Li, L; Feng, J; Xie, SH; Geng, LC				Li, Li; Feng, Jie; Xie, Shu Hua; Geng, Li Cheng			A chin-lift mask produces a patent airway more effectively than an oropharyngeal airway using the EC-clamp technique in obese patients	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						Mask ventilation; bag-valve mask; EC-clamp technique	VENTILATION; ADVANCEMENT; PREDICTION; MANAGEMENT	Objective: To evaluate the efficiency of ventilation using a novel chin-lift mask compared with an oropharyngeal airway (OPA) with EC-clamp technique in obese patients. Methods: Obese patients scheduled for cholecystectomy under general anaesthesia were divided into two groups: the OPA group, in which a standard mask and OPA with the EC-clamp technique were used; the CL group, in which the chin-lift mask was used. Respiratory data were compared. Results: One hundred patients were recruited and assigned to the OPA (n = 50) and CL (n = 50) groups. Compared with the OPA group, expired tidal volume, peripheral oxygen saturation (SpO2), tidal volume/peak inspiratory pressure ratio and end-tidal carbon dioxide were higher, and the peak and mean inspiratory pressures were lower, in the CL group. In the CL group, no patient had an SpO2 <= 95% and the lowest SpO2 was 99%, whereas in the OPA group, 23 patients had an SpO2 <= 95% and the lowest SpO2 was 92%. Difficult mask ventilation occurred in eight patients in the OPA group but in none in the CL group. Conclusion: The chin-lift mask provided a patent airway and better quality mask ventilation than an OPA with EC-clamp technique in obese patients.	[Li, Li; Feng, Jie; Xie, Shu Hua; Geng, Li Cheng] Tianjin Union Med Ctr, Dept Anaesthesia, Tianjin 300121, Peoples R China	Feng, J (reprint author), Tianjin Union Med Ctr, Dept Anaesthesia, 190 Jieyuan Rd, Tianjin 300121, Peoples R China.	74lily@sina.com					Aceto P, 2013, SURG OBES RELAT DIS, V9, P809, DOI 10.1016/j.soard.2013.04.013; Berg MD, 2010, CIRCULATION, V122, pS862, DOI 10.1161/CIRCULATIONAHA.110.971085; Breznikar B, 2009, J INT MED RES, V37, P1632, DOI 10.1177/147323000903700543; Cook TM, 2012, BRIT J ANAESTH, V109, pI68, DOI 10.1093/bja/aes393; Gautam P, 2005, EUR J ANAESTH, V22, P638, DOI 10.1017/S026502150523106X; Hagberg CA, 2007, BENUMOFS AIRWAY MANA, P1181; Hart D, 2013, J EMERG MED, V44, P1028, DOI 10.1016/j.jemermed.2012.11.005; Hodzovic I, 2012, ACTA CLIN CROAT, V51, P525; Isono S, 1997, ANESTHESIOLOGY, V87, P1055, DOI 10.1097/00000542-199711000-00008; Joffe AM, 2010, ANESTHESIOLOGY, V113, P873, DOI 10.1097/ALN.0b013e3181ec6414; Koga T, 2009, J CLIN ANESTH, V21, P178, DOI 10.1016/j.jclinane.2008.06.037; Kuna ST, 2008, ANESTHESIOLOGY, V109, P605, DOI 10.1097/ALN.0b013e31818709fa; Kwak HJ, 2012, J INT MED RES, V40, P1476, DOI 10.1177/147323001204000426; Mahmoodpoor A, 2013, INT J PREVENTIVE MED, V4, P1063; Matioc AA, 2012, J CLIN ANESTH, V24, P167, DOI 10.1016/j.jclinane.2010.04.002; Murphy C, 2013, CAN J ANESTH, V60, P929, DOI 10.1007/s12630-013-9991-x; Reber A, 2001, BRIT J ANAESTH, V86, P217, DOI 10.1093/bja/86.2.217; Schneider RE, 2004, MANUAL EMERGENCY AIR, P43; Soleimanpour H, 2011, BMC EMERG MED, V11, DOI 10.1186/1471-227X-11-8; Ul Haq Muhammad Irfan, 2013, J Anaesthesiol Clin Pharmacol, V29, P313, DOI 10.4103/0970-9185.117059	20	0	0	0	1	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0300-0605	1473-2300		J INT MED RES	J. Int. Med. Res.	JUN	2014	42	3					693	701		10.1177/0300060514522204			9	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	AM9JI	WOS:000340197300010	24709884	DOAJ Gold			2020-06-30	J	Chen, ZY; Wang, HQ; Xu, WP; Xu, H; Fu, XC				Chen, Zhi-Yang; Wang, Huaqing; Xu, Weiping; Xu, Hui; Fu, Xinchun			Effect of intravenous general anaesthesia with epidural block on the expression of pre-endogenous opioid peptide genes	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						Pre-endogenous opioid peptides; beta-endorphin; leucine-enkephalin; dynorphin A; intravenous general anaesthesia; epidural block	PROOPIOMELANOCORTIN GENE; INDUCED ANALGESIA; BETA-ENDORPHIN; MOVEMENT; NEUROENDOCRINE; MECHANISMS; PREDICTION; RESPONSES	Objective: To measure the plasma concentrations of three endogenous opioid peptides and the levels of preproenkephalin (PPE) and preprodynorphin (PPD) mRNA in peripheral blood lymphocytes of patients during scheduled surgery performed under intravenous general anaesthesia combined with an epidural block. Methods: Patients were anaesthetized and arterial blood was collected at 0 (baseline), 20, 40, 60, and 80 min during surgery. The plasma concentrations of beta-endorphin, leucine-enkephalin and dynorphin A were measured using radioimmunoassay. Reverse transcription-polymerase chain reaction was used to measure the levels of PPD and PPE mRNA in peripheral blood lymphocytes collected during surgery. Results: Fifteen patients participated in this prospective study. The plasma concentrations of b-endorphin were significantly lower at all time-points compared with the baseline value. The plasma concentrations of leucine-enkephalin and dynorphin A were significantly lower at 40, 60, and 80 min compared with baseline. The PPD/beta-actin ratio was significantly lower at 80 min compared with baseline, while the PPE/beta-actin ratio showed no significant change. Conclusion: The level of mRNA from two pre-endogenous opioid peptide genes either decreased or remained unchanged during surgery under intravenous general anaesthesia with epidural block, suggesting that patients remained pain free during surgery.	[Chen, Zhi-Yang] Fudan Univ, Shanghai Med Coll, Canc Hosp, Dept Anaesthesiol, Shanghai 200032, Peoples R China; [Wang, Huaqing; Xu, Weiping; Xu, Hui; Fu, Xinchun] Taizhou First Peoples Hosp, Dept Anaesthesiol, Taizhou, Zhejiang, Peoples R China	Chen, ZY (reprint author), Fudan Univ, Shanghai Med Coll, Canc Hosp, Dept Anaesthesiol, 270 Dongan Rd, Shanghai 200032, Peoples R China.	chzhygg@sina.cn					ADAMS JU, 1994, BRAIN RES, V667, P129, DOI 10.1016/0006-8993(94)91723-X; Andersen GN, 2005, SCAND J IMMUNOL, V61, P279, DOI 10.1111/j.1365-3083.2005.01565.x; BELLUZZI JD, 1976, NATURE, V260, P625, DOI 10.1038/260625a0; Borner C, 2009, J IMMUNOL, V183, P882, DOI 10.4049/jimmunol.0802763; Chen CP, 2006, ALCOHOL CLIN EXP RES, V30, P1925, DOI 10.1111/j.1530-0277.2006.00237.x; CHOWENBREED J, 1989, ENDOCRINOLOGY, V124, P1697, DOI 10.1210/endo-124-4-1697; Cooper A, 2005, J IMMUNOL, V175, P4806, DOI 10.4049/jimmunol.175.7.4806; DEBOLD CR, 1988, MOL ENDOCRINOL, V2, P862, DOI 10.1210/mend-2-9-862; HUGHES J, 1975, BRAIN RES, V88, P295, DOI 10.1016/0006-8993(75)90391-1; Katahira M, 1998, ENDOCRINOLOGY, V139, P2414, DOI 10.1210/en.139.5.2414; KEARSE LA, 1994, ANESTHESIOLOGY, V81, P1365, DOI 10.1097/00000542-199412000-00010; Kissin I, 2000, ANESTH ANALG, V90, P1114, DOI 10.1097/00000539-200005000-00021; Koneru A, 2009, GLOBAL J PHARM, V3, P149; Leone M, 1994, CEPHALALGIA, V13, P413; Leslie K, 1996, ANESTHESIOLOGY, V84, P52, DOI 10.1097/00000542-199601000-00006; MORLEY JE, 1983, PSYCHONEUROENDOCRINO, V8, P361, DOI 10.1016/0306-4530(83)90016-1; Murao K, 1998, ENDOCR J, V45, P399, DOI 10.1507/endocrj.45.399; Pan ZZ, 1998, TRENDS PHARMACOL SCI, V19, P94, DOI 10.1016/S0165-6147(98)01169-9; Parikh D, 2011, EUR J PHARMACOL, V650, P563, DOI 10.1016/j.ejphar.2010.10.050; Pfaff DW, 1996, J NEUROENDOCRINOL, V8, P325, DOI 10.1046/j.1365-2826.1996.04691.x; POKELA ML, 1993, BIOL NEONATE, V64, P360; Serrats J, 2006, J COMP NEUROL, V495, P236, DOI 10.1002/cne.20872; Sitte N, 2007, J NEUROIMMUNOL, V183, P133, DOI 10.1016/j.jneuroim.2006.11.033; TAKEMORI AE, 1988, J PHARMACOL EXP THER, V246, P255; Verma-Gandhu M, 2007, AM J PHYSIOL-GASTR L, V292, pG344, DOI 10.1152/ajpgi.00318.2006; VERNON JM, 1995, ANESTH ANALG, V80, P780, DOI 10.1097/00000539-199504000-00023; Wang H-Q, 2010, NEW MED, V4, P228; WEATHERSTONE KB, 1993, PEDIATRICS, V92, P710	28	3	3	0	4	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0300-0605	1473-2300		J INT MED RES	J. Int. Med. Res.	JUN	2014	42	3					765	772		10.1177/0300060513515642			8	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	AM9JI	WOS:000340197300018	24743873	DOAJ Gold			2020-06-30	J	Goudra, BG; Singh, PM				Goudra, Basavana Gouda; Singh, Preet Mohinder			SEDASYS, sedation, and the unknown	JOURNAL OF CLINICAL ANESTHESIA			English	Letter							ANESTHESIA; PROPOFOL		[Goudra, Basavana Gouda] Univ Penn, Hosp Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Singh, Preet Mohinder] PGIMER, Dept Anesthesia, Chandigarh 160012, India	Goudra, BG (reprint author), Univ Penn, Hosp Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA.	goudrab@uphs.upenn.edu; preetrajpal@gmail.com	Singh, Preet Mohinder/V-3471-2017	Singh, Preet Mohinder/0000-0001-7642-529X			Goudra Basavana Gouda, 2013, J Anaesthesiol Clin Pharmacol, V29, P426, DOI 10.4103/0970-9185.117102; Goudra BG, 2013, ANN M INT SOC AN PHA; Goudra BG, 2013, OPEN J ANESTHESIOL, V03, P74, DOI DOI 10.4236/ojanes.2013.32019; Liu HS, 2012, JAMA-J AM MED ASSOC, V307, P1178, DOI 10.1001/jama.2012.270; Metzner J, 2009, CURR OPIN ANESTHESIO, V22, P502, DOI 10.1097/ACO.0b013e32832dba50; Pambianco DJ, 2011, GASTROINTEST ENDOSC, V73, P765, DOI 10.1016/j.gie.2010.10.031; Paspatis GA, 2011, COLORECTAL DIS, V13, pE137, DOI 10.1111/j.1463-1318.2011.02555.x; VESELIS RA, 1992, BRIT J ANAESTH, V69, P246, DOI 10.1093/bja/69.3.246; Vuyk J, 1998, ANAESTHESIA, V53, P35, DOI 10.1111/j.1365-2044.1998.53s109.x; Vuyk J, 1997, J CLIN ANESTH, V9, pS23, DOI 10.1016/S0952-8180(97)00117-7	10	10	10	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	JUN	2014	26	4					334	336		10.1016/j.jclinane.2014.02.003			3	Anesthesiology	Anesthesiology	AL7IL	WOS:000339307300018	24916898				2020-06-30	J	Kosugi, T; Hamada, S; Takigawa, C; Shinozaki, K; Kunikane, H; Goto, F; Tanda, S; Shima, Y; Yomiya, K; Matoba, M; Adachi, I; Yoshimoto, T; Eguchi, K				Kosugi, Toshifumi; Hamada, Sasagu; Takigawa, Chizuko; Shinozaki, Katsunori; Kunikane, Hiroshi; Goto, Fumio; Tanda, Shigeru; Shima, Yasuo; Yomiya, Kinomi; Matoba, Motohiro; Adachi, Isamu; Yoshimoto, Tetsusuke; Eguchi, Kenji			A Randomized, Double-Blind, Placebo-Controlled Study of Fentanyl Buccal Tablets for Breakthrough Pain: Efficacy and Safety in Japanese Cancer Patients	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Fentanyl buccal tablet; breakthrough pain; cancer pain; rapid-onset opioids; palliative medicine; oral transmucosal opioid	DOSE-TITRATION; CITRATE; TRIAL; TOLERABILITY; PREVALENCE; MANAGEMENT	Context. Rapid-onset opioids for treating breakthrough pain (BTP) in patients with cancer are needed in the Japanese care setting. Objectives. To examine the efficacy and safety of fentanyl buccal tablets (FBTs) for treating BTP in Japanese cancer patients. Methods. This was a randomized, double-blinded, placebo-controlled study. In subjects receiving around-the-clock (ATC) opioids at doses of 30 mg or more to less than 60 mg or 60-1000 mg of oral morphine equivalents (low and high ATC groups), dose titration was started from 50 to 100 mu g FBT, respectively. Subjects whose effective dose was identified were randomly allocated to a prearranged administration order of nine tablets (six FBTs and three placebos), one tablet each for nine episodes of BTP (double blinded). Efficacy and safety of FBT were assessed for patients overall, and also for the low and high ATC groups. Results. A significant difference was observed between FBT and placebo for the primary endpoint of pain intensity difference at 30 minutes. The analgesic onset of FBT was observed from 15 minutes in several secondary variables (e.g., pain relief). Adverse events were somnolence and other events associated with opioids were mostly mild or moderate. Of the low and high ATC group subjects, an effective FBT dose was identified in 72.2% and 73.1%, respectively. Conclusion. The safety of FBT and its analgesic effect on BTP were confirmed in Japanese cancer patients receiving opioids. Our findings suggest that analgesic onset may occur from 15 minutes after FBT, and that FBT can be administered to patients with low doses of ATC opioids. (C) 2014 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.	[Kosugi, Toshifumi; Hamada, Sasagu] Saga Ken Med Ctr, Dept Palliat Care, Saga 8408571, Japan; [Takigawa, Chizuko] KKR Sapporo Med Ctr, Dept Palliat Med, Sapporo, Hokkaido, Japan; [Shinozaki, Katsunori] Hiroshima Prefectural Hosp, Div Clin Oncol, Hiroshima, Japan; [Kunikane, Hiroshi] Yokohama Municipal Citizens Hosp, Dept Palliat Med, Yokohama, Kanagawa, Japan; [Goto, Fumio] Int Univ Hlth & Welf Hosp, Tokyo, Japan; [Tanda, Shigeru] Tohoku Rosai Hosp, Dept Med Oncol, Sendai, Miyagi, Japan; [Shima, Yasuo] Tsukuba Med Ctr Hosp, Dept Palliat Med, Tsukuba, Ibaraki, Japan; [Yomiya, Kinomi] Saitama Canc Ctr, Dept Palliat Care, Saitama, Japan; [Matoba, Motohiro] Natl Canc Ctr, Dept Palliat Med, Tokyo, Japan; [Adachi, Isamu] Shizuoka Canc Ctr, Div Palliat Med, Shizuoka, Japan; [Yoshimoto, Tetsusuke] Social Insurance Chukyo Hosp, Dept Palliat & Support Care, Nagoya, Aichi, Japan; [Eguchi, Kenji] Teikyo Univ, Sch Med, Dept Internal Med & Med Oncol, Tokyo 173, Japan	Kosugi, T (reprint author), Saga Ken Med Ctr, Dept Palliat Care, 400 Kase Machi, Saga 8408571, Japan.	kosugi0416@gmail.com			Taiho Pharmaceuticals, Co., Ltd., Tokyo, Japan	This study was funded by Taiho Pharmaceuticals, Co., Ltd., Tokyo, Japan. The authors have no other financial disclosures and declare no conflicts of interest.	BENNETT D, 2005, [No title captured], V30, P296; BENNETT D, 2005, [No title captured], V30, P354; Burton AW, 2004, CLIN J PAIN, V20, P195, DOI 10.1097/00002508-200405000-00011; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Eichman JD, 1998, PHARM RES-DORDR, V15, P925, DOI 10.1023/A:1011936901638; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Foley KM, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P981; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; Koizumi W, 2004, JPN J CLIN ONCOL, V34, P608, DOI 10.1093/jjco/hyh104; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Lennernas B, 2010, PALLIATIVE MED, V24, P286, DOI 10.1177/0269216309356138; Mercadante S, 1998, CANCER TREAT REV, V24, P425, DOI 10.1016/S0305-7372(98)90005-6; Messina J, 2008, DRUG TODAY, V44, P41, DOI 10.1358/dot.2008.44.1.1178469; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy Russell K, 2010, J Opioid Manag, V6, P97; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Slatkin Neal E, 2007, J Support Oncol, V5, P327; STREISAND JB, 1995, ANESTHESIOLOGY, V82, P759, DOI 10.1097/00000542-199503000-00018; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5	26	8	8	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	JUN	2014	47	6					990	1000		10.1016/j.jpainsymman.2013.07.006			11	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	AL0YO	WOS:000338853200007	24099893	Bronze			2020-06-30	J	Taylor, D; Radbruch, L; Revnic, J; Torres, LM; Ellershaw, JE; Perelman, M				Taylor, Donald; Radbruch, Lukas; Revnic, Julia; Torres, Luis M.; Ellershaw, John E.; Perelman, Michael			A Report on the Long-Term Use of Fentanyl Pectin Nasal Spray in Patients With Recurrent Breakthrough Pain	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Breakthrough; cancer; fentanyl; FPNS; long-term; palliative care; pain	CANCER PAIN; CLINICAL ONCOLOGY; AMERICAN SOCIETY; MANAGEMENT; ACCEPTABILITY; TOLERABILITY; EFFICACY; CARE	Context. As patients with cancer are living longer, there is a need to ensure that treatments used for palliative care are well tolerated and effective during long-term use. Objectives. To investigate the long-term use of fentanyl pectin nasal spray (FPNS) for the treatment of breakthrough pain in cancer (BTPc) in patients receiving regular opioid therapy. Methods. Adult patients (N = 401) taking at least 60 mg/day oral morphine or equivalent, experiencing one to four episodes of BTPc a day, entered an open-label long-term study (NCT00458510). Patients had either completed an FPNS randomized controlled trial or were newly identified. Of these, 171 patients continued into an extension study. Up to four episodes of BTPc a day were treated with FPNS at 100-800 mu g titrated doses. During the extension study, patients visited the clinic every four weeks for assessment and reporting of adverse events (AEs). Results. There were 163 patients with documented FPNS use. The mean duration of use was 325 days; 46 patients used FPNS for >= 360 days; the maximum duration was 44 months. Seventy percent of patients did not change their FPNS dose; 2% of patients withdrew from the study because of the lack of efficacy. The most common AEs, aside from disease progression, were insomnia, 9.9%; nausea, 9.4%; vomiting, 9.4%; and peripheral edema, 9.4%. The overall incidence of FPNS-related AEs was 11.1%, the most common being constipation (4.1%), with no apparent dose relationship. Ten patients (5.8%) experienced nasal AEs, most of which were mild or moderate. Conclusion. FPNS appeared to provide sustained benefit and was well tolerated during long-term treatment of BTPc. (C) 2014 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.	[Taylor, Donald] Georgia Ctr Canc Pain Management & Palliat Med, Marietta, GA USA; [Radbruch, Lukas] Univ Klinikum Bonn, Klin Palliativmed, Bonn, Germany; [Revnic, Julia] Hop Jean Jaures, Paris, France; [Torres, Luis M.] Hosp Univ Puerta Mar, Cadiz, Spain; [Ellershaw, John E.] Marie Curie Palliat Care Inst, Liverpool, Merseyside, England; [Perelman, Michael] Archimedes Dev Ltd, Nottingham, England	Taylor, D (reprint author), Taylor Res LLC, Comprehens Pain Care, PC, 840 Church St NE, Marietta, GA 30060 USA.	dtaylor@cpcnopain.com	Torres, Luis M/Q-6983-2019; Torres, Luis Miguel/O-1720-2015	Torres, Luis Miguel/0000-0002-0194-7875	Archimedes Development Ltd, Nottingham, UK	This study was funded by Archimedes Development Ltd, Nottingham, UK. D. T. is on the speakers' bureaus of INSYS Therapeutics and Reckitt Benckiser Pharmaceuticals. L. R. reports no conflicts of interest. J. R. had been paid for educational presentations by Archimedes; her previous institution received research support from Archimedes. L. M. T. is a consultant for Ferrer and ProStrakan and is on the speakers' bureaus of Cephalon and Archimedes Development Ltd. J. E. E. reports no conflicts of interest. M. P. is employed by Archimedes Development Ltd. Medical writing support and editorial assistance were provided by Victoria Paddock, Karen Munro, Sharon Suntag, and Julie Gerke of Quintiles Medical Communications, Parsippany, NJ, and supported by Archimedes Development Ltd, Nottingham, UK. Statistical analysis was provided by Alastair D. Knight of Evicom Ltd, Teddington, UK.	[Anonymous], 2012, LAZANDA; [Anonymous], 2012, PECFENT SUMM PROD CH; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Ferris FD, 2009, J CLIN ONCOL, V27, P3052, DOI 10.1200/JCO.2008.20.1558; McCorkle R, 2011, CA-CANCER J CLIN, V61, P50, DOI 10.3322/caac.20093; Pergolizzi JV, 2012, J PSYCHOSOM RES, V72, P443, DOI 10.1016/j.jpsychores.2012.02.009; Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Portenoy Russell K, 2010, J Opioid Manag, V6, P319; Radbruch L, 2012, SUPPORT CARE CANCER, V20, P565, DOI 10.1007/s00520-011-1124-x; Schey J., 2011, J ADV PRACT ONCOL, V2, P402; Smith H, 2012, CNS DRUGS, V26, P509, DOI 10.2165/11630580-000000000-00000; Smith TJ, 2012, J CLIN ONCOL, V30, P880, DOI 10.1200/JCO.2011.38.5161; Starr TD, 2010, CURR PAIN HEADACHE R, V14, P268, DOI 10.1007/s11916-010-0118-6; Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality, 2012, NSDUH SER H, VH-44; Taylor Donald, 2010, J Support Oncol, V8, P184	18	10	10	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	JUN	2014	47	6					1001	1007		10.1016/j.jpainsymman.2013.07.012			7	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	AL0YO	WOS:000338853200008	24128821	Bronze			2020-06-30	J	Pinna, MAC				Cuervo Pinna, Miguel Angel			A Randomized Crossover Clinical Trial to Evaluate the Efficacy of Oral Transmucosal Fentanyl Citrate in the Treatment of Dyspnea on Exertion in Patients With Advanced Cancer	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter									Reg Programme Palliat Care Extremadura, Palliat Care Team Badajoz, Badajoz, Spain	Pinna, MAC (reprint author), Reg Programme Palliat Care Extremadura, Palliat Care Team Badajoz, Badajoz, Spain.	miguelangel.cuervop@gmail.com					Pinna MA, 2013, AM J HOSP PALLIAT CA; Simon ST, 2013, J PAIN SYMPTOM MANAG, V46, P874, DOI 10.1016/j.jpainsymman.2013.02.019	2	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	JUN	2014	47	6					E4	E5		10.1016/j.jpainsymman.2013.12.235			2	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	AL0YO	WOS:000338853200002	24685724	Bronze			2020-06-30	J	Tedders, KM; McNorton, KN; Edwin, SB				Tedders, Kristen M.; McNorton, Kelly N.; Edwin, Stephanie B.			Efficacy and Safety of Analgosedation with Fentanyl Compared with Traditional Sedation with Propofol	PHARMACOTHERAPY			English	Article						analgosedation; fentanyl; propofol; sedation; critical care	INTENSIVE-CARE-UNIT; MECHANICALLY VENTILATED PATIENTS; ANALGESIA-BASED SEDATION; CRITICALLY-ILL PATIENTS; RANDOMIZED-TRIAL; DOUBLE-BLIND; ICU PATIENTS; REMIFENTANIL; ADULT; DELIRIUM	OBJECTIVES To compare the efficacy and safety of analgosedation with fentanyl versus traditional sedation with propofol in critically ill patients receiving mechanical ventilation. METHODS Retrospective, observational study evaluating adult critically ill patients on mechanical ventilation at a community teaching hospital who received continuous infusion fentanyl (n=50) or propofol (n=50) from September 2011-March 2013. RESULTS Median duration of mechanical ventilation was similar between patients receiving propofol and fentanyl infusions (46.7 hr vs 46.0 hr, p=0.19). No difference was noted in median intensive care unit length of stay between groups (p=0.42). A larger percentage of patients receiving propofol required rescue opioids compared with patients receiving fentanyl (56% vs 34%, p=0.04). Furthermore, patients receiving propofol required significantly more rescue opioid therapy during the course of mechanical ventilation as calculated by fentanyl equivalents (150 mu g vs 100 mu g, p=0.03). No difference in the rate of intensive care unit delirium was noted between groups (fentanyl 23% vs propofol 27%, p=0.80). CONCLUSION Analgosedation with fentanyl appears to be a safe and effective strategy to facilitate mechanical ventilation. This regimen does not appear to affect duration of mechanical ventilation when compared with propofol, but may allow for more optimal pain management in critically ill patients.	[Tedders, Kristen M.] St John Macomb Oakland Hosp, Dept Pharm, Warren, MI USA; [McNorton, Kelly N.; Edwin, Stephanie B.] St John Hosp & Med Ctr, Dept Pharm, Detroit, MI USA	Tedders, KM (reprint author), 11800 East 12 Mile Rd, Warren, MI 48093 USA.	kristen.ted-ders@stjohn.org					Barr J, 2001, ANESTHESIOLOGY, V95, P286, DOI 10.1097/00000542-200108000-00007; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Battershill AJ, 2006, DRUGS, V66, P365, DOI 10.2165/00003495-200666030-00013; Breen D, 2005, CRIT CARE, V9, pR200, DOI 10.1186/cc3495; CARRASCO G, 1993, CHEST, V103, P557, DOI 10.1378/chest.103.2.557; Devabhakthuni S, 2012, ANN PHARMACOTHER, V46, P530, DOI 10.1345/aph.1Q525; Devlin JW, 2013, SEMIN RESP CRIT CARE, V34, P201, DOI 10.1055/s-0033-1342983; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Gelinas C, 2007, CLIN J PAIN, V23, P497, DOI 10.1097/ajp.0b013e31806a23fb; Gill KV, 2012, ANN PHARMACOTHER, V46, P1331, DOI 10.1345/aph.1R037; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Mattia C, 2006, MINERVA ANESTESIOL, V72, P769; Muellejans B, 2004, CRIT CARE, V8, pR1, DOI 10.1186/cc2398; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Park G, 2007, BRIT J ANAESTH, V98, P76, DOI 10.1093/bja/ael320; Rauf K, 2005, BRIT J ANAESTH, V95, P611, DOI 10.1093/bja/aei237; Rozendaal F, 2009, INTENS CARE MED, V35, P291, DOI 10.1007/s00134-008-1328-9; Schelling G, 1998, CRIT CARE MED, V26, P651, DOI 10.1097/00003246-199804000-00011; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9; Tonner Peter H, 2003, Curr Opin Anaesthesiol, V16, P113; Wunsch H, 2009, CRIT CARE MED, V37, P3031, DOI 10.1097/CCM.0b013e3181b02eff	23	13	13	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0277-0008	1875-9114		PHARMACOTHERAPY	Pharmacotherapy	JUN	2014	34	6					643	647		10.1002/phar.1429			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AJ5BV	WOS:000337696600161	24753262				2020-06-30	J	Yon, JH; Choi, GJ; Kang, H; Park, JM; Yang, HS				Yon, Jun Heum; Choi, Geun Joo; Kang, Hyun; Park, Joong-Min; Yang, Hoon Shik			Intraoperative systemic lidocaine for pre-emptive analgesics in subtotal gastrectomy: a prospective, randomized, double-blind, placebo-controlled study	CANADIAN JOURNAL OF SURGERY			English	Article							EFFECTIVE PAIN RELIEF; INTRAVENOUS LIDOCAINE; GRANULOCYTE-ADHERENCE; HOSPITAL STAY; RECOVERY; LENGTH	Background: Pre-emptive intravenous lidocaine infusion is known to improve postoperative pain in abdominal surgery. We assessed the effect of intravenous lidocaine infusion in patients who underwent subtotal gastrectomy. Methods: We conducted a double-blind, placebo-controlled study with patients undergoing subtotal gastrectomy for early gastric cancer divided into 2 groups: 1 group received intravenous lidocaine infusion preoperatively and throughout surgery, and the other received normal saline infusion (placebo). We assessed postoperative outcomes, including pain scores on a visual analogue scale (VAS), administration frequency of patient-controlled analgesia (PCA) and the amount of consumed fentanyl. Postoperative nausea and vomiting, length of hospital stay (LOS), time to return to regular diet and patient satisfaction at discharge were evaluated. Results: There were 36 patients in our study. Demographic characteristics were similar between the groups. The VAS pain scores and administration frequency of PCA were significantly lower in the lidocaine group until 24 hours after surgery, and fentanyl consumption was significantly lower in this group until 12 hours postoperatively compared with the placebo group. The total amount of consumed fentanyl and the total administration frequency of PCA were significantly lower in the lidocaine than the control group. No significant differences were detected in terms of nausea and vomiting, return to regular diet, LOS and patient satisfaction, and there were no reported side-effects of lidocaine. Conclusion: Intravenous lidocaine infusion reduces pain during the postoperative period after subtotal gastrectomy.	[Yon, Jun Heum] Inje Univ, Sanggye Paik Hosp, Dept Anesthesiol & Pain Med, Seoul, South Korea; [Choi, Geun Joo; Kang, Hyun] Chung Ang Univ, Dept Anaesthesiol & Pain Med, Coll Med, Seoul 156755, South Korea; [Park, Joong-Min] Chung Ang Univ, Dept Surg, Coll Med, Seoul 156755, South Korea; [Yang, Hoon Shik] Chung Ang Univ, Dept Otolaryngol & Head Neck Surg, Coll Med, Seoul 156755, South Korea	Kang, H (reprint author), Chung Ang Univ, Dept Anaesthesiol & Pain Med, Coll Med, 224-1 Heukseok Dong, Seoul 156755, South Korea.	roman00@naver.com	Kang, Hyun/AAE-7872-2020	Kang, Hyun/0000-0003-2844-5880	Inje University	This work was supported by the 2012 Inje University research grant. Trial registration: ACTRN12612000545864.	Amir R, 2006, J PAIN, V7, pS1, DOI 10.1016/j.jpain.2006.01.444; Aronsen KF, 1972, SCAND J CLIN LAB I S, V124, P127; Bae JM, 2002, J KOREAN MED SCI, V17, P611, DOI 10.3346/jkms.2002.17.5.611; Bellows Charles F, 2006, JSLS, V10, P345; Bryson GL, 2010, CAN J ANESTH, V57, P759, DOI 10.1007/s12630-010-9332-2; Cole DS, 2008, ANN ROY COLL SURG, V90, P317, DOI 10.1308/003588408X285865; De Oliveira GS, 2012, ANESTH ANALG, V115, P262, DOI 10.1213/ANE.0b013e318257a380; Grady Philip, 2012, AANA J, V80, P282; HALEVY A, 1995, SURG ENDOSC-ULTRAS, V9, P280; Hollmann MW, 2000, ANESTHESIOLOGY, V93, P858, DOI 10.1097/00000542-200009000-00038; Hwang SI, 2009, SURG ENDOSC, V23, P1252, DOI 10.1007/s00464-008-0140-5; Jin FL, 1998, CAN J ANAESTH, V45, P293, DOI 10.1007/BF03012017; Junger A, 2001, EUR J ANAESTH, V18, P314, DOI 10.1046/j.0265-0215.2000.00837.x; Kaba A, 2007, ANESTHESIOLOGY, V106, P11, DOI 10.1097/00000542-200701000-00007; Kang H, 2011, J INT MED RES, V39, P435, DOI 10.1177/147323001103900211; Kim TH, 2011, SURG ENDOSC, V25, P3183, DOI 10.1007/s00464-011-1684-3; Koppert W, 2000, PAIN, V85, P217, DOI 10.1016/S0304-3959(99)00268-7; MACGREGOR RR, 1980, BLOOD, V56, P203; MACGREGOR RR, 1976, AM J MED, V61, P597, DOI 10.1016/0002-9343(76)90137-6; Martin F, 2008, ANESTHESIOLOGY, V109, P118, DOI 10.1097/ALN.0b013e31817b5a9b; Pavlin DJ, 1998, ANESTH ANALG, V87, P816, DOI 10.1097/00000539-199810000-00014; Petrenko AB, 2003, ANESTH ANALG, V97, P1108, DOI 10.1213/01.ANE.0000081061.12235.55; ROWLAND M, 1971, ANN NY ACAD SCI, V179, P383, DOI 10.1111/j.1749-6632.1971.tb46915.x; Swenson BR, 2010, REGION ANESTH PAIN M, V35, P370, DOI 10.1097/AAP.0b013e3181e8d5da; Wongyingsinn M, 2011, REGION ANESTH PAIN M, V36, P241, DOI 10.1097/AAP.0b013e31820d4362; Wuethrich PY, 2012, EUR J ANAESTH, V29, P537, DOI 10.1097/EJA.0b013e328356bad6; Yano H, 2001, Gastric Cancer, V4, P93, DOI 10.1007/PL00011730	27	12	13	0	3	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0008-428X	1488-2310		CAN J SURG	Can. J. Surg.	JUN	2014	57	3					175	182		10.1503/cjs.009613			8	Surgery	Surgery	AJ5SU	WOS:000337748900015	24869609	Green Published, Bronze			2020-06-30	J	Devlin, JW; Al-Qadheeb, NS; Chi, A; Roberts, RJ; Qawi, I; Garpestad, E; Hill, NS				Devlin, John W.; Al-Qadheeb, Nada S.; Chi, Amy; Roberts, Russel J.; Qawi, Imrana; Garpestad, Erik; Hill, Nicholas S.			Efficacy and Safety of Early Dexmedetomidine During Noninvasive Ventilation for Patients With Acute Respiratory Failure	CHEST			English	Article							POSITIVE-PRESSURE VENTILATION; INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; MECHANICAL VENTILATION; SEDATION; MIDAZOLAM; DELIRIUM; ANALGESICS; TOLERANCE; PROPOFOL	Background: Successful application of noninvasive ventilation (NIV) for acute respiratory failure (ARF) requires patient cooperation and comfort. The efficacy and safety of early IV dexmedetomidine when added to protocolized, as-needed IV midazolam and fentanyl remain unclear. Methods: Adults with ARF and within 8 h of starting NIV were randomized to receive IV dexmedetomidine (0.2 mu g/kg/h titrated every 30 min to 0.7 mu g/kg/h to maintain a Sedation-Agitation Scale [SAS] score of 3 to 4) or placebo in a double-blind fashion up to 72 h, until NIV was stopped for > 2 h, or until intubation. Patients with agitation (SAS > 5) or pain (visual analog scale >= 5 of 10 cm) 15 min after each dexmedetomidine and placebo increase could receive IV midazolam 0.5 to 1.0 mg or IV fentanyl 25 to 50 m g, respectively, at a minimum interval of every 3 h. Results: The dexmedetomidine (n 5 16) and placebo (n 5 17) groups were similar at baseline. Use of early dexmedetomidine did not improve NIV tolerance (score, 1 of 4; OR, 1.44; 95% CI, 0.44-4.70; P =.54) nor, vs placebo, led to a greater median (interquartile range) percent time either tolerating NIV (99% [61%-100%] vs 67% [40%-100%], P =.56) or remaining at the desired sedation level (SAS score 5 3 or 4, 100% [86%-100%] vs 100% [100%-100%], P =.28], or fewer intubations (P =.79). Although use of dexmedetomidine was associated with a greater duration of NIV vs placebo (37 [16-72] vs 12 [4-22] h, P =.03), the total ventilation duration (NIV 1 invasive) was similar (3.3 [2-4] days vs 3.8 [2-5] days, P =.52). More patients receiving dexmedetomidine had one or more episodes of deep sedation vs placebo (SAS <= 2, 25% vs 0%, P =.04). Use of midazolam (P =.40) and episodes of either severe bradycardia (heart rate <= 50 beats/min, P =.18) or hypotension (systolic BP <= 90 mm Hg, P =.64) were similar. Conclusions: Initiating dexmedetomidine soon after NIV initiation in patients with ARF neither improves NIV tolerance nor helps to maintain sedation at a desired goal. Randomized, multicenter trials targeting patients with initial intolerance are needed to further elucidate the role for dexmedetomidine in this population.	[Devlin, John W.; Al-Qadheeb, Nada S.] Northeastern Univ, Sch Pharm, Boston, MA 02115 USA; [Devlin, John W.; Chi, Amy; Qawi, Imrana; Garpestad, Erik; Hill, Nicholas S.] Tufts Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA USA; [Roberts, Russel J.] Tufts Med Ctr, Dept Pharm, Boston, MA USA	Devlin, JW (reprint author), Northeastern Univ, Sch Pharm, 360 Huntington Ave,R218 TF, Boston, MA 02115 USA.	j.devlin@neu.edu			Hospira, Inc.	This study was supported by an unrestricted investigator-initiated grant from Hospira, Inc.	Akada S, 2008, ANESTH ANALG, V107, P167, DOI 10.1213/ane.0b013e3181732dc2; Antonelli M, 2001, INTENS CARE MED, V27, P1718, DOI 10.1007/s00134-001-1114-4; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Bello G, 2013, CURR OPIN CRIT CARE, V19, P1, DOI 10.1097/MCC.0b013e32835c34a5; Bergeron N, 2001, INTENS CARE MED, V27, P859, DOI 10.1007/s001340100909; Carlucci A, 2013, CRIT CARE, V17, DOI 10.1186/cc12580; Carron M, 2013, BRIT J ANAESTH, V110, P896, DOI 10.1093/bja/aet070; Charlesworth M, 2012, LUNG, V190, P597, DOI 10.1007/s00408-012-9403-y; Clouzeau B, 2010, INTENS CARE MED, V36, P1675, DOI 10.1007/s00134-010-1904-7; Devlin JW, 2008, CRIT CARE, V12, DOI 10.1186/cc6793; Devlin JW, 2007, CRIT CARE MED, V35, P2298, DOI 10.1097/01.CCM.0000284512.21942.F8; Devlin John W, 2011, Anesthesiol Clin, V29, P567, DOI 10.1016/j.anclin.2011.09.001; Devlin JW, 2010, CRIT CARE MED, V38, pS231, DOI 10.1097/CCM.0b013e3181de125a; Duan M, 2012, RESP CARE, V57, P1967, DOI 10.4187/respcare.01733; Groeben H, 2004, ANESTHESIOLOGY, V100, P359, DOI 10.1097/00000542-200402000-00026; Gupta P, 2013, RESP CARE, V58, P778, DOI 10.4187/respcare.02096; Hess DR, 2011, RESP CARE, V56, P153, DOI 10.4187/respcare.01049; Hilbert G, 2012, MINERVA ANESTESIOL, V78, P842; Hill NS, 2007, CRIT CARE MED, V35, P2402, DOI 10.1097/01.CCM.0000284587.36541.7F; Ho K, 1996, ANN EMERG MED, V27, P427, DOI 10.1016/S0196-0644(96)70223-8; Huang Z, 2012, INTERNAL MED, V51, P2299, DOI 10.2169/internalmedicine.51.7810; HUSKISSON EC, 1983, [No title captured], P33; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MacLaren R, 2013, PHARMACOTHERAPY, V33, P165, DOI 10.1002/phar.1175; Maheshwari V, 2006, CHEST, V129, P1226, DOI 10.1378/chest.129.5.1226; Mehta S, 1997, CRIT CARE MED, V25, P620, DOI 10.1097/00003246-199704000-00011; Nava S, 1997, THORAX, V52, P249, DOI 10.1136/thx.52.3.249; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Reardon DP, 2013, AM J HEALTH-SYST PH, V70, P767, DOI 10.2146/ajhp120211; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Riker RR, 1999, CRIT CARE MED, V27, P1325, DOI 10.1097/00003246-199907000-00022; Rocco M, 2010, INTENS CARE MED, V36, P2060, DOI 10.1007/s00134-010-2026-y; Schneider E, 2006, ANAESTHESIA, V61, P20, DOI 10.1111/j.1365-2044.2005.04400.x; Senoglu N, 2010, CURR THER RES CLIN E, V71, P141, DOI 10.1016/j.curtheres.2010.06.003; Stauffer JL, 1994, PRINCIPLES PRACTICE, P711; Takasaki Y, 2009, J ANESTH, V23, P147, DOI 10.1007/s00540-008-0712-5; Venn RM, 2000, CRIT CARE, V4, P302, DOI 10.1186/cc712; VITACCA M, 1993, INTENS CARE MED, V19, P450, DOI 10.1007/BF01711086; Walkey Allan J, 2013, Ann Am Thorac Soc, V10, P10, DOI 10.1513/AnnalsATS.201206-034OC	40	30	34	0	5	AMER COLL CHEST PHYSICIANS	GLENVIEW	2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA	0012-3692			CHEST	Chest	JUN	2014	145	6					1204	1212		10.1378/chest.13-1448			9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	AJ0OV	WOS:000337355600012	24577019				2020-06-30	J	Sun, L; Guo, R; Sun, L				Sun, Liang; Guo, Rui; Sun, Li			The impact of prophylactic intravenous lidocaine on opioid-induced cough: a meta-analysis of randomized controlled trials	JOURNAL OF ANESTHESIA			English	Article						Lidocaine; Opioid-induced cough; Fentanyl-induced cough; Remifentanil-induced cough; Meta-analysis	DOUBLE-BLIND; FENTANYL; ALFENTANIL; QUALITY	Opioids are commonly used for general anesthesia, but reflex cough can occur after an intravenous injection. We have performed a meta-analysis of randomized controlled trials (RCTs) that evaluated the effectiveness and safety of prophylactic lidocaine administered intravenously (IV) on opioid-induced cough (OIC) during induction in patients undergoing general anesthesia. We searched three bibliographic databases (PubMed, Embase, and the Cochrane Central Register of Controlled Trials) to identify studies meeting a priori inclusion criteria and also conducted a secondary reference review. The information used to calculate the relationship between lidocaine prophylaxis and the risk and severity of OIC was extracted by two principal investigators, respectively. Six RCTs with a total of 1,740 participants were included in this meta-analysis. Overall, prophylactic lidocaine administered IV reduced both the risk of OIC [pooled risk ratio (RR) 0.471; 95 % confidence interval (CI) 0.355-0.625; P = 0.074; heterogeneity test, I (2) = 50.3 %] and its severity (weighed mean difference -0.316; 95 % CI -0.480 to -0.151; P = 0.038; heterogeneity test, I (2) = 60.5 %). Sub-group analysis indicated a significant reduction in the incidence of both fentanyl-induced cough (FIC) and remifentanil-induced cough (RIC), but it appeared that lidocaine only alleviated the severity of FIC. Further sub-group analysis indicated that the lowest effect dose of lidocaine for preventing the prevalence of OIC was 0.5 mg/kg. No severe adverse effects were reported. Our meta-analysis establishes the effectiveness of prophylactic lidocaine administered IV for the prevention of OIC during induction. The lowest effective dose of lidocaine on the risk of OIC appeared to be 0.5 mg/kg.	[Sun, Liang; Sun, Li] Chinese Acad Med Sci, Canc Inst & Hosp, Dept Anesthesiol, Peking Union Med Coll,Natl Canc Ctr, 17 Panjiayuannanli Rd, Beijing 100021, Peoples R China; [Guo, Rui] Chinese Acad Med Sci, Fuwai Hosp, Peking Union Med Coll, Natl Ctr Cardiovascular Dis Control & Res,Natl He, Beijing 100037, Peoples R China	Sun, L (reprint author), Chinese Acad Med Sci, Canc Inst & Hosp, Dept Anesthesiol, Peking Union Med Coll,Natl Canc Ctr, 17 Panjiayuannanli Rd, Beijing 100021, Peoples R China.	heimingway1984@163.com					Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; Ambesh SP, 2010, BRIT J ANAESTH, V104, P40, DOI 10.1093/bja/aep333; Ambesh SP, 2009, INT J ANESTHESIOL, V20, P7; Armitage P, 2002, ANAL MEANS PROPORTIO, P83; Bang SR, 2010, KOREAN J ANESTHESIOL, V59, P319, DOI 10.4097/kjae.2010.59.5.319; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BENTHUYSEN JL, 1986, ANESTHESIOLOGY, V64, P440, DOI 10.1097/00000542-198604000-00005; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; Cho HB, 2010, ACTA ANAESTH SCAND, V54, P717, DOI 10.1111/j.1399-6576.2009.02203.x; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ferrari J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000964.pub3; Guler G, 2010, CURR THER RES CLIN E, V71, P289, DOI 10.1016/j.curtheres.2010.10.004; Han JI, 2011, KOREAN J ANESTHESIOL, V60, P391, DOI 10.4097/kjae.2011.60.6.391; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hirota K, 1999, BRIT J ANAESTH, V82, P87; Horng HC, 2007, ACTA ANAESTH SCAND, V51, P862, DOI 10.1111/j.1399-6576.2007.01335.x; Hung KC, 2010, ANAESTHESIA, V65, P4, DOI 10.1111/j.1365-2044.2009.06109.x; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jalota L, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1110; Kim JY, 2008, ANAESTH INTENS CARE, V36, P746; Kim JY, 2008, ANAESTHESIA, V63, P495, DOI 10.1111/j.1365-2044.2007.05414.x; Kim JY, 2009, KOREAN J ANESTHESIOL, V56, P624; Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010; Lim JH, 2010, KOREAN J ANESTHESIOL, V58, P117, DOI 10.4097/kjae.2010.58.2.117; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; Lui PW, 1996, CAN J ANAESTH, V43, P1216; Marret E, 2008, BRIT J SURG, V95, P1331, DOI 10.1002/bjs.6375; NISHINO T, 1990, BRIT J ANAESTH, V64, P682, DOI 10.1093/bja/64.6.682; Oshima T, 2006, CAN J ANAESTH, V53, P753, DOI 10.1007/BF03022790; Pandey CK, 2005, CAN J ANAESTH, V52, P172, DOI 10.1007/BF03027724; Pandey CK, 2004, ANESTH ANALG, V99, P1696, DOI 10.1213/01.ANE.0000136967.82197.82; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; POULTON TJ, 1979, ANESTHESIOLOGY, V50, P470, DOI 10.1097/00000542-197905000-00018; REITAN JA, 1978, ANESTH ANALG, V57, P31; Tanaka Y, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004081.pub2; Tweed WA, 2001, ANESTH ANALG, V92, P1442; Vigneault L, 2011, CAN J ANESTH, V58, P22, DOI 10.1007/s12630-010-9407-0; YASUDA I, 1978, ANESTHESIOLOGY, V49, P117, DOI 10.1097/00000542-197808000-00012; Yu MS, 2011, KOREAN J ANESTHESIOL, V60, P403, DOI 10.4097/kjae.2011.60.6.403; YUKIOK H, 1993, ANESTH ANALG, V77, P309, DOI 10.1213/00000539-199377020-00016	41	11	12	0	5	SPRINGER JAPAN KK	TOKYO	SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	JUN	2014	28	3					325	333		10.1007/s00540-013-1732-3			9	Anesthesiology	Anesthesiology	AJ6HL	WOS:000337791800002	24173406				2020-06-30	J	Tanaka, N; Naito, T; Yagi, T; Doi, M; Sato, S; Kawakami, J				Tanaka, Noriaki; Naito, Takafumi; Yagi, Tatsuya; Doi, Matsuyuki; Sato, Shigehito; Kawakami, Junichi			Impact of CYP3A5*3 on Plasma Exposure and Urinary Excretion of Fentanyl and Norfentanyl in the Early Postsurgical Period	THERAPEUTIC DRUG MONITORING			English	Article						fentanyl; postoperative pain; CYP3A5; plasma exposure; urinary excretion	GENETIC POLYMORPHISMS; P-GLYCOPROTEIN; LIVER-TRANSPLANTATION; TRANSDERMAL PATCHES; HUMAN KIDNEY; PHARMACOKINETICS; BLOOD; EXPRESSION; CYP3A5; ABCB1	Background:The pharmacokinetic characteristics of intravenous fentanyl have not been fully clarified in the early postsurgical period. The aim of this study was to evaluate the plasma exposure and urinary excretion of fentanyl and norfentanyl according to cytochrome P450 (CYP) 3A5 genetic polymorphism.Methods:Fifty-two adult Japanese postoperative patients receiving a continuous intravenous fentanyl infusion were enrolled. Plasma concentrations of fentanyl and norfentanyl were determined at 24 hours after the operation, and their urinary excretion from 12 to 36 hours was evaluated.Results:Plasma concentrations of fentanyl normalized for infusion rate were significantly higher in the *3/*3 group than in the *1 carrier group. The plasma concentration ratio of norfentanyl to fentanyl was significantly lower in the *3/*3 group than in the *1 carrier group. Urinary excretion rates of fentanyl and norfentanyl were 4.4% and 71%, respectively, and no significant differences were observed between the CYP3A5 genotypes. Renal clearance ratios of fentanyl and norfentanyl to creatinine were 0.34 and 3.4, respectively. There were no significant differences in the renal clearance ratios between the genotypes. Free fractions of fentanyl and norfentanyl in human plasma were 4.9% and 95%, respectively. Total and nonrenal clearance of fentanyl were significantly lower in the *3/*3 group than in the *1 carrier group.Conclusions:CYP3A5*3 affected the plasma exposure of fentanyl but not urinary excretion in our postoperative patients. The renal clearance ratios of fentanyl and norfentanyl to creatinine were much higher than their free fractions in plasma. These findings suggest a slight contribution of renal tubular secretion of fentanyl and norfentanyl to their plasma exposures.	[Tanaka, Noriaki; Naito, Takafumi; Yagi, Tatsuya; Kawakami, Junichi] Hamamatsu Univ Sch Med, Dept Hosp Pharm, Hamamatsu, Shizuoka 4313192, Japan; [Doi, Matsuyuki] Hamamatsu Univ Sch Med, Intens Care Unit, Univ Hosp, Hamamatsu, Shizuoka 4313192, Japan; [Sato, Shigehito] Hamamatsu Univ Sch Med, Dept Anesthesiol & Intens Care, Hamamatsu, Shizuoka 4313192, Japan	Kawakami, J (reprint author), Hamamatsu Univ Sch Med, Dept Hosp Pharm, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	kawakami-ham@umin.ac.jp			Japan Research Foundation for Clinical Pharmacology	Supported by a Research Grant provided by Japan Research Foundation for Clinical Pharmacology.	Alvarez JM, 2001, J THORAC CARDIOV SUR, V122, P457, DOI 10.1067/mtc.2001.115701; Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; BAXTER AD, 1994, CAN J ANAESTH, V41, P184, DOI 10.1007/BF03009829; CARTWRIGHT P, 1983, ANESTH ANALG, V62, P966; Dagenais C, 2004, BIOCHEM PHARMACOL, V67, P269, DOI 10.1016/j.bcp.2003.08.027; Elkiweri IA, 2009, ANESTH ANALG, V108, P149, DOI 10.1213/ane.0b013e31818e0bd1; Fukuda K, 2009, PAIN, V147, P194, DOI 10.1016/j.pain.2009.09.004; Fukuen S, 2002, PHARMACOGENETICS, V12, P331, DOI 10.1097/00008571-200206000-00009; GOROMARU T, 1984, ANESTHESIOLOGY, V61, P73, DOI 10.1097/00000542-198461010-00013; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Haehner BD, 1996, MOL PHARMACOL, V50, P52; Hagenbuch B, 2002, NEWS PHYSIOL SCI, V17, P231, DOI 10.1152/nips.01402.2002; Heiskanen T, 2009, PAIN, V144, P218, DOI 10.1016/j.pain.2009.04.012; HENDERSON JM, 1992, HEPATOLOGY, V16, P715, DOI 10.1002/hep.1840160316; HESS R, 1972, EUR J CLIN PHARMACOL, V4, P137, DOI 10.1007/BF00561135; Jin M, 2005, J ANAL TOXICOL, V29, P590, DOI 10.1093/jat/29.7.590; Jin SJ, 2011, CLIN PHARMACOL THER, V90, P423, DOI 10.1038/clpt.2011.133; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; Kim KM, 2013, INT J CLIN PHARM TH, V51, P383, DOI 10.5414/CP201824; Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Motohashi H, 2002, J AM SOC NEPHROL, V13; Nishimura Masuhiro, 2005, Drug Metab Pharmacokinet, V20, P452, DOI 10.2133/dmpk.20.452; Park HJ, 2007, CLIN PHARMACOL THER, V81, P539, DOI 10.1038/sj.clpt.6100046; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; Rivory LP, 2002, BRIT J CANCER, V87, P277, DOI 10.1038/sj.bjc.6600448; Ryan AM, 2007, J GASTROINTEST SURG, V11, P1355, DOI 10.1007/s11605-007-0223-y; SCHWARTZ JG, 1994, AM J FOREN MED PATH, V15, P236, DOI 10.1097/00000433-199409000-00011; SILVERSTEIN JH, 1993, ANESTH ANALG, V76, P618; Skrobik Y, 2013, CRIT CARE MED, V41, P999, DOI 10.1097/CCM.0b013e318275d014; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; Tabata M, 2011, ANN THORAC SURG, V91, P899, DOI 10.1016/j.athoracsur.2010.11.030; Takashina Y, 2009, J CLIN PHARM THER, V34, P523, DOI 10.1111/j.1365-2710.2009.01033.x; Takashina Y, 2012, DRUG METAB PHARMACOK, V27, P414, DOI 10.2133/dmpk.DMPK-11-RG-134; VANKALKEN CK, 1991, ANN ONCOL, V2, P55, DOI 10.1093/oxfordjournals.annonc.a057825; vanLemmen RJ, 1996, EUR J PEDIATR, V155, P1067, DOI 10.1007/s004310050538	39	5	6	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0163-4356	1536-3694		THER DRUG MONIT	Ther. Drug Monit.	JUN	2014	36	3					345	352		10.1097/FTD.0000000000000029			8	Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology	Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology	AJ4XE	WOS:000337682000010	24365989				2020-06-30	J	Aldington, D; Jagdish, S				Aldington, Dominic; Jagdish, S.			The fentanyl 'lozenge' story: from books to battlefield	JOURNAL OF THE ROYAL ARMY MEDICAL CORPS			English	Article						Accident & Emergency Medicine; Pain Management	PAIN MANAGEMENT; CITRATE	This article outlines the process that led to the introduction of the fentanyl lozenge for acute pain management. It starts with the historical context before discussing the recognition of an ongoing problem and then identifies the options that were considered. There follows a description of the pharmacology of fentanyl before describing the trial of concept that was conducted. This leads into an outline of the meetings and committees that had to be engaged with before the final acceptance and subsequent ushering in. The final section describes an option that was unsuccessful.	[Aldington, Dominic] Royal Hampshire Cty Hosp, Dept Pain Med, Winchester SO22 5DG, Hants, England; [Jagdish, S.] Queen Alexandra Hosp, Dept Anaesthesia, Portsmouth, Hants, England	Aldington, D (reprint author), Royal Hampshire Cty Hosp, Dept Pain Med, Winchester SO22 5DG, Hants, England.	daldington@me.com		Aldington, Dominic/0000-0001-6253-1649			Aldington DJ, 2011, PHILOS T R SOC B, V366, P268, DOI 10.1098/rstb.2010.0214; Aronoff GM, 2005, PAIN MED, V6, P305, DOI 10.1111/j.1526-4637.2005.00045.x; Davey CMT, 2012, J ROY ARMY MED CORPS, V158, P190, DOI 10.1136/jramc-158-03-08; Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI [10.1586/ERN.11.63, 10.1586/ern.11.63]; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Hodgetts TJ, 2006, BATTLEFIELD ANALGESI; Moore RA, 2013, ANAESTHESIA, V68, P400, DOI 10.1111/anae.12148; Park C L, 2010, J R Army Med Corps, V156, P295; Roberts F, 2007, BJA EDUC, V7, P25, DOI 10.1093/bjaceaccp/mkl058; Smith J E, 2009, J R Army Med Corps, V155, P44; Wedmore IS, 2012, J TRAUMA ACUTE CARE, V73, pS490, DOI 10.1097/TA.0b013e3182754674; Younge GH, 1904, J ROY ARMY MED CORPS, V3, P138	12	7	8	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0035-8665	2052-0468		J ROY ARMY MED CORPS	J. R. Army Med. Corps	JUN	2014	160	2					102	104		10.1136/jramc-2013-000227			3	Medicine, General & Internal	General & Internal Medicine	AI9YA	WOS:000337302200005	24413475				2020-06-30	J	Ely, EW				Ely, E. Wesley			Our Enlightened Understanding of the Risks of Persistent Delirium	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Letter							INTENSIVE-CARE-UNIT; SEDATION		Vanderbilt Univ, Med Ctr, Nashville, TN 37235 USA	Ely, EW (reprint author), Vanderbilt Univ, Med Ctr, Nashville, TN 37235 USA.		Ely, E. Wesley/Z-2018-2019	Ely, E. Wesley/0000-0003-3957-2172			Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Patel SB, 2014, AM J RESP CRIT CARE, V189, P658, DOI 10.1164/rccm.201310-1815OC; Pisani MA, 2009, AM J RESP CRIT CARE, V180, P1092, DOI 10.1164/rccm.200904-0537OC; Takala J, 2014, AM J RESP CRIT CARE, V189, P622, DOI 10.1164/rccm.201401-0195ED	5	1	1	0	2	AMER THORACIC SOC	NEW YORK	25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA	1073-449X	1535-4970		AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUN 1	2014	189	11					1442	1443		10.1164/rccm.201403-0550LE			2	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	AI4GH	WOS:000336823200023	24881943				2020-06-30	J	Pandharipande, PP; Hughes, CG; Girard, TD				Pandharipande, Pratik P.; Hughes, Christopher G.; Girard, Timothy D.			Only a Small Subset of Sedation-related Delirium Is Innocuous: We Cannot Let Our Guard Down	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Letter							INTENSIVE-CARE-UNIT		[Pandharipande, Pratik P.; Hughes, Christopher G.; Girard, Timothy D.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Girard, Timothy D.] Tennessee Valley Healthcare Syst, Nashville, TN USA	Pandharipande, PP (reprint author), Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.		Girard, Timothy/I-3008-2019	Girard, Timothy/0000-0002-9833-4871; Pandharipande, Pratik/0000-0002-1389-8580			Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Patel SB, 2014, AM J RESP CRIT CARE, V189, P658, DOI 10.1164/rccm.201310-1815OC	3	2	2	1	5	AMER THORACIC SOC	NEW YORK	25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA	1073-449X	1535-4970		AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUN 1	2014	189	11					1443	1444		10.1164/rccm.201403-0506LE			2	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	AI4GH	WOS:000336823200024	24881944				2020-06-30	J	Kress, JP; Patel, SB; Hall, JB				Kress, John P.; Patel, Shruti B.; Hall, Jesse B.			The Importance of Determining the Reason for Intensive Care Unit Delirium Reply	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Letter									[Kress, John P.; Patel, Shruti B.; Hall, Jesse B.] Univ Chicago, Chicago, IL 60637 USA	Kress, JP (reprint author), Univ Chicago, Chicago, IL 60637 USA.				NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000430]		Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Levitt DG, 2005, BMC ANESTHESIOL, V5, P4, DOI DOI 10.1186/1471-2253-5-4; Page VJ, 2013, LANCET RESP MED, V1, P515, DOI 10.1016/S2213-2600(13)70166-8; Patel SB, 2014, AM J RESP CRIT CARE, V189, P658, DOI 10.1164/rccm.201310-1815OC; Schuttler J, 2000, ANESTHESIOLOGY, V92, P727, DOI 10.1097/00000542-200003000-00017; van Eijk MMJ, 2010, LANCET, V376, P1829, DOI 10.1016/S0140-6736(10)61855-7	7	0	2	0	2	AMER THORACIC SOC	NEW YORK	25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA	1073-449X	1535-4970		AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUN 1	2014	189	11					1444	1445		10.1164/rccm.201404-0637LE			2	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	AI4GH	WOS:000336823200026	24881946	Green Published			2020-06-30	J	Takala, J				Takala, Jukka			Reply: Is the Glass of Delirium Half Full or Half Empty?	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Letter									[Takala, Jukka] Univ Hosp Bern, CH-3010 Bern, Switzerland; [Takala, Jukka] Univ Bern, Bern, Switzerland	Takala, J (reprint author), Univ Hosp Bern, CH-3010 Bern, Switzerland.						Brummel NE, 2014, INTENS CARE MED, V40, P135, DOI 10.1007/s00134-013-3083-9; Devlin JW, 2013, INTENS CARE MED, V39, P2196, DOI 10.1007/s00134-013-3105-7; Haenggi M, 2013, INTENS CARE MED, V39, P2171, DOI 10.1007/s00134-013-3034-5; Patel SB, 2014, AM J RESP CRIT CARE, V189, P658, DOI 10.1164/rccm.201310-1815OC	4	0	0	0	2	AMER THORACIC SOC	NEW YORK	25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA	1073-449X	1535-4970		AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUN 1	2014	189	11					1444	1444		10.1164/rccm.201404-0642LE			1	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	AI4GH	WOS:000336823200025	24881945				2020-06-30	J	Cao, LH; Chang, Y; Lin, WQ; Zhou, JH; Tan, HY; Yuan, YF; Zeng, WA				Cao, Longhui; Chang, Yi; Lin, Wenqian; Zhou, Jianhua; Tan, Hongying; Yuan, Yunfei; Zeng, Weian			Long-Term Survival after Resection of Hepatocelluar Carcinoma: A Potential Risk Associated with the Choice of Postoperative Analgesia	ANESTHESIA AND ANALGESIA			English	Article							KILLER-CELL CYTOTOXICITY; CANCER RECURRENCE; EPIDURAL ANALGESIA; RADICAL PROSTATECTOMY; PERIOPERATIVE PERIOD; ANESTHETIC TECHNIQUE; CERVICAL-CANCER; TUMOR-GROWTH; SURGERY; MORPHINE	BACKGROUND: Associations between anesthetic management and cancer recurrence or longtime survival remain uncertain. In this study, we compared the effects of postoperative epidural morphine analgesia with that of postoperative IV fentanyl analgesia on cancer recurrence and long-term survival in patients undergoing resection of hepatocellular carcinoma. METHODS: A retrospective cohort study was performed on patients with hepatocellular carcinoma receiving hepatic resection at this institution (n = 1846, 1997-2007). Recurrence-free survival and long-term survival were assessed using Kaplan-Meier survival estimates and compared using a multivariate Cox proportional hazards regression, adjusted with propensity scores. RESULTS: Eight hundred nineteen patients met the inclusion criteria and were divided into 2 groups: patients receiving postoperative epidural analgesia with morphine (EA, n = 451) and patients receiving postoperative IV analgesia with fentanyl (IA, n = 368). The median time of follow-up for all patients was 4.2 years (2-9). The rates of recurrence of cancer (37.7% vs 30.7%, P = 0.036) and death (40.6% vs 30.4%, P = 0.003) were higher in the EA group versus IA group. Recurrence-free survival was similar in both the EA and IA groups (hazards ratio 2.224, 95% confidence interval, 0.207-23.893, P = 0.509). Using a multivariate Cox proportional hazards regression adjusted with propensity scores, independent risk factors for long-term survival in patients after resection of hepatocellular carcinoma were ASA physical status, tumor diameter, preoperative alpha-fetoprotein (+) as well as postoperative epidural analgesia with morphine. CONCLUSION: Compared with postoperative IV analgesia with fentanyl, postoperative epidural analgesia with morphine was associated with increased cancer recurrence and death but had no significant effect on recurrence-free survival in patients undergoing resection of hepatocellular carcinoma.	[Cao, Longhui; Chang, Yi; Lin, Wenqian; Tan, Hongying; Zeng, Weian] Sun Yat Sen Univ, Ctr Canc, Dept Anesthesiol, State Key Lab South China, Guangzhou 510060, Guangdong, Peoples R China; [Zhou, Jianhua] Sun Yat Sen Univ, Ctr Canc, Dept Ultrasound, State Key Lab South China, Guangzhou 510060, Guangdong, Peoples R China; [Yuan, Yunfei] Sun Yat Sen Univ, Ctr Canc, Dept Hepatobiliary Surg, State Key Lab South China, Guangzhou 510060, Guangdong, Peoples R China	Zeng, WA (reprint author), Sun Yat Sen Univ, Ctr Canc, Dept Anesthesiol, State Key Lab South China, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China.	zengwa@sysu.edu.cn		Yuan, Yunfei/0000-0003-2467-3683			Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; Bar-Yosef S, 2001, ANESTHESIOLOGY, V94, P1066, DOI 10.1097/00000542-200106000-00022; Beilin B, 1996, ANESTH ANALG, V82, P492, DOI 10.1097/00000539-199603000-00011; Biki B, 2008, ANESTHESIOLOGY, V109, P180, DOI 10.1097/ALN.0b013e31817f5b73; BRYANT HU, 1991, ENDOCRINOLOGY, V128, P3253, DOI 10.1210/endo-128-6-3253; Exadaktylos AK, 2006, ANESTHESIOLOGY, V105, P660, DOI 10.1097/00000542-200610000-00008; Farooqui M, 2007, BRIT J CANCER, V97, P1523, DOI 10.1038/sj.bjc.6604057; Gaspani L, 2002, J NEUROIMMUNOL, V129, P18, DOI 10.1016/S0165-5728(02)00165-0; Gottschalk A, 2010, ANESTHESIOLOGY, V113, P27, DOI 10.1097/ALN.0b013e3181de6d0d; Gottschalk A, 2010, ANESTH ANALG, V110, P1636, DOI 10.1213/ANE.0b013e3181de0ab6; Gupta K, 2002, CANCER RES, V62, P4491; Hong JY, 2008, REGION ANESTH PAIN M, V33, P44, DOI 10.1016/j.rapm.2007.07.010; Ismail H, 2010, BRIT J ANAESTH, V105, P145, DOI 10.1093/bja/aeq156; Liu SS, 2004, ANESTHESIOLOGY, V101, P153, DOI 10.1097/00000542-200407000-00024; Llovet JM, 2008, J NATL CANCER I, V100, P698, DOI 10.1093/jnci/djn134; NORDBERG G, 1984, EUR J CLIN PHARMACOL, V26, P233, DOI 10.1007/BF00630291; Page GG, 2001, PAIN, V90, P191, DOI 10.1016/S0304-3959(00)00403-6; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Poon RTP, 2002, J CLIN ONCOL, V20, P1775, DOI 10.1200/JCO.2002.07.089; Sacerdote P, 2000, ANESTH ANALG, V90, P1411, DOI 10.1097/00000539-200006000-00028; Sala M, 2005, SEMIN LIVER DIS, V25, P171, DOI 10.1055/s-2005-871197; Semela D, 2004, J HEPATOL, V41, P864, DOI 10.1016/j.jhep.2004.09.006; Singleton PA, 2006, MICROVASC RES, V72, P3, DOI 10.1016/j.mvr.2006.04.004; Tiouririne M, 2011, ANESTHESIOLOGY, V114, P717, DOI 10.1097/ALN.0b013e3182084b48; TONNESEN E, 1988, BRIT J ANAESTH, V60, P500, DOI 10.1093/bja/60.5.500; Tsui BCH, 2010, CAN J ANAESTH, V57, P107, DOI 10.1007/s12630-009-9214-7; VAUTHEY JN, 1995, AM J SURG, V169, P28, DOI 10.1016/S0002-9610(99)80106-8; Wahbi K, 2012, JAMA-J AM MED ASSOC, V307, P1292, DOI 10.1001/jama.2012.346; Wuethrich PY, 2010, ANESTHESIOLOGY, V113, P570, DOI 10.1097/ALN.0b013e3181e4f6ec; YEAGER MP, 1995, ANESTHESIOLOGY, V83, P500, DOI 10.1097/00000542-199509000-00008; Yeager MP, 2002, ANESTH ANALG, V94, P94, DOI 10.1097/00000539-200201000-00018	31	11	12	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUN	2014	118	6					1309	1316		10.1213/ANE.0000000000000207			8	Anesthesiology	Anesthesiology	AH7YZ	WOS:000336352600022	24842178				2020-06-30	J	Ting, CK; Johnson, KB; Teng, WN; Synoid, ND; LaPierre, C; Yu, L; Westenskow, DR				Ting, Chien-Kun; Johnson, Ken B.; Teng, Wei-Nung; Synoid, Noah D.; LaPierre, Cris; Yu, Lu; Westenskow, Dwayne R.			Response Surface Model Predictions of Wake-Up Time During Scoliosis Surgery	ANESTHESIA AND ANALGESIA			English	Article							ALVEOLAR ANESTHETIC CONCENTRATION; PROPOFOL-REMIFENTANIL ANESTHESIA; SEVOFLURANE REQUIREMENTS; INHALATION ANESTHESIA; CONCENTRATION-AWAKE; CONTROLLED INFUSION; SYSTEM MODEL; FENTANYL; MAC; DESFLURANE	BACKGROUND: With the use of previously published data, new sevoflurane remifentanil interaction models of various degrees of sedation were created and adapted to desflurane-fentanyl by using minimal alveolar concentration and opioid equivalencies. These models were used to predict return of responsiveness in patients undergoing scoliosis surgery during a wake-up test. Our hypothesis was that one of the interaction models would accurately predict return of responsiveness during a wake-up test. METHODS: Three new sevoflurane remifentanil interaction models were constructed from previous observations in volunteers by using the Observer's Assessment of Alertness/Sedation (OAA/S) scores. These models included predictions of OAA/S<2 (unresponsive), OAA/S<3, and OAA/S<4 (sedation). Twenty-three patients scheduled for scoliosis surgery received a fentanyl desflurane anesthetic. With the use of published pharmacokinetic models, predictions of fentanyl and desflurane effect-site concentrations were recorded throughout surgery and converted to equivalent remifentanil and sevoflurane effect-site concentrations. Data were recorded every 10 seconds from the time when desflurane was turned off until 10 minutes after the patients responded by moving their hands and toes. Model predictions were compared with observations with graphical and temporal analyses. RESULTS: The average difference between the time when a patient first responded and the time when the model predicted that there was a 50% probability that the patient would respond were -2.6 +/- 3.6 minutes (mean +/- SD) for the OAA/S<2 model, 2.8 +/- 5.6 minutes for the OAA/S<3 model and 52.6 +/- 32.3 minutes for the OAA/S<4 model. CONCLUSIONS: The results confirmed our study hypothesis; a sevoflurane remifentanil interaction model built from observations in volunteers and adapted to desflurane and fentanyl accurately predicted patient response during a wake-up test. These results were similar to our previous study comparing model predictions and patient observations after a sevoflurane-remifentanil/fentanyl anesthetic. The OAA/S <2 model most accurately predicted the time patients would respond by moving their fingers and toes. This model may help anesthesiologists better predict return of responsiveness during a wake-up test in patients undergoing spine surgery.	[Ting, Chien-Kun; Teng, Wei-Nung] Taipei Vet Gen Hosp, Dept Anesthesiol, Taipei, Taiwan; [Ting, Chien-Kun; Teng, Wei-Nung] Natl Yang Ming Univ, Taipei 112, Taiwan; [Johnson, Ken B.; Synoid, Noah D.; Westenskow, Dwayne R.] Univ Utah, Sch Med, Dept Anesthesiol, Salt Lake City, UT USA; [Johnson, Ken B.; Westenskow, Dwayne R.] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA; [LaPierre, Cris] Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; [LaPierre, Cris] Massachusetts Gen Hosp, Dept Radiol, AA Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Yu, Lu] China Med Univ, Dept Biomed Engn, Coll Basic Med Sci, Shenyang, Liaoning, Peoples R China	Ting, CK (reprint author), Taipei Vet Gen Hosp, Dept Anesthesiol, 201,Sect 2,Shi Pai Rd, Taipei, Taiwan.	ckting2@gmail.com	Ting, Chien-Kun/C-1389-2012	Ting, Chien-Kun/0000-0002-3156-8139			Bol CJJG, 2000, J PHARMACOL EXP THER, V294, P347; Chen Yi-Chun, 2010, Acta Anaesthesiol Taiwan, V48, P185, DOI 10.1016/j.aat.2010.12.005; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; CHORTKOFF BS, 1995, ANESTH ANALG, V81, P737, DOI 10.1097/00000539-199510000-00014; Daniel M, 1998, ANESTHESIOLOGY, V88, P43, DOI 10.1097/00000542-199801000-00009; EGER EI, 1992, ANESTH ANALG, V75, pS3; Eger EI, 2001, ANESTH ANALG, V93, P947, DOI 10.1097/00000539-200110000-00029; Eger EI, 2003, PHARM INHALED ANESTH; Eggspuehler A, 2007, EUR SPINE J, V16, pS188, DOI 10.1007/s00586-007-0427-6; Gin T, 2010, ANESTH ANALG, V111, P256, DOI 10.1213/ANE.0b013e3181e63008; GRECO WR, 1995, PHARMACOL REV, V47, P331; Inomata S, 1999, ANESTH ANALG, V89, P204; Johnson KB, 2010, ANESTH ANALG, V111, P387, DOI 10.1213/ANE.0b013e3181afe31c; JONES RM, 1990, ANESTH ANALG, V70, P3; Katoh T, 1998, ANESTHESIOLOGY, V88, P18, DOI 10.1097/00000542-199801000-00006; Katoh T, 1999, ANESTHESIOLOGY, V90, P398, DOI 10.1097/00000542-199902000-00012; KATOH T, 1993, ANESTH ANALG, V76, P348; KATOH T, 1987, ANESTHESIOLOGY, V66, P301, DOI 10.1097/00000542-198703000-00006; Kennedy RR, 2010, ANESTH ANALG, V111, P252, DOI 10.1213/ANE.0b013e3181e62ff1; KIMURA T, 1994, ANESTH ANALG, V79, P378; Lang E, 1996, ANESTHESIOLOGY, V85, P721, DOI 10.1097/00000542-199610000-00006; LEROU JGC, 1991, ANESTHESIOLOGY, V75, P345, DOI 10.1097/00000542-199108000-00025; Lerou JGC, 2001, BRIT J ANAESTH, V86, P12, DOI 10.1093/bja/86.1.12; Luk KDK, 2001, SPINE, V26, P1772; Manyam SC, 2006, ANESTHESIOLOGY, V105, P267, DOI 10.1097/00000542-200608000-00009; Miller RD, 2010, MILLERS ANESTHESIA; RAMPIL IJ, 1991, ANESTHESIOLOGY, V74, P429, DOI 10.1097/00000542-199103000-00007; Rehberg S, 2008, ANESTHESIOLOGY, V109, P629, DOI 10.1097/ALN.0b013e31818629c2; SCHELLER MS, 1988, CAN J ANAESTH, V35, P153, DOI 10.1007/BF03010656; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; SEBEL PS, 1992, ANESTHESIOLOGY, V76, P52, DOI 10.1097/00000542-199201000-00008; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; Short TG, 2010, ANESTH ANALG, V111, P249, DOI 10.1213/ANE.0b013e3181e5f0ce; Somma J, 1998, ANESTHESIOLOGY, V89, P1430, DOI 10.1097/00000542-199812000-00021; Suzuki A, 1998, ANESTH ANALG, V86, P179, DOI 10.1097/00000539-199801000-00035; Syroid ND, 2010, ANESTH ANALG, V111, P380, DOI 10.1213/ane.0b013e3181b11289; van Oud-Alblas HJB, 2008, ANESTH ANALG, V107, P1683, DOI 10.1213/ane.0b013e3181852d94; VOZEH S, 1990, J PHARMACOKINET BIOP, V18, P161, DOI 10.1007/BF01063558; Yamaguchi Kyoko, 2010, Masui, V59, P1522; Yao WL, 2007, CHINESE MED J-PEKING, V120, P1013, DOI 10.1097/00029330-200706010-00014	40	1	2	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUN	2014	118	6					1396	1403		10.1213/ANE.0000000000000094			8	Anesthesiology	Anesthesiology	AH7YZ	WOS:000336352600040					2020-06-30	J	Bakkour, W; Chalmers, RJG				Bakkour, W.; Chalmers, R. J. G.			Contact leucoderma induced by fentanyl patches	CLINICAL AND EXPERIMENTAL DERMATOLOGY			English	Letter									[Bakkour, W.; Chalmers, R. J. G.] Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester, Lancs, England	Bakkour, W (reprint author), Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester, Lancs, England.	waseem.bakkour@srft.nhs.uk					Boissy RE, 2004, PIGM CELL RES, V17, P208, DOI 10.1111/j.1600-0749.2004.00130.x; Chapman M Shane, 2002, Am J Contact Dermat, V13, P46; Kwok C, 2011, CONTACT DERMATITIS, V64, P292, DOI 10.1111/j.1600-0536.2011.01879.x; O'Reilly KE, 2001, DERMATOL ONLINE J, V17, P29; Pandhi D, 2011, CLIN EXP DERMATOL, V36, P366, DOI 10.1111/j.1365-2230.2010.03930.x	5	0	0	0	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0307-6938	1365-2230		CLIN EXP DERMATOL	Clin. Exp. Dermatol.	JUN	2014	39	4					533	534		10.1111/ced.12302			2	Dermatology	Dermatology	AH6AG	WOS:000336212500021	24707960				2020-06-30	J	Ruggeri, M; Turriziani, A; Oradei, M				Ruggeri, Matteo; Turriziani, Adriana; Oradei, Marco			Cost-effectiveness analysis of transnasal fentanyl citrate for the treatment of breakthrough cancer pain	EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH			English	Article						BTcP; cost-effectiveness; Markov model; QALYs; sensitivity analysis	CROSSOVER TRIAL; OPEN-LABEL; PREVALENCE; SPRAY	Introduction: Pain is a symptom of cancer and is categorized in two forms: background pain to be treated with analgesics, and breakthrough cancer pain (BTcP), which needs drug treatment on demand. We present a cost-effectiveness analysis of transnasal fentanyl citrate as an alternative to morphine. Methods: A Markov model considers a cohort of 100 patients on a daily basis. Effectiveness was included by selecting three clinical studies. Side effects, hospitalizations and visits were valued by referring to national formularies. Utility data were used to differentiate the health status inherent to BTcP. Results: The incremental cost-effectiveness ratio of transnasal fentanyl citrate is 10,140 euros/QALY. Sensitivity analysis shows that with a threshold of 30,000 euros/QALY, the treatment of BTcP with transnasal fentanyl citrate would have an 86% probability of being cost-effective. Conclusion: Transnasal Fentanyl citrate is cost-effective, therefore represents a good investment in health.	[Ruggeri, Matteo] Univ Cattolica Sacro Cuore, ALTEMS Post Grad Sch Hlth Econ & Management, Rome, Italy; [Ruggeri, Matteo] Univ Cattolica Sacro Cuore, Ist Polit Econom, Rome, Italy; [Turriziani, Adriana] Hosp Villa Speranza, Palliat Care Unit, Rome, Italy; [Oradei, Marco] Univ Cattolica Sacro Cuore, HTA Unit, Policlin Univ A Gemelli, Rome, Italy	Ruggeri, M (reprint author), Univ Cattolica Sacro Cuore, ALTEMS Post Grad Sch Hlth Econ & Management, Rome, Italy.	mruggeri@rm.unicatt.it			Grunenthal pharmaceuticals Italy	This paper has been sponsored with a grant by Grunenthal pharmaceuticals Italy. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.	Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; Fortner BV, 2003, J PAIN SYMPTOM MANAG, V25, P334, DOI 10.1016/S0885-3924(02)00679-6; Frei Andreas, 2003, J Pain Palliat Care Pharmacother, V17, P5; Gomez-Batiste X, 2002, J PAIN SYMPTOM MANAG, V24, P45, DOI 10.1016/S0885-3924(02)00421-9; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Kuo Kuan-Ling, 2013, J Pain Palliat Care Pharmacother, V27, P167, DOI 10.3109/15360288.2013.787137; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Micheli A, 2002, ANN ONCOL, V13, P840, DOI 10.1093/annonc/mdf127; Ministero della Salute, PROGR SAN QUAL LEGG; Negri E, 2002, TUMORI, V88, P89; Popper L, 2008, 12 WORLD C PAIN 17 2; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Ruggeri M, WORKING PAPER; Song Yifan, 2004, Crit Rev Ther Drug Carrier Syst, V21, P195, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i3.20; Vissers DCJ, 2011, VALUE HLTH 14, V27, P4; Zeppetella G, 2003, EXPERT OPIN PHARMACO, V4, P493, DOI 10.1517/14656566.4.4.493; Zeppetella G, 2001, PALLIATIVE MED, V15, P323, DOI 10.1191/026921601678320304; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5	20	5	5	0	3	EXPERT REVIEWS	LONDON	UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND	1473-7167	1744-8379		EXPERT REV PHARM OUT	Expert Rev. Pharmacoecon. Outcomes Res.	JUN	2014	14	3					459	464		10.1586/14737167.2014.904750			6	Health Care Sciences & Services; Health Policy & Services; Pharmacology & Pharmacy	Health Care Sciences & Services; Pharmacology & Pharmacy	AH2YP	WOS:000335988400013	24702061				2020-06-30	J	Bortone, L; Bertolizio, G; Engelhardt, T; Frawley, G; Somaini, M; Ingelmo, PM				Bortone, Luciano; Bertolizio, Gianluca; Engelhardt, Thomas; Frawley, Geoff; Somaini, Marta; Ingelmo, Pablo M.			The effect of fentanyl and clonidine on early postoperative negative behavior in children: a double-blind placebo controlled trial	PEDIATRIC ANESTHESIA			English	Article						emergence; delirium; intravenous drugs; general anesthesia; child	SEVOFLURANE-INDUCED AGITATION; EMERGENCE DELIRIUM SCALE; PEDIATRIC ANESTHESIA; DESFLURANE ANESTHESIA; PREOPERATIVE ANXIETY; YOUNG-CHILDREN; PREVENTION; MIDAZOLAM; SURGERY; PREMEDICATION	BackgroundEarly negative postoperative behavior (e-PONB) is common in children and manifests itself as emergence agitation (EA), emergence delirium (ED), and pain. The objective of this prospective double blind, randomized, placebo-controlled trial was to determine whether IV clonidine or IV fentanyl prior to surgery modifies e-PONB in children. MethodsNinety children scheduled for subumbilical surgery under sevoflurane anesthesia supplemented with regional anesthesia were randomized to either receive IV clonidine 2mcgkg(-1), IV fentanyl 2mcgkg(-1) or placebo (IV saline) before surgery. Primary outcome measures were the incidence of EA, ED and pain during the first hour after awakening. Secondary outcome measures were side effects such as nausea and vomiting and delayed discharge from PACU. ResultsEighty-seven children (n=29 per group) completed the study. EA was present in 10 children (six clonidine, none fentanyl, and four placebo, P=0.04) whereas ED was observed in 20 children (nine clonidine, three fentanyl, and eight placebo P=0.13). Sixteen children who received placebo had a CHIPPS score of 4 compared with nine children in fentanyl group and 18 children receiving clonidine (P=0.04). Ten children receiving fentanyl vomited during the first postoperative day, compared with six children in placebo group and none in clonidine group (P=0.003). Discharge from PACU was not affected. ConclusionsIV fentanyl before surgery but not IV clonidine modifies e-PONB in children undergoing lower abdominal surgery under general anesthesia supplemented with regional anesthesia. The use of fentanyl in this population was also associated with reduced pain scores after awakening but with significantly greater incidence of PONV.	[Bortone, Luciano] Azienda Osped Parma, Serv Anaesthesia & Intens Care 1, Parma, Italy; [Bertolizio, Gianluca; Ingelmo, Pablo M.] McGill Univ, Montreal Childrens Hosp, Ctr Hlth, Dept Anesthesia, Montreal, PQ H3H 1P3, Canada; [Engelhardt, Thomas] Royal Aberdeen Childrens Hosp, Dept Anaesthesia, Aberdeen, Scotland; [Frawley, Geoff] Royal Childrens Hosp, Dept Anaesthesia & Pain Management, Melbourne, Vic, Australia; [Somaini, Marta] San Gerardo Hosp, Serv Anaesthesia & Intens Care, Monza, Italy	Ingelmo, PM (reprint author), Montreal Childrens Hosp, Dept Anaesthesia, 2300 Rue Tupper, Montreal, PQ H3H 1P3, Canada.	pablo.ingelmo@muhc.mcgill.ca	Bertolizio, Gianluca/AAM-7595-2020		First Service of Anaesthesia and Intensive Care; Azienda Ospedaliera di Parma, Italy; Department of Experimental Medicine, Milan Bicocca University, Monza, Italy	This study was supported by the First Service of Anaesthesia and Intensive Care, Azienda Ospedaliera di Parma, Italy and by the Department of Experimental Medicine, Milan Bicocca University, Monza, Italy. Authors declare no conflict of interests on this study.	Bergendahl HTG, 2004, ACTA ANAESTH SCAND, V48, P1292, DOI 10.1111/j.1399-6576.2004.00525.x; Bock M, 2002, BRIT J ANAESTH, V88, P790, DOI 10.1093/bja/88.6.790; Breschan C, 2007, PEDIATR ANESTH, V17, P347, DOI 10.1111/j.1460-9592.2006.02101.x; Buttner W, 2000, PAEDIATR ANAESTH, V10, P303, DOI 10.1046/j.1460-9592.2000.00530.x; Cohen IT, 2001, ANESTH ANALG, V93, P88; Cravero J, 2000, PAEDIATR ANAESTH, V10, P419, DOI 10.1046/j.1460-9592.2000.00560.x; Cravero JP, 2003, ANESTH ANALG, V97, P364, DOI 10.1213/01.ANE.0000070227.78670.43; Dahmani S, 2010, ACTA ANAESTH SCAND, V54, P397, DOI 10.1111/j.1399-6576.2009.02207.x; Finkel JC, 2001, ANESTH ANALG, V92, P1164; Holzki J, 1999, PAEDIATR ANAESTH, V9, P283, DOI 10.1046/j.1460-9592.1999.00415.x; Kain ZN, 1997, ANESTH ANALG, V85, P783, DOI 10.1097/00000539-199710000-00012; Kain ZN, 2004, ANESTH ANALG, V99, P1648, DOI 10.1213/01.ANE.0000136471.36680.97; Kulka PJ, 2001, ANESTH ANALG, V93, P335, DOI 10.1097/00000539-200108000-00019; Lankinen U, 2006, ANESTH ANALG, V102, P1383, DOI 10.1213/01.ane.0000205745.84044.31; Locatelli BG, 2013, PEDIATR ANESTH, V23, P301, DOI 10.1111/pan.12038; Malarbi S, 2011, PEDIATR ANESTH, V21, P942, DOI 10.1111/j.1460-9592.2011.03646.x; Malviya S, 2006, PEDIATR ANESTH, V16, P554, DOI 10.1111/j.1460-9592.2006.01818.x; Parwar D., 2012, INDIAN J ANAESTH, V56, P496; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; Tazeroualti N, 2007, BRIT J ANAESTH, V98, P667, DOI 10.1093/bja/aem071; Tesoro S, 2005, ANESTH ANALG, V101, P1619, DOI 10.1213/01.ANE.0000184204.81877.53; Veyckemans F, 2001, Curr Opin Anaesthesiol, V14, P339, DOI 10.1097/00001503-200106000-00010; Vlajkovic GP, 2007, ANESTH ANALG, V104, P84, DOI 10.1213/01.ane.0000250914.91881.a8; Voepel-Lewis Terri, 2004, J Perianesth Nurs, V19, P298, DOI 10.1016/j.jopan.2004.07.001; Wells LT, 1999, ANESTH ANALG, V88, P1308, DOI 10.1097/00000539-199906000-00020	25	23	26	0	11	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	JUN	2014	24	6					614	619		10.1111/pan.12388			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	AG9QG	WOS:000335753700010	24666767				2020-06-30	J	Kongsgaard, UE; Eeg, M; Greisen, H				Kongsgaard, Ulf E.; Eeg, Martin; Greisen, Hanna			The use of InstanylA (R) in the treatment of breakthrough pain in cancer patients: a 3-month observational, prospective, cohort study	SUPPORTIVE CARE IN CANCER			English	Article						Cancer; Breakthrough pain; Fentanyl; Instanyl; Intranasal; Observational	TRANSMUCOSAL FENTANYL CITRATE; OPEN-LABEL; LONG-TERM; INTRANASAL; TRIAL; PREVALENCE; TITRATION; SPRAY	InstanylA (R) (intranasal fentanyl spray) is a novel treatment for breakthrough pain (BTP) in cancer patients. It has shown a rapid onset of pain relief in clinical trials. This study examines the use of InstanylA (R) in real-life settings. A 3-month observational, prospective, cohort study of cancer patients with BTP receiving InstanylA (R) (50, 100, or 200 mu g) under routine clinical practice. Data were collected at three time points corresponding with routine clinic visits - baseline, Week 4, and Week 13. Primary outcomes: success of titration and maintenance dose after titration. Secondary outcomes: change in maintenance dose of InstanylA (R) and level of background pain medication; Brief Pain Inventory-Short Form (BPI-SF) and Patient Treatment Satisfaction Scale (PTSS) scores; adverse drug reactions (ADRs). Titration with InstanylA (R) was successful in 84.5 % of 309 patients; most patients were titrated at the lowest dose (50 mu g). The majority showed no change in maintenance dose, with little change in the level of background pain medication. BPI-SF and PTSS scores significantly improved from baseline to Week 4. The main reason for terminating InstanylA (R) was death, as expected due to the underlying disease; incidence of ADRs was low and no fatal ADRs were reported. In a real-life group of cancer patients with disease progression, InstanylA (R) was titrated successfully at doses < 200 mu g in the majority of patients, requiring only one dose, with no further change in maintenance dose. Pain severity, impact of pain on daily life, and treatment satisfaction significantly improved with InstanylA (R) treatment. No unexpected ADRs occurred.	[Kongsgaard, Ulf E.] Univ Oslo, Oslo Univ Hosp, Dept Anaesthesiol, Div Emergencies & Crit Care, Oslo, Norway; [Kongsgaard, Ulf E.] Univ Oslo, Fac Med, Oslo, Norway; [Eeg, Martin; Greisen, Hanna] Takeda Pharma AS, Roskilde, Denmark; [Kongsgaard, Ulf E.] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Anaesthesiol, N-0313 Oslo, Norway	Kongsgaard, UE (reprint author), Oslo Univ Hosp, Norwegian Radium Hosp, Dept Anaesthesiol, N-0313 Oslo, Norway.	ulf.kongsgaard@medisin.uio.no		Eeg, Martin Krogager/0000-0003-3824-744X	TakedaTakeda Pharmaceutical Company Ltd	The authors thank the investigators involved in the study. Assistance with preparing the manuscript was provided by Cambridge Medical Communication Ltd., funded by the study Sponsor, Takeda.	Abernethy Amy P, 2008, Am J Manag Care, V14, pS129; BENNETT D, 2005, [No title captured], V30, P354; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Caraceni A, 2012, J PAIN SYMPTOM MANAG, V43, P833, DOI 10.1016/j.jpainsymman.2011.05.018; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; Fortner BV, 2003, J PAIN SYMPTOM MANAG, V25, P9, DOI 10.1016/S0885-3924(02)00597-3; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Hagen NA, 2007, J PALLIAT MED, V10, P47, DOI 10.1089/jpm.2006.0151; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; Haugen DF, 2010, PAIN, V149, P476, DOI 10.1016/j.pain.2010.02.035; Kleeberg UR, 2011, PAIN PRACT, V11, P185, DOI 10.1111/j.1533-2500.2010.00414.x; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Mercadante S, 2011, SUPPORT CARE CANCER, V19, P979, DOI 10.1007/s00520-010-0919-5; Portenoy R K, 1997, Semin Oncol, V24, pS16; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Rustoen T, 2013, EUR J ONCOL NURS, V17, P95, DOI 10.1016/j.ejon.2012.05.005; Takeda UK Ltd, 2013, INST 50 100 200 MCG; Verheggen FWSM, 1998, INT J QUAL HEALTH C, V10, P319, DOI 10.1093/intqhc/10.4.319; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279; Zeppetella G, 2011, CLIN ONCOL-UK, V23, P393, DOI 10.1016/j.clon.2010.12.002	25	10	11	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	JUN	2014	22	6					1655	1662		10.1007/s00520-014-2128-0			8	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	AG9YC	WOS:000335775000026	24510192	Green Published			2020-06-30	J	Aguar, M; Cernada, M; Brugada, M; Gimeno, A; Gutierrez, A; Vento, M				Aguar, Marta; Cernada, Maria; Brugada, Maria; Gimeno, Ana; Gutierrez, Antonio; Vento, Maximo			Minimally invasive surfactant therapy with a gastric tube is as effective as the intubation, surfactant, and extubation technique in preterm babies	ACTA PAEDIATRICA			English	Article						Intubation - surfactant - extubation; Minimally invasive surfactant therapy; Newborn; Respiratory distress; Surfactant	POSITIVE AIRWAY PRESSURE; INFANTS; MANAGEMENT; BIRTH; NCPAP	AimPreterm infants requiring surfactant replacement have been treated using the INSURE technique, which requires sedation and comprises tracheal intubation, surfactant instillation and extubation. However, minimally invasive surfactant therapy (MIST) does not require sedation, minimises airway injury and avoids placing positive pressure ventilation on an immature lung. This study compared the feasibility of the two techniques and the outcomes in preterm babies with respiratory distress syndrome (RDS). MethodsPreterm infants with RDS prospectively received surfactant via a gastric tube placed in the trachea by direct laryngoscopy with no sedation. Technique-related complications and respiratory outcomes were analysed. ResultsWe compared 44 patients who received MIST with a historic cohort of 31 patients who received INSURE. This showed no differences in the rate of intubation and mechanical ventilation in the first 72h, or secondary respiratory outcomes and relevant morbidities, between the babies who received INSURE and those who received MIST. More babies in the MIST group (35%) needed a second dose of surfactant than the INSURE group (6.5%) (p<0.0001). ConclusionSurfactant administration using MIST, with no sedation, is feasible in preterm infants with RDS. No significant differences in secondary respiratory outcomes were found between the MIST and INSURE techniques.	[Aguar, Marta; Brugada, Maria; Gimeno, Ana; Gutierrez, Antonio; Vento, Maximo] Univ Valencia, Div Neonatol, Valencia 46026, Spain; [Aguar, Marta; Brugada, Maria; Gimeno, Ana; Gutierrez, Antonio; Vento, Maximo] Polytech Hosp La Fe, Valencia, Spain; [Aguar, Marta; Cernada, Maria; Brugada, Maria; Gimeno, Ana; Vento, Maximo] Hlth Res Inst La Fe, Neonatal Res Grp, Valencia, Spain	Vento, M (reprint author), Univ Valencia, Div Neonatol, Bulevar Sur S-N, Valencia 46026, Spain.	maximo.vento@uv.es	Vento, Maximo/F-3596-2015	Vento, Maximo/0000-0003-0061-4742; Cernada, Maria/0000-0001-8861-6384			Allen KA, 2012, ADV NEONAT CARE, V12, P107, DOI 10.1097/ANC.0b013e31824c1583; Attar Mohammad Ali, 2002, Semin Neonatol, V7, P353, DOI 10.1053/siny.2002.0129; Dargaville PA, 2013, ARCH DIS CHILD-FETAL, V98, pF122, DOI 10.1136/archdischild-2011-301314; De Klerk AM, 2001, J PAEDIATR CHILD H, V37, P161, DOI 10.1046/j.1440-1754.2001.00624.x; Dunn MS, 2011, PEDIATRICS, V128, pE1069, DOI 10.1542/peds.2010-3848; Finer NN, 2010, NEW ENGL J MED, V362, P1970, DOI 10.1056/NEJMoa0911783; Finer NN, 2004, PEDIATRICS, V114, P651, DOI 10.1542/peds.2004-0394; Gopel W, 2011, LANCET, V378, P1627, DOI 10.1016/S0140-6736(11)60986-0; JOBE AH, 1993, NEW ENGL J MED, V328, P861; Kanmaz HG, 2013, PEDIATRICS, V131, pE502, DOI 10.1542/peds.2012-0603; Kolatat Thrathip, 2002, Journal of the Medical Association of Thailand, V85, pS455; Kribs A, 2008, ACTA PAEDIATR, V97, P293, DOI 10.1111/j.1651-2227.2007.00617.x; Kribs A, 2007, PEDIATR ANESTH, V17, P364, DOI 10.1111/j.1460-9592.2006.02126.x; Lindner W, 1999, PEDIATRICS, V103, P961, DOI 10.1542/peds.103.5.961; Michna J, 1999, AM J RESP CRIT CARE, V160, P634, DOI 10.1164/ajrccm.160.2.9902016; Morley CJ, 2008, NEW ENGL J MED, V358, P700, DOI 10.1056/NEJMoa072788; Sandri F, 2010, PEDIATRICS, V125, pE1402, DOI 10.1542/peds.2009-2131; Soll R., 1998, COCHRANE DB SYST REV, V3; Venkatesh V, 2011, EUR J PEDIATR, V170, P223, DOI 10.1007/s00431-010-1290-8; Vento M, 2009, NEONATOLOGY, V95, P286, DOI 10.1159/000178770; VERDER H, 1994, NEW ENGL J MED, V331, P1051, DOI 10.1056/NEJM199410203311603	21	35	37	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0803-5253	1651-2227		ACTA PAEDIATR	Acta Paediatr.	JUN	2014	103	6					E229	E233		10.1111/apa.12611			5	Pediatrics	Pediatrics	AG9QQ	WOS:000335754700001	24628379				2020-06-30	J	Lindholm, EE; Aune, E; Froland, G; Kirkeboen, KA; Otterstad, JE				Lindholm, E. E.; Aune, E.; Froland, G.; Kirkeboen, K. A.; Otterstad, J. E.			Analysis of transthoracic echocardiographic data in major vascular surgery from a prospective randomised trial comparing sevoflurane and fentanyl with propofol and remifentanil anaesthesia	ANAESTHESIA			English	Article							VENTRICULAR DIASTOLIC FUNCTION; ABDOMINAL AORTIC-ANEURYSM; NORMAL REFERENCE RANGES; NATRIURETIC PEPTIDE; NONCARDIAC SURGERY; HEART-FAILURE; OPEN REPAIR; DESFLURANE; GUIDELINES; MORTALITY	The aim of this study was to define pre-operative echocardiographic data and explore if postoperative indices of cardiac function after open abdominal aortic surgery were affected by the anaesthetic regimen. We hypothesised that volatile anaesthesia would improve indices of cardiac function compared with total intravenous anaesthesia. Transthoracic echocardiography was performed pre-operatively in 78 patients randomly assigned to volatile anaesthesia and 76 to total intravenous anaesthesia, and compared with postoperative data. Pre-operatively, 16 patients (10%) had left ventricular ejection fraction <46%. In 138 patients with normal left ventricular ejection fraction, 5/8 (62%) with left ventricular dilatation and 41/130 (33%) without left ventricular dilatation had evidence of left ventricular diastolic dysfunction (p<0.001). Compared with pre-operative findings, significant increases in left ventricular end-diastolic volume, left atrial maximal volume, cardiac output, velocity of early mitral flow and early myocardial relaxation occurred postoperatively (all p<0.001). The ratio of the velocity of early mitral flow to early myocardial relaxation remained unchanged. There were no significant differences in postoperative echocardiographic findings between patients anaesthetised with volatile anaesthesia or total intravenous anaesthesia. Patients had an iatrogenic surplus of approximately 4.1l of fluid volume by the first postoperative day. N-terminal prohormone of brain natriuretic peptide increased on the first postoperative day (p<0.001) and remained elevated after 30days (p<0.001) in both groups. Although postoperative echocardiographic alterations were most likely to be related to increased preload due to a substantial iatrogenic surplus of fluid, a component of peri-operative myocardial ischaemia cannot be excluded. Our hypothesis that volatile anaesthesia improved indices of cardiac function compared with total intravenous anaesthesia could not be verified.	[Lindholm, E. E.] Vestfold Hosp Trust, Dept Anaesthesiol, Tonsberg, Norway; [Aune, E.; Froland, G.; Otterstad, J. E.] Vestfold Hosp Trust, Dept Cardiol, Tonsberg, Norway; [Kirkeboen, K. A.] Oslo Univ Hosp, Dept Anaesthesiol, Oslo, Norway; [Kirkeboen, K. A.] Univ Oslo, Fac Med, Oslo, Norway	Lindholm, EE (reprint author), Vestfold Hosp Trust, Dept Anaesthesiol, Tonsberg, Norway.	espen.lindholm@siv.no			Vestfold Hospital Trust, Tonsberg, Norway; Baxter AS Norway, Oslo, Norway	Funding was provided solely from institutional and departmental sources. We thank Camilla Noren, Marit Eide and Tone Naess, who are study nurses in the department of Anaesthesiology, Vestfold Hospital Trust, Tonsberg, Norway. We also thank Else-Marie Ringvold, head of department and Odd Helmers, former head of department of Anaesthesiology at Vestfold Hospital Trust. We are also grateful to Ingar Holme, professor in statistics, University Hospital in Oslo, Norway for performing the post hoc power analysis. Finally, we also thank Gisle Kjosen for proofreading the manuscript and Erna Engelstad, who is a laboratory assistant at the Vestfold Hospital Trust. The study was funded by the Vestfold Hospital Trust, Tonsberg, Norway. EL has received fees for presentations by Baxter AS Norway, Oslo, Norway.	Aune E, 2010, SCAND CARDIOVASC J, V44, P24, DOI 10.3109/14017430903114446; Aune E, 2009, CARDIOVASC ULTRASOUN, V7, DOI 10.1186/1476-7120-7-35; Aune E, 2009, EUR J ECHOCARDIOGR, V10, P738, DOI 10.1093/ejechocard/jep054; Biccard BM, 2012, ANAESTHESIA, V67, P55, DOI 10.1111/j.1365-2044.2011.06958.x; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Bitoh Hiroyasu, 2007, Journal of Nippon Medical School, V74, P393, DOI 10.1272/jnms.74.393; Bolliger D, 2010, BRIT J ANAESTH, V104, P547, DOI 10.1093/bja/aeq066; Bown MJ, 2001, EUR J VASC ENDOVASC, V22, P485, DOI 10.1053/ejvs.2001.1522; Buse GALL, 2012, CIRCULATION, V126, P2696, DOI 10.1161/CIRCULATIONAHA.112.126144; Canty DJ, 2012, ANAESTHESIA, V67, P714, DOI 10.1111/j.1365-2044.2012.07118.x; Canty DJ, 2012, ANAESTHESIA, V67, P618, DOI 10.1111/j.1365-2044.2012.07074.x; Chiesa R, 2012, J CARDIOVASC SURG, V53, P119; Dickstein K, 2008, EUR HEART J, V29, P2388, DOI 10.1093/eurheartj/ehn309; Filipovic M, 2007, BRIT J ANAESTH, V98, P12, DOI 10.1093/bja/ael277; Fleisher LA, 2007, CIRCULATION, V116, P1971, DOI 10.1161/CIRCULATIONAHA.107.185700; GELMAN S, 1995, ANESTHESIOLOGY, V82, P1026, DOI 10.1097/00000542-199504000-00027; Graham MR, 1998, ANESTH ANALG, V86, P717, DOI 10.1097/00000539-199804000-00008; Gualandro DM, 2012, ATHEROSCLEROSIS, V222, P191, DOI 10.1016/j.atherosclerosis.2012.02.021; Hirsch AT, 2006, CIRCULATION, V113, pE463, DOI 10.1161/CIRCULATIONAHA.106.174526; Hur DJ, 2012, AM J CARDIOL, V110, P736, DOI 10.1016/j.amjcard.2012.04.059; KNUTSEN KM, 1989, J INTERN MED, V225, P111, DOI 10.1111/j.1365-2796.1989.tb00049.x; Kragelund C, 2005, NEW ENGL J MED, V352, P666, DOI 10.1056/NEJMoa042330; Landoni G, 2007, J CARDIOTHOR VASC AN, V21, P502, DOI 10.1053/j.jvca.2007.02.013; Lederle FA, 2009, JAMA-J AM MED ASSOC, V302, P1535, DOI 10.1001/jama.2009.1426; Lindholm EE, 2013, ANESTHESIOLOGY, V119, P802, DOI 10.1097/ALN.0b013e31829bd883; McFalls EO, 2004, NEW ENGL J MED, V351, P2795, DOI 10.1056/NEJMoa041905; Mullenheim J, 2001, CAN J ANAESTH, V48, P784; Nagueh SF, 2009, J AM SOC ECHOCARDIOG, V22, P107, DOI 10.1016/j.echo.2008.11.023; Ommen SR, 2000, CIRCULATION, V102, P1788; Otterstad JE, 1997, EUR HEART J, V18, P507; PAGEL PS, 1992, ANESTHESIOLOGY, V76, P419, DOI 10.1097/00000542-199203000-00015; Panagopoulou V, 2013, CURR TOP MED CHEM, V13, P82, DOI 10.2174/1568026611313020002; Paulus WJ, 2007, EUR HEART J, V28, P2539, DOI 10.1093/eurheartj/ehm037; Poole-Wilson PA, 2004, LANCET, V364, P849, DOI 10.1016/S0140-6736(04)16980-8; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; Sarkar S, 2010, ANN CARD ANAESTH, V13, P130, DOI 10.4103/0971-9784.62945; Symons JA, 2006, BRIT J ANAESTH, V97, P127, DOI 10.1093/bja/ael149; Thygesen K, 2007, CIRCULATION, V116, P2634, DOI 10.1161/CIRCULATIONAHA.107.187397; Wang TJ, 2004, NEW ENGL J MED, V350, P655, DOI 10.1056/NEJMoa031994; White HD, 2011, J AM COLL CARDIOL, V57, P2406, DOI 10.1016/j.jacc.2011.01.029; Wong GTC, 2010, J CARDIOTHOR VASC AN, V24, P790, DOI 10.1053/j.jvca.2009.09.012; Zangrillo A, 2011, J CARDIOTHOR VASC AN, V25, P902, DOI 10.1053/j.jvca.2011.06.016; Zaugg M, 2002, ANESTHESIOLOGY, V97, P15, DOI 10.1097/00000542-200207000-00004	43	6	6	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	JUN	2014	69	6					558	572		10.1111/anae.12604			15	Anesthesiology	Anesthesiology	AJ3LV	WOS:000337568900008	24720268				2020-06-30	J	Karlsen, APH; Pedersen, DMB; Trautner, S; Dahl, JB; Hansen, MS				Karlsen, Anders P. H.; Pedersen, Danny M. B.; Trautner, Sven; Dahl, Jorgen B.; Hansen, Morten S.			Safety of Intranasal Fentanyl in the Out-of-Hospital Setting: A Prospective Observational Study	ANNALS OF EMERGENCY MEDICINE			English	Article							DOUBLE-BLIND; ACUTE PAIN; PHARMACOKINETICS; CROSSOVER; MORPHINE; ADULTS; BIOAVAILABILITY; TOLERABILITY; DIFFERENCE; ANALGESIA	Study objective: Initial out-of-hospital analgesia is sometimes hampered by difficulties in achieving intravenous access or lack of skills in administering intravenous opioids. We study the safety profile and apparent analgesic effect of intranasal fentanyl in the out-of-hospital setting. Methods: In this prospective observational study, we administered intranasal fentanyl in the out-of-hospital setting to adults and children older than 8 years with severe pain resulting from orthopedic conditions, abdominal pain, or acute coronary syndrome refractory to nitroglycerin spray. Patients received 1 to 3 doses of either 50 or 100 mu g, and the ambulance crew recorded adverse effects and numeric rating scale (0 to 10) pain scores before and after treatment. Results: Our 903 evaluable patients received a mean cumulative fentanyl dose of 114 pg (range 50 to 300 mu g). There were no serious adverse effects and no use of naloxone. Thirty-six patients (4%) experienced mild adverse effects: mild hypotension, nausea, vomiting, vertigo, abdominal pain, rash, or decrease of Glasgow Coma Scale score to 14. The median reduction in pain score was 3 (interquartile range 2 to 5) after fentanyl administration. Conclusion: The out-of-hospital administration of intranasal fentanyl in doses of 50 to 100 mu g is safe and appears effective.	[Karlsen, Anders P. H.; Dahl, Jorgen B.; Hansen, Morten S.] Copenhagen Univ Hosp, Rigshosp, Ctr Head & Orthopaed, Dept Anaesthesia 4231, Copenhagen, Denmark; [Pedersen, Danny M. B.] Ambulance Co Feick Danmark AS, Emergency Med Serv, Copenhagen, Denmark; [Trautner, Sven] Ambulance Co Feick Danmark AS, Dept Med, Copenhagen, Denmark	Hansen, MS (reprint author), Copenhagen Univ Hosp, Rigshosp, Ctr Head & Orthopaed, Dept Anaesthesia 4231, Copenhagen, Denmark.	morten.sejer.hansen@dadlnet.dk	Hansen, Morten/S-7809-2016		Ambulance Company Falck	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). APHK was funded by The Ambulance Company Falck. ST and DMBP were employed by Falck during the study period. The study is reported according to the Strengthening the Reporting of Observational studies in Epidemiology guidelines.	Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Fleischman RJ, 2010, PREHOSP EMERG CARE, V14, P167, DOI 10.3109/10903120903572301; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Hansen MS, 2012, ACTA ANAESTH SCAND, V56, P407, DOI 10.1111/j.1399-6576.2011.02613.x; Henry JB, 2002, J CLIN APHERESIS, V17, P55, DOI 10.1002/jca.10022; Hjermstad MJ, 2011, J PAIN SYMPTOM MANAG, V41, P1073, DOI 10.1016/j.jpainsymman.2010.08.016; Jorgensen Benny, 2013, PREHOSPITAL CTR REGI; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Lzsak E, 2008, PREHOSP EMERG CARE, V12, P182, DOI 10.1080/10903120801907471; Middleton PM, 2010, PREHOSP EMERG CARE, V14, P439, DOI 10.3109/10903127.2010.497896; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Nave R, 2013, DRUG DELIV, V20, P216, DOI 10.3109/10717544.2012.762435; O'Donnell DP, 2013, PREHOSP DISASTER MED, V28, P520, DOI 10.1017/S1049023X13003579; Panagiotou I, 2010, EXPERT REV ANTICANC, V10, P1009, DOI [10.1586/era.10.77, 10.1586/ERA.10.77]; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Toussaint S, 2000, CAN J ANAESTH, V47, P299, DOI 10.1007/BF03020941; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.1016/j.jclinepi.2007.11.008	20	26	28	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	JUN	2014	63	6					699	703		10.1016/j.annemergmed.2013.10.025			5	Emergency Medicine	Emergency Medicine	AI7XA	WOS:000337115100013	24268523				2020-06-30	J	Lavi, S; Jolly, SS; Bainbridge, D; Manji, F; Randhawa, V; Lavi, R				Lavi, Shahar; Jolly, Sanjit S.; Bainbridge, Daniel; Manji, Farah; Randhawa, Varinder; Lavi, Ronit			Sedation, Analgesia, and Anaesthesia Variability in Laboratory-Based Cardiac Procedures: An International Survey	CANADIAN JOURNAL OF CARDIOLOGY			English	Article							AORTIC-VALVE IMPLANTATION; CONSCIOUS SEDATION; AMERICAN-SOCIETY; INTRAVENOUS SEDATION; GUIDELINES; INTERVENTIONS; FEASIBILITY; VENTILATION	Background: There is a paucity of data regarding the type of anaesthesia used and the perception toward anaesthesia among cardiologists, anaesthesiologists, and nurses. Our objective was to describe the use of sedation during nonsurgical cardiac procedures. Methods: We designed a Web-based survey to assess anaesthesia practices during cardiac procedures. The survey was distributed to cardiologists, anaesthesiologists, and nurses through national societies and international investigator networks. The questions addressed the type of practice, type of anaesthesia used during procedures, and perceptions regarding anaesthesia. Results: The survey was completed by 497 participants. Sedation during cardiac catheterization was used by 77/84 (92%) of cardiologists in North America, but only by 46/121 (38%) in other countries (P < 0.0001). Use of general anaesthesia for complex procedures such as transaortic valve replacement is also more common in North America (92%) compared with other countries (76%; P = 0.004). Specific sedation-related training was provided to less than a third of nonanaesthesiologists. Although more than half of the nurses received training regarding procedural sedation, such training is provided to less than a quarter of the cardiologists. The lack of training was noted in all geographic regions. Conclusions: Anaesthesia and especially sedation is frequently used during percutaneous cardiac procedures. The rate of use and perceptions regarding sedation differs among professionals and might be influenced by culture, training, and geography. There is a lack of adequate formal training in the use of sedation and analgesia for nonanaesthesia professionals.	[Lavi, Shahar; Randhawa, Varinder] London Hlth Sci Ctr, Dept Med, London, ON, Canada; [Lavi, Shahar; Randhawa, Varinder] Univ Western Ontario, London, ON N6A 5A5, Canada; [Jolly, Sanjit S.] McMaster Univ, Hamilton, ON, Canada; [Jolly, Sanjit S.] Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada; [Bainbridge, Daniel; Manji, Farah; Lavi, Ronit] Univ Western Ontario, London Hlth Sci Ctr, Dept Anesthesia & Perioperat Med, London, ON N6A 5A5, Canada	Lavi, S (reprint author), Univ Western Ontario, Div Cardiol, 339 Windermere Rd,POB 5339, London, ON N6A 5A5, Canada.	shahar.lavi@lhsc.on.ca	Jolly, Sanjit/O-2534-2015; Lavi, Shahar/G-3317-2011	Lavi, Shahar/0000-0002-6105-8084	Program of Experimental Medicine in the Department of Medicine, Western University	This work was supported by the Program of Experimental Medicine in the Department of Medicine, Western University.	Ang CK, 2007, INT J CARDIOL, V116, P321, DOI 10.1016/j.ijcard.2006.04.045; [Anonymous], DIST MON AN CAR MAC; Beddoes L, 2008, HEART LUNG, V37, P196, DOI 10.1016/j.hrtlng.2007.05.012; Bergmann L, 2011, ANAESTHESIA, V66, P977, DOI 10.1111/j.1365-2044.2011.06788.x; Bufton KA, 2013, J CARDIOTHOR VASC AN, V27, P46, DOI 10.1053/j.jvca.2012.08.008; Burns KEA, 2008, CAN MED ASSOC J, V179, P245, DOI 10.1503/cmaj.080372; Deftereos S, 2013, JACC-CARDIOVASC INTE, V6, P267, DOI 10.1016/j.jcin.2012.11.005; Devlin JW, 2007, CRIT CARE MED, V35, P2298, DOI 10.1097/01.CCM.0000284512.21942.F8; Epstein BS, 2003, ANESTHESIOLOGY, V98, P1261, DOI 10.1097/00000542-200305000-00031; Gaitan BD, 2011, J CARDIOTHOR VASC AN, V25, P647, DOI 10.1053/j.jvca.2010.11.006; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Hahn RT, 2013, J AM SOC ECHOCARDIOG, V26, P921, DOI 10.1016/j.echo.2013.07.009; Kezerashvili A, 2008, J INTERV CARD ELECTR, V21, P43, DOI 10.1007/s10840-007-9191-0; Merchant R, 2013, CAN J ANESTH, V60, P63, DOI 10.1007/s12630-012-9820-7; Motloch LJ, 2012, CLIN RES CARDIOL, V101, P45, DOI 10.1007/s00392-011-0362-8; Salukhe TV, 2012, EUROPACE, V14, P325, DOI 10.1093/europace/eur328; Ussia GP, 2010, CATHETER CARDIO INTE, V75, P1137, DOI 10.1002/ccd.22415; Yamamoto M, 2013, AM J CARDIOL, V111, P94, DOI 10.1016/j.amjcard.2012.08.053	18	15	15	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0828-282X	1916-7075		CAN J CARDIOL	Can. J. Cardiol.	JUN	2014	30	6					627	633		10.1016/j.cjca.2014.03.034			7	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	AL6NT	WOS:000339250300007	24882533				2020-06-30	J	Bista, SR; Lobb, M; Haywood, A; Hardy, J; Tapuni, A; Norris, R				Bista, Sudeep R.; Lobb, Michael; Haywood, Alison; Hardy, Janet; Tapuni, Angela; Norris, Ross			Development, validation and application of an HPLC-MS/MS method for the determination of fentanyl and nor-fentanyl in human plasma and saliva	JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES			English	Article						Fentanyl; HPLC-MS/MS; Plasma; Saliva; Salivette (R); Adsorption	CHROMATOGRAPHY-MASS-SPECTROMETRY; GAS-CHROMATOGRAPHY; PHARMACOKINETICS; METABOLITES; BIOAVAILABILITY; NORFENTANYL; METHADONE; MATRIX; BLOOD	Monitoring fentanyl concentration in saliva and plasma may be useful in pharmacokinetic/pharmacodynamic studies. Salivettes (R) have been used widely for collecting saliva samples. However due to its lipophilicity, fentanyl adsorbs to the cotton dental bud (CDB) used in this device. Furthermore, due to dry mouth being a common adverse effect seen in patients treated with opioids, obtaining enough saliva for analysis is often a challenge. Hence, a simple simultaneous method to quantify fentanyl and its metabolite in both human plasma and saliva was developed and validated. A novel extraction method was also developed and validated to recover fentanyl in saliva directly from the CDB. This extraction method utilises acetonitrile to recover the fentanyl directly from the CDB rather than recovery by centrifugation, which is not always possible. Reverse phase chromatographic separation was performed on a Shimadzu LC 20A HPLC system using gradient elution. The electrospray ion source (ESI) was operated in positive ion mode using an Applied Biosystems API 3200 LC/MS/MS as detector. Deuterated fentanyl (D-5) and nor-fentanyl (D-5) were used as internal standards (IS). The retention times for fentanyl and nor-fentanyl were 3.70 min and 3.20 min respectively. The lower limit of quantitation (LLOQ) was determined to be 0.030 mu g/L in plasma and 0.045 in saliva for fentanyl and nor-fentanyl. Acceptable linearity for fentanyl and nor-fentanyl in both plasma and saliva was demonstrated from 0.02 to 10 mu g/L (R-2 0.9988-0.9994). Accuracy for fentanyl and nor-fentanyl in both plasma and saliva samples was between 96% and 108%. Total imprecision expressed as the co-efficient of variation was between 1.0 and 15.5% for both analytes in both matrices. The validated method was applied successfully in 11 paired plasma and saliva samples obtained from patients with cancer pain receiving transdermal fentanyl (Duragesic (R)) at doses from 25 mu g to 100 mu g. (C) 2014 Elsevier B.V. All rights reserved.	[Bista, Sudeep R.; Haywood, Alison; Norris, Ross] Griffith Univ, Griffith Hlth Inst, Sch Pharm, Nathan, Qld 4222, Australia; [Lobb, Michael; Hardy, Janet; Tapuni, Angela; Norris, Ross] Australian Ctr Paediat Pharmacokinet, Mater Res Inst, South Brisbane, Qld 4101, Australia; [Lobb, Michael; Hardy, Janet; Tapuni, Angela; Norris, Ross] Australian Ctr Paediat Pharmacokinet, Mater Pathol Serv, South Brisbane, Qld 4101, Australia; [Norris, Ross] Univ Queensland, Sch Pharm, St Lucia, Qld, Australia	Bista, SR (reprint author), Griffith Univ, Griffith Hlth Inst, Sch Pharm, Gold Coast Campus, Nathan, Qld 4222, Australia.	srbista75@hotmail.com	Hardy, Janet/F-2501-2012	Haywood, Alison/0000-0002-5354-8868	Mater Palliative Care; Mater Research Institute Griffith Health Institute (Griffith University)	The study to conduct research on plasma and saliva from patients has research ethics approved by Mater Health Services Human Research Ethics Committee and Human Research Ethics Committee, Griffith University. We thank Mater Palliative Care, Mater Research Institute Griffith Health Institute (Griffith University) for partially funding this study.	[Anonymous], EMEACHMPEWP192217200; Arhakis A., 2011, J BEHAV BRAIN SCI, V1, P194; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Gandia P, 2003, J CLIN PHARMACOL, V43, P1235, DOI 10.1177/0091270003257229; Gorodischer R, 1997, THER DRUG MONIT, V19, P637, DOI 10.1097/00007691-199712000-00006; GOROMARU T, 1984, ANESTHESIOLOGY, V61, P73, DOI 10.1097/00000542-198461010-00013; Hardy J., 2012, SUPPORT CARE CANC; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; Kopecky EA, 1997, THER DRUG MONIT, V19, P530, DOI 10.1097/00007691-199710000-00008; KROUWER JS, 1981, CLIN CHEM, V27, P202; Langel K, 2008, J ANAL TOXICOL, V32, P393, DOI 10.1093/jat/32.6.393; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Moolchan ET, 2001, J ADDICT DIS, V20, P55, DOI 10.1300/J069v20n02_05; Navarro M, 2001, CLIN CHEM, V47, P1788; Navazesh M, 2008, J AM DENT ASSOC, V139, p35S, DOI 10.14219/jada.archive.2008.0353; O'Neal CL, 1999, J ANAL TOXICOL, V23, P452, DOI 10.1093/jat/23.6.452; Pourzitaki C, 2006, REV CLIN PHARM PHARM, V20, P108; RITSCHEL WA, 1987, J CLIN PHARMACOL, V27, P647, DOI 10.1002/j.1552-4604.1987.tb03082.x; Shiran MR, 2005, THER DRUG MONIT, V27, P580, DOI 10.1097/01.ftd.0000164392.01779.db; Skopp G, 2001, INT J LEGAL MED, V114, P133, DOI 10.1007/PL00007717; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Taylor PJ, 2005, CLIN BIOCHEM, V38, P328, DOI 10.1016/j.clinbiochem.2004.11.007; Tesseromatis C, 2011, ACUTE PHASE PROTEINS - REGULATION AND FUNCTIONS OF ACUTE PHASE PROTEINS, P247; VANROOY HH, 1981, J CHROMATOGR, V223, P85, DOI 10.1016/S0378-4347(00)80070-5; Verplaetse R, 2010, J CHROMATOGR B, V878, P1987, DOI 10.1016/j.jchromb.2010.05.033	27	18	21	5	53	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1570-0232	1873-376X		J CHROMATOGR B	J. Chromatogr. B	JUN 1	2014	960						27	33		10.1016/j.jchromb.2014.04.019			7	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	AI4FR	WOS:000336821600005	24780703	Green Published			2020-06-30	J	Mercadante, S; Prestia, G; Adile, C; Casuccio, A				Mercadante, Sebastiano; Prestia, Giovanna; Adile, Claudio; Casuccio, Alessandra			Intranasal Fentanyl Versus Fentanyl Pectin Nasal Spray for the Management of Breakthrough Cancer Pain in Doses Proportional to Basal Opioid Regimen	JOURNAL OF PAIN			English	Article						Cancer pain; breakthrough pain; rapid-onset opioids; intranasal fentanyl; fentanyl pectin nasal spray	INTRAVENOUS MORPHINE; TRANSMUCOSAL FENTANYL; CROSSOVER TRIAL; BUCCAL TABLETS; DRUG-DELIVERY; DOUBLE-BLIND; OPEN-LABEL; MU-G; PHARMACOKINETICS; TOLERABILITY	The aim of this randomized, crossover, comparison study was to assess the analgesic and adverse effects of 2 nasal preparations, intranasal fentanyl (INFS) and fentanyl pectin nasal spray (FPNS), for breakthrough pain, given in doses proportional to opioid basal regimen. Each patient randomly received INFS or FPNS in doses proportional to opioid dosages used for background analgesia for 2 pairs of episodes. For each episode of breakthrough pain, pain intensity and adverse effects intensity were recorded just before starting the INFS or FPNS (TO) and 5 minutes (T5), 10 minutes (110), and 20 minutes (120) after the administration of the nasal drugs. Sixty-nine patients were studied. The mean age was 63.4 years, and 37 patients were males. For the present analysis, 188 episodes were considered. A statistical decrease in pain intensity was observed with both nasal drugs after 5, 10, and 20 minutes. A decrease in pain intensity of >33% was observed in 16, 102, and 159 treated episodes at T5, T10, and T20, respectively. Adverse effects were of mild nature in most cases or were preexistent because of basal opioid therapy. No differences were found in summed pain intensity difference 20 minutes after dosing. Most of patients did not find substantial preferences. INFS and FPNS were effective and well-tolerated treatments for breakthrough pain management. Both delivery systems, in doses proportional to the basal opioid regimen, provided significant analgesia within 10 minutes, without producing relevant adverse effects. Perspective: This article showed that INFS and FPNS in doses proportional to basal opioid regimen are equally safe and effective for the management of breakthrough pain in cancer patients. These data provide new insights on the use of nasal preparations of fentanyl. (C) 2014 by the American Pain Society	[Mercadante, Sebastiano; Prestia, Giovanna; Adile, Claudio] La Maddalena Canc Ctr, I-90145 Palermo, Italy; [Casuccio, Alessandra] G DAlessandro Univ, Dept Sci Hlth Promot & Mother Child Care, Palermo, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Anesthesia & Intens Care Unit, Via san Lorenzo 312, I-90145 Palermo, Italy.	terapiadeldolore@lamaddalenanet.it	casuccio, alessandra/B-1730-2013	casuccio, alessandra/0000-0002-5676-9535; Adile, Claudio/0000-0002-0664-3520			Davies A, 2013, J PAIN SYMPTOM MANAG, V46, P619, DOI 10.1016/j.jpainsymman.2012.12.009; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Diectrich R, 2012, ANN PHARMACOTHER, V46, P1382; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Grassin-Delyle S, 2012, PHARMACOL THERAPEUT, V134, P366, DOI 10.1016/j.pharmthera.2012.03.003; Hans GH, 2013, CURR MED RES OPIN, V29, P1523, DOI 10.1185/03007995.2013.837816; Jandhyala R, 2013, J PAIN SYMPTOM MANAG, V46, P573, DOI 10.1016/j.jpainsymman.2012.09.009; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Lyseng-Williamson KA, 2011, CNS DRUGS, V25, P511, DOI 10.2165/11207470-000000000-00000; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V27, P352, DOI 10.1016/j.jpainsymman.2003.09.006; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Mercadante S, 2013, CURR MED RES OPIN, V29, P1527, DOI 10.1185/03007995.2013.826640; Mercadante S, 2013, SUPPORT CARE CANCER, V21, P2335, DOI 10.1007/s00520-013-1799-2; Mercadante S, 2013, CURR MED RES OPIN, V29, P93, DOI 10.1185/03007995.2012.755120; Mercadante S, 2012, CURR MED RES OPIN, V28, P963, DOI 10.1185/03007995.2012.683112; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; Mercadante S, 2011, CRIT REV ONCOL HEMAT, V80, P460, DOI 10.1016/j.critrevonc.2010.12.002; Mercadante S, 2011, J PAIN SYMPTOM MANAG, V42, P464, DOI 10.1016/j.jpainsymman.2010.12.010; Mercadante S, 2010, LANCET ONCOL, V11, P484, DOI 10.1016/S1470-2045(09)70350-X; Mercadante S, 2010, CLIN J PAIN, V26, P306, DOI 10.1097/AJP.0b013e3181c4458a; Mercadante S, 2009, EUR J PAIN, V13, P329, DOI 10.1016/j.ejpain.2008.11.021; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Taylor Donald, 2010, J Support Oncol, V8, P184; Watts P, 2009, EXPERT OPIN DRUG DEL, V6, P543, DOI [10.1517/17425240902939135, 10.1517/17425240902939135 ]; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012	30	21	23	0	11	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1526-5900			J PAIN	J. Pain	JUN	2014	15	6					602	607		10.1016/j.jpain.2014.02.002			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AJ0HM	WOS:000337331400003	24561001				2020-06-30	J	Hempstead, K; Yildirim, EO				Hempstead, Katherine; Yildirim, Emel O.			SUPPLY-SIDE RESPONSE TO DECLINING HEROIN PURITY: FENTANYL OVERDOSE EPISODE IN NEW JERSEY	HEALTH ECONOMICS			English	Article						supply-side; illegal drugs; substance abuse	ILLICIT DRUG; OPIOID ANALGESICS; DEATHS; PRICE; ENFORCEMENT; REDUCTION; MARKETS; COCAINE; HEALTH; ABUSE	The inelastic price demand observations characteristic of illegal drug markets have led to the conclusion that the burden of a negative supply shock would be completely reflected to consumers. This paper argues that the increasing availability of prescription opioids may threaten heroin sellers' profit margin and force them to find alternative methods to compensate buyers in the event of a supply shock. We investigate the 2006 fentanyl overdose episode in New Jersey and argue that the introduction of non-pharmaceutical fentanyl, its spatial distribution, and the timing of overdose deaths may have been related to trends in heroin purity. Using medical examiner data, as well as data from the Drug Enforcement Administration, Office of Diversion Control on retail sales of prescription opioids in a negative binomial specification, we show that month-to-month fluctuations in heroin purity have a significant effect on fentanyl-related overdoses, particularly in those areas where prescription opioids are highly available. Copyright (c) 2013 John Wiley & Sons, Ltd.	[Hempstead, Katherine] Rutgers State Univ, Ctr State Hlth Policy, New Brunswick, NJ 08903 USA; [Yildirim, Emel O.] Rutgers State Univ, Dept Econ, New Brunswick, NJ 08903 USA	Hempstead, K (reprint author), Rutgers Ctr State Hlth Policy, 112 Paterson St,5th Floor, New Brunswick, NJ 08901 USA.	khempstead@ifh.rutgers.edu					Becker GS, 2006, J POLIT ECON, V114, P38, DOI 10.1086/498918; CAMERON AC, 1986, J APPL ECONOMET, V1, P29, DOI DOI 10.1002/JAE.3950010104; Cameron CA, 1998, REGRESSION ANAL COUN; Caulkins JP, 2007, DRUG ALCOHOL DEPEN, V90, pS61, DOI 10.1016/j.drugalcdep.2006.08.014; Caulkins JP, 1998, SOCIOECONOMIC PLANNI, V32, P256; Cicero TJ, 2005, J PAIN, V6, P662, DOI 10.1016/j.jpain.2005.05.004; DINARDO J, 1993, MATH COMPUT MODEL, V17, P53, DOI 10.1016/0895-7177(93)90239-U; Dobkin C, 2009, AM ECON REV, V99, P324, DOI 10.1257/aer.99.1.324; Ellenhorn MJ, 1997, ELLENHORNS MED TOXIC; Galenianos M, 2008, 14980 NBER; GREENE WH, 1994, ACCOUNTING EXCESS ZE; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; Horowitz JL, 2001, J AM STAT ASSOC, V96, P1254, DOI 10.1198/016214501753381904; Hull MJ, 2007, J FORENSIC SCI, V52, P1383, DOI 10.1111/j.1556-4029.2007.00564.x; Jofre-Bonet M, 2006, J ECON BEHAV ORGAN, V66, P281; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Levitt SD, 2000, Q J ECON, V115, P755, DOI 10.1162/003355300554908; Manchikanti Laxmaiah, 2007, Pain Physician, V10, P399; Manski F, 2001, INFORM AM POLICY ILL; MMWR, 2008, MMWR-MORBID MORTAL W, V57, P793; NDIC, 2008, 2008Q0317005 NDIC US; Paulozzi LJ, 2006, PHARMACOEPIDEM DR S, V15, P618, DOI 10.1002/pds.1276; Petry NM, 1998, ADDICTION, V93, P321, DOI 10.1046/j.1360-0443.1998.9333212.x; REUTER P., 2001, DRUG WAR HERESIES LE; Saffer H, 1999, ECON INQ, V37, P401, DOI 10.1111/j.1465-7295.1999.tb01439.x; SILVERMAN LP, 1977, J URBAN ECON, V4, P80, DOI 10.1016/0094-1190(77)90032-8; SMIALEK JE, 1994, J FORENSIC SCI, V39, P159; Smithson M, 2004, ADDICTION, V99, P340, DOI 10.1046/j.1360-0443.2003.00603.x; VUONG QH, 1989, ECONOMETRICA, V57, P307, DOI 10.2307/1912557; WAGSTAFF A, 1989, BRIT J ADDICT, V84, P1173; Weatherburn D, 2003, ADDICTION, V98, P83, DOI 10.1046/j.1360-0443.2003.00248.x; Wendel T, 2000, J DRUG ISSUES, V30, P225, DOI 10.1177/002204260003000201	34	18	18	0	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1057-9230	1099-1050		HEALTH ECON	Health Econ.	JUN	2014	23	6					688	705		10.1002/hec.2937			18	Economics; Health Care Sciences & Services; Health Policy & Services	Business & Economics; Health Care Sciences & Services	AG4BD	WOS:000335362800004	23740651				2020-06-30	J	Fan, HG; Jiang, S; Lin, DQ; Lu, DZ; Li, L; Ji, W; Li, WZ				Fan, H. G.; Jiang, S.; Lin, D. Q.; Lu, D. Z.; Li, L.; Ji, W.; Li, W. Z.			Comparison of anaesthetic and analgesic effects of emulsified isoflurane used alone or combined with lidocaine and fentanyl in dogs	NEW ZEALAND VETERINARY JOURNAL			English	Article						dogs; lidocaine; fentanyl; anaesthesia; Emulsified isoflurane	MINIMUM ALVEOLAR CONCENTRATION; INTRAVENOUS LIDOCAINE; NEUROPATHIC PAIN; LIPID EMULSION; RATS; REMIFENTANIL; FLUMAZENIL; HALOTHANE; SURGERY; PIGS	AIM: The objective of this study was to investigate the effects of a combination of emulsified isoflurane, lidocaine, and fentanyl (EI-L-F) compared with the efficacy of emulsified isoflurane alone (EI), a combination of emulsified isoflurane and lidocaine (EI-L) or emulsified isoflurane and fentanyl (EI-F) for anaesthetising dogs. METHODS: Eight mongrel dogs were anesthetised with EI (8 mL/kg/hour), EI-L (3 mg/kg/hour lidocaine and 6 mL/kg/hour of emulsified isoflurane), EI-F (1.5 mu g/kg/hour fentanyl and 6 mL/kg/hour of emulsified isoflurane), and EI-L-F (5 mL/kg/hour of emulsified isoflurane, 1 mu g/kg/hour of fentanyl and 2.4 mg/kg/hour of lidocaine). Each dog received all four treatments and there was a 15-day washout period between the treatments. The dogs' anaesthesia and analgesia scores and physiological parameters were determined before and 5, 10, 20, 30, 40, 50, 60, 70 and 80 minutes after the administration of anaesthetic agents. RESULTS: The dogs in each of the four groups became laterally recumbent within 1 minute. Respiration rate and heart rate increased (p<0.05) during the first 5 minutes of anaesthesia in all groups. Respiration rate in the EI-F-L group was higher (p=0.037) than other groups from 30 to 50 minutes. Heart rate was higher in the EI than EI-F-L group (p=0.018) from 10 to 20 minutes, then returned to near baseline. Arterial oxygen saturation decreased during the period of anaesthesia but was higher (p=0.032) from 10 to 50 minutes in EI-F-L group than in other groups. The total anaesthesia scores in the EI-L-F group were higher than the EI and EI-L groups (p<0.05). The mean time to body movement was 5 (SD 2), 5 (SD 2), 7 (SD 2) and 8 (SD 2) minutes for the EI, EI-L, EI-F and EI-F-L groups, respectively. The mean time to standing was 8 (SD 2), 9 (SD 2), 10 (SD 2) and 13 (SD 3) minutes for the EI, EI-L, EI-F and EI-F-L groups, respectively. No excitement was observed during recovery after anaesthesia. CONCLUSIONS: The EI-F-L combination that was used in this study provided an adequate anaesthesia effect in dogs, which was characterised by adequate analgesia and muscle relaxation without any complications.	[Fan, H. G.; Li, W. Z.] Harbin Med Univ, Dept Anesthesiol, Affiliated Hosp 2, Harbin 150086, Peoples R China; [Fan, H. G.; Jiang, S.; Lin, D. Q.; Ji, W.] Northeast Agr Univ, Dept Vet Surg, Coll Vet Med, Harbin 150030, Peoples R China; [Lu, D. Z.] Northwest A&F Univ, Dept Vet Surg, Coll Vet Med, Yangling 712100, Peoples R China; [Li, L.] Shenyang Agr Univ, Coll Anim Husb & Vet Med, Shenyang 110866, Peoples R China	Li, WZ (reprint author), Harbin Med Univ, Dept Anesthesiol, Affiliated Hosp 2, Harbin 150086, Peoples R China.	wenzhili9@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [31001092]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2011M500685]	This study was supported by the National Natural Science Foundation of China (Grant no.: 31001092), and China Postdoctoral Science Foundation Grant (Grant No.: 2011M500685). Thanks are due to Dr. Sheng Jiang for design and modification with this thesis, he contributed equally to Dr. Fan, and should be considered as co-first authors. The editorial help from Dr. Zhang Hui is appreciated.	COLLINSWORTH KA, 1974, CIRCULATION, V50, P1217, DOI 10.1161/01.CIR.50.6.1217; Criado AB, 2003, VET ANAESTH ANALG, V30, P250, DOI 10.1046/j.1467-2995.2003.00123.x; De Rick AF, 1977, J PHARM EXPT THERAPE, V203, P507; Dellemijn PLI, 1998, J PAIN SYMPTOM MANAG, V16, P220, DOI 10.1016/S0885-3924(98)00070-0; EGER EI, 1984, BRIT J ANAESTH, V56, P71; Ferrante FM, 1996, ANESTH ANALG, V82, P91, DOI 10.1097/00000539-199601000-00016; Haga HA, 2002, VET ANAESTH ANALG, V29, P69, DOI 10.1046/j.1467-2995.2002.00061.x; Hayashida M, 2003, ANESTH ANALG, V97, P1340, DOI 10.1213/01.ANE.0000083369.63589.A5; Hellyer PW, 2001, AM J VET RES, V62, P555, DOI 10.2460/ajvr.2001.62.555; Ilkiw JE, 1992, VET CLIN N AM-SMALL, V22, P281; KAWAMOTO M, 1992, ANESTH ANALG, V74, P747; KURZ A, 1993, ANESTHESIOLOGY, V79, P465, DOI 10.1097/00000542-199309000-00008; LOPER KA, 1990, ANESTH ANALG, V70, P72; Lu DZ, 2011, VET ANAESTH ANALG, V38, P301, DOI 10.1111/j.1467-2995.2011.00625.x; MATHIAS LA, 2004, REV BRAS ANESTESIOL, V54, P656; MOLLER JT, 1991, BRIT J ANAESTH, V66, P437, DOI 10.1093/bja/66.4.437; Musser JB, 1999, ANESTH ANALG, V88, P671, DOI 10.1097/00000539-199903000-00038; Picker O, 2001, BRIT J ANAESTH, V87, P748, DOI 10.1093/bja/87.5.748; Pypendop BH, 2005, ANESTH ANALG, V100, P97, DOI 10.1213/01.ANE.0000139350.88158.38; Sawyer RJ, 2002, ANESTH ANALG, V95, P224, DOI 10.1097/00000539-200207000-00040; SESSLER DI, 1991, ANESTHESIOLOGY, V74, P226, DOI 10.1097/00000542-199102000-00006; SHINGU K, 1983, ANESTH ANALG, V62, P151; SMITH ER, 1972, AM HEART J, V83, P365, DOI 10.1016/0002-8703(72)90438-3; Smith LJ, 2004, VET ANAESTH ANALG, V31, P53, DOI 10.1111/j.1467-2995.2004.00142.x; Valverde A, 2004, VET ANAESTH ANALG, V31, P264, DOI 10.1111/j.1467-2995.2004.00165.x; Van Hoogmoed LM, 2004, VET SURG, V33, P279, DOI 10.1111/j.1532-950X.2004.04041.x; Yang XL, 2006, ANESTHESIOLOGY, V104, P482, DOI 10.1097/00000542-200603000-00015; ZHANG WS, 2005, ANESTHESIOLOGY, V103, pA745; Zhou JX, 2006, ANESTH ANALG, V102, P129, DOI 10.1213/01.ane.0000189612.24147.07	29	2	2	0	14	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0048-0169	1176-0710		NEW ZEAL VET J	N. Z. Vet. J.	MAY 4	2014	62	3					123	129		10.1080/00480169.2013.859976			7	Veterinary Sciences	Veterinary Sciences	AE3JF	WOS:000333872100005	24341657				2020-06-30	J	Ortiz, J; Chang, LC; Tolpin, DA; Minard, CG; Scott, BG; Rivers, JM				Ortiz, Jaime; Chang, Lee C.; Tolpin, Daniel A.; Minard, Charles G.; Scott, Bradford G.; Rivers, Jose M.			Randomized, controlled trial comparing the effects of anesthesia with propofol, isoflurane, desflurane and sevoflurane on pain after laparoscopic cholecystectomy	REVISTA BRASILEIRA DE ANESTESIOLOGIA			English	Article						Laparoscopic cholecystectomy; Pain; Propofol; Inhalational anesthetics	LESS POSTOPERATIVE PAIN; ANALGESIA; RECOVERY; HYPERALGESIA; MATTERS	Background: Pain is the primary complaint and the main reason for prolonged recovery after laparoscopic cholecystectomy. The authors hypothesized that patients undergoing laparoscopic cholecystectomy will have less pain four hours after surgery when receiving maintenance of anesthesia with propofol when compared to isoflurane, desflurane, or sevoflurane. Methods: In this prospective, randomized trial, 80 patients scheduled for laparoscopic cholecystectomy were assigned to propofol, isoflurane, desfiurane, or sevoflurane for the maintenance of anesthesia. Our primary outcome was pain measured on the numeric analog scale four hours after surgery. We also recorded intraoperative use of opioids as well as analgesic consumption during the first 24h after surgery. Results: There was no statistically significant difference in pain scores four hours after surgery (p = 0.72). There were also no statistically significant differences in pain scores between treatment groups during the 24 h after surgery (p = 0.45). Intraoperative use of fentanyl and morphine did not vary significantly among the groups (p = 0.21 and 0.24, respectively). There were no differences in total morphine and hydrocodone/APAP use during the first 24h (p = 0.61 and 0.53, respectively). Conclusion: Patients receiving maintenance of general anesthesia with propofol do not have less pain after laparoscopic cholecystectomy when compared to isoflurane, desflurane, or sevoflurane. (C) 2013 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. All rights reserved.	[Ortiz, Jaime; Chang, Lee C.; Tolpin, Daniel A.; Rivers, Jose M.] Baylor Coll Med, Dept Anesthesiol, Houston, TX 77030 USA; [Minard, Charles G.] Baylor Coll Med, Dan L Duncan Inst Clin & Translat Res, Houston, TX 77030 USA; [Scott, Bradford G.] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA	Ortiz, J (reprint author), Baylor Coll Med, Dept Anesthesiol, Houston, TX 77030 USA.	jaimeo@bcm.edu			Dan L. Duncan Institute for Clinical and Translational Research	We are grateful to Dr. Robert M. Bryan Jr., Professor of Anesthesiology at Baylor College of Medicine, for assisting us with data analysis. This study was supported, in part, by the Dan L. Duncan Institute for Clinical and Translational Research.	Bisgaard T, 2006, ANESTHESIOLOGY, V104, P835, DOI 10.1097/00000542-200604000-00030; Bisgaard T, 2001, PAIN, V90, P261, DOI 10.1016/S0304-3959(00)00406-1; Bisgaard T, 2001, ARCH SURG-CHICAGO, V136, P917, DOI 10.1001/archsurg.136.8.917; Cheng SS, 2008, ANESTH ANALG, V106, P264, DOI 10.1213/01.ane.0000287653.77372.d9; Eilers H, 2010, ANESTHESIOLOGY, V112, P1452, DOI 10.1097/ALN.0b013e3181d94e00; Fassoulaki A, 2008, ANESTH ANALG, V107, P1715, DOI 10.1213/ane.0b013e318182d84e; Flood P, 2002, ANESTHESIOLOGY, V97, P192, DOI 10.1097/00000542-200207000-00027; Flood P, 2010, ANESTH ANALG, V111, P86, DOI 10.1213/ANE.0b013e3181dde32e; Gupta A, 2002, ANESTH ANALG, V95, P450, DOI 10.1097/00000539-200208000-00040; Hofer CK, 2003, BRIT J ANAESTH, V91, P631, DOI 10.1093/bja/aeg243; Jensen K, 2007, ACTA ANAESTH SCAND, V51, P464, DOI 10.1111/j.1399-6576.2006.01251.x; Michaloliakou C, 1996, ANESTH ANALG, V82, P44, DOI 10.1097/00000539-199601000-00009; Munoz HR, 2002, BRIT J ANAESTH, V88, P814, DOI 10.1093/bja/88.6.814; Raeder JC, 1998, ACTA ANAESTH SCAND, V42, P106; Shafer SL, 2008, ANESTH ANALG, V106, P3, DOI 10.1213/01.ane.0000299045.22629.86; Sinha S, 2007, ANN ROY COLL SURG, V89, P374, DOI 10.1308/003588407X183337; Tan T, 2010, ANESTH ANALG, V111, P83, DOI 10.1213/ANE.0b013e3181c0ee9e; White PF, 2010, ANESTH ANALG, V111, P88, DOI 10.1213/ANE.0b013e3181dce13c; Zajaczkowska R, 2004, REGION ANESTH PAIN M, V29, P424, DOI 10.1016/j.rapm.2004.05.009; Zhang Y, 2000, ANESTH ANALG, V91, P462, DOI 10.1097/00000539-200008000-00044	20	15	20	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0034-7094	1806-907X		REV BRAS ANESTESIOL	Rev. Bras. Anestesiol.	MAY-JUN	2014	64	3					145	151		10.1016/j.bjane.2013.03.011			7	Anesthesiology	Anesthesiology	AL4XY	WOS:000339139300001	24907871	DOAJ Gold, Green Published			2020-06-30	J	Samanta, S; Samanta, S; Ghatak, T; Grover, VK				Samanta, Sukhen; Samanta, Sujay; Ghatak, Tanmoy; Grover, V. K.			Chest ultrasonography in emergency Cesarean delivery in multi-valvular heart disease with pulmonary edema during spinal anesthesia	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Valvular heart disease; Cesarean section; Spinal anaesthesia; Chest ultrasound	CARDIAC-DISEASE; MANAGEMENT; WOMEN	Valvular heart disease in a parturient presenting for Cesarean section is challenging. A 25 year old primigravida parturient with severe mitral stenosis, mild mitral regurgitation, mild aortic regurgitation, and mild pulmonary arterial hypertension required Cesarean delivery after developing pulmonary edema. Low-dose spinal with hyperbaric bupivacine 0.5% 1.8 mL plus 25 mu g of fentanyl was used for anesthesia. Chest ultrasonography (US) and transthoracic echocardiography (TTE) were used for monitoring purposes. Spinal-induced preload reduction improved the pulmonary edema, as evidenced by chest US. Chest US and TTE helped in fluid management. (C) 2014 Elsevier Inc. All rights reserved.	[Samanta, Sukhen] AIIMS, JPNA Trauma Ctr, Trauma Ctr, Dept Anesthesia & Crit Care, New Delhi 110029, India; [Samanta, Sujay; Ghatak, Tanmoy] Sanjay Gandhi Post Grad Inst Med Sci, Dept Crit Care Med, Luckow 226014, India; [Grover, V. K.] Post Grad Inst Med Educ & Res, Dept Anesthesia & Intens Care, Chandigarh 160012, India	Samanta, S (reprint author), 17 Dr AN Paul Lane, Howrah 711201, W Bengal, India.	dr.sukhensamanta@gmail.com					Bonow RO, 1998, J AM COLL CARDIOL, V32, P1486, DOI 10.1016/S0735-1097(98)00454-9; HEMMINGS GT, 1987, CAN J ANAESTH, V34, P182, DOI 10.1007/BF03015343; Langesaeter E, 2010, ACTA ANAESTH SCAND, V54, P46, DOI 10.1111/j.1399-6576.2009.02080.x; Picano E, 2006, J AM SOC ECHOCARDIOG, V19, P356, DOI 10.1016/j.echo.2005.05.019; Siu SC, 2002, CIRCULATION, V105, P2179, DOI 10.1161/01.CIR.0000015699.48605.08; Steer PJ, 2006, HEART DIS PREGNANCY, P157	6	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	MAY	2014	26	3					235	237		10.1016/j.jclinane.2013.12.009			3	Anesthesiology	Anesthesiology	AI6RY	WOS:000337005900012	24793700				2020-06-30	J	Musk, GC; Murdoch, FR; Tuke, J; Kemp, MW; Dixon, MJ; Taylor, PM				Musk, Gabrielle C.; Murdoch, Fraser R.; Tuke, Jonathan; Kemp, Matthew W.; Dixon, Michael J.; Taylor, Polly M.			Thermal and mechanical nociceptive threshold testing in pregnant sheep	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						analgesia; nociceptive threshold testing; sheep	CONSCIOUS DOGS; PAIN; BUPRENORPHINE; CATS; ACEPROMAZINE; ANALGESIA; XYLAZINE; FENTANYL; STIMULI	Objective Analgesic regimes were compared in pregnant ewes after laparotomy by measuring thermal (TT) and mechanical (MT) nociceptive thresholds. Study design Prospective randomised experimental study. Animals Pregnant ewes at 121days gestation underwent laparotomy as part of another research project. Methods Thermal and mechanical thresholds were measured before, and 2, 6, 24 and 48hours after surgery. Thermal stimuli were delivered to the lateral aspect of the metatarsus via a skin-mounted probe, and mechanical stimuli to the contralateral site via a pneumatically driven 1.5mm diameter pin. Each test was performed five times, alternating thermal and mechanical stimuli, with tenminutes between thermal stimuli. At the end of surgery ewes received either: 75ghour-1 transdermal fentanyl patch (medial thigh) (group FP) (n=8), or 3gkg-1hour-1 intra-peritoneal medetomidine via an osmotic pump (group IPM) (n=8) inserted immediately prior to closure. Data were analysed using the Kruskal-Wallis RS Test (p<0.05). Once a significant effect was identified, pairwise comparisons were performed using paired Wilcoxon RS tests. To compensate for multiple hypotheses testing, p<0.005 was considered significant. Results Prior to surgery mean +/- SD TT was 56.1 +/- 5.0 degrees C (FP) and 55.6 +/- 5.0 degrees C (IPM); MT was 5.3 +/- 2.6N (FP) and 8.0 +/- 5.0N (IPM). In FP there was no significant change in either TT or MT over time. In IPM there was no significant change in MT over time but TT increased at two hours to 59.2 +/- 3.0 degrees C (p=0.003). Skin temperature (ST) ranged from 33.0 to 34.7 degrees C and did not change over time. There were no significant differences between groups in TT, MT or ST. Conclusions and clinical relevance Administration of intra-peritoneal medetomidine (3gkg-1hour-1) by an osmotic pump increases the thermal nociceptive threshold in the immediate post operative period in pregnant sheep, suggesting that this agent may have a role in providing post-operative analgesia.	[Musk, Gabrielle C.; Murdoch, Fraser R.] Murdoch Univ, Sch Vet & Life Sci, Murdoch, WA 6150, Australia; [Musk, Gabrielle C.] Univ Western Australia, Anim Care Serv, Crawley, WA, Australia; [Musk, Gabrielle C.] Univ Western Australia, Vet Serv, Crawley, WA, Australia; [Tuke, Jonathan] Univ Adelaide, Sch Math Sci, Adelaide, SA, Australia; [Kemp, Matthew W.] Univ Western Australia, Sch Womens & Infants Hlth, Crawley, WA, Australia; [Dixon, Michael J.; Taylor, Polly M.] Topcat Metrol Ltd, Little Downham, Cambs, England	Musk, GC (reprint author), Murdoch Univ, Sch Vet & Life Sci, Coll Vet Med, Murdoch Dr, Murdoch, WA 6150, Australia.	g.musk@murdoch.edu.au	Taylor, Polly/M-3239-2015	Taylor, Polly/0000-0003-1322-3468; Tuke, Jonathan/0000-0002-1688-8951	Women and Infants Research Foundation	Funding for this project was generously made available from the Women and Infants Research Foundation. We wish to thank researchers from the School of Women's and Infants' Health for allowing us to assess sheep involved in their studies for the purposes of this project.	Ahern BJ, 2010, AM J VET RES, V71, P1127, DOI 10.2460/ajvr.71.10.1127; Ahern BJ, 2009, AM J VET RES, V70, P418, DOI 10.2460/ajvr.70.3.418; Australian Government, 2004, AUSTR COD PRACT CAR; BEECHER HK, 1957, PHARMACOL REV, V9, P59; Bergadano A, 2006, AM J VET RES, V67, P882, DOI 10.2460/ajvr.67.5.882; Bergadano A, 2009, VET ANAESTH ANALG, V36, P261, DOI 10.1111/j.1467-2995.2009.00447.x; Dixon MJ, 2007, RES VET SCI, V82, P85, DOI 10.1016/j.rvsc.2006.03.010; Dixon MJ, 2010, LAB ANIM-UK, V44, P247, DOI 10.1258/la.2010.009080; Djouhri L, 2004, BRAIN RES REV, V46, P131, DOI 10.1016/j.brainresrev.2004.07.015; Fitzpatrick J, 2006, SMALL RUMINANT RES, V62, P55, DOI 10.1016/j.smallrumres.2005.07.028; Grant C, 2004, AUST VET J, V82, P304, DOI 10.1111/j.1751-0813.2004.tb12712.x; Grant C, 2001, LAB ANIM-UK, V35, P277, DOI 10.1258/0023677011911606; Hoffmann MV, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-206; Hothersall B, 2011, J NEUROSCI METH, V201, P220, DOI 10.1016/j.jneumeth.2011.07.028; Hunter JC, 1997, BRIT J PHARMACOL, V122, P1339, DOI 10.1038/sj.bjp.0701520; JEDRUCH J, 1989, ACTA VET SCAND, P129; Kastner SBR, 2006, VET ANAESTH ANALG, V33, P79, DOI 10.1111/j.1467-2995.2005.00243.x; Kemp MW, 2010, REPROD SCI, V17, P619, DOI 10.1177/1933719110373148; Lizarraga I, 2006, RES VET SCI, V80, P194, DOI 10.1016/j.rvsc.2005.06.001; Lizarraga I, 2011, NZ VET J, V60, P87; Lizarraga I, 2008, ANESTH ANALG, V107, P2061, DOI 10.1213/ane.0b013e318187ac06; Love EJ, 2011, VET ANAESTH ANALG, V38, P3, DOI 10.1111/j.1467-2995.2010.00580.x; Murdoch FR, 2013, LAB ANIM-UK, V47, P66, DOI 10.1177/0023677212473712; NOLAN A, 1987, J PHARMACOL METHOD, V17, P39, DOI 10.1016/0160-5402(87)90035-0; NOLAN A, 1987, BRIT J PHARMACOL, V92, P527, DOI 10.1111/j.1476-5381.1987.tb11353.x; Nolan A, 2000, PAIN ITS NATURE MANA, P93; Rasmussen DB, 2011, ACTA VET SCAND, V53, DOI 10.1186/1751-0147-53-32; Robertson SA, 2003, VET REC, V153, P462, DOI 10.1136/vr.153.15.462; Sandercock DA, 2009, J NEUROSCI METH, V182, P64, DOI 10.1016/j.jneumeth.2009.05.019; Talke PO, 2000, ANESTH ANALG, V90, P1060, DOI 10.1097/00000539-200005000-00011; Taylor PM, 2007, J FELINE MED SURG, V9, P313, DOI 10.1016/j.jfms.2007.03.008; WATERMAN AE, 1990, VET ANAESTH ANALG, V17, P20	32	15	15	1	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	MAY	2014	41	3					305	311		10.1111/vaa.12103			7	Veterinary Sciences	Veterinary Sciences	AJ2SH	WOS:000337511200013	24256147	Green Published			2020-06-30	J	Davis, MP; Bruera, E				Davis, Mellar P.; Bruera, Eduardo			Trial Design for Breakthrough Pain: Is It Ethical to Have a Placebo in a Trial?	CLINICAL THERAPEUTICS			English	Letter							CANCER; MANAGEMENT; FENTANYL; ASSOCIATION; GUIDELINES; OPIOIDS		[Davis, Mellar P.] Case Western Reserve Univ, Cleveland Clin, Lerner Sch Med, Cleveland, OH 44106 USA; [Davis, Mellar P.] Cleveland Clin, Taussig Canc Inst, Div Solid Tumor, Palliat Med & Support Oncol Serv, Cleveland, OH 44106 USA; [Bruera, Eduardo] FT McGraw Chair Treatment Canc, Dept Palliat Care & Rehabil Med, Houston, TX 77030 USA	Davis, MP (reprint author), Case Western Reserve Univ, Cleveland Clin, Lerner Sch Med, Cleveland, OH 44106 USA.						Caraceni A, 2013, J NATL COMPR CANC NE, V11, pS29; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Davis MP, 2012, J PAIN SYMPTOM MANAG, V44, pE1, DOI 10.1016/j.jpainsymman.2012.06.002; Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI [10.1586/ERN.11.63, 10.1586/ern.11.63]; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Novotna S, 2014, CLIN THER, V36, P357, DOI 10.1016/j.clinthera.2014.01.006; Zeppetella G, 2011, CLIN ONCOL-UK, V23, P393, DOI 10.1016/j.clon.2010.12.002; Zeppetella G, 2013, J NATL COMPR CANC NE, V11, pS37; Zeppetella G, 2011, PALLIATIVE MED, V25, P516, DOI 10.1177/0269216310385601	10	0	0	0	3	ELSEVIER	BRIDGEWATER	685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA	0149-2918	1879-114X		CLIN THER	Clin. Ther.	MAY	2014	36	5					814	815		10.1016/j.clinthera.2014.03.005			2	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AI3QY	WOS:000336778200020	24726089				2020-06-30	J	Trinquet, F				Trinquet, Francoise			Trial Design for Breakthrough Pain: Is It Ethical to Have a Placebo in a Trial? Reply	CLINICAL THERAPEUTICS			English	Letter							DOUBLE-BLIND; CANCER		Ethypharm Corp, St Cloud, France	Trinquet, F (reprint author), Ethypharm Corp, St Cloud, France.						[Anonymous], 1999, STAT MED, V18, P1905; European Medicines Association, 2011, EUR MED ASS PUBL; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Smith H, 2012, CNS DRUGS, V26, P509, DOI 10.2165/11630580-000000000-00000; Zeppetella G, 2013, J NATL COMPR CANC NE, V11, pS37	7	0	0	0	1	ELSEVIER	BRIDGEWATER	685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA	0149-2918	1879-114X		CLIN THER	Clin. Ther.	MAY	2014	36	5					816	816		10.1016/j.clinthera.2014.03.006			1	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AI3QY	WOS:000336778200021	24726087				2020-06-30	J	Lee, JS; Kim, JS; Kim, MK; Kim, SH; Kim, JY				Lee, J. S.; Kim, J. S.; Kim, M. K.; Kim, S. H.; Kim, J. Y.			Intrathecal fentanyl decreases the optimal effect site concentration of propofol during spinal anaesthesia	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							CEREBRAL STATE INDEX; EPIDURAL-ANESTHESIA; BISPECTRAL INDEX; SEDATION; PHENYLEPHRINE; REQUIREMENT; EPHEDRINE; INJECTION; INFUSION; MORPHINE	BackgroundThe aim of this study was to assess the possible difference in the optimal effect site concentration of propofol for conscious sedation during spinal anaesthesia with or without intrathecal fentanyl in patients undergoing urologic surgery. The hypothesis was that intrathecal fentanyl would decrease the effect site concentration of propofol needed for conscious sedation. MethodsAmong 43 patients, 23 patients received fentanyl 25mcg and 20 patients received normal saline in addition to hyperbaric bupivacaine 10mg during spinal anaesthesia. Propofol was infused at a dose determined by a modified Dixon's up-and-down method. The Cerebral State Index was recorded once target effect site concentration was reached to determine the effect of the successfulness of the conscious sedation. ResultsThe half maximal effective concentration (EC50) of the effect-site concentration of propofol for sedation was 1.670.28mcg/ml in the control group and 0.87 +/- 0.15mcg/ml in the fentanyl group (P=0.02). The propofol dose for conscious sedation during spinal anaesthesia was decreased by 48% when intrathecal fentanyl 25mcg was added to local anaesthetics. ConclusionThe EC50 of the effect-site concentration of propofol for sedation decreased from 1.67 +/- 0.28mcg/ml to 0.87 +/- 0.15mcg/ml with the addition of 25mcg fentanyl to a spinal anaesthetic in patients undergoing urologic surgery.	[Lee, J. S.; Kim, J. S.; Kim, M. K.; Kim, S. H.; Kim, J. Y.] Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Anesthesia & Pain Res Inst, Seoul 120752, South Korea	Kim, JY (reprint author), Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Anesthesia & Pain Res Inst, 50 Yonsei Ro, Seoul 120752, South Korea.	toughalex@hotmail.com		Lee, Jong Seok/0000-0002-7945-2530; Kim, Ji Young/0000-0001-5822-0338			Borgeat A, 2009, CURR OPIN ANESTHESIO, V22, P678, DOI 10.1097/ACO.0b013e32832f3320; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Dahlgren G, 1997, ANESTH ANALG, V85, P1288, DOI 10.1097/00000539-199712000-00020; DIXON WJ, 1991, NEUROSCI BIOBEHAV R, V15, P47, DOI 10.1016/S0149-7634(05)80090-9; Doufas AG, 2004, BRIT J ANAESTH, V93, P228, DOI 10.1093/bja/aeh192; DUTTON RC, 1995, J CLIN MONITOR, V11, P35, DOI 10.1007/BF01627418; Eisenach JC, 2003, ANESTHESIOLOGY, V99, P166, DOI 10.1097/00000542-200307000-00027; Gehling M, 2009, ANAESTHESIA, V64, P643, DOI 10.1111/j.1365-2044.2008.05817.x; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Hu CP, 2005, ANESTHESIOLOGY, V102, P639, DOI 10.1097/00000542-200503000-00024; Ishiyama T, 2003, ANESTH ANALG, V97, P780, DOI 10.1213/01.ANE.0000073355.63287.E4; Jang I, 2010, REGION ANESTH PAIN M, V35, P145, DOI 10.1097/AAP.0b013e3181c75c05; Jensen EW, 2006, ANESTHESIOLOGY, V105, P28, DOI 10.1097/00000542-200607000-00009; Kim JY, 2009, ANAESTHESIA, V64, P1307, DOI 10.1111/j.1365-2044.2009.06127.x; Nishiyama T, 2010, J ANESTH, V24, P380, DOI 10.1007/s00540-010-0906-5; Ozkan-Seyhan T, 2006, BRIT J ANAESTH, V96, P645, DOI 10.1093/bja/ael055; Pace NL, 2007, ANESTHESIOLOGY, V107, P144, DOI 10.1097/01.anes.0000267514.42592.2a; Pilge S, 2006, ANESTHESIOLOGY, V104, P488, DOI 10.1097/00000542-200603000-00016; Schnider TW, 1999, ANESTHESIOLOGY, V90, P1502, DOI 10.1097/00000542-199906000-00003; Shende D, 1998, ANAESTHESIA, V53, P702; Takizawa D, 2006, EUR J ANAESTH, V23, P654, DOI 10.1017/S0265021506000433; Zhong T, 2005, BRIT J ANAESTH, V95, P798, DOI 10.1093/bja/aei253	22	1	1	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAY	2014	58	5					597	603		10.1111/aas.12307			7	Anesthesiology	Anesthesiology	AE8RQ	WOS:000334269600012	24628076				2020-06-30	J	Granata, R; Bossi, P; Bertulli, R; Saita, L				Granata, Roberta; Bossi, Paolo; Bertulli, Rossella; Saita, Luigi			Rapid-Onset Opioids for the Treatment of Breakthrough Cancer Pain: Two Cases of Drug Abuse	PAIN MEDICINE			English	Article						Rapid-Onset Opioids; Abuse; Breakthrough Cancer Pain	FENTANYL; EFFICACY; SPRAY	SettingIn the last few years, the use of opioids for cancer pain has rapidly increased and new molecules have been developed. Currently, rapid-onset opioids are widely used in clinical practice for breakthrough cancer pain (BTcP). However, the tolerability of these molecules is still a matter of debate. PatientsWe describe two cases of rapid-onset opioids misuse that have been recently observed at our palliative care unit. DiscussionThe reported cases are explicative as they occurred in patients suffering from different types of cancer and with different causes of BTcP. Further investigations are needed to identify factors predicting addiction to this new class of molecules.	[Granata, Roberta; Bossi, Paolo] Fdn IRCCS Ist Nazl Tumori, Head & Neck Med Oncol Unit, I-20133 Milan, Italy; [Bertulli, Rossella] Fdn IRCCS Ist Nazl Tumori, Adult Sarcoma Med Oncol Unit, I-20133 Milan, Italy; [Saita, Luigi] Fdn IRCCS Ist Nazl Tumori, I-20133 Milan, Italy	Granata, R (reprint author), Fdn IRCCS Ist Nazl Tumori, Head & Neck Canc Unit, Via Venezian 1, I-20133 Milan, Italy.	roberta.granata@istitutotumori.mi.it	Bertulli, Rossella/G-8916-2017; Bossi, Paolo/I-2376-2019; Granata, Roberta/B-8649-2017; Bossi, Paolo/D-1807-2017	Bertulli, Rossella/0000-0002-7237-7515; Bossi, Paolo/0000-0003-0135-0224; Granata, Roberta/0000-0001-6584-3138; Bossi, Paolo/0000-0003-0135-0224			[Anonymous], 2011, PROPOSED TRANSMUCOSA; Betses M, 2013, NEW ENGL J MED, V369, P989, DOI 10.1056/NEJMp1308222; Bohn TM, 2011, ADV PSYCHOSOM MED, V30, P113, DOI 10.1159/000324069; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Colliver JD, 2008, J PAIN, V9, P487, DOI 10.1016/j.jpain.2008.03.001; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Foley KM, 2011, PALLIATIVE MED, V25, P398, DOI 10.1177/0269216311400480; Food and Drug Administration, 2012, TRANSM IMM REL FENT; Hojsted J, 2007, EUR J PAIN, V11, P490, DOI 10.1016/j.ejpain.2006.08.004; Passik Steven D, 2002, J Pain Palliat Care Pharmacother, V16, P39; Rauck R, 2012, CURR MED RES OPIN, V28, P859, DOI 10.1185/03007995.2012.683111; Smith H, 2012, CNS DRUGS, V26, P509, DOI 10.2165/11630580-000000000-00000; Starr TD, 2010, CURR PAIN HEADACHE R, V14, P268, DOI 10.1007/s11916-010-0118-6; Veldhorst-Janssen NML, 2012, J PALLIAT MED, V15, P631, DOI 10.1089/jpm.2012.0013; Zeppetella G, 2013, J NATL COMPR CANC NE, V11, pS37; Zeppetella G, 2011, PALLIATIVE MED, V25, P516, DOI 10.1177/0269216310385601	18	6	6	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	MAY	2014	15	5					758	761		10.1111/pme.12382			4	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	AH9JS	WOS:000336458900008	24967472	Bronze			2020-06-30	J	Patel, NC; Heckman, MG; Palmer, WC; Cangemi, D; DeVault, KR				Patel, Neal C.; Heckman, Michael G.; Palmer, William C.; Cangemi, David; DeVault, Kenneth R.			A Comparison of Patient Satisfaction With Sedation Between Fentanyl/Midazolam and Meperidine/Midazolam in Patients Undergoing Endoscopy	AMERICAN JOURNAL OF GASTROENTEROLOGY			English	Letter							COLONOSCOPY; FENTANYL; TRIAL		[Patel, Neal C.] Mayo Clin Arizon, Dept Gastroenterol & Hepatol, Scottsdale, AZ USA; [Heckman, Michael G.] Mayo Clin Florida, Biostat Sect, Jacksonville, FL 32224 USA; [Palmer, William C.; DeVault, Kenneth R.] Mayo Clin Florida, Dept Gastroenterol & Hepatol, Jacksonville, FL 32224 USA; [Cangemi, David] Mayo Clin Florida, Dept Internal Med, Jacksonville, FL 32224 USA	Palmer, WC (reprint author), Mayo Clin Florida, Dept Gastroenterol & Hepatol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	Palmer.william@mayo.edu					Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; Hayee B, 2009, GASTROINTEST ENDOSC, V69, P681, DOI 10.1016/j.gie.2008.09.033; Robertson DJ, 2009, ALIMENT PHARM THER, V29, P817, DOI 10.1111/j.1365-2036.2009.03943.x; Vargo J, 2009, CLIN GASTROENTEROL H, V7, P156, DOI 10.1016/j.cgh.2008.09.004	4	1	2	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0002-9270	1572-0241		AM J GASTROENTEROL	Am. J. Gastroenterol.	MAY	2014	109	5					772	774		10.1038/ajg.2014.31			4	Gastroenterology & Hepatology	Gastroenterology & Hepatology	AG5HU	WOS:000335450900022	24797008				2020-06-30	J	Burjek, NE; Wagner, CE; Hollenbeck, RD; Wang, L; Yu, C; McPherson, JA; Billings, FT				Burjek, Nicholas E.; Wagner, Chad E.; Hollenbeck, Ryan D.; Wang, Li; Yu, Chang; McPherson, John A.; Billings, Frederic T.			Early Bispectral Index and Sedation Requirements During Therapeutic Hypothermia Predict Neurologic Recovery Following Cardiac Arrest	CRITICAL CARE MEDICINE			English	Article						therapeutic hypothermia; ischemia reperfusion; bispectral index; intensive care unit; cardiac arrest; sedation; neurologic function	AMERICAN-HEART-ASSOCIATION; INTERNATIONAL LIAISON COMMITTEE; EUROPEAN RESUSCITATION COUNCIL; CARE-UNIT PATIENTS; STROKE FOUNDATION; SOUTHERN AFRICA; RISK-FACTORS; CARDIOPULMONARY; PROGNOSTICATION; MORTALITY	Objectives: To test the hypothesis that low bispectral index scores and low sedative requirements during therapeutic hypothermia predict poor neurologic outcome. Design: Observational study of a prospectively collected cohort. Setting: Cardiovascular ICU. Patients: One hundred sixty consecutive cardiac arrest patients treated with therapeutic hypothermia. Interventions: None. Measurements and Results: Eighty-four of the 141 subjects (60%) who survived hypothermia induction were discharged from the ICU with poor neurologic outcome, defined as a cerebral performance category score of 3, 4, or 5. These subjects had lower bispectral index (p < 0.001) and sedative requirements (p < 0.001) during hypothermia compared with the 57 subjects discharged with good outcome. Early prediction of neurologic recovery was best 7 hours after ICU admission, and median bispectral index scores at that time were 31 points lower in subjects discharged with poor outcome (11 [interquartile range, 4-29] vs 42 [37-49], p < 0.001). Median sedation requirements decreased by 17% (interquartile range, -50 to 0%) 7 hours after ICU admission in subjects with poor outcome but increased by 50% (interquartile range, 0-142%) in subjects with good outcome (p < 0.001). Each 10-point decrease in bispectral index was independently associated with a 59% increase in the odds of poor outcome (95% CI, 32-76%; p < 0.001). The model including bispectral index and sedative requirement correctly reclassified 15% of subjects from good to poor outcome and 1% of subjects from poor to good outcome. The model incorrectly reclassified 1% of subjects from poor to good outcome but did not incorrectly reclassify any from good to poor outcome. Conclusions: Bispectral index scores and sedative requirements early in the course of therapeutic hypothermia improve the identification of patients who will not recover from brain anoxia. The ability to accurately predict nonrecovery after cardiac arrest could facilitate discussions with families, reduce patient suffering, and limit use of ICU resources in futile cases.	[Burjek, Nicholas E.; Wagner, Chad E.; Billings, Frederic T.] Vanderbilt Univ, Sch Med, Dept Anesthesiol, Div Crit Care Med, Nashville, TN 37212 USA; [Hollenbeck, Ryan D.; McPherson, John A.] Vanderbilt Univ, Sch Med, Dept Med, Div Cardiol, Nashville, TN 37212 USA; [Wang, Li; Yu, Chang] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA	Billings, FT (reprint author), Vanderbilt Univ, Sch Med, Dept Anesthesiol, Div Crit Care Med, Nashville, TN 37212 USA.	frederic.t.billings@vanderbilt.edu		Billings, Josh/0000-0001-7135-7785	Vanderbilt University Department of Anesthesiology; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23GM102676]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL 1RR024975]	Supported, in part, by the Vanderbilt University Department of Anesthesiology. Dr. Burjek received support for travel from the Society of Critical Care Anesthesiologists. Dr. Wagner consulted and lectured for Imacor. Dr. McPherson consulted for Velomedix Corp. Dr. Billings IV received support from the National Institutes of Health (NIH) (K23GM102676). Dr. Burjek's, Wagner's, Hollenbeck's, Yu's, McPherson's, and Billings' institution received grant support from the NIH (UL 1RR024975).	[Anonymous], 2001, REGRESSION MODELING; [Anonymous], 2002, N ENGL J MED, V346, P549; Avidan MS, 2011, NEW ENGL J MED, V365, P591, DOI 10.1056/NEJMoa1100403; Badjatia N, 2007, NEUROCRIT CARE, V6, P186, DOI 10.1007/s12028-007-0011-2; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Blondin NA, 2011, NEUROLOGIST, V17, P241, DOI 10.1097/NRL.0b013e318224ee0e; Cloostermans MC, 2012, CRIT CARE MED, V40, P2867, DOI 10.1097/CCM.0b013e31825b94f0; COTEV S, 1975, ANESTHESIOLOGY, V43, P117, DOI 10.1097/00000542-197507000-00029; de Jonghe Bernard, 2009, Crit Care Med, V37, pS309, DOI 10.1097/CCM.0b013e3181b6e64c; Fugate JE, 2012, CIRCULATION, V126, P546, DOI 10.1161/CIRCULATIONAHA.111.088807; Garnacho-Montero J, 2001, INTENS CARE MED, V27, P1288, DOI 10.1007/s001340101009; Hayakawa K, 2011, RESUSCITATION, V82, P874, DOI 10.1016/j.resuscitation.2011.02.045; Jacobs I, 2004, RESUSCITATION, V63, P233, DOI 10.1016/j.resuscitation.2004.09.008; JENNETT B, 1975, LANCET, V1, P480; Leary M, 2010, RESUSCITATION, V81, P1133, DOI 10.1016/j.resuscitation.2010.04.021; Legriel S, 2013, RESUSCITATION, V84, P343, DOI 10.1016/j.resuscitation.2012.11.001; McNally Bryan, 2011, Morbidity and Mortality Weekly Report, V60, P1; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Nielsen N, 2009, ACTA ANAESTH SCAND, V53, P926, DOI 10.1111/j.1399-6576.2009.02021.x; Pandharipande P, 2008, J TRAUMA, V65, P34, DOI 10.1097/TA.0b013e31814b2c4d; Pundik S, 2012, NEUROLOGY, V79, pS44, DOI 10.1212/WNL.0b013e3182695a14; R Core Team, 2012, R LANG ENV STAT COMP; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Samaniego EA, 2011, NEUROCRIT CARE, V15, P113, DOI 10.1007/s12028-010-9412-8; Scirica BM, 2013, CIRCULATION, V127, P244, DOI 10.1161/CIRCULATIONAHA.111.076851; Seder DB, 2010, INTENS CARE MED, V36, P281, DOI 10.1007/s00134-009-1691-1; Shehabi Y, 2012, AM J RESP CRIT CARE, V186, P724, DOI 10.1164/rccm.201203-0522OC; Sims NR, 2010, BBA-MOL BASIS DIS, V1802, P80, DOI 10.1016/j.bbadis.2009.09.003; Vandesteene A, 1988, Anaesthesia, V43 Suppl, P42, DOI 10.1111/j.1365-2044.1988.tb09067.x; Vivien B, 2003, ANESTHESIOLOGY, V99, P9, DOI 10.1097/00000542-200307000-00006	30	19	24	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAY	2014	42	5					1204	1212		10.1097/CCM.0000000000000126			9	Critical Care Medicine	General & Internal Medicine	AG4IU	WOS:000335383900037	24365859	Green Accepted			2020-06-30	J	Hoedemaekers, CWE; Abdo, WF				Hoedemaekers, C. W. E.; Abdo, W. F.			Bispectral Index for Prognostication After Cardiac Arrest: The Holy Grail at Last?	CRITICAL CARE MEDICINE			English	Editorial Material						electroencephalographic; prognostication; cardiac arrest; bispectral index	POSTANOXIC STATUS EPILEPTICUS; THERAPEUTIC HYPOTHERMIA; CONTINUOUS EEG; PREDICTORS		[Hoedemaekers, C. W. E.; Abdo, W. F.] Radboud Univ Nijmegen Med Ctr, Dept Intens Care, Nijmegen, Netherlands	Hoedemaekers, CWE (reprint author), Radboud Univ Nijmegen Med Ctr, Dept Intens Care, Nijmegen, Netherlands.		Hoedemaekers, C.W.E./L-4375-2015; Abdo, Wilson F/B-7348-2014	Abdo, Wilson F/0000-0002-5783-8643			Burjek NE, 2014, CRIT CARE MED, V42, P1204, DOI 10.1097/CCM.0000000000000126; Cloostermans MC, 2012, CRIT CARE MED, V40, P2867, DOI 10.1097/CCM.0b013e31825b94f0; Crepeau AZ, 2013, NEUROLOGY, V80, P339, DOI 10.1212/WNL.0b013e31827f089d; Duarte Leonardo Teixeira Domingues, 2009, Rev. Bras. Anestesiol., V59, P99, DOI 10.1590/S0034-70942009000100013; Fernandez-Torre JL, 2012, SEIZURE-EUR J EPILEP, V21, P61, DOI 10.1016/j.seizure.2011.09.001; Kamps MJA, 2013, INTENS CARE MED, V39, P1671, DOI 10.1007/s00134-013-3004-y; Leary M, 2010, RESUSCITATION, V81, P1133, DOI 10.1016/j.resuscitation.2010.04.021; Legriel S, 2013, RESUSCITATION, V84, P343, DOI 10.1016/j.resuscitation.2012.11.001; Punjasawadwong Y, 2007, COCHRANE DB SYST REV, V4; Riker RR, 2013, RESUSCITATION, V84, P794, DOI 10.1016/j.resuscitation.2012.10.014; Rossetti AO, 2010, CRIT CARE, V14, DOI 10.1186/cc9276; Rossetti AO, 2010, ANN NEUROL, V67, P301, DOI 10.1002/ana.21984; Rossetti AO, 2009, NEUROLOGY, V72, P744, DOI 10.1212/01.wnl.0000343006.60851.62; Seder DB, 2010, INTENS CARE MED, V36, P281, DOI 10.1007/s00134-009-1691-1; Stammet P, 2013, J AM COLL CARDIOL, V62, P851, DOI 10.1016/j.jacc.2013.04.039; Vivien B, 2003, ANESTHESIOLOGY, V99, P9, DOI 10.1097/00000542-200307000-00006	16	1	2	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAY	2014	42	5					1312	1313		10.1097/CCM.0000000000000187			2	Critical Care Medicine	General & Internal Medicine	AG4IU	WOS:000335383900064	24736353				2020-06-30	J	Rodriguez, MAP; Suarez-Gonzalo, L; Laporta-Baez, Y				Palomero Rodriguez, Miguel Angel; Suarez-Gonzalo, Luis; Laporta-Baez, Yolanda			Thoracic Epidural Anesthesia in Abdominal Aortic Surgery: Use and Advantages	ANESTHESIOLOGY			English	Letter							ANALGESIA		[Palomero Rodriguez, Miguel Angel; Suarez-Gonzalo, Luis; Laporta-Baez, Yolanda] Ramon y Cajal Univ Hosp, Madrid, Spain	Rodriguez, MAP (reprint author), Ramon y Cajal Univ Hosp, Madrid, Spain.	mapalomero@gmail.com					Jakobsen CJ, 2012, J CARDIOTHOR VASC AN, V26, P1039, DOI 10.1053/j.jvca.2012.05.007; Lindholm EE, 2013, ANESTHESIOLOGY, V119, P802, DOI 10.1097/ALN.0b013e31829bd883; LIU S, 1995, ANESTHESIOLOGY, V82, P1474, DOI 10.1097/00000542-199506000-00019; Magnusdottir H, 1999, ANESTHESIOLOGY, V91, P1299, DOI 10.1097/00000542-199911000-00021; Olausson K, 1997, CIRCULATION, V96, P2178; Rigg JRA, 2002, LANCET, V359, P1276, DOI 10.1016/S0140-6736(02)08266-1; Rodriguez MAP, 2008, MINERVA ANESTESIOL, V74, P619	7	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	MAY	2014	120	5					1288	1289		10.1097/ALN.0000000000000185			2	Anesthesiology	Anesthesiology	AG1KW	WOS:000335175100039	24755799				2020-06-30	J	Zaugg, M; Lucchinetti, E				Zaugg, Michael; Lucchinetti, Eliana			Sevoflurane-Compared with - Propofol-based Anesthesia Reduces the Need for Inotropic Support in Patients Undergoing Abdominal Aortic Aneurysm Repair: Evidence of Cardioprotection by Volatile Anesthetics in Noncardiac Surgery	ANESTHESIOLOGY			English	Letter							BYPASS GRAFT-SURGERY; CORONARY; REMIFENTANIL		[Zaugg, Michael; Lucchinetti, Eliana] Univ Alberta, Edmonton, AB, Canada	Zaugg, M (reprint author), Univ Alberta, Edmonton, AB, Canada.	michael.zaugg@ualberta.ca	Zaugg, Michael/G-4287-2016	Lucchinetti, Eliana/0000-0003-3338-1279; Zaugg, Michael/0000-0002-2016-8973			Bein B, 2005, ANESTH ANALG, V100, P610, DOI 10.1213/01.ANE.0000145012.27484.A7; Bignami E, 2009, J CARDIOTHOR VASC AN, V23, P594, DOI 10.1053/j.jvca.2009.01.022; De Hert S, 2009, ANAESTHESIA, V64, P953, DOI 10.1111/j.1365-2044.2009.06008.x; Garcia C, 2005, BRIT J ANAESTH, V94, P159, DOI 10.1093/bja/aei026; Jakobsen CJ, 2007, J CARDIOTHOR VASC AN, V21, P664, DOI 10.1053/j.jvca.2007.03.002; Julier K, 2003, ANESTHESIOLOGY, V98, P1315, DOI 10.1097/00000542-200306000-00004; Kim TY, 2011, ANAESTH INTENS CARE, V39, P418, DOI 10.1177/0310057X1103900312; Law-Koune JD, 2006, J CARDIOTHOR VASC AN, V20, P484, DOI 10.1053/j.jvca.2005.08.001; Lindholm EE, 2013, ANESTHESIOLOGY, V119, P802, DOI 10.1097/ALN.0b013e31829bd883; Lu Chih-Cherng, 2003, Acta Anaesthesiol Sin, V41, P165; Lucchinetti E, 2007, ANESTHESIOLOGY, V106, P444, DOI 10.1097/00000542-200703000-00008; Lucchinetti E, 2012, ANESTHESIOLOGY, V116, P296, DOI 10.1097/ALN.0b013e318242349a; Wong GTC, 2010, J CARDIOTHOR VASC AN, V24, P790, DOI 10.1053/j.jvca.2009.09.012; Zaugg M, 2013, CIRCULATION, V127, pE875, DOI 10.1161/CIRCULATIONAHA.112.000201; Zaugg M, 2012, ANESTHESIOLOGY, V116, P648, DOI 10.1097/ALN.0b013e318247225a; Zaugg M, 2012, CIRC RES, V110, pE42, DOI 10.1161/CIRCRESAHA.112.265116	16	3	3	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	MAY	2014	120	5					1289	1290		10.1097/ALN.0000000000000186			2	Anesthesiology	Anesthesiology	AG1KW	WOS:000335175100040	24755800				2020-06-30	J	Xue, FS; Cui, XL; Cheng, Y; Wang, SY				Xue, Fu-Shan; Cui, Xin-Long; Cheng, Yi; Wang, Shi-Yu			Comparing Cardioprotective Effects of Anesthesia Methods in Patients Undergoing Elective Abdominal Aortic Surgery	ANESTHESIOLOGY			English	Letter							PERIOPERATIVE MYOCARDIAL-INFARCTION; VASCULAR-SURGERY; RAT-HEART; COMPLICATIONS; INJURY		[Xue, Fu-Shan] Chinese Acad Med Sci, Beijing 100730, Peoples R China; Peking Union Med Coll, Beijing 100021, Peoples R China	Xue, FS (reprint author), Chinese Acad Med Sci, Beijing 100730, Peoples R China.	xuefushan@aliyun.com					Barbagallo M, 2006, J CLIN ANESTH, V18, P280, DOI 10.1016/j.jclinane.2005.11.005; Bunkelgrun M, 2008, AM J CARDIOL, V101, P1196, DOI 10.1016/j.amjcard.2007.11.072; Gross ER, 2005, AM J PHYSIOL-HEART C, V288, pH2744, DOI 10.1152/ajpheart.00918.2004; Gupta PK, 2013, ANN SURG, V258, P1096, DOI 10.1097/SLA.0b013e318288e957; Kim GS, 2011, YONSEI MED J, V52, P339, DOI [10.3349/ymj.2011.52.2.339, 10.3349/ymj.2011.52.2.333]; Lindholm EE, 2013, ANESTHESIOLOGY, V119, P802, DOI 10.1097/ALN.0b013e31829bd883; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P851, DOI 10.1016/0735-1097(91)90864-6; Martinez EA, 2005, J CARDIOTHOR VASC AN, V19, P577, DOI 10.1053/j.jvca.2005.07.002; Modesti PA, 2006, INTERN EMERG MED, V1, P177, DOI 10.1007/BF02934735; Obal D, 2001, BRIT J ANAESTH, V87, P905, DOI 10.1093/bja/87.6.905; Valentijn TM, 2013, EUR J ANAESTH, V30, P664, DOI 10.1097/EJA.0b013e328362a5fd; Zhang Y, 2004, ANESTHESIOLOGY, V101, P918, DOI 10.1097/00000542-200410000-00017	12	1	1	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	MAY	2014	120	5					1291	1292		10.1097/ALN.0000000000000187			2	Anesthesiology	Anesthesiology	AG1KW	WOS:000335175100041	24755801				2020-06-30	J	Lindholm, EE; Aune, E; Otterstad, JE; Kirkeboen, KA				Lindholm, Espen E.; Aune, Erlend; Otterstad, Jan E.; Kirkeboen, Knut A.			Comparing Cardioprotective Effects of Anesthesia Methods in Patients Undergoing Elective Abdominal Aortic Surgery In Reply	ANESTHESIOLOGY			English	Letter							ARTERY-BYPASS SURGERY; DELTA-OPIOID RECEPTORS; CARDIOPULMONARY BYPASS; CORONARY SURGERY; EPIDURAL ANALGESIA; RANDOMIZED-TRIAL; BIOCHEMICAL MARKERS; GENERAL-ANESTHESIA; MYOCARDIAL INJURY; DOSE PROPOFOL		[Lindholm, Espen E.; Aune, Erlend; Otterstad, Jan E.; Kirkeboen, Knut A.] Vestfold Hosp Trust, Tonsberg, Norway	Lindholm, EE (reprint author), Vestfold Hosp Trust, Tonsberg, Norway.	espen.lindholm@siv.no					Beattie WS, 2001, ANESTH ANALG, V93, P853, DOI 10.1097/00000539-200110000-00010; Bois S, 1997, ANESTH ANALG, V85, P1233, DOI 10.1097/00000539-199712000-00010; Conzen PF, 2003, ANESTHESIOLOGY, V99, P826, DOI 10.1097/00000542-200310000-00013; DAVIES MJ, 1993, ANAESTH INTENS CARE, V21, P790, DOI 10.1177/0310057X9302100607; De Hert SG, 2004, ANESTHESIOLOGY, V101, P299, DOI 10.1097/00000542-200408000-00009; De Hert SG, 2004, ANESTHESIOLOGY, V101, P9, DOI 10.1097/00000542-200407000-00005; Garnett RL, 1996, CAN J ANAESTH, V43, P769, DOI 10.1007/BF03013027; Gauss A, 2011, ANAESTHESIST, V60, P950, DOI 10.1007/s00101-011-1941-9; Gelissen HPMM, 1996, ANESTHESIOLOGY, V84, P397, DOI 10.1097/00000542-199602000-00019; Husedzinovic I, 2003, COLLEGIUM ANTROPOL, V27, P205; Kato R, 2000, BRIT J ANAESTH, V84, P608, DOI 10.1093/bja/84.5.608; Kehl F, 2002, ANESTHESIOLOGY, V96, P675, DOI 10.1097/00000542-200203000-00025; Kokita N, 1996, ANESTHESIOLOGY, V84, P117, DOI 10.1097/00000542-199601000-00014; Kottenberg E, 2012, ACTA ANAESTH SCAND, V56, P30, DOI 10.1111/j.1399-6576.2011.02585.x; Landoni G, 2007, J CARDIOTHOR VASC AN, V21, P502, DOI 10.1053/j.jvca.2007.02.013; Leslie K, 2013, BRIT J ANAESTH, V111, P382, DOI 10.1093/bja/aet120; Lindholm EE, 2014, ANAESTHESIA IN PRESS; Lindholm EE, 2013, ANESTHESIOLOGY, V119, P802, DOI 10.1097/ALN.0b013e31829bd883; Lucchinetti E, 2012, ANESTHESIOLOGY, V116, P296, DOI 10.1097/ALN.0b013e318242349a; Mullenheim J, 2001, CAN J ANAESTH, V48, P784; Nishimori M, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005059.pub2; Norris EJ, 2001, ANESTHESIOLOGY, V95, P1054, DOI 10.1097/00000542-200111000-00006; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; Selvanayagam JB, 2004, CIRCULATION, V109, P345, DOI 10.1161/01.CIR.0000109489.71945.BD; Symons JA, 2006, BRIT J ANAESTH, V97, P127, DOI 10.1093/bja/ael149; Thielmann M, 2013, LANCET, V382, P597, DOI 10.1016/S0140-6736(13)61450-6; Tritapepe L, 2007, EUR J ANAESTH, V24, P323, DOI 10.1017/S0265021506001931; Werewatganon T, 2005, COCHRANE DATABASE SY, V1; Wong GTC, 2010, J CARDIOTHOR VASC AN, V24, P790, DOI 10.1053/j.jvca.2009.09.012; Xia ZY, 2006, ANESTH ANALG, V103, P527, DOI 10.1213/01.ane.0000230612.29452.a6; Xia ZY, 2004, CAN J PHYSIOL PHARM, V82, P919, DOI 10.1139/Y04-097; Zaugg M, 2002, ANESTHESIOLOGY, V97, P15, DOI 10.1097/00000542-200207000-00004; Zhang Y, 2005, ANESTHESIOLOGY, V102, P371, DOI 10.1097/00000542-200502000-00020; Zhang Y, 2004, ANESTHESIOLOGY, V101, P918, DOI 10.1097/00000542-200410000-00017	34	0	0	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	MAY	2014	120	5					1292	1297		10.1097/ALN.0000000000000188			6	Anesthesiology	Anesthesiology	AG1KW	WOS:000335175100042	24755802				2020-06-30	J	Takahashi, H; Chiba, T; Tairabune, T; Kimura, Y; Wakabayashi, G; Takahashi, K; Kudo, K				Takahashi, Hiroaki; Chiba, Takeshi; Tairabune, Tomohiko; Kimura, Yusuke; Wakabayashi, Go; Takahashi, Katsuo; Kudo, Kenzo			A Retrospective Study on the Influence of Nutritional Status on Pain Management in Cancer Patients Using the Transdermal Fentanyl Patch	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						fentanyl patch; nutritional status; Nutrition Risk Screening 2002; pain control	EFFICACY	It is unknown whether nutritional status influences pain intensity in cancer patients receiving a transdermal fentanyl patch (FP). This study aimed to determine whether nutritional status is associated with pain intensity and to evaluate the influence of changes in nutritional status on pain intensity in cancer patients receiving transdermal FP treatment. We included 92 patients receiving transdermal FP treatment for the first time with switching from oxycodone. The patients were classified into low- and normal-nutrition groups based on their nutritional status, which was assessed according to the Nutrition Risk Screening 2002 (NRS 2002) parameters. The pain intensity of each patient was evaluated by a numeric rating scale (11-point scale from 0 to 10). NRS 2002 score and pain intensity were obtained on day 3 after the FP was applied to the skin. Pain intensities were significantly higher among patients in the low-nutrition group than among patients in the normal-nutrition group. NRS 2002 scores showed a significant positive correlation with the pain intensities. In 52 of 92 patients, who were evaluated using the NRS 2002 score and pain intensity on day 30 after FP application, the changes in NRS 2002 scores were significantly related to changes in pain intensities (odds ratio, 30.0; 95% confidence interval, 4.48-200.97; p=0.0005). These results suggest that an increase in the NRS 2002 score is a risk factor for an increase in pain intensity in cancer patients receiving FP treatment. Malnutrition may lead to poor pain management in cancer patients receiving FP treatment.	[Takahashi, Hiroaki; Tairabune, Tomohiko; Kudo, Kenzo] Iwate Med Univ Hosp, Dept Pharm, Morioka, Iwate 0208505, Japan; [Kimura, Yusuke; Wakabayashi, Go] Iwate Med Univ, Sch Med, Dept Surg, Morioka, Iwate 0208505, Japan; [Chiba, Takeshi; Takahashi, Katsuo; Kudo, Kenzo] Iwate Med Univ, Dept Clin Pharmaceut & Pharm Practice, Sch Pharm, Yahaba, Iwate 0283603, Japan	Chiba, T (reprint author), Iwate Med Univ, Dept Clin Pharmaceut & Pharm Practice, Sch Pharm, 2-1-1 Nishitokuta, Yahaba, Iwate 0283603, Japan.	chibat@iwate-med.ac.jp		Takahashi, Hiroaki/0000-0002-2336-243X			Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Chiba T, 2010, PALLIATIVE CARE RES, V5, P206; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; Heiskanen T, 2009, PAIN, V144, P218, DOI 10.1016/j.pain.2009.04.012; Kondrup J, 2003, CLIN NUTR, V22, P415, DOI 10.1016/S0261-5614(03)00098-0; Kondrup J, 2003, CLIN NUTR, V22, P321, DOI 10.1016/S0261-5614(02)00214-5; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Ooi K, 2008, JPN PHARMACOL THER, V36, P589; Sarhill Nabeel, 2003, Am J Hosp Palliat Care, V20, P465, DOI 10.1177/104990910302000610; Solassol I, 2005, ONCOL REP, V14, P1029; Tairabune T, 2012, PALLIATIVE CARE RES, V7, P395; Yamamoto K, 2008, YAKUGAKU ZASSHI, V128, P959, DOI 10.1248/yakushi.128.959	12	5	6	1	7	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	MAY	2014	37	5					853	857		10.1248/bpb.b13-00717			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AG2UX	WOS:000335273700019	24790008	Bronze			2020-06-30	J	Eastwood, EC; Phillips, TJ				Eastwood, Emily C.; Phillips, Tamara J.			Opioid sensitivity in mice selectively bred to consume or not consume methamphetamine	ADDICTION BIOLOGY			English	Article						mu-opioid receptor; Amphetamine; selective breeding	MORPHINE PREFERENCE; NUCLEUS-ACCUMBENS; SLOW MICE; MOUSE; RECEPTOR; DOPAMINE; ETHANOL; ANTINOCICEPTION; IDENTIFICATION; POLYMORPHISMS	There has been little investigation of genetic factors and associated mechanisms that influence risk for development of methamphetamine (MA) dependence. Selectively bred mouse lines that exhibit high (MAHDR) or low (MALDR) levels of MA intake in a two-bottle choice MA drinking (MADR) procedure provide a genetic tool for this purpose. These lines were used to determine whether opioid sensitivity and MA intake are genetically associated, because opioid-mediated pathways influence some effects of MA. Sensitivity to the analgesic effects of the mu-opioid receptor (MOP-r) agonist fentanyl (0.05, 0.1, 0.2, 0.4 mg/kg) was examined using two acute thermal tests (hot plate and tail flick) and one chronic pain test (magnesium sulfate abdominal constriction). Locomotor stimulant responses to fentanyl (0.05, 0.1, 0.2, 0.4 mg/kg) and morphine (10, 20, 30 mg/kg) were also examined. In addition, MADR was measured in the progenitor strains [(C57BL/6J (B6), DBA/2J (D2)] of the F2 population from which the selected lines were generated. The MADR lines did not differ in sensitivity to the analgesic effects of fentanyl; however, MALDR mice exhibited greater locomotor activation than MAHDR mice to both fentanyl and morphine. D2 mice consumed more MA than B6 mice. The line differences for MA consumption and morphine activation recapitulated B6 and D2 strain differences for these two traits, but not strain differences previously found for opioid analgesic responses. These results support a negative genetic correlation between MA consumption and sensitivity to the stimulant effects of opioids and suggest the involvement of MOP-r regulated systems in MA intake.	[Eastwood, Emily C.; Phillips, Tamara J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA; [Eastwood, Emily C.; Phillips, Tamara J.] Oregon Hlth & Sci Univ, Methamphetamine Abuse Res Ctr, Portland, OR 97201 USA; [Phillips, Tamara J.] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Portland, OR 97201 USA	Phillips, TJ (reprint author), Portland VA Med Ctr VAMC, R&D 32,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.	phillipt@ohsu.edu		Eastwood, Emily/0000-0002-8329-2090	Department of Veterans AffairsUS Department of Veterans Affairs; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 DA07262, P50 DA018165, R24 AA020245]	This work was supported by the Department of Veterans Affairs, and NIH grants T32 DA07262, P50 DA018165, and R24 AA020245. The authors would like to thank John Harkness and Harue Baba for assistance in the tail flick and MA two-bottle choice experiments. The authors have no financial conflicts of interest to disclose.	Altier N, 1999, LIFE SCI, V65, P2269, DOI 10.1016/S0024-3205(99)00298-2; BARTON C, 1980, BRAIN RES, V188, P487, DOI 10.1016/0006-8993(80)90047-5; BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; BELKNAP JK, 1995, LIFE SCI, V57, pPL117, DOI 10.1016/0024-3205(95)02040-P; BELKNAP JK, 1993, PSYCHOPHARMACOLOGY, V112, P503, DOI 10.1007/BF02244901; Belknap JK, 1997, BEHAV GENET, V27, P55, DOI 10.1023/A:1025615409383; BELKNAP JK, 1989, PHYSIOL BEHAV, V46, P69, DOI 10.1016/0031-9384(89)90324-7; Bergeson SE, 2001, MAMM GENOME, V12, P546, DOI 10.1007/s003350020022; Berrettini W. H., 1994, Psychiatric Genetics, V4, P81, DOI 10.1097/00041444-199422000-00003; BERRETTINI WH, 1994, NAT GENET, V7, P54, DOI 10.1038/ng0594-54; Bryant CD, 2009, GENES BRAIN BEHAV, V8, P795, DOI 10.1111/j.1601-183X.2009.00525.x; Bryant CD, 2009, DRUG ALCOHOL DEPEN, V103, P74, DOI 10.1016/j.drugalcdep.2009.03.016; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Chiu CT, 2005, BRAIN RES BULL, V67, P100, DOI 10.1016/j.brainresbull.2005.05.028; CRABBE JC, 1990, ALCOHOL CLIN EXP RES, V14, P141, DOI 10.1111/j.1530-0277.1990.tb00461.x; Di Chiara G, 2004, NEUROPHARMACOLOGY, V47, P227, DOI 10.1016/j.neuropharm.2004.06.032; Doyle GA, 2007, GENE, V388, P135, DOI 10.1016/j.gene.2006.10.017; Doyle GA, 2006, NEUROSCI RES, V55, P244, DOI 10.1016/j.neures.2006.03.005; Ferraro TN, 2005, NEUROPSYCHOPHARMACOL, V30, P742, DOI 10.1038/sj.npp.1300592; HENDERSHOT LC, 1959, J PHARMACOL EXP THER, V125, P237; Ide S, 2005, GENE, V364, P139, DOI 10.1016/j.gene.2005.05.040; Ide S, 2004, ANN NY ACAD SCI, V1025, P316, DOI 10.1196/annals.1316.039; JOHNSON SW, 1992, J NEUROSCI, V12, P483; JONES DNC, 1994, PSYCHOPHARMACOLOGY, V114, P215, DOI 10.1007/BF02244839; Kalvass JC, 2007, J PHARMACOL EXP THER, V323, P346, DOI 10.1124/jpet.107.119560; Luo P, 2010, J PHARMACOL EXP THER, V335, P735, DOI 10.1124/jpet.110.170852; Mogil JS, 1996, J PHARMACOL EXP THER, V276, P532; MOGIL JS, 1995, PAIN, V60, P125, DOI 10.1016/0304-3959(94)00098-Y; PHILLIPS TJ, 1992, J PHARMACOL EXP THER, V261, P525; PHILLIPS TJ, 1994, ALCOHOL CLIN EXP RES, V18, P931, DOI 10.1111/j.1530-0277.1994.tb00062.x; PHILLIPS TJ, 1995, ALCOHOL CLIN EXP RES, V19, P269, DOI 10.1111/j.1530-0277.1995.tb01502.x; PHILLIPS TJ, 1992, ANN NY ACAD SCI, V654, P499, DOI 10.1111/j.1749-6632.1992.tb26012.x; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; Romero A, 2010, PHARMACOL BIOCHEM BE, V97, P363, DOI 10.1016/j.pbb.2010.09.005; Shabani S, 2011, GENES BRAIN BEHAV, V10, P625, DOI 10.1111/j.1601-183X.2011.00700.x; Shabani S, 2012, NEUROPHARMACOLOGY, V62, P2169, DOI 10.1016/j.neuropharm.2012.01.002; Shabani S, 2012, NEUROPHARMACOLOGY, V62, P1134, DOI 10.1016/j.neuropharm.2011.11.005; Shen XE, 2010, J NEUROSCI RES, V88, P2294, DOI 10.1002/jnr.22386; Taber Katherine H, 2012, J Neuropsychiatry Clin Neurosci, V24, P1, DOI 10.1176/appi.neuropsych.24.1.1; Volpe DA, 2011, REGUL TOXICOL PHARM, V59, P385, DOI 10.1016/j.yrtph.2010.12.007; Wheeler JM, 2009, GENES BRAIN BEHAV, V8, P758, DOI 10.1111/j.1601-183X.2009.00522.x	41	19	19	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1355-6215	1369-1600		ADDICT BIOL	Addict. Biol.	MAY	2014	19	3					370	379		10.1111/adb.12003			10	Biochemistry & Molecular Biology; Substance Abuse	Biochemistry & Molecular Biology; Substance Abuse	AF3FS	WOS:000334597500007	23145527	Green Accepted			2020-06-30	J	Afolayan, JM; Olajumoke, TO; Amadasun, FE; Edomwonyi, NP				Afolayan, J. M.; Olajumoke, T. O.; Amadasun, F. E.; Edomwonyi, N. P.			Intrathecal tramadol versus intrathecal fentanyl for visceral pain control during bupivacaine subarachnoid block for open appendicectomy	NIGERIAN JOURNAL OF CLINICAL PRACTICE			English	Article						Analgesia; appendicectomy; intrathecal opioid; spinal anaesthesia	POSTOPERATIVE PAIN; SPINAL-ANESTHESIA; DOSE-RESPONSE; ANALGESIA; SURGERY; SUFENTANIL; LIDOCAINE; LABOR	Context: Profound side-effects following intrathecal use of local anesthetics as the sole drugs of choice make spinal anesthesia for open appendicectomy uncommon. Aim: The aim of this study was to evaluate the effectiveness of intra-operative analgesia produced by intrathecal tramadol and fentanyl during bupivacaine spinal anesthesia for open appendicectomy. Settings and Design: A prospective randomized study was performed. Materials and Methods: A total of 186 American Society of Anesthesiologists 1 or 11 patients scheduled for emergency open appendicectomy were analyzed. Group FB ( n = 62) received intrathecal fentanyl 25 g plus 3 ml of 0.5% hyperbaric bupivacaine, Group SB ( n = 62) received 0.5 ml normal saline plus 3 ml of 0.5% hyperbaric bupivacaine and Group TB ( n = 62) received intrathecal tramadol 25 mg plus 3 ml of 0.5% hyperbaric bupivacaine. Visual analog scale scores and frequency of subjective symptoms among patients in the three groups formed the primary outcome measure of this study. Results: Effective intraoperative sensory block was achieved in 100% of patients in group FB and TB while 29 (46.8%) patients in group SB had ineffective sensory block ( P = 0.0001). The pain free period was significantly longer in patients in Group FB than Group SB and TB. Mean time for Group FB with regard to first analgesic request was 304.73 67.91 min, Group SB was 146.59 36.62 and Group TB was 238.39 61.28 min. Incidence of complications were comparable among the three groups. Conclusion: This study showed that intrathecal tramadol (25 mg) can safely replace intrathecal fentanyl (25 g) in the management of visceral pain and discomfort during subarachnoid block for appendicectomy.	[Afolayan, J. M.] Ekiti State Univ, Teaching Hosp, Dept Anaesthesia, Ado Ekiti, Ekiti State, Nigeria; [Olajumoke, T. O.] LAUTECH Teaching Hosp, Oshogbo, Osun State, Nigeria; [Amadasun, F. E.; Edomwonyi, N. P.] Univ Benin, Teaching Hosp, Benin, Edo State, Nigeria	Afolayan, JM (reprint author), Ekiti State Univ, Teaching Hosp, Dept Anaesthesia, Ado Ekiti, Ekiti State, Nigeria.	jidmic2011@yahoo.com					Acalovschi I, 2001, ANESTH ANALG, V92, P209; Alhashemi JA, 2003, BRIT J ANAESTH, V91, P536, DOI 10.1093/bja/aeg213; Barrett NA, 2003, BRIT J ANAESTH, V91, P918, DOI 10.1093/bja/aeg265; Ben-David B, 2009, BRIT J ANAESTH, V103, P705; Biswas BN, 2002, INDIAN J ANAESTH, V46, P469; BOGRA J, 2005, BMC ANESTHESIOL, V5, DOI DOI 10.1186/1471-2253-5-5); Brijesh J, 2001, INDIAN J ANAESTH, V45, P282; Casey WF, 2000, UPDATE ANAESTHESIA, V12, P1; Chakraborty S, 2008, INDIAN J PHARMACOL, V40, P180, DOI 10.4103/0253-7613.43166; Cherng CH, 2001, REGION ANESTH PAIN M, V26, P523, DOI 10.1053/rapm.2001.27852; COOPER DW, 1993, BRIT J ANAESTH, V70, P503, DOI 10.1093/bja/70.5.503; Duthie DJR, 1998, BRIT J ANAESTH, V81, P51; Frikha N., 2007, Middle East Journal of Anesthesiology, V19, P87; Frikha N, 2008, OBSTET ANAESTH, V8, P72; Gangopadhyay S, 2010, J ANAESTH CLIN PHARM, V26, P59; Goel S, 2003, EUR J ANAESTH, V20, P294, DOI 10.1097/00003643-200304000-00004; Halfpenny DM, 1999, BRIT J ANAESTH, V83, P909, DOI 10.1093/bja/83.6.909; Hamber EA, 1999, REGION ANESTH PAIN M, V24, P255; HONET JE, 1992, ANESTH ANALG, V75, P734; Kolawole I K, 2002, Niger J Med, V11, P153; Kuusniemi KS, 2000, ANESTH ANALG, V91, P1452, DOI 10.1097/00000539-200012000-00029; Motiani Poonam, 2011, J Anaesthesiol Clin Pharmacol, V27, P67; Parthasarathy S, 2002, J ANAESTHESIOL CLIN, V18, P419; RANDALLS B, 1991, BRIT J ANAESTH, V66, P314, DOI 10.1093/bja/66.3.314; Rathmell JP, 2005, ANESTH ANALG, V101, pS30, DOI 10.1213/01.ANE.0000177101.99398.22; REUBEN SS, 1994, ANESTHESIOLOGY, V81, P1371, DOI 10.1097/00000542-199412000-00011; Roussel J R, 1999, AANA J, V67, P337; Seewal R, 2007, REGION ANESTH PAIN M, V32, P20, DOI 10.1016/j.rapm.2006.09.007; SINGH H, 1995, CAN J ANAESTH, V42, P987, DOI 10.1007/BF03011070; Singh I, 2008, INDIAN J ANAESTH, V52, P301; Techanivate A, 2004, CHULA MED J, V48, P9; Wiles MD, 2010, ANAESTHESIA, V65, P22, DOI 10.1111/j.1365-2044.2009.06201.x	32	4	4	0	3	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	1119-3077			NIGER J CLIN PRACT	Niger. J. Clin. Pract.	MAY-JUN	2014	17	3					324	330		10.4103/1119-3077.130234			7	Medicine, General & Internal	General & Internal Medicine	AF7HU	WOS:000334886300012	24714011				2020-06-30	J	Shin, S; Min, KT; Shin, YS; Joo, HM; Yoo, YC				Shin, Seokyung; Min, Keoung Tae; Shin, Yang Sik; Joo, Hyung Min; Yoo, Young Chul			Finding the 'Ideal' Regimen for Fentanyl-Based Intravenous Patient-Controlled Analgesia: How to Give and What to Mix?	YONSEI MEDICAL JOURNAL			English	Article						Analgesia; patient-controlled; fentanyl; background infusion rate; adjuvant drug	POSTOPERATIVE PAIN MANAGEMENT; BACKGROUND INFUSION; BALANCED ANALGESIA; MORPHINE; SAFETY; ONDANSETRON; EFFICACY; SURGERY; OPIOIDS; NAUSEA	Purpose: This analysis was done to investigate the optimal regimen for fentanyl-based intravenous patient-controlled analgesia (IV-PCA) by finding a safe and effective background infusion rate and assessing the effect of adding adjuvant drugs to the PCA regimen. Materials and Methods: Background infusion rate of fentanyl, type of adjuvant analgesic and/or antiemetic that was added to the IV-PCA, and patients that required rescue analgesics and/or antiemetics were retrospectively reviewed in 1827 patients who underwent laparoscopic abdominal surgery at a single tertiary hospital. Results: Upon multivariate analysis, lower background infusion rates, younger age, and IV-PCA without adjuvant analgesics were identified as independent risk factors of rescue analgesic administration. Higher background infusion rates, female gender, and IV-PCA without additional 5HT3 receptor blockers were identified as risk factors of rescue antiemetics administration. A background infusion rate of 0.38 mu g/kg/hr [area under the curve (AUC) 0.638] or lower required rescue analgesics in general, whereas, addition of adjuvant analgesics decreased the rate to 0.37 mu g/kg/hr (AUC 0.712) or lower. A background infusion rate of 0.36 mu g/kg/hr (AUC 0.638) or higher was found to require rescue antiemetics in general, whereas, mixing antiemetics with IV-PCA increased the rate to 0.37 mu g/kg/hr (AUC 0.651) or higher. Conclusion: Background infusion rates of fentanyl between 0.12 and 0.67 mu g/kg/hr may safely be used without any serious side effects for IV-PCA. In order to approach the most reasonable background infusion rate for effective analgesia without increasing postoperative nausea and vomiting, adding an adjuvant analgesic and an antiemetic should always be considered.	[Shin, Seokyung; Min, Keoung Tae; Shin, Yang Sik; Joo, Hyung Min; Yoo, Young Chul] Severance Hosp, Dept Anesthesiol & Pain Med, Seoul, South Korea; [Shin, Seokyung; Min, Keoung Tae; Shin, Yang Sik; Yoo, Young Chul] Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Seoul 120752, South Korea	Yoo, YC (reprint author), Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med,Severance Hosp, 50-1 Yonsei Ro, Seoul 120752, South Korea.	seaoyster@yuhs.ac		Yoo, Young Chul/0000-0002-6334-7541; Shin, Seokyung/0000-0002-2641-0070			BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; Cepeda MS, 2003, CLIN PHARMACOL THER, V74, P102, DOI 10.1016/S0009-9236(03)00152-8; FLEMING BM, 1992, J PAIN SYMPTOM MANAG, V7, P463, DOI 10.1016/0885-3924(92)90132-2; Fletcher D, 2008, PAIN, V137, P441, DOI 10.1016/j.pain.2008.02.026; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; Guler T, 2004, CAN J ANAESTH, V51, P718, DOI 10.1007/BF03018432; Hagle Mary E, 2004, Orthop Nurs, V23, P18, DOI 10.1097/00006416-200401000-00007; HUTCHISON RW, 2006, [No title captured], V41, P659; Kehlet H, 1999, DRUGS, V58, P793, DOI 10.2165/00003495-199958050-00002; KEHLET H, 1993, ANESTH ANALG, V77, P1048; Kim SH, 2013, YONSEI MED J, V54, P1273, DOI 10.3349/ymj.2013.54.5.1273; Kim SY, 2008, THYROID, V18, P1285, DOI 10.1089/thy.2008.0007; Lui F, 2011, EXPERT OPIN PHARMACO, V12, P363, DOI 10.1517/14656566.2011.521743; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; MATHER LE, 1995, CLIN EXP PHARMACOL P, V22, P833, DOI 10.1111/j.1440-1681.1995.tb01945.x; Momeni M, 2006, DRUGS, V66, P2321, DOI 10.2165/00003495-200666180-00005; Palmer Pamela P, 2010, Anesthesiol Clin, V28, P587, DOI 10.1016/j.anclin.2010.08.010; Pasero C, 2009, J PERIANESTH NURS, V24, P186, DOI 10.1016/j.jopan.2009.03.005; Pasero Chris, 2004, J Perianesth Nurs, V19, P42, DOI 10.1016/j.jopan.2003.11.006; Sam WJ, 2011, J CLIN ANESTH, V23, P102, DOI 10.1016/j.jclinane.2010.08.002; SCHUG SA, 1993, PAIN, V55, P387, DOI 10.1016/0304-3959(93)90016-I; Sidebotham D, 1997, J PAIN SYMPTOM MANAG, V14, P202, DOI 10.1016/S0885-3924(97)00182-6; Song JW, 2011, ANAESTHESIA, V66, P263, DOI 10.1111/j.1365-2044.2011.06648.x; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x; White I, 2012, PHARMACOL RES, V66, P185, DOI 10.1016/j.phrs.2012.03.016; White PF, 2010, ANESTHESIOLOGY, V112, P220, DOI 10.1097/ALN.0b013e3181c6316e; Wu CL, 2011, LANCET, V377, P2215, DOI 10.1016/S0140-6736(11)60245-6	27	8	9	0	2	YONSEI UNIV COLL MEDICINE	SEOUL	50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA	0513-5796	1976-2437		YONSEI MED J	Yonsei Med. J.	MAY 1	2014	55	3					800	806		10.3349/ymj.2014.55.3.800			7	Medicine, General & Internal	General & Internal Medicine	AF6JI	WOS:000334820700034	24719151	DOAJ Gold, Green Published			2020-06-30	J	Tuominen, L; Nummenmaa, L; Keltikangas-Jarvinen, L; Raitakari, O; Hietala, J				Tuominen, Lauri; Nummenmaa, Lauri; Keltikangas-Jarvinen, Liisa; Raitakari, Olli; Hietala, Jarmo			Mapping neurotransmitter networks with PET: An example on serotonin and opioid systems	HUMAN BRAIN MAPPING			English	Article						positron emission tomography; serotonin transporter; connectivity; mu-opioid receptor; correlation	RECEPTOR-BINDING; IN-VIVO; TRANSPORTER BINDING; TEST-RETEST; C957T POLYMORPHISM; HUMAN BRAIN; AVAILABILITY; RADIOLIGAND; 5-HT1A; QUANTIFICATION	All functions of the human brain are consequences of altered activity of specific neural pathways and neurotransmitter systems. Although the knowledge of "system level" connectivity in the brain is increasing rapidly, we lack "molecular level" information on brain networks and connectivity patterns. We introduce novel voxel-based positron emission tomography (PET) methods for studying internal neurotransmitter network structure and intercorrelations of different neurotransmitter systems in the human brain. We chose serotonin transporter and mu-opioid receptor for this analysis because of their functional interaction at the cellular level and similar regional distribution in the brain. Twenty-one healthy subjects underwent two consecutive PET scans using [C-11]MADAM, a serotonin transporter tracer, and [C-11]carfentanil, a mu-opioid receptor tracer. First, voxel-by-voxel "intracorrelations" (hub and seed analyses) were used to study the internal structure of opioid and serotonin systems. Second, voxel-level opioid-serotonin intercorrelations (between neurotransmitters) were computed. Regional mu-opioid receptor binding potentials were uniformly correlated throughout the brain. However, our analyses revealed nonuniformity in the serotonin transporter intracorrelations and identified a highly connected local network (midbrain-striatum-thalamus-amygdala). Regionally specific intercorrelations between the opioid and serotonin tracers were found in anteromedial thalamus, amygdala, anterior cingulate cortex, dorsolateral prefrontal cortex, and left parietal cortex, i.e., in areas relevant for several neuropsychiatric disorders, especially affective disorders. This methodology enables in vivo mapping of connectivity patterns within and between neurotransmitter systems. Quantification of functional neurotransmitter balances may be a useful approach in etiological studies of neuropsychiatric disorders and also in drug development as a biomarker-based rationale for targeted modulation of neurotransmitter networks. Hum Brain Mapp 35:1875-1884, 2014. (c) 2013 Wiley Periodicals, Inc.	[Tuominen, Lauri; Nummenmaa, Lauri; Hietala, Jarmo] Univ Turku, Turku PET Ctr, Turku, Finland; [Tuominen, Lauri; Nummenmaa, Lauri; Raitakari, Olli; Hietala, Jarmo] Turku Univ Hosp, FIN-20520 Turku, Finland; [Tuominen, Lauri; Hietala, Jarmo] Aalto Univ, Sch Sci, OV Lounasmaa Lab, Brain Res Unit, Espoo, Finland; [Nummenmaa, Lauri] Aalto Univ, Sch Sci, Dept Biomed Engn & Computat Sci, Espoo, Finland; [Keltikangas-Jarvinen, Liisa] Univ Helsinki, Dept Behav Sci, Helsinki, Finland; [Raitakari, Olli] Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, Turku, Finland	Hietala, J (reprint author), Univ Turku, Dept Psychiat, Kunnallissairaalantie 20,Bldg 9, Turku 20700, Finland.	jahi@utu.fi	Nummenmaa, Lauri/G-6910-2012	Nummenmaa, Lauri/0000-0002-2497-9757; Hietala, Jarmo/0000-0002-3179-6780	Academy of FinlandAcademy of Finland; EVO (Hospital District of Southwest Finland and Turku City); National Graduate School of Clinical Investigation	Contract grant sponsors: Academy of Finland; EVO-Funding (Hospital District of Southwest Finland and Turku City); The National Graduate School of Clinical Investigation.	Bailer UF, 2013, PSYCHIAT RES-NEUROIM, V211, P160, DOI 10.1016/j.pscychresns.2012.06.010; Bencherif B, 2002, PAIN, V99, P589, DOI 10.1016/S0304-3959(02)00266-X; Berger B, 2006, BRIT J PHARMACOL, V148, P795, DOI 10.1038/sj.bjp.0706782; Bose SK, 2011, NEUROPSYCHOPHARMACOL, V36, P2258, DOI 10.1038/npp.2011.113; Cervenka S, 2010, SYNAPSE, V64, P478, DOI 10.1002/syn.20765; Comtat C, 2004, IEEE NUCL SCI CONF R, P3492; Conturo TE, 1999, P NATL ACAD SCI USA, V96, P10422, DOI 10.1073/pnas.96.18.10422; Emond P, 2002, J MED CHEM, V45, P1253, DOI 10.1021/jm010939a; Endres CJ, 2003, NUCL MED BIOL, V30, P177, DOI 10.1016/S0969-8051(02)00411-0; Erritzoe D, 2010, J NEUROSCI, V30, P3391, DOI 10.1523/JNEUROSCI.2852-09.2010; FROST JJ, 1985, J COMPUT ASSIST TOMO, V9, P231, DOI 10.1097/00004728-198503000-00001; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; Hahn A, 2010, J NEUROSCI, V30, P14482, DOI 10.1523/JNEUROSCI.2409-10.2010; Hietala J, 1999, J CEREBR BLOOD F MET, V19, P210; Hirvonen J, 2011, CNS NEUROSCI THER, V17, P89, DOI 10.1111/j.1755-5949.2010.00223.x; Hirvonen J, 2009, EUR J NUCL MED MOL I, V36, P275, DOI 10.1007/s00259-008-0935-6; Hirvonen M, 2004, MOL PSYCHIATR, V9, P1060, DOI 10.1038/sj.mp.4001561; Hirvonen MM, 2009, PROG NEURO-PSYCHOPH, V33, P630, DOI 10.1016/j.pnpbp.2009.02.021; Ide S, 2010, J PHARMACOL SCI, V114, P107, DOI 10.1254/jphs.10136SC; Jovanovic H, 2008, NEUROIMAGE, V39, P1408, DOI 10.1016/j.neuroimage.2007.10.016; Kobiella A, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.29; Laje G, 2010, INT J NEUROPSYCHOPH, V13, P715, DOI 10.1017/S1461145709991027; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Liberzon I, 2002, P NATL ACAD SCI USA, V99, P7084, DOI 10.1073/pnas.102174799; Lopez-Gimenez JF, 2008, MOL PHARMACOL, V74, P1278, DOI 10.1124/mol.108.048272; Lundberg J, 2005, J NUCL MED, V46, P1505; Lundberg J, 2007, PSYCHOPHARMACOLOGY, V195, P425, DOI 10.1007/s00213-007-0928-3; Lundberg J, 2006, SYNAPSE, V60, P256, DOI 10.1002/syn.20297; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Marsman A, 2013, SCHIZOPHRENIA BULL, V39, P120, DOI 10.1093/schbul/sbr069; Martikainen IK, 2007, BRAIN RES, V1172, P21, DOI 10.1016/j.brainres.2007.07.036; Mayberg HS, 1997, J NEUROPSYCH CLIN N, V9, P471; Meyer JH, 2007, J PSYCHIATR NEUROSCI, V32, P86; MOORE RY, 1978, J COMP NEUROL, V180, P417, DOI 10.1002/cne.901800302; Murthy NV, 2010, NEUROIMAGE, V52, P50, DOI 10.1016/j.neuroimage.2010.04.032; Nakamura K, 2010, ARCH GEN PSYCHIAT, V67, P59, DOI 10.1001/archgenpsychiatry.2009.137; Palomero-Gallagher N, 2009, HUM BRAIN MAPP, V30, P2336, DOI 10.1002/hbm.20667; Price JL, 2010, NEUROPSYCHOPHARMACOL, V35, P192, DOI 10.1038/npp.2009.104; Rahmim A, 2005, PHYS MED BIOL, V50, P4887, DOI 10.1088/0031-9155/50/20/010; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ray R, 2011, P NATL ACAD SCI USA, V108, P9268, DOI 10.1073/pnas.1018699108; Sbrenna S, 2000, BRIT J PHARMACOL, V130, P425, DOI 10.1038/sj.bjp.0703321; Scott DJ, 2007, SYNAPSE, V61, P707, DOI 10.1002/syn.20404; Simmons ML, 1996, INT REV NEUROBIOL, V39, P145, DOI 10.1016/S0074-7742(08)60666-2; Sporns O, 2005, PLOS COMPUT BIOL, V1, P245, DOI 10.1371/journal.pcbi.0010042; Takano H, 2011, SYNAPSE, V65, P624, DOI 10.1002/syn.20883; TAO R, 1995, NEUROSCIENCE, V68, P553, DOI 10.1016/0306-4522(95)00154-B; Tao R, 2002, J PHARMACOL EXP THER, V303, P549, DOI 10.1124/jpet.102.037861; Tarkiainen J, 2001, J LABELLED COMPD RAD, V44, P1013, DOI 10.1002/jlcr.523; Varnas K, 2004, HUM BRAIN MAPP, V22, P246, DOI 10.1002/hbm.20035; Willeit M, 2010, NEUROIMAGE, V53, P878, DOI 10.1016/j.neuroimage.2010.04.030; Zilles K, 2009, CURR OPIN NEUROL, V22, P331, DOI 10.1097/WCO.0b013e32832d95db	53	26	26	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	MAY	2014	35	5					1875	1884		10.1002/hbm.22298			10	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	AE5FB	WOS:000334012100006	23671038	Green Published			2020-06-30	J	Subramanyam, R; Varughese, A; Kurth, CD; Eckman, MH				Subramanyam, Rajeev; Varughese, Anna; Kurth, Charles Dean; Eckman, Mark H.			Cost-effectiveness of intravenous acetaminophen for pediatric tonsillectomy	PEDIATRIC ANESTHESIA			English	Article						adverse events; decision analysis; intravenous acetaminophen; cost-effectiveness; cost savings; tonsillectomy	RANDOMIZED CONTROLLED-TRIAL; POSTOPERATIVE ANALGESIA; CHILDREN; PAIN; PARACETAMOL; ADENOTONSILLECTOMY; ONDANSETRON; MEPERIDINE	Objective The primary outcome of this study was to examine the cost-effectiveness of the intraoperative combination of intravenous (IV) acetaminophen and IV opioids, versus IV opioids alone, as a part of an inhalational anesthetic technique for tonsillectomy in children. Methods We used Decision Maker((R)) software to construct and analyze a decision analytic model. Base-case and sensitivity analyses were performed. We studied the use of rescue analgesics in the postanesthesia care unit (PACU), adverse effects of acetaminophen and opioids, and costs associated with adverse effects. Costs were in 2013 US dollars, and effectiveness was measured as frequency of avoiding the need for rescue analgesics. Direct medical costs included medication, equipment, supplies, and labor associated with the treatment of adverse events from pain medications. Medication costs assumed single-dose vials. Results In the base case, IV acetaminophen in combination with opioids was both less costly ($17.12) and more effective (3.3% fewer rescue events). In sensitivity analyses, the combination strategy remained cost-effective as long as the frequency of rescue analgesic administration was less than that in the opioid-alone strategy. Although medication costs of the combination strategy were higher, the overall costs were less than the competing strategy due to reduced adverse effects and reduced time spent in PACU. Conclusions The routine use of IV acetaminophen as an adjuvant to IV opioids for tonsillectomy with or without adenoidectomy in children aged	[Subramanyam, Rajeev; Varughese, Anna; Kurth, Charles Dean] Cincinnati Childrens Hosp Med Ctr, Dept Anesthesia, Cincinnati, OH 45229 USA; [Eckman, Mark H.] Univ Cincinnati, Dept Internal Med, Ctr Clin Effectiveness, Cincinnati, OH USA	Subramanyam, R (reprint author), Cincinnati Childrens Hosp Med Ctr, Dept Anesthesia, 3333 Burnet Ave,MLC 2001, Cincinnati, OH 45229 USA.	rajeev.subramanyam@cchmc.org		Eckman, Mark/0000-0001-8253-269X	American Society of Anesthesiology Committee on Professional Diversity; Center for Clinical and Translational Science;  [UL1-RR026314]	Mentoring Grant from American Society of Anesthesiology Committee on Professional Diversity and Center for Clinical and Translational Science and Training grant support (UL1-RR026314).	Alhashemi JA, 2007, EUR J ANAESTH, V24, P128, DOI 10.1017/S0265021506001232; Alhashemi JA, 2006, BRIT J ANAESTH, V96, P790, DOI 10.1093/bja/ael084; Amer Soc Anesthesiologists, 2006, ANESTHESIOLOGY, V104, P1081; American Academy of Otolaryngology, HEAD NECK SURG; Anderson BJ, 2001, EUR J CLIN PHARMACOL, V57, P559, DOI 10.1007/s002280100367; [Anonymous], 2011, Med Lett Drugs Ther, V53, P53; Capici F, 2008, BRIT J ANAESTH, V100, P251, DOI 10.1093/bja/aem377; Cardwell M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003591.pub2; Cullen Karen A, 2009, Natl Health Stat Report, P1; Eckman MH, 1997, NEW ENGL J MED, V337, P357, DOI 10.1056/NEJM199707313370525; ECKMAN MH, 1990, JAMA-J AM MED ASSOC, V263, P1513, DOI 10.1001/jama.263.11.1513; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; FURST SR, 1994, ANESTHESIOLOGY, V81, P799, DOI 10.1097/00000542-199410000-00005; Gibb IA, 2008, ARCH DIS CHILD, V93, P241, DOI 10.1136/adc.2007.126896; Gross JB, 2006, ANESTHESIOLOGY, V104, P1117; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hermans V, 2012, BRIT J ANAESTH, V109, P427, DOI 10.1093/bja/aes249; Hong JY, 2010, ANESTHESIOLOGY, V113, P672, DOI 10.1097/ALN.0b013e3181e2c34b; Hunink M, 2001, DECISION MAKING HLTH, P252; Kocum AI, 2013, BRAZ J OTORHINOLAR, V79, P89, DOI 10.5935/1808-8694.20130015; LITMAN RS, 1994, ANESTH ANALG, V78, P478; Macario A, 2011, PAIN PRACT, V11, P290, DOI 10.1111/j.1533-2500.2010.00426.x; Mills N, 2004, INT J PEDIATR OTORHI, V68, P1367, DOI 10.1016/j.ijporl.2004.04.009; Rawlinson E, 2011, ANAESTHESIA, V66, P919, DOI 10.1111/j.1365-2044.2011.06851.x; Sadhasivam S, 2012, PEDIATRICS, V129, P832, DOI 10.1542/peds.2011-2607; Subramanyam R, 2013, INT J PEDIATR OTORHI, V77, P194, DOI 10.1016/j.ijporl.2012.10.016; Uysal HY, 2011, J CLIN ANESTH, V23, P53, DOI 10.1016/j.jclinane.2010.07.001; Varughese AM, 2006, INT ANESTHESIOL CLIN, V44, P119, DOI 10.1097/01.aia.0000196253.46033.f9; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; Wong I, 2013, PEDIATR ANESTH, V23, P475, DOI 10.1111/pan.12163; Yeh YC, 2012, PHARMACOTHERAPY, V32, P559, DOI 10.1002/j.1875-9114.2011.01085.x	31	19	19	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	MAY	2014	24	5					467	475		10.1111/pan.12359			9	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	AE4BH	WOS:000333922700001	24597962				2020-06-30	J	Moss, JR; Watcha, MF; Bendel, LP; McCarthy, DL; Witham, SL; Glover, CD				Moss, Jonathan R.; Watcha, Mehernoor F.; Bendel, Laima P.; McCarthy, Denise L.; Witham, Stacy L.; Glover, Chris D.			A multicenter, randomized, double-blind placebo-controlled, single dose trial of the safety and efficacy of intravenous ibuprofen for treatment of pain in pediatric patients undergoing tonsillectomy	PEDIATRIC ANESTHESIA			English	Article						ibuprofen; NSAIDs; pain; pediatric; tonsillectomy	CHILDREN; KETOROLAC	Background Tonsillectomy is one of the most common pediatric procedures in the United States. An optimal perioperative pain control regimen remains a challenge. Intravenous ibuprofen administered at induction of anesthesia may be a safe and efficacious option for postoperative tonsillectomy pain. Objectives To determine whether preoperative administration of intravenous ibuprofen (IV-ibuprofen) can significantly decrease the number of doses of postoperative fentanyl when compared with placebo in pediatric tonsillectomy surgical patients. Methods This was a multicenter, randomized, double-blind placebo-controlled trial conducted at six hospitals in the United States. A total of 161 pediatric patients aged 6-17years undergoing tonsillectomy were randomized to receive either a single preoperative dose of 10mg center dot kg(-1) IV-ibuprofen or placebo (normal saline). Postoperative pain was managed with intravenous fentanyl (0.5 mu g center dot kg(-1)) on an as needed basis when the visual analog scale (VAS) was >30mm and deemed appropriate by recovery room nurse/physician. The primary endpoint was the number of doses and amount of postoperative fentanyl administered postoperatively for rescue analgesia. Results There was a significant reduction in the number of postoperative doses and the amount of fentanyl administered after surgery in the IV-ibuprofen group compared with the placebo group (P=0.021). There were no differences in the time to first analgesia request or the number of patients who required postoperative analgesia. There were no significant differences in the incidence of serious adverse events, surgical blood loss (P=0.662), incidence of postoperative bleeding, or a need for surgical re-exploration between the treatment groups. Conclusion Administration of IV-ibuprofen, 10mg center dot kg(-1), significantly reduced fentanyl use in pediatric tonsillectomy patients.	[Moss, Jonathan R.] Charlotte Eye Ear Nose & Throat Associates PA, Charlotte, NC 28210 USA; [Watcha, Mehernoor F.; Glover, Chris D.] Texas Childrens Hosp, Houston, TX 77030 USA; [Bendel, Laima P.; McCarthy, Denise L.] Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; [Witham, Stacy L.] Cumberland Pharmaceut Inc, Nashville, TN USA	Moss, JR (reprint author), Charlotte Eye Ear Nose & Throat Associates PA, 6035 Fairview Rd, Charlotte, NC 28210 USA.	jmoss@ceenta.com			Cumberland Pharmaceuticals Inc.	Supported by Cumberland Pharmaceuticals Inc. Stacy L. Witham PharmD is an employee of Cumberland Pharmaceuticals Inc.	Bailey R, 1997, LARYNGOSCOPE, V107, P166, DOI 10.1097/00005537-199702000-00006; Baugh RF, 2011, OTOLARYNG HEAD NECK, V144, pS1, DOI 10.1177/0194599810389949; Botting RM, 1998, AM J MED, V104, p21S; Cardwell M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003591.pub2; FDA Drug Safety Communication, 2012, SAF REV UPD COD US C; Garcia-Martin E, 2004, CLIN PHARMACOL THER, V76, P119, DOI 10.1016/j.clpt.2004.04.006; Hollis LJ, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858; Judkins JH, 1996, ARCH OTOLARYNGOL, V122, P937; Kokki H, 2007, PEDIATRICS, V120, pE1002, DOI 10.1542/peds.2007-0064; Laboratories B, 2009, KET TROM; Marret E, 2003, ANESTHESIOLOGY, V98, P1497; Moss JR, 2011, ARCH OTOLARYNGOL, V137, P591, DOI 10.1001/archoto.2011.45; Salonen A, 2002, INT J PEDIATR OTORHI, V62, P143, DOI 10.1016/S0165-5876(01)00610-3; Singla N, 2010, PAIN MED, V11, P1284, DOI 10.1111/j.1526-4637.2010.00896.x; TOMA AG, 1995, J LARYNGOL OTOL, V109, P963, DOI 10.1017/S0022215100131767; Vane JR, 1998, AM J MED, V104, p2S, DOI DOI 10.1016/S0002-9343(97)00203-9; Wheeler M, 2002, J PAIN, V3, P159, DOI 10.1054/jpai.2002.123652	17	30	31	0	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	MAY	2014	24	5					483	489		10.1111/pan.12381			7	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	AE4BH	WOS:000333922700003	24646068				2020-06-30	J	Anderson, TA; Kasser, JR; Holzman, RS				Anderson, Thomas Anthony; Kasser, James R.; Holzman, Robert S.			Anesthetic considerations in Sheldon-Hall syndrome	PEDIATRIC ANESTHESIA			English	Article						congenital anomalies & syndromes; congenital; airway; arthrogryposis; orthopedics; anomalies		Arthrogryposis is characterized by multiple, nonprogressive joint contractures which may be caused by maternal disorders such as oligohydramnios as well as fetal akinesia resulting from primary disorders of muscle, connective tissue, or neurologic tissue. Its prevalence is about 1:3000. Distal arthrogryposis (DA) is a heterogenous group of genetic disorders with a characteristic flexion of the joints of the hands and feet divided into different types with additional features. Sheldon-Hall Syndrome (SHS), also known as distal arthrogryposis type 2A (DA2A), has some nonorthopedic features of specific importance to anesthetic care.	[Anderson, Thomas Anthony] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA; [Kasser, James R.] Childrens Hosp Boston, Dept Orthoped Surg, Boston, MA USA; [Holzman, Robert S.] Childrens Hosp Boston, Dept Anesthesiol Perioperat & Pain Med, Boston, MA USA	Anderson, TA (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA.	tanderson9@partners.org					HALL JG, 1982, AM J MED GENET, V11, P185, DOI 10.1002/ajmg.1320110208; JONES R, 1992, ANESTHESIOLOGY, V77, P599, DOI 10.1097/00000542-199209000-00031; LAISHLEY RS, 1986, CAN J ANAESTH, V33, P388, DOI 10.1007/BF03010755; McCann M, 2008, PRACTICAL APPROACH P, P496; Stevenson DA, 2006, PEDIATRICS, V117, P754, DOI 10.1542/peds.2005-1219	5	0	0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	MAY	2014	24	5					538	540		10.1111/pan.12303			3	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	AE4BH	WOS:000333922700013	24829975				2020-06-30	J	Ngan Kee, WD; Khaw, KS; Ng, FF; Ng, KKL; So, R; Lee, A				Ngan Kee, Warwick D.; Khaw, Kim S.; Ng, Floria F.; Ng, Karman K. L.; So, Rita; Lee, Anna			Synergistic Interaction between Fentanyl and Bupivacaine Given Intrathecally for Labor Analgesia	ANESTHESIOLOGY			English	Article							EPIDURAL ANALGESIA; MORPHINE; COMBINATION; LIDOCAINE; AGENTS; RATS	Background: Lipophilic opioids and local anesthetics are often given intrathecally in combination for labor analgesia. However, the nature of the pharmacologic interaction between these drugs has not been clearly elucidated in humans. Methods: Three hundred nulliparous women randomly received 1 of 30 different combinations of fentanyl and bupivacaine intrathecally using a combined spinal-epidural technique for analgesia in the first stage of labor. Visual analogue scale pain scores were recorded for 30 min. Response was defined by percentage decrease in pain score from baseline at 15 and 30 min. Dose-response curves for individual drugs were fitted to a hyperbolic dose-response model using nonlinear regression. The nature of the drug interaction was determined using dose equivalence methodology to compare observed effects of drug combinations with effects predicted by additivity. Results: The derived dose-response models for individual drugs (doses in micrograms) at 15 min were: Effect = 100 x dose / (13.82 + dose) for fentanyl, and Effect = 100 x dose / (1,590 + dose) for bupivacaine. Combinations of fentanyl and bupivacaine produced greater effects than those predicted by additivity at 15 min (P < 0.001) and 30 min (P = 0.015) (mean differences, 9.1 [95% CI, 4.1-14.1] and 6.4 [95% CI, 1.2-11.5] units of the normalized response, respectively), indicating a synergistic interaction. Conclusions: The pharmacologic interaction between intrathecal fentanyl and bupivacaine is synergistic. Characterization and quantification of this interaction provide a theoretical basis and support for the clinical practice of combining intrathecal opioids and local anesthetics.	[Ngan Kee, Warwick D.; Khaw, Kim S.; Ng, Floria F.; Ng, Karman K. L.; So, Rita; Lee, Anna] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anaesthesia & Intens Care, Shatin, Hong Kong, Peoples R China	Ngan Kee, WD (reprint author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anaesthesia & Intens Care, Shatin, Hong Kong, Peoples R China.	warwick@cuhk.edu.hk	Ngan Kee, Warwick/J-8817-2013; Lee, Anna/B-2773-2009; Khaw, K/J-9469-2013	Ngan Kee, Warwick/0000-0003-1000-7735; Lee, Anna/0000-0003-2864-0045; Khaw, K/0000-0002-5950-0275	Research Grants Council of the Hong Kong Special Administrative Region, ChinaHong Kong Research Grants Council [473409]	The work described in this article was substantially supported by a grant from the Research Grants Council of the Hong Kong Special Administrative Region, China (Project No. 473409).	BELZARENA SD, 1992, ANESTH ANALG, V74, P653; BERENBAUM MC, 1985, J THEOR BIOL, V114, P413, DOI 10.1016/S0022-5193(85)80176-4; BOGRA J, 2005, BMC ANESTHESIOL, V5, DOI DOI 10.1186/1471-2253-5-5); Boslaugh S, 2005, INTERMEDIATE GUIDE S, p133 6; Camann W, 1998, REGION ANESTH PAIN M, V23, P457, DOI 10.1016/S1098-7339(98)90027-X; Casella G, 2002, STAT INFERENCE, P240; COLLIS RE, 1995, LANCET, V345, P1413, DOI 10.1016/S0140-6736(95)92602-X; GRECO WR, 1995, PHARMACOL REV, V47, P331; KANEKO M, 1994, ANESTHESIOLOGY, V80, P137, DOI 10.1097/00000542-199401000-00021; Lamarre NS, 2008, EUR J PHARMACOL, V586, P350, DOI 10.1016/j.ejphar.2008.02.071; MacArthur C, 2001, LANCET, V358, P19; MAVES TJ, 1992, ANESTHESIOLOGY, V76, P91, DOI 10.1097/00000542-199201000-00014; McLeod GA, 2007, BRIT J ANAESTH, V98, P497, DOI 10.1093/bja/ael373; Montgomery D. C, 2001, DESIGN ANAL EXPT, P427; Ngan Kee WD, 2010, ANESTHESIOLOGY, V113, P445, DOI 10.1097/ALN.0b013e3181bdf9da; Popping DM, 2013, PAIN, V154, P1383, DOI 10.1016/j.pain.2013.04.023; Saito Y, 1998, ANESTHESIOLOGY, V89, P1455, DOI 10.1097/00000542-199812000-00023; Shafer SL, 2008, ANESTH ANALG, V107, P507, DOI 10.1213/ane.0b013e31817b7140; Silva GF, 2011, FUEL PROCESS TECHNOL, V92, P407, DOI 10.1016/j.fuproc.2010.10.002; Tallarida RJ, 1997, LIFE SCI, V61, pPL417, DOI 10.1016/S0024-3205(97)01030-8; Tallarida RJ, 1999, J PHARMACOL EXP THER, V289, P8; Tallarida RJ, 2002, DRUG SYNERGISM DOSE, P57; Tallarida RJ, 2010, PHARMACOL THERAPEUT, V127, P165, DOI 10.1016/j.pharmthera.2010.04.011	23	6	6	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	MAY	2014	120	5					1126	1136		10.1097/ALN.0000000000000118			11	Anesthesiology	Anesthesiology	AG1KW	WOS:000335175100012	24398818				2020-06-30	J	Baik, JS; Oh, AY; Cho, CW; Shin, HJ; Han, SH; Ryu, JH				Baik, Ji Seok; Oh, Ah-Young; Cho, Chan Woo; Shin, Hyun-Jung; Han, Sung Hee; Ryu, Jung Hee			Thoracic Paravertebral Block for Nephrectomy: A Randomized, Controlled, Observer-Blinded Study	PAIN MEDICINE			English	Article						Fentanyl; Nephrectomy; Patient-Controlled Analgesia; Postoperative Pain; Thoracic Paravertebral Block; Pre-Emptive Analgesia	INTERCOSTAL APPROACH; CHRONIC PAIN; SURGERY; ANALGESIA; EFFICACY	ObjectiveThis study evaluated whether adding a preoperative single thoracic paravertebral block (TPVB) to intravenous patient-controlled analgesia (IV PCA) would improve postoperative analgesia compared with using IV PCA alone in patients undergoing nephrectomy. DesignProspective, randomized, controlled, observer-blinded trial. SettingUniversity hospital. SubjectsThirty-four adult patients undergoing elective open nephrectomy. MethodsThe patients were randomized to receive a TPVB plus IV PCA (group T) or IV PCA alone (group C). A single 18-mL injection of 0.75% ropivacaine was administered preoperatively under ultrasound guidance; fentanyl was used for IV PCA. Each patient's postoperative pain score based on a verbal numerical rating scale, postoperative fentanyl consumption, inspiratory volume by incentive spirometry, and complications were evaluated at 1, 3, 6, 12, and 24 hours after surgery. Changes in heart rate (HR), systolic arterial pressure (SAP), and mean arterial pressure (MAP) were evaluated following skin incision. ResultsThe postoperative pain score and fentanyl consumption were significantly lower in group T than in group C at all time points up to 24 hours after surgery. The postoperative inspiratory volumes were not significantly different. The changes in HR were similar, while the increases in SAP and MAP after skin incision were lower in group T than in group C. ConclusionsA preoperative single TPVB improved postoperative analgesia by reducing the postoperative pain score and fentanyl consumption in patients undergoing nephrectomy.	[Baik, Ji Seok; Oh, Ah-Young; Cho, Chan Woo; Shin, Hyun-Jung; Han, Sung Hee; Ryu, Jung Hee] Seoul Natl Univ, Bundang Hosp, Dept Anesthesiol & Pain Med, Songnam 463707, Gyeonngi Do, South Korea	Oh, AY (reprint author), Seoul Natl Univ, Bundang Hosp, Dept Anesthesiol & Pain Med, 82 Gumi Ro,173 Beon Gil, Songnam 463707, Gyeonngi Do, South Korea.	ohahyoung@hanmail.net					Batra Ravinder Kumar, 2011, J Anaesthesiol Clin Pharmacol, V27, P5; Ben-Ari A, 2009, ANESTH ANALG, V109, P1691, DOI 10.1213/ANE.0b013e3181b72d50; Buckenmaier CC, 2010, PAIN MED, V11, P790, DOI 10.1111/j.1526-4637.2010.00842.x; CHEEMA SPS, 1995, ANAESTHESIA, V50, P118, DOI 10.1111/j.1365-2044.1995.tb15092.x; Davies RG, 2006, BRIT J ANAESTH, V96, P418, DOI 10.1093/bja/ael020; Dillenburg W, 2006, EUR UROL, V49, P314, DOI 10.1016/j.eururo.2005.10.021; Dillenburg W, 2006, EUR UROL, V49, P22; Eroglu Muzaffer, 2005, International Urology and Nephrology, V37, P675, DOI 10.1007/s11255-005-0250-0; GIESECKE K, 1988, BRIT J ANAESTH, V61, P652, DOI 10.1093/bja/61.6.652; Kairaluoma PM, 2006, ANESTH ANALG, V103, P703, DOI 10.1213/01.ane.0000230603.92574.4e; Kissin I, 2000, ANESTHESIOLOGY, V93, P1138, DOI 10.1097/00000542-200010000-00040; Langille GM, 2013, UROLOGY, V81, P675, DOI 10.1016/j.urology.2012.11.043; Lin Y, 2013, CLIN ANESTH, P561; Luyet C, 2012, ANAESTHESIA, V67, P1321, DOI 10.1111/j.1365-2044.2012.07234.x; Owen M, 2010, EUR J PAIN, V14, P732, DOI 10.1016/j.ejpain.2009.11.013; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; Richardson J, 2011, BRIT J ANAESTH, V106, P164, DOI 10.1093/bja/aeq378; Richardson J, 1998, ANESTH ANALG, V87, P373, DOI 10.1097/00000539-199808000-00025; Saito T, 2001, ACTA ANAESTH SCAND, V45, P30, DOI 10.1034/j.1399-6576.2001.450105.x; Shibata Y, 2009, ANESTH ANALG, V109, P996, DOI 10.1213/ane.0b013e3181af7e7b; Wedel DJ, 2009, MILLERS ANESTHESIA, P1639	21	12	13	0	5	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1526-2375	1526-4637		PAIN MED	Pain Med.	MAY	2014	15	5					850	856		10.1111/pme.12320			7	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	AH9JS	WOS:000336458900018	24341324	Bronze			2020-06-30	J	DeClue, AE; Yu, DH; Prochnow, S; Axiak-Bechtel, S; Amorim, J; Tsuruta, K; Donaldson, R; Lino, G; Monibi, F; Honaker, A; Dodam, J				DeClue, Amy E.; Yu, Do-Hyeon; Prochnow, Sarah; Axiak-Bechtel, Sandra; Amorim, Juliana; Tsuruta, Kaoru; Donaldson, Rebecca; Lino, Giulia; Monibi, Farrah; Honaker, Allison; Dodam, John			Effects of opioids on phagocytic function, oxidative burst capacity, cytokine production and apoptosis in canine leukocytes	VETERINARY JOURNAL			English	Article						Opioid; Immune response; Pharmacodynamics	KAPPA-B ACTIVATION; IN-VITRO; POLYMORPHONUCLEAR LEUKOCYTES; RECEPTOR EXPRESSION; NEUTROPHIL FUNCTION; RESPIRATORY BURST; WHOLE-BLOOD; MORPHINE; DOGS; IMMUNE	Opioids alter immune and apoptotic pathways in several species. They are commonly used in companion animals affected with infectious and/or inflammatory disease, but the immunomodulatory and apoptotic effects of these drugs in dogs are relatively unknown. The aim of the present study was to evaluate the effects of morphine, buprenorphine and fentanyl on canine phagocyte function, oxidative burst capacity, leukocyte cytokine production, and lymphocyte apoptosis. Blood from six healthy adult dogs was incubated in the presence or absence of morphine (200 ng/mL), buprenorphine (10 ng/mL) or fentanyl (10 ng/mL) for 3 h (phagocytic function; cytokine production) or 8 h (apoptosis). Neutrophil phagocytosis of opsonized Escherichia call, respiratory burst capacity after stimulation with opsonized E. coli or phorbol 12-myristate 13-acetate (PMA), and Annexin V-FITC staining of apoptotic lymphocytes were evaluated using flow cytometry. Leukocyte production of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and IL-10 was assessed after incubation with lipopolysaccharide (LPS), lipoteichoic acid (LTA) or peptidoglycan. Morphine promoted a more intense respiratory burst. Morphine, buprenorphine and fentanyl all promoted LPS- or LTA-induced TNF-alpha and IL-10 production. However, the opioids tested did not alter TNF-alpha:IL-10 ratios. Morphine, buprenorphine and fentanyl all inhibited neutrophil apoptosis, an effect that was not concentration dependent in nature. These data indicate that opioids alter immune and apoptotic pathways in dogs. The possible effects of opioids on immune and cellular responses should be considered when designing studies and interpreting outcomes of studies involving administration of opioids in dogs. (C) 2014 Elsevier Ltd. All rights reserved.	[DeClue, Amy E.; Prochnow, Sarah; Axiak-Bechtel, Sandra; Amorim, Juliana; Tsuruta, Kaoru; Donaldson, Rebecca; Lino, Giulia; Monibi, Farrah; Dodam, John] Univ Missouri, Coll Vet Med, Comparat Internal Med Lab, Columbia, MO 65211 USA; [Yu, Do-Hyeon] Chonnam Natl Univ, Coll Vet Med, Kwangju, South Korea; [Honaker, Allison] Chicago Zool Soc, Mote Marine Lab, Sarasota Dolphin Res Program, Sarasota, FL USA	DeClue, AE (reprint author), Univ Missouri, Coll Vet Med, Comparat Internal Med Lab, 900 East Campus Dr, Columbia, MO 65211 USA.	decluea@missouri.edu	Fiumefreddo, Andrea/T-2977-2019	Axiak-Bechtel, Sandra/0000-0002-7773-5959; dodam, john/0000-0003-1094-7567			Azuma Y, 2002, IMMUNOL LETT, V81, P31, DOI 10.1016/S0165-2478(01)00335-2; Bastami S, 2013, ACTA ONCOL, V52, P1022, DOI 10.3109/0284186X.2012.737932; Bhaskaran M, 2001, J INFECT DIS, V184, P1524, DOI 10.1086/324667; Bilfinger TV, 1996, INT J CARDIOL, V53, pS39, DOI 10.1016/0167-5273(96)02574-0; Bonnet MP, 2008, ANESTH ANALG, V106, P1142, DOI 10.1213/ane.0b013e318165de89; Bouaziz H, 1996, ANESTHESIOLOGY, V84, P143, DOI 10.1097/00000542-199601000-00017; Budd K, 2006, BIOMED PHARMACOTHER, V60, P310, DOI 10.1016/j.biopha.2006.06.015; Carr DB, 1999, LANCET, V353, P2051, DOI 10.1016/S0140-6736(99)03313-9; CASTANAS E, 1985, J NEUROCHEM, V45, P688, DOI 10.1111/j.1471-4159.1985.tb04047.x; Chavez-Valdez R, 2013, J PERINATOL, V33, P374, DOI 10.1038/jp.2012.124; CLARK WG, 1980, BRAIN RES BULL, V5, P415, DOI 10.1016/S0361-9230(80)80011-6; DeClue AE, 2008, AM J VET RES, V69, P228, DOI 10.2460/ajvr.69.2.228; Deitschel SJ, 2010, J VET EMERG CRIT CAR, V20, P494, DOI 10.1111/j.1476-4431.2010.00565.x; Eisenstein TK, 1998, J NEUROIMMUNOL, V83, P36, DOI 10.1016/S0165-5728(97)00219-1; Eisenstein TK, 2011, BRIT J PHARMACOL, V164, P1826, DOI 10.1111/j.1476-5381.2011.01513.x; Fowler BL, 2011, VET IMMUNOL IMMUNOP, V144, P167, DOI 10.1016/j.vetimm.2011.07.011; Gomez-Flores R, 2000, IMMUNOPHARMACOLOGY, V48, P145, DOI 10.1016/S0162-3109(00)00198-3; Happel C, 2011, J LEUKOCYTE BIOL, V89, P301, DOI 10.1189/jlb.0710402; Hellyer PW, 2003, VET ANAESTH ANALG, V30, P172, DOI 10.1046/j.1467-2995.2003.00143.x; Jaeger K, 1998, ACTA ANAESTH SCAND, V42, P1110, DOI 10.1111/j.1399-6576.1998.tb05386.x; Karlsson I, 2012, REPROD DOMEST ANIM, V47, P337, DOI 10.1111/rda.12034; KRUMHOLZ W, 1995, ACTA ANAESTH SCAND, V39, P624, DOI 10.1111/j.1399-6576.1995.tb04138.x; LeBlanc CJ, 2010, VET CLIN PATH, V39, P157, DOI 10.1111/j.1939-165X.2009.00200.x; McCarthy L, 2001, DRUG ALCOHOL DEPEN, V62, P111, DOI 10.1016/S0376-8716(00)00181-2; Menzebach A, 2003, BRIT J ANAESTH, V91, P546, DOI 10.1093/bja/aeg219; Odunayo A, 2010, J VET EMERG CRIT CAR, V20, P376, DOI 10.1111/j.1476-4431.2010.00561.x; Ohara T, 2005, ANESTH ANALG, V101, P1117, DOI 10.1213/01.ane.0000167772.16584.0f; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6; Pekcan Z, 2010, VET ANAESTH ANALG, V37, P557, DOI 10.1111/j.1467-2995.2010.00571.x; Peng XH, 2000, J LEUKOCYTE BIOL, V68, P723; Roy S, 1999, J NEUROIMMUNOL, V95, P107, DOI 10.1016/S0165-5728(98)00265-3; Roy S, 1998, MOL BRAIN RES, V56, P281, DOI 10.1016/S0169-328X(98)00051-5; Roy S, 1998, BIOCHEM BIOPH RES CO, V245, P392, DOI 10.1006/bbrc.1998.8415; Sacerdote P, 1997, BRIT J PHARMACOL, V121, P834, DOI 10.1038/sj.bjp.0701138; Schofferman J, 1999, CLIN J PAIN, V15, P136, DOI 10.1097/00002508-199906000-00011; SHARP BM, 1985, ENDOCRINOLOGY, V117, P793, DOI 10.1210/endo-117-2-793; Sulowska Z, 2002, MEDIAT INFLAMM, V11, P245, DOI 10.1080/096293502900000104; Tomassini N, 2004, J NEUROIMMUNOL, V147, P131, DOI 10.1016/j.jneuroim.2003.10.028; Waldhoer M, 2004, ANNU REV BIOCHEM, V73, P953, DOI 10.1146/annurev.biochem.73.011303.073940; Wang JH, 2002, J LEUKOCYTE BIOL, V71, P782; Wang J, 2008, ARCH IMMUNOL THER EX, V56, P299, DOI 10.1007/s00005-008-0035-0; Wang JH, 2011, J BIOL CHEM, V286, P10225, DOI 10.1074/jbc.M110.188680; Welters ID, 2000, J NEUROIMMUNOL, V111, P139, DOI 10.1016/S0165-5728(00)00401-X; Wu Y, 2009, MOL BIOL REP, V36, P1113, DOI 10.1007/s11033-008-9286-4; Wypasek E, 2012, ARCH IMMUNOL THER EX, V60, P373, DOI 10.1007/s00005-012-0186-x	45	16	16	1	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1090-0233	1532-2971		VET J	Vet. J.	MAY	2014	200	2					270	275		10.1016/j.tvjl.2014.02.019			6	Veterinary Sciences	Veterinary Sciences	AI4IF	WOS:000336828200013	24679456				2020-06-30	J	Xiang, XH; Chen, YM; Zhang, JM; Tian, JH; Han, JS; Cui, CL				Xiang, Xiao-Hui; Chen, Ying-Mao; Zhang, Jin-Ming; Tian, Jia-He; Han, Ji-Sheng; Cui, Cai-Lian			Low- and high-frequency transcutaneous electrical acupoint stimulation induces different effects on cerebral mu-opioid receptor availability in rhesus monkeys	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						transcutaneous electrical acupoint stimulation (TEAS); positron emission tomography (PET); mu-opioid receptor (MOR)	ACUPUNCTURE ANALGESIA; NERVE-STIMULATION; HUMAN BRAIN; PAIN; ELECTROACUPUNCTURE; FMRI; RESPONSES; ANTINOCICEPTION; NALOXONE; SYSTEM	Although systematic studies have demonstrated that acupuncture or electroacupuncture (EA) analgesia is based on their accelerating endogenous opioid release to activate opioid receptors and that EA of different frequencies is mediated by different opioid receptors in specific areas of the central nervous system, there is little direct, real-time evidence to confirm this in vivo. The present study was designed to investigate the effects of transcutaneous electrical acupoint stimulation (TEAS), an analogue of EA, at low and high frequencies on mu-opioid receptor (MOR) availability in the brain of rhesus monkeys. Monkeys underwent 95-min positron emission tomography (PET) with C-11-carfentanil three times randomly while receiving 0, 2, or 100 Hz TEAS, respectively. Each TEAS was administered in the middle 30 min during the 95-min PET scan, and each session of PET and TEAS was separated by at least 2 weeks. The results revealed that 2 Hz but not 100 Hz TEAS evoked a significant increase in MOR binding potential in the anterior cingulate cortex, the caudate nucleus, the putamen, the temporal lobe, the somatosensory cortex, and the amygdala compared with 0 Hz TEAS. The effect remained after the end of TEAS in the anterior cingulate cortex and the temporal lobe. The selective increase in MOR availability in multiple brain regions related to pain and sensory processes may play a role in mediating low-frequency TEAS efficacy. (c) 2014 Wiley Periodicals, Inc.	[Xiang, Xiao-Hui; Han, Ji-Sheng; Cui, Cai-Lian] Peking Univ, Sch Basic Med Sci, Neurosci Res Inst, Beijing 100191, Peoples R China; [Xiang, Xiao-Hui; Han, Ji-Sheng; Cui, Cai-Lian] Peking Univ, Sch Basic Med Sci, Dept Neurobiol, Beijing 100191, Peoples R China; [Xiang, Xiao-Hui; Han, Ji-Sheng; Cui, Cai-Lian] Minist Educ, Key Lab Neurosci, Beijing, Peoples R China; [Xiang, Xiao-Hui; Han, Ji-Sheng; Cui, Cai-Lian] Minist Publ Hlth, Beijing, Peoples R China; [Chen, Ying-Mao; Zhang, Jin-Ming; Tian, Jia-He] Chinese Peoples Liberat Army Gen Hosp, Dept Nucl Med, Beijing, Peoples R China; [Xiang, Xiao-Hui] Logist Univ Chinese Peoples Armed Police Forces, Affiliated Hosp, Dept Hepatopancreatobiliary & Splen Med, Tianjin, Peoples R China	Cui, CL (reprint author), Peking Univ, Hlth Sci Ctr, Neurosci Res Inst, 38 Xue Yuan Rd, Beijing 100191, Peoples R China.	clcui@bjmu.edu.cn	Xiang, Xiaohui/D-8093-2015	Xiang, Xiaohui/0000-0002-5762-5007	National Basic Research Program of ChinaNational Basic Research Program of China [2013CB531905]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [31200838]; International Scientific and Technological Cooperation Project from the Ministry of Science and Technology of China [2009DFA32960]	Contract grant sponsor: National Basic Research Program of China; Contract grant number: 2013CB531905; Contract grant sponsor: National Natural Science Foundation of China; Contract grant number: 31200838; Contract grant sponsor: International Scientific and Technological Cooperation Project from the Ministry of Science and Technology of China; Contract grant number: 2009DFA32960.	ANDERSSON SA, 1973, BRAIN RES, V63, P393, DOI 10.1016/0006-8993(73)90111-X; Bencherif B, 2004, J NUCL MED, V45, P402; Biella G, 2001, NEUROIMAGE, V14, P60, DOI 10.1006/nimg.2001.0798; Chao AS, 2007, PAIN, V127, P214, DOI 10.1016/j.pain.2006.08.016; Chen XH, 1996, J PHARMACOL EXP THER, V277, P654; CHEN XH, 1992, BEHAV BRAIN RES, V47, P143, DOI 10.1016/S0166-4328(05)80120-2; CHEN XH, 1992, EUR J PHARMACOL, V211, P203; Cui CL, 2008, NEUROCHEM RES, V33, P2013, DOI 10.1007/s11064-008-9784-8; Endres CJ, 2003, NUCL MED BIOL, V30, P177, DOI 10.1016/S0969-8051(02)00411-0; Fang Z, 2012, EVID BASED COMPLEMEN, V2012; Coura LEF, 2011, ACUPUNCT MED, V29, P16, DOI 10.1136/aim.2010.003251; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; FRISTON KJ, 1995, NEUROIMAGE, V2, P166, DOI 10.1006/nimg.1995.1019; Gao M, 1997, ACUPUNCTURE ELECTRO, V22, P161, DOI 10.3727/036012997816356662; GEAR RW, 1995, J NEUROSCI, V15, P3154; Gupta S, 1999, ANAESTHESIA, V54, P1204, DOI 10.1046/j.1365-2044.1999.01030.x; Han JS, 2011, NEUROSCI BIOBEHAV R, V35, P680, DOI 10.1016/j.neubiorev.2010.08.006; Han JS, 2011, PAIN, V152, pS41, DOI 10.1016/j.pain.2010.10.012; HAN JS, 1991, PAIN, V47, P295, DOI 10.1016/0304-3959(91)90218-M; HAN JS, 1994, CHINESE MED J-PEKING, V107, P6; Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1; Harris RE, 2007, J NEUROSCI, V27, P10000, DOI 10.1523/JNEUROSCI.2849-07.2007; Harris RE, 2009, NEUROIMAGE, V47, P1077, DOI 10.1016/j.neuroimage.2009.05.083; HE LF, 1985, PAIN, V23, P83; Henriksen G, 2008, BRAIN, V131, P1171, DOI 10.1093/brain/awm255; HO WKK, 1989, NEUROPHARMACOLOGY, V28, P961, DOI 10.1016/0028-3908(89)90196-2; Hui KKS, 2009, BRAIN RES, V1287, P84, DOI 10.1016/j.brainres.2009.06.061; Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; Jiang Y, 2013, PLOS ONE, V8; Kennedy SE, 2006, ARCH GEN PSYCHIAT, V63, P1199, DOI 10.1001/archpsyc.63.11.1199; Kim NH, 2013, EVID BASED COMPLEMEN, V2013; Logan J, 2001, J CEREBR BLOOD F MET, V21, P307, DOI 10.1097/00004647-200103000-00014; MAYER DJ, 1977, BRAIN RES, V121, P368, DOI 10.1016/0006-8993(77)90161-5; McLaren DG, 2009, NEUROIMAGE, V45, P52, DOI 10.1016/j.neuroimage.2008.10.058; Napadow V, 2005, HUM BRAIN MAPP, V24, P193, DOI 10.1002/hbm.20081; Napadow V., 2012, CEREB CORTEX; POMERANZ B, 1976, LIFE SCI, V19, P1757, DOI 10.1016/0024-3205(76)90084-9; Scott DJ, 2006, J NEUROSCI, V26, P10789, DOI 10.1523/JNEUROSCI.2577-06.2006; Sprenger T, 2005, EUR J PAIN, V9, P117, DOI 10.1016/j.ejpain.2004.07.010; WANG JQ, 1992, INT J NEUROSCI, V65, P117, DOI 10.3109/00207459209003283; Wu GC, 2007, CHIN J INTEGR MED, V13, P163, DOI 10.1007/s11655-007-0163-0; Zhang JM, 2011, J ISOTOPES, V24, P182; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4; Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005; Zubieta JK, 2003, ARCH GEN PSYCHIAT, V60, P1145, DOI 10.1001/archpsyc.60.11.1145; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	48	23	29	1	26	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	MAY	2014	92	5					555	563		10.1002/jnr.23351			9	Neurosciences	Neurosciences & Neurology	AC5IC	WOS:000332553400002	24482187				2020-06-30	J	Moehring, RW; Lewis, SS; Isaacs, PJ; Schell, WA; Thomann, WR; Althaus, MM; Hazen, KC; Dicks, KV; LiPuma, JJ; Chen, LF; Sexton, DJ				Moehring, Rebekah W.; Lewis, Sarah S.; Isaacs, Pamela J.; Schell, Wiley A.; Thomann, Wayne R.; Althaus, Mary M.; Hazen, Kevin C.; Dicks, Kristen V.; LiPuma, John J.; Chen, Luke F.; Sexton, Daniel J.			Outbreak of Bacteremia Due to Burkholderia contaminans Linked to Intravenous Fentanyl From an Institutional Compounding Pharmacy	JAMA INTERNAL MEDICINE			English	Article							CEPACIA BACTEREMIA; MULTISTATE OUTBREAK; COLONIZATION; INFECTION; COMPLEX	IMPORTANCE Many health care facilities compound medications on site to fulfill local demands when customized formulations are needed, national supply is critically low, or costs for manufactured pharmaceuticals are excessive. Small, institutional compounding facilities may perform the same high-risk procedures as large distributors of compounded medications. OBJECTIVES To investigate an outbreak related to contamination of compounded sterile preparations and to determine processes to prevent future outbreaks. DESIGN, SETTING, AND PARTICIPANTS We performed an outbreak investigation of inpatients at Duke University Hospital from August 31 through September 6, 2012. The investigation included a case-control study, compounding facility inspection and environmental sampling, observation of a mock compounding demonstration, and microbiologic and molecular testing of sequestered medication. EXPOSURES Intravenous fentanyl prepared by an institutional compounding pharmacy. MAIN OUTCOMES AND MEASURES Microbiologic and molecular evidence of contamination of a compounded sterile preparation and failure of routine sterility testing. RESULTS Blood cultures of 7 patients during a 7-day period at Duke University Hospital yielded pan-susceptible Burkholderia cepacia complex bacteria. The risk factor common to all patients was receipt of continuous fentanyl infusion prepared by our institutional compounding pharmacy (odds ratio, 11.22; 95% CI, 2.09-infinity; P = .01). The outbreak was terminated after sequestration of compounded fentanyl. An intensive evaluation of the compounding facility, its practice, and its procedures was completed. Investigators evaluated the clean room, collected targeted microbiologic samples within the compounding pharmacy environment, and observed a mock demonstration of compounding practice. The B cepacia complex was found in the anteroom sink drain and pH probe calibration fluid from the compounding clean room. Multiple microbiologic analyses of sequestered fentanyl initially failed. Ultimately, a batched, vacuum-assisted filtration method produced B cepacia complex from a single lot. Molecular analyses using repetitive element polymerase chain reaction and pulsed-field gel electrophoresis confirmed a clonal Burkholderia contaminans strain from patients, fentanyl, and environmental samples. CONCLUSIONS AND RELEVANCE An outbreak of B contaminans bacteremia was linked to contamination of locally compounded intravenous fentanyl. Health care facilities that house institutional compounding facilities must be vigilant in efforts to prevent, recognize, and terminate medication-related outbreaks.	[Moehring, Rebekah W.; Lewis, Sarah S.; Schell, Wiley A.; Hazen, Kevin C.; Dicks, Kristen V.; Chen, Luke F.; Sexton, Daniel J.] Duke Univ, Med Ctr, Div Infect Dis, Dept Med, Durham, NC 27710 USA; [Moehring, Rebekah W.; Lewis, Sarah S.; Isaacs, Pamela J.; Chen, Luke F.; Sexton, Daniel J.] Duke Univ, Med Ctr, Program Infect Prevent & Healthcare Epidemiol, Durham, NC 27710 USA; [Moehring, Rebekah W.] Durham Vet Affairs Med Ctr, Durham, NC USA; [Moehring, Rebekah W.; Thomann, Wayne R.] Duke Univ, Med Ctr, Durham, NC 27710 USA; [Althaus, Mary M.; Hazen, Kevin C.] Duke Univ, Med Ctr, Clin Microbiol Lab, Durham, NC 27710 USA; [LiPuma, John J.] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA	Moehring, RW (reprint author), Duke Univ, Med Ctr, Campus Box 102359, Durham, NC 27710 USA.	Rebekah.moehring@duke.edu					[Anonymous], 2013, PHARM PURCH PROD, V10, pS1; Balkhy HH, 2005, AM J INFECT CONTROL, V33, P182, DOI 10.1016/j.ajic.2005.01.001; Centers for Disease Control and Prevention, 2013, MULT FUNG MEN OUTBR; Centers for Disease Control and Prevention, 2012, PROC REC LEG ENV MAN; Coutinho CP, 2011, FRONT CELL INFECT MI, V1, DOI 10.3389/fcimb.2011.00012; Doit C, 2004, J CLIN MICROBIOL, V42, P2227, DOI 10.1128/JCM.42.5.2227-2230.2004; Kutty PK, 2007, CHEST, V132, P1825, DOI 10.1378/chest.07-1545; Mahenthiralingam E, 2000, J CLIN MICROBIOL, V38, P3165, DOI 10.1128/JCM.38.9.3165-3173.2000; Mahenthiralingam E, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000017; Maragalkis LL, 2009, EMERG INFECT DIS, V15, P12, DOI 10.3201/eid1501.081054; Martin M, 2011, INFECT CONT HOSP EP, V77, P267; Martina P, 2013, J CLIN MICROBIOL, V51, P339, DOI 10.1128/JCM.02500-12; Myers CE, 2013, AM J HEALTH-SYST PH, V70, P1414, DOI 10.2146/ajhp130112; Nasser RM, 2004, INFECT CONT HOSP EP, V25, P231, DOI 10.1086/502384; Ohji G, 2013, J INFECT CHEMOTHER, V19, P969, DOI 10.1007/s10156-012-0547-8; Romero-Gomez MP, 2008, INFECT CONT HOSP EP, V29, P377, DOI 10.1086/529032; Smith RM, 2013, NEW ENGL J MED, V369, P1598, DOI 10.1056/NEJMoa1213978; Sunenshine RH, 2007, CLIN INFECT DIS, V45, P527, DOI 10.1086/520664; United States Pharmacopeial Convention, 2008, US PHARM, P319; United States Pharmacopeial Convention, 2008, US PHARM, P85; US Food and Drug Administration, 2013, 2013 PHARM INSP; Vanlaere E, 2009, INT J SYST EVOL MICR, V59, P102, DOI 10.1099/ijs.0.001123-0; Wright S, 2013, OEI011300150; Yang CJ, 2008, J HOSP INFECT, V69, P398, DOI 10.1016/j.jhin.2008.03.011	24	21	23	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6106	2168-6114		JAMA INTERN MED	JAMA Intern. Med.	APR	2014	174	4					606	612		10.1001/jamainternmed.2013.13768			7	Medicine, General & Internal	General & Internal Medicine	AI4NK	WOS:000336841900024	24493147	Bronze			2020-06-30	J	Coukell, A				Coukell, Allan			Risks of Compounded Drugs	JAMA INTERNAL MEDICINE			English	Editorial Material									Pew Charitable Trusts, Washington, DC 20004 USA	Coukell, A (reprint author), Pew Charitable Trusts, 901 E St NW, Washington, DC 20004 USA.	ACoukell@pewtrusts.org					Boyce JM, 2014, JAMA INTERN MED, V174, P630, DOI 10.1001/jamainternmed.2013.13772; Douglass K, 2011, PHARM PURCH PROD CLE, V8, pS8; Moehring RW, 2014, JAMA INTERN MED, V174, P606, DOI 10.1001/jamainternmed.2013.13768; Office of the Inspector General Department of Health and Human Services, 2013, OEI011300150 DEP HLT; The Pew Charitable Trusts, US ILLN DEATHS ASS C; The Pew Charitable Trusts American Society of Health-System Pharmacists American Hospital Association, 2013, PHARM STER COMP SUMM; US Centers for Disease Control and Prevention, MULT FUNG MEN OUTBR; US Food and Drug Administration, PHARM COMP FDA ACT	8	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6106	2168-6114		JAMA INTERN MED	JAMA Intern. Med.	APR	2014	174	4					613	614		10.1001/jamainternmed.2013.12812			2	Medicine, General & Internal	General & Internal Medicine	AI4NK	WOS:000336841900025	24492958				2020-06-30	J	Yang, SY; Kang, H; Choi, GJ; Shin, HY; Baek, CW; Jung, YH; Choi, YS				Yang, So Young; Kang, Hyun; Choi, Geun Joo; Shin, Hwa Yong; Baek, Chong Wha; Jung, Yong Hun; Choi, Yoo Shin			Efficacy of intraperitoneal and intravenous lidocaine on pain relief after laparoscopic cholecystectomy	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						Intraperitoneal; intravenous; laparoscopic cholecystectomy; lidocaine; postoperative pain	DOUBLE-BLIND; PREEMPTIVE ANALGESIA; POSTOPERATIVE PAIN; LOCAL-ANESTHETICS; CONTROLLED-TRIAL; BOWEL FUNCTION; RECOVERY; HOSPITALIZATION; STERILIZATION; HYPERALGESIA	Objectives This randomized, double-blind, placebo-controlled trial evaluated intraperitoneal (IP) lidocaine administration and intravenous (IV) lidocaine infusion for postoperative pain control after laparoscopic cholecystectomy (LC). Methods Patients who underwent LC were randomized to either group IV (intravenous lidocaine infusion), group IP (intraperitoneal lidocaine administration), or group C (control, IP and IV saline). Outcome measures were total postoperative pain severity (TPPS), total fentanyl consumption (TFC), frequency of administering patient-controlled analgesia (FPB), and a pain control satisfaction score (PCSS). Results Significantly reduced TPPS, TFC and FPB scores were observed in groups IP (n=22) and IV (n=26) compared with controls (n=24). PCSS was higher in groups IP and IV than in controls. At 2h postoperation, TPPS was significantly lower in group IP than group IV; at 0-2h postoperation, FPB was lower in group IP than group IV. Conclusions The IP administration of lidocaine and IV lidocaine infusion significantly reduced postoperative pain and opioid consumption in LC patients, compared with control infusions. For convenience, IV lidocaine could be used for pain reduction following LC; IP administration places additional burden on the surgeon.	[Yang, So Young; Kang, Hyun; Choi, Geun Joo; Shin, Hwa Yong; Baek, Chong Wha; Jung, Yong Hun] Chung Ang Univ, Dept Anaesthesiol & Pain Med, Coll Med, Seoul 156755, South Korea; [Choi, Yoo Shin] Chung Ang Univ, Dept Surg, Coll Med, Seoul 156755, South Korea	Kang, H (reprint author), Chung Ang Univ, Dept Anaesthesiol & Pain Med, Coll Med, 224-1 Heukseok Dong, Seoul 156755, South Korea.	roman00@naver.com	Kang, Hyun/AAE-7872-2020	Kang, Hyun/0000-0003-2844-5880	Basic Science Research Program through the National Research Foundation of Korea (NRF); Ministry of Education, Science and TechnologyMinistry of Education, Science and Technology, Republic of Korea [2012R1A1A1003700]	This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2012R1A1A1003700).	Alexander JI, 1997, BRIT J ANAESTH, V79, P369, DOI 10.1093/bja/79.3.369; ANDERSON JL, 1984, CLIN THER, V6, P125; BENHAMOU D, 1994, OBSTET GYNECOL, V84, P877; BERGGREN U, 1994, BRIT J SURG, V81, P1362, DOI 10.1002/bjs.1800810936; Bisgaard T, 2006, ANESTHESIOLOGY, V104, P835, DOI 10.1097/00000542-200604000-00030; Boddy AP, 2006, ANESTH ANALG, V103, P682, DOI 10.1213/01.ane.0000226268.06279.5a; Cha SM, 2012, J SURG RES, V175, P251, DOI 10.1016/j.jss.2011.04.033; Clarke C, 2008, PAIN RES MANAG, V13, P421, DOI 10.1155/2008/768231; DOBBS FF, 1987, BRIT J OBSTET GYNAEC, V94, P262, DOI 10.1111/j.1471-0528.1987.tb02365.x; Elhakim M, 2000, ACTA ANAESTH SCAND, V44, P929, DOI 10.1034/j.1399-6576.2000.440806.x; GRACE PA, 1991, BRIT J SURG, V78, P160, DOI 10.1002/bjs.1800780209; Groudine SB, 1998, ANESTH ANALG, V86, P235, DOI 10.1097/00000539-199802000-00003; Hollmann MW, 2000, ANESTHESIOLOGY, V93, P858, DOI 10.1097/00000542-200009000-00038; JORIS J, 1995, ANESTH ANALG, V81, P379, DOI 10.1097/00000539-199508000-00029; Kawamata M, 2002, PAIN, V100, P77, DOI 10.1016/S0304-3959(02)00233-6; Khan MR, 2012, J SURG RES, V178, P662, DOI 10.1016/j.jss.2012.06.005; Kim TH, 2011, SURG ENDOSC, V25, P3183, DOI 10.1007/s00464-011-1684-3; Kissin I, 1996, ANESTHESIOLOGY, V84, P1015, DOI 10.1097/00000542-199605000-00001; Koppert W, 2000, PAIN, V85, P217, DOI 10.1016/S0304-3959(99)00268-7; Lauretti Gabriela Rocha, 2008, Rev. Bras. Anestesiol., V58, P280, DOI 10.1590/S0034-70942008000300011; Marret E, 2008, BRIT J SURG, V95, P1331, DOI 10.1002/bjs.6375; Mitra S, 2012, PAIN PRACT, V12, P485, DOI 10.1111/j.1533-2500.2011.00513.x; Pasqualucci A, 1996, ANESTHESIOLOGY, V85, P11, DOI 10.1097/00000542-199607000-00003; RAHM WE, 1962, ANN OTO RHINOL LARYN, V71, P116, DOI 10.1177/000348946207100111; RIMBACK G, 1990, ANESTH ANALG, V70, P414; Roberts KJ, 2011, SURG ENDOSC, V25, P3698, DOI 10.1007/s00464-011-1757-3; Sarac AM, 1996, SURG LAPAROSC ENDOSC, V6, P362, DOI 10.1097/00019509-199610000-00005; SOPER NJ, 1992, ARCH SURG-CHICAGO, V127, P917; Soper NJ, 1992, ARCH SURG-CHICAGO, V127, P921, DOI [DOI 10.1001/ARCHSURG.1992.01420080051008, 10.1001/archsurg.1992.01420080051008]; Vigneault L, 2011, CAN J ANESTH, V58, P22, DOI 10.1007/s12630-010-9407-0; Wu CT, 2005, ANESTH ANALG, V100, P448, DOI 10.1213/01.ANE.0000142551.92340.CC	31	21	21	0	9	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0300-0605	1473-2300		J INT MED RES	J. Int. Med. Res.	APR	2014	42	2					307	319		10.1177/0300060513505493			13	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	AD1PX	WOS:000333007000007	24648482	DOAJ Gold			2020-06-30	J	Wu, W; Chen, Q; Zhang, LC; Chen, WH				Wu, Wei; Chen, Qiang; Zhang, Liang-cheng; Chen, Wen-hua			Dexmedetomidine versus midazolam for sedation in upper gastrointestinal endoscopy	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						Dexmedetomidine; sedation; gastrointestinal endoscopy	INTENSIVE-CARE-UNIT; CONSCIOUS SEDATION; NATIONWIDE SURVEY; PAIN; REQUIREMENTS; COMBINATION; ANESTHESIA; MEPERIDINE; RESPONSES; PRESSURE	Objectives To investigate the efficacy and safety of sedation with dexmedetomidine in upper gastrointestinal endoscopy. Methods Patients with ASA physical status I-II undergoing elective upper gastrointestinal endoscopy were randomly allocated to receive dexmedetomidine or midazolam for conscious sedation. Continuous peripheral oxygen saturation (SpO(2)), heart rate, mean arterial pressure (MAP), Ramsay Sedation Scale (RSS) and numeric rating scale pain scores were recorded before, during and after the procedure. Patients completed a post-procedure satisfaction questionnaire. Results Patients in the midazolam group (n=30) experienced a significant decrease in MAP during sedation compared with pre-sedation values. Patients in the dexmedetomidine group (n=30) had significantly higher SpO(2) and RSS scores during sedation than those in the midazolam group. Overall satisfaction was higher in the dexmedetomidine group than the midazolam group. There were no clinically significant complications in either group. Conclusion Dexmedetomidine has a good safety profile and is an effective sedative for use in upper gastrointestinal endoscopy.	[Wu, Wei; Zhang, Liang-cheng; Chen, Wen-hua] Fujian Med Univ, Union Hosp, Dept Anaesthesia, Fuzhou 350001, Peoples R China; [Chen, Qiang] Fujian Med Univ, Union Hosp, Dept Cardiovasc Surg, Fuzhou 350001, Peoples R China	Zhang, LC (reprint author), Fujian Med Univ, Union Hosp, Dept Anaesthesia, 29 Xinquan Rd, Fuzhou 350001, Peoples R China.	wuwei2196@163.com					ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Anger KE, 2013, CURR PHARM DESIGN, V19, P4003; Baudet JS, 2009, EUR J GASTROEN HEPAT, V21, P882, DOI 10.1097/MEG.0b013e328314b7ca; Bekker A, 2008, ANESTH ANALG, V107, P1340, DOI 10.1213/ane.0b013e3181804298; Berkenbosch John W, 2003, Pediatr Crit Care Med, V4, P203, DOI 10.1097/01.PCC.0000059737.86673.28; Bhana N, 2000, DRUGS, V59, P263, DOI 10.2165/00003495-200059020-00012; Blaudszun G, 2012, ANESTHESIOLOGY, V116, P1312, DOI 10.1097/ALN.0b013e31825681cb; Dere K, 2010, EUR J ANAESTH, V27, P648, DOI 10.1097/EJA.0b013e3283347bfe; Deutsch E, 2007, PEDIATR ANESTH, V17, P438, DOI 10.1111/j.1460-9592.2006.02139.x; Ergul B, 2013, DIGEST ENDOSC, V25, P90, DOI 10.1111/j.1443-1661.2012.01383.x; Fanti L, 2011, DIGEST LIVER DIS, V43, P726, DOI 10.1016/j.dld.2011.04.012; Garg PK, 2012, J LAPAROENDOSC ADV S, V22, P315, DOI 10.1089/lap.2011.0463; Gould D, 2001, J CLIN NURS, V10, P697, DOI 10.1046/j.1365-2702.2001.00525.x; Guo Ying, 2012, Middle East Journal of Anesthesiology, V21, P505; Haq MM, 2012, EUR J GASTROEN HEPAT, V24, P1214, DOI 10.1097/MEG.0b013e328356ae49; Huang Z, 2012, INTERNAL MED, V51, P2299, DOI 10.2169/internalmedicine.51.7810; JAAKOLA ML, 1992, BRIT J ANAESTH, V68, P570, DOI 10.1093/bja/68.6.570; Jones GM, 2011, ANN PHARMACOTHER, V45, P740, DOI 10.1345/aph.1P726; Lawrence CJ, 1997, ANAESTHESIA, V52, P736, DOI 10.1111/j.1365-2044.1997.169-az0303.x; Mazo V, 2007, Rev Esp Anestesiol Reanim, V54, P391; Ozel AM, 2008, TURK J GASTROENTEROL, V19, P8; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Riphaus A, 2010, Z GASTROENTEROL, V48, P392, DOI 10.1055/s-0028-1109765; Sulaiman S, 2012, ANN CARD ANAESTH, V15, P39, DOI 10.4103/0971-9784.91480; Talke P, 2000, ANESTH ANALG, V90, P834, DOI 10.1213/00000539-200004000-00011; Tellor Bethany R, 2012, Hosp Pract (1995), V40, P186, DOI 10.3810/hp.2012.02.959; Unlugenc H, 2005, EUR J ANAESTH, V22, P386, DOI 10.1017/S0265021505000669; Vazquez-Reta J A, 2011, Rev Gastroenterol Mex, V76, P13; Waring JP, 2003, GASTROINTEST ENDOSC, V58, P317, DOI 10.1067/S0016-5107(03)00001-4; Wong J, 2012, ANESTH ANALG, V114, P193, DOI 10.1213/ANE.0b013e3182326d5a; Wong RCK, 2001, GASTROINTEST ENDOSC, V54, P122, DOI 10.1067/mge.2001.116115; Yuksel O, 2007, EUR J GASTROEN HEPAT, V19, P1002	32	12	15	0	10	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0300-0605	1473-2300		J INT MED RES	J. Int. Med. Res.	APR	2014	42	2					516	522		10.1177/0300060513515437			7	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	AD1PX	WOS:000333007000027	24514431	DOAJ Gold			2020-06-30	J	Cohen, SP; Hameed, H; Kurihara, C; Pasquina, PF; Patel, AM; Babade, M; Griffith, SR; Erdek, ME; Jamison, DE; Hurley, RW				Cohen, Steven P.; Hameed, Haroon; Kurihara, Connie; Pasquina, Paul F.; Patel, Amit M.; Babade, Mosunmola; Griffith, Scott R.; Erdek, Michael E.; Jamison, David E.; Hurley, Robert W.			The Effect of Sedation on the Accuracy and Treatment Outcomes for Diagnostic Injections: A Randomized, Controlled, Crossover Study	PAIN MEDICINE			English	Article						Diagnostic Block; False Positive; Sacroiliac Joint; Sedation; Specificity; Sympathetic Block	LOW-BACK-PAIN; MEDIAL BRANCH BLOCKS; FACET JOINT; COST-EFFECTIVENESS; NERVE BLOCKS; LUMBAR; SPECIFICITY; MULTICENTER; PREDICTORS; MANAGEMENT	Background and ObjectiveDiagnostic injections are used to diagnose myriad pain conditions, but are characterized by a high false-positive rate. One potential cause of inaccurate diagnostic blocks is the use of sedation. We sought to determine the effect of sedation on the validity of diagnostic injections. DesignRandomized, crossover study in which 73 patients were allocated to receive a diagnostic sacroiliac joint or sympathetic nerve block performed either with or without sedation using midazolam and fentanyl. Those who obtained equivocal relief, good relief lasting less than 3 months, or who were otherwise deemed good candidates for a repeat injection, received a subsequent crossover injection within 3 months (N=46). Setting and PatientsA tertiary care teaching hospital and a military treatment facility. ResultsIn the primary crossover analysis, blocks performed with sedation resulted in a larger mean reduction in pain diary score than those done without sedation (1.2 [2.6]; P=0.006), less procedure-related pain (difference in means 2.3 [2.5]; P<0.0001), and a higher proportion of patients who obtained >= 50% pain relief on their pain diaries (70% vs. 54%; P=0.039). The increased pain reduction was not accompanied by increased satisfaction (sedation mean 3.9 [1.1] vs. 3.7 [1.3]; P=0.26). Similar findings were observed for the parallel group (N=73) and omnibus (all sedation vs. no sedation blocks, N=110) analyses. No differences in outcomes were noted between the use and non-use of sedation at 1-month. ConclusionsThe use of sedation during diagnostic injections may increase the rate of false-positive blocks and lead to misdiagnoses and unnecessary procedures, but has no effect on satisfaction or outcomes at 1-month.	[Cohen, Steven P.] Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21029 USA; [Cohen, Steven P.; Hameed, Haroon] Johns Hopkins Sch Med, Dept Phys Med & Rehabil, Baltimore, MD 21029 USA; [Erdek, Michael E.] Johns Hopkins Sch Med, Dept Anesthesiol, Baltimore, MD 21029 USA; [Kurihara, Connie; Griffith, Scott R.; Jamison, David E.] Walter Reed Natl Mil Med Ctr, Pain Management Serv, Bethesda, MD USA; [Pasquina, Paul F.] Uniformed Serv Univ Hlth Sci, Dept Phys Med & Rehabil, Bethesda, MD 20814 USA; [Cohen, Steven P.] Uniformed Serv Univ Hlth Sci, Dept Anesthesiol, Bethesda, MD 20814 USA; [Cohen, Steven P.] Uniformed Serv Univ Hlth Sci, Dept Phys Med & Rehabil, Bethesda, MD 20814 USA; [Patel, Amit M.] Mayo Clin, Dept Anesthesiol, Scottsdale, AZ USA; [Babade, Mosunmola] Cleveland Clin Fdn, Dept Anesthesiol, Cleveland, OH 44195 USA; [Hurley, Robert W.] Univ Florida, Dept Anesthesiol Neurol Psychiat Orthopaed & Reha, Gainesville, FL USA	Cohen, SP (reprint author), Johns Hopkins Sch Med, 550 North Broadway,Suite 301, Baltimore, MD 21029 USA.	scohen40@jhmi.edu	MD/PhD, Robert W. Hurley/V-6619-2019	Hurley, Robert/0000-0001-6591-9390	Centers for Rehabilitation and Sciences Research, Uniformed Services University of the Health Sciences, Bethesda, MD	Funded in part by the Centers for Rehabilitation and Sciences Research, Uniformed Services University of the Health Sciences, Bethesda, MD.	Ackerman William E, 2004, Pain Pract, V4, P286, DOI 10.1111/j.1533-2500.2004.04402.x; Anderberg L, 2004, ACTA NEUROCHIR, V146, P559, DOI 10.1007/s00701-004-0241-4; Boas RA, 1998, REGION ANESTH PAIN M, V23, P292, DOI 10.1016/S1098-7339(98)90058-X; Bogduk N, 2008, SPINE J, V8, P56, DOI 10.1016/j.spinee.2007.10.010; Bruehl S, 2010, ANESTHESIOLOGY, V113, P713, DOI 10.1097/ALN.0b013e3181e3db38; Buchowski Jacob M, 2005, Spine J, V5, P520, DOI 10.1016/j.spinee.2005.02.022; Carlino E, 2011, CURR OPIN ANESTHESIO, V24, P540, DOI 10.1097/ACO.0b013e328349d0c2; Chou R, 2009, SPINE, V34, P1078, DOI 10.1097/BRS.0b013e3181a103b1; Cohen SP, 2008, ANESTHESIOLOGY, V109, P279, DOI 10.1097/ALN.0b013e31817f4c7c; Cohen SP, 2007, ANESTH ANALG, V105, P1756, DOI 10.1213/01.ane.0000287637.30163.a2; Cohen SP, 2013, NAT REV RHEUMATOL, V9, P101, DOI 10.1038/nrrheum.2012.198; Cohen SP, 2013, EXPERT REV NEUROTHER, V13, P99, DOI [10.1586/ern.12.148, 10.1586/ERN.12.148]; Cohen SP, 2011, J PAIN, V12, P859, DOI 10.1016/j.jpain.2011.01.009; Cohen SP, 2010, ANESTHESIOLOGY, V113, P395, DOI 10.1097/ALN.0b013e3181e33ae5; Cohen SP, 2010, ANESTHESIOLOGY, V112, P144, DOI 10.1097/ALN.0b013e3181c38a82; Cucuzzella Tony R, 2006, Spine J, V6, P364, DOI 10.1016/j.spinee.2005.09.005; Day Miles, 2008, Pain Pract, V8, P98, DOI 10.1111/j.1533-2500.2008.00177.x; DePalma MJ, 2011, PAIN MED, V12, P224, DOI 10.1111/j.1526-4637.2010.01045.x; Di Filippo A, 2006, ANAESTH INTENS CARE, V34, P334; Dick AM, 1996, ANAESTHESIA, V51, P750, DOI 10.1111/j.1365-2044.1996.tb07889.x; DOOLEY JF, 1988, SPINE, V13, P79, DOI 10.1097/00007632-198801000-00019; Dreyfuss P, 1997, SPINE, V22, P895, DOI 10.1097/00007632-199704150-00013; Fairbank J C, 1980, Physiotherapy, V66, P271; Falco FJE, 2009, PAIN PHYSICIAN, V12, P323; Flaten MA, 2011, PHILOS T R SOC B, V366, P1818, DOI 10.1098/rstb.2010.0407; Hanchak NA, 1996, J GEN INTERN MED, V11, P325, DOI 10.1007/BF02600041; Hancock MJ, 2007, EUR SPINE J, V16, P1539, DOI 10.1007/s00586-007-0391-1; Harden RN, 2010, PAIN, V150, P268, DOI 10.1016/j.pain.2010.04.030; HAUEISEN DC, 1985, CLIN ORTHOP RELAT R, P179; HINGORANI K, 1966, Annals of Physical Medicine, V8, P303; Hogan QH, 1997, ANESTHESIOLOGY, V86, P216, DOI 10.1097/00000542-199701000-00026; HOGAN QH, 1992, REGION ANESTH, V17, P78; Hong JH, 2010, ANESTH ANALG, V111, P802, DOI 10.1213/ANE.0b013e3181e9eb35; Huang JHY, 2012, PAIN MED, V13, P489, DOI 10.1111/j.1526-4637.2012.01348.x; IHC IHSCS, 2004, CEPHALALGIA, V24, P1; Jasper J F, 2001, Pain Physician, V4, P285; Kaptchuk TJ, 2006, BMJ-BRIT MED J, V332, P391, DOI 10.1136/bmj.38726.603310.55; Kim D, 2011, NEUROMODULATION, V14, P165, DOI 10.1111/j.1525-1403.2011.00333.x; Kim N, 2007, SPINE, V32, pE748, DOI 10.1097/BRS.0b013e31815b7e9f; Kim WH, 2010, KOREAN J PAIN, V23, P11, DOI 10.3344/kjp.2010.23.1.11; Koshi Edvin B, 2007, Pain Pract, V7, P4, DOI 10.1111/j.1533-2500.2007.00104.x; Lim JTK, 2005, ARTHROSCOPY, V21, P680, DOI 10.1016/j.arthro.2005.03.015; Lovely TJ, 1997, J SPINAL DISORD, V10, P512; Lum YW, 2012, J VASC SURG, V55, P1370, DOI 10.1016/j.jvs.2011.11.132; Maigne JY, 1996, SPINE, V21, P1889, DOI 10.1097/00007632-199608150-00012; Manchikanti Laxmaiah, 2004, Pain Physician, V7, P301; Manchikanti Laxmaiah, 2004, Pain Physician, V7, P411; Manchikanti Laxmaiah, 2006, Pain Physician, V9, P47; Manchikanti Laxmaiah, 2005, Pain Physician, V8, P349; Manchikanti L, 2009, PAIN PHYSICIAN, V12, P9; Miller TA, 2012, CAN J NEUROL SCI, V39, P577, DOI 10.1017/S0317167100015298; Murata Y, 2003, CLIN ANAT, V16, P108, DOI 10.1002/ca.10069; North RB, 1996, PAIN, V65, P77, DOI 10.1016/0304-3959(95)00170-0; Novak S, 2008, SPINE J, V8, P412, DOI 10.1016/j.spinee.2007.11.002; Ohtori Seiji, 2009, Spine (Phila Pa 1976), V34, P1345, DOI 10.1097/BRS.0b013e3181a401bf; OSLER GE, 1987, S AFR MED J, V71, P363; Pateder Dhruv B, 2009, J Surg Orthop Adv, V18, P170; Patijn J, 2011, PAIN PRACT, V11, P302, DOI 10.1111/j.1533-2500.2011.00458.x; Peterson C, 2010, SKELETAL RADIOL, V39, P5, DOI 10.1007/s00256-009-0783-x; Rathmell JP, 2011, ANESTHESIOLOGY, V114, P918, DOI 10.1097/ALN.0b013e31820fc7f2; Rosenberg JM, 2000, CLIN J PAIN, V16, P18, DOI 10.1097/00002508-200003000-00004; Rudolph U, 2011, NAT REV DRUG DISCOV, V10, P685, DOI 10.1038/nrd3502; Rupert MP, 2009, PAIN PHYSICIAN, V12, P399; Safeer RS, 2005, AM FAM PHYSICIAN, V72, P463; Saper JR, 2011, CEPHALALGIA, V31, P271, DOI 10.1177/0333102410381142; Sasso RC, 2005, J SPINAL DISORD TECH, V18, P471, DOI 10.1097/01.bsd.0000146761.36658.45; Schmid MR, 2006, RADIOLOGY, V241, P595, DOI 10.1148/radiol.2412051229; Schwartz PH, 2013, FAM MED, V45, P83; Schweizer E, 1997, J CLIN PSYCHIAT, V58, P30; Smith HS, 2009, PAIN PHYSICIAN, V12, P195; Staal JB, 2009, SPINE, V34, P49, DOI 10.1097/BRS.0b013e3181909558; Szadek KM, 2009, J PAIN, V10, P354, DOI 10.1016/j.jpain.2008.09.014; Umscheid CA, 2011, POSTGRAD MED, V123, P194, DOI 10.3810/pgm.2011.09.2475; VONGAZA W, 1924, ARCH KLIN CHIR, V133, P479; Wise CL, 2008, J SPINAL DISORD TECH, V21, P579, DOI 10.1097/BSD.0b013e31815ecc4b; WOOLF CJ, 1985, PAIN, V23, P361, DOI 10.1016/0304-3959(85)90006-5; Yoong P, 2012, SKELETAL RADIOL, V41, P981, DOI 10.1007/s00256-011-1290-4	77	11	11	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	APR	2014	15	4					588	602		10.1111/pme.12389			15	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	AE6NS	WOS:000334111300011	24524866	Bronze			2020-06-30	J	Patel, A; Stasiowska, M; Waheed, U; Brett, SJ; Patel, PB				Patel, Amit; Stasiowska, Maria; Waheed, Umeer; Brett, Stephen J.; Patel, Parind B.			Poor Analgesic Efficacy of Epidural Analgesia in Critical Care Patients After Pancreaticoduodenectomy	PANCREAS			English	Article						epidural abortion; patient-controlled analgesia; pancreaticoduodenectomy; critical care; intensive care	ANESTHESIA; SURGERY; PAIN; COMPLICATIONS; SEVERITY	Objectives The objective of this study was to investigate the analgesic efficacy of functional and prematurely aborted epidurals after pancreaticoduodenectomy in critical care, as this is unknown. Methods Data from elective pancreaticoduodenectomy recipients admitted to the critical care unit over 44 months were prospectively collected. Epidural (0.1% bupivacaine and 2 mu g/mL fentanyl) analgesic efficacy was assessed with a ranked categorical verbal pain score (primary end point). If no epidural was placed, intravenous (IV) fentanyl patient-controlled analgesia (PCA) was used. Results Eighty-six pancreaticoduodenectomy patients had a mean age of 66.5 years; 61.6% were men; and 73 received an epidural, whereas 13 received an IV PCA. Epidural abortion rate was 42.5%, associated with a higher 24-hour (P = 0.02) but not 48-hour pain score. Overall, fewer patients reported any pain (P = 0.010; number needed to harm, 3.2; 95% confidence interval, 1.7-3.2) or severe pain (P = 0.006; number needed to harm, 2.9; 95% confidence interval, 2.1-4.7) with functional epidurals. Pain (sensitivity, 93.8%) and severe pain (specificity, 87.8%) were predictive of epidural abortion. Most postepidural analgesia was IV PCA (P = 0.097) after both functional and aborted epidurals. Conclusions Premature epidural abortion rate was high and associated with analgesic morbidity. Pain score was predictive of epidural abortion. Thus, preference toward epidural analgesia cannot be supported.	[Patel, Amit; Stasiowska, Maria; Waheed, Umeer; Brett, Stephen J.; Patel, Parind B.] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Ctr Perioperat Med & Crit Care Res, London W12 0HS, England; [Patel, Amit] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Ctr Clin Sci, MRC, London, England; [Patel, Amit] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Ctr Haematol, London, England	Patel, A (reprint author), Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Gen Intens Care Unit, Ctr Perioperat Med & Crit Care Res, Du Cane Rd, London W12 0HS, England.	amit.patel@imperial.ac.uk			Medical Research Council Chain-Florey Fellowship scheme based at the Clinical Sciences Centre, Imperial College London; National Institute for Health Research Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London	Funding was received from the Medical Research Council Chain-Florey Fellowship scheme based at the Clinical Sciences Centre, Imperial College London, and the National Institute for Health Research Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London.	Agarwal A, 2004, ANESTH ANALG, V99, P1684, DOI 10.1213/01.ANE.0000136422.70531.5A; Amini A, 2012, AM J SURG, V204, P1000, DOI 10.1016/j.amjsurg.2012.05.022; [Anonymous], 2000, JAMA, V284, P3043; [Anonymous], 2002, NURS ETHICS, V9, P105; Beattie WS, 2001, ANESTH ANALG, V93, P853, DOI 10.1097/00000539-200110000-00010; Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; Carli F, 2002, ANESTHESIOLOGY, V97, P540, DOI 10.1097/00000542-200209000-00005; Choi DX, 2010, PANCREAS, V39, P492, DOI 10.1097/MPA.0b013e3181bdfc76; Foss NB, 2005, ANESTHESIOLOGY, V102, P1197, DOI 10.1097/00000542-200506000-00020; Gottschalk A, 1998, JAMA-J AM MED ASSOC, V279, P1076, DOI 10.1001/jama.279.14.1076; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Kennedy EP, 2007, J AM COLL SURGEONS, V204, P917, DOI 10.1016/j.jamcollsurg.2007.01.057; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Marandola M, 2008, TRANSPL P, V40, P1195, DOI 10.1016/j.transproceed.2008.03.114; Moher D, 2010, BMJ-BRIT MED J, V340, DOI [10.1136/bmj.c869, 10.1016/j.jclinepi.2010.03.004]; NAKASHIMA H, 1995, INT SURG, V80, P125; Nishimori M, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005059.pub2; Park WY, 2001, ANN SURG, V234, P560; Popping DM, 2008, ARCH SURG-CHICAGO, V143, P990, DOI 10.1001/archsurg.143.10.990; Pratt WB, 2008, J GASTROINTEST SURG, V12, P1207, DOI 10.1007/s11605-008-0467-1; Rigg JRA, 2002, LANCET, V359, P1276, DOI 10.1016/S0140-6736(02)08266-1; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; Sakowska M, 2009, WORLD J SURG, V33, P1802, DOI 10.1007/s00268-009-0131-2; Senagore AJ, 2003, BRIT J SURG, V90, P1195, DOI 10.1002/bjs.4223; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Werawatganon T, 2005, COCHRANE DATABASE SY, V1; World Medical Association General Assembly, 2004, J Int Bioethique, V15, P124; World Medical Association Inc, 2009, J Indian Med Assoc, V107, P403; Wu CL, 2005, ANESTHESIOLOGY, V103, P1079, DOI 10.1097/00000542-200511000-00023	30	6	6	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	APR	2014	43	3					373	379		10.1097/MPA.0000000000000031			7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	AD3SQ	WOS:000333166800008	24622066				2020-06-30	J	Osborne, V; Layton, D; Fogg, C; Al-Shukri, M; Shakir, SAW				Osborne, V.; Layton, D.; Fogg, C.; Al-Shukri, M.; Shakir, S. A. W.			Utilization of fentanyl buccal tablets in England: Exploring off-label use reported in a cohort study	EUROPEAN JOURNAL OF PAIN			English	Article							OPIOID-TOLERANT PATIENTS; ADVERSE DRUG-REACTIONS; BREAKTHROUGH PAIN; GENERAL-PRACTICE; DOUBLE-BLIND; RELIEF	BackgroundFentanyl citrate buccal tablets are indicated for the treatment of breakthrough pain (BTP) in cancer, in adults who are receiving maintenance opioid therapy for chronic cancer pain. ObjectiveOne of the objectives of this study was to describe the utilization characteristics of patients prescribed fentanyl buccal and to assess how the product is being used in relation to the terms of license of marketing approval. MethodsAn observational post-marketing cohort study was conducted. For the analysis of this study, exposure data were collected from dispensed prescriptions issued by general practitioners (GPs) between March 2009 and June 2011. Outcome data (indication, event, patient demographic and selected clinical characteristics) were collected by sending questionnaires to GPs at least 6 months after the drug was first prescribed. Summary descriptive statistics were calculated. ResultsThe cohort consisted of 551 patients, of which 54.8% (n=302 patients) were female. The median age for the cohort was 62 years (interquartile range: 50-72 years), with one patient (0.2%) aged less than 18 years. A primary indication of BTP in cancer was reported for 61.9% (n=341) patients. Regular opioid therapy was reported upon starting the treatment for 383 patients (69.5% of cohort). In total, 69 patients (12.5%) had one or more contraindications for use. The most frequent initial titration dose was 100g/day (n=247). ConclusionsThe final study results show that fentanyl buccal is largely being prescribed according to the terms of the license in general practice in England, but off-licence use and use in the presence of contraindications and warnings have been reported.	[Osborne, V.; Layton, D.; Fogg, C.; Al-Shukri, M.; Shakir, S. A. W.] Drug Safety Res Unit, Southampton, Hants, England; [Osborne, V.; Layton, D.; Fogg, C.; Shakir, S. A. W.] Univ Portsmouth, Sch Pharm & Biomed Sci, Portsmouth PO1 2UP, Hants, England	Osborne, V (reprint author), Drug Safety Res Unit, Southampton, Hants, England.	vicki.osborne@dsru.org		Osborne, Vicki/0000-0002-3669-6084	Cephalon	The Drug Safety Research Unit (DSRU) is an independent charity (No. 327206) that works in association with the University of Portsmouth. It receives unconditional donations from pharmaceutical companies. The companies have no control on the conduct or the publication of the studies conducted by the DSRU. The unit has received such funds from the manufacturer of fentanyl buccal tablets (Cephalon). The DSRU retained its academic independence with respect to the conduct of the study and external communications of the results of the study.	Ashburn MA, 2011, ANESTH ANALG, V112, P693, DOI 10.1213/ANE.0b013e318209d320; Ballantyne JC, 2011, ANESTHESIOLOGY, V114, P243, DOI 10.1097/ALN.0b013e3182039f87; British Medical Association Board of Sciences, 2006, REP ADV DRUG REACT G; Cephalon, 2010, SUMM PROD CHAR EFF 1; Cephalon Inc, 2006, FENT EFF BUCC TABL C; *CIOMS WHO, 2002, [No title captured]; Farrar JT, 2010, PAIN MED, V11, P1313, DOI 10.1111/j.1526-4637.2010.00939.x; *GEN MED COUNC, 2004, FREQ ASK QUEST SUPPL, P9; Heeley E, 2001, LANCET, V358, P1872, DOI 10.1016/S0140-6736(01)06898-2; Layton D., 2011, DRUG SAF; Martin K, 2004, BRIT J CLIN PHARMACO, V57, P86, DOI 10.1046/j.1365-2125.2003.01953.x; Martin RM, 1998, BRIT MED J, V317, P119, DOI 10.1136/bmj.317.7151.119; McAvoy BR, 1996, BRIT MED J, V313, P732; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Royal College of Physicians of London, 1996, GUID MAN COL CANC, P3; SHAKIR SAW, 2007, PHARMACOVIGILANCE, P307; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007	18	3	3	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	APR	2014	18	4					506	512		10.1002/j.1532-2149.2013.00389.x			7	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	AC0IH	WOS:000332177500006	24038573				2020-06-30	J	Mangar, D; Karlnoski, RA; Sprenker, CJ; Downes, KL; Taffe, N; Wainwright, R; Gustke, K; Bernasek, TL; Camporesi, E				Mangar, Devanand; Karlnoski, Rachel A.; Sprenker, Collin J.; Downes, Katheryne L.; Taffe, Narrene; Wainwright, Robert; Gustke, Kenneth; Bernasek, Thomas L.; Camporesi, Enrico			Knee strength retention and analgesia with continuous perineural fentanyl infusion after total knee replacement: randomized controlled trial	JOURNAL OF ANESTHESIA			English	Article						Total knee arthroplasty; Femoral nerve block; Fentanyl; Knee strength; Knee flexion and extension	FEMORAL NERVE BLOCK; BRACHIAL-PLEXUS BLOCK; POSTOPERATIVE PAIN; IMPROVES ANALGESIA; REHABILITATION; ROPIVACAINE; ARTHROPLASTY; MANAGEMENT; OPIOIDS; HIP	Purpose Despite providing adequate pain relief, a femoral nerve block can induce postoperative muscle weakness after total knee arthoplasty (TKA). Fentanyl has been shown to have peripheral effects but has not been used as a perineural infusate alone after TKA. Methods Sixty patients scheduled for TKA were randomized to one of three blinded groups: a continuous 24 h infusion of either fentanyl 3 mu g/ml, ropivacaine 0.1 %, or 0.9 % normal saline through a femoral nerve sheath catheter at 10 ml/h. The main outcome was maximum voluntary isometric contraction (MVIC) in the quadriceps femoris (knee extension), measured by a handheld dynamometer (Nm/kg). Other variables assessed were preoperative and postoperative visual analog scale (VAS) scores, hamstrings MVIC (knee flexion), active range of motion of the operative knee, distance ambulated, incidence of knee buckling, supplemental morphine usage, postoperative side effects, and serum fentanyl levels. Results Quadriceps MVIC values were significantly greater in the fentanyl group compared to the group that received ropivacaine (median values, 0.08 vs. 0.03 Nm/kg; p = 0.028). The incidence of postoperative knee buckling upon ambulation was higher in the ropivacaine group compared to the fentanyl group, although not statistically significant (40 % vs. 15 %, respectively; p = 0.077). VAS scores while ambulating were not significantly different between the fentanyl group and the ropivacaine group (p = 0.270). Postoperative morphine consumption, nausea and vomiting, and resting VAS scores were similar among the three groups. Conclusions A continuous perineural infusion of fentanyl produced greater strength retention than ropivacaine post-TKA.	[Mangar, Devanand; Karlnoski, Rachel A.; Sprenker, Collin J.; Taffe, Narrene; Wainwright, Robert; Camporesi, Enrico] Florida Gulf Bay Anesthesiol Associates LLC, Tampa, FL 33606 USA; [Karlnoski, Rachel A.; Camporesi, Enrico] Univ S Florida, Dept Surg, Tampa, FL 33620 USA; [Sprenker, Collin J.] SUNY Stony Brook, Phys Assistant Program, Stony Brook, NY 11794 USA; [Downes, Katheryne L.] Univ S Florida, Biostat CORE, Tampa, FL USA; [Taffe, Narrene; Wainwright, Robert] Univ N Florida, Nurse Anesthesia Program, Jacksonville, FL USA; [Gustke, Kenneth; Bernasek, Thomas L.] Univ S Florida, Florida Orthoped Inst, Dept Orthoped Surg, Tampa, FL USA; [Camporesi, Enrico] Univ S Florida, Tampa Gen Hosp, Coll Med, Tampa, FL 33620 USA	Camporesi, E (reprint author), Univ S Florida, Tampa Gen Hosp, Coll Med, Tampa, FL 33620 USA.	ecampore@health.usf.edu					Allen HW, 1998, ANESTH ANALG, V87, P93, DOI 10.1097/00000539-199807000-00020; Bauer M, 2012, ANESTHESIOLOGY, V116, P665, DOI 10.1097/ALN.0b013e3182475c35; Borgeat A, 2001, ANESTH ANALG, V92, P218; Capdevila X, 1999, ANESTHESIOLOGY, V91, P8, DOI 10.1097/00000542-199907000-00006; Charous MT, 2011, ANESTHESIOLOGY, V115, P774, DOI 10.1097/ALN.0b013e3182124dc6; EDWARDS ND, 1992, ANESTH ANALG, V75, P265; Fanelli G, 2001, ACTA ANAESTH SCAND, V45, P590, DOI 10.1034/j.1399-6576.2001.045005590.x; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Ilfeld BM, 2010, ANESTH ANALG, V111, P1552, DOI 10.1213/ANE.0b013e3181fb9507; Ilfeld BM, 2009, REGION ANESTH PAIN M, V34, P85, DOI 10.1097/AAP.0b013e3181962547; Kwoh CK, 1997, ARTHRIT CARE RES, V10, P128, DOI 10.1002/art.1790100208; Leffler A, 2012, ANESTHESIOLOGY, V116, P1335, DOI 10.1097/ALN.0b013e3182557917; Magistris L, 2000, EUR J ANAESTH, V17, P348, DOI 10.1046/j.1365-2346.2000.00685.x; Mangar D, 2010, P 20 ANN M AM ASS HI, P72; Martin HJ, 2006, GERONTOLOGY, V52, P154, DOI 10.1159/000091824; Mascha EJ, 2012, ANESTH ANALG, V114, P1304, DOI 10.1213/ANE.0b013e3182504435; Moshourab R, 2012, J NEUROPHYSIOL, V108, P2827, DOI 10.1152/jn.00082.2012; Murphy DB, 2000, ANESTH ANALG, V90, P1122, DOI 10.1097/00000539-200005000-00023; Nishikawa K, 2000, ANESTH ANALG, V91, P384, DOI 10.1097/00000539-200008000-00028; Paauwe JJ, 2008, ANAESTHESIA, V63, P948, DOI 10.1111/j.1365-2044.2008.05538.x; Paul JE, 2010, ANESTHESIOLOGY, V113, P1144, DOI 10.1097/ALN.0b013e3181f4b18; Picard PR, 1997, PAIN, V72, P309, DOI 10.1016/S0304-3959(97)00040-7; RAJ PP, 1987, ANESTH ANALG, V66, P401, DOI 10.1213/00000539-198705000-00005; Richman JM, 2006, ANESTH ANALG, V102, P248, DOI 10.1213/01.ANE.0000181289.09675.7D; Singelyn FJ, 1998, ANESTH ANALG, V87, P88, DOI 10.1097/00000539-199807000-00019; STEIN C, 1993, ANESTH ANALG, V76, P182; Stein C, 2009, CURR OPIN PHARMACOL, V9, P3, DOI 10.1016/j.coph.2008.12.009; Wang H, 2002, REGION ANESTH PAIN M, V27, P139, DOI 10.1053/rapm.2002.29253; Williams BA, 2004, ANESTHESIOLOGY, V100, P697, DOI 10.1097/00000542-200403000-00034	29	4	4	0	5	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	APR	2014	28	2					214	221		10.1007/s00540-013-1700-y			8	Anesthesiology	Anesthesiology	AF0PU	WOS:000334417300010	23978948				2020-06-30	J	Kim, JE; Min, SK; Chae, YJ; Lee, YJ; Moon, BK; Kim, JY				Kim, Ji Eun; Min, Sang Kee; Chae, Yun Jeong; Lee, Yeon Ju; Moon, Bong Ki; Kim, Jong Yeop			Pharmacological and nonpharmacological prevention of fentanyl-induced cough: a meta-analysis	JOURNAL OF ANESTHESIA			English	Review						Anesthesia; Fentanyl-induced cough; Meta-analysis; Prevention	PROLONGED INJECTION TIME; DOUBLE-BLIND; INTRAVENOUS LIDOCAINE; ANESTHESIA INDUCTION; PREMEDICATION; PRETREATMENT; PROPOFOL; KETAMINE	Fentanyl-induced cough (FIC) is often observed after intravenous bolus administration of fentanyl during anesthesia induction. This meta-analysis assessed the efficacy of pharmacological and nonpharmacological interventions to reduce the incidence of FIC. We searched for randomized controlled trials comparing pharmacological or nonpharmacological interventions with controls to prevent FIC; we included 28 studies retrieved from PubMed, Embase, and Cochrane Library. Overall incidence of FIC was approximately 31 %. Lidocaine [odds ratio (OR) = 0.29, 95 % confidence interval (CI) 0.21-0.39], N-methyl-D-aspartate (NMDA) receptor antagonists (OR 0.09, 95 % CI 0.02-0.42), propofol (OR 0.07, 95 % CI 0.01-0.36), alpha(2) agonists (OR 0.32, 95 % CI 0.21-0.48), beta(2) agonists (OR 0.10, 95 % CI 0.03-0.30), fentanyl priming (OR 0.33, 95 % CI 0.19-0.56), and slow injection of fentanyl (OR 0.25, 95 % CI 0.11-0.58)] were effective in decreasing the incidence of FIC, whereas atropine (OR 1.10, 95 % CI 0.58-2.11) and benzodiazepines (OR 2.04, 95 % CI 1.33-3.13) were not effective. This meta-analysis found that lidocaine, NMDA receptor antagonists, propofol, alpha(2) agonists, beta(2) agonists, and priming dose of fentanyl were effective in preventing FIC, but atropine and benzodiazepines were not. Slow injection of fentanyl was effective in preventing FIC, but results depend on the speed of administration.	[Kim, Ji Eun] Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul, South Korea; [Min, Sang Kee; Chae, Yun Jeong; Lee, Yeon Ju; Moon, Bong Ki; Kim, Jong Yeop] Ajou Univ, Sch Med, Dept Anesthesiol & Pain Med, Suwon 443721, South Korea	Kim, JY (reprint author), Ajou Univ, Sch Med, Dept Anesthesiol & Pain Med, San 5, Suwon 443721, South Korea.	kjyeop@ajou.ac.kr		/0000-0002-4854-3907			Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; Ai Q, 2010, PHARMACOL REP, V62, P747, DOI 10.1016/S1734-1140(10)70333-9; Ambesh SP, 2010, BRIT J ANAESTH, V104, P40, DOI 10.1093/bja/aep333; Ambesh SP, 2009, INT J ANESTHESIOL, V20, P7; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; Chen Ye-ming, 2009, Nan Fang Yi Ke Da Xue Xue Bao, V29, P339; Cheng EY, 1996, ANESTH ANALG, V83, P162, DOI 10.1097/00000539-199607000-00028; Dimitriou V, 2006, Middle East Journal of Anesthesiology, V18, P943; Elmenesy TM, 2011, EGYPT J ANAESTH, V27, P25, DOI 10.1016/j.egja.2011.01.003; Ferrari J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000964.pub3; Gu CY, 2012, PHARMACOL REP, V64, P321, DOI 10.1016/S1734-1140(12)70771-5; Guler G, 2010, CURR THER RES CLIN E, V71, P289, DOI 10.1016/j.curtheres.2010.10.004; He L, 2012, UPSALA J MED SCI, V117, P18, DOI 10.3109/03009734.2011.629749; Horng HC, 2007, ACTA ANAESTH SCAND, V51, P862, DOI 10.1111/j.1399-6576.2007.01335.x; Horng Huei-Chi, 2012, Acta Anaesthesiol Taiwan, V50, P147, DOI 10.1016/j.aat.2012.12.003; Hung KC, 2010, ANAESTHESIA, V65, P4, DOI 10.1111/j.1365-2044.2009.06109.x; HUNG KC, 2009, ACTA ANAESTH SCAND, V53, P1227; Jung HJ, 2011, J INT MED RES, V39, P2379, DOI 10.1177/147323001103900638; Kamei Junzo, 2013, Cough, V9, P3, DOI 10.1186/1745-9974-9-3; Kim JY, 2012, KOREAN J ANESTHESIOL, V63, P30, DOI 10.4097/kjae.2012.63.1.30; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; Lui PW, 1996, CAN J ANAESTH, V43, P1216; Moher D, 2009, PHYS THER, V89, P873, DOI 10.1093/ptj/89.9.873; Mukherjee Avik, 2011, J Anaesthesiol Clin Pharmacol, V27, P489, DOI 10.4103/0970-9185.86593; Pandey CK, 2005, CAN J ANAESTH, V52, P172, DOI 10.1007/BF03027724; Pandey CK, 2004, ANESTH ANALG, V99, P1696, DOI 10.1213/01.ANE.0000136967.82197.82; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; POULTON TJ, 1979, ANESTHESIOLOGY, V50, P470, DOI 10.1097/00000542-197905000-00018; Schapermeier U, 2008, ACTA ANAESTH SCAND, V52, P1071, DOI 10.1111/j.1399-6576.2008.01721.x; Schlimp CJ, 2005, CAN J ANAESTH, V52, P207, DOI 10.1007/BF03027731; Shrestha S K, 2012, Kathmandu Univ Med J (KUMJ), V10, P16; Sun ZT, 2011, J ANESTH, V25, P860, DOI 10.1007/s00540-011-1237-x; Tang QF, 2010, UPSALA J MED SCI, V115, P121, DOI 10.3109/03009730903291034; Terrin N, 2005, J CLIN EPIDEMIOL, V58, P894, DOI 10.1016/j.jclinepi.2005.01.006; Thornton A, 2000, J CLIN EPIDEMIOL, V53, P207, DOI 10.1016/S0895-4356(99)00161-4; Tweed WA, 2001, ANESTH ANALG, V92, P1442; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Yakici U, 2013, ANESTZI DERGISI, V1, P17; YASUDA I, 1978, ANESTHESIOLOGY, V49, P117, DOI 10.1097/00000542-197808000-00012; Yeh CC, 2007, J CLIN ANESTH, V19, P53, DOI 10.1016/j.jclinane.2006.05.021; Yu H, 2007, ANAESTHESIA, V62, P919, DOI 10.1111/j.1365-2044.2007.05147.x; Yu J, 2012, IRISH J MED SCI, V181, P517, DOI 10.1007/s11845-012-0807-8	43	13	18	0	5	SPRINGER JAPAN KK	TOKYO	SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	APR	2014	28	2					257	266		10.1007/s00540-013-1695-4			10	Anesthesiology	Anesthesiology	AF0PU	WOS:000334417300016	23958914				2020-06-30	J	Nomura, Y; Kawaraguchi, Y; Sugimoto, H; Furuya, H; Kawaguchi, M				Nomura, Yasumitsu; Kawaraguchi, Yoshitaka; Sugimoto, Hiroshi; Furuya, Hitoshi; Kawaguchi, Masahiko			Effects of morphine and fentanyl on 5-fluorouracil sensitivity in human colon cancer HCT116 cells	JOURNAL OF ANESTHESIA			English	Article						Opioid; Colon cancer; 5-Fluorouracil	ANESTHETIC TECHNIQUE; RETROSPECTIVE ANALYSIS; OPIOID RECEPTOR; APOPTOSIS; RECURRENCE; ADENOCARCINOMA; ACTIVATION; PATHWAYS; GROWTH; DEATH	Opioids are widely used for perioperative pain management in cancer surgery patients. It has been reported that opioids may alter cancer recurrence or progression; however, there are no published reports regarding the effects of opioids on chemotherapy after cancer surgery. Here we investigated the effects of opioids (morphine or fentanyl) on cell proliferation and 5-fluorouracil sensitivity in the human colon cancer cell line, HCT116. First, we exposed cancer cells to the opioid at various concentrations for 6 or 24 h and evaluated cell proliferation using a MTT assay. Next, to simulate the potential postoperative situation in which anticancer drugs are administered after cancer surgery, cancer cells were incubated with the opioid for 6 or 24 h, followed by treatment with 5-fluorouracil for 48 h. Although fentanyl did not affect cell proliferation, morphine exposure for 6 h enhanced the proliferation. However, sensitivity of HCT116 cells to 5-fluorouracil was not altered in all treatment groups. The current study demonstrated that the opioids commonly used during postoperative periods do not affect 5-fluorouracil sensitivity in human colon cancer HCT116 cells.	[Nomura, Yasumitsu; Kawaraguchi, Yoshitaka; Sugimoto, Hiroshi; Furuya, Hitoshi; Kawaguchi, Masahiko] Nara Med Univ, Dept Anesthesiol, Kashihara, Nara, Japan	Kawaraguchi, Y (reprint author), Nara Med Univ, Dept Anesthesiol, 840 Shijo Cho, Kashihara, Nara, Japan.	ykawara@naramed-u.ac.jp					Biki B, 2008, ANESTHESIOLOGY, V109, P180, DOI 10.1097/ALN.0b013e31817f5b73; Eisenstein TK, 1998, J NEUROIMMUNOL, V83, P36, DOI 10.1016/S0165-5728(97)00219-1; Exadaktylos AK, 2006, ANESTHESIOLOGY, V105, P660, DOI 10.1097/00000542-200610000-00008; Gupta K, 2002, CANCER RES, V62, P4491; Lazarczyk M, 2010, PEPTIDES, V31, P1606, DOI 10.1016/j.peptides.2010.05.002; Leo Sandra, 2009, J Pain Res, V2, P59; Lin L, 2011, BRIT J ANAESTH, V106, P814, DOI 10.1093/bja/aer055; Lin X, 2007, BIOCHEM J, V406, P215, DOI 10.1042/BJ20070186; Lin X, 2009, FEBS J, V276, P2022, DOI 10.1111/j.1742-4658.2009.06938.x; Mathew B, 2011, ANESTH ANALG, V112, P558, DOI 10.1213/ANE.0b013e31820568af; Odunayo A, 2010, J VET EMERG CRIT CAR, V20, P376, DOI 10.1111/j.1476-4431.2010.00561.x; PETERSON PK, 1993, BIOCHEM PHARMACOL, V46, P343, DOI 10.1016/0006-2952(93)90508-T; Sacerdote P, 1997, BRIT J PHARMACOL, V121, P834, DOI 10.1038/sj.bjp.0701138; Singleton PA, 2010, FUTURE ONCOL, V6, P1237, DOI [10.2217/fon.10.99, 10.2217/FON.10.99]; Suzuki S, 2003, BIOCHEM BIOPH RES CO, V308, P802, DOI 10.1016/S0006-291X(03)01472-4; Tegeder I, 2003, CANCER RES, V63, P1846; Wang CZ, 2009, ANTICANCER RES, V29, P2927; YEAGER MP, 1991, ARCH SURG-CHICAGO, V126, P454; Yin DL, 2006, J NEUROIMMUNOL, V174, P101, DOI 10.1016/j.jneuroim.2006.02.001; Zagon IS, 2003, NEUROPEPTIDES, V37, P79, DOI 10.1016/S0143-4179(03)00007-6; Zhao M, 2009, NEOPLASMA, V56, P108, DOI 10.4149/neo_2009_02_108	21	7	9	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	APR	2014	28	2					298	301		10.1007/s00540-013-1717-2			4	Anesthesiology	Anesthesiology	AF0PU	WOS:000334417300022	24097124				2020-06-30	J	Melcer, T; Walker, J; Sechriest, VF; Lebedda, M; Quinn, K; Galarneau, M				Melcer, Ted; Walker, Jay; Sechriest, V. Franklin, II; Lebedda, Martin; Quinn, Kimberly; Galarneau, Michael			Glasgow Coma Scores, Early Opioids, and Posttraumatic Stress Disorder Among Combat Amputees	JOURNAL OF TRAUMATIC STRESS			English	Article							TRAUMATIC BRAIN-INJURY; SYMPTOMS; MORPHINE; IRAQ; PTSD	A recent study found that combat amputees had a reduced prevalence of posttraumatic stress disorder (PTSD) compared with nonamputees with serious extremity injuries. We hypothesized that an extended period of impaired consciousness or early treatment with morphine could prevent consolidation of traumatic memory and the development of PTSD. To examine this hypothesis, we retrospectively reviewed 258 combat casualty records from the Iraq or Afghanistan conflicts from 2001-2008 in the Expeditionary Medical Encounter Database, including medications and Glasgow Coma Scale (GCS) scores recorded at in-theater facilities within hours of the index injury. All patients sustained amputations from injuries. Psychological diagnoses were extracted from medical records for 24 months postinjury. None of 20 patients (0%) with GCS scores of 12 or lower had PTSD compared to 20% of patients with GCS scores of 12 or greater who did have PTSD. For patients with traumatic brain injury, those treated with intravenous morphine within hours of injury had a significantly lower prevalence of PTSD (6.3%) and mood disorders (15.6%) compared to patients treated with fentanyl only (prevalence of PTSD = 41.2%, prevalence of mood disorder = 47.1%). GCS scores and morphine and fentanyl treatments were not significantly associated with adjustment, anxiety, or substance abuse disorders.	[Melcer, Ted; Walker, Jay; Quinn, Kimberly; Galarneau, Michael] Naval Hlth Res Ctr, Dept Med Modeling & Simulat & Mission Support, San Diego, CA 92106 USA; [Sechriest, V. Franklin, II] Orthoped Med Grp, San Diego, CA USA; [Lebedda, Martin] Naval Med Ctr, San Diego, CA USA	Melcer, T (reprint author), Naval Hlth Res Ctr, Med Modeling & Simulat Dept, 140 Sylvester Rd, San Diego, CA 92106 USA.	ted.melcer@med.navy.mil					AC Hart, 2008, ICD 9 CM PROFESSIONA; Andero R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005656; Armed Forces Health Surveillance Center, 2011, MED SURVEILLANCE MON, V18, P17; Benedek DM, 2007, MIL MED, V172, P681; Black IH, 2009, PREHOSP EMERG CARE, V13, P223, DOI 10.1080/10903120802290778; Brown TA, 2001, J ABNORM PSYCHOL, V110, P585, DOI 10.1037//0021-843X.110.4.585; Bryant RA, 2009, BIOL PSYCHIAT, V65, P438, DOI 10.1016/j.biopsych.2008.10.032; Centers for Disease Control and Prevention, 2012, BLAST INJ TRAUM BRAI; Centers for Disease Control and Prevention, 2012, TRAUM BRAIN INJ US R; Chiu KB, 2011, ACAD EMERG MED, V18, P1156, DOI 10.1111/j.1553-2712.2011.01206.x; Claxton AR, 1997, ANESTH ANALG, V84, P509, DOI 10.1097/00000539-199703000-00008; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Fox DJ, 1995, ANESTHESIA PERIOPERA, P211; Galarneau MR, 2006, MIL MED, V171, P691, DOI 10.7205/MILMED.171.8.691; Gravely AA, 2011, J REHABIL RES DEV, V48, P21, DOI 10.1682/JRRD.2009.08.0116; Hart AC, 2008, ICD 9 CM PROFESSIONA; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Holbrook TL, 2010, NEW ENGL J MED, V362, P110, DOI 10.1056/NEJMoa0903326; Kacprowicz R. F., 2008, J SPEC OPER MED, V8, P48, DOI [10.1097/TA. 0b013e3182754674, DOI 10.1097/TA.0B013E3182754674]; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; MacGregor AJ, 2009, MIL MED, V174, P224, DOI 10.7205/MILMED-D-03-9107; McGhee LL, 2011, J BURN CARE RES, V32, P46, DOI 10.1097/BCR.0b013e318204b359; Melcer T, 2013, J ORTHOP TRAUMA, V27, pE31, DOI 10.1097/BOT.0b013e3182517e1c; Pasternak GW, 2012, PAIN MED, V13, pS4, DOI 10.1111/j.1526-4637.2012.01335.x; Pittman JOE, 2012, QUAL LIFE RES, V21, P99, DOI 10.1007/s11136-011-9918-3; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Steckler T, 2012, NEUROPHARMACOLOGY, V62, P617, DOI 10.1016/j.neuropharm.2011.06.012; Stoddard FJ, 2009, J BURN CARE RES, V30, P836, DOI 10.1097/BCR.0b013e3181b48102; Sumpter RE, 2006, BRAIN INJURY, V20, P93, DOI 10.1080/02699050500394090; TEASDALE G, 1974, LANCET, V2, P81; Wain HJ, 2009, CARE COMBAT AMPUTEE, P265	33	8	9	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-9867	1573-6598		J TRAUMA STRESS	J. Trauma Stress	APR	2014	27	2					152	159		10.1002/jts.21909			8	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	AF2II	WOS:000334535400005	24668780				2020-06-30	J	Nath, SS; Tripathi, M; Banerjee, S				Nath, Soumya S.; Tripathi, Mukesh; Banerjee, Sudipto			Propofol and Fentanyl Take Longer for Induction of Anesthesia in Aortic Regurgitation: A Case-Controlled Prospective Study	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						aortic regurgitation; bispectral index; induction time; propofol; fentanyl	BISPECTRAL INDEX; HEART RATE; HEMODYNAMICS; DISEASE	Objectives: This study was conducted to determine if induction time of anesthesia in patients with aortic regurgitation (AR) is different from patients with a normal aortic valve (AV). Design: A prospective, case-control study. Setting: A single institutional study conducted in a tertiary care teaching hospital. Participants: Twenty-four male patients scheduled for cardiac surgery, group I (n = 12) patients with competent AV and group 2 (n = 12) with severe AR. Interventions: General anesthesia was induced by intravenous infusion of propofol and fentanyl. Measurements and Main Results: Continuous measurements of heart rate, intra-arterial blood pressure, and bispectral index were recorded. Induction doses of propofol and fentanyl were analyzed and compared. There was significant difference between the 2 groups in terms of induction time of anesthesia (mean +/- SD 308 +/- 68.2 seconds in group 1 v 445 +/- 97.9 seconds in group 2). The patients in group 2 (AR) required significantly larger doses of propofol (0.91 +/- 0.40 mg/kg) than the patients in group 1 (0.49 +/- 0.17 mg/kg). Similarly, fentanyl dose was increased in the group 2 patients (20.8 +/- 15.9 mu g/kg) compared with the group 1 patients (9.2 +/- 2.9 mu g/kg). Conclusion: The authors concluded that there was a significant prolongation of the induction time of anesthesia and the need of larger doses of propofol and fentanyl by slow intravenous infusion regimen in patients with AR compared with patients with a competent aortic valve. (C) 2014 Elsevier Inc. All rights reserved.	[Nath, Soumya S.] Sahara Hosp, Dept Anesthesiol, Lucknow, Uttar Pradesh, India; [Tripathi, Mukesh] Sanjay Gandhi Post Grad Inst Med Sci, Dept Anaesthesiol, Lucknow 226010, Uttar Pradesh, India; [Banerjee, Sudipto] Medanta Medicity, Dept Anaesthesiol, Gurgaon, India	Tripathi, M (reprint author), Sanjay Gandhi Post Grad Inst Med Sci, Lucknow 226010, Uttar Pradesh, India.	mukesh_tripathi@yahoo.com	Tripathi, Mukesh/U-8188-2019				Adachi YU, 2001, ANESTH ANALG, V92, P656, DOI 10.1213/00000539-200103000-00020; Baumert JH, 2005, ACTA ANAESTH SCAND, V49, P743, DOI 10.1111/j.1399-6576.2005.00662.x; BRAWLEY RK, 1967, CIRCULATION, V35, P32, DOI 10.1161/01.CIR.35.1.32; Drumm C, 2010, ESSENTIALS CRITICAL, P323; El-Tahan MR, 2011, ANN CARD ANAESTH, V14, P30, DOI 10.4103/0971-9784.74397; Enriquez-Sarano M, 2004, NEW ENGL J MED, V351, P1539, DOI 10.1056/NEJMcp030912; Goyal P, 2002, ANAESTH INTENS CARE, V30, P584, DOI 10.1177/0310057X0203000506; Haessler R, 1992, J Cardiothorac Vasc Anesth, V6, P173, DOI 10.1016/1053-0770(92)90193-B; JUDGE TP, 1971, CIRCULATION, V44, P355, DOI 10.1161/01.CIR.44.3.355; Kazama T, 1999, ANESTHESIOLOGY, V90, P1517, DOI 10.1097/00000542-199906000-00004; LEPAGE JYM, 1988, ANESTH ANALG, V67, P949; Lysakowski C, 2001, BRIT J ANAESTH, V86, P523, DOI 10.1093/bja/86.4.523; O'Gara P, 2008, HARRISONS PRINCIPLES, P1465; Otto CM, 2011, BONOW BRAUNWALDS HEA, P1478; ROTHLIN M, 1968, Z KREISLAUFFORSCH, V57, P497; SCHENK WG, 1961, ANN SURG, V154, P295, DOI 10.1097/00000658-196108000-00017; Schnider TW, 1999, ANESTHESIOLOGY, V90, P1502, DOI 10.1097/00000542-199906000-00003; SIGL JC, 1994, J CLIN MONITOR, V10, P392, DOI 10.1007/BF01618421; Tripathi M, 2008, BRIT J ANAESTH, V101, P576, DOI 10.1093/bja/aen257; Tripathi M, 2009, ANN CARD ANAESTH, V12, P34, DOI 10.4103/0971-9784.45011	20	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	APR	2014	28	2					290	294		10.1053/j.jvca.2013.05.038			5	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	AD8VS	WOS:000333544400014	24064202				2020-06-30	J	Law, CJ; Jacobson, GM; Kluger, M; Chaddock, M; Scott, M; Sleigh, JW				Law, C. J.; Jacobson, G. M.; Kluger, M.; Chaddock, M.; Scott, M.; Sleigh, J. W.			Randomized controlled trial of the effect of depth of anaesthesia on postoperative pain	BRITISH JOURNAL OF ANAESTHESIA			English	Article						depth of anaesthesia; postoperative pain	NITROUS-OXIDE; BISPECTRAL INDEX; DESFLURANE; REQUIREMENTS; SEVOFLURANE; PROPOFOL	Our hypothesis was that deep anaesthesia, as estimated by a low target bispectral index (BIS) of 3040, would result in less postoperative pain than that achieved at a conventional depth of anaesthesia. We undertook a randomized double-blind controlled study at two tertiary teaching hospitals in New Zealand (20101) recruiting 135 adult patients ASA III presenting for non-emergent surgery under general anaesthesia requiring tracheal intubation. Anaesthesia was maintained with desflurane and a multimodal analgesia regimen comprising fentanyl infusion, i.v. paracetamol, and parecoxib. Patients were randomly assigned to either a low BIS (3040) group or a high BIS (4560) group. Desflurane concentrations were titrated to achieve these targets. Postoperative pain was assessed by: the pain on awakening (010, verbal rating scale, VRSawake) in the post-anaesthetic care unit; pain on activity at 2024 h after operation (VRSd1A); and the rate of morphine patient-controlled analgesia (PCA) usage over the first 24 h. There was no statistically significant difference between the two groups for any of the pain scores. The median [inter-quartile range (IQR)] VRSawake was 4.0 (08) for the low and 4.0 (08) for the high BIS groups (P0.56). The median (IQR) VRSd1A was 3.0 (15) for the low and 3.0 (1.54.5) for the high BIS groups (P0.83). The median PCA morphine consumption in the low BIS group was 0.61 mg h(1) (0.041.5) vs 0.43 mg h(1) (01.59) in the high BIS group (P0.98). We conclude that there is no clinically useful analgesic effect of a deep anaesthesia regimen.	[Law, C. J.] Anglesea Hosp, Knox St Clin, Dept Anaesthesia, Hamilton Waikato 3204, New Zealand; [Jacobson, G. M.] Univ Waikato, Dept Biol Sci, Hamilton, New Zealand; [Kluger, M.; Chaddock, M.] Waitemata Dist Hlth Board, Auckland, New Zealand; [Scott, M.] Nelson Hosp, Dept Anaesthesia, Nelson, New Zealand; [Sleigh, J. W.] Univ Auckland, Waikato Clin Sch, Hamilton, New Zealand	Law, CJ (reprint author), Anglesea Hosp, Knox St Clin, Dept Anaesthesia, POB 228, Hamilton Waikato 3204, New Zealand.	drcozi@xtra.co.nz	Jacobson, Gregory/AAJ-4670-2020	Jacobson, Gregory/0000-0003-2804-274X	Australian and New Zealand College of Anaesthetists; University of Waikato; Fitzgibbon Research Fund, University of Auckland	This study was funded by Research Grants from the Australian and New Zealand College of Anaesthetists (C.J.L. and G.M.J.); University of Waikato (G.M.J.); and the Fitzgibbon Research Fund, University of Auckland.	Baldini G, 2008, ACTA ANAESTH SCAND, V52, P99, DOI 10.1111/j.1399-6576.2007.01470.x; Bessiere B, 2007, NEUROPHARMACOLOGY, V53, P733, DOI 10.1016/j.neuropharm.2007.08.003; Chan MTV, 2011, PAIN, V152, P2514, DOI 10.1016/j.pain.2011.07.015; Gupta A, 2004, ANESTH ANALG, V98, P632, DOI 10.1213/01.ANE.0000103187.70627.57; Gurman GM, 2003, ACTA ANAESTH SCAND, V47, P804, DOI 10.1034/j.1399-6576.2003.00148.x; Henneberg SW, 2005, ACTA ANAESTH SCAND, V49, P293, DOI 10.1111/j.1399-6576.2005.00598.x; Hong JY, 2008, EUR J ANAESTH, V25, P460, DOI 10.1017/S026502150800375X; KEHLET H, 1982, ACTA ANAESTH SCAND, V26, P173, DOI 10.1111/j.1399-6576.1982.tb01872.x; Merry AF, 2001, ANESTH ANALG, V93, P385, DOI 10.1097/00000539-200108000-00030; Richebe P, 2005, ANESTHESIOLOGY, V103, P845, DOI 10.1097/00000542-200510000-00024; Sahni Neeru, 2012, J Anaesthesiol Clin Pharmacol, V28, P266, DOI 10.4103/0970-9185.94920; Sessler DI, 2012, ANESTHESIOLOGY, V116, P1195, DOI 10.1097/ALN.0b013e31825683dc; Soumpasis I, 2010, EUR J ANAESTH, V27, P801, DOI 10.1097/EJA.0b013e328337cbf4; WHITE PF, 1992, ANESTH ANALG, V75, pS47; White PF, 1992, ANESTH ANALG, V75, pS53; Whitlock EL, 2011, ANESTHESIOLOGY, V115, P1209, DOI 10.1097/ALN.0b013e3182395dcb	16	6	6	0	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	APR	2014	112	4					675	680		10.1093/bja/aet419			6	Anesthesiology	Anesthesiology	AD4WC	WOS:000333251000011	24322572	Bronze			2020-06-30	J	Czarnecki, ML; Hainsworth, K; Simpson, PM; Arca, MJ; Uhing, MR; Varadarajan, J; Weisman, SJ				Czarnecki, Michelle L.; Hainsworth, Keri; Simpson, Pippa M.; Arca, Marjorie J.; Uhing, Michael R.; Varadarajan, Jaya; Weisman, Steven J.			Is there an alternative to continuous opioid infusion for neonatal pain control? A preliminary report of parent/nurse-controlled analgesia in the neonatal intensive care unit	PEDIATRIC ANESTHESIA			English	Article						opioid infusion; pediatric; parent/nurse-controlled analgesia; neonate; patient-controlled devices by proxy; pain management	PATIENT-CONTROLLED ANALGESIA; RANDOMIZED CONTROLLED-TRIAL; LOWER ABDOMINAL-SURGERY; MORPHINE REQUIREMENTS; POSTOPERATIVE INFANTS; BACKGROUND INFUSION; MAJOR SURGERY; CHILDREN; MANAGEMENT; PREVENTION	Background Continuous opioid infusion (COI) remains the mainstay of analgesic therapy in the neonatal intensive care unit (NICU). Parent/nurse-controlled analgesia (PNCA) has been accepted as safe and effective for pediatric patients, but few reports include use in neonates. This study sought to compare outcomes of PNCA and COI in postsurgical neonates and young infants. Methods Twenty infants treated with morphine PNCA were retrospectively compared with 13 infants treated with fentanyl COI in a Midwestern pediatric hospital in the United States. Outcome measures included opioid consumption, pain scores, frequency of adverse events, and subsequent methadone use. Results The PNCA group (median 6.4 mu g center dot kg(-1)center dot h(-1) morphine equivalents, range 0.0-31.4) received significantly less opioid (P<0.001) than the COI group (median 40.0 mu g center dot kg(-1)center dot h(-1) morphine equivalents; range 20.0-153.3), across postoperative days 0-3. Average daily pain scores (based on 0-10 scale) were low for both groups, but median scores differed nonetheless (0.8 PNCA vs 0.3 COI, P<0.05). There was no significant difference in the frequency of adverse events or methadone use. Conclusion Results suggest PNCA may be a feasible and effective alternative to COI for pain management in postsurgical infants in the NICU. Results also suggest PNCA may provide more individualized care for this vulnerable population and in doing so, may potentially reduce opioid consumption; however, more studies are needed.	[Czarnecki, Michelle L.; Hainsworth, Keri; Varadarajan, Jaya; Weisman, Steven J.] Childrens Hosp Wisconsin, Jane B Pettit Pain Management Ctr, Milwaukee, WI 53201 USA; [Hainsworth, Keri; Varadarajan, Jaya; Weisman, Steven J.] Med Coll Wisconsin, Dept Anesthesiol, Milwaukee, WI 53226 USA; [Simpson, Pippa M.] Med Coll Wisconsin, Dept Quantitat Hlth Sci, Milwaukee, WI 53226 USA; [Simpson, Pippa M.; Arca, Marjorie J.; Uhing, Michael R.; Weisman, Steven J.] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA; [Arca, Marjorie J.] Med Coll Wisconsin, Dept Surg, Milwaukee, WI 53226 USA; [Uhing, Michael R.] Med Coll Wisconsin, Dept Neonatol, Milwaukee, WI 53226 USA	Czarnecki, ML (reprint author), Childrens Hosp WI, Jane B Pettit Pain Management Ctr, 9000 W Wisconsin Ave,POB 1997,MS 792, Milwaukee, WI 53201 USA.	mczarnecki@chw.org		Varadarajan, Jaya/0000-0001-5640-8097	NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000055]		Anand KJS, 2006, ARCH DIS CHILD-FETAL, V91, pF448, DOI 10.1136/adc.2005.082263; Anand KJS, 2010, PEDIATRICS, V125, pE1208, DOI 10.1542/peds.2009-0489; Anand KJS, 2006, PEDIATRICS, V117, pS9, DOI 10.1542/peds.2005-0620C; Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; Anghelescu DL, 2005, ANESTH ANALG, V101, P1623, DOI 10.1213/01.ANE.0000184198.13285.33; Berde CB, 2005, CLIN THER, V27, P900, DOI 10.1016/j.clinthera.2005.06.020; BERDE CB, 1991, J PEDIATR-US, V118, P460, DOI 10.1016/S0022-3476(05)82169-9; Berde CB, 2002, NEW ENGL J MED, V347, P1094, DOI 10.1056/NEJMra012626; Bouwmeester NJ, 2003, INTENS CARE MED, V29, P2009, DOI 10.1007/s00134-003-1899-4; Bouwmeester NJ, 2003, BRIT J ANAESTH, V90, P642, DOI 10.1093/bja/aeg121; Czarnecki ML, 2008, CLIN J PAIN, V24, P817, DOI 10.1097/AJP.0b013e3181773b69; Czarnecki ML, 2011, CLIN J PAIN, V27, P102, DOI 10.1097/AJP.0b013e3181f0972c; de Graaf J, 2011, PAIN, V152, P1391, DOI 10.1016/j.pain.2011.02.017; De Lima J, 2010, BEST PRACT RES-CLIN, V24, P291, DOI 10.1016/j.bpa.2010.04.001; DOYLE E, 1993, BRIT J ANAESTH, V71, P670, DOI 10.1093/bja/71.5.670; DOYLE E, 1993, BRIT J ANAESTH, V71, P818, DOI 10.1093/bja/71.6.818; Ferguson SA, 2012, NEUROTOXICOL TERATOL, V34, P47, DOI 10.1016/j.ntt.2011.10.008; Fitzgerald M, 2009, NAT CLIN PRACT NEURO, V5, P35, DOI 10.1038/ncpneuro0984; Franck L S, 1998, Am J Crit Care, V7, P364; Franck Linda S, 2002, Neonatal Netw, V21, P37; Hoffman GM, 2002, PEDIATRICS, V109, P236, DOI 10.1542/peds.109.2.236; Howard RF, 2010, PEDIATR ANESTH, V20, P126, DOI 10.1111/j.1460-9592.2009.03242.x; Kart T, 1997, PAEDIATR ANAESTH, V7, P93; Kelly JJ, 2006, PEDIATR ANESTH, V16, P1051, DOI 10.1111/j.1460-9592.2006.01932.x; Lemons JA, 2000, PEDIATRICS, V105, P454; Lynn AM, 2000, PAIN, V88, P89, DOI 10.1016/S0304-3959(00)00313-4; Malviya S, 2001, PAEDIATR ANAESTH, V11, P453, DOI 10.1046/j.1460-9592.2001.00686.x; Manworren Renee C B, 2003, Pediatr Nurs, V29, P140; McNeely JK, 1997, J PAIN SYMPTOM MANAG, V13, P268, DOI 10.1016/S0885-3924(96)00324-7; Monitto CL, 2000, ANESTH ANALG, V91, P573, DOI 10.1213/00000539-200009000-00014; Morton NS, 2010, PEDIATR ANESTH, V20, P119, DOI 10.1111/j.1460-9592.2009.03187.x; Orge FH, 2013, J AAPOS, V17, P135, DOI 10.1016/j.jaapos.2012.11.020; Patanwala AE, 2007, ANN PHARMACOTHER, V41, P255, DOI 10.1345/aph.1H421; PURCELLJONES G, 1987, ANAESTHESIA, V42, P1316, DOI 10.1111/j.1365-2044.1987.tb05283.x; Saarenmaa E, 1999, J PEDIATR-US, V134, P144, DOI 10.1016/S0022-3476(99)70407-5; Simons SHP, 2006, SEMIN FETAL NEONAT M, V11, P260, DOI 10.1016/j.siny.2006.02.008; Suarez Amanda, 2010, J Pediatr Pharmacol Ther, V15, P142; Taddio Anna, 2004, Best Pract Res Clin Anaesthesiol, V18, P291, DOI 10.1016/j.bpa.2003.12.008; Tibboel D, 2005, SEMIN FETAL NEONAT M, V10, P195, DOI 10.1016/j.siny.2004.11.002; van Dijk M, 2002, PAIN, V98, P305, DOI 10.1016/S0304-3959(02)00031-3; Voepel-Lewis T, 2008, ANESTH ANALG, V107, P70, DOI 10.1213/ane.0b013e318172fa9e; Walter-Nicolet Elizabeth, 2010, Paediatr Drugs, V12, P353, DOI 10.2165/11318900-000000000-00000; Yildiz K, 2003, PAEDIATR ANAESTH, V13, P427, DOI 10.1046/j.1460-9592.2003.01061.x	43	9	9	0	5	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	APR	2014	24	4					377	385		10.1111/pan.12332			9	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	AC8HG	WOS:000332773500003	24417623	Green Accepted			2020-06-30	J	Sharma, A; Singh, PM; Trikha, A; Rewari, V; Chandralekha				Sharma, Ankur; Singh, Preet Mohinder; Trikha, Anjan; Rewari, Vimi; Chandralekha			Entropy correlates with Richmond Agitation Sedation Scale in mechanically ventilated critically ill patients	JOURNAL OF CLINICAL MONITORING AND COMPUTING			English	Article						Entropy; Richmond Agitation and Sedation Scale; Sedation; ICU	INTENSIVE-CARE-UNIT; BISPECTRAL INDEX; SPECTRAL ENTROPY; STATE INDEX; DAY-SURGERY; PROPOFOL; CONSCIOUSNESS; DEPTH; RELIABILITY; ANALGESIA	Sedation is routinely used in intensive care units. However due to absence of objective scoring systems like Bispectral Index and entropy our ability to regulate the degree of sedation is limited. This deficiency is further highlighted by the fact that agitation scores used in intensive care units (ICU) have no role in paralyzed patients. The present study compares entropy as a sedation scoring modality with Richmond Agitation Sedation Scale (RASS) in mechanically ventilated, critically ill patients in an ICU. Twenty-seven, mechanically ventilated, critically ill patients of either sex, 16-65 years of age, were studied over a period of 24 h. They received a standard sedation regimen consisting of a bolus dose of propofol 0.5 mg/kg and fentanyl 1 mu g/kg followed by infusions of propofol and fentanyl ranging from 1.5 to 5 mg/kg/h and 0.5 to 2.0 mu g/kg/h, respectively. Clinically relevant values of RASS for optimal ICU sedation (between 0 and -3) in non-paralyzed patients were compared to corresponding entropy values, to find if any significant correlation exists between the two. These entropy measurements were obtained using the Datex-Ohmeda-M-Entropy (TM) module. This module is presently not approved by Food and Drug Administration (FDA) for monitoring sedation in ICU. A total of 527 readings were obtained. There was a statistically significant correlation between the state entropy (SE) and RASS [Spearman's rho/r(s) = 0.334, p < 0.0001]; response entropy (RE) and RASS [Spearman's rho/r(s) = 0.341, p < 0.0001]). For adequate sedation as judged by a RASS value of 0 to -3, the mean SE was 57.86 +/- A 16.50 and RE was 67.75 +/- A 15.65. The present study illustrates that entropy correlates with RASS (between scores 0 and -3) when assessing the level of sedation in mechanically ventilated critically ill patients.	[Sharma, Ankur; Singh, Preet Mohinder; Trikha, Anjan; Rewari, Vimi; Chandralekha] All India Inst Med Sci, Dept Anaesthesia, New Delhi, India	Trikha, A (reprint author), All India Inst Med Sci, Dept Anaesthesia, New Delhi, India.	ankuranaesthesia@gmail.com; Preetrajpal@gmail.com; anjantrikha@gmail.com; vimirewari@gmail.com; clekha28@hotmail.com	Singh, Preet Mohinder/V-3471-2017	Singh, Preet Mohinder/0000-0001-7642-529X			Almgren M, 2010, ACTA ANAESTH SCAND, V54, P729, DOI 10.1111/j.1399-6576.2009.02173.x; Anderson RE, 2007, BRIT J ANAESTH, V98, P645, DOI 10.1093/bja/aem061; Anderson RE, 2006, EUR J ANAESTH, V23, P208, DOI 10.1017/S0265021505002206; Artusi R, 2002, INT J BIOL MARKER, V17, P148; AVRAMOV MN, 1995, CRIT CARE CLIN, V11, P803; Berkenbosch JW, 2002, ANESTH ANALG, V94, P506, DOI 10.1097/00000539-200203000-00006; Biau DJ, 2010, CLIN ORTHOP RELAT R, V468, P885, DOI 10.1007/s11999-009-1164-4; De Jonghe B, 2003, CRIT CARE MED, V31, P2344, DOI 10.1097/01.CCM.0000084850.16444.94; Entropy Bein B., 2006, BEST PRACT RES CLIN, V20, P101; Haenggi M, 2009, ANESTH ANALG, V109, P807, DOI 10.1213/ane.0b013e3181acc85d; Haenggi M, 2009, CRIT CARE, V13, DOI 10.1186/cc7723; Haenggi M, 2008, CRIT CARE, V12, DOI 10.1186/cc7015; Hernandez-Gancedo Carmen, 2007, J Clin Monit Comput, V21, P295, DOI 10.1007/s10877-007-9087-7; Hession Peter M, 2010, Anesthesiol Clin, V28, P281, DOI 10.1016/j.anclin.2010.02.007; Karamchandani K, 2010, J ANESTH, V24, P394, DOI 10.1007/s00540-010-0915-4; Kaskinoro K, 2011, BRIT J ANAESTH, V107, P573, DOI 10.1093/bja/aer196; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kwon MY, 2012, KOREAN J ANESTHESIOL, V62, P234, DOI 10.4097/kjae.2012.62.3.234; Lefoll-Masson U, 2007, ANESTH ANALG, V105, P1319, DOI 10.1213/01.ane.0000287247.30810.aa; Liu N, 2005, ANESTH ANALG, V101, P1713, DOI 10.1213/01.ANE.0000184038.49429.8F; Lu CH, 2010, J FORMOS MED ASSOC, V109, P589, DOI 10.1016/S0929-6646(10)60096-4; Malviya S, 2002, BRIT J ANAESTH, V88, P241, DOI 10.1093/bja/88.2.241; McGrane S, 2012, MINERVA ANESTESIOL, V78, P369; Mi WD, 2004, EUR J ANAESTH, V21, P807, DOI 10.1017/S0265021504000092; Mirski MA, 2010, CRIT CARE MED, V38, P1674, DOI 10.1097/CCM.0b013e3181e7c73e; Nasraway SA, 2002, CRIT CARE MED, V30, P1483, DOI 10.1097/00003246-200207000-00014; Patel SB, 2012, AM J RESP CRIT CARE, V185, P486, DOI 10.1164/rccm.201102-0273CI; Prabhakar H, 2009, J ANESTH, V23, P154, DOI 10.1007/s00540-008-0679-2; Rassin M, 2007, DIMENS CRIT CARE NUR, V26, P76, DOI 10.1097/00003465-200703000-00010; Rautee R, 2004, P ANN INT IEEE EMBS, V26, P3481; Rozendaal F, 2009, INTENS CARE MED, V35, P291, DOI 10.1007/s00134-008-1328-9; Schneider G, 2004, INTENS CARE MED, V30, P213, DOI 10.1007/s00134-003-2092-5; Schraag S, 1999, J CLIN ANESTH, V11, P391, DOI 10.1016/S0952-8180(99)00076-8; Sessler CN, 2008, CRIT CARE, V12, DOI 10.1186/cc6148; Stefani F, 2011, ASSIST INFERM RIC, V30, P135, DOI 10.1702/970.10587; Tukenmez Baris, 2008, J Opioid Manag, V4, P34; Viertio-Oja H, 2004, ACTA ANAESTH SCAND, V48, P154, DOI 10.1111/j.0001-5172.2004.00322.x; Walsh TS, 2008, INTENS CARE MED, V34, P308, DOI 10.1007/s00134-007-0858-x; Weber F, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507001329; Wong CA, 2005, ANESTH ANALG, V100, P141, DOI 10.1213/01.ANE.0000138057.61904.FD	40	0	3	0	5	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1387-1307	1573-2614		J CLIN MONIT COMPUT	J. Clin. Monitor. Comp.	APR	2014	28	2					193	201		10.1007/s10877-013-9517-7			9	Anesthesiology	Anesthesiology	AC8RB	WOS:000332800200014	24122077				2020-06-30	J	Barratt, DT; Bandak, B; Klepstad, P; Dale, O; Kaasa, S; Christrup, LL; Tuke, J; Somogyi, AA				Barratt, Daniel T.; Bandak, Benedikte; Klepstad, Pal; Dale, Ola; Kaasa, Stein; Christrup, Lona L.; Tuke, Jonathan; Somogyi, Andrew A.			Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study	PHARMACOGENETICS AND GENOMICS			English	Article						cancer; pain management; transdermal patch; pharmacogenetics; fentanyl; cytochrome P-450 CYP3A; pharmacokinetics	PLASMA-PROTEIN BINDING; PAIN; VARIABILITY; ASSOCIATION; DISPOSITION; ABSORPTION; CLEARANCE; EFFICACY	Objective This study aimed to investigate whether CYP3A4/5 genetic variants, together with clinical and patient factors, influence serum fentanyl and norfentanyl concentrations and their ratio in cancer pain patients receiving transdermal fentanyl. Methods CYP3A4*22 and CYP3A5*3 polymorphisms were analysed in 620 cancer pain patients receiving transdermal fentanyl (12.5-700 mu g/h) from the European Pharmacogenetic Opioid Study. Using stepwise linear regression, CYP3A4/5 genetic variability was examined in combination with patient factors relating to organ drug elimination function and ABCB1 genetics for their association with serum fentanyl and norfentanyl concentrations and metabolic ratio (MR) (norfentanyl : fentanyl). Results Delivery rate-adjusted serum fentanyl concentrations (0.0012-1.1 nmol/l/mu g.h) and MRs (0.08-499) varied widely. Only 43% of variability in serum fentanyl concentrations was accounted for by delivery rate and less than 50% by CYP3A4/5 genotypes and clinical variables (delivery rate, sex, comedications, kidney disease, BMI, serum albumin). CYP3A4*22 and CYP3A5*3 variants, CYP3A inhibitors and variables relating to liver and kidney function (serum albumin, glomerular filtration rate, kidney disease, BMI) were associated with MR, but accounted for only 14% of variability. Conclusion Serum fentanyl concentrations and MR vary considerably between cancer pain patients on transdermal fentanyl patches. CYP3A4*22 and CYP3A5*3 genotypes, and multiple clinical factors, combine to influence transdermal fentanyl pharmacokinetics, but accounted for only a small proportion of variability in this study. Identification of the remaining factors determining serum fentanyl concentrations, and their relationship to efficacy and adverse effects may aid in improving the safety and effectiveness of transdermal fentanyl.	[Barratt, Daniel T.; Bandak, Benedikte; Somogyi, Andrew A.] Univ Adelaide, Discipline Pharmacol, Sch Med Sci, Adelaide, SA 5005, Australia; [Tuke, Jonathan] Univ Adelaide, Sch Math Sci, Adelaide, SA 5005, Australia; [Somogyi, Andrew A.] Royal Adelaide Hosp, Dept Clin Pharmacol, Adelaide, SA 5000, Australia; [Bandak, Benedikte; Christrup, Lona L.] Univ Copenhagen, Dept Drug Design & Pharmacol, Copenhagen, Denmark; [Klepstad, Pal; Dale, Ola] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, N-7034 Trondheim, Norway; [Kaasa, Stein] European Palliat Care Res Ctr, Dept Canc Res & Mol Med, Trondheim, Norway	Barratt, DT (reprint author), Univ Adelaide, Discipline Pharmacol, Sch Med Sci, Level 5 Med Sch North, Adelaide, SA 5005, Australia.	daniel.barratt@adelaide.edu.au		Barratt, Daniel/0000-0001-6261-353X; Christrup, Lona/0000-0002-4128-7373; Tuke, Jonathan/0000-0002-1688-8951	Norwegian Research CouncilResearch Council of Norway; European UnionEuropean Union (EU) [037777]; National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia [1011521]	The Norwegian Research Council and the European Union's 6th framework (Contract No. 037777) financially supported the EPOS program. This study was supported by the National Health and Medical Research Council of Australia (Project Grant 1011521).	Andreassen TN, 2011, EUR J CLIN PHARMACOL, V67, P493, DOI 10.1007/s00228-010-0948-5; BOWER S, 1981, J PHARM PHARMACOL, V33, P507, DOI 10.1111/j.2042-7158.1981.tb13849.x; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Elens L, 2013, PHARMACOGENOMICS, V14, P47, DOI [10.2217/PGS.12.187, 10.2217/pgs.12.187]; Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056; Flockhart DA, 2007, DRUG INTERACTIONS CY; Galvan A, 2012, PHARMACOGENOMICS J, V12, P412, DOI 10.1038/tpj.2011.27; Gromping U, 2006, J STAT SOFTW, V17, DOI 10.18637/jss.v017.i01; Heiskanen T, 2009, PAIN, V144, P218, DOI 10.1016/j.pain.2009.04.012; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; HOLDSWORTH MT, 1994, GERONTOLOGY, V40, P32; KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L; Klepstad P, 2005, PALLIATIVE MED, V19, P477, DOI 10.1191/0269216305pm1054oa; Klepstad P, 2011, PAIN, V152, P1139, DOI 10.1016/j.pain.2011.01.040; Klepstad P, 2003, ACTA ANAESTH SCAND, V47, P725, DOI 10.1034/j.1399-6576.2003.00138.x; Kokubun H, 2007, J PHARM HLTH CARE SC, V33, P200; Kokubun Hideya, 2012, J Pain Palliat Care Pharmacother, V26, P98, DOI 10.3109/15360288.2012.679725; Kotlyar M, 1999, INT J CLIN PHARM TH, V37, P8; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lamba JK, 2002, ADV DRUG DELIVER REV, V54, P1271, DOI 10.1016/S0169-409X(02)00066-2; Lane ME, 2013, EUR J PHARM BIOPHARM, V84, P449, DOI 10.1016/j.ejpb.2013.01.018; Levey A, 2005, J AM SOC NEPHROL, V11; Lindeman R.H., 1980, INTRO BIVARIATE MULT; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; Park HJ, 2007, CLIN PHARMACOL THER, V81, P539, DOI 10.1038/sj.clpt.6100046; R Core Team, 2013, R LANG ENV STAT COMP; Ripamonti CI, 2012, ANN ONCOL, V23, P294, DOI 10.1093/annonc/mds360; Saari TI, 2008, EUR J CLIN PHARMACOL, V64, P25, DOI 10.1007/s00228-007-0398-x; SCHNEIDER E, 1986, N-S ARCH PHARMACOL, V334, P267, DOI 10.1007/BF00508781; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; Solassol I, 2005, ONCOL REP, V14, P1029; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; Somogyi AA, 2007, CLIN PHARMACOL THER, V81, P429, DOI 10.1038/sj.clpt.6100095; Takashina Y, 2012, DRUG METAB PHARMACOK, V27, P414, DOI 10.2133/dmpk.DMPK-11-RG-134; Tucker GT, 1998, XENOBIOTICA, V28, P1255, DOI 10.1080/004982598238895; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Venables W. N., 2002, MODERN APPL STAT S; Wang D, 2011, PHARMACOGENOMICS J, V11, P274, DOI 10.1038/tpj.2010.28; WHO, 2013, WHOS PAIN LADD AD; Wiesner G, 1996, ANAESTHESIST, V45, P323, DOI 10.1007/s001010050267; Wilson AS, 1997, ANESTH ANALG, V84, P315, DOI 10.1097/00000539-199702000-00013; Wolbold R, 2003, HEPATOLOGY, V38, P978, DOI 10.1053/jhep.2003.50393; Yassen A, 2007, CLIN PHARMACOL THER, V81, P50, DOI 10.1038/sj.clpt.6100025; Zhang W, 2011, EUR J ANAESTH, V28, P245, DOI 10.1097/EJA.0b013e3283438b39	49	27	27	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1744-6872	1744-6880		PHARMACOGENET GENOM	Pharmacogenet. Genomics	APR	2014	24	4					185	194		10.1097/FPC.0000000000000032			10	Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy	Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy	AD1WK	WOS:000333024200001	24469018				2020-06-30	J	Lord, B; Bendall, J; Reinten, T				Lord, Bill; Bendall, Jason; Reinten, Tracie			THE INFLUENCE OF PARAMEDIC AND PATIENT GENDER ON THE ADMINISTRATION OF ANALGESICS IN THE OUT-OF-HOSPITAL SETTING	PREHOSPITAL EMERGENCY CARE			English	Article						analgesia; emergency medical services; morphine, pain, prehospital, sex factors	EMERGENCY-DEPARTMENT; PAIN MANAGEMENT; PREHOSPITAL ANALGESIA; SEX-DIFFERENCES; CHEST-PAIN; IMPACT; WOMEN; MEN	Objective. To determine whether analgesic administration in the out-of-hospital setting is influenced by the gender of the patient or the gender of the paramedic. Methods. This retrospective cohort study of patient care records included adult patients (age > 15 years) with moderate to severe pain (verbal numerical rating score 4-10) treated by paramedics between January 1, 2008 and December 31, 2009. Data extracted included patient pain severity score, analgesia provided by paramedics, and gender of the treating paramedic. Data was analyzed by descriptive statistics, chi(2) test, and logistic regression. The primary outcome measures were the effect of patient and paramedic gender on analgesic administration. Results. The study population comprised 42,051 patients, median age of 57 years (38-75); 50.4% were female and 51% were administered an analgesic agent. For the outcome of receiving any analgesia, neither patient gender nor paramedic gender was predictive (p = NS). In a multivariate model for the outcome of receiving any analgesia, patient gender, paramedic gender, and the interaction between patient and paramedic gender were all nonsignificant (p = NS). For the outcome of receiving opioid analgesia (i.e., morphine or fentanyl), male patients were at greater odds of receiving an opioid (OR 1.52, 95% CI 1.29-1.79, p < 0.0001). Paramedic gender was not predictive of whether an opioid was given (p = NS). Conclusions. The gender of the paramedic did not appear to influence the odds of analgesic administration. Female patients were less likely to receive opioids. Paramedic gender does not explain this finding.	[Lord, Bill] Univ Sunshine Coast, Sch Hlth & Sport Sci, Maroochydore, Qld, Australia; [Bendall, Jason] Gosford Hosp, Dept Anaesthesia, Gosford, NSW, Australia; [Reinten, Tracie] Ambulance Serv New South Wales, Rozelle, NSW, Australia	Lord, B (reprint author), Univ Sunshine Coast, Maroochydore, Qld, Australia.	wlord@usc.edu.au		Bendall, A/Prof Jason/0000-0002-8688-2192; Lord, Bill/0000-0001-8821-5353			Anderson KO, 2009, J PAIN, V10, P1187, DOI 10.1016/j.jpain.2009.10.002; Bendall JC, 2011, PREHOSP DISASTER MED, V26, P422, DOI 10.1017/S1049023X12000180; BENDELOW G, 1993, SOCIOL HEALTH ILL, V15, P273, DOI 10.1111/1467-9566.ep10490526; Chen EH, 2008, ACAD EMERG MED, V15, P414, DOI 10.1111/j.1553-2712.2008.00100.x; Cousins MJ, 2011, PAIN, V152, P2673, DOI 10.1016/j.pain.2011.09.012; Coventry LL, 2013, PREHOSP EMERG CARE, V17, P193, DOI 10.3109/10903127.2012.722175; Doherty S, 2013, EMERG MED AUSTRALAS, V25, P120, DOI 10.1111/1742-6723.12022; Fillingim RB, 2009, J PAIN, V10, P447, DOI 10.1016/j.jpain.2008.12.001; Galinski M, 2010, PREHOSP EMERG CARE, V14, P334, DOI 10.3109/10903121003760218; HOSMER D. W., 2000, APPL LOGISTIC REGRES; Jennings PA, 2011, EMERG MED J, V28, P530, DOI 10.1136/emj.2010.098954; Lord B, 2009, AM J EMERG MED, V27, P525, DOI 10.1016/j.ajem.2008.04.003; McLean Samuel A, 2002, Prehosp Emerg Care, V6, P402, DOI 10.1080/10903120290938021; Meisel ZF, 2010, ACAD EMERG MED, V17, P80, DOI 10.1111/j.1553-2712.2009.00618.x; Michael GE, 2007, AM J EMERG MED, V25, P901, DOI 10.1016/j.ajem.2007.02.001; New South Wales Department of Health, ANN REP 2008 2009 NS; Ravn-Fischer A, 2012, AM J EMERG MED, V30, P1515, DOI 10.1016/j.ajem.2011.12.020; Robinson ME, 2003, J PAIN, V4, P40, DOI 10.1054/jpai.2003.4; Safdar B, 2009, PAIN MED, V10, P364, DOI 10.1111/j.1526-4637.2008.00524.x; Strong J, 2009, PAIN, V145, P86, DOI 10.1016/j.pain.2009.05.018; Terrell KM, 2010, PAIN MED, V11, P1072, DOI 10.1111/j.1526-4637.2010.00884.x; Walsh B, 2013, PREHOSP EMERG CARE, V17, P78, DOI 10.3109/10903127.2012.717167; Williams DM, 2012, PREHOSP EMERG CARE, V16, P519, DOI 10.3109/10903127.2012.695436	23	9	9	0	4	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1090-3127	1545-0066		PREHOSP EMERG CARE	Prehosp. Emerg. Care	APR-JUN	2014	18	2					195	200		10.3109/10903127.2013.856502			6	Emergency Medicine; Public, Environmental & Occupational Health	Emergency Medicine; Public, Environmental & Occupational Health	AD2WU	WOS:000333098000005	24401105				2020-06-30	J	Sukhtankar, DD; Lee, H; Rice, KC; Ko, MC				Sukhtankar, Devki D.; Lee, Heeseung; Rice, Kenner C.; Ko, Mei-Chuan			Differential effects of opioid-related ligands and NSAIDs in nonhuman primate models of acute and inflammatory pain	PSYCHOPHARMACOLOGY			English	Article						Opioids; Opioid receptors; NSAIDs; Monkey pain model; Carrageenan; Nociceptin/orphanin FQ; NOP receptors; Hyperalgesia	CARRAGEENAN-INDUCED INFLAMMATION; DORSAL-ROOT GANGLIA; RHESUS-MONKEYS; DOUBLE-BLIND; RECEPTOR AGONIST; NEUROPATHIC PAIN; THERMAL HYPERALGESIA; INDUCED ITCH; DELTA; RAT	Carrageenan-induced hyperalgesia is a widely used pain model in rodents. However, characteristics of carrageenan-induced hyperalgesia and effects of analgesic drugs under these conditions are unknown in nonhuman primates. The aims of this study were to develop carrageenan-induced hyperalgesia in rhesus monkeys and determine the efficacy and potency of agonists selective for the four opioid receptor subtypes in this model versus acute pain, as compared to non-steroidal anti-inflammatory drugs (NSAIDs). Tail injection of carrageenan produced long-lasting thermal hyperalgesia in monkeys. Systemically administered agonists selective for opioid receptor subtypes, i.e., fentanyl (mu/MOP), U-50488H (kappa/KOP), SNC80 (delta/DOP) and Ro 64-6198 (nociceptin/orphanin FQ/NOP) dose-dependently attenuated carrageenan-induced thermal hyperalgesia with different potencies. In absence of carrageenan, these agonists, except SNC80, blocked acute thermal nociception. Opioid-related ligands, especially Ro 64-6198, were much more potent for their antihyperalgesic than antinociceptive effects. Both effects were mediated by the corresponding receptor mechanisms. Only fentanyl produced scratching at antihyperalgesic and antinociceptive doses consistent with its pruritic effects in humans, illustrating a translational profile of MOP agonists in nonhuman primates. Similar to SNC80, systemically administered NSAIDs ketorolac and naproxen dose-dependently attenuated carrageenan-induced hyperalgesia but not acute nociception. Using two different pain modalities in nonhuman primates, effectiveness of clinically available analgesics like fentanyl, ketorolac and naproxen was distinguished and their efficacies and potencies were compared with the selective KOP, DOP, and NOP agonists. The opioid-related ligands displayed differential pharmacological properties in regulating hyperalgesia and acute nociception in the same subjects. Such preclinical primate models can be used to investigate novel analgesic agents.	[Sukhtankar, Devki D.; Ko, Mei-Chuan] Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA; [Lee, Heeseung] Ewha Womans Univ, Sch Med, Dept Anesthesiol & Pain Med, Seoul 158710, South Korea; [Rice, Kenner C.] NIDA, Chem Biol Res Branch, Bethesda, MD 20892 USA; [Ko, Mei-Chuan] Wake Forest Univ, Bowman Gray Sch Med, Ctr Comparat Med Res, Winston Salem, NC 27157 USA	Sukhtankar, DD (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	dsukhtan@wakehealth.edu; leehee@ewha.ac.kr	Ko, Mei-Chuan/C-9468-2009	Ko, Mei-Chuan/0000-0003-2436-4506	National Institutes of Health, the National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01-AR-059193]; National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01-DA-032568]	We thank Tristan Edwards and John Busenbark for technical assistance of data collection. Research reported in this publication was supported by the National Institutes of Health, the National Institute of Arthritis and Musculoskeletal and Skin Diseases under Award number R01-AR-059193, and the National Institute on Drug Abuse under Award number R01-DA-032568. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	BARBER A, 1994, BRIT J PHARMACOL, V113, P1317, DOI 10.1111/j.1476-5381.1994.tb17142.x; BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; Bianchi BR, 2012, J PHARMACOL EXP THER, V341, P360, DOI 10.1124/jpet.111.189902; Brandt MR, 2001, J PHARMACOL EXP THER, V296, P939; BUCKLEY MMT, 1990, DRUGS, V39, P86, DOI 10.2165/00003495-199039010-00008; Butelman ER, 2003, J PHARMACOL EXP THER, V306, P1106, DOI 10.1124/jpet.103.052381; BUTELMAN ER, 1993, J PHARMACOL EXP THER, V267, P1269; Butelman ER, 2001, J PHARMACOL EXP THER, V298, P1049; BUTELMAN ER, 1995, EUR J PHARMACOL, V277, P285, DOI 10.1016/0014-2999(95)00134-7; Cahill CM, 2003, PAIN, V101, P199, DOI 10.1016/S0304-3959(02)00333-0; Calo' G, 2013, ACS SYM SER, V1131, P275; Castellsague J, 2012, DRUG SAFETY, V35, P1127, DOI 10.2165/11633470-000000000-00000; Chen Y, 2006, J PERIPHER NERV SYST, V11, P232, DOI 10.1111/j.1529-8027.2006.0093.x; COMER SD, 1993, J PHARMACOL EXP THER, V267, P888; Correa JD, 2010, LIFE SCI, V86, P951, DOI 10.1016/j.lfs.2010.04.012; Dirig DM, 1998, J PHARMACOL EXP THER, V285, P1031; DYKSTRA LA, 1993, J PHARMACOL EXP THER, V267, P875; ELLIS DJ, 1990, ANESTHESIOLOGY, V72, P981, DOI 10.1097/00000542-199006000-00006; Fraser GL, 2000, BRIT J PHARMACOL, V129, P1668, DOI 10.1038/sj.bjp.0703248; Hameed H, 2010, CURR PAIN HEADACHE R, V14, P96, DOI 10.1007/s11916-010-0093-y; Hawkinson JE, 2007, J PHARMACOL EXP THER, V322, P619, DOI 10.1124/jpet.107.120352; Herrero JF, 1996, BRIT J PHARMACOL, V118, P968, DOI 10.1111/j.1476-5381.1996.tb15494.x; Hill R, 2000, TRENDS PHARMACOL SCI, V21, P244, DOI 10.1016/S0165-6147(00)01502-9; Hu E, 2010, PAIN, V148, P107, DOI 10.1016/j.pain.2009.10.026; Hutchinson Mark R, 2007, ScientificWorldJournal, V7, P98; Ikoma A, 2006, NAT REV NEUROSCI, V7, P535, DOI 10.1038/nrn1950; Itoh M, 2001, NEUROSCI RES, V40, P227, DOI 10.1016/S0168-0102(01)00230-9; Ji RR, 1995, J NEUROSCI, V15, P8156; Jia YP, 1998, NEUROSCI LETT, V250, P21, DOI 10.1016/S0304-3940(98)00430-3; JORIS JL, 1987, ANESTH ANALG, V66, P1277; Ko MC, 1998, J PHARMACOL EXP THER, V285, P518; Ko MCH, 2004, J PHARMACOL EXP THER, V310, P169, DOI 10.1124/jpet.103.061101; Ko MCH, 2002, BRIT J PHARMACOL, V135, P943, DOI 10.1038/sj.bjp.0704535; Ko MC, 2009, J PAIN, V10, P509, DOI 10.1016/j.jpain.2008.11.006; Ko MC, 2009, J PHARMACOL EXP THER, V328, P193, DOI 10.1124/jpet.108.143925; Krekels EHJ, 2011, PHARM RES-DORDR, V28, P1561, DOI 10.1007/s11095-011-0389-6; Kumagai H, 2010, NEPHROL DIAL TRANSPL, V25, P1251, DOI 10.1093/ndt/gfp588; Kupers RC, 1997, PAIN, V72, P269, DOI 10.1016/S0304-3959(97)00052-3; Lin AP, 2013, ACS CHEM NEUROSCI, V4, P214, DOI 10.1021/cn300124f; NEGUS SS, 1995, J PHARMACOL EXP THER, V274, P805; Negus SS, 1998, J PHARMACOL EXP THER, V286, P362; NEGUS SS, 1993, J PHARMACOL EXP THER, V266, P1355; Obara I, 2005, PAIN, V116, P17, DOI 10.1016/j.pain.2005.03.012; Raghavendra V, 2004, NEUROPSYCHOPHARMACOL, V29, P327, DOI 10.1038/sj.npp.1300315; Reich A, 2010, CLIN EXP DERMATOL, V35, P2, DOI 10.1111/j.1365-2230.2009.03463.x; Sawynok J, 2003, PHARMACOL REV, V55, P1, DOI 10.1124/pr.55.1.1; STANFA LC, 1992, PAIN, V50, P345, DOI 10.1016/0304-3959(92)90040-I; Stein C, 2009, BRAIN RES REV, V60, P90, DOI 10.1016/j.brainresrev.2008.12.017; Stein C, 2009, CURR OPIN PHARMACOL, V9, P3, DOI 10.1016/j.coph.2008.12.009; Sukhtankar D, 2013, ACS SYM SER, V1131, P393; Sukhtankar DD, 2013, J PHARMACOL EXP THER, V346, P11, DOI 10.1124/jpet.113.203984; Wallace MS, 2002, NEUROLOGY, V59, P1694, DOI 10.1212/01.WNL.0000036273.98213.34; Wallace MS, 2002, J PAIN, V3, P227, DOI 10.1054/jpai.2002.123650; Warner EA, 2012, AM J MED, V125, P1155, DOI 10.1016/j.amjmed.2012.04.032; Watkins LR, 2003, NAT REV DRUG DISCOV, V2, P973, DOI 10.1038/nrd1251; Whiteside GT, 2005, J PHARMACOL EXP THER, V314, P1234, DOI 10.1124/jpet.105.088351; Zhang X, 1998, NEUROSCIENCE	57	17	17	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0033-3158	1432-2072		PSYCHOPHARMACOLOGY	Psychopharmacology	APR	2014	231	7					1377	1387		10.1007/s00213-013-3341-0			11	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	AD0WI	WOS:000332954600010	24217900	Green Accepted			2020-06-30	J	Wasan, AD				Wasan, Ajay D.			Efficacy vs Effectiveness and Explanatory vs Pragmatic: Where Is the Balance Point in Pain Medicine Research?	PAIN MEDICINE			English	Editorial Material									[Wasan, Ajay D.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA; [Wasan, Ajay D.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15261 USA	Wasan, AD (reprint author), Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA.		Wasan, Ajay D./M-8084-2019	Wasan, Ajay D./0000-0002-6394-6077			Cohen SP, 2014, PAIN MED, V15, P588, DOI 10.1111/pme.12389; Rowbotham MC, 2013, PAIN, V154, P643, DOI 10.1016/j.pain.2013.02.034; Thorpe KE, 2009, J CLIN EPIDEMIOL, V62, P464, DOI 10.1016/j.jclinepi.2008.12.011	3	3	3	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1526-2375	1526-4637		PAIN MED	Pain Med.	APR	2014	15	4					539	540		10.1111/pme.12420			2	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	AE6NS	WOS:000334111300001	24716587	Bronze			2020-06-30	J	Hatipoglu, S; Yildiz, H; Bulbuloglu, E; Coskuner, I; Kurutas, EB; Hatipoglu, F; Ciralik, H; Berhuni, MS				Hatipoglu, Sinan; Yildiz, Huseyin; Bulbuloglu, Ertan; Coskuner, Ismail; Kurutas, Ergul Belge; Hatipoglu, Filiz; Ciralik, Harun; Berhuni, Mehmet Sait			Protective effects of intravenous anesthetics on kidney tissue in obstructive jaundice	WORLD JOURNAL OF GASTROENTEROLOGY			English	Article						Obstructive jaundice; Postoperative acute renal failure; Oxidative stress; Intravenous anesthetics; Renal tissue damage	ACUTE-RENAL-FAILURE; ISCHEMIA-REPERFUSION INJURY; DUCT-LIGATED RATS; BILE-DUCT; LIPID-PEROXIDATION; OXIDATIVE STRESS; ISCHEMIA/REPERFUSION INJURY; HYDROXYL RADICALS; CEREBRAL-ISCHEMIA; PROPOFOL	AIM: To evaluate the protective effects on kidney tissue of frequently used intravenous anesthetics (ketamine, propofol, thiopental, and fentanyl) in rats with obstructive jaundice. METHODS: There is an increased incidence of postoperative acute renal failure in patients with obstructive jaundice. Thirty-two Wistar-albino rats were randomly divided into four equal groups. Laparatomy was performed on each animal in the four groups and common bile ducts were ligated and severed on day 0. After 7 d, laparotomy was again performed using ketamine, propofol, thiopental, or fentanyl anesthesia whose antioxidative properties are well known in oxidative stress in a rat liver model of obstructive jaundice. After 2 h, the rats were sacrificed. Renal tissue specimens were analyzed for catalase, superoxide dismutase and malondialdehyde enzymes activities. All values are expressed as the mean +/- SD. P values less than 0.05 were considered statistically significant. RESULTS: All animals survived without complications until the end of the study. Enlargement in the bile duct and obstructive jaundice were observed in all rats. Catalase was found to be significantly lower in the fentanyl group than in the ketamine (P = 0.039), propofol (P = 0.012), and thiopental (P = 0.001) groups. Superoxide dismutase activities were similar in all groups (P > 0.05). Malondialdehyde was found to be significantly lower in the ketamine group than in the propofol (P = 0.028), thiopental (P = 0.002) and fentanyl (P = 0.005) groups. Malondialdehyde was also lower in the fentanyl group than in the thiopental group (P = 0.001). The results showed that obstructive jaundice sensitizes renal tissue to damage under the different anesthetics. CONCLUSION: Among the agents tested, ketamine and propofol generated the least amount of oxidative stres on renal tissues in this rat model of obstructive jaundice created by common bile duct ligation. The importance of free radical injury in renal tissue in obstructive jaundice under different intravenous anesthetics during hepatobiliary and liver transplant surgery should be considered for prevention of postoperative acute renal failure. (c) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.	[Hatipoglu, Sinan] Adiyaman Univ, Sch Med, Dept Gen Surg Unit, TR-02040 Adiyaman, Turkey; [Yildiz, Huseyin; Coskuner, Ismail] Kahramanmaras Sutcuimam Univ, Sch Med, Dept Anesthesiol & Reanimat Unit, TR-46100 Kahramanmaras, Turkey; [Bulbuloglu, Ertan; Berhuni, Mehmet Sait] Kahramanmaras Sutcuimam Univ, Sch Med, Dept Gen Surg Unit, TR-46100 Kahramanmaras, Turkey; [Kurutas, Ergul Belge] Kahramanmaras Sutcuimam Univ, Sch Med, Dept Biochem Unit, TR-46100 Kahramanmaras, Turkey; [Hatipoglu, Filiz] Adiyaman Univ, Sch Med, Dept Obstet & Gynecol Unit, TR-02040 Adiyaman, Turkey; [Ciralik, Harun] Kahramanmaras Sutcuimam Univ, Sch Med, Dept Pathol Unit, TR-46100 Kahramanmaras, Turkey	Hatipoglu, S (reprint author), Adiyaman Univ, Sch Med, Dept Gen Surg Unit, Altinsehir St, TR-02040 Adiyaman, Turkey.	hamitsinanh@gmail.com	hatipoglu, sinan/V-9137-2017	hatipoglu, sinan/0000-0002-4423-084X			Abidova S. S., 2002, Eksperimental'naya i Klinicheskaya Farmakologiya, V65, P46; ACALOVSCHI I, 1984, REV ROUM MED-MED INT, V22, P203; Allison MEM, 1990, SURG LIVER BILIARY T, P405; Almaas R, 2000, ANESTHESIOLOGY, V92, P764, DOI 10.1097/00000542-200003000-00020; Assimakopoulos SF, 2007, WORLD J GASTROENTERO, V13, P6458, DOI 10.3748/wjg.13.6458; Assimakopoulos SF, 2008, REDOX REP, V13, P179, DOI 10.1179/135100008X308902; Bachowski S, 1997, ANN CLIN LAB SCI, V27, P196; Balyasnikova IV, 2005, ANESTH ANALG, V100, P929, DOI 10.1213/01.ANE.0000147707.49192.88; BEUTLER E, 1975, [No title captured], P66; BOUILLOT JL, 1985, GASTROEN CLIN BIOL, V9, P238; Burke TJ, 1993, DISEASES KIDNEY, P1257; Byers J, 2001, Curr Opin Anaesthesiol, V14, P699, DOI 10.1097/00001503-200112000-00017; CAHILL CJ, 1987, SURG GYNECOL OBSTET, V165, P519; Camara CR, 2008, WORLD J GASTROENTERO, V14, P5192, DOI 10.3748/wjg.14.5192; CHINEV S, 1995, EUR J ANAESTH, V12, P155; Clarke DL, 2006, ANN ROY COLL SURG, V88, P610, DOI 10.1308/003588406X149327; CORATELLI P, 1990, MINER ELECTROL METAB, V16, P61; Cruz A, 2001, EUR J PHARMACOL, V425, P135, DOI 10.1016/S0014-2999(01)01173-6; DEMOPOULOS HB, 1977, ACTA NEUROL SCAND, V56, P152; Ergun R, 2002, NEUROSURG REV, V25, P95, DOI 10.1007/s101430100171; FASSOULAKI A, 1986, ANAESTH INTENS CARE, V14, P145, DOI 10.1177/0310057X8601400208; FOGARTY BJ, 1995, BRIT J SURG, V82, P877, DOI 10.1002/bjs.1800820707; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; Govil D, 1993, J Assoc Physicians India, V41, P151; GREIG JD, 1988, BRIT J SURG, V75, P216, DOI 10.1002/bjs.1800750309; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Kaler B, 2004, RENAL FAILURE, V26, P507, DOI 10.1081/JDI-200031753; Kato R, 2002, CAN J ANAESTH, V49, P777, DOI 10.1007/BF03017409; Kevin LG, 2005, ANESTH ANALG, V101, P1275, DOI 10.1213/01.ANE.0000180999.81013.D0; KONO Y, 1982, J BIOL CHEM, V257, P5751; Kramer HJ, 1997, NEPHRON, V77, P1, DOI 10.1159/000190241; Kramer HJ, 1997, CLIN SCI, V92, P579, DOI 10.1042/cs0920579; Kucuk C, 2003, EUR SURG RES, V35, P143, DOI 10.1159/000070043; Lazzara S, 1997, Chir Ital, V49, P51; LEE E, 1972, BRIT J SURG, V59, P875, DOI 10.1002/bjs.1800591107; Lee HT, 2004, ANESTHESIOLOGY, V101, P1313; Lim KHH, 2005, EXP BIOL MED, V230, P413, DOI 10.1177/15353702-0323006-09; Lin Li-na, 2004, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V16, P42; MURPHY PG, 1993, EUR J ANAESTH, V10, P261; NANJI AA, 1985, J CLIN GASTROENTEROL, V7, P431, DOI 10.1097/00004836-198510000-00013; Naranjo A, 2011, J GASTROINTEST LIVER, V20, P161; Nielsen F, 1997, CLIN CHEM, V43, P1209; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; OKUTOMI T, 1995, ACTA ANAESTH SCAND, V39, P338, DOI 10.1111/j.1399-6576.1995.tb04073.x; ONEILL PA, 1991, AM J SURG, V161, P662, DOI 10.1016/0002-9610(91)91251-D; PAIN JA, 1985, BRIT J SURG, V72, P942, DOI 10.1002/bjs.1800721203; PALLER MS, 1984, J CLIN INVEST, V74, P1156, DOI 10.1172/JCI111524; Raicevic Sibinovic Suzana, 2011, Med Pregl, V64, P503; Reeker W, 2000, CAN J ANAESTH, V47, P572, DOI 10.1007/BF03018950; Salman AE, 2005, EUR J ANAESTH, V22, P712, DOI 10.1017/S0265021505001171; SCHRIER RW, 1994, NEPHROL DIAL TRANSPL, V9, P9; SIKULER E, 1991, AM J PHYSIOL, V260, pG161; SINGH S, 1992, GASTROENTEROLOGY, V103, P1625, DOI 10.1016/0016-5085(92)91187-9; SMITH DS, 1980, ANESTHESIOLOGY, V53, P186, DOI 10.1097/00000542-198009000-00002; Sural S, 2000, RENAL FAILURE, V22, P623, DOI 10.1081/JDI-100100903; Tajiri K, 1997, HEPATO-GASTROENTEROL, V44, P789; THOMPSON JN, 1987, BRIT J SURG, V74, P843, DOI 10.1002/bjs.1800740932; TSAI LY, 1993, CLIN CHIM ACTA, V215, P41, DOI 10.1016/0009-8981(93)90247-2; Tsai LY, 1997, J FORMOS MED ASSOC, V96, P17; WAIT RB, 1989, AM J SURG, V157, P256, DOI 10.1016/0002-9610(89)90540-0; Wang HH, 2007, ACTA PHARMACOL SIN, V28, P1175, DOI 10.1111/j.1745-7254.2007.00566.x; Yamamoto T, 1994, Nihon Rinsho, V52, P159; Yildiz H, 2012, BRATISL MED J, V113, P139, DOI 10.4149/BLL_2012_034; YOSHIOKA T, 1992, KIDNEY INT, V41, P1008, DOI 10.1038/ki.1992.153; YOSHIOKA T, 1994, NEPHROL DIAL TRANSPL, V9, P34	65	3	4	3	13	BAISHIDENG PUBLISHING GROUP INC	PLEASANTON	8226 REGENCY DR, PLEASANTON, CA 94588 USA	1007-9327	2219-2840		WORLD J GASTROENTERO	World J. Gastroenterol.	MAR 28	2014	20	12					3320	3326		10.3748/wjg.v20.i12.3320			7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	AE0PH	WOS:000333667700025	24695809	Green Published, Other Gold			2020-06-30	J	Takala, J				Takala, Jukka			Of Delirium and Sedation	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Editorial Material							INTENSIVE-CARE-UNIT; MECHANICALLY VENTILATED PATIENTS; CAM-ICU; RELIABILITY; PREVALENCE; VALIDITY		[Takala, Jukka] Univ Bern, Inselspital, Univ Hosp Bern, Dept Intens Care Med, CH-3010 Bern, Switzerland; [Takala, Jukka] Univ Bern, Bern, Switzerland	Takala, J (reprint author), Univ Bern, Inselspital, Univ Hosp Bern, Dept Intens Care Med, CH-3010 Bern, Switzerland.						American Psychiatric Association, 2011, DIAGN STAT MAN MENT; Barr J, 2001, ANESTHESIOLOGY, V95, P324, DOI 10.1097/00000542-200108000-00011; Bergeron N, 2001, INTENS CARE MED, V27, P859, DOI 10.1007/s001340100909; Brummel NE, 2014, INTENS CARE MED, V40, P135, DOI 10.1007/s00134-013-3083-9; Devlin JW, 2013, INTENS CARE MED, V39, P2196, DOI 10.1007/s00134-013-3105-7; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Haenggi M, 2013, INTENS CARE MED, V39, P2171, DOI 10.1007/s00134-013-3034-5; Ouimet S, 2007, INTENS CARE MED, V33, P66, DOI 10.1007/s00134-006-0399-8; Page VJ, 2014, AM J RESP CRIT CARE, V189, P666, DOI 10.1164/rccm.201306-1150OC; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Pandharipande P, 2008, J TRAUMA, V65, P34, DOI 10.1097/TA.0b013e31814b2c4d; Patel SB, 2014, AM J RESP CRIT CARE, V189, P658, DOI 10.1164/rccm.201310-1815OC; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138	15	6	6	0	5	AMER THORACIC SOC	NEW YORK	25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA	1073-449X	1535-4970		AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	MAR 15	2014	189	6					622	624		10.1164/rccm.201401-0195ED			3	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	AD6OQ	WOS:000333381100003	24628309				2020-06-30	J	Patel, SB; Poston, JT; Pohlman, A; Hall, JB; Kress, JP				Patel, Shruti B.; Poston, Jason T.; Pohlman, Anne; Hall, Jesse B.; Kress, John P.			Rapidly Reversible, Sedation-related Delirium versus Persistent Delirium in the Intensive Care Unit	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						delirium; mechanical ventilation; sedation; analgesia; critical care	CRITICALLY-ILL PATIENTS; MECHANICALLY VENTILATED PATIENTS; TERM COGNITIVE IMPAIRMENT; DOUBLE-BLIND; ICU; MORTALITY; DURATION; EFFICACY; SAFETY; DEXMEDETOMIDINE	Rationale: Intensive care unit (ICU) delirium is associated with ventilator, ICU, and hospital days; discharge functional status; and mortality. Whether rapidly reversible, sedation-related delirium (delirium that abates shortly after sedative interruption) occurs with the same frequency and portends the same prognosis as persistent delirium (delirium that persists despite a short period of sedative interruption) is unknown. Objectives: To compare rapidly reversible, sedation-related delirium and persistent delirium. Methods: This Was a prospective cohort study of 102 adult, intubated medical ICU subjects in a tertiary care teaching hospital. Confusion Assessment Method for the ICU evaluation was performed before and after daily interruption of continuous sedation (DIS). Investigators were blinded to each other's assessments and as to whether evaluations were before or after DIS. The primary outcome was proportion of days with no delirium versus rapidly reversible, sedation-related delirium versus persistent delirium. Secondary outcomes were ventilator, ICU, and hospital days; discharge disposition; and 1-year mortality. Measurements and Main Results: The median proportion of ICU days with delirium was 0.57 before versus 0.50 after DIS (P < 0.001). The Confusion Assessment Method for the ICU indicated patients are 10.5 times more likely to have delirium before DIS versus after (P < 0.001). Rapidly reversible, sedation-related delirium showed fewer ventilator (P < 0.001), ICU (P = 0.001), and hospital days (P < 0.001) than persistent delirium. Subjects with no delirium and rapidly reversible, sedation-related delirium were more likely to be discharged home (P < 0.001). Patients with persistent delirium had increased 1-year mortality versus those with no delirium and rapidly reversible, sedation-related delirium (P < 0.001). Conclusions: Rapidly reversible, sedation-related delirium does not signify the same poor prognosis as persistent delirium. Degree of sedation should be considered in delirium assessments. Coordinating delirium assessments with daily sedative interruption will improve such assessments' ability to prognosticate ICU delirium outcomes.	[Patel, Shruti B.; Poston, Jason T.; Pohlman, Anne; Hall, Jesse B.; Kress, John P.] Univ Chicago, Dept Med, Sect Pulm & Crit Care, Chicago, IL 60637 USA	Kress, JP (reprint author), Univ Chicago, Dept Med, Sect Pulm & Crit Care, 5841 South Maryland,MC 6026, Chicago, IL 60637 USA.	jkress@medicine.bsd.uchicago.edu					Barr J, 2001, ANESTHESIOLOGY, V95, P324, DOI 10.1097/00000542-200108000-00011; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Brummel NE, 2014, INTENS CARE MED, V40, P135, DOI 10.1007/s00134-013-3083-9; Devlin JW, 2010, CRIT CARE MED, V38, P419, DOI 10.1097/CCM.0b013e3181b9e302; Dubois MJ, 2001, INTENS CARE MED, V27, P1297, DOI 10.1007/s001340101017; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1; Girard TD, 2010, CRIT CARE MED, V38, P428, DOI 10.1097/CCM.0b013e3181c58715; Haenggi M, 2014, INTENS CARE MED, V40, P136, DOI 10.1007/s00134-013-3092-8; Haenggi M, 2013, INTENS CARE MED, V39, P2171, DOI 10.1007/s00134-013-3034-5; Heymann A, 2010, J INT MED RES, V38, P1584, DOI 10.1177/147323001003800503; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kress JP, 1996, AM J RESP CRIT CARE, V153, P1012, DOI 10.1164/ajrccm.153.3.8630539; Ouimet S, 2007, INTENS CARE MED, V33, P66, DOI 10.1007/s00134-006-0399-8; Page VJ, 2013, LANCET RESP MED, V1, P515, DOI 10.1016/S2213-2600(13)70166-8; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; Patel SB, 2012, AM J RESP CRIT CARE, V185, P486, DOI 10.1164/rccm.201102-0273CI; Patel SB, 2011, AM J RESP CRIT CARE, V184, P287, DOI 10.1164/rccm.201106-0988ED; Pisani MA, 2010, J CRIT CARE, V25, DOI 10.1016/j.jcrc.2010.02.009; Pisani MA, 2009, AM J RESP CRIT CARE, V180, P1092, DOI 10.1164/rccm.200904-0537OC; Pisani MA, 2009, CRIT CARE MED, V37, P177, DOI 10.1097/CCM.0b013e318192fcf9; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Shehabi Y, 2010, CRIT CARE MED, V38, P2311, DOI 10.1097/CCM.0b013e3181f85759; Skrobik YK, 2004, INTENS CARE MED, V30, P444, DOI 10.1007/s00134-003-2117-0; Skrobik Y, 2013, CRIT CARE MED, V41, P999, DOI 10.1097/CCM.0b013e318275d014; Unroe M, 2010, ANN INTERN MED, V153, P167, DOI 10.7326/0003-4819-153-3-201008030-00007; van den Boogaard M, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e420; van Eijk MMJ, 2010, LANCET, V376, P1829, DOI 10.1016/S0140-6736(10)61855-7	34	119	125	0	25	AMER THORACIC SOC	NEW YORK	25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA	1073-449X	1535-4970		AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	MAR 15	2014	189	6					658	665		10.1164/rccm.201310-1815OC			8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	AD6OQ	WOS:000333381100010	24423152				2020-06-30	J	Rey-Santano, C; Mielgo, V; Valls-i-Soler, A; Encinas, E; Lukas, JC; Vozmediano, V; Suarez, E				Rey-Santano, Carmen; Mielgo, Victoria; Valls-i-Soler, Adolfo; Encinas, Esther; Lukas, John C.; Vozmediano, Valvanera; Suarez, Elena			Evaluation of Fentanyl Disposition and Effects in Newborn Piglets as an Experimental Model for Human Neonates	PLOS ONE			English	Article							CHEST-WALL RIGIDITY; CONTINUOUS-INFUSION FENTANYL; PATENT DUCTUS-ARTERIOSUS; PRETERM INFANTS; DOSE FENTANYL; JUVENILE PIGS; ANESTHESIA; PHARMACOKINETICS; ANALGESIA; RESPONSES	Background: Fentanyl is widely used off-label in NICU. Our aim was to investigate its cerebral, cardiovascular and pulmonary effects as well as pharmacokinetics in an experimental model for neonates. Methods: Fentanyl (5 mu g/kg bolus immediately followed by a 90 minute infusion of 3 mu g/kg/h) was administered to six mechanically ventilated newborn piglets. Cardiovascular, ventilation, pulmonary and oxygenation indexes as well as brain activity were monitored from T = 0 up to the end of experiments (T = 225-300 min). Also plasma samples for quantification of fentanyl were drawn. Results: A "reliable degree of sedation" was observed up to T = 210-240 min, consistent with the selected dosing regimen and the observed fentanyl plasma levels. Unlike cardiovascular parameters, which were unmodified except for an increasing trend in heart rate, some of the ventilation and oxygenation indexes as well as brain activity were significantly altered. The pulmonary and brain effects of fentanyl were mostly recovered from T = 210 min to the end of experiment. Conclusion: The newborn piglet was shown to be a suitable experimental model for studying fentanyl disposition as well as respiratory and cardiovascular effects in human neonates. Therefore, it could be extremely useful for further investigating the drug behaviour under pathophysiological conditions.	[Rey-Santano, Carmen; Mielgo, Victoria; Valls-i-Soler, Adolfo] Cruces Univ Hosp, Expt Neonatal Physiol Unit, BioCruces Hlth Res Inst, Baracaldo, Bizkaia, Spain; [Encinas, Esther; Lukas, John C.; Suarez, Elena] Univ Basque Country, UPV EHU, Dept Pharmacol, Fac Med, Leioa, Bizkaia, Spain; [Lukas, John C.; Vozmediano, Valvanera] Dynakin SL, Drug Modeling & Consulting, Derio, Bizkaia, Spain	Rey-Santano, C (reprint author), Cruces Univ Hosp, Expt Neonatal Physiol Unit, BioCruces Hlth Res Inst, Baracaldo, Bizkaia, Spain.	macarmen.reysantano@osakidetza.net		Suarez, Elena/0000-0002-6683-4847	Spanish Carlos III Health Institute [FIS 10/943, RD12/0026/0001]; Basque Country GovernmentBasque Government; INNPACTO project of the Spanish Ministry of Science and Innovation - MICINN [ITP-09000-2010-002]; European Regional Development Fund (FEDER)European Union (EU)	This study was partially supported by grants from the Spanish Carlos III Health Institute: FIS 10/943 and RD12/0026/0001 (Red SAMID: Maternal, Child Health and Development Research Network, within the framework of the VI Spanish National Plan for R+D+i 2008-2012). It was also supported by a predoctoral grant to one of the authors (EE) from the Research Staff Training Program (Basque Country Government) and by an INNPACTO project of the Spanish Ministry of Science and Innovation - MICINN (ITP-09000-2010-002), which is financed by the European Regional Development Fund (FEDER). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alvarez FJ, 2008, PEDIATR RES, V64, P653, DOI 10.1203/PDR.0b013e318186e5dd; ANAND KJS, 1987, LANCET, V1, P62; Anzenbacher P, 1998, DRUG METAB DISPOS, V26, P56; Aranda JV, 2005, CLIN THER, V27, P877, DOI 10.1016/j.clinthera.2005.06.019; Bernet V, 2010, PEDIATR RES, V67, P650, DOI 10.1203/PDR.0b013e3181da44ba; Calvo R, 2006, CURR PHARM DESIGN, V12, P977, DOI 10.2174/138161206776055967; COLLINS C, 1985, ANESTH ANALG, V64, P1078; da Silva O, 1999, J Perinatol, V19, P120, DOI 10.1038/sj.jp.7200145; Dewhirst E, 2012, PEDIATR EMERG CARE, V28, P465, DOI 10.1097/PEC.0b013e3182535a2a; Encinas E, 2013, PEDIATR DRUGS, V15, P10; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; FRIESEN RH, 1986, ANESTHESIOLOGY, V64, P238, DOI 10.1097/00000542-198602000-00018; Fritz HG, 2005, ANESTH ANALG, V100, P996, DOI 10.1213/01.ANE.0000146517.17910.54; Guinsburg R, 1996, J PEDIAT, V132, P954; HICKEY PR, 1985, ANESTH ANALG, V64, P483; Hsu Benson, 2009, WMJ, V108, P343; IRAZUZTA J, 1993, CRIT CARE MED, V21, P1001, DOI 10.1097/00003246-199307000-00013; ITOH H, 1993, CAN J VET RES, V57, P74; Kuroha M, 2001, J VET PHARMACOL THER, V24, P423, DOI 10.1046/j.1365-2885.2001.00367.x; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; McNamara PJ, 2002, AAPS PHARMSCI, V4; Modanlou HCD, 1996, J INVEST MED, V44, P362; Norman E, 2013, PEDIATR RES, V73, P87, DOI 10.1038/pr.2012.153; Prakash Smita, 2010, J Anaesthesiol Clin Pharmacol, V26, P567; Rajan V, 1998, BIOL NEONATE, V74, P39, DOI 10.1159/000014009; ROBINSON S, 1981, ANESTH ANALG, V60, P331; ROSOW CE, 1982, ANESTHESIOLOGY, V56, P93, DOI 10.1097/00000542-198202000-00003; Roth WJ, 2013, AAPS J, V15, P763, DOI 10.1208/s12248-013-9482-6; SCHIEBER RA, 1985, ANESTHESIOLOGY, V63, P166, DOI 10.1097/00000542-198508000-00009; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; Sen S, 2004, INTENS CARE MED, V30, P496, DOI 10.1007/s00134-003-2141-0; Smith RP, 2004, AM J OBSTET GYNECOL, V190, P836, DOI 10.1016/j.ajog.2003.09.064; Tsuji M, 1998, PEDIATR RES, V44, P591, DOI 10.1203/00006450-199810000-00020; WELLS S, 1994, HEART LUNG, V23, P196; YASTER M, 1987, ANESTHESIOLOGY, V66, P524, DOI 10.1097/00000542-198704000-00013; YASTER M, 1987, ANESTHESIOLOGY, V66, P433, DOI 10.1097/00000542-198703000-00035	36	7	7	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2014	9	3							e90728	10.1371/journal.pone.0090728			10	Multidisciplinary Sciences	Science & Technology - Other Topics	AC4FD	WOS:000332475500092	24595018	DOAJ Gold, Green Published			2020-06-30	J	Nacitarhan, C; Minareci, E; Sadan, G				Nacitarhan, C.; Minareci, E.; Sadan, G.			The Effect of Benfotiamine on Mu-opioid Receptor Mediated Antinociception in Experimental Diabetes	EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES			English	Article						diabetic neuropathy; benfotiamine; nociception; opioid	NEUROPATHIC PAIN; DOUBLE-BLIND; B VITAMINS; PERIPHERAL NEUROPATHY; THIAMINE-DEFICIENCY; RATS; EFFICACY; GLYCATION; MELLITUS; MODEL	Diabetic neuropathy is a prevalent, disabling disorder. Currently, the only treatments available to patients with diabetic neuropathy are glucose control and pain management. B vitamin present neuroprotective effects, which are suggested to be related to their analgesic action in various models of neuropathic pain. According to our literature knowledge there is no report about antinociceptive effects of thiamine as benfotiamine and opioids together in diabetic mice. The purpose of this study was to determine the effects of benfotiamine on the antinociception produced by mu-opioid receptor agonist fentanyl in diabetic mice. The effects of benfotiamine on antinociception produced by fentanyl in diabetic mice were studied in 4 groups. Antinociceptive effect was determined with tail flick, hot plate and formalin test. Our results showed that, mu-opioid agonist fentanyl in benfotiamine applied diabetic group caused more potent antinociceptive effect than in diabetic group without benfotiamine treatment. In brief benfotiamine supplement in diet did not bring out antinociceptive effect itself, but during development of STZ diabetes, benfotiamine replacement increased the antinociceptive effect of fentanyl in mice tail-flick test. This effect is probably due to the replacement of benfotiamine efficiency occuring in diabetes mellitus. Finally, we suppose that oral benfotiamine replacement therapy may be useful to ameliorate analgesic effect of mu-opioid agonists on neuropathic pain in diabetic case.	[Nacitarhan, C.; Minareci, E.; Sadan, G.] Akdeniz Univ, Sch Med, Dept Pharmacol, TR-07058 Antalya, Turkey	Nacitarhan, C (reprint author), Akdeniz Univ, Sch Med, Dept Pharmacol, TR-07058 Antalya, Turkey.	cahitnt@akdeniz.edu.tr	Karasu Minareci, Edibe/B-9971-2016				Agrawal RP, 2009, DIABETES RES CLIN PR, V83, P371, DOI 10.1016/j.diabres.2008.12.018; Aley KO, 2001, J PAIN, V2, P146, DOI 10.1054/jpai.2001.21592; ARNER S, 1988, PAIN, V33, P11, DOI 10.1016/0304-3959(88)90198-4; Balakumar P, 2010, PHARMACOL RES, V61, P482, DOI 10.1016/j.phrs.2010.02.008; Beltramo E, 2008, ACTA DIABETOL, V45, P131, DOI 10.1007/s00592-008-0042-y; BERNSTEIN AL, 1993, J AM COLL NUTR, V12, P73; Bierhaus A, 2012, NAT MED, V18, P926, DOI 10.1038/nm.2750; Bosi E, 2005, DIABETOLOGIA, V48, P817, DOI 10.1007/s00125-005-1734-2; BRADY JA, 1995, J AM DIET ASSOC, V95, P541, DOI 10.1016/S0002-8223(95)00148-4; Bril V, 2011, NEUROLOGY, V76, P1758, DOI 10.1212/WNL.0b013e3182166ebe; Bril V, 2012, J PERIPHER NERV SYST, V17, P22, DOI 10.1111/j.1529-8027.2012.00391.x; Callaghan BC, 2012, LANCET NEUROL, V11, P521, DOI 10.1016/S1474-4422(12)70065-0; Cameron NE, 2005, ANN NY ACAD SCI, V1043, P784, DOI 10.1196/annals.1333.091; Centers for Disease Control and Prevention, 2011, NAT DIAB FACT SHEET; Chen SR, 2002, ANESTHESIOLOGY, V97, P1602, DOI 10.1097/00000542-200212000-00037; Courteix C, 1998, J PHARMACOL EXP THER, V285, P63; COURTEIX C, 1993, PAIN, V53, P81, DOI 10.1016/0304-3959(93)90059-X; COURTEIX C, 1994, PAIN, V57, P153, DOI 10.1016/0304-3959(94)90218-6; Ertas M, 1998, PAIN, V75, P257, DOI 10.1016/S0304-3959(98)00003-7; ESCHALIER A, 1983, PSYCHOPHARMACOLOGY, V81, P228, DOI 10.1007/BF00427267; Eyigor C, 2009, PEDIATR ANESTH, V19, P193, DOI 10.1111/j.1460-9592.2008.02819.x; Feldman EL, 1999, CURR OPIN NEUROL, V12, P553, DOI 10.1097/00019052-199910000-00009; Forst T, 2002, ACTA DIABETOL, V39, P1, DOI 10.1007/s005920200005; Gale EAM, 2001, DIABETES, V50, P217, DOI 10.2337/diabetes.50.2.217; Gastaldi G, 2000, KIDNEY INT, V57, P2043, DOI 10.1046/j.1523-1755.2000.00053.x; Gong Ya-Hong, 2011, Acta Anaesthesiol Taiwan, V49, P16, DOI 10.1016/j.aat.2011.01.003; Granados-Soto V, 2004, P W PHARMACOL SOC, P92; Harati Y, 1998, NEUROLOGY, V50, P1842, DOI 10.1212/WNL.50.6.1842; HAVIVI E, 1991, INT J VITAM NUTR RES, V61, P328; Jolivalt CG, 2009, EUR J PHARMACOL, V612, P41, DOI 10.1016/j.ejphar.2009.04.028; Kadiroglu AK, 2008, J DIABETES COMPLICAT, V22, P241, DOI 10.1016/j.jdiacomp.2007.03.010; Kamenov ZA, 2013, ADV EXP MED BIOL, V771, P155; Kasuya Daichi, 2012, Rinsho Shinkeigaku, V52, P1290; Khalil H, 2013, INT J EVID-BASED HEA, V11, P77, DOI 10.1111/1744-1609.12010; Koivisto A, 2013, SCAND J PAIN, V4, P129, DOI 10.1016/j.sjpain.2012.11.001; Kopruszinski CM, 2012, LIFE SCI, V91, P1187, DOI 10.1016/j.lfs.2012.08.025; Kukkar A, 2013, ARCH PHARM RES, V36, P237, DOI 10.1007/s12272-013-0057-y; KURAISHI Y, 1983, BRAIN RES, V273, P245, DOI 10.1016/0006-8993(83)90849-1; Mibielli MA, 2009, CURR MED RES OPIN, V25, P2589, DOI 10.3111/13696990903246911; Mibielli Marco Antonio, 2010, Proc West Pharmacol Soc, V53, P5; Montiel-Ruiz Rosa Mariana, 2009, Proc West Pharmacol Soc, V52, P67; Nagai R, 2014, AMINO ACIDS, V46, P261, DOI 10.1007/s00726-013-1487-z; Obrenovich Mark E, 2003, Sci Aging Knowledge Environ, V2003, pPE6, DOI 10.1126/sageke.2003.10.pe6; Ohsawa M, 1999, EUR J PHARMACOL, V372, P221, DOI 10.1016/S0014-2999(99)00228-9; Page GLJ, 2011, INT J CLIN PRACT, V65, P684, DOI 10.1111/j.1742-1241.2011.02680.x; Pitel S, 2007, J NUTR, V137, P368; Rabbani N, 2011, DIABETES OBES METAB, V13, P577, DOI 10.1111/j.1463-1326.2011.01384.x; Radu BM, 2012, CELL MOL NEUROBIOL, V32, P1047, DOI 10.1007/s10571-012-9823-5; SAARTO T, 2005, [No title captured], V3, DOI DOI 10.1002/14651858.CD005454; SAITO N, 1987, J NUTR SCI VITAMINOL, V33, P421, DOI 10.3177/jnsv.33.421; Sanchez-Ramirez GM, 2006, EUR J PHARMACOL, V530, P48, DOI 10.1016/j.ejphar.2005.11.016; Shaibani AI, 2012, PAIN MED, V13, P243, DOI 10.1111/j.1526-4637.2011.01316.x; Shaqura M, 2013, J PAIN, V14, P720, DOI 10.1016/j.jpain.2013.01.776; Sindrup SH, 2005, BASIC CLIN PHARMACOL, V96, P399, DOI 10.1111/j.1742-7843.2005.pto_96696601.x; Stirban A, 2006, DIABETES CARE, V29, P2064, DOI 10.2337/dc06-0531; Stracke H, 2008, EXP CLIN ENDOCR DIAB, V116, P600, DOI 10.1055/s-2008-1065351; Stracke H, 2001, EXP CLIN ENDOCR DIAB, V109, P330, DOI 10.1055/s-2001-17399; Thornalley PJ, 2007, DIABETOLOGIA, V50, P2164, DOI 10.1007/s00125-007-0771-4; Thornalley PJ, 2002, INT REV NEUROBIOL, V50, P37; TOMIYASU K, 1991, ACTA NEUROPATHOL, V81, P396, DOI 10.1007/BF00293460; Varkonyi T, 2008, DIABETES OBES METAB, V10, P99, DOI 10.1111/j.1463-1326.2007.00741.x; Verrotti A, 2001, J CHILD NEUROL, V16, P389; Vincent AM, 2011, NAT REV NEUROL, V7, P573, DOI 10.1038/nrneurol.2011.137; Vindedzis SA, 2008, DIABETES VASC DIS RE, V5, P215, DOI 10.3132/dvdr.2008.035; Vinik AI, 2007, PAIN, V128, P169, DOI 10.1016/j.pain.2006.09.040; Wernicke JF, 2006, NEUROLOGY, V67, P1411, DOI 10.1212/01.wnl.0000240225.04000.1a; Wright JM, 1997, ANN PHARMACOTHER, V31, P29, DOI 10.1177/106002809703100103; Wyatt KM, 1999, BMJ-BRIT MED J, V318, P1375, DOI 10.1136/bmj.318.7195.1375; Yamamoto H, 2009, NEUROPHARMACOLOGY, V57, P403, DOI 10.1016/j.neuropharm.2009.06.037; Zurek JR, 2001, PAIN, V90, P57, DOI 10.1016/S0304-3959(00)00386-9	70	5	5	0	7	JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH	STUTTGART	RUEDIGERSTR 14, D-70469 STUTTGART, GERMANY	0947-7349	1439-3646		EXP CLIN ENDOCR DIAB	Exp. Clin. Endocrinol. Diabet.	MAR	2014	122	3					173	178		10.1055/s-0033-1363977			6	Endocrinology & Metabolism	Endocrinology & Metabolism	AY2FF	WOS:000347403300241	24643695				2020-06-30	J	Chen, SY; Lin, PL; Yang, YH; Yang, YM; Lee, CN; Fan, SZ; Chen, LK				Chen, Shin-Yan; Lin, Pei-Lin; Yang, Yu-Hsuan; Yang, Ya-Min; Lee, Chien-Nan; Fan, Shou-Zen; Chen, Li-Kuei			The effects of different epidural analgesia formulas on labor and mode of delivery in nulliparous women	TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY			English	Article						analgesia; analgesic techniques (epidural); anesthetics local (bupivacaine); anesthetics local (ropivacaine); patient-controlled analgesic techniques	MOTOR BLOCKING POTENCIES; VAGINAL DELIVERY; CESAREAN DELIVERY; ROPIVACAINE; BUPIVACAINE; LEVOBUPIVACAINE; FENTANYL; 0.2-PERCENT; ANESTHESIA; INFUSIONS	Objectives: Patient-controlled epidural analgesia (PCEA) and continuous epidural infusion (CEI) are popular and effective methods for pain relief during labor; however, there are concerns about increasing rates of cesarean section (C/S) and instrumental delivery. This prospective study investigated the effect of PCEA and CEI with different formulas on labor and the mode of delivery in nulliparous women. Materials and methods: A total of 480 nulliparous women were randomized into four groups, with 120 in each. Group A received a loading dose of 10 mL of 1 mg/mL. ropivacaine with 2 mu g/mL fentanyl, then an intermittent bolus of 5 mL. with a background infusion of 5 mL/hour by PCEA. Group B received the same PCEA formula as Group A with 0.8 mg/mL bupivacaine. Group C received the same formula as Group A by CEI with 1 mg/mL ropivacaine at a rate of 10 mL/hour. Group D received the same formula as Group C with 0.8 mg/mL. bupivacaine. The rates of C/S and instrumental delivery and the incidence of side effects were recorded. Results: The rates of C/S were significantly different between Groups A and C. Groups A and D, and Groups B and D. The rates of instrumental delivery for normal spontaneous delivery were significantly different between Groups A and B, A and D, B and C. and C and D. Conclusion: The C/S rate was higher in Groups C and D; however, the instrumental delivery rate was lower in Groups A and C. We conclude that PCEA with 1 mg/mL ropivacaine might provide the greatest benefit for labor analgesia. Copyright (C) 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.	[Chen, Shin-Yan] Taipei Med Univ, Shuang Ho Hosp, Dept Anesthesiol, New Taipei City, Taiwan; [Lin, Pei-Lin; Yang, Yu-Hsuan; Yang, Ya-Min; Fan, Shou-Zen; Chen, Li-Kuei] Natl Taiwan Univ Hosp, Coll Med, Dept Anesthesiol, Taipei, Taiwan; [Lee, Chien-Nan] Natl Taiwan Univ Hosp, Coll Med, Dept Obstet & Gynecol, Taipei, Taiwan; [Chen, Li-Kuei] Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; [Chen, Li-Kuei] Natl Taiwan Univ Hosp, Dept Anesthesiol, Hsin Chu Branch, Hsinchu, Taiwan	Chen, LK (reprint author), Natl Taiwan Univ Hosp, Dept Anesthesiol, 7 Chung Shan South Rd, Taipei, Taiwan.	clk0619kimo@msn.com		LIN, PEI-LIN/0000-0002-0513-6228; CHEN, LI-KUEI/0000-0003-1946-4828; Fan, Shou-Zen/0000-0002-6849-8453; Lee, Chien-Nan/0000-0002-1725-0407			Asik I, 2002, EUR J ANAESTH, V19, P263; Beilin Y, 2000, ACTA ANAESTH SCAND, V44, P959, DOI 10.1034/j.1399-6576.2000.440811.x; Beilin Y, 2007, ANESTH ANALG, V105, P756, DOI 10.1213/01.ane.0000278131.73472.f4; Beilin Y, 2010, ANESTH ANALG, V111, P482, DOI 10.1213/ANE.0b013e3181e3a08e; Bolukbasi D, 2005, INT J OBSTET ANESTH, V14, P288, DOI 10.1016/j.ijoa.2005.04.007; Cederholm I, 1997, DRUG SAFETY, V16, P391, DOI 10.2165/00002018-199716060-00005; Cherian MN, 2007, ANAESTHESIA, V62, P65, DOI 10.1111/j.1365-2044.2007.05302.x; Eddleston JM, 1996, BRIT J ANAESTH, V76, P66; Evron S, 2004, INT J OBSTET ANESTH, V13, P5, DOI 10.1016/S0959-289X(03)00092-X; Gaiser RR, 1997, J CLIN ANESTH, V9, P564, DOI 10.1016/S0952-8180(97)00145-1; Halonen P, 2004, ACTA ANAESTH SCAND, V48, P732, DOI 10.1111/j.0001-5172.2004.00413.x; Halpern SH, 2003, ANESTHESIOLOGY, V98, P1431, DOI 10.1097/00000542-200306000-00020; Halpern SH, 2003, ANESTH ANALG, V96, P1473, DOI 10.1213/01.ANE.0000052383.01056.8F; Halpern S, 2005, CURR OPIN ANESTHESIO, V18, P247, DOI 10.1097/01.aco.0000169229.75938.c8; Halpern SH, 2009, ANESTH ANALG, V108, P921, DOI 10.1213/ane.0b013e3181951a7f; Hawkins JL, 1997, ANESTHESIOLOGY, V87, P135, DOI 10.1097/00000542-199707000-00018; Hofmann-Kiefer K, 2002, ACTA ANAESTH SCAND, V46, P316, DOI 10.1034/j.1399-6576.2002.t01-1-460315.x; Hwa HL, 2006, J FORMOS MED ASSOC, V105, P722, DOI 10.1016/S0929-6646(09)60200-X; Kuczkowski KM, 2004, INT J CLIN PRACT, V58, P604, DOI 10.1111/j.1368-5031.2004.00114.x; Lacassie HJ, 2007, REGION ANESTH PAIN M, V32, P323, DOI 10.1016/j.rapm.2007.05.003; Lacassie HJ, 2002, ANESTH ANALG, V95, P204, DOI 10.1097/00000539-200207000-00036; Lacassie HJ, 2003, ANESTH ANALG, V97, P1509, DOI 10.1213/01.ANE.0000083375.48151.FF; Lee BB, 2004, ANESTH ANALG, V98, P1145, DOI 10.1213/01.ANE.0000103264.71747.0F; Liu EHC, 2004, BMJ-BRIT MED J, V328, P1410, DOI 10.1136/bmj.38097.590810.7C; Owen MD, 2002, ANESTH ANALG, V94, P179, DOI 10.1097/00000539-200201000-00034; RAMIN SM, 1995, OBSTET GYNECOL, V86, P783, DOI 10.1016/0029-7844(95)00269-W; Schabel JE, 1997, GYNECOL OBSTET INVES, V44, P73, DOI 10.1159/000291491; SMEDSTAD KG, 1988, CAN J ANAESTH, V35, P234, DOI 10.1007/BF03010616; STIENSTRA R, 1995, ANESTH ANALG, V80, P285, DOI 10.1097/00000539-199502000-00014; Stienstra Rudolf, 2001, Current Topics in Medicinal Chemistry, V1, P215, DOI 10.2174/1568026013395218; Yancey MK, 1999, AM J OBSTET GYNECOL, V180, P353, DOI 10.1016/S0002-9378(99)70213-9	31	12	17	0	7	ELSEVIER TAIWAN	TAIPEI	RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2, TAIPEI, 10449, TAIWAN	1028-4559			TAIWAN J OBSTET GYNE	Taiwan. J. Obstet. Gynecol.	MAR	2014	53	1					8	11		10.1016/j.tjog.2012.01.039			4	Obstetrics & Gynecology	Obstetrics & Gynecology	AT8JC	WOS:000345178400003	24767638	DOAJ Gold			2020-06-30	J	Ting, CK; Johnson, KB; Teng, WN; Synoid, ND; LaPierre, C; Yu, L; Westenskow, DR				Ting, Chien-Kun; Johnson, Ken B.; Teng, Wei-Nung; Synoid, Noah D.; LaPierre, Cris; Yu, Lu; Westenskow, Dwayne R.			Response Surface Model Predictions of Wake- Up Time During Scoliosis Surgery	ANESTHESIA AND ANALGESIA			English	Article							ALVEOLAR ANESTHETIC CONCENTRATION; PROPOFOL-REMIFENTANIL ANESTHESIA; SEVOFLURANE REQUIREMENTS; UP TEST; INHALATION ANESTHESIA; CONCENTRATION-AWAKE; CONTROLLED INFUSION; SYSTEM MODEL; FENTANYL; DESFLURANE	BACKGROUND: With the use of previously published data, new sevoflurane-remifentanil interaction models of various degrees of sedation were created and adapted to desflurane-fentanyl by using minimal alveolar concentration and opioid equivalencies. These models were used to predict return of responsiveness in patients undergoing scoliosis surgery during a wake-up test. Our hypothesis was that one of the interaction models would accurately predict return of responsiveness during a wake-up test. METHODS: Three new sevoflurane-remifentanil interaction models were constructed from previous observations in volunteers by using the Observer's Assessment of Alertness/Sedation (OAA/S) scores. These models included predictions of OAA/S<2 (unresponsive), OAA/S< 3, and OAA/S<4 (sedation). Twenty-three patients scheduled for scoliosis surgery received a fentanyl-desflurane anesthetic. With the use of published pharmacokinetic models, predictions of fentanyl and desflurane effect-site concentrations were recorded throughout surgery and converted to equivalent remifentanil and sevoflurane effect-site concentrations. Data were recorded every 10 seconds from the time when desflurane was turned off until 10 minutes after the patients responded by moving their hands and toes. Model predictions were compared with observations with graphical and temporal analyses. RESULTS: The average difference between the time when a patient first responded and the time when the model predicted that there was a 50% probability that the patient would respond were -2.6 3.6 minutes (mean +/- SD) for the OAA/S<2 model, 2.8 +/- 5.6 minutes for the OAA/S<3 model and 52.6 +/- 32.3 minutes for the OAA/S<4 model. CONCLUSIONS: The results confirmed our study hypothesis; a sevoflurane-remifentanil interaction model built from observations in volunteers and adapted to desflurane and fentanyl accurately predicted patient response during a wake-up test. These results were similar to our previous study comparing model predictions and patient observations after a sevoflurane-remifentanil/fentanyl anesthetic. The OAA/S <2 model most accurately predicted the time patients would respond by moving their fingers and toes. This model may help anesthesiologists better predict return of responsiveness during a wake-up test in patients undergoing spine surgery.	[Ting, Chien-Kun; Teng, Wei-Nung] Taipei Vet Gen Hosp, Dept Anesthesiol, Taipei, Taiwan; [Ting, Chien-Kun; Teng, Wei-Nung] Natl Yang Ming Univ, Taipei 112, Taiwan; [Johnson, Ken B.; Synoid, Noah D.; Westenskow, Dwayne R.] Univ Utah Sch Med, Dept Anesthesiol, Salt Lake City, UT USA; [Johnson, Ken B.; Westenskow, Dwayne R.] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA; [LaPierre, Cris] Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; [LaPierre, Cris] Massachusetts Gen Hosp, Dept Radiol, AA Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Yu, Lu] China Med Univ, Dept Biomed Engn, Coll Basic Med Sci, Shenyang, Liaoning, Peoples R China	Ting, CK (reprint author), Taipei Vet Gen Hosp, Dept Anesthesiol, 201,Sect 2,Shi Pai Rd, Taipei, Taiwan.	ckting2@gmail.com	Ting, Chien-Kun/C-1389-2012	Ting, Chien-Kun/0000-0002-3156-8139; Teng, Wei-Nung/0000-0002-9619-9848			Bol CJJG, 2000, J PHARMACOL EXP THER, V294, P347; Chen Yi-Chun, 2010, Acta Anaesthesiol Taiwan, V48, P185, DOI 10.1016/j.aat.2010.12.005; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; CHORTKOFF BS, 1995, ANESTH ANALG, V81, P737, DOI 10.1097/00000539-199510000-00014; Daniel M, 1998, ANESTHESIOLOGY, V88, P43, DOI 10.1097/00000542-199801000-00009; EGER EI, 1992, ANESTH ANALG, V75, pS3; Eger EI, 2001, ANESTH ANALG, V93, P947, DOI 10.1097/00000539-200110000-00029; Eger II EI, 2003, PHARM INHALED ANESTH; Eggspuehler A, 2007, EUR SPINE J, V16, pS188, DOI 10.1007/s00586-007-0427-6; Gin T, 2010, ANESTH ANALG, V111, P256, DOI 10.1213/ANE.0b013e3181e63008; GRECO WR, 1995, PHARMACOL REV, V47, P331; Inomata S, 1999, ANESTH ANALG, V89, P204; Johnson KB, 2010, ANESTH ANALG, V111, P387, DOI 10.1213/ANE.0b013e3181afe31c; JONES RM, 1990, ANESTH ANALG, V70, P3; Katoh T, 1998, ANESTHESIOLOGY, V88, P18, DOI 10.1097/00000542-199801000-00006; Katoh T, 1999, ANESTHESIOLOGY, V90, P398, DOI 10.1097/00000542-199902000-00012; KATOH T, 1993, ANESTH ANALG, V76, P348; KATOH T, 1987, ANESTHESIOLOGY, V66, P301, DOI 10.1097/00000542-198703000-00006; Kennedy RR, 2010, ANESTH ANALG, V111, P252, DOI 10.1213/ANE.0b013e3181e62ff1; KIMURA T, 1994, ANESTH ANALG, V79, P378; Lang E, 1996, ANESTHESIOLOGY, V85, P721, DOI 10.1097/00000542-199610000-00006; LEROU JGC, 1991, ANESTHESIOLOGY, V75, P345, DOI 10.1097/00000542-199108000-00025; Lerou JGC, 2001, BRIT J ANAESTH, V86, P12, DOI 10.1093/bja/86.1.12; Luk KDK, 2001, SPINE, V26, P1772; Manyam SC, 2006, ANESTHESIOLOGY, V105, P267, DOI 10.1097/00000542-200608000-00009; Miller RD, 2010, MILLERS ANESTHESIA; RAMPIL IJ, 1991, ANESTHESIOLOGY, V74, P429, DOI 10.1097/00000542-199103000-00007; Rehberg S, 2008, ANESTHESIOLOGY, V109, P629, DOI 10.1097/ALN.0b013e31818629c2; SCHELLER MS, 1988, CAN J ANAESTH, V35, P153, DOI 10.1007/BF03010656; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; SEBEL PS, 1992, ANESTHESIOLOGY, V76, P52, DOI 10.1097/00000542-199201000-00008; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; Short TG, 2010, ANESTH ANALG, V111, P249, DOI 10.1213/ANE.0b013e3181e5f0ce; Somma J, 1998, ANESTHESIOLOGY, V89, P1430, DOI 10.1097/00000542-199812000-00021; Suzuki A, 1998, ANESTH ANALG, V86, P179, DOI 10.1097/00000539-199801000-00035; Syroid ND, 2010, ANESTH ANALG, V111, P380, DOI 10.1213/ane.0b013e3181b11289; van Oud-Alblas HJB, 2008, ANESTH ANALG, V107, P1683, DOI 10.1213/ane.0b013e3181852d94; VOZEH S, 1990, J PHARMACOKINET BIOP, V18, P161, DOI 10.1007/BF01063558; Yamaguchi Kyoko, 2010, Masui, V59, P1522; Yao WL, 2007, CHINESE MED J-PEKING, V120, P1013, DOI 10.1097/00029330-200706010-00014	40	12	13	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAR	2014	118	3					546	553		10.1213/ANE.0000000000000094			8	Anesthesiology	Anesthesiology	AG4NG	WOS:000335396200012	24557102				2020-06-30	J	Yoshida, T; Fujiwara, T; Furutani, K; Ohashi, N; Baba, H				Yoshida, T.; Fujiwara, T.; Furutani, K.; Ohashi, N.; Baba, H.			Effects of ropivacaine concentration on the spread of sensory block produced by continuous thoracic paravertebral block: a prospective, randomised, controlled, double-blind study	ANAESTHESIA			English	Article							POSTOPERATIVE ANALGESIA; EPIDURAL-ANESTHESIA; INFUSION; SURGERY; THORACOTOMY; INJECTION; LIDOCAINE; SPACE	Factors affecting the distribution of continuous thoracic paravertebral block have never been examined. We designed this prospective, double-blind study to check whether continuous thoracic paravertebral block with a higher ropivacaine concentration would provide a wider segmental sensory block spread. Sixty consecutive patients undergoing pulmonary lobectomy or segmentectomy were randomly allocated to receive continuous paravertebral infusion of either 0.2% or 0.5% ropivacaine (6ml.h(-1)). The primary outcome was the number of anaesthetised dermatomes as determined by loss of cold sensation 24h after surgery. Twenty-seven patients per group were included in the final analysis. The median (IQR [range]) number of anaesthetised dermatomes 24h after surgery was 4 (3-6 [1-9]) with ropivacaine 0.2% and 4 (3-6 [2-11]) with ropivacaine 0.5% (p=0.66). Contrary to our expectation, the segmental spread of sensory block produced by continuous thoracic paravertebral block does not depend on ropivacaine concentration.	[Yoshida, T.; Fujiwara, T.; Furutani, K.; Ohashi, N.; Baba, H.] Niigata Univ, Grad Sch Med & Dent Sci, Div Anesthesiol, Niigata, Japan	Yoshida, T (reprint author), Niigata Univ, Grad Sch Med & Dent Sci, Div Anesthesiol, Niigata, Japan.	ytaka@mac.com	Yoshida, Takayuki/X-3812-2019	Yoshida, Takayuki/0000-0002-5083-894X			BROMAGE PR, 1975, BRIT J ANAESTH, V47, P199; Casati A, 2006, EUR J ANAESTH, V23, P999, DOI 10.1017/S0265021506001104; Catala E, 1996, J CARDIOTHOR VASC AN, V10, P586, DOI 10.1016/S1053-0770(96)80133-9; Cheema S, 2003, ANAESTHESIA, V58, P684, DOI 10.1046/j.1365-2044.2003.03189_1.x; CHEEMA SPS, 1995, ANAESTHESIA, V50, P118, DOI 10.1111/j.1365-2044.1995.tb15092.x; Curatolo M, 2000, ANESTHESIOLOGY, V93, P1517, DOI 10.1097/00000542-200012000-00025; Daly DJ, 2009, CURR OPIN ANESTHESIO, V22, P38, DOI 10.1097/ACO.0b013e32831a4074; Dernedde M, 2003, ANESTH ANALG, V96, P796, DOI 10.1213/01/ANE.0000048977.66133.D5; Joshi GP, 2008, ANESTH ANALG, V107, P1026, DOI 10.1213/01.ane.0000333274.63501.ff; Kamiya Y, 2009, ANESTHESIOLOGY, V110, P1127, DOI 10.1097/ALN.0b013e31819daf15; Karmakar MK, 2001, ANESTHESIOLOGY, V95, P771, DOI 10.1097/00000542-200109000-00033; Kotze A, 2009, BRIT J ANAESTH, V103, P626, DOI 10.1093/bja/aep272; Lonnqvist PA, 1993, PAEDIATRIC ANAESTHES, V3, P83; Marhofer D, 2013, ANESTHESIOLOGY, V118, P1106, DOI 10.1097/ALN.0b013e318289465f; Naja MZ, 2004, ANAESTHESIA, V59, P459, DOI 10.1111/j.1365-2044.2004.03705.x; Powell ES, 2011, BRIT J ANAESTH, V106, P364, DOI 10.1093/bja/aeq379; Renes SH, 2010, REGION ANESTH PAIN M, V35, P212, DOI 10.1097/AAP.0b013e3181c75a8b; Saito T, 2001, ACTA ANAESTH SCAND, V45, P30, DOI 10.1034/j.1399-6576.2001.450105.x; Scawn NDA, 2001, ANESTH ANALG, V93, P260, DOI 10.1097/00000539-200108000-00004; SCOTT DA, 1995, ANESTH ANALG, V81, P982, DOI 10.1097/00000539-199511000-00015; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Shibata Y, 2009, ANESTH ANALG, V109, P996, DOI 10.1213/ane.0b013e3181af7e7b; Visser WA, 2008, ANESTH ANALG, V107, P708, DOI 10.1213/ane.0b013e31817e7065	23	22	26	0	5	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	MAR	2014	69	3					231	239		10.1111/anae.12531			9	Anesthesiology	Anesthesiology	AA8PZ	WOS:000331358700008	24447266				2020-06-30	J	Joshi, GP; Kamali, A; Meng, J; Rosero, E; Gasanova, I				Joshi, Girish P.; Kamali, Amin; Meng, Jin; Rosero, Eric; Gasanova, Irina			Effects of fentanyl administration before induction of anesthesia and placement of the Laryngeal Mask Airway: a randomized, placebo-controlled trial	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Airway responses; Desflurane; Fentanyl pretreatment; Laryngeal Mask Airway	AMBULATORY ANESTHESIA; DESFLURANE; SEVOFLURANE; MAINTENANCE; RESPONSES; RECOVERY; PROPOFOL; DEVICES; PAIN	Study Objective: To assess the effects of fentanyl administered before induction of anesthesia on movement and airway responses during desflurane anesthesia via the Laryngeal Mask Airway (LMA). Design: Randomized, double-blinded, controlled trial. Study Setting: Tertiary-care academic center. Patients: 100 adult, ASA physical status 1, 2, and 3 patients undergoing ambulatory surgery. Interventions: Patients were administered fentanyl 1 mu g/kg (n=51) or saline (n=49) 3 to 5 minutes before induction with propofol 2-2.5 mg/kg intravenously (IV), followed by LMA placement. Anesthesia was maintained with desflurane titrated to a bispectral index (BIS) of 50-60 and 50% nitrous oxide in oxygen, and fentanyl 25 mu g boluses were titrated to respiratory rate. Measurements: Apnea occurrence and duration of manual ventilation, as well as frequency and severity of movement, coughing, breath holding, and laryngospasm were recorded. Main Results: Two patients in each group were excluded from analysis. The fentanyl pretreatment group had a higher frequency of apnea (94% vs 64%; P=0.0003) and longer duration of manual ventilation (3 [interquartile range (IQR), 1.5-5] min vs 1 [0-1.5] min; P<0.0001) at induction. In contrast, the fentanyl pretreatment group had a lower frequency of movements (16% vs 51%; P=0.0001). The rates of intraoperative breath holding (6.1% vs 8.5%) and laryngospasm (2% vs 4.3%) in the two groups were similar. All subjects experiencing laryngospasm were smokers. Adjusting for smoking status did not affect the differences noted in apnea, duration of manual ventilation, or movement between groups; however, coughing occurrence was statistically higher in the placebo group (P=0.043). Conclusions: Preinduction fentanyl increased the frequency of apnea at induction and duration of manual ventilation, but reduced the frequency of movements. In addition, it reduced intraoperative coughing in smokers. (C) 2014 Elsevier Inc. All rights reserved.	[Joshi, Girish P.; Kamali, Amin; Meng, Jin; Rosero, Eric; Gasanova, Irina] Univ Texas SW Med Ctr Dallas, Dept Anesthesiol & Pain Management, Dallas, TX 75390 USA	Joshi, GP (reprint author), Univ Texas SW Med Ctr Dallas, Dept Anesthesiol & Pain Management, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	girish.joshi@utsouthwestem.edu	kamali, alireza/H-1752-2017		Baxter Healthcare Corporation, Deerfield, IL, USA	Baxter Healthcare Corporation, Deerfield, IL, USA. Girish P. Joshi, MB BS, MD, FFARCSI, has received honoraria for speaking from Baxter Healthcare Corporation. No other authors have any conflicts of interest to disclose.	Arain SR, 2005, ANESTHESIOLOGY, V103, P495, DOI 10.1097/00000542-200509000-00011; Chan A, 1996, ANAESTHESIA, V51, P663; De Oliveira GS, 2011, ANESTHESIOLOGY, V115, P575, DOI 10.1097/ALN.0b013e31822a24c2; Dexter F, 2010, ANESTH ANALG, V110, P570, DOI 10.1213/ANE.0b013e3181b5dcb7; Eger EI, 2005, ANESTH ANALG, V101, P688, DOI 10.1213/01.ANE.0000158611.15820.3D; Eger EI, 2001, ANESTH ANALG, V93, P947, DOI 10.1097/00000539-200110000-00029; Eshima RW, 2003, ANESTH ANALG, V96, P701, DOI 10.1213/01.ANE.0000048978.40522.AB; Hendrickx JFA, 2008, ANESTH ANALG, V107, P494, DOI 10.1213/ane.0b013e31817b859e; JONES RM, 1990, BRIT J ANAESTH, V65, P527, DOI 10.1093/bja/65.4.527; Joshi Girish P, 2003, Anesthesiol Clin North Am, V21, P263, DOI 10.1016/S0889-8537(02)00074-3; Joshi GP, 1997, ANESTH ANALG, V85, P573, DOI 10.1097/00000539-199709000-00016; JOSHI GP, 2001, SEMIN ANESTH PERIO M, V20, P257; LENLCOVSKY F, 2007, J CHIN ANESTH, V19, P530; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; Luba Katarzyna, 2010, Anesthesiol Clin, V28, P295, DOI 10.1016/j.anclin.2010.02.004; Mahmoud NA, 2001, ANAESTHESIA, V56, P171, DOI 10.1046/j.1365-2044.2001.01528.x; McKay RE, 2010, BRIT J ANAESTH, V104, P175, DOI 10.1093/bja/aep374; Mckay RE, 2006, ANESTH ANALG, V103, P1147, DOI 10.1213/01.ane.0000237293.39466.65; Nyktari V, 2011, BRIT J ANAESTH, V107, P454, DOI 10.1093/bja/aer155; Sahiner Y, 2011, EUR J ANAESTH, V28, P187, DOI 10.1097/EJA.0b013e3283433b83; Saros GB, 2006, ACTA ANAESTH SCAND, V50, P549, DOI 10.1111/j.1399-6576.2006.001022.x; SMITH I, 1993, J CLIN ANESTH, V5, pS22; Tan ASB, 2010, ANAESTH INTENS CARE, V38, P65, DOI 10.1177/0310057X1003800112; White PF, 2009, ANESTH ANALG, V109, P387, DOI 10.1213/ane.0b013e3181adc21a; Wong CM, 2007, ANAESTHESIA, V62, P654, DOI 10.1111/j.1365-2044.2007.05057.x	25	1	1	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	MAR	2014	26	2					136	142		10.1016/j.jclinane.2013.09.008			7	Anesthesiology	Anesthesiology	AF8QR	WOS:000334981200007	24629823				2020-06-30	J	Novotna, S; Valentova, K; Fricova, J; Richterova, E; Harabisova, S; Bullier, F; Trinquet, F				Novotna, Stanislava; Valentova, Klara; Fricova, Jitka; Richterova, Eva; Harabisova, Sarka; Bullier, Francoise; Trinquet, Francoise		ETHYFYL Study Grp	A Randomized, Placebo-Controlled Study of a New Sublingual Formulation of Fentanyl Citrate (Fentanyl Ethypharm) for Breakthrough Pain in Opioid-Treated Patients With Cancer	CLINICAL THERAPEUTICS			English	Article						breakthrough pain; cancer pain; fentanyl citrate; sublingual tablet	DOSE-TITRATION; DOUBLE-BLIND; TRIAL; MULTICENTER; PREVALENCE; CROSSOVER; SPRAY	Background: Oromucosal fentanyl is currently used for the treatment of breakthrough pain (BTP) in opioid-treated cancer patients. Ethypharm developed a sublingual formulation of fentanyl suprabioavailable to oral transmucosal fentanyl citrate with a higher early systemic exposure and a shorter T-max. Objectives: This study evaluated the efficacy and safety profile of fentanyl Ethypharm (FE) in relieving BTP in opioid-treated cancer patients. Methods: Opioid-treated adult cancer patients, experiencing 1 to 4 episodes of BTP per day, were included in the study. After an open-label titration period to identify an optimal dose that would provide adequate pain relief for 2 consecutive episodes of BTP with an acceptable level of adverse events, patients were randomly assigned to a double-blind, placebo-controlled, crossover period with 1 of 13 prespecified sequences of 9 tablets (6 tablets of FE of the dose identified during the open-label titration and 3 placebo). Pain intensity and pain relief were recorded at 3, 6, 10, 15, 30, and 60 minutes after study drug administration. Adverse events were recorded. The primary end point was the sum of pain intensity differences (SPID) at 30 minutes. Results: The distribution of optimal dosages of FE was as follows: 133 mu g, 35.9%; 267 mu g, 30.8%; 400 mu g, 14.1%; 533 mu g, 12.8%; and 800 mu g, 6.4%. In the modified intention-to-treat population (n = 73), FE significantly improved mean (SE) SPID compared with placebo at 30 minutes (75.0 [49.8] vs 52.5 [52.8]; P < 0.0001). FE significantly improved SPID, pain intensity difference, and pain relief compared with placebo from 6 to 60 minutes' postadministration. Patients with BTP who received placebo required the use of rescue medication more often than those treated with FE (38.4% vs 17.5%; P < 0.0001). A significant improvement in pain scores ( > 33% and > 50% reductions) was also reported for BTP treated with FE. Pain scores for patients with BTP with a neuropathic component (13 patients) were lower with FE than for those receiving placebo, but the difference was not significant. AEs were of mild or moderate severity and typical of opioid drugs. Conclusions: This newly developed galenic formulation with a higher early systemic exposure and a shorter T-max compared with oral transmucosal fentanyl citrate makes FE a particularly suitable formulation for the management of BTP in opioid-treated cancer patients due to the very rapid onset of action. FE provided significant improvement in pain intensity of BTP compared with placebo as early as 6 minutes' postadministration with a sustained effect over 60 minutes. FE was well tolerated by patients. (C) 2014 Elsevier HS Journals, Inc. All rights reserved.	[Novotna, Stanislava] Vysokomytska Nemocnice, Vysoke Myto, Czech Republic; [Valentova, Klara] Nemocnice S Poliklinikou Semilech, Semily, Czech Republic; [Fricova, Jitka] Vseobecna Fak Nemocnice, Prague, Czech Republic; [Richterova, Eva] Ambulance Lecby Chronicke Bolesti Paliativni Med, Hradec Kralove, Czech Republic; [Harabisova, Sarka] Metstska Nemocnice Ostrava, Ostrava, Czech Republic; [Bullier, Francoise] ICTA PM, Fontaine Les Dijon, France; [Trinquet, Francoise] Ethypharm, St Cloud, France	Trinquet, F (reprint author), 194 Bureaux Colline, F-92213 St Cloud, France.	trinquet.francoise@ethypharm.com		Fricova, Jitka/0000-0002-0113-7020	Ethypharm	This study was sponsored by Ethypharm, and the investigators (ETHYFYL Study Group) received fees from Ethypharm for enrolling patients in the study.	Bouhassira D, 2005, PAIN, V114, P29, DOI 10.1016/j.pain.2004.12.010; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5; Zeppetella Giovambattista, 2009, Curr Opin Support Palliat Care, V3, P1, DOI 10.1097/SPC.0b013e3283260658	19	14	16	1	16	ELSEVIER	BRIDGEWATER	685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA	0149-2918	1879-114X		CLIN THER	Clin. Ther.	MAR	2014	36	3					357	367		10.1016/j.clinthera.2014.01.006			11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AE0MW	WOS:000333661400008	24508417				2020-06-30	J	Lu, Y; Hu, J; Zhang, Y; Dong, CS				Lu, Yao; Hu, Jun; Zhang, Ye; Dong, Chunshan			Spinal neuronal NOS activation mediates intrathecal fentanyl preconditioning induced remote cardioprotection in rats	INTERNATIONAL IMMUNOPHARMACOLOGY			English	Article						Fentanyl; Remote preconditioning; Opioid receptors; Spinal cord; Nitric oxide synthase	NITRIC-OXIDE SYNTHASE; REGULATED KINASE; MORPHINE; CORD; EXPRESSION; RECEPTORS	Fentanyl has been widely used in anesthesia and analgesia, especially for cardiovascular surgeries. The aim of the study was to evaluate whether remote intrathecal fentanyl preconditioning (RFPC) provides cardioprotection and the role of spinal nitric oxide synthase (NOS) system in this effect. Fentanyl (0.3 mu g/kg) was administered intrathecally during RFPC by 3 cycles of 5-minute infusions interspersed with 5-minute infusion free periods. A non-specific nitric oxide synthase (NOS) inhibitor NG-nitro L-arginine methyl ester (L-NAME, 30 nmol) and a selective nNOS inhibitor 7-nitroindazole (7-NI, 100 nmol) were administered intrathecally 10 mm before RFPC, and were used to evaluate the involvement of the NOS system of the spinal cord. RFPC group markedly reduced the infarct size compared with control. However, the cardioprotection of RFPC could be abolished by pretreatment with L-NAME and 7-NI. RFPC merely increased the expression of nNOS and did not affect iNOS and eNOS expression. L-NAME reversed nNOS expression up-regulation induced by RFPC treatment. The present study demonstrated that RFPC effectively induced cardioprotection through activating the nNOS in the spinal cord. (C) 2014 Elsevier B.V. All rights reserved.	[Lu, Yao; Hu, Jun; Zhang, Ye] Anhui Med Univ, Affiliated Hosp 2, Dept Anesthesiol, Hefei 230061, Peoples R China; [Lu, Yao; Dong, Chunshan] Anhui Med Univ, Affiliated Hosp 3, Dept Anesthesiol, Hefei 230061, Peoples R China	Zhang, Y (reprint author), Anhui Med Univ, Affiliated Hosp 2, Dept Anesthesiol, Hefei 230061, Peoples R China.	zhangye_hassan@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81100105]	This work was supported by National Natural Science Foundation of China (No. 81100105).	Brock SC, 2008, ANESTH ANALG, V106, P965, DOI 10.1213/ane.0b013e318162cebf; De Pietri L, 2006, ANESTH ANALG, V102, P1157, DOI 10.1213/01.ane.0000198567.85040.ce; DUN NJ, 1992, NEUROSCI LETT, V147, P217, DOI 10.1016/0304-3940(92)90599-3; Ferriero DM, 1996, NEUROBIOL DIS, V3, P64, DOI 10.1006/nbdi.1996.0006; Freire MAM, 2007, NEUROTOXICOLOGY, V28, P175, DOI 10.1016/j.neuro.2006.06.007; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Jones WK, 2009, CIRCULATION, V120, pS1, DOI 10.1161/CIRCULATIONAHA.108.843938; Komatsu T, 2007, NEUROPHARMACOLOGY, V52, P1237, DOI 10.1016/j.neuropharm.2007.01.003; Konstantinov IE, 2005, J THORAC CARDIOV SUR, V130, P1326, DOI 10.1016/j.jtcvs.2005.03.050; Li X, 2008, BRAIN RES MOL BRAIN, V95, P96; MELLER ST, 1992, EUR J PHARMACOL, V214, P93, DOI 10.1016/0014-2999(92)90102-A; Nakamura T, 2001, CAN J ANAESTH, V48, P993, DOI 10.1007/BF03016590; NARAYANAN K, 1994, J MED CHEM, V37, P885, DOI 10.1021/jm00033a004; Roh DH, 2011, BRIT J PHARMACOL, V163, P1707, DOI 10.1111/j.1476-5381.2011.01316.x; Sabino JPJ, 2011, PFLUG ARCH EUR J PHY, V461, P23, DOI 10.1007/s00424-010-0903-4; Wong GTC, 2012, J CARDIOVASC PHARM, V60, P172, DOI 10.1097/FJC.0b013e31825e2195; Yao L, 2011, J CARDIOTHOR VASC AN, V25, P444, DOI 10.1053/j.jvca.2010.05.012; Yapici D, 2008, J CARDIAC SURG, V23, P140, DOI 10.1111/j.1540-8191.2007.00566.x; Yonehara N, 1997, JPN J PHARMACOL, V75, P327, DOI 10.1254/jjp.75.327; Zhang Y, 2011, EUR J PHARMACOL, V656, P74, DOI 10.1016/j.ejphar.2011.01.027	20	14	14	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1567-5769	1878-1705		INT IMMUNOPHARMACOL	Int. Immunopharmacol.	MAR	2014	19	1					127	131		10.1016/j.intimp.2014.01.013			5	Immunology; Pharmacology & Pharmacy	Immunology; Pharmacology & Pharmacy	AD8GZ	WOS:000333505800018	24462544				2020-06-30	J	Lammers, EM; Johnson, PN; Ernst, KD; Hagemann, TM; Lawrence, SM; Williams, PK; Anderson, MP; Miller, JL				Lammers, Erin M.; Johnson, Peter N.; Ernst, Kimberly D.; Hagemann, Tracy M.; Lawrence, Shelley M.; Williams, Patricia K.; Anderson, Michael P.; Miller, Jamie L.			Association of Fentanyl With Neurodevelopmental Outcomes in Very-Low-Birth-Weight Infants	ANNALS OF PHARMACOTHERAPY			English	Article						opioid; fentanyl; midazolam; neurodevelopment; premature; neonate	PRETERM INFANTS; ANALGESIA; MORPHINE; PAIN; SEDATION	Background: Opioids are commonly used in the neonatal intensive care unit (NICU). Negative neurodevelopmental effects in the short-term setting have been associated with opioids; however, long-term studies have been limited. Objective: The primary objective was to determine if there is a dose relationship between fentanyl and neurodevelopmental outcomes, as measured by Bayley Scales of Infant and Toddler Development (Bayley-III) composite scores for language, cognition, and motor skills. Secondary objectives included comparison of Bayley-III scores and neurodevelopmental impairment classification based on fentanyl exposure. Methods: A retrospective evaluation of 147 very-low-birth-weight infants with Bayley-III scores obtained at a chronological age of 6 months to 2 years at clinic follow-up was conducted. Univariate and msultivariable linear regression analyses were used to determine if there was a dose-related association between fentanyl and neurodevelopmental outcomes. To evaluate secondary outcomes, patients were divided based on cumulative fentanyl dose ("high-dose" versus "low/no-dose"). Results: The univariate analysis found a statistically significant decrease in cognition (P = .034) and motor skills scores (P = .006). No association was found in the multi-variable regression between fentanyl cumulative dose and Bayley-III scores. There was a significant decrease in the motor skills score between the high-dose versus low/no-dose group, 94 +/- 20 versus 102 +/- 15, respectively (P = .026); however, no statistical differences were noted for language or cognition scores or neurological impairment classification. Conclusions: When controlling for other variables, the cumulative fentanyl dose did not correlate with neurodevelopmental outcomes. Further evaluation of benefits and risks of opioids in premature infants are needed.	[Lammers, Erin M.] Univ Missouri Hlth Care, Columbia, MO 65201 USA; [Johnson, Peter N.; Hagemann, Tracy M.; Miller, Jamie L.] Univ Oklahoma, Coll Pharm, Oklahoma City, OK USA; [Ernst, Kimberly D.; Lawrence, Shelley M.; Williams, Patricia K.] Univ Oklahoma, Coll Med, Oklahoma City, OK 73190 USA; [Anderson, Michael P.] Univ Oklahoma, Coll Publ Hlth, Oklahoma City, OK USA	Lammers, EM (reprint author), Univ Missouri Hlth Care, Womens & Childrens Hosp, 404 N Keene St,DC546-00, Columbia, MO 65201 USA.	LammersEM@health.missouri.edu	Anderson, Michael/I-3309-2019	Anderson, Michael/0000-0002-2319-2282; Ernst, Kimberly/0000-0001-6164-4502			Abdulkader HM, 2008, EARLY HUM DEV, V84, P351, DOI 10.1016/j.earlhumdev.2007.09.018; Amer Acad Pediat, 2006, PEDIATRICS, V118, P2231, DOI 10.1542/peds.2006-2277; Anand KJ, 1996, PEDIATR RES, V39, P192; Anand KJS, 1998, BIOL NEONATE, V73, P1, DOI 10.1159/000013953; Aranda JV, 2005, CLIN THER, V27, P877, DOI 10.1016/j.clinthera.2005.06.019; Bayley N, 2006, BAYLEY SCALES INFANT; Carbajal R, 2005, PEDIATRICS, V115, P1494, DOI 10.1542/peds.2004-1425; de Graaf J, 2011, PAIN, V152, P1391, DOI 10.1016/j.pain.2011.02.017; Fanaroff JM, 2006, PEDIATRICS, V117, P1131, DOI 10.1542/peds.2005-1230; Felber A, 2011, PED AC SOC AS SOC PE; Haslam MD, 2011, PED AC SOC AS SOC PE; Kan E, 2008, EARLY HUM DEV, V84, P409, DOI 10.1016/j.earlhumdev.2007.11.002; MacGregor R, 1998, ARCH DIS CHILD-FETAL, V79, pF40, DOI 10.1136/fn.79.1.F40; NG E, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002052; Olney JW, 2002, BRAIN PATHOL, V12, P488, DOI 10.1111/j.1750-3639.2002.tb00467.x; Parry G, 2003, LANCET, V361, P1789, DOI 10.1016/S0140-6736(03)13397-1; Roze JC, 2008, ARCH PEDIAT ADOL MED, V162, P728, DOI 10.1001/archpedi.162.8.728; Saarenmaa E, 1999, J PEDIATR-US, V134, P144, DOI 10.1016/S0022-3476(99)70407-5; Short EJ, 2007, ARCH PEDIAT ADOL MED, V161, P1082, DOI 10.1001/archpedi.161.11.1082; Spinillo A, 2009, DEV MED CHILD NEUROL, V51, P518, DOI 10.1111/j.1469-8749.2009.03273.x; Spittle AJ, 2008, DEV MED CHILD NEUROL, V50, P254, DOI 10.1111/j.1469-8749.2008.02025.x; Taddio A, 2010, CLIN J PAIN, V26, P422, DOI 10.1097/AJP.0b013e3181d36da7; Vaucher Yvonne E, 2002, Pediatr Rev, V23, P349, DOI 10.1542/pir.23-10-349; Walter-Nicolet Elizabeth, 2010, Paediatr Drugs, V12, P353, DOI 10.2165/11318900-000000000-00000	24	10	11	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1060-0280	1542-6270		ANN PHARMACOTHER	Ann. Pharmacother.	MAR	2014	48	3					335	342		10.1177/1060028013514026			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AC4NI	WOS:000332497600005	24311724				2020-06-30	J	Tas, A; Mistanoglu, V; Darcin, S; Kececioglu, M				Tas, Ayca; Mistanoglu, Veli; Darcin, Sevtap; Kececioglu, Melahat			Tramadol versus fentanyl during propofol- based deep sedation for uterine dilatation and curettage: A prospective study	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						fentanyl; tramadol; uterine dilatation and curettage	DILATION	AimDilatation and curettage (D&C) is a common day-care procedure in obstetrics and gynecology, with patients discharged after a brief hospital stay on the same day of the surgery. Although it has a short duration, severe pain occurs during the procedure. Therefore, this surgical procedure requires an anesthetic to provide adequate analgesia, rapid onset, and rapid recovery. The main objective of the present study was to compare the analgesic effectiveness and safety of tramadol with those of fentanyl during D&C. MethodsThe study comprised 100 women with American Society of Anesthesiologists classification I-II who were scheduled for a D&C procedure. Baseline anesthesia was maintained with 1mg/kg propofol, and the patients were then randomly allocated to receive tramadol 1mg/kg (Group T, n=50) or fentanyl 1g/kg (Group F, n=50). Hemodynamic variables, sedation, pain, the Aldrete recovery score, and side-effects were recorded. ResultsSpO(2) levels in Group F in the 5th min and at the end of the procedure were significantly lower than those in Group T (P=0.024 and 0.021, respectively). ConclusionTramadol provides similar analgesic efficacy to fentanyl. Furthermore, tramadol may provide better respiratory stability in patients undergoing a D&C procedure.	[Tas, Ayca; Mistanoglu, Veli; Darcin, Sevtap; Kececioglu, Melahat] Dr Faruk Sukan Matern & Child Hosp, Dept Anesthesiol, TR-42000 Nalcaci, Konya, Turkey	Tas, A (reprint author), Dr Faruk Sukan Matern & Child Hosp, Dept Anesthesiol, TR-42000 Nalcaci, Konya, Turkey.	aycatas@yahoo.com					Castillo T, 2004, EUR J ANAESTH, V21, P408, DOI 10.1017/S0265021504005101; Horn E, 2001, GASTROINTEST ENDOSC, V14, P247; Kucuk M, 2012, GYNECOL ENDOCRINOL, V28, P736, DOI 10.3109/09513590.2011.652248; Ogurlu M, 2010, CLIN EXP OBSTET GYN, V37, P209; Putland AJ, 1999, ANAESTHESIA, V54, P382, DOI 10.1046/j.1365-2044.1999.00739.x; Sahin L, 2012, CLIN EXP OBSTET GYN, V39, P72; Scott LJ, 2000, DRUGS, V60, P139, DOI 10.2165/00003495-200060010-00008; Seitsonen ERJ, 2007, ACTA ANAESTH SCAND, V51, P751, DOI 10.1111/j.1399-6576.2007.01309.x; Siddiqui Khalid Maudood, 2007, JPMA Journal of the Pakistan Medical Association, V57, P67; Toledano Roulhac D, 2009, Rev Obstet Gynecol, V2, P93; Uerpairojkit K, 2003, J OBSTET GYNAECOL RE, V29, P79, DOI 10.1046/j.1341-8076.2003.00083.x; Vanlersberghe C., 2008, V182, P227, DOI 10.1007/978-3-540-74806-9_11; VICKERS MD, 1992, ANAESTHESIA, V47, P291, DOI 10.1111/j.1365-2044.1992.tb02166.x; Yamanaka T, 2013, RESPIROLOGY, V18, P255, DOI 10.1111/j.1440-1843.2012.02307.x	14	2	2	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	MAR	2014	40	3					749	753		10.1111/jog.12259			5	Obstetrics & Gynecology	Obstetrics & Gynecology	AB8MC	WOS:000332043400016	24320560				2020-06-30	J	Raeder, J				Raeder, Johan			Opioids in the treatment of postoperative pain: old drugs with new options?	EXPERT OPINION ON PHARMACOTHERAPY			English	Editorial Material						opioid; pain; pharmacology; postoperative; safety	DOUBLE-BLIND; TAPENTADOL; EFFICACY; PLACEBO; RELEASE; SAFETY	New approved options with opioids in the postoperative setting may include new ways of administration, new combinations with other drugs and new opioid drugs. Newly approved devices for administration include sublingual sufentanil dispenser and transdermal iontophoretic fentanyl, with the purpose of almost mimicking the rapid and reliable onset of intravenous (IV) administration, without the problems of an ongoing IV cannula and cumbersome equipment. Still, potential problems of overdosing and misuse must be in focus when these devices come into use. Tapentadol is a new partial mu-receptor opioid agonist with a combined action on norepinephrine-induced analgesia, representing a promising drug in terms of less side effects at equianalgesic doses compared with pure agonists. The mixture of different opioids given together, such as oxycodone and morphine, for oral use may also have some analgesic synergy with an improved side-effect profile, although more studies are needed. Oral oxycodone is a reliable oral opioid option, but when combined with paracetamol in the same tablet or mixture, care should also be taken to avoid serious side effects from inadvertent paracetamol overdose.	[Raeder, Johan] Univ Oslo, Oslo Univ Hosp, Dept Anesthesiol, N-0424 Oslo, Norway; [Raeder, Johan] Univ Oslo, Fac Med, N-0424 Oslo, Norway	Raeder, J (reprint author), Univ Oslo, Oslo Univ Hosp, Dept Anesthesiol, P Box 4950 Nydalen, N-0424 Oslo, Norway.	johan.rader@medisin.uio.no					Argoff CE, 2013, PAIN PRACT; Daniels SE, 2009, CURR MED RES OPIN, V25, P765, DOI 10.1185/03007990902728183 ; Hua S, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00123; Kjetil H, 2007, ANESTH ANALG, V105, P481, DOI 10.1213/01.ane.0000267261.61444.69; Kleinert R, 2008, ANESTH ANALG, V107, P2048, DOI 10.1213/ane.0b013e31818881ca; Lange B, 2010, ADV THER, V27, P381, DOI 10.1007/s12325-010-0036-3; Lennon FE, 2012, ANESTHESIOLOGY, V116, P940, DOI 10.1097/ALN.0b013e31824b9512; Lenz H, 2011, PAIN, V152, P1289, DOI 10.1016/j.pain.2011.02.007; Lesniak A, 2011, ACTA NEUROBIOL EXP, V71, P129; Mayes S, 2006, ANN PHARMACOTHER, V40, P2178, DOI 10.1345/aph.1H135; Minkowitz HS, 2013, REGION ANESTH PAIN M, V38, P131, DOI 10.1097/AAP.0b013e3182791157; Minkowitz Harold S, 2010, J Opioid Manag, V6, P203; Passmore MJ, 2011, INT PSYCHOGERIATR, V23, P844, DOI 10.1017/S1041610211000275; Pasternak GW, 2012, PAIN MED, V13, pS4, DOI 10.1111/j.1526-4637.2012.01335.x; Schroder B, 2012, J PHARM SCI-US, V101, P2262, DOI 10.1002/jps.23108; Silverman SM, 2009, PAIN PHYSICIAN, V12, P679; Stegmann JU, 2008, CURR MED RES OPIN, V24, P3185, DOI [10.1185/03007990802448056, 10.1185/03007990802448056 ]; Webster L, 2012, PAIN MED, V13, pS12, DOI 10.1111/j.1526-4637.2012.01330.x; Wiegand TJ, 2012, J MED TOXICOL, V8, P360, DOI 10.1007/s13181-012-0264-9	19	6	6	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1465-6566	1744-7666		EXPERT OPIN PHARMACO	Expert Opin. Pharmacother.	MAR	2014	15	4					449	452		10.1517/14656566.2014.879292			4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AC5XQ	WOS:000332594700002	24437530	Bronze			2020-06-30	J	Segal, D; Awad, N; Nasir, H; Mustafa, S; Lowenstein, L				Segal, Dror; Awad, Nibal; Nasir, Hawash; Mustafa, Susana; Lowenstein, Lior			Combined spinal and general anesthesia vs general anesthesia for robotic sacrocervicopexy: a randomized controlled trial	INTERNATIONAL UROGYNECOLOGY JOURNAL			English	Article						Combined anesthesia; Pain; Robotic surgeries; Sacrocolpopexy; Sacrocervicopexy	INTRATHECAL MORPHINE; PAIN; SACROCOLPOPEXY; PROLAPSE	Gynecologic laparoscopic surgery is frequently accompanied by early postoperative pain. This study assessed the effect of combined general and spinal anesthesia on postoperative pain score, analgesic use, and patient satisfaction following robotic surgeries. This was a randomized controlled trial. Thirty-eight consecutive women who underwent robotic surgeries for pelvic organ prolapse (sacrocolpopexy with or without subtotal hysterectomy) were randomly assigned to receive general anesthesia (control group, n = 20) or combined general with spinal anesthesia (study group, n = 18). Pain scores were assessed at rest and while coughing using a visual analog scale (VAS) 0-10. Dosage of analgesic medication consumption was retrieved from patients' charts. There were no statistically significant differences between the two groups with respect to demographic data and intraoperative hemodynamic parameters. In the postanesthesia care unit (PACU) mean total IV morphine and meperidine dosages were significantly lower for the study than the control group (0.33 vs 7.59 mg, 1.39 vs 27.89 mg, respectively, P < 0.003, < 0.001, respectively). In addition, a significantly lower percentage of patients belonging to the study group demanded analgesic medications while in the PACU (33 vs 53 %, P = 0.042). Pain scores in the PACU and during postoperative day 1 were significantly lower in the study group than in the control group (delta VAS 1.9 vs 3.0, P = 0.04). Satisfaction with pain treatment among both patients and nurses was significantly higher in the study group. Reported levels of pain and analgesic use during the first 24 h following robotic gynecologic surgery were significantly lower following general and spinal anesthesia compared to general anesthesia alone.	[Segal, Dror; Nasir, Hawash] Technion Israel Inst Technol, Dept Anesthesiol, Haifa, Israel; [Awad, Nibal; Mustafa, Susana; Lowenstein, Lior] Technion Israel Inst Technol, Rambam Med Ctr, Ruth & Bruce Rappaport Fac Med, Haifa, Israel; [Lowenstein, Lior] Rambam Hlth Care Campus, Dept Obstet & Gynecol, Haifa, Israel	Lowenstein, L (reprint author), Rambam Hlth Care Campus, Dept Obstet & Gynecol, Haifa, Israel.	lowensteinmd@gmail.com					Alessandri F, 2006, ACTA OBSTET GYN SCAN, V85, P844, DOI 10.1080/00016340500494846; Bang-Vojdanovski B, 1991, Reg Anaesth, V14, P47; Berberoglu M, 1998, J LAPAROENDOSC ADV A, V8, P273, DOI 10.1089/lap.1998.8.273; Bump RC, 1996, AM J OBSTET GYNECOL, V175, P10, DOI 10.1016/S0002-9378(96)70243-0; CARLSSON AM, 1983, PAIN, V16, P87, DOI 10.1016/0304-3959(83)90088-X; Ekstein P, 2006, ANN SURG, V243, P41, DOI 10.1097/01.sla.0000193806.81428.6f; GUPTA AM, 1992, GASTROINTEST ENDOSC, V38, P103, DOI 10.1016/S0016-5107(92)70362-9; Katz J, 1999, SURG CLIN N AM, V79, P231, DOI 10.1016/S0039-6109(05)70381-9; Kong SK, 2002, ANAESTHESIA, V57, P1168, DOI 10.1046/j.1365-2044.2002.02873.x; Luchetti M, 1996, REGION ANESTH, V21, P465; Mueller ER, 2012, CONTEMP CLIN TRIALS, V33, P1011, DOI 10.1016/j.cct.2012.05.007; Nygaard IE, 2004, OBSTET GYNECOL, V104, P805, DOI 10.1097/01.AOG.0000139514.90897.07; Paraiso MFR, 2011, OBSTET GYNECOL, V118, P1005, DOI 10.1097/AOG.0b013e318231537c; Rodanant Oraluxna, 2003, Journal of the Medical Association of Thailand, V86, pS331; Segal D, 2011, EUR J ANAESTH, V28, P201; Siddiqui NY, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2012.01.035; Van Glabeke E, 1998, Prog Urol, V8, P586; Wu Z, 2012, J ANESTH, V26, P752, DOI 10.1007/s00540-012-1421-7	18	12	12	0	4	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0937-3462	1433-3023		INT UROGYNECOL J	Int. Urogynecol. J.	MAR	2014	25	3					369	374		10.1007/s00192-013-2194-8			6	Obstetrics & Gynecology; Urology & Nephrology	Obstetrics & Gynecology; Urology & Nephrology	AC6UN	WOS:000332660600011	23928955				2020-06-30	J	Fassoulaki, A; Paraskeva, A; Tsaroucha, A				Fassoulaki, Argyro; Paraskeva, Anteia; Tsaroucha, Athanasia			Cesarean delivery under spinal anesthesia is associated with decreases in cerebral oxygen saturation as assessed by NIRS: an observational study	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						Cerebral oxygen saturation; Cesarean delivery; Near-infrared spectroscopy (NIRS); Spinal anesthesia	NEAR-INFRARED SPECTROSCOPY; CAROTID-ENDARTERECTOMY; SUPPLEMENTARY OXYGEN; SECTION; PHENYLEPHRINE; HEMODYNAMICS	Objectives: To investigate the effect of spinal anesthesia on cerebral rSO(2) during elective cesarean delivery (CD). Methods: Thirty-four women scheduled for elective CD under spinal anesthesia were recruited. In the operating room rSO(2) of the left and right frontal area and right thigh was recorded using three disposable sensors. A combination of 1.8-2.0 ml of 0.75% ropivacaine plus 10 mg of fentanyl were injected intrathecally. Systolic and diastolic blood pressure, heart rate, SpO(2) as well as rSO(2) of the left and right forehead areas and right thigh were recorded before, 5, 10, and 25 to 50 minutes after spinal injection, after uterine incision and placenta delivery, and analyzed with ANOVA repeated measures. The study was approved by the Aretaieio Hospital Institutional Review Board and registered with ClinicalTrials.gov (ID: NCT01669135). Results: The rSO(2) left and right frontal area values decreased significantly from baseline (p = 0.0001 and p = 0.0001 respectively), with most remarkable decreases 5 and 10 minutes after spinal injection, from 65 (SD 8.7) % to 56 (SD 9.3)% and 56 (SD 9.5) %(p = 0.0001 and p = 0.0001) for the left and from 63 (SD 7.7) % to 55 (SD 9.3) % and 56 (SD 8.9) % (p = 0,0001 and p = 0.0001) for the right frontal area respectively. The rSO(2) right thigh values increased significantly during the study period (p = 0.0001). Key limitations: Contribution of extracranial circulation to the rSO(2), lack of PaCO2 and cardiac output measurements. Conclusions: Women undergoing CD under spinal anesthesia may present decreases in cerebral rSO(2). The clinical impact of these results remains to be determined.	[Fassoulaki, Argyro; Paraskeva, Anteia; Tsaroucha, Athanasia] Univ Athens, Sch Med, Aretaieio Hosp, GR-11527 Athens, Greece	Fassoulaki, A (reprint author), Aretaieio Hosp, Dept Anesthesiol, 76 Vassilissis Sofias Ave, Athens 11528, Greece.	fassoula@aretaieio.uoa.gr	Tsaroucha, Athanasia/AAF-1978-2019	Tsaroucha, Athanasia/0000-0003-3331-0323	'Kapodistrias' Program, National and Kapodistrian University of Athens [70/4/6596]; Athens University	This study was supported by a grant from 'Kapodistrias' Program Code Number 70/4/6596, National and Kapodistrian University of Athens. Funding was from the Athens University to the Chairman of the Department. Role of the sponsor: none.	Atallah MM, 1998, REGION ANESTH PAIN M, V23, P119, DOI 10.1097/00115550-199823020-00002; Berlac P A, 2005, Int J Obstet Anesth, V14, P26, DOI 10.1016/j.ijoa.2004.06.003; Casati A, 2005, ANESTH ANALG, V101, P740, DOI 10.1213/01.ane.0000166974.96219.cd; Cho H, 1998, J NEUROSURG, V89, P533, DOI 10.3171/jns.1998.89.4.0533; Delis KT, 2004, THROMB HAEMOSTASIS, V92, P1003, DOI 10.1160/TH04-04-0233; Fassoulaki A, 2013, INT J OBSTET ANESTH, V22, P42, DOI 10.1016/j.ijoa.2012.09.009; Hoppenstein D, 2005, J CLIN ANESTH, V17, P431, DOI 10.1016/j.jclinane.2004.09.013; Khaw KS, 2009, BRIT J ANAESTH, V102, P90, DOI 10.1093/bja/aen321; Khaw KS, 2004, BRIT J ANAESTH, V92, P518, DOI 10.1093/bja/aeh092; Khaw KS, 2002, BRIT J ANAESTH, V88, P18, DOI 10.1093/bja/88.1.18; Lee A, 2012, WORLD J SURG, V36, P2328, DOI 10.1007/s00268-012-1676-z; Meng L, 2011, BRIT J ANAESTH, V107, P209, DOI 10.1093/bja/aer150; Nishikawa Koichi, 2007, J Clin Monit Comput, V21, P109; Nissen P, 2010, NEUROCRIT CARE, V12, P17, DOI 10.1007/s12028-009-9313-x; Plachky J, 2004, ANESTH ANALG, V99, P344; Samra SK, 2000, ANESTHESIOLOGY, V93, P964, DOI 10.1097/00000542-200010000-00015; Sorensen H, 2012, ANESTHESIOLOGY, V117, P263, DOI 10.1097/ALN.0b013e3182605afe; Tihtonen K, 2005, ACTA OBSTET GYN SCAN, V84, P355, DOI 10.1111/j.0001-6349.2005.00489.x; Van de Velde M, 2009, BRIT J ANAESTH, V102, P1, DOI 10.1093/bja/aen329; Vernieri F, 2004, STROKE, V35, P64, DOI 10.1161/01.STR.0000106486.26626.E2	20	3	3	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.	MAR	2014	30	3					331	337		10.1185/03007995.2013.852526			7	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	AB8IT	WOS:000332034300001	24106922				2020-06-30	J	Kong, TW; Park, HY; Cheong, JY; Min, SK; Ryu, HS				Kong, Tae-Wook; Park, Hyogyeong; Cheong, Ji-Yoon; Min, Sang-Ki; Ryu, Hee-Sug			Efficacy of continuous wound infiltration of local anesthetic for pain relief after gynecologic laparoscopy	INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS			English	Article						Continuous ropivacaine wound infiltration; Gynecologic laparoscopy; Postoperative pain	POSTOPERATIVE PAIN; ABDOMINAL HYSTERECTOMY; ANALGESIC EFFICACY; CESAREAN DELIVERY; RANDOMIZED-TRIAL; BUPIVACAINE; MANAGEMENT; INFUSION; CHOLECYSTECTOMY; INSTILLATION	Objective: To assess the efficacy of analgesia provided by continuous ropivacaine wound infiltration after gynecologic laparoscopy. Methods: Sixty patients who underwent gynecologic laparoscopy at Ajou University School of Medicine, Suwon, Republic of Korea, between March and May 2012 were randomized to receive either intravenous fentanyl and ketorolac infusion on demand by patient-controlled analgesia (IV PCA group, n = 31) or continuous wound infiltration of local ropivacaine (CWI group, n = 29). Postoperative pain and postoperative nausea and vomiting (PONV) were assessed via a visual analog scale. The number of patients who requested rescue analgesia was recorded. Results: There was no significant difference in postoperative pain between the 2 groups, but more patients requested rescue analgesia in the CWI group than in the IV PCA group in 24 hours (18 versus 9 patients, respectively; P = 0.010). The PONV scores at 12 and 24 hours were, respectively, 0.28 and 027 in the CWI group, and 0.71 and 0.73 in the IV PCA group (P = 0.004). Nine patients requested cessation of IV PCA because of severe nausea or vomiting. Conclusion: Continuous ropivacaine wound infiltration was found to be as effective as patient-controlled analgesia for postoperative pain relief after gynecologic laparoscopy. This technique provides good analgesia with less opioid analgesic requirement and few adverse effects. (C) 2013 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.	[Kong, Tae-Wook; Park, Hyogyeong; Cheong, Ji-Yoon; Ryu, Hee-Sug] Ajou Univ, Sch Med, Dept Obstet & Gynecol, Suwon 443721, South Korea; [Min, Sang-Ki] Ajou Univ, Sch Med, Dept Anesthesiol & Pain Med, Suwon 443721, South Korea	Ryu, HS (reprint author), Ajou Univ, Sch Med, Dept Obstet & Gynecol, San 5 Wonchon Dong, Suwon 443721, South Korea.	hsryu@ajou.ac.kr		Kong, Tae-Wook/0000-0002-9007-565X			Coskun F, 2001, CURR OPIN OBSTET GYN, V13, P371, DOI 10.1097/00001703-200108000-00001; Coughlin SM, 2010, SURG ENDOSC, V24, P3167, DOI 10.1007/s00464-010-1111-1; Forastiere E, 2008, BRIT J ANAESTH, V101, P841, DOI 10.1093/bja/aen309; Fredman B, 2000, ANESTH ANALG, V91, P1436, DOI 10.1097/00000539-200012000-00025; Givens VA, 2002, AM J OBSTET GYNECOL, V186, P1188, DOI 10.1067/mob.2002.122984; Gupta A, 2004, ANESTH ANALG, V99, P1173, DOI 10.1213/01.ANE.0000130260.24433.A2; Hollmann MW, 2000, ANESTHESIOLOGY, V93, P858, DOI 10.1097/00000542-200009000-00038; JORIS J, 1995, ANESTH ANALG, V81, P379, DOI 10.1097/00000539-199508000-00029; Kristensen BB, 1999, REGION ANESTH PAIN M, V24, P576, DOI 10.1016/S1098-7339(99)90052-4; Kushner DM, 2005, OBSTET GYNECOL, V106, P227, DOI 10.1097/01.AOG.0000171111.68015.af; LeBlanc KA, 2005, J AM COLL SURGEONS, V200, P198, DOI 10.1016/j.jamcollsurg.2004.10.011; Leong WM, 2002, AUST NZ J OBSTET GYN, V42, P515, DOI 10.1111/j.0004-8666.2002.00515.x; LEWIS DL, 1953, BRIT MED J, V1, P973, DOI 10.1136/bmj.1.4817.973; Liu SS, 2006, J AM COLL SURGEONS, V203, P914, DOI 10.1016/j.jamcollsurg.2006.08.007; MECKLEM DWJ, 1995, AUST NZ J OBSTET GYN, V35, P416, DOI 10.1111/j.1479-828X.1995.tb02156.x; Pan PH, 2006, INT J OBSTET ANESTH, V15, P185, DOI 10.1016/j.ijoa.2006.04.004; Pan PH, 2006, ANESTHESIOLOGY, V104, P417, DOI 10.1097/00000542-200603000-00007; Tilleul P, 2012, BRIT J ANAESTH, V108, P998, DOI 10.1093/bja/aes091; URE BM, 1994, SURG ENDOSC-ULTRAS, V8, P90, DOI 10.1007/BF00316616; WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023; YNDGAARD S, 1994, ANESTH ANALG, V79, P324; Zohar E, 2001, ANESTH ANALG, V93, P482, DOI 10.1097/00000539-200108000-00048	22	15	15	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0020-7292	1879-3479		INT J GYNECOL OBSTET	Int. J. Gynecol. Obstet.	MAR	2014	124	3					212	215		10.1016/j.ijgo.2013.08.019			4	Obstetrics & Gynecology	Obstetrics & Gynecology	AB5VJ	WOS:000331856500006	24461464				2020-06-30	J	Kim, J; Kim, SY; Lee, JH; Kang, YR; Koo, BN				Kim, Jeongmin; Kim, So Yeon; Lee, Jae Hoon; Kang, Young Ran; Koo, Bon-Nyeo			Low-Dose Dexmedetomidine Reduces Emergence Agitation after Desflurane Anaesthesia in Children Undergoing Strabismus Surgery	YONSEI MEDICAL JOURNAL			English	Article						Dexmedetomidine; emergence agitation; objective pain score; pediatrics	PEDIATRIC AMBULATORY PATIENTS; POSTANESTHESIA CARE-UNIT; SEVOFLURANE ANESTHESIA; RECOVERY CHARACTERISTICS; DELIRIUM SCALE; BILATERAL MYRINGOTOMY; GENERAL-ANESTHESIA; FENTANYL; PROPOFOL; PREVENTION	Purpose: Emergence agitation (EA) is frequently observed in children undergoing general anaesthesia. This study tested whether the addition of an intra-operative low-dose infusion of dexmedetomidine to fentanyl treatment reduced the incidence of emergence delirium following desfiurane anesthesia in children undergoing strabismus surgery Materials and Methods: A total of 96 children (1-5 years old) undergoing strabismus surgery were enrolled. Anaesthesia was induced with propofol and maintained with desfiurane. After induction, fentanyl (1 mu g/kg) was administered to all children. During surgery, patients were infused with 0.2 mu g/ (kg.h)(-1) dexmedetomidine (Group FD, n=47) or normal saline (Group F, n=47). Postoperative objective pain score (OPS), Paediatric Agitation and Emergence Delirium (PAED) score, and EA score were documented every 10 minutes in the post-anaesthesia care unit. Results: There were no significant differences between the two groups in demographic characteristics and haemodynamic changes. The mean values of maximum EA, maximum PAED, and maximum OPS score were significantly lower in Group FD than in Group F at 0, 10, and 20 minutes after arrival at the post-anaesthesia care unit (p<0.001). The frequency of fentanyl rescue was lower in Group FD than in Group F (p<0.001). The incidence of severe EA was significantly lower in Group FD than in Group F (12.8% vs. 74.5%, p<0.001). Conclusion: Intra-operative low-dose infusion of dexmedetomidine in addition to fentanyl reduces EA following desflurane anaesthesia in children undergoing strabismus surgeries.	[Kim, Jeongmin; Kim, So Yeon; Lee, Jae Hoon; Kang, Young Ran; Koo, Bon-Nyeo] Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Anesthesia & Pain Res Inst, Seoul 120752, South Korea	Koo, BN (reprint author), Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Anesthesia & Pain Res Inst, 50-1 Yonsei Ro, Seoul 120752, South Korea.	koobn@yuhs.ac		Koo, Bon-Nyeo/0000-0002-3189-1673; Kim, Jeongmin/0000-0002-0468-8012; Kim, So Yeon/0000-0001-5352-157X; Lee, Jae Hoon/0000-0001-6679-2782			Akin A, 2012, PEDIATR ANESTH, V22, P871, DOI 10.1111/j.1460-9592.2012.03802.x; Aouad MT, 2007, ANESTHESIOLOGY, V107, P733, DOI 10.1097/01.anes.0000287009.46896.a7; Bhana N, 2000, DRUGS, V59, P263, DOI 10.2165/00003495-200059020-00012; Blankespoor RJ, 2012, MINERVA ANESTESIOL, V78, P896; Bong CL, 2009, PEDIATR ANESTH, V19, P593, DOI 10.1111/j.1460-9592.2009.03024.x; BRAUN U, 1993, ACTA ANAESTH SCAND, V37, P390, DOI 10.1111/j.1399-6576.1993.tb03735.x; Chen JY, 2010, PEDIATR ANESTH, V20, P873, DOI 10.1111/j.1460-9592.2010.03375.x; CHUNG F, 1995, J CLIN ANESTH, V7, P500, DOI 10.1016/0952-8180(95)00130-A; Cohen IT, 2002, ANESTH ANALG, V94, P1178, DOI 10.1097/00000539-200205000-00023; Cole JW, 2002, PAEDIATR ANAESTH, V12, P442, DOI 10.1046/j.1460-9592.2002.00868.x; Cravero JP, 2003, ANESTH ANALG, V97, P364, DOI 10.1213/01.ANE.0000070227.78670.43; Dahmani S, 2010, BRIT J ANAESTH, V104, P216, DOI 10.1093/bja/aep376; Davis PJ, 1999, ANESTH ANALG, V88, P34, DOI 10.1097/00000539-199901000-00007; DAVIS PJ, 1994, ANESTHESIOLOGY, V80, P298, DOI 10.1097/00000542-199402000-00009; Demirbilek S, 2004, EUR J ANAESTH, V21, P538, DOI 10.1017/S0265021504007069; Deutsch E, 2007, PEDIATR ANESTH, V17, P438, DOI 10.1111/j.1460-9592.2006.02139.x; Dexter F, 1999, ANESTH ANALG, V88, P1053, DOI 10.1097/00000539-199905000-00016; Erdil F, 2009, ANAESTH INTENS CARE, V37, P571, DOI 10.1177/0310057X0903700405; Finkel JC, 2001, ANESTH ANALG, V92, P1164; Finley GA, 1996, PAIN, V64, P83; Grundman U, 1998, ACTA ANAESTH SCAND, V42, P845, DOI 10.1111/j.1399-6576.1998.tb05332.x; Guler G, 2005, PEDIATR ANESTH, V15, P762, DOI 10.1111/j.1460-9592.2004.01541.x; HANNALLAH RS, 1987, ANESTHESIOLOGY, V66, P832, DOI 10.1097/00000542-198706000-00023; Isik B, 2006, PEDIATR ANESTH, V16, P748, DOI 10.1111/j.1460-9592.2006.01845.x; Janssen NJJF, 2011, INTENS CARE MED, V37, P1331, DOI 10.1007/s00134-011-2244-y; Jung HJ, 2010, KOREAN J ANESTHESIOL, V58, P148, DOI 10.4097/kjae.2010.58.2.148; Kim MS, 2013, BRIT J ANAESTH, V110, P274, DOI 10.1093/bja/aes382; Messerer B, 2010, PEDIATR SURG INT, V26, P879, DOI 10.1007/s00383-010-2642-1; Mizrak A, 2011, MED PRIN PRACT, V20, P427, DOI 10.1159/000324554; Mizrak A, 2010, CLIN OPHTHALMOL, V4, P673; Patel A, 2010, ANESTH ANALG, V111, P1004, DOI 10.1213/ANE.0b013e3181ee82fa; Saadawy I, 2009, ACTA ANAESTH SCAND, V53, P251, DOI 10.1111/j.1399-6576.2008.01818.x; Shukry M, 2005, PEDIATR ANESTH, V15, P1098, DOI 10.1111/j.1460-9592.2005.01660.x; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; Singh R, 2012, INDIAN J ANAESTH, V56, P156, DOI 10.4103/0019-5049.96325; Tufanogullari B, 2008, ANESTH ANALG, V106, P1741, DOI 10.1213/ane.0b013e318172c47c; Vlajkovic GP, 2007, ANESTH ANALG, V104, P84, DOI 10.1213/01.ane.0000250914.91881.a8; Voepel-Lewis T, 2003, ANESTH ANALG, V96, P1625, DOI 10.1213/01.ANE.0000062522.21048.61; Wachtel RE, 2011, CAN J ANESTH, V58, P714, DOI 10.1007/s12630-011-9519-1; Welborn LG, 1996, ANESTH ANALG, V83, P917, DOI 10.1097/00000539-199611000-00005; WELDON BC, 1992, ANESTH ANALG, V75, P51; White PF, 2009, ANESTH ANALG, V109, P387, DOI 10.1213/ane.0b013e3181adc21a	42	23	27	0	16	YONSEI UNIV COLL MEDICINE	SEOUL	50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA	0513-5796	1976-2437		YONSEI MED J	Yonsei Med. J.	MAR 1	2014	55	2					508	516		10.3349/ymj.2014.55.2.508			9	Medicine, General & Internal	General & Internal Medicine	AB6RI	WOS:000331916800032	24532525	DOAJ Gold, Green Published			2020-06-30	J	Mao, W; Wei, XQ; Tao, J; Zhen, FP; Wen, ZF; Wu, B				Mao, Wei; Wei, Xiu Qing; Tao, Jin; Zhen, Feng Ping; Wen, Zhuo Fu; Wu, Bin			The safety of combined sedation with propofol plus fentanyl for endoscopy screening and endoscopic variceal ligation in cirrhotic patients	JOURNAL OF DIGESTIVE DISEASES			English	Article							UPPER GASTROINTESTINAL ENDOSCOPY; UPPER GI ENDOSCOPY; SUBCLINICAL HEPATIC-ENCEPHALOPATHY; NURSE-ADMINISTERED PROPOFOL; RANDOMIZED-TRIAL; ESOPHAGEAL-VARICES; MIDAZOLAM; PHARMACOKINETICS; COLONOSCOPY; IMPAIRMENT		[Mao, Wei; Wei, Xiu Qing; Tao, Jin; Zhen, Feng Ping; Wen, Zhuo Fu; Wu, Bin] Sun Yat Sen Univ, Dept Gastroenterol, Affiliated Hosp 3, Guangzhou 510630, Guangdong, Peoples R China	Wu, B (reprint author), Sun Yat Sen Univ, Dept Gastroenterol, Affiliated Hosp 3, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China.	binwu001@hotmail.com					Amoros A, 2009, GASTROINTEST ENDOSC, V70, P262, DOI 10.1016/j.gie.2008.10.038; Assy N, 1999, GASTROINTEST ENDOSC, V49, P690, DOI 10.1016/S0016-5107(99)70283-X; Blei AT, 2001, AM J GASTROENTEROL, V96, P1968, DOI 10.1016/S0002-9270(01)02527-8; Bosch J, 2003, LANCET, V361, P952, DOI 10.1016/S0140-6736(03)12778-X; Bosilkovska M, 2012, DRUGS, V72, P1645, DOI 10.2165/11635500-000000000-00000; Correia LM, 2011, GASTROINTEST ENDOSC, V73, P45, DOI 10.1016/j.gie.2010.09.025; D'Amico G, 2003, HEPATOLOGY, V38, P599, DOI 10.1053/jhep.2003.50385; DeWitt J, 2008, GASTROINTEST ENDOSC, V68, P499, DOI 10.1016/j.gie.2008.02.092; Disma N, 2005, EUR J ANAESTH, V22, P848, DOI 10.1017/S0265021505001432; El-Serag HB, 2000, AM J GASTROENTEROL, V95, P3566; Faga E, 2012, EUR J GASTROEN HEPAT, V24, P70, DOI 10.1097/MEG.0b013e32834c16ab; Ferenci P, 2002, HEPATOLOGY, V35, P716, DOI 10.1053/jhep.2002.31250; Garcia-Tsao G, 2007, HEPATOLOGY, V46, P922, DOI 10.1002/hep.21907; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Hayee B, 2009, GASTROINTEST ENDOSC, V69, P681, DOI 10.1016/j.gie.2008.09.033; ISHIDO S, 1992, GASTROINTEST ENDOSC, V38, P689, DOI 10.1016/S0016-5107(92)70565-3; KEATS AS, 1978, ANESTHESIOLOGY, V49, P233, DOI 10.1097/00000542-197810000-00001; Khamaysi I, 2011, J HEPATOL, V54, P72, DOI 10.1016/j.jhep.2010.06.023; LaPierre CD, 2012, ANESTHESIOLOGY, V117, P252, DOI 10.1097/ALN.0b013e31825fb1b2; Lichtenstein DR, 2008, GASTROINTEST ENDOSC, V68, P815, DOI 10.1016/j.gie.2008.09.029; Merli M, 2003, J HEPATOL, V38, P266, DOI 10.1016/S0168-8278(02)00420-8; Moitinho E, 1999, GASTROENTEROLOGY, V117, P626, DOI 10.1016/S0016-5085(99)70455-5; MORGAN DJ, 1990, BRIT J CLIN PHARMACO, V30, P144, DOI 10.1111/j.1365-2125.1990.tb03755.x; Padmanabhan U, 2009, ANESTH ANALG, V109, P1448, DOI 10.1213/ane.0b013e3181a6ad31; Qureshi W, 2005, GASTROINTEST ENDOSC, V62, P651, DOI 10.1016/j.gie.2005.07.031; Riphaus A, 2012, SCAND J GASTROENTERO, V47, P1078, DOI 10.3109/00365521.2012.685758; Riphaus A, 2009, SCAND J GASTROENTERO, V44, P1244, DOI 10.1080/00365520903194591; Sachdeva Atul, 2010, Saudi J Gastroenterol, V16, P280, DOI 10.4103/1319-3767.70616; Sanyal AJ, 2006, GASTROINTEST ENDOSC, V64, P855, DOI 10.1016/j.gie.2006.03.007; Seip B, 2008, SCAND J GASTROENTERO, V43, P1004, DOI 10.1080/00365520801958592; SERVIN F, 1990, BRIT J ANAESTH, V65, P177, DOI 10.1093/bja/65.2.177; SERVIN F, 1988, ANESTHESIOLOGY, V69, P887, DOI 10.1097/00000542-198812000-00014; SHAFER A, 1988, ANESTHESIOLOGY, V69, P348, DOI 10.1097/00000542-198809000-00011; Sharma P, 2011, ENDOSCOPY, V43, P400, DOI 10.1055/s-0030-1256182; Sipe BW, 2002, GASTROINTEST ENDOSC, V55, P815, DOI 10.1067/mge.2002.124636; Talaie R, 2009, HEPATO-GASTROENTEROL, V56, P158; Thuluvath PJ, 2009, GASTROINTEST ENDOSC, V70, P269, DOI 10.1016/j.gie.2009.01.029; Vasudevan AE, 2002, AM J GASTROENTEROL, V97, P1717; Weston BR, 2003, AM J GASTROENTEROL, V98, P2440, DOI 10.1016/S0002-9270(03)01701-5; 1988, N ENGL J MED, V13, P983	40	2	5	0	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1751-2972	1751-2980		J DIGEST DIS	J. Dig. Dis.	MAR	2014	15	3					124	130		10.1111/1751-2980.12115			7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	AA9HK	WOS:000331404200004	24224839				2020-06-30	J	Vardanyan, RS; Hruby, VJ				Vardanyan, Ruben S.; Hruby, Victor J.			Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications	FUTURE MEDICINAL CHEMISTRY			English	Review							MU-OPIOID-RECEPTOR; PRELIMINARY PHARMACOLOGICAL EVALUATION; I-2-IMIDAZOLINE BINDING-SITES; DELTA-OPIATE RECEPTORS; ANALGESIC ACTIVITY; 4-ANILIDOPIPERIDINE ANALGESICS; SYNTHETIC ANALGESICS; MEDIATED ANTINOCICEPTION; BASIC ANILIDES; 1-SUBSTITUTED 4-(PROPANANILIDO)PERHYDROAZEPINES	Fentanyl and its analogs have been mainstays for the treatment of severe to moderate pain for many years. In this review, we outline the structural and corresponding synthetic strategies that have been used to understand the structure-biological activity relationship in fentanyl-related compounds and derivatives and their biological activity profiles. We discuss how changes in the scaffold structure can change biological and pharmacological activities. Finally, recent efforts to design and synthesize novel multivalent ligands that act as mu and delta opioid receptors and NK-1 receptors are discussed.	[Vardanyan, Ruben S.; Hruby, Victor J.] Univ Arizona, Dept Chem & Biochem, Tucson, AZ 85721 USA	Vardanyan, RS (reprint author), Univ Arizona, Dept Chem & Biochem, Tucson, AZ 85721 USA.	vardanyr@email.arizona.edu	Vardanyan, Ruben S/G-8173-2016		NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [P01 DA006284, R01 DA013449]		Abraham DJ, 2010, BURGERS MED CHEM DRU; Andrews C, 1983, CLIN ANAESTHESIOL, V1, P97; BAGLEY JR, 1991, MED RES REV, V11, P403, DOI 10.1002/med.2610110404; BAGLEY JR, 1977, J HETEROCYCLIC CHEM, V14, P599, DOI 10.1002/jhet.5570140412; BAGLEY JR, 1989, J MED CHEM, V32, P663, DOI 10.1021/jm00123a028; BAGLEY JR, 1991, J MED CHEM, V34, P827, DOI 10.1021/jm00106a051; Balboni G, 2011, EUR J MED CHEM, V46, P799, DOI 10.1016/j.ejmech.2010.12.001; Barutell C, 2004, DOLOR, V19, P98; Battershill AJ, 2006, DRUGS, V66, P365, DOI 10.2165/00003495-200666030-00013; Beers R, 2004, CNS DRUGS, V52, P1095; BERGER JG, 1977, J MED CHEM, V20, P600, DOI 10.1021/jm00214a035; Black J, 2005, J MED CHEM, V48, P1687, DOI 10.1021/jm040195b; BLOCK J, 2003, WILSON GISVOLDS TXB; BOAS RA, 1985, BRIT J ANAESTH, V57, P192, DOI 10.1093/bja/57.2.192; BORNE RF, 1980, J PHARM SCI, V69, P1104, DOI 10.1002/jps.2600690934; Brandt W, 1993, Drug Des Discov, V10, P257; BRINE GA, 1995, J MED CHEM, V38, P1547, DOI 10.1021/jm00009a015; BURKE TR, 1986, J MED CHEM, V29, P1087, DOI 10.1021/jm00156a030; BURKE TR, 1984, J MED CHEM, V27, P1570, DOI 10.1021/jm00378a008; Burkle H, 1996, ANESTH ANALG, V83, P646, DOI 10.1097/00000539-199609000-00038; BUSCHMANN H, 2002, ANALGESICS CHEM PHAR; CASY AF, 1969, J PHARM PHARMACOL, V21, P434, DOI 10.1111/j.2042-7158.1969.tb08284.x; CASY AF, 1967, J PHARM PHARMACOL, V19, P17, DOI 10.1111/j.2042-7158.1967.tb07988.x; CASY AF, 1988, J PHARM PHARMACOL, V40, P605, DOI 10.1111/j.2042-7158.1988.tb05318.x; CASY AF, 1986, [No title captured]; Chen BY, 1999, LIFE SCI, V65, P1589, DOI 10.1016/S0024-3205(99)00404-X; Cheng BK-M, 2008, [No title captured], Patent No. [WO2008066708, 2008066708]; CHRUBASIK J, 1988, ANESTHESIOLOGY, V68, P929, DOI 10.1097/00000542-198806000-00016; COLAPRET JA, 1989, J MED CHEM, V32, P968, DOI 10.1021/jm00125a008; COMETTAMORINI C, 1992, MOL PHARMACOL, V41, P185; COMETTAMORINI C, 1991, J COMPUT AID MOL DES, V5, P335, DOI 10.1007/BF00126667; [崔艳英 Cui Yanying], 2003, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V12, P268; Dardonville C, 2004, BIOORG MED CHEM LETT, V14, P491, DOI 10.1016/j.bmcl.2003.10.048; Dardonville C, 2006, BIOORGAN MED CHEM, V14, P6570, DOI 10.1016/j.bmc.2006.06.007; Darwish M, 2008, EXPERT REV CLIN PHAR, V1, P39, DOI 10.1586/17512433.1.1.39; Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI [10.1586/ERN.11.63, 10.1586/ern.11.63]; DERUITER J, 1992, J HETEROCYCLIC CHEM, V29, P779, DOI 10.1002/jhet.5570290417; DeStevens G., 1965, ANALGETICS MED CHEM, V5; Dietis N, 2009, BRIT J ANAESTH, V103, P38, DOI 10.1093/bja/aep129; Dosen-Micovic L, 2006, BIOORGAN MED CHEM, V14, P2887, DOI 10.1016/j.bmc.2005.12.010; Dzhingozyan V. K., 1996, Khimiko-Farmatsevticheskii Zhurnal, V30, P40; ESSAWI MYH, 1983, J MED CHEM, V26, P348, DOI 10.1021/jm00357a007; FELDMAN PL, 1991, J MED CHEM, V34, P2202, DOI 10.1021/jm00111a041; Feldman PL, 1990, Patent No. [EP 383579, 383579]; FERNANDEZ MJ, 1992, J CHEM SOC PERK T 2, P687, DOI 10.1039/p29920000687; FINNEY ZG, 1980, J MED CHEM, V23, P895, DOI 10.1021/jm00182a016; Floegel O, 2010, [No title captured], Patent No. [WO2010000282, 2010000282]; Galemmo RA, 2005, J MED CHEM, V48, P1686, DOI 10.1021/jm040194j; GARDOCKI JF, 1964, TOXICOL APPL PHARM, V6, P48, DOI 10.1016/0041-008X(64)90021-3; Giron R, 2002, LIFE SCI, V71, P1023, DOI 10.1016/S0024-3205(02)01798-8; Goicoechea C, 2008, EUR J PHARMACOL, V595, P22, DOI 10.1016/j.ejphar.2008.07.052; Gomes I, 2004, P NATL ACAD SCI USA, V101, P5135, DOI 10.1073/pnas.0307601101; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; GRASS JA, 1992, J PAIN SYMPTOM MANAG, V7, P419, DOI 10.1016/0885-3924(92)90022-A; Gupta PK, 2013, MED CHEM RES, V22, P3888, DOI 10.1007/s00044-012-0390-6; Hellerbach J, 1966, ORGANIC CHEM, VVIII; HELSLEY GC, 1969, J MED CHEM, V12, P583, DOI 10.1021/jm00304a005; Henriksen G, 2005, J MED CHEM, V48, P7720, DOI 10.1021/jm0507274; HEYMAN JS, 1989, EUR J PHARMACOL, V165, P1, DOI 10.1016/0014-2999(89)90764-4; HEYMAN JS, 1989, EUR J PHARMACOL, V169, P43, DOI 10.1016/0014-2999(89)90815-7; HORAN PJ, 1993, J PHARMACOL EXP THER, V265, P1446; Hruby VJ, 2006, AAPS J, V8, pE450, DOI 10.1208/aapsj080353; Ivanovic MD, 2004, J SERB CHEM SOC, V69, P955, DOI 10.2298/JSC0411955I; Ivanovic MD, 2004, J SERB CHEM SOC, V69, P511, DOI 10.2298/JSC0407511I; Jacob M, 2001, WO, Patent No. 2001040184; Jagerovic N, 2002, BIOORGAN MED CHEM, V10, P817, DOI 10.1016/S0968-0896(01)00345-5; James MK, 1994, EXPERT OPIN INV DRUG, V3, P331; Janssen A. J., 1964, US Patent, Patent No. [3,141,823, 3141823]; Janssen P. A. J, 1979, US Patent, Patent No. [4179569, US4179569A]; JANSSEN PAJ, 1960, J MED PHARMACEUT CH, V2, P271, DOI 10.1021/jm50010a003; JANSSEN PAJ, 1959, J MED PHARMACEUT CH, V1, P309, DOI 10.1021/jm50005a002; JANSSEN PAJ, 1959, J MED PHARMACEUT CH, V1, P105, DOI 10.1021/jm50002a008; JANSSEN PAJ, 1963, ARZNEIMITTEL-FORSCH, V13, P502; Janssen PAJ, 1964, M2430 FR, Patent No. FR M2430; Janssen PAJ, 1983, OPIOIDS ANESTHESIA, P37; Janssen PAJ, 1960, DIPHENYLPROPYLAMIN 1, V3; JANSSENS F, 1986, J MED CHEM, V29, P2290, DOI 10.1021/jm00161a027; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; JILEK J, 1990, COLLECT CZECH CHEM C, V55, P1828, DOI 10.1135/cccc19901828; Jimeno ML, 2003, CHEM PHARM BULL, V51, P929; JIN WQ, 1983, LIFE SCI, V33, P251, DOI 10.1016/0024-3205(83)90490-3; JIN WQ, 1981, SCI SINICA, V24, P710; JONCZYK A, 1978, PRZEM CHEM, V57, P131; KARAPETYAN AA, 1989, KHIM FARM ZH+, V23, P565; KARAPETYAN AA, 1992, KHIM FARM ZH+, V26, P25; Karapetyan HA, 1990, ZH STRUKT KHIM, V31, P141; Kiricojevic VD, 2002, J SERB CHEM SOC, V67, P793, DOI 10.2298/JSC0212793K; Kissin I, 2010, ANESTH ANALG, V110, P780, DOI 10.1213/ANE.0b013e3181cde882; KLEIN W, 1974, ARCH PHARM, V307, P360, DOI 10.1002/ardp.19743070509; KOCH MHJ, 1976, ACTA CRYSTALLOGR B, V32, P2529, DOI 10.1107/S0567740876008145; KUDZMA LV, 1995, BIOORG MED CHEM LETT, V5, P1177, DOI 10.1016/0960-894X(95)00190-5; KUDZMA LV, 1989, J MED CHEM, V32, P2534, DOI 10.1021/jm00132a007; Kudzma LV, 1989, [No title captured], Patent No. [US4801615, 4801615]; LALINDE N, 1991, [No title captured], Patent No. 4994471; Lalinde NL, 1990, [No title captured], Patent No. [US4939161, 4939161]; LAW SJ, 1978, J HETEROCYCLIC CHEM, V15, P273, DOI 10.1002/jhet.5570150218; Lednicer D, 1982, CENTRAL ANALGETICS C, V1; Lee YS, 2007, J MED CHEM, V50, P5528, DOI 10.1021/jm061465o; Lee YS, 2007, BIOORG MED CHEM LETT, V17, P2161, DOI 10.1016/j.bmcl.2007.01.114; Lee YS, 2011, J MED CHEM, V54, P382, DOI 10.1021/jm100982d; Lee Y, 2009, ADV EXP MED BIOL, V611, P517, DOI 10.1007/978-0-387-73657-0_225; LEHMANN KA, 1982, ANAESTHESIST, V31, P221; LEHMANN KA, 1983, ANAESTHESIST, V32, P165; Lemke T. L., 2013, FOYES PRINCIPLES MED; Lenz G. R., 1986, OPIATES; Lin B-S, 1988, [No title captured], Patent No. [US4791120, 4791120]; Liu ZL, 2009, CURR PHARM DESIGN, V15, P682, DOI 10.2174/138161209787315639; LOBBEZOO MW, 1981, J MED CHEM, V24, P777, DOI 10.1021/jm00139a003; MAGNAN J, 1982, N-S ARCH PHARMACOL, V319, P197, DOI 10.1007/BF00495865; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; Malaquin S, 2010, TETRAHEDRON LETT, V51, P2983, DOI 10.1016/j.tetlet.2010.03.120; Martin J, 1987, J Comput Aided Mol Des, V1, P53, DOI 10.1007/BF01680557; MARYANOFF BE, 1981, J MED CHEM, V24, P79, DOI 10.1021/jm00133a017; Massey Jim, 2011, JEMS, V36, P54, DOI 10.1016/S0197-2510(11)70206-6; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Micovic IV, 1996, J CHEM SOC PERK T 1, P2041, DOI 10.1039/p19960002041; Micovic IV, 1998, HETEROCYCL COMMUN, V4, P171; Micovic IV, 2000, BIOORG MED CHEM LETT, V10, P2011, DOI 10.1016/S0960-894X(00)00394-2; Micovic IV, 1996, J SERB CHEM SOC, V61, P849; Montero A, 2002, BIOORGAN MED CHEM, V10, P1009, DOI 10.1016/S0968-0896(01)00356-X; Morphy R, 2005, J MED CHEM, V48, P6523, DOI 10.1021/jm058225d; Mystakidou K, 2011, EXPERT OPIN PHARMACO, V12, P1653, DOI 10.1517/14656566.2011.585637; Nathan B, 1966, BENZOMORPHANS INT 2B, V8; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Nichol GS, 2010, J CHEM CRYSTALLOGR, V40, P961, DOI 10.1007/s10870-010-9771-1; NIEMEGEERS CJE, 1981, DRUG DEVELOP RES, V1, P83, DOI 10.1002/ddr.430010111; NIEMEGEERS CJE, 1976, ARZNEIMITTEL-FORSCH, V26, P1551; Nora FS, 2001, REV BRAS ANESTESIOL, V51, P146; Pasero Chris, 2005, J Perianesth Nurs, V20, P279, DOI 10.1016/j.jopan.2005.03.007; Patel SS, 1996, DRUGS, V52, P417, DOI 10.2165/00003495-199652030-00009; Peacock JE, 1997, DRUGS TODAY, V33, P619, DOI 10.1358/dot.1997.33.9.445595; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Peters D, 2009, [No title captured], Patent No. [WO2009077584, 2009077584]; Petrov RR, 2006, BIOORG MED CHEM LETT, V16, P4946, DOI 10.1016/j.bmcl.2006.06.040; Planas E, 2000, DOLOR, V15, P7; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; PORRECA F, 1992, J PHARMACOL EXP THER, V263, P147; Reynolds L, 2004, PAIN, V110, P182, DOI 10.1016/j.pain.2004.03.024; RICE KC, 1983, SCIENCE, V220, P314, DOI 10.1126/science.6132444; RILEY TN, 1979, J MED CHEM, V22, P1167, DOI 10.1021/jm00196a004; RILEY TN, 1973, J PHARM SCI, V62, P983, DOI 10.1002/jps.2600620627; Riley TN, 1975, [No title captured], Patent No. [3923992, US3923992]; Rong SB, 1997, ACTA PHARMACOL SIN, V18, P128; Rosow CE, 1999, ANESTH ANALG, V89, pS1; Rozenfeld R, 2007, FASEB J, V21, P2455, DOI 10.1096/fj.06-7793com; Sawynok J, 1999, NOVEL ASPECTS PAIN M; Scherrer G, 2009, CELL, V137, P1148, DOI 10.1016/j.cell.2009.04.019; Schiller PW, 2010, LIFE SCI, V86, P598, DOI 10.1016/j.lfs.2009.02.025; Schiller PW, 1999, J MED CHEM, V42, P3520, DOI 10.1021/jm980724+; SCHULZ R, 1981, J PHARMACOL EXP THER, V219, P547; Scott LJ, 2005, DRUGS, V65, P1793, DOI 10.2165/00003495-200565130-00007; Shonberg J, 2011, CHEMMEDCHEM, V6, P963, DOI 10.1002/cmdc.201100101; SPICKETT RG, 1966, J MED CHEM, V9, P436, DOI 10.1021/jm00321a051; Srimurugan S, 2009, CHEM PHARM BULL, V57, P1421, DOI 10.1248/cpb.57.1421; SRULEVITCH DB, 1991, ACTA PHARM JUGOSL, V41, P89; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Stanley TH, 2005, J PAIN SYMPTOM MANAG, V29, pS67, DOI 10.1016/j.jpainsymman.2005.01.009; Stanley TH, 2008, ANESTH ANALG, V106, P451, DOI 10.1213/ane.0b013e3181605add; Subramanian G, 2000, J MED CHEM, V43, P381, DOI 10.1021/jm9903702; Taylor DR, 2007, EXPERT OPIN PHARMACO, V8, P3043, DOI 10.1517/14656566.8.17.3043; Teiggle DJ, 2006, COMPREHENSIVE MED 2; Thomas G., 2003, FUNDAMENTALS MED CHE; Thompson RG, 1987, OPIATE RECEPTOR BIND; Tollenaere J P, 1986, Prog Drug Res, V30, P91; Tollenaere JP, 1979, ATLAS 3 DIMENSIONAL, V1; VANBEVER WF, 1974, J MED CHEM, V17, P1047, DOI 10.1021/jm00256a003; VANBEVER WFM, 1976, ARZNEIMITTELFORSCH, V26, P1548; VANDAELE PGH, 1976, ARZNEIMITTELFORSCH, V26, P1521; VANDYKE JW, 1972, J MED CHEM, V15, P91, DOI 10.1021/jm00271a025; VANGESTEL S, 1986, DRUG DEVELOP RES, V8, P1, DOI 10.1002/ddr.430080103; Vardanyan RS, 2006, SYNTHESIS OF ESSENTIAL DRUGS, P1; Vardanyan R, 2011, J FLUORINE CHEM, V132, P920, DOI 10.1016/j.jfluchem.2011.07.006; Vardanyan R, 2011, BIOORGAN MED CHEM, V19, P6135, DOI 10.1016/j.bmc.2011.08.027; Vardanyan R, 2009, BIOORGAN MED CHEM, V17, P5044, DOI 10.1016/j.bmc.2009.05.065; Vartanian RS, 1984, [No title captured], Patent No. [SU1139125, 1139125]; Vartanian RS, 1984, [No title captured], Patent No. [SU1100848, 1100848]; VARTANYAN RS, 1989, KHIM FARM ZH+, V23, P573; VARTANYAN RS, 1989, KHIM FARM ZH+, V23, P562; VARTANYAN RS, 1982, KHIM FARM ZH+, V16, P947; Vartanyan RS, 1987, ARM KHIM ZH, V40, P563; Vartanyan SA, 1985, [No title captured], Patent No. [SU736583, 736583]; Vuckovic S, 2000, JPN J PHARMACOL, V84, P188, DOI 10.1254/jjp.84.188; Vuckovic S, 2009, CURR MED CHEM, V16, P2468, DOI 10.2174/092986709788682074; WALKER GN, 1965, J MED CHEM, V8, P626, DOI 10.1021/jm00329a016; WANG ZX, 1995, J MED CHEM, V38, P3652, DOI 10.1021/jm00018a026; Weltrowska G, 2010, J MED CHEM, V53, P2875, DOI 10.1021/jm9019068; Wilhelm W, 2003, ANAESTHESIST, V52, P473, DOI 10.1007/s00101-003-0540-9; Woodcock J, 2007, NAT REV DRUG DISCOV, V6, P703, DOI 10.1038/nrd2335; Woolf CJ, 2003, PAIN CURRENT UNDERST, P1; WRIGHT WB, 1963, J MED CHEM, V6, P128, DOI 10.1021/jm00338a009; WRIGHT WB, 1961, J ORG CHEM, V26, P485, DOI 10.1021/jo01061a049; WYNN RL, 1991, DRUG DEVELOP RES, V22, P189, DOI 10.1002/ddr.430220209; XU H, 1991, NEUROPHARMACOLOGY, V30, P455, DOI 10.1016/0028-3908(91)90006-W; Yadav P., 2010, PHARMACIA SINICA, V1, P126; YAKSH TL, 1986, ANESTHESIOLOGY, V64, P54, DOI 10.1097/00000542-198601000-00009; ZEE SH, 1980, J CHIN CHEM SOC-TAIP, V27, P147, DOI 10.1002/jccs.198000026	196	88	92	1	55	FUTURE SCI LTD	LONDON	UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND	1756-8919	1756-8927		FUTURE MED CHEM	Future Med. Chem.	MAR	2014	6	4					385	412		10.4155/fmc.13.215			28	Chemistry, Medicinal	Pharmacology & Pharmacy	AD2ZO	WOS:000333106200008	24635521	Green Accepted			2020-06-30	J	Sousa, A; Neto, JD; Guimaraes, GMN; Cascudo, GM; Neto, JOB; Ashmawi, HA				Sousa, Angela Maria; de Santana Neto, Jose; Guimaraes, Gabriel M. N.; Cascudo, Giovana M.; Neto, Jose Osvaldo B.; Ashmawi, Hazem A.			Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study	SUPPORTIVE CARE IN CANCER			English	Article						Analgesia; Patient-controlled; Adverse effects; Pain management; Neoplasms	OUTPATIENTS; MORPHINE; BIOAVAILABILITY; MANAGEMENT; PCA	The WHO analgesic ladder supports medication choice according to pain intensity. The use of the analgesic ladder in an inverse way, has the advantage of using the same principles of the original ladder to treat crisis of pain in cancer patients. The purpose of this study is to describe the use of intravenous patient-controlled analgesia (IV-PCA) technique in patients admitted to an oncological Hospital. This is a case series study. Patients assigned to receive IV-PCA between March 2011 and May 2012 were selected for the study. Medical records were reviewed, patients stratified according to the Karnofsky Performance Score (KPS). The primary outcome was to verify if different IV-PCA opioid solutions could be equally effective providing pain relief. Secondary outcomes were the incidence of clinical side effects that can be associated to IV-PCA infusions. A total of 95 medical records were reviewed. Most patients used IV-PCA with morphine (42.1 %), fentanyl (42.1 %) or methadone (15.7 %) to treat exacerbation periods of cancer pain. IV-PCA used as supplementary therapy successfully improved pain control in 78.9 % of the patients, without any difference related to opioid solution. KPS < 40 was related to higher rate of pain relief, without any difference in side effects in this group of patients. The most common side effects were sedation (10.5 %) followed by constipation (9.4 %) and nausea (4.2 %). Morphine presented a higher risk than fentanyl for sedation. Analgesia-related delirium or respiratory depression were not reported in this case series study. IV-PCA provided timely, safe and useful analgesia for patients with severe breakthrough pain and may be useful to help titration of opioids, weaning to oral analgesia and to decide for interventional procedures.	[Sousa, Angela Maria] Canc Inst State Sao Paulo, Pain Management Serv, BR-05403000 Sao Paulo, Brazil; [de Santana Neto, Jose; Guimaraes, Gabriel M. N.; Cascudo, Giovana M.; Neto, Jose Osvaldo B.] Canc Inst State Sao Paulo, Dept Anesthesia, BR-05403000 Sao Paulo, Brazil; [Ashmawi, Hazem A.] Univ Sao Paulo, Clin Hosp, Dept Anesthesia, BR-05403000 Sao Paulo, Brazil	Sousa, A (reprint author), Canc Inst State Sao Paulo, Pain Management Serv, Av Dr Eneas Carvalho de Aguiar 255, BR-05403000 Sao Paulo, Brazil.	angela-sousa@uol.com.br	Neto, Jose Osvaldo Barbosa/F-5907-2013; Guimaraes, Gabriel Magalhaes Nunes/AAF-8455-2019; sousa, angela maria/J-8157-2015	Neto, Jose Osvaldo Barbosa/0000-0003-2005-3137; Guimaraes, Gabriel Magalhaes Nunes/0000-0001-6289-2233; sousa, angela maria/0000-0003-1732-9083			Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030; Aubrun F, 2012, BRIT J ANAESTH, V108, P193, DOI 10.1093/bja/aer458; Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001; Brogan SE, 2011, PAIN MED, V12, P1758, DOI 10.1111/j.1526-4637.2011.01262.x; Bush SH, 2009, ONCOLOGIST, V14, P1039, DOI 10.1634/theoncologist.2009-0122; Caraceni A, 1999, PAIN, V82, P263, DOI 10.1016/S0304-3959(99)00073-1; Craft Jennifer, 2010, Proc (Bayl Univ Med Cent), V23, P434; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; Dev R, 2011, J PAIN SYMPTOM MANAG, V42, P296, DOI 10.1016/j.jpainsymman.2010.11.020; Duarte RV, 2012, PAIN PHYSICIAN, V15, P363; Genf World Health Organization, 1986, CANC PAIN REL; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; Greco MT, 2011, CLIN J PAIN, V27, P9, DOI 10.1097/AJP.0b013e3181edc250; Haugen DF, 2010, PAIN, V149, P476, DOI 10.1016/j.pain.2010.02.035; HOSKIN PJ, 1989, BRIT J CLIN PHARMACO, V27, P499, DOI 10.1111/j.1365-2125.1989.tb05399.x; Ilias Wilfried, 2008, Pain Pract, V8, P164, DOI 10.1111/j.1533-2500.2008.00187.x; KERR IG, 1988, ANN INTERN MED, V108, P554, DOI 10.7326/0003-4819-108-4-554; Ketwaroo Gyanprakash A, 2013, Curr Gastroenterol Rep, V15, P344, DOI 10.1007/s11894-013-0344-2; Kim SH, 2013, PAIN PHYSICIAN, V16, pE247; Lux EA, 2011, SCHMERZ, V25, P663, DOI 10.1007/s00482-011-1101-9; Margarit Cesar, 2012, J Pain Res, V5, P559, DOI 10.2147/JPR.S36428; Mercadante S, 2011, PALLIATIVE MED, V25, P504, DOI 10.1177/0269216311406577; N.I. of Cancer (INCA), 2012, EST 2012 INC CANC BR; Nassar AP, 2008, SAO PAULO MED J, V126, P215, DOI 10.1590/S1516-31802008000400003; Nave R, 2013, DRUG DELIV, V20, P216, DOI 10.3109/10717544.2012.762435; NOLAN MF, 1995, PHYS THER, V75, P374, DOI 10.1093/ptj/75.5.374; R Core Team, 2013, R LANG ENV STAT COMP; Santini D, 2013, EXPERT OPIN PHARMACO, V14, P425, DOI 10.1517/14656566.2013.774375; Sardin B, 2012, ANN FR ANESTH, V31, P813, DOI 10.1016/j.annfar.2012.08.013; Schiessl C, 2007, SCHMERZ, V21, P35, DOI 10.1007/s00482-006-0500-9; Schiessl C, 2008, SUPPORT CARE CANCER, V16, P917, DOI 10.1007/s00520-007-0352-6; Schiessl C, 2008, SUPPORT CARE CANCER, V16, P531, DOI 10.1007/s00520-008-0408-2; Smith H, 2012, CNS DRUGS, V26, P509, DOI 10.2165/11630580-000000000-00000; Smith HS, 2013, J PAIN RES, V6, P189, DOI 10.2147/JPR.S40745; Taylor DR, 2013, CLIN PHARMACOL-ADV A, V5, P131, DOI 10.2147/CPAA.S26649; Vargas-Schaffer G, 2010, CAN FAM PHYSICIAN, V56, P514	36	13	16	0	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	MAR	2014	22	3					795	801		10.1007/s00520-013-2036-8			7	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	AA3FR	WOS:000330978800025	24258354				2020-06-30	J	Aoki, Y; Mizoguchi, H; Watanabe, C; Sakurada, T; Sakurada, S				Aoki, Yuta; Mizoguchi, Hirokazu; Watanabe, Chizuko; Sakurada, Tsukasa; Sakurada, Shinobu			Differential alternation of the antinociceptive effect of narcotic analgesics on the inflammatory pain state	NEUROSCIENCE LETTERS			English	Article						Inflammatory pain; Narcotic analgesic; Antinociception; mu-Receptor; Mice	PERIPHERAL INFLAMMATION; TOLERANCE; HYPERALGESIA; MODEL	Antinociceptive effect of narcotic analgesics, fentanyl, oxycodone and methadone in inflammatory pain state was described in the von Frey filament test using the complete Freund's adjuvant (CFA)-induced mouse inflammatory pain model. After the i.pl. injection of CFA, mechanical allodynia (decrease of mechanical threshold) was observed in ipsilateral paw. The antinociceptive effect of fentanyl and oxycodone injected s.c. against mechanical allodynia in inflammatory pain state was reduced bilaterally at 1 day after CFA pretreatment. However, the antinociceptive effect of methadone injected s.c. against mechanical allodynia in inflammatory pain state was reduced unilaterally at 1 day after CFA pretreatment. Moreover, the reduction of the antinociceptive effect of methadone in ipsilateral paw on inflammatory pain state was smaller than those of fentanyl or oxycodone. In conclusion, the alternation of the antinociceptive effect of narcotic analgesics in inflammatory pain state is variable among the narcotic analgesics used. (C) 2013 Elsevier Ireland Ltd. All rights reserved.	[Aoki, Yuta; Mizoguchi, Hirokazu; Watanabe, Chizuko; Sakurada, Shinobu] Tohoku Pharmaceut Univ, Dept Physiol & Anat, Aoba Ku, Sendai, Miyagi 9818558, Japan; [Sakurada, Tsukasa] Daiichi Coll Pharmaceut Sci, Dept Pharmacol 1, Minami Ku, Fukuoka 8158511, Japan	Sakurada, S (reprint author), Tohoku Pharmaceut Univ, Dept Physiol & Anat, Aoba Ku, 4-4-1 Komatsushima, Sendai, Miyagi 9818558, Japan.	s-sakura@tohoku-pharm.ac.jp			JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [22600009, 24590731]; MEXT (Ministry of Education, Culture, Sports, Science and Technology)Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)	This work was supported by JSPS KAKENHI Grant Numbers 22600009 and 24590731, and a MEXT (Ministry of Education, Culture, Sports, Science and Technology)-Supported Program for the Strategic Research Foundation at Private Universities (2010-2014).	Aoki Y., 2013, J PHARM SCI S1, V121; Cervero F, 1996, PAIN, V68, P13, DOI 10.1016/S0304-3959(96)03165-X; CLINE MA, 1989, BRAIN, V112, P621, DOI 10.1093/brain/112.3.621; Fernandez-Duenas V, 2007, J PHARMACOL EXP THER, V322, P360, DOI 10.1124/jpet.106.118901; HELFGOTT SM, 1988, J IMMUNOL, V140, P1838; Inturrisi C E, 2005, Minerva Anestesiol, V71, P435; MALDONADO R, 1994, PAIN, V58, P77, DOI 10.1016/0304-3959(94)90186-4; Mao JR, 1998, NEUROSCI LETT, V250, P193, DOI 10.1016/S0304-3940(98)00472-8; Ohsawa M, 2000, EUR J PHARMACOL, V403, P81, DOI 10.1016/S0014-2999(00)00571-9; Sanchez-Blazquez P, 2013, EUR J PHARMACOL, V716, P94, DOI 10.1016/j.ejphar.2013.01.066	10	2	2	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	FEB 7	2014	560						122	125		10.1016/j.neulet.2013.12.020			4	Neurosciences	Neurosciences & Neurology	AA3VK	WOS:000331022700025	24361775				2020-06-30	J	Patton, AL; Seely, KA; Pulla, S; Rusch, NJ; Moran, CL; Fantegrossi, WE; Knight, LD; Marraffa, JM; Kennedy, PD; James, LP; Endres, GW; Moran, JH				Patton, Amy L.; Seely, Kathryn A.; Pulla, Sharon; Rusch, Nancy J.; Moran, Cindy L.; Fantegrossi, William E.; Knight, Laura D.; Marraffa, Jeanna M.; Kennedy, Paul D.; James, Laura P.; Endres, Gregory W.; Moran, Jeffery H.			Quantitative Measurement of Acetyl Fentanyl and Acetyl Norfentanyl in Human Urine by LC-MS/MS	ANALYTICAL CHEMISTRY			English	Article							METABOLISM; OPIOIDS	Opioid abuse involving emerging opioid compounds is a growing public health problem, which was highlighted recently by cases of human morbidity and mortality linked to acetyl fentanyl abuse. Unfortunately, the lack of information available on the toxicology and metabolism of acetyl fentanyl precludes its detection in human samples. The following study was conducted to test a new analytical procedure for the simultaneous quantification of acetyl fentanyl and its predicted metabolite, acetyl norfentanyl, in human urine. Metabolic reference standards and deuterium-labeled internal standards were synthesized for use in an assay that coupled solid-phase extraction (SPE) with liquid chromatography-tandem mass spectrometry (LC-MS/MS). The accuracy (% Relative Error <5%) and inter- and intrarun precision (%CV <20%) of this new method resulted in low levels of quantification (similar to 1 ng/mL). Similar results were obtained using liquid chromatography columns manufactured with phenyl-hexyl and biphenyl stationary phases (r(2) > 0.98). Preliminary human liver microsomal and in vivo rodent studies demonstrated that acetyl fentanyl is metabolized by cytochrome P450s to acetyl norfentanyl. Urine samples from rats treated with a toxic dose of acetyl fentanyl contained high concentrations of acetyl fentanyl and acetyl norfentanyl. Further toxicokinetic studies are required to fully elucidate the metabolic pathways responsible for acetyl fentanyl detoxification and excretion.	[Patton, Amy L.; Seely, Kathryn A.; Moran, Jeffery H.] Arkansas Dept Hlth, Publ Hlth Lab, Little Rock, AR 72205 USA; [Pulla, Sharon; Rusch, Nancy J.; Fantegrossi, William E.; Moran, Jeffery H.] Univ Arkansas Med Sci, Coll Med, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA; [Moran, Cindy L.] Arkansas State Crime Lab, Little Rock, AR 72205 USA; [Knight, Laura D.] Onondaga Cty Med Examiners Off, Syracuse, NY 13210 USA; [Marraffa, Jeanna M.] SUNY Upstate Med Univ, Upstate New York Poison Ctr, Syracuse, NY 13210 USA; [Kennedy, Paul D.; Endres, Gregory W.] Cayman Chem Co, Ann Arbor, MI 48108 USA; [James, Laura P.] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Sect Clin Pharmacol & Toxicol, Little Rock, AR 72205 USA; [James, Laura P.] Univ Arkansas Med Sci, Dept Pediat, Coll Med, Little Rock, AR 72205 USA; [James, Laura P.] Arkansas Childrens Hosp, Little Rock, AR 72205 USA	Moran, JH (reprint author), Arkansas Dept Hlth, Publ Hlth Lab, 201 S Monroe St, Little Rock, AR 72205 USA.	jeffery.moran@arkansas.gov			Association of Public Health Laboratories [Grant Innovations in Quality Public health Laboratory Practice]; Centers for Disease ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [200-2007-21729]	This work was supported by the Association of Public Health Laboratories [Grant Innovations in Quality Public health Laboratory Practice] (J.H.M.) and by the Centers for Disease Control (Contract No. 200-2007-21729) (J.H.M.).	CDC, 2013, CDC HEALTH ALERT NET, P00350; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Johnston L. D., 2011, MONITORING THE FUTUR; KRAM TC, 1981, ANAL CHEM, V53, P1379, DOI 10.1021/ac00235a003; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Mack KA, 2013, MMWR-MORBID MORTAL W, V62, P537; Manchikanti L, 2008, PAIN PHYSICIAN, V11, pS63; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; Perger L, 2009, EUR J PHARM SCI, V36, P421, DOI 10.1016/j.ejps.2008.11.008; Reisinger M, 2006, HEROIN ADDICT REL CL, V8, P29; Smith HS, 2009, MAYO CLIN PROC, V84, P613, DOI 10.1016/S0025-6196(11)60750-7; Watson WA, 2005, AM J EMERG MED, V23, P589, DOI 10.1016/j.ajem.2005.05.001	13	28	29	3	38	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0003-2700	1520-6882		ANAL CHEM	Anal. Chem.	FEB 4	2014	86	3					1760	1766		10.1021/ac4036197			7	Chemistry, Analytical	Chemistry	AA3TI	WOS:000331014800061	24354295				2020-06-30	J	Leppert, W				Leppert, Wojciech			A successful Switch From Transdermal Fentanyl to Transdermal Buprenorphine in a Patient with Neuropathic Pain: A Case Report	AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE			English	Article						analgesia; neuropathic pain; opioid switch; transdermal buprenorphine; transdermal fentanyl; treatment	CANCER PAIN; DOUBLE-BLIND; PHARMACOLOGY; MULTICENTER; EFFICACY; MORPHINE; SAFETY; DRUGS	Buprenorphine is a frequently used opioid in the treatment of neuropathic pain component that is often present in patients with cancer. A case of a 41-year-old patient was depicted whose pain syndrome was associated with the chondrosarcoma growth originating from the sacral bone and numerous surgical interventions and radiotherapy. Improvement in analgesia and good toleration of therapy were observed after switching from transdermal fentanyl to transdermal buprenorphine while maintaining treatment with antidepressants and anticonvulsants. This case report indicates a possibility of a safe switch of transdermal opioids at home, which may provide benefits in terms of analgesia and adverse effects and in consequence have positive impact on the patients' quality of life. This is also accompanied by constant psychological, social, and spiritual support provided to the patient and family.	Poznan Univ Med Sci, Chair & Dept Palliat Med, PL-61245 Poznan, Poland	Leppert, W (reprint author), Poznan Univ Med Sci, Chair & Dept Palliat Med, Osiedle Rusa 25 A, PL-61245 Poznan, Poland.	wojciechleppert@wp.pl					[Anonymous], 2008, SUMM PROD CHAR TRANS; Barutell CDE, 2004, REV SOC ESP DOLOR S5, V11, P31; Bennett MI, 2011, PALLIATIVE MED, V25, P553, DOI 10.1177/0269216310378546; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Christoph T, 2005, EUR J PHARMACOL, V507, P87, DOI 10.1016/j.ejphar.2004.11.052; Cialkowska-Rysz A, 2009, MED PALIATYWNA, V1, P40; Cowan A, 2006, BUPRENORPHINE UNIQUE, P3; Davis MP, 2005, SUPPORT CARE CANCER, V13, P878, DOI 10.1007/s00520-005-0849-9; Griessinger N, 2005, CURR MED RES OPIN, V21, P1147, DOI 10.1185/030079905X53315; Kerr CW, 2012, J PAIN SYMPTOM MANAG, V43, P68, DOI 10.1016/j.jpainsymman.2011.03.026; Kogel B, 2005, EUR J PAIN, V9, P599, DOI 10.1016/j.ejpain.2005.02.002; Kress HG, 2009, EUR J PAIN, V13, P219, DOI 10.1016/j.ejpain.2008.04.011; Kusnik Stefan, 2008, Expert Rev Clin Pharmacol, V1, P729, DOI 10.1586/17512433.1.6.729; Leppert W, 2009, EUR J PAIN S1, V13, pS142; Leppert W, 2008, EXPERT REV, P10; Likar R, 2008, INT J CLIN PRACT, V62, P152, DOI 10.1111/j.1742-1241.2007.01531.x; Malec-Milewska M, 2010, TERAPIA, V18, P45; Mercadante S, 2007, J PAIN SYMPTOM MANAG, V34, P532, DOI 10.1016/j.jpainsymman.2007.01.006; Mercadante S, 2007, SUPPORT CARE CANCER, V15, P441, DOI 10.1007/s00520-006-0169-8; Mercadante S, 2006, J PAIN SYMPTOM MANAG, V32, P175, DOI 10.1016/j.jpainsymman.2006.01.013; Mercadante S, 2009, SUPPORT CARE CANCER, V17, P715, DOI 10.1007/s00520-008-0546-6; Mordarski S, 2009, J APPL THER RES, V7, P46; Pergolizzi JV, 2009, CURR MED RES OPIN, V25, P1517, DOI 10.1185/03007990902920731; Przeklasa-Muszynska A, 2011, CURR MED RES OPIN, V27, P1109, DOI 10.1185/03007995.2011.569017; RODRIGUEZLOPEZ MJ, 2004, REV SOC ESP DOLOR, V11, P11; Schmid-Grendelmeier P, 2006, CURR MED RES OPIN, V22, P501, DOI 10.1185/030079906X89829; Schmitz S, 2008, J APPL THER RES, V6, P20; Sittl R, 2003, CLIN THER, V25, P150, DOI 10.1016/S0149-2918(03)90019-1; Sittl R, 2006, PALLIATIVE MED, V20, pS25, DOI 10.1191/0269216306pm1125oa; WALSH SL, 1994, CLIN PHARMACOL THER, V55, P569, DOI 10.1038/clpt.1994.71; Wang J, 2012, PHARMACOL REP, V64, P870, DOI 10.1016/S1734-1140(12)70881-2; Zarth R, 2008, J APPL THER RES, V6, P15	32	1	1	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-9091	1938-2715		AM J HOSP PALLIAT ME	Am. J. Hosp. Palliat. Med.	FEB	2014	31	1					101	104		10.1177/1049909112472722			4	Health Care Sciences & Services	Health Care Sciences & Services	AA6ID	WOS:000331201100014	23349342				2020-06-30	J	Cambic, CR; Avram, MJ; Gupta, DK; Wong, CA				Cambic, C. R.; Avram, M. J.; Gupta, D. K.; Wong, C. A.			Effect of ritonavir-induced cytochrome P450 3A4 inhibition on plasma fentanyl concentrations during patient-controlled epidural labor analgesia: a pharmacokinetic simulation	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Obstetric Analgesia; Analgesic techniques; Extradural; Pharmacokinetics fentanyl; Ritonavir	INTERINDIVIDUAL VARIABILITY; ALFENTANIL; CLEARANCE; METABOLISM; METHADONE; FLUID	Background: Ritonavir inhibition of cytochrome P450 3A4 decreases the elimination clearance of fentanyl by 67%. We used a pharmacokinetic model developed from published data to simulate the effect of sample patient-controlled epidural labor analgesic regimens on plasma fentanyl concentrations in the absence and presence of ritonavir-induced cytochrome P450 3A4 inhibition. Methods: Fentanyl absorption from the epidural space was modeled using tanks-in-series delay elements. Systemic fentanyl disposition was described using a three-compartment pharmacokinetic model. Parameters for epidural drug absorption were estimated by fitting the model to reported plasma fentanyl concentrations measured after epidural administration. The validity of the model was assessed by comparing predicted plasma concentrations after epidural administration to published data. The effect of ritonavir was modeled as a 67% decrease in fentanyl elimination clearance. Plasma fentanyl concentrations were simulated for six sample patient-controlled epidural labor analgesic regimens over 24 h using ritonavir and control models. Simulated data were analyzed to determine if plasma fentanyl concentrations producing a 50% decrease in minute ventilation (6.1 ng/mL) were achieved. Results: Simulated plasma fentanyl concentrations in the ritonavir group were higher than those in the control group for all sample labor analgesic regimens. Maximum plasma fentanyl concentrations were 1.8 ng/mL and 3.4 ng/mL for the normal and ritonavir simulations, respectively, and did not reach concentrations associated with 50% decrease in minute ventilation. Conclusion: Our model predicts that even with maximal clinical dosing regimens of epidural fentanyl over 24 h, ritonavir-induced cytochrome P450 3A4 inhibition is unlikely to produce plasma fentanyl concentrations associated with a decrease in minute ventilation. (C) 2013 Elsevier Ltd. All rights reserved.	[Cambic, C. R.; Avram, M. J.; Gupta, D. K.; Wong, C. A.] Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, Chicago, IL 60611 USA	Cambic, CR (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, 251 E Huron,F5-704, Chicago, IL 60611 USA.	c-cambic@md.northwestern.edu	Avram, Michael/M-7681-2019	Wong, Cynthia/0000-0002-7144-7008	Northwestern University Feinberg School of Medicine, Department of Anesthesiology	The work was supported by the Northwestern University Feinberg School of Medicine, Department of Anesthesiology.	Avram MJ, 2007, DRUG METAB DISPOS, V35, P262, DOI 10.1124/dmd.106.010652; Bernards CM, 2003, ANESTHESIOLOGY, V99, P455, DOI 10.1097/00000542-200308000-00029; Eap CB, 2002, CLIN PHARMACOKINET, V41, P1153, DOI 10.2165/00003088-200241140-00003; Ginosar Y, 2003, ANESTH ANALG, V97, P1428, DOI 10.1213/01.ANE.0000081793.60059.10; Halpern SH, 2009, ANESTH ANALG, V108, P921, DOI 10.1213/ane.0b013e3181951a7f; He P, 2005, CLIN PHARMACOL THER, V77, P373, DOI 10.1016/j.clpt.2004.11.112; Holford N, 2010, CLIN PHARMACOL THER, V88, P166, DOI 10.1038/clpt.2010.114; JUSTINS DM, 1983, ANAESTHESIA, V38, P937, DOI 10.1111/j.1365-2044.1983.tb12022.x; Kharasch ED, 2012, CLIN PHARMACOL THER, V91, P673, DOI 10.1038/clpt.2011.276; Krejcie TC, 1996, J PHARMACOL EXP THER, V278, P1050; Kumar GN, 1996, J PHARMACOL EXP THER, V277, P423; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Mildh LH, 2001, ANESTH ANALG, V93, P939, DOI 10.1097/00000539-200110000-00028; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; Olofsen E, 2008, ANESTHESIOLOGY, V109, P664, DOI 10.1097/01.anes.0000334302.50559.c9; Schneeweiss S, 2011, CLIN PHARMACOL THER, V90, P777, DOI 10.1038/clpt.2011.235; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; Ummenhofer WC, 2000, ANESTHESIOLOGY, V92, P739, DOI 10.1097/00000542-200003000-00018; Volmink J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003510.pub2; Zeldin RK, 2004, J ANTIMICROB CHEMOTH, V53, P4, DOI 10.1093/jac/dkh029; Zhang J, 2010, OBSTET GYNECOL, V116, P1281, DOI 10.1097/AOG.0b013e3181fdef6e; Zhao P, 2011, CLIN PHARMACOL THER, V89, P259, DOI 10.1038/clpt.2010.298	22	2	3	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	FEB	2014	23	1					45	51		10.1016/j.ijoa.2013.08.011			7	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	AC1MS	WOS:000332261300010	24333052				2020-06-30	J	Liu, J; Zhou, X				Liu, Ji; Zhou, Xiao			Bioequivalence assessment of two transdermal delivery systems of fentanyl in healthy Chinese volunteers	INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS			English	Article						fentanyl patch; LC-MS/MS; pharmacokinetics; bioequivalence	TANDEM MASS-SPECTROMETRY; PERFORMANCE LIQUID-CHROMATOGRAPHY; PHARMACOLOGICAL-PROPERTIES; THERAPEUTIC-EFFICACY; PAIN-CONTROL; HUMAN PLASMA; CANCER PAIN; NORFENTANYL; SAMPLES; WATER	The objective of this study was to investigate the bioequivalence of two formulations (generic preparation and Durogesic patch) of 4.2 mg fentanyl. They were assessed in relative bioavailability in 20 healthy Chinese male volunteers according to a single dose, 2-sequence, crossover randomized design. The two formulations were administered at two treatment days, separated by a washout period of 14 days. Blood samples were collected at specified time intervals over 144 hours post-dosing. Plasma samples were separated and assayed for fentanyl using a sensitive LC-MS/MS method. Pharmacokinetic parameters were analyzed based on noncompartmental analysis. The value of two formulations was as follows: C-max, 0.789 (0.256) and 0.821 (0.278) ng/mL; t(max), 45.3 and 41.2 h;.t(1/2), 21.5 (8.8) and 22.6 (7.2) h; AUC(0-T), 52.5 (18.6) and 55.7 (19.7) ng/mLxh; and AUC(0-infinity), 54.6 (19.3) and 57.5 (21.1) ng/mLxh, respectively. ANOVA and two one-sided t-test procedures showed no significant difference in log-transformed C-max, AUC(0-T) and AUC(0-infinity) while the 90% confidence interval (CI) of the ratio of the geometric means of their values were also used to assess bioequivalence between the two formulations. Based on these statistical inferences it was concluded that the two formulations exhibited comparable pharmacokinetic profiles and that test formulation is bioequivalent to reference formulation. The point estimate (90% CI) of two formulations was: AUC(0-T), 96.7% (85 - 105%); AUC(0-infinity), 97.5% (89 - 110%); C-max, 96.2% (91 - 104%); t(max), 97.1% (93 - 101%), respectively.	[Liu, Ji; Zhou, Xiao] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Anesthesia, Shanghai 200433, Peoples R China	Zhou, X (reprint author), Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Anesthesia, 507 Zheng Min Rd, Shanghai 200433, Peoples R China.	liuji0515@163.com					Boleda MR, 2007, J CHROMATOGR A, V1175, P38, DOI 10.1016/j.chroma.2007.10.029; Center for Drug Evaluation, 2006, GUID PRINC BIOAV CHI; Chang YW, 2007, J CHROMATOGR B, V857, P195, DOI 10.1016/j.jchromb.2007.07.014; Day J, 2003, J ANAL TOXICOL, V27, P513, DOI 10.1093/jat/27.7.513; Ebrahimzadeh H, 2008, ANAL CHIM ACTA, V626, P193, DOI 10.1016/j.aca.2008.07.047; FISET P, 1995, ANESTHESIOLOGY, V83, P459, DOI 10.1097/00000542-199509000-00004; Hisada T, 2013, BIOL PHARM BULL, V36, P412, DOI 10.1248/bpb.b12-00825; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Kaestli LZ, 2008, DRUG AGING, V25, P269, DOI 10.2165/00002512-200825040-00001; Lambropoulos J, 2000, J PHARMACEUT BIOMED, V23, P421, DOI 10.1016/S0731-7085(00)00312-5; Malkawi AH, 2008, AAPS J, V10, P261, DOI 10.1208/s12248-008-9031-x; Marier JF, 2007, BRIT J CLIN PHARMACO, V63, P121, DOI 10.1111/j.1365-2125.2006.02758.x; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Nugent M, 2001, J PAIN SYMPTOM MANAG, V21, P385, DOI 10.1016/S0885-3924(01)00257-3; *US DEP HHS, 1999, SKIN IRR SENS TEST G; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Zhang BJ, 2007, CHINESE J HOSP PHARM, V27, P112	18	2	2	0	9	DUSTRI-VERLAG DR KARL FEISTLE	DEISENHOFEN-MUENCHEN	BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY	0946-1965			INT J CLIN PHARM TH	Int. J. Clin. Pharmacol. Ther.	FEB	2014	52	2					175	180		10.5414/CP201901			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AB0LB	WOS:000331482300011	24424109				2020-06-30	J	Pergolizzi, JV; Taylor, R; Nalamachu, S; Raffa, RB; Carlson, DR; Varanasi, RK; Kopecky, EA				Pergolizzi, Joseph V., Jr.; Taylor, Robert, Jr.; Nalamachu, Srinivas; Raffa, Robert B.; Carlson, Douglas R.; Varanasi, Ravi K.; Kopecky, Ernest A.			Challenges of treating patients with chronic pain with dysphagia (CPD): physician and patient perspectives	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						Dysphagia; Chronic pain; Swallowing; Analgesia Patient; education	QUALITY-OF-LIFE; UNITED-STATES; PRIMARY-CARE; RISK-FACTORS; PREVALENCE; IMPACT; DEPRESSION; ADULTS; COSTS; EPIDEMIOLOGY	Objective: Dysphagia-difficulty eating and swallowing-can significantly impair a patient's ability to maintain adequate nutritional and medication intake. There are a large number of patients with chronic pain, including pediatric, geriatric, and palliative care patients, who suffer from dysphagia and, therefore, have difficulty achieving optimal pain management with solid, oral formulations. The objective of this study was to survey physicians and patients in the US to understand their knowledge, attitudes, and clinical management/analgesic usage patterns in the treatment of patients with chronic pain with dysphagia (CPD). Research design and methods: Two separate surveys were administered to physicians and patients. The physician survey design was qualitative; physicians participated in a semi-structured phone interview. The patient survey design was quantitative; patients participated in a structured online survey. Purposive sampling was used to recruit participants into both studies. Physician participants were identified based on their specialty, prescribing practices, and geographic location. Patient participants were recruited through a consumer panel of preidentified individuals who, for 3 months or longer, had chronic pain and were taking opioids. Results: Thirty-four physicians and 1021 patients were surveyed. Physicians indicated that 5-20% of their patients had difficulty swallowing. Treatment for CPD consisted of the fentanyl patch, immediate-release opioids, methadone liquid, or extended-release morphine products. Physicians were not satisfied with currently available treatment options. Twenty-nine per cent of patients surveyed had trouble swallowing or disliked swallowing pills. Eighty per cent of patients were not asked about their ability to swallow solid, oral dosage forms by their physician. To circumvent swallowing difficulties, some patients (16%) cut/crush/grind their medication to facilitate swallowing. Most of these patients (65%) did not know that altering tablets could potentially change the drug release (pharmacokinetic) characteristics of the tablet and lead to serious adverse events. Limitations: Qualitative survey research can be influenced by responder bias as well as selection bias. The number of survey participants for both the physician and patient surveys was small, thus responses may not reflect those in the general population. Conclusion: A proportion of patients with chronic pain have dysphagia and cannot swallow solid, oral dosage forms, which creates a serious treatment challenge for pain specialists and other healthcare providers. Currently available treatment options have limitations; new treatment options would be welcomed by both physicians and patients. Physician and patient education should be enhanced in order to promote awareness of the deleterious consequences associated with altering currently available analgesic formulations. Facilitating patient-physician communication on this topic may help to improve treatment outcomes.	[Pergolizzi, Joseph V., Jr.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Pergolizzi, Joseph V., Jr.] Georgetown Univ, Sch Med, Washington, DC USA; [Pergolizzi, Joseph V., Jr.] Temple Univ, Sch Med, Philadelphia, PA 19122 USA; [Taylor, Robert, Jr.] NEMA Res Inc, Naples, FL USA; [Nalamachu, Srinivas] Int Clin Res Inst, Overland Pk, KS USA; [Raffa, Robert B.] Temple Univ, Sch Pharm, Philadelphia, PA 19122 USA; [Carlson, Douglas R.; Varanasi, Ravi K.; Kopecky, Ernest A.] Collegium Pharmaceut Inc, Canton, MA USA	Taylor, R (reprint author), 840 111th Ave N,9, Naples, FL 34108 USA.	robert.taylor.phd@gmail.com			Collegium Pharmaceutical, Inc	The funding for the surveys was provided by Collegium Pharmaceutical, Inc.	Actavis Elizabeth LLC, 2012, KADIAN MORPH SULF EX; Altman KW, 2010, ARCH OTOLARYNGOL, V136, P784, DOI 10.1001/archoto.2010.129; American Pain Foundation, 2006, VOIC CHRON PAIN NAT; Arnow BA, 2006, PSYCHOSOM MED, V68, P262, DOI 10.1097/01.psy.0000204851.15499.fc; Arnow BA, 2009, PSYCHIAT SERV, V60, P344, DOI 10.1176/appi.ps.60.3.344; Bair MJ, 2004, PSYCHOSOM MED, V66, P17, DOI 10.1097/01.PSY.0000106883.94059.C5; Bair MJ, 2003, ARCH INTERN MED, V163, P2433, DOI 10.1001/archinte.163.20.2433; Carnaby-Mann G, 2005, ARCH OTOLARYNGOL, V131, P970, DOI 10.1001/archotol.131.11.970; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Cornish P, 2005, CAN MED ASSOC J, V172, P871, DOI 10.1503/cmaj.050176; Crary Michael A, 2006, Nutr Clin Pract, V21, P576, DOI 10.1177/0115426506021006576; Davis Jessica A, 2011, J Pain Res, V4, P331, DOI 10.2147/JPR.S24170; Davis LA, 2007, TOP GERIATR REHABIL, V23, P211; Eslick GD, 2008, ALIMENT PHARM THERAP, V27, P971, DOI 10.1111/j.1365-2036.2008.03664.x; Garcia-Peris P, 2007, CLIN NUTR, V26, P710, DOI 10.1016/j.clnu.2007.08.006; Gasiorowska A, 2009, GASTROENTEROL HEPATO, V5, P269; Gaskin DJ, 2012, J PAIN, V13, P715, DOI 10.1016/j.jpain.2012.03.009; Gorodetsky AA, 2009, AIP CONF PROC, V1087, P485, DOI 10.1063/1.3076861; Houghton Mifflin Company, 2007, AM HER MED DICT; Humbert IA, 2008, PHYS MED REH CLIN N, V19, P853, DOI 10.1016/j.pmr.2008.06.002; IOM, 2011, REL PAIN AM BLUEPR T; Johannes CB, 2010, J PAIN, V11, P1230, DOI 10.1016/j.jpain.2010.07.002; Kelly Jennifer, 2012, Nurs Times, V108, P12; Kelly J, 2011, J ADV NURS, V67, P2615, DOI 10.1111/j.1365-2648.2011.05700.x; Kelly Jennifer, 2009, Nurs Stand, V23, P62; Kelly J, 2010, J ADV NURS, V66, P82, DOI 10.1111/j.1365-2648.2009.05145.x; Kelly J, 2009, DYSPHAGIA, V24, P49, DOI 10.1007/s00455-008-9170-3; Lee Stephanie J, 2002, Hematology Am Soc Hematol Educ Program, P464, DOI 10.1182/asheducation-2002.1.464; Management of Opioid Therapy for Chronic Pain Working Group, 2010, VA DOD CLIN PRACT GU; Manchikanti L, 2009, PAIN PHYSICIAN, V12, pE35; Mandal TK, 1996, J CLIN PHARM THER, V21, P155, DOI 10.1111/j.1365-2710.1996.tb00015.x; Mann G, 2000, CEREBROVASC DIS, V10, P380, DOI 10.1159/000016094; Roy N, 2007, ANN OTO RHINOL LARYN, V116, P858, DOI 10.1177/000348940711601112; Sareen J, 2005, DEPRESS ANXIETY, V21, P193, DOI 10.1002/da.20072; Sheehan NJ, 2008, RHEUMATOLOGY, V47, P746, DOI 10.1093/rheumatology/ken029; Singh S, 2006, POSTGRAD MED J, V82, P383, DOI 10.1136/pgmj.2005.043281; Spieker MR, 2000, AM FAM PHYSICIAN, V61, P3639; Stewart WF, 2003, J OCCUP ENVIRON MED, V45, P1234, DOI 10.1097/01.jom.0000099999.27348.78; Sura L, 2012, CLIN INTERV AGING, V7, P287, DOI 10.2147/CIA.S23404; The American Academy of Pain Medicine, 2013, AAPM FACTS FIG PAIN; US Bureau of the Census, 2011, STAT ABSTR US; Wilkins T, 2007, J AM BOARD FAM MED, V20, P144, DOI 10.3122/jabfm.2007.02.060045	42	22	22	0	16	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.	FEB	2014	30	2					191	202		10.1185/03007995.2013.854197			12	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	AA1HW	WOS:000330848200004	24117419				2020-06-30	J	Malk, K; Metsaranta, M; Vanhatalo, S				Malk, Kaija; Metsaranta, Marjo; Vanhatalo, Sampsa			Drug effects on endogenous brain activity in preterm babies	BRAIN & DEVELOPMENT			English	Article						Neonatal EEG; Preterm EEG; SAT; iSAT; Drug therapy	ELECTRICAL-ACTIVITY; ACTIVITY TRANSIENTS; ACTIVITY PATTERNS; CORTICAL ACTIVITY; EEG ACTIVITY; FULL-TERM; BIRTH; PREMATURE; OSCILLATIONS; CORTEX	Background: Animal experiments have suggested that the quality of the early intermittent brain activity is important for shaping neuronal connectivity during developmental phase that corresponds to early prematurity. This is a pilot study aiming to assess whether spontaneous activity transients (SAT) in the early preterm babies are affected by drugs that are routinely used in neonatal intensive care. Methods: We collected retrospectively seventeen EEG recordings (15 babies, conceptional age 26-33 weeks, no brain lesions) that were divided into groups according to drug administration at the time of EEG: phenobarbital, fentanyl, theophylline, and controls. SATs were extracted from the EEG for further analysis with several advanced time-series analysis paradigms. Results: The visual appearance of SATs was unaffected by drugs. Phenobarbital reduced the total power of the SAT events. Both fentanyl and phenobarbital reduced the length of SATs, and enhanced the oscillations at higher frequencies. Theophylline reduced the oscillatory activity at middle frequencies during SAT, but enhanced oscillations at higher frequencies during time-period prior to SAT. Conclusions: Our findings suggest, that (i) all drugs examined affect brain activity in ways that are not seen in the visual EEG interpretation, and that (ii) both acute and long term (i.e. developmental) effects of these drugs on brain may warrant more attention as a part of optimizing preterm neurological care. (C) 2013 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.	[Malk, Kaija; Vanhatalo, Sampsa] Univ Helsinki, Cent Hosp, Dept Childrens Clin Neurophysiol, Helsinki, Finland; [Metsaranta, Marjo] Univ Helsinki, Cent Hosp, Chidrens Hosp, Helsinki, Finland; [Metsaranta, Marjo] Univ Helsinki, Helsinki, Finland; [Vanhatalo, Sampsa] Univ Helsinki, Dept Neurol Sci, Helsinki, Finland	Vanhatalo, S (reprint author), HUCH, Dept Clin Neurophysiol, POB 280, FIN-00029 Helsinki, Finland.	sampsa.vanhatalo@helsinki.fi			Arvo and Lea Ylppo Foundation; Helsinki University Central Hospital; Finnish Medical Foundation; Juselius Foundation; European Community's Seventh Framework ProgrammeEuropean Union (EU) [FP7-PEOPLE-2009-IOF, 254235]	We want to thank Arvo and Lea Ylppo Foundation, Helsinki University Central Hospital, Finnish Medical Foundation, and Juselius Foundation for supporting this work. During the course of this study, S.V. was partly supported by the European Community's Seventh Framework Programme (FP7-PEOPLE-2009-IOF, grant agreement no. 254235).	Allen MC, 2008, CURR OPIN NEUROL, V21, P123, DOI 10.1097/WCO.0b013e3282f88bb4; Ball G, 2012, CEREB CORTEX, V22, P1016, DOI 10.1093/cercor/bhr176; BELL AH, 1993, ACTA PAEDIATR, V82, P35, DOI 10.1111/j.1651-2227.1993.tb12511.x; Bhutta AT, 2001, TRENDS NEUROSCI, V24, P129, DOI 10.1016/S0166-2236(00)01747-1; Bittigau P, 2002, P NATL ACAD SCI USA, V99, P15089, DOI 10.1073/pnas.222550499; Brockmann MD, 2011, NEURON, V71, P332, DOI 10.1016/j.neuron.2011.05.041; Colonnese MT, 2010, NEURON, V67, P480, DOI 10.1016/j.neuron.2010.07.015; Counsell SJ, 2008, BRAIN, V131, P3201, DOI 10.1093/brain/awn268; Dupont E, 2006, NATURE, V439, P79, DOI 10.1038/nature04264; EATON DGM, 1992, DEV MED CHILD NEUROL, V34, P155; Gressens P, 2002, J PEDIATR-US, V140, P646, DOI 10.1067/mpd.2002.123214; HELLSTROMWESTAS L, 1991, NEUROPEDIATRICS, V22, P27, DOI 10.1055/s-2008-1071411; Hooks BM, 2006, NEURON, V52, P281, DOI 10.1016/j.neuron.2006.07.007; Inder TE, 2005, PEDIATRICS, V115, P286, DOI 10.1542/peds.2004-0326; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Katz LC, 2002, NAT REV NEUROSCI, V3, P34, DOI 10.1038/nrn703; Khazipov R, 2006, TRENDS NEUROSCI, V29, P414, DOI 10.1016/j.tins.2006.05.007; Kidokoro H, 2009, PEDIATRICS, V124, pE468, DOI 10.1542/peds.2008-2967; Kilb W, 2011, EUR J NEUROSCI, V34, P1677, DOI 10.1111/j.1460-9568.2011.07878.x; Lamblin MD, 1999, NEUROPHYSIOL CLIN, V29, P123, DOI 10.1016/S0987-7053(99)80051-3; LOMBROSO CT, 1985, J CLIN NEUROPHYSIOL, V2, P105, DOI 10.1097/00004691-198504000-00002; Minlebaev M, 2007, J NEUROPHYSIOL, V97, P692, DOI 10.1152/jn.00759.2006; Minlebaev M, 2011, SCIENCE, V334, P226, DOI 10.1126/science.1210574; Narberhaus A, 2007, J CHILD NEUROL, V22, P761, DOI 10.1177/0883073807304006; Palmu K, 2010, CLIN NEUROPHYSIOL, V121, P1015, DOI 10.1016/j.clinph.2010.02.010; Parikh NA, 2007, PEDIATRICS, V119, P265, DOI 10.1542/peds.2006-1354; Peterson BS, 2000, JAMA-J AM MED ASSOC, V284, P1939, DOI 10.1001/jama.284.15.1939; Safiulina VF, 2005, J NEUROPHYSIOL, V94, P2797, DOI 10.1152/jn.00445.2005; Sipila Sampsa T., 2008, V44, P99, DOI 10.1007/400_2007_033; Smith GC, 2011, ANN NEUROL, V70, P541, DOI 10.1002/ana.22545; Stanwood GD, 2004, CURR OPIN PHARMACOL, V4, P65, DOI 10.1016/j.coph.2003.09.003; Supcun S, 2010, J PEDIATR-US, V156, P490, DOI 10.1016/j.jpeds.2009.10.033; Thompson BL, 2009, NAT REV NEUROSCI, V10, P303, DOI 10.1038/nrn2598; Tich SNT, 2003, PEDIATRICS, V111, P123, DOI 10.1542/peds.111.1.123; Tolonen M, 2007, NEUROSCIENCE, V145, P997, DOI 10.1016/j.neuroscience.2006.12.070; Tommiska V, 2007, PEDIATRICS, V119, P29, DOI 10.1542/peds.2006-1472; Vanhatalo S, 2002, CLIN NEUROPHYSIOL, V113, P1822, DOI 10.1016/S1388-2457(02)00292-4; Vanhatalo S, 2005, EUR J NEUROSCI, V22, P2799, DOI 10.1111/j.1460-9568.2005.04459.x; Vanhatalo S, 2010, NEWBORN BRAIN NEUROS, P229; Vanhatalo S, 2006, SEMIN FETAL NEONAT M, V11, P471, DOI 10.1016/j.siny.2006.07.008; Victor S, 2005, PEDIATR RES, V58, P579, DOI 10.1203/01.pdr.0000169402.13435.09; Volpe JJ, 2003, PEDIATRICS, V112, P176, DOI 10.1542/peds.112.1.176; Wikstrom S, 2008, ACTA PAEDIATR, V97, P915, DOI 10.1111/j.1651-2227.2008.00787.x; Young GB, 2000, CLIN NEUROPHYSIOL, V111, P1955, DOI 10.1016/S1388-2457(00)00433-8	44	21	21	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0387-7604	1872-7131		BRAIN DEV-JPN	Brain Dev.	FEB	2014	36	2					116	123		10.1016/j.braindev.2013.01.009			8	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	295YD	WOS:000330151400004	23422259				2020-06-30	J	Pypendop, BH; Brosnan, RJ; Majewski-Tiedeken, CR; Stanley, SD; Ilkiw, JE				Pypendop, B. H.; Brosnan, R. J.; Majewski-Tiedeken, C. R.; Stanley, S. D.; Ilkiw, J. E.			Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats	JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS			English	Article							MINIMUM ALVEOLAR CONCENTRATION; ANESTHESIA; BUPRENORPHINE; METABOLITE; REDUCTION; LIDOCAINE; MORPHINE	The aim of this study was to compare the pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. Six adult cats were used. Anesthesia was induced and maintained with isoflurane in oxygen. End-tidal isoflurane concentration was set at 2% and adjusted as required due to spontaneous movement. Fentanyl (10g/kg), alfentanil (100g/kg), or sufentanil (1g/kg) was administered intravenously as a bolus, on separate days. Blood samples were collected immediately before and for 8h following drug administration. Plasma drug concentration was determined using liquid chromatography/mass spectrometry. Compartment models were fitted to concentration-time data. A 3-compartment model best fitted the concentration-time data for all drugs, except for 1 cat in the sufentanil group (excluded from analysis). The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean +/- SEM (range)], the clearance (mL/min/kg) [harmonic mean +/- pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 +/- 0.04 (0.09-0.34), 2.18 +/- 0.16 (1.79-2.83), 18.6 +/- 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 +/- 0.01 (0.07-0.14), 0.89 +/- 0.16 (0.68-1.83), 11.6 +/- 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 +/- 0.01 (0.04-0.10), 0.77 +/- 0.07 (0.63-0.99), 17.6 +/- 4.3 (13.9-24.3), and 54 (46-76) for sufentanil. Differences in clearance and volume of distribution result in similar terminal half-lives for fentanyl and alfentanil, longer than for sufentanil.	[Pypendop, B. H.; Brosnan, R. J.; Majewski-Tiedeken, C. R.; Ilkiw, J. E.] Univ Calif Davis, Dept Surg & Radiol Sci, Sch Vet Med, Davis, CA 95616 USA; [Stanley, S. D.] Calif Anim Hlth & Food Safety Lab, KL Maddy Equine Analyt Chem Lab, Davis, CA USA	Pypendop, BH (reprint author), Univ Calif Davis, Dept Surg & Radiol Sci, Sch Vet Med, 1 Shields Ave, Davis, CA 95616 USA.	bhpypendop@ucdavis.edu		Pypendop, Bruno/0000-0002-0894-0991	George and Phyllis Miller Feline Health Fund, San Francisco Foundation; Center for Companion Animal Health, School of Veterinary Medicine, University of CaliforniaUniversity of California System	This study was funded by the George and Phyllis Miller Feline Health Fund, San Francisco Foundation, and the Center for Companion Animal Health, School of Veterinary Medicine, University of California.	Avram MJ, 2000, ANESTHESIOLOGY, V92, P1757, DOI 10.1097/00000542-200006000-00036; Barter LS, 2004, BRIT J ANAESTH, V92, P275, DOI 10.1093/bja/aeh047; BOVILL JG, 1982, ANESTHESIOLOGY, V57, P439, DOI 10.1097/00000542-198212000-00002; BOVILL JG, 1984, ANESTHESIOLOGY, V61, P731; BRUNNER MD, 1994, BRIT J ANAESTH, V72, P42, DOI 10.1093/bja/72.1.42; CHELLY JE, 1987, J PHARMACOL EXP THER, V241, P899; Cooper R. A., 1983, DATA MODELS STAT ANA, P49; Escobar A, 2012, J VET PHARMACOL THER, V35, P163, DOI 10.1111/j.1365-2885.2011.01301.x; Gabrielsson J, 2006, PHARMACOKINETIC PHAR, P11; GEPTS E, 1995, ANESTHESIOLOGY, V83, P1194, DOI 10.1097/00000542-199512000-00010; Gibaldi M., 1982, PHARMACOKINETICS, P45; Glass PSA, 1997, J CLIN ANESTH, V9, pS18, DOI 10.1016/S0952-8180(97)00122-0; Hodgson DS, 1998, AM J VET RES, V59, P182; Ilkiw JE, 2002, AM J VET RES, V63, P1198, DOI 10.2460/ajvr.2002.63.1198; Ilkiw JE, 1997, AM J VET RES, V58, P1274; LAM FC, 1985, J PHARM SCI, V74, P229, DOI 10.1002/jps.2600740229; Lee DD, 2000, AM J VET RES, V61, P672, DOI 10.2460/ajvr.2000.61.672; MCEWAN AI, 1993, ANESTHESIOLOGY, V78, P864, DOI 10.1097/00000542-199305000-00009; Mendes GM, 2003, J AM VET MED ASSOC, V223, P1608, DOI 10.2460/javma.2003.223.1608; MEULDERMANS WEG, 1982, ARCH INT PHARMACOD T, V257, P4; MURPHY MR, 1983, ANESTHESIOLOGY, V59, P537, DOI 10.1097/00000542-198312000-00009; O'Neil M.J., 2006, MERCK INDEX ENCY CHE; Pascoe P. J., 1993, VET ANAESTH ANALG, V20, P9; Pypendop BH, 2005, ANESTH ANALG, V100, P97, DOI 10.1213/01.ANE.0000139350.88158.38; Pypendop BH, 2003, AM J VET RES, V64, P273, DOI 10.2460/ajvr.2003.64.273; Pypendop BH, 2008, AM J VET RES, V69, P531, DOI 10.2460/ajvr.69.4.531; Pypendop BH, 2006, AM J VET RES, V67, P1471, DOI 10.2460/ajvr.67.9.1471; Reid P, 2010, ANESTH ANALG, V111, P633, DOI 10.1213/ANE.0b013e3181e51245; SHAFER SL, 1992, ANESTHESIOLOGY, V76, P327, DOI 10.1097/00000542-199203000-00001; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; Thomasy SM, 2007, EQUINE VET J, V39, P54, DOI 10.2746/042516407X153011; Thomasy SM, 2005, AM J VET RES, V66, P1162, DOI 10.2460/ajvr.2005.66.1162; WESTMORELAND CL, 1994, ANESTH ANALG, V78, P23; Yackey M, 2004, VET ANAESTH ANALG, V31, P183, DOI 10.1111/j.1467-2987.2004.00125.x; YAMAOKA K, 1978, J PHARMACOKINET BIOP, V6, P165, DOI 10.1007/BF01117450	35	7	7	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0140-7783	1365-2885		J VET PHARMACOL THER	J. Vet. Pharmacol. Ther.	FEB	2014	37	1					13	17		10.1111/jvp.12047			5	Pharmacology & Pharmacy; Veterinary Sciences	Pharmacology & Pharmacy; Veterinary Sciences	286WG	WOS:000329499400004	23895731				2020-06-30	J	Hwang, IC; Bruera, E; Park, SM				Hwang, In Cheol; Bruera, Eduardo; Park, Sang Min			Use of Intravenous Fentanyl Against Morphine Tolerance in Breakthrough Cancer Pain: A Case Series and Literature Review	AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE			English	Article						breakthrough cancer pain; intravenous fentanyl; morphine tolerance	MANAGEMENT; ANALGESIA; INFUSION; SAFETY	Palliative care physicians are accustomed to using transdermal fentanyl patch for cancer pain control but not so familiar with its intravenous administration. Historically, fentanyl has been used to treat breakthrough pain because it is a very potent analgesic with a rapid onset and short duration of action. Although several formulations of fentanyl have been recently developed for breakthrough cancer pain, these are unavailable or too expensive in some countries. Also, all opioids can induce tolerance potentially and different opioids cause significantly different degrees of tolerance. Therefore, sequential opioid trials may be a reasonable approach in patients with poor analgesic effect after dose escalation. Here, we present 2 morphine-tolerant patients with cancer in whom the intravenous fentanyl was effectively used for their refractory breakthrough pain.	[Hwang, In Cheol] Incheon Reg Canc Ctr, Palliat Care Unit, Inchon 405760, South Korea; [Bruera, Eduardo] Univ Texas MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Houston, TX 77030 USA; [Park, Sang Min] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Family Med, Seoul, South Korea	Hwang, IC (reprint author), Incheon Reg Canc Ctr, Palliat Care Unit, 1198 Guwol Dong, Inchon 405760, South Korea.	spfe0211@gmail.com	Park, Sang Min/V-9194-2019				Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Arttamangkul S, 2008, MOL PHARMACOL, V74, P972, DOI 10.1124/mol.108.048512; Fleischman RJ, 2010, PREHOSP EMERG CARE, V14, P167, DOI 10.3109/10903120903572301; JAGOX A, 1994, NEW ENGL J MED, V330, P651, DOI 10.1056/NEJM199403033300926; Lenz KL, 1998, ANN PHARMACOTHER, V32, P316, DOI 10.1345/aph.17285; Martini L, 2007, CURR OPIN NEUROBIOL, V17, P556, DOI 10.1016/j.conb.2007.10.004; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Mercadante S, 2004, SUPPORT CARE CANCER, V12, P762, DOI 10.1007/s00520-004-0650-1; Mercadante S, 2011, CURR PAIN HEADACHE R, V15, P244, DOI 10.1007/s11916-011-0191-5; Ossipov MH, 2005, BIOPOLYMERS, V80, P319, DOI 10.1002/bip.20254; Parsons HA, 2008, J PALLIAT MED, V11, P1319, DOI 10.1089/jpm.2008.0155; Ruggiero A, 2007, SUPPORT CARE CANCER, V15, P569, DOI 10.1007/s00520-006-0193-8; Swarm R, 2010, J NATL COMPR CANC NE, V8, P1046, DOI 10.6004/jnccn.2010.0076; Watanabe S, 1998, J PAIN SYMPTOM MANAG, V16, P323, DOI 10.1016/S0885-3924(98)00095-5	14	2	2	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-9091	1938-2715		AM J HOSP PALLIAT ME	Am. J. Hosp. Palliat. Med.	FEB	2014	31	1					109	111		10.1177/1049909112474112			3	Health Care Sciences & Services	Health Care Sciences & Services	AA6ID	WOS:000331201100016	23345613				2020-06-30	J	Cata, JP; Gottumukkala, V; Thakar, D; Keerty, D; Gebhardt, R; Liu, DD				Cata, Juan P.; Gottumukkala, Vijaya; Thakar, Dilip; Keerty, Dinesh; Gebhardt, Rodolfo; Liu, Diane D.			Effects of postoperative epidural analgesia on recurrence-free and overall survival in patients with nonsmall cell lung cancer	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Analgesia; Postoperative; Epidural; Intravenous; Patient-controlled; Nonsmall cell lung carcinoma	ANESTHETIC TECHNIQUE; BREAST-CANCER; RETROSPECTIVE ANALYSIS; RADICAL PROSTATECTOMY; RANDOMIZED-TRIAL; STRESS-RESPONSE; GASTRIC-CANCER; GROWTH-FACTOR; SURGERY; MORPHINE	Study Objective: To determine whether postoperative epidural analgesia is associated with better recurrence-free survival and overall survival after lung cancer surgery. Design: Retrospective study. Setting: Academic hospital. Measurements: Data of patients with stage 1, stage 2, and stage 3 nonsmall cell lung cancer, who underwent tumor resection surgery, were studied. Patient data were grouped into three different postoperative pain management interventions; intravenous patient-controlled analgesia, patient-controlled epidural analgesia, and their combination. Univariate and multicovariate Cox proportional hazards models were applied to assess the effects of covariates of interest on overall survival and recurrence-free survival. Main Results: The type of postoperative analgesia used for patients who underwent surgery for nonsmall cell lung cancer did not affect recurrence-free survival or overall survival. However, certain variables, including age >= 65 years, male gender, body mass index >= 25 kg/m(2), ASA physical status 4, and the need for preoperative blood transfusions, pneumonectomy, and postoperative radiation, were associated with decreased recurrence-free survival and overall survival. Conclusions: The type of postoperative analgesia used after surgery for nonsmall cell lung cancer is not associated with better 2-year or 5-year recurrence-free survival or overall survival rates. (c) 2014 Elsevier Inc. All rights reserved.	[Cata, Juan P.; Gottumukkala, Vijaya; Thakar, Dilip; Keerty, Dinesh] Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Perioperat Med, Houston, TX 77030 USA; [Gebhardt, Rodolfo] Univ Texas MD Anderson Canc Ctr, Dept Pain Med, Houston, TX 77030 USA; [Liu, Diane D.] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	Cata, JP (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Perioperat Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.	jcata@mdanderson.org		Keerty, Dinesh/0000-0002-0287-8664	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [CA016672]	The University of Texas MD Anderson Cancer Center is supported in part by a Cancer Center Support Grant (CA016672) from the National Institutes of Health.	Ahlers O, 2008, BRIT J ANAESTH, V101, P781, DOI 10.1093/bja/aen287; Akural EI, 2004, ACTA ANAESTH SCAND, V48, P750, DOI 10.1111/j.1399-6576.2004.00402.x; Bartal I, 2010, BRAIN BEHAV IMMUN, V24, P376, DOI 10.1016/j.bbi.2009.02.010; Beagles K, 2004, MOL PHARMACOL, V65, P437, DOI 10.1124/mol.65.2.437; Beilin B, 1996, ANESTH ANALG, V82, P492, DOI 10.1097/00000539-199603000-00011; Ben-Eliyahu S, 1999, INT J CANCER, V80, P880; Biki B, 2008, ANESTHESIOLOGY, V109, P180, DOI 10.1097/ALN.0b013e31817f5b73; Brand JM, 1997, CLIN IMMUNOL IMMUNOP, V83, P190, DOI 10.1006/clin.1997.4351; Caputo M, 2011, ANESTHESIOLOGY, V114, P380, DOI 10.1097/ALN.0b013e318201f571; Carbone DP, 2011, CLIN LUNG CANCER, V12, P261, DOI 10.1016/j.cllc.2011.06.002; Cata JP, 2012, EUR J PAIN S, V5, P345; Coleman MH, 2011, SURG ONCOL CLIN N AM, V20, P757, DOI 10.1016/j.soc.2011.07.011; Cummings KC, 2012, ANESTHESIOLOGY, V116, P797, DOI 10.1097/ALN.0b013e31824674f6; Deegan CA, 2010, REGION ANESTH PAIN M, V35, P490, DOI 10.1097/AAP.0b013e3181ef4d05; Exadaktylos AK, 2006, ANESTHESIOLOGY, V105, P660, DOI 10.1097/00000542-200610000-00008; Franchi S, 2007, BRAIN BEHAV IMMUN, V21, P767, DOI 10.1016/j.bbi.2007.01.001; Gottschalk A, 2010, ANESTHESIOLOGY, V113, P27, DOI 10.1097/ALN.0b013e3181de6d0d; Gupta A, 2011, BRIT J ANAESTH, V107, P164, DOI 10.1093/bja/aer100; Hirai T, 1998, SURG TODAY, V28, P576, DOI 10.1007/s005950050187; Hong JY, 2011, ACTA ANAESTH SCAND, V55, P282, DOI 10.1111/j.1399-6576.2010.02360.x; Ismail H, 2010, BRIT J ANAESTH, V105, P145, DOI 10.1093/bja/aeq156; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI 10.3322/caac.20073; Jung IK, 2008, J SURG ONCOL, V98, P54, DOI 10.1002/jso.21075; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Koltun WA, 1996, AM J SURG, V171, P68, DOI 10.1016/S0002-9610(99)80076-2; Lai RC, 2012, ANESTH ANALG, V114, P290, DOI 10.1213/ANE.0b013e318239c2e3; Liao XH, 2010, ONCOL REP, V24, P1669, DOI 10.3892/or_00001032; Liu X, 2008, J PHARMACOL EXP THER, V326, P69, DOI 10.1124/jpet.107.134528; LUNDY J, 1978, CANCER, V41, P827, DOI 10.1002/1097-0142(197803)41:3<827::AID-CNCR2820410307>3.0.CO;2-#; Manser R, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004699.pub2; MARKOVIC SN, 1993, ANESTHESIOLOGY, V78, P700, DOI 10.1097/00000542-199304000-00013; Mathew B, 2011, ANESTH ANALG, V112, P558, DOI 10.1213/ANE.0b013e31820568af; Melamed R, 2005, BRAIN BEHAV IMMUN, V19, P114, DOI 10.1016/j.bbi.2004.07.004; MELCHI CF, 1995, DERMATOL SURG, V21, P786, DOI 10.1111/j.1524-4725.1995.tb00297.x; Mojadadi S, 2009, CELL MOL IMMUNOL, V6, P111, DOI 10.1038/cmi.2009.15; Myles PS, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1491; Page GG, 1997, BREAST CANCER RES TR, V45, P159, DOI 10.1023/A:1005826403235; Roy S, 1997, CELL IMMUNOL, V179, P1, DOI 10.1006/cimm.1997.1147; Sacerdote P, 2000, ANESTH ANALG, V90, P1411, DOI 10.1097/00000539-200006000-00028; Sessler DI, 2008, CONTEMP CLIN TRIALS, V29, P517, DOI 10.1016/j.cct.2008.01.002; Sessler DI, 2008, EUR J CANCER PREV, V17, P269, DOI 10.1097/CEJ.0b013e3282f0c005; Singleton PA, 2006, MICROVASC RES, V72, P3, DOI 10.1016/j.mvr.2006.04.004; Tsui BCH, 2010, CAN J ANAESTH, V57, P107, DOI 10.1007/s12630-009-9214-7; Udagava T, 2008, APMIS, V116, P615, DOI 10.1111/j.1600-0463.2008.01077.x; Weddle DL, 2001, CARCINOGENESIS, V22, P473, DOI 10.1093/carcin/22.3.473; Whitson BA, 2008, ANN THORAC SURG, V86, P1735, DOI 10.1016/j.athoracsur.2008.07.001; Wuethrich PY, 2010, ANESTHESIOLOGY, V113, P570, DOI 10.1097/ALN.0b013e3181e4f6ec; Yang EV, 2006, CANCER RES, V66, P10357, DOI 10.1158/0008-5472.CAN-06-2496; Yokota Tetsuya, 2004, J Anesth, V18, P190	49	22	26	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	FEB	2014	26	1					3	17		10.1016/j.jclinane.2013.06.007			15	Anesthesiology	Anesthesiology	AD7IK	WOS:000333437200002	24095887				2020-06-30	J	Hui, D; Xu, A; Frisbee-Hume, S; Chisholm, G; Morgado, M; Reddy, S; Bruera, E				Hui, David; Xu, Angela; Frisbee-Hume, Susan; Chisholm, Gary; Morgado, Margarita; Reddy, Suresh; Bruera, Eduardo			Effects of Prophylactic Subcutaneous Fentanyl on Exercise-Induced Breakthrough Dyspnea in Cancer Patients: A Preliminary Double-Blind, Randomized, Controlled Trial	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Dyspnea; exercise; opioids; fentanyl; neoplasms; randomized controlled trial; prophylaxis; subcutaneous	CITRATE	Context. Dyspnea is one of the most distressing symptoms in patients with cancer, and often worsens with breakthrough episodes on exertion. We hypothesized that fentanyl given prophylactically may alleviate breakthrough dyspnea. Objectives. To determine the feasibility of conducting a randomized trial of subcutaneous fentanyl in patients with cancer, and examine the effects of fentanyl on dyspnea, walk distance, vital signs, and adverse events. Methods. In this double-blind, randomized, controlled trial, we asked ambulatory patients with breakthrough dyspnea to perform a baseline six minute walk test (6MWT), and then assigned them to either subcutaneous fentanyl or placebo 15 minutes before a second 6MWT. We documented the change in dyspnea Numeric Rating Scale (NRS) score, walk distance, vital signs, and adverse events between the first and second 6MWT. Results. A total of 20 patients were enrolled (1: 1 ratio) without attrition. Comparison between baseline and second walk showed that fentanyl was associated with significant improvements in dyspnea NRS score at the end of the 6MWT (mean [95% CI] -1.8 [-3.2, -0.4]), dyspnea NRS score at rest of 15 minutes after drug administration (-0.9 [-1.8, -0.04]), Borg Scale fatigue score at the end of the 6MWT (-1.3 [-2.4, -0.2]), 6MWT distance (+37.2 m [5.8, 68.6]), and respiratory rate (-2.4 [-4.5, -0.3]). Nonstatistically significant improvements also were observed in the placebo arm, with no difference between the two study arms. No significant adverse effects were observed. Conclusion. Prophylactic fentanyl was safe and improved dyspnea, fatigue, walk distance, and respiratory rate. We also observed a large placebo effect. Our results justify larger randomized controlled trials with higher fentanyl doses (clinicaltrials.gov registration: NCT01515566). (C) 2014 U. S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.	[Hui, David; Xu, Angela; Frisbee-Hume, Susan; Morgado, Margarita; Reddy, Suresh; Bruera, Eduardo] Univ Texas MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Houston, TX 77030 USA; [Chisholm, Gary] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	Hui, D (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Unit 1414, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dhui@mdanderson.org			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1NR010162-01A1, RO1CA122292-01, RO1CA124481-01]; M. D. Anderson Cancer Center Support Grant [CA 016672];  [18075582]	Dr. E. B. is supported in part by National Institutes of Health grants RO1NR010162-01A1, RO1CA122292-01, and RO1CA124481-01. Dr. D. H. is supported in part by an Institutional Startup grant (#18075582). This study also was supported by the M. D. Anderson Cancer Center Support Grant (CA 016672). The funding sources were not involved in the conduct of the study or development of the submission. The authors declare no conflicts of interest.	Benitez-Rosario MA, 2005, J PAIN SYMPTOM MANAG, V30, P395, DOI 10.1016/j.jpainsymman.2005.10.002; BRUERA E, 1993, ANN INTERN MED, V119, P906, DOI 10.7326/0003-4819-119-9-199311010-00007; Bruera E, 2012, 48 AM SOC CLIN ONC A; Capper SJ, 2010, EUR J ANAESTH, V27, P241, DOI 10.1097/EJA.0b013e328331a361; Charles MA, 2008, J PAIN SYMPTOM MANAG, V36, P29, DOI 10.1016/j.jpainsymman.2007.08.016; Cook C, 2010, J MAN MANIP THER, V18, P61, DOI 10.1179/106698110X12640740712617; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; de la Cruz M, 2010, CANCER-AM CANCER SOC, V116, P766, DOI 10.1002/cncr.24751; Dorman S, 2007, PALLIATIVE MED, V21, P177, DOI 10.1177/0269216307076398; Gauna AA, 2008, J PALLIAT MED, V11, P643, DOI 10.1089/jpm.2007.0161; Gift A G, 1998, Am J Crit Care, V7, P200; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; Hui D, 2013, J PALLIAT MED, V16, P274, DOI 10.1089/jpm.2012.0364; Reddy SK, 2009, J PALLIAT MED, V12, P29, DOI 10.1089/jpm.2008.0158; Redelmeier DA, 1996, J CLIN EPIDEMIOL, V49, P1215, DOI 10.1016/S0895-4356(96)00206-5; Sitte Thomas, 2008, J Pain Symptom Manage, V36, pe3, DOI 10.1016/j.jpainsymman.2008.08.002; Tanaka K, 2000, BRIT J CANCER, V82, P800, DOI 10.1054/bjoc.1999.1002; Tishelman C, 2007, J CLIN ONCOL, V25, P5381, DOI 10.1200/JCO.2006.08.7874	18	31	31	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	FEB	2014	47	2					209	217		10.1016/j.jpainsymman.2013.03.017			9	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	AA5OS	WOS:000331150000006	23830530	Bronze, Green Accepted			2020-06-30	J	Henderson, F; May, WJ; Gruber, RB; Discala, JF; Puskovic, V; Young, AP; Baby, SM; Lewis, SJ				Henderson, Fraser; May, Walter J.; Gruber, Ryan B.; Discala, Joseph F.; Puskovic, Veljko; Young, Alex P.; Baby, Santhosh M.; Lewis, Stephen J.			Role of central and peripheral opiate receptors in the effects of fentanyl on analgesia, ventilation and arterial blood-gas chemistry in conscious rats	RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY			English	Article						Fentanyl; Naloxone methiodide; Ventilation; Arterial blood gases; Analgesia, Rats	INDUCED RESPIRATORY DEPRESSION; MU-OPIOID RECEPTOR; NALOXONE METHIODIDE; AUTORADIOGRAPHIC LOCALIZATION; MYOCARDIAL-METABOLISM; BODY-TEMPERATURE; AREA POSTREMA; BRAIN-STEM; MORPHINE; ANTINOCICEPTION	This study determined the effects of the peripherally restricted mu-opiate receptor (mu-OR) antagonist, naloxone methiodide (NLXmi) on fentanyl (25 mu g/kg, i.v.)-induced changes in (1) analgesia, (2) arterial blood gas chemistry (ABG) and alveolar-arterial gradient (A-a gradient), and (3) ventilatory parameters, in conscious rats. The fentanyl-induced increase in analgesia was minimally affected by a 1.5 mg/kg of NLXmi but was attenuated by a 5.0 mg/kg dose. Fentanyl decreased arterial blood pH, pO(2) and sO(2) and increased pCO(2) and A-a gradient. These responses were markedly diminished in NLXmi (1.5 mg/kg)-pretreated rats. Fentanyl caused ventilatory depression (e.g., decreases in tidal volume and peak inspiratory flow). Pretreatment with NLXmi (1.5 mg/kg, i.v.) antagonized the fentanyl decrease in tidal volume but minimally affected the other responses. These findings suggest that (1) the analgesia and ventilatory depression caused by fentanyl involve peripheral mu-ORs and (2) NLXmi prevents the fentanyl effects on ABG by blocking the negative actions of the opioid on tidal volume and A-a gradient. (C) 2013 Elsevier B.V. All rights reserved.	[Henderson, Fraser; May, Walter J.; Young, Alex P.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA; [Gruber, Ryan B.; Discala, Joseph F.; Puskovic, Veljko; Baby, Santhosh M.] Div Biol, Horsham, PA 19044 USA; [Lewis, Stephen J.] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA	Lewis, SJ (reprint author), Case Western Reserve Univ, Dept Pediat, 0900 Euclid Ave, Cleveland, OH 44106 USA.	sjl78@case.edu			Galleon Pharmaceuticals	This work was supported by grants from Galleon Pharmaceuticals.	ATWEH SF, 1977, BRAIN RES, V134, P393, DOI 10.1016/0006-8993(77)90817-4; Bennett JA, 1997, ANESTHESIOLOGY, V87, P1070, DOI 10.1097/00000542-199711000-00010; BHANDARI P, 1992, NEUROPHARMACOLOGY, V31, P735, DOI 10.1016/0028-3908(92)90034-M; BIANCHETTI A, 1983, LIFE SCI, V33, P415, DOI 10.1016/0024-3205(83)90530-1; BLAISE GA, 1990, ANESTHESIOLOGY, V72, P535, DOI 10.1097/00000542-199003000-00023; Bowdle T.A., 1998, DRUG SAFETY, V19, P189; Butelman ER, 2002, PSYCHOPHARMACOLOGY, V164, P115, DOI 10.1007/s00213-002-1195-y; Cabot PJ, 1996, EUR J PHARMACOL, V310, P47, DOI 10.1016/0014-2999(96)00363-9; Cao WH, 2005, AM J PHYSIOL-REG I, V288, pR723, DOI 10.1152/ajpregu.00669.2004; Chapman CD, 2012, NEUROREPORT, V23, P425, DOI 10.1097/WNR.0b013e32835271d1; COHENDY R, 1992, BRIT J ANAESTH, V69, P595, DOI 10.1093/bja/69.6.595; Colman AS, 2002, EXP BIOL MED, V227, P377; Dahan A, 1998, ANESTHESIOLOGY, V88, P903, DOI 10.1097/00000542-199804000-00009; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; DeHaven-Hudkins DL, 2004, CURR PHARM DESIGN, V10, P743, DOI 10.2174/1381612043453036; GELLER EB, 1983, J PHARMACOL EXP THER, V225, P391; GENTIL B, 1989, EUR J PHARMACOL, V159, P181, DOI 10.1016/0014-2999(89)90703-6; Gharagozlou Parham, 2006, BMC Pharmacol, V6, P3, DOI 10.1186/1471-2210-6-3; Groneberg DA, 2001, PULM PHARMACOL THER, V14, P383, DOI 10.1006/pupt.2001.0305; Guan JL, 1999, PEPTIDES, V20, P873, DOI 10.1016/S0196-9781(99)00075-3; Haji A, 2003, NEUROSCI LETT, V351, P37, DOI 10.1016/S0304-3940(03)00951-0; Haji A, 2000, PHARMACOL THERAPEUT, V86, P277, DOI 10.1016/S0163-7258(00)00059-0; Hajiha M, 2009, J PHYSIOL-LONDON, V587, P2677, DOI 10.1113/jphysiol.2009.171678; HAKIM TS, 1992, PULM PHARMACOL, V5, P159, DOI 10.1016/0952-0600(92)90036-G; HATTORI Y, 1991, BRAIN RES, V538, P283, DOI 10.1016/0006-8993(91)90441-W; He L, 2009, J PAIN, V10, P369, DOI 10.1016/j.jpain.2008.09.011; Huang P, 2001, J PHARMACOL EXP THER, V297, P688; Inglis JJ, 2008, ARTHRITIS RHEUM-US, V58, P3110, DOI 10.1002/art.23870; JOHNSON AK, 1993, FASEB J, V7, P678; Johnston KD, 2010, ACTA ANAESTH SCAND, V54, P132, DOI 10.1111/j.1399-6576.2009.02115.x; Kanbar R, 2010, AM J RESP CRIT CARE, V182, P1184, DOI 10.1164/rccm.201001-0047OC; KEYKHAH MM, 1988, ANESTHESIOLOGY, V69, P566, DOI 10.1097/00000542-198810000-00017; Kohno K, 1997, ANESTHESIOLOGY, V87, P658, DOI 10.1097/00000542-199709000-00028; Kregel KC, 1997, AM J PHYSIOL-HEART C, V273, pH1537; Laferriere A, 1999, DEV BRAIN RES, V112, P1, DOI 10.1016/S0165-3806(98)00149-7; Latasch L, 2002, ARZNEIMITTEL-FORSCH, V52, P870; Lewanowitsch T, 2006, LIFE SCI, V78, P682, DOI 10.1016/j.lfs.2005.05.062; Lewanowitsch T, 2003, BRAIN RES, V964, P302, DOI 10.1016/S0006-8993(02)04117-3; Lewanowitsch T, 2002, EUR J PHARMACOL, V445, P61, DOI 10.1016/S0014-2999(02)01715-6; LEWIS SJ, 1991, CLIN EXP HYPERTENS A, V13, P849, DOI 10.3109/10641969109042089; LING GSF, 1985, J PHARMACOL EXP THER, V232, P149; Lonergan T, 2003, RESP PHYSIOL NEUROBI, V138, P165, DOI 10.1016/S1569-9048(03)00173-3; Lonergan T, 2003, NEUROSCIENCE, V121, P959, DOI 10.1016/S0306-4522(03)00591-8; MAGNAN J, 1982, N-S ARCH PHARMACOL, V319, P197, DOI 10.1007/BF00495865; MAYER N, 1989, ANESTH ANALG, V69, P756; Mendoza J, 2013, RESP PHYSIOL NEUROBI, V189, P136, DOI 10.1016/j.resp.2013.07.007; MILDE LN, 1990, ANESTH ANALG, V70, P138; MILDE LN, 1989, BRIT J ANAESTH, V63, P710, DOI 10.1093/bja/63.6.710; MITAKA C, 1985, Bulletin of Tokyo Medical and Dental University, V32, P31; Mortola JP, 1998, CAN J PHYSIOL PHARM, V76, P937, DOI 10.1139/cjpp-76-10-11-937; MOSQUEDAGARCIA R, 1993, CIRC RES, V72, P20, DOI 10.1161/01.RES.72.1.20; Moss J, 2008, MAYO CLIN PROC, V83, P1116, DOI 10.4065/83.10.1116; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; NETO PPR, 1992, CAN J ANAESTH, V39, P458, DOI 10.1007/BF03008710; Niedhart P., 1989, ACTA ANAESTH SCAND, V33, P1; PERT CB, 1976, P NATL ACAD SCI USA, V73, P3729, DOI 10.1073/pnas.73.10.3729; POPIO KA, 1978, CLIN PHARMACOL THER, V23, P281; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; Reichert JA, 2001, PAIN, V89, P221, DOI 10.1016/S0304-3959(00)00365-1; RENEMAN RS, 1982, ANGIOLOGY, V33, P51, DOI 10.1177/000331978203300108; Sarton E, 1999, ANESTHESIOLOGY, V90, P1329, DOI 10.1097/00000542-199905000-00017; SCHURIG JE, 1978, ARCH INT PHARMACOD T, V233, P296; SHOOK JE, 1990, AM REV RESPIR DIS, V142, P895, DOI 10.1164/ajrccm/142.4.895; Stein C, 2009, BRAIN RES REV, V60, P90, DOI 10.1016/j.brainresrev.2008.12.017; Stein C, 2009, CURR OPIN PHARMACOL, V9, P3, DOI 10.1016/j.coph.2008.12.009; STEIN PD, 1995, CHEST, V107, P139, DOI 10.1378/chest.107.1.139; Stengel A, 2010, ENDOCRINOLOGY, V151, P4224, DOI 10.1210/en.2010-0195; Story DA, 1996, ANESTHESIOLOGY, V84, P1011, DOI 10.1097/00000542-199604000-00036; Su YF, 1998, J PHARMACOL EXP THER, V287, P815; Taguchi H, 1986, Masui, V35, P379; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; VALENTINO RJ, 1983, LIFE SCI, V32, P2887, DOI 10.1016/0024-3205(83)90325-9; van Klinken JB, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00094; Verborgh C, 1999, PAIN, V83, P17, DOI 10.1016/S0304-3959(99)00068-8; Verborgh C, 1999, PHARMACOL BIOCHEM BE, V63, P175, DOI 10.1016/S0091-3057(98)00238-X; Verborgh CML, 1997, ACTA ANAESTH SCAND, V41, P895, DOI 10.1111/j.1399-6576.1997.tb04806.x; Vujovic KRS, 2013, ARCH PHARM RES, V36, P501, DOI 10.1007/s12272-013-0072-z; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; Wang QP, 2003, NEUROSCI LETT, V341, P107, DOI 10.1016/S0304-3940(03)00182-4; WILLETTE RN, 1983, EUR J PHARMACOL, V91, P181, DOI 10.1016/0014-2999(83)90463-6; WILLETTE RN, 1982, EUR J PHARMACOL, V80, P57, DOI 10.1016/0014-2999(82)90177-7; WILLETTE RN, 1987, J PHARMACOL METHOD, V17, P15, DOI 10.1016/0160-5402(87)90033-7; YASUDA I, 1978, ANESTHESIOLOGY, V49, P117, DOI 10.1097/00000542-197808000-00012; YEADON M, 1990, GEN PHARMACOL, V21, P655, DOI 10.1016/0306-3623(90)91013-H; Young AP, 2013, RESP PHYSIOL NEUROBI, V186, P255, DOI 10.1016/j.resp.2013.02.028; Zebraski SE, 2000, LIFE SCI, V66, P2221, DOI 10.1016/S0024-3205(00)00434-3; Zhu JM, 1996, FEBS LETT, V384, P198, DOI 10.1016/0014-5793(96)00312-2	87	9	11	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1569-9048	1878-1519		RESP PHYSIOL NEUROBI	Respir. Physiol. Neuro.	JAN 15	2014	191						95	105		10.1016/j.resp.2013.11.005			11	Physiology; Respiratory System	Physiology; Respiratory System	AA3XP	WOS:000331028800012	24284037	Green Accepted			2020-06-30	J	Zhang, XL; Chen, ML; Zhou, SL				Zhang, Xiu-Lai; Chen, Min-Li; Zhou, Sheng-Li			Fentanyl Increases Colorectal Carcinoma Cell Apoptosis by Inhibition of NF-kappa B in a Sirt1-dependent Manner	ASIAN PACIFIC JOURNAL OF CANCER PREVENTION			English	Article						Colorectal carcinoma cells; fentanyl; NF-kappa B; Sirt 1	SIRT1 EXPRESSION; CANCER; PROGRESSION	Background: Fentanyl is used as an analgesic to treat pain in a variety of patients with cancer and recently it has become considered to also act as an antitumor agent. The study present was designed to investigate the effects of fentanyl on colorectal cancer cell growth and plausible mechanisms. Materials and Methods: The human colorectal carcinoma cell line HCT116 was subcutaneously injected into nude mice. The viability of HCT116 was tested by MTT assay, and apoptosis by flow cytometry and caspase-3 activity. The expression of Sirtl and NF-kappa B were evaluated by Western blotting and the levels of Sirtl and NF-kappa B by fluorescence method. SiRNA was used to silence and Ad-Sirtl to overexpress Sirtl. Results: Our data showed that fentanyl could inhibit tumor growth, with increased expression of Sirtl and down-regulation of Ac-p65 in tumors. Compared with control cells without treatment, HCT116 cells that were incubated with fentanyl had a higher apoptotic rate. Moreover, fentanyl could increase expression and activity of Sirtl and inhibitor expression and activity of NF-kappa B, which might be mechanisms of fentanyl action. Conclusions: Fentanyl increased colorectal carcinoma cell apoptosis by inhibition of NF-kappa B activation in a Sirtl-dependent manner.	[Zhang, Xiu-Lai; Chen, Min-Li; Zhou, Sheng-Li] Zhejiang Univ, Dept Anesthesiol & Surg, Int Healthcare Ctr, Affiliated Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China	Zhou, SL (reprint author), Zhejiang Univ, Dept Anesthesiol & Surg, Int Healthcare Ctr, Affiliated Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China.	sheli_zhou0811@163.com					Bovill JG, 2010, ANESTH ANALG, V110, P1524, DOI 10.1213/ANE.0b013e3181d8d183; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Ding G, 2013, MOL BIOL REP, V40, P2461, DOI 10.1007/s11033-012-2326-0; Domingo-Domenech J, 2006, CLIN CANCER RES, V12, P5578, DOI 10.1158/1078-0432.CCR-05-2767; Ford J, 2005, CANCER RES, V65, P10457, DOI 10.1158/0008-5472.CAN-05-1923; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Jung W, 2013, KOREAN J PATHOL, V47, P332, DOI 10.4132/KoreanJPathol.2013.47.4.332; Kabra N, 2009, J BIOL CHEM, V284, P18210, DOI 10.1074/jbc.M109.000034; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Lee JH, 2009, DIABETES, V58, P344, DOI 10.2337/db07-1795; Lennon FE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091577; Lennon FE, 2012, ANESTHESIOLOGY, V116, P940, DOI 10.1097/ALN.0b013e31824b9512; Lv L, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0965-9; Nuckols TK, 2014, ANN INTERN MED, V160, P38, DOI 10.7326/0003-4819-160-1-201401070-00732; Qin Y, 2012, ONCOL RES, V20, P61, DOI 10.3727/096504012X13473664562501; Xu TP, 2013, ASIAN PAC J CANCER P, V14, P2325, DOI 10.7314/APJCP.2013.14.4.2325; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Yi JJ, 2010, BBA-PROTEINS PROTEOM, V1804, P1684, DOI 10.1016/j.bbapap.2010.05.002	20	11	12	1	3	ASIAN PACIFIC ORGANIZATION CANCER PREVENTION	GYEONGGI-DO	APJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN -RO, ILSANDONG-GU, GOYANG-SI, GYEONGGI-DO, 410-769, SOUTH KOREA	1513-7368			ASIAN PAC J CANCER P	Asian Pac. J. Cancer Prev.		2014	15	22					10015	10020		10.7314/APJCP.2014.15.22.10015			6	Oncology	Oncology	CD4ML	WOS:000351056900078	25520062	DOAJ Gold			2020-06-30	J	Hwang, BY; Kwon, JY; Kim, E; Lee, DW; Kim, TK; Kim, HK				Hwang, Boo-Young; Kwon, Jae-Young; Kim, Eunsoo; Lee, Do-Won; Kim, Tae-Kyun; Kim, Hae-Kyu			Oxycodone vs. Fentanyl Patient-Controlled Analgesia after Laparoscopic Cholecystectomy	INTERNATIONAL JOURNAL OF MEDICAL SCIENCES			English	Article						Fentanyl; Laparoscopic cholecystectomy surgery; Oxycodone; Patient-controlled analgesia; Postoperative pain	INTRAVENOUS MORPHINE; POSTOPERATIVE PAIN; OPIOIDS; NAUSEA	Objectives Oxycodone is semi-synthetic opioid, oral and parenteral preparations have been widely used for acute and chronic pain. The aim of this study was to assess the efficacy and side effects of oxycodone and fentanyl in patient controlled analgesia (PCA) after laparoscopic cholecystectomy. Methods A prospective, randomized, double-blind study was conducted. 81 patients were randomly divided into two groups; fentanyl (10 mcg fentanyl and 1.5 mg ketorolac) and oxycodone group (1 mg oxycodone and 1.5 mg ketorolac). After the operation, a blinded observer assessed pain using a numerical rating scale (NRS), infused PCA dose, side effects, sedation levels, and satisfaction. Results Cumulative PCA dose of oxycodone group at 48 h (31.4 +/- 16.0 ml) was significantly less than that of fentanyl group (43.8 +/- 23.1 ml, P = 0.009). Oxycodone group showed more nausea at 6 - 24 h after the operation (P = 0.001), but there was no difference in satisfaction score (P = 0.073). There were no significant differences in other side effects, sedation and NRS scores between two groups. Conclusion Oxycodone showed comparable effects for pain relief compared to fentanyl in spite of less cumulative PCA dose. Based on these results, we could conclude that oxycodone may be useful as an alternative to fentanyl for PCA after laparoscopic cholecystectomy.	[Hwang, Boo-Young; Kwon, Jae-Young; Kim, Eunsoo; Lee, Do-Won; Kim, Tae-Kyun; Kim, Hae-Kyu] Pusan Natl Univ Hosp, Biomed Res Inst, Dept Anesthesia & Pain Med, Pusan 602793, South Korea	Kwon, JY (reprint author), Pusan Natl Univ Hosp, Biomed Res Inst, Dept Anesthesia & Pain Med, 179 Gudeok Ro, Pusan 602793, South Korea.	jykwon@pusan.ac.kr			Korean Heath Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [A070001]	This study was supported by a grant of the Korean Heath Technology R&D Project, Ministry of Health and Welfare, Republic of Korea. (A070001).	Blumenthal S, 2007, ANESTH ANALG, V105, P233, DOI 10.1213/01.ane.0000266451.77524.0d; Chan H. S., 1995, Singapore Medical Journal, V36, P406; Hudcova J, 2006, COCHRANE DB SYST REV, DOI 10.1002/146518583.CD003348.pub2; KALSO E, 1991, ACTA ANAESTH SCAND, V35, P642, DOI 10.1111/j.1399-6576.1991.tb03364.x; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Koch S, 2008, ACTA ANAESTH SCAND, V52, P845, DOI 10.1111/j.1399-6576.2008.01643.x; Kokki H, 2012, EXPERT OPIN PHARMACO, V13, P1045, DOI 10.1517/14656566.2012.677823; Kokki M, 2012, BASIC CLIN PHARMACOL, V110, P469, DOI 10.1111/j.1742-7843.2011.00839.x; Lenz H, 2009, ANESTH ANALG, V109, P1279, DOI 10.1213/ane.0b013e3181b0f0bb; Lorenzini KI, 2012, BASIC CLIN PHARMACOL, V110, P219, DOI 10.1111/j.1742-7843.2011.00814.x; Pedersen KV, 2013, UROLITHIASIS, V41, P423, DOI 10.1007/s00240-013-0587-2; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; Picard P, 1997, PAIN, V73, P401, DOI 10.1016/S0304-3959(97)00128-0; POYHIA R, 1994, EUR J ANAESTH, V11, P221; Silvasti M, 1998, ACTA ANAESTH SCAND, V42, P576, DOI 10.1111/j.1399-6576.1998.tb05169.x; Smith HS, 2014, EUR J PHARMACOL, V722, P67, DOI 10.1016/j.ejphar.2013.09.074; Staahl C, 2007, SCAND J GASTROENTERO, V42, P383, DOI 10.1080/00365520601014414; WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023; Yilmaz H, 2013, J KOREAN SURG SOC, V85, P149, DOI 10.4174/jkss.2013.85.4.149	20	32	37	1	14	IVYSPRING INT PUBL	LAKE HAVEN	PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA	1449-1907			INT J MED SCI	Int. J. Med. Sci.		2014	11	7					658	662		10.7150/ijms.8331			5	Medicine, General & Internal	General & Internal Medicine	AT0OX	WOS:000344636200001	24843313	DOAJ Gold, Green Published			2020-06-30	J	Melcer, T; Walker, J; Bhatnagar, V; Richard, E; Han, P; Sechriest, VF; Lebedda, M; Quinn, K; Galarneau, M				Melcer, Ted; Walker, Jay; Bhatnagar, Vibha; Richard, Erin; Han, Peggy; Sechriest, V. Franklin, II; Lebedda, Martin; Quinn, Kimberly; Galarneau, Michael			Glasgow Coma Scale scores, early opioids, and 4-year psychological outcomes among combat amputees	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						combat amputee; fentanyl; Glasgow Coma Scale; Iraq/Afghanistan conflicts; long-term psychological outcomes; loss of consciousness; military and VA health data; morphine; posttraumatic stress disorder; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; OPERATION IRAQI FREEDOM; VETERANS; HEALTH; AFGHANISTAN; CARE; SOLDIERS; DIAGNOSES; CONFLICTS	Morphine and fentanyl are frequently used for analgesia after trauma, but there is debate over the advantages and disadvantages of these opioids. Among combat amputees, intravenous (IV) morphine (vs IV fentanyl) after injury was associated with reduced likelihood of posttraumatic stress disorder (PTSD). The previous results were based on military health diagnoses over 2 yr postinjury. The present study followed psychological diagnoses of patients with amputation for 4 yr using military and Department of Veterans Affairs health data. In-theater combat casualty records (n = 145) documented Glasgow Coma Scale (GCS) scores and/or morphine, fentanyl, or no opioid treatment within hours of injury. We found that (1) GCS scores were not significantly associated with PTSD; (2) longitudinal modeling using four (yearly) time points showed significantly reduced odds of PTSD for patients treated with morphine (vs fentanyl) across years (adjusted odds ratio = 0.40; 95% confidence interval = 0.17-0.94); (3) reduced PTSD prevalence for morphine (vs IV fentanyl; morphine = 25%, fentanyl = 59%, p < 0.05) was significant, specifically among patients with traumatic brain injury during the first 2 yr postinjury; and (4) PTSD prevalence, but not other disorders (e. g., mood), increased between year 1 (PTSD = 18%) and years 2 through 4 postinjury (PTSD range = 30%-32%).	[Melcer, Ted; Walker, Jay; Han, Peggy; Lebedda, Martin; Quinn, Kimberly; Galarneau, Michael] Naval Hlth Res Ctr, Dept Med Modeling Simulat & Mission Support, San Diego, CA 92106 USA; [Bhatnagar, Vibha; Richard, Erin] Dept Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; [Bhatnagar, Vibha; Richard, Erin] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA; [Sechriest, V. Franklin, II] Naval Med Ctr San Diego, San Diego, CA USA	Melcer, T (reprint author), Naval Hlth Res Ctr, 140 Sylvester Rd, San Diego, CA 92106 USA.	ted.melcer@med.navy.mil			Navy Bureau of Medicine Wounded Ill and Injured Program [61108]; VAUS Department of Veterans Affairs	Funding/Support: This material was based on work supported by the Navy Bureau of Medicine Wounded Ill and Injured Program (work unit 61108). This work was also supported by the VA.	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Andrews B, 2007, AM J PSYCHIAT, V164, P1319, DOI 10.1176/appi.ajp.2007.06091491; Armed Forces Health Surveillance Center, 2011, MED SURVEILLANCE MON, V18, P17; Benedek DM, 2007, MIL MED, V172, P681; Black IH, 2009, PREHOSP EMERG CARE, V13, P223, DOI 10.1080/10903120802290778; Brown TA, 2001, J ABNORM PSYCHOL, V110, P585, DOI 10.1037//0021-843X.110.4.585; Bryant RA, 2009, BIOL PSYCHIAT, V65, P438, DOI 10.1016/j.biopsych.2008.10.032; Centers for Disease Control and Prevention, BLAST INJ TRAUM BRAI; Cesur R., 2011, PSYCHOL COSTS WAR MI; Chiu KB, 2011, ACAD EMERG MED, V18, P1156, DOI 10.1111/j.1553-2712.2011.01206.x; Claxton AR, 1997, ANESTH ANALG, V84, P509, DOI 10.1097/00000539-199703000-00008; Cohen BE, 2010, J GEN INTERN MED, V25, P18, DOI 10.1007/s11606-009-1117-3; Copeland LA, 2011, J AFFECT DISORDERS, V130, P226, DOI 10.1016/j.jad.2010.10.017; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Dohrenwend BP, 2006, SCIENCE, V313, P979, DOI 10.1126/science.1128944; Fletcher S, 2010, AUST NZ J PSYCHIAT, V44, P1064, DOI 10.3109/00048674.2010.509858; Forbes D, 2012, J ANXIETY DISORD, V26, P95, DOI 10.1016/j.janxdis.2011.09.004; Fox DJ, 1995, ANESTHESIA PERIOPERA, P211; Galarneau MR, 2006, MIL MED, V171, P691, DOI 10.7205/MILMED.171.8.691; Gravely AA, 2011, J REHABIL RES DEV, V48, P21, DOI 10.1682/JRRD.2009.08.0116; Gunderson EKE, 2005, MIL MED, V170, P172; Health Services Research & Development, 2012, COP DAT WAR; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holbrook TL, 2010, NEW ENGL J MED, V362, P110, DOI 10.1056/NEJMoa0903326; Horesh D, 2011, SOC PSYCH PSYCH EPID, V46, P863, DOI 10.1007/s00127-010-0255-6; Kacprowicz R. F., 2008, J SPEC OPER MED, V8, P48, DOI [10.1097/TA. 0b013e3182754674, DOI 10.1097/TA.0B013E3182754674]; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; MacGregor AJ, 2009, MIL MED, V174, P224, DOI 10.7205/MILMED-D-03-9107; MacGregor AJ, 2009, INJURY, V40, P1004, DOI 10.1016/j.injury.2009.04.006; Malchow R. J., 2009, CARE COMBAT AMPUTEE, P229; Matis G, 2008, ACTA NEUROL BELG, V108, P75; Melcer T, 2014, J TRAUMA STRESS, V27, P152, DOI 10.1002/jts.21909; Melcer T, 2013, J TRAUMA ACUTE CARE, V75, pS247, DOI 10.1097/TA.0b013e318299d95e; Melcer T, 2010, MIL MED, V175, P147, DOI 10.7205/MILMED-D-09-00120; Pasternak GW, 2012, PAIN MED, V13, pS4, DOI 10.1111/j.1526-4637.2012.01335.x; Pittman JOE, 2012, QUAL LIFE RES, V21, P99, DOI 10.1007/s11136-011-9918-3; Potter Benjamin K, 2006, J Am Acad Orthop Surg, V14, pS188; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Stinner DJ, 2010, J TRAUMA, V68, P1476, DOI 10.1097/TA.0b013e3181bb9a6c; TEASDALE G, 1974, LANCET, V2, P81; The Congress of the United States Congressional Budget Office, 2012, CBO STUD VET ADM TRE; U.S. Department of Veterans Affairs, HLTH BEN RET SERV OI; Wain HJ, 2009, CARE COMBAT AMPUTEE, P265; Wedmore IS, 2012, J TRAUMA ACUTE CARE, V73, pS490, DOI 10.1097/TA.0b013e3182754674	48	4	5	0	4	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2014	51	5					697	709		10.1682/JRRD.2013.06.0143			13	Rehabilitation	Rehabilitation	AP9FJ	WOS:000342383900005	25509056	Bronze			2020-06-30	J	Jeyabalan, A; Medford, ARL				Jeyabalan, Abiramy; Medford, Andrew R. L.			Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: Patient Satisfaction under Light Conscious Sedation	RESPIRATION			English	Article						Patient satisfaction; Endobronchial ultrasound; Transbronchial needle aspiration; Conscious sedation	LUNG-CANCER; PERFORMANCE	Background: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is an increasingly used mediastinal sampling technique. Many centres use conscious sedation in an ambulatory setting to optimise the flow of patients, save costs and shorten recovery time. The only EBUS-TBNA patient satisfaction study published so far used deep conscious sedation with propofol. To our knowledge, ours is the largest prospective study evaluating the experience of patients undergoing EBUS-TBNA using light conscious sedation without propofol. Objectives: To evaluate the patient tolerability of EBUS-TBNA under mild conscious sedation. Methods: Eighty-two consecutive patients between January 2011 and November 2011 requiring EBUS-TBNA under light conscious sedation for either mediastinal staging of lung cancer or the diagnosis of suspected mediastinal disease due to malignancy or granulomatous disease were invited to complete a questionnaire after the intervention. The collection of data included the diagnostic yield, the number and size of nodes sampled and the dose of sedative medication administered. Results: The average dose of sedative agents administered was 59.4 mu g fentanyl and 3.2 mg midazolam. The sensitivity of EBUS-TBNA for the cancer staging, cancer diagnosis and granulomatous disease cohorts was 90.0, 94.1 and 87.5%, respectively. The most commonly reported symptom was a cough in 65 (93%) patients. Of these patients, 46 (71%) described the severity as being mild. All but 9 patients (61/70 or 87%) stated that they would definitely or probably undergo a repeat EBUS-TBNA. Conclusions: This single-centre UK study confirms that EBUS-TBNA under light conscious sedation is a well-tolerated procedure maintaining the expected diagnostic performance, with patients reporting a high degree of satisfaction with both the test and the information received beforehand. (C) 2014 S. Karger AG, Basel	[Jeyabalan, Abiramy; Medford, Andrew R. L.] North Bristol NHS Trust, Southmead Hosp, North Bristol Lung Ctr, Bristol, Avon, England	Medford, ARL (reprint author), North Bristol Lung Ctr, Bristol BS10 5NB, Avon, England.	andrewmedford@hotmail.com		Medford, Andrew/0000-0001-5445-5949			Carrasquillo O, 1999, J GEN INTERN MED, V14, P82, DOI 10.1046/j.1525-1497.1999.00293.x; Gompelmann D, 2014, RESPIRATION, V87, P3, DOI 10.1159/000356921; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Konge L, 2013, RESPIRATION, V86, P59, DOI 10.1159/000350428; Lechtzin N, 2002, AM J RESP CRIT CARE, V166, P1326, DOI 10.1164/rccm.200203-231OC; Lilenbaum RC, 2004, CLIN LUNG CANCER, pS71; Low A, 2013, REV RECENT CLIN TRIA, V8, P61, DOI 10.2174/1574887111308010009; Maguire G P, 1998, Respirology, V3, P81, DOI 10.1111/j.1440-1843.1998.tb00101.x; Medford ARL, 2010, RESPIRATION, V79, P482, DOI 10.1159/000277931; Medford ARL, 2009, QJM-INT J MED, V102, P859, DOI 10.1093/qjmed/hcp136; Medford ARL, 2012, CHEST, V141, P1643, DOI 10.1378/chest.12-0317; Medford ARL, 2011, BRIT J HOSP MED, V72, P312, DOI 10.12968/hmed.2011.72.6.312; Medford ARL, 2009, CURR OPIN PULM MED, V15, P334, DOI 10.1097/MCP.0b013e32832b8a45; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Oki M, 2013, RESPIRATION, V85, P486, DOI 10.1159/000346987; Pillai A, 2013, RESPIRATION, V85, P417, DOI 10.1159/000346574; Stather DR, 2011, RESPIRATION, V81, P325, DOI 10.1159/000323520; Steinfort DP, 2010, RESP CARE, V55, P702; Sun BC, 2000, ANN EMERG MED, V35, P426, DOI 10.1067/mem.2000.104195	19	19	19	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0025-7931	1423-0356		RESPIRATION	Respiration		2014	88	3					244	250		10.1159/000363063			7	Respiratory System	Respiratory System	AP8WT	WOS:000342360800009	25170748	Bronze			2020-06-30	J	Baumunk, D; Strang, CM; Kropf, S; Schafer, M; Schrader, M; Weikert, S; Cash, H; Breckwoldt, J; Miller, K; Hachenberg, T; Schostak, M				Baumunk, Daniel; Strang, Christof Maria; Kropf, Siegfried; Schaefer, Michael; Schrader, Mark; Weikert, Steffen; Cash, Hannes; Breckwoldt, Jan; Miller, Kurt; Hachenberg, Thomas; Schostak, Martin			Impact of Thoracic Epidural Analgesia on Blood Loss in Radical Retropubic Prostatectomy	UROLOGIA INTERNATIONALIS			English	Article						Thoracic epidural analgesia; Radical retropubic prostatectomy; Blood loss; Prospective randomised clinical trial	GENERAL-ANESTHESIA; RETROSPECTIVE ANALYSIS; INDUCED HYPOTENSION; SURGERY; CANCER; METAANALYSIS; TRANSFUSION; COMPLICATIONS; REQUIREMENTS; RECURRENCE	Introduction: Radical retropubic prostatectomy (RRP) is associated with an increased risk of intraoperative blood loss and the necessity of transfusions. This prospective randomised clinical study evaluates the influence of thoracic epidural analgesia (TEA) on blood loss in RRP. Materials and Methods: 235 patients were randomised: TEA in group 1 (n = 116; general anaesthesia + TEA) comprised continuous administration of 0.25% bupivacaine, while group 2 (n = 119; general anaesthesia alone) received intravenous analgesia with fentanyl (intubation: 2 mu g/kg; maintenance: 0.1-0.3 mg). A restrictive infusion regimen (<1,000 ml until specimen removal) was administered in both groups. Blood loss, infusion rates and anaesthesiological parameters were recorded and analysed using regression models and analyses of variance. Results: Haemoglobin difference between the pre- and the first postoperative day (group 1: 3.35 +/- 1.16 g/dl; group 2: 3.56 +/- 1.42 g/dl; p = 0.19), overall blood loss (group 1: 665 +/- 431.5 ml; group 2: 705 +/- 881 ml; p = 0.73) and transfusion rates (0.4% intraoperatively; 2.55% postoperatively; p = 1.0) did not show group differences. In regression analysis blood loss was influenced by preoperative haemoglobin levels (p < 0.0001), patients' weight (p = 0.018) and duration of the operation (p = 0.017). Conclusions: This study did not demonstrate a direct impact of TEA on intraoperative blood loss and transfusion rates in RRP. Further randomised clinical trials are needed to evaluate an impact of the different anaesthetic procedures presented alone or in combination on blood loss. (C) 2014 S. Karger AG, Basel	[Baumunk, Daniel; Schostak, Martin] Univ Magdeburg, Med Ctr, Dept Urol & Paediat Urol, DE-39120 Magdeburg, Germany; [Strang, Christof Maria; Hachenberg, Thomas] Univ Magdeburg, Med Ctr, Dept Anaesthesiol & Intens Care Med, DE-39120 Magdeburg, Germany; [Kropf, Siegfried] Univ Magdeburg, Med Ctr, Dept Biometry & Med Informat, DE-39120 Magdeburg, Germany; [Schaefer, Michael; Breckwoldt, Jan] Charite, Dept Anaesthesiol & Operat Intens Care Med, D-13353 Berlin, Germany; [Cash, Hannes; Miller, Kurt] Charite, Dept Urol, D-13353 Berlin, Germany; [Weikert, Steffen] Vivantes Humboldt Klinikum Berlin, Dept Urol, Berlin, Germany; [Schrader, Mark] Univ Ulm, Med Ctr, Dept Urol, D-89069 Ulm, Germany	Baumunk, D (reprint author), Univ Magdeburg, Med Ctr, Dept Urol & Paediat Urol, Leipziger Str 44, DE-39120 Magdeburg, Germany.	daniel.baumunk@med.ovgu.de	Schafer, Michael/AAB-1395-2020	Breckwoldt, Jan/0000-0003-1716-1970			Ahlers O, 2008, BRIT J ANAESTH, V101, P781, DOI 10.1093/bja/aen287; Augustin H, 2003, EUR UROL, V43, P113, DOI 10.1016/S0302-2838(02)00495-5; Barre C, 2002, WORLD J SURG, V26, P1094, DOI 10.1007/s00268-002-6226-7; Biki B, 2008, ANESTHESIOLOGY, V109, P180, DOI 10.1097/ALN.0b013e31817f5b73; Bonnet F, 2005, BRIT J ANAESTH, V95, P52, DOI 10.1093/bja/aei038; Budaus L, 2009, EUR UROL, V56, P317, DOI 10.1016/j.eururo.2009.05.044; Bundesarztekammer, 2003, GUID THER BLOOD COMP; Chang SS, 2004, J UROLOGY, V171, P1861, DOI 10.1097/01.ju.0000120441.96995.e3; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Davies BJ, 2004, UROLOGY, V64, P712, DOI 10.1016/j.urology.2004.05.006; Dunet F, 2004, Can J Urol, V11, P2200; Egevad L, 2002, BJU INT, V89, P538, DOI 10.1046/j.1464-410X.2002.02669.x; Eroglu A, 2005, J CLIN ANESTH, V17, P420, DOI 10.1016/j.jclinane.2004.09.006; Fant F, 2011, BRIT J ANAESTH, V107, P782, DOI 10.1093/bja/aer296; Frank E, 1998, J SURG ONCOL, V67, P117, DOI 10.1002/(SICI)1096-9098(199802)67:2<117::AID-JSO8>3.0.CO;2-D; Freise H, 2011, BRIT J ANAESTH, V107, P859, DOI 10.1093/bja/aer339; Friederich PW, 2003, LANCET, V361, P201, DOI 10.1016/S0140-6736(03)12268-4; Gattas DJ, 2012, ANESTH ANALG, V114, P159, DOI 10.1213/ANE.0b013e318236b4d6; Graefen M, 2004, UROLOGE A, V43, P156, DOI 10.1007/s00120-003-0525-y; Gupta A, 2006, ANESTHESIOLOGY, V105, P784, DOI 10.1097/00000542-200610000-00025; Heidenreich A, 2002, J UROLOGY, V167, P1681, DOI 10.1016/S0022-5347(05)65177-4; Heller AR, 2000, ANAESTHESIST, V49, P949, DOI 10.1007/s001010070030; Hong JY, 2009, J ENDOUROL, V23, P1843, DOI 10.1089/end.2009.0059; Kettner SC, 2011, BRIT J ANAESTH, V107, P90, DOI 10.1093/bja/aer340; Kirsh EJ, 2000, UROLOGY, V56, P101, DOI 10.1016/S0090-4295(00)00594-X; LARSEN R, 1995, ANAESTHESIST, V44, P291, DOI 10.1007/s001010050157; Lepor H, 2003, UROLOGY, V62, P702, DOI 10.1016/S0090-4295(03)00515-6; Lloyd JC, 2010, BJU INT, V105, P347, DOI 10.1111/j.1464-410X.2009.08792.x; McCullough TC, 2004, UROL INT, V72, P13, DOI 10.1159/000075266; McLeod GA, 2006, BRIT J ANAESTH, V96, P633, DOI 10.1093/bja/ael049; Novara G, 2012, EUR UROL, V62, P431, DOI 10.1016/j.eururo.2012.05.044; O'Connor PJ, 2006, CAN J ANAESTH, V53, P873, DOI 10.1007/BF03022829; OEFELEIN MG, 1995, J UROLOGY, V154, P442, DOI 10.1016/S0022-5347(01)67070-8; Sayah DM, 2012, CRIT CARE CLIN, V28, P363, DOI 10.1016/j.ccc.2012.04.001; Schostak M, 2005, BJU INT, V96, P316, DOI 10.1111/j.1464-410X.2005.05622.x; Schostak M, 2012, BJU INT, V109, P355, DOI 10.1111/j.1464-410X.2011.10356.x; SHIR Y, 1995, UROLOGY, V45, P993, DOI 10.1016/S0090-4295(99)80120-4; SHIR Y, 1994, ANESTHESIOLOGY, V80, P49, DOI 10.1097/00000542-199401000-00011; Tagawa ST, 2008, BJU INT, V102, P1086, DOI 10.1111/j.1464-410X.2008.07780.x; Tewari A, 2012, EUR UROL, V62, P1, DOI 10.1016/j.eururo.2012.02.029; Tikuisis R, 2009, MED LITH, V45, P772, DOI 10.3390/medicina45100100; Wolters U, 1996, BRIT J ANAESTH, V77, P217, DOI 10.1093/bja/77.2.217; Wuethrich PY, 2013, EUR UROL	43	3	3	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0042-1138	1423-0399		UROL INT	Urol.Int.		2014	93	2					193	201		10.1159/000360300			9	Urology & Nephrology	Urology & Nephrology	AP6TU	WOS:000342211500010	24851943				2020-06-30	J	Chen, SY; Liu, FL; Cherng, YG; Fan, SZ; Leighton, BL; Chang, HC; Chen, LK				Chen, Shin-Yan; Liu, Feng-Lin; Cherng, Yih-Giun; Fan, Shou-Zen; Leighton, Barbara L.; Chang, Hung-Chi; Chen, Li-Kuei			Patient-Controlled Epidural Levobupivacaine with or without Fentanyl for Post-Cesarean Section Pain Relief	BIOMED RESEARCH INTERNATIONAL			English	Article							CESAREAN-SECTION; INTRATHECAL MORPHINE; ANALGESIA; LABOR; BUPIVACAINE; ROPIVACAINE; ANESTHESIA; INFUSION; VOLUME; EFFICACY	Purpose. The purpose of this study was to compare the analgesic properties of levobupivacaine with or without fentanyl for patient-controlled epidural analgesia after Cesarean section in a randomized, double-blinded study. Methods. We enrolled American Society of Anesthesiologists class I/II, full-term pregnant women at National Taiwan University Hospital who received patient-controlled epidural analgesia after Cesarean section between 2009 and 2010. Eighty women were randomly assigned into two groups. In group A, the 40 subjects received drug solutions made of 0.6 mg/ml levobupivacaine plus 2 mcg/ml fentanyl, and in group B the 40 subjects received 1 mg/ml levobupivacaine. Maintenance was self-administered boluses and a continuous background infusion. Results. There were no significant differences in the resting and dynamic pain scales and total volume of drug used between the two groups. Patient satisfaction was good in both groups. Conclusion. Our study showed that pure epidural levobupivacaine can provide comparative analgesic properties to the levobupivacaine-fentanyl combination after Cesarean section. Pure levobupivacaine may serve as an alternative pain control regimen to avoid opioid-related adverse events in parturients.	[Chen, Shin-Yan; Liu, Feng-Lin; Cherng, Yih-Giun; Chang, Hung-Chi] Taipei Med Univ, Shuang Ho Hosp, Dept Anesthesiol, New Taipei City 10361, Taiwan; [Cherng, Yih-Giun] Taipei Med Univ, Coll Med, Sch Med, Dept Anesthesiol, Taipei 10031, Taiwan; [Fan, Shou-Zen; Chen, Li-Kuei] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Anesthesiol, Taipei 10002, Taiwan; [Leighton, Barbara L.; Chen, Li-Kuei] Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; [Chen, Li-Kuei] Natl Taiwan Univ Hosp, Dept Anesthesiol, Hsin Chu Branch, Hsinchu 30059, Taiwan	Chen, LK (reprint author), Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Anesthesiol, Taipei 10002, Taiwan.	clk0619@ntu.edu.tw		Fan, Shou-Zen/0000-0002-6849-8453; Cherng, Yih-Giun/0000-0002-0201-4380; CHEN, LI-KUEI/0000-0003-1946-4828			Bromage PR, 1978, EPIDURAL ANALGESIA, P144; Burlacu Crina L, 2008, Ther Clin Risk Manag, V4, P381; CHANEY MA, 1995, CAN J ANAESTH, V42, P891, DOI 10.1007/BF03011037; Chen LK, 2011, TAIWAN J OBSTET GYNE, V50, P441, DOI 10.1016/j.tjog.2011.10.008; Cooper DW, 1996, BRIT J ANAESTH, V76, P611; Dernedde M, 2006, ACTA ANAESTH SCAND, V50, P613, DOI 10.1111/j.1399-6576.2006.001004.x; Dernedde M, 2003, ANESTH ANALG, V96, P796, DOI 10.1213/01/ANE.0000048977.66133.D5; DUGGAN J, 1988, BRIT J ANAESTH, V61, P324, DOI 10.1093/bja/61.3.324; Halpern SH, 2009, ANESTH ANALG, V108, P921, DOI 10.1213/ane.0b013e3181951a7f; Hogan Q, 2002, REGION ANESTH PAIN M, V27, P150, DOI 10.1053/rapm.2002.29748; Kleinman W, 2006, CLIN ANAESTHESIOL, P289; Komatsu H, 1998, ANESTH ANALG, V87, P907; Lacassie HJ, 2007, REGION ANESTH PAIN M, V32, P323, DOI 10.1016/j.rapm.2007.05.003; Lim Y., 2005, SMJ Singapore Medical Journal, V46, P392; Lim Y, 2008, ANESTH ANALG, V107, P1968, DOI 10.1213/ane.0b013e3181887ffb; Liu SS, 1997, ANESTHESIOLOGY, V86, P1288, DOI 10.1097/00000542-199706000-00009; Liu SS, 1999, ANESTHESIOLOGY, V90, P727, DOI 10.1097/00000542-199903000-00014; Mikuni I, 2010, J CLIN ANESTH, V22, P268, DOI 10.1016/j.jclinane.2009.09.003; Okutomi T, 2009, INT J OBSTET ANESTH, V18, P28, DOI 10.1016/j.ijoa.2008.06.006; Palmer CM, 2000, ANESTH ANALG, V90, P887, DOI 10.1213/00000539-200004000-00021; RappZingraff N, 1997, INT J OBSTET ANESTH, V6, P87, DOI 10.1016/S0959-289X(97)80003-9; Robinson AP, 2001, ANESTH ANALG, V92, P410, DOI 10.1213/00000539-200102000-00025; Sanford M, 2010, DRUGS, V70, P761, DOI 10.2165/11203250-000000000-00000; Sarvela J, 2002, ANESTH ANALG, V95, P436, DOI 10.1097/00000539-200208000-00037; Vercauteren M, 2002, ACTA ANAESTH SCAND, V46, P85, DOI 10.1034/j.1399-6576.2002.460115.x; Visser WA, 2008, ANESTH ANALG, V107, P708, DOI 10.1213/ane.0b013e31817e7065; Wheatley RG, 2001, BRIT J ANAESTH, V87, P47, DOI 10.1093/bja/87.1.47	27	2	2	0	4	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2314-6133	2314-6141		BIOMED RES INT	Biomed Res. Int.		2014									965152	10.1155/2014/965152			5	Biotechnology & Applied Microbiology; Medicine, Research & Experimental	Biotechnology & Applied Microbiology; Research & Experimental Medicine	AI1EK	WOS:000336592900001	24982917	DOAJ Gold, Green Published			2020-06-30	J	Guo, SP; Wu, SG; Zhou, J; Feng, HX; Li, FY; Wu, YJ; Sun, JY; He, ZY				Guo, Su-Ping; Wu, San-Gang; Zhou, Juan; Feng, Hui-Xia; Li, Feng-Yan; Wu, Ying-Jia; Sun, Jia-Yuan; He, Zhen-Yu			Transdermal fentanyl for pain due to chemoradiotherapy-induced oral mucositis in nasopharyngeal cancer patients: evaluating efficacy, safety, and improvement in quality of life	DRUG DESIGN DEVELOPMENT AND THERAPY			English	Article						nasopharyngeal cancer; transdermal fentanyl; noncancerous pain; quality of life; mucositis	CONCURRENT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; RANDOMIZED-TRIAL; STAGE-III; MORPHINE; RADIOTHERAPY; MANAGEMENT; CARCINOMA; SYSTEM; INFUSION	This study evaluated the efficacy, safety, and quality of life (QoL) measure of transdermal fentanyl (TDF) for moderate- to- severe pain due to oral mucositis caused by chemoradiotherapy in patients with advanced nasopharyngeal carcinoma (NPC). Patients with NPC who experienced moderate- to- severe oral mucosal pain during chemoradiotherapy (n= 78) received TDF for pain relief. Pain relief and QoL were compared before and after treatment. The mean numeric rating scale score was reduced from 7.41 +/- 0.96 before treatment to 5.54 +/- 0.86, 3.27 +/- 0.73, 2.88 +/- 0.62, and 2.82 +/- 0.68 on days 1, 4, 7, and 10, respectively, after treatment (P, 0.001). Karnofsky performance status and SPAASMS (Score for pain, Physical activity levels, Additional pain medication, Additional physician/emergency room visits, Sleep, Mood, and Side effects) scores showed significant improvement after treatment, indicating an improved QoL of patients (both P, 0.001). The most common adverse reactions were nausea and vomiting (10.26%). No serious life- threatening adverse events and no symptoms of drug withdrawal were observed. TDF is effective, safe, and improves QoL in treating pain due to oral mucositis caused by chemoradiotherapy in NPC patients.	[Guo, Su-Ping; Feng, Hui-Xia; Li, Feng-Yan; Wu, Ying-Jia; Sun, Jia-Yuan; He, Zhen-Yu] Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, Collaborat Innovat Ctr Canc Med,State Key Lab Onc, Guangzhou 510060, Guangdong, Peoples R China; [Wu, San-Gang] Xiamen Univ, Affiliated Hosp 1, Xiamen Canc Ctr, Dept Radiat Oncol, Xiamen, Peoples R China; [Zhou, Juan] Xiamen Univ, Affiliated Hosp 1, Xiamen Canc Ctr, Dept Obstet & Gynecol, Xiamen, Peoples R China	He, ZY (reprint author), Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, Collaborat Innovat Ctr Canc Med,State Key Lab Onc, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China.	hezhy@sysucc.org.cn			Sci-Tech Office of Guangdong Province [2008B060600019]; Youth Foundation of the First Affiliated Hospital of Xiamen University [XYY2012005]	This study was supported by a grant from the Sci-Tech Office of Guangdong Province (2008B060600019) and the Youth Foundation of the First Affiliated Hospital of Xiamen University (XYY2012005).	Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310, DOI 10.1200/JCO.1998.16.4.1310; Cai QQ, 2008, EXPERT OPIN PHARMACO, V9, P3137, DOI [10.1517/14656560802504508, 10.1517/14656560802504508 ]; Chang JTC, 2010, JPN J CLIN ONCOL, V40, P307, DOI 10.1093/jjco/hyp166; Chen WH, 2011, J CLIN ANESTH, V23, P124, DOI 10.1016/j.jclinane.2010.08.008; Chen Y, 2013, CANCER-AM CANCER SOC, V119, P2230, DOI 10.1002/cncr.28049; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Demarosi F, 2004, BONE MARROW TRANSPL, V33, P1247, DOI 10.1038/sj.bmt.1704515; Farzana M, 2011, MEASURING CLIN OUTCO; Hong JP, 2009, EUR J CANCER CARE, V18, P636, DOI 10.1111/j.1365-2354.2008.00971.x; ICRU, 1993, 50 ICRU; *ICRU, 1999, 50 ICRU; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Kim JG, 2005, TRANSPL P, V37, P4488, DOI 10.1016/j.transproceed.2005.11.038; Lee AWM, 2011, EUR J CANCER, V47, P656, DOI 10.1016/j.ejca.2010.10.026; Liu Q, 2013, CHIN J CANCER, V32, P325, DOI 10.5732/cjc.012.10189; Mao YP, 2008, CLIN CANCER RES, V14, P7497, DOI 10.1158/1078-0432.CCR-08-0271; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Naidu MUR, 2004, NEOPLASIA, V6, P423, DOI 10.1593/neo.04169; National Cancer Institute National Institutes of Health US Department of Health and Human Services, 2006, COMM TERM CRIT ADV E; Peterson DE, 2008, ANN ONCOL, V19, P122, DOI 10.1093/annonc/mdn109; Peterson DE, 2011, ANN ONCOL, V22, pvi78, DOI 10.1093/annonc/mdr391; Pillitteri LC, 1998, BONE MARROW TRANSPL, V22, P495, DOI 10.1038/sj.bmt.1701370; Saroja G, 2010, INDIAN J PALLIAT CAR, V16, DOI 10.4103/0973-1075.63138; Saunders DP, 2013, SUPPORT CARE CANCER, V21, P3191, DOI 10.1007/s00520-013-1871-y; Stiff P, 2006, BONE MARROW TRANSPL, V38, P757, DOI 10.1038/sj.bmt.1705525; Strupp C, 2000, ONCOL REP, V7, P659; Tawfik MO, 2004, CURR MED RES OPIN, V20, P259, DOI 10.1185/030079903125003026; van Seventer R, 2003, CURR MED RES OPIN, V19, P457, DOI 10.1185/030079903125002045; Wee J, 2005, J CLIN ONCOL, V23, P6730, DOI 10.1200/JCO.2005.16.790; Worthington HV, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000978.pub5	32	11	13	0	5	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1177-8881			DRUG DES DEV THER	Drug Des. Dev. Ther.		2014	8						497	502		10.2147/DDDT.S60187			6	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	AG8CG	WOS:000335645700001	24872680	DOAJ Gold, Green Published			2020-06-30	J	Fernandez-Fernandez, C; Callado, LF; Giron, R; Sanchez, E; Erdozain, AM; Lopez-Moreno, JA; Morales, P; de Fonseca, FR; Fernandez-Ruiz, J; Goya, P; Meana, JJ; Martin, MI; Jagerovic, N				Fernandez-Fernandez, Cristina; Callado, Luis F.; Giron, Rocio; Sanchez, Eva; Erdozain, Amaia M.; Antonio Lopez-Moreno, Jose; Morales, Paula; Rodriguez de Fonseca, Fernando; Fernandez-Ruiz, Javier; Goya, Pilar; Javier Meana, J.; Isabel Martin, M.; Jagerovic, Nadine			Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results	DRUG DESIGN DEVELOPMENT AND THERAPY			English	Article						fentanyl; rimonabant; cannabinoid; opioid; behavioral assays	POSTMORTEM HUMAN BRAIN; RECEPTOR ANTAGONIST SR-141716; I-2-IMIDAZOLINE BINDING-SITES; ALCOHOL DEPRIVATION; OPIOID INTERACTIONS; FOOD-INTAKE; CB1; RATS; LIGANDS; DERIVATIVES	Based on numerous pharmacological studies that have revealed an interaction between cannabinoid and opioid systems at the molecular, neurochemical, and behavioral levels, a new series of hybrid molecules has been prepared by coupling the molecular features of two well-known drugs, ie, rimonabant and fentanyl. The new compounds have been tested for their affinity and functionality regarding CB1 and CB2 cannabinoid and mu opioid receptors. In [S-35]-GTP.S (guanosine 5'-O-[gamma-thio] triphosphate) binding assays from the post-mortem human frontal cortex, they proved to be CB1 cannabinoid antagonists and mu opioid antagonists. Interestingly, in vivo, the new compounds exhibited a significant dual antagonist action on the endocannabinoid and opioid systems.	[Fernandez-Fernandez, Cristina; Morales, Paula; Goya, Pilar; Jagerovic, Nadine] CSIC, Inst Quim Med, E-28006 Madrid, Spain; [Callado, Luis F.; Erdozain, Amaia M.; Javier Meana, J.] Univ Basque Country, Dept Farmacol, UPV EHU, CIBERSAM, Leioa, Spain; [Giron, Rocio; Sanchez, Eva; Isabel Martin, M.] Univ Rey Juan Carlos, Dept Farmacol & Nutr, Alcorcon, Spain; [Antonio Lopez-Moreno, Jose] Univ Complutense Madrid, Dept Psicobiol, Madrid, Spain; [Rodriguez de Fonseca, Fernando] Hosp Carlos Haya, Lab Med Regenerativa, Fdn IMABIS, Malaga, Spain; [Fernandez-Ruiz, Javier] Univ Complutense Madrid, Dept Bioquim & Biol Mol, Fac Med, CIBERNED,IRYCIS, Madrid, Spain	Jagerovic, N (reprint author), CSIC, Inst Quim Med, C Juan Cierva 3, E-28006 Madrid, Spain.	nadine@iqm.csic.es	GIRON, ROCIO/H-7074-2015; Morales, Paula/R-9647-2019; Callado, Luis F/A-7024-2008; Goya, Pilar/I-3243-2015; Lopez-Moreno, Jose Antonio/A-2827-2011; Morales, Paula/H-5887-2015; Morales, Paula/N-6391-2019; Erdozain, Amaia M/Q-9664-2018; Sanchez-Robles, Eva M/H-2600-2015	GIRON, ROCIO/0000-0001-8530-8378; Morales, Paula/0000-0002-6209-8600; Callado, Luis F/0000-0001-9941-012X; Morales, Paula/0000-0002-6209-8600; Sanchez-Robles, Eva M/0000-0002-2740-2750; CALLADO HERNANDO, LUIS FELIPE/0000-0002-5564-3447; Jagerovic, Nadine/0000-0003-2642-6969; LOPEZ MORENO, JOSE ANTONIO/0000-0003-3552-6101; MEANA, JOSE JAVIER/0000-0002-7913-6714; Erdozain, Amaia Maite/0000-0003-0207-9122	Spanish Ministry of Economy and Competitivity [SAF2012-40075, SAF2009-12422, SAF2010-20521, SAF2011-26818]; Red de Trastornos AdictivosInstituto de Salud Carlos III [RETICS RD06/001]; Madrid Government (CANNAB-CM) [S2010/BMD-2308]; University of the Basque CountryUniversity of Basque Country [UFI 11/35]; Basque GovernmentBasque Government [IT-199-07, SAIOTEK S-PE10UN14]; Instituto de Salud Carlos III, Centro de Investigacion Biomedica en Red de Salud Mental, CIBERSAMInstituto de Salud Carlos III; Junta para la Ampliacion de Estudios [JAE-Pre-2010-01119]; European Social FundEuropean Social Fund (ESF)	This work was supported by grants from the Spanish Ministry of Economy and Competitivity (SAF2012-40075, SAF2009-12422, SAF2010-20521, SAF2011-26818), Red de Trastornos Adictivos (RETICS RD06/001), the Madrid Government (CANNAB-CM, S2010/BMD-2308), the University of the Basque Country (UFI 11/35), the Basque Government (IT-199-07, SAIOTEK S-PE10UN14), and the Instituto de Salud Carlos III, Centro de Investigacion Biomedica en Red de Salud Mental, CIBERSAM. AME is the recipient of a pre-doctoral fellowship from the Basque Government. PM is the recipient of a fellowship (JAE-Pre-2010-01119) from Junta para la Ampliacion de Estudios, cofinanced by the European Social Fund. The authors thank Laura Hernandez-Folgado for her help in preparation of the manuscript.	Abrams DI, 2011, CLIN PHARMACOL THER, V90, P844, DOI 10.1038/clpt.2011.188; Bowen JP, 2013, CURR TOP MED CHEM, V13, P1257; Christie MJ, 2006, BRIT J PHARMACOL, V148, P385, DOI 10.1038/sj.bjp.0706756; Christopoulou FD, 2011, J CLIN PHARM THER, V36, P10, DOI 10.1111/j.1365-2710.2010.01164.x; Cumella J, 2012, CHEMMEDCHEM, V7, P452, DOI 10.1002/cmdc.201100568; Dardonville C, 2004, BIOORG MED CHEM LETT, V14, P491, DOI 10.1016/j.bmcl.2003.10.048; Dardonville C, 2006, BIOORGAN MED CHEM, V14, P6570, DOI 10.1016/j.bmc.2006.06.007; Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI [10.1586/ERN.11.63, 10.1586/ern.11.63]; Erdozain AM, 2012, BIOCHEM PHARMACOL, V83, P260, DOI 10.1016/j.bcp.2011.10.018; Fernandez-Fernandez C, 2013, ARCH PHARM, V346, P171, DOI 10.1002/ardp.201200392; Gonzalez-Maeso J, 2000, EUR J PHARMACOL, V390, P25, DOI 10.1016/S0014-2999(99)00827-4; Heyser CJ, 2003, NEUROPSYCHOPHARMACOL, V28, P1463, DOI 10.1038/sj.npp.1300175; Jagerovic N, 2008, CURR TOP MED CHEM, V8, P205, DOI 10.2174/156802608783498050; Jorgensen WL, 2002, ADV DRUG DELIVER REV, V54, P355, DOI 10.1016/S0169-409X(02)00008-X; Krishnamurthy M, 2004, BIOORGAN MED CHEM, V12, P393, DOI 10.1016/j.bmc.2003.10.045; Le Naour M, 2013, J MED CHEM, V56, P5505, DOI 10.1021/jm4005219; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; de Jesus ML, 2006, NEUROSCIENCE, V140, P635, DOI 10.1016/j.neuroscience.2006.02.024; Lopez-Moreno JA, 2004, J NEUROSCI, V24, P8245, DOI 10.1523/JNEUROSCI.2179-04.2004; Maldonado R, 2010, CURR DRUG TARGETS, V11, P440, DOI 10.2174/138945010790980358; Manzanares J, 1999, TRENDS PHARMACOL SCI, V20, P287, DOI 10.1016/S0165-6147(99)01339-5; Montero A, 2002, BIOORGAN MED CHEM, V10, P1009, DOI 10.1016/S0968-0896(01)00356-X; Morphy R, 2009, CURR PHARM DESIGN, V15, P587, DOI 10.2174/138161209787315594; PERTWEE RG, 1972, BRIT J PHARMACOL, V46, P753, DOI 10.1111/j.1476-5381.1972.tb06900.x; PERTWEE RG, 1992, BRIT J PHARMACOL, V105, P980, DOI 10.1111/j.1476-5381.1992.tb09088.x; Robledo P, 2008, ADDICT BIOL, V13, P213, DOI 10.1111/j.1369-1600.2008.00107.x; Rowland NE, 2001, PSYCHOPHARMACOLOGY, V159, P111, DOI 10.1007/s002130100910; Sasmal PK, 2011, BIOORG MED CHEM LETT, V21, P562, DOI 10.1016/j.bmcl.2010.10.055; Scavone JL, 2013, NEUROSCIENCE, V248, P637, DOI 10.1016/j.neuroscience.2013.04.034; Serra S, 2001, EUR J PHARMACOL, V430, P369, DOI 10.1016/S0014-2999(01)01379-6; Shonberg J, 2011, CHEMMEDCHEM, V6, P963, DOI 10.1002/cmdc.201100101; Tallett AJ, 2009, PHARMACOL BIOCHEM BE, V91, P358, DOI 10.1016/j.pbb.2008.08.007; Thomas BF, 2005, BIOORGAN MED CHEM, V13, P5463, DOI 10.1016/j.bmc.2005.06.005; Trang T, 2007, NEUROSCIENCE, V146, P1275, DOI 10.1016/j.neuroscience.2007.02.031; Vigano D, 2005, PHARMACOL BIOCHEM BE, V81, P360, DOI 10.1016/j.pbb.2005.01.021; Wright FL, 2013, PSYCHOPHARMACOLOGY, V226, P415, DOI 10.1007/s00213-012-2916-5	36	9	9	0	23	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1177-8881			DRUG DES DEV THER	Drug Des. Dev. Ther.		2014	8						263	277		10.2147/DDDT.S55045			15	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	AB6AG	WOS:000331869200001	24591816	DOAJ Gold, Green Published			2020-06-30	J	Gracia, MR; Hortelano, LC; Langa, MJS; Sanchez, DG; Morant, MAC				Ramos Gracia, M.; Catala Hortelano, L.; Sala Langa, M. J.; Gomez Sanchez, D.; Conejero Morant, M. A.			Accidental poisoning by intranasal fentanyl	ANALES DE PEDIATRIA			Spanish	Letter							ACUTE PAIN		[Ramos Gracia, M.; Catala Hortelano, L.; Sala Langa, M. J.; Gomez Sanchez, D.; Conejero Morant, M. A.] Ctr Salud Beniopa, Valencia, Spain	Hortelano, LC (reprint author), Ctr Salud Beniopa, Valencia, Spain.	mramosgracia@hotmail.com					Cole J, 2009, EMERG MED AUSTRALAS, V21, P395, DOI 10.1111/j.1742-6723.2009.01216.x; Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI [10.1586/ERN.11.63, 10.1586/ern.11.63]; Hansen MS, 2012, ACTA ANAESTH SCAND, V56, P407, DOI 10.1111/j.1399-6576.2011.02613.x; Lotsch J, 2012, CLIN PHARMACOKINET; Mudd S, 2011, J PEDIATR HEALTH CAR, V25, P316, DOI 10.1016/j.pedhc.2010.04.011; Paech MJ, 2012, DRUG TODAY, V48, P119, DOI 10.1358/dot.2012.48.2.1745275; Saunders M, 2010, ACAD EMERG MED, V17, P1155, DOI 10.1111/j.1553-2712.2010.00905.x; Striebel H W, 1993, Schmerz, V7, P131, DOI 10.1007/BF02530420; Teske J, 2007, INT J LEGAL MED, V121, P147, DOI 10.1007/s00414-006-0137-3	9	0	0	0	1	EDICIONES DOYMA S A	BARCELONA	TRAV DE GRACIA 17-21, 08021 BARCELONA, SPAIN	1695-4033	1696-4608		AN PEDIATR	An. Pediatr.	JAN	2014	80	1					62	64		10.1016/j.anpedi.2013.03.007			3	Pediatrics	Pediatrics	AA2MU	WOS:000330929500013	23684172				2020-06-30	J	Rivera, IV; Garrido, JCM; Velasco, PG; de Enciso, IEX; Clavarana, LV				Velazquez Rivera, Ignacio; Munoz Garrido, Jose Carlos; Garcia Velasco, Pilar; Espana Ximenez de Enciso, Inmaculada; Velazquez Clavarana, Lourdes			Efficacy of Sublingual Fentanyl vs. Oral Morphine for Cancer-Related Breakthrough Pain	ADVANCES IN THERAPY			English	Article						Breakthrough pain; Cancer; Oncology; Oral morphine; Sublingual fentanyl	RAPID-ONSET OPIOIDS; BUCCAL TABLET; OPEN-LABEL; CITRATE; ASSOCIATION; PREVALENCE; MANAGEMENT	Breakthrough cancer pain (BTcP) is recognized as a clinically significant complication of chronic cancer pain with most BTcP episodes peaking in intensity within a few minutes and lasting for approximately 30 min. Although a number of rapid-onset fentanyl preparations have been developed in the last decade, BTcP is still typically managed through the use of rescue doses of oral morphine but a comparative study of sublingual fentanyl and oral morphine is still lacking. The aim of this study was to determine the efficacy, tolerability, and patient satisfaction of sublingual fentanyl citrate (SLF) and oral morphine solution (OM) in the treatment of BTcP. In this prospective, longitudinal, controlled-study, 40 patients with BTcP were allocated to receive oral morphine (OM) or sublingual fentanyl (SLF). Pain intensity level on a 0-10 numerical rating visual analog scale (VAS), frequency of BTcP throughout the day, onset of relief (0-5, 6-10, 11-15, or over 16 min), time required for dose titration, patient satisfaction and adverse effects were assessed at 3, 7, 15, and 30 days after starting the treatment. Mean doses of opioids for BTcP were 235 +/- A 23.4 mu g (SLF) and 38 +/- A 5.2 mg (OM). The mean pain intensity levels were significantly lower with SLF than OM at 3 days (6.0 vs. 6.95; p = 0,001), 7 days (4.15 vs. 6.25, p < 0.001), 15 days (3.45 vs. 5.35, p < 0.001), and 30 days (3.05 vs. 4.45, p < 0.001). SLF provided significantly faster relief for BTcP than OM (p < 0.001) with a shorter dose titration period (mean 6.6 +/- A 3.3 vs. 13.3 +/- A 4.9 days; p < 0.001) and better satisfaction scores and with a very good safety profile. Administration of SLF might provide a more effective treatment option than oral morphine for BTcP.	[Velazquez Rivera, Ignacio; Garcia Velasco, Pilar] Hosp Alta Resoluc Guadix, Unidad Dolor, Granada, Spain; [Munoz Garrido, Jose Carlos; Espana Ximenez de Enciso, Inmaculada] Hosp Comarcal Melilla, Unidad Dolor, Melilla, Spain; [Velazquez Clavarana, Lourdes] Ctr Gamez Moron de Melilla, Melilla, Spain	Rivera, IV (reprint author), Hosp Alta Resoluc Guadix, Unidad Dolor, Granada, Spain.	ignavel50@hotmail.com			Prostrakan	Sponsorship and article processing charges for this study was funded by Prostrakan. We thank Ana Isabel Ortega for her editorial assistance and styling of the manuscript prior to submission, on behalf of inScience Communications, Springer Healthcare. This assistance was funded by Prostrakan.	American Pain Foundation, 2011, J Pain Palliat Care Pharmacother, V25, P252, DOI 10.3109/15360288.2011.599920; APS 2008 American Pain Society (APS), 2008, PRINC AN US TREATM A; BENNETT D, 2005, [No title captured], V30, P354; Bredenberg S, 2003, EUR J PHARM SCI, V20, P327, DOI 10.1016/j.ejps.2003.07.002; Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Chwieduk CM, 2010, DRUGS, V70, P2281, DOI 10.2165/11200910-000000000-00000; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; DICKMAN A, 2009, PHARM J, V283, P213; FINE PG, 1991, PAIN, V45, P149, DOI 10.1016/0304-3959(91)90181-V; Foley KM, 1998, OXFORD TXB PALLIATIV, P310; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; Fortner BV, 2003, J PAIN SYMPTOM MANAG, V25, P9, DOI 10.1016/S0885-3924(02)00597-3; Gomez-Batiste X, 2002, J PAIN SYMPTOM MANAG, V24, P45, DOI 10.1016/S0885-3924(02)00421-9; Greco MT, 2011, CLIN J PAIN, V27, P9, DOI 10.1097/AJP.0b013e3181edc250; Haugen DF, 2010, PAIN, V149, P476, DOI 10.1016/j.pain.2010.02.035; Jandhyala R, 2013, J PAIN SYMPTOM MANAG, V12, P1; Kuo Kuan-Ling, 2013, J Pain Palliat Care Pharmacother, V27, P167, DOI 10.3109/15360288.2013.787137; Lennernas B, 2010, PALLIATIVE MED, V24, P286, DOI 10.1177/0269216309356138; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Mercadante S, 1998, CANCER TREAT REV, V24, P425, DOI 10.1016/S0305-7372(98)90005-6; Mercadante S, 2012, CURR MED RES OPIN, V28, P963, DOI 10.1185/03007995.2012.683112; Mercadante S, 2012, EXPERT OPIN PHARMACO, V13, P873, DOI 10.1517/14656566.2012.663353; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; Mercadante S, 2011, CRIT REV ONCOL HEMAT, V80, P460, DOI 10.1016/j.critrevonc.2010.12.002; Mercadante S, 2009, J PAIN SYMPTOM MANAG, V38, P554, DOI [10.1016/j.jpainsymman.2009.04.016, 10.1016/j.jpainsymman.2008.12.008]; Nalamachu S, 2011, CURR MED RES OPIN, V27, P519, DOI 10.1185/03007995.2010.545380; National Comprehensive Cancer Network, 2010, CLIN PRACT GUID ONC; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2004, OXFORD TXB PALLIATIV, P438; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Rubio C, 2013, REP PRACT ONCOL RADI, V18, P362; Smith HS, 2013, J PAIN RES, V6, P189, DOI 10.2147/JPR.S40745; Uberall MA, 2011, CURR MED RES OPIN, V27, P1385, DOI 10.1185/03007995.2011.583231; Vissers DCJ, 2011, VALUE HEALTH, V14, P274, DOI 10.1016/j.jval.2010.09.007; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012	40	13	14	0	5	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0741-238X	1865-8652		ADV THER	Adv. Ther.	JAN	2014	31	1					107	117		10.1007/s12325-013-0086-4			11	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	AA0FN	WOS:000330771100006	24385406				2020-06-30	J	Mordarski, S				Mordarski, Sylwester			Pain Management in the Elderly: Transdermal Fentanyl for the Treatment of Pain Caused by Osteoarthritis of the Knee and Hip	BIOMED RESEARCH INTERNATIONAL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RANDOMIZED CONTROLLED-TRIAL; OUTCOMES; THERAPY; UPDATE; RISKS; WOMAC	This study was designed to evaluate the utility of transdermal fentanyl (transdermal fentanyl, TDF) for the treatment of pain due to osteoarthritis (osteoarthritis, OA) of the knee and hip, which was not adequately controlled by nonopioid analgesics or weak opioids. WOMAC is a reliable, valid, and responsive multidimensional, self-administrated outcome measure designed specifically to evaluate patients with OA of the knee or hip. TDF significantly increased pain control and improved functioning and quality of life. Metoclopramide appeared to be of limited value in preventing nausea and vomiting.	Univ Med, Pain Clin, Dept Anaesthesiol & Intens Care, PL-50368 Wroclaw, Poland	Mordarski, S (reprint author), Univ Med, Pain Clin, Dept Anaesthesiol & Intens Care, Chalubinskiego 1A, PL-50368 Wroclaw, Poland.	sylwester_mordarski@pro.onet.pl		Mordarski, Sylwester/0000-0002-1988-3726			ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Antman EM, 2007, CIRCULATION, V115, P1634, DOI 10.1161/CIRCULATIONAHA.106.181424; Bachmeier CJM, 2001, OSTEOARTHR CARTILAGE, V9, P137, DOI 10.1053/joca.2000.0369; BELLAMY N, 1992, J RHEUMATOL, V19, P153; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Bhatt DL, 2008, CIRCULATION, V118, P1894, DOI 10.1161/CIRCULATIONAHA.108.191087; Biswal S, 2006, J RHEUMATOL, V33, P1841; Bossen D, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2662; Ferrell B, 2009, J AM GERIATR SOC, V57, P1331, DOI 10.1111/j.1532-5415.2009.02376.x; Findlay DM, 2007, RHEUMATOLOGY, V46, P1763, DOI 10.1093/rheumatology/kem191; Fine PG, 2004, CLIN J PAIN, V20, P220, DOI 10.1097/00002508-200407000-00003; LAWRENCE JS, 1966, ANN RHEUM DIS, V25, P1; Likert R., 1932, ARCH PSYCHOL, V22140, P55; McKellar G, 2008, CURR OPIN RHEUMATOL, V20, P239, DOI 10.1097/BOR.0b013e3282fb03ec; Mordarski S., 2000, BOL, V3, P44; Mordarski S., 2002, NOWA MED, V9, P17; Mordarski S., 2009, LECZENIE BOLOW NOWOT; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; Shmerling RH, 1996, ARTHRITIS RHEUM, V39, P1; Underwood M, 2008, BMJ-BRIT MED J, V336, P138, DOI 10.1136/bmj.39399.656331.25	20	3	4	0	6	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2314-6133	2314-6141		BIOMED RES INT	Biomed Res. Int.		2014									262961	10.1155/2014/262961			6	Biotechnology & Applied Microbiology; Medicine, Research & Experimental	Biotechnology & Applied Microbiology; Research & Experimental Medicine	299OB	WOS:000330403900001	24527441	DOAJ Gold, Green Published			2020-06-30	J	Saito, T; Fujii, M; Saito, S; Shimada, K; Fujiwara, K; Kobayashi, K				Saito, Takefumi; Fujii, Masato; Saito, Shiro; Shimada, Ken; Fujiwara, Keiichi; Kobayashi, Kunihiko			Pharmacokinetics of a New Fentanyl Tape with a Novel Delivery System of Transdermal Matrix Patches in Patients with Cancer Pain	ONCOLOGY			English	Article						Cancer; Fentanyl; Pain; Patch; Pharmacokinetics		Objectives: A novel delivery system for transdermal matrix patches of fentanyl has been developed. The new fentanyl tape consists of a backing layer, a drug-containing layer and a release liner that is originally made of rubber adhesive. This open-label prospective study investigated the pharmacokinetics and safety of the fentanyl tape in patients with cancer pain. Methods: The tape was applied to the patient's chest for 72 h, and serum samples were collected from 0 to 72 h. Fentanyl concentrations were determined using liquid chromatography with mass spectrometry. Pharmacokinetic parameters were calculated, and adverse events were evaluated according to the Common Terminology Criteria for Adverse Events (version 3.0). Results: Since 1 patient treated with 2.1 mg fentanyl was found to represent unique pharmacokinetic parameters by Shapiro-Wilk test, only 15 of the 16 study patients were investigated. Maximum serum concentrations (C-max) and area under the curve (AUC) 0-72 at 2.1 and 4.2 mg were 0.26 and 0.35 ng/ml, and 11.58 and 15.95 ng.h/ml, respectively. The C-max and AUC 0-72 tended to increase with dosage from 2.1 to 4.2 mg. There were no grade 3 toxicities, and only grade 1 ALT and AST elevations were observed. Conclusion: The novel delivery system of fentanyl may be a very promising approach to manage cancer pain clinically. (C) 2013 S. Karger AG, Basel	[Saito, Takefumi] Natl Hosp Org, Ibaraki Higashi Natl Hosp, Dept Resp Med, Ibaraki, Japan; [Fujii, Masato] Natl Hosp Org, Tokyo Med Ctr, Dept Otolaryngol, Tokyo, Japan; [Saito, Shiro] Natl Hosp Org, Tokyo Med Ctr, Dept Urol, Tokyo, Japan; [Shimada, Ken] Showa Univ, Northern Yokohama Hosp, Dept Internal Med, Kawasaki, Kanagawa, Japan; [Fujiwara, Keiichi] Natl Hosp Org, Okayama Med Ctr, Dept Resp Med, Okayama, Japan; [Kobayashi, Kunihiko] Saitama Med Univ, Int Med Ctr, Dept Resp Med, Hidaka City 3501298, Japan	Kobayashi, K (reprint author), Saitama Med Univ, Int Med Ctr, Dept Resp Med, 1397-1 Yamane, Hidaka City 3501298, Japan.	kobakuni@saitama-med.ac.jp			Meiji Seika Pharma Co., Ltd.	This research was supported by Meiji Seika Pharma Co., Ltd., and fentanyl patches were provided by Yutoku Pharmaceutical Industry Co., Ltd.	Cashman JN, 2004, BRIT J ANAESTH, V93, P212, DOI 10.1093/bja/aeh180; Dong PP, 2011, ACTA PHARMACOL SIN, V32, P399, DOI 10.1038/aps.2010.218; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Gharagozlou Parham, 2003, BMC Pharmacol, V3, P1, DOI 10.1186/1471-2210-3-1; Newshan G, 1998, J PAIN SYMPTOM MANAG, V16, P277; ROSE PG, 1993, ANESTH ANALG, V77, P390, DOI 10.1213/00000539-199377020-00029; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004	8	0	0	0	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0030-2414	1423-0232		ONCOLOGY-BASEL	Oncology		2014	86	1					10	15		10.1159/000356625			6	Oncology	Oncology	292TA	WOS:000329924100002	24335580	Other Gold			2020-06-30	J	McIntyre, IM; Gary, RD; Estrada, J; Nelson, CL				McIntyre, Iain M.; Gary, Ray D.; Estrada, Julio; Nelson, Craig L.			Antemortem and postmortem fentanyl concentrations: a case report	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article							BLOOD; REDISTRIBUTION; DEATHS		[McIntyre, Iain M.; Gary, Ray D.; Estrada, Julio; Nelson, Craig L.] Cty San Diego Med Examiners Off, Dept Forens Toxicol, San Diego, CA 92123 USA	McIntyre, IM (reprint author), Cty San Diego Med Examiners Off, Dept Forens Toxicol, 5570 Overland Ave,Suite 101, San Diego, CA 92123 USA.	iain.mcintyre@sdcounty.ca.gov		McIntyre, Iain/0000-0002-0284-6152			Andresen H, 2012, J ANAL TOXICOL, V36, P182, DOI 10.1093/jat/bks005; [Anonymous], 2008, PHYS DESK REFERENCE; Ceelen L, 2012, AM J FOREN MED PATH, V33, P119, DOI 10.1097/PAF.0b013e3181fbbb49; Isenschmid DS, 2007, P ANN M AM AC FOR SC; Krinsky CS, 2011, AM J FOREN MED PATH, V32, P347, DOI 10.1097/PAF.0b013e31822ad269; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; McIntyre I.M., 2012, J FORENSIC RES, V3, P157, DOI [DOI 10.4172/2157-7145.1000157, 10.4172/2157-7145.1000157]; McIntyre IM, 2012, FORENSIC SCI INT, V223, P349, DOI 10.1016/j.forsciint.2012.10.020; McIntyre IM, 2012, J ANAL TOXICOL, V36, P177, DOI 10.1093/jat/bks011; MCINTYRE IM, 1993, J ANAL TOXICOL, V17, P202, DOI 10.1093/jat/17.4.202; Olson KN, 2010, AM J CLIN PATHOL, V133, P447, DOI 10.1309/AJCP4X5VHFSOERFT; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x	12	11	11	0	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0937-9827	1437-1596		INT J LEGAL MED	Int. J. Legal Med.	JAN	2014	128	1					65	67		10.1007/s00414-013-0897-5			3	Medicine, Legal	Legal Medicine	281JI	WOS:000329096700010	23881042				2020-06-30	J	Mitzelfelt, JD; Carter, CS; Morgan, D				Mitzelfelt, Jeremiah D.; Carter, Christy S.; Morgan, Drake			Thermal sensitivity across ages and during chronic fentanyl administration in rats	PSYCHOPHARMACOLOGY			English	Article						Aging; Antinociception; Chronic administration; Geriatric pharmacotherapy; Pain; Thermal sensitivity; Tolerance; Withdrawal	CHRONIC NONCANCER PAIN; NEUROPATHIC PAIN; PHYSICAL PERFORMANCE; OLDER-ADULTS; INDUCED ANTINOCICEPTION; TRANSDERMAL FENTANYL; LOCOMOTOR-ACTIVITY; MORPHINE; OPIOIDS; ANALGESIA	Chronic pain is becoming a more common medical diagnosis and is especially prevalent in older individuals. As such, prescribed use of opioids is on the rise, even though the efficacy for pain management in older individuals is unclear. Thus, the present preclinical study assessed the effectiveness of chronic fentanyl administration to produce antinociception in aging rats (16, 20, and 24 months). Animals were tested in a thermal sensitivity procedure known to involve neural circuits implicated in chronic pain in humans. Sensitivity to heat and cold thermal stimulation was assessed during 28 days of fentanyl administration (1.0 mg/kg/day), and 28 days of withdrawal. Fentanyl resulted in decreased thermal sensitivity to heat but not cold stimulation indicated by more time spent in the hot compartment relative to time spent in the cold or neutral compartments. Unlike previous findings using a hot-water tail withdrawal procedure, tolerance did not develop to the antinociceptive effects of fentanyl over a 28-day period of drug administration. The oldest animals were least sensitive, and the youngest animals most sensitive to the locomotor-stimulating effects of fentanyl. The effect on the antinociceptive response to fentanyl in the oldest group of rats was difficult to interpret due to profound changes in the behavior of saline-treated animals. Overall, aging modifies the behavioral effects of opioids, a finding that may inform future studies for devising appropriate treatment strategies.	[Mitzelfelt, Jeremiah D.; Morgan, Drake] Univ Florida, Coll Med, Dept Psychiat, Gainesville, FL 32610 USA; [Carter, Christy S.] Univ Florida, Coll Med, Dept Aging & Geriatr Res, Gainesville, FL 32610 USA; [Carter, Christy S.; Morgan, Drake] Univ Florida, Coll Med, Inst Aging, Gainesville, FL 32610 USA	Morgan, D (reprint author), Univ Florida, Coll Med, Inst Aging, Gainesville, FL 32610 USA.	drakem@ufl.edu	Morgan, Drake/F-6664-2012		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21DA023022]; T32 training grant [AG00196]; University of Florida Alumni FellowshipUniversity of Florida	This research was primarily supported by a grant from the NIH (R21DA023022 to DM). JDM was supported by a T32 training grant (AG00196) and the University of Florida Alumni Fellowship. This article was used in partial fulfillment for the requirements of the doctoral degree at the University of Florida for the first author.	Agarwal S, 2007, PAIN MED, V8, P554, DOI 10.1111/j.1526-4637.2006.00246.x; Akkaya T, 2009, AGRI, V21, P1; Apkarian AV, 2009, PROG NEUROBIOL, V87, P81, DOI 10.1016/j.pneurobio.2008.09.018; Atluri Sairam, 2003, Pain Physician, V6, P233; Bell JS, 2009, AM J GERIATR PHARMAC, V7, P355, DOI 10.1016/j.amjopharm.2009.11.006; Benyamin R, 2008, PAIN PHYSICIAN, V11, pS105; Bhambhani Y, 2010, EUR J APPL PHYSIOL, V109, P241, DOI 10.1007/s00421-009-1332-y; Binsack Ralf, 2006, J Zhejiang Univ Sci B, V7, P892, DOI 10.1631/jzus.2006.B0892; Brixner Diana I, 2006, J Pain Palliat Care Pharmacother, V20, P5; Bruckenthal P, 2009, PAIN MED, V10, pS67, DOI 10.1111/j.1526-4637.2009.00667.x; Carter CS, 2009, J GERONTOL A-BIOL, V64, P850, DOI 10.1093/gerona/glp060; Carter CS, 2004, J GERONTOL A-BIOL, V59, P416; Carter CS, 2002, J GERONTOL A-BIOL, V57, pB193, DOI 10.1093/gerona/57.5.B193; Caudill-Slosberg MA, 2004, PAIN, V109, P514, DOI 10.1016/j.pain.2004.03.006; Cavenagh J, 2006, INTERN MED J, V36, P251, DOI 10.1111/j.1445-5994.2006.01046.x; CHAN SHH, 1982, EXP NEUROL, V75, P112, DOI 10.1016/0014-4886(82)90011-5; Chenot Jean-Francois, 2007, BMC Complement Altern Med, V7, P42, DOI 10.1186/1472-6882-7-42; Colliver JD, 2006, ANN EPIDEMIOL, V16, P257, DOI 10.1016/j.annepidem.2005.08.003; Colombo B, 2006, NEUROL SCI, V27, pS183, DOI 10.1007/s10072-006-0598-7; CRISP T, 1994, NEUROBIOL AGING, V15, P169, DOI 10.1016/0197-4580(94)90108-2; Dalpiaz O, 2008, BJU INT, V102, P1061, DOI 10.1111/j.1464-410X.2008.07771.x; del Pozo JG, 2008, EUR J CLIN PHARMACOL, V64, P411, DOI 10.1007/s00228-007-0419-9; Gagliese L, 2000, NEUROSCI BIOBEHAV R, V24, P843, DOI 10.1016/S0149-7634(00)00041-5; Ghodse H, 2003, BRIT J PSYCHIAT, V183, P15, DOI 10.1192/bjp.183.1.15; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; HOSKINS B, 1986, PHARMACOL BIOCHEM BE, V25, P599, DOI 10.1016/0091-3057(86)90148-6; ILAR (Institute of Laboratory Animal Resources), 1996, GUIDE CARE USE LAB A, V85-23; ISLAM AK, 1993, PHYSIOL BEHAV, V54, P45, DOI 10.1016/0031-9384(93)90042-E; Jensen TS, 2009, CURR OPIN NEUROL, V22, P467, DOI 10.1097/WCO.0b013e3283311e13; Kalapatapu RK, 2010, AM J ADDICTION, V19, P515, DOI 10.1111/j.1521-0391.2010.00080.x; Kalso E, 2003, EUR J PAIN, V7, P381, DOI 10.1016/S1090-3801(02)00143-X; KAVALIERS M, 1983, LIFE SCI, V32, P2279, DOI 10.1016/0024-3205(83)90427-7; KAVALIERS M, 1983, BRAIN RES, V279, P387, DOI 10.1016/0006-8993(83)90216-0; KRAMER E, 1986, NEUROBIOL AGING, V7, P185, DOI 10.1016/0197-4580(86)90041-2; Kwilasz AJ, 2012, J PHARMACOL EXP THER, V343, P389, DOI 10.1124/jpet.112.197780; Levine AS, 1998, PHARM BIOCH BEHAV, V29, P495; Li P, 2010, BIOCHEM PHARMACOL, V79, P1015, DOI 10.1016/j.bcp.2009.11.003; Lugo Ralph A, 2002, J Pain Palliat Care Pharmacother, V16, P5; Manchikanti L, 2008, PAIN PHYSICIAN, V11, pS63; Marcinkiewcz CA, 2009, BRAIN RES, V1251, P112, DOI 10.1016/j.brainres.2008.11.042; McCarthy LH, 2009, J AM GERIATR SOC, V57, P115, DOI 10.1111/j.1532-5415.2008.02089.x; Millan MJ, 1999, PROG NEUROBIOL, V57, P1, DOI 10.1016/S0301-0082(98)00048-3; Mitzelfelt JD, 2011, EXP GERONTOL, V46, P65, DOI 10.1016/j.exger.2010.10.004; Morgan D, 2008, EXP CLIN PSYCHOPHARM, V16, P367, DOI 10.1037/a0013520; Morgan D, 2012, J GERONTOL A-BIOL, V67, P705, DOI 10.1093/gerona/glr210; Negus SS, 2006, J PHARMACOL EXP THER, V319, P507, DOI 10.1124/jpet.106.106377; Neubert JK, 2007, BEHAV BRAIN FUNCT, V3, DOI 10.1186/1744-9081-3-49; Neville A, 2008, ISR MED ASSOC J, V10, P676; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; RAJA SN, 1988, ANESTHESIOLOGY, V68, P571, DOI 10.1097/00000542-198804000-00016; Raut A, 2009, NEUROBIOL AGING, V30, P910, DOI 10.1016/j.neurobiolaging.2007.09.010; Rowbotham MC, 2003, NEW ENGL J MED, V348, P1223, DOI 10.1056/NEJMoa021420; Rustoen T, 2005, CLIN J PAIN, V21, P513, DOI 10.1097/01.ajp.0000146217.31780.ef; Scarpace PJ, 1997, ANN NY ACAD SCI, V813, P111, DOI 10.1111/j.1749-6632.1997.tb51680.x; Schmelz M, 2009, EXP BRAIN RES, V196, P173, DOI 10.1007/s00221-009-1809-2; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; Smith MA, 2001, PSYCHOPHARMACOLOGY, V156, P445, DOI 10.1007/s002130100750; Staud R, 2008, PAIN, V139, P315, DOI 10.1016/j.pain.2008.04.024; Stein C, 2013, EUR J PHARMACOL, V716, P179, DOI 10.1016/j.ejphar.2013.01.076; Stevenson GW, 2009, LIFE SCI, V85, P309, DOI 10.1016/j.lfs.2009.06.006; Trescot A, 2008, PAIN PHYSICIAN, V11, pS181; Turturro A, 1999, J GERONTOL A-BIOL, V54, pB492, DOI 10.1093/gerona/54.11.B492; VanCrugten JT, 1997, PAIN, V71, P199, DOI 10.1016/S0304-3959(97)03363-0; Vierck CJ, 2008, PAIN, V135, P7, DOI 10.1016/j.pain.2007.12.008; Vierck CJ, 2008, J PAIN, V9, P739, DOI 10.1016/j.jpain.2008.03.008; Walid MS, 2009, PAIN PHYSICIAN, V12, P877; WEBSTER G W, 1976, Experimental Aging Research, V2, P221, DOI 10.1080/03610737608257178; Wilder-Smith OHG, 2005, EUR J PAIN, V9, P137, DOI 10.1016/j.ejpain.2004.07.011; Yeomans DC, 1996, PAIN, V66, P253, DOI 10.1016/0304-3959(96)03082-5; Yezierski RP, 2010, J GERONTOL A-BIOL, V65, P353, DOI 10.1093/gerona/glq024	70	0	0	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0033-3158	1432-2072		PSYCHOPHARMACOLOGY	Psychopharmacology	JAN	2014	231	1					75	84		10.1007/s00213-013-3208-4			10	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	281NI	WOS:000329107900008	23900640	Green Accepted			2020-06-30	J	Shin, S; Lee, SK; Min, KT; Kim, HJ; Park, CH; Yoo, YC				Shin, Seokyung; Lee, Sang Kil; Min, Kyung Tae; Kim, Hyun Ju; Park, Chan Hyuk; Yoo, Young Chul			Sedation for interventional gastrointestinal endoscopic procedures: are we overlooking the "pain"?	SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES			English	Article						Endoscopy; Sedation; Analgesia	RETROGRADE CHOLANGIOPANCREATOGRAPHY; PROPOFOL USE; FENTANYL; COMPLICATIONS; ANESTHESIA	Although interventional gastrointestinal (GI) endoscopic procedures are known to cause greater pain and discomfort than diagnostic procedures, the efficacy of adequate pain control or the difference in pain and amount of analgesic required according to type of intervention is not well known. This study was done to investigate the safety and efficacy of combining fentanyl with propofol for interventional GI endoscopic procedures and determine whether this method is superior to propofol monosedation. The data of 810 patients that underwent interventional GI endoscopic procedures under sedation with either propofol alone (Group P, n = 499) or propofol/fentanyl (Group PF, n = 311) at a single tertiary-care hospital between May 2012 and December 2012 were retrospectively reviewed. Rates of respiratory and cardiovascular events, propofol and fentanyl requirements, and risk factors of respiratory events of the two groups were analyzed. The incidence of respiratory events (P = 0.001), number of cases in which the procedure had to be interrupted for assisted mask bagging (P = 0.044), and propofol infusion rates were significantly lower in Group PF compared to Group P (P < 0.0001). The amount of fentanyl required for diagnostic procedures was significantly lower than that for interventional procedures (P < 0.001). Patients of Group PF showed a lower risk of developing respiratory events compared to Group P (OR 0.224, 95 % CI 0.069-0.724). Combining fentanyl with propofol seems to reduce the risk of respiratory events compared with propofol monosedation during GI endoscopic procedures by providing effective analgesia.	[Shin, Seokyung; Min, Kyung Tae; Yoo, Young Chul] Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med, Seoul 120752, South Korea; [Lee, Sang Kil; Kim, Hyun Ju; Park, Chan Hyuk] Yonsei Univ, Coll Med, Inst Gastroenterol, Dept Internal Med, Seoul 120752, South Korea	Yoo, YC (reprint author), Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med, 50 Yonsei Ro, Seoul 120752, South Korea.	skshin@yuhs.ac; sklee@yuhs.ac; ktmin501@yuhs.ac; hj390041@yuhs.ac; chan100@yuhs.ac; seaoyster@yuhs.ac	Park, Chan Hyuk/I-1794-2016	Park, Chan Hyuk/0000-0003-3824-3481; Yoo, Young Chul/0000-0002-6334-7541; Lee, Sang Kil/0000-0002-0721-0364; Shin, Seokyung/0000-0002-2641-0070			Ankichetty Saravanan, 2011, J Anaesthesiol Clin Pharmacol, V27, P447, DOI 10.4103/0970-9185.86574; Bo LL, 2011, WORLD J GASTROENTERO, V17, P3538, DOI 10.3748/wjg.v17.i30.3538; Cohen LB, 2004, GASTROINTEST ENDOSC, V59, P795, DOI 10.1016/S0016-5107(04)00349-9; Cote GA, 2010, CLIN GASTROENTEROL H, V8, P137, DOI 10.1016/j.cgh.2009.07.008; Faulx AL, 2005, GASTROINTEST ENDOSC, V62, P9, DOI 10.1016/S0016-5107(05)00518-3; Garewal D, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007274.pub2; Garewal Davinder, 2012, Diagn Ther Endosc, V2012, P639190, DOI 10.1155/2012/639190; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Han T, 2000, ANESTH ANALG, V90, P1365, DOI 10.1097/00000539-200006000-00019; Jeurnink SM, 2012, SURG ENDOSC, V26, P2213, DOI 10.1007/s00464-012-2162-2; Kapoor H, 2011, ACTA ANAESTH SCAND, V55, P918, DOI 10.1111/j.1399-6576.2011.02462.x; Martindale SJ, 2006, ANAESTH INTENS CARE, V34, P475, DOI 10.1177/0310057X0603400401; Müller Suzana, 2004, Arq. Gastroenterol., V41, P162, DOI 10.1590/S0004-28032004000300005; Park CH, 2013, DIGEST DIS SCI, V58, P540, DOI 10.1007/s10620-012-2376-0; Seifert H, 2000, ALIMENT PHARM THERAP, V14, P1207; Sharara AI, 2010, GASTROINTEST ENDOSC, V71, P1224, DOI 10.1016/j.gie.2009.11.049; SMITH C, 1994, ANESTHESIOLOGY, V81, P820, DOI 10.1097/00000542-199410000-00008; Trummel J, 2007, CURR OPIN ANESTHESIO, V20, P359, DOI 10.1097/ACO.0b013e32827ab467; VANAKEN H, 1988, ANESTHESIOLOGY, V68, P157; VanNatta ME, 2006, AM J GASTROENTEROL, V101, P2209, DOI 10.1111/j.1572-0241.2006.00760.x; Wehrmann T, 2008, SCAND J GASTROENTERO, V43, P368, DOI 10.1080/00365520701679181	21	13	14	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0930-2794	1432-2218		SURG ENDOSC	Surg. Endosc.	JAN	2014	28	1					100	107		10.1007/s00464-013-3133-y			8	Surgery	Surgery	277TR	WOS:000328842700013	23959522				2020-06-30	J	Fleet, J; Jones, M; Belan, I				Fleet, Julie; Jones, Meril; Belan, Ingrid			Subcutaneous administration of fentanyl in childbirth: An observational study on the clinical effectiveness of fentanyl for mother and neonate	MIDWIFERY			English	Article						Fentanyl; Pain relief; Labour; Subcutaneous	PATIENT-CONTROLLED ANALGESIA; SIGNIFICANT DIFFERENCE; LABOR; PAIN; PHARMACOKINETICS; MEPERIDINE; ANESTHESIA; PCA	Objective: to explore the maternal and neonatal effects of fentanyl administered subcutaneously to women during labour. Design: two methods were used: (1) A retrospective audit of the birth register and maternal and neonatal records for the period from January 2000 to December 2007. (2) A pilot study was also conducted on a convenience sample of women between July 2008 and October 2008. Setting: this study was conducted within a maternity unit at a rural South Australian hospital where approximately 350 babies are birthed each year. Participants: audit participants included women who had uncomplicated pregnancies and birthed at term (37-42 weeks gestation). Women in the experimental group consisted of those who had utilised only subcutaneous fentanyl for pain relief (n=75), or nitrous oxide and oxygen prior to being administered subcutaneous fentanyl (n=196). Stratified random selection based on parity and age was used to determine the control group, which consisted of women who used no pharmacological pain relief (n=196). The pilot study involved a convenience sample of women (n=10) assessed to have an uncomplicated pregnancy and labour occurring at term (>= 37 weeks gestation). Measurements: audit variables examined included the women's age, parity, labour duration, mode of birth (spontaneous or assisted), analgesia used, total dosage, time administered prior to birth, time of birth, neonatal Apgar scores, time to establish breathing, naloxone use, days spent in hospital post birth and breast-feeding outcomes upon discharge. The pilot study explored maternal effects assessed pre- and 30 minutes post administration of subcutaneously administered fentanyl by observing pain scores, vital signs, sedation levels, nausea/vomiting scores and anti emetic use To assess possible adverse effects in the neonate Apgar scores, time to establish respiration, naloxone use, transfer to neonatal nursery and breast-feeding outcomes upon discharge were recorded. Findings: women in the experimental groups were more likely to be induced, experienced a longer duration of labour and had an increased likelihood of an assisted vaginal birth. The average total dose of fentanyl administered was 250 mu g. Neonatal outcomes were comparable between groups when examining Apgar scores < 7 at 1 and 5 minutes and time to establish breathing. There was, however, a significant difference with naloxone administration between the groups. There was no significant difference between groups in hospital stay or breast-feeding on discharge. The pilot study identified a clinically significant reduction in pain scores for 78% of women following the administration of subcutaneous tentanyl, with the average pain score decreasing born SA (+/- 1.4) to 7.2 (+/- 1.1) (paired t-test, p=0.017). Vital signs were not affected, no anti-emetics were required and all women remained alert with no sedation noted. Key conclusions: the audit identified fentanyl use was associated with a longer length of labour, but this may be explained by more women in the experimental groups requiring induction of labour than those in the control group. However, length or hospital stay, breast-feeding rates and neonatal outcomes were comparable amongst the three groups. Results of the pilot study are consistent with those of the audit in relation to the effects on mother and neonate. In addition, the pilot study begins to provide evidence that fentanyl is efficacious in providing pain relief. Implications for practice: results of this study are the first to explore the effects of fentanyl administered subcutaneously to women during labour. This method of analgesia offers women an additional choice of pain relief during childbirth and may be particularly beneficial in remote and rural settings where resources are often limited and access to specialist services difficult. Further research, however, is required to be able to generalise the outcomes and provide further data to support the clinical effectiveness of this route of administration of fentanyl. (C) 2013 Elsevier Ltd. All rights reserved.	[Fleet, Julie; Jones, Meril; Belan, Ingrid] Flinders Univ S Australia, Sch Nursing & Midwifery, Adelaide, SA 5001, Australia	Fleet, J (reprint author), Flinders Univ S Australia, Sch Nursing & Midwifery, GPO Box 2100, Adelaide, SA 5001, Australia.	julie-anne.fleet@flinders.edu.au	Fleet, Julie-Anne/I-3015-2015	Fleet, Julie-Anne/0000-0001-6228-5636; Belan, Ingrid/0000-0002-7007-2961			Agaram R, 2009, INT J OBSTET ANESTH, V18, P10, DOI 10.1016/j.ijoa.2007.10.008; Albers LL, 1996, OBSTET GYNECOL, V87, P355, DOI 10.1016/0029-7844(95)00423-8; Althaus J, 2005, OBSTET GYN CLIN N AM, V32, P231, DOI 10.1016/j.ogc.2005.01.002; ATKINSON BD, 1994, AM J OBSTET GYNECOL, V171, P993, DOI 10.1016/0002-9378(94)90021-3; Bricker L, 2002, AM J OBSTET GYNECOL, V186, pS94, DOI 10.1067/mob.2002.121549; Capper SJ, 2010, EUR J ANAESTH, V27, P241, DOI 10.1097/EJA.0b013e328331a361; Castro C, 2003, CAN J ANAESTH, V50, P1039, DOI 10.1007/BF03018370; Chan A, 2011, PREGNANCY OUTCOME S; Craft J. B., 1983, J ANESTHESIA ANALGES, V63, P894; Dietrich C. C., 2003, AM J PAIN MANAGEMENT, V13, P146; Douma MR, 2010, BRIT J ANAESTH, V104, P209, DOI 10.1093/bja/aep359; Fleet J, 2011, MIDWIFERY, V27, pE106, DOI 10.1016/j.midw.2009.11.002; Gallagher EJ, 2001, ANN EMERG MED, V38, P633, DOI 10.1067/mem.2001.118863; Hunt R, 1999, J PAIN SYMPTOM MANAG, V18, P111, DOI 10.1016/S0885-3924(99)00051-2; Jones L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009234.pub2; Kelly AM, 1998, ACAD EMERG MED, V5, P1086, DOI 10.1111/j.1553-2712.1998.tb02667.x; Kelly AJ, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003101.pub2; KLEIMAN SJ, 1991, CAN J ANAESTH, V38, P489, DOI 10.1007/BF03007585; KOEHNTOP DE, 1986, ANESTH ANALG, V65, P227; KUHNERT BR, 1985, AM J OBSTET GYNECOL, V151, P410, DOI 10.1016/0002-9378(85)90314-X; Lehne RA, 2010, PHARM NURSING CARE; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; McCool WF, 2004, J MIDWIFERY WOM HEAL, V49, P505, DOI 10.1016/j.jmwh.2004.08.028; Morley-Forster PK, 2000, CAN J ANAESTH, V47, P113, DOI 10.1007/BF03018845; Nikkola E M, 2000, J Clin Monit Comput, V16, P597, DOI 10.1023/A:1012268617009; Nikkola EM, 1997, CAN J ANAESTH, V44, P1248, DOI 10.1007/BF03012771; Powell CV, 2001, ANN EMERG MED, V37, P28; Ransjo-Arvidson AB, 2001, BIRTH-ISS PERINAT C, V28, P5, DOI 10.1046/j.1523-536x.2001.00005.x; RAYBURN W, 1989, AM J OBSTET GYNECOL, V161, P202, DOI 10.1016/0002-9378(89)90266-4; RAYBURN WF, 1989, OBSTET GYNECOL, V74, P604; ROSAEG OP, 1992, CAN J ANAESTH, V39, P277, DOI 10.1007/BF03008789; Ross A, 1998, BAILLIERE CLIN OB GY, V12, P499, DOI 10.1016/S0950-3552(98)80081-3; Rowlands S, 1998, BAILLIERE CLIN OB GY, V12, P347, DOI 10.1016/S0950-3552(98)80071-0; Sosa CG, 2006, EUR J OBSTET GYN R B, V129, P135, DOI 10.1016/j.ejogrb.2005.11.033; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X	35	8	8	0	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0266-6138	1532-3099		MIDWIFERY	Midwifery	JAN	2014	30	1					36	42		10.1016/j.midw.2013.01.014			7	Nursing	Nursing	272XK	WOS:000328496200012	23523191				2020-06-30	J	Saritas, ZK; Saritas, TB; Pamuk, K; Korkmaz, M; Demirkan, I; Yaprakci, MV; Sivaci, RG				Saritas, Z. K.; Saritas, T. B.; Pamuk, K.; Korkmaz, M.; Demirkan, I; Yaprakci, M., V; Sivaci, R. G.			Comparison of the effects of lidocaine and fentanyl in epidural anesthesia in dogs	BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY			English	Article						epidural; dogs; lidocaine; fentanyl	MORPHINE; ANALGESIA; BUPIVACAINE; SEVOFLURANE; ISOFLURANE; HALOTHANE	The study included 12 clinically healthy, adult male dogs of various breeds, admitted to our clinic for castration. After general anesthesia with sevoflurane, we administered epidural fentanyl (1 mcg/kg) to fentanyl group, while lidocaine group was given Lidocaine (3 mg/kg) through epidural administration. When hemodynamic parameters were stabilized, first measurements were recorded at minutes 0, 15, 30, 60 in both groups, which included Heart Rate (HR), body temperature, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), sodium (Na+), potassium (K+), glucose (GLC), and hemoglobin (HB) measurements. In addition, serum samples were obtained from arterial blood at the same measurement times, and pH, pO(2), pCO(2), HCO3, %O-2 Saturation, BE levels were measured. For hematological analysis, WBC, RBC, HCT, THR counts were performed. For serum biochemical analysis, venous blood samples were collected at minutes 0 and 60 and CK, TP, UREA, ALT, AST, ALB, GGT, CRE, CK-MB parameters were assessed using auto-analyzer. Moreover, cortisol levels were measured in the samples collected at minutes 0, 30, and 60. Mean arterial blood pressure values measured at minutes 15, 30 and 60 were found significantly lower in the fentanyl group (p<0.01). In conclusion, we suggest that epidural anesthesia with lidocaine and fentanyl can provide an effective and safe option in high-risk groups (Tab. 5, Fig. 1, Ref. 24). Text in PDF www.elis.sk.	[Saritas, Z. K.; Saritas, T. B.; Pamuk, K.; Korkmaz, M.; Demirkan, I; Yaprakci, M., V; Sivaci, R. G.] Afyon Kocatepe Univ, Fac Vet Med, Dept Surg, TR-03200 Afyon, Turkey	Saritas, ZK (reprint author), Afyon Kocatepe Univ, Fac Vet Med, Dept Surg, TR-03200 Afyon, Turkey.	zksaritas@hotmail.com	de Souza, Roberto L/G-1278-2014; /AAF-3377-2019	de Souza, Roberto L/0000-0002-8079-7181; KORKMAZ, MUSA/0000-0002-7646-0009			Aminkov B, 2001, REV MED VET-TOULOUSE, V152, P71; Aminkov B, 1996, REV MED VET, P147; Apaydin N., 2005, Veteriner Cerrahi Dergisi, V11, P31; Collins VJ, 1967, AM J MED SCI, V253, P380; Gunay C., 2004, Veteriner Cerrahi Dergisi, V10, P5; Herperger LJ, 1998, CAN VET J, V39, P650; Iff I, 2008, VET ANAESTH ANALG, V35, P265, DOI 10.1111/j.1467-2987.2007.00373.x; Jones RS, 2001, VET J, V161, P123, DOI 10.1053/tvjl.2000.0528; Korkmaz M, 2013, ACTA SCI VET, V41; Naganobu K, 2004, JAVMA-J AM VET MED A, V224, P67, DOI 10.2460/javma.2004.224.67; Otero P, 2006, EPIDURAL ANAESTHESIA, P199; Pekcan Z, 2010, VET ANAESTH ANALG, V37, P557, DOI 10.1111/j.1467-2995.2010.00571.x; Perez TE, 2013, JAVMA-J AM VET MED A, V242, P631, DOI 10.2460/javma.242.5.631; Rauser P, 2004, VET MED-CZECH, V49, P421, DOI 10.17221/5732-VETMED; Robertson SA, 2005, PERFORM EPIDURAL INJ, P72; Sakonju I, 2011, J VET MED SCI, V73, P393, DOI 10.1292/jvms.10-0212; Savvas I, 2006, VET ANAESTH ANALG, V33, P175, DOI 10.1111/j.1467-2995.2005.00255.x; Simeonova G, 2004, TURK J VET ANIM SCI, V28, P769; Skarda R, 1987, LOCAL REGIONAL ANALG, P91; Skarda RT, 1996, LUMB JONES VET ANEST, P426; Torske KE, 2000, VET CLIN N AM-SMALL, V30, P859, DOI 10.1016/S0195-5616(08)70011-1; Valverde A, 2008, VET CLIN N AM-SMALL, V38, P1205, DOI 10.1016/j.cvsm.2008.06.004; Vnuk D, 2006, VET MED-CZECH, V51, P432, DOI 10.17221/5569-VETMED; Yuan ZK, 2012, VET ANAESTH ANALG, V39, P296, DOI 10.1111/j.1467-2995.2011.00706.x	24	4	4	2	7	COMENIUS UNIV	BRATISLAVA I	SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA	0006-9248	1336-0345		BRATISL MED J	Bratisl. Med. J.		2014	115	8					508	513		10.4149/BLL_2014_099			6	Medicine, General & Internal	General & Internal Medicine	AP6JV	WOS:000342185000011	25246289	Bronze			2020-06-30	J	He, XY; Cao, JP; He, Q; Shi, XY				He, Xing-Ying; Cao, Jian-Ping; He, Qian; Shi, Xue-Yin			Dexmedetomidine for the management of awake fibreoptic intubation	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Review							TARGET-CONTROLLED INFUSION; CONSCIOUS SEDATION; PROPOFOL; MIDAZOLAM	Background Awake fibreoptic intubation (AFOI) frequently requires sedation, anxiolysis and relief of discomfort without impairing ventilation and depressing cardiovascular function. The goal is to allow the patient to be responsive and co-operative. Medications such as fentanyl, remifentanil, midazolam and propofol have been reported to assist AFOI; however, these agents are associated with cardiovascular or respiratory adverse effects. Dexmedetomidine has been proposed as an alternative to facilitate AFOI. Objectives The primary objective of this review is to evaluate and compare the efficacy and safety of dexmedetomidine in the management of patients with a difficult or unstable airway undergoing awake fibreoptic intubation (AFOI). Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2012, Issue 5), MEDLINE (1966 to May 2012) through Ovid, EMBASE (1980 to May 2012) and Web of Science (1945 to May 2012); we screened the reference lists of all eligible trials and reviews to look for further trials and contacted authors of trials to ask for additional information. We searched for ongoing trials at http://www.controlledtrials.com/ and http://clinicaltrials.gov/. We reran our search of all databases listed above on 21 November 2013. Selection criteria We included published and unpublished randomized controlled trials, regardless of blinding or language of publication, in participants 18 years of age or older who were scheduled for an elective AFOI because of an anticipated difficult airway. Participants received dexmedetomidine or control medications. Data collection and analysis Three review authors independently extracted data on study design, participants, interventions and outcomes. We assessed risk of bias using The Cochrane Collaboration's tool. We estimated risk ratios (RRs) or mean differences (MDs) with 95% confidence internals (CIs) for outcomes with sufficient data; for other outcomes, we performed a qualitative analysis. Main results We identified four randomized controlled trials (RCTs), which included 211 participants. The four trials compared dexmedetomidine with midazolam, fentanyl, propofol or a sodium chloride placebo, respectively. The trials showed low or unclear risk of bias primarily because information provided on allocation concealment and other potential sources of bias was inadequate. Owing to clinical heterogeneity and potential methodological heterogeneity, it was impossible to conduct a full meta-analysis. We described findings from individual studies or presented them in tabular form. Limited evidence was available for assessment of the outcomes of interest for this review. Results of the limited included trials showed that dexmedetomidine significantly reduced participants' discomfort with no significant differences in airway obstruction, low oxygen levels or treatment-emergent cardiovascular adverse events noted during AFOI compared with control groups. When the search was rerun (from May 2012 to November 2013), it was noted that four studies are awaiting assessment. We will deal with these studies when we update the review. Authors' conclusions Small, limited trials provide weak evidence to support dexmedetomidine as an option for patients with an anticipated difficult airway who undergo AFOI. The findings of this review should be further corroborated by additional controlled investigations.	[He, Xing-Ying; Shi, Xue-Yin] Second Mil Med Univ, Dept Anaesthesiol, Changzheng Hosp, Shanghai 200003, Peoples R China; [Cao, Jian-Ping] 455 Hosp PLA, Dept Anaesthesiol, Shanghai, Peoples R China; [He, Qian] Second Mil Med Univ, Dept Hlth Stat, Fac Hlth Serv, Shanghai, Peoples R China	Shi, XY (reprint author), Second Mil Med Univ, Dept Anaesthesiol, Changzheng Hosp, Fengyang Rd 415, Shanghai 200003, Peoples R China.	shixueyin1128@163.com			Natural Scientific Foundation of China, ChinaNational Natural Science Foundation of China [81100049]	External sources; Natural Scientific Foundation of China (81100049), China.	Abdelmalak B, 2007, J CLIN ANESTH, V19, P370, DOI 10.1016/j.jclinane.2006.09.006; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Bergese SD, 2007, J CLIN ANESTH, V19, P141, DOI 10.1016/j.jclinane.2006.07.005; Bergese SD, 2010, AM J THER, V17, P586, DOI 10.1097/MJT.0b013e3181d69072; Bergese SD, 2010, J CLIN ANESTH, V22, P35, DOI 10.1016/j.jclinane.2009.02.016; Boyd BC, 2011, J ORAL MAXIL SURG, V69, P1608, DOI 10.1016/j.joms.2010.11.004; Cattano D, 2012, ANESTHESIOL RES PRAC, V2012, DOI 10.1155/2012/753107; Chu KS, 2010, EUR J ANAESTH, V27, P36, DOI 10.1097/EJA.0b013e32832e0d2b; Coursin D B, 2001, Curr Opin Crit Care, V7, P221, DOI 10.1097/00075198-200108000-00002; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Gerlach AT, 2007, ANN PHARMACOTHER, V41, P245, DOI 10.1345/aph.1H314; Grant SA, 2004, J CLIN ANESTH, V16, P124, DOI 10.1016/j.jclinane.2003.05.010; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; He X, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009798, DOI 10.1002/14651858.CD009798]; Higgins JPT, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184; Hu R, 2013, J ANESTH, V27, P211, DOI 10.1007/s00540-012-1499-y; Jooste EH, 2005, ANESTH ANALG, V101, P1248, DOI 10.1213/01.ANE.0000173765.94392.80; Juni P, 2001, BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Kamibayashi T, 2000, ANESTHESIOLOGY, V93, P1345, DOI 10.1097/00000542-200011000-00030; Knolle E, 2003, EUR J ANAESTH, V20, P565, DOI 10.1097/00003643-200307000-00009; Lallo A, 2009, ANESTH ANALG, V108, P852, DOI 10.1213/ane.0b013e318184eb31; [李新白 Li Xinbai], 2012, [吉林大学学报. 医学版, Journal of Jilin Univeristy. Medicine edition], V38, P328; Machata AM, 2003, ANESTH ANALG, V97, P904, DOI 10.1213/01.ANE.0000074089.39416.F1; Maroof M, 2005, CAN J ANAESTH, V52, P776, DOI 10.1007/BF03016576; [仇琳 Qiu Lin], 2013, [药学服务与研究, Pharmaceutical Care and Research], V13, P208; Rai MR, 2008, BRIT J ANAESTH, V100, P125, DOI 10.1093/bja/aem279; Rucker G, 2008, STAT MED, V27, P746, DOI 10.1002/sim.2971; Swaniker J, 2011, 2011 ANN M INT AN RE; The Nordic Cochrane Centre The Cochrane Collaboration, 2011, REV MAN REVMAN 5 1; Tsai CJ, 2010, ANAESTHESIA, V65, P254, DOI 10.1111/j.1365-2044.2009.06226.x; Venn RM, 2000, CRIT CARE, V4, P302, DOI 10.1186/cc712; VIRTANEN R, 1988, EUR J PHARMACOL, V150, P9, DOI 10.1016/0014-2999(88)90744-3	32	3	3	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1469-493X	1361-6137		COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2014		1							CD009798	10.1002/14651858.CD009798.pub2			31	Medicine, General & Internal	General & Internal Medicine	301BT	WOS:000330508400022	24442817				2020-06-30	J	Lambert, P; Cyna, AM; Knight, N; Middleton, P				Lambert, Paul; Cyna, Allan M.; Knight, Nicholas; Middleton, Philippa			Clonidine premedication for postoperative analgesia in children	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Review							SEVOFLURANE-INDUCED AGITATION; ORAL CLONIDINE; INTRAVENOUS CLONIDINE; PREANESTHETIC MEDICATIONS; MIDAZOLAM PREMEDICATION; PEDIATRIC TONSILLECTOMY; ANESTHESIA; PAIN; PREVENTION; EFFICACY	Background Postoperative pain remains a significant problem following paediatric surgery. Premedication with a suitable agent may improve its management. Clonidine is an alpha-2 adrenergic agonist which has sedative, anxiolytic and analgesic properties. It may therefore be a useful premedication for reducing postoperative pain in children. Objectives To evaluate the evidence for the effectiveness of clonidine, when given as a premedication, in reducing postoperative pain in children less than 18 years of age. We also sought evidence of any clinically significant side effects. Search methods We searched theCochraneCentralRegister of Controlled Trials (CENTRAL) in The Cochrane Library (Issue 12, 2012), Ovid MEDLINE (1966 to 21 December 2012) and Ovid EMBASE (1982 to 21 December 2012), as well as reference lists of other relevant articles and online trial registers. Selection criteria We included all randomized (or quasi-randomized), controlled trials comparing clonidine premedication to placebo, a higher dose of clonidine, or another agent when used for surgical or other invasive procedures in children under the age of 18 years and where pain or a surrogate (principally the need for supplementary analgesia) was reported. Data collection and analysis Two authors independently performed the database search, decided on the inclusion eligibility of publications, ascertained study quality and extracted data. They then resolved any differences between their results by discussion. The data were entered into RevMan 5 for analyses and presentation. Sensitivity analyses were performed, as appropriate, to exclude studies with a high risk of bias. Main results We identified 11 trials investigating a total of 742 children in treatment arms relevant to our study question. Risks of bias in the studies were mainly low or unclear, but two studies had aspects of their methodology that had a high risk of bias. Overall, the quality of the evidence from pooled studies was low or had unclear risk of bias. Four trials compared clonidine with a placebo or no treatment, six trials compared clonidine with midazolam, and one trial compared clonidine with fentanyl. There was substantial methodological heterogeneity between trials; the dose and route of clonidine administration varied as did the patient populations, the types of surgery and the outcomes measured. It was therefore difficult to combine the outcomes of some trials for meta-analysis. When clonidine was compared to placebo, pooling studies of low or unclear risk of bias, the need for additional analgesia was reduced when clonidine premedication was given orally at 4 mu g/kg (risk ratio (RR) 0.24, 95% confidence interval (CI) 0.11 to 0.51). Only one small trial (15 patients per arm) compared clonidine to midazolam for the same outcome; this also found a reduction in the need for additional postoperative analgesia (RR 0.25, 95% CI 0.09 to 0.71) when clonidine premedication was given orally at 2 or 4 mu g/kg compared to oral midazolam at 0.5 mg/kg. A trial comparing oral clonidine at 4 mu g/kg with intravenous fentanyl at 3 mu g/kg found no statistically significant difference in the need for rescue analgesia (RR 0.89, 95% CI 0.56 to 1.42). When clonidine 4 mu g/kg was compared to clonidine 2 mu g/kg, there was a statistically significant difference in the number of patients requiring additional analgesia, in favour of the higher dose, as reported by a single, higher-quality trial (RR 0.38, 95% CI 0.23 to 0.65). The effect of clonidine on pain scores was hard to interpret due to differences in study methodology, the doses and route of drug administration, and the pain scale used. However, when given at a dose of 4 mu g/kg, clonidine may have reduced analgesia requirements after surgery. There were no significant side effects of clonidine that were reported such as severe hypotension, bradycardia, or excessive sedation requiring intervention. However, several studies used atropine prophylactically with the aim of preventing such adverse effects. Authors' conclusions There were only 11 relevant trials studying 742 children having surgery where premedication with clonidine was compared to placebo or other drug treatment. Despite heterogeneity between trials, clonidine premedication in an adequate dosage (4 mu g/kg) was likely to have a beneficial effect on postoperative pain in children. Side effects were minimal, but some of the studies used atropine prophylactically with the intention of preventing bradycardia and hypotension. Further research is required to determine under what conditions clonidine premedication is most effective in providing postoperative pain relief in children.	[Lambert, Paul; Cyna, Allan M.] Womens & Childrens Hosp, Dept Womens Anaesthesia, Adelaide, SA 5006, Australia; [Knight, Nicholas] Royal Adelaide Hosp, Dept Anaesthesia, Adelaide, SA 5000, Australia; [Middleton, Philippa] Univ Adelaide, ARCH Australian Res Ctr Hlth Women & Babies, Discipline Obstet & Gynaecol, Adelaide, SA, Australia	Cyna, AM (reprint author), Womens & Childrens Hosp, Dept Womens Anaesthesia, 72 King William Rd, Adelaide, SA 5006, Australia.	allan.cyna@health.sa.gov.au					Akin A, 2010, PEDIATR ANESTH, V20, P350, DOI 10.1111/j.1460-9592.2010.03259.x; Almenrader N, 2007, PEDIATR ANESTH, V17, P230, DOI 10.1111/j.1460-9592.2006.02080.x; Almerader N, 2007, PEDIATR ANESTH, V17, P1143, DOI 10.1111/j.1460-9592.2007.02332.x; Bergendahl H, 2006, ACTA ANAESTH SCAND, V50, P135, DOI 10.1111/j.1399-6576.2006.00940.x; Bergendahl HTG, 2004, ACTA ANAESTH SCAND, V48, P1292, DOI 10.1111/j.1399-6576.2004.00525.x; Beyer J E, 1990, J Pain Symptom Manage, V5, P350, DOI 10.1016/0885-3924(90)90029-J; Bock M, 2002, BRIT J ANAESTH, V88, P790, DOI 10.1093/bja/88.6.790; Cao JP, 2011, PEDIATR ANESTH, V21, P399, DOI 10.1111/j.1460-9592.2011.03543.x; Cao JP, 2009, BIOSCI TRENDS, V3, P115; Collins Corey E, 2010, Anesthesiol Clin, V28, P315, DOI 10.1016/j.anclin.2010.02.005; Constant I, 2004, BRIT J ANAESTH, V92, P504, DOI 10.1093/bja/aeh093; Cyna AM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002251.pub2; D'Mello R, 2008, BRIT J ANAESTH, V101, P8, DOI 10.1093/bja/aen088; Dahmani S, 2010, ACTA ANAESTH SCAND, V54, P397, DOI 10.1111/j.1399-6576.2009.02207.x; De Kort R, 2007, ACTA ANAESTHESIOLOGI, V58, P148; Fazi L, 2001, ANESTH ANALG, V92, P56; Frank T, 2000, ANASTH INTENSIV NOTF, V35, P428, DOI 10.1055/s-2000-5946; Freeman KO, 2002, PAEDIATR ANAESTH, V12, P617, DOI 10.1046/j.1460-9592.2002.00914.x; Fujii Y, 2000, PAEDIATR ANAESTH, V10, P65, DOI 10.1046/j.1460-9592.2000.00441.x; Gentili F, 2007, CURR TOP MED CHEM, V7, P163, DOI 10.2174/156802607779318235; Georgiou M, 1999, BRIT J ANAESTH, V82, P148; Ghai B, 2010, ANAESTH INTENS CARE, V38, P530, DOI 10.1177/0310057X1003800319; Golparvar M, 2004, PEDIATR ANESTH, V14, P924, DOI 10.1111/j.1460-9592.2004.01349.x; Gulhas N, 2003, ACTA ANAESTH SCAND, V47, P90, DOI 10.1034/j.1399-6576.2003.470116.x; GULHAS N, 2001, TURK ANESTEZIYOLOJI, V29, P202; Guyatt GH, BMJ, V336, P995; Hackmann T, 2003, ANESTH ANALG, V96, P976, DOI 10.1213/01.ANE.0000052713.72875.13; Handa F, 2001, PAEDIATR ANAESTH, V11, P71, DOI 10.1046/j.1460-9592.2001.00615.x; HANNALLAH RS, 1987, ANESTHESIOLOGY, V66, P832, DOI 10.1097/00000542-198706000-00023; HANNALLAH RS, 1992, CAN J ANAESTH, V39, P641, DOI 10.1007/BF03008222; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Duedahl TH, 2007, PEDIATR ANESTH, V17, P756, DOI 10.1111/j.1460-9592.2007.02213.x; Hozo S. P., 2005, BMC MED RES METHODOL, V5, DOI DOI 10.1186/1471-2288-5-13; Jatti K, 1998, INT J CLIN PHARM TH, V36, P336; Kihara S, 2000, ANESTH ANALG, V91, P305, DOI 10.1097/00000539-200008000-00012; Kulka PJ, 2001, ANESTH ANALG, V93, P335, DOI 10.1097/00000539-200108000-00019; Kuvaki B, 1998, TURK ANESTEZIYOLOJI, V26, P30; Lambert P, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009633, DOI 10.1002/14651858.CD009633]; Lankinen U, 2006, ANESTH ANALG, V102, P1383, DOI 10.1213/01.ane.0000205745.84044.31; Larsson P, 2011, PEDIATR ANESTH, V21, P335, DOI 10.1111/j.1460-9592.2010.03397.x; LONNQVIST PA, 1994, ANESTHESIOLOGY, V81, P1097; Macintyre PE, 2009, ACUTE PAIN MANAGEMENT, P204, DOI 10.1017/CBO9780511576706.016; Mattila K, 2005, ANESTH ANALG, V101, P1643, DOI 10.1213/01.ANE.0000184189.79572.28; McGraw T, 1998, PAEDIATR ANAESTH, V8, P117, DOI 10.1046/j.1460-9592.1998.00724.x; MIKAWA K, 1995, CAN J ANAESTH, V42, P977, DOI 10.1007/BF03011068; MIKAWA K, 1993, ANESTHESIOLOGY, V79, P926, DOI 10.1097/00000542-199311000-00009; Mikawa K, 1996, ANESTH ANALG, V82, P225, DOI 10.1097/00000539-199602000-00001; Motsch J, 1997, ACTA ANAESTH SCAND, V41, P877, DOI 10.1111/j.1399-6576.1997.tb04803.x; Nishina K, 2000, PAEDIATR ANAESTH, V10, P645, DOI 10.1046/j.1460-9592.2000.00589.x; NISHINA K, 1994, ANESTH ANALG, V79, P766; Nishina K, 1999, PAEDIATR ANAESTH, V9, P187; NISHINA K, 1995, ANESTHESIOLOGY, V82, P1126, DOI 10.1097/00000542-199505000-00006; Nishina K, 1998, ANESTHESIOLOGY, V88, P922, DOI 10.1097/00000542-199804000-00011; Qteshat BS, 2011, RAWAL MED J, V36, P114; Ramesh VJ, 1997, INT J CLIN PHARM TH, V35, P218; Reimer EJ, 1998, CAN J ANAESTH, V45, P1162, DOI 10.1007/BF03012457; Schmidt AP, 2007, PEDIATR ANESTH, V17, P667, DOI 10.1111/j.1460-9592.2006.02185.x; Sfyra E, 2005, EUROPEAN J ANAES S34, V22, P141; Shiga M, 2000, ANESTHESIOLOGY, V93, P954, DOI 10.1097/00000542-200010000-00013; Stewart DW, 2012, PEDIATR ANESTH, V22, P136, DOI 10.1111/j.1460-9592.2011.03713.x; Sumiya K, 2003, BIOL PHARM BULL, V26, P421; Tazeroualti N, 2007, BRIT J ANAESTH, V98, P667, DOI 10.1093/bja/aem071; Tesoro S, 2005, ANESTH ANALG, V101, P1619, DOI 10.1213/01.ANE.0000184204.81877.53; The Nordic Cochrane Centre, 2012, REV MAN REVMAN 5 1; Tomecka MJ, 2012, PEDIATR ANESTH, V22, P130, DOI 10.1111/j.1460-9592.2011.03711.x; Trevor S, 2012, SAUDI J ANAESTH, V6, P8, DOI 10.4103/1658-354X.93045; TYLER DC, 1993, PAIN, V52, P301, DOI 10.1016/0304-3959(93)90163-J; Wallace AW, 2006, CURR OPIN ANESTHESIO, V19, P411, DOI 10.1097/01.aco.0000236141.15852.0b; Yun MJ., 2003, KOREAN J ANESTHESIOL, V45, P715	70	16	17	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1469-493X	1361-6137		COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2014		1							CD009633	10.1002/14651858.CD009633.pub2			69	Medicine, General & Internal	General & Internal Medicine	301BT	WOS:000330508400017	24470114				2020-06-30	J	Murphy, A; O'Sullivan, R; Wakai, A; Grant, TS; Barrett, MJ; Cronin, J; McCoy, SC; Hom, J; Kandamany, N				Murphy, Adrian; O'Sullivan, Ronan; Wakai, Abel; Grant, Timothy S.; Barrett, Michael J.; Cronin, John; McCoy, Siobhan C.; Hom, Jeffrey; Kandamany, Nandini			Intranasal fentanyl for the management of acute pain in children	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Review							PEDIATRIC EMERGENCY-DEPARTMENT; MORPHINE; PREVALENCE; PHARMACOKINETICS; ANALGESIA	Background Pain is the most common symptom in the emergency setting; however, timely management of acute pain in children continues to be suboptimal. Intranasal drug delivery has emerged as an alternative method of achieving quicker drug delivery without adding to the distress of a child by inserting an intravenous cannula. Objectives We identified and evaluated all randomized controlled trials (RCTs) and quasi-randomized trials to assess the effects of intranasal fentanyl (INF) versus alternative analgesic interventions in children with acute pain, with respect to reduction in pain score, occurrence of adverse events, patient tolerability, use of "rescue analgesia," patient/parental satisfaction and patient mortality. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 1); MEDLINE (Ovid SP, from 1995 to January 2014); EMBASE (Ovid SP, from 1995 to January 2014); the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (EBSCO Host, from 1995 to January 2014); the Latin American and Caribbean Health Science Information Database (LILACS) (BIREME, from 1995 to January 2014); Commonwealth Agricultural Bureaux (CAB) Abstracts (from 1995 to January 2014); the Institute for Scientific Information (ISI) Web of Science (from 1995 to January 2014); BIOSIS Previews (from 1995 to January 2014); the China National Knowledge Infrastructure (CNKI) (from 1995 to January 2014); International Standard Randomized Controlled Trial Number (ISRCTN) (from 1995 to January 2014); ClinicalTrials.gov (from 1995 to January 2014); and the International Clinical Trials Registry Platform (ICTRP) (to January 2014). Selection criteria We included RCTs comparing INF versus any other pharmacological/non-pharmacological intervention for the treatment of children in acute pain (aged < 18 years). Data collection and analysis Two independent review authors assessed each title and abstract for relevance. Full copies of all studies that met the inclusion criteria were retrieved for further assessment. Mean difference (MD), odds ratio (OR) and 95% confidence interval (CI) were used to measure effect sizes. Two review authors independently assessed and rated themethodological quality of each trial using the tool of The Cochrane Collaboration to assess risk of bias, as per Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions. Main results Three studies (313 participants) met the inclusion criteria. One study compared INF versus intramuscular morphine (IMM); another study compared INF versus intravenous morphine (IVM); and another study compared standard concentration INF (SINF) versus high concentration INF (HINF). All three studies reported a reduction in pain score following INF administration. INF produced a greater reduction in pain score at 10 minutes post administration when compared with IMM (INF group pain score: 1/5 vs IMM group pain score: 2/5; P value 0.014). No other statistically significant differences in pain scores were reported at any other time point. When INF was compared with IVM and HINF, no statistically significant differences in pain scores were noted between treatment arms, before analgesia or at 5, 10, 20 and 30 minutes post analgesia. Specifically, when INF was compared with IVM, both agents were seen to produce a statistically significant reduction in pain score up to 20 minutes post analgesia. No further reduction in pain score was noted after this time. When SINF was compared with HINF, a statistically and clinically significant reduction in pain scores over study time was observed (median decrease for both groups 40 mm, P value 0.000). No adverse events (e.g. opiate toxicity, death) were reported in any study following INF administration. One study described better patient tolerance to INF compared with IMM, which achieved statistical significance. The other studies described reports of a "bad taste" and vomiting with INF. Overall the risk of bias in all studies was considered low. Authors' conclusions INF may be an effective analgesic for the treatment of patients with acute moderate to severe pain, and its administration appears to cause minimal distress to children. However, this review of published studies does not allow any definitive conclusions regarding whether INF is superior, non-inferior or equivalent to intramuscular or intravenous morphine. Limitations of this review include the following: few eligible studies for inclusion (three); no study examined the use of INF in children younger than three years of age; no study included children with pain from a "medical" cause (e.g. abdominal pain seen in appendicitis); and all eligible studies were conducted in Australia. Consequently, the findings may not be generalizable to other healthcare settings, to children younger than three years of age and to those with pain from a "medical" cause.	[Murphy, Adrian; Barrett, Michael J.; Cronin, John] Univ Coll Dublin, Our Ladys Childrens Hosp Crumlin, Paediat Emergency Res Unit PERU, Dept Emergency Med,Natl Childrens Res Ctr, Dublin 12, Ireland; [O'Sullivan, Ronan] Our Ladys Childrens Hosp Crumlin, Natl Childrens Res Ctr, Dublin, Ireland; [O'Sullivan, Ronan] Cork Univ Hosp, Cork, Ireland; [Wakai, Abel] Royal Coll Surgeons Ireland, Div Populat Hlth Sci PHS, Emergency Care Res Unit ECRU, Dublin 2, Ireland; [Grant, Timothy S.] ICON Clin Res, Biostat & Programming, Dublin, Ireland; [McCoy, Siobhan C.] Cork Univ Hosp, Dept Emergency Med, Cork, Ireland; [Hom, Jeffrey] SUNY Stony Brook, Sch Med, Dept Pediat Emergency, Stony Brook, NY 11794 USA; [Hom, Jeffrey] SUNY Stony Brook, Sch Med, Dept Emergency Med, Stony Brook, NY 11794 USA; [Kandamany, Nandini] Our Ladys Childrens Hosp, Dept Emergency Med, Dublin, Ireland	Murphy, A (reprint author), Univ Coll Dublin, Our Ladys Childrens Hosp Crumlin, Paediat Emergency Res Unit PERU, Dept Emergency Med,Natl Childrens Res Ctr, Dublin 12, Ireland.	adrianmurphy06@eircom.net	Barrett, Michael/AAH-2075-2020	Wakai, Abel/0000-0003-2021-2388; Murphy, Anne/0000-0002-0112-7148; Barrett, Michael/0000-0003-1775-8347	National Children's Research Centre, Ireland	Internal sources; National Children's Research Centre, Ireland.	Alonso-Serra Hector M, 2003, Prehosp Emerg Care, V7, P482; [Anonymous], 2012, ONGOING STUDY; Bendall JC, 2011, PREHOSP EMERG CARE, V15, P158, DOI 10.3109/10903127.2010.541980; Berde CB, 2002, NEW ENGL J MED, V347, P1094, DOI 10.1056/NEJMra012626; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland M, 2011, EMERG MED AUSTRALAS, V23, P202, DOI 10.1111/j.1742-6723.2011.01391.x; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Chung S, 2010, PEDIATR RADIOL, V40, P1236, DOI 10.1007/s00247-009-1521-1; Cook D, 1998, SYSTEMATIC REV SYNTH, V1, P91; Cordell WH, 2002, AM J EMERG MED, V20, P165, DOI 10.1053/ajem.2002.32643; DEEKS JJ, 2001, SYSTEMATIC REV HLTH, P285, DOI DOI 10.1002/9780470693926.CH15; Egger M, 1997, BMJ-BRIT MED J, V315, P1533, DOI 10.1136/bmj.315.7121.1533; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; FRIEDLAND LR, 1994, ANN EMERG MED, V23, P203, DOI 10.1016/S0196-0644(94)70031-1; Galinski M, 2011, AM J EMERG MED, V29, P1062, DOI 10.1016/j.ajem.2010.06.031; GLASZIOU P, 2001, [No title captured]; Groenewald CB, 2012, PEDIATR ANESTH, V22, P661, DOI 10.1111/j.1460-9592.2012.03807.x; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE; Hansen MS, 2013, DAN MED J, V60, P1; Hennes Halim, 2005, Prehosp Emerg Care, V9, P32, DOI 10.1080/10903120590891705; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Kart T, 1997, PAEDIATR ANAESTH, V7, P93; Light RJ, 1984, SUMMING SCI REV RES, V1; Lzsak E, 2008, PREHOSP EMERG CARE, V12, P182, DOI 10.1080/10903120801907471; MacLean S, 2007, PEDIATR EMERG CARE, V23, P87, DOI 10.1097/PEC.0b013e31803; Mudd S, 2011, J PEDIATR HEALTH CAR, V25, P316, DOI 10.1016/j.pedhc.2010.04.011; Murphy A, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009942, DOI 10.1002/14651858.CD009942]; Panagiotou I, 2010, EXPERT REV ANTICANC, V10, P1009, DOI [10.1586/era.10.77, 10.1586/ERA.10.77]; Paris PM, 1988, PAIN MANAGEMENT EMER, V1, pxiii; Probst BD, 2005, PEDIATR EMERG CARE, V21, P298, DOI 10.1097/01.pec.0000159074.85808.14; Rupp T, 2004, ANN EMERG MED, V43, P494, DOI 10.1016/j.annemergmed.2003.11.019; SANDLER ES, 1992, PEDIATRICS, V89, P631; Saunders M, 2010, ACAD EMERG MED, V17, P1155, DOI 10.1111/j.1553-2712.2010.00905.x; SCHECHTER NL, 1989, PEDIATR CLIN N AM, V36, P781; The Nordic Cochrane Centre The Cochrane Collaboration, 2011, REV MAN REVMAN 5 2; Verghese Susan T, 2010, J Pain Res, V3, P105; Wilsey B, 2004, AM J EMERG MED, V22, P51, DOI 10.1016/j.ajem.2003.09.005; WILSON JE, 1989, AM J EMERG MED, V7, P620, DOI 10.1016/0735-6757(89)90286-6; Younge P, 1999, EMERGEN MED, V11, P90	40	38	38	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1469-493X	1361-6137		COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2014		10							CD009942	10.1002/14651858.CD009942.pub2			32	Medicine, General & Internal	General & Internal Medicine	AY5YW	WOS:000347646000067	25300594	Green Published			2020-06-30	J	Wiffen, PJ; Derry, S; Moore, RA				Wiffen, Philip J.; Derry, Sheena; Moore, R. Andrew			Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Review							CONTROLLED-RELEASE MORPHINE; LIVERPOOL CARE PATHWAY; ADVERSE DRUG-REACTIONS; DOUBLE-BLIND; ORAL MORPHINE; IMMEDIATE-RELEASE; TRANSDERMAL FENTANYL; ANALGESIC EFFICACY; RANDOMIZED CROSSOVER; CLINICAL-EFFICACY	Background There is increasing focus on providing high quality care for people at the end of life, irrespective of disease or cause, and in all settings. In the last ten years the use of care pathways to aid those treating patients at the end of life has become common worldwide. The use of the Liverpool Care Pathway in the UK has been criticised. In England the LCP was the subject of an independent review, commissioned by a Health Minister. The Neuberger Review acknowledged that the LCP was based on the sound ethical principles that provide the basis of good quality care for patients and families when implemented properly. It also found that the LCP often was not implemented properly, and had instead become a barrier to good care; it made over 40 recommendations, including education and training, research and development, access to specialist palliative care services, and the need to ensure care and compassion for all dying patients. In July 2013, the Department of Health released a statement that stated the use of the LCP should be "phased out over the next 6-12 months and replaced with an individual approach to end of life care for each patient". The impact of opioids was a particular concern because of their potential influence on consciousness, appetite and thirst in people near the end of life. There was concern that impaired patient consciousness may lead to an earlier death, and that effects of opioids on appetite and thirst may result in unnecessary suffering. This rapid review, commissioned by the National Institute for Health Research, used standard Cochrane methodology to examine adverse effects of morphine, fentanyl, oxycodone, and codeine in cancer pain studies as a close approximation to possible effects in the dying patient. Objectives To determine the impact of opioid treatment on patient consciousness, appetite and thirst in randomised controlled trials of morphine, fentanyl, oxycodone or codeine for treating cancer pain. Search methods We assessed adverse event data reported in studies included in current Cochrane reviews of opioids for cancer pain: specifically morphine, fentanyl, oxycodone, and codeine. Selection criteria We included randomised studies using multiple doses of four opioid drugs (morphine, fentanyl, oxycodone, and codeine) in cancer pain. These were taken from four existing or ongoing Cochrane reviews. Participants were adults aged 18 and over. We included only full journal publication articles. Data collection and analysis Two review authors independently extracted adverse event data, and examined issues of study quality. The primary outcomes sought were numbers of participants experiencing adverse events of reduced consciousness, appetite, and thirst. Secondary outcomes were possible surrogate measures of the primary outcomes: delirium, dizziness, hallucinations, mood change and somnolence relating to patient consciousness, and nausea, vomiting, constipation, diarrhoea, dyspepsia, dysphagia, anorexia, asthenia, dehydration, or dry mouth relating to appetite or thirst. Comparative measures of harm were known to be unlikely, and we therefore calculated the proportion of participants experiencing each of the adverse events of interest with each opioid, and for all four opioid drugs combined. Main results We included 77 studies with 5619 randomised participants. There was potential bias in most studies, with small size being the most common; individual treatment groups had fewer than 50 participants in 60 studies. Participants were relatively young, with mean age in the studies typically between 50 and 70 years. Multiple major problems with adverse event reporting were found, including failing to report adverse events in all participants who received medication, all adverse events experienced, how adverse events were collected, and not defining adverse event terminology or whether a reporting system was used. Direct measures of patient consciousness, patient appetite, or thirst were not apparent. For opioids used to treat cancer pain adverse event incidence rates were 25% for constipation, 23% for somnolence, 21% for nausea, 17% for dry mouth, and 13% for vomiting, anorexia, and dizziness. Asthenia, diarrhoea, insomnia, mood change, hallucinations and dehydration occurred at incidence rates of 5% and below. Authors' conclusions We found no direct evidence that opioids affected patient consciousness, appetite or thirst when used to treat cancer pain. However, somnolence, dry mouth, and anorexia were common adverse events in people with cancer pain treated with morphine, fentanyl, oxycodone, or codeine. We are aware that there is an important literature concerning the problems that exist with adverse event measurement, reporting, and attribution. Together with the known complications concerning concomitant medication, data collection and reporting, and nomenclature, this means that these adverse events cannot always be attributed unequivocally to the use of opioids, and so they provide only a broad picture of adverse events with opioids in cancer pain. The research agenda includes developing definitions for adverse events that have a spectrum of severity or importance, and the development of appropriate measurement tools for recording such events to aid clinical practice and clinical research.	[Wiffen, Philip J.; Derry, Sheena; Moore, R. Andrew] Univ Oxford, Oxford OX3 7LE, Oxon, England; [Wiffen, Philip J.; Derry, Sheena; Moore, R. Andrew] Univ Oxford, Nuffield Dept Clin Neurosci, Nuffield Div Anaesthet, Oxford OX3 7LE, Oxon, England	Wiffen, PJ (reprint author), Univ Oxford, Churchill Hosp, Pain Res Unit, Oxford OX3 7LE, Oxon, England.	phil.wiffen@ndcn.ox.ac.uk			NIHR Incentive Award, UK [13/180/08]	External sources; NIHR Incentive Award (Reference: 13/180/08), UK.	Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Ahmedzai SH, 2012, PALLIATIVE MED, V26, P50, DOI 10.1177/0269216311418869; ARKINSTALL WW, 1989, CAN MED ASSOC J, V140, P653; Avorn J, 2008, BRIT MED J, V336, P956, DOI 10.1136/bmj.39520.671053.94; Babul N, 1998, J CLIN PHARMACOL, V38, P74, DOI 10.1002/j.1552-4604.1998.tb04380.x; Bailey FA, 2005, ARCH INTERN MED, V165, P1722, DOI 10.1001/archinte.165.15.1722; BEAVER WT, 1978, J PHARMACOL EXP THER, V207, P92; BEAVER WT, 1978, J PHARMACOL EXP THER, V207, P101; Bookbinder M, 2005, J PAIN SYMPTOM MANAG, V29, P529, DOI 10.1016/j.jpainsymman.2004.05.011; BOUREAU F, 1992, J PAIN SYMPTOM MANAG, V7, P393, DOI 10.1016/0885-3924(92)90018-D; Broomhead A, 1997, J PAIN SYMPTOM MANAG, V14, P63, DOI 10.1016/S0885-3924(97)00012-2; Bruera E, 1998, J CLIN ONCOL, V16, P3222, DOI 10.1200/JCO.1998.16.10.3222; Bruera E, 2004, J CLIN ONCOL, V22, P185, DOI 10.1200/JCO.2004.03.172; Capretti G, 1970, Clin Ter, V52, P361; CARLSON RW, 1990, PHARMACOTHERAPY, V10, P211; Chan RJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008006.pub3; Chen Y, 2003, CHINESE J CLIN REHAB, V7, P1290; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; Costantini M, 2014, LANCET, V383, P226, DOI 10.1016/S0140-6736(13)61725-0; CUNDIFF D, 1989, CANCER, V63, P2355, DOI 10.1002/1097-0142(19890601)63:11<2355::AID-CNCR2820631147>3.0.CO;2-#; CUNDIFF D, 1988, [No title captured], V3, P18; Currow DC, 2007, J PAIN SYMPTOM MANAG, V34, P17, DOI 10.1016/j.jpainsymman.2006.10.011; Dale O, 2009, J PAIN SYMPTOM MANAG, V37, P68, DOI 10.1016/j.jpainsymman.2007.12.016; DECONNO F, 1995, J CLIN ONCOL, V13, P1004, DOI 10.1200/JCO.1995.13.4.1004; DELLEMIJN PLI, 1994, EUR J CANCER, V30A, P1244, DOI 10.1016/0959-8049(94)90166-X; DERRY S, 2008, SYSTEMATIC REV PAIN, P67; DESCHAMPS M, 1992, J PAIN SYMPTOM MANAG, V7, P384, DOI 10.1016/0885-3924(92)90017-C; Dhaliwal HS, 1995, J PAIN SYMPTOM MANAG, V10, P612, DOI 10.1016/0885-3924(95)00123-9; Edwards JE, 1999, J PAIN SYMPTOM MANAG, V18, P427, DOI 10.1016/S0885-3924(99)00093-7; Ellershaw J, 2003, BRIT MED J, V326, P30, DOI 10.1136/bmj.326.7379.30; Rodriguez RF, 2007, CLIN THER, V29, P581, DOI 10.1016/j.clinthera.2007.04.004; Ferrell B, 1989, Oncol Nurs Forum, V16, P521; FINN JW, 1993, J CLIN ONCOL, V11, P967, DOI 10.1200/JCO.1993.11.5.967; Floter T, 1997, CLIN DRUG INVEST, V14, P183; Gabrail Nashat Y, 2004, CURRENT MED RES OPIN, V20, P911; Gabrail NY, 2003, OXYMORPHONE EXTENDED, V22, P737; George R, 2014, PALLIATIVE MED, V28, P3, DOI 10.1177/0269216313514706; Gillette JF, 1997, CLIN DRUG INVEST, V14, P22, DOI 10.2165/00044011-199700141-00006; GOUGHNOUR BR, 1989, CANCER, V63, P2294, DOI 10.1002/1097-0142(19890601)63:11<2294::AID-CNCR2820631139>3.0.CO;2-X; Gourlay GK, 1997, PAIN, V69, P295, DOI 10.1016/S0304-3959(96)03269-1; Hadley G, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD010270, DOI 10.1002/14651858.CD010270]; Hagen NA, 2005, J PAIN SYMPTOM MANAG, V29, P80, DOI 10.1016/j.jpainsymman.2004.04.015; Hagen NA, 1997, CANCER-AM CANCER SOC, V79, P1428; HANKS GW, 1995, J PAIN SYMPTOM MANAG, V10, P6, DOI 10.1016/0885-3924(94)00067-U; HANKS GW, 1987, ANAESTHESIA, V42, P840, DOI 10.1111/j.1365-2044.1987.tb04107.x; Hanna Magdi, 2008, BMC Palliat Care, V7, P17, DOI 10.1186/1472-684X-7-17; Harris JT, 2003, PALLIATIVE MED, V17, P248, DOI 10.1191/0269216303pm695oa; Heiskanen T, 1997, PAIN, V73, P37, DOI 10.1016/S0304-3959(97)00072-9; Heiskanen TE, 2000, ACTA ONCOL, V39, P941; Henriksen H, 1986, ADV CANC PAIN MAN IN; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Homsi J, 2010, AM J HOSP PALLIAT ME, V27, P99, DOI 10.1177/1049909109345146; HOSKIN PJ, 1989, ANAESTHESIA, V44, P897, DOI 10.1111/j.1365-2044.1989.tb09143.x; Imanaka K, 2013, CURR MED RES OPIN, V29, P1399, DOI 10.1185/03007995.2013.831816; Independent Review of the Liverpool Care Pathway, 2013, MORE CARE LESS PATHW; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V285, P437, DOI 10.1001/jama.285.4.437; Ioannidis JPA, 2004, ANN INTERN MED, V141, P781, DOI 10.7326/0003-4819-141-10-200411160-00009; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JOCHIMSEN PR, 1978, CLIN PHARMACOL THER, V24, P223; KALSO E, 1990, CLIN PHARMACOL THER, V47, P639, DOI 10.1038/clpt.1990.85; Kaplan R, 1998, J CLIN ONCOL, V16, P3230, DOI 10.1200/JCO.1998.16.10.3230; Kerr RO, 2000, CLIN DRUG INVEST, V19, P25, DOI 10.2165/00044011-200019010-00004; Klepstad P, 2003, PAIN, V101, P193, DOI 10.1016/S0304-3959(02)00328-7; Knights D, 2013, BRIT J GEN PRACT, V63, P509, DOI 10.3399/bjgp13X673559; Knudsen J, 1985, Ugeskr Laeger, V147, P780; Kongsgaard UE, 1998, EUR J PAIN-LONDON, V2, P53, DOI 10.1016/S1090-3801(98)90046-5; KOSSMAN B, 1983, [No title captured], V64, P73; Kress HG, 2008, J PAIN SYMPTOM MANAG, V36, P268, DOI 10.1016/j.jpainsymman.2007.10.023; Lauretti GR, 2003, BRIT J CANCER, V89, P2027, DOI 10.1038/sj.bjc.6601365; LEOW KP, 1995, ANESTH ANALG, V80, P296, DOI 10.1097/00000539-199502000-00016; LEPPERT W, 2001, NOWOTWORY, V51, P257; Loke Y K, 2001, BMC Clin Pharmacol, V1, P3, DOI 10.1186/1472-6904-1-3; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; MELZACK R, 1979, CAN MED ASSOC J, V120, P435; Mercadante S, 1998, J PAIN SYMPTOM MANAG, V15, P76, DOI 10.1016/S0885-3924(97)00257-1; Mercadante S, 2008, EUR J PAIN, V12, P1040, DOI 10.1016/j.ejpain.2008.01.013; Mercadante S, 2010, CLIN J PAIN, V26, P794, DOI 10.1097/AJP.0b013e3181ecd895; Meyer FP, 1996, CLIN PHARMACOL THER, V60, P347, DOI 10.1016/S0009-9236(96)90062-4; MIGNAULT GG, 1995, J PAIN SYMPTOM MANAG, V10, P416, DOI 10.1016/0885-3924(95)00063-5; Mizuguchi K, 1990, RINSHOU IGAKU, V6, P2357; MOERTEL CG, 1971, GASTROENTEROLOGY, V60, P552; Moore A, 2009, CLIN GASTROENTEROL H, V7, P1156, DOI 10.1016/j.cgh.2009.03.032; Moore RA, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4176; Moore RA, 2010, PAIN, V150, P386, DOI 10.1016/j.pain.2010.05.011; Moore RA, 2005, ARTHRITIS RES THER, V7, pR1046, DOI 10.1186/ar1782; Moore RA, 1998, PAIN, V78, P209, DOI 10.1016/S0304-3959(98)00140-7; Moriarty M, 1999, J CLIN RES, V2, P1; Mucci-LoRusso P, 1998, EUR J PAIN-LONDON, V2, P239, DOI 10.1016/S1090-3801(98)90020-9; Murray SA, 2008, BRIT MED J, V336, P958, DOI 10.1136/bmj.39535.491238.94; Mystakidou Kyriaki, 2005, J Opioid Manag, V1, P204; NOYES R, 1975, CLIN PHARMACOL THER, V18, P84; Nuesch E, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3515; Nuovo J, 2007, PHARMACOEPIDEM DR S, V16, P349, DOI 10.1002/pds.1310; OBrien T, 1997, PALLIATIVE MED, V11, P475, DOI 10.1177/026921639701100608; Olsen H, 1999, BLOOD PRESSURE, V8, P94; Ozturk T, 2008, AGRI, V20, P20; Panich Arara, 1993, Journal of the Medical Association of Thailand, V76, P672; Parris WCV, 1998, J PAIN SYMPTOM MANAG, V16, P205, DOI 10.1016/S0885-3924(98)00064-5; Pistevou-Gompaki K, 2004, CURR MED RES OPIN, V20, P159, DOI 10.1185/030079903125002829; PORTENOY RK, 1989, CANCER, V63, P2284, DOI 10.1002/1097-0142(19890601)63:11<2284::AID-CNCR2820631137>3.0.CO;2-3; Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0; Portenoy RK, 1988, J PAIN SYMPTOM MAN S, V3, P16; Regnard C, 2014, AGE AGEING, V43, P171, DOI 10.1093/ageing/aft195; Reid CM, 2010, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003870.pub3, DOI 10.1002/14651858.CD003870.PUB3]; REIDENBERG MM, 1968, NEW ENGL J MED, V279, P678, DOI 10.1056/NEJM196809262791304; Rico MA, 2000, REV SOC ESP DOLOR, V7, P345; Ridgway D, 2010, J PAIN SYMPTOM MANAG, V39, P712, DOI 10.1016/j.jpainsymman.2009.08.013; Rief W, 2006, ARCH INTERN MED, V166, P155, DOI 10.1001/archinte.166.2.155; Rief W, 2009, DRUG SAFETY, V32, P1041, DOI 10.2165/11316580-000000000-00000; RODRIGUEZ M, 1994, EUR J CANCER, V30A, P584, DOI 10.1016/0959-8049(94)90524-X; Rodriguez RF, 2008, CLIN J PAIN, V24, P1, DOI 10.1097/AJP.0b013e318156ca4d; Rodriguez RF, 2007, J PALLIAT MED, V10, P56, DOI 10.1089/jpm.2006.0117; Salzman RT, 1999, J PAIN SYMPTOM MANAG, V18, P271, DOI 10.1016/S0885-3924(99)00079-2; Schremmer C, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006601.pub3, DOI 10.1002/14651858.CD006601.PUB3]; SMITH KJ, 1991, POSTGRAD MED J, V67, pS55; STAMBAUGH JE, 1987, J CLIN PHARMACOL, V27, P162, DOI 10.1002/j.1552-4604.1987.tb02178.x; Stambaugh JE, 2001, J CLIN PHARMACOL, V41, P500, DOI 10.1177/00912700122010375; Stambuch J. E., 1997, Clinical Pharmacology and Therapeutics, V61, P197; STAQUET M, 1978, CLIN PHARMACOL THER, V23, P397; STAQUET M, 1993, CURR THER RES CLIN E, V53, P435, DOI 10.1016/S0011-393X(05)80203-6; STAQUET M, 1971, J CLIN PHARMACOL N D, V11, P450; Tassi P, 2001, NEUROSCI BIOBEHAV R, V25, P175, DOI 10.1016/S0149-7634(01)00006-9; The Nordic Cochrane Centre The Cochrane Collaboration, 2012, REV MAN REVMAN 5 2; THIRLWELL MP, 1989, CANCER, V63, P2275, DOI 10.1002/1097-0142(19890601)63:11<2275::AID-CNCR2820631136>3.0.CO;2-4; Todd J, 2002, PALLIATIVE MED, V16, P507, DOI 10.1191/0269216302pm591oa; Tramer MR, 2000, PAIN, V85, P169, DOI 10.1016/S0304-3959(99)00267-5; Tramer MR, 1997, BRIT J ANAESTH, V78, P642, DOI 10.1093/bja/78.6.642; TWYCROSS RG, 1976, J INT MED RES, V4, P58; TWYCROSS RG, 1977, PAIN, V3, P93, DOI 10.1016/0304-3959(77)90072-0; VAINIO A, 1988, ACTA ANAESTH SCAND, V32, P179, DOI 10.1111/j.1399-6576.1988.tb02711.x; van Seventer R, 2003, CURR MED RES OPIN, V19, P457, DOI 10.1185/030079903125002045; Ventafridda V, 1989, J Pain Symptom Manage, V4, P124, DOI 10.1016/0885-3924(89)90005-5; Ventafridda V, 1986, J Pain Symptom Manage, V1, P203, DOI 10.1016/S0885-3924(86)80042-2; Vielvoye-Kerkmeer A, 2002, EUROPEAN J PALLIATIV, V9, P137; WALSH TD, 1985, ADV PAIN RES THER, V9, P727; WALSH TD, 1992, AM J CLIN ONCOL-CANC, V15, P268, DOI 10.1097/00000421-199206000-00018; WALSH TD, 1984, ADV MORPHINE THERAPY, P99; Wiffen PJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003868.pub3; WILDERSMITH CH, 1994, ANN ONCOL, V5, P141, DOI 10.1093/oxfordjournals.annonc.a058765; WILKINSON TJ, 1992, CANCER CHEMOTH PHARM, V31, P251, DOI 10.1007/BF00685556; Wong J O, 1997, Acta Anaesthesiol Sin, V35, P25; Xu GZ, 1997, CLIN DRUG INVEST, V14, P34, DOI 10.2165/00044011-199700141-00008	143	19	20	1	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1469-493X	1361-6137		COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2014		5							CD011056	10.1002/14651858.CD011056.pub2			109	Medicine, General & Internal	General & Internal Medicine	AI2AD	WOS:000336657000039	24874470	Green Published			2020-06-30	J	Blagus, T; Markelc, B; Cemazar, M; Kosjek, T; Preat, V; Miklavcic, D; Sersa, G				Blagus, Tanja; Markelc, Bostjan; Cemazar, Maja; Kosjek, Tina; Preat, Veronique; Miklavcic, Damijan; Sersa, Gregor			In vivo real-time monitoring system of electroporation mediated control of transdermal and topical drug delivery	JOURNAL OF CONTROLLED RELEASE			English	Article						Electroporation; Transdermal drug delivery; Topical drug delivery; Multi-array electrodes; Monitoring system; Controlled delivery	SKIN ELECTROPORATION; PLASMID DNA; GENE ELECTROTRANSFER; PHYSICAL ENHANCER; INSULIN DELIVERY; ELECTRIC PULSES; VOLTAGE PULSE; EX-VIVO; THERAPY; ELECTROCHEMOTHERAPY	Electroporation (EP) is a physical method for the delivery of molecules into cells and tissues, including the skin. In this study, in order to control the degree of transdermal and topical drug delivery, EP at different amplitudes of electric pulses was evaluated. A new in vivo real-time monitoring system based on fluorescently labeled molecules was developed, for the quantification of transdermal and topical drug delivery. EP of the mouse skin was performed with new non-invasive multi-array electrodes, delivering different amplitudes of electric pulses ranging from 70 to 570 V, between the electrode pin pairs. Patches, soaked with 4 kDa fluorescein-isothiocyanate labeled dextran (FD), doxorubicin (DOX) or fentanyl (FEN), were applied to the skin before and after EP. The new monitoring system was developed based on the delivery of FD to and through the skin. FD relative quantity was determined with fluorescence microscopy imaging, in the treated region of the skin for topical delivery and in a segment of the mouse tail for transdermal delivery. The application of electric pulses for FD delivery resulted in enhanced transdermal delivery. Depending on the amplitude of electric pulses, it increased up to the amplitude of 360 V, and decreased at higher amplitudes (460 and 570 V). Topical delivery steadily enhanced with increasing the amplitude of the delivered electric pulses, being even higher than after tape stripping used as a positive control. The non-invasive monitoring of the delivery of DOX, a fluorescent chemotherapeutic drug, qualitatively and quantitatively confirmed the effects of EP at 360 and 570 V pulse amplitudes on topical and transdermal drug delivery. Delivery of FEN at 360 and 570 V pulse amplitudes verified the observed effects as obtained with FD and DOX, by the measured physiological responses of the mice as well as FEN plasma concentration. This study demonstrates that with the newly developed non-invasive multi-array electrodes and with the varying electric pulse amplitude, the amount of topical and transdermal drug delivery to the skin can be controlled. Furthermore, the newly developed monitoring system provides a tool for rapid real-time determination of both, transdermal and topical delivery, when the delivered molecule is fluorescent. (C) 2013 Elsevier B.V. All rights reserved.	[Blagus, Tanja; Markelc, Bostjan; Cemazar, Maja; Sersa, Gregor] Inst Oncol Ljubljana, Dept Expt Oncol, SI-1000 Ljubljana, Slovenia; [Cemazar, Maja] Univ Primorska, Fac Hlth Sci, SI-6310 Izola, Slovenia; [Kosjek, Tina] Jozef Stefan Inst, Dept Environm Sci, SI-1000 Ljubljana, Slovenia; [Preat, Veronique] Catholic Univ Louvain, Louvain Drug Res Inst, B-1200 Brussels, Belgium; [Miklavcic, Damijan] Univ Ljubljana, Fac Elect Engn, SI-1000 Ljubljana, Slovenia	Sersa, G (reprint author), Inst Oncol Ljubljana, Dept Expt Oncol, Zaloska 2, SI-1000 Ljubljana, Slovenia.	gsersa@onko-i.si	Cemazar, Maja/K-6182-2013; Kosjek, Tina/D-2313-2014; Miklavcic, Damijan/A-9497-2008	Cemazar, Maja/0000-0002-1418-1928; Kosjek, Tina/0000-0002-6421-0344; Miklavcic, Damijan/0000-0003-3506-9449; Markelc, Bostjan/0000-0002-8674-702X	Competency Center for Biomedical Engineering (CC BME)	This study was financially supported by Competency Center for Biomedical Engineering (CC BME) and was conducted within the scope of the EBAM European Associated Laboratory (LEA). This work is a result of networking efforts within COST TD1104 Action (www.electroporation.net). We would like to thank Iskra Medical d.o.o. for the providing of multi-array electrodes with spring loaded pins. We would like to thank Prof. Andrej Coer (Faculty of Health Sciences, University of Primorska, Slovenia) for his valuable comments in the evaluation of histological specimen. We would also like to thank Dr. Matej Rebersek, Barbara Zorec (University of Ljubljana, Faculty of Electrical Engineering, Slovenia), and Maja Ota (Institute of Oncology Ljubljana, Slovenia) for their technical support and all the work they contributed to this research.	Babiuk S, 2003, MOL THER, V8, P992, DOI 10.1016/j.ymthe.2003.09.008; Bellard E, 2012, J CONTROL RELEASE, V163, P396, DOI 10.1016/j.jconrel.2012.09.010; Bodles-Brakhop AM, 2009, MOL THER, V17, P585, DOI 10.1038/mt.2009.5; Broderick KE, 2011, GENE THER, V18, P258, DOI 10.1038/gt.2010.137; Cemazar M, 2010, CURR GENE THER, V10, P300, DOI 10.2174/156652310791823425; Chen HB, 2009, J CONTROL RELEASE, V139, P63, DOI 10.1016/j.jconrel.2009.05.031; Daugimont L, 2010, J MEMBRANE BIOL, V236, P117, DOI 10.1007/s00232-010-9283-0; Denet AR, 2004, ADV DRUG DELIVER REV, V56, P659, DOI 10.1016/j.addr.2003.10.027; Donate A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019181; Escoffre JM, 2010, J MEMBRANE BIOL, V236, P61, DOI 10.1007/s00232-010-9275-0; Ferraro B, 2011, GENE THER, V18, P496, DOI 10.1038/gt.2010.171; Ferraro B, 2010, GENE THER, V17, P763, DOI 10.1038/gt.2010.43; Ferraro B, 2009, MOL THER, V17, P651, DOI 10.1038/mt.2009.12; Gehl J, 2002, BBA-GEN SUBJECTS, V1569, P51, DOI 10.1016/S0304-4165(01)00233-1; Gehl J, 2003, ACTA PHYSIOL SCAND, V177, P437, DOI 10.1046/j.1365-201X.2003.01093.x; Glasspool-Malone J, 2000, MOL THER, V2, P140, DOI 10.1006/mthe.2000.0107; Godin B, 2007, ADV DRUG DELIVER REV, V59, P1152, DOI 10.1016/j.addr.2007.07.004; Gothelf A, 2010, GENE THER, V17, P1077, DOI 10.1038/gt.2010.46; Gothelf A, 2010, CURR GENE THER, V10, P287, DOI 10.2174/156652310791823443; Guo S., 2013, PLOS ONE, V8; Guo SQ, 2011, J CONTROL RELEASE, V151, P256, DOI 10.1016/j.jconrel.2011.01.014; Haberl S, 2013, IEEE ELECTR INSUL M, V29, P29, DOI 10.1109/MEI.2013.6410537; Heller LC, 2007, GENE THER, V14, P275, DOI 10.1038/sj.gt.3302867; Heller LC, 2006, HUM GENE THER, V17, P890, DOI 10.1089/hum.2006.17.890; Heller Loree C, 2008, Genet Vaccines Ther, V6, P16, DOI 10.1186/1479-0556-6-16; Heller R, 2010, HUM GENE THER, V21, P357, DOI 10.1089/hum.2009.065; Henry S, 1999, J PHARM SCI, V88, P948; Herkenne C, 2008, PHARM RES-DORDR, V25, P87, DOI 10.1007/s11095-007-9429-7; Jarm T, 2010, EXPERT REV ANTICANC, V10, P729, DOI [10.1586/era.10.43, 10.1586/ERA.10.43]; Escobar-Chavez JJ, 2011, J CLIN PHARMACOL, V51, P964, DOI 10.1177/0091270010378859; Escobar-Chavez JJ, 2009, J CLIN PHARMACOL, V49, P1262, DOI 10.1177/0091270009344984; Kanthou C, 2006, MOL CANCER THER, V5, P3145, DOI 10.1158/1535-7163.MCT-06-0410; Kotnik T, 2012, IEEE ELECTR INSUL M, V28, P14, DOI 10.1109/MEI.2012.6268438; Lee PY, 2004, J INVEST DERMATOL, V123, P791, DOI 10.1111/j.0022-202X.2004.23309.x; Linnert M, 2012, RADIOL ONCOL, V46, P271, DOI 10.2478/v10019-012-0042-y; Lombry C, 2000, PHARMACEUT RES, V17, P32, DOI 10.1023/A:1007510323344; Markelc B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059557; Markelc B, 2012, J MEMBRANE BIOL, V245, P545, DOI 10.1007/s00232-012-9435-5; Martanto W, 2004, PHARM RES-DORDR, V21, P947, DOI 10.1023/B:PHAM.0000029282.44140.2e; Mazeres S, 2009, J CONTROL RELEASE, V134, P125, DOI 10.1016/j.jconrel.2008.11.003; Medi Babu M., 2008, V423, P225, DOI 10.1007/978-1-59745-194-9_16; Miklavcic D, 2012, MED BIOL ENG COMPUT, V50, P1213, DOI 10.1007/s11517-012-0991-8; Mitragotri S, 2001, PHARMACEUT RES, V18, P1151, DOI 10.1023/A:1010979010907; Park EJ, 2007, PHARM RES-DORDR, V24, P1396, DOI 10.1007/s11095-007-9306-4; Pavselj N, 2005, J CONTROL RELEASE, V106, P407, DOI 10.1016/j.jconrel.2005.05.003; Pillai O, 2003, J CONTROL RELEASE, V89, P127, DOI 10.1016/S0168-3659(03)00094-4; Polat BE, 2012, J CONTROL RELEASE, V158, P250, DOI 10.1016/j.jconrel.2011.11.008; Polat BE, 2011, J PHARM SCI-US, V100, P512, DOI 10.1002/jps.22280; PRAUSNITZ MR, 1993, P NATL ACAD SCI USA, V90, P10504, DOI 10.1073/pnas.90.22.10504; PRAUSNITZ MR, 1994, PHARMACEUT RES, V11, P1834, DOI 10.1023/A:1018944223290; Prausnitz MR, 1999, ADV DRUG DELIVER REV, V35, P61, DOI 10.1016/S0169-409X(98)00063-5; Regnier V, 2000, J CONTROL RELEASE, V67, P337, DOI 10.1016/S0168-3659(00)00223-6; Regnier V, 1998, J DRUG TARGET, V5, P275, DOI 10.3109/10611869808995881; Roos AK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007226; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Sersa G, 2008, EJSO-EUR J SURG ONC, V34, P232, DOI 10.1016/j.ejso.2007.05.016; Sersa G, 1999, EUR J CANCER, V35, P672, DOI 10.1016/S0959-8049(98)00426-2; Smith NB, 2003, ULTRASOUND MED BIOL, V29, P1205, DOI 10.1016/S0301-5629(03)00908-6; Vanbever R, 1996, PHARMACEUT RES, V13, P559, DOI 10.1023/A:1016093920875; Vanbever R, 1998, J CONTROL RELEASE, V50, P225, DOI 10.1016/S0168-3659(97)00147-8; Vanbever R, 1999, ADV DRUG DELIVER REV, V35, P77, DOI 10.1016/S0169-409X(98)00064-7; Vanbever R, 1998, SKIN PHARMACOL APPL, V11, P23, DOI 10.1159/000029805; Vanbever R, 2000, METH MOLEC MED, V37, P457, DOI 10.1385/1-59259-080-2:457; Vanbever R, 1996, PHARMACEUT RES, V13, P1360, DOI 10.1023/A:1016073917125; Vaughan TE, 2000, METH MOLEC MED, V37, P187, DOI 10.1385/1-59259-080-2:187; Wang YP, 2005, EUR J PHARM BIOPHARM, V60, P179, DOI 10.1016/j.ejpb.2004.12.008; Wong TW, 2011, DIABETES TECHNOL THE, V13, P929, DOI 10.1089/dia.2011.0077; Wong TW, 2006, J CONTROL RELEASE, V110, P557, DOI 10.1016/j.jconrel.2005.11.003; Zorec B, 2013, ZDR VESTN, V82, P339	69	36	37	0	50	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0168-3659	1873-4995		J CONTROL RELEASE	J. Control. Release	DEC 28	2013	172	3					862	871		10.1016/j.jconrel.2013.09.030			10	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	272WH	WOS:000328492800029	24113487				2020-06-30	J	Podolsky, AT; Sandweiss, A; Hu, J; Bilsky, EJ; Cain, JP; Kumirov, VK; Lee, YS; Hruby, VJ; Vardanyan, RS; Vanderah, TW				Podolsky, Alexander T.; Sandweiss, Alexander; Hu, Jackie; Bilsky, Edward J.; Cain, Jim P.; Kumirov, Vlad K.; Lee, Yeon Sun; Hruby, Victor J.; Vardanyan, Ruben S.; Vanderah, Todd W.			Novel fentanyl-based dual mu/delta-opioid agonists for the treatment of acute and chronic pain	LIFE SCIENCES			English	Article						Chronic pain; Allodynia; Hyperalgesia; Inflammatory; Mice; Rat; Fentanyl; mu opioid; Delta opioid; Spinal nerve ligation; Formalin flinch; Naloxone	NEUROPATHIC PAIN; FORMALIN TEST; RECEPTOR AGONIST; DELTA; LIGANDS; MODEL; MICE; RAT; MORPHINE; POTENT	Approximately one third of the adult U.S. population suffers from some type of on-going, chronic pain annually, and many more will have some type of acute pain associated with trauma or surgery. First-line therapies for moderate to severe pain include prescriptions for common mu opioid receptor agonists such as morphine and its various derivatives. The epidemic use, misuse and diversion of prescription opioids have highlighted just one of the adverse effects of mu opioid analgesics. Alternative approaches include novel opioids that target delta or kappa opioid receptors, or compounds that interact with two or more of the opioid receptors. Aims: Here we report the pharmacology of a newly synthesized bifunctional opioid agonist (RV-Jim-C3) derived from combined structures of fentanyl and enkephalin in rodents. RV-Jim-C3 has high affinity binding to both mu and delta opioid receptors. Main methods: Mice and rats were used to test RV-Jim-C3 in a tailflick test with and without opioid selective antagonist for antinociception. RV-Jim-C3 was tested for anti-inflammatory and antihypersensitivity effects in a model of formalin-induced flinching and spinal nerve ligation. To rule out motor impairment, rotarod was tested in rats. Key findings: RV-Jim-C3 demonstrates potent-efficacious activity in several in vivo pain models including inflammatory pain, antihyperalgesia and antiallodynic with no significant motor impairment. Significance: This is the first report of a fentanyl-based structure with delta and mu opioid receptor activity that exhibits outstanding antinociceptive efficacy in neuropathic pain, reducing the propensity of unwanted side effects driven by current therapies that are unifunctional mu opioid agonists. (C) 2013 Elsevier Inc. All rights reserved.	[Podolsky, Alexander T.; Sandweiss, Alexander; Hu, Jackie; Vanderah, Todd W.] Univ Arizona, Coll Med, Dept Pharmacol, Tucson, AZ 85724 USA; [Cain, Jim P.; Kumirov, Vlad K.; Lee, Yeon Sun; Hruby, Victor J.; Vardanyan, Ruben S.] Univ Arizona, Dept Chem, Tucson, AZ 85721 USA; [Bilsky, Edward J.; Vanderah, Todd W.] Univ New England, Coll Osteopath Med, Dept Biomed Sci, Biddeford, ME USA	Vanderah, TW (reprint author), POB 245050,1501 N Campbell Ave,LSN 647, Tucson, AZ 85724 USA.	vanderah@email.arizona.edu	Vardanyan, Ruben S/G-8173-2016	Bilsky, Edward/0000-0002-4664-5256	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [P01 DA006284, R01 DA013449]		Abbott FV, 1999, PAIN, V83, P561, DOI 10.1016/S0304-3959(99)00168-2; Ananthan S, 2012, J MED CHEM, V55, P8350, DOI 10.1021/jm300686p; [Anonymous], 2009, AC OV LIV INJ BACKGR; BASBAUM AI, 1991, PAIN, V47, P359, DOI 10.1016/0304-3959(91)90229-Q; Cavalli A, 2008, J MED CHEM, V51, P347, DOI 10.1021/jm7009364; Chen L, 2002, VET HUM TOXICOL, V44, P370; Codd EE, 2009, J PHARMACOL EXP THER, V329, P241, DOI 10.1124/jpet.108.146969; Decaillot FM, 2008, P NATL ACAD SCI USA, V105, P16045, DOI 10.1073/pnas.0804106105; DICKENSON AH, 1987, NEUROSCI LETT, V83, P207, DOI 10.1016/0304-3940(87)90242-4; Dietis N, 2009, BRIT J ANAESTH, V103, P38, DOI 10.1093/bja/aep129; Dubner R, 1999, PAIN, pS45; DUBUISSON D, 1977, PAIN, V4, P161, DOI 10.1016/0304-3959(77)90130-0; Due MR, 2012, J NEUROINFLAMM, V9, P1; Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9; Elliott AM, 1999, LANCET, V354, P1248, DOI 10.1016/S0140-6736(99)03057-3; Elmagbari NO, 2004, J PHARMACOL EXP THER, V311, P290, DOI 10.1124/jpet.104.069393; Franchi S, 2012, BRAIN BEHAV IMMUN, V26, P480, DOI 10.1016/j.bbi.2011.12.010; Gendron L, 2007, NEUROSCIENCE, V150, P807, DOI 10.1016/j.neuroscience.2007.09.060; Harvey JH, 2012, ACS MED CHEM LETT, V3, P640, DOI 10.1021/ml300083p; Holdridge SV, 2007, EUR J PAIN, V11, P685, DOI 10.1016/j.ejpain.2006.10.008; HUNSKAAR S, 1987, PAIN, V30, P103, DOI 10.1016/0304-3959(87)90088-1; Hutchinson MR, 2010, NEUROSCIENCE, V167, P880, DOI 10.1016/j.neuroscience.2010.02.011; HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4; Institute of Medicine Report From the Committee on Advancing Pain Research Care and Education, 2011, REP COMM ADV PAIN RE; JANSSEN PAJ, 1963, ARZNEIMITTEL-FORSCH, V13, P502; Jensen TS, 2009, LANCET, V374, P1218, DOI 10.1016/S0140-6736(09)61205-8; Kayser V, 2007, PAIN, V130, P235, DOI 10.1016/j.pain.2006.11.015; KIM SH, 1992, PAIN, V50, P355; Kotlinska JH, 2013, PEPTIDES, V39, P103, DOI 10.1016/j.peptides.2012.11.008; Largent-Milnes TM, 2008, J PAIN, V9, P700, DOI 10.1016/j.jpain.2008.03.005; Largent-Milnes TM, 2010, BRIT J PHARMACOL, V161, P968; Lee YS, 2011, J MED CHEM, V54, P382, DOI 10.1021/jm100982d; Li J, 2013, PHARMACOL THERAPEUT, V138, P441, DOI 10.1016/j.pharmthera.2013.03.003; Loram LC, 2012, BRAIN BEHAV IMMUN, V26, P1256, DOI 10.1016/j.bbi.2012.08.003; Lowery JJ, 2011, J PHARMACOL EXP THER, V336, P767, DOI 10.1124/jpet.110.172866; Lutz PE, 2012, TRENDS NEUROSCI, V12; Morinville A, 2004, PAIN, V109, P266, DOI 10.1016/j.pain.2004.01.011; Morphy R, 2005, J MED CHEM, V48, P6523, DOI 10.1021/jm058225d; Mosberg HI, 2013, J MED CHEM, V56, P2139, DOI 10.1021/jm400050y; MURRAY CW, 1988, J PHARMACOL METHOD, V20, P175, DOI 10.1016/0160-5402(88)90078-2; O'Connor AB, 2009, AM J MED, V122, pS22, DOI 10.1016/j.amjmed.2009.04.007; Petrillo P, 2003, J PHARMACOL EXP THER, V307, P1079, DOI 10.1124/jpet.103.055590; Puig S, 1996, PAIN, V64, P345, DOI 10.1016/0304-3959(95)00121-2; Rowbotham MC, 2003, NEW ENGL J MED, V348, P1223, DOI 10.1056/NEJMoa021420; Schiller PW, 2010, LIFE SCI, V86, P598, DOI 10.1016/j.lfs.2009.02.025; Turk DC, 2011, LANCET, V377, P2226, DOI 10.1016/S0140-6736(11)60402-9; Vanderah TW, 2008, EUR J PHARMACOL, V583, P62, DOI 10.1016/j.ejphar.2008.01.011; Vanderah TW, 2010, CLIN J PAIN, V26, pS10, DOI 10.1097/AJP.0b013e3181c49e3a; YAKSH TL, 1976, PHYSIOL BEHAV, V17, P1031, DOI 10.1016/0031-9384(76)90029-9; Yamamoto T, 2011, J MED CHEM, V54, P2029, DOI 10.1021/jm101023r; Zhao CS, 2003, EXP NEUROL, V184, P839, DOI 10.1016/S0014-4886(03)00346-7	51	26	26	0	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205	1879-0631		LIFE SCI	Life Sci.	DEC 18	2013	93	25-26					1010	1016		10.1016/j.lfs.2013.09.016			7	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	280ES	WOS:000329012100007	24084045	Green Accepted			2020-06-30	J	Shankaran, H; Adeshina, F; Teeguarden, JG				Shankaran, Harish; Adeshina, Femi; Teeguarden, Justin G.			Physiologically-based pharmacokinetic model for Fentanyl in support of the development of Provisional Advisory Levels	TOXICOLOGY AND APPLIED PHARMACOLOGY			English	Article						Computational modeling; Inhalation; Oral transmucosal; Anesthetic; Route-to-route extrapolation; Risk assessment	DRUG-INTERACTIONS; INTERINDIVIDUAL VARIABILITY; DOSE PROPORTIONALITY; HEALTHY-VOLUNTEERS; BIOMONITORING DATA; CANCER-PATIENTS; BUCCAL TABLETS; DOUBLE-BLIND; CHRONIC PAIN; BLOOD-FLOW	Provisional Advisory Levels (PALs) are tiered exposure limits for toxic chemicals in air and drinking water that are developed to assist in emergency responses. Physiologically-based pharmacokinetic (PBPK) modeling can support this process by enabling extrapolations across doses, and exposure routes, thereby addressing gaps in the available toxicity data. Here, we describe the development of a PBPK model for Fentanyl - a synthetic opioid used clinically for pain management - to support the establishment of PALS. Starting from an existing model for intravenous Fentanyl, we first optimized distribution and clearance parameters using several additional IV datasets. We then calibrated the model using pharmacokinetic data for various formulations, and determined the absorbed fraction, F, and time taken for the absorbed amount to reach 90% of its final value, t90. For aerosolized pulmonary Fentanyl, F = 1 and t90 < 1 min indicating complete and rapid absorption. The F value ranged from 0.35 to 0.74 for oral and various transmucosal routes. Oral Fentanyl was absorbed the slowest (t90 similar to 300 min); the absorption of intranasal Fentanyl was relatively rapid (t90 similar to 20-40 min); and the various oral transmucosal routes had intermediate absorption rates (t90 similar to 160-300 min). Based on these results, for inhalation exposures, we assumed that all of the Fentanyl inhaled from the air during each breath directly, and instantaneously enters the arterial circulation. We present model predictions of Fentanyl blood concentrations in oral and inhalation scenarios relevant for PAL development, and provide an analytical expression that can be used to extrapolate between oral and inhalation routes for the derivation of PALs. Published by Elsevier Inc.	[Shankaran, Harish] Pacific NW Natl Lab, Computat Biol & Bioinformat Grp, Richland, WA 99352 USA; [Adeshina, Femi] US EPA, Natl Homeland Secur Res Ctr, Washington, DC 20460 USA; [Teeguarden, Justin G.] Pacific NW Natl Lab, Syst Toxicol Grp, Richland, WA 99352 USA	Shankaran, H (reprint author), Pacific NW Natl Lab, Computat Biol & Bioinformat Grp, POB 999,MS J4-33, Richland, WA 99352 USA.	harish.shankaran@pnnl.gov		Teeguarden, Justin/0000-0003-3817-4391	US EPA under Battelle Prime Contract [EP-C-09-0006]; Battelle for the U.S. Department of EnergyUnited States Department of Energy (DOE) [DE-AC06-76RL01830]	This work was funded by the US EPA under Battelle Prime Contract EP-C-09-0006. Pacific Northwest National Laboratory is a multiprogram national laboratory operated by Battelle for the U.S. Department of Energy under Contract DE-AC06-76RL01830.	Abduljalil K, 2012, CLIN PHARMACOKINET, V51, P365, DOI 10.2165/11597440-000000000-00000; Adeshina F, 2009, INHAL TOXICOL, V21, P12, DOI 10.3109/08958370903202788; BEAVIS RE, 1991, ANAESTH INTENS CARE, V19, P28, DOI 10.1177/0310057X9101900105; BENTLEY JB, 1982, ANESTH ANALG, V61, P968; BJORKMAN S, 1993, J PHARMACOKINET BIOP, V21, P255, DOI 10.1007/BF01059779; BJORKMAN S, 1994, J PHARMACOKINET BIOP, V22, P381, DOI 10.1007/BF02353862; BJORKMAN S, 1990, ANESTHESIOLOGY, V72, P865, DOI 10.1097/00000542-199005000-00017; Bjorkman S, 1998, ANESTHESIOLOGY, V88, P657, DOI 10.1097/00000542-199803000-00016; Bjorkman S, 2003, J PHARMACOKINET PHAR, V30, P285, DOI 10.1023/A:1026194618660; Bois FY, 2010, TOXICOLOGY, V278, P256, DOI 10.1016/j.tox.2010.06.007; Bouzom F, 2012, BIOPHARM DRUG DISPOS, V33, P55, DOI 10.1002/bdd.1767; Brown RP, 1997, TOXICOL IND HEALTH, V13, P407, DOI 10.1177/074823379701300401; CARTWRIGHT P, 1983, ANESTH ANALG, V62, P966; [CDC National Center for Health Statistics], 2007, NAT HLTH NUTR EX SUR; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Clewell HJ, 2000, ENVIRON HEALTH PERSP, V108, P283, DOI 10.1289/ehp.00108s2283; Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; Darwish M, 2007, J CLIN PHARMACOL, V47, P56, DOI 10.1177/0091270006294129; Darwish M, 2006, CLIN PHARMACOKINET, V45, P843, DOI 10.2165/00003088-200645080-00006; Delic JI, 2000, REGUL TOXICOL PHARM, V32, P144, DOI 10.1006/rtph.2000.1419; Dumas EO, 2008, AAPS J, V10, P537, DOI 10.1208/s12248-008-9056-1; Fredheim OMS, 2007, EUR J PAIN, V11, P599, DOI 10.1016/j.ejpain.2006.09.006; FUNG DL, 1980, J CLIN PHARMACOL, V20, P652, DOI 10.1002/j.1552-4604.1980.tb01682.x; Glass D, 2009, INHAL TOXICOL, V21, P73, DOI 10.3109/08958370903202820; Goldhaber S, 2009, INHAL TOXICOL, V21, P17, DOI 10.3109/08958370903202804; GOLDSTEINDRESNER MC, 1991, ANESTHESIOLOGY, V74, P28, DOI 10.1097/00000542-199101000-00006; GOROMARU T, 1984, ANESTHESIOLOGY, V61, P73, DOI 10.1097/00000542-198461010-00013; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; HUDSON RJ, 1986, ANESTH ANALG, V65, P1369; Ibrahim AE, 2003, ANESTHESIOLOGY, V98, P853, DOI 10.1097/00000542-200304000-00011; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P738, DOI 10.1097/00000542-200409000-00023; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lee M, 2003, J PAIN SYMPTOM MANAG, V26, P743, DOI 10.1016/S0885-3924(03)00241-0; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; LIND GH, 1991, ANN EMERG MED, V20, P1117, DOI 10.1016/S0196-0644(05)81387-3; Marshall T, 2009, INHAL TOXICOL, V21, P56, DOI 10.3109/08958370903202812; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; MCQUAY HJ, 1979, BRIT J ANAESTH, V51, P543, DOI 10.1093/bja/51.6.543; Mildh LH, 2001, ANESTH ANALG, V93, P939, DOI 10.1097/00000539-200110000-00028; Miller FJ, 2000, TOXICOLOGY, V149, P21, DOI 10.1016/S0300-483X(00)00229-8; Modesti C, 2006, MINERVA ANESTESIOL, V72, P627; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Price PS, 2003, CRIT REV TOXICOL, V33, P469, DOI 10.1080/10408440390242324; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; SAWE J, 1983, BRIT J CLIN PHARMACO, V16, P85, DOI 10.1111/j.1365-2125.1983.tb02148.x; Schiermeier Q, 2002, NATURE, V420, P7, DOI 10.1038/420007a; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; SILVERSTEIN JH, 1993, ANESTH ANALG, V76, P618; SINGLETON MA, 1988, BRIT J ANAESTH, V60, P619, DOI 10.1093/bja/60.6.619; STANLEY TH, 1989, ANESTH ANALG, V69, P21; STOECKEL H, 1982, BRIT J ANAESTH, V54, P1087, DOI 10.1093/bja/54.10.1087; STREISAND JB, 1989, ANESTH ANALG, V69, P28; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Striebel H W, 1993, Schmerz, V7, P122, DOI 10.1007/BF02527870; Sweeney BP, 2006, ANAESTHESIA, V61, P159, DOI 10.1111/j.1365-2044.2005.04462.x; Tan YM, 2007, J EXPO SCI ENV EPID, V17, P591, DOI 10.1038/sj.jes.7500540; Tan YM, 2006, J TOXICOL ENV HEAL A, V69, P1727, DOI 10.1080/15287390600631367; Tanaka E, 1998, J CLIN PHARM THER, V23, P403, DOI 10.1046/j.1365-2710.1998.00086.x; TENBERGE WF, 1986, J HAZARD MATER, V13, P301, DOI 10.1016/0304-3894(86)85003-8; Thompson CM, 2009, J TOXICOL ENV HEAL B, V12, P1, DOI 10.1080/10937400802545060; Upton RN, 2012, J PHARMACOKINET PHAR, V39, P561, DOI 10.1007/s10928-012-9268-y; Waara-Wolleat KL, 2006, PAIN MED, V7, P251, DOI 10.1111/j.1526-4637.2006.00155.x; Wheeler M, 2004, ANESTH ANALG, V99, P1347, DOI 10.1213/01.ANE.0000132777.00967.A3; Wheeler M, 2002, PAEDIATR ANAESTH, V12, P594, DOI 10.1046/j.1460-9592.2002.00949.x; Yassen A, 2006, J PHARMACOL EXP THER, V319, P682, DOI 10.1124/jpet.106.107953; Yokley K, 2006, RISK ANAL, V26, P925, DOI 10.1111/j.1539-6924.2006.00789.x; Young RA, 2009, INHAL TOXICOL, V21, P1, DOI 10.3109/08958370903202747	73	18	18	2	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0041-008X	1096-0333		TOXICOL APPL PHARM	Toxicol. Appl. Pharmacol.	DEC 15	2013	273	3					464	476		10.1016/j.taap.2013.05.024			13	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	275XC	WOS:000328711700005	23732079				2020-06-30	J	Gram, M; Graversen, C; Nielsen, AK; Arendt-Nielsen, T; Morch, CD; Andresen, T; Drewes, AM				Gram, Mikkel; Graversen, Carina; Nielsen, Anders K.; Arendt-Nielsen, Thomas; Morch, Carsten D.; Andresen, Trine; Drewes, Asbjorn M.			A novel approach to pharmaco-EEG for investigating analgesics: assessment of spectral indices in single-sweep evoked brain potentials	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						analgesic; electroencephalographic; EP; evoked potentials; opioids; pharmaco-EEG; single-sweep	EXPERIMENTAL PAIN MODELS; TRANSDERMAL BUPRENORPHINE; HEALTHY-VOLUNTEERS; NONCANCER PAIN; OPIOIDS; EFFICACY; SAFETY; REPRODUCIBILITY; RESPONSIVENESS; OSCILLATIONS	AIMS To compare results from analysis of averaged and single-sweep evoked brain potentials (EPs) by visual inspection and spectral analysis in order to identify an objective measure for the analgesic effect of buprenorphine and fentanyl. METHODS Twenty-two healthy males were included in a randomized study to assess the changes in EPs after 110 sweeps of painful electrical stimulation to the median nerve following treatment with buprenorphine, fentanyl or placebo patches. Bone pressure, cutaneous heat and electrical pain ratings were assessed. EPs and pain assessments were obtained before drug administration, 24, 48, 72 and 144 h after beginning of treatment. Features from EPs were extracted by three different approaches: (i) visual inspection of amplitude and latency of the main peaks in the average EPs, (ii) spectral distribution of the average EPs and (iii) spectral distribution of the EPs from single-sweeps. RESULTS Visual inspection revealed no difference between active treatments and placebo (all P > 0.05). Spectral distribution of the averaged potentials showed a decrease in the beta (12-32 Hz) band for fentanyl (P = 0.036), which however did not correlate with pain ratings. Spectral distribution in the single-sweep EPs revealed significant increases in the theta, alpha and beta bands for buprenorphine (all P < 0.05) as well as theta band increase for fentanyl (P = 0.05). For buprenorphine, beta band activity correlated with bone pressure and cutaneous heat pain (both P = 0.04, r = 0.90). CONCLUSION In conclusion single-sweep spectral band analysis increases the information on the response of the brain to opioids and may be used to identify the response to analgesics.	[Gram, Mikkel; Graversen, Carina; Nielsen, Anders K.; Arendt-Nielsen, Thomas; Andresen, Trine; Drewes, Asbjorn M.] Aalborg Univ Hosp, Dept Gastroenterol & Hepatol, DK-9100 Aalborg, Denmark; [Gram, Mikkel; Arendt-Nielsen, Thomas; Morch, Carsten D.; Drewes, Asbjorn M.] Aalborg Univ, Dept Hlth Sci & Technol, Ctr Sensory Motor Interact SMI, Aalborg, Denmark; [Graversen, Carina] Aalborg Univ Hosp, Dept Radiol, DK-9100 Aalborg, Denmark; [Graversen, Carina] Univ Gottingen, Univ Med Ctr Gottingen, Bernstein Ctr Computat Neurosci, Dept Neurorehabil Engn, D-37073 Gottingen, Germany	Drewes, AM (reprint author), Aalborg Univ Hosp, Dept Gastroenterol & Hepatol, Molleparkvej 4, DK-9100 Aalborg, Denmark.	amd@mech-sense.com	Morch, Carsten Dahl/J-5639-2019	Morch, Carsten Dahl/0000-0001-6693-2028; Drewes, Asbjorn/0000-0001-7465-964X	Danish Council for Strategic Research, The Danish Agency for Science, Technology and Innovation	The study was supported by Danish Council for Strategic Research, The Danish Agency for Science, Technology and Innovation.	Akin M, 2002, J Med Syst, V26, P241, DOI 10.1023/A:1015075101937; Andresen T, 2011, BRIT J PHARMACOL, V164, P934, DOI 10.1111/j.1476-5381.2010.01180.x; Andresen T, 2011, BASIC CLIN PHARMACOL, V108, P274, DOI 10.1111/j.1742-7843.2010.00649.x; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; BROMM B, 1986, PAIN, V25, P245, DOI 10.1016/0304-3959(86)90100-4; DAWSON GD, 1951, J PHYSL, V115, P2; Domnick Claudia, 2009, J Pain Res, V2, P49; Finocchietti S, 2012, EUR J PAIN, V16, P534, DOI 10.1016/j.ejpain.2011.08.001; Gilbert DL, 2003, NEUROLOGY, V60, P564, DOI 10.1212/01.WNL.0000044152.79316.27; Graversen C, 2012, IEEE ENG MED BIO, P5242, DOI 10.1109/EMBC.2012.6347176; Graversen C, 2012, BRIT J CLIN PHARMACO, V73, P363, DOI 10.1111/j.1365-2125.2011.04104.x; Graversen C, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/5/056014; Greenwald MK, 2005, NEUROPSYCHOPHARMACOL, V30, P212, DOI 10.1038/sj.npp.1300596; Heldestad V, 2010, CLIN NEUROPHYSIOL, V121, P1878, DOI 10.1016/j.clinph.2010.03.055; HUBBARD BB, 1996, WORLD ACCORDING WAVE; Iannetti GD, 2008, J NEUROPHYSIOL, V100, P815, DOI 10.1152/jn.00097.2008; Kalso E, 2004, PAIN, V112, P372, DOI 10.1016/j.pain.2004.09.019; Lecyby R, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-5; Leiser SC, 2011, BIOCHEM PHARMACOL, V81, P1408, DOI 10.1016/j.bcp.2010.10.002; LIBERATI D, 1992, IEEE T BIO-MED ENG, V39, P943, DOI 10.1109/10.256428; Lotsch J, 1995, BRIT J CLIN PHARMACO, V40, P545, DOI 10.1111/j.1365-2125.1995.tb05799.x; Luck S. J., 2004, EVENT RELATED POTENT; Maier C, 2002, PAIN, V97, P223, DOI 10.1016/S0304-3959(02)00020-9; Olesen AE, 2012, PHARMACOL REV, V64, P722, DOI 10.1124/pr.111.005447; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Picton TW, 2000, PSYCHOPHYSIOLOGY, V37, P127, DOI 10.1111/1469-8986.3720127; PRICE DD, 1983, PAIN, V17, P45, DOI 10.1016/0304-3959(83)90126-4; Sanchez-Simon FM, 2012, NEUROSCIENCE, V200, P237, DOI 10.1016/j.neuroscience.2011.10.026; Sanei S, 2007, EEG SIGNAL PROCESSIN; Schmidt GN, 2007, ANESTHESIOLOGY, V106, P707, DOI 10.1097/01.anes.0000264774.09910.c6; Sittl R, 2005, CLIN THER, V27, P1022, DOI 10.1016/j.clinthera.2005.06.024; Staahl C, 2004, BASIC CLIN PHARMACOL, V95, P97; Staahl C, 2011, BASIC CLIN PHARMACOL, V109, P321, DOI 10.1111/j.1742-7843.2011.00727.x; Staahl C, 2009, BRIT J CLIN PHARMACO, V68, P149, DOI 10.1111/j.1365-2125.2009.03456.x; Storti SF, 2010, BRAIN TOPOGR, V23, P46, DOI 10.1007/s10548-009-0117-2; Tremblay J, 2010, METABOLISM, V59, pS5, DOI 10.1016/j.metabol.2010.07.015; van der Post JP, 2005, BRIT J CLIN PHARMACO, V60, P128, DOI 10.1111/j.1365-2125.2005.02396.x; Yordanova J, 1998, PSYCHOPHYSIOLOGY, V35, P116, DOI 10.1111/1469-8986.3510116; Zhang ZG, 2012, J NEUROSCI, V32, P7429, DOI 10.1523/JNEUROSCI.5877-11.2012	39	18	18	0	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0306-5251	1365-2125		BRIT J CLIN PHARMACO	Br. J. Clin. Pharmacol.	DEC	2013	76	6					951	963		10.1111/bcp.12120			13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	296IQ	WOS:000330178900013	23521205	Green Published			2020-06-30	J	Khanykin, B; Siddiqi, R; Jensen, PF; Bigler, DR; Atroshchenko, GV				Khanykin, Boris; Siddiqi, Rizwan; Jensen, Per F.; Bigler, Dennis R.; Atroshchenko, Gennady V.			Comparison of Remifentanil and Low-Dose Fentanyl for Fast-Track Cardiac Anesthesia: A Prospective Randomized Study	HEART SURGERY FORUM			English	Article							STRESS-RESPONSE; SURGERY; INFUSION; TRIAL	Background: Different anesthetic techniques have been used for fast tracking in cardiac anesthesia. Remifentanil, with its unique pharmacokinetic profile, could be an ideal drug for fast tracking. Possible limitations of remifentanil are rapid onset of postoperative pain after discontinuation of the drug infusion, which may increase the risk of an ischemic event. We conducted this randomized study to compare the efficacy of remifentanil versus low doses of fentanyl in fast-track cardiac anesthesia. It has been hypothesized that remifentanil would provide a safe anesthesia with no impact on myocardial function and with positive effects on extubation time and mobilization. Methods: We compared the postoperative course of patients, the remifentanil group (RG) and the low-dose fentanyl group (LDFG), in whom remifentanil and low-dose fentanyl, respectively, were used for fast-track cardiac anesthesia. The study was designed as a prospective randomized study. The primary outcomes were changes in the cardiac index and creatine kinase MB fraction (CKMB), extubation times, mobilization times, and lengths of stay in the intensive care unit (ICU) and the hospital. Frequency of myocardial infarction (MI), reoperations due to excessive bleeding, renal impairment, and cerebral complications were registered as well. Results: Seventy-one patients were enrolled in the study, and 7 were excluded due to difficult airway, bleeding, and technical difficulties. The RG comprised 33 patients and the LDFG comprised of 31 patients. There were no differences between the groups in terms of age, Euroscore, types of surgery, extracorporeal circulation, and aortic cross-clamp time. We did not find significant difference in cardiac index, CKMB, extubation times, mobilization times, length of stay in the ICU and in the hospital between the groups. Postoperative complications such as MI, rates of reoperations, renal and cerebral complications and incidence of atrial fibrillation did not show any significant differences. Conclusions: Remifentanil fast-track anesthesia for cardiac patients has no negative impact on myocardial function. Both remifentanil and low-dose fentanyl are equally effective and safe for fast-track cardiac anesthesia. The study did not highlight any statistical superiority of remifentanil anesthesia over low-dose fentanyl anesthesia.	[Khanykin, Boris; Siddiqi, Rizwan; Jensen, Per F.; Bigler, Dennis R.] Copenhagen Univ Hosp, Ctr Heart, Dept Thorac Anesthesiol, Rigshosp, Copenhagen, Denmark; [Atroshchenko, Gennady V.] Copenhagen Univ Hosp, Ctr Heart, Dept Cardiothorac Surg, Rigshosp, Copenhagen, Denmark	Khanykin, B (reprint author), Rigshosp, Ctr Heart, Dept Thorac Anesthesiol, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark.	bkhanykin@dadlnet.dk					BELL J, 1994, BRIT J ANAESTH, V73, P162, DOI 10.1093/bja/73.2.162; Burkhart CS, 2010, J CARDIOTHOR VASC AN, V24, P555, DOI 10.1053/j.jvca.2010.01.003; Komatsu R, 2007, ANAESTHESIA, V62, P1266, DOI 10.1111/j.1365-2044.2007.05221.x; Lison S, 2007, J CARDIOTHOR VASC AN, V21, P35, DOI 10.1053/j.jvca.2006.03.011; Myles PS, 2002, ANESTH ANALG, V95, P805, DOI 10.1097/00000539-200210000-00004; Panzer O, 2009, CRIT CARE CLIN, V25, P451, DOI 10.1016/j.ccc.2009.04.004; Sullivan BL, 2012, SEMIN CARDIOTHORAC V, V16, P187, DOI 10.1177/1089253212452343; Svircevic V, 2009, ANESTH ANALG, V108, P727, DOI 10.1213/ane.0b013e318193c423; von Dossow V, 2008, J INT MED RES, V36, P1235, DOI 10.1177/147323000803600610; Weale NK, 2004, BRIT J ANAESTH, V92, P187, DOI 10.1093/bja/aeh038; Winterhalter M, 2008, EUR J ANAESTH, V25, P326, DOI 10.1017/S0265021507003043; Zhu F, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003587.pub2	12	7	8	0	1	FORUM MULTIMEDIA PUBLISHING, LLC	CHARLOTTESVILLE	375 GREENBRIER DR, CHARLOTTESVILLE, VA 22901 USA	1098-3511	1522-6662		HEART SURG FORUM	Heart Surg. Forum	DEC	2013	16	6					E324	E328		10.1532/HSF98.2013229			5	Cardiac & Cardiovascular Systems; Surgery	Cardiovascular System & Cardiology; Surgery	281PF	WOS:000329112800006	24370801				2020-06-30	J	Perelman, M; Knight, A				Perelman, Michael; Knight, Alastair			A pharmacokinetic assessment of an alternate titration strategy for fentanyl pectin nasal spray	INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS			English	Article						cancer pain; dose titration; fentanyl; FPNS; pharmacokinetics	ACCEPTABILITY; TOLERABILITY; EFFICACY	Objective: Fentanyl pectin nasal spray (FPNS) is approved for management of breakthrough pain in cancer. It is available in 100 and 400 mu g strength products which allow for doses of 100 - 800 mu g (1 or 2 sprays). Existing titration strategies require a transition from the 100 mu g product to the 400 mu g product when increasing the dose from 200 to 400 mu g. This study assessed the pharmacokinetic (PK) profile of FPNS administered as 4 sprays of 100 mu g as an alternate titration strategy. Methods: In this 3-way, crossover study, healthy subjects aged 18 - 65 years were randomized to receive each of 3 dosages of FPNS (4 x 100 mu g(,) 2 x 100 mu g, and 1 x 400 mu g). PK samples were collected over 24 hours. Results: Of 22 subjects randomized, 20 were included in the PK analysis. Administration of both 400 mu g regimens (4 x 100 mu g and 1 x 400 mu g) provided greater systemic fentanyl exposure compared with the 200 mu g dose (C-max: 1,748 and 1,485 pg/ml vs. 1,051 pg/ml; AUC(0-1h): 1,012 and 944 pgxh/ml vs. 665 pgxh/ml; and t(max): 0.25 hours and 0.50 hours vs. 0.25 hours); fentanyl exposure after 4 x 100 mu g and 1 x 400 mu g regimens was similar. Adverse events (AEs) were all mild or moderate in intensity; most common AEs were nausea (50%) and headache (23%). AE frequency was similar across treatments without reports of nasal effects. Conclusions: Given that systemic fentanyl exposure from FPNS administered as 4 x 100 mu g is similar to that from FPNS as 1 x 400 mu g, the 4 x 100 mu g regimen provides an alternate titration strategy for patients needing more than 200 mu g. This alternate strategy will facilitate a patient's ability to achieve an optimized FPNS regimen and reduce opioid wastage.	[Perelman, Michael] Archimedes Dev Ltd, Nottingham, England; [Knight, Alastair] Evicom Ltd, Teddington, Middx, England	Perelman, M (reprint author), Michael Perelman Archimedes Dev Ltd, Albert Einstein Ctr, Nottingham Sci & Technol Pk,Univ Blvd, Nottingham NG7 2TN, England.	michaelperelman@archimedespharma.com			Archimedes Development Ltd	Medical writing support and editorial assistance were provided by Carol Berry, Sharon Suntag, and Julie Gerke of Quintiles Communications, and supported by Archimedes Development Ltd. The authors wish to acknowledge ICON Development Solutions for study implementation and analysis of data.	[Anonymous], 2012, LAZ PACK INS; [Anonymous], 2012, PECFENT SUMM PROD CH; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Fisher A, 2010, INT J CLIN PHARM TH, V48, P138; Lor M, 2005, CLIN PHARMACOL THER, V77, pP76, DOI 10.1016/j.clpt.2004.12.181; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Portenoy Russell K, 2010, J Opioid Manag, V6, P319; Radbruch L, 2012, SUPPORT CARE CANCER, V20, P565, DOI 10.1007/s00520-011-1124-x; Taylor Donald, 2010, J Support Oncol, V8, P184; The European Agency for the Evaluation of Me-dicinal Products, 2002, CPMPICH13595; Watts P, 2009, EXPERT OPIN DRUG DEL, V6, P543, DOI [10.1517/17425240902939135, 10.1517/17425240902939135 ]	13	0	0	0	4	DUSTRI-VERLAG DR KARL FEISTLE	DEISENHOFEN-MUENCHEN	BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY	0946-1965			INT J CLIN PHARM TH	Int. J. Clin. Pharmacol. Ther.	DEC	2013	51	12					942	947		10.5414/CP201913			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	278UK	WOS:000328915200004	24120713				2020-06-30	J	Ziesenitz, VC; van den Anker, JN				Ziesenitz, Victoria C.; van den Anker, John N.			Impact of CYP3A and ABCB1 polymorphisms on the pharmacokinetics and pharmacodynamics of fentanyl	INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS			English	Letter							GENETIC POLYMORPHISMS; MIDAZOLAM		[Ziesenitz, Victoria C.; van den Anker, John N.] Childrens Natl Med Ctr, Div Pediat Clin Pharmacol, Washington, DC 20010 USA; [Ziesenitz, Victoria C.] Univ Heidelberg Hosp, Dept Clin Pharmacol & Pharmacoepidemiol, D-69120 Heidelberg, Germany	Ziesenitz, VC (reprint author), Univ Heidelberg Hosp, Dept Clin Pharmacol & Pharmacoepidemiol, Neuenheimer Feld 410, D-69120 Heidelberg, Germany.	Victoria.Ziesenitz@med.uni-heidelberg.de	Ziesenitz, Victoria/J-2945-2019	Ziesenitz, Victoria/0000-0003-2836-4212			Eap CB, 2004, EUR J CLIN PHARMACOL, V60, P231, DOI 10.1007/s00228-004-0767-7; Kim KM, 2013, INT J CLIN PHARM TH, V51, P383, DOI 10.5414/CP201824; Lee SJ, 2007, DRUG METAB DISPOS, V35, P2095, DOI 10.1124/dmd.107.016733; Lepper ER, 2005, CLIN CANCER RES, V11, P7398, DOI 10.1158/1078-0432.CCR-05-0520; Park HJ, 2007, CLIN PHARMACOL THER, V81, P539, DOI 10.1038/sj.clpt.6100046; Takashina Y, 2012, DRUG METAB PHARMACOK, V27, P414, DOI 10.2133/dmpk.DMPK-11-RG-134; Tan PCS, 2012, J CLIN PHARM THER, V37, P100, DOI 10.1111/j.1365-2710.2010.01232.x	7	2	2	0	9	DUSTRI-VERLAG DR KARL FEISTLE	DEISENHOFEN-MUENCHEN	BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY	0946-1965			INT J CLIN PHARM TH	Int. J. Clin. Pharmacol. Ther.	DEC	2013	51	12					991	992		10.5414/CP201987			2	Pharmacology & Pharmacy	Pharmacology & Pharmacy	278UK	WOS:000328915200012	24161162				2020-06-30	J	Kasagi, Y; Hayashida, M; Sugasawa, Y; Kikuchi, I; Yamaguchi, K; Okutani, R; Takeda, S; Inada, E				Kasagi, Yoshihiro; Hayashida, Masakazu; Sugasawa, Yusuke; Kikuchi, Iwaho; Yamaguchi, Keisuke; Okutani, Ryu; Takeda, Satoru; Inada, Eiichi			Antiemetic effect of naloxone in combination with dexamethasone and droperidol in patients undergoing laparoscopic gynecological surgery	JOURNAL OF ANESTHESIA			English	Article						Laparoscopic surgery; Postoperative nausea and vomiting; Dexamethasone; Droperidol; Naloxone	POSTOPERATIVE NAUSEA; CONTROLLED ANALGESIA; PREVENTION; MORPHINE; MANAGEMENT	Purpose We examined the effects of dexamethasone, droperidol, naloxone, and a combination of these three agents on postoperative nausea and vomiting (PONV) in female patients. Methods In this randomized, controlled study, 120 female patients with ASA PS I or II undergoing laparoscopic gynecological surgery were randomly allocated into four groups. Patients received dexamethasone 8 mg (Dx group) or droperidol 1 mg (Dr group) before induction of general anesthesia. Anesthesia was induced and maintained with propofol and remifentanil. Postoperative analgesia was provided by intravenous patient-controlled analgesia using a disposable infusion pump filled with fentanyl 20 mu g/kg alone (Dx group), fentanyl 20 mu g/kg with droperidol 2 mg (Dr group), fentanyl 20 mu g/kg with naloxone 0.1 mg (Nx group), or fentanyl 20 mu g/kg with droperidol 2 mg and naloxone 0.1 mg (Cm group) in a total volume of 80 ml, with a constant infusion rate of 4 ml/h and a bolus dose 2 ml with a 30-min lockout time. Results The number of patients who developed PONV and required a rescue antiemetic was significantly less in the Cm group than in the Nx group (p < 0.001 for all). The incidence of PONV was 43, 43, 70, and 17 % in the Dx, Dr, Nx, and Cm groups, respectively. Conclusion A combination of naloxone, droperidol, and dexamethasone was effective for preventing PONV in patients receiving fentanyl for postoperative analgesia after laparoscopic gynecological surgery, although further investigations are required to examine the effect of adding naloxone to other antiemetics.	[Kasagi, Yoshihiro; Hayashida, Masakazu; Sugasawa, Yusuke; Yamaguchi, Keisuke; Inada, Eiichi] Juntendo Univ, Fac Med, Dept Anesthesiol & Pain Med, Bunkyo Ku, Tokyo 1138421, Japan; [Kasagi, Yoshihiro; Okutani, Ryu] Osaka City Gen Hosp, Dept Anesthesiol, Miyakojima Ku, Osaka 5340021, Japan; [Kasagi, Yoshihiro; Okutani, Ryu] Childrens Hosp, Miyakojima Ku, Osaka 5340021, Japan; [Kikuchi, Iwaho; Takeda, Satoru] Juntendo Univ, Fac Med, Dept Obstet & Gynecol, Bunkyo Ku, Tokyo 1138421, Japan	Kasagi, Y (reprint author), Juntendo Univ, Fac Med, Dept Anesthesiol & Pain Med, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	yoshihirokasagi@hotmail.com		Takeda, Satoru/0000-0001-9547-1435			Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Apfel CC, 2004, NEW ENGL J MED, V350, P2441, DOI 10.1056/NEJMoa032196; Cepeda MS, 2004, PAIN, V107, P41, DOI 10.1016/j.pain.2003.09.011; Crain SM, 2000, PAIN, V84, P121, DOI 10.1016/S0304-3959(99)00223-7; Eriksson H, 1996, ANESTH ANALG, V82, P533, DOI 10.1097/00000539-199603000-00019; Gan TJ, 1997, ANESTHESIOLOGY, V87, P1075, DOI 10.1097/00000542-199711000-00011; Gan TJ, 2007, ANESTH ANALG, V105, P1615, DOI 10.1213/01.ane.0000295230.55439.f4; Habib AS, 2004, ANESTH ANALG, V99, P77, DOI 10.1213/01.ANE.0000120161.30788.04; Halvorsen P, 2003, ANESTH ANALG, V96, P1578, DOI 10.1213/01.ANE.0000063922.90966.3A; Klahsen AJ, 1996, CAN J ANAESTH, V43, P1100, DOI 10.1007/BF03011835; Koivusalo AM, 1997, SURG ENDOSC-ULTRAS, V11, P42, DOI 10.1007/s004649900292; Lachaine J, 2006, PHARMACOECONOMICS, V24, P955, DOI 10.2165/00019053-200624100-00004; Murphy GS, 2011, J CARDIOTHOR VASC AN, V25, P950, DOI 10.1053/j.jvca.2011.03.002; Song D, 2002, BRIT J ANAESTH, V88, P819, DOI 10.1093/bja/88.6.819; Sumikura Hiroyuki, 2004, J Anesth, V18, P262, DOI 10.1007/s00540-004-0265-1; Thangaswamy CR, 2010, J ANESTH, V24, P24, DOI 10.1007/s00540-009-0830-8; Tramer MR, 1999, ANESTH ANALG, V88, P1354, DOI 10.1097/00000539-199906000-00030; Wang JJ, 2000, BRIT J ANAESTH, V84, P459	18	2	2	1	3	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	DEC	2013	27	6					879	884		10.1007/s00540-013-1630-8			6	Anesthesiology	Anesthesiology	270VU	WOS:000328348100013	23666451				2020-06-30	J	De Oliveira, GS; Fitzgerald, PC; Ahmad, S; Marcus, RJ; McCarthy, RJ				De Oliveira, Gildasio S., Jr.; Fitzgerald, Paul C.; Ahmad, Shireen; Marcus, R. Jay; McCarthy, Robert J.			Desflurane/fentanyl compared with sevoflurane/fentanyl on awakening and quality of recovery in outpatient surgery using a Laryngeal Mask Airway: a randomized, double-blinded controlled trial	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Awakening from anesthesia; Desflurane; Recovery from surgery; Sevoflurane	POSTOPERATIVE QUALITY; GENERAL-ANESTHESIA; METAANALYSIS; ISOFLURANE; MORBIDITY; EMERGENCE; ANALGESIA; DISCHARGE; COUGH	Study Objective: To compare time to awakening and upper airway morbidity between desflurane and sevoflurane using a Laryngeal Mask Airway (LMA) and a balanced anesthetic regimen inclusive of opioids. Design: Randomized, double-blinded, placebo-controlled clinical trial. Setting: Ambulatory surgery unit of a university hospital. Patients: 80 subjects receiving general anesthesia for outpatient gynecological surgery using a LMA. Interventions: Desflurane/fentanyl or sevoflurane/fentanyl were used for anesthetic maintenance. Measurements: Patients were randomly assigned to receive desflurane or sevoflurane. The primary outcome was time to awakening as determined by an observer who was blinded to study group allocation. Secondary outcomes included the frequency of sore throat, cough, and pain perioperatively and at 2 and 24 hours postoperatively. Quality of recovery (QoR; via QoR-40 questionnaire) at 24 hours also was determined. Main Results: The median (IQR) time to eye opening following desflurane was 6.8 (5.0 - 9.8) minutes versus 11.8 (8.8 - 14.6) minutes following sevoflurane (P < 0.001), or a difference of 5.0(99% CI 2.3 - 6.8) minutes. The median difference in response to verbal commands was 5.3 (99% CI 2.4 - 7.1) minutes. The frequency of cough, laryngospasm, sore throat, and hoarseness did not differ between groups. Quality of recovery at 24 hours was better in the desflurane group: difference in medians 6(99% CI - 12; P = 0.003). Conclusions: Desflurane retains faster awakening properties than does sevoflurane when used in combination with fentanyl as part of anesthetic maintenance in outpatient surgery with a LMA. The balanced anesthetic maintenance regimen seems to reduce the potential airway reactivity properties of desflurane. (C) 2013 Elsevier Inc. All rights reserved.	[De Oliveira, Gildasio S., Jr.; Fitzgerald, Paul C.; Ahmad, Shireen; Marcus, R. Jay; McCarthy, Robert J.] Northwestern Univ, Dept Anesthesiol, Feinberg Sch Med, Chicago, IL 60611 USA	De Oliveira, GS (reprint author), Northwestern Univ, Dept Anesthesiol, Feinberg Sch Med, 251 E Huron St,Feinberg 5-704, Chicago, IL 60611 USA.	g-jr@northwestern.edu	McCarthy, Robert J/J-9113-2018	McCarthy, Robert J/0000-0002-0966-5311	Baxter Healthcare Corp., Deerfield, IL, USA	Supported by a grant from Baxter Healthcare Corp., Deerfield, IL, USA.	Agoliati A, 2010, ANESTH ANALG, V110, P1433, DOI 10.1213/ANE.0b013e3181d58052; Awad IT, 2006, CAN J ANAESTH, V53, P858, DOI 10.1007/BF03022828; Ayoub CM, 1998, ANESTH ANALG, V87, P714, DOI 10.1097/00000539-199809000-00042; Brimacombe J, 2000, ANAESTHESIA, V55, P338, DOI 10.1046/j.1365-2044.2000.01285.x; De Oliveira GS, 2011, BRIT J ANAESTH, V107, P362, DOI 10.1093/bja/aer156; de Oliveira GS, 2013, J CLIN ANESTH, V25, P452, DOI 10.1016/j.jclinane.2013.03.012; De Oliveira GS, 2011, ANESTH ANALG, V113, P1218, DOI 10.1213/ANE.0b013e3182303a1a; Fassoulaki A, 2008, ANESTH ANALG, V107, P1715, DOI 10.1213/ane.0b013e318182d84e; Flood P, 2010, ANESTH ANALG, V111, P86, DOI 10.1213/ANE.0b013e3181dde32e; Garcia AG, 2003, BRIT DENT J, V194, P453, DOI 10.1038/sj.bdj.4810032; Katz J, 2011, ANESTH ANALG, V113, P1242, DOI 10.1213/ANE.0b013e31822c9a59; Ledolter J, 2011, ANESTH ANALG, V113, P888, DOI 10.1213/ANE.0b013e318227518f; Macintyre PE, 2001, ACUTE PAIN MANAGEMEN, P15; Magni G, 2009, ANESTH ANALG, V109, P567, DOI 10.1213/ane.0b013e3181ac1265; Mahmoud NA, 2001, ANAESTHESIA, V56, P171, DOI 10.1046/j.1365-2044.2001.01528.x; Mckay RE, 2006, ANESTH ANALG, V103, P1147, DOI 10.1213/01.ane.0000237293.39466.65; Myles PS, 2000, BRIT J ANAESTH, V84, P11; Peng PWH, 2010, BRIT J ANAESTH, V105, P155, DOI 10.1093/bja/aeq116; Saros GB, 2006, ACTA ANAESTH SCAND, V50, P549, DOI 10.1111/j.1399-6576.2006.001022.x; Schwarz SKW, 2004, CAN J ANAESTH, V51, P892, DOI 10.1007/BF03018886; Sivolella S, 2010, Minerva Stomatol, V59, P611; Vallejo MC, 2007, J CLIN ANESTH, V19, P3, DOI 10.1016/j.jclinane.2006.04.003; White PF, 2009, ANESTH ANALG, V109, P387, DOI 10.1213/ane.0b013e3181adc21a; White PF, 1999, ANESTH ANALG, V88, P1069, DOI 10.1097/00000539-199905000-00018; Yoo YC, 2011, ACTA ANAESTH SCAND, V55, P1215, DOI 10.1111/j.1399-6576.2011.02529.x	25	12	12	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	DEC	2013	25	8					651	658		10.1016/j.jclinane.2013.07.006			8	Anesthesiology	Anesthesiology	280FC	WOS:000329013100009	24095885				2020-06-30	J	Yang, WC; Geng, YJ; Liu, Y; Li, AM; Liu, J; Xing, JC; Li, WZ				Yang, Wanchao; Geng, Yingjie; Liu, Yan; Li, Aimin; Liu, Jing; Xing, Jingchun; Li, Wenzhi			Comparison of Effects of Thoracic Epidural and Intravenous Administration of Lidocaine on Target-Controlled Infusion of Propofol and Tracheal Intubation Response During Induction of Anesthesia	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						thoracic epidural blockade; lidocaine; propofol; catecholamines; target-controlled infusion	BISPECTRAL INDEX; LARYNGOSCOPY; DECREASES	Objective: To compare the effects of thoracic epidural anesthesia (TEA) and intravenous (IV) lidocaine on the effect-site concentration (C.) of propofol target-controlled infusion (TCI) and the intubation-induced stress responses during general IV anesthesia induction. Design: A prospective, randomized trial. Setting: A university hospital. Participants: Sixty patients undergoing elective surgery for thoracotomies. Interventions: Patients scheduled for thoracotomies were divided into 3 groups as group TEA, group IV, and control group. Group TEA or group IV received the same doses but not the same concentration of lidocaine via TEA (0.15 mL/kg of 1.35% lidocaine) or IV (2 mg/kg of 2% lidocaine), respectively, 15 minutes before induction of anesthesia, and the control group received the same volume of 0.9% normal saline epidurally. Measurements and Main Results: Heart rate and mean arterial pressure as well as the time to loss of consciousness (LOC), total doses of propofol TCI, and C-e at LOC were recorded during anesthesia induction. Plasma lidocaine concentration detected was 1.9 (0.3) mu g/mL in the IV group and 1.0 (0.3) mu g/mL in the TEA group (p < 0.001). The time to LOC, total doses of propofol TCI, and C. at LOC were significantly lower in the IV group than in the TEA group and the control group (p < 0.001). Both lidocaine groups showed significant decreases in the elevation of mean arterial pressure and heart rate and plasma concentrations of epinephrine and norepinephrine induced by intubation compared to the control group (p < 0.05). Conclusion: Lidocaine administered via both TEA and IV decreased the induction doses of propofol and suppressed cardiovascular and stress responses to tracheal intubation. Administration of 2 mg/kg of 2% lidocaine IV was better, with no side effects of lidocaine toxicity. (C) 2013 Elsevier Inc. All rights reserved.	[Yang, Wanchao; Geng, Yingjie; Liu, Yan; Li, Aimin; Liu, Jing; Xing, Jingchun; Li, Wenzhi] Harbin Med Univ, Affiliated Hosp 2, Dept Anesthesiol, Anesthesiol Key Lab, Harbin 150086, Peoples R China; [Yang, Wanchao; Geng, Yingjie; Liu, Yan; Li, Aimin; Liu, Jing; Xing, Jingchun; Li, Wenzhi] Educ Dept Heilongjiang Prov, Harbin, Peoples R China	Li, WZ (reprint author), Harbin Med Univ, Affiliated Hosp 2, Dept Anesthesiol, XueFu Rd 246, Harbin 150086, Peoples R China.	Wenzhili9@126.com	garcia, waynice np/K-3914-2015		Department of Anaesthesiology of Second Affiliated Hospital of Harbin Medical University	Assistance with the study: This work was supported by the Department of Anaesthesiology of Second Affiliated Hospital of Harbin Medical University.	Baik HJ, 2009, EUR J ANAESTH, V26, P377, DOI 10.1097/EJA.0b013e32831dcd4d; BenShlomo I, 1997, BRIT J ANAESTH, V78, P375; DENLINGE.JK, 1974, ANESTHESIOLOGY, V41, P409, DOI 10.1097/00000542-197410000-00024; DRAYER DE, 1983, CLIN PHARMACOL THER, V34, P14, DOI 10.1038/clpt.1983.122; Gottschalk A, 2012, J CLIN ANESTH, V24, P121, DOI 10.1016/j.jclinane.2011.06.018; Hans GA, 2010, BRIT J ANAESTH, V105, P471, DOI 10.1093/bja/aeq189; HARA M, 1993, ANESTHESIOLOGY, V79, P781, DOI 10.1097/00000542-199310000-00021; Hodgson PS, 1999, ANESTHESIOLOGY, V91, P1687, DOI 10.1097/00000542-199912000-00021; Hodgson PS, 2001, ANESTHESIOLOGY, V94, P799, DOI 10.1097/00000542-200105000-00018; Kelsaka E, 2011, MED PRIN PRACT, V20, P71, DOI 10.1159/000319761; LICKER M, 1995, J CLIN ANESTH, V7, P281, DOI 10.1016/0952-8180(95)00025-D; Nakatani T, 2005, ANAESTHESIA, V60, P530, DOI 10.1111/j.1365-2044.2005.04182.x; Nordmark J, 1997, NEUROREPORT, V8, P465, DOI 10.1097/00001756-199701200-00018; Senturk M, 2008, BRIT J ANAESTH, V101, P255, DOI 10.1093/bja/aen160; Senturk M, 2002, BRIT J ANAESTH, V89, P849, DOI 10.1093/bja/aef287; SHRIBMAN AJ, 1987, BRIT J ANAESTH, V59, P295, DOI 10.1093/bja/59.3.295; WATTWIL M, 1987, ACTA ANAESTH SCAND, V31, P529, DOI 10.1111/j.1399-6576.1987.tb02616.x	17	6	11	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	DEC	2013	27	6					1295	1300		10.1053/j.jvca.2012.12.020			6	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	268OZ	WOS:000328181700035	23706644				2020-06-30	J	Kodaka, M; Tsukakoshi, M; Miyao, H; Tsuzaki, K; Ichikawa, J; Komori, M				Kodaka, Mitsuharu; Tsukakoshi, Mikiko; Miyao, Hideki; Tsuzaki, Koichi; Ichikawa, Junko; Komori, Makiko			The fentanyl concentration required for immobility under propofol anesthesia is reduced by pre-treatment with flurbiprofen axetil	CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							MORPHINE; CONSCIOUSNESS; PERFORMANCE; REDUCTION; INFUSION; GENDER	We hypothesized that nonsteroidal anti-inflammatory drugs decrease the plasma fentanyl concentration required to produce immobility in 50% of patients in response to skin incision (Cp50(incision)) compared with placebo under target-controlled infusion (TCI) propofol anesthesia. Sixty-two unpremedicated patients scheduled to undergo gynecologic laparoscopy were randomly assigned to receive placebo (control group) or flurbiprofen axetil 1 mg center dot kg(-1) (flurbiprofen group) preoperatively. General anesthesia was induced with fentanyl and propofol, and intubation was performed after succinylcholine 1 mg center dot kg(-1). Propofol was administered via a target-controlled infusion (TCI) system (Diprifusor (TM)) set at an effect-site concentration of 5 mu g center dot mL(-1). Fentanyl was given by a TCI system using the STANPUMP software (Schafer model). The concentration for the first patient was set at 3 ng center dot mL(-1) and modified in each group according to the up-down method. Skin incision was performed after more than ten minutes equilibration time. Serum fentanyl concentration, bispectral index (BIS), and hemodynamic parameters were measured two minutes before and after skin incision. The Cp50(incision) of fentanyl was derived from the mean of the crossovers (i.e., the serum fentanyl concentrations of successive participants who responded and those who did not or vice versa). Ten and 11 independent crossover pairs were collected in the control and flurbiprofen groups, respectively, representing 42 of 62 enrolled patients. The mean (SD) fentanyl Cp50(incision) was less in the flurbiprofen group [0.84 (0.63) ng center dot mL(-1)] than in the control group [1.65 (1.15) ng center dot mL(-1)]; P = 0.007; however, there were no differences in BIS, blood pressure, or heart rate, between groups. Preoperative flurbiprofen axetil decreased the Cp50(incision) of fentanyl by 49% during propofol anesthesia without changing the BIS or hemodynamic variables.	[Kodaka, Mitsuharu; Ichikawa, Junko; Komori, Makiko] Tokyo Womens Med Univ, Sch Med, Dept Anesthesiol, Arakawa Ku, Tokyo 1168567, Japan; [Tsukakoshi, Mikiko; Miyao, Hideki] Saitama Med Univ, Saitama Med Ctr, Dept Anesthesiol, Saitama, Japan; [Tsuzaki, Koichi] Keio Univ, Sch Med, Keio, Japan	Kodaka, M (reprint author), Tokyo Womens Med Univ, Sch Med, Dept Anesthesiol, Arakawa Ku, Med Ctr East 2-1-10, Tokyo 1168567, Japan.	kmkodaka@cb3.so-net.ne.jp; mtsukakoshi@saitama-med.ac.jp; miyaoh@saitama-med.ac.jp; ktsuzaki@sc.itc.keio.ac.jp; htwfx872@yahoo.co.jp; komorim@nifty.com					Dirig DM, 1998, J PHARMACOL EXP THER, V285, P1031; Dirig DM, 1997, EUR J PHARMACOL, V331, P155, DOI 10.1016/S0014-2999(97)01053-4; DIXON WJ, 1991, NEUROSCI BIOBEHAV R, V15, P47, DOI 10.1016/S0149-7634(05)80090-9; Fletcher D, 1997, ANESTHESIOLOGY, V87, P317, DOI 10.1097/00000542-199708000-00019; GEPTS E, 1987, ANESTH ANALG, V66, P1256; IZEKI M, 2005, PAIN CLINIC, V26, pS225; Kazama T, 1997, ANESTHESIOLOGY, V87, P213, DOI 10.1097/00000542-199708000-00007; Kodaka M, 2005, ANESTH ANALG, V101, P377, DOI 10.1213/01.ANE.0000154534.71371.4F; Kodaka M, 2006, J CLIN ANESTH, V18, P486, DOI 10.1016/j.jclinane.2006.08.004; Kolesnikov YA, 2003, ANESTH ANALG, V97, P1721, DOI 10.1213/01.ANE.0000087801.20395.97; Lashbrook JM, 1999, PAIN, V82, P65, DOI 10.1016/S0304-3959(99)00031-7; MARSH B, 1991, BRIT J ANAESTH, V67, P41, DOI 10.1093/bja/67.1.41; PLUMMER GF, 1987, J CHROMATOGR-BIOMED, V421, P171, DOI 10.1016/0378-4347(87)80394-8; Robinson BJ, 1997, ANESTHESIOLOGY, V86, P64, DOI 10.1097/00000542-199701000-00010; Santos M, 2004, ANESTH ANALG, V98, P359, DOI 10.1213/01.ANE.0000097849.18820.C4; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; SMITH C, 1994, ANESTHESIOLOGY, V81, P820, DOI 10.1097/00000542-199410000-00008; Swinhoe CF, 1998, ANAESTHESIA, V53, P61, DOI 10.1111/j.1365-2044.1998.53s104.x; Vaughan CW, 1997, NATURE, V390, P611, DOI 10.1038/37610; White PF, 2002, ANESTH ANALG, V94, P577, DOI 10.1097/00000539-200203000-00019; Williams JT, 1997, NATURE, V390, P557, DOI 10.1038/37486; Yamashita Kazunori, 2006, J Anesth, V20, P92, DOI 10.1007/s00540-006-0389-6	22	1	1	0	3	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0832-610X	1496-8975		CAN J ANESTH	Can. J. Anesth.	DEC	2013	60	12					1204	1211		10.1007/s12630-013-0040-6			8	Anesthesiology	Anesthesiology	264IR	WOS:000327870700005	24078554	Bronze			2020-06-30	J	Pontarelli, EM; Matthews, JA; Goodhue, CJ; Stein, JE				Pontarelli, Elizabeth M.; Matthews, Jamil A.; Goodhue, Catherine J.; Stein, James E.			On-Q(A (R)) pain pump versus epidural for postoperative analgesia in children	PEDIATRIC SURGERY INTERNATIONAL			English	Article						On-Q; Subcutaneous; Epidural; Pediatric; Analgesia; Postoperative	CONTINUOUS SUBCUTANEOUS MORPHINE; PREEMPTIVE ANALGESIA; EXTRADURAL MORPHINE; INFUSION; RELIEF; MANAGEMENT; SURGERY; COMPLICATIONS; THORACOTOMY; SYSTEM	The On-Q(A (R)) pain pump provides a continuous infusion of local anesthesia for management of postoperative pain. The objective of this study was to assess the efficacy and outcomes of the On-Q(A (R)) pump compared to continuous epidural in children postoperatively. We performed a retrospective review of patients in our hospital who received a postoperative epidural or On-Q(A (R)) pump from 2005 to 2008. Patients were sub-categorized by incision type. Seventy patients received epidural and 66 On-Q(A (R)). On-Q(A (R)) therapy was longer by 1 day (p < 0.0001), but did not affect postoperative length of stay. Patients with On-Q(A (R)) pumps had a decreased rate of Foley catheter placement (p = 0.002) and shorter duration of catheter use by more than a day (p < 0.001). Moderate to severe pain was similar in the two groups on postoperative days 0-5. Supplemental narcotic use was higher in the On-Q(A (R)) group only on postoperative day 1 (p = 0.005) and in patients with midline and transverse abdominal incisions. No differences were seen in time to ambulation or recovery of postoperative ileus. The On-Q(A (R)) pain pump is an effective method for postoperative pain control, without the inherent risks of epidural catheters.	[Pontarelli, Elizabeth M.; Matthews, Jamil A.; Goodhue, Catherine J.; Stein, James E.] Childrens Hosp Los Angeles, Dept Pediat Surg, Los Angeles, CA 90027 USA	Pontarelli, EM (reprint author), Childrens Hosp Los Angeles, Dept Pediat Surg, 4650 W Sunset Blvd,Mailstop 100, Los Angeles, CA 90027 USA.	epontarelli@chla.usc.edu					Baig MK, 2006, J AM COLL SURGEONS, V202, P297, DOI 10.1016/j.jamcollsurg.2005.10.022; Cheong WK, 2001, BRIT J SURG, V88, P357, DOI 10.1046/j.1365-2168.2001.01717.x; CHRUBASIK J, 1994, ANESTH ANALG, V78, P1114; ErikssonMjoberg M, 1997, BRIT J ANAESTH, V78, P10; Giebler RM, 1997, ANESTHESIOLOGY, V86, P55, DOI 10.1097/00000542-199701000-00009; GOUDIE TA, 1985, ANAESTHESIA, V40, P1086, DOI 10.1111/j.1365-2044.1985.tb10607.x; GUSTAFSSON LL, 1982, BRIT J ANAESTH, V54, P479, DOI 10.1093/bja/54.5.479; HINDSHOLM KB, 1993, BRIT J ANAESTH, V71, P580, DOI 10.1093/bja/71.4.580; Iyer CP, 2010, SURG OBES RELAT DIS, V6, P181, DOI 10.1016/j.soard.2009.08.008; Machida M, 2004, J PEDIATR ORTHOPED, V24, P576, DOI 10.1097/01241398-200409000-00021; Popping DM, 2008, ARCH SURG-CHICAGO, V143, P990, DOI 10.1001/archsurg.143.10.990; Rampersad SE, 2009, PEDIATR ANESTH, V19, P1025, DOI 10.1111/j.1460-9592.2009.03118.x; Ruppen W, 2006, ANESTHESIOLOGY, V105, P394, DOI 10.1097/00000542-200608000-00023; Sprigge JS, 2008, ANAESTHESIA, V63, P36, DOI 10.1111/j.1365-2044.2007.05285.x; Terasako K, 2011, J ANESTH, V25, P950, DOI 10.1007/s00540-011-1226-0; Tirotta CF, 2009, PEDIATR ANESTH, V19, P571, DOI 10.1111/j.1460-9592.2009.03009.x; Wheatley GH, 2005, J THORAC CARDIOV SUR, V130, P464, DOI 10.1016/j.jtcvs.2005.02.011; Yukawa Y, 2005, SPINE, V30, P2357, DOI 10.1097/01.brs.0000184377.31427.fa	18	8	8	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0179-0358	1437-9813		PEDIATR SURG INT	Pediatr. Surg. Int.	DEC	2013	29	12					1267	1271		10.1007/s00383-013-3342-4			5	Pediatrics; Surgery	Pediatrics; Surgery	258NO	WOS:000327466200006	23860616				2020-06-30	J	Nguyen, NQ; Toscano, L; Lawrence, M; Moore, J; Holloway, RH; Bartholomeusz, D; Lidums, I; Tam, W; Roberts-Thomson, IC; Mahesh, VN; Debreceni, TL; Schoeman, MN				Nguyen, Nam Q.; Toscano, Leanne; Lawrence, Matthew; Moore, James; Holloway, Richard H.; Bartholomeusz, Dylan; Lidums, Ilmars; Tam, William; Roberts-Thomson, Ian C.; Mahesh, Venkataswamy N.; Debreceni, Tamara L.; Schoeman, Mark N.			Patient-controlled analgesia with inhaled methoxyflurane versus conventional endoscopist-provided sedation for colonoscopy: a randomized multicenter trial	GASTROINTESTINAL ENDOSCOPY			English	Article							TRAIT ANXIETY INVENTORY; CARBON-DIOXIDE INSUFFLATION; GASTROINTESTINAL ENDOSCOPY; PSYCHOMETRIC PROPERTIES; INCOMPLETE COLONOSCOPY; UNSEDATED COLONOSCOPY; PREOPERATIVE ANXIETY; PRACTICE GUIDELINES; NITROUS-OXIDE; QUALITY	Objective: Inhaled methoxyflurane (Penthrox, Medical Device International, Melbourne, Australia) has been used extensively in Australasia (Australia and New Zealand) to manage trauma-related pain. The aim is to evaluate the efficacy, safety, and outcome of Penthrox for colonoscopy. Design: Prospective randomized study. Setting: Three tertiary endoscopic centers. Patients: Two hundred fifty-one patients were randomized to receive either Penthrox (n = 125, 70 men, 51.4 +/- 1.1 years old) or intravenous midazolam and fentanyl (M & F; n = 126, 72 men, 54.9 +/- 1.1 years old) during colonoscopy. Main Outcome Measurement: Discomfort (visual analogue scale [VAS] pain score), anxiety (State-Trait Anxiety Inventory Form Y [STAI-Y] anxiety score), colonoscopy performance, adverse events, and recovery time. Results: Precolonoscopy VAS pain and STAI-Y scores were comparable between the 2 groups. There were no differences between groups in (1) pain VAS or STAI Y-1 anxiety scores during or immediately after colonoscopy, (2) procedural success rate (Penthrox: 121/125 vs M&F: 124/126), (3) hypotension during colonoscopy (7/125 vs 8/126), (4) tachycardia (5/125 vs 3/126), (5) cecal arrival time (8 +/- 1 vs 8 +/- 1 minutes), or (6) polyp detection rate (30/125 vs 43/126). Additional intravenous sedation was required in 10 patients (8%) who received Penthrox. Patients receiving Penthrox alone had no desaturation (oxygen saturation [SaO(2)] < 90%) events (0/115 vs 5/126; P = .03), awoke quicker (3 +/- 0 vs 19 +/- 1 minutes; P < .001) and were ready for discharge earlier (37 +/- 1 vs 66 +/- 2 minutes; P < .001) than those receiving intravenous M&F. Limitations: Inhaled Penthrox is not yet available in the United States and Europe. Conclusions: Patient-controlled analgesia with inhaled Penthrox is feasible and as effective as conventional sedation for colonoscopy with shorter recovery time, is not associated with respiratory depression, and does not influence the procedural success and polyp detection.	[Nguyen, Nam Q.; Toscano, Leanne; Holloway, Richard H.; Bartholomeusz, Dylan; Tam, William; Mahesh, Venkataswamy N.; Debreceni, Tamara L.; Schoeman, Mark N.] Royal Adelaide Hosp, Dept Gastroenterol & Hepatol, Adelaide, SA 5000, Australia; [Lawrence, Matthew; Moore, James] Royal Adelaide Hosp, Colorectal Surg Unit, Adelaide, SA 5000, Australia; [Lidums, Ilmars; Roberts-Thomson, Ian C.] Queen Elizabeth Hosp, Dept Gastroenterol, Adelaide, SA, Australia; [Tam, William] Lyell McEwin Hlth Serv, Dept Gastroenterol, Adelaide, SA, Australia	Nguyen, NQ (reprint author), Royal Adelaide Hosp, Dept Gastroenterol, North Terrace, Adelaide, SA 5000, Australia.						Aboumarzouk OM, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008506.pub2; Amato A, 2013, DIS COLON RECTUM, V56, P511, DOI 10.1097/DCR.0b013e318279addd; Bannert C, 2012, AM J GASTROENTEROL, V107, P1837, DOI 10.1038/ajg.2012.347; Bendall JC, 2011, PREHOSP DISASTER MED, V26, P422, DOI 10.1017/S1049023X12000180; Bourke MJ, 2009, J GASTROEN HEPATOL, V24, pS43, DOI 10.1111/j.1440-1746.2009.06070.x; Brahmania M, 2012, CAN J GASTROENTEROL, V26, P589, DOI 10.1155/2012/353457; Buntine P, 2007, EMERG MED AUSTRALAS, V19, P509, DOI 10.1111/j.1742-6723.2007.01017.x; Cardin F, 2012, BMC SURG, V12, DOI 10.1186/1471-2482-12-S1-S9; Chen PJ, 2013, GASTROINTEST ENDOSC, V77, P79, DOI 10.1016/j.gie.2012.09.012; CHURCH JM, 1994, AM J GASTROENTEROL, V89, P556; Cohen Lawrence B, 2010, Gastrointest Endosc Clin N Am, V20, P615, DOI 10.1016/j.giec.2010.07.003; Dahlgren G, 2010, ACTA ANAESTH SCAND, V54, P907, DOI 10.1111/j.1399-6576.2010.02271.x; Fanti L, 2011, DIGEST LIVER DIS, V43, P726, DOI 10.1016/j.dld.2011.04.012; FORSBERG C, 1993, QUAL LIFE RES, V2, P349, DOI 10.1007/BF00449430; Gasparovic S, 2003, ACTA MED AUST, V30, P13, DOI 10.1046/j.1563-2571.2003.02050.x; George B, 2008, J GASTROEN HEPATOL, V23, pA227; Grindlay J, 2009, EMERG MED AUSTRALAS, V21, P4, DOI 10.1111/j.1742-6723.2009.01153.x; Hayee B, 2009, GASTROINTEST ENDOSC, V69, P681, DOI 10.1016/j.gie.2008.09.033; Holte K, 2004, DIS COLON RECTUM, V47, P1397, DOI 10.1007/s10350-004-0592-1; Horiuchi A, 2012, WORLD J GASTROENTERO, V18, P3420, DOI 10.3748/wjg.v18.i26.3420; Iwata N, 1998, PSYCHOL REP, V82, P651, DOI 10.2466/PR0.82.2.651-656; Johnston S, 2011, EMERG MED J, V28, P57, DOI 10.1136/emj.2009.078717; Jover R, 2012, ENDOSCOPY, V44, P444, DOI 10.1055/s-0032-1306690; Kindler CH, 2000, ANESTH ANALG, V90, P706, DOI 10.1097/00000539-200003000-00036; KNIGHT RG, 1983, BRIT J CLIN PSYCHOL, V22, P245, DOI 10.1111/j.2044-8260.1983.tb00610.x; Kvaal K, 2001, INT J GERIATR PSYCH, V16, P980, DOI 10.1002/gps.458; Ladas SD, 2010, DIGESTION, V82, P74, DOI 10.1159/000285248; Lee D. W. H., 2004, Hong Kong Medical Journal, V10, P84; Lee TJW, 2012, GUT, V61, P1050, DOI 10.1136/gutjnl-2011-300651; Leung FW, 2010, GASTROINTEST ENDOSC, V72, P693, DOI 10.1016/j.gie.2010.05.020; Leung FW, 2009, GASTROINTEST ENDOSC, V69, P546, DOI 10.1016/j.gie.2008.08.014; Leung JW, 2009, GASTROINTEST ENDOSC, V70, P505, DOI 10.1016/j.gie.2008.12.253; Lieberman D, 2012, DIGEST DIS, V30, P34, DOI 10.1159/000341891; Loberg M, 2011, GASTROINTEST ENDOSC, V74, P1347, DOI 10.1016/j.gie.2011.07.071; Maslekar S, 2009, BRIT J SURG, V96, P361, DOI 10.1002/bjs.6467; MILLAR K, 1995, BRIT J ANAESTH, V74, P180, DOI 10.1093/bja/74.2.180; Plumb AA, 2012, CLIN RADIOL, V12, P549; Royal College of General Practioner and Pharmaceutical Society of Australia, 2012, AUSTR MED HDB 2012; RUBINGER D, 1975, ANESTHESIOLOGY, V43, P593, DOI 10.1097/00000542-197511000-00025; Shah HA, 2007, GASTROENTEROLOGY, V132, P2297, DOI 10.1053/j.gastro.2007.03.032; SPIELBERGER CD, 1984, J PERS ASSESS, V48, P95; TOOMATH RJ, 1987, NEW ZEAL MED J, V100, P707; Vargo JJ, 2010, CURR OPIN GASTROEN, V26, P421, DOI 10.1097/MOG.0b013e32833d1786; Welchman S, 2010, ALIMENT PHARM THER, V32, P324, DOI 10.1111/j.1365-2036.2010.04359.x	44	17	17	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107	1097-6779		GASTROINTEST ENDOSC	Gastrointest. Endosc.	DEC	2013	78	6					892	901		10.1016/j.gie.2013.05.023			10	Gastroenterology & Hepatology	Gastroenterology & Hepatology	257OJ	WOS:000327394000014	23810328				2020-06-30	J	Biswas, I; Mathew, PJ; Singh, RS; Puri, GD				Biswas, Indranil; Mathew, Preethy J.; Singh, Rana S.; Puri, Goverdhan D.			Evaluation of closed-loop anesthesia delivery for propofol anesthesia in pediatric cardiac surgery	PEDIATRIC ANESTHESIA			English	Article						closed-loop anesthesia; propofol; pediatric; BIS; cardiac surgery	BISPECTRAL INDEX; INFUSION; CHILDREN; PERFORMANCE; ADULTS	ObjectiveThe objective of this study was to compare the feasibility of closed-loop anesthesia delivery with manual control of propofol in pediatric patients during cardiac surgery. MethodsForty ASA II-III children, undergoing elective cardiac surgery under cardiopulmonary bypass (CPB) in a tertiary care hospital, were randomized to receive propofol either through a closed-loop anesthesia delivery system (CL group) or through traditional manual control (manual group) to achieve a target BIS of 50. Patients were induced and subsequently maintained with a propofol infusion. The propofol usage and the efficacy of closed-loop system in controlling BIS within 10 of the target were compared with that of manual control. ResultsThe maintenance of BIS within +/- 10 of target and intraoperative hemodynamic stability were similar between the two groups. However, induction dose of propofol was less in the CL group (2.06 +/- 0.79mg<bold></bold>kg(-1)) than the manual group (2.95 +/- 1.03mg<bold></bold>kg(-1)) (P=0.006) with less overshoot of BIS during induction in the closed-loop group (P=0.007). Total propofol used in the off-CPB period was less in the CL group (6.29 +/- 2.48mg<bold></bold>kg(-1) h(-1) vs 7.82 +/- 2.1mg<bold></bold>kg(-1) h(-1)) (P=0.037). Phenylephrine use in the pre-CPB period was more in the manual group (16.92 +/- 10.92g<bold></bold>kg(-1) vs 5.79 +/- 5.98g<bold></bold>kg(-1)) (P=0.014). Manual group required a median of 18 (range 8-29) dose adjustments per hour, while the CL group required none. ConclusionThis study demonstrated the feasibility of closed-loop controlled propofol anesthesia in children, even in challenging procedures such as cardiac surgery. Closed-loop system needs further and larger evaluation to establish its safety and efficacy.	[Biswas, Indranil; Mathew, Preethy J.; Puri, Goverdhan D.] Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh 160012, India; [Singh, Rana S.] Postgraduate Inst Med Educ & Res, Dept Cardiovasc & Thorac Surg, Chandigarh, India	Puri, GD (reprint author), Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Sect 12, Chandigarh 160012, India.	gdpuri007@hotmail.com			Department of Information Technology, Govt. of India, New Delhi, India	The study was supported financially by Department of Information Technology, Govt. of India, New Delhi, India.	Agarwal J, 2009, ACTA ANAESTH SCAND, V53, P390, DOI 10.1111/j.1399-6576.2008.01884.x; FRANKE RH, 1978, AM SOCIOL REV, V43, P623, DOI 10.2307/2094540; HYNYNEN M, 1994, CAN J ANAESTH, V41, P583, DOI 10.1007/BF03009997; Liu N, 2006, ANESTHESIOLOGY, V104, P686, DOI 10.1097/00000542-200604000-00012; Liu N, 2007, PEDIATR ANESTH, V17, P909, DOI 10.1111/j.1460-9592.2007.02303.x; Lopez U, 2007, ANAESTHESIA, V62, P778, DOI 10.1111/j.1365-2044.2007.05133.x; Madhavan JS, 2011, ACTA ANAESTHESIOL TA, V4, P130; MASSEY NJA, 1990, BRIT J ANAESTH, V65, P475, DOI 10.1093/bja/65.4.475; McFarlan CS, 1999, PAEDIATR ANAESTH, V9, P209; Munoz HR, 2006, ACTA ANAESTH SCAND, V50, P882, DOI 10.1111/j.1399-6576.2006.01062.x; Mychaskiw G, 2001, ANESTH ANALG, V92, P808; Puri GD, 2007, ANAESTH INTENS CARE, V35, P357, DOI 10.1177/0310057X0703500306; Puri Goverdhan D, 2012, INDIAN J ANAESTH, V56, P238; Rigouzzo A, 2008, ANESTH ANALG, V106, P1109, DOI 10.1213/ane.0b013e318164f388; Solanki A, 2010, EUR J ANAESTH, V27, P708, DOI 10.1097/EJA.0b013e328335b2d4; Struys MMRF, 2001, ANESTHESIOLOGY, V95, P6, DOI 10.1097/00000542-200107000-00007; VARVEL JR, 1992, J PHARMACOKINET BIOP, V20, P63, DOI 10.1007/BF01143186; Wong GLS, 2011, PEDIATR ANESTH, V21, P560, DOI 10.1111/j.1460-9592.2011.03565.x	18	19	23	0	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	DEC	2013	23	12					1145	1152		10.1111/pan.12265			8	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	248WZ	WOS:000326737800006	24118468				2020-06-30	J	Breschan, C; Jost, R; Stettner, H; Feigl, G; Semmelrock, S; Graf, G; Likar, R				Breschan, Christian; Jost, Robert; Stettner, Haro; Feigl, Georg; Semmelrock, Sandra; Graf, Gudrun; Likar, Rudolf			Ultrasound-guided rectus sheath block for pyloromyotomy in infants: a retrospective analysis of a case series	PEDIATRIC ANESTHESIA			English	Article						infant; hypertrophic pyloric stenosis; ultrasound-guided rectus sheath block	HYPERTROPHIC PYLORIC-STENOSIS; EPIDURAL-ANESTHESIA; CHILDREN	ObjectivesTo analyze the applicability of US-guided rectus sheath block and to find out the efficacy of analgesia provided using this method without the need for opioids in conventional Hypertrophic pyloric stenosis (HPS) surgery in infants. BackgroundThis study describes the provision of intra- as well as postoperative analgesia by the use of an ultrasound-guided rectus sheath block in infants undergoing conventional HPS surgery under general anesthesia. Methods/MaterialsThe anesthetic protocols of 26 infants undergoing HPS surgery were reviewed retrospectively. ResultsThe weight of the infants ranged from 2.6 to 4.6kg. The rectus sheath block was regarded as successful in all patients as there was no heart rate increase upon surgical skin incision in any of the patients. Two out of 26 (7.6%) babies needed additional intraoperative rescue analgesia and were administered fentanyl at 20 and 40min after skin incision. Two more (a total of 4; 15.3%) babies required postoperative analgesia and were administered tramadol droplets and liquid ibuprofen at 15, 120 and 150min postoperatively. Duration of surgery was significantly longer in those two patients who required intraoperative rescue analgesia (Wilcoxon-Mann-Whitney test: P<0.05). These were also the only two patients who received one intra- and one postoperative dose of opioid each (7.6%). ConclusionUS-guided rectus sheath block seems to be a simple and quick method for the provision of intra- and postoperative analgesia in infants undergoing conventional HPS surgery.	[Breschan, Christian; Semmelrock, Sandra; Graf, Gudrun; Likar, Rudolf] Klinikum Klagenfurt, Dept Anaesthesia, A-9020 Klagenfurt, Austria; [Jost, Robert] Krankenhaus Spittal Drau, Dept Anaesthesia, Spittal an der Drau, Austria; [Stettner, Haro] Univ Klagenfurt, Dept Stat, Klagenfurt, Austria; [Feigl, Georg] Med Univ Graz, Dept Anat, Graz, Austria	Breschan, C (reprint author), Klinikum Klagenfurt, Dept Anaesthesia, Feschnigstr 11, A-9020 Klagenfurt, Austria.	breschan.ch@chello.at					Aguirreurreta N Busto, 2000, CIR PEDIAT, V13, P153; APPLEGATE MS, 1995, ARCH PEDIAT ADOL MED, V149, P1123, DOI 10.1001/archpedi.1995.02170230077011; Breschan C, 2001, PAEDIATR ANAESTH, V11, P105, DOI 10.1046/j.1460-9592.2001.00593.x; Maria BD, 2007, PEDIATR ANESTH, V17, P44, DOI 10.1111/j.1460-9592.2006.02025.x; FLANDINBLETY C, 1995, PAEDIATR ANAESTH, V5, P41, DOI 10.1111/j.1460-9592.1995.tb00239.x; Frei FJ, 2004, KINDERANASTHESIE, P80; Fuzaylov G, 2005, PEDIATR ANESTH, V15, P435, DOI 10.1111/j.1460-9592.2005.01611.x; Garza JJ, 2002, J PEDIATR SURG, V37, P493, DOI 10.1053/jpsu.2002.30874; Gurnaney HG, 2011, BRIT J ANAESTH, V107, P790, DOI 10.1093/bja/aer263; Merkel S I, 1997, Pediatr Nurs, V23, P293; Moyao-Garcia D, 2002, PAEDIATR ANAESTH, V12, P404, DOI 10.1046/j.1460-9592.2002.00855.x; Nielsen JP, 2000, DAN MED BULL, V47, P223; ODONOGHUE JM, 1993, IRISH J MED SCI, V162, P175, DOI 10.1007/BF02945178; Somri M, 2003, PAEDIATR ANAESTH, V13, P32, DOI 10.1046/j.1460-9592.2003.00972.x; Wang J, 2008, BIRTH DEFECTS RES A, V82, P763, DOI 10.1002/bdra.20527; Willschke H, 2006, BRIT J ANAESTH, V97, P244, DOI 10.1093/bja/ael143; Willschke H, 2011, PEDIATR ANESTH, V21, P110, DOI 10.1111/j.1460-9592.2010.03452.x	17	13	13	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	DEC	2013	23	12					1199	1204		10.1111/pan.12267			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	248WZ	WOS:000326737800014	24112798				2020-06-30	J	Toyoda, T; Terao, Y; Oji, M; Okada, M; Fukusaki, M; Sumikawa, K				Toyoda, Tomomi; Terao, Yoshiaki; Oji, Makito; Okada, Mai; Fukusaki, Makoto; Sumikawa, Koji			The interaction of antiemetic dose of droperidol with propofol on QT interval during anesthetic induction	JOURNAL OF ANESTHESIA			English	Article						Droperidol; Propofol; QT interval; QT dispersion; Arrhythmia	POSTOPERATIVE NAUSEA; PROLONGATION; ONDANSETRON	We investigated the effect of low-dose droperidol on heart rate-corrected QT (QTc) interval and interaction with propofol. Seventy-two patients undergoing upper limb surgery were included in this study. Patients were randomly allocated to one of three groups: group S (n = 24), which received 1 ml saline; group D1 (n = 24), which received 1.25 mg droperidol; or group D2 (n = 24), which received 2.5 mg droperidol. One minute later, fentanyl (3 mu g/kg) was administered. Two minutes after fentanyl administration, anesthesia was induced using propofol (1.5 mg/kg) and vecronium. Tracheal intubation was performed 3 min after the administration of propofol. Heart rate, mean arterial pressure, bispectral index, and QTc interval were recorded at the following time points: immediately before the droperidol injection (baseline); 3 min after the saline or droperidol injection; 3 min after the propofol injection; and 2 min after tracheal intubation. Compared to baseline, the QTc interval in group S and group D1 was significantly shorter after propofol injection, but recovered after tracheal intubation. In group D2, the QTc interval was significantly prolonged after droperidol injection, but recovered after propofol injection, and was significantly prolonged after tracheal intubation. We found that saline or 1.25 mg droperidol did not prolong QTc interval, whereas 2.5 mg droperidol prolonged the QTc interval significantly, and that propofol injection counteracted the prolongation of the QTc interval induced by 2.5 mg droperidol.	[Toyoda, Tomomi; Terao, Yoshiaki; Oji, Makito; Okada, Mai; Fukusaki, Makoto] Nagasaki Rosai Hosp, Dept Anesthesia, Sasebo 8570134, Japan; [Sumikawa, Koji] Nagasaki Univ, Sch Med, Dept Anesthesiol, Nagasaki 8528501, Japan	Terao, Y (reprint author), Nagasaki Rosai Hosp, Dept Anesthesia, 2-12-5 Setogoe, Sasebo 8570134, Japan.	yoterao@na-robyo.jp			Japan Labor Health and Welfare OrganizationMinistry of Health, Labour and Welfare, Japan	This research was supported, in part, by research funds to promote hospital functions of the Japan Labor Health and Welfare Organization.	Chan MTV, 2006, ANESTH ANALG, V103, P1155, DOI 10.1213/01.ane.0000239223.74552.0a; Chang DJ, 2008, ANAESTHESIA, V63, P1056, DOI 10.1111/j.1365-2044.2008.05559.x; Charbit B, 2006, ANESTHESIOLOGY, V104, P255, DOI 10.1097/00000542-200602000-00009; Charbit B, 2005, ANESTHESIOLOGY, V102, P1094, DOI 10.1097/00000542-200506000-00006; Charbit B, 2008, ANESTHESIOLOGY, V109, P206, DOI 10.1097/ALN.0b013e31817fd8c8; Chu CC, 2008, ANESTH ANALG, V106, P1402, DOI 10.1213/ane.0b013e3181609424; COWAN JC, 1988, AM J CARDIOL, V61, P83, DOI 10.1016/0002-9149(88)91309-4; Darpo B, 2006, J CLIN PHARMACOL, V46, P498, DOI 10.1177/0091270006286436; Gan TJ, 2003, ANESTH ANALG, V97, P62, DOI 10.1213/01.ANE.0000068580.00245.95; Hatakeyama N, 2009, J PHARMACOL SCI, V110, P334, DOI 10.1254/jphs.09060FP; Higashijima U, 2010, ANAESTHESIA, V65, P679, DOI 10.1111/j.1365-2044.2010.06341.x; Ichinomiya T, 2010, NEUROCRIT CARE, V13, P347, DOI 10.1007/s12028-010-9411-9; Kleinsasser A, 2001, ANAESTHESIA, V56, P248, DOI 10.1046/j.1365-2044.2001.01717.x; LISCHKE V, 1994, ANESTH ANALG, V79, P983; Luo T, 2008, ANESTH ANALG, V106, P1161, DOI 10.1213/ane.0b013e3181684974; MIYAUCHI Y, 2008, JPN J ELECTROCARDIOL, V28, P210; Nuttall GA, 2007, ANESTHESIOLOGY, V107, P531, DOI 10.1097/01.anes.0000281893.39781.64; Oji M, 2013, J CLIN MONI IN PRESS; White PF, 2005, ANESTHESIOLOGY, V102, P1101, DOI 10.1097/00000542-200506000-00007; White PF, 2002, ANESTH ANALG, V95, P789, DOI 10.1097/00000539-200210000-00001	20	3	4	0	3	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	DEC	2013	27	6					885	889		10.1007/s00540-013-1625-5			5	Anesthesiology	Anesthesiology	270VU	WOS:000328348100014	23660990				2020-06-30	J	Simon, ST; Koskeroglu, P; Gaertner, J; Voltz, R				Simon, Steffen T.; Koeskeroglu, Peyla; Gaertner, Jan; Voltz, Raymond			Fentanyl for the Relief of Refractory Breathlessness: A Systematic Review	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Dyspnea; fentanyl; systematic review; palliative	NEBULIZED FENTANYL; BREAKTHROUGH PAIN; PALLIATIVE CARE; DYSPNEA; CITRATE; MANAGEMENT; OPIOIDS	Context. Fentanyl is a potent opioid that has been proven to provide effective treatment for breakthrough cancer pain. Although opioids are the only drug group with evidence for the symptomatic treatment of breathlessness, evidence about the efficacy of fentanyl for the relief of breathlessness is unknown. Objectives. We performed a systematic review to evaluate the current evidence for the use of fentanyl for the relief of breathlessness. Methods. The review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses recommendation for systematic reviews. Four databases (MEDLINE, EMBASE, Cochrane Library, International Pharmaceutical Abstracts) were screened using "fentanyl" and "dyspnoea" (and synonyms) as search terms. Hand search and contact with relevant authors completed the search. Results. A total of 622 references were retrieved, 13 of which met the inclusion criteria for this review. Two randomized controlled trials (RCTs) evaluated fentanyl for breathlessness, but one only included two patients. The other studies were before-after (n = 2) and case studies (n = 9). All studies reported successful relief of breathlessness after fentanyl application, but the only (pilot-) RCT failed to demonstrate a statistically significant difference compared with placebo. The nature and incidence of adverse events were comparable with other opioids, and no respiratory depression was observed. Conclusion. Descriptive studies yielded promising results for the use of fentanyl for the relief of breathlessness; however, efficacy trials are lacking. Fully powered RCTs are warranted to determine the efficacy of fentanyl for breathlessness relief, but these require pilot studies to evaluate effective size, study procedures, and outcome measures. (C) 2013 U. S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.	[Simon, Steffen T.; Koeskeroglu, Peyla; Voltz, Raymond] Univ Hosp Cologne, Ctr Palliat Med, D-50924 Cologne, Germany; [Simon, Steffen T.; Koeskeroglu, Peyla; Voltz, Raymond] Univ Hosp Cologne, Clin Trials Unit BMBF 01KN1106, D-50924 Cologne, Germany; [Simon, Steffen T.; Voltz, Raymond] Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, D-50924 Cologne, Germany; [Gaertner, Jan] Univ Med Ctr Freiburg, Dept Palliat Care, Freiburg, Germany	Simon, ST (reprint author), Univ Hosp Cologne, Dept Palliat Med, Clin Trials Unit Palliat Med, Kerpener Str 62, D-50924 Cologne, Germany.	steffen@steffensimon.de	gaertner, jan/G-9208-2011	Gaertner, Jan/0000-0002-1176-3164; Gaertner, Jan/0000-0002-8824-7117	German Federal Ministry of Education and ResearchFederal Ministry of Education & Research (BMBF) [BMBF 01KN1106]; TEVA Ltd.	This research was supported by a grant from the German Federal Ministry of Education and Research (grant ID BMBF 01KN1106). Drs. Simon, Gaertner, and Voltz are responsible for a clinical trial on the buccal administration form of fentanyl funded by TEVA Ltd. (formerly Cephalon); however, TEVA Ltd. had no involvement in the conduct of the systematic review or development of this submission. Ms. Koskeroglu declares no competing interests.	Abernethy A P, 2003, BMJ-BRIT MED J, V327, P1; Altfelder N, 2010, PALLIATIVE MED, V24, pS37; Benitez-Rosario MA, 2005, J PAIN SYMPTOM MANAG, V30, P395, DOI 10.1016/j.jpainsymman.2005.10.002; Booth Sara, 2003, Palliat Support Care, V1, P337; Booth Sara, 2009, Expert Rev Respir Med, V3, P21, DOI 10.1586/17476348.3.1.21; Burburan M., 2009, EUR J PALLIAT CARE, P39; Clemens KE, 2007, J PAIN SYMPTOM MANAG, V33, P473, DOI 10.1016/j.jpainsymman.2006.09.015; Coyne PJ, 2002, J PAIN SYMPTOM MANAG, V23, P157, DOI 10.1016/S0885-3924(01)00391-8; Currow DC, 2011, J PAIN SYMPTOM MANAG, V42, P388, DOI 10.1016/j.jpainsymman.2010.11.021; Currow DC, 2009, J PAIN SYMPTOM MANAG, V38, P533, DOI 10.1016/j.jpainsymman.2009.01.006; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI [10.1586/ERN.11.63, 10.1586/ern.11.63]; Freye Enno, 2007, Pain Pract, V7, P324, DOI 10.1111/j.1533-2500.2007.00157.x; Gauna AA, 2008, J PALLIAT MED, V11, P643, DOI 10.1089/jpm.2007.0161; Gika Masatoshi, 2010, Gan To Kagaku Ryoho, V37, P547; Graff GR, 2004, RESPIRATION, V71, P646, DOI 10.1159/000081769; Gysels Marjolein, 2007, Palliat Support Care, V5, P281; Jennings AL, 2001, COCHRANE DB SYST REV, V4; Jensen D, 2012, J PAIN SYMPTOM MANAG, V43, P706, DOI 10.1016/j.jpainsymman.2011.05.007; Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006; Mercadante S, 1999, J PAIN SYMPTOM MANAG, V17, P387; Mercadante S, 2011, J PAIN SYMPTOM MANAG, V42, P464, DOI 10.1016/j.jpainsymman.2010.12.010; O'Siorain L, 1998, CLIN DRUG INVEST, V16, P88; Parshall MB, 2012, AM J RESP CRIT CARE, V185, P435, DOI 10.1164/rccm.201111-2042ST; Reddy SK, 2009, J PALLIAT MED, V12, P29, DOI 10.1089/jpm.2008.0158; REUBEN DB, 1986, CHEST, V89, P234, DOI 10.1378/chest.89.2.234; Simon ST, 2013, J PAIN SYMPTOM MANAG, V45, P1019, DOI 10.1016/j.jpainsymman.2012.06.008; Sitte T, 2009, WIEN MED WOCHENSCHR, V159, P566, DOI 10.1007/s10354-009-0724-2; Sitte Thomas, 2008, J Pain Symptom Manage, V36, pe3, DOI 10.1016/j.jpainsymman.2008.08.002; Smith TJ, 2009, J PALLIAT MED, V12, P771, DOI 10.1089/jpm.2009.0113; Trujillo Vilchez R, 2005, MED PALIATIVA, V12, P194	32	33	33	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	DEC	2013	46	6					874	886		10.1016/j.jpainsymman.2013.02.019			13	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	262WM	WOS:000327768600010	23742735	Bronze			2020-06-30	J	Mercadante, S; Porzio, G; Valle, A; Fusco, F; Aielli, F; Adile, C; Casuccio, A				Mercadante, Sebastiano; Porzio, Giampiero; Valle, Alessandro; Fusco, Flavio; Aielli, Federica; Adile, Claudio; Casuccio, Alessandra		Home Care Italy Grp HOCAI Grp	Orphan symptoms in advanced cancer patients followed at home	SUPPORTIVE CARE IN CANCER			English	Article						Palliative care; Home care; Myoclonus; Sweating; Pruritus; Hiccup; Tenesmus	PALLIATIVE CARE; MYOCLONUS; HICCUPS	Orphan symptoms are rarely assessed, particularly at home. The aim of this multicenter prospective study was to assess the prevalence of these symptoms and eventual factors possibly associated in advanced cancer patients at admission of a home care program. A prospective study was performed at three home care programs in Italy. Patients' data were collected, including age, sex, diagnosis, and Karnofsky status. Possible contributing factors were analyzed; preexisting neurological diseases, cerebral metastases, hyperthermia, diabetes, a state of dehydration clinically evident and/or oliguria, possible biochemical parameters when available, data regarding recent chemotherapy, opioids and doses, use of neuroleptics, benzodiazepine or anticonvulsants, corticosteroids, anti-inflammatory, and antibiotics were collected. Myoclonus, hiccup, sweating, pruritus, and tenesmus, either rectal or vesical, were assessed, according to a preliminary definition, at time of home care program admission. Three hundred sixty-two patients were surveyed at the three home care programs. Globally, 48 patients presented one or more orphan symptoms in the period taken into consideration, and 7 patients presented more than 1 symptom. One patient presented occasional and diffuse myoclonus. Nineteen patients presented sweating, 13 patients presented pruritus, and 14 patients presented hiccup. Finally, nine patients presented rectal or vesical tenesmus. There was a significant correlation between sweating and transdermal fentanyl use (P = 0.044), fever (P = 0.001), hiccup (P < 0.0005), and vesical tenesmus (P = 0.028). Pruritus was not associated to any factor. Hiccup was associated with gender (males, P = 0.006) and sweating (P < 0.0005). Vesical tenesmus was associated with fever (P = 0.019) and sweating (P = 0.028). Although the symptoms examined have a low prevalence in advanced cancer patients admitted to home care, the distress for patients may be high and deserve further analyses. Given the low prevalence of these symptoms, large studies are needed to find possible associated factors.	[Mercadante, Sebastiano; Fusco, Flavio; Adile, Claudio] La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, I-90146 Palermo, Italy; [Mercadante, Sebastiano] Univ Palermo, Dept Anesthesia & Intens Care, Palermo, Italy; [Porzio, Giampiero; Aielli, Federica] Aquila Vita, Home Care Program, Laquila, Italy; [Valle, Alessandro] Fdn FARO, Home Care Program, Turin, Italy; [Casuccio, Alessandra] Univ Palermo, Dept Sci Hlth Promot & Mother Child Care G DAless, Palermo, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, Via San Lorenzo 312, I-90146 Palermo, Italy.	terapiadeldolore@lamaddalenanet.it	casuccio, alessandra/B-1730-2013	casuccio, alessandra/0000-0002-5676-9535; Porzio, Giampiero/0000-0002-9875-9220; Adile, Claudio/0000-0002-0664-3520; AIELLI, Federica/0000-0003-2785-0702			Ang SK, 2009, PALLIATIVE MED, P947; Bobb B, 2013, PRINCIPLES PRACTICE, P890; Bruera E, 1991, J Palliat Care, V7, P6; Calsina-Berna A, 2012, J PALLIAT MED, V15, P1142, DOI 10.1089/jpm.2012.0087; Ewing G, 2012, J PAIN SYMPTOM MANAG; Gilbert JE, 2012, J PAIN SYMPTOM MANAG, V43, P663, DOI 10.1016/j.jpainsymman.2011.04.028; Ito S, 2008, J PALLIAT MED, V11, P838, DOI 10.1089/jpm.2008.0040; Khoshknabi DS, 2013, PRINCIPLES PRACTICE, P916; Marinella Mark A, 2009, J Support Oncol, V7, P122; McCann Shawn, 2010, J Opioid Manag, V6, P87; Mercadante S, 1998, PAIN, V74, P5, DOI 10.1016/S0304-3959(97)00090-0; Mercadante S, 2011, J PAIN SYMPTOM MANAG, V42, P702, DOI 10.1016/j.jpainsymman.2011.01.014; Nekolaichuk C, 2008, PALLIATIVE MED, V22, P111, DOI 10.1177/0269216307087659; Richardson LA, 2009, CURR ONCOL, V16, P53; Sarhill N, 2013, PALLIATIVE CARE SUPP, P223; Seccareccia D, 2011, CAN FAM PHYSICIAN, V57, P1010; Smith HS, 2013, PRINCIPLES PRACTICE, P895; Woelk CJ, 2011, CAN FAM PHYSICIAN, V57, P672; Yelverton C, 2013, PRINCIPLES PRACTICE, P309	19	6	6	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	DEC	2013	21	12					3525	3528		10.1007/s00520-013-2007-0			4	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	250YE	WOS:000326892100035	24122405				2020-06-30	J	Kubat, B				Kubat, Bela			Drugs, muscle pallor, and pyomyositis	FORENSIC SCIENCE MEDICINE AND PATHOLOGY			English	Article						Pyomyositis; Muscle pallor; Rhabdomyolysis; Gluteal muscles; Bacterial myositis		A 33-year-old athletic male was unexpectedly found dead in his bed. For several days prior to his death he complained of tenderness and swelling of his right buttock. The post-mortem examination revealed unilateral pale gluteal muscles and pustular impetiginized skin lesions of the right lower leg. The muscle histology demonstrated pronounced acute inflammation and limited necrosis of muscle fibers confined to the right gluteal muscles. Vascular occlusion and renal abnormalities were excluded by post-mortem angiography and histology respectively, and the diagnosis of non-tropical pyomyositis, possibly originating from the dermatological infection, was made. Toxicological testing revealed a potentially lethal intoxication with fentanyl and morphine. Pyomyositis is etiologically attributed to an infection and predominantly affects large limb or trunk muscles. Males are affected more frequently than females. Histologically, it is dominated by acute inflammatory infiltrates and may lead to sepsis and subsequent death. Although occurring less frequently, pyomyositis must be considered in the differential diagnosis of macroscopic localized muscle pallor, together with vascular occlusion and rhabdomyolysis. In such cases, only the examination of fresh frozen muscle tissue samples from different locations, together with the histological examination of the internal organs, particularly the kidneys, will facilitate the confirmation of the correct diagnosis.	Netherlands Forens Inst, NL-2497 GB The Hague, Netherlands	Kubat, B (reprint author), Netherlands Forens Inst, Laan Ypenburg 6, NL-2497 GB The Hague, Netherlands.	belakubat@gmail.com					Byard RW, 2011, FORENSIC SCI MED PAT, V7, P364, DOI 10.1007/s12024-011-9229-6; CHIEDOZI LC, 1979, AM J SURG, V137, P255, DOI 10.1016/0002-9610(79)90158-2; Drosos Georgios, 2005, Acta Orthop Belg, V71, P9; GOMEZREINO JJ, 1994, SEMIN ARTHRITIS RHEU, V23, P396, DOI 10.1016/0049-0172(94)90090-6; Kamal Tamer, 2008, J Med Case Rep, V2, P204, DOI 10.1186/1752-1947-2-204; KUBAT K, 1993, MODERN PATHOL, V6, P743; MUSCAT I, 1986, J CLIN PATHOL, V39, P1116, DOI 10.1136/jcp.39.10.1116; Ojeda VJ, 1988, INFLAMMATORY DIS MUS, P154; Sheppard MN, 2011, PRACTICAL CARDIOVASC, P43; Wan S. H., 1995, Hong Kong Medical Journal, V1, P266	10	1	1	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1547-769X	1556-2891		FORENSIC SCI MED PAT	Forensic Sci. Med. Pathol.	DEC	2013	9	4					564	567		10.1007/s12024-013-9475-x			4	Medicine, Legal; Pathology	Legal Medicine; Pathology	243WH	WOS:000326348600016	23864208				2020-06-30	J	Bestas, A; Goksu, H; Erhan, OL				Bestas, Azize; Goksu, Hulya; Erhan, Omer Lutfi			The effect of preoperative consumption of potatoes on succinylcholine-induced block and recovery from anesthesia	JOURNAL OF CLINICAL MONITORING AND COMPUTING			English	Article						Anesthesia; Succinylcholine; Potatoes; Solanaceous glycoalkaloids	GLYCOALKALOIDS; PREMEDICATION	Potatoes contain solanaceous glycoalkaloids (SGAs), which inhibit both butyrylcholinesterase (BuChE) and acetylcholinesterase (AChE). The present study investigated the effect of preoperative consumption of potatoes on succinylcholine-induced block and recovery from anesthesia. ASA I-II, adult patients, scheduled for elective surgery, were included in a randomized, blind and controlled study. Patients were randomly divided into two groups. Patients in Group P (n = 21) ate a standard portion of potatoes in their last meal prior to pre-operative fasting, while patients in Group C (n = 23) ate food not containing SGAs. Patients were premedicated with midazolam. Anesthesia was induced with thiopental and fentanyl, and maintained with sevoflurane in 50 % O-2/air and fentanyl, as needed. Succinylcholine 1 mg kg(-1) was administered to facilitate endotracheal intubation. Duration of succinylcholine blockade, awakening and recovery times from anesthesia were measured. Serum BuChE levels were also measured at baseline and 4 time-points within 24 h post-consumption. Duration of succinylcholine-induced neuromuscular block, awakening and recovery time from anesthesia was significantly longer in Group P than in Group C (p < 0.05). Serum BuChE levels decreased at 6 h after consumption start in Group P. In addition, in both groups, BuChE levels markedly decreased after succinylcholine blockade, increased thereafter, but did not return to baseline within 24 h of consumption start. None of these differences observed in BuChE levels was statistically significant. This study suggests that potatoes eaten before anesthesia can prolong the duration of succinylcholine-induced neuromuscular block and delay recovery from anesthesia.	[Bestas, Azize; Erhan, Omer Lutfi] Firat Univ, Sch Med, Dept Anesthesiol & Reanimat, TR-23119 Elazig, Turkey; [Goksu, Hulya] Van Reg Training & Res Hosp, Dept Anesthesiol & Reanimat, Van, Turkey	Bestas, A (reprint author), Firat Univ, Sch Med, Dept Anesthesiol & Reanimat, TR-23119 Elazig, Turkey.	abestas@firat.edu.tr					ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; BANG U, 1990, ACTA ANAESTH SCAND, V34, P596, DOI 10.1111/j.1399-6576.1990.tb03152.x; Barceloux DG, 2009, DM-DIS MON, V55, P318, DOI [10.1016/j.disamonth.2009.03.007, 10.1016/j.disamonth.2009.03.008, 10.1016/j.disamonth.2009.03.002, 10.1016/j.disamonth.2009.03.006, 10.1016/j.disamonth.2009.03.003, 10.1016/j.disamonth.2009.03.005, 10.1016/j.disamonth.2009.03.011, 10.1016/j.disamonth.2009.03.010, 10.1016/j.disamonth.2009.03.004]; Corsi L, 2004, BIOCHEM BIOPH RES CO, V313, P62, DOI 10.1016/j.bbrc.2003.11.089; Fredman B, 1999, ANESTH ANALG, V89, P1161, DOI 10.1213/00000539-199911000-00014; Kavvadias D, 2000, BIOCHEM BIOPH RES CO, V269, P290, DOI 10.1006/bbrc.2000.2283; Krasowski MD, 1997, CAN J ANAESTH, V44, P525, DOI 10.1007/BF03011943; MAGA JA, 1994, FOOD REV INT, V10, P385, DOI 10.1080/87559129409541010; McGehee DS, 2000, ANESTHESIOLOGY, V93, P510, DOI 10.1097/00000542-200008000-00031; MCMILLAN M, 1979, Q J MED, V48, P227; Mensinga TT, 2005, REGUL TOXICOL PHARM, V41, P66, DOI 10.1016/j.yrtph.2004.09.004; Naguib M, 2010, MILLERS ANESTHESIA; Sparr HJ, 2001, EUR J ANAESTH, V18, P71; Viitanen H, 1999, ANESTH ANALG, V89, P75, DOI 10.1097/00000539-199907000-00014	14	3	3	0	7	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1387-1307	1573-2614		J CLIN MONIT COMPUT	J. Clin. Monitor. Comp.	DEC	2013	27	6					609	612		10.1007/s10877-013-9476-z			4	Anesthesiology	Anesthesiology	245HV	WOS:000326455400002	23700201				2020-06-30	J	Wade, CL; Krumenacher, P; Kitto, KF; Peterson, CD; Wilcox, GL; Fairbanks, CA				Wade, Carrie L.; Krumenacher, Perry; Kitto, Kelley F.; Peterson, Cristina D.; Wilcox, George L.; Fairbanks, Carolyn A.			Effect of Chronic Pain on Fentanyl Self-Administration in Mice	PLOS ONE			English	Article							MESOLIMBIC DOPAMINE SYSTEM; SIGNAL-REGULATED KINASE; SPINAL NERVE LIGATION; NEUROPATHIC PAIN; PERIPHERAL NEUROPATHY; NUCLEUS-ACCUMBENS; ANIMAL-MODEL; MORPHINE; RATS; VINCRISTINE	The development of opioid addiction in subjects with established chronic pain is an area that is poorly understood. It is critically important to clearly understand the neurobiology associated with propensity toward conversion to addiction under conditions of chronic pain. To pose the question whether the presence of chronic pain influences motivation to self-administer opioids for reward, we applied a combination of rodent models of chronic mechanical hyperalgesia and opioid self-administration. We studied fentanyl self-administration in mice under three conditions that induce chronic mechanical hyperalgesia: inflammation, peripheral nerve injury, and repeated chemotherapeutic injections. Responding for fentanyl was compared among these conditions and their respective standard controls (naive condition, vehicle injection or sham surgery). Acquisition of fentanyl self-administration behavior was reduced or absent in all three conditions of chronic hyperalgesia relative to control mice with normal sensory thresholds. To control for potential impairment in ability to learn the lever-pressing behavior or perform the associated motor tasks, all three groups were evaluated for acquisition of food-maintained responding. In contrast to the opioid, chronic hyperalgesia did not interfere with the reinforcing effect of food. These studies indicate that the establishment of chronic hyperalgesia is associated with reduced or ablated motivation to seek opioid reward in mice.	[Wade, Carrie L.; Wilcox, George L.; Fairbanks, Carolyn A.] Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; [Krumenacher, Perry; Kitto, Kelley F.; Wilcox, George L.; Fairbanks, Carolyn A.] Univ Minnesota, Dept Neurosci, Minneapolis, MN USA; [Peterson, Cristina D.; Fairbanks, Carolyn A.] Univ Minnesota, Dept Pharmaceut, Minneapolis, MN 55455 USA; [Wade, Carrie L.; Krumenacher, Perry; Kitto, Kelley F.; Peterson, Cristina D.; Wilcox, George L.; Fairbanks, Carolyn A.] Univ Minnesota, Ctr Pain Res, Minneapolis, MN USA	Fairbanks, CA (reprint author), Univ Minnesota, Dept Pharmacol, 3-249 Millard Hall, Minneapolis, MN 55455 USA.	carfair@umn.edu			NIH/NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [F31DA021054];  [R21 DA23545 NIH/NIDA]	Funding for the project was provided to C. A. Fairbanks by R21 DA23545 NIH/NIDA; C. L. Wade was supported by F31DA021054, NIH/NIDA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aley KO, 1996, NEUROSCIENCE, V73, P259, DOI 10.1016/0306-4522(96)00020-6; Altier N, 1999, LIFE SCI, V65, P2269, DOI 10.1016/S0024-3205(99)00298-2; Authier N, 2003, NEUROTOXICOLOGY, V24, P797, DOI 10.1016/S0161-813X(03)00043-3; Bailey JA, 2010, PAIN MED, V11, P1803, DOI 10.1111/j.1526-4637.2010.00982.x; Baliki MN, 2010, NEURON, V66, P149, DOI 10.1016/j.neuron.2010.03.002; Ballantyne JC, 2007, PAIN, V129, P235, DOI 10.1016/j.pain.2007.03.028; Barrueto F, 2004, VET HUM TOXICOL, V46, P30; BELKNAP JK, 1993, PSYCHOPHARMACOLOGY, V112, P352, DOI 10.1007/BF02244932; Berhow MT, 1996, J NEUROSCI, V16, P4707; BERHOW MT, 1995, NEUROSCIENCE, V68, P969, DOI 10.1016/0306-4522(95)00207-Y; Betourne A, 2008, NEUROSCIENCE, V157, P12, DOI 10.1016/j.neuroscience.2008.08.045; Colpaert FC, 2001, PAIN, V91, P33, DOI 10.1016/S0304-3959(00)00413-9; Ewan EE, 2011, ANESTHESIOLOGY, V115, P1271, DOI 10.1097/ALN.0b013e3182330448; Ewan EE, 2011, ANESTHESIOLOGY, V114, P624, DOI 10.1097/ALN.0b013e31820a4edb; Fairbanks CA, 2000, ANESTHESIOLOGY, V93, P765, DOI 10.1097/00000542-200009000-00026; Gutierrez T, 2011, PAIN, V152, P1976, DOI 10.1016/j.pain.2011.03.038; IOM, 2011, REL PAIN AM BLUEPR T; Kiguchi N, 2008, EUR J PHARMACOL, V592, P87, DOI 10.1016/j.ejphar.2008.07.008; KIM SH, 1992, PAIN, V50, P355; Koltzenburg M, 1999, TRENDS NEUROSCI, V22, P122, DOI 10.1016/S0166-2236(98)01302-2; Koob GF, 2008, PHILOS T R SOC B, V363, P3113, DOI 10.1098/rstb.2008.0094; Kuner R, 2010, NAT MED, V16, P1258, DOI 10.1038/nm.2231; Lynch JJ, 2005, EUR J PHARMACOL, V509, P43, DOI 10.1016/j.ejphar.2004.12.034; LYNESS WH, 1989, LIFE SCI, V45, P2217, DOI 10.1016/0024-3205(89)90062-3; Martin TJ, 2008, EXP CLIN PSYCHOPHARM, V16, P357, DOI 10.1037/a0013597; Martin TJ, 2006, PAIN, V125, P257, DOI 10.1016/j.pain.2006.05.027; Martin TJ, 2007, ANESTHESIOLOGY, V106, P312, DOI 10.1097/00000542-200702000-00020; Narita M, 2006, NEUROPSYCHOPHARMACOL, V31, P739, DOI 10.1038/sj.npp.1300858; Niikura K, 2008, NEUROSCI LETT, V435, P257, DOI 10.1016/j.neulet.2008.02.059; Nunez-Olarte JM, 2011, J PAIN SYMPTOM MANAG, V42, pE6, DOI 10.1016/j.jpainsymman.2011.07.006; Ozaki S, 2004, J NEUROCHEM, V88, P1389, DOI 10.1046/j.1471-4159.2003.02272.x; Passik SD, 2011, J PAIN SYMPTOM MANAG, V41, P116, DOI 10.1016/j.jpainsymman.2010.03.012; Rahn EJ, 2007, BRIT J PHARMACOL, V152, P765, DOI 10.1038/sj.bjp.0707333; SHAHAM Y, 1993, PHARMACOL BIOCHEM BE, V46, P315, DOI 10.1016/0091-3057(93)90359-2; TZSCHENTKE TM, 1995, NEUROSCI LETT, V193, P37, DOI 10.1016/0304-3940(95)11662-G; Urban MO, 1999, P NATL ACAD SCI USA, V96, P7687, DOI 10.1073/pnas.96.14.7687; Wade CL, 2008, EUR J PHARMACOL, V587, P135, DOI 10.1016/j.ejphar.2008.04.007; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x; Woolf CJ, 2004, ANN INTERN MED, V140, P441, DOI 10.7326/0003-4819-140-8-200404200-00010; Woolf Clifford J., 1994, Current Opinion in Neurobiology, V4, P525, DOI 10.1016/0959-4388(94)90053-1; Zhu CZ, 2004, EUR J PHARMACOL, V506, P107, DOI 10.1016/j.ejphar.2004.11.005; Zieglgansberger W, 2005, CNS SPECTRUMS, V10, P298, DOI 10.1017/S1092852900022628	42	22	22	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2013	8	11							e79239	10.1371/journal.pone.0079239			11	Multidisciplinary Sciences	Science & Technology - Other Topics	255RX	WOS:000327258600023	24260176	DOAJ Gold, Green Published			2020-06-30	J	Devine, JW; Trice, S; Nwokeji, E; Yarger, S; Anekwe, TM; Davies, W; Lawrence, J				Devine, Joshua W.; Trice, Shana; Nwokeji, Esmond; Yarger, Stephen; Anekwe, Teresa M.; Davies, William; Lawrence, Joseph			Automated Profile Review for Transdermal Fentanyl to Verify Opioid Tolerance in the Military Health System	MILITARY MEDICINE			English	Review								Objective: Describe a patient safety program designed to decrease use of transdermal fentanyl (TF) among opioid-naive patients in the U.S. Military Health System (MHS). Methods: The program automatically reviewed patient profiles for prior strong opioid use when starting treatment with TF. New prescriptions for TF among users without a prior strong opioid generated a rejection message indicating that the patient may not be opioid tolerant and stopped the fill. However, pharmacists could override the rejection. We collected pharmacy claims data to measure the use of TF among seemingly opioid-naive patients following implementation of the program in August 2007. Results: During the first 10 months, 26,366 patients attempted to fill TF prescriptions in the MHS; 10,025 patients (38%) encountered a claim rejection, with a warning message advising the pharmacist to verify opioid tolerance. The majority of rejection messages were overridden by the pharmacist; however, 1,402 patients did not receive a TF prescription following the rejection, representing a 14% decrease in TF claims dispensed to patients who appeared opioid naive in the MHS. Conclusion: A patient safety program with targeted pharmacy messaging reduced TF use among seemingly opioid-naive patients in the MHS without disrupting treatment for patients whose rejections were overridden.	[Devine, Joshua W.; Trice, Shana; Nwokeji, Esmond; Anekwe, Teresa M.; Lawrence, Joseph] Dept Def Pharmacoecon Ctr, Ft Sam Houston, TX 78234 USA; [Yarger, Stephen] Seton Healthcare Family, Austin, TX 78723 USA; [Davies, William] Pharmaceut Operat Directorate, TRICARE Management Act TMA, Falls Church, VA 22041 USA	Devine, JW (reprint author), Dept Def Pharmacoecon Ctr, 4130 Stanley Rd,Bldg 1000,Suite 208, Ft Sam Houston, TX 78234 USA.						[Anonymous], DUR PACK INS; Centers for Disease Control and Prevention, MMWR MORB MORTAL WKL, V60, P1487; Controlled Substance Schedules, DEF CONTR SUBST SCHE; Okie S, 2011, NEW ENGL J MED, V364, P290; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; The Department of Defense Pharmacoeconomic Center, 2006, DEC PAP; The Department of Defense Pharmacoeconomic Center, 2009, DEP DEF PHARM THER C; Trice S, 2009, J MANAGE CARE PHARM, V15, P133, DOI 10.18553/jmcp.2009.15.2.133; U. S. Food and Drug Administration, 2007, FDA CONS UPD	10	1	1	0	5	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075	1930-613X		MIL MED	Milit. Med.	NOV	2013	178	11					1241	1244		10.7205/MILMED-D-13-00184			4	Medicine, General & Internal	General & Internal Medicine	AN7UE	WOS:000340805700015	24183773	Bronze			2020-06-30	J	Kojima, A; Ito, Y; Kitagawa, H; Matsuura, H; Nosaka, S				Kojima, Akiko; Ito, Yuki; Kitagawa, Hirotoshi; Matsuura, Hiroshi; Nosaka, Shuichi			Remifentanil Has a Minimal Direct Effect on Sinoatrial Node Pacemaker Activity in the Guinea Pig Heart	ANESTHESIA AND ANALGESIA			English	Article							HUMAN RIGHT ATRIA; ANESTHESIA; FENTANYL; CELLS; BRADYCARDIA; SEVOFLURANE; ACTIVATION	BACKGROUND: Whereas remifentanil administration is associated with severe bradycardia, it has yet to be fully investigated whether the negative chronotropic action of remifentanil is mediated by its direct action on sinoatrial (SA) node pacemaker activity in the heart versus indirect results of enhanced vagal activity. METHODS: We examined the effects of remifentanil and fentanyl on the spontaneous action potentials of guinea pig SA node cells at concentrations of 5, 10, 100, and 1000 nM using the amphotericin B-perforated whole-cell patch-clamp technique. Isolated guinea pig hearts were perfused in a Langendorff mode with 5, 10, 100, and 1000 nM remifentanil. RESULTS: The spontaneous firing rate and diastolic depolarization rate (DDR) of the SA node action potentials were 189.1 +/- 14.8/min and 74.1 +/- 2.9 mV/s (n = 8), respectively, under control conditions, and were not significantly affected by exposure to 5 nM (P = 1.0 for both spontaneous firing rate and DDR; n = 6), 10 nM (P = 0.62 for spontaneous firing rate, P = 0.99 for DDR; n = 6), or 100 nM (P = 0.23 for spontaneous firing rate, P = 0.38 for DDR; n = 6) remifentanil. However, 1000 nM remifentanil modestly but significantly decreased the spontaneous firing rate (P = 0.0087) and DDR (P = 0.0072, n = 6). Remifentanil did not affect the heart rate of isolated Langendorff-perfused guinea pig hearts at concentrations of 5 nM (P = 0.98), 10 nM (P = 0.35), or 100 nM (P = 0.24) but significantly reduced the heart rate at 1000 nM (P < 0.0001). Fentanyl did not affect the spontaneous firing rate and DDR at concentrations of 5 nM (P = 1.0 for both spontaneous firing rate and DDR) and 10 nM (P = 0.62 for spontaneous firing rate, P = 0.79 for DDR), but it significantly reduced both at 100 nM (P = 0.00038 for spontaneous firing rate, P = 0.0080 for DDR) and 1000 nM (P < 0.0001 for both spontaneous firing rate and DDR). CONCLUSIONS: Clinically relevant concentrations (nanomolar order concentrations) of remifentanil do not produce significant direct effects on intrinsic cardiac automaticity; thus, suggesting that remifentanil-induced bradycardia in the clinical setting is independent of its direct cardiac effects.	[Kojima, Akiko; Ito, Yuki; Kitagawa, Hirotoshi; Nosaka, Shuichi] Shiga Univ Med Sci, Dept Anesthesiol, Otsu, Shiga 5202192, Japan; [Matsuura, Hiroshi] Shiga Univ Med Sci, Dept Physiol, Otsu, Shiga 5202192, Japan	Kojima, A (reprint author), Shiga Univ Med Sci, Dept Anesthesiol, Seta Tsukinowa Cho, Otsu, Shiga 5202192, Japan.	akiko77@belle.shiga-med.ac.jp			Japan Society for the Promotion of Science (JSPS, Tokyo, Japan)Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [24791590, 24592335, 24591086, 25460287]	This study was supported by a Grant-in-Aid for Young Scientists (B) (No. 24791590 to Akiko Kojima) and Grant-in-Aid for Scientific Research (C) (No. 24592335 to Hirotoshi Kitagawa; Nos. 24591086 and 25460287 to Hiroshi Matsuura) from The Japan Society for the Promotion of Science (JSPS, Tokyo, Japan).	Altermatt FR, 2000, BRIT J ANAESTH, V84, P696; Bowdle TA, 1998, DRUG SAFETY, V19, P173, DOI 10.2165/00002018-199819030-00002; DERSHWITZ M, 1995, ANESTH ANALG, V81, P619, DOI 10.1097/00000539-199509000-00035; DeSouza G, 1997, ANESTHESIOLOGY, V87, P1019, DOI 10.1097/00000542-199710000-00061; Duman A, 2003, J CARDIOTHOR VASC AN, V17, P465, DOI 10.1016/S1053-0770(03)00151-4; Fattorini F, 2003, Minerva Anestesiol, V69, P673; Fattorini F, 2003, MINERVA ANESTESIOL, V69, P677; Gibbs NM, 2012, ANESTH ANALG, V114, P471, DOI 10.1213/ANE.0b013e31823d2ab7; Gurkan Aydin, 2005, Ann Card Anaesth, V8, P140; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hanouz JL, 2001, ANESTH ANALG, V93, P543, DOI 10.1097/00000539-200109000-00005; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Kojima A, 2012, BRIT J PHARMACOL, V166, P2117, DOI 10.1111/j.1476-5381.2012.01914.x; Komatsu R, 2007, ANAESTHESIA, V62, P1266, DOI 10.1111/j.1365-2044.2007.05221.x; Mangoni ME, 2008, PHYSIOL REV, V88, P919, DOI 10.1152/physrev.00018.2007; Matsuura H, 2002, J PHYSIOL-LONDON, V540, P815; Ogletree ML, 2005, J CARDIOTHOR VASC AN, V19, P763, DOI 10.1053/j.jvca.2004.11.034; REITAN JA, 1978, ANESTH ANALG, V57, P31; SAEKI T, 1995, J CARDIOVASC PHARM, V26, P160, DOI 10.1097/00005344-199507000-00025; Shafer SL, 2012, ANESTH ANALG, V114, P931, DOI 10.1213/ANE.0b013e31824a0b5b; Verheijck EE, 1998, J GEN PHYSIOL, V111, P95, DOI 10.1085/jgp.111.1.95; Wang JYY, 1999, ANAESTH INTENS CARE, V27, P363, DOI 10.1177/0310057X9902700405	22	6	6	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999	1526-7598		ANESTH ANALG	Anesth. Analg.	NOV	2013	117	5					1072	1077		10.1213/ANE.0b013e3182a470ec			6	Anesthesiology	Anesthesiology	300AB	WOS:000330435700009	24108259				2020-06-30	J	Faure, D; Ginies, P; Eiden, C; Portet, L; Peyriere, H				Faure, Delinger; Ginies, Patrick; Eiden, Celine; Portet, Laure; Peyriere, Helene			Opioid Therapy for Chronic Noncancer Pain: Retrospective Analysis of Patients Hospitalized for Withdrawal	THERAPIE			French	Article						analgesics; opioid; prescription drug misuse; withdrawal; chronic non-cancer pain	EPIDEMIOLOGY; DEPRESSION; HEALTH; MISUSE	Objective. The prescription of opioids for the treatment of chronic non-cancer pain (CNCP) is not recommended for all of them, and can expose the patients to a benefit/risk ratio unfavorable. The objective of this study was to evaluate the management of patients hospitalized at the centre for evaluation and treatment of pain for opioid withdrawal, their outcome during hospitalization. Method. This is a retrospective descriptive study. The medical record of each patient was consulted to identify relevant data (demographics, treatments at the entrance and discharge of hospitalization, comorbidities, rating scale of pain). Results. During the study period (3 years), 53 patients (64% of women), with a median age of 52 years, were included. Pain was mainly back pain and neck pain (52%). Morphine (43%) and fentanyl (42%) were the most frequently used opioids. At admission, 62% of patients had a depressive state. At hospital discharge, withdrawal was total in 18 patients (34%) and a total improvement of pain was observed for 19% of them. Conclusion. In this study, 57% of patients received, at admission to hospital, an opioid other than morphine in the treatment of CNCP. The management of pain offered by the pain clinic led to a total or partial opioid withdrawal in 94% of patients.	[Faure, Delinger; Eiden, Celine; Portet, Laure; Peyriere, Helene] Hop Lapeyronie, CHRU Montpellier, Ctr Addictovigilance, Dept Med Pharmacol & Toxicol, F-34295 Montpellier 5, France; [Ginies, Patrick] Hop St Eloi, CHRU Montpellier, CETD, Montpellier, France	Peyriere, H (reprint author), Hop Lapeyronie, Dept Med Pharmacol & Toxicol, 191 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France.	h-peyriere@chu-montpellier.fr	eiden, celine/M-2567-2019	eiden, celine/0000-0002-7839-9811			Agence nationale de securite du medicament et des produits de sante, STUP PSYCH COMPT REN; Agence nationale de securite du medicament et des produits de sante, 2004, MIS POINT BON US OP; Bannwarth B, 2010, JOINT BONE SPINE, V77, P1, DOI 10.1016/j.jbspin.2009.11.001; Bekkering GE, 2011, NETH J MED, V69, P141; Ben-Porath YS, 2008, J PERS ASSESS, V90, P119, DOI 10.1080/00223890701845120; Calandre EP, 2012, CNS DRUGS, V26, P135, DOI 10.2165/11597130-000000000-00000; Currie SR, 2004, PAIN, V107, P54, DOI 10.1016/j.pain.2003.09.015; Dowell D, 2013, JAMA-J AM MED ASSOC, V309, P2219, DOI 10.1001/jama.2013.5794; Dupen A, 2007, PAIN MANAG NURS, V8, P113, DOI 10.1016/j.pmn.2007.02.004; Fishbain DA, 2004, PAIN MED, V5, P359, DOI 10.1111/j.1526-4637.2004.04054.x; Fishbain DA, 2008, PAIN MED, V9, P444, DOI 10.1111/j.1526-4637.2007.00370.x; Fitzcharles MA, 2011, AM J MED, V124, P955, DOI 10.1016/j.amjmed.2011.05.031; Grattan A, 2012, ANN FAM MED, V10, P304, DOI 10.1370/afm.1371; Harstall C, 2003, PAIN CLIN UPDATES, V11, P1, DOI DOI 10.1016/S1070-7212(03)00004-6; Haute autorite de sante, DUR PATCH FENT ANT A; Haute autorite de sante, DOUL CHRON REC PAT D; HUDSON JI, 1985, AM J PSYCHIAT, V142, P441; Knotkova H, 2009, J PAIN SYMPTOM MANAG, V38, P426, DOI 10.1016/j.jpainsymman.2009.06.001; Malinoff Herbert L, 2005, Am J Ther, V12, P379, DOI 10.1097/01.mjt.0000160935.62883.ff; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pES9; Noble M, 2008, J PAIN SYMPTOM MANAG, V35, P214, DOI 10.1016/j.jpainsymman.2007.03.015; Pauly V, 2011, THERAPIE, V66, P369, DOI 10.2515/therapie/2011037; Reid KJ, 2011, CURR MED RES OPIN, V27, P449, DOI 10.1185/03007995.2010.545813; Rokyta R, 2012, PHYSIOL RES, V61, pS23; Rome JD, 2004, MAYO CLIN PROC, V79, P759; Sullivan MD, 2010, PAIN, V149, P345, DOI 10.1016/j.pain.2010.02.037; Verdu B, 2008, DRUGS, V68, P2611, DOI 10.2165/0003495-200868180-00007; WEISSMAN DE, 1989, PAIN, V36, P363, DOI 10.1016/0304-3959(89)90097-3	28	0	0	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0040-5957	1958-5578		THERAPIE	Therapie	NOV-DEC	2013	68	6					385	392		10.2515/therapie/2013066			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	300JJ	WOS:000330459900006	24356190				2020-06-30	J	Gutierrez-Blanco, E; Victoria-Mora, JM; Ibancovichi-Camarillo, JA; Sauri-Arceo, CH; Bolio-Gonzalez, ME; Acevedo-Arcique, CM; Marin-Cano, G; Steagall, PVM				Gutierrez-Blanco, Eduardo; Victoria-Mora, Jose M.; Ibancovichi-Camarillo, Jose A.; Sauri-Arceo, Carlos H.; Bolio-Gonzalez, Manuel E.; Acevedo-Arcique, Carlos M.; Marin-Cano, Gabriela; Steagall, Paulo V. M.			Evaluation of the isoflurane-sparing effects of fentanyl, lidocaine, ketamine, dexmedetomidine, or the combination lidocaine-ketamine-dexmedetomidine during ovariohysterectomy in dogs	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						analgesia; anesthesia; balanced anesthesia; dog; isoflurane	MINIMUM ALVEOLAR CONCENTRATION; CONSTANT RATE INFUSION; INTRAVENOUS LIDOCAINE; ANESTHETIZED DOGS; POSTOPERATIVE ANALGESIA; BALANCED ANESTHESIA; HEALTHY-VOLUNTEERS; SEVOFLURANE; BUTORPHANOL; MORPHINE	Objective To evaluate the isoflurane-sparing effects of an intravenous (IV) constant rate infusion (CRI) of fentanyl, lidocaine, ketamine, dexmedetomidine, or lidocaine-ketamine-dexmedetomidine (LKD) in dogs undergoing ovariohysterectomy. Study design Randomized, prospective, blinded, clinical study. Animals Fifty four dogs. Methods Anesthesia was induced with propofol and maintained with isoflurane with one of the following IV treatments: butorphanol/saline (butorphanol 0.4 mg kg(-1), saline 0.9% CRI, CONTROL/BUT); fentanyl (5 mu g kg(-1), 10 mu g kg(-1) hour(-1), FENT); ketamine (1 mg kg(-1), 40 mu g kg(-1) minute(-1), KET), lidocaine (2 mg kg(-1), 100 mu g kg(-1) minute(-1), LIDO); dexmedetomidine (1 mu g kg(-1), 3 mu g kg(-1) hour(-1), DEX); or a LKD combination. Positive pressure ventilation maintained eucapnia. An anesthetist unaware of treatment and end-tidal isoflurane concentration (FE'Iso) adjusted vaporizer settings to maintain surgical anesthetic depth. Cardiopulmonary variables and FE'Iso concentrations were monitored. Data were analyzed using ANOVA (p < 0.05). Results At most time points, heart rate (HR) was lower in FENT than in other groups, except for DEX and LKD. Mean arterial blood pressure (MAP) was lower in FENT and CONTROL/BUT than in DEX. Overall mean +/- SD FE'Iso and % reduced isoflurane requirements were 1.01 +/- 0.31/41.6% (range, 0.75 +/- 0.31/56.6% to 1.12 +/- 0.80/35.3%, FENT), 1.37 +/- 0.19/20.8% (1.23 +/- 0.14/28.9% to 1.51 +/- 0.22/12.7%, KET), 1.34 +/- 0.19/22.5% (1.24 +/- 0.19/28.3% to 1.44 +/- 0.21/16.8%, LIDO), 1.30 +/- 0.28/24.8% (1.16 +/- 0.18/32.9% to 1.43 +/- 0.32/17.3%, DEX), 0.95 +/- 0.19/54.9% (0.7 +/- 0.16/59.5% to 1.12 +/- 0.16/35.3%, LKD) and 1.73 +/- 0.18/0.0% (1.64 +/- 0.21 to 1.82 +/- 0.14, CONTROL/BUT) during surgery. FENT and LKD significantly reduced FE'Iso. Conclusions and clinical relevance At the doses administered, FENT and LKD had greater isoflurane-sparing effect than LIDO, KET or CONTROL/BUT, but not at all times. Low HR during FENT may limit improvement in MAP expected with reduced FE'Iso.	[Gutierrez-Blanco, Eduardo; Sauri-Arceo, Carlos H.; Bolio-Gonzalez, Manuel E.; Marin-Cano, Gabriela] Yucatan Autonomous Univ, Fac Vet Med, Dept Anim Hlth & Prevent Med, Merida, Venezuela; [Gutierrez-Blanco, Eduardo; Ibancovichi-Camarillo, Jose A.; Acevedo-Arcique, Carlos M.] Mexico State Autonomous Univ, Fac Vet Med, Dept Vet Anesthesiol, Toluca, Mexico; [Victoria-Mora, Jose M.] Mexico State Autonomous Univ, Dept Vet Orthoped & Traumatol, Fac Vet Med, Toluca, Mexico; [Steagall, Paulo V. M.] Univ Montreal, Dept Clin Sci, Fac Vet Med, St Hyacinthe, PQ J2S 2M2, Canada	Steagall, PVM (reprint author), Univ Montreal, Dept Clin Sci, Fac Vet Med, 3200 Rue Sicotte, St Hyacinthe, PQ J2S 2M2, Canada.	psteagall@gmail.com	Steagall, Paulo/W-6043-2019	Steagall, Paulo/0000-0003-4150-6043; Ibancovichi, Jose Antonio/0000-0003-1760-687X	SEP-PROMEP	Eduardo Gutierrez-Blanco was sponsored by a scholarship provided by SEP-PROMEP.	Aguado D, 2011, VET J, V189, P63, DOI 10.1016/j.tvjl.2010.05.029; Camargo JB, 2011, VET ANAESTH ANALG, V38, P252, DOI 10.1111/j.1467-2995.2011.00609.x; Campagnol D, 2007, AM J VET RES, V68, P1310; Columbano N, 2012, VET J, V193, P448, DOI 10.1016/j.tvjl.2011.12.005; Congdon JM, 2013, VET ANAESTH ANALG, V40, P464, DOI 10.1111/vaa.12036; Doherty T, 2007, VET ANAESTH ANALG, V34, P125, DOI 10.1111/j.1467-2995.2006.00301.x; Dyson DH, 1999, CAN VET J, V40, P327; Frolich MA, 2010, REGION ANESTH PAIN M, V35, P249, DOI 10.1097/AAP.0b013e3181d23386; Hendrickx JFA, 2008, ANESTH ANALG, V107, P494, DOI 10.1213/ane.0b013e31817b859e; Ilkiw JE, 1993, CAN J VET RES, V57, P248; Khan ZP, 1999, BRIT J ANAESTH, V83, P372; Khan ZP, 1999, ANAESTHESIA, V54, P146, DOI 10.1046/j.1365-2044.1999.00659.x; Ko JCH, 2000, J AM VET MED ASSOC, V217, P1025, DOI 10.2460/javma.2000.217.1025; Lin GY, 2008, VET ANAESTH ANALG, V35, P141, DOI 10.1111/j.1467-2995.2007.00365.x; Matsubara LM, 2009, VET ANAESTH ANALG, V36, P407, DOI 10.1111/j.1467-2995.2009.00471.x; Muir WW, 2003, AM J VET RES, V64, P1155, DOI 10.2460/ajvr.2003.64.1155; Murrell JC, 2005, VET ANAESTH ANALG, V32, P117, DOI 10.1111/j.1467-2995.2005.00233.x; Ortega M, 2011, CAN VET J, V52, P856; Pascoe PJ, 2006, VET ANAESTH ANALG, V33, P97, DOI 10.1111/j.1467-2995.2005.00236.x; Pawson P, 2008, SMALL ANIMAL CLIN PH, P113; Pozzi A, 2006, JAVMA-J AM VET MED A, V228, P53, DOI 10.2460/javma.228.1.53; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; Solano AM, 2006, AM J VET RES, V67, P21, DOI 10.2460/ajvr.67.1.21; Steagall PVM, 2006, JAVMA-J AM VET MED A, V229, P522, DOI 10.2460/javma.229.4.522; STEFFEY EP, 1977, AM J VET RES, V38, P1833; Ueyama Y, 2009, AM J VET RES, V70, P1459, DOI 10.2460/ajvr.70.12.1459; Uilenreef JJ, 2008, VET ANAESTH ANALG, V35, P1, DOI 10.1111/j.1467-2995.2007.00344.x; Valverde A, 2004, VET ANAESTH ANALG, V31, P264, DOI 10.1111/j.1467-2995.2004.00165.x; Wagner AE, 2002, J AM VET MED ASSOC, V221, P72, DOI 10.2460/javma.2002.221.72; Wilson J, 2008, VET ANAESTH ANALG, V35, P289, DOI 10.1111/j.1467-2995.2007.00389.x	30	24	24	0	20	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	NOV	2013	40	6					599	609		10.1111/vaa.12079			11	Veterinary Sciences	Veterinary Sciences	297JS	WOS:000330252300018	23910822				2020-06-30	J	Tutunaru, AC; Sonea, A; Drion, P; Serteyn, D; Sandersen, C				Tutunaru, Alexandru C.; Sonea, Alexandru; Drion, Pierre; Serteyn, Didier; Sandersen, Charlotte			Anaesthetic induction with alfaxalone may produce hypoxemia in rabbits premedicated with fentanyl/droperidol	VETERINARY ANAESTHESIA AND ANALGESIA			English	Letter									[Tutunaru, Alexandru C.; Serteyn, Didier; Sandersen, Charlotte] Univ Liege, Clin Dept Compan Anim & Horses, Fac Vet Med, Liege, Belgium; [Tutunaru, Alexandru C.; Sonea, Alexandru] Univ Agron Sci & Vet Med Bucharest, Dept Clin Sci, Fac Vet Med, Bucharest, Romania; [Drion, Pierre] GIGA Univ Liege, Cent Anim Res Facil, Liege, Belgium	Tutunaru, AC (reprint author), Univ Liege, Clin Dept Compan Anim & Horses, Fac Vet Med, Liege, Belgium.	actutunaru@ulg.ac.be		Tutunaru, Alexandru/0000-0003-3848-762X			Gil AG, 2012, VET REC, V170, P444, DOI 10.1136/vr.100573; Grint NJ, 2008, VET REC, V163, P395, DOI 10.1136/vr.163.13.395; Hawkins MG, 2008, AM J VET RES, V69, P572, DOI 10.2460/ajvr.69.5.572; Marsh MK, 2009, VET REC, V164, P122, DOI 10.1136/vr.164.4.122; Murphy KL, 2010, VET ANAESTH ANALG, V37, P222, DOI 10.1111/j.1467-2995.2009.00525.x	5	2	2	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	NOV	2013	40	6					657	659		10.1111/vaa.12071			4	Veterinary Sciences	Veterinary Sciences	297JS	WOS:000330252300029	23837732				2020-06-30	J	Liao, X; Xue, FS; Wang, SY; Li, RP				Liao, Xu; Xue, Fu S.; Wang, Shi Y.; Li, Rui P.			Breast Implant Procedures under Conscious Sedation: A 6-Year Experience in 461 Consecutive Patients	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Letter							RECALL		[Xue, Fu S.] Chinese Acad Med Sci, Plast Surg Hosp, Dept Anesthesiol, Beijing 100144, Peoples R China; Peking Union Med Coll, Beijing 100144, Peoples R China	Xue, FS (reprint author), Chinese Acad Med Sci, Plast Surg Hosp, Dept Anesthesiol, 33 Ba Da Chu Rd, Beijing 100144, Peoples R China.	xuefushan@aliyun.com					Freeston JA, 2012, EMERG MED J, V29, P670, DOI 10.1136/emj.2010.092916; Gart MS, 2013, PLAST RECONSTR SURG, V131, P1169, DOI 10.1097/PRS.0b013e31828e2196; Kent CD, 2013, BRIT J ANAESTH, V110, P381, DOI 10.1093/bja/aes386; Sanchez A, 2007, BENUMOFS AIRWAY MANA, P256; Tourtier JP, 2011, NEW ENGL J MED, V365, P1159, DOI 10.1056/NEJMc1108378	5	0	0	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0032-1052	1529-4242		PLAST RECONSTR SURG	Plast. Reconstr. Surg.	NOV	2013	132	5					864E	865E		10.1097/PRS.0b013e3182a4c45e			2	Surgery	Surgery	293RI	WOS:000329991000021	24165641				2020-06-30	J	Gart, MS; Ko, JH; Mustoe, TA				Gart, Michael S.; Ko, Jason H.; Mustoe, Thomas A.			Reply: Breast Implant Procedures under Conscious Sedation: A 6-Year Experience in 461 Consecutive Patients	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Letter							SURGERY		[Gart, Michael S.; Mustoe, Thomas A.] NW Mem Hosp, Dept Surg, Div Plast & Reconstruct Surg, Chicago, IL 60611 USA; [Ko, Jason H.] Univ Washington, Dept Surg, Div Plast Surg, Seattle, WA 98195 USA	Mustoe, TA (reprint author), Northwestern Univ, Feinberg Sch Med, Div Plast & Reconstruct Surg, 675 North St Clair St,Galter Suite 19-250, Chicago, IL 60611 USA.	tmustoe@nmh.org					Bun MY, 1999, PLAST RECONSTR SURG, V103, P1260; Gart MS, 2013, PLAST RECONSTR SURG, V131, P1169, DOI 10.1097/PRS.0b013e31828e2196; Hasen KV, 2003, PLAST RECONSTR SURG, V112, P1683, DOI 10.1097/01.PRS.0000086363.34535.A4; Marcus JR, 2002, PLAST RECONSTR SURG, V109, P2487, DOI 10.1097/00006534-200206000-00049	4	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0032-1052	1529-4242		PLAST RECONSTR SURG	Plast. Reconstr. Surg.	NOV	2013	132	5					865E	866E		10.1097/01.prs.0000436782.70720.72			2	Surgery	Surgery	293RI	WOS:000329991000022	24165642				2020-06-30	J	Takakuwa, O; Oguri, T; Maeno, K; Yokoyama, M; Hijikata, H; Uemura, T; Ozasa, H; Ohkubo, H; Miyazaki, M; Niimi, A				Takakuwa, Osamu; Oguri, Tetsuya; Maeno, Ken; Yokoyama, Midori; Hijikata, Hisatoshi; Uemura, Takehiro; Ozasa, Hiroaki; Ohkubo, Hirotsugu; Miyazaki, Mikinori; Niimi, Akio			Analgesic Effect of Switching From Oral Opioids to a Once-a-Day Fentanyl Citrate Transdermal Patch in Patients With Lung Cancer	AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE			English	Article						fentanyl citrate; analgesic effect; face scale; lung cancer; oral opioid; transdermal fentanyl	PAIN; MORPHINE; MULTICENTER; EFFICACY	A new once-a-day fentanyl citrate transdermal patch was developed in Japan. We retrospectively investigated analgesic and adverse effects of this drug in 24 patients with lung cancer. All patients were started on this patch by switching from an oral opioid. The mean pain score before switching was 2.45 (0-5); 48 hours after switching, 15 of the 24 patients showed a decreased pain score and the mean score (2.00) was significantly lower than that before switching. Of the 16 patients who had adverse effects of oral opioids, 7 patients showed improvement in their symptoms after switching. Two patients showed adverse effects of the drug but their symptoms were mild, and no patient required dose decrease. This new transdermal patch could be a useful treatment option for cancer pain.	[Takakuwa, Osamu; Oguri, Tetsuya; Maeno, Ken; Yokoyama, Midori; Hijikata, Hisatoshi; Uemura, Takehiro; Ozasa, Hiroaki; Ohkubo, Hirotsugu; Miyazaki, Mikinori; Niimi, Akio] Nagoya City Univ, Grad Sch Med Sci, Dept Med Oncol & Immunol, Nagoya, Aichi 4678601, Japan	Oguri, T (reprint author), Nagoya City Univ, Grad Sch Med Sci, Dept Med Oncol & Immunol, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.	t-oguri@med.nagoya-cu.ac.jp		Ohkubo, Hirotsugu/0000-0002-8538-1150			Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056; Kokubun H, 2007, J PHARM HLTH CARE SC, V33, P200; Kress HG, 2008, J PAIN SYMPTOM MANAG, V36, P268, DOI 10.1016/j.jpainsymman.2007.10.023; Mercadante S, 2008, EUR J PAIN, V12, P1040, DOI 10.1016/j.ejpain.2008.01.013; Miyazaki Toyo, 2010, Gan To Kagaku Ryoho, V37, P1747; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Mystakidou K, 2003, INT J CANCER, V107, P486, DOI 10.1002/ijc.11416; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; Tassinari D, 2008, J PALLIAT MED, V11, P492, DOI 10.1089/jpm.2007.0200; Uchida E, 2010, RINSHO YAKUGAKU, V26, P335	13	4	4	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-9091	1938-2715		AM J HOSP PALLIAT ME	Am. J. Hosp. Palliat. Med.	NOV	2013	30	7					726	729		10.1177/1049909112470020			4	Health Care Sciences & Services	Health Care Sciences & Services	287EY	WOS:000329525600017	23264661				2020-06-30	J	Akyol, S; Tureci, E; Tanriverdi, T; Hanci, M				Akyol, Sibel; Tureci, Ercan; Tanriverdi, Taner; Hanci, Murat			How Analgesia-Sedation Alters Monocyte mCD14 and HLA-DR Levels in Patients Undergoing Cerebral Angiography?	TURKISH NEUROSURGERY			English	Article						Analgesia; Anesthesia; HLA-DR; Monocyte; Sedation	IMMUNE-RESPONSE; SURGERY; EXPRESSION; INTERLEUKIN-10; CELLS; ANESTHESIA; INFECTION; TRAUMA; SYSTEM	AIM: This study aims to evaluate how analgesia-sedation causes alterations of HLA-DR and cytokines (IL-10 and IL-6) in patients undergoing cerebral angiography for several cerebral vascular diseases. MATERIAL and METHODS:This study includes 41 males who underwent cerebral angiography.The study sample was divided into two: Group 1 had 7 patients who did not receive and group II had 34 patients who received analgesia-sedation before cerebral angiography. A venous blood sample was collected before and after cerebral angiography. RESULTS: Analgesia-sedation caused significant increase CD4+ and CD19T lymphocytes (p < 0.001) but group I showed significant increase in CD40, CD154, and MHC-II levels (p < 0.001) after cerebral angiography. CONCLUSION: We suggest that the effects of fentanyl and midazolam on the immune response are the reflection of the effects by the monocyte, mHLA-DR expression. In the future, depending on the immunological status of the patients, different anesthetic applications including the new anesthetic agents that will be able to decrease immune system suppression will be required.	[Akyol, Sibel] Istanbul Univ, Cerrahpasa Med Fac, Dept Physiol, Istanbul, Turkey; [Tureci, Ercan] Istanbul Univ, Cerrahpasa Med Fac, Dept Anesthesiol, Istanbul, Turkey; [Tanriverdi, Taner; Hanci, Murat] Istanbul Univ, Cerrahpasa Med Fac, Dept Neurosurg, Istanbul, Turkey	Tanriverdi, T (reprint author), Istanbul Univ, Cerrahpasa Med Fac, Dept Neurosurg, Istanbul, Turkey.	tanerato2000@yahoo.com	AKYOL, Sibel/D-7323-2019; HANCI, MURAT/A-7976-2016; Tanriverdi, Taner/C-9003-2019	HANCI, MURAT/0000-0001-9261-6686; 			Bauer M, 1998, ANAESTHESIST, V47, P538, DOI 10.1007/s001010050595; Benjamini E, 1991, IMMUNOLOGY SHORT COU, P175; Cardinale F, 2011, INT J IMMUNOPATH PH, V24, P3, DOI 10.1177/03946320110240S302; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; Griffis Charles A, 2008, AANA J, V76, P449; HERSHMAN MJ, 1990, BRIT J SURG, V77, P204, DOI 10.1002/bjs.1800770225; Levine S, 1991, STRESS NEUROBIOLOGY, P3; Lewis L, 1999, BASIC CLIN IMMUNOL, P61; Lyons A, 1997, ANN SURG, V226, P450, DOI 10.1097/00000658-199710000-00006; MALEFYT RD, 1991, J EXP MED, V174, P915; Mokart D, 2005, BRIT J ANAESTH, V94, P767, DOI 10.1093/bja/aei143; Ogata M, 2000, CRIT CARE MED, V28, P3166, DOI 10.1097/00003246-200009000-00007; SALO M, 1992, ACTA ANAESTH SCAND, V36, P201, DOI 10.1111/j.1399-6576.1992.tb03452.x; Schneider N, 2001, NEURORADIOLOGY, V43, P472, DOI 10.1007/s002340000522; Spittler A, 1997, IMMUNOLOGY, V90, P286, DOI 10.1046/j.1365-2567.1997.00148.x; STEVENSON GW, 1990, ANESTHESIOLOGY, V72, P542, DOI 10.1097/00000542-199003000-00024; Tureci E, 2011, TURK NEUROSURG, V21, P340, DOI 10.5137/1019-5149.JTN.4296-11.1; WAKEFIELD CH, 1993, BRIT J SURG, V80, P205, DOI 10.1002/bjs.1800800224	18	0	0	0	0	TURKISH NEUROSURGICAL SOC	BAHCELIEVLER	TASKENT CADDESI 13-4, BAHCELIEVLER, ANKARA 06500, TURKEY	1019-5149			TURK NEUROSURG	Turk. Neurosurg.	NOV	2013	23	6					791	795		10.5137/1019-5149.JTN.8218-13.0			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	288FZ	WOS:000329598700015	24310464				2020-06-30	J	Brustugun, J; Troland, S; Breivik, H				Brustugun, J.; Troland, S.; Breivik, H.			The stability of a sulphite-free epidural analgesic solution containing fentanyl, bupivacaine, and adrenaline	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							SODIUM METABISULFITE; MAJOR SURGERY; DOUBLE-BLIND; EPINEPHRINE; INFUSION; PHOTOSTABILITY; DEGRADATION; BISULFITE; ADMIXTURE; AGENTS	BackgroundThoracic epidural infusion analgesia is optimised by using a triple component infusion containing a local anaesthetic, an opioid, and adrenaline. Adrenaline in solution is prone to oxidation, and stabilisers, such as antioxidants (e.g. sulphites) or chelators (edetates), are therefore commonly added. Sulphites may, however, have unwanted effects, especially allergic reactions. The aim of this study was to evaluate the stability of an analgesic infusion solution for epidural administration free of sulphites, containing adrenaline, fentanyl, bupivacaine, and disodium edetate. MethodsAn epidural infusion solution containing adrenaline 2g/ml, fentanyl 2g/ml, bupivacaine 1mg/ml, and disodium edetate 0.18g/ml was stored at 2-8 degrees C for 4.5 months. A concentrate 11 times more potent, used for the production of the ready-to-use solution, was stored at 2-8 degrees C for 9 months. Concentrations of the active ingredients were determined, pH was measured throughout the period, the clarity of the solutions was investigated, and the weight of the infusion bags recorded. ResultsAfter 4.5 months at 2-8 degrees C, the infusion solution contained adrenaline 97.5%, bupivacaine 100.9%, and fentanyl 102.6%. The pH stayed between 4.76 and 4.79, the solutions remained clear, and the weight was 99.9% of that found initially. The solution was also stable for 7 days at room temperature. The concentrate was stable (>90%) for 9 months at 2-8 degrees C. ConclusionThe solution containing adrenaline, fentanyl, and bupivacaine, stabilised with disodium edetate, is stable for several months at 2-8 degrees C, and at least for 7 days at room temperature without the addition of sulphites. Accepted for publication 2 September 2013 (c) 2013 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd	[Brustugun, J.; Troland, S.] Sykehusapotekene HF, Hosp Pharm, Oslo Univ Hosp, Rikshosp, Oslo, Norway; [Breivik, H.] Univ Oslo, Oslo, Norway; [Breivik, H.] Natl Hosp Norway, Dept Anaesthesia, Oslo Univ Hosp, N-0424 Oslo, Norway; [Breivik, H.] Natl Hosp Norway, Dept Pain Management & Res, Oslo Univ Hosp, N-0424 Oslo, Norway	Brustugun, J (reprint author), Natl Hosp Norway, Hosp Pharm, Oslo Univ Hosp, Pb 4950 Nydalen, N-0424 Oslo, Norway.	Jorgen.Brustugun@sykehusapotekene.no	Breivik, Harald/AAG-2978-2020	Breivik, Harald/0000-0002-1738-9337	Fresenius Kabi, Halden, Norway; Hospital Pharmacy at Oslo University Hospital, Rikshospitalet, Oslo, Norway; Inven2	The study was supported by Fresenius Kabi, Halden, Norway, and the Hospital Pharmacy at Oslo University Hospital, Rikshospitalet, Oslo, Norway.; Inven2, a government institution for funding and commercialisation of research at the Oslo University Hospital, receives royalties of sales of the ready-to-use epidural solution from Fresenius Kabi, Halden, Norway. The authors have previously received research funding from Inven2.	Basketter DA, 1997, FOOD CHEM TOXICOL, V35, P845, DOI 10.1016/S0278-6915(97)00053-7; BROMAGE PR, 1983, ANESTHESIOLOGY, V58, P257, DOI 10.1097/00000542-198303000-00010; Brustugun J, 2000, PDA J PHARM SCI TECH, V54, P136; Brustugun J, 2004, PDA J PHARM SCI TECH, V58, P296; Brustugun J, 2004, PHARMAZIE, V59, P457; COLLINS JG, 1984, ANESTHESIOLOGY, V60, P269, DOI 10.1097/00000542-198404000-00001; Connors K. A., 1986, CHEM STABILITY PHARM, P438; Curatolo M, 2000, ANESTHESIOLOGY, V92, P325, DOI 10.1097/00000542-200002000-00012; DOOMSGOOSSENS A, 1989, CONTACT DERMATITIS, V20, P124, DOI 10.1111/j.1600-0536.1989.tb03120.x; EISENACH JC, 1987, ANESTH ANALG, V66, P447, DOI 10.1213/00000539-198705000-00014; Forster JG, 2008, ANESTH ANALG, V106, P301, DOI 10.1213/01.ane.0000287673.27439.19; Ginosar Y, 2003, ANESTH ANALG, V97, P1428, DOI 10.1213/01.ANE.0000081793.60059.10; Heacock RA, 1973, PROG MED CHEM, V9, P275; Helin-Tanninen M, 2013, J CLIN PHARM THER, V38, P104, DOI 10.1111/jcpt.12035; Kjonniksen I, 2000, ACTA ANAESTH SCAND, V44, P864, DOI 10.1034/j.1399-6576.2000.440713.x; Madan V, 2007, CONTACT DERMATITIS, V57, P173, DOI 10.1111/j.1600-0536.2007.01188.x; Niemi G, 1998, ACTA ANAESTH SCAND, V42, P897, DOI 10.1111/j.1399-6576.1998.tb05348.x; Niemi G, 2003, ACTA ANAESTH SCAND, V47, P439, DOI 10.1034/j.1399-6576.2003.00077.x; Owen SC, 2003, HDB PHARM EXCIPIENTS, P225; Priston MJ, 2004, ANAESTHESIA, V59, P979, DOI 10.1111/j.1365-2044.2004.03803.x; ROSCOE CW, 1956, J AM PHARM ASSOC, V45, P464, DOI 10.1002/jps.3030450711; SMOLINSKE SC, 1992, J TOXICOL-CLIN TOXIC, V30, P597, DOI 10.3109/15563659209017945; Stepensky D, 2004, J PHARM SCI-US, V93, P969, DOI 10.1002/jps.20010; Vally H, 2009, CLIN EXP ALLERGY, V39, P1643, DOI 10.1111/j.1365-2222.2009.03362.x	24	2	2	0	12	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	NOV	2013	57	10					1321	1327		10.1111/aas.12206			7	Anesthesiology	Anesthesiology	272UT	WOS:000328487700011	24134445				2020-06-30	J	Ercan, S; Davutoglu, V; Yuce, M				Ercan, Suleyman; Davutoglu, Vedat; Yuce, Murat			Anxiety Score as a Risk Factor for Radial Artery Spasm During Transradial Procedures	JACC-CARDIOVASCULAR INTERVENTIONS			English	Letter									[Ercan, Suleyman] Gaziantep Univ, Sch Med, Dept Cardiol, TR-27310 Gaziantep, Turkey	Ercan, S (reprint author), Gaziantep Univ, Sch Med, Dept Cardiol, TR-27310 Gaziantep, Turkey.	sleymanercan@yahoo.com					Deftereos S, 2013, JACC-CARDIOVASC INTE, V6, P267, DOI 10.1016/j.jcin.2012.11.005; Ercan S, 2014, ANGIOLOGY, V65, P67, DOI 10.1177/0003319713488931	2	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1936-8798	1876-7605		JACC-CARDIOVASC INTE	JACC-Cardiovasc. Interv.	NOV	2013	6	11					1214	1215		10.1016/j.jcin.2013.04.025			3	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	272KB	WOS:000328458100017	24262623	Bronze			2020-06-30	J	Deftereos, S; Giannopoulos, G				Deftereos, Spyridon; Giannopoulos, Georgios			On the Relation of Anxiety to Radial Spasm and the Use of Smaller-Diameter Sheaths Reply	JACC-CARDIOVASCULAR INTERVENTIONS			English	Letter									[Giannopoulos, Georgios] Athens Gen Hosp G Gennimatas, Athens 11527, Greece	Giannopoulos, G (reprint author), Athens Gen Hosp G Gennimatas, 154 Mesoge Ave, Athens 11527, Greece.	ggiann@med.uoa.gr	Giannopoulos, Georgios/AAL-1228-2020	Giannopoulos, Georgios/0000-0002-7287-3850			Deftereos S, 2013, JACC-CARDIOVASC INTE, V6, P267, DOI 10.1016/j.jcin.2012.11.005	1	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1936-8798	1876-7605		JACC-CARDIOVASC INTE	JACC-Cardiovasc. Interv.	NOV	2013	6	11					1215	1215		10.1016/j.jcin.2013.05.021			1	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	272KB	WOS:000328458100018	24262625	Bronze			2020-06-30	J	Honda, CKY; Freitas, FGR; Stanich, P; Mazza, BF; Castro, I; Nascente, PM; Bafi, AT; Azevedo, LCP; Machado, FR				Yamamoto Honda, Carolina Keiko; Rezende Freitas, Flavio Geraldo; Stanich, Patricia; Mazza, Bruno Franco; Castro, Isac; Nascente, Paula Metran; Bafi, Antonio Toneti; Pontes Azevedo, Luciano Cesar; Machado, Flavia Ribeiro			NURSE TO BED RATIO AND NUTRITION SUPPORT IN CRITICALLY ILL PATIENTS	AMERICAN JOURNAL OF CRITICAL CARE			English	Article							INTENSIVE-CARE-UNIT; MECHANICALLY VENTILATED PATIENTS; EARLY ENTERAL NUTRITION; PARENTERAL-NUTRITION; ENERGY-EXPENDITURE; DELIVERY; METAANALYSIS; TRIAL; INTOLERANCE; GUIDELINES	Background Inadequate nutrition support is common among critically ill patients, and identification of risk factors for such inadequacy might help in improving nutrition support. Objective To determine how often daily calorie goals are met and the factors responsible for inadequate nutrition support. Methods A single-center prospective cohort study. Each patient's demographic and clinical characteristics, the need for ventilatory support, the use and dosage of medications, the number of nursing staff per bed, the time elapsed from admission to the intensive care unit until the effective start of enteral feeding, and the causes for nonadministration were recorded. Achievement of daily calorie goals was determined and correlated with risk factors. Results A total of 262 daily evaluations were done in 40 patients. Daily calorie goal was achieved in only 46.2% of the evaluations (n = 121), with a mean of 74.8% of the prescribed volume of enteral nutrition infused daily. Risk factors for inadequate nutrition support were the use of midazolam (odds ratio, 1.58; 95% CI, 1.18-2.11) and fewer nursing professionals per bed (odds ratio, 2.56; 95% CI, 1.43-4.57). Conclusion Achievement of daily calorie goals was inadequate, and the main factors associated with this failure were the use and dosage of midazolam and the number of nurses available.	[Machado, Flavia Ribeiro] Univ Fed Sao Paulo, Anesthesiol Pain & Intens Care Dept, BR-04024900 Sao Paulo, Brazil; [Yamamoto Honda, Carolina Keiko; Rezende Freitas, Flavio Geraldo; Stanich, Patricia; Mazza, Bruno Franco; Castro, Isac; Nascente, Paula Metran; Bafi, Antonio Toneti; Pontes Azevedo, Luciano Cesar; Machado, Flavia Ribeiro] Hosp Sao Paulo, Sao Paulo, Brazil	Machado, FR (reprint author), Univ Fed Sao Paulo, Anesthesiol Pain & Intens Care Dept, R Pedro Toledo 715 5 Andar, BR-04024900 Sao Paulo, Brazil.	frmachado@unifesp.br	Azevedo, Luciano CP/H-2652-2012; Machado, Flavia R/G-4651-2012; Castro, Isac/J-1984-2015; Bafi, Antonio/H-2015-2012	Machado, Flavia R/0000-0002-2356-4867; Bafi, Antonio/0000-0003-2283-9109			Adam S, 1997, INTENS CARE MED, V23, P261, DOI 10.1007/s001340050326; Binnekade JM, 2005, CRIT CARE, V9, pR218, DOI 10.1186/cc3504; Bou R, 2013, ENFERM INFEC MICR CL, DOI [10.1016/j.eimc.2012.11.010, DOI 10.1016/J.EIMC.2012.11.010.[]; Braunschweig CL, 2001, AM J CLIN NUTR, V74, P534; Cartolano Flavia De Conti, 2009, Rev Bras Ter Intensiva, V21, P376; Casaer MP, 2011, NEW ENGL J MED, V365, P506, DOI 10.1056/NEJMoa1102662; Cheng CH, 2002, CLIN NUTR, V21, P165, DOI 10.1054/clnu.2002.0526; De Jonghe B, 2001, CRIT CARE MED, V29, P8, DOI 10.1097/00003246-200101000-00002; Dhaliwal R, 2004, INTENS CARE MED, V30, P1666, DOI 10.1007/s00134-004-2345-y; Doig GS, 2009, INTENS CARE MED, V35, P2018, DOI 10.1007/s00134-009-1664-4; Doig GS, 2008, JAMA-J AM MED ASSOC, V300, P2731, DOI 10.1001/jama.2008.826; Elpern EH, 2004, AM J CRIT CARE, V13, P221, DOI 10.4037/ajcc2004.13.3.221; Engel JM, 2003, CLIN NUTR, V22, P187, DOI 10.1054/clnu.2002.0622; Gramlich L, 2004, NUTRITION, V20, P843, DOI 10.1016/j.nut.2004.06.003; HEYLAND D, 1995, CRIT CARE MED, V23, P1055, DOI 10.1097/00003246-199506000-00010; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P355, DOI 10.1177/0148607103027005355; Heyland DK, 1998, JAMA-J AM MED ASSOC, V280, P2013, DOI 10.1001/jama.280.23.2013; Ibrahim EH, 2002, JPEN-PARENTER ENTER, V26, P174, DOI 10.1177/0148607102026003174; Japur CC, 2009, J CRIT CARE, V24, DOI 10.1016/j.jcrc.2008.12.007; Koretz RL, 2007, AM J GASTROENTEROL, V102, P412, DOI 10.1111/j.1572-0241.2006.01024.x; Kyle UG, 2006, CLIN NUTR, V25, P727, DOI 10.1016/j.clnu.2006.03.011; MacLeod JBA, 2007, J TRAUMA, V63, P57, DOI 10.1097/01.ta.0000249294.58703.11; Marik PE, 2001, CRIT CARE MED, V29, P2264, DOI 10.1097/00003246-200112000-00005; Martin CM, 2004, CAN MED ASSOC J, V170, P197, DOI 10.1503/cmaj.1040621; McClave SA, 1999, CRIT CARE MED, V27, P1252, DOI 10.1097/00003246-199907000-00003; Mentec H, 2001, CRIT CARE MED, V29, P1955, DOI 10.1097/00003246-200110000-00018; Miles JM, 2006, MAYO CLIN PROC, V81, P809, DOI 10.4065/81.6.809; Nguyen NQ, 2007, INTENS CARE MED, V33, P1740, DOI 10.1007/s00134-007-0712-1; Nishizaki Y, 2010, J MULTIDISCIP HEALTH, V3, P49; O'Leary-Kelley CM, 2005, AM J CRIT CARE, V14, P222; O'Meara D, 2008, AM J CRIT CARE, V17, P53; Oliveira Suzana Meira de, 2010, Rev. bras. ter. intensiva, V22, P270, DOI 10.1590/S0103-507X2010000300009; Peter JV, 2005, CRIT CARE MED, V33, P213, DOI 10.1097/01.CCM.0000150960.36228.C0; Petros S, 2006, CLIN NUTR, V25, P51, DOI 10.1016/j.clnu.2005.08.013; Rice TW, 2011, CRIT CARE MED, V39, P967, DOI 10.1097/CCM.0b013e31820a905a; Rice TW, 2005, NUTRITION, V21, P786, DOI 10.1016/j.nut.2004.11.014; Santos Laura Jurema dos, 2009, Rev. bras. ter. intensiva, V21, P129, DOI 10.1590/S0103-507X2009000200003; Schwab F, 2012, J HOSP INFECT, V80, P133, DOI 10.1016/j.jhin.2011.11.014; Serpa Letícia Faria, 2003, Rev. Hosp. Clin., V58, P9, DOI 10.1590/S0041-87812003000100003; Simpson F, 2005, INTENS CARE MED, V31, P12, DOI 10.1007/s00134-004-2511-2; Stapleton RD, 2007, CRIT CARE MED, V35, pS535, DOI 10.1097/01.CCM.0000279204.24648.44; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; Teixeira Ana Carolina de Castro, 2006, Rev. bras. ter. intensiva, V18, P331, DOI 10.1590/S0103-507X2006000400003; van den Broek PWJH, 2009, BRIT J NUTR, V101, P68, DOI 10.1017/S0007114508986852; van Schijndel RJMS, 2009, CRIT CARE, V13, DOI 10.1186/cc7993; Woien H, 2006, J CLIN NURS, V15, P168, DOI 10.1111/j.1365-2702.2006.01262.x; Woo SH, 2010, NUTR CLIN PRACT, V25, P205, DOI 10.1177/0884533610361605	47	4	4	0	3	AMER ASSOC CRITICAL CARE NURSES	ALISO VIEJO	101 COLUMBIA, ALISO VIEJO, CA 92656 USA	1062-3264	1937-710X		AM J CRIT CARE	Am. J. Crit. Care	NOV 1	2013	22	6					E71	E78		10.4037/ajcc2013610			8	Critical Care Medicine; Nursing	General & Internal Medicine; Nursing	268KB	WOS:000328167700002	24186828	Bronze			2020-06-30	J	Subedi, A; Biswas, BK; Tripathi, M; Bhattarai, BK; Pokharel, K				Subedi, A.; Biswas, B. K.; Tripathi, M.; Bhattarai, B. K.; Pokharel, K.			Analgesic effects of intrathecal tramadol in patients undergoing caesarean section: a randomised, double-blind study	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Caesarean section; Spinal anaesthesia; Tramadol	SOMATOSENSORY-EVOKED POTENTIALS; POSTOPERATIVE ANALGESIA; EPIDURAL-ANESTHESIA; PAIN RELIEF; LABOR PAIN; RATS; BUPIVACAINE; SUFENTANIL; MOTOR; RESPIRATION	Background: Intrathecal tramadol combined with local anaesthetics has been used for postoperative analgesia following lower abdominal and perineal surgery. The present study evaluated the effect of intrathecal tramadol on spinal block characteristics and neonatal outcome after elective caesarean section. Methods: Eighty full-term parturients scheduled for elective caesarean section were randomly divided into two groups. In the fentanyl group, patients received intrathecal 0.5% bupivacaine 10 mg with fentanyl 10 jig; in the tramadol group, patients were given the same dose of bupivacaine with tramadol 10 mg. Sensory and motor block characteristics, duration of postoperative analgesia, maternal side effects, and neonatal outcome were compared. Results: One patient in the tramadol group and two patients in the fentanyl group were excluded from data analysis. Median [interquartile range] duration of postoperative analgesia in the tramadol and the fentanyl groups was 300 [240-360] min and 260 [233-300] min respectively (P = 0.02). The incidence of shivering was lower in patients who received tramadol (5%) than those who had fentanyl (32%) (P = 0.003). Apgar scores, umbilical cord acid base measurement and neurologic and adaptive capacity scores were comparable between the two groups. Conclusion: Compared to intrathecal fentanyl 10 jig, tramadol 10 mg, as an adjunct to bupivacaine for subarachnoid block for caesarean section, showed a longer duration of analgesia with a reduced incidence of shivering. (C) 2013 Elsevier Ltd. All rights reserved.	[Subedi, A.; Bhattarai, B. K.; Pokharel, K.] BP Koirala Inst Hlth Sci, Dept Anaesthesiol, Dharan, Nepal; [Biswas, B. K.] ESI Postgrad Inst Med Sci & Res, Dept Anesthesiol, Kolkata, India; [Tripathi, M.] Sanjay Gandhi Postgrad Inst Med Sci, Dept Anaesthesiol, Lucknow, Uttar Pradesh, India	Subedi, A (reprint author), BP Koirala Inst Hlth Sci, Dept Anaesthesiol & Crit Care, Dharan, Nepal.	subediasish@yahoo.com	Tripathi, Mukesh/U-8188-2019	Pokharel, Krishna/0000-0001-7338-4891			ABBOUD TK, 1983, ANESTHESIOLOGY, V59, P1, DOI 10.1097/00000542-198307000-00001; Ahci HA, 2006, EAJM, V38, P61; Alhashemi JA, 2003, BRIT J ANAESTH, V91, P536, DOI 10.1093/bja/aeg213; Bamigbade TA, 1998, PAIN REV, V5, P155, DOI 10.1191/096813098668122984; BARAKA A, 1993, CAN J ANAESTH, V40, P308, DOI 10.1007/BF03009627; Barrett NA, 2003, BRIT J ANAESTH, V91, P918, DOI 10.1093/bja/aeg265; BERNATZKY G, 1986, EUR J PHARMACOL, V120, P75, DOI 10.1016/0014-2999(86)90642-4; Borgeat A, 2003, ANESTHESIOLOGY, V98, P530, DOI 10.1097/00000542-200302000-00036; Bromage P R, 1965, Acta Anaesthesiol Scand Suppl, V16, P55; CAMPBELL DC, 1995, ANESTH ANALG, V81, P305, DOI 10.1097/00000539-199508000-00017; CARLSSON KH, 1987, EUR J PHARMACOL, V139, P1, DOI 10.1016/0014-2999(87)90491-2; Chakraborty S, 2008, INDIAN J PHARMACOL, V40, P180, DOI 10.4103/0253-7613.43166; Claahsen-van der Grinten HL, 2005, EUR J CLIN PHARMACOL, V61, P523, DOI 10.1007/s00228-005-0955-0; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; Dahlgren G, 1997, ANESTH ANALG, V85, P1288, DOI 10.1097/00000539-199712000-00020; Dayer P, 1997, DRUGS, V53, P18, DOI 10.2165/00003495-199700532-00006; De Andres J, 2010, PAIN MED, V11, P1059, DOI 10.1111/j.1526-4637.2010.00885.x; deWitte J, 1997, ACTA ANAESTH SCAND, V41, P506, DOI 10.1111/j.1399-6576.1997.tb04732.x; Duthie DJR, 1998, BRIT J ANAESTH, V81, P51; Frikha N., 2007, Middle East Journal of Anesthesiology, V19, P87; Halpern SH, 2001, ANESTHESIOLOGY, V94, P958, DOI 10.1097/00000542-200106000-00007; Jou IM, 2003, ANESTH ANALG, V96, P783, DOI 10.1213/01.ANE.0000049683.58980.30; Jung JI, 1999, KOREAN J ANESTHESIOL, V37, P227, DOI DOI 10.4097/KJAE.1999.37.2.227]; Kimura M, 2012, ANESTH ANALG, V115, P443, DOI 10.1213/ANE.0b013e31825683c3; KOENIGSTEIN H, 1948, ARCH DERMATOL SYPH, V57, P828, DOI 10.1001/archderm.1948.01520180045006; Koga A, 2005, BRIT J PHARMACOL, V145, P602, DOI 10.1038/sj.bjp.0706225; LEE CR, 1993, DRUGS, V46, P313, DOI 10.2165/00003495-199346020-00008; Lew E, 2004, ANESTH ANALG, V98, P810; Li C, 2012, J ANESTH, V26, P230, DOI 10.1007/s00540-011-1267-4; Liu NJ, 1999, PAIN, V83, P359, DOI 10.1016/S0304-3959(99)00120-7; Long JJ, 2003, CHINESE MED J-PEKING, V116, P1752; Mathews S, 2002, ANAESTHESIA, V57, P394; Mostafa MG, 2011, J AM SCI, V7, P480; Parthasarathy S, 2002, J ANAESTHESIOL CLIN, V18, P419; Porter J, 1998, ANESTHESIOLOGY, V89, P79, DOI 10.1097/00000542-199807000-00014; Prosser DP, 1997, BRIT J ANAESTH, V79, P293, DOI 10.1093/bja/79.3.293; RAFFA RB, 1992, J PHARMACOL EXP THER, V260, P275; Salman MA, 2003, ACTA ANAESTH SCAND, V47, P1006, DOI 10.1034/j.1399-6576.2003.00180.x; Scott LJ, 2000, DRUGS, V60, P139, DOI 10.2165/00003495-200060010-00008; Selve N, 1996, BRAIN RES, V735, P177, DOI 10.1016/0006-8993(96)00543-4; SPIELMAN FJ, 1985, ANESTHESIOLOGY, V62, P193, DOI 10.1097/00000542-198502000-00022; Tarkkila P, 1998, EUR J ANAESTH, V15, P64, DOI 10.1097/00003643-199801000-00013; Tsai YC, 2001, ANESTH ANALG, V92, P1547; VICKERS MD, 1992, ANAESTHESIA, V47, P291, DOI 10.1111/j.1365-2044.1992.tb02166.x	44	8	8	1	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	NOV	2013	22	4					316	321		10.1016/j.ijoa.2013.05.009			6	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	253AO	WOS:000327054200010	23962470				2020-06-30	J	Takeuchi, Y				Takeuchi, Yoji			Screening Colonoscopy: Still the Best Choice, but for How Long?	DIGESTIVE DISEASES AND SCIENCES			English	Editorial Material							COLORECTAL-CANCER; POLYPECTOMY; PREVENTION; RISK		Osaka Med Ctr Canc & Cardiovasc Dis, Dept Gastrointestinal Oncol, Higashinari Ku, Tokyo 5378511, Japan	Takeuchi, Y (reprint author), Osaka Med Ctr Canc & Cardiovasc Dis, Dept Gastrointestinal Oncol, Higashinari Ku, 1-3-3 Nakamichi, Tokyo 5378511, Japan.	takeuti-yo@mc.pref.osaka.jp	Takeuchi, Yoji/H-3395-2019	Takeuchi, Yoji/0000-0003-3814-298X			Atkin WS, 2012, ENDOSCOPY, V44, pSE151, DOI 10.1055/s-0032-1309821; Brenner H, 2010, GASTROENTEROLOGY, V138, P870, DOI 10.1053/j.gastro.2009.10.054; Czwornog J, DIGEST DIS SCI, DOI [10.1007/s10620-013-2746-2., DOI 10.1007/S10620-013-2746-2]; de Jonge V, 2012, AM J GASTROENTEROL, V107, P878, DOI 10.1038/ajg.2012.40; Lieberman DA, 2012, GASTROENTEROLOGY, V143, P844, DOI 10.1053/j.gastro.2012.06.001; Schoenfeld P, 2005, NEW ENGL J MED, V352, P2061, DOI 10.1056/NEJMoa042990; Sonnenberg A, 2000, ANN INTERN MED, V133, P573, DOI 10.7326/0003-4819-133-8-200010170-00007; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; Young PE, 2013, J CANCER, V4, P217, DOI 10.7150/jca.5829; Zauber AG, 2012, NEW ENGL J MED, V366, P687, DOI 10.1056/NEJMoa1100370	10	0	0	0	2	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0163-2116	1573-2568		DIGEST DIS SCI	Dig. Dis. Sci.	NOV	2013	58	11					3064	3065		10.1007/s10620-013-2881-9			2	Gastroenterology & Hepatology	Gastroenterology & Hepatology	241SU	WOS:000326188800002	24061592	Bronze			2020-06-30	J	Czwornog, J; Austin, GL				Czwornog, Jennifer; Austin, Gregory L.			Body Mass Index, Age, and Gender Affect Prep Quality, Sedation Use, and Procedure Time During Screening Colonoscopy	DIGESTIVE DISEASES AND SCIENCES			English	Article						Colorectal cancer screening; Age; Gender; Body mass index; Adenoma prevalence	FECAL OCCULT-BLOOD; COLORECTAL-CANCER; OBESITY; RISK; METAANALYSIS; MORTALITY; ADULTS	Body mass index (BMI), age, and gender influence colorectal cancer (CRC) and adenoma risk. Their effects on colonoscopy characteristics are unclear, but might inform the screening approach in patient subgroups. The aims of this study were to assess the effect of BMI, age, and gender on prep quality, amount of sedation, procedure time, and adenoma prevalence for screening colonoscopy. We conducted a review of 773 eligible colonoscopies performed for average-risk CRC screening. We performed multivariable regression analyses to assess the outcomes of prep quality, amount of fentanyl and midazolam used, procedure time, and the adenoma prevalence rate (APR). Obese patients were less likely (p = 0.01) to have a good or excellent prep, had similar procedure times, and received similar amounts of fentanyl and midazolam. Increasing age had no effect on prep quality or procedure time, but was associated with decreased fentanyl and midazolam (both p a parts per thousand currency sign 0.001). Women had similar prep quality, longer procedure times (increased by 2.8 +/- A 0.7 min, p < 0.001) for colonoscopies in which no polyps were detected, and received more fentanyl and midazolam (both p = 0.01). Increasing BMI, increasing age, and male gender were associated with an increased APR. The APR for women aged 50-59 with a normal BMI was 17.9 %. Normal-weight females, particularly those under age 60, have the lowest APR but have longer procedure times and require higher amounts of sedation. Screening options other than colonoscopy might be well-suited to this population.	[Czwornog, Jennifer; Austin, Gregory L.] Univ Colorado Denver, Div Gastroenterol & Hepatol, Aurora, CO 80045 USA	Austin, GL (reprint author), Univ Colorado Denver, Div Gastroenterol & Hepatol, 12631 East 17th Ave,Room 7609, Aurora, CO 80045 USA.	jennifer.czwornog@ucdenver.edu; gregory.austin@ucdenver.edu					Atkin WS, 2010, LANCET, V375, P1624, DOI 10.1016/S0140-6736(10)60551-X; Borg BB, 2009, CLIN GASTROENTEROL H, V7, P670, DOI 10.1016/j.cgh.2009.02.014; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Elphick DA, 2009, EUR J GASTROEN HEPAT, V21, P1076, DOI 10.1097/MEG.0b013e32832357b3; Flegal KM, 2012, JAMA-J AM MED ASSOC, V307, P491, DOI 10.1001/jama.2012.39; GIOVANNUCCI E, 1995, ANN INTERN MED, V122, P327, DOI 10.7326/0003-4819-122-5-199503010-00002; Hoffmeister M, 2010, CLIN GASTROENTEROL H, V8, P870, DOI 10.1016/j.cgh.2010.07.004; Hsieh YH, 2008, J GASTROEN HEPATOL, V23, P215, DOI 10.1111/j.1440-1746.2006.04818.x; Imperiale TF, 2012, AM J MED, V125, P1181, DOI 10.1016/j.amjmed.2012.05.026; Khiani VS, 2009, GASTROINTEST ENDOSC, V70, P1116, DOI 10.1016/j.gie.2009.05.036; Mandel JS, 2000, NEW ENGL J MED, V343, P1603, DOI 10.1056/NEJM200011303432203; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; Nguyen SP, 2009, CLIN GASTROENTEROL H, V7, P676, DOI 10.1016/j.cgh.2009.01.008; Okabayashi K, 2012, AM J GASTROENTEROL, V107, P1175, DOI 10.1038/ajg.2012.180; Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X; Shapiro JA, 2012, CANCER EPIDEM BIOMAR, V21, P895, DOI 10.1158/1055-9965.EPI-12-0192; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Winawer SJ, 2006, CA-CANCER J CLIN, V56, P143, DOI 10.3322/canjclin.56.3.143	18	9	10	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0163-2116	1573-2568		DIGEST DIS SCI	Dig. Dis. Sci.	NOV	2013	58	11					3127	3133		10.1007/s10620-013-2746-2			7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	241SU	WOS:000326188800013	23812829				2020-06-30	J	Hans, GH				Hans, Guy H.			Treatment of breakthrough cancer pain: to titrate or to proportionate?	CURRENT MEDICAL RESEARCH AND OPINION			English	Editorial Material						Breakthrough cancer pain; Fentanyl; Pain; Rapid-onset formulation	PALLIATIVE MEDICINE; RECOMMENDATIONS; MANAGEMENT; PREVALENCE; OPIOIDS; SOCIETY	Breakthrough cancer pain can be treated effectively by rapid-onset opioids, such as sublingual fentanyl. However, it remained unclear how the optimal dose of sublingual fentanyl should be determined. Dosing proportional to basic opioid regimen is now proposed as an alternative to dose titration.	[Hans, Guy H.] Antwerp Univ Hosp UZA, Dept Anesthesiol, Edegem, Belgium; [Hans, Guy H.] Antwerp Univ Hosp UZA, Multidisciplinary Pain Ctr PCT, B-2650 Edegem, Belgium; [Hans, Guy H.] Univ Antwerp, Fac Med & Hlth Sci, Lab Pain Res, Antwerp, Belgium	Hans, GH (reprint author), Antwerp Univ Hosp UZA, Multidisciplinary Pain Ctr PCT, Wilrijkstr 10, B-2650 Edegem, Belgium.	guy.hans@uza.be	Hans, Guy H./B-8507-2008	Hans, Guy H./0000-0003-4522-9055			Beutlhauser T, 2013, ANAESTHESIST, V62, P431, DOI 10.1007/s00101-013-2193-7; Caraceni A, 2013, J NATL COMPR CANC NE, V11, pS29; Caraceni A, 2012, J PAIN SYMPTOM MANAG, V43, P833, DOI 10.1016/j.jpainsymman.2011.05.018; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Elsner F, 2011, CLIN DRUG INVEST, V31, P605, DOI 10.2165/11592910-000000000-00000; Gordon DB, 2005, ARCH INTERN MED, V165, P1574, DOI 10.1001/archinte.165.14.1574; Hagelberg NM, 2010, PAIN, V151, P565, DOI 10.1016/j.pain.2010.08.026; Mercadante S, 2013, CURR MED RES OPIN, V29, P1527, DOI 10.1185/03007995.2013.826640; Mercadante S, 2013, SUPPORT CARE CANCER, V21, P2335, DOI 10.1007/s00520-013-1799-2; Meriggi F, 2013, REV RECENT CLIN TRIA, V8, P42, DOI 10.2174/15748871112079990039; Patt RB, 1998, ONCOLOGY-NY, V12, P1035; Patt RB, 1998, ONCOLOGY WILLISTON P, V12, P1049; Portenoy Russell K, 2010, J Opioid Manag, V6, P109; Rustoen T, 2013, EUR J ONCOL NURS, V17, P95, DOI 10.1016/j.ejon.2012.05.005; Simpson KH, 2004, BRIT J ANAESTH, V92, P326, DOI 10.1093/bja/aeh059; Yamaguchi T, 2013, JPN J CLIN ONCOL, V43, P896, DOI 10.1093/jjco/hyt099; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5; Zeppetella G, 2013, J NATL COMPR CANC NE, V11, pS37	18	6	6	0	1	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.	NOV	2013	29	11					1523	1526		10.1185/03007995.2013.837816			4	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	237FD	WOS:000325853100014	23971682				2020-06-30	J	Okic, M; Cnossen, L; Crifasi, JA; Long, C; Mitchell, EK				Okic, Merisa; Cnossen, Leslie; Crifasi, Joseph A.; Long, Christopher; Mitchell, Erik K.			Opioid Overdose Mortality in Kansas, 20012011: Toxicologic Evaluation of Intent	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							UNITED-STATES; PRESCRIPTION OPIOIDS; DEATHS; OXYCONTIN(R); FENTANYL; ABUSE; ANALGESICS; RISK	Drug concentration is a factor in the determination of the manner of death, but considerable overlap exists between therapeutic and toxic concentrations. This study aims to quantify opioid mortality in Kansas from use of fentanyl, methadone and oxycodone and to evaluate utility of drug concentrations for the determination of the manner of death. Cases referred to a forensic pathology practice in Kansas for autopsy from 1 January 2001 to 31 December 2011 were considered. The criterion for inclusion was detection of fentanyl, methadone and/or oxycodone in postmortem toxicology. Of 9,789 cases, 3,315 had positive toxicology: 180 of fentanyl, 299 of methadone and 310 of oxycodone. There were 207 single opioid fatalities, 264 polydrug overdoses and 318 deaths where an opioid was present but not contributory to the mechanism of death. In line with published studies, incidence of opioid overdose deaths increased over the time of the study. Drug concentrations within each cause and manner of death covered broad ranges. Non-natural and natural manners had less overlap than existed within non-natural manners in limited comparisons. This study shows that drug concentration is independent of manner for non-natural deaths and although insufficient to identify intent, can provide a guideline in differentiating non-natural from natural deaths.	[Okic, Merisa; Mitchell, Erik K.] Frontier Forens Midwest LLC, Kansas City, KS 66102 USA; [Crifasi, Joseph A.; Long, Christopher] St Louis Univ, Forens Toxicol Lab, Berkeley, MO 63134 USA	Okic, M (reprint author), Frontier Forens Midwest LLC, 40 S 18th St, Kansas City, KS 66102 USA.	coroner@frontierforensics.com			Frontier Forensics Midwest, LLC of Kansas City, KS, USA	This work was supported by Frontier Forensics Midwest, LLC of Kansas City, KS, USA.	Anderson DT, 2002, J ANAL TOXICOL, V26, P448, DOI 10.1093/jat/26.7.448; Aquina CT, 2009, POSTGRAD MED, V121, P163, DOI 10.3810/pgm.2009.03.1988; Cicero TJ, 2005, J PAIN, V6, P662, DOI 10.1016/j.jpain.2005.05.004; EBADI MS, 2008, DESK REFERENCE CLIN, P420; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; *INT NARC CONTR BO, 2012, T12XI2 INT NARC CONT; *INT NARC CONTR BO, 2003, EFS03XI2 INT NARC CO; Jones T. S., 2008, Morbidity and Mortality Weekly Report, V57, P793; Jumbelic MI, 2010, AM J FOREN MED PATH, V31, P18, DOI 10.1097/PAF.0b013e31818738b8; Katz N, 2011, AM J DRUG ALCOHOL AB, V37, P205, DOI 10.3109/00952990.2011.569623; LIPMAN AG, 2004, PAIN MANAGEMENT PRIM, P65; McLellan AT, 2008, JAMA-J AM MED ASSOC, V300, P2672, DOI 10.1001/jama.2008.793; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; Palmer RB, 2010, CLIN TOXICOL, V48, P771, DOI 10.3109/15563650.2010.525514; Paulozzi LJ, 2008, PHARMACOEPIDEM DR S, V17, P997, DOI 10.1002/pds.1626; Paulozzi LJ, 2006, PHARMACOEPIDEM DR S, V15, P618, DOI 10.1002/pds.1276; Paulozzi Leonard J., 2012, Morbidity and Mortality Weekly Report, V61, P493; Paulozzi LJ, 2012, PAIN MED, V13, P87, DOI 10.1111/j.1526-4637.2011.01260.x; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; *PDR NETW LLC, 2010, PHYS DESK REFERENCE, P2403; Toombs JD, 2005, AM FAM PHYSICIAN, V71, P1353; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133	23	6	6	1	17	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	NOV-DEC	2013	37	9					629	635		10.1093/jat/bkt085			7	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	236AP	WOS:000325766200003	24123621	Bronze			2020-06-30	J	Sethi, S; Ghai, B; Sen, I; Ram, J; Wig, J				Sethi, Sameer; Ghai, Babita; Sen, Indu; Ram, Jagat; Wig, Jyotsna			Efficacy of subtenon block in infants - a comparison with intravenous fentanyl for perioperative analgesia in infantile cataract surgery	PEDIATRIC ANESTHESIA			English	Article						subtenon block; infants; cataract surgery; fentanyl; analgesia	STRABISMUS SURGERY; PAIN; ANESTHESIA; SCORE	BackgroundGeneral anesthesia with opioids provides good perioperative analgesia in infantile ocular surgeries but is associated with the risk of respiratory depression and postoperative emesis. This study aimed to assess the effectiveness of subtenon block for providing perioperative analgesia in infants undergoing cataract surgeries. MethodsIn this prospective, randomized, controlled, double-blinded trial, 63 infants of ASA grade I and II (1-12months) were recruited to receive either subtenon block (Group SB) or 1g<bold></bold>kg(-1) i.v. fentanyl (Group F) after induction of anesthesia. Primary outcome was the number of infants requiring rescue analgesia during 4-h study period before discharge of the infants. Secondary outcomes assessed were CRIES pain score, incidence of oculocardiac reflex, surgical difficulty, and incidence of postoperative emesis. ResultsThe number of infants requiring rescue analgesia during 4-h study period was significantly less in Group SB (n=6/32, 18.8%) compared to Group F (n=14/31, 45.2%, P=0.032). CRIES scores were significantly lower at and after 40min compared to immediate postoperative period in Group F while these were comparable at all time intervals in Group SB. CRIES scores were significantly lower in Group SB compared to Group F at all time intervals except at 1h. The incidence of oculocardiac reflex and the postoperative emesis were comparable in both the groups. ConclusionSubtenon block is an effective superior technique for postoperative analgesia compared to intravenous fentanyl in infants undergoing cataract surgery.	[Sethi, Sameer; Ghai, Babita; Sen, Indu; Wig, Jyotsna] PGIMER, Dept Anesthesia & Intens Care, Chandigarh 160012, India; [Ram, Jagat] PGIMER, Dept Ophthalmol, Chandigarh 160012, India	Ghai, B (reprint author), PGIMER, Dept Anesthesia & Intens Care, Chandigarh 160012, India.	ghaibabita@hotmail.com					ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Bildner J, 1996, Neonatal Netw, V15, P11; Chambers CT, 1996, PAIN, V68, P307, DOI 10.1016/S0304-3959(96)03209-5; Chambers CT, 1998, CLIN J PAIN, V14, P336, DOI 10.1097/00002508-199812000-00011; Chhabra A, 2009, BRIT J ANAESTH, V103, P739, DOI 10.1093/bja/aep230; Ghai B, 2009, ANESTH ANALG, V108, P1132, DOI 10.1213/ane.0b013e318198a3fd; Guise PA, 2003, ANESTHESIOLOGY, V98, P964, DOI 10.1097/00000542-200304000-00025; KRECHEL SW, 1995, PAEDIATR ANAESTH, V5, P53, DOI 10.1111/j.1460-9592.1995.tb00242.x; Kumar CM, 2006, ANN ACAD MED SINGAP, V35, P158; Lambert SR, 2004, BRIT J OPHTHALMOL, V88, P854, DOI 10.1136/bjo.2004.045401; Lambert SR, 1996, SURV OPHTHALMOL, V40, P427, DOI 10.1016/S0039-6257(96)82011-X; McGoldrick KE, 1996, SMITHS ANESTHESIA IN, P633; McNair C, 2004, ARCH DIS CHILD-FETAL, V89, pF537, DOI 10.1136/adc.2003.032961; Merkel S I, 1997, Pediatr Nurs, V23, P293; Sheard RM, 2004, J AAPOS, V8, P314, DOI 10.1016/j.jaapos.2004.01.017; Smith GB, 1996, OPHTHALMIC ANAESTHES, P189; Steib A, 2005, REGION ANESTH PAIN M, V30, P478, DOI 10.1016/j.rapm.2005.04.011; Suraseranivongse S, 2006, BRIT J ANAESTH, V97, P540, DOI 10.1093/bja/ael184	18	4	4	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	NOV	2013	23	11					1015	1020		10.1111/pan.12227			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	227EY	WOS:000325094200009	23919432				2020-06-30	J	Dillow, JM; Rosett, RL; Petersen, TR; Vagh, FS; Hruschka, JA; Lam, NCK				Dillow, Jennifer M.; Rosett, Randy L.; Petersen, Timothy R.; Vagh, Firoz S.; Hruschka, James A.; Lam, Nicholas C. K.			Ultrasound-guided parasacral approach to the sciatic nerve block in children	PEDIATRIC ANESTHESIA			English	Article						nerve block technique; sciatic nerve; ultrasound-guided regional anesthesia; analgesia; orthopedic procedures; lower extremity	ULTRASONOGRAPHIC GUIDANCE; REGIONAL ANESTHESIA; SACRAL PLEXUS; INFANTS	Background: The parasacral (PS) approach to sciatic nerve blockade has the potential for safe and effective use in children, but has never been studied in this population. Its potential advantages include increased posterior cutaneous nerve block reliability, potential for hip joint analgesia, and decreased nerve depth, making ultrasound guidance easier. Objective: To assess the efficacy of an ultrasound-guided PS sciatic nerve block in children. Methods: Nineteen patients, 1-16years old, scheduled for lower limb surgery with peripheral nerve blockade (PNB) were prospectively enrolled. A PS sciatic block was performed using both ultrasound guidance and nerve stimulation, and 0.5 ml.kg(-1) ropivacaine 0.2% (maximum 20 ml) was administered. Patient demographics, the time to perform the block, the lowest intensity of nerve stimulation, evoked response, identification of gluteal arteries, and amount of narcotic given were recorded. Postoperatively, pain scores, block success or failure, block duration, and complications were recorded. Results: The block was performed using the PS approach in 95% of the cases. The success rate was 100% in the PS sciatic blocks performed. The pain scores for all patients in the first postsurgical hour were zero, except one patient that had a pain score of 3 of 10 at 30min; his pain improved to 0 of 10 after administration of one dose of fentanyl and distraction techniques. The blocks lasted 17.3+/-5.4 h. No complications were identified. Conclusion: The PS approach is an effective option for sciatic nerve blockade to provide postoperative pain relief in children having lower extremity surgery.	[Dillow, Jennifer M.; Rosett, Randy L.; Petersen, Timothy R.; Vagh, Firoz S.; Lam, Nicholas C. K.] Univ New Mexico Hosp, Dept Anesthesiol & Crit Care Med, Albuquerque, NM USA; [Petersen, Timothy R.] Univ New Mexico, Dept Anthropol, Albuquerque, NM 87131 USA; [Hruschka, James A.] Maine Med Ctr, Portland, ME 04102 USA	Dillow, JM (reprint author), 1 Univ New Mexico, Dept Anesthesiol & Crit Care Med, MSC10-6000, Albuquerque, NM 87131 USA.	jdillow@salud.unm.edu		Petersen, Timothy/0000-0002-2483-5614			Ben-Ari AY, 2009, ANESTH ANALG, V108, P1977, DOI 10.1213/ane.0b013e3181a04d8e; Bendtsen TF, 2011, BRIT J ANAESTH, V107, P278, DOI 10.1093/bja/aer216; Dadure C, 2006, ANESTH ANALG, V102, P744, DOI 10.1213/01.ane.0000195439.54650.dc; Di Benedetto P, 2002, EUR J ANAESTH, V19, P682, DOI 10.1017/S0265021502001126; Ghai B, 2008, PEDIATR ANESTH, V18, P462, DOI 10.1111/j.1460-9592.2008.02433.x; Marhofer P, 2004, ANAESTHESIA, V59, P642, DOI 10.1111/j.1365-2044.2004.03669.x; Marhofer P, 2006, PEDIATR ANESTH, V16, P1008, DOI 10.1111/j.1460-9592.2006.02020.x; Oberndorfer U, 2007, BRIT J ANAESTH, V98, P797, DOI 10.1093/bja/aem092; Ponde VC, 2010, PEDIATR ANESTH, V20, P633, DOI 10.1111/j.1460-9592.2010.03325.x; Ripart J, 2005, REGION ANESTH PAIN M, V30, P193, DOI 10.1016/j.rapm.2004.08.026; Smoll NR, 2010, CLIN ANAT, V23, P8, DOI 10.1002/ca.20893; Taha AM, 2012, CAN J ANESTH, V59, P263, DOI 10.1007/s12630-011-9630-3; Tsui BCH, 2010, ANESTHESIOLOGY, V112, P473, DOI 10.1097/ALN.0b013e3181c5dfd7; van Geffen GJ, 2010, J CLIN ANESTH, V22, P241, DOI 10.1016/j.jclinane.2009.07.009; Willschke H, 2006, ANESTH ANALG, V102, P1680, DOI 10.1213/01.ane.0000217196.34354.5a; Willschke H, 2005, BRIT J ANAESTH, V95, P226, DOI 10.1093/bja/aei157	16	6	9	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	NOV	2013	23	11					1042	1047		10.1111/pan.12194			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	227EY	WOS:000325094200013	23683056				2020-06-30	J	Mercadante, S; Prestia, G; Casuccio, A				Mercadante, Sebastiano; Prestia, Giovanna; Casuccio, Alessandra			The use of sublingual fentanyl for breakthrough pain by using doses proportional to opioid basal regimen	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						Breakthrough-episodic pain; Cancer pain; Opioids Sublingual tablet	ADVANCED CANCER-PATIENTS; PALLIATIVE CARE-UNIT; INTRAVENOUS MORPHINE; TRANSMUCOSAL FENTANYL; BUCCAL TABLETS; INTENSITY; RECOMMENDATIONS; MEDICATION; RELIEF; HOME	Objective: The aim of this study was to prospectively assess the efficacy and safety of sublingual fentanyl (SLF) in doses proportional to opioid doses used for background analgesia for the treatment of BTP of cancer patients. Methods: A sample of patients admitted to an acute palliative care unit, presenting breakthrough pain (BTP) episodes and receiving stable doses of opioids for background pain was selected to assess the efficacy and safety of SLF used in doses proportional to the basal opioid regimen used for the management of BTP. For each patient, data from four consecutive episodes were collected. For each episode, nurses collected changes in pain intensity and adverse effects when pain got severe (T0), and 5, 10, and 15 minutes after SLF was given (T15). Results: Seventy patients were recruited for the study. The mean age was 61.7 (+/- 11.5). Forty-one patients were males. A total of 173 episodes of BTP were recorded (mean 2.5 episodes/patient). In 19 events, documentation regarding changes in pain intensity was incomplete. Of the 154 evaluable episodes, 143 were successfully treated (92%). Mean doses of SLF were 637 mu g (SD786), and 51 patients (72.8%) received SLF doses >= 800 mu g. When compared to younger adult patients, older patients received significantly lower doses of FBT (p<0.0005), similarly to their lower basal opioid regimen. Pain intensity significantly decreased at T5, 10 and T15 (p<0.0005). The number of patients with a pain reduction of more than 33% at T5, T10, and T15 were 11, 79, and 137, respectively, and the number of patients with a reduction in pain intensity of more than 50% were 1, 21, 114 at the same intervals, respectively. No differences in changes in pain intensity for gender (p<0.9) or age (p<0.85) were observed. No significant changes in the number of patients reporting adverse effects of mild-moderate intensity were reported after SLF administration in comparison with baseline, and no adverse effects severe enough in intensity to require medical intervention were observed. Limitations of this study are represented by the uncontrolled design. Conclusion: This study suggests that SLF given in doses proportional to the basal opioid regimen for the management of BTP is safe and effective in clinical practice.	[Mercadante, Sebastiano] Maddalena Canc Ctr, Anesthesia & Intens Care Unit, I-90145 Palermo, Italy; Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, I-90145 Palermo, Italy; [Casuccio, Alessandra] Univ Palermo, Chair Clin Neurosci, Palermo, Italy	Mercadante, S (reprint author), Maddalena Canc Ctr, Anesthesia & Intens Care Unit, Via S Lorenzo 312, I-90145 Palermo, Italy.	terapiadeldolore@lamaddalenanet.it	casuccio, alessandra/B-1730-2013	casuccio, alessandra/0000-0002-5676-9535			[Anonymous], 2013, SUPPORT CARE CANC, V21, P2335; Aronoff GM, 2005, PAIN MED, V6, P305, DOI 10.1111/j.1526-4637.2005.00045.x; Chwieduk CM, 2010, DRUGS, V70, P2281, DOI 10.2165/11200910-000000000-00000; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Davies AN, 2008, J PAIN SYMPTOM MANAG, V35, P406, DOI 10.1016/j.jpainsymman.2007.05.010; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Farrar JT, 2010, ANESTHESIOLOGY, V112, P1464, DOI 10.1097/ALN.0b013e3181de0e6d; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Kleeberg UR, 2011, PAIN PRACT, V11, P185, DOI 10.1111/j.1533-2500.2010.00414.x; Lennernas B, 2004, BR J CLIN PHARM, V52, P249; Lennernas B, 2010, PALLIATIVE MED, V24, P286, DOI 10.1177/0269216309356138; Mercadante S, 2000, SUPPORT CARE CANCER, V8, P123, DOI 10.1007/s005200050026; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V27, P352, DOI 10.1016/j.jpainsymman.2003.09.006; Mercadante S, 2011, EUR J PAIN, V5, P443; Mercadante S, 2008, J PAIN SYMPTOM MANAG, V35, P307, DOI 10.1016/j.jpainsymman.2007.04.018; Mercadante S, 2013, CURR MED RES OPIN, V29, P667, DOI 10.1185/03007995.2013.792247; Mercadante S, 2013, CURR MED RES OPIN, V29, P93, DOI 10.1185/03007995.2012.755120; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; Mercadante S, 2011, CRIT REV ONCOL HEMAT, V80, P460, DOI 10.1016/j.critrevonc.2010.12.002; Mercadante S, 2011, J PAIN SYMPTOM MANAG, V42, P464, DOI 10.1016/j.jpainsymman.2010.12.010; Mercadante S, 2010, CLIN J PAIN, V26, P306, DOI 10.1097/AJP.0b013e3181c4458a; Mercadante S, 2009, EUR J PAIN, V13, P329, DOI 10.1016/j.ejpain.2008.11.021; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Vigano A, 1998, CANCER-AM CANCER SOC, V83, P1244, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1244::AID-CNCR26>3.3.CO;2-P; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012; Zeppetella G, 2010, PAIN PRACT, V10, P287, DOI 10.1111/j.1533-2500.2010.00359.x	29	14	14	0	7	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.	NOV	2013	29	11					1527	1532		10.1185/03007995.2013.826640			6	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	237FD	WOS:000325853100015	23869428	Green Published			2020-06-30	J	Aminian, A; Lalmand, J; Dolatabadi, D				Aminian, Adel; Lalmand, Jacques; Dolatabadi, Dariouch			Prevention of Radial Artery Spasm: Importance of a Multifactorial Approach	JACC-CARDIOVASCULAR INTERVENTIONS			English	Letter							DIAMETER		[Aminian, Adel] Ctr Hosp Univ Charleroi, B-6000 Charleroi, Belgium	Aminian, A (reprint author), Ctr Hosp Univ Charleroi, Bd Paul Janson 92, B-6000 Charleroi, Belgium.	adaminian@hotmail.com					Aminian A, 2012, J INVASIVE CARDIOL, V24, P290; Deftereos S, 2013, JACC-CARDIOVASC INTE, V6, P267, DOI 10.1016/j.jcin.2012.11.005; Gwon Hyeon-Cheol, 2006, J Interv Cardiol, V19, P141, DOI 10.1111/j.1540-8183.2006.00121.x; Saito S, 1999, CATHETER CARDIO INTE, V46, P173, DOI 10.1002/(SICI)1522-726X(199902)46:2<173::AID-CCD12>3.0.CO;2-4; Yoo BS, 2005, INT J CARDIOL, V101, P421, DOI 10.1016/j.ijcard.2004.03.061	5	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1936-8798	1876-7605		JACC-CARDIOVASC INTE	JACC-Cardiovasc. Interv.	NOV	2013	6	11					1214	1214		10.1016/j.jcin.2013.04.026			1	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	272KB	WOS:000328458100016	24262624	Bronze			2020-06-30	J	Orlov, D; Ankichetty, S; Chung, F; Brull, R				Orlov, David; Ankichetty, Saravanan; Chung, Frances; Brull, Richard			Cardiorespiratory complications of neuraxial opioids in patients with obstructive sleep apnea: a systematic review	JOURNAL OF CLINICAL ANESTHESIA			English	Review						Analgesics; Apnea; Epidural injections; Intrathecal injections; Neuraxial anesthesia; Obstructive sleep apnea; Opioid analgesics; Postoperative complications	POSITIVE AIRWAY PRESSURE; RESPIRATORY DEPRESSION; INTRATHECAL MORPHINE; POSTOPERATIVE PAIN; PERIOPERATIVE MANAGEMENT; EPISODIC HYPOXEMIA; EPIDURAL MORPHINE; CESAREAN-SECTION; ANALGESIA; SAFETY	We sought to determine the rate of cardiorespiratory complications following neuraxial opioid administration in the setting of obstructive sleep apnea (OSA). This systematic review of the leading biomedical databases originated from a university-affiliated, tertiary-care teaching hospital. A systematic search of Medline, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and the International Pharmaceutical Abstracts Database (1970- September 2011) was undertaken. Cardiorespiratory complications were stratified into minor and major based on existing OSA literature. Five studies, including a total of 121 patients, were selected for analysis. All studies comprised low-quality evidence. Six major cardiorespiratory complications were reported among 5(4.1%) patients and included three deaths, one cardiorespiratory arrest, and two episodes of severe respiratory depression. Five of these complications occurred during continuous fentanyl-containing epidural infusions and without concurrent positive airway pressure treatment. The rate of cardiorespiratory complications following the administration of neuraxial opioids to surgical patients with OSA is difficult to determine. (C) 2013 Elsevier Inc. All rights reserved.	[Orlov, David; Ankichetty, Saravanan; Chung, Frances; Brull, Richard] Univ Toronto, Toronto Western Hosp, Univ Hlth Network, Dept Anesthesia, Toronto, ON M5T 2S8, Canada	Brull, R (reprint author), Toronto Western Hosp, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.	richard.brull@uhn.ca	Chung, Frances/F-5618-2015	Chung, Frances/0000-0001-9576-3606; Orlov, David/0000-0002-4096-3878			ABOULEISH E, 1991, REGION ANESTH, V16, P137; Abrishami A, 2010, CAN J ANAESTH, V57, P423, DOI 10.1007/s12630-010-9280-x; Adesanya AO, 2010, CHEST, V138, P1489, DOI 10.1378/chest.10-1108; Amer Soc Anesthesiologists, 2006, ANESTHESIOLOGY, V104, P1081; BAILEY PL, 1993, ANESTHESIOLOGY, V79, P49, DOI 10.1097/00000542-199307000-00010; Berend KR, 2010, J ARTHROPLASTY, V25, P54, DOI 10.1016/j.arth.2010.04.034; Brown KA, 2004, ANESTHESIOLOGY, V100, P806, DOI 10.1097/00000542-200404000-00009; Brown KA, 2006, ANESTHESIOLOGY, V105, P665, DOI 10.1097/00000542-200610000-00009; Carvalho B, 2008, ANESTH ANALG, V107, P956, DOI 10.1213/ane.0b013e318168b443; Chambers W, 2007, PERIOPERATIVE MANAGE, P1; Chung F, 2008, ANESTHESIOLOGY, V108, P812, DOI 10.1097/ALN.0b013e31816d83e4; Chung F, 2008, ANESTHESIOLOGY, V108, P822, DOI 10.1097/ALN.0b013e31816d91b5; Cole PJ, 2000, BRIT J ANAESTH, V85, P233, DOI 10.1093/bja/85.2.233; Cook TM, 2009, BRIT J ANAESTH, V102, P179, DOI 10.1093/bja/aen360; COUSINS MJ, 1984, ANESTHESIOLOGY, V61, P276; Drummond GB, 2002, ANESTHESIOLOGY, V96, P817, DOI 10.1097/00000542-200204000-00007; Eastwood PR, 2002, LANCET, V359, P1207, DOI 10.1016/S0140-6736(02)08224-7; Fleetham John, 2006, Can Respir J, V13, P387; Flisberg P, 2003, ACTA ANAESTH SCAND, V47, P457, DOI 10.1034/j.1399-6576.2003.00104.x; FULLER JG, 1990, CAN J ANAESTH, V37, P636, DOI 10.1007/BF03006481; GLASS PSA, 1984, ANESTHESIOLOGY, V60, P256, DOI 10.1097/00000542-198403000-00024; Gupta RM, 2001, MAYO CLIN PROC, V76, P897, DOI 10.4065/76.9.897; Gwirtz KH, 1999, ANESTH ANALG, V88, P599, DOI 10.1097/00000539-199903000-00026; Haeck PC, 2009, PLAST RECONSTR SURG, V124, p45S, DOI 10.1097/PRS.0b013e3181b5338d; Horlocker TT, 2009, ANESTHESIOLOGY, V110, P218, DOI 10.1097/ALN.0b013e31818ec946; Iber C, 2007, AASM MANUAL SCORING, p[17, 45]; Kaldjian LC, 2006, JT COMM J QUAL PATIE, V32, P188, DOI 10.1016/S1553-7250(06)32024-7; Kaldjian LC, 2006, J GEN INTERN MED, V21, P942, DOI 10.1007/BF02743142; Kapala M, 2009, REGION ANESTH PAIN M, V34, P69, DOI 10.1097/AAP.0b013e31819266b2; Kato R, 2008, J ANESTH, V22, P112, DOI 10.1007/s00540-007-0593-z; Kaw R, 2006, CHEST, V129, P198, DOI 10.1378/chest.129.1.198; KNILL RL, 1990, ANESTHESIOLOGY, V73, P52, DOI 10.1097/00000542-199007000-00009; Kopka A, 2007, BRIT J ANAESTH, V99, P567, DOI 10.1093/bja/aem206; KOTELKO DM, 1984, OBSTET GYNECOL, V63, P409; Leape LL, 2002, NEW ENGL J MED, V347, P1633, DOI 10.1056/NEJMNEJMhpr011493; Lee LA, 2004, ANESTHESIOLOGY, V101, P143, DOI 10.1097/00000542-200407000-00023; Liao P, 2009, CAN J ANAESTH, V56, P819, DOI 10.1007/s12630-009-9190-y; Macintyre PE, 2011, ANAESTH INTENS CARE, V39, P545, DOI 10.1177/0310057X1103900405; Mackay T, 2003, MANAGEMENT OBSTR SLE, P1; Mador MJ, 2011, SLEEP BREATH, V15, P393, DOI 10.1007/s11325-010-0346-3; Meoli AL, 2003, SLEEP, V26, P1060; Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535; Moss IR, 2002, RESP PHYSIOL NEUROBI, V131, P15, DOI 10.1016/S1569-9048(02)00034-4; Murphy PM, 2003, ANESTH ANALG, V97, P1709, DOI 10.1213/01.ANE.0000089965.75585.0D; OCEBM Levels of Evidence Working Group, OXF 2011 LEV EV; Ostermeier AM, 1997, ANESTH ANALG, V85, P452, DOI 10.1097/00000539-199708000-00037; Parikh SN, 2002, J ARTHROPLASTY, V17, P635, DOI 10.1054/arth.2002.32701; PELLECCHIA DJ, 1987, ANESTH ANALG, V66, P280; Ramachandran SK, 2011, J CLIN ANESTH, V23, P207, DOI 10.1016/j.jclinane.2010.09.003; Ramachandran SK, 2009, ANESTHESIOLOGY, V110, P928, DOI 10.1097/ALN.0b013e31819c47b6; Rathmell JP, 2003, ANESTH ANALG, V97, P1452, DOI 10.1213/01.ANE.0000083374.44039.9E; READY LB, 1988, ANESTHESIOLOGY, V68, P100, DOI 10.1097/00000542-198801000-00016; RENNOTTE MT, 1995, CHEST, V107, P367, DOI 10.1378/chest.107.2.367; ROSENBERG J, 1994, BRIT J ANAESTH, V72, P145, DOI 10.1093/bja/72.2.145; Rygnestad T, 1997, ACTA ANAESTH SCAND, V41, P868, DOI 10.1111/j.1399-6576.1997.tb04802.x; Seet E, 2010, CAN J ANESTH, V57, P849, DOI 10.1007/s12630-010-9344-y; Shapiro A, 2005, J CLIN ANESTH, V17, P537, DOI 10.1016/j.jclinane.2005.01.006; Squadrone V, 2005, JAMA-J AM MED ASSOC, V293, P589, DOI 10.1001/jama.293.5.589; Tsui SL, 1997, ANAESTHESIA, V52, P1042, DOI 10.1111/j.1365-2044.1997.232-az0371.x; WANG JK, 1979, ANESTHESIOLOGY, V50, P149, DOI 10.1097/00000542-197902000-00013; Weinger M., 2006, APSF NEWSL, V21, P61; Weinger M. G., 2011, APSF NEWSLETTER, V26, P21; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	63	12	13	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	NOV	2013	25	7					591	599		10.1016/j.jclinane.2013.02.015			9	Anesthesiology	Anesthesiology	275EK	WOS:000328658900012	23994284				2020-06-30	J	Hsu, DT; Sanford, BJ; Meyers, KK; Love, TM; Hazlett, KE; Wang, H; Ni, L; Walker, SJ; Mickey, BJ; Korycinski, ST; Koeppe, RA; Crocker, JK; Langenecker, SA; Zubieta, JK				Hsu, D. T.; Sanford, B. J.; Meyers, K. K.; Love, T. M.; Hazlett, K. E.; Wang, H.; Ni, L.; Walker, S. J.; Mickey, B. J.; Korycinski, S. T.; Koeppe, R. A.; Crocker, J. K.; Langenecker, S. A.; Zubieta, J-K			Response of the mu-opioid system to social rejection and acceptance	MOLECULAR PSYCHIATRY			English	Article						acceptance; mu; opioid; PET; rejection; social	PREFRONTAL CORTEX ABNORMALITIES; POSITRON-EMISSION-TOMOGRAPHY; PITUITARY-ADRENAL RESPONSES; RECEPTOR MESSENGER-RNA; IN-SITU HYBRIDIZATION; ANTERIOR CINGULATE; NUCLEUS-ACCUMBENS; IMMUNOHISTOCHEMICAL LOCALIZATION; PARAVENTRICULAR NUCLEUS; PERIAQUEDUCTAL GRAY	The endogenous opioid system, which alleviates physical pain, is also known to regulate social distress and reward in animal models. To test this hypothesis in humans (n = 18), we used an mu-opioid receptor (MOR) radiotracer to measure changes in MOR availability in vivo with positron emission tomography during social rejection (not being liked by others) and acceptance (being liked by others). Social rejection significantly activated the MOR system (i.e., reduced receptor availability relative to baseline) in the ventral striatum, amygdala, midline thalamus and periaqueductal gray (PAG). This pattern of activation is consistent with the hypothesis that the endogenous opioids have a role in reducing the experience of social pain. Greater trait resiliency was positively correlated with MOR activation during rejection in the amygdala, PAG and subgenual anterior cingulate cortex (sgACC), suggesting that MOR activation in these areas is protective or adaptive. In addition, MOR activation in the pregenual ACC was correlated with reduced negative affect during rejection. In contrast, social acceptance resulted in MOR activation in the amygdala and anterior insula, and MOR deactivation in the midline thalamus and sgACC. In the left ventral striatum, MOR activation during acceptance predicted a greater desire for social interaction, suggesting a role for the MOR system in social reward. The ventral striatum, amygdala, midline thalamus, PAG, anterior insula and ACC are rich in MORs and comprise a pathway by which social cues may influence mood and motivation. MOR regulation of this pathway may preserve and promote emotional well being in the social environment.	[Hsu, D. T.; Sanford, B. J.; Meyers, K. K.; Love, T. M.; Wang, H.; Ni, L.; Mickey, B. J.; Korycinski, S. T.; Langenecker, S. A.; Zubieta, J-K] Univ Michigan, Mol & Behav Neurosci Inst, Dept Psychiat, Ann Arbor, MI 48109 USA; [Hazlett, K. E.] Marquette Univ, Dept Psychol, Milwaukee, WI 53233 USA; [Walker, S. J.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA; [Koeppe, R. A.; Zubieta, J-K] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA; [Crocker, J. K.] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA	Hsu, DT (reprint author), Univ Michigan, Mol & Behav Neurosci Inst, 205 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	dthsu@umich.edu	Hsu, David/J-5814-2014; Love, Tiffany/W-8427-2019; Mickey, Brian/J-1756-2014; Langenecker, Scott/F-3548-2012	Love, Tiffany/0000-0001-9299-3190; Mickey, Brian/0000-0002-7847-7680; Langenecker, Scott/0000-0002-7932-5494; Crocker, Jennifer/0000-0002-6590-4647	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K01 MH085035, K23 MH074459, R01 DA022520, R01 DA027494]; National Alliance for Research on Schizophrenia and Depression Young Investigator AwardNARSAD; Michigan Institute for Clinical and Health Research; Rachel Upjohn Clinical Scholars Award; Phil F Jenkins Foundation	This research was supported by National Institute of Health Grants K01 MH085035 (DTH), K23 MH074459 (SAL), R01 DA022520 and R01 DA027494 (JKZ), a National Alliance for Research on Schizophrenia and Depression Young Investigator Award (DTH), pilot grants from the Michigan Institute for Clinical and Health Research (DTH), a Rachel Upjohn Clinical Scholars Award (DTH) and the Phil F Jenkins Foundation (JKZ).	Baumeister RF, 2005, J PERS SOC PSYCHOL, V88, P589, DOI 10.1037/0022-3514.88.4.589; Bencherif B, 2002, PAIN, V99, P589, DOI 10.1016/S0304-3959(02)00266-X; Bhatnagar S, 1998, NEUROSCIENCE, V84, P1025, DOI 10.1016/S0306-4522(97)00577-0; Bhatnagar S, 2002, J NEUROENDOCRINOL, V14, P403, DOI 10.1046/j.0007-1331.2002.00792.x; Block J, 1965, CHALLENGE RESPONSE S, P168; Bolling DZ, 2011, NEUROIMAGE, V54, P2462, DOI 10.1016/j.neuroimage.2010.10.049; Brunton J, 1998, J NEUROSCI, V18, P1671; CARR KD, 1988, BRAIN RES, V441, P173, DOI 10.1016/0006-8993(88)91396-0; Colasanti A, 2012, BIOL PSYCHIAT, V72, P371, DOI 10.1016/j.biopsych.2012.01.027; Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555; Davey CG, 2010, HUM BRAIN MAPP, V31, P660, DOI 10.1002/hbm.20895; DELFS JM, 1994, J COMP NEUROL, V345, P46, DOI 10.1002/cne.903450104; DeWall CN, 2010, PSYCHOL SCI, V21, P931, DOI 10.1177/0956797610374741; Ding YQ, 1996, J COMP NEUROL, V367, P375; Drevets WC, 1997, NATURE, V386, P824, DOI 10.1038/386824a0; Ehnvall A, 2009, ACTA PSYCHIAT SCAND, V119, P375, DOI 10.1111/j.1600-0447.2008.01316.x; Eisenberger NI, 2007, EMOTION, V7, P745, DOI 10.1037/1528-3542.7.4.745; Eisenberger NI, 2012, NAT REV NEUROSCI, V13, P421, DOI 10.1038/nrn3231; Eisenberger NI, 2003, SCIENCE, V302, P290, DOI 10.1126/science.1089134; Fang A, 2011, J ANXIETY DISORD, V25, P946, DOI 10.1016/j.janxdis.2011.06.001; Fisher HE, 2010, J NEUROPHYSIOL, V104, P51, DOI 10.1152/jn.00784.2009; Gear RW, 1999, J NEUROSCI, V19, P7175, DOI 10.1523/JNEUROSCI.19-16-07175.1999; Greenwald MK, 2003, NEUROPSYCHOPHARMACOL, V28, P2000, DOI 10.1038/sj.npp.1300251; HELMSTETTER FJ, 1995, J PHARMACOL EXP THER, V275, P381; HERMAN BH, 1981, SCIENCE, V211, P1060, DOI 10.1126/science.7466377; Hsu DT, 2009, J COMP NEUROL, V512, P825, DOI 10.1002/cne.21934; Kalin NH, 1995, PSYCHONEUROENDOCRINO, V20, P735, DOI 10.1016/0306-4530(95)00023-2; KALIN NH, 1988, BRAIN RES, V440, P285, DOI 10.1016/0006-8993(88)90997-3; Keay KA, 2001, NEUROSCI BIOBEHAV R, V25, P669, DOI 10.1016/S0149-7634(01)00049-5; Kelley AE, 2002, PHYSIOL BEHAV, V76, P365, DOI 10.1016/S0031-9384(02)00751-5; Koepp MJ, 2009, NEUROIMAGE, V44, P252, DOI 10.1016/j.neuroimage.2008.08.032; Kross E, 2011, P NATL ACAD SCI USA, V108, P6270, DOI 10.1073/pnas.1102693108; Levinson CA, 2012, EAT BEHAV, V13, P27, DOI 10.1016/j.eatbeh.2011.11.006; Li S, 2008, J COMP NEUROL, V506, P263, DOI 10.1002/cne.21502; Li S, 2012, BRAIN STRUCT FUNCT, V217, P257, DOI 10.1007/s00429-011-0360-7; MacDonald G, 2011, SOCIAL PAIN NEUROPSY, P264; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Mallott MA, 2009, DEPRESS ANXIETY, V26, P438, DOI 10.1002/da.20555; MANSOUR A, 1994, BRAIN RES, V643, P245, DOI 10.1016/0006-8993(94)90031-0; MANSOUR A, 1995, J CHEM NEUROANAT, V8, P283, DOI 10.1016/0891-0618(95)00055-C; Masten CL, 2011, DEV PSYCHOPATHOL, V23, P283, DOI 10.1017/S0954579410000799; Masten CL, 2009, SOC COGN AFFECT NEUR, V4, P143, DOI 10.1093/scan/nsp007; Mayberg HS, 1999, AM J PSYCHIAT, V156, P675; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; MICZEK KA, 1985, PSYCHOPHARMACOLOGY, V87, P39, DOI 10.1007/BF00431775; MINAMI M, 1994, NEUROSCI RES, V18, P315, DOI 10.1016/0168-0102(94)90167-8; Najib A, 2004, AM J PSYCHIAT, V161, P2245, DOI 10.1176/appi.ajp.161.12.2245; Panksepp J, 2003, SCIENCE, V302, P237, DOI 10.1126/science.1091062; PANKSEPP J, 1978, BIOL PSYCHIAT, V13, P607; PANKSEPP J, 1980, NEUROSCI BIOBEHAV R, V4, P473, DOI 10.1016/0149-7634(80)90036-6; Pecina S, 2008, PHYSIOL BEHAV, V94, P675, DOI 10.1016/j.physbeh.2008.04.006; Pizzagalli DA, 2004, MOL PSYCHIATR, V9, P393, DOI 10.1038/sj.mp.4001469; Quirarte GL, 1998, BRAIN RES, V808, P134, DOI 10.1016/S0006-8993(98)00795-1; Schmidt BL, 2002, J NEUROSCI, V22, P6773; SCHNEIER FR, 1989, J ANXIETY DIORD, V3, P15, DOI DOI 10.1016/0887-6185(89)90025-X; SHAIKH MB, 1991, BRAIN RES, V557, P344, DOI 10.1016/0006-8993(91)90158-R; SIEGEL MA, 1985, BEHAV NEURAL BIOL, V44, P509, DOI 10.1016/S0163-1047(85)91024-6; Slavich GM, 2010, NEUROSCI BIOBEHAV R, V35, P39, DOI 10.1016/j.neubiorev.2010.01.003; Smith YR, 1998, J CLIN ENDOCR METAB, V83, P4498, DOI 10.1210/jc.83.12.4498; Somerville LH, 2006, NAT NEUROSCI, V9, P1007, DOI 10.1038/nn1728; Sprenger T, 2005, EUR J PAIN, V9, P117, DOI 10.1016/j.ejpain.2004.07.010; Stafford Linda, 2007, Issues Ment Health Nurs, V28, P359, DOI 10.1080/01612840701244250; TITELER M, 1989, EUR J PHARMACOL, V167, P221, DOI 10.1016/0014-2999(89)90582-7; Trezza V, 2011, J NEUROSCI, V31, P6362, DOI 10.1523/JNEUROSCI.5492-10.2011; Trezza V, 2010, TRENDS PHARMACOL SCI, V31, P463, DOI 10.1016/j.tips.2010.06.008; Troisi A, 2011, SOC NEUROSCI-UK, V6, P88, DOI 10.1080/17470919.2010.482786; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; VANDERSCHUREN LJMJ, 1995, EUR J PHARMACOL, V276, P257, DOI 10.1016/0014-2999(95)00040-R; Vivian JA, 1999, PSYCHOPHARMACOLOGY, V146, P153, DOI 10.1007/s002130051101; Way BM, 2009, P NATL ACAD SCI USA, V106, P15079, DOI 10.1073/pnas.0812612106; Weerts E.M., 2012, ADDICT BIOL; Williams KD, 2007, ANNU REV PSYCHOL, V58, P425, DOI 10.1146/annurev.psych.58.110405.085641; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005; Zubieta JK, 2003, ARCH GEN PSYCHIAT, V60, P1145, DOI 10.1001/archpsyc.60.11.1145; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	76	118	119	2	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1359-4184	1476-5578		MOL PSYCHIATR	Mol. Psychiatr.	NOV	2013	18	11					1211	1217		10.1038/mp.2013.96			7	Biochemistry & Molecular Biology; Neurosciences; Psychiatry	Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry	240KN	WOS:000326094800012	24153054	Green Accepted, Bronze			2020-06-30	J	Pavlidou, K; Savvas, I; Moens, YPS; Vasilakos, D; Raptopoulos, D				Pavlidou, Kiriaki; Savvas, Ioannis; Moens, Yves P. S.; Vasilakos, Dimitrios; Raptopoulos, Dimitrios			The Effect of Four Anaesthetic Protocols for Maintenance of Anaesthesia on Trans-Diaphragmatic Pressure in Dogs	PLOS ONE			English	Article							TRANSDIAPHRAGMATIC PRESSURE; INTRAABDOMINAL PRESSURE; RESPIRATORY MUSCLE; BLOOD-FLOW; PROPOFOL; KETAMINE; HALOTHANE; INFUSION; SEVOFLURANE; FENTANYL	The diaphragm is the main inspiratory muscle and the main indicator of diaphragmatic contractility is the transdiaphragmatic pressure (P-di). The aim of this clinical study was to determine the effect of four different anaesthetic protocols on P-di in anaesthetized healthy dogs. Eighty client-owned dogs were recruited in this clinical study. All the animals received dexmedetomidine and morphine as premedication and propofol for induction. Anaesthesia was maintained with one of four protocols: isoflurane (I), isoflurane with CRI of propofol (IP), isoflurane with CRI of fentanyl (IF), and isoflurane with CRI of ketamine (IK). When the surgical plane of anaesthesia was achieved, two balloon catheters were inserted, one into the stomach and one into the mid-third of the oesophagus for P-di measurement. P-di value was the highest in groups I (14.9 +/- 4.7 mmHg) and IK (15.2 +/- 3.5 mmHg) and the lowest in groups IP (12.2 +/- 3.2 mmHg) and IF (12.0 +/- 5.9 mmHg). There was a statistically significant difference (p = 0.029) between groups IK and IF. PE'CO2 was statistically significantly higher (p<0.0005) in group IF (7.7 +/- 0.8 kPa) than in group IK (6.5 +/- 0.7 kPa). Isoflurane alone or isoflurane with ketamine for the maintenance of anaesthesia seem to better preserve the respiratory function and the diaphragmatic contractility than isoflurane with either propofol or fentanyl in dogs. Therefore, the use of isoflurane or isoflurane with ketamine may be of benefit when animals with respiratory problems have to be anaesthetized.	[Pavlidou, Kiriaki; Savvas, Ioannis; Raptopoulos, Dimitrios] Aristotle Univ Thessaloniki, Fac Vet Med, Compan Anim Clin, Anaesthesiol & Intens Care Unit, GR-54006 Thessaloniki, Greece; [Moens, Yves P. S.] Vet Univ Vienna, A-1030 Vienna, Austria; [Vasilakos, Dimitrios] AHEPA Univ Hosp, Anaesthesiol & ICU Dept, Thessaloniki, Greece	Savvas, I (reprint author), Aristotle Univ Thessaloniki, Fac Vet Med, Compan Anim Clin, Anaesthesiol & Intens Care Unit, GR-54006 Thessaloniki, Greece.	isavas@vet.auth.gr	Savvas, Ioannis/H-9622-2019	Savvas, Ioannis/0000-0001-5575-7244; Pavlidou, Kiriaki/0000-0002-1771-3811	European Union (European Social Fund - ESF)European Union (EU)European Social Fund (ESF); Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF) - Research Funding Program: Heracleitus II	This research has been co-financed by the European Union (European Social Fund - ESF) and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF) - Research Funding Program: Heracleitus II. Investing in knowledge society through the European Social Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADAMS JM, 1988, J APPL PHYSIOL, V64, P2279; ANDREWS CJH, 1983, BRIT J ANAESTH, V55, pS211; AUBIER M, 1981, NEW ENGL J MED, V305, P249, DOI 10.1056/NEJM198107303050503; Benditt Joshua O, 2005, Respir Care, V50, P68; Boriek AM, 2006, J APPL PHYSIOL, V101, P794, DOI 10.1152/japplphysiol.00865.2004; Bufalari A, 2012, SCHWEIZ ARCH TIERH, V154, P105, DOI 10.1024/0036-7281/a000308; CLERGUE F, 1986, ANESTHESIOLOGY, V64, P181, DOI 10.1097/00000542-198602000-00009; De Keulenaer BL, 2009, INTENS CARE MED, V35, P969, DOI 10.1007/s00134-009-1445-0; Dorfelt R, 2012, VET ANAESTH ANALG, V39, P390, DOI 10.1111/j.1467-2995.2012.00710.x; Drummond GB, 1996, BRIT J ANAESTH, V76, P663; Drummond GB, 2002, BRIT J ANAESTH, V88, P384, DOI 10.1093/bja/88.3.384; FARKAS G, 1990, CHEST, V97, pS39; GILBERT R, 1979, J APPL PHYSIOL, V47, P628; Hamid Q., 2005, PHYSL BASIS RESP DIS, P639; HASKINS SC, 1985, AM J VET RES, V46, P1855; HIGGS BD, 1983, ANESTHESIOLOGY, V59, P340, DOI 10.1097/00000542-198310000-00012; HILLMAN DR, 1990, J APPL PHYSIOL, V68, P2296; HUBMAYR RD, 1990, J APPL PHYSIOL, V69, P2050; HUSSAIN SNA, 1988, J APPL PHYSIOL, V64, P329; IDE T, 1992, ANESTH ANALG, V74, P739; IDE T, 1991, CAN J ANAESTH, V38, P116, DOI 10.1007/BF03009174; IDE T, 1993, ACTA ANAESTH SCAND, V37, P253, DOI 10.1111/j.1399-6576.1993.tb03710.x; Kagawa T, 1998, ANESTH ANALG, V86, P392, DOI 10.1097/00000539-199802000-00033; KOCHI T, 1990, ANESTH ANALG, V70, P362; KOCHI T, 1992, BRIT J ANAESTH, V68, P562, DOI 10.1093/bja/68.6.562; Kuusela E, 2003, J VET PHARMACOL THER, V26, P199, DOI 10.1046/j.1365-2885.2003.00465.x; Lambert DM, 2005, OBES SURG, V15, P1225, DOI 10.1381/096089205774512546; Lamont L. A., 2007, LUMB JONES VET ANEST, V4, P241; LAPORTA D, 1985, J APPL PHYSIOL, V58, P1469; Laredo FG, 2004, VET REC, V155, P667, DOI 10.1136/vr.155.21.667; Lumb AB, 2010, NUNNS APPL RESP PHYS, P327; MAGDER S, 1985, J APPL PHYSIOL, V58, P1148; MANKIKIAN B, 1986, ANESTHESIOLOGY, V65, P492, DOI 10.1097/00000542-198611000-00007; Mannarino R, 2012, VET ANAESTH ANALG, V39, P160, DOI 10.1111/j.1467-2995.2011.00679.x; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; McDonell WC, 2007, LUMB JONES VET ANEST, P117; Moore RL, 1927, J EXP MED, V45, P1065, DOI 10.1084/jem.45.6.1065; Nishina K, 2003, ANESTH ANALG, V96, P1674, DOI 10.1213/01.ANE.0000060455.94684.69; Ora J, 2011, J APPL PHYSIOL, V111, P10, DOI 10.1152/japplphysiol.01131.2010; Pavlidou K, 2014, VET ANAESTH ANALG, V41, P278, DOI 10.1111/vaa.12073; POLKEY MI, 1995, THORAX, V50, P1131, DOI 10.1136/thx.50.11.1131; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; SANTIAGO TV, 1979, J APPL PHYSIOL, V47, P112; SANTIAGO TV, 1985, J APPL PHYSIOL, V59, P1675; Seliskar A, 2007, VET REC, V160, P85, DOI 10.1136/vr.160.3.85; SPRUNG J, 1990, J APPL PHYSIOL, V69, P2296; Udeshi A, 2010, J CRIT CARE, V25, DOI 10.1016/j.jcrc.2009.12.014; ULKER S, 1991, INT J EXP PATHOL, V72, P527; WANKE T, 1993, CLIN PHYSIOL, V13, P349, DOI 10.1111/j.1475-097X.1993.tb00335.x; WATERMAN AE, 1991, VET REC, V129, P261, DOI 10.1136/vr.129.12.261; Zakynthinos S., 2005, PHYSL BASIS RESP DIS, P289; Zhang XJ, 2009, BRIT J ANAESTH, V102, P61, DOI 10.1093/bja/aen327	52	5	5	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2013	8	10							e75341	10.1371/journal.pone.0075341			7	Multidisciplinary Sciences	Science & Technology - Other Topics	232JF	WOS:000325489100039	24124482	DOAJ Gold, Green Published			2020-06-30	J	Iizuka, T; Kamata, M; Yanagawa, M; Nishimura, R				Iizuka, Tomoya; Kamata, Masatoshi; Yanagawa, Masashi; Nishimura, Ryohei			Incidence of intraoperative hypotension during isoflurane-fentanyl and propofol-fentanyl anaesthesia in dogs	VETERINARY JOURNAL			English	Article						Intraoperative hypotension; Dogs; Propofol; Isoflurane; Fentanyl	SURGERY	Most anaesthetic and analgesic drugs affect the cardiovascular system and can cause intraoperative hypotension (IOH). This study aimed to compare the incidence of IOH in anaesthetised dogs when isoflurane-fentanyl was used, compared to propofol-fentanyl. Intraoperative hypotension was defined as an episode of mean blood pressure below 60 mmHg for more than 5 mm during anaesthesia. The incidence of IOH was 65.3% for isoflurane-fentanyl and 27.6% for propofol-fentanyl. The adjusted odds ratio for IOH when propofol-fentanyl was compared to isoflurane-fentanyl was 0.2 (95% CI 0.11-0.38). These results suggest that propofol-fentanyl is associated with a lower risk of IOH than isoflurane-fentanyl anaesthesia. (C) 2013 Elsevier Ltd. All rights reserved.	[Iizuka, Tomoya; Kamata, Masatoshi; Yanagawa, Masashi; Nishimura, Ryohei] Univ Tokyo, Grad Sch Agr & Life Sci, Lab Vet Emergency Med, Bunkyo Ku, Tokyo 1138657, Japan	Nishimura, R (reprint author), Univ Tokyo, Grad Sch Agr & Life Sci, Lab Vet Emergency Med, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	arn@mail.ecc.u-tokyo.ac.jp					ASKITOPOULOU H, 1985, ANESTHESIOLOGY, V63, P255, DOI 10.1097/00000542-198509000-00003; Beths T, 2001, VET REC, V148, P198, DOI 10.1136/vr.148.7.198; Dyson DH, 2008, VET CLIN N AM-SMALL, V38, P1309, DOI 10.1016/j.cvsm.2008.06.006; GOODCHILD CS, 1989, BRIT J ANAESTH, V63, P87, DOI 10.1093/bja/63.1.87; Hughes JML, 1999, VET SURG, V28, P513, DOI 10.1111/j.1532-950X.1999.00513.x; Liehmann L, 2006, VET ANAESTH ANALG, V33, P158, DOI 10.1111/j.1467-2995.2005.00251.x; Mutoh T, 1997, AM J VET RES, V58, P885; RAMPIL IJ, 1993, ANESTHESIOLOGY, V78, P707, DOI 10.1097/00000542-199304000-00014; Short CE, 1999, VET CLIN N AM-SMALL, V29, P747, DOI 10.1016/S0195-5616(99)50059-4; Waddell LS, 2000, CLIN TECH SMALL AN P, V15, P111, DOI 10.1053/svms.2000.18292	10	11	11	0	15	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1090-0233	1532-2971		VET J	Vet. J.	OCT	2013	198	1					289	291		10.1016/j.tvjl.2013.06.021			3	Veterinary Sciences	Veterinary Sciences	270FW	WOS:000328305300054	23938002				2020-06-30	J	Wulf, H; Hampl, K; Steinfeldt, T				Wulf, Hinnerk; Hampl, Karl; Steinfeldt, Thorsten			Speed spinal anesthesia revisited: new drugs and their clinical effects	CURRENT OPINION IN ANESTHESIOLOGY			English	Review						articaine; chloroprocaine; day-case surgery; fentanyl; neurotoxicity; prilocaine; spinal anesthesia; transient neurologic symptoms	CASE KNEE ARTHROSCOPY; LOW-DOSE BUPIVACAINE; TRANSIENT NEUROLOGIC SYMPTOMS; HYPERBARIC BUPIVACAINE; DOUBLE-BLIND; LAPAROSCOPIC CHOLECYSTECTOMY; TRANSURETHRAL PROSTATECTOMY; INGUINAL HERNIORRHAPHY; OUTPATIENT SURGERY; GENERAL-ANESTHESIA	Purpose of reviewSpinal anesthesia (SPA) has not been popular for day-case surgery because of prolonged neurologic blockade with long-acting local anesthetics such as bupivacaine, thereby delaying discharge. Although the intermediate duration of action of lidocaine and mepivacaine appears to be more suitable for day-case surgery, their use is not deemed appropriate by many because of a high incidence of transient neurologic symptoms (TNSs). The present review summarizes recent clinical data on the intrathecal use of alternative local anesthetics and adjuvants that may offer valuable alternatives to general anesthesia in day-case surgery.Recent findingsPrilocaine has a similar intrathecal pharmacokinetic profile as lidocaine but with a significantly lower risk of TNSs. Onset of spinal after 2-chloroprocaine is comparable with lidocaine or prilocaine, but with a considerably shorter duration of action. Also, TNS is clearly less frequent compared with lidocaine. Although its intrathecal use has recently been approved in Europe, this is still considered to be off-label in the USA. Articaine provides an extraordinary fast onset and a short duration of spinal block, the latter being approximately intermediate between chloroprocaine and prilocaine. However, articaine is associated with a high risk for intraoperative hypotension and a small risk for TNS, albeit but less frequent than after lidocaine. Concerns regarding possible neurotoxicity of articaine remain to be resolved.SummarySPA for day cases might become a most valuable method for ambulatory surgery when using short acting local anesthetics. This, however, not only depends on drugs being used but also on infrastructure (post anaesthesia care unit) and organizational issues.	[Wulf, Hinnerk; Steinfeldt, Thorsten] Univ Marburg, Univ Hosp, Dept Anesthesiol & Intens Care Med, D-35033 Marburg, Germany; [Hampl, Karl] Spitalzentrum Biel AG, Dept Anesthesia, Biel, Switzerland	Wulf, H (reprint author), Univ Marburg, Univ Hosp, Dept Anesthesiol & Intens Care Med, Baldinger Str 1, D-35033 Marburg, Germany.	h.wulf@med.uni-marburg.de			Astra-ZenecaAstraZeneca; B. Braun; Boehringer IngelheimBoehringer Ingelheim; CLS-Behring; Covidien; Edwards; Meduna; MSD; Pajunk; Sintetica; Sonosite; Teleflex; DFG (Governmental German Research Society); BMFT (Ministry of Research and Technology); ESRA (European Society of Regional Anaesthesia)	H. W. has received honorarium and/or research funding from Astra-Zeneca, B. Braun, Boehringer Ingelheim, CLS-Behring, Covidien, Edwards, Meduna, MSD, Pajunk, Sintetica, Sonosite, Teleflex, and Vygon and has received grants from the DFG (Governmental German Research Society) and BMFT (Ministry of Research and Technology) and Pohl-Stiftung. T. S. has received honorarium and/or research funding from B. Braun, Teleflex and Vygon and a research grant from ESRA (European Society of Regional Anaesthesia). K. H. has received honorarium from Sintetica.	Afolabi BB, 2012, COCHRANE DATABASE SY, V10; Atef Hossam, 2012, Middle East Journal of Anesthesiology, V21, P591; Bachmann M, 2012, EUR J ANAESTH, V29, P22, DOI 10.1097/EJA.0b013e32834a11be; Bajwa Sukhminder Jit Singh, 2012, J Anaesthesiol Clin Pharmacol, V28, P444, DOI 10.4103/0970-9185.101898; Beilin Y, 2010, ANESTH ANALG, V111, P482, DOI 10.1213/ANE.0b013e3181e3a08e; Bessa SS, 2012, J LAPAROENDOSC ADV S, V22, P550, DOI 10.1089/lap.2012.0110; Black AS, 2011, BRIT J ANAESTH, V106, P183, DOI 10.1093/bja/aeq272; BODILY MN, 1992, CAN J ANAESTH, V39, P770, DOI 10.1007/BF03008286; Canturk M, 2012, REV BRAS ANESTESIOL, V62, P298, DOI 10.1016/S0034-7094(12)70131-9; Casati A, 2007, ANESTH ANALG, V104, P959, DOI 10.1213/01.ane.0000258766.73612.d8; Casati A, 2006, ANESTH ANALG, V103, P234, DOI 10.1213/01.ane.0000221441.44387.82; de Weert K, 2000, ANAESTHESIA, V55, P1020, DOI 10.1046/j.1365-2044.2000.01618-4.x; Dijkstra T, 2008, BRIT J ANAESTH, V100, P104, DOI 10.1093/bja/aem332; Erbay RH, 2010, MINERVA ANESTESIOL, V76, P992; Esmaoglu A, 2004, KNEE SURG SPORT TR A, V12, P155, DOI 10.1007/s00167-003-0350-2; Florio P, 2012, J MINIM INVAS GYN, V19, P107, DOI 10.1016/j.jmig.2011.08.728; Forster JG, 2013, ACTA ANAESTH SCAND, V57, P911, DOI 10.1111/aas.12107; Forster JG, 2011, ACTA ANAESTH SCAND, V55, P273, DOI 10.1111/j.1399-6576.2010.02325.x; Forster JG, 2011, CURR OPIN ANESTHESIO, V24, P633, DOI 10.1097/ACO.0b013e32834aca1b; Gebhardt V, 2013, ACTA ANAESTH SCAND, V57, P249, DOI 10.1111/aas.12031; Goldblum E, 2013, ACTA ANAESTH SCAND, V57, P545, DOI 10.1111/aas.12071; Hampl KF, 1998, ANESTHESIOLOGY, V88, P629, DOI 10.1097/00000542-199803000-00012; Hejtmanek MR, 2011, ACTA ANAESTH SCAND, V55, P267, DOI 10.1111/j.1399-6576.2010.02371.x; Hendriks MP, 2009, BRIT J ANAESTH, V102, P259, DOI 10.1093/bja/aen357; Imbelloni LE, 2011, LOCAL REG ANESTH, V4, P41, DOI 10.2147/LRA.S19979; Imbelloni LE, 2010, REV BRAS ANESTESIOL, V60, P217, DOI [10.1590/S0034-70942010000300001, 10.1016/S0034-7094(10)70030-1]; Imbelloni LE, 2010, REV BRAS ANESTESIOL, V60, P113, DOI 10.1590/S0034-70942010000200002; Jacobsen J, 2011, ANESTH ANALG, V113, P1272, DOI 10.1213/ANE.0b013e31822d676f; Kairaluoma P, 2013, ACTA ANAESTH SCAND, V57, P118, DOI 10.1111/j.1399-6576.2012.02794.x; Kallio H, 2006, BRIT J ANAESTH, V97, P704, DOI 10.1093/bja/ael222; Kararmaz A, 2003, ANAESTHESIA, V58, P526, DOI 10.1046/j.1365-2044.2003.03153.x; Korhonen AM, 2003, ACTA ANAESTH SCAND, V47, P342, DOI 10.1034/j.1399-6576.2003.00092.x; Lacasse MA, 2011, CAN J ANESTH, V58, P384, DOI 10.1007/s12630-010-9450-x; Lee SJ, 2008, ANESTH ANALG, V107, P824, DOI 10.1213/ane.0b013e3181806149; Leone Stefania, 2008, Acta Biomed, V79, P92; Malinovsky JM, 2012, EUR J ANAESTH, V29, P5, DOI 10.1097/EJA.0b013e32834de295; MAROOF M, 1995, CAN J ANAESTH, V42, P691, DOI 10.1007/BF03012666; Martinez-Bourio R, 1998, ANESTHESIOLOGY, V88, P624, DOI 10.1097/00000542-199803000-00011; Mehrabi S, 2013, UROL J, V10, P756; Nair GS, 2009, BRIT J ANAESTH, V102, P307, DOI 10.1093/bja/aen389; Ostgaard G, 2000, ACTA ANAESTH SCAND, V44, P436, DOI 10.1034/j.1399-6576.2000.440413.x; Pollock JE, 2012, INT ANESTHESIOL CLIN, V50, P93, DOI 10.1097/AIA.0b013e31821bbb35; Qiu MT, 2012, CNS NEUROSCI THER, V18, P426, DOI 10.1111/j.1755-5949.2012.00306.x; Roofthooft E, 2008, CURR OPIN ANESTHESIO, V21, P259, DOI 10.1097/ACO.0b013e3282ff5e41; Sell A, 2008, ACTA ANAESTH SCAND, V52, P695, DOI 10.1111/j.1399-6576.2008.01639.x; Snoeck M, 2012, LOCAL REG ANESTH, V5, P23, DOI 10.2147/LRA.S16682; Song DJ, 2000, ANESTH ANALG, V91, P876, DOI 10.1097/00000539-200010000-00020; Taspinar V, 2011, J ANESTH, V25, P219, DOI 10.1007/s00540-010-1089-9; Vaghadia H, 2012, ACTA ANAESTH SCAND, V56, P217, DOI 10.1111/j.1399-6576.2011.02599.x; Wulf H, 2011, ACTA ANAESTH SCAND, V55, P257, DOI 10.1111/j.1399-6576.2010.02384.x	50	4	4	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	OCT	2013	26	5					613	620		10.1097/ACO.0b013e3283606b71			8	Anesthesiology	Anesthesiology	264SF	WOS:000327900100015	26057879				2020-06-30	J	Skrobik, Y; Laverdiere, M				Skrobik, Yoanna; Laverdiere, Michel			Why Candida Sepsis Should Matter to ICU Physicians	CRITICAL CARE CLINICS			English	Article						Candidemia; Invasive candidiasis; Sepsis; Critical care; Intensive care	CRITICALLY-ILL PATIENTS; CARE-UNIT PATIENTS; INVASIVE CANDIDIASIS; RISK-FACTORS; GENETIC-POLYMORPHISM; PREEMPTIVE TREATMENT; SPECIES INFECTIONS; ANTIFUNGAL THERAPY; HOSPITAL MORTALITY; PERITONEAL-FLUID	The incidence of candidemia and invasive Candida infections has increased substantially over the last 2 decades. These infections are associated with risk factors that characterize intensive care unit patients. Candidemia and invasive Candida are highly morbid and associated with significantly increased mortality. Outcomes in the intensive care setting depend on physician awareness and rapid intervention. The epidemiology of the disease, its diagnostic challenges, and management strategies, including prophylactic, preemptive, and definitive therapeutic approaches, are presented herein.	[Skrobik, Yoanna] Univ Montreal, Dept Med, Montreal, PQ H1T 2M4, Canada; [Skrobik, Yoanna] FRQS, Resp Hlth Network, Resp Crit Care Grp, Montreal, PQ, Canada; [Laverdiere, Michel] Univ Montreal, Hop Maison Neuve Rosemont, Dept Med, Montreal, PQ H1T 2M4, Canada	Skrobik, Y (reprint author), Univ Montreal, 5415 Blvd Assompt, Montreal, PQ H1T 2M4, Canada.	yoanna.skrobik@umontreal.ca	Skrobik, Yoanna/J-6393-2013; Skrobik, Yoanna/K-8165-2014	Skrobik, Yoanna/0000-0002-5315-6020			AbeleHorn M, 1996, INFECTION, V24, P426, DOI 10.1007/BF01713042; Albrecht S, 1999, CLIN PHARMACOL THER, V65, P630, DOI 10.1016/S0009-9236(99)90084-X; Azoulay E, 2012, CRIT CARE MED, V40, P813, DOI 10.1097/CCM.0b013e318236f297; Bow EJ, 2010, CAN J INFECT DIS MED, V21, pE122, DOI 10.1155/2010/357076; Charles PE, 2003, INTENS CARE MED, V29, P2162, DOI 10.1007/s00134-003-2002-x; Chen LL, 2008, PHARMACOGENOMICS, V9, P691, DOI 10.2217/14622416.9.6.691; Cleveland AA, 2012, CLIN INFECT DIS, V55, P1352, DOI 10.1093/cid/cis697; De Pauw B, 2008, CLIN INFECT DIS, V46, P1813, DOI 10.1086/588660; de Wildt SN, 2003, CRIT CARE MED, V31, P1952, DOI 10.1097/01.CCM.0000084806.15352.da; Delisle MS, 2011, CAN RESPIR J, V18, P131, DOI 10.1155/2011/827692; Diekema DJ, 2002, J CLIN MICROBIOL, V40, P1298, DOI 10.1128/JCM.40.4.1298-1302.2002; Dresser GK, 2003, CLIN PHARMACOL THER, V73, P41, DOI 10.1067/mcp.2003.10; Dupont H, 2003, CRIT CARE MED, V31, P752, DOI 10.1097/01.CCM.0000053525.49267.77; Dupont H, 2002, ARCH SURG-CHICAGO, V137, P1341, DOI 10.1001/archsurg.137.12.1341; Eggimann P, 2003, LANCET INFECT DIS, V3, P772, DOI 10.1016/S1473-3099(03)00831-4; Eggimann P, 2003, LANCET INFECT DIS, V3, P685, DOI 10.1016/S1473-3099(03)00801-6; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Garey KW, 2006, CLIN INFECT DIS, V43, P25, DOI 10.1086/504810; Garnacho-Montero J, 2013, J ANTIMICROB CHEMOTH, V68, P206, DOI 10.1093/jac/dks347; Garnacho-Montero J, 2010, ANTIMICROB AGENTS CH, V54, P3149, DOI 10.1128/AAC.00479-10; GORSKI JC, 1994, BIOCHEM PHARMACOL, V47, P1643; GREENBLATT DJ, 1984, ANESTHESIOLOGY, V61, P27, DOI 10.1097/00000542-198461010-00006; Group A.K.a.t.C.D.R., 2007, ICAAC 2007; Hamaoka N, 1999, CLIN PHARMACOL THER, V66, P110, DOI 10.1016/S0009-9236(99)90047-4; Kett DH, 2011, CRIT CARE, V15, DOI 10.1186/cc10514; Kimura M, 1998, THER DRUG MONIT, V20, P243, DOI 10.1097/00007691-199806000-00001; Kollef M, 2012, CLIN INFECT DIS, V54, P1739, DOI 10.1093/cid/cis305; Kotwal A, 2011, MED SCI MONITOR, V17, pCR663, DOI 10.12659/MSM.882053; Kumar A, 2009, CHEST, V136, P1237, DOI 10.1378/chest.09-0087; Labbe AC, 2009, CAN J INFECT DIS MED, V20, P45, DOI 10.1155/2009/731070; Labelle AJ, 2008, CRIT CARE MED, V36, P2967, DOI 10.1097/CCM.0b013e31818b3477; Leon C, 2009, CRIT CARE MED, V37, P1624, DOI 10.1097/CCM.0b013e31819daa14; Leroy O, 2009, CRIT CARE MED, V37, P1612, DOI 10.1097/CCM.0b013e31819efac0; MALACRIDA R, 1992, CRIT CARE MED, V20, P1123, DOI 10.1097/00003246-199208000-00010; Marchetti O, 2004, CLIN INFECT DIS, V38, P311, DOI 10.1086/380637; McKillop D, 1998, XENOBIOTICA, V28, P845, DOI 10.1080/004982598239092; Mehta S, 2006, CRIT CARE MED, V34, P374, DOI 10.1097/01.CCM.0000196830.61965.F1; Mikus G, 2011, PHARMACOGENOMICS, V12, P861, DOI [10.2217/pgs.11.18, 10.2217/PGS.11.18]; Montravers P, 2006, CRIT CARE MED, V34, P646, DOI 10.1097/01.CCM.0000201889.39443.D2; Morrell M, 2005, ANTIMICROB AGENTS CH, V49, P3640, DOI 10.1128/AAC.49.9.3640-3645.2005; Nguyen MH, 2012, CLIN INFECT DIS, V54, P1240, DOI 10.1093/cid/cis200; Ostrosky-Zeichner L, 2007, EUR J CLIN MICROBIOL, V26, P271, DOI 10.1007/s10096-007-0270-z; Ostrosky-Zeichner L, 2006, CRIT CARE MED, V34, P857, DOI 10.1097/01.CCM.0000201897.78123.44; Ostrosky-Zeichner L, 2003, CURR OPIN INFECT DIS, V16, P533, DOI 10.1097/00001432-200312000-00004; Ovakim D, 2012, CRIT CARE MED S1, V16; Pelz R K, 2000, Surg Infect (Larchmt), V1, P273, DOI 10.1089/109629600750067200; Pfaller MA, 2011, INT J ANTIMICROB AG, V38, P65, DOI 10.1016/j.ijantimicag.2011.02.016; Piarroux R, 2004, CRIT CARE MED, V32, P2443, DOI 10.1097/01.CCM.0000147726.62304.7F; Playford EG, 2010, CURR OPIN CRIT CARE, V16, P470, DOI 10.1097/MCC.0b013e32833e10e8; Saari TI, 2008, EUR J CLIN PHARMACOL, V64, P25, DOI 10.1007/s00228-007-0398-x; Scholz I, 2009, BRIT J CLIN PHARMACO, V68, P906, DOI 10.1111/j.1365-2125.2009.03534.x; Schuster MG, 2008, ANN INTERN MED, V149, P83, DOI 10.7326/0003-4819-149-2-200807150-00004; Shehabi Y, 2012, AM J RESP CRIT CARE, V186, P724, DOI 10.1164/rccm.201203-0522OC; Skrobik Y, 2013, CRIT CARE MED, V41, P999, DOI 10.1097/CCM.0b013e318275d014; Trifilio SM, 2009, ANTIMICROB AGENTS CH, V53, P1793, DOI 10.1128/AAC.01316-08; Zakrzewski-Jakubiak H, 2011, AM J GERIATR PHARMAC, V9, P461, DOI 10.1016/j.amjopharm.2011.09.006	56	10	11	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0749-0704	1557-8232		CRIT CARE CLIN	Crit. Care Clin.	OCT	2013	29	4					853	+		10.1016/j.ccc.2013.06.007			13	Critical Care Medicine	General & Internal Medicine	244CJ	WOS:000326364400006	24094381				2020-06-30	J	Niemi, G; Breivik, H				Niemi, G.; Breivik, H.			Thoracic epidural fentanyl has spinal cord analgesic effects	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Editorial Material							LOW-DOSE INFUSION; DOUBLE-BLIND; ANTINOCICEPTIVE INTERACTIONS; BUPIVACAINE; EPINEPHRINE; ADRENALINE; LIDOCAINE; MECHANISM; MORPHINE; SYNERGY		[Niemi, G.; Breivik, H.] Natl Hosp Norway, Oslo Univ Hosp, Dept Anaesthesiol & Intens Care, N-0424 Oslo, Norway; [Niemi, G.; Breivik, H.] Natl Hosp Norway, Oslo Univ Hosp, Dept Pain Management & Res, N-0424 Oslo, Norway; [Breivik, H.] Univ Oslo, Fac Med, Oslo, Norway	Niemi, G (reprint author), Natl Hosp Norway, Oslo Univ Hosp, Dept Anaesthesiol & Intens Care, Postboks 4950 Nydalen, N-0424 Oslo, Norway.	geir.niemi@ous-hf.no	Breivik, Harald/AAG-2978-2020; Niemi, Geir/O-1308-2017	Niemi, Geir/0000-0001-5931-1389; Breivik, Harald/0000-0002-1738-9337			Baron CM, 1996, ANESTH ANALG, V82, P760, DOI 10.1097/00000539-199604000-00015; BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; Breivik H, 1995, BEST PRACT RES CLIN, V9, P493; BROMAGE PR, 1989, REGION ANESTH, V14, P189; Cohen S, 2002, ANESTH ANALG, V94, P674, DOI 10.1097/00000539-200203000-00036; COLLINS JG, 1984, ANESTHESIOLOGY, V60, P269, DOI 10.1097/00000542-198404000-00001; D'Angelo R, 1998, ANESTHESIOLOGY, V88, P1519, DOI 10.1097/00000542-199806000-00016; Ginosar Y, 2003, ANESTH ANALG, V97, P1439, DOI 10.1213/01.ANE.0000081792.84877.A2; Ginosar Y, 2003, ANESTH ANALG, V97, P1428, DOI 10.1213/01.ANE.0000081793.60059.10; GRANT RP, 1992, CAN J ANAESTH, V39, P214, DOI 10.1007/BF03008779; KANEKO M, 1994, ANESTHESIOLOGY, V80, P137, DOI 10.1097/00000542-199401000-00021; MAVES TJ, 1992, ANESTHESIOLOGY, V76, P91, DOI 10.1097/00000542-199201000-00014; Niemi G, 1998, ACTA ANAESTH SCAND, V42, P897, DOI 10.1111/j.1399-6576.1998.tb05348.x; Niemi G, 2001, ACTA ANAESTH SCAND, V45, P221, DOI 10.1034/j.1399-6576.2001.450214.x; Niemi G, 2004, THESIS U OSLO OSLO, P1; Niemi G, 2005, BEST PRACT RES-CLIN, V19, P229, DOI 10.1016/j.bpa.2004.12.004; OSSIPOV MH, 1989, ANESTH ANALG, V68, P194; REDDY SVR, 1980, J PHARMACOL EXP THER, V213, P525; Sadurni M, 2013, ACTA ANAESTH SCAND, V57, P1103, DOI 10.1111/aas.12118; SOLOMON RE, 1994, ANESTH ANALG, V78, P1164; WANG C, 1993, ANESTHESIOLOGY, V79, P766, DOI 10.1097/00000542-199310000-00019; WELCHEW EA, 1983, ANAESTHESIA, V38, P1037, DOI 10.1111/j.1365-2044.1983.tb12476.x	22	3	3	0	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	2013	57	9					1089	1091		10.1111/aas.12146			3	Anesthesiology	Anesthesiology	216XN	WOS:000324320200001	24028206				2020-06-30	J	Sadurni, M; de Heredia, SB; Dursteler, C; Perez-Ramos, A; Langohr, K; Escolano, F; Puig, MM				Sadurni, M.; Beltran de Heredia, S.; Duersteler, C.; Perez-Ramos, A.; Langohr, K.; Escolano, F.; Puig, M. M.			Epidural vs. intravenous fentanyl during colorectal surgery using a double-blind, double-dummy design	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							DOSE INFUSION; MAJOR SURGERY; ANALGESIA; SITE; PAIN; BUPIVACAINE; THORACOTOMY; EQUIVALENT; ADRENALINE; CROSSOVER	Background The overall therapeutic effectiveness of epidural fentanyl vs. the intravenous route is controversial. The present work describes a randomized, controlled, double-blind, double-dummy study of the intraoperative requirements of fentanyl administered by the intravenous or epidural routes during open colon surgery. Methods Thirty patients were randomized to receive intraoperative analgesia with boluses of fentanyl administered by either the epidural or intravenous route (2 mu g/kg). The first fentanyl bolus was administered 10 min before incision, and repeated boluses were given when mean arterial pressure or heart rate increased more than 20% over basal values. General anaesthesia was maintained with a propofol infusion. Intraoperative fentanyl and propofol requirements, time to awakening, time to analgesia request, and incidence of adverse effects were recorded. Results Median [interquartile range (range)] fentanyl requirements in the epidural and intravenous groups were 0.81 [0.65 (0.47-2.61)] and 2.5 [1.08 (1.07-4.85)] mu g/kg/h, respectively (P < 0.001). The epidural group had a shorter time to awakening, with a median of 8 min [4.5 (3-18)] compared with 20 min [12.5 (7-34)] for the intravenous group (P < 0.001). There were no significant differences in propofol requirements. The time to analgesia request was also delayed in the epidural group, with a median of 5 h [5.5 (1-16)] vs. 2 h [1 (1-5)] when fentanyl was administered intravenously (P < 0.001). The incidence of adverse effects was similar in both groups. Conclusion During major abdominal surgery, epidural administration requires lower doses of intraoperative fentanyl when compared with the intravenous route. Epidural fentanyl also facilitates early awakening and residual analgesia without increasing adverse events.	[Sadurni, M.; Beltran de Heredia, S.; Duersteler, C.; Perez-Ramos, A.; Langohr, K.; Escolano, F.; Puig, M. M.] Hosp del Mar, Consorci Parc Salut Mar, Barcelona, Spain	Sadurni, M (reprint author), Consorci Parc Salut Mar, Dept Anaesthesia, Passeig Maritim 25-29, Barcelona 08003, Spain.	msadurni@parcdesalutmar.cat	Langohr, Klaus/AAA-3943-2019; Langohr, Klaus/B-7825-2012	Langohr, Klaus/0000-0001-7075-9192; Langohr, Klaus/0000-0001-7075-9192; Dursteler, Christian/0000-0003-0840-2787			Bernards CM, 2003, ANESTHESIOLOGY, V99, P455, DOI 10.1097/00000542-200308000-00029; Cohen S, 2002, ANESTH ANALG, V94, P674, DOI 10.1097/00000539-200203000-00036; ELLIS DJ, 1990, ANESTHESIOLOGY, V72, P981, DOI 10.1097/00000542-199006000-00006; George MJ, 2006, ANAESTHESIA, V61, P659, DOI 10.1111/j.1365-2044.2006.04713.x; Ginosar Y, 2003, ANESTH ANALG, V97, P1428, DOI 10.1213/01.ANE.0000081793.60059.10; GLASS PSA, 1992, ANESTH ANALG, V74, P345; GUINARD JP, 1995, ANESTHESIOLOGY, V82, P377, DOI 10.1097/00000542-199502000-00008; GUINARD JP, 1992, ANESTHESIOLOGY, V77, P1108, DOI 10.1097/00000542-199212000-00011; HARUKUNI I, 1995, ANESTH ANALG, V81, P1169, DOI 10.1097/00000539-199512000-00009; INAGAKI Y, 1992, ANESTH ANALG, V74, P856; Liu SS, 1996, ANESTH ANALG, V82, P98, DOI 10.1097/00000539-199601000-00017; LOPER KA, 1990, ANESTH ANALG, V70, P72; Niemi G, 2002, ANESTH ANALG, V94, P1598, DOI 10.1097/00000539-200206000-00044; Niemi G, 2003, ACTA ANAESTH SCAND, V47, P439, DOI 10.1034/j.1399-6576.2003.00077.x; Niemi G, 2001, ACTA ANAESTH SCAND, V45, P221, DOI 10.1034/j.1399-6576.2001.450214.x; Pozos-Guillen AJ, 2006, LIFE SCI, V79, P2275, DOI 10.1016/j.lfs.2006.07.029; Raffa RB, 2000, J PHARMACOL EXP THER, V295, P291; SALOMAKI TE, 1991, ANESTHESIOLOGY, V75, P790, DOI 10.1097/00000542-199111000-00010; SANDLER AN, 1992, ANESTHESIOLOGY, V77, P626, DOI 10.1097/00000542-199210000-00003	19	8	8	2	8	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	2013	57	9					1103	1110		10.1111/aas.12118			8	Anesthesiology	Anesthesiology	216XN	WOS:000324320200003	23560884				2020-06-30	J	Elizarov, AY; Kozlovsky, AV; Tupitsyn, II; Faizov, II				Elizarov, A. Yu; Kozlovsky, A. V.; Tupitsyn, I. I.; Faizov, I. I.			Mass-Spectrometric Monitoring of Anesthesia Adequacy	BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE			English	Article						intravenous anesthesia; propofol; fentanyl; metabolism; mass spectrometry	PROPOFOL	Anesthesia adequacy was assessed with mass-spectrometric method by monitoring the ratio of mass concentrations of end-tidal CO2 and inhaled O-2 in every respiratory cycle during surgery. For real-time monitoring, we used a mass spectrometer with electron ionization connected to the respiratory contour of inhalation anesthesia machine. The study has demonstrated advantages of the novel method in real-time assessment of adequacy of the total intravenous anesthesia.	[Elizarov, A. Yu; Kozlovsky, A. V.; Tupitsyn, I. I.; Faizov, I. I.] Russian Acad Sci, AF Ioffe Phys & Technol Inst, St Petersburg 196140, Russia	Elizarov, AY (reprint author), Russian Acad Sci, AF Ioffe Phys & Technol Inst, St Petersburg 196140, Russia.	a.elizarov@mail.ru	Tupitsyn, Ilya Igorevich/J-6611-2013; Elizarov, Andrei/C-2560-2014	Tupitsyn, Ilya Igorevich/0000-0001-9237-5667; Elizarov, Andrei/0000-0001-6846-1282	Russian Foundation for Basic ResearchRussian Foundation for Basic Research (RFBR) [12-08-00402]	This work was supported by the Russian Foundation for Basic Research (grant No. 12-08-00402).	Critchley A, 2004, INT J MASS SPECTROM, V239, P235, DOI 10.1016/j.ijms.2004.08.008; [Елизаров Андрей Юрьевич Elizarov A.Y.], 2011, [Масс-спектрометрия, Mass-spektrometriya], V8, P143; Harrison GR, 2003, BRIT J ANAESTH, V91, P797, DOI 10.1093/bja/aeg271; Hornuss C, 2007, ANESTHESIOLOGY, V106, P665, DOI 10.1097/01.anes.0000264746.01393.e0; Levshankov A. I., 2011, ZH TEKH FIZ, V81, P155; Likhvantsev V. V., 2005, ANESTHESIA MINIMALLY; Smith I., 2006, TOTAL INTRAVENOUS AN; Takita A, 2007, ANESTHESIOLOGY, V106, P659, DOI 10.1097/01.anes.0000264745.63275.59	8	0	0	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0007-4888	1573-8221		B EXP BIOL MED+	Bull. Exp. Biol. Med.	OCT	2013	155	6					814	816		10.1007/s10517-013-2259-1			3	Medicine, Research & Experimental	Research & Experimental Medicine	240RK	WOS:000326114500029	24288773				2020-06-30	J	Gusmao-Flores, D; Carvalho, JPLM; Quarantini, LC				Gusmao-Flores, Dimitri; Carvalho, Joao Pedro L. M.; Quarantini, Lucas C.			Use of Hydrocortisone for Refractory Shock in Children Reply	CRITICAL CARE MEDICINE			English	Letter							DELIRIUM; LORAZEPAM		Univ Fed, Inst Ciencias, Programa pos graduacAo Processo Interativo rgAos, Saude, Salvador, BA, Brazil; Univ Fed, Faculdade Medicina, Bahia, Bahia, Salvador, BA, Brazil; Univ Fed, Programa pos graduacAo Medicina Saude, Bahia, Salvador, BA, Brazil	Gusmao-Flores, D (reprint author), Univ Fed, Inst Ciencias, Programa pos graduacAo Processo Interativo rgAos, Saude, Salvador, BA, Brazil.		quarantini, l/K-8483-2014	Gusmao-Flores, Dimitri/0000-0002-1973-6099			Gusmao-Flores D, 2012, CRIT CARE, V16, DOI 10.1186/cc11407; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; Skrobik Y, 2013, CRIT CARE MED, V41, P999, DOI 10.1097/CCM.0b013e318275d014; Ungur LA, 2013, ALCOHOL CLIN EXP RES, V37, P675, DOI 10.1111/acer.12002	5	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	OCT	2013	41	10					E295	E296		10.1097/CCM.0b013e31829824f0			2	Critical Care Medicine	General & Internal Medicine	225AP	WOS:000324935000013	24060798				2020-06-30	J	Song, ZM; Du, BX; Wang, K; Shi, XY				Song, Zheming; Du, Boxiang; Wang, Kai; Shi, Xueyin			Effects of OPRM1 A118G Polymorphism on Epidural Analgesia with Fentanyl During Labor: A Meta-Analysis	GENETIC TESTING AND MOLECULAR BIOMARKERS			English	Article							MU-OPIOID RECEPTOR; SINGLE-NUCLEOTIDE POLYMORPHISM; MORPHINE CONSUMPTION; GENE; PAIN; REQUIREMENTS; ASSOCIATION; HETEROGENEITY; DEPRESSION; SURGERY	Background: Emerging evidence has shown that the most common polymorphism (A118G; rs1799971 A>G) in the -opioid receptor (OPRM1) gene may influence the response to labor analgesia, but individually published studies showed inconclusive results. Objective: This meta-analysis aimed to derive a more precise estimation of the effects of the OPRM1 A118G polymorphism on epidural analgesia with fentanyl during labor. Methods: A literature search was conducted on PubMed, Embase, Web of Science, and China BioMedicine databases before April 1st, 2013. The crude standardized mean difference (SMD) or odds ratio (OR) with 95% confidence interval (CI) was calculated. Results: Six clinical studies were included with a total 838 women who received epidural analgesia with fentanyl during labor. The meta-analysis results indicated that women carrying the G allele (AG+GG) of the OPRM1 A118G polymorphism required less fentanyl doses to achieve adequate pain relief compared with those with the AA homozygote (SMD=-0.24, 95% CI [-0.44, -0.03], p=0.022). The 118G variant was associated with a decreased ED50 of fentanyl for labor analgesia (SMD=-1.56, 95% CI [-1.97, -1.15], p<0.001). The analgesia satisfaction in women carrying the G allele (AG+GG) was higher than those with the AA homozygote (SMD=0.22, 95% CI [0.05, 0.39], p=0.012). However, there were no statistically significant differences between an AA homozygote and a G carrier (AG+GG) in the incidence of nausea and vomiting (OR=1.99, 95% CI [0.88, 4.52], p=0.101). Conclusion: In conclusion, the current meta-analysis indicates that women carrying the G allele (AG+GG) of OPRM1 A118G polymorphism may have a good response to epidural analgesia with fentanyl during labor. The OPRM1 A118G polymorphism may help predict individuals' response to epidural labor analgesia and so optimize postoperative pain control.	[Song, Zheming; Du, Boxiang; Shi, Xueyin] Second Mil Med Univ, Changzheng Hosp, Dept Anesthesiol, Shanghai 200003, Peoples R China; [Wang, Kai] Xuzhou Med Coll, Jiangsu Prov Key Lab Anesthesiol, Xuzhou, Peoples R China	Shi, XY (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Anesthesiol, Fengyang Rd 415, Shanghai 200003, Peoples R China.	xueyinshi@yahoo.com					Agaram R, 2009, INT J OBSTET ANESTH, V18, P10, DOI 10.1016/j.ijoa.2007.10.008; Bauchat JR, 2012, ANESTH ANALG, V115, P348, DOI 10.1213/ANE.0b013e3182575e1b; Camorcia M, 2012, INT J OBSTET ANESTH, V21, P40, DOI 10.1016/j.ijoa.2011.10.001; Chou WY, 2006, ACTA ANAESTH SCAND, V50, P787, DOI 10.1111/j.1399-6576.2006.01058.x; Chou WY, 2006, ANESTHESIOLOGY, V105, P334, DOI 10.1097/00000542-200608000-00016; De Capraris A, 2011, INT J IMMUNOPATH PH, V24, P993, DOI 10.1177/039463201102400417; Deb I, 2010, J NEUROCHEM, V112, P486, DOI 10.1111/j.1471-4159.2009.06472.x; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Gambling D, 2013, ANESTH ANALG, V116, P636, DOI 10.1213/ANE.0b013e31827e4e29; Hawkins JL, 2010, NEW ENGL J MED, V362, P1503, DOI 10.1056/NEJMct0909254; Hayashida M, 2008, PHARMACOGENOMICS, V9, P1605, DOI 10.2217/14622416.9.11.1605; Jackson D, 2012, STAT MED, V31, P3805, DOI 10.1002/sim.5453; Kleinjan M, 2012, ADDICT BIOL, DOI 10.1111/j.1369-1600.2011.00422.x; Landau R, 2008, PAIN, V139, P5, DOI 10.1016/j.pain.2008.02.023; Landau R, 2013, ANESTH ANALG, V116, P386, DOI 10.1213/ANE.0b013e318273f2c7; Liao Q, 2013, MOL MED REP, V7, P901, DOI 10.3892/mmr.2013.1270; Lowe NK, 2002, AM J OBSTET GYNECOL, V186, pS16, DOI 10.1067/mob.2002.121427; Oertel BG, 2006, PHARMACOGENET GENOM, V16, P625, DOI 10.1097/01.fpc.0000220566.90466.a2; Orejuela FJ, 2012, J IMMIGR MINOR HEALT, V14, P287, DOI 10.1007/s10903-011-9440-2; Oremus M, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001368; Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676; Pettersson FD, 2012, REPROD SCI, V19, P962, DOI 10.1177/1933719112438970; Rhodin A, 2013, MOL BRAIN, V6, DOI 10.1186/1756-6606-6-8; Sia AT, 2008, ANESTHESIOLOGY, V109, P520, DOI 10.1097/ALN.0b013e318182af21; Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z; van Melle JP, 2004, PSYCHOSOM MED, V66, P814, DOI 10.1097/01.psy.0000146294.82810.9c; Wong CA, 2010, INT J OBSTET ANESTH, V19, P246, DOI 10.1016/j.ijoa.2009.09.005; Zhang Shuangquan, 2013, Nan Fang Yi Ke Da Xue Xue Bao, V33, P309; Zhang W, 2011, MINERVA ANESTESIOL, V77, P33; Zhang W, 2010, ANAESTHESIA, V65, P130, DOI 10.1111/j.1365-2044.2009.06193.x; Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536	31	14	17	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1945-0265	1945-0257		GENET TEST MOL BIOMA	Genet. Test. Mol. Biomark.	OCT 1	2013	17	10					743	749		10.1089/gtmb.2013.0282			7	Biochemistry & Molecular Biology; Genetics & Heredity	Biochemistry & Molecular Biology; Genetics & Heredity	220YH	WOS:000324622900005	23909491				2020-06-30	J	Narahara, H; Kadoi, Y; Hinohara, H; Kunimoto, F; Saito, S				Narahara, Hajime; Kadoi, Yuji; Hinohara, Hiroshi; Kunimoto, Fumio; Saito, Shigeru			Comparative effects of flurbiprofen and fentanyl on natural killer cell cytotoxicity, lymphocyte subsets and cytokine concentrations in post-surgical intensive care unit patients: prospective, randomized study	JOURNAL OF ANESTHESIA			English	Article						Natural killer cell cytotoxicity; Fentanyl; Flurbiprofen; Long-term sedation	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MECHANICALLY VENTILATED PATIENT; TUMOR-METASTASIS; IMMUNE-RESPONSES; SURGERY; SEDATION; PAIN; IMMUNOMODULATION; SUPPRESSION; VOLUNTEERS	The purpose of this study was to compare the effect of the long-term administration of flurbiprofen and fentanyl in the intensive care unit on natural killer cell cytotoxicity (NKCC), lymphocyte subsets and cytokine levels. In this prospective study, patients scheduled for at least 48 h sedation after neck surgery were randomly assigned to two groups called group N and group F. Group N patients were sedated with propofol and flurbiprofen after surgery (n = 12), while group F patients were sedated with propofol and fentanyl (n = 13). The NKCC, lymphocyte subsets, and plasma levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta, IL-6, and IL-10 were measured before and at the end of surgery, on postoperative day (POD) 1 and POD2. The NKCC was significantly higher on POD1 in group N than in group F (14.5 +/- A 11.2 versus 6.3 +/- A 4.1 %, p < 0.05), the difference between the groups disappearing on POD2. Lymphocyte subsets and plasma levels of cytokines were not significantly different between the two groups during the study period. Transient suppressive effects on NKCC were observed in the fentanyl group as compared to the flurbiprofen group. This suggests that when choosing postoperative analgesics, physicians should bear in mind the potential immunosuppressive effects of these agents in patients requiring prolonged sedation in the intensive care unit.	[Narahara, Hajime; Hinohara, Hiroshi; Kunimoto, Fumio; Saito, Shigeru] Gunma Univ Hosp, Intens Care Unit, Maebashi, Gunma 3718511, Japan; [Kadoi, Yuji] Gunma Univ Hosp, Dept Anesthesiol, Maebashi, Gumma, Japan	Narahara, H (reprint author), Gunma Univ Hosp, Intens Care Unit, 3-39-22 Showa Machi, Maebashi, Gunma 3718511, Japan.	hnarahara@gunma-u.ac.jp					Bastami S, 2012, ACTA ONCOL, DOI [10.3109/0284186X.2012.737932, DOI 10.3109/0284]; Beilin B, 1996, ANESTH ANALG, V82, P492, DOI 10.1097/00000539-199603000-00011; Benish M, 2008, ANN SURG ONCOL, V15, P2042, DOI 10.1245/s10434-008-9890-5; Carr DJJ, 1996, P SOC EXP BIOL MED, V213, P248; Cronin AJ, 2003, BRIT J ANAESTH, V91, P805, DOI 10.1093/bja/aeg273; DASTA JF, 1994, CRIT CARE MED, V22, P974, DOI 10.1097/00003246-199406000-00016; Eisenstein TK, 1998, J NEUROIMMUNOL, V83, P36, DOI 10.1016/S0165-5728(97)00219-1; Hussain M, 2012, PHARMACOL RES, V66, P7, DOI 10.1016/j.phrs.2012.02.003; Inada T, 2011, J ANESTH, V25, P569, DOI 10.1007/s00540-011-1163-y; Inaoka M, 2006, EXP DERMATOL, V15, P981, DOI 10.1111/j.1600-0625.2006.00505.x; Jacobs R, 1999, INT J IMMUNOPHARMACO, V21, P445, DOI 10.1016/S0192-0561(99)00025-9; Kadoi Y, 2005, J CLIN ANESTH, V17, P598, DOI 10.1016/j.jclinane.2005.04.004; Kress JP, 2006, CRIT CARE MED, V34, P2541, DOI 10.1097/01.CCM.0000239117.39890.E3; Kundu N, 2005, CANCER IMMUNOL IMMUN, V54, P981, DOI 10.1007/s00262-005-0669-2; Kurosawa S, 2008, J ANESTH, V22, P263, DOI 10.1007/s00540-008-0626-2; LYSLE DT, 1993, J PHARMACOL EXP THER, V265, P1071; MEAKINS JL, 1991, ARCH SURG-CHICAGO, V126, P494; Melamed R, 2003, ANESTH ANALG, V97, P1331, DOI 10.1213/01.ANE.0000082995.44040.07; Nelson CJ, 1997, ANESTH ANALG, V85, P620, DOI 10.1097/00000539-199709000-00024; Ogawa K, 2000, SURGERY, V127, P329, DOI 10.1067/msy.2000.103498; Patel SB, 2012, AM J RESP CRIT CARE, V185, P486, DOI 10.1164/rccm.201102-0273CI; Payen JF, 2001, CRIT CARE MED, V29, P2258, DOI 10.1097/00003246-200112000-00004; Sanders RD, 2009, CRIT CARE CLIN, V25, P551, DOI 10.1016/j.ccc.2009.05.001; Schneemilch CE, 2005, EUR J ANAESTH, V22, P616, DOI 10.1017/S0265021505001031; Shavit Y, 2004, NEUROIMMUNOMODULAT, V11, P255, DOI 10.1159/000078444; SLADE MS, 1975, SURGERY, V78, P363; Soliman HM, 2001, BRIT J ANAESTH, V87, P186, DOI 10.1093/bja/87.2.186; Volk T, 2004, ANESTH ANALG, V98, P1086, DOI 10.1213/01.ANE.0000104586.12700.3A; Watling SM, 1997, ANN PHARMACOTHER, V31, P148, DOI 10.1177/106002809703100202; Yardeni Israel Z, 2008, J Opioid Manag, V4, P27; YEAGER MP, 1995, ANESTHESIOLOGY, V83, P500, DOI 10.1097/00000542-199509000-00008; Yeager MP, 2002, ANESTH ANALG, V94, P94, DOI 10.1097/00000539-200201000-00018; Yokoyama M, 2001, ANESTH ANALG, V92, P463, DOI 10.1213/00000539-200102000-00035	33	8	8	0	2	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	OCT	2013	27	5					676	683		10.1007/s00540-013-1597-5			8	Anesthesiology	Anesthesiology	234DI	WOS:000325620400006	23543346				2020-06-30	J	Lindholm, EE; Aune, E; Noren, CB; Seljeflot, I; Hayes, T; Otterstad, JE; Kirkeboen, KA				Lindholm, Espen E.; Aune, Erlend; Noren, Camilla B.; Seljeflot, Ingebjorg; Hayes, Thomas; Otterstad, Jan E.; Kirkeboen, Knut A.			The Anesthesia in Abdominal Aortic Surgery (ABSENT) Study A Prospective, Randomized, Controlled Trial Comparing Troponin T Release with Fentanyl-Sevoflurane and Propofol-Remifentanil Anesthesia in Major Vascular Surgery	ANESTHESIOLOGY			English	Article							ARTERY-BYPASS SURGERY; FOR-VASCULAR-SURGERY; LONG-TERM SURVIVAL; HEART IN-VIVO; NONCARDIAC SURGERY; CARDIOPULMONARY BYPASS; CARDIAC TROPONIN; MYOCARDIAL-INFARCTION; CORONARY SURGERY; RAT-HEART	Background: On the basis of data indicating that volatile anesthetics induce cardioprotection in cardiac surgery, current guidelines recommend volatile anesthetics for maintenance of general anesthesia during noncardiac surgery in hemodynamic stable patients at risk for perioperative myocardial ischemia. The aim of the current study was to compare increased troponin T (TnT) values in patients receiving sevoflurane-based anesthesia or total intravenous anesthesia in elective abdominal aortic surgery. Methods: A prospective, randomized, open, parallel-group trial comparing sevoflurane-based anesthesia (group S) and total intravenous anesthesia (group T) with regard to cardioprotection in 193 patients scheduled for elective abdominal aortic surgery. Increased TnT level on the first postoperative day was the primary endpoint. Secondary endpoints were postoperative complications, nonfatal coronary events and mortality. Results: On the first postoperative day increased TnT values (>13 ng/l) were found in 43 (44%) patients in group S versus 41 (43%) in group T (P = 0.999), with no significant differences in TnT levels between the groups at any time point. Although underpowered, the authors found no differences in postoperative complications, nonfatal coronary events or mortality between the groups. Conclusions: In elective abdominal aortic surgery sevoflurane-based anesthesia did not reduce myocardial injury, evaluated by TnT release, compared with total intravenous anesthesia. These data indicate that potential cardioprotective effects of volatile anesthetics found in cardiac surgery are less obvious in major vascular surgery.	[Lindholm, Espen E.; Aune, Erlend; Noren, Camilla B.; Seljeflot, Ingebjorg; Hayes, Thomas; Otterstad, Jan E.; Kirkeboen, Knut A.] Vestfold Hosp Trust, Dept Anesthesiol, N-3103 Tonsberg, Norway	Lindholm, EE (reprint author), Vestfold Hosp Trust, Dept Anesthesiol, POB 2168, N-3103 Tonsberg, Norway.	espen.lindholm@siv.no			Baxter AS Norway, Oslo, Norway	Support was provided solely from institutional and/or departmental sources. Dr. Lindholm has received fees for presentations by Baxter AS Norway, Oslo, Norway.	Abraham N, 2005, J VASC SURG, V41, P377, DOI 10.1016/j.jvs.2004.11.038; Alcalai R, 2007, ARCH INTERN MED, V167, P276, DOI 10.1001/archinte.167.3.276; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Brewster DC, 2003, J VASC SURG, V37, P1106, DOI 10.1067/mva.2003.363; Buse GALL, 2012, CIRCULATION, V126, P2696, DOI 10.1161/CIRCULATIONAHA.112.126144; Chiesa R, 2012, J CARDIOVASC SURG, V53, P119; Conzen PF, 2003, ANESTHESIOLOGY, V99, P826, DOI 10.1097/00000542-200310000-00013; Cope DK, 1997, ANESTHESIOLOGY, V86, P699, DOI 10.1097/00000542-199703000-00023; De Hert SG, 2008, ACTA ANAESTH BELG, V59, P19; De Hert SG, 2004, ANESTHESIOLOGY, V101, P299, DOI 10.1097/00000542-200408000-00009; De Hert SG, 2004, ANESTHESIOLOGY, V101, P9, DOI 10.1097/00000542-200407000-00005; Fleisher LA, 2007, CIRCULATION, V116, P1971, DOI 10.1161/CIRCULATIONAHA.107.185700; Frassdorf J, 2010, CAN J ANESTH, V57, P767, DOI 10.1007/s12630-010-9325-1; Gho BCG, 1996, CIRCULATION, V94, P2193, DOI 10.1161/01.CIR.94.9.2193; Giannitsis E, 2010, CLIN CHEM, V56, P254, DOI 10.1373/clinchem.2009.132654; Hirsch AT, 2006, CIRCULATION, V113, pE463, DOI 10.1161/CIRCULATIONAHA.106.174526; Hocker J, 2006, ANAESTHESIA, V61, P752, DOI 10.1111/j.1365-2044.2006.04715.x; Jakobsen CJ, 2007, J CARDIOTHOR VASC AN, V21, P664, DOI 10.1053/j.jvca.2007.03.002; Kehl F, 2002, ANESTHESIOLOGY, V96, P675, DOI 10.1097/00000542-200203000-00025; Kokita N, 1996, ANESTHESIOLOGY, V84, P117, DOI 10.1097/00000542-199601000-00014; Landesberg G, 2003, J AM COLL CARDIOL, V42, P1547, DOI 10.1016/j.jacc.2003.05.001; Landoni G, 2007, J CARDIOTHOR VASC AN, V21, P502, DOI 10.1053/j.jvca.2007.02.013; Landoni G, 2009, ANN CARD ANAESTH, V12, P4, DOI 10.4103/0971-9784.45006; Lang SC, 2006, BASIC RES CARDIOL, V101, P149, DOI 10.1007/s00395-005-0565-0; Licka M, 2002, HEART, V87, P520, DOI 10.1136/heart.87.6.520; LopezJimenez F, 1997, J AM COLL CARDIOL, V29, P1241, DOI 10.1016/S0735-1097(97)82754-4; MANGANO DT, 1992, JAMA-J AM MED ASSOC, V268, P233, DOI 10.1001/jama.268.2.233; Mullenheim J, 2001, CAN J ANAESTH, V48, P784; Nathan DP, 2011, J VASC SURG, V54, P1237, DOI 10.1016/j.jvs.2011.05.028; Neilipovitz DT, 2001, ANESTH ANALG, V93, P573, DOI 10.1097/00000539-200109000-00009; Newman AB, 2001, ANN INTERN MED, V134, P182, DOI 10.7326/0003-4819-134-3-200102060-00008; Obal D, 2001, BRIT J ANAESTH, V87, P905, DOI 10.1093/bja/87.6.905; Okmen Ertan, 2005, J Invasive Cardiol, V17, P63; Panteghini M, 2002, CLIN CHEM, V48, P1432; Poole-Wilson PA, 2004, LANCET, V364, P849, DOI 10.1016/S0140-6736(04)16980-8; Preckel B, 1998, BRIT J ANAESTH, V81, P905; Redfern G, 2011, ANAESTHESIA, V66, P604, DOI 10.1111/j.1365-2044.2011.06763.x; Schouten O, 2007, EUR J VASC ENDOVASC, V33, P544, DOI 10.1016/j.ejvs.2006.11.028; Symons JA, 2006, BRIT J ANAESTH, V97, P127, DOI 10.1093/bja/ael149; Thygesen K, 2007, CIRCULATION, V116, P2634, DOI 10.1161/CIRCULATIONAHA.107.187397; Toller WG, 1999, ANESTHESIOLOGY, V91, P1437, DOI 10.1097/00000542-199911000-00037; Tritapepe L, 2007, EUR J ANAESTH, V24, P323, DOI 10.1017/S0265021506001931; Twerenbold R, 2012, EUR HEART J, V33, P579, DOI 10.1093/eurheartj/ehr492; Xia ZY, 2006, ANESTH ANALG, V103, P527, DOI 10.1213/01.ane.0000230612.29452.a6; Xia ZY, 2004, CAN J PHYSIOL PHARM, V82, P919, DOI 10.1139/Y04-097; Young JR, 1986, ANN VASC SURG, V1, P36; Yu CK, 2007, BRIT J ANAESTH, V99, P632, DOI 10.1093/bja/aem261; Zangrillo A, 2011, J CARDIOTHOR VASC AN, V25, P902, DOI 10.1053/j.jvca.2011.06.016; Zaugg M, 2002, ANESTHESIOLOGY, V97, P15, DOI 10.1097/00000542-200207000-00004; Zhang Y, 2004, ANESTHESIOLOGY, V101, P918, DOI 10.1097/00000542-200410000-00017	50	34	36	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	OCT	2013	119	4					802	812		10.1097/ALN.0b013e31829bd883			11	Anesthesiology	Anesthesiology	219AJ	WOS:000324475400020	23838709	Bronze			2020-06-30	J	Song, JW; Shim, JK; Song, Y; Yang, SY; Park, SJ; Kwak, YL				Song, J. W.; Shim, J. K.; Song, Y.; Yang, S. Y.; Park, S. J.; Kwak, Y. L.			Effect of ketamine as an adjunct to intravenous patient-controlled analgesia, in patients at high risk of postoperative nausea and vomiting undergoing lumbar spinal surgery	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesia, patient-controlled; ketamine; postoperative nausea and vomiting	HUMAN LIVER-MICROSOMES; ABDOMINAL-SURGERY; N-DEMETHYLATION; PAIN; MORPHINE; INFUSION; HYPERALGESIA; PREVENTION; IMPROVES; CYP2B6	Background. We evaluated the effect of ketamine as an adjunct to a fentanyl-based i.v. patient-controlled analgesia (IV-PCA) on postoperative nausea and vomiting (PONV) in patients at high risk of PONV undergoing lumbar spinal surgery. Methods. Fifty non-smoking female patients were evenly randomized to either the control or ketamine group. According to randomization, patients received either ketamine 0.3 mg kg(-1) i.v. or normal saline after anaesthetic induction with fentanyl-based IV-PCA either with or without ketamine mixture (3 mg kg-1 in 180 ml). The incidence and severity of PONV, volume of IV-PCA consumed, and pain intensity were assessed in the postanaesthesia care unit, and at postoperative 6, 12, 24, 36, and 48 h. Results. The overall incidence of PONV during the first 48 h after surgery was similar between the two groups (68 vs 56%, ketamine and control group, P=0.382). The total dose of fentanyl used during the first 48 h after operation was lower in the ketamine group than in the control group [mean (SD), 773 (202) mu g vs 957 (308) mu g, P=0.035]. The intensity of nausea (11-point verbal numerical rating scale) was higher in the ketamine group during the first 6 h after operation [median (interquartile range), 6 (3-7) vs 2 (1.5-3.5), P=0.0391, postoperative 1224 h [5 (4-7) vs 2 (1-3), P=0.014], and postoperative 36-48 h [5 (4-7) vs 2 (1-3), P=0.036]. Pain intensities were similar between the groups. Conclusions. Ketamine did not reduce the incidence of PONV and exerted a negative influence on the severity of nausea. It was, however, able to reduce postoperative fentanyl consumption in patients at high-risk of PONV.	[Song, J. W.; Shim, J. K.; Song, Y.; Park, S. J.; Kwak, Y. L.] Yonsei Univ, Coll Med, Dept Anaesthesiol & Pain Med, Seoul 120752, South Korea; [Song, J. W.; Shim, J. K.; Song, Y.; Kwak, Y. L.] Yonsei Univ, Coll Med, Anaesthesia & Pain Res Inst, Seoul 120752, South Korea; [Kwak, Y. L.] Yonsei Univ, Coll Med, Severance Biomed Sci Inst, Seoul 120752, South Korea; [Yang, S. Y.] Chung Ang Univ, Coll Med, Dept Anaesthesiol & Pain Med, Seoul 156756, South Korea	Kwak, YL (reprint author), Yonsei Univ, Coll Med, Dept Anaesthesiol & Pain Med, Anaesthesia & Pain Res Inst, 250 Seongsan No, Seoul 120752, South Korea.	ylkwak@yuhs.ac		Song, Jong Wook/0000-0001-7518-2070; Kwak, Young-Lan/0000-0002-2984-9927; park, soo jung/0000-0003-2963-1394; Shim, Jae-Kwang/0000-0001-9093-9692; Song, Young/0000-0003-4597-387X			Adam F, 2005, ANESTH ANALG, V100, P475, DOI 10.1213/01.ANE.0000142117.82241.DC; Adriaenssens G, 1999, BRIT J ANAESTH, V83, P393; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Apfel CC, 2004, NEW ENGL J MED, V350, P2441, DOI 10.1056/NEJMoa032196; Bell RF, 2005, ACTA ANAESTH SCAND, V49, P1405, DOI 10.1111/j.1399-6576.2005.00814.x; Bonnet F, 2007, BEST PRACT RES-CLIN, V21, P99, DOI 10.1016/j.bpa.2006.12.007; BOVILL JG, 1971, LANCET, V1, P1285; De Kock MF, 2007, BEST PRACT RES-CLIN, V21, P85, DOI 10.1016/j.bpa.2006.12.006; Elia N, 2005, PAIN, V113, P61, DOI 10.1016/j.pain.2004.09.036; Gepstein R, 2007, SURG NEUROL, V67, P360, DOI 10.1016/j.surneu.2006.09.033; GHONEIM MM, 1985, J CLIN PSYCHOPHARM, V5, P70, DOI 10.1097/00004714-198504000-00003; Hijazi Y, 2002, DRUG METAB DISPOS, V30, P853, DOI 10.1124/dmd.30.7.853; Kranke P, 2011, EUR J ANAESTH, V28, P758, DOI 10.1097/EJA.0b013e32834a4e1e; Lamba JK, 2002, ADV DRUG DELIVER REV, V54, P1271, DOI 10.1016/S0169-409X(02)00066-2; Laskowski K, 2011, CAN J ANESTH, V58, P911, DOI 10.1007/s12630-011-9560-0; Leung A, 2001, PAIN, V91, P177, DOI 10.1016/S0304-3959(00)00433-4; Marret E, 2005, ANESTHESIOLOGY, V102, P1249, DOI 10.1097/00000542-200506000-00027; MARTIN DC, 1988, BRAIN RES, V455, P360, DOI 10.1016/0006-8993(88)90095-9; Mo SL, 2009, CURR DRUG METAB, V10, P730, DOI 10.2174/138920009789895534; Paksoy Y, 2004, SPINE, V29, P2419, DOI 10.1097/01.brs.0000144354.36449.2f; Rybaczyk Leszek A, 2005, BMC Womens Health, V5, P12, DOI 10.1186/1472-6874-5-12; Stubhaug A, 1997, ACTA ANAESTH SCAND, V41, P1124, DOI 10.1111/j.1399-6576.1997.tb04854.x; Subramaniam K, 2004, ANESTH ANALG, V99, P482, DOI 10.1213/01.ANE.0000118109.12855.07; Suppa E, 2012, MINERVA ANESTESIOL, V78, P774; Suzuki M, 2006, ANESTHESIOLOGY, V105, P111, DOI 10.1097/00000542-200607000-00020; Urban Michael K, 2008, HSS J, V4, P62, DOI 10.1007/s11420-007-9069-9; WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023; Webb AR, 2002, ANESTH ANALG, V95, P1713, DOI 10.1097/00000539-200212000-00045; Yamauchi M, 2008, ANESTH ANALG, V107, P1041, DOI 10.1213/ane.0b013e31817f1e4a; Yanagihara Y, 2001, DRUG METAB DISPOS, V29, P887; Zakine J, 2008, ANESTH ANALG, V106, P1856, DOI 10.1213/ane.0b013e3181732776	31	27	27	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	OCT	2013	111	4					630	635		10.1093/bja/aet192			6	Anesthesiology	Anesthesiology	226OJ	WOS:000325045400017	23744819	Bronze			2020-06-30	J	Caputi, FF; Lattanzio, F; Carretta, D; Mercatelli, D; Candeletti, S; Romualdi, P				Caputi, Francesca Felicia; Lattanzio, Francesca; Carretta, Donatella; Mercatelli, Daniela; Candeletti, Sanzio; Romualdi, Patrizia			Morphine and Fentanyl Differently Affect MOP and NOP Gene Expression in Human Neuroblastoma SH-SY5Y Cells	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						Morphine; Fentanyl; MOP; NOP; Opioid gene expression	RECEPTOR MESSENGER-RNA; OPIOID TOLERANCE; MICE LACKING; ENDOCYTOSIS; DEPENDENCE; RATS; ANALGESIA; FQ	Morphine is widely used for the treatment of severe acute and chronic pain, but long-term therapy rapidly leads to tolerance. Morphine effects are mediated by mu opioid receptor (MOP) activation as well as for fentanyl that, in contrast to morphine, induces less tolerance to analgesia. The mechanisms underlying opioid tolerance involve complex processes, such as MOP desensitization, internalization, and/or changes of gene expression. The development of morphine tolerance also involves adaptive changes of the anti-opioid nociceptin/orphanin FQ-nociceptin receptor system, as suggested by the reduction of morphine tolerance in nociceptin opioid receptor (NOP) knockout mice. The aim of the present study was to investigate the MOP and NOP gene expression in the SH-SY5Y cells following morphine and fentanyl exposure. Results showed that cell exposure to 10 mu M morphine for 5 h induced a significant decrease of MOP and NOP gene expression and that the MOP downregulation was reverted by the pretreatment with naloxone. Conversely, SH-SY5Y cells exposed to 0.1 and 1 mu M fentanyl for 5 and 72 h showed a significant MOP upregulation, also reverted by naloxone pretreatment. Fentanyl induced no changes of NOP gene expression. The present findings showed a different effect by morphine and fentanyl on MOP mRNA levels that contributes to define the role of MOP gene expression changes in the mechanisms underlying the tolerance. Morphine also triggers an altered NOP-related signaling confirming that the nociceptin/orphanin FQ-nociceptin receptor system also plays a significant role in the development of morphine tolerance.	[Caputi, Francesca Felicia; Lattanzio, Francesca; Carretta, Donatella; Mercatelli, Daniela; Candeletti, Sanzio; Romualdi, Patrizia] Univ Bologna, Dept Pharm & Biotechnol, Alma Mater Studiorum, I-40126 Bologna, Italy	Romualdi, P (reprint author), Univ Bologna, Dept Pharm & Biotechnol, Alma Mater Studiorum, Via Irnerio 48, I-40126 Bologna, Italy.	patrizia.romualdi@unibo.it		Caputi, Francesca Felicia/0000-0002-2352-3010; Romualdi, Patrizia/0000-0002-3610-2928			CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung SJ, 2006, J PHARMACOL EXP THER, V318, P262, DOI 10.1124/jpet.106.103960; EMMETTOGLESBY MW, 1988, J PHARMACOL EXP THER, V245, P17; Gach K, 2008, BIOCHEM CELL BIOL, V86, P217, DOI 10.1139/o08-001; Hashimoto T, 2006, ANESTHESIOLOGY, V105, P574, DOI 10.1097/00000542-200609000-00023; Kieffer BL, 2002, CELL, V108, P587, DOI 10.1016/S0092-8674(02)00666-9; Koch T, 2008, PHARMACOL THERAPEUT, V117, P199, DOI 10.1016/j.pharmthera.2007.10.003; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lyon E, 2001, Expert Rev Mol Diagn, V1, P92, DOI 10.1586/14737159.1.1.92; Martini L, 2007, CURR OPIN NEUROBIOL, V17, P556, DOI 10.1016/j.conb.2007.10.004; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Mohan S, 2010, J NEUROIMMUNOL, V227, P26, DOI 10.1016/j.jneuroim.2010.06.007; Narita M, 2002, LIFE SCI, V70, P2341, DOI 10.1016/S0024-3205(01)01550-8; PARONIS CA, 1992, J PHARMACOL EXP THER, V262, P1; Prenus RV, 2012, INT J MOL MED, V30, P1493, DOI 10.3892/ijmm.2012.1132; Romualdi P, 2002, NEUROREPORT, V13, P645, DOI 10.1097/00001756-200204160-00022; Rozen S, 2000, Methods Mol Biol, V132, P365; Scoto GM, 2010, PEPTIDES, V31, P696, DOI 10.1016/j.peptides.2009.12.028; Takayama N, 2005, PEPTIDES, V26, P2513, DOI 10.1016/j.peptides.2005.05.005; Ueda H, 1997, NEUROSCI LETT, V237, P136, DOI 10.1016/S0304-3940(97)00832-X; Ueda H, 2000, J NEUROSCI, V20, P7640; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Yoshikawa M, 2000, BRAIN RES, V859, P217, DOI 10.1016/S0006-8993(00)01961-2; Yu X, 2003, J PHARMACOL EXP THER, V306, P447, DOI 10.1124/jpet.103.048694; Yuan L, 1999, BRAIN RES, V826, P330, DOI 10.1016/S0006-8993(99)01337-2; Zhu ZP, 2012, MOL MED REP, V5, P513, DOI 10.3892/mmr.2011.677	26	10	10	0	11	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696			J MOL NEUROSCI	J. Mol. Neurosci.	OCT	2013	51	2					532	538		10.1007/s12031-013-0019-3			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	221DG	WOS:000324637200038	23715695				2020-06-30	J	McWilliams, K; Fallon, M				McWilliams, K.; Fallon, M.			Fast-acting fentanyl preparations and pain management	QJM-AN INTERNATIONAL JOURNAL OF MEDICINE			English	Review							BREAKTHROUGH CANCER PAIN; CITRATE OTFC(R); PREVALENCE; CROSSOVER; DYSPNEA; TRIAL; SPRAY	Cancer-related pain is a common clinical problem, experienced by similar to 90% of patients with cancer. The mainstay of treatment remains opioids and the WHO analgesic ladder. Following the principles of the analgesic ladder, 80% of patients can achieve pain control. However, breakthrough pain remains a form of cancer-related pain that is particularly difficult to manage in both specialist and generalist settings. The focus of this article is the mismatch between the temporal characteristics of the majority of cancer-related breakthrough pain which is fast onset and resolution, with the pharmacological profile of oral morphine. The contribution of fast-acting fentanyl preparations to the treatment of breakthrough pain and the evidence for the various commercially available preparations will be considered.	[McWilliams, K.; Fallon, M.] Univ Edinburgh, Edinburgh Canc Res UK Ctr, Dept Palliat Med, Edinburgh EH4 2XR, Midlothian, Scotland	McWilliams, K (reprint author), Univ Edinburgh, Edinburgh Canc Res UK Ctr, Dept Palliat Med, Crewe Rd South, Edinburgh EH4 2XR, Midlothian, Scotland.	kerry.mcwilliams@nhs.net		Fallon, Marie/0000-0001-9214-0091			Benitez-Rosario MA, 2005, J PAIN SYMPTOM MANAG, V30, P395, DOI 10.1016/j.jpainsymman.2005.10.002; BENNETT D, 2005, [No title captured], V30, P354; Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001; Caraceni A, 1999, PAIN, V82, P263, DOI 10.1016/S0304-3959(99)00073-1; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Fallon MT, 2010, J SUPPORT ONCOL, V9, P224; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Gauna AA, 2008, J PALLIAT MED, V11, P643, DOI 10.1089/jpm.2007.0161; Jandhyala R, 2012, BMJ SUPPORT PALLIAT, V2, P156, DOI 10.1136/bmjspcare-2011-000139; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Laird BJA, 2011, SUPPORT CARE CANCER, V19, P1393, DOI 10.1007/s00520-010-0961-3; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Nunez-Olarte JM, 2011, J PAIN SYMPTOM MANAG, V42, pE6, DOI 10.1016/j.jpainsymman.2011.07.006; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Taylor DR, 2007, PAIN MED, V8, P281, DOI 10.1111/j.1526-4637.2007.00298.x; VENTAFRIDDA V, 1987, CANCER, V59, P850, DOI 10.1002/1097-0142(19870215)59:4<850::AID-CNCR2820590432>3.0.CO;2-1; Zeppetella G, 2009, EUR J CANCER CARE, V18, P331, DOI 10.1111/j.1365-2354.2008.01009.x	22	4	4	0	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1460-2725	1460-2393		QJM-INT J MED	QJM-An Int. J. Med.	OCT	2013	106	10					887	890		10.1093/qjmed/hct092			4	Medicine, General & Internal	General & Internal Medicine	224HT	WOS:000324874700003	23613597	Bronze			2020-06-30	J	Kuivalainen, AM; Ebeling, F; Rosenberg, PH				Kuivalainen, A. -M.; Ebeling, F.; Rosenberg, P. H.			Pre-medication with sublingual fentanyl did not relieve pain associated with bone marrow aspiration and biopsy: A randomized feasibility trial	EUROPEAN JOURNAL OF PAIN			English	Article							CANCER-PATIENTS; PHARMACOKINETICS; TOLERABILITY; CITRATE; TABLET	Background Bone marrow aspiration and/or biopsy (BMAB) is often an unpleasant and painful procedure in spite of local anaesthetic infiltration. This randomized placebo-controlled trial compared the pain relieving effect of sublingual fentanyl and placebo during BMAB. Methods One hundred sixty patients were randomized to receive either sublingual fentanyl 200g, 100g (patients70 years old, weight50kg or in poor health) or placebo before BMAB. The grade of anxiety before the procedure and the grade of pain during local anaesthetic infiltration, aspiration, biopsy and immediately after the BMAB were assessed using the Numeral Rating Scale (0-10). Possible side effects of the study drugs were recorded. Results Sublingual fentanyl proved inadequate in relieving pain during BMAB as no significant differences in the pain scores of the fentanyl and placebo patients were observed. However, fentanyl caused significantly more dizziness than placebo. Conclusions The results suggest that sublingual fentanyl in a dose of 200g (100g in infirm patients) is not a feasible preventive analgesic during BMAB. Pain scores were similar and side effects more frequent in the fentanyl group than in the placebo group.	[Kuivalainen, A. -M.; Rosenberg, P. H.] Univ Helsinki, Dept Anaesthesiol & Intens Care Med, FIN-00014 Helsinki, Finland; [Ebeling, F.] Helsinki Univ Hosp, Dept Haematol, Helsinki, Finland	Kuivalainen, AM (reprint author), Univ Helsinki, Dept Anaesthesiol & Intens Care Med, FIN-00014 Helsinki, Finland.	anna-maria.kuivalainen@helsinki.fi			Helsinki University Hospital Research Funds (EVO); Signe and Ane Gyllenberg Foundation	Helsinki University Hospital Research Funds (EVO) and Signe and Ane Gyllenberg Foundation.	Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Kuivalainen AM, 2012, SCAND J PAIN, V3, P92, DOI 10.1016/j.sjpain.2011.11.002; Kuivalainen AM, 2010, EUR J PAIN, V14, P160, DOI 10.1016/j.ejpain.2009.04.012; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Lennernas B, 2010, PALLIATIVE MED, V24, P286, DOI 10.1177/0269216309356138; Liden Y, 2009, ACTA ANAESTH SCAND, V53, P354, DOI 10.1111/j.1399-6576.2008.01874.x; Lister N, 2011, J CLIN PHARMACOL, V51, P1195, DOI 10.1177/0091270010379410; McMenamin Erin, 2002, Expert Rev Neurother, V2, P625, DOI 10.1586/14737175.2.5.625; Nalamachu SR, 2012, PAIN PRACT, V12, P449, DOI 10.1111/j.1533-2500.2011.00525.x; Park SH, 2008, PAIN MED, V9, P249, DOI 10.1111/j.1526-4637.2006.00284.x; Proud Carol, 2007, Clin J Oncol Nurs, V11, P561, DOI 10.1188/07.CJON.561-567; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; SCHECHTER NL, 1995, PEDIATRICS, V95, P335; Vanhelleputte PA, 2003, J PAIN SYMPTOM MANAG, V26, P860, DOI 10.1016/S0885-3924(03)00312-9; Wolanskyj A P, 2000, Clin Lymphoma, V1, P154, DOI 10.3816/CLM.2000.n.014	15	5	6	0	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801			EUR J PAIN	Eur. J. Pain	OCT	2013	17	9					1357	1364		10.1002/j.1532-2149.2013.00303.x			8	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	211SM	WOS:000323930700012	23509019				2020-06-30	J	Porhomayon, J; Nader, ND; El-Solh, AA; Hite, M; Scott, J; Silinskie, K				Porhomayon, Jahan; Nader, Nader D.; El-Solh, Ali A.; Hite, Mindee; Scott, Jonathan; Silinskie, Kevin			Pre- and post-intervention study to assess the impact of a sedation protocol in critically ill surgical patients	JOURNAL OF SURGICAL RESEARCH			English	Article						Mechanical ventilation days; Sedation; Protocol; Midazolam; Fentanyl; Dose; Length of stay; Score	INTENSIVE-CARE-UNIT; RECEIVING MECHANICAL VENTILATION; CLINICAL-PRACTICE GUIDELINES; DAILY INTERRUPTION; RANDOMIZED-TRIAL; ANALGESIA; ADULT; MULTICENTER; DURATION; RELIABILITY	Introduction: Sedation and pain management for mechanically ventilated critically ill surgical patients pose many challenges for the intensivist. Even though daily interruption of sedatives and opioids is appropriate in medical intensive care unit (ICU) patients, it may not be feasible in the surgical patients with pain from surgical incision or trauma. Therefore we developed an analgesia/sedation based protocol for the surgical ICU population. Methods: We performed a two-phase prospective observational control study. We evaluated a prescriber driven analgesia/sedation protocol (ASP) in a 12-bed surgical ICU. The pre-ASP group was sedated as usual (n = 100) and the post-ASP group was managed with the new ASP (n = 100). Each phase of the study lasted for 5 mo. Comparisons between the two groups were performed by c 2 or Fisher's exact test for categorical variables and the Mann-Whitney test for nonparametric variables. A P value <0.05 was statistically significant. Results: We found a significant reduction in the use of fentanyl (P < 0.001) and midazolam (P = 0.001). We achieved sedation goals of 86.8% in the post-ASP group compared to 74.4% in the pre-ASP (P < 0.001). Mean mechanical ventilations days in pre- and post-ASP group were 5.9 versus 3.8 (P = 0.033). Conclusion: In our cohort of critically ill surgery patients implementation of an ASP resulted in reduced use of continuously infused benzodiazepines and opioids, a decline in cumulative benzodiazepine and analgesic dosages, and a greater percentage of Richmond Agitation Sedation Scale scores at goal. We also showed reduced mechanical ventilation days. Published by Elsevier Inc.	[Porhomayon, Jahan] SUNY Buffalo, Sch Med & Biomed Sci, VA Western New York Healthcare Syst, Buffalo, NY 14260 USA; [Porhomayon, Jahan] SUNY Buffalo, Sch Med & Biomed Sci, Rochester Gen Hosp, Div Crit Care Med,Dept Anesthesiol & Surg, Buffalo, NY 14260 USA; [Nader, Nader D.] SUNY Buffalo, VA Western New York Healthcare Syst, Div Cardiothorac Anesthesia & Pain Med, Sch Med & Biomed Sci,Dept Anesthesiol, Buffalo, NY 14260 USA; [El-Solh, Ali A.] SUNY Buffalo, VA Western New York Healthcare Syst, Div Pulm Crit Care & Sleep Med, Dept Med, Buffalo, NY 14260 USA; [Hite, Mindee; Silinskie, Kevin] Rochester Gen Hosp, Dept Pharm Rochester, New York, NY USA; [Scott, Jonathan] Rochester Gen Hosp, Div Crit Care Med, Dept Surg Adjunct Fac, Rochester Inst Technol,Coll Sci, Rochester, NY 14621 USA	Porhomayon, J (reprint author), VA Med Ctr, Rm 203C,3495 Bailey Ave, Buffalo, NY 14215 USA.	jahanpor@buffalo.edu	Nader, Nader/AAO-9442-2020	Nader, Nader/0000-0002-5744-7319; porhomayon,, jahan/0000-0001-7096-1825			Arias-Rivera S, 2008, ENFERM INTENSIV, V19, P71, DOI 10.1016/S1130-2399(08)72747-0; Arias-Rivera S, 2008, CRIT CARE MED, V36, P2054, DOI 10.1097/CCM.0b013e31817bfd60; Augustes R, 2011, ANAESTH INTENS CARE, V39, P401, DOI 10.1177/0310057X1103900310; Bayat A, 2003, BRIT J PLAST SURG, V56, P272, DOI 10.1016/S0007-1226(03)00110-3; Blamoun J, 2009, AM J INFECT CONTROL, V37, P172, DOI 10.1016/j.ajic.2008.05.010; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; de Wit M, 2008, CRIT CARE, V12, DOI 10.1186/cc6908; Egerod I, 2006, INTENS CARE MED, V32, P60, DOI 10.1007/s00134-005-2856-1; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; GANDEVIA B, 1964, Med J Aust, V2, P320; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Horn Ed, 2004, Gastrointest Endosc Clin N Am, V14, P247, DOI 10.1016/j.giec.2004.01.001; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; JENSEN MP, 1989, CLIN J PAIN, V5, P153, DOI 10.1097/00002508-198906000-00005; Kanouff AJ, 2008, CRIT CARE NURS Q, V31, P302, DOI 10.1097/01.CNQ.0000336815.81676.88; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Lutz A, 2011, ANASTH INTENSIV NOTF, V46, P568, DOI 10.1055/s-0031-1286607; Marshall J, 2008, CRIT CARE MED, V36, P427, DOI 10.1097/01.CCM.0000300275.63811.B3; Martin Jorg, 2010, Ger Med Sci, V8, pDoc02, DOI 10.3205/000091; Mattia C, 2006, MINERVA ANESTESIOL, V72, P769; Mehta S, 2008, CRIT CARE MED, V36, P2092, DOI 10.1097/CCM.0b013e31817bff85; Mehta S, 2007, J CRIT CARE, V22, P191, DOI 10.1016/j.jcrc.2006.11.006; Nasraway SA, 2002, CRIT CARE MED, V30, P117, DOI 10.1097/00003246-200201000-00019; Payen JF, 2007, ANESTHESIOLOGY, V106, P687, DOI 10.1097/01.anes.0000264747.09017.da; Puntillo K A, 2001, Am J Crit Care, V10, P238; Roberts R, 2012, CRIT CARE MED, V40, P406, DOI 10.1097/CCM.0b013e31822f0af5; Robinson BRH, 2008, J TRAUMA, V65, P517, DOI 10.1097/TA.0b013e318181b8f6; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Shehabi Y, 2011, ANAESTH INTENS CARE, V39, P339, DOI 10.1177/0310057X1103900302; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Weisbrodt L, 2011, AM J CRIT CARE, V20, pE90, DOI 10.4037/ajcc2011415; Youngquist P, 2007, JT COMM J QUAL PATIE, V33, P219, DOI 10.1016/S1553-7250(07)33026-2	35	12	12	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804			J SURG RES	J. Surg. Res.	OCT	2013	184	2					966	U567		10.1016/j.jss.2013.03.065			11	Surgery	Surgery	215XE	WOS:000324243500044	23622725				2020-06-30	J	Ledowski, T; Tiong, WS; Lee, C; Wong, B; Fiori, T; Parker, N				Ledowski, T.; Tiong, W. S.; Lee, C.; Wong, B.; Fiori, T.; Parker, N.			Analgesia nociception index: evaluation as a new parameter for acute postoperative pain	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesia, postoperative; pain, postoperative	SURGICAL STRESS INDEX; SKIN-CONDUCTANCE; PLASMA-LEVELS; ANESTHESIA	Background. A means of identifying the presence and severity of pain that is not reliant on the subjective assessment of pain is desirable whenever a patient self-rating of pain cannot be easily obtained (e.g. sedated patients, very young children, individuals with learning difficulties). The heart rate variability based analgesia nociception index (ANT) has been proposed to reflect different levels of acute pain. The aim of this study was to compare ANT scores with a numeric rating scale (NRS, 0-10) based on self-assessment of pain in the recovery room. Methods. One hundred and twenty patients after non-emergency surgery were included. On arrival in the post-anaesthesia care unit (PACU) and subsequently at 5 min intervals, patients were asked to rate their level of pain on a 0-10 NRS. ANI values 0-100 points (low values indicating higher levels of pain) were recorded simultaneously. Results. Eight hundred and sixteen pain ratings from 114 patients were included in the analysis. A small but statistically significant negative correlation was found between ANT and the NRS scores (p=-0.075; P=0.034). A small but significant difference in ANT was found comparing the extremes of pain [mean (SE): NRS 0: 63 (1.4) vs NRS 6-10: 59 (1.4); P=0.027]. However, a receiver-operating analysis testing the value of ANT to distinguish between NRS 0 and NRS 6-10 revealed only low sensitivity and specificity. Conclusion. ANT did not reflect different states of acute postoperative pain measured on a NRS scale after adult sevoflurane-based general anaesthesia.	[Ledowski, T.; Parker, N.] Royal Perth Hosp, Dept Anaesthesia & Pain Med, Perth, WA 6000, Australia; [Ledowski, T.; Tiong, W. S.; Lee, C.; Wong, B.; Fiori, T.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia	Ledowski, T (reprint author), Royal Perth Hosp, Dept Anaesthesia & Pain Med, Wellington St Campus, Perth, WA 6000, Australia.	thomas.ledowski@health.wa.gov.au			investigators The Analgesia Nociception Monitor	This study was funded by the investigators The Analgesia Nociception Monitor was provided as a free loan by its manufacturer, Metrodoloris, France.	Ilies C, 2010, BRIT J ANAESTH, V105, P533, DOI 10.1093/bja/aeq203; Jeanne M, 2012, J CLIN MONIT COMPUT, V26, P289, DOI 10.1007/s10877-012-9354-0; Jeanne M, 2009, IEEE ENG MED BIO, P1840, DOI 10.1109/IEMBS.2009.5332598; Le Guen M, 2012, INT J OBSTET ANESTH, V21, P146, DOI 10.1016/j.ijoa.2012.01.001; Ledowski T, 2006, BRIT J ANAESTH, V97, P862, DOI 10.1093/bja/ael280; Ledowski T, 2005, ANESTH ANALG, V101, P1700, DOI 10.1213/01.ane.0000184041.32175.14; Ledowski T, 2010, ANAESTHESIA, V65, P1001, DOI 10.1111/j.1365-2044.2010.06480.x; Ledowski T, 2009, ANAESTHESIA, V64, P727, DOI 10.1111/j.1365-2044.2008.05834.x; Ledowski T, 2012, PAIN, V153, P759, DOI 10.1016/j.pain.2011.11.002; Logier R, 2011, IEEE ENG MED BIO, P3776, DOI 10.1109/IEMBS.2011.6090645; Sabourdin N, 2013, PEDIATR ANESTH, V23, P149, DOI 10.1111/pan.12071	11	50	53	0	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	OCT	2013	111	4					627	629		10.1093/bja/aet111			3	Anesthesiology	Anesthesiology	226OJ	WOS:000325045400016	23611914	Green Published, Bronze			2020-06-30	J	Jandhyala, R; Fullarton, JR; Bennett, MI				Jandhyala, Ravi; Fullarton, John R.; Bennett, Michael I.			Efficacy of Rapid-Onset Oral Fentanyl Formulations vs. Oral Morphine for Cancer-Related Breakthrough Pain: A Meta-Analysis of Comparative Trials	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Review						Episodic pain; incident pain; breakthrough cancer pain; rescue medication; buccal; sublingual	TRANSMUCOSAL FENTANYL; BUCCAL TABLET; OPIOIDS; CITRATE	Context. Breakthrough cancer pain (BTcP) is widely recognized as a clinically significant complication of chronic cancer pain. With most BTcP episodes peaking in intensity within a few minutes and lasting for approximately 30 minutes, speed of onset is crucial for effective pain management. Although the last decade has seen the development of a number of rapid-onset fentanyl preparations, BTcP is still typically managed by supplemental or rescue doses of the patient's aroundthe-clock medication, such as oral morphine. Importantly, although the fentanyl preparations, such as fentanyl buccal tablet (FBT), sublingual fentanyl citrate orally disintegrating tablet (ODT), and oral transmucosal fentanyl citrate lozenge (OTFC), have all been proven to be efficacious in clinical studies, oral morphine has never been specifically tested in BTcP, other than as a comparator in studies of OTFC and fentanyl pectin nasal spray. Objectives. To determine the relative contributions to pain relief from oral morphine and the fentanyl preparations using placebo as a common comparator. Methods. Relevant studies were identified by review of the literature and used in a mixed-treatment meta-analysis to indirectly compare fentanyl preparations, morphine, and placebo for the treatment of BTcP. Results. Analysis incorporating the five relevant studies identified revealed that although the fentanyl preparations provide superior pain relief vs. placebo in the first 30 minutes after dosing (FBT provided an 83% probability of superior pain relief, ODT 66%, and OTFC 73% vs. placebo), oral morphine performed little better than placebo (56% probability). Conclusion. This mixed-treatment analysis suggests that FBT, ODT, and OTFC might provide more efficacious treatment options than oral morphine for BTcP. (C) 2013 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.	[Jandhyala, Ravi] Cephalon UK Ltd, Welwyn Garden City, Herts, England; [Fullarton, John R.] Strategen Ltd, Basingstoke, Hants, England; [Bennett, Michael I.] Univ Leeds, Leeds, W Yorkshire, England	Jandhyala, R (reprint author), Jandhyala Inst, Main St, Great Bourton OX17 1QW, Banbury, England.	rjandhyala@latralis.com	Bennett, Michael I/A-1620-2009	Bennett, Michael I/0000-0002-8369-8349	Cephalon UK, Ltd.	This study was funded by Cephalon UK, Ltd. M. I. B. has acted as an expert advisor for Cephalon UK, Ltd. and Archimedes and has received honoraria in this regard. R. J. is contracted by Cephalon UK, Ltd., as an Interim Medical Manager. J. R. F. has received fees from Cephalon UK, Ltd., for work on various projects. M. I. B. and R. J. contributed to the concept and design of the review. J. R. F. carried out the statistical analyses with input from R. J. and M. I. B. while R. J. undertook the clinical interpretation of the data. All authors contributed to the manuscript.	American Pain Foundation, BREAKTHR CANC PAIN M; [Anonymous], MRC BIOST UN; Bennett D, 2005, PHARMACOL THERAPEUT, V30, P296; BENNETT D, 2005, [No title captured], V30, P354; Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Cephalon UK Limited/Teva UK Limited, 200013 AC CEPH UK LT; Cephalon UK Limited/Teva UK Limited, 600001 AC CEPH UK LT; Cephalon UK Limited/Teva UK Limited, 9914 CEPH UK LTD TEV; Cephalon UK Limited/Teva UK Limited, 3039 CEPH UK LTD TEV; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Davies AN, 2008, J PAIN SYMPTOM MANAG, V35, P406, DOI 10.1016/j.jpainsymman.2007.05.010; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; DICKMAN A, 2009, PHARM J, V283, P213; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; Fortner BV, 2003, J PAIN SYMPTOM MANAG, V25, P9, DOI 10.1016/S0885-3924(02)00597-3; Greco MT, 2011, CLIN J PAIN, V27, P9, DOI 10.1097/AJP.0b013e3181edc250; Jandhyala R, 2012, BMJ SUPPORT PALLIAT, V2, P156, DOI 10.1136/bmjspcare-2011-000139; Lossignol DA, 2010, CURR OPIN ONCOL, V22, P302, DOI 10.1097/CCO.0b013e32833a873a; Lunn DJ, 2000, STAT COMPUT, V10, P325, DOI 10.1023/A:1008929526011; Mercadante S, 2009, J PAIN SYMPTOM MANAG, V38, P554, DOI [10.1016/j.jpainsymman.2009.04.016, 10.1016/j.jpainsymman.2008.12.008]; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Slatkin Neal E, 2007, J Support Oncol, V5, P327; VENTAFRIDDA V, 1987, CANCER, V59, P850, DOI 10.1002/1097-0142(19870215)59:4<850::AID-CNCR2820590432>3.0.CO;2-1; Vissers D, 2010, CURR MED RES OPIN, V26, P1037, DOI 10.1185/03007991003694340; Vissers DCJ, 2011, VALUE HEALTH, V14, P274, DOI 10.1016/j.jval.2010.09.007; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279; World Health Organization, 1996, CANC PAIN REL; Zeppetella G, 2003, EXPERT OPIN PHARMACO, V4, P493, DOI 10.1517/14656566.4.4.493; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012; Zeppetella G, 2011, PALLIATIVE MED, V25, P516, DOI 10.1177/0269216310385601	34	42	44	1	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	OCT	2013	46	4					573	580		10.1016/j.jpainsymman.2012.09.009			8	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	232BL	WOS:000325463300015	23380337	Other Gold, Green Published			2020-06-30	J	Ly, HG; Dupont, P; Geeraerts, B; Bormans, G; Van Laere, K; Tack, J; Van Oudenhove, L				Ly, Huynh Giao; Dupont, Patrick; Geeraerts, Brecht; Bormans, Guy; Van Laere, Koen; Tack, Jan; Van Oudenhove, Lukas			Lack of endogenous opioid release during sustained visceral pain: A [C-11]carfentanil PET study	PAIN			English	Article						[C-11]carfentanil; Endogenous opioid release; Positron emission tomography; Visceral pain	POSITRON-EMISSION-TOMOGRAPHY; BOWEL-SYNDROME PATIENTS; RECEPTOR-BINDING; GASTRIC DISTENSION; SOMATIC PAIN; HUMAN BRAIN; TIME-COURSE; IN-VIVO; ACTIVATION; OXYCODONE	Opioidergic neurotransmission in the central nervous system is involved in somatic pain, but its role in visceral pain remains unknown. We aimed to quantify endogenous opioid release in the brain during sustained painful gastric distension. Therefore, 2 dynamic [C-11]carfentanil positron emission tomography scans were performed in 20 healthy subjects during 2 conditions: sustained (20 minutes) painful proximal gastric balloon distension at predetermined individual discomfort threshold (PAIN) and no distension (NO PAIN), in counterbalanced order. Pain levels were assessed during scanning using visual analogue scales and after scanning using the McGill Pain Questionnaire. Emotional state was rated after scanning using the Positive and Negative Affect Schedule. Distribution volume ratios in 21 volumes of interest in the pain matrix were used to quantify endogenous opioid release. During the PAIN compared to the NO PAIN condition, volunteers reported a significantly higher increase in negative affect (5.50 +/- 1.29 versus 0.10 +/- 1.08, P = .0147) as well as higher pain ratings (sensory: 74.05 +/- 9.23 versus 1.50 +/- 0.95, P < .0001; affective: 91.42 +/- 8.13 versus 4.33 +/- 6.56, P < .0001). No difference in endogenous opioid release was demonstrated in any of the volumes of interest. Thus, contrary to its somatic counterpart, no opioid release is detected in the brain during sustained visceral pain, despite similar pain intensities. Endogenous opioids may play a less important role in visceral compared to somatic pain. (C) 2013 International Association for the Study of Pain. Published by Elsevier B. V. All rights reserved.	[Ly, Huynh Giao; Geeraerts, Brecht; Tack, Jan; Van Oudenhove, Lukas] Univ Leuven, Translat Res Ctr Gastrointestinal Dis TARGID, Dept Clin & Expt Med, Louvain, Belgium; [Dupont, Patrick] Univ Leuven, Lab Cognit Neurol, Div Expt Neurol, Dept Neurosci, Louvain, Belgium; [Dupont, Patrick] Univ Leuven, Med Imaging Res Ctr, Dept Med Diagnost Sci, Louvain, Belgium; [Bormans, Guy; Van Laere, Koen] Univ Leuven, Nucl Med Sect, Dept Med Diagnost Sci, Louvain, Belgium; [Bormans, Guy] Univ Leuven, Lab Radiopharm, Fac Pharmaceut Sci, Louvain, Belgium; [Van Oudenhove, Lukas] Univ Hosp Gasthuisberg, Univ Psychiat Ctr, B-3000 Louvain, Belgium	Van Oudenhove, L (reprint author), Univ Hosp Gasthuisberg, Translat Res Ctr Gastrointestinal Dis TARGID, O & N 1,Box 701,Herestr 49, B-3000 Louvain, Belgium.	lukas.vanoudenhove@med.kuleuven.be	Dupont, Patrick/B-8044-2009	Dupont, Patrick/0000-0003-1980-2540; Van Oudenhove, Lukas/0000-0002-6540-3113	University of LeuvenKU Leuven; Research Foundation-Flanders (FWO-Vlaanderen)FWO	This study was funded by a Methusalem grant from the University of Leuven and a research grant from the Research Foundation-Flanders (FWO-Vlaanderen) to Jan Tack. Lukas Van Oudenhove is a postdoctoral research fellow of the Research Foundation-Flanders (FWO-Vlaanderen) and a research professor of the KU Leuven Special Research Fund (BOF). Koen Van Laere is senior clinical research fellow of the Research Foundation-Flanders. The authors thank Dominique Vanderghinste for help with the production of the radiotracer and Stijn Dirix for help with scanning. The authors thank all volunteers who participated in this study.	Arendt-Nielsen L, 2009, ANESTHESIOLOGY, V111, P616, DOI 10.1097/ALN.0b013e3181af6356; Baumgartner U, 2006, NEUROIMAGE, V30, P692, DOI 10.1016/j.neuroimage.2005.10.033; Bencherif B, 2002, PAIN, V99, P589, DOI 10.1016/S0304-3959(02)00266-X; Dunckley P, 2005, J NEUROSCI, V25, P7333, DOI 10.1523/JNEUROSCI.1100-05.2005; Dunckley P, 2007, NEUROGASTROENT MOTIL, V19, P569, DOI 10.1111/j.1365-2982.2007.00908.x; Geeraerts B, 2008, NEUROGASTROENT MOTIL, V20, P1094, DOI 10.1111/j.1365-2982.2008.01144.x; Geeraerts B, 2011, NEUROGASTROENT MOTIL, V23, P533, DOI 10.1111/j.1365-2982.2010.01642.x; Geeraerts B, 2009, NEUROGASTROENT MOTIL, V21, pe26; Gorelick DA, 2005, BIOL PSYCHIAT, V57, P1573, DOI 10.1016/j.biopsych.2005.02.026; Harris RE, 2007, J NEUROSCI, V27, P10000, DOI 10.1523/JNEUROSCI.2849-07.2007; Henriksen G, 2008, BRAIN, V131, P1171, DOI 10.1093/brain/awm255; Hirvonen J, 2009, EUR J NUCL MED MOL I, V36, P275, DOI 10.1007/s00259-008-0935-6; JONES AKP, 1994, BRIT J RHEUMATOL, V33, P909; JONES AKP, 1991, NEUROSCI LETT, V126, P25, DOI 10.1016/0304-3940(91)90362-W; Jones AKP, 2004, EUR J PAIN, V8, P479, DOI 10.1016/j.ejpain.2003.11.017; Kennedy SE, 2006, ARCH GEN PSYCHIAT, V63, P1199, DOI 10.1001/archpsyc.63.11.1199; Kern MK, 1998, GASTROENTEROLOGY, V115, P1353, DOI 10.1016/S0016-5085(98)70013-7; Ladabaum U, 2001, GASTROENTEROLOGY, V120, P369, DOI 10.1053/gast.2001.21201; Ladabaum U, 2007, NEUROIMAGE, V34, P724, DOI 10.1016/j.neuroimage.2006.07.033; Larsson MH, 2008, NEUROGASTROENT MOTIL, V20, P1157, DOI 10.1111/j.1365-2982.2008.01161.x; Lembo T, 2000, PAIN, V87, P137, DOI 10.1016/S0304-3959(00)00282-7; Liberzon I, 2007, BIOL PSYCHIAT, V61, P1030, DOI 10.1016/j.biopsych.2006.06.021; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; Lu CL, 2004, NEUROGASTROENT MOTIL, V16, P575, DOI 10.1111/j.1365-2982.2004.00562.x; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Nelissen N, 2012, POSITRON EMISSION TO, P55; Olesen AE, 2010, BRIT J CLIN PHARMACO, V70, P189, DOI 10.1111/j.1365-2125.2010.03700.x; PRICE DD, 1987, PAIN, V28, P297, DOI 10.1016/0304-3959(87)90065-0; Scott DJ, 2007, SYNAPSE, V61, P707, DOI 10.1002/syn.20404; Smith YR, 1998, J CLIN ENDOCR METAB, V83, P4498, DOI 10.1210/jc.83.12.4498; Song GH, 2006, PAIN, V126, P79, DOI 10.1016/j.pain.2006.06.017; Sprenger T, 2006, PAIN, V122, P63, DOI 10.1016/j.pain.2006.01.003; Staahl C, 2006, PAIN, V123, P28, DOI 10.1016/j.pain.2006.02.006; Stephan E, 2003, J GASTROINTEST SURG, V7, P740, DOI 10.1016/S1091-255X(03)00071-4; Strigo IA, 2003, J NEUROPHYSIOL, V89, P3294, DOI 10.1152/jn.01048.2002; Van Oudenhove L, 2007, WORLD J GASTROENTERO, V13, P3438, DOI 10.3748/wjg.v13.i25.3438; Vandenbergh J, 2005, GASTROENTEROLOGY, V128, P564, DOI 10.1053/j.gastro.2004.11.054; Vandenberghe J, 2005, GUT, V54, P914, DOI 10.1136/gut.2004.052605; Wager TD, 2007, P NATL ACAD SCI USA, V104, P11056, DOI 10.1073/pnas.0702413104; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005; Zubieta JK, 2003, ARCH GEN PSYCHIAT, V60, P1145, DOI 10.1001/archpsyc.60.11.1145; Zubieta JK, 2002, J NEUROSCI, V22, P5100, DOI 10.1523/JNEUROSCI.22-12-05100.2002; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	45	6	6	0	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0304-3959			PAIN	Pain	OCT	2013	154	10					2072	2077		10.1016/j.pain.2013.06.026			6	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	219AK	WOS:000324475500025	23792286				2020-06-30	J	O'Donnell, DP; Schafer, LC; Stevens, AC; Weinstein, E; Miramonti, CM; Kozak, MA				O'Donnell, Daniel P.; Schafer, Luke C.; Stevens, Andrew C.; Weinstein, Elizabeth; Miramonti, Charles M.; Kozak, Mary Ann			Effect of Introducing the Mucosal Atomization Device for Fentanyl Use in Out-of-Hospital Pediatric Trauma Patients	PREHOSPITAL AND DISASTER MEDICINE			English	Article						device; Emergency Medical Services; fentanyl; intranasal; pain assessment; pediatric; trauma		Background: Pain associated with pediatric trauma is often under-assessed and under-treated in the out-of-hospital setting. Administering an opioid such as fentanyl via the intranasal route is a safe and efficacious alternative to traditional routes of analgesic delivery and could potentially improve pain management in pediatric trauma patients. Objective: The study sought to examine the effect of introducing the mucosal atomization device (MAD) on analgesia administration as an alternative to intravenous fentanyl delivery in pediatric trauma patients. The hypothesis for the study is that the introduction of the MAD would increase the administration of fentanyl in pediatric trauma patients. Methods: The research utilized a 2-group design (pre-MAD and post-MAD) to study 946 pediatric trauma patients (age,16) transported by a large, urban EMS agency to one of eight hospitals in Marion County, which is located in Indianapolis Indiana. Two emergency medicine physicians independently determined whether the patient met criteria for pain medication receipt and a third reviewer resolved any disagreements. A comparison of the rates of fentanyl administration in both groups was then conducted. Results: There was no statistically significant difference in the rate of fentanyl administration between the pre-MAD (30.4%) and post-MAD groups (37.8%) (P = .238). A subgroup analysis showed that age and mechanism of injury were stronger predictors of fentanyl administration. Conclusion: Contrary to the hypothesis, the addition of the MAD device did not increase fentanyl administration rates in pediatric trauma patients. Future research is needed to address the barriers to analgesia administration in pediatric trauma patients.	[O'Donnell, Daniel P.; Schafer, Luke C.; Stevens, Andrew C.; Weinstein, Elizabeth; Miramonti, Charles M.; Kozak, Mary Ann] Indiana Univ, Sch Med, Dept Emergency Med, 3930 Georgetown Rd, Indianapolis, IN 46254 USA	O'Donnell, DP (reprint author), Indiana Univ, Sch Med, Dept Emergency Med, 3930 Georgetown Rd, Indianapolis, IN 46254 USA.	dapodonn@iupui.edu					Alexander J, 2003, ANN EMERG MED, V41, P617, DOI 10.1067/mem.2003.138; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Fleiss JL, 1981, STAT METHODS RATES P; Hagan JF, 2001, PEDIATRICS, V108, P793; Hennes Halim, 2005, Prehosp Emerg Care, V9, P32, DOI 10.1080/10903120590891705; Lzsak E, 2008, PREHOSP EMERG CARE, V12, P182, DOI 10.1080/10903120801907471; Maio RF, 2002, ANN EMERG MED, V40, P172, DOI 10.1067/mem.2002.124756; Swor Robert, 2005, Prehosp Emerg Care, V9, P40, DOI 10.1080/10903120590891930; Zempsky WT, 2004, PEDIATRICS, V114, P1348, DOI 10.1542/peds.2004-1752	10	8	8	0	1	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1049-023X	1945-1938		PREHOSP DISASTER MED	Prehospital Disaster Med.	OCT	2013	28	5					520	522		10.1017/S1049023X13003579			3	Emergency Medicine	Emergency Medicine	VG1BB	WOS:000445145000019	23702188	Green Published			2020-06-30	J	Credie, LDGA; Luna, SPL; Futema, F; da Silva, LCBA; Gomes, GB; Garcia, JNN; de Carvalho, LR				Guimaraes Arcoverde Credie, Leonardo de Freitas; Loureiro Luna, Stelio Pacca; Futema, Fabio; Baruffaldi Almeida da Silva, Luciano Cacciari; Gomes, Giancarlo Bressane; Negrette Garcia, Jaqueline Neratika; de Carvalho, Lidia Raquel			Perioperative evaluation of tumescent anaesthesia technique in bitches submitted to unilateral mastectomy	BMC VETERINARY RESEARCH			English	Article						Dogs; Mastectomy; Regional anaesthesia; Lidocaine	MINIMUM ALVEOLAR CONCENTRATION; BREAST-CANCER SURGERY; LOCAL-ANESTHESIA; INTRAVENOUS LIDOCAINE; POSTOPERATIVE PAIN; SYSTEMIC LIDOCAINE; BOWEL FUNCTION; INFUSION; MORPHINE; LIPOSUCTION	Background: Tumescent anaesthesia (TA) is a widely used technique in oncologic surgeries necessitating large resection margins. This technique produces transoperative and postoperative analgesia, reduces surgical bleeding, and facilitates tissue divulsion. This prospective, randomised, blind study evaluated the use of TA in bitches submitted to mastectomy and compared the effect of TA with an intravenous fentanyl bolus. A 2.5-mcg/kg intravenous fentanyl bolus (n = 10) was compared with TA using 0.275% lidocaine (n = 10) in bitches submitted to unilateral mastectomy. Sedation was performed by intramuscular (IM) injection of 0.05 mg/kg of acepromazine combined with 2 mg/kg of meperidine. Anaesthesia was induced with 5 mg/kg of intravenous propofol and maintained with isoflurane/O-2. Heart and respiratory rates; systolic, mean, and diastolic arterial blood pressures; central venous pressure; SpO(2); ETCO2; inspired and expired isoflurane concentrations; and temperature were measured transoperatively. Visual analogue scales for sedation and pain and the Glasgow composite and Melbourne pain scales were used for postoperative assessment. The surgeon investigated the quality of the surgical approach, considering bleeding and resection ability, and the incidence of postoperative wound complications. Results: The heart rate was lower and the end-tidal isoflurane concentration was higher in dogs treated with fentanyl than in dogs treated with TA. A fentanyl bolus was administered to 8 of 10 dogs treated with fentanyl and to none treated with TA. Intraoperative bleeding and the mammary gland excision time were lower in dogs treated with TA. The maximal mean and individual plasma lidocaine concentrations were 1426 +/- 502 ng/ml and 2443 ng/ml at 90 minutes after infiltration, respectively. The Glasgow Composite Pain Scale scores were higher in dogs treated with fentanyl than in dogs treated with TA until 2 hours after extubation. Conclusions: Compared with intravenous fentanyl, TA in bitches: may be easily performed in non-inflamed, ulcerated, adhered mammary tumours; has an isoflurane-sparing effect; improves transoperative and immediate postoperative analgesia; is apparently safe for use in clinical conditions as evidenced by the fact that it did not produce any adverse signs or lidocaine plasma concentrations compatible with toxicity; does not modify the recovery time; and facilitates the surgical procedure without interfering with wound healing.	[Guimaraes Arcoverde Credie, Leonardo de Freitas] UNESP Univ Estadual Paulista, Fac Med, Dept Anaesthesiol, Sao Paulo, Brazil; [Loureiro Luna, Stelio Pacca] UNESP Univ Estadual Paulista, Dept Vet Surg & Anaesthesiol, Fac Vet Med & Anim Sci, Sao Paulo, Brazil; [Futema, Fabio; Baruffaldi Almeida da Silva, Luciano Cacciari; Gomes, Giancarlo Bressane; Negrette Garcia, Jaqueline Neratika] Univ Guarulhos, Sao Paulo, Brazil; [de Carvalho, Lidia Raquel] UNESP Univ Estadual Paulista, Dept Biostat, Biosci Inst, Sao Paulo, Brazil	Luna, SPL (reprint author), UNESP Univ Estadual Paulista, Dept Vet Surg & Anaesthesiol, Fac Vet Med & Anim Sci, Sao Paulo, Brazil.	stelio@fmvz.unesp.br	LUCRECIA HELENA, LOUREIRO/L-1916-2013; Luna, Stelio P L/C-4527-2013; Carvalho, L.R./C-2973-2013	Luna, Stelio P L/0000-0001-5312-9076; Carvalho, L.R./0000-0003-0575-2263; Silva, Luciano Cacciari/0000-0001-9349-0499	CAPESCAPES	To CAPES for supporting Credie's grant; Galeno Research laboratory for lidocaine measurements and University of Guarulhos for offering the physical space to perform the study.	Armstrong SR, 2005, J VET EMERG CRIT CAR, V15, P32, DOI 10.1111/j.1476-4431.2005.04033.x; Bar-Yosef S, 2001, ANESTHESIOLOGY, V94, P1066, DOI 10.1097/00000542-200106000-00022; Biki B, 2008, ANESTHESIOLOGY, V109, P180, DOI 10.1097/ALN.0b013e31817f5b73; Brown Amanda K, 2004, Best Pract Res Clin Anaesthesiol, V18, P703, DOI 10.1016/j.bpa.2004.05.004; Bussolin L, 2003, ANESTHESIOLOGY, V99, P1371, DOI 10.1097/00000542-200312000-00020; Carlson GW, 2005, BREAST J, V11, P100, DOI 10.1111/j.1075-122X.2005.21536.x; CASSUTO J, 1985, ANESTH ANALG, V64, P971; Clarke C, 2008, PAIN RES MANAG, V13, P421, DOI 10.1155/2008/768231; de Jong RH, 2001, PLAST RECONSTR SURG, V107, P1039, DOI 10.1097/00006534-200104010-00022; De Nardi A., 2009, ONCOLOGIA CAES GATOS, P371; Eichhorn K, 2004, DERMATOL SURG, V30, P253, DOI 10.1111/j.1524-4725.2004.30084.x; Exadaktylos AK, 2006, ANESTHESIOLOGY, V105, P660, DOI 10.1097/00000542-200610000-00008; Fossum TW, 2002, CIRURGIA PEQUENOS AN, P48; Gach K, 2011, N-S ARCH PHARMACOL, V384, P221, DOI 10.1007/s00210-011-0672-4; Gilliland MD, 1997, PLAST RECONSTR SURG, V99, P215, DOI 10.1097/00006534-199701000-00032; Groudine SB, 1998, ANESTH ANALG, V86, P235, DOI 10.1097/00000539-199802000-00003; Gupta K, 2002, CANCER RES, V62, P4491; Habbema L, 2009, DERMATOL SURG, V35, P41, DOI 10.1111/j.1524-4725.2008.34381.x; Hanke CW, 2001, DERMATOL SURG, V27, P1003, DOI 10.1046/j.1524-4725.2001.01852.x; Jones BM, 2004, PLAST RECONSTR SURG, V113, P398, DOI 10.1097/01.PRS.0000097297.89136.8D; Klein JA, 1999, DERMATOL CLIN, V17, P751, DOI 10.1016/S0733-8635(05)70124-8; KLEIN JA, 1993, PLAST RECONSTR SURG, V92, P1085, DOI 10.1097/00006534-199311000-00014; KLEIN JA, 1990, J DERMATOL SURG ONC, V16, P248, DOI 10.1111/j.1524-4725.1990.tb03961.x; KLEIN JA, 1987, AM J COSMET SURG, V4, P263, DOI DOI 10.1177/074880688700400403; Koppert W, 2004, ANESTH ANALG, V98, P1050, DOI 10.1213/01.ANE.0000104582.71710.EE; Kukanich B, 2012, J VET PHARMACOL THER, V35, P3, DOI 10.1111/j.1365-2885.2012.01416.x; Kuo CP, 2006, BRIT J ANAESTH, V97, P640, DOI 10.1093/bja/ael217; Lapid O, 2011, AESTHET PLAST SURG, V35, P601, DOI 10.1007/s00266-010-9625-4; Lehnhardt Marcus, 2008, Plast Reconstr Surg, V121, p396e, DOI 10.1097/PRS.0b013e318170817a; Lemo N, 2007, VET REC, V160, P374, DOI 10.1136/vr.160.11.374; LIU P, 1982, ANESTH ANALG, V61, P317; LIU PL, 1983, ANESTH ANALG, V62, P375; Liu SS, 2005, ANESTH ANALG, V101, P1634, DOI 10.1213/01.ANE.0000180829.70036.4F; Mammoto T, 2002, J CELL PHYSIOL, V192, P351, DOI 10.1002/jcp.10145; Martins CAS, 2010, ANESTESIA REGIONAL P, P91; McCarthy GC, 2010, DRUGS, V70, P1149, DOI 10.2165/10898560-000000000-00000; Mizukami Taketomo, 2007, Ann Thorac Cardiovasc Surg, V13, P352; Oderda G, 2012, PHARMACOTHERAPY, V32, p6S, DOI 10.1002/j.1875-9114.2012.01177.x; Ostad A, 1996, DERMATOL SURG, V22, P921, DOI 10.1111/j.1524-4725.1996.tb00634.x; PFLUG AE, 1981, ANESTHESIOLOGY, V55, P120; Poleshuck EL, 2006, J PAIN, V7, P626, DOI 10.1016/j.jpain.2006.02.007; Pypendop BH, 2005, ANESTH ANALG, V100, P97, DOI 10.1213/01.ANE.0000139350.88158.38; Robertson SA, 2005, EQUINE VET J, V37, P122, DOI 10.2746/0425164054223723; Sacerdote P, 2000, ANESTH ANALG, V90, P1411, DOI 10.1097/00000539-200006000-00028; SAMDAL F, 1994, AESTHET PLAST SURG, V18, P157, DOI 10.1007/BF00454476; Santamaria LB, 2010, SURG ONCOL, V19, P63, DOI 10.1016/j.suronc.2009.03.007; Shakhar G, 2003, ANN SURG ONCOL, V10, P972, DOI 10.1245/ASO.2003.02.007; Shavit Y, 2004, NEUROIMMUNOMODULAT, V11, P255, DOI 10.1159/000078444; Smith LJ, 2004, VET ANAESTH ANALG, V31, P53, DOI 10.1111/j.1467-2995.2004.00142.x; Smith LJ, 2002, PAIN, V97, P267, DOI 10.1016/S0304-3959(02)00028-3; Snyder GL, 2010, BRIT J ANAESTH, V105, P106, DOI 10.1093/bja/aeq164; Steagall PVM, 2006, JAVMA-J AM VET MED A, V229, P522, DOI 10.2460/javma.229.4.522; Thomas J, 2001, AESTHET PLAST SURG, V25, P343, DOI 10.1007/s002660010146; Upadya Madhusudan, 2005, Indian J Dermatol Venereol Leprol, V71, P145; Valverde A, 2004, VET ANAESTH ANALG, V31, P264, DOI 10.1111/j.1467-2995.2004.00165.x	55	2	2	0	9	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1746-6148		BMC VET RES	BMC Vet. Res.	SEP 11	2013	9								178	10.1186/1746-6148-9-178			12	Veterinary Sciences	Veterinary Sciences	216XC	WOS:000324318900001	24020364	DOAJ Gold, Green Published			2020-06-30	J	Martikainen, IK; Pecina, M; Love, TM; Nuechterlein, EB; Cummiford, CM; Green, CR; Harris, RE; Stohler, CS; Zubieta, JK				Martikainen, Ilkka K.; Pecina, Marta; Love, Tiffany M.; Nuechterlein, Emily B.; Cummiford, Chelsea M.; Green, Carmen R.; Harris, Richard E.; Stohler, Christian S.; Zubieta, Jon-Kar			Alterations in Endogenous Opioid Functional Measures in Chronic Back Pain	JOURNAL OF NEUROSCIENCE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; RECEPTOR-BINDING; NEUROPATHIC PAIN; GRAY-MATTER; PERIPHERAL MONONEUROPATHY; AFFECTIVE DIMENSIONS; CEREBROSPINAL-FLUID; IN-VIVO; BRAIN; PET	The absence of consistent end organ abnormalities in many chronic pain syndromes has led to a search for maladaptive CNS mechanisms that may explain their clinical presentations and course. Here, we addressed the role of brain regional mu-opioid receptor-mediated neurotransmission, one of the best recognized mechanisms of pain regulation, in chronic back pain in human subjects. We compared mu-opioid receptor availability in vivo at baseline, during pain expectation, and with moderate levels of sustained pain in 16 patients with chronic nonspecific back pain (CNBP) and in 16 age- and gender-matched healthy control subjects, using the mu-opioid receptor-selective radioligand [C-11]carfentanil and positron emission tomography. We found that CNBP patients showed baseline increases in thalamic mu-opioid receptor availability, contrary to a previously studied sample of patients diagnosed with fibromyalgia. During both pain expectation and sustained pain challenges, CNBP patients showed regional reductions in the capacity to activate this neurotransmitter system compared with their control sample, further associated with clinical pain and affective state ratings. Our results demonstrate heterogeneity in endogenous opioid system functional measures across pain conditions, and alterations in both receptor availability and endogenous opioid function in CNBP that are relevant to the clinical presentation of these patients and the effects of opioid analgesics on mu-opioid receptors.	[Martikainen, Ilkka K.; Pecina, Marta; Love, Tiffany M.; Nuechterlein, Emily B.; Cummiford, Chelsea M.; Zubieta, Jon-Kar] Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA; [Love, Tiffany M.; Zubieta, Jon-Kar] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA; [Green, Carmen R.; Harris, Richard E.] Univ Michigan, Dept Anesthesiol, Ann Arbor, MI 48109 USA; [Green, Carmen R.] Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA; [Zubieta, Jon-Kar] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA; [Nuechterlein, Emily B.] Univ Michigan, Neurosci Grad Program, Ann Arbor, MI 48104 USA; [Green, Carmen R.] Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA; [Stohler, Christian S.] Univ Maryland, Sch Dent, Baltimore, MD 21201 USA	Zubieta, JK (reprint author), Univ Michigan, Mol & Behav Neurosci Inst, 205 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	zubieta@umich.edu	Pecina, Marta/W-7135-2019; Love, Tiffany/W-8427-2019; STOHLER, CHRISTIAN/AAQ-7539-2020	Love, Tiffany/0000-0001-9299-3190; Kaplan, Chelsea/0000-0001-9324-655X	National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA 022520, R01 027494]; Phil F. Jenkins Foundation; Swedish Cultural Foundation in Finland, Helsinki, Finland; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIH 5T32EY017878, NIH 5T32DA007281]	The study was supported by National Institute on Drug Abuse Grants R01 DA 022520 and R01 027494, and the Phil F. Jenkins Foundation. I.K.M. was supported by the Swedish Cultural Foundation in Finland, Helsinki, Finland. E.B.N. was in part supported by National Institutes of Health Grants NIH 5T32EY017878 and NIH 5T32DA007281. We thank nurse Kathleen Singer and Laurie Carr for patient screening and recruitment, and the nuclear medicine technologists at the Center for Positron Emission Tomography at the University of Michigan for the assistance in positron emission tomography data acquisition and reconstruction.	Andersson GBJ, 1999, LANCET, V354, P581, DOI 10.1016/S0140-6736(99)01312-4; Apkarian AV, 2004, J NEUROSCI, V24, P10410, DOI 10.1523/JNEUROSCI.2541-04.2004; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Balague F, 2012, LANCET, V379, P482, DOI 10.1016/S0140-6736(11)60610-7; Baliki MN, 2012, NAT NEUROSCI, V15, P1117, DOI 10.1038/nn.3153; Baliki MN, 2011, J NEUROSCI, V31, P13981, DOI 10.1523/JNEUROSCI.1984-11.2011; Bencherif B, 2002, PAIN, V99, P589, DOI 10.1016/S0304-3959(02)00266-X; Bruehl S, 2004, CLIN J PAIN, V20, P283, DOI 10.1097/00002508-200409000-00002; Bruehl S, 2006, PAIN, V124, P287, DOI 10.1016/j.pain.2006.04.018; Bruehl S, 2010, PAIN, V148, P167, DOI 10.1016/j.pain.2009.09.025; Brunton J, 1998, J NEUROSCI, V18, P1671; CARR KD, 1988, BRAIN RES, V441, P173, DOI 10.1016/0006-8993(88)91396-0; CHERNY NI, 1994, NEUROLOGY, V44, P857, DOI 10.1212/WNL.44.5.857; Clark L. A., 1999, MANUAL POSITIVE NEGA; Dadabhoy D, 2006, NAT CLIN PRACT RHEUM, V2, P364, DOI 10.1038/ncprheum0221; DANNALS RF, 1985, INT J APPL RADIAT IS, V36, P303, DOI 10.1016/0020-708X(85)90089-4; Flor H, 1997, NEUROSCI LETT, V224, P5, DOI 10.1016/S0304-3940(97)13441-3; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; Giesecke T, 2004, ARTHRITIS RHEUM-US, V50, P613, DOI 10.1002/art.20063; Grachev ID, 2000, PAIN, V89, P7, DOI 10.1016/S0304-3959(00)00340-7; GUILBAUD G, 1990, J NEUROPHYSIOL, V64, P1537; Gustin SM, 2011, J NEUROSCI, V31, P5956, DOI 10.1523/JNEUROSCI.5980-10.2011; Harris RE, 2007, J NEUROSCI, V27, P10000, DOI 10.1523/JNEUROSCI.2849-07.2007; Harris RE, 2009, NEUROIMAGE, V47, P1077, DOI 10.1016/j.neuroimage.2009.05.083; Helmstetter FJ, 1998, BRAIN RES, V779, P104, DOI 10.1016/S0006-8993(97)01104-9; Henderson LA, 2013, J NEUROSCI, V33, P7574, DOI 10.1523/JNEUROSCI.0174-13.2013; IADAROLA MJ, 1995, PAIN, V63, P55, DOI 10.1016/0304-3959(95)00015-K; Ivo R, 2013, EUR SPINE J, DOI [10.1007/s00586-013-2692-x, DOI 10.1007/S00586-013-2692-X.CR0SSREF]; JADAD AR, 1992, LANCET, V339, P1367, DOI 10.1016/0140-6736(92)91194-D; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; JONES AKP, 1994, BRIT J RHEUMATOL, V33, P909; Jones AKP, 1999, J CEREBR BLOOD F MET, V19, P803, DOI 10.1097/00004647-199907000-00011; Jones AKP, 2004, EUR J PAIN, V8, P479, DOI 10.1016/j.ejpain.2003.11.017; Kuijpers T, 2011, EUR SPINE J, V20, P40, DOI 10.1007/s00586-010-1541-4; LIPMAN JJ, 1990, PSYCHOPHARMACOLOGY, V102, P112, DOI 10.1007/BF02245754; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; Maarrawi J, 2007, PAIN, V127, P183, DOI 10.1016/j.pain.2006.10.013; MANSOUR A, 1987, J NEUROSCI, V7, P2445; McGaraughty S, 2002, PAIN, V96, P153, DOI 10.1016/S0304-3959(01)00440-7; MELZACK R, 1971, ANESTHESIOLOGY, V34, P50; MINOSHIMA S, 1993, J NUCL MED, V34, P322; Neugebauer V, 2004, NEUROSCIENTIST, V10, P221, DOI 10.1177/1073858403261077; O'Neill S, 2007, EUR J PAIN, V11, P415, DOI 10.1016/j.ejpain.2006.05.009; Paulson PE, 2002, PAIN, V95, P31, DOI 10.1016/S0304-3959(01)00370-0; Phelps EA, 2005, NEURON, V48, P175, DOI 10.1016/j.neuron.2005.09.025; PORRINO LJ, 1981, J COMP NEUROL, V198, P121, DOI 10.1002/cne.901980111; PUIG MM, 1982, ANESTHESIOLOGY, V57, P1, DOI 10.1097/00000542-198207000-00001; RINALDI PC, 1991, J NEUROSURG, V74, P415, DOI 10.3171/jns.1991.74.3.0415; Rodriguez-Raecke R, 2009, J NEUROSCI, V29, P13746, DOI 10.1523/JNEUROSCI.3687-09.2009; Ruscheweyh R, 2011, PAIN, V152, P904, DOI 10.1016/j.pain.2011.01.013; Schmidt CO, 2009, EUR J PAIN, V13, P1030, DOI 10.1016/j.ejpain.2008.12.003; Schmidt-Wilcke T, 2006, PAIN, V125, P89, DOI 10.1016/j.pain.2006.05.004; Seminowicz DA, 2011, J NEUROSCI, V31, P7540, DOI 10.1523/JNEUROSCI.5280-10.2011; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; Stohler CS, 1999, PAIN, V79, P165, DOI 10.1016/S0304-3959(98)00171-7; Von Korff M, 2005, PAIN, V113, P331, DOI 10.1016/j.pain.2004.11.010; Wiesinger B, 2007, PAIN, V131, P311, DOI 10.1016/j.pain.2007.03.018; Willoch F, 2004, PAIN, V108, P213, DOI 10.1016/j.pain.2003.08.014; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; ZHANG X, 1993, IEEE T BIO-MED ENG, V40, P344, DOI 10.1109/10.222327; Zubieta JK, 2002, J NEUROSCI, V22, P5100, DOI 10.1523/JNEUROSCI.22-12-05100.2002; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952; Zubieta JK, 2008, SCI PAIN, P821	65	30	30	0	14	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	SEP 11	2013	33	37					14729	14737		10.1523/JNEUROSCI.1400-13.2013			9	Neurosciences	Neurosciences & Neurology	216WG	WOS:000324316200011	24027273	Green Published, Bronze			2020-06-30	J	Ketterer, W				Ketterer, Willi			Fentanyl for the Treatment of Tumor-Related Breakthrough Pain Lack of Precision in Colloquial Language Results in Incorrect Therapeutic Recommendation	DEUTSCHES ARZTEBLATT INTERNATIONAL			English	Letter											willi.ketterer@drk-kh-neuwied.de					Bornemann-Cimenti H, 2013, DTSCH ARZTEBL INT, V110, P271, DOI 10.3238/arztebl.2013.0271	1	0	0	0	0	DEUTSCHER AERZTE-VERLAG GMBH	COLOGNE	DIESELSTRABE 2, POSTFACH 400265, D-50859 COLOGNE, GERMANY	1866-0452			DTSCH ARZTEBL INT	Dtsch. Arztebl. Int.	SEP 2	2013	110	35-36					598	598		10.3238/arztebl.2013.0598a			1	Medicine, General & Internal	General & Internal Medicine	248TT	WOS:000326727500005	24078840	Green Published			2020-06-30	J	Wejbora, M; Szilagyi, IS; Sandner-Kiesling, A				Wejbora, Mischa; Szilagyi, Istvan S.; Sandner-Kiesling, Andreas			Lack of Precision in Colloquial Language Results in Incorrect Therapeutic Recommendation Reply	DEUTSCHES ARZTEBLATT INTERNATIONAL			English	Letter							BREAKTHROUGH PAIN		[Wejbora, Mischa; Szilagyi, Istvan S.; Sandner-Kiesling, Andreas] Med Univ Graz, Univ Klin Anasthesiol & Intensivmed, Graz, Austria	Wejbora, M (reprint author), Med Univ Graz, Univ Klin Anasthesiol & Intensivmed, Graz, Austria.	helmar.bornemann@medunigraz.at	Bornemann-Cimenti, Helmar/C-1252-2009	Bornemann-Cimenti, Helmar/0000-0002-1201-3752			Bornemann-Cimenti H, 2013, DTSCH ARZTEBL INT, V110, P271, DOI 10.3238/arztebl.2013.0271; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249	2	0	0	0	0	DEUTSCHER AERZTE-VERLAG GMBH	COLOGNE	DIESELSTRABE 2, POSTFACH 400265, D-50859 COLOGNE, GERMANY	1866-0452			DTSCH ARZTEBL INT	Dtsch. Arztebl. Int.	SEP 2	2013	110	35-36					598	598		10.3238/arztebl.2013.0598b			1	Medicine, General & Internal	General & Internal Medicine	248TT	WOS:000326727500006		Green Published			2020-06-30	J	Rainwater, KL; Valitutto, MT; Kalk, P; Moore, RP; Sykes, JM				Rainwater, Kimberly L.; Valitutto, Marc T.; Kalk, Penny; Moore, Robert P.; Sykes, John M.			COMPARISON OF TWO INJECTABLE IMMOBILIZATION COMBINATIONS IN HIMALAYAN TAHR (HEMITRAGUS JEMLAHICUS): MEDETOMIDINE, KETAMINE, AND ATIPAMEZOLE VERSUS CARFENTANIL, XYLAZINE, NALTREXONE, AND ATIPAMEZOLE	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						Carfentanil; chemical immobilization; Hemitragus jemlahicus; Himalayan tahr; ketamine; medetomidine; xylazine	CAPRA-FALCONERI-MEGACEROS; MALE GOATS; STRESS RESPONSE; CORTISOL; REVERSAL; ANESTHESIA; SERUM; PROGESTERONE; TESTOSTERONE; VALIDATION	A crossover study was performed in 12 Himalayan tahr (Hemitragus jemlahicus) undergoing pre-shipment examinations to compare a partially reversible to a fully reversible intramuscular chemical immobilization protocol. The partially reversible protocol (MKA) consisted of induction with medetomidine (0.06 +/- 0.009 mg/kg) and ketamine (2.03 +/- 0.315 mg/kg) and antagonism by atipamezole (0.30 +/- 0.044 mg/kg). The fully reversible protocol (CXNA) consisted of induction with carfentanil (0.009 +/- 0.003 mg/kg) and xylazine (0.08 +/- 0.019 mg/kg) and antagonism by naltrexone (0.867 +/- 0.332 mg/kg) and atipamezole (0.105 +/- 0.023 mg/kg). Animals were monitored for quality and length of induction and recovery, depth of immobilization, heart rate, respiratory rate, rectal temperature, indirect mean blood pressure (MBP), oxygen saturation, and end-tidal carbon dioxide concentration. Blood was collected for serum cortisol measurement. Significant (P < 0.05) differences included a higher MBP, higher serum cortisol, and longer recovery time with MKA compared to CXNA. In addition, the quality of induction and recovery were different. With MKA, animals ambulated less during induction, remained recumbent longer during recovery, and demonstrated more ataxia on rising. Despite differences between the protocols, both provided an acceptable level of immobilization for pre-shipment testing to be done and appeared to be safe in the study population. These differences should be taken into consideration when selecting the anesthetic protocol because either regimen may be more or less desirable for different medical or immobilization settings.	[Rainwater, Kimberly L.; Valitutto, Marc T.; Kalk, Penny; Moore, Robert P.; Sykes, John M.] Wildlife Conservat Soc, Zool Hlth Program, Bronx, NY 10460 USA; [Rainwater, Kimberly L.; Valitutto, Marc T.] Cornell Univ, Coll Vet Med, Dept Clin Sci, Sect Zool Med, Ithaca, NY 14853 USA	Rainwater, KL (reprint author), Wildlife Conservat Soc, Zool Hlth Program, 2300 Soouthern Blvd, Bronx, NY 10460 USA.	klrainwater@gmail.com					Allen J. L., 1991, P AM ASS ZOO VET, V1991, P343; Arnemo Jon M., 2007, P103, DOI 10.1002/9780470376478.ch8; Bhatnagar Y. V., 2008, IUCN 2011 IUCN RED L; Carroll GL, 1998, LAB ANIM SCI, V48, P387; Carroll GL, 2005, VET ANAESTH ANALG, V32, P147, DOI 10.1111/j.1467-2995.2005.00187.x; CAULKETT NA, 1994, J ZOO WILDLIFE MED, V25, P376; Dematteis A, 2006, J WILDLIFE DIS, V42, P633, DOI 10.7589/0090-3558-42.3.633; Donaldson MT, 2005, J VET INTERN MED, V19, P217, DOI 10.1892/0891-6640(2005)19&lt;217:VIPAHC&gt;2.0.CO;2; EISSA HM, 1990, ARCH EXP VET MED, V44, P621; FRANZMANN AW, 1975, CAN J ZOOL, V53, P1424, DOI 10.1139/z75-172; Heard DJ, 1996, AM J VET RES, V57, P87; Honkavaara J., 2004, P AM ASS ZOO VET, V2004, P514; JALANKA H, 1988, J ZOO WILDLIFE MED, V19, P95, DOI 10.2307/20094864; JALANKA HH, 1990, J ZOO WILDLIFE MED, V21, P259; JALANKA HH, 1989, J ZOO WILDLIFE MED, V20, P413; LEE DE, 1991, AM J VET RES, V52, P1489; Morris P. J., 2000, P AM ASS ZOO VET, V2000, P102; MORTON DJ, 1995, VET REC, V136, P60, DOI 10.1136/vr.136.3.60; Olsson K, 2011, ACTA VET SCAND, V53, DOI 10.1186/1751-0147-53-60; PEARSON RA, 1975, RES VET SCI, V19, P102, DOI 10.1016/S0034-5288(18)33565-3; Probo M, 2011, REPROD DOMEST ANIM, V46, P1004, DOI 10.1111/j.1439-0531.2011.01775.x; Reimers TJ, 1996, COMP HAEMATOL INT, V6, P170, DOI 10.1007/BF00368462; Russell NJ, 2007, AUST VET J, V85, P487, DOI 10.1111/j.1751-0813.2007.00232.x; SANHOURI AA, 1991, BRIT VET J, V147, P42, DOI 10.1016/0007-1935(91)90065-U; SANHOURI AA, 1992, BRIT VET J, V148, P119, DOI 10.1016/0007-1935(92)90103-8; SANHOURI AA, 1990, BRIT VET J, V146, P36, DOI 10.1016/0007-1935(90)90074-D; Singh AK, 1997, J VET DIAGN INVEST, V9, P261, DOI 10.1177/104063879700900307; Smith KM, 2006, J ZOO WILDLIFE MED, V37, P513, DOI 10.1638/06-027.1; Weinser H., 1984, J ZOO ANIM MED, V15, P18	29	2	2	0	10	AMER ASSOC ZOO VETERINARIANS	YULEE	581705 WHITE OAK ROAD, YULEE, FL 32097 USA	1042-7260	1937-2825		J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	SEP	2013	44	3					596	604		10.1638/2012-0140R1.1			9	Veterinary Sciences	Veterinary Sciences	AM1WM	WOS:000339639100009	24063087				2020-06-30	J	Coruh, B; Tonelli, MR; Park, DR				Coruh, Basak; Tonelli, Mark R.; Park, David R.			Use of Fentanyl and Safety of Endobronchial Ultrasound Response	CHEST			English	Letter									[Coruh, Basak; Tonelli, Mark R.; Park, David R.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA	Coruh, B (reprint author), Univ Washington, Box 356522,1959 NE Pacific St, Seattle, WA 98195 USA.	bcoruh@u.washington.edu					Coruh B, 2013, CHEST, V143, P1145, DOI 10.1378/chest.12-2131	1	1	1	0	1	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692	1931-3543		CHEST	Chest	SEP	2013	144	3					1083	1084		10.1378/chest.13-1082			2	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	241JC	WOS:000326161700056	24008969				2020-06-30	J	Medford, ARL				Medford, Andrew R. L.			Use of Fentanyl and Safety of Endobronchial Ultrasound	CHEST			English	Letter							TRANSBRONCHIAL NEEDLE ASPIRATION		Southmead Hosp, North Bristol Lung Ctr, Bristol BS10 5NB, Avon, England	Medford, ARL (reprint author), Southmead Hosp, North Bristol Lung Ctr, Bristol BS10 5NB, Avon, England.	andrewmedford@hotmail.com		Medford, Andrew/0000-0001-5445-5949			Coruh B, 2013, CHEST, V143, P1145, DOI 10.1378/chest.12-2131; Jeyabalan A, 2012, THORAX, V67, pA94, DOI 10.1136/thoraxjnl-2012-202678.313; Medford ARL, 2009, QJM-INT J MED, V102, P859, DOI 10.1093/qjmed/hcp136; Medford ARL, 2013, THORAC CANCER, V4, P90, DOI 10.1111/j.1759-7714.2012.00168.x; Medford ARL, 2010, CHEST, V138, P1274, DOI 10.1378/chest.10-0617	5	0	0	0	1	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692	1931-3543		CHEST	Chest	SEP	2013	144	3					1083	1083		10.1378/chest.13-1027			1	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	241JC	WOS:000326161700055	24008968				2020-06-30	J	Kim, SH; Shin, YS; Oh, YJ; Lee, JR; Chung, SC; Choi, YS				Kim, Shin Hyung; Shin, Yang-Sik; Oh, Young Jun; Lee, Jeong Rim; Chung, Sung Chan; Choi, Yong Seon			Risk Assessment of Postoperative Nausea and Vomiting in the Intravenous Patient-Controlled Analgesia Environment: Predictive Values of the Apfel's Simplified Risk Score for Identification of High-Risk Patients	YONSEI MEDICAL JOURNAL			English	Article						Apfel's simplified risk score; patient-controlled analgesia; postoperative nausea and vomiting	RANDOMIZED CONTROLLED-TRIAL; POSTANESTHESIA CARE-UNIT; DOUBLE-BLIND; SURGERY; ONDANSETRON; ANESTHESIA; PREVENTION; DEXAMETHASONE; MANAGEMENT; INFUSION	Purpose: Opioid-based intravenous patient-controlled analgesia (IV PCA) is popular method of postoperative pain control, but many patients suffer from IV PCA-related postoperative nausea and vomiting (PONV). In this retrospective observational study, we have determined independent predictors of IV PCA-related PONY and predictive values of the Apfel's simplified risk score in pursuance of identifying high-risk patients. Materials and Methods: We analyzed 7000 patients who received IV PCA with background infusion after elective surgery. Patients who maintained IV PCA for a postoperative period of 48 hr (completion group, n=6128) were compared with those who have discontinued IV PCA within 48 hr of surgery due to intractable PONY (cessation group, n=872). Patients, anesthetics, and surgical factors known for predicting PONY were evaluated by logistic regression analysis to identify independent predictors of IV PCA related intractable PONY. Results: In a stepwise multivariate analysis, weight, background infusion dose of fentanyl, addition of ketolorac to PCA, duration of anesthesia, general anesthesia, head and neck surgery, and Apfel's simplified risk score were revealed as independent risk factors for intractable PONY followed by the cessation of IV PCA. In addition, Apfel's simplified risk score, which demonstrated the highest odds ratio among the predictors, was strongly correlated with the cessation rate of IV PCA. Conclusion: Multimodal prophylactic antiemetic strategies and dose reduction of opioids may be considered as strategies for the prevention of PONY with the use of IV PCA, especially in patients with high Apfel's simplified risk scores.	[Kim, Shin Hyung; Shin, Yang-Sik; Oh, Young Jun; Lee, Jeong Rim; Chung, Sung Chan; Choi, Yong Seon] Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med, Seoul 120752, South Korea	Choi, YS (reprint author), Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med, 50 Yonsei Ro, Seoul 120752, South Korea.	yschoi@yuhs.ac		Oh, Young Jun/0000-0002-6258-5695; Kim, Shin Hyung/0000-0003-4058-7697; CHOI, YONG SEON/0000-0002-5348-864X; Lee, Jeong-Rim/0000-0002-7425-0462			Apfel CC, 2002, BRIT J ANAESTH, V88, P234, DOI 10.1093/bja/88.2.234; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Apfel CC, 2004, NEW ENGL J MED, V350, P2441, DOI 10.1056/NEJMoa032196; Apfel CC, 2002, BRIT J ANAESTH, V88, P659, DOI 10.1093/bja/88.5.659; Apfel CC, 2001, BRIT J ANAESTH, V86, P822, DOI 10.1093/bja/86.6.822; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; Borgeat A, 2003, ANESTHESIOLOGY, V98, P530, DOI 10.1097/00000542-200302000-00036; Buvanendran A, 2003, JAMA-J AM MED ASSOC, V290, P2411, DOI 10.1001/jama.290.18.2411; Chen PP, 2001, ANESTH ANALG, V92, P224; Choi DK, 2010, ACTA ANAESTH SCAND, V54, P962, DOI 10.1111/j.1399-6576.2010.02275.x; DOYLE E, 1993, BRIT J ANAESTH, V71, P670, DOI 10.1093/bja/71.5.670; Gan TJ, 2006, ANESTH ANALG, V102, P1884, DOI 10.1213/01.ANE.0000219597.16143.4D; Ishikawa Yuko, 2011, Masui, V60, P920; Junger A, 2001, ANESTH ANALG, V92, P1203, DOI 10.1097/00000539-200105000-00023; Kim SY, 2008, THYROID, V18, P1285, DOI 10.1089/thy.2008.0007; Koivuranta M, 1997, ANAESTHESIA, V52, P443, DOI 10.1111/j.1365-2044.1997.117-az0113.x; Kovac AL, 2000, DRUGS, V59, P213, DOI 10.2165/00003495-200059020-00005; Kranke P, 2001, ACTA ANAESTH SCAND, V45, P160, DOI 10.1034/j.1399-6576.2001.450205.x; Macario A, 1999, ANESTH ANALG, V89, P652, DOI 10.1097/00000539-199909000-00022; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; Maxwell LG, 2005, ANESTH ANALG, V100, P953, DOI 10.1213/01.ANE.0000148618.17736.3C; Pierre S, 2002, CAN J ANAESTH, V49, P237, DOI 10.1007/BF03020521; Roberts GW, 2005, ANESTH ANALG, V101, P1343, DOI 10.1213/01.ANE.0000180204.64588.EC; Ruiz JR, 2010, ANESTH ANALG, V110, P403, DOI 10.1213/ane.0b013e3181a9d076; Sinclair DR, 1999, ANESTHESIOLOGY, V91, P109, DOI 10.1097/00000542-199907000-00018; Song JW, 2011, ANAESTHESIA, V66, P263, DOI 10.1111/j.1365-2044.2011.06648.x; Stadler M, 2003, ANESTHESIOLOGY, V98, P46, DOI 10.1097/00000542-200301000-00011; Tramer MR, 1999, ANESTH ANALG, V88, P1354, DOI 10.1097/00000539-199906000-00030; Wallenborn J, 2007, J CLIN ANESTH, V19, P180, DOI 10.1016/j.jclinane.2006.09.004; Wallenborn J, 2006, BRIT MED J, V333, P324, DOI 10.1136/bmj.38903.419549.80; Woodhouse A, 1997, ANAESTHESIA, V52, P770, DOI 10.1111/j.1365-2044.1997.144-az0148.x; Yen CR, 2010, ANESTHESIOLOGY, V112, P688, DOI 10.1097/ALN.0b013e3181cbd1f3	32	23	24	0	7	YONSEI UNIV COLLEGE MEDICINE	SEOUL	IN-HONG CHOI, M.D., PH D, 50 SEONGSAN-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA	0513-5796	1976-2437		YONSEI MED J	Yonsei Med. J.	SEP 1	2013	54	5					1273	1281		10.3349/ymj.2013.54.5.1273			9	Medicine, General & Internal	General & Internal Medicine	240WN	WOS:000326128500028	23918581	DOAJ Gold, Green Published			2020-06-30	J	Michel-Lauter, B; Bernardy, K; Schwarzer, A; Nicolas, V; Maier, C				Michel-Lauter, B.; Bernardy, K.; Schwarzer, A.; Nicolas, V.; Maier, C.			Dependency syndrome and hyperalgesia due to an opioid therapy for curative treatable pain. Case report of an apparent palliative patient	SCHMERZ			German	Article						Pain therapy; Tumor patients; False dosage; Pancreatic cancer; Scar herniation	PATHOPHYSIOLOGY; ADDICTION	Opioids are an essential part of cancer pain management but particularly in this patient group physicians could misinterpret opioid-induced potentially life-threatening side effects within the central nervous system (CNS) or hyperalgesia as a consequence of tumor progression. In this case increasing the opioid dose or switching to rapidly acting opioids may trigger a vicious circle. We describe a case report of a male patient who was treated with high doses of transdermal and endonasal fentanyl 2 years after pancreatomy due to cancer. The patient was referred to the palliative care unit presenting with delirious behavior and 30-40 severe abdominal pain attacks/day. After withdrawal of the opioid medication all CNS symptoms disappeared. Further diagnostics revealed multiple incisional hernia as the reason of the pain syndrome. The patient recovered after herniotomy and has now been pain free without any pain medication for more than 16 months. This case report underlines again the necessity of pain diagnostics also in assumed palliative patients with the risks of high dose opioid treatment.	[Michel-Lauter, B.; Bernardy, K.; Schwarzer, A.; Maier, C.] Ruhr Univ Bochum, Berufsgenossenschaftliches Univ Klinikum Bergmann, Klin Anasthesiol Intens Palliat & Schmerzmed, Abt Schmerzmed, D-44789 Bochum, Germany; [Nicolas, V.] Ruhr Univ Bochum, Berufsgenossenschaftliches Univ Klinikum Bergmann, Inst Diagnost Radiol Intervent Radiol & Nukl Med, D-44789 Bochum, Germany	Maier, C (reprint author), Ruhr Univ Bochum, Berufsgenossenschaftliches Univ Klinikum Bergmann, Klin Anasthesiol Intens Palliat & Schmerzmed, Abt Schmerzmed, Burkle de la Camp Pl 1, D-44789 Bochum, Germany.	christoph.maier@rub.de					Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Ballantyne Jane C, 2007, Curr Pain Headache Rep, V11, P276, DOI 10.1007/s11916-007-0204-6; Ballantyne JC, 2012, ARCH INTERN MED, V172, P1342, DOI 10.1001/archinternmed.2012.3212; Ballantyne JC, 2010, PAIN, V148, P365, DOI 10.1016/j.pain.2009.10.020; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Carlsen BT, 2007, PLAST RECONSTR SURG, V119, P1247, DOI 10.1097/01.prs.0000254401.33682.e9; Cicero TJ, 2005, J PAIN, V6, P662, DOI 10.1016/j.jpain.2005.05.004; de Leon-Casasola OA, 2008, CLIN J PAIN S10, V24, P3; Erowid Experience Vaults, 2013, LEG EXP FENT EXP FEN; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Gronnier C, 2012, WORLD J SURG, V36, P1548, DOI 10.1007/s00268-012-1523-2; Heger S, 1999, BRIT MED J, V319, P627, DOI 10.1136/bmj.319.7210.627; Kindler D, 2005, SCHMERZ, V19, P144, DOI 10.1007/s00482-004-0327-1; Klinge U, 1997, CHIRURG, V68, P293, DOI 10.1007/s001040050192; Koppert W, 2004, ANAESTHESIST, V53, P455, DOI 10.1007/s00101-004-0669-1; Krumova EK, 2013, CLIN J PAIN; Lee M, 2011, PAIN PHYSICIAN, V14, P145; Maier C, 2008, SCHMERZ, V22, P639, DOI 10.1007/s00482-008-0716-y; Markman JD, 2008, PAIN, V136, P227, DOI 10.1016/j.pain.2008.03.011; Michel-Lauter B, 2012, SCHMERZ, V26, P721, DOI 10.1007/s00482-012-1229-2; Nunez-Olarte JM, 2011, J PAIN SYMPTOM MANAG, V42, pE6, DOI 10.1016/j.jpainsymman.2011.07.006; O'Connor AB, 2008, PAIN MED, V9, P258, DOI 10.1111/j.1526-4637.2008.00413.x; Office for National Statistics Special Bulletin, 2011, OFF NAT STAT SPEC B; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; Passik SD, 2010, J PAIN SYMPTOM MANAG, V150, P332; Ramasubbu Chitra, 2011, J Pain Palliat Care Pharmacother, V25, P219, DOI 10.3109/15360288.2011.589490; Schubert I, 2013, DTSCH ARZTEBL INT, V110, P45, DOI 10.3238/arztebl.2013.0045; Solomon DH, 2010, ARCH INTERN MED, V170, P1979, DOI 10.1001/archinternmed.2010.450; Sorgatz H, 2010, LANGZEITANWENDUNG OP, P1; Stannard C, 2012, BRIT J PAIN, V6, P7, DOI 10.1177/2049463712439131; Webster LR, 2011, PAIN MED, V12, pS26, DOI 10.1111/j.1526-4637.2011.01134.x; Zingg Urs, 2012, Ther Umsch, V69, P39, DOI 10.1024/0040-5930/a000249	32	3	3	0	3	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0932-433X	1432-2129		SCHMERZ	Schmerz	SEP	2013	27	5					506	+		10.1007/s00482-013-1353-7			6	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	227IF	WOS:000325105200008	24005817				2020-06-30	J	Pisani, MA; Bramley, K; Vest, MT; Akgun, KM; Araujo, KLB; Murphy, TE				Pisani, Margaret A.; Bramley, Kyle; Vest, Michael T.; Akguen, Kathleen M.; Araujo, Katy L. B.; Murphy, Terrence E.			PATTERNS OF OPIATE, BENZODIAZEPINE, AND ANTIPSYCHOTIC DRUG DOSING IN OLDER PATIENTS IN A MEDICAL INTENSIVE CARE UNIT	AMERICAN JOURNAL OF CRITICAL CARE			English	Article							MECHANICALLY VENTILATED PATIENTS; DELIRIUM; SEDATION; AGITATION; IMPACT	Background Anecdotal observation suggests that older patients in medical intensive care units receive higher doses of psychoac tive medications during evening shifts than day and night shifts. Objectives To determine the dosing patterns and total doses of fentanyl, lorazepam, and haloperidol according to nursing shift in a cohort of older patients in a medical intensive care unit. Methods The sample consisted of 309 patients 60 years and older admitted to the medical intensive care unit at Yale-New Haven Hospital, New Haven, Connecticut. Data on time, dosage, and route of administration of the drugs were collected. Data were analyzed by using a Bayesian random effects Poisson model adjusted for individual heterogeneity, excess zero doses, and important clinical covariates. Results Mean age of the patients was 75 years; 58% received fentanyl, 55% received lorazepam, and 32% received haloperidol. Although dosing with fentanyl did not differ according to shift, doses of both lorazepam and haloperidol were higher during the evening shifts (4 PM to midnight) than during the day or night shifts. Compared with women, men received higher doses of both haloperidol and lorazepam and variability between shifts was greater. Conclusions In this longitudinal, observational sample of older patients, data indicated a positive association between dose levels of lorazepam and haloperidol during the evening nursing shifts relative to other shifts. Further investigation is needed to determine potential causes and to evaluate the impact on outcomes of sleep deprivation and delirium.	[Pisani, Margaret A.; Bramley, Kyle; Akguen, Kathleen M.; Araujo, Katy L. B.; Murphy, Terrence E.] Yale Univ, Sch Med, Dept Med, New Haven, CT 06511 USA; [Vest, Michael T.] Yale Univ, Sch Med, New Haven, CT 06511 USA	Murphy, TE (reprint author), Yale Univ, Sch Med, 300 George St,Ste 775, New Haven, CT 06511 USA.	terrence.murphy@yale.edu	Vest, Michael/M-1512-2019	Vest, Michael/0000-0002-3525-6095	American Lung Association and Connecticut Thoracic Society [CG-002-N]; Americans Independence Center at Yale University School of Medicine [2P30AG021342-06]; CHEST Foundation; ASP; Hartford Foundation; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K23AG 23023, 1R21NR011066]; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR024139]	This work was supported in part by the American Lung Association and Connecticut Thoracic Society (CG-002-N), Claude D. Pepper Older Americans Independence Center at Yale University School of Medicine (2P30AG021342-06), the T. Franklin Williams Geriatric Development Initiative through The CHEST Foundation, ASP, Hartford Foundation, grants from the National Institute on Aging (K23AG 23023 and 1R21NR011066, Dr Pisani; 1R21AG033130-01A2, Dr Murphy), and CTSA UL1 RR024139 from the National Center for Research Resources (Dr Murphy).	[Anonymous], 2009, SAS STAT 9 2 US MAN; Baker JA, 2008, J CLIN NURS, V17, P1122, DOI 10.1111/j.1365-2702.2007.02236.x; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Dubois MJ, 2001, INTENS CARE MED, V27, P1297, DOI 10.1007/s001340101017; Ely EW, 2001, INTENS CARE MED, V27, P1892, DOI 10.1007/s00134-001-1132-2; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Frisk U, 2004, CLIN SCI, V107, P47, DOI 10.1042/CS20030374; Gehlbach BK, 2012, SLEEP, V35, P1105, DOI 10.5665/sleep.1998; Gelman A., 2007, DATA ANAL USING REGR; Gill KV, 2012, ANN PHARMACOTHER, V46, P1331, DOI 10.1345/aph.1R037; Guttormson Jill L, 2010, Intensive Crit Care Nurs, V26, P44, DOI 10.1016/j.iccn.2009.10.004; Jaber S, 2005, CHEST, V128, P2749, DOI 10.1378/chest.128.4.2749; JORM AF, 1994, PSYCHOL MED, V24, P145, DOI 10.1017/S003329170002691X; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kross EK, 2008, CRIT CARE CLIN, V24, P875, DOI 10.1016/j.ccc.2008.06.002; LAWTON MP, 1969, GERONTOLOGIST, V9, P9, DOI 10.1093/geront/9.1.9; Lin SM, 2004, CRIT CARE MED, V32, P2254, DOI 10.1097/01.CCM.0000145587.16421.BB; Lunn DJ, 2000, STAT COMPUT, V10, P325, DOI 10.1023/A:1008929526011; Milbrandt EB, 2004, CRIT CARE MED, V32, P955, DOI 10.1097/01.CCM.0000119429.16055.92; Monger E, 1995, Intensive Crit Care Nurs, V11, P140, DOI 10.1016/S0964-3397(95)80631-8; Murphy TE, 2011, AM J EPIDEMIOL, V174, P1230, DOI 10.1093/aje/kwr252; Ouimet S, 2007, INTENS CARE MED, V33, P66, DOI 10.1007/s00134-006-0399-8; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Patel RP, 2009, CRIT CARE MED, V37, P825, DOI 10.1097/CCM.0b013e31819b8608; Pisani MA, 2007, ARCH INTERN MED, V167, P1629, DOI 10.1001/archinte.167.15.1629; Pisani MA, 2006, CRIT CARE, V10, DOI 10.1186/cc5027; Pisani MA, 2009, AM J RESP CRIT CARE, V180, P1092, DOI 10.1164/rccm.200904-0537OC; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Stevens RD, 2006, CRIT CARE CLIN, V22, P787, DOI 10.1016/j.ccc.2006.11.006; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9	32	7	7	0	11	AMER ASSOC CRITICAL CARE NURSES	ALISO VIEJO	101 COLUMBIA, ALISO VIEJO, CA 92656 USA	1062-3264	1937-710X		AM J CRIT CARE	Am. J. Crit. Care	SEP 1	2013	22	5					E62	E69		10.4037/ajcc2013835			8	Critical Care Medicine; Nursing	General & Internal Medicine; Nursing	219UM	WOS:000324536100002	23996429	Green Accepted, Bronze			2020-06-30	J	Ginosar, Y; Birnbach, DJ; Shirov, TT; Arheart, K; Caraco, Y; Davidson, EM				Ginosar, Y.; Birnbach, D. J.; Shirov, T. T.; Arheart, K.; Caraco, Y.; Davidson, E. M.			Duration of analgesia and pruritus following intrathecal fentanyl for labour analgesia: no significant effect of A118G mu-opioid receptor polymorphism, but a marked effect of ethnically distinct hospital populations	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesia; obstetric; analgesics opioid; fentanyl; genetic factors	SINGLE-NUCLEOTIDE POLYMORPHISM; EPIDURAL ANALGESIA; GENETIC VARIANT; CANCER PAIN; MORPHINE; OPRM1; REQUIREMENTS; ALFENTANIL; VARIABILITY; BUPIVACAINE	Genetic polymorphism (A118G) in the -opioid receptor has been reported to affect systemic opioid analgesia. However, reported pharmacogenetic effects on spinal opioid analgesia, particularly in labour, have been equivocal. We prospectively assessed effects of the -opioid receptor A118G single nucleotide polymorphism (SNP) on analgesia after 20 g of spinal fentanyl. We studied two ethnically distinct hospital populations (Miami and Jerusalem). Independent variables were A118G, ethnicity, and hospital. Primary outcome was time from spinal analgesia until analgesic request. Secondary outcomes were pain and pruritus, assessed at repeated intervals until analgesia request. One hundred and twenty-five nulliparous parturients in early labour were analysed. The allelic frequency of A118G was 14.8 (14.4 in Miami; 15.5 in Jerusalem). Time to analgesia request (sd) in Miami was 122 (44) min and in Jerusalem was 87 (32) min, P0.001; Hispanic 123 (46) min vs Jew/Arab 87 (32) min, P0.001; Black 121 (41) min vs Jew/Arab 87 (32) min, P0.015. There was no significant effect of A118G. Survival analysis showed Miami Jerusalem, P0.001; Hispanics and Black Jew/Arab, P0.001; no effect of A118G. Within hospital groups, A118G had no effect on time to analgesic request; within genomic groups there was a significant difference between hospitals. The time-course for pruritus exactly paralleled the time-course for analgesia and was affected by hospital (P0.006) and by ethnic group (P0.03), but not by A118G. We found no significant effect for the A118G single nucleotide polymorphism (SNP) on analgesic duration after spinal fentanyl for labour. In contrast, ethnically distinct hospital population groups exerted a marked effect on the time-course of both analgesia and pruritus.	[Ginosar, Y.; Shirov, T. T.; Davidson, E. M.] Hadassah Hebrew Univ Med Ctr, Dept Anesthesiol & Crit Care Med, Jerusalem, Israel; [Caraco, Y.] Hadassah Hebrew Univ Med Ctr, Dept Med, Jerusalem, Israel; [Caraco, Y.] Hadassah Hebrew Univ Med Ctr, Dept Clin Pharmacol, Jerusalem, Israel; [Birnbach, D. J.; Davidson, E. M.] Univ Miami, Miller Sch Med, Dept Anesthesiol, Miami, FL 33136 USA; [Birnbach, D. J.; Arheart, K.] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA	Ginosar, Y (reprint author), Hadassah Hebrew Univ Med Ctr, Dept Anesthesiol & Crit Care Med, Jerusalem, Israel.	yginosar@netvision.net.il					Belfer I, 2004, ANESTHESIOLOGY, V100, P1562, DOI 10.1097/00000542-200406000-00032; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; Camorcia M, 2012, INT J OBSTET ANESTH, V21, P40, DOI 10.1016/j.ijoa.2011.10.001; Capogna G, 1998, BRIT J ANAESTH, V80, P11; Capogna G, 2001, ANESTHESIOLOGY, V94, P740, DOI 10.1097/00000542-200105000-00009; Fillingim RB, 2005, J PAIN, V6, P159, DOI 10.1016/j.jpain.2004.11.008; FLOBERG J, 1987, ACTA OBSTET GYN SCAN, V66, P121, DOI 10.3109/00016348709083032; Fukuda K, 2009, PAIN, V147, P194, DOI 10.1016/j.pain.2009.09.004; Gehling MHG, 2009, EUR J ANAESTH, V26, P683, DOI 10.1097/EJA.0b013e328329b045; Ginosar Y, 2009, BRIT J ANAESTH, V103, P420, DOI 10.1093/bja/aep192; Glance LG, 2007, ANESTHESIOLOGY, V106, P19, DOI 10.1097/00000542-200701000-00008; GREENWALD HP, 1991, PAIN, V44, P157, DOI 10.1016/0304-3959(91)90130-P; Herman NL, 1999, ANESTH ANALG, V89, P378, DOI 10.1097/00000539-199908000-00024; Hess PE, 2001, ANESTH ANALG, V93, P414; Klepstad P, 2004, ACTA ANAESTH SCAND, V48, P1232, DOI 10.1111/j.1399-6576.2004.00517.x; Klepstad P, 2011, PAIN, V152, P1139, DOI 10.1016/j.pain.2011.01.040; Ko MCH, 2000, ANESTHESIOLOGY, V92, P795, DOI 10.1097/00000542-200003000-00023; Kolesnikov Y, 2011, ANESTH ANALG, V112, P448, DOI 10.1213/ANE.0b013e318202cc8d; Landau R, 2008, PAIN, V139, P5, DOI 10.1016/j.pain.2008.02.023; Lim Y, 2004, ANESTH ANALG, V98, P235, DOI 10.1213/01.ANE.0000094338.80430.C5; Liu XY, 2011, CELL, V147, P447, DOI 10.1016/j.cell.2011.08.043; Lotsch J, 2009, PHARMACOL THERAPEUT, V124, P168, DOI 10.1016/j.pharmthera.2009.06.010; Lotsch J, 2002, PHARMACOGENETICS, V12, P3, DOI 10.1097/00008571-200201000-00002; Mahmoud S, 2011, ANESTHESIOLOGY, V115, P1054, DOI 10.1097/ALN.0b013e318231fc11; Max MB, 2008, NAT REV DRUG DISCOV, V7, P647, DOI 10.1038/nrd2595; Mayer P, 2006, PHARMACOGENET GENOM, V16, P1, DOI 10.1097/01.fpc.0000182781.87932.0d; Meyer MR, 2011, PHARMACOGENOMICS, V12, P215, DOI [10.2217/pgs.10.171, 10.2217/PGS.10.171]; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Nelson KE, 2010, ANESTHESIOLOGY, V112, P174, DOI 10.1097/ALN.0b013e3181c38c0b; Oertel BG, 2006, PHARMACOGENET GENOM, V16, P625, DOI 10.1097/01.fpc.0000220566.90466.a2; Oertel BG, 2009, J BIOL CHEM, V284, P6530, DOI 10.1074/jbc.M807030200; Pan PH, 2005, ANESTHESIOLOGY, V103, P595, DOI 10.1097/00000542-200509000-00023; Reyes-Gibby CC, 2007, PAIN, V130, P25, DOI 10.1016/j.pain.2006.10.023; SCOTT PV, 1982, POSTGRAD MED J, V58, P531, DOI 10.1136/pgmj.58.683.531; Sheiner E, 1998, INT J GYNECOL OBSTET, V63, P287, DOI 10.1016/S0020-7292(98)00164-7; Sia AT, 2008, ANESTHESIOLOGY, V109, P520, DOI 10.1097/ALN.0b013e318182af21; Tan EC, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-32; Toledo P, 2012, ANESTH ANALG, V114, P172, DOI 10.1213/ANE.0b013e318239dc7c; Ummenhofer WC, 2000, ANESTHESIOLOGY, V92, P739, DOI 10.1097/00000542-200003000-00018; Voronov P, 2007, PEDIATR ANESTH, V17, P684, DOI 10.1111/j.1460-9592.2006.02182.x; Walter C, 2009, PAIN, V146, P270, DOI 10.1016/j.pain.2009.07.013; Wei SQ, 2009, OBSTET GYNECOL, V114, P641, DOI 10.1097/AOG.0b013e3181b11cb8; Wong CA, 2010, INT J OBSTET ANESTH, V19, P246, DOI 10.1016/j.ijoa.2009.09.005; WUITCHIK M, 1990, PAIN, V41, P125, DOI 10.1016/0304-3959(90)90016-7; Zhang Y, 2005, J BIOL CHEM, V280, P32618, DOI 10.1074/jbc.M504942200	45	5	6	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	SEP	2013	111	3					433	444		10.1093/bja/aet075			12	Anesthesiology	Anesthesiology	204EC	WOS:000323346900017	23592691	Bronze			2020-06-30	J	Landau, R				Landau, Ruth			Genetic Contributions to Labor Pain and Progress	CLINICS IN PERINATOLOGY			English	Article						Genetics; Polymorphism; OPRM1; ADRB2; Labor pain	MU-OPIOID-RECEPTOR; SINGLE-NUCLEOTIDE POLYMORPHISM; CATECHOL-O-METHYLTRANSFERASE; PHARMACOGENETICS IMPLEMENTATION CONSORTIUM; BETA-2-ADRENERGIC RECEPTOR; MORPHINE CONSUMPTION; A118G POLYMORPHISM; CANCER PAIN; OPRM1; ANALGESIA	Studies on genetic contributions to labor analgesia have essentially evaluated the mu-opioid receptor gene (OPRM1), with some evidence that p.118A/G of OPRM1 influences the response to neuraxial opioids. As for labor progress, the beta(2)-adrenergic receptor gene (ADRB2) is associated with preterm labor and delivery, and impacts the course of labor. Taken together though, there is no evidence that pharmacogenetic testing is needed or beneficial in the context of obstetric anesthesia; however, realizing the influence of genetic variants on specific phenotypes provides the rationale for a more cautious interpretation of clinical studies that attempt to find a dose-regimen that fits all.	Univ Washington, Med Ctr, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA	Landau, R (reprint author), Univ Washington, Med Ctr, Dept Anesthesiol & Pain Med, 1959 NE Pacific St,Suite BB 1415B, Seattle, WA 98195 USA.	rulandau@u.washington.edu			Millennium Research Institute (Millennium Laboratories); Swiss National Foundation Research grant (SNF) [3200B0-114129]; OPRM1 genetic research conducted in Switzerland	The author declares receiving funding for research projects that are not related with the topic of this review from the Millennium Research Institute (Millennium Laboratories).; Ruth Landau is the recipient of the Swiss National Foundation Research grant (SNF #3200B0-114129) that funded, in part, the OPRM1 genetic research conducted in Switzerland. Department of Anesthesiology and Pain Medicine, University of Washington Medical Center, 1959 NE Pacific Street, Suite BB 1415B, Seattle, WA 98195-6540, USA	Algovik M, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-105; Andersen S, 2009, PHARMACOGENOMICS, V10, P669, DOI 10.2217/PGS.09.13; Belfer I, 2011, DRUG TODAY, V47, P457, DOI 10.1358/dot.2011.47.6.1611895; Beyer A, 2004, J NEUROCHEM, V89, P553, DOI 10.1111/j.1471-4159.2004.02340.x; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; Camorcia M, 2012, INT J OBSTET ANESTH, V21, P40, DOI 10.1016/j.ijoa.2011.10.001; Candiotti K, 2009, ANESTH ANALG, V109, P1377, DOI 10.1213/ANE.0b013e3181b9857a; Carroll CL, 2012, J ASTHMA, V49, P563, DOI 10.3109/02770903.2012.701362; Carvalho B, 2013, INT J OBSTET ANESTH, V22, P6, DOI 10.1016/j.ijoa.2012.10.002; Chou WY, 2006, ANESTHESIOLOGY, V105, P334, DOI 10.1097/00000542-200608000-00016; Conell-Price J, 2008, ANESTH ANALG, V106, P1509, DOI 10.1213/ane.0b013e31816d14f3; Coulbault L, 2006, CLIN PHARMACOL THER, V79, P316, DOI 10.1016/j.clpt.2006.01.007; Crews KR, 2012, CLIN PHARMACOL THER, V91, P321, DOI 10.1038/clpt.2011.287; Crowley JJ, 2003, PSYCHIAT GENET, V13, P169, DOI 10.1097/00041444-200309000-00006; Dabo F, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-41; Debiec J, 2009, ANESTHESIOLOGY, V111, P1093, DOI 10.1097/ALN.0b013e3181ba3f28; Diatchenko L, 2006, PAIN, V125, P216, DOI 10.1016/j.pain.2006.05.024; Doehring A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017724; Doh K, 2004, J PERINAT MED, V32, P413, DOI 10.1515/JPM.2004.138; Donahue BS, 2003, ANESTHESIOLOGY, V99, P7, DOI 10.1097/00000542-200307000-00005; Esplin S, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.09.021; Fillingim RB, 2005, J PAIN, V6, P159, DOI 10.1016/j.jpain.2004.11.008; Fukuda K, 2009, PAIN, V147, P194, DOI 10.1016/j.pain.2009.09.004; Gracie S, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-71; Hastie BA, 2012, PAIN, V153, P1610, DOI 10.1016/j.pain.2012.03.022; Hickey OT, 2011, J CLIN ANESTH, V23, P482, DOI 10.1016/j.jclinane.2011.01.009; Huang CJ, 2008, ANAESTHESIA, V63, P1288, DOI 10.1111/j.1365-2044.2008.05760.x; Jensen KB, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006016; Kannan S, 2001, REGION ANESTH PAIN M, V26, P468, DOI 10.1053/rapm.2001.24260; Klepstad P, 2004, ACTA ANAESTH SCAND, V48, P1232, DOI 10.1111/j.1399-6576.2004.00517.x; Klepstad P, 2011, PAIN, V152, P1139, DOI 10.1016/j.pain.2011.01.040; Kolesnikov Y, 2011, ANESTH ANALG, V112, P448, DOI 10.1213/ANE.0b013e318202cc8d; Kroslak T, 2007, J NEUROCHEM, V103, P77, DOI 10.1111/j.1471-4159.2007.04738.x; Landau R, 2005, CLIN PHARMACOL THER, V78, P656, DOI 10.1016/j.clpt.2005.08.021; Landau R, 2004, ANESTHESIOLOGY, V100, P1030, DOI 10.1097/00000542-200404000-00042; Landau R, 2002, AM J OBSTET GYNECOL, V187, P1294, DOI 10.1067/mob.2002.128524; Landau R, 2008, PAIN, V139, P5, DOI 10.1016/j.pain.2008.02.023; Landau R, 2013, ANESTH ANALG, V116, P386, DOI 10.1213/ANE.0b013e318273f2c7; Landau R, 2013, ANESTH ANALG, V116, P8, DOI 10.1213/ANE.0b013e318275355a; Landau R, 2011, ANESTH ANALG, V113, P432, DOI 10.1213/ANE.0b013e31821f154f; Lee PJ, 2011, CLIN J PAIN, V27, P93, DOI 10.1097/AJP.0b013e3181f15885; Lotsch J, 2007, ANESTHESIOLOGY, V107, P168; Loggia ML, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027764; Mahmoud S, 2011, ANESTHESIOLOGY, V115, P1054, DOI 10.1097/ALN.0b013e318231fc11; Martinez-Jauand M, 2013, EUR J PAIN, V17, P16, DOI 10.1002/j.1532-2149.2012.00153.x; MELZACK R, 1984, PAIN, V19, P321, DOI 10.1016/0304-3959(84)90079-4; Miller RS, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.03.045; Mogil JS, 2009, PAIN, V146, P231, DOI 10.1016/j.pain.2009.07.023; Nagele P, 2011, ANESTHESIOLOGY, V115, P1316, DOI 10.1097/ALN.0b013e3182315eb2; Nielsen DA, 2010, HUM GENET, V127, P639, DOI 10.1007/s00439-010-0807-6; Oertel BG, 2009, J BIOL CHEM, V284, P6530, DOI 10.1074/jbc.M807030200; Ozkur M, 2002, INT J GYNECOL OBSTET, V77, P209, DOI 10.1016/S0020-7292(02)00035-8; Pettersson FD, 2012, REPROD SCI, V19, P962, DOI 10.1177/1933719112438970; Reitman E, 2011, ANESTHESIOLOGY, V114, P927, DOI 10.1097/ALN.0b013e318211004e; Relling MV, 2011, CLIN PHARMACOL THER, V89, P464, DOI 10.1038/clpt.2010.279; Reyes-Gibby CC, 2007, PAIN, V130, P25, DOI 10.1016/j.pain.2006.10.023; Schwinn DA, 2002, ANESTHESIOLOGY, V96, P261, DOI 10.1097/00000542-200202000-00006; Sia AT, 2008, ANESTHESIOLOGY, V109, P520, DOI 10.1097/ALN.0b013e318182af21; Stein DJ, 2006, CNS SPECTRUMS, V11, P745, DOI 10.1017/S1092852900014863; Tammimaki A, 2012, PHARMACOGENET GENOM, V22, P673, DOI 10.1097/FPC.0b013e3283560c46; Tan EC, 2003, NEUROREPORT, V14, P569, DOI 10.1097/00001756-200303240-00008; Terkawi AS, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.06.079; Villar J, 2012, AM J OBSTET GYNECOL, V206, P119, DOI 10.1016/j.ajog.2011.10.866; Vossen H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013641; Vuilleumier PH, 2012, PHARMACOGN PERS MED, V5, P73, DOI 10.2147/PGPM.S23422; Walter C, 2009, PAIN, V146, P270, DOI 10.1016/j.pain.2009.07.013; Wong CA, 2012, INT J OBSTET ANESTH, V21, P105, DOI 10.1016/j.ijoa.2012.02.003; Wong CA, 2010, INT J OBSTET ANESTH, V19, P246, DOI 10.1016/j.ijoa.2009.09.005; Wu WD, 2009, MOL DIAGN THER, V13, P331, DOI 10.2165/11317320-000000000-00000; Zhang W, 2010, ANAESTHESIA, V65, P130, DOI 10.1111/j.1365-2044.2009.06193.x; Zhang Y, 2005, J BIOL CHEM, V280, P32618, DOI 10.1074/jbc.M504942200; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546; Zwisler ST, 2010, FUND CLIN PHARMACOL, V24, P517, DOI 10.1111/j.1472-8206.2009.00781.x	73	6	6	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0095-5108	1557-9840		CLIN PERINATOL	Clin. Perinatol.	SEP	2013	40	3					575	+		10.1016/j.clp.2013.05.014			14	Obstetrics & Gynecology; Pediatrics	Obstetrics & Gynecology; Pediatrics	224OP	WOS:000324898200018	23972758				2020-06-30	J	Atashkhoyi, S; Negargar, S; Hatami-Marandi, P				Atashkhoyi, Simin; Negargar, Sohrab; Hatami-Marandi, Pouya			Effects of the addition of low-dose ketamine to propofol-fentanyl anaesthesia during diagnostic gynaecological laparoscopy	EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY			English	Article						Diagnostic gynecologic laparoscopy (DGL); Anaesthesia; Propofol; Ketamine	IMPROVES POSTOPERATIVE ANALGESIA; RANDOMIZED CONTROLLED-TRIAL; EMERGENCY-DEPARTMENT; PROCEDURAL SEDATION; PEDIATRIC-PATIENTS; PAIN; COMBINATION; INJECTION; DELIVERY	Objectives: Diagnostic gynaecological laparoscopy (DGL) is a brief procedure, generally performed on an outpatient basis. Propofol-fentanyl is often used for anaesthesia in minor outpatient procedures because of its rapid onset, short duration of action and smooth patient awakening. However, propofol has various cardiovascular effects such as reduced arterial pressure, cardiac output and cardiac index. Ketamine is an intravenous anaesthetic and short-acting analgesic that could alleviate the haemodynamic effects of propofol due to its sympathomimetic activity. The aim of this placebo-controlled trial was to evaluate the effects of the addition of low-dose ketamine to propofol-fentanyl anaesthesia in DGL. Study design: In this double-blind randomized trial, 60 healthy women undergoing gynaecological laparoscopy to investigate infertility were studied. Following injection of midazolam and fentanyl in all patients, the study group (n = 30) received ketamine 0.5 mg/kg and propofol 1-2.5 mg/kg, and the placebo group (n = 30) received saline 0.9% and propofol 1-2.5 mg/kg. Propofol was subsequently infused for the maintenance of anaesthesia. Results: Patients in the study group had a significantly lower incidence of pain than patients in the placebo group during propofol injection (13% vs 87%, respectively; p < 0.0001). After induction of anaesthesia, 16 (53%) patients in the placebo group and three (10%) patients in the study group had a decreased heart rate (p < 0.001). The decrease in mean arterial pressure was greater in the placebo group compared with the study group (37% vs 7%, respectively; p < 0.001). During the procedure, the total mean +/- standard deviation dose of propofol was 420 +/- 65 mg in the placebo group and 330 +/- 35 mg in the study group (p < 0.001). Pain scores for the first 3 h after the operation were significantly lower in the study group (p < 0.001). Conclusion: Use of low-dose ketamine with propofol-fentanyl anaesthesia in patients undergoing DGL was associated with less pain during propofol injection, lower incidence of haemodynamic changes, lower total dose of propofol and improved postoperative analgesia. (C) 2013 Elsevier Ireland Ltd. All rights reserved.	[Atashkhoyi, Simin] Tabriz Univ Med Sci, Womens Reprod Hlth Res Ctr, Tabriz, Iran; [Negargar, Sohrab] Cardiovasc Res Ctr, Tabriz, Iran; [Hatami-Marandi, Pouya] Tabriz Univ Med Sci, Tabriz, Iran	Atashkhoyi, S (reprint author), Tabriz Univ Med Sci, Womens Reprod Hlth Res Ctr, Tabriz, Iran.	satashkhoyi@gmail.com					Bauchat JR, 2011, INT J OBSTET ANESTH, V20, P3, DOI 10.1016/j.ijoa.2010.10.002; Bonneau C, 2012, EUR J OBSTET GYN R B, V163, P57, DOI 10.1016/j.ejogrb.2012.03.036; Donnelly RF, 2008, CAN J HOSP PHARM, V61, P426; Erden IA, 2009, PEDIATR ANESTH, V19, P500, DOI 10.1111/j.1460-9592.2009.02971.x; Gerges FJ, 2006, J CLIN ANESTH, V18, P67, DOI 10.1016/j.jclinane.2005.01.013; Goulson DT, 2007, CURR OPIN ANESTHESIO, V20, P195, DOI 10.1097/ACO.0b013e328136c1be; Hasanein R, 2011, EGYPT J ANAESTH, V27, P255, DOI 10.1016/j.egja.2011.07.009; Hashemi A, 2011, IRAN J PEDIATR HEMAT, V1, P126; Javid MJ, 2011, PERITON DIALYSIS INT, V31, P308, DOI 10.3747/pdi.2010.00110; Javid-Jafari M, 2012, ANESTH PAIN, V2, P274; Koo SW, 2006, ANESTH ANALG, V103, P1444, DOI 10.1213/01.ane.0000243334.83816.53; Kwok RFK, 2004, ANESTH ANALG, V98, P1044, DOI 10.1213/01.ANE.0000105911.66089.59; Menkiti ID, 2012, INT J OBSTET ANESTH, V21, P217, DOI 10.1016/j.ijoa.2012.04.004; Miller RD, 2010, MILLERS ANESTHESIA, P742; Miner JR, 2010, ACAD EMERG MED, V17, P604, DOI 10.1111/j.1553-2712.2010.00776.x; Naito Aya, 2009, Masui, V58, P77; Saadawy Iman, 2007, Middle East Journal of Anesthesiology, V19, P631; Safavi M, 2011, PAIN MED, V12, P1418, DOI 10.1111/j.1526-4637.2011.01205.x; Sanjay A, 2008, W J EMERG MED, V9, P20; Schmid RL, 1999, PAIN, V82, P11; Subramaniam K, 2004, ANESTH ANALG, V99, P482, DOI 10.1213/01.ANE.0000118109.12855.07; Tang YY, 2010, J MINIM INVAS GYN, V17, P325, DOI 10.1016/j.jmig.2010.01.017; Tosun Z, 2008, PEDIATR ANESTH, V18, P43, DOI 10.1111/j.1460-9592.2007.02380.x; Vallejo MC, 2002, J CLIN ANESTH, V14, P426, DOI 10.1016/S0952-8180(02)00391-4; Vosoughin M, 2012, J ANESTH, V26, P732, DOI 10.1007/s00540-012-1399-1; Willman EV, 2007, ANN EMERG MED, V49, P23, DOI 10.1016/j.annemergmed.2006.08.002	26	6	6	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0301-2115			EUR J OBSTET GYN R B	Eur. J. Obstet. Gynecol. Reprod. Biol.	SEP	2013	170	1					247	250		10.1016/j.ejogrb.2013.06.026			4	Obstetrics & Gynecology; Reproductive Biology	Obstetrics & Gynecology; Reproductive Biology	227OA	WOS:000325122000049	23870189				2020-06-30	J	van den Anker, JN				van den Anker, Johannes N.			Treating Pain in Newborn Infants: Navigating between Scylla and Charybdis	JOURNAL OF PEDIATRICS			English	Editorial Material							INTRAVENOUS PARACETAMOL		[van den Anker, Johannes N.] George Washington Univ, Sch Med & Hlth Sci, Childrens Natl Med Ctr, Dept Pediat,Div Pediat Clin Pharmacol, Washington, DC 20052 USA; [van den Anker, Johannes N.] George Washington Univ, Sch Med & Hlth Sci, Childrens Natl Med Ctr, Dept Pharmacol,Div Pediat Clin Pharmacol, Washington, DC 20052 USA; [van den Anker, Johannes N.] George Washington Univ, Sch Med & Hlth Sci, Childrens Natl Med Ctr, Dept Physiol,Div Pediat Clin Pharmacol, Washington, DC 20052 USA; [van den Anker, Johannes N.] George Washington Univ, Sch Med & Hlth Sci, Childrens Natl Med Ctr, Dept Integrat Syst Biol,Div Pediat Clin Pharmacol, Washington, DC 20052 USA	van den Anker, JN (reprint author), Childrens Natl Med Ctr, Dept Pediat, 111 Michigan Ave NW, Washington, DC 20010 USA.	jvandena@cnmc.org					Anand KJS, 2013, JAMA-J AM MED ASSOC, V309, P183, DOI 10.1001/jama.2012.208359; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; Ancora G, 2013, J PEDIATR-US, V163, P645, DOI 10.1016/j.jpeds.2013.02.039; Ceelie I, 2013, JAMA-J AM MED ASSOC, V309, P149, DOI 10.1001/jama.2012.148050; de Graaf J, 2013, PAIN, V154, P449, DOI 10.1016/j.pain.2012.12.006; Henderson AJ, 2013, PAEDIATR RESPIR REV, V14, P9, DOI 10.1016/j.prrv.2012.04.004; Knibbe CAJ, 2009, CLIN PHARMACOKINET, V48, P371, DOI 10.2165/00003088-200948060-00003; Taddio A, 1997, LANCET, V349, P599, DOI 10.1016/S0140-6736(96)10316-0; van den Anker JN, 2011, ARCH DIS CHILD, V96, P573, DOI 10.1136/adc.2011.211060	9	4	5	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476			J PEDIATR-US	J. Pediatr.	SEP	2013	163	3					618	619		10.1016/j.jpeds.2013.04.004			2	Pediatrics	Pediatrics	212LQ	WOS:000323985300002	23683745				2020-06-30	J	Ancora, G; Lago, P; Garetti, E; Pirelli, A; Merazzi, D; Mastrocola, M; Pierantoni, L; Faldella, G				Ancora, Gina; Lago, Paola; Garetti, Elisabetta; Pirelli, Anna; Merazzi, Daniele; Mastrocola, Maura; Pierantoni, Luca; Faldella, Giacomo			Efficacy and Safety of Continuous Infusion of Fentanyl for Pain Control in Preterm Newborns on Mechanical Ventilation	JOURNAL OF PEDIATRICS			English	Article							ROUTINE MORPHINE INFUSION; PROCEDURAL PAIN; ANALGESIA; INFANTS; TERM; CARE; MANAGEMENT; TOLERANCE; SEDATION; OUTCOMES	Objective To evaluate the analgesic superiority and the safety equivalence of continuous fentanyl infusions versus fentanyl boluses in preterm infants on mechanical ventilation. Study design In this multicenter, double-blind, randomized controlled trial, mechanically ventilated newborns (<= 32(+6) weeks gestational age) were randomized to fentanyl (continuous infusion of fentanyl plus open-label boluses of fentanyl) or placebo (continuous infusion of placebo plus open-label boluses of fentanyl). The primary endpoint was analgesic efficacy, as evaluated by the Echelle Douleur Inconfort Nouveau-Ne (EDIN) and Premature Infant Pain Profile scales. Safety variables were evaluated as well. Results Sixty-four infants were allocated to the fentanyl group, and 67 were allocated to the placebo group. The need for open-label boluses of fentanyl was similar in the 2 groups (P = .949). EDIN scores were comparable in the 2 groups; 65 of 961 (6.8%) EDIN scores were >6 in the fentanyl group and 91 of 857 (10.6%) in the placebo group (P = .003). The median Premature Infant Pain Profile score was clinically and statistically higher in the placebo group compared with the fentanyl group on days 1, 2, and 3 of treatment (P < .05). Mechanical ventilation at age 1 week was required in 27 of 64 infants in the fentanyl group (42.2%), compared with 17 of 67 infants in the placebo group (25.4%) (P = .042). The first cycle of mechanical ventilation was longer and the first meconium passage occurred later in the fentanyl group (P = .019 and .027, respectively). Conclusion In very preterm infants on mechanical ventilation, continuous fentanyl infusion plus open-label boluses of fentanyl does not reduce prolonged pain, but does reduce acute pain and increase side effects compared with open-label boluses of fentanyl alone.	[Ancora, Gina; Mastrocola, Maura; Pierantoni, Luca; Faldella, Giacomo] St Orsola Malpighi Hosp, Dept Womens Childs & Adolescents Hlth, Neonatol & Neonatal Intens Care Unit, Bologna, Italy; [Lago, Paola] Univ Padua, Dept Womans & Childs Hlth, Neonatal Intens Care Unit, Padua, Italy; [Garetti, Elisabetta] Univ Modena, Neonatal Intens Care Unit, I-41100 Modena, Italy; [Pirelli, Anna] San Gerardo Hosp, Fdn MBBM, Monza, Italy; [Merazzi, Daniele] St Anna Hosp, Neonatal Intens Care Unit, Como, Italy; [Merazzi, Daniele] St Anna Hosp, Como, Italy	Ancora, G (reprint author), Azienda Osped Univ St Orsola Malpighi, Neonatol & Neonatal Intens Care Unit, Dipartimento Salute Donna Bambino & Adolescente, Via Massarenti 13, Bologna, Italy.	gina.ancora@libero.it	ancora, gina/AAP-8311-2020	Lago, Paola/0000-0002-4866-0775; Pierantoni, Luca/0000-0001-8175-5488	Italian Medicines Agency	Approved and funded by the Italian Medicines Agency within the 2005 funding plan for independent research on drugs. The authors declare no conflicts of interest.	Agostino R, 2009, FARMACOTERAPIA NEONA, P168; Als Heidelise, 1998, Current Opinion in Pediatrics, V10, P138, DOI 10.1097/00008480-199804000-00004; Amer Acad Pediat, 2006, PEDIATRICS, V118, P2231, DOI 10.1542/peds.2006-2277; Anand KJS, 2010, PEDIATRICS, V125, pE1208, DOI 10.1542/peds.2009-0489; Anand KJS, 2004, LANCET, V363, P1673, DOI 10.1016/S0140-6736(04)16251-X; Anand KJS, 1999, ARCH PEDIAT ADOL MED, V153, P331; Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; Ancora G, 2009, ARCH DIS CHILD-FETAL, V94, pF35, DOI 10.1136/adc.2007.133777; Aranda JV, 2005, CLIN THER, V27, P877, DOI 10.1016/j.clinthera.2005.06.019; ARNOLD JH, 1990, ANESTHESIOLOGY, V73, P1136, DOI 10.1097/00000542-199012000-00011; Barker DP, 1996, ARCH DIS CHILD-FETAL, V75, pF187, DOI 10.1136/fn.75.3.F187; Bellieni CV, 2007, CLIN J PAIN, V23, P219, DOI 10.1097/AJP.0b013e31802e3bd7; Bellu R, 2008, COCHRANE DB SYST REV, V23; de Graaf J, 2011, PAIN, V152, P1391, DOI 10.1016/j.pain.2011.02.017; Debillon T, 2001, ARCH DIS CHILD-FETAL, V85, pF36, DOI 10.1136/fn.85.1.F36; Durrmeyer X, 2010, PEDIATR RES, V67, P117, DOI 10.1203/PDR.0b013e3181c8eef3; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; Ferguson SA, 2012, NEUROTOXICOL TERATOL, V34, P47, DOI 10.1016/j.ntt.2011.10.008; FIELD T, 1984, PEDIATRICS, V74, P1012; FINNEGAN LP, 1975, ADDICT DIS, V2, P141; Gomella TL, 2009, NEONATOLOGY MANAGEME, P750; GREER JJ, 1995, J PHYSIOL-LONDON, V485, P845, DOI 10.1113/jphysiol.1995.sp020774; Guinsburg R, 1998, J PEDIATR-US, V132, P954, DOI 10.1016/S0022-3476(98)70390-7; Hall RW, 2005, PEDIATRICS, V115, P1351, DOI 10.1542/peds.2004-1398; Johnston CC, 2003, ARCH PEDIAT ADOL MED, V157, P1084, DOI 10.1001/archpedi.157.11.1084; Kurz A, 2003, DRUGS, V63, P649, DOI 10.2165/00003495-200363070-00003; Lago P, 1998, ARCH DIS CHILD-FETAL, V79, pF194, DOI 10.1136/fn.79.3.F194; Lago P, 2009, ACTA PAEDIATR, V98, P932, DOI 10.1111/j.1651-2227.2009.01291.x; Ma PL, 2010, J CRIT CARE, V25, P451, DOI 10.1016/j.jcrc.2009.11.006; Orsini AJ, 1996, J PEDIATR-US, V129, P140, DOI 10.1016/S0022-3476(96)70201-9; Rotondi AJ, 2002, CRIT CARE MED, V30, P746, DOI 10.1097/00003246-200204000-00004; Saarenmaa E, 1999, J PEDIATR-US, V134, P144, DOI 10.1016/S0022-3476(99)70407-5; Simons SHP, 2003, JAMA-J AM MED ASSOC, V290, P2419, DOI 10.1001/jama.290.18.2419; Slater R, 2010, LANCET, V376, P1225, DOI 10.1016/S0140-6736(10)61303-7; Stevens B, 1996, CLIN J PAIN, V12, P13, DOI 10.1097/00002508-199603000-00004; Stevens B, 1999, NURS RES, V48, P35, DOI 10.1097/00006199-199901000-00006; Stevens B, 2002, CLIN PERINATOL, V29, P459, DOI 10.1016/S0095-5108(02)00016-7; Taddio A, 2002, CLIN PERINATOL, V29, P493, DOI 10.1016/S0095-5108(02)00017-9; Volpe JJ., 2001, NEUROLOGY NEWBORN, P451	39	26	29	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	SEP	2013	163	3					645	+		10.1016/j.jpeds.2013.02.039			8	Pediatrics	Pediatrics	212LQ	WOS:000323985300009	23582138				2020-06-30	J	Lee, SH; Gwak, MS; Choi, SJ; Park, HG; Kim, GS; Kim, MH; Ahn, HJ; Kim, J; Kwon, CH; Kim, TS				Lee, Sang Hyun; Gwak, Mi Sook; Choi, Soo Joo; Park, Hui Gyeong; Kim, Gaab Soo; Kim, Myung Hee; Ahn, Hyun Joo; Kim, Jieae; Kwon, Choon Hyuck; Kim, Tae Seok			Prospective, randomized study of ropivacaine wound infusion versus intrathecal morphine with intravenous fentanyl for analgesia in living donors for liver transplantation	LIVER TRANSPLANTATION			English	Article							ABDOMINAL-WALL COMPLICATIONS; PATIENT-CONTROLLED ANALGESIA; POSTOPERATIVE PAIN-CONTROL; GRAND-MAL CONVULSION; HEPATOCELLULAR-CARCINOMA; EPIDURAL CATHETER; SURGERY; HEPATECTOMY; MANAGEMENT; INSTILLATION	Postoperative analgesia and care for living liver donors have become particular interests for clinicians as the use of living donor liver transplantation has increased. Local anesthetic-based analgesia has been known to provide effective pain control. In this prospective, randomized study, we compared the postoperative analgesic efficacy of local anesthetic-based analgesia (PainBuster) with the efficacy of opioid-based analgesia [intrathecal morphine (ITM) with intravenous (IV) fentanyl] in liver donors. Forty adult donors were randomly allocated to 1 of 2 groups: an ITM/IV fentanyl group (n = 21) and a PainBuster group (n = 19). Donors in the PainBuster group received 0.5% ropivacaine via a multi-orifice catheter (ON-Q PainBuster) placed at the wound. Donors in the ITM/IV fentanyl group received ITM sulfate (400 g) preoperatively and a continuous IV fentanyl infusion postoperatively. A visual analogue scale (VAS) at rest and with coughing and rescue IV fentanyl and meperidine consumption were assessed for 72 hours after the operation. Side effects, including sedation, dizziness, nausea, vomiting, pruritus, respiratory depression, wound seroma or hematoma, and the first time to flatus, were recorded. The VAS score at rest during the first 12 postoperative hours was significantly lower for the ITM/IV fentanyl group. At other times, the VAS scores were comparable between the groups. In the PainBuster group, rescue IV fentanyl and meperidine use was significantly reduced 24 to 48 hours and 48 to 72 hours after surgery in comparison with the first 24 postoperative hours. The time to first flatus was significantly reduced in the PainBuster group. There were no differences in side effects. In conclusion, analgesia was more satisfactory with ITM/IV fentanyl versus PainBuster during the first 12 hours after surgery, but they became comparable thereafter, with a shortened bowel recovery time in the PainBuster group. The concurrent use of ITM with PainBuster may be considered in a future investigation. Liver Transpl 19:1036-1045, 2013. (c) 2013 AASLD.	[Lee, Sang Hyun; Gwak, Mi Sook; Choi, Soo Joo; Park, Hui Gyeong; Kim, Gaab Soo; Kim, Myung Hee; Ahn, Hyun Joo; Kim, Jieae] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Anesthesiol & Pain Med, Seoul, South Korea; [Kwon, Choon Hyuck] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul, South Korea; [Lee, Sang Hyun] Hallym Univ, Coll Med, Dongtan Sacred Heart Hosp, Dept Anesthesiol & Pain Med, Hwasung City, South Korea; [Kim, Tae Seok] Catholic Univ Korea, Uljeongbu St Marys Hosp, Dept Surg, Seoul, South Korea	Choi, SJ (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Anesthesiol & Pain Med, Seoul, South Korea.	sjoo.choi@samsung.com	Kwon, Choon Hyuck David/H-7263-2019	Kwon, Choon Hyuck David/0000-0002-1082-3321; Kim, Myunghee/0000-0002-1340-435X			Beaussier M, 2007, ANESTHESIOLOGY, V107, P461, DOI 10.1097/01.anes.0000278903.91986.19; Belghiti J, 2009, TRANSPLANTATION, V88, P19, DOI 10.1097/TP.0b013e3181a9ea53; Bianconi M, 2004, ANESTH ANALG, V98, P166, DOI 10.1213/01.ANE.0000093310.47375.44; Bianconi M, 2003, BRIT J ANAESTH, V91, P830, DOI 10.1093/bja/aeg277; Borromeo CJ, 2000, ANESTH ANALG, V91, P1139, DOI 10.1097/00000539-200011000-00018; Callum JL, 2009, TRANSFUS MED REV, V23, P177, DOI 10.1016/j.tmrv.2009.03.001; Cammu G, 2002, EUR J ANAESTH, V19, P93, DOI 10.1017/S0265021502000169; Chan SK, 2010, ANAESTHESIA, V65, P1180, DOI 10.1111/j.1365-2044.2010.06530.x; Chhibber A, 2007, LIVER TRANSPLANT, V13, P537, DOI 10.1002/lt.21074; Choi SJ, 2007, LIVER TRANSPLANT, V13, P62, DOI 10.1002/lt.20933; Clarke H, 2011, LIVER TRANSPLANT, V17, P315, DOI 10.1002/lt.22221; Coolsen MME, 2013, HPB, V15, P245, DOI 10.1111/j.1477-2574.2012.00572.x; Cywinski JB, 2004, ANESTH ANALG, V99, P1747, DOI 10.1213/01.ANE.0000136423.17446.5D; De Villa V, 2007, ONCOLOGIST, V12, P1321, DOI 10.1634/theoncologist.12-11-1321; Dernedde M, 2004, ANESTH ANALG, V98, P521, DOI 10.1213/01.ANE.0000096008.24193.05; Fredman B, 2001, ANESTH ANALG, V92, P189; Harvey KP, 2009, AM J SURG, V198, P231, DOI 10.1016/j.amjsurg.2008.10.015; Hashikura Y, 2009, TRANSPLANTATION, V88, P110, DOI 10.1097/TP.0b013e3181aaccb0; Heavner JE, 2012, ANESTHESIOLOGY, P767; Heisterkamp J, 2008, LIVER TRANSPLANT, V14, P1655, DOI 10.1002/lt.21594; Heisterkamp J, 2009, LIVER TRANSPLANT, V15, P453, DOI 10.1002/lt.21750; Ho AMH, 2004, BRIT J ANAESTH, V93, P458, DOI 10.1093/bja/aeh212; Holte K, 2002, DRUGS, V62, P2603, DOI 10.2165/00003495-200262180-00004; Hwang GS, 2010, CURR OPIN ORGAN TRAN, V15, P377, DOI 10.1097/MOT.0b013e3283387f75; Iwama H, 2005, EUR J ANAESTH, V22, P322, DOI 10.1017/S0265021505280535; Ko JS, 2009, LIVER TRANSPLANT, V15, P381, DOI 10.1002/lt.21625; Lauprecht AE, 2011, J ANESTH, V25, P369, DOI 10.1007/s00540-011-1107-6; Lee SG, 2006, J GASTROEN HEPATOL, V21, P572, DOI 10.1111/j.1440-1746.2006.04283.x; Lee SG, 2009, SURG TODAY, V39, P367, DOI 10.1007/s00595-008-3917-1; Lee S, 2010, J HEPATO-BIL-PAN SCI, V17, P539, DOI 10.1007/s00534-009-0167-6; Marret E, 2008, BRIT J SURG, V95, P1331, DOI 10.1002/bjs.6375; Moore KL, 1992, CLIN ORIENTED ANATOM, P137; Moussa Ashraf A., 2008, Middle East Journal of Anesthesiology, V19, P789; Muller M, 2001, BRIT J ANAESTH, V87, P784, DOI 10.1093/bja/87.5.784; Niraj G, 2011, ANAESTHESIA, V66, P465, DOI 10.1111/j.1365-2044.2011.06700.x; Revie EJ, 2012, HPB, V14, P611, DOI 10.1111/j.1477-2574.2012.00490.x; Sato Y, 2003, HEPATO-GASTROENTEROL, V50, P196; Satsumae T, 2008, BRIT J ANAESTH, V101, P860, DOI 10.1093/bja/aen297; Schumann R, 2004, LIVER TRANSPLANT, V10, P363, DOI 10.1002/lt.20059; Slevin KA, 2012, ANESTHESIOLOGY, P1297; Story SK, 2009, DIGEST SURG, V26, P265, DOI 10.1159/000227765; Sun YX, 2012, DIS COLON RECTUM, V55, P1183, DOI 10.1097/DCR.0b013e318259bcd8; Wang LW, 2010, ANZ J SURG, V80, P794, DOI 10.1111/j.1445-2197.2010.05339.x; Wen TF, 2007, HEPATOB PANCREAT DIS, V6, P590; Yong BH, 2000, TRANSPLANT P, V32, P2110, DOI 10.1016/S0041-1345(00)01592-X	45	15	16	0	11	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1527-6465			LIVER TRANSPLANT	Liver Transplant.	SEP	2013	19	9					1036	1045		10.1002/lt.23691			10	Gastroenterology & Hepatology; Surgery; Transplantation	Gastroenterology & Hepatology; Surgery; Transplantation	208CU	WOS:000323654800014	23788468				2020-06-30	J	Kharasch, ED; Rosow, CE				Kharasch, Evan D.; Rosow, Carl E.			Assessing the Utility of the Utility Function	ANESTHESIOLOGY			English	Editorial Material							MODEL; PHARMACODYNAMICS; PHARMACOKINETICS		[Kharasch, Evan D.] Washington Univ, Dept Anesthesiol, Div Clin & Translat Res, St Louis, MO 63130 USA; [Kharasch, Evan D.] Washington Univ, Div Clin & Translat Res, Dept Biochem & Mol Biophys, St Louis, MO USA; [Rosow, Carl E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA	Kharasch, ED (reprint author), Washington Univ, Dept Anesthesiol, Div Clin & Translat Res, St Louis, MO 63130 USA.	kharasch@wustl.edu			National Institutes of Health (Bethesda, Maryland)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-DA14211, R01-DA02931]	Funding was provided by the National Institutes of Health (Bethesda, Maryland) Grants R01-DA14211 and R01-DA02931 (to Dr. Kharasch). The authors declare no competing interests.	Avram MJ, 2003, ANESTHESIOLOGY, V99, P1078, DOI 10.1097/00000542-200311000-00013; Bailey JM, 2002, CLIN PHARMACOKINET, V41, P793, DOI 10.2165/00003088-200241110-00001; Boom M, 2013, ANESTHESIOLOGY, V119, P663, DOI 10.1097/ALN.0b013e31829ce4cb; Fedorov V, 2009, PHARM STAT, V8, P50, DOI 10.1002/pst.331; Fedorov VV, 2007, J BIOPHARM STAT, V17, P1085, DOI 10.1080/10543400701645132; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; HENTHORN TK, 1992, AM J PHYSIOL, V262, pH903; HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003; HULL CJ, 1978, BRIT J ANAESTH, V50, P1113, DOI 10.1093/bja/50.11.1113; PRICE HL, 1960, ANESTHESIOLOGY, V21, P40, DOI 10.1097/00000542-196001000-00008; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; Sheiner L B, 1978, Ann N Y Acad Sci, V304, P112, DOI 10.1111/j.1749-6632.1978.tb25582.x; SHEINER LB, 1979, CLIN PHARMACOL THER, V25, P358; Zanderigo E, 2006, ANESTHESIOLOGY, V104, P742, DOI 10.1097/00000542-200604000-00019	14	9	9	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	SEP	2013	119	3					504	506		10.1097/ALN.0b013e31829ce70b			3	Anesthesiology	Anesthesiology	205CX	WOS:000323420000009	23770599	Green Accepted			2020-06-30	J	Boom, M; Olofsen, E; Neukirchen, M; Fussen, R; Hay, J; Groeneveld, GJ; Aarts, L; Sarton, E; Dahan, A				Boom, Merel; Olofsen, Erik; Neukirchen, Meike; Fussen, Rene; Hay, Justin; Groeneveld, Geert Jan; Aarts, Leon; Sarton, Elise; Dahan, Albert			Fentanyl Utility Function: A Risk-Benefit Composite of Pain Relief and Breathing Responses	ANESTHESIOLOGY			English	Article							COMPARATIVE PHARMACODYNAMICS; VENTILATORY RESPONSE; SEX-DIFFERENCES; ANALGESIA; BUPRENORPHINE; ALFENTANIL; REMIFENTANIL; QUANTITATION	Introduction: Integrating opioid risk and benefit into a single function may give a useful single measure of the opioid's positive and negative effects. An explorative study on the effects of fentanyl on antinociception and respiratory depression was performed to construct fentanyl risk-benefit (utility) functions. Methods: Twelve volunteers received a 3.5-g/kg fentanyl intravenous injection on 2 separate study days. On one occasion, ventilation at a clamped increased carbon dioxide concentration was measured and on another the pain tolerance to electrical stimulation. In both sessions, arterial plasma samples were obtained. The data were analyzed with a population pharmacokinetic-pharmacodynamic model. A simulation study was performed, using the model parameter estimates and their variances, in which simulated subjects received 3.5 g/kg of fentanyl. The resultant distributions were used to calculate the utility functions, defined as the probability of at least 50% analgesia (an increase in pain tolerance by 50%) minus the probability of at least 50% respiratory depression (a reduction in ventilation by 50%). Utility functions were constructed in concentration and time domains. Results: Fentanyl produced significant respiratory depression and analgesia. The pharmacokinetic and pharmacodynamic models adequately described the data. The constructed utility functions were negative at effect-site concentrations of greater than 0.5ng/ml in the first 90min after the 3.5 g/kg bolus infusion. Conclusions: Utility functions based on fentanyl's experimental effects on respiration and pain relief were successfully constructed. These functions are useful in multiple effect comparisons among experimental drugs. Further studies are required to assess whether this risk-benefit analysis is valuable in clinical practice.	[Boom, Merel; Olofsen, Erik; Aarts, Leon; Sarton, Elise; Dahan, Albert] Leiden Univ, Med Ctr, Dept Anesthesiol, NL-2300 RC Leiden, Netherlands; [Neukirchen, Meike; Fussen, Rene] Grunenthal GmbH, Compound Dev & Branding, Aachen, Germany; [Hay, Justin; Groeneveld, Geert Jan] Ctr Human Drug Res, Leiden, Netherlands	Dahan, A (reprint author), Leiden Univ, Med Ctr, Dept Anesthesiol, P5-Q,POB 9600, NL-2300 RC Leiden, Netherlands.	a.dahan@lumc.nl			Grunenthal GmbH, Aachen, Germany; Mundipharma Research, Ltd. (Cambridge, United Kingdom); Galleon Pharmaceuticals Corporation (Horsham, Pennsylvania)	Received from the Leiden University Medical Center, Leiden, The Netherlands. Submitted for publication July 7, 2012. Accepted for publication April 12, 2013. This study was supported in part by Grunenthal GmbH, Aachen, Germany. The Anesthesia and Pain Research Unit has in recent years been involved in studies on analgesic agents and respiration sponsored by Grunenthal GmbH (Aachen, Germany), Mundipharma Research, Ltd. (Cambridge, United Kingdom), and Galleon Pharmaceuticals Corporation (Horsham, Pennsylvania). This study in part has been presented at the 2011 Society of Anesthesia and Sleep Medicine meeting, October 14, 2011, Chicago, Illinois, and at the 2012 American Society of Anesthesiologists meeting, October 15, 2012, Washington, D. C. (Abstract A998), and at the Annual Research Conference of the Dutch Society of Anesthesiologists, September 28, 2012, Ede, The Netherlands. Dr. Boom and Mr. Olofsen contributed equally to this article.	Babenco HD, 2000, ANESTHESIOLOGY, V92, P393, DOI 10.1097/00000542-200002000-00020; BEAL BL, 1989, NONMEM USERS GUIDE; Cartwright CR, 1998, ANESTHESIOLOGY, V89, P612, DOI 10.1097/00000542-199809000-00009; CHOI SD, 1985, ANESTHESIOLOGY, V62, P442, DOI 10.1097/00000542-198504000-00012; Coda BA, 1999, ANESTHESIOLOGY, V90, P98, DOI 10.1097/00000542-199901000-00015; Cullberg M, 2005, CLIN PHARMACOL THER, V77, P279, DOI 10.1016/j.clpt.2004.11.001; DAHAN A, 1990, J PHYSIOL-LONDON, V428, P485, DOI 10.1113/jphysiol.1990.sp018223; Dahan A, 2005, BRIT J ANAESTH, V94, P825, DOI 10.1093/bja/aei145; Dahan A, 2004, ANESTHESIOLOGY, V101, P1201, DOI 10.1097/00000542-200411000-00021; Dahan A, 2007, PLOS MED, V4, P1195, DOI 10.1371/journal.pmed.0040239; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; Hill LR, 2009, EUR J ANAESTH, V26, P435, DOI 10.1097/EJA.0b013e32831dccf4; Lotsch J, 2006, CLIN PHARMACOKINET, V45, P1051; MCEWAN AI, 1993, ANESTHESIOLOGY, V78, P864, DOI 10.1097/00000542-199305000-00009; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; Olofsen E, 2005, ANESTHESIOLOGY, V103, P130, DOI 10.1097/00000542-200507000-00020; Olofsen E, 2010, ANESTHESIOLOGY, V112, P1382, DOI 10.1097/ALN.0b013e3181d69087; Overdyk F, 2012, ANN M AM SOC AN WASH; Sarton E, 2000, ANESTHESIOLOGY, V93, P1245, DOI 10.1097/00000542-200011000-00018; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; Yassen A, 2007, CLIN PHARMACOL THER, V81, P50, DOI 10.1038/sj.clpt.6100025; Yassen A, 2008, PHARM RES, V25, P183, DOI 10.1007/s11095-007-9440-z	23	20	21	4	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	SEP	2013	119	3					663	674		10.1097/ALN.0b013e31829ce4cb			12	Anesthesiology	Anesthesiology	205CX	WOS:000323420000026	23756452				2020-06-30	J	Hawley, P				Hawley, Pippa			Case report of severe bradycardia due to transdermal fentanyl	PALLIATIVE MEDICINE			English	Article						Palliative care; side effects; bradycardia; fentanyl	THERAPY	Background: This case report describes a patient who developed severe bradycardia due to transdermal fentanyl. There have been no prior case reports of this occurring in palliative care, but the frequency of association of fentanyl with bradycardia in the anesthesia setting suggests it may be more common than realized. Palliative care settings often have a policy of not routinely checking vital signs, and symptoms of bradycardia could be misinterpreted as the dying process. Case presentation: A patient with recurrent ovarian cancer was admitted with nausea and abdominal pain due to bowel obstruction and fever from a urinary tract infection. A switch from injectable hydromorphone to transdermal fentanyl resulted in symptomatic severe bradycardia within 36 h, without any other signs of opioid toxicity and with good analgesic effect. Case management: The fentanyl patch was removed. Atropine was not required. Case outcome: The patient made an uneventful recovery. Transdermal buprenorphine was subsequently used satisfactorily for long-term background pain control, with additional hydromorphone when needed. Conclusions: The delayed absorption of fentanyl via the transdermal route makes early identification of fentanyl-induced bradycardia key to prompt reversal. Patients with resting or relative bradycardia may be at higher than average risk.	[Hawley, Pippa] BC Canc Agcy, Pain & Symptom Management Palliat Care Program, Vancouver, BC V5Z 4E6, Canada	Hawley, P (reprint author), BC Canc Agcy, Vancouver Ctr, Pain & Symptom Management Palliat Care Program, 600 West 10th Ave, Vancouver, BC V5Z 4E6, Canada.	pippahawley@shaw.ca			Gordon Dunn Pioneer Award from the Prostate Cancer Foundation of BC	The author received the 2010 Gordon Dunn Pioneer Award from the Prostate Cancer Foundation of BC. This salary support award facilitated the preparation of this report.	BOVILL JG, 1984, ANESTHESIOLOGY, V61, P731; Buchanan D, 2010, PALLIATIVE MED, V24, P742, DOI 10.1177/0269216310373526; COVENTRY DM, 1987, ANAESTHESIA, V42, P835, DOI 10.1111/j.1365-2044.1987.tb04106.x; Gonullu G, 2012, SUPPORT CARE CANCER, V20, P1435, DOI 10.1007/s00520-011-1226-5; Griffioen KJS, 2004, BRAIN RES, V1007, P109, DOI 10.1016/j.brainres.2004.02.010; Prakanrattana Ungkab, 2002, Journal of the Medical Association of Thailand, V85, pS807; Prommer E, 2009, J PALLIAT MED, V12, P947, DOI 10.1089/jpm.2009.0051; Yeh ETH, 2009, J AM COLL CARDIOL, V53, P2231, DOI 10.1016/j.jacc.2009.02.050	8	2	3	0	1	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2163			PALLIATIVE MED	Palliat. Med.	SEP	2013	27	8					793	795		10.1177/0269216312472383			3	Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal	Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine	203XE	WOS:000323327100013	23341102				2020-06-30	J	Webster, LR; Slevin, KA; Narayana, A; Earl, CQ; Yang, RH				Webster, Lynn R.; Slevin, Kieran A.; Narayana, Arvind; Earl, Craig Q.; Yang, Ronghua			Fentanyl Buccal Tablet Compared with Immediate-Release Oxycodone for the Management of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Cancer and Noncancer Pain: A Randomized, Double-Blind, Crossover Study Followed by a 12-Week Open-Label Phase to Evaluate Patient Outcomes	PAIN MEDICINE			English	Article						Breakthrough Pain; Fentanyl Buccal Tablet; Opioid Tolerant; Oxycodone	CLINICAL-PRACTICE GUIDELINE; AMERICAN ACADEMY; TREATED PATIENTS; LONG-TERM; PREVALENCE; SAFETY; HOSPICE; SOCIETY; RELIEF	Abstract Objective Evaluate analgesic efficacy, functional benefit, and patient satisfaction with fentanyl buccal tablet vs immediate-release oxycodone for breakthrough pain (BTP). Design Randomized, double-blind, active-controlled crossover trial and 12-week open-label extension. Setting Forty-two U.S. sites. Patients Opioid-tolerant patients with predominantly chronic noncancer pain experiencing BTP. Intervention Patients were randomized to open-label titration periods with fentanyl buccal tablet followed by oxycodone or vice versa for BTP management. After titrating to a successful dose of both medications (single dose providing adequate analgesia without unacceptable adverse events), patients were re-randomized to treat 10 BTP episodes with one medication and 10 with the other. Outcome Measures The primary efficacy measure was pain intensity (PI) difference 15 minutes postdose. Secondary measures included PI difference 5, 10, 30, 45, and 60 minutes postdose; sum of PI differences 30 and 60 minutes postdose; >= 33% and >= 50% reduction in PI; and pain relief. Questionnaires assessed functional status/satisfaction. Results Of 213 patients enrolled, 149 achieved a successful dose of both medications; 131 completed the double-blind phase and 112 the open-label phase. PI difference at 15 minutes (mean [standard deviation]) was greater with fentanyl buccal tablet (0.88 [1.20]) vs oxycodone (0.76 [1.13]; P < 0.001). Patients preferred fentanyl buccal tablet (47%) over oxycodone (35%); 18% had no preference. Patients and clinicians reported consistently better functional improvement and satisfaction with fentanyl buccal tablet vs short-acting opioids (P < 0.05). Conclusions Fentanyl buccal tablet was associated with rapid onset of analgesia and improvements in functional status and patient satisfaction compared with immediate-release oxycodone.	[Webster, Lynn R.] CRI Lifetree, Salt Lake City, UT 84106 USA; [Slevin, Kieran A.] Virtua Pain & Spine Specialists, Voorhees, NJ USA; [Narayana, Arvind; Earl, Craig Q.; Yang, Ronghua] Teva Pharmaceut, Frazer, PA USA	Webster, LR (reprint author), CRI Lifetree, 3838 South 700 East,Suite 200, Salt Lake City, UT 84106 USA.	lrwebstermd@gmail.com			Cephalon, Inc. (Frazer, PA, USA); Teva Pharmaceuticals	This study (Clinicaltrials.gov, NCT00813488) was sponsored by Cephalon, Inc. (Frazer, PA, USA), now a wholly owned subsidiary of Teva Pharmaceuticals. Writing support was provided by Peloton Advantage, LLC, funded by Teva Pharmaceuticals.	[Anonymous], 2011, FENTORA PACK INS; Ashburn MA, 2011, ANESTH ANALG, V112, P693, DOI 10.1213/ANE.0b013e318209d320; Chou R, 2009, J PAIN, V10, P147, DOI 10.1016/j.jpain.2008.10.007; Chou R, 2009, J PAIN, V10, P131, DOI 10.1016/j.jpain.2008.10.009; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Farrar J, 2008, J PAIN S2, V9, P39; Farrar JT, 2010, PAIN MED, V11, P1313, DOI 10.1111/j.1526-4637.2010.00939.x; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Fine PG, 2010, J PAIN SYMPTOM MANAG, V40, P747, DOI 10.1016/j.jpainsymman.2010.02.009; Fine PG, 2010, PAIN MED, V11, P1024, DOI 10.1111/j.1526-4637.2010.00891.x; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; International Conference on Harmonisation Working Group, 1996, ICH HARM TRIP GUID G; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Passik S, 2011, PAINWEEK 2011 NAT C; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; Portenoy Russell K, 2010, J Opioid Manag, V6, P97; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Stull DE, 2011, 30 ANN SCI M AM PAIN; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279; Zeppetella G, 2001, PALLIATIVE MED, V15, P243, DOI 10.1191/026921601678576220; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5	29	19	19	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	SEP	2013	14	9					1332	1345		10.1111/pme.12184			14	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	216TY	WOS:000324308600009	23855816	Bronze			2020-06-30	J	Zhao, LH; Shi, ZH; Yin, NN; Zhou, JX				Zhao, Li-Hong; Shi, Zhong-Hua; Yin, Ning-Ning; Zhou, Jian-Xin			Use of dexmedetomidine for prophylactic analgesia and sedation in delayed extubation patients after craniotomy: a study protocol and statistical analysis plan for a randomized controlled trial	TRIALS			English	Article						Dexmedetomidine; Analgesia; Sedation; Prophylactic; Delayed extubation; Craniotomy	POSTOPERATIVE PAIN; AGONIST DEXMEDETOMIDINE; MARKER; HIPPOCAMPUS; PROTEIN; S100B; RAT	Background: Pain and agitation are common in patients after craniotomy. They can result in tachycardia, hypertension, immunosuppression, increased catecholamine production and increased oxygen consumption. Dexmedetomidine, an alpha-2 agonist, provides adequate sedation without respiratory depression, while facilitating frequent neurological evaluation. Methods/design: The study is a prospective, randomized, double-blind, controlled, parallel-group design. Consecutive patients are randomly assigned to one of the two treatment study groups, labeled 'Dex group' or 'Saline group.' Dexmedetomidine group patients receive a continuous infusion of 0.6 mu g/kg/h (10 ug/ml). Placebo group patients receive a maintenance infusion of 0.9% sodium chloride for injection at a volume and rate equal to that of dexmedetomidine. The mean percentages of time in optimal sedation, vital signs, various and adverse events, the percentage of patients requiring propofol for rescue to achieve/maintain targeted sedation (Sedation-Agitation Scale, SAS 3 to 4) and total dose of propofol required throughout the study drug infusion are collected. The percentage of patients requiring fentanyl for additional rescue to analgesia and total dose of fentanyl required are recorded. The effects of dexmedetomidine on hemodynamic and recovery responses during extubation are measured. Intensive care unit and hospital length of stay also are collected. Plasma levels of epinephrine, norepinephrine, dopamine, cortisol, neuron-specific enolase and S100-B are measured before infusion (T1), at two hours (T2), four hours (T3) and eight hours (T4) after infusion and at the end of infusion (T5) in 20 patients in each group. Discussion: The study has been initiated as planned in July 2012. One interim analysis advised continuation of the trial. The study will be completed in July 2013.	[Zhao, Li-Hong; Shi, Zhong-Hua; Yin, Ning-Ning; Zhou, Jian-Xin] Capital Med Univ, Beijing Tiantan Hosp, Dept Crit Care Med, Beijing 100050, Peoples R China	Zhou, JX (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Crit Care Med, 6 Tiantan Xili, Beijing 100050, Peoples R China.	zhoujx.cn@gmail.com		Shi, Zhong-Hua/0000-0001-6331-0397	Beijing Health Bureau [2009-3-28]	The study was funded by Beijing Health Bureau (No: 2009-3-28). The sponsors had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The authors wish to acknowledge the support of John Boyd, professor, University of British Columbia, in revising the manuscript for important intellectual content.	Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Basali A, 2000, ANESTHESIOLOGY, V93, P48, DOI 10.1097/00000542-200007000-00012; Bekker A, 2005, NEUROSURGERY, V57, P1, DOI 10.1227/01.NEU.0000163476.42034.A1; Bekker AY, 2004, J NEUROSURG ANESTH, V16, P126, DOI 10.1097/00008506-200404000-00004; Beretta L, 2011, MINERVA ANESTESIOL, V77, P828; Chrysostomou C, 2008, EXPERT OPIN DRUG MET, V4, P619, DOI [10.1517/17425255.4.5.619, 10.1517/17425255.4.5.619 ]; Cosar M, 2009, SURG NEUROL, V71, P54, DOI 10.1016/j.surneu.2007.08.020; DeBenedittis G, 1996, NEUROSURGERY, V38, P466, DOI 10.1227/00006123-199603000-00008; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Epstein J, 1999, CRIT CARE CLIN, V15, P17, DOI 10.1016/S0749-0704(05)70037-3; Eser O, 2008, BRAIN RES, V1218, P250, DOI 10.1016/j.brainres.2008.04.045; Fairbanks CA, 2002, J PHARMACOL EXP THER, V300, P282, DOI 10.1124/jpet.300.1.282; Fraser GL, 2000, PHARMACOTHERAPY, V20, P75, DOI 10.1592/phco.20.1.75.34663; Gehlbach Brian K, 2002, Curr Opin Crit Care, V8, P290, DOI 10.1097/00075198-200208000-00004; Gerlach AT, 2007, ANN PHARMACOTHER, V41, P245, DOI 10.1345/aph.1H314; Gottschalk A, 2007, J NEUROSURG, V106, P210, DOI 10.3171/jns.2007.106.2.210; HOFFMAN WE, 1991, ANESTHESIOLOGY, V75, P328, DOI 10.1097/00000542-199108000-00022; Huupponen E, 2008, ACTA ANAESTH SCAND, V52, P289, DOI 10.1111/j.1399-6576.2007.01537.x; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Klimek M, 2006, J NEUROSURG, V104, P350, DOI 10.3171/jns.2006.104.3.350; Kuhmonen J, 1997, ANESTHESIOLOGY, V87, P371, DOI 10.1097/00000542-199708000-00025; MAIER C, 1993, ANESTHESIOLOGY, V79, P306, DOI 10.1097/00000542-199308000-00016; Mordhorst C, 2010, J NEUROSURG ANESTH, V22, P202, DOI 10.1097/ANA.0b013e3181df0600; Nelson LE, 2003, ANESTHESIOLOGY, V98, P428, DOI 10.1097/00000542-200302000-00024; Nemergut EC, 2007, BEST PRACT RES-CLIN, V21, P557, DOI 10.1016/j.bpa.2007.06.005; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Prielipp RC, 2002, ANESTH ANALG, V95, P1052, DOI 10.1097/00000539-200210000-00048; Quiney N, 1996, BRIT J NEUROSURG, V10, P295, DOI 10.1080/02688699650040179; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Rothoerl RD, 2000, ACT NEUR S, V76, P97; Sanchez-Pena P, 2008, CRIT CARE MED, V36, P2267, DOI 10.1097/CCM.0b013e3181809750; Soliman Rabie Nasr, 2011, Middle East Journal of Anesthesiology, V21, P325; Talke P, 2000, ANESTH ANALG, V90, P834, DOI 10.1213/00000539-200004000-00011; Tan JA, 2010, INTENS CARE MED, V36, P926, DOI 10.1007/s00134-010-1877-6; Tanskanen PE, 2006, BRIT J ANAESTH, V97, P658, DOI 10.1093/bja/ael220; Thibault M, 2007, CAN J ANAESTH, V54, P544, DOI 10.1007/BF03022318; Tobias JD, 2004, SOUTH MED J, V97, P451, DOI 10.1097/00007611-200405000-00007; Turan G, 2008, EUR J ANAESTH, V25, P816, DOI 10.1017/S0265021508004201; Venn RM, 2001, BRIT J ANAESTH, V87, P684, DOI 10.1093/bja/87.5.684; Venn RM, 1999, ANAESTHESIA, V54, P1136, DOI 10.1046/j.1365-2044.1999.01114.x; Venn RM, 2000, CRIT CARE, V4, P302, DOI 10.1186/cc712; Weinbroum AA, 2001, EUR J SURG, V167, P563; Weiss N, 2006, ANESTHESIOLOGY, V104, P658, DOI 10.1097/00000542-200604000-00008; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933	45	5	6	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1745-6215			TRIALS	Trials	AUG 13	2013	14								251	10.1186/1745-6215-14-251			6	Medicine, Research & Experimental	Research & Experimental Medicine	201VK	WOS:000323170900001	23941549	DOAJ Gold, Green Published			2020-06-30	J	Ide, S; Nishizawa, D; Fukuda, K; Kasai, S; Hasegawa, J; Hayashida, M; Minami, M; Ikeda, K				Ide, Soichiro; Nishizawa, Daisuke; Fukuda, Ken-ichi; Kasai, Shinya; Hasegawa, Junko; Hayashida, Masakazu; Minami, Masabumi; Ikeda, Kazutaka			Association between Genetic Polymorphisms in Ca(v)2.3 (R-type) Ca2+ Channels and Fentanyl Sensitivity in Patients Undergoing Painful Cosmetic Surgery	PLOS ONE			English	Article							E CALCIUM-CHANNEL; MORPHINE ANALGESIA; ANTAGONISTS; DEPENDENCE; TOLERANCE; RESPONSES; SUBUNIT; POWER	Individual differences in the sensitivity to fentanyl, a widely used opioid analgesic, lead to different proper doses of fentanyl, which can hamper effective pain treatment. Voltage-activated Ca2+ channels (VACCs) play a crucial role in the nervous system by controlling membrane excitability and calcium signaling. Ca(v)2.3 (R-type) VACCs have been especially thought to play critical roles in pain pathways and the analgesic effects of opioids. However, unknown is whether single-nucleotide polymorphisms (SNPs) of the human CACNA1E (calcium channel, voltage-dependent, R type, alpha 1E subunit) gene that encodes Ca(v)2.3 VACCs influence the analgesic effects of opioids. Thus, the present study examined associations between fentanyl sensitivity and SNPs in the human CACNA1E gene in 355 Japanese patients who underwent painful orofacial cosmetic surgery, including bone dissection. We first conducted linkage disequilibrium (LD) analyses of 223 SNPs in a region that contains the CACNA1E gene using genomic samples from 100 patients, and a total of 13 LD blocks with 42 Tag SNPs were observed within and around the CACNA1E gene region. In the preliminary study using the same 100 genomic samples, only the rs3845446 A/G SNP was significantly associated with perioperative fentanyl use among these 42 Tag SNPs. In a confirmatory study using the other 255 genomic samples, this SNP was also significantly associated with perioperative fentanyl use. Thus, we further analyzed associations between genotypes of this SNP and all of the clinical data using a total of 355 samples. The rs3845446 A/G SNP was associated with intraoperative fentanyl use, 24 h postoperative fentanyl requirements, and perioperative fentanyl use. Subjects who carried the minor G allele required significantly less fentanyl for pain control compared with subjects who did not carry this allele. Although further validation is needed, the present findings show the possibility of the involvement of CACNA1E gene polymorphisms in fentanyl sensitivity.	[Ide, Soichiro; Nishizawa, Daisuke; Kasai, Shinya; Hasegawa, Junko; Ikeda, Kazutaka] Tokyo Metropolitan Inst Med Sci, Addict Subst Project, Tokyo 113, Japan; [Ide, Soichiro; Minami, Masabumi] Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sapporo, Hokkaido, Japan; [Fukuda, Ken-ichi] Suidoubashi Hosp, Tokyo Dent Coll, Orofacial Pain Ctr, Dept Oral Hlth & Clin Sci,Div Dent Anesthesiol, Tokyo, Japan; [Hayashida, Masakazu] Juntendo Univ, Sch Med, Dept Anesthesiol & Pain Med, Tokyo 113, Japan	Ikeda, K (reprint author), Tokyo Metropolitan Inst Med Sci, Addict Subst Project, Tokyo 113, Japan.	ikeda-kz@igakuken.or.jp	Minami, Masabumi/A-3883-2012	Minami, Masabumi/0000-0002-0144-0679	Ministry of Education, Culture, Sports, Science and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [20390162, 22790518, 23390377, 25116532]; Japanese Ministry of Health, Labour and WelfareMinistry of Health, Labour and Welfare, Japan [H21-3jigan-ippan-011, H22-Iyaku-015]; Smoking Research Foundation; Astellas Foundation for Research on Metabolic Disorders	This research was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (20390162, 22790518, 23390377, 25116532), Japanese Ministry of Health, Labour and Welfare (H21-3jigan-ippan-011, H22-Iyaku-015), Smoking Research Foundation, and Astellas Foundation for Research on Metabolic Disorders. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angst MS, 2012, PAIN, V153, P1397, DOI 10.1016/j.pain.2012.02.022; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bisgaard T, 2001, PAIN, V90, P261, DOI 10.1016/S0304-3959(00)00406-1; Carlson CS, 2003, NAT GENET, V33, P518, DOI 10.1038/ng1128; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; CONTRERAS E, 1988, EUR J PHARMACOL, V148, P463, DOI 10.1016/0014-2999(88)90129-X; Coulbault L, 2006, CLIN PHARMACOL THER, V79, P316, DOI 10.1016/j.clpt.2006.01.007; de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669; Dogrul A, 2002, LIFE SCI, V71, P725, DOI 10.1016/S0024-3205(02)01736-8; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fukuda K, 2009, PAIN, V147, P194, DOI 10.1016/j.pain.2009.09.004; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Holmkvist J, 2007, DIABETOLOGIA, V50, P2467, DOI 10.1007/s00125-007-0846-2; Ikeda K, 2005, TRENDS PHARMACOL SCI, V26, P311, DOI 10.1016/j.tips.2005.04.001; Kasai S, 2011, PHARMACOGENOMICS, V12, P1305, DOI [10.2217/pgs.11.68, 10.2217/PGS.11.68]; Loh HH, 1998, MOL BRAIN RES, V54, P321, DOI 10.1016/S0169-328X(97)00353-7; Marubio LM, 1996, RECEPTOR CHANNEL, V4, P243; Michaluk J, 1998, EUR J PHARMACOL, V352, P189, DOI 10.1016/S0014-2999(98)00373-2; Muller YL, 2007, DIABETES, V56, P3089, DOI 10.2337/db07-0587; Murakami M, 2004, BRAIN RES, V1024, P122, DOI 10.1016/j.brainres.2004.07.066; Newcomb R, 1998, BIOCHEMISTRY-US, V37, P15353, DOI 10.1021/bi981255g; Park JF, 2010, CHANNELS, V4, P510, DOI 10.4161/chan.4.6.12869; Pereverzev A, 2002, MOL CELL NEUROSCI, V21, P352, DOI 10.1006/mcne.2002.1179; Perret D, 2009, NEUROTHERAPEUTICS, V6, P679, DOI 10.1016/j.nurt.2009.07.006; Saegusa H, 2000, P NATL ACAD SCI USA, V97, P6132, DOI 10.1073/pnas.100124197; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; Sora I, 2001, NEUROPSYCHOPHARMACOL, V25, P41, DOI 10.1016/S0893-133X(00)00252-9; Westenbroek RE, 1998, J NEUROSCI, V18, P6319; YOKOYAMA CT, 1995, J NEUROSCI, V15, P6419; Yokoyama K, 2004, EUR J NEUROSCI, V20, P3516, DOI 10.1111/j.1460-9568.2004.03810.x; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	33	15	16	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2013	8	8							e70694	10.1371/journal.pone.0070694			9	Multidisciplinary Sciences	Science & Technology - Other Topics	218XC	WOS:000324465000124	23940630	DOAJ Gold, Green Published			2020-06-30	J	Sabir, H; Bishop, S; Cohen, N; Maes, E; Liu, X; Dingley, J; Thoresen, M				Sabir, Hemmen; Bishop, Sarah; Cohen, Nicki; Maes, Elke; Liu, Xun; Dingley, John; Thoresen, Marianne			Neither Xenon nor Fentanyl Induces Neuroapoptosis in the Newborn Pig Brain	ANESTHESIOLOGY			English	Article							HYPOXIC-ISCHEMIC ENCEPHALOPATHY; WHOLE-BODY HYPOTHERMIA; RANDOMIZED-CONTROLLED-TRIAL; MILD SYSTEMIC HYPOTHERMIA; DEVELOPING RAT-BRAIN; NEURONAL CELL-DEATH; ANESTHETIC AGENTS; APOPTOTIC NEURODEGENERATION; OPIOID NEUROTOXICITY; GENERAL-ANESTHETICS	Background: Some inhalation anesthetics increase apoptotic cell death in the developing brain. Xenon, an inhalation anesthetic, increases neuroprotection when combined with therapeutic hypothermia after hypoxic-ischemic brain injury in newborn animals. The authors, therefore, examined whether there was any neuroapoptotic effect of breathing 50% xenon with continuous fentanyl sedation for 24 h at normothermia or hypothermia on newborn pigs. Methods: Twenty-six healthy pigs (< 24-h old) were randomized into four groups: (1) 24 h of 50% inhaled xenon with fentanyl at hypothermia (Trec = 33.5 degrees C), (2) 24 h of 50% inhaled xenon with fentanyl at normothermia (Trec = 38.5 degrees C), (3) 24 h of fentanyl at normothermia, or (4) nonventilated juvenile controls at normothermia. Five additional nonrandomized pigs inhaled 2% isoflurane at normothermia for 24 h to verify any proapoptotic effect of inhalation anesthetics in our model. Pathological cells were morphologically assessed in cortex, putamen, hippocampus, thalamus, and white matter. To quantify the findings, immunostained cells (caspase-3 and terminal deoxynucleotidyl transferase-mediated deoxyuridine-triphosphate nick-end labeling) were counted in the same brain regions. Results: For groups (1) to (4), the total number of apoptotic cells was less than 5 per brain region, representing normal developmental neuroapoptosis. After immunostaining and cell counting, regression analysis showed that neither 50% xenon with fentanyl nor fentanyl alone increased neuroapoptosis. Isoflurane caused on average a 5-to 10-fold increase of immunostained cells. Conclusion: At normothermia or hypothermia, neither 24 h of inhaled 50% xenon with fentanyl sedation nor fentanyl alone induces neuroapoptosis in the neonatal pig brain. Breathing 2% isoflurane increases neuroapoptosis in neonatal pigs.	[Sabir, Hemmen; Bishop, Sarah; Cohen, Nicki; Maes, Elke; Liu, Xun; Dingley, John; Thoresen, Marianne] Univ Bristol, Sch Clin Sci, St Michaels Hosp, Bristol BS2 8EG, Avon, England	Thoresen, M (reprint author), Univ Bristol, Sch Clin Sci, St Michaels Hosp, Bristol BS2 8EG, Avon, England.	marianne.thoresen@bristol.ac.uk			Sport Aiding Medical Research for Kids (SPARKS, London, United Kingdom); Laerdal Foundation for Acute Medicine (Stavanger, Norway); Sparks Charity [05BTL01]	Received from Neonatal Neuroscience, School of Clinical Sciences, University of Bristol, St. Michael's Hospital, Bristol, United Kingdom. Submitted for publication June 11, 2012. Accepted for publication March 13, 2013. This study was supported by Sport Aiding Medical Research for Kids (SPARKS, London, United Kingdom) and the Laerdal Foundation for Acute Medicine (Stavanger, Norway).	Al-Jahdari WS, 2006, CAN J ANAESTH, V53, P1078, DOI 10.1007/BF03022874; Azzopardi D, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-17; Cattano D, 2008, CAN J ANAESTH, V55, P429, DOI 10.1007/BF03016309; Chakkarapani E, 2009, ANESTH ANALG, V109, P451, DOI 10.1213/ane.0b013e3181aa9550; Chakkarapani E, 2010, ANN NEUROL, V68, P330, DOI 10.1002/ana.22016; Chiang MC, 2007, NEUROSCI LETT, V421, P67, DOI 10.1016/j.neulet.2007.05.024; Cilio MR, 2010, SEMIN FETAL NEONAT M, V15, P293, DOI 10.1016/j.siny.2010.02.002; CULLEN SC, 1951, SCIENCE, V113, P580, DOI 10.1126/science.113.2942.580; Dinse A, 2005, BRIT J ANAESTH, V94, P479, DOI 10.1093/bja/aei080; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; Fatemi A, 2009, CLIN PERINATOL, V36, P835, DOI 10.1016/j.clp.2009.07.011; Faulkner S, 2011, ANN NEUROL, V70, P133, DOI 10.1002/ana.22387; Franks NP, 1998, NATURE, V396, P324, DOI 10.1038/24525; Fredriksson A, 2007, ANESTHESIOLOGY, V107, P427, DOI 10.1097/01.anes.0000278892.62305.9c; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gressens P, 2008, BRAIN PATHOL, V18, P10, DOI 10.1111/j.1750-3639.2007.00095.x; Haaland K, 1997, PEDIATR RES, V41, P505, DOI 10.1203/00006450-199704000-00009; Hobbs C, 2008, STROKE, V39, P1307, DOI 10.1161/STROKEAHA.107.499822; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Istaphanous GK, 2009, CURR OPIN ANESTHESIO, V22, P368, DOI 10.1097/ACO.0b013e3283294c9e; Jacobs SE, 2011, ARCH PEDIAT ADOL MED, V165, P692, DOI 10.1001/archpediatrics.2011.43; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876, DOI 10.1523/jneurosci.23-03-00876.2003; Johnston MV, 2011, LANCET NEUROL, V10, P372, DOI 10.1016/S1474-4422(11)70016-3; Kofke WA, 1996, ANESTH ANALG, V83, P1298, DOI 10.1097/00000539-199612000-00029; Kofke WA, 1999, BRAIN RES, V818, P326, DOI 10.1016/S0006-8993(98)01228-1; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Loepke AW, 2008, ANESTH ANALG, V106, P1681, DOI 10.1213/ane.0b013e318167ad77; Ma DQ, 2007, ANESTHESIOLOGY, V106, P746, DOI 10.1097/01.anes.0000264762.48920.80; Mellon RD, 2007, ANESTH ANALG, V104, P509, DOI 10.1213/01.ane.0000255729.96438.b0; Northington FJ, 2011, ANN NEUROL, V69, P743, DOI 10.1002/ana.22419; Olney JW, 2004, ANESTHESIOLOGY, V101, P273, DOI 10.1097/00000542-200408000-00004; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; Perlman JM, 2010, CIRCULATION, V122, P8516, DOI 10.1161/CIRCULATIONAHA.110.971127; Rakic S, 2000, EUR J NEUROSCI, V12, P2721, DOI 10.1046/j.1460-9568.2000.00153.x; Reddy S Velayudha, 2012, J Anaesthesiol Clin Pharmacol, V28, P6, DOI 10.4103/0970-9185.92426; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; Rizzi S, 2008, BRAIN PATHOL, V18, P198, DOI 10.1111/j.1750-3639.2007.00116.x; Rizzi S, 2010, ANN NY ACAD SCI, V1199, P43, DOI 10.1111/j.1749-6632.2009.05173.x; Rossaint R, 2003, ANESTHESIOLOGY, V98, P6, DOI 10.1097/00000542-200301000-00005; Satas S, 1996, ACTA ANAESTH SCAND, V40, P452, DOI 10.1111/j.1399-6576.1996.tb04468.x; Schubert H, 2012, INTENS CARE MED, V38, P1205, DOI 10.1007/s00134-012-2576-2; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Slikker W, 2007, TOXICOL SCI, V98, P145, DOI 10.1093/toxsci/kfm084; Soriano SG, 2005, J NEUROSURG ANESTH, V17, P207, DOI 10.1097/01.ana.0000178113.72714.4b; Stratmann G, 2011, ANESTH ANALG, V113, P1170, DOI 10.1213/ANE.0b013e318232066c; Thoresen M, 2001, PEDIATR RES, V50, P405, DOI 10.1203/00006450-200109000-00017; Thoresen M, 1996, PEDIATR RES, V40, P738, DOI 10.1203/00006450-199611000-00014; Todd MM, 2004, ANESTHESIOLOGY, V101, P272, DOI 10.1097/00000542-200408000-00003; Tooley J, 2002, PEDIATRICS, V109, P643, DOI 10.1542/peds.109.4.643; Tooley JR, 2003, ANN NEUROL, V53, P65, DOI 10.1002/ana.10402; Tu SF, 2011, BRAIN RES BULL, V86, P29, DOI 10.1016/j.brainresbull.2011.06.017; Wilhelm S, 2002, ANESTHESIOLOGY, V96, P1485, DOI 10.1097/00000542-200206000-00031; WYATT JS, 1989, ARCH DIS CHILD-FETAL, V64, P953, DOI 10.1136/adc.64.7_Spec_No.953; YAGER JY, 1992, AM J PHYSIOL, V262, pH672; Yon JH, 2005, NEUROSCIENCE, V135, P815, DOI 10.1016/j.neuroscience.2005.03.064; Zhou Wen-hao, 2003, Zhonghua Er Ke Za Zhi, V41, P460	56	22	22	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	AUG	2013	119	2					345	357		10.1097/ALN.0b013e318294934d			13	Anesthesiology	Anesthesiology	280WS	WOS:000329062100014	23591070	Bronze			2020-06-30	J	Takasusuki, T; Yamaguchi, S; Hamaguchi, S; Yaksh, TL				Takasusuki, Toshifumi; Yamaguchi, Shigeki; Hamaguchi, Shinsuke; Yaksh, Tony L.			Effects of General Anesthetics on Substance P Release and c-Fos Expression in the Spinal Dorsal Horn	ANESTHESIOLOGY			English	Article							MINIMUM ALVEOLAR CONCENTRATION; CAPSAICIN-EVOKED RELEASE; NITROUS-OXIDE; NOXIOUS-STIMULATION; VOLATILE ANESTHETICS; SUBCUTANEOUS FORMALIN; GABA(B) RECEPTORS; AFFERENT INPUT; MOTOR-NEURONS; CORD INVIVO	Background: The authors examined in vivo the effects of general anesthetics on evoked substance P release (primary afferent excitability) and c-Fos expression (neuronal activation) in superficial dorsal horn. Methods: Rats received saline, propofol (100 mg/kg), pentobarbital (50 mg/kg), isoflurane (2 minimum alveolar concentration), nitrous oxide (66%), or fentanyl (30 mu g/kg). During anesthesia, rats received intraplantar 5% formalin (50 mu l) to left hind paw. Ten minutes later, rats underwent transcardial perfusion with 4% paraformaldehyde. Substance P release from small primary afferents was assessed by incidence of neurokinin 1 receptor internalization in the superficial dorsal horn. In separate studies, rats were sacrificed after 2 h and c-Fos expression measured. Results: Intraplantar formalin-induced robust neurokinin 1 receptor internalization in ipsilateral dorsal horn (ipsilateral: 54 +/- 6% [mean +/- SEM], contralateral: 12 +/- 2%; P < 0.05; n = 4). Fentanyl, but not propofol, pentobarbital, isoflurane, nor nitrous oxide alone inhibited neurokinin 1 receptor internalization. However, 2 minimum alveolar concentration isoflurane + nitrous oxide reduced neurokinin 1 receptor internalization (27 +/- 3%; P < 0.05; n = 5). All agents reduced c-Fos expression (control: 34 +/- 4, fentanyl: 8 +/- 2, isoflurane: 12 +/- 3, nitrous oxide: 11 +/- 2, isoflurane + nitrous oxide: 12 +/- 1, pentobarbital: 11 +/- 2, propofol: 13 +/- 3; P < 0.05; n = 3). Conclusion: General anesthetics at anesthetic concentrations block spinal neuron activation through a mechanism that is independent of an effect on small primary afferent peptide release. The effect of fentanyl alone and the synergistic effect of isoflurane and nitrous oxide on substance P release suggest a correlative rationale for the therapeutic use of these anesthetic protocols by blocking nociceptive afferent transmitter release and preventing the initiation of cascade, which is immediately postsynaptic to the primary afferent.	[Takasusuki, Toshifumi; Yamaguchi, Shigeki; Hamaguchi, Shinsuke; Yaksh, Tony L.] Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA	Yaksh, TL (reprint author), Univ Calif San Diego, Dept Anesthesiol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	tyaksh@ucsd.edu	Yaksh, Tony/D-4119-2009	Hamaguchi, Shinsuke/0000-0001-5872-4421	National Institutes of Health, Bethesda, MarylandUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIH-DA02110]; Japan Society for the Promotion of Science, Tokyo, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [24791623]	Received from the Department of Anesthesiology, University of California, San Diego, La Jolla, California. Submitted for publication December 11, 2012. Accepted for publication April 15, 2013. This research was supported by funding from National Institutes of Health: NIH-DA02110, Bethesda, Maryland (to Dr. Yaksh), and Japan Society for the Promotion of Science: Grant-in-Aid for Scientific Research (B) 24791623, Tokyo, Japan. Preliminary data were presented as posters at the 14th World Congress on Pain, September 30, 2012, Milan, Italy.	ABRAM SE, 1993, ANESTHESIOLOGY, V78, P713, DOI 10.1097/00000542-199304000-00015; AIMONE LD, 1989, PEPTIDES, V10, P1127, DOI 10.1016/0196-9781(89)90003-X; Antognini JF, 2000, CAN J ANAESTH, V47, P273, DOI 10.1007/BF03018926; Antognini JF, 2000, ANESTHESIOLOGY, V92, P559, DOI 10.1097/00000542-200002000-00040; ANTOGNINI JF, 1993, ANESTHESIOLOGY, V79, P1244, DOI 10.1097/00000542-199312000-00015; BORGES M, 1994, ANESTHESIOLOGY, V81, P1511, DOI 10.1097/00000542-199412000-00027; Buerkle H, 1998, BRIT J ANAESTH, V80, P348; Castro AR, 2005, NEUROSCIENCE, V132, P905, DOI 10.1016/j.neuroscience.2005.01.048; Cheng G, 2003, ANESTH ANALG, V96, P1354, DOI 10.1213/01.ANE.0000055649.06649.D2; de Sousa SLM, 2000, ANESTHESIOLOGY, V92, P1055, DOI 10.1097/00000542-200004000-00024; DICKENSON AH, 1990, TRENDS PHARMACOL SCI, V11, P307, DOI 10.1016/0165-6147(90)90228-Z; DildyMayfield JE, 1996, J PHARMACOL EXP THER, V276, P1058; Downie DL, 1996, BRIT J PHARMACOL, V118, P493, DOI 10.1111/j.1476-5381.1996.tb15430.x; Fagerlund MJ, 2010, BRIT J ANAESTH, V104, P472, DOI 10.1093/bja/aeq023; FFRENCHMULLEN JMH, 1993, J NEUROSCI, V13, P3211; FIELDS HL, 1980, NATURE, V284, P351, DOI 10.1038/284351a0; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Fujinaga M, 2002, MOL NEUROBIOL, V25, P167, DOI 10.1385/MN:25:2:167; Gilron I, 1999, ANESTH ANALG, V88, P414, DOI 10.1097/00000539-199902000-00036; GO VLW, 1987, J PHYSIOL-LONDON, V391, P141, DOI 10.1113/jphysiol.1987.sp016731; Goto T, 1996, BRIT J ANAESTH, V76, P702; Hagihira S, 1997, BRAIN RES, V751, P124, DOI 10.1016/S0006-8993(96)01398-4; Haseneder R, 2004, ANESTH ANALG, V98, P1718, DOI 10.1213/01.ANE.0000112309.80017.3F; Hashimoto T, 2001, ANESTHESIOLOGY, V95, P463, DOI 10.1097/00000542-200108000-00031; Himukashi S, 2006, ANESTH ANALG, V103, P738, DOI 10.1213/01.ane.0000230601.64098.cc; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; JEWETT BA, 1992, ANESTHESIOLOGY, V77, P1148, DOI 10.1097/00000542-199212000-00016; Jinks SL, 2005, ANESTHESIOLOGY, V102, P624, DOI 10.1097/00000542-200503000-00022; Jinks SL, 2002, ANESTH ANALG, V95, P1622, DOI 10.1097/00000539-200212000-00028; Kameyama K, 1999, BRIT J ANAESTH, V82, P402, DOI 10.1093/bja/82.3.402; Kondo I, 2005, J NEUROSCI, V25, P3651, DOI 10.1523/JNEUROSCI.0252-05.2005; Lao LJ, 2003, NEUROSCIENCE, V121, P667, DOI 10.1016/S0306-4522(03)00501-3; Lever IJ, 2002, BRIT J PHARMACOL, V135, P21, DOI 10.1038/sj.bjp.0704506; Lin Feng-Sheng, 2003, Acta Anaesthesiol Sin, V41, P115; Malkmus SA, 2004, METH MOLEC MED, P109; MALMBERG AB, 1994, J NEUROSCI, V14, P4882; Mantyh PW, 2002, J CLIN PSYCHIAT, V63, P6; MANTYH PW, 1995, P NATL ACAD SCI USA, V92, P2622, DOI 10.1073/pnas.92.7.2622; Marvizon JCG, 2003, NEUROSCIENCE, V118, P535, DOI 10.1016/S0306-4522(02)00977-6; MENDELL LM, 1966, EXP NEUROL, V16, P316, DOI 10.1016/0014-4886(66)90068-9; MURRAY DJ, 1991, ANESTHESIOLOGY, V75, P186, DOI 10.1097/00000542-199108000-00003; Nikonorov IM, 2003, ANESTHESIOLOGY, V99, P392, DOI 10.1097/00000542-200308000-00021; Orestes P, 2009, MOL PHARMACOL, V75, P542, DOI 10.1124/mol.108.051664; Patel AJ, 1999, NAT NEUROSCI, V2, P422; PRESLEY RW, 1990, J NEUROSCI, V10, P323; Rampil IJ, 1996, ANESTHESIOLOGY, V85, P129, DOI 10.1097/00000542-199607000-00018; Riley RC, 2001, NEUROSCIENCE, V103, P725, DOI 10.1016/S0306-4522(00)00571-6; Santos M, 2005, ANESTH ANALG, V100, P404, DOI 10.1213/01.ANE.0000142423.87593.CE; Sommers MG, 2008, ANESTH ANALG, V106, P1303, DOI 10.1213/ane.0b013e3181678831; Soyguder Z, 2005, BRAIN RES, V1033, P202, DOI 10.1016/j.brainres.2004.11.044; STEVENS WC, 1975, ANESTHESIOLOGY, V42, P197, DOI 10.1097/00000542-197502000-00014; STUDY RE, 1994, ANESTHESIOLOGY, V81, P104, DOI 10.1097/00000542-199407000-00016; Sun WZ, 1996, BRIT J ANAESTH, V76, P99; Takasusuki T, 2011, ANESTHESIOLOGY, V115, P153, DOI 10.1097/ALN.0b013e31821950c2; Wakai A, 2005, ANESTHESIOLOGY, V102, P379, DOI 10.1097/00000542-200502000-00021; WAKAMORI M, 1991, J NEUROPHYSIOL, V66, P2014; YAKSH TL, 1980, NATURE, V286, P155, DOI 10.1038/286155a0; YAKSH TL, 1976, PHYSIOL BEHAV, V17, P1031, DOI 10.1016/0031-9384(76)90029-9; YAKSH TL, 1993, CURR OPIN NEUROL NEU, V6, P250; YAKSH TL, 1976, SCIENCE, V192, P1357, DOI 10.1126/science.1273597; Yaksh TL, 1999, P NATL ACAD SCI USA, V96, P7680, DOI 10.1073/pnas.96.14.7680; Ying SW, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-2; Zhang ET, 2007, PAIN, V129, P143, DOI 10.1016/j.pain.2006.10.009; ZHANG RX, 1994, NEUROSCIENCE, V58, P299, DOI 10.1016/0306-4522(94)90036-1	64	5	6	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	AUG	2013	119	2					433	442		10.1097/ALN.0b013e31829996b6			10	Anesthesiology	Anesthesiology	280WS	WOS:000329062100022	23708866	Other Gold, Green Accepted			2020-06-30	J	Saettele, AK; Sharma, A; Murray, DJ				Saettele, Angela K.; Sharma, Anshuman; Murray, David J.			Case Scenario: Hypotonia in Infancy Anesthetic Dilemma	ANESTHESIOLOGY			English	Article							MUSCLE BIOPSY; MITOCHONDRIAL; PROPOFOL; CHILDREN; RISK		[Saettele, Angela K.; Sharma, Anshuman; Murray, David J.] Washington Univ, Dept Anesthesiol, St Louis, MO 63110 USA	Murray, DJ (reprint author), Washington Univ, Dept Anesthesiol, 660 South Euclid,Campus Box 8054, St Louis, MO 63110 USA.	murrayd@anest.wustl.edu		Murray, David/0000-0001-6264-3210			Acco A, 2004, BASIC CLIN PHARMACOL, V95, P166; Chinnery PF, 1999, J MED GENET, V36, P425; Crean P, 2009, PRACTICE ANESTHESIA, P491; Driessen J, 2007, PEDIATR ANESTH, V17, P16, DOI 10.1111/j.1460-9592.2006.02043.x; Flick RP, 2007, PEDIATR ANESTH, V17, P22, DOI 10.1111/j.1460-9592.2006.02105.x; Footitt EJ, 2008, BRIT J ANAESTH, V100, P436, DOI 10.1093/bja/aen014; Hsing CH, 2012, ANESTHESIOLOGY, V116, P868, DOI 10.1097/ALN.0b013e31824af68a; Kam PCA, 2007, ANAESTHESIA, V62, P690, DOI 10.1111/j.1365-2044.2007.05055.x; Klingler W, 2009, ANESTH ANALG, V109, P1167, DOI 10.1213/ANE.0b013e3181b5ae2d; Lerman J, 2011, BRIT J ANAESTH, V107, P79, DOI 10.1093/bja/aer335; Levine S, 2008, NEW ENGL J MED, V358, P1327, DOI 10.1056/NEJMoa070447; Morgan PG, 2002, ANESTHESIOLOGY, V96, P1268, DOI 10.1097/00000542-200205000-00036; Mrozek S, 2012, ANESTHESIOLOGY, V117, P560, DOI 10.1097/ALN.0b013e318261e7f8; Muravchick S, 2006, ANESTHESIOLOGY, V105, P819, DOI 10.1097/00000542-200610000-00029; Rigoulet M, 1996, EUR J BIOCHEM, V241, P280; Ross AK, 2007, PEDIATR ANESTH, V17, P1, DOI 10.1111/j.1460-9592.2006.02106.x; Short Timothy G, 2003, Best Pract Res Clin Anaesthesiol, V17, P77, DOI 10.1053/bean.2002.0266; Thompson VA, 1997, ANESTH ANALG, V85, P1404, DOI 10.1097/00000539-199712000-00041; Wong LJC, 2007, MITOCHONDRION, V7, P45, DOI 10.1016/j.mito.2006.11.025	19	5	5	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	AUG	2013	119	2					443	446		10.1097/ALN.0b013e31829c2dc8			4	Anesthesiology	Anesthesiology	280WS	WOS:000329062100023	23845921	Bronze			2020-06-30	J	Conway, DH; Hussain, OA; Gall, I				Conway, Daniel H.; Hussain, Osman A.; Gall, Iain			A comparison of noninvasive bioreactance with oesophageal Doppler estimation of stroke volume during open abdominal surgery An observational study	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article							CARDIAC-OUTPUT MEASUREMENT; CRITICALLY-ILL PATIENTS; PULSE CONTOUR; CONTROLLED TRIAL; THERMODILUTION; METAANALYSIS; PERFORMANCE; VALIDATION; OUTCOMES	CONTEXTThe anaesthetist must maintain tissue perfusion by ensuring optimal perioperative fluid balance. This can be achieved using less invasive cardiac output monitors such as oesophageal Doppler monitoring (ODM). Other less invasive cardiac output monitors using bio-impedence technology (noninvasive cardiac output monitoring, NICOM) may have a role in monitoring the circulation and informing fluid management decisions.OBJECTIVETo compare estimates of stroke volume from ODM with those from NICOM, a noninvasive monitor using bioreactance, a modification of transthoracic bio-impedence.DESIGNAn observational study.SETTINGManchester Royal Infirmary, UK. Data collected in 2011 and 2012.PARTICIPANTSTwenty-two patients scheduled for major, open abdominal surgery. Reasons for noninclusion: atrial fibrillation; heart failure; oesophageal disease; lack of capacity; and known sensitivity to colloid.INTERVENTIONAll patients had oesophageal Doppler cardiac output monitoring as a standard element of anaesthesia care. We placed NICOM Bioreactance electrodes and recorded stroke volume estimates from both devices. Fluid challenges were given by the anaesthetist and the haemodynamic responses were recorded.MAIN OUTCOME MEASUREStroke volume during surgery. The Bland-Altman method was used to compare bias and limits of agreement for stroke volume and cardiac output. Fluid responders were defined as patients who increased stroke volume by at least 10% after fluid loading. The precision of each device was calculated during periods of haemodynamic stability.RESULTSWe made 788 acceptable measurements of cardiac output. The bias was -6.9ml and the limits of agreement were -22.9 to 36.8ml. The percentage error was 57%. Average precision for both the ODM and NICOM were similar, 8.5% (SD 5.4%) and 8.7% (SD 3.2%). The concordance for the stroke volume change following fluid challenge was 90.5%. Both devices produced unacceptable readings with electrical diathermy.CONCLUSIONSimultaneous stroke volume estimations made by noninvasive Bioreactance (NICOM) and oesophageal Doppler showed bias and limits of agreement that are not clinically acceptable. The measurements made by these two devices cannot be regarded as interchangeable.	[Conway, Daniel H.; Gall, Iain] Manchester Royal Infirm, Dept Anaesthesia, Manchester M13 9WL, Lancs, England; [Hussain, Osman A.] Univ Manchester, Sch Med, Fac Med & Human Sci, Manchester, Lancs, England	Conway, DH (reprint author), Manchester Royal Infirm, Dept Anaesthesia, Oxford Rd, Manchester M13 9WL, Lancs, England.	daniel.conway@cmft.nhs.uk			generosity of the Anaesthesia Research Society	the purchase of the NICOM monitor and disposables was entirely funded by the generosity of the Anaesthesia Research Society and was awarded following an open competitive application to the National Institute of Academic Anaesthesia Small Project Grant Round 2010.	Abbas SM, 2008, ANAESTHESIA, V63, P44, DOI 10.1111/j.1365-2044.2007.05233.x; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Broch O, 2011, CRIT CARE, V15, DOI 10.1186/cc10065; Bundgaard-Nielsen M, 2007, ACTA ANAESTH SCAND, V51, P331, DOI 10.1111/j.1399-6576.2006.01221.x; Cecconi M, 2009, CRIT CARE, V13, DOI 10.1186/cc7909; Chatti R, 2009, BRIT J ANAESTH, V102, P463, DOI 10.1093/bja/aep020; Columb M, 2008, CURR ANAESTH CRIT CA, V19, P328, DOI DOI 10.1016/J.CACC.2008.07.001; Conway DH, 2002, ANAESTHESIA, V57, P845, DOI 10.1046/j.1365-2044.2002.02708.x; Critchley LAH, 1999, J CLIN MONITOR COMP, V15, P85, DOI 10.1023/A:1009982611386; Dark PM, 2004, INTENS CARE MED, V30, P2060, DOI 10.1007/s00134-004-2430-2; de Wilde RBP, 2009, ANAESTHESIA, V64, P1004, DOI 10.1111/j.1365-2044.2009.06009.x; Giglio MT, 2009, BRIT J ANAESTH, V103, P637, DOI 10.1093/bja/aep279; Gunn SR, 2006, INTENS CARE MED, V32, P1537, DOI 10.1007/s00134-006-0284-5; Hamilton MA, 2011, ANESTH ANALG, V112, P1392, DOI 10.1213/ANE.0b013e3181eeaae5; Hofer CK, 2005, CHEST, V128, P848, DOI 10.1378/chest.128.2.848; Keren H, 2007, AM J PHYSIOL-HEART C, V293, pH583, DOI 10.1152/ajpheart.00195.2007; Lafanechere A, 2006, J CARDIOTHOR VASC AN, V20, P26, DOI 10.1053/j.jvca.2005.07.029; LeTulzo Y, 1996, J CLIN MONITOR, V12, P379; Maisch S, 2011, CRIT CARE MED, V39, P2173, DOI 10.1097/CCM.0b013e3182227e65; Marque S, 2009, CRIT CARE, V13, DOI 10.1186/cc7884; Medin DL, 1998, J CRIT CARE, V13, P184, DOI 10.1016/S0883-9441(98)90004-1; Metzelder S, 2011, BRIT J ANAESTH, V106, P776, DOI 10.1093/bja/aer066; Mowatt G, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI 10.3310/hta13070; MYTHEN MG, 1995, ARCH SURG-CHICAGO, V130, P423; Raval Nirav Y, 2008, J Clin Monit Comput, V22, P113, DOI 10.1007/s10877-008-9112-5; RUBINI A, 1995, INTENS CARE MED, V21, P154, DOI 10.1007/BF01726539; Sakka SG, 2007, BRIT J ANAESTH, V99, P337, DOI 10.1093/bja/aem177; Sandham JD, 2003, NEW ENGL J MED, V348, P5, DOI 10.1056/NEJMoa021108; Schober P, 2009, ANESTH ANALG, V109, P340, DOI 10.1213/ane.0b013e3181aa0af3; Squara P, 2007, INTENS CARE MED, V33, P1191, DOI 10.1007/s00134-007-0640-0; Squara P, 2009, CRIT CARE, V13, DOI 10.1186/cc7981; Squara P, 2009, INTENS CARE MED, V35, P1801, DOI 10.1007/s00134-009-1570-9; Su Nuan-Yen, 2002, Acta Anaesthesiol Sin, V40, P127; THOMAS AN, 1991, INTENS CARE MED, V17, P383, DOI 10.1007/BF01720674; Valtier B, 1998, AM J RESP CRIT CARE, V158, P77, DOI 10.1164/ajrccm.158.1.9707031; Wilson J, 2010, CRIT CARE, V14, DOI 10.1186/cc9082	36	15	15	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	AUG	2013	30	8					501	508		10.1097/EJA.0b013e3283603250			8	Anesthesiology	Anesthesiology	247GB	WOS:000326603500008	23549128				2020-06-30	J	Wipfli, M; Arnold, M; Luginbuhl, M				Wipfli, Marius; Arnold, Marcel; Luginbuehl, Martin			Repeated spinal anesthesia in a tetraparetic patient with Guillain-Barre syndrome	JOURNAL OF CLINICAL ANESTHESIA			English	Editorial Material						Anesthesia, spinal; Guillain-Barre syndrome; Tetraparesis	EPIDURAL-ANESTHESIA; NEURAXIAL ANESTHESIA; REGIONAL ANESTHESIA; RANDOMIZED-TRIALS; CESAREAN DELIVERY; ANALGESIA; LABOR; COMPLICATIONS; MANAGEMENT; PREGNANCY	A 78 year old man with tetraparesis, reduced forced vital capacity, and neurogenic bladder dysfunction due to Guillain-Barre syndrome was admitted for elective transurethral prostate resection and percutaneous lithotripsy of a bladder stone. On the sixth postoperative day, he was readmitted for emergency evacuation of a clot in the bladder. Both operations were performed with spinal anesthesia (hyperbaric bupivacaine + fentanyl) without neurologic sequelae. (c) 2013 Elsevier Inc. All rights reserved.	[Wipfli, Marius; Luginbuehl, Martin] Univ Hosp Bern, Dept Anesthesiol & Pain Therapy, CH-3010 Bern, Switzerland; [Wipfli, Marius; Arnold, Marcel; Luginbuehl, Martin] Univ Bern, CH-3010 Bern, Switzerland; [Arnold, Marcel] Univ Hosp Bern, Dept Neurol, CH-3010 Bern, Switzerland	Wipfli, M (reprint author), Lindenhofspital Bern, Dept Anesthesiol & Pain Therapy, CH-3012 Bern, Switzerland.	mariuswipfli@yahoo.com					Alici HA, 2005, INT J OBSTET ANESTH, V14, P269, DOI 10.1016/j.ijoa.2005.02.008; Auroy Y, 2002, ANESTHESIOLOGY, V97, P1274, DOI 10.1097/00000542-200211000-00034; Bamberger PD, 2005, ANESTH ANALG, V100, P1197, DOI 10.1213/01.ANE.0000144826.77316.ED; Brooks H, 2000, ANAESTHESIA, V55, P894, DOI 10.1046/j.1365-2044.2000.01367.x; Flores-Barragan JM, 2006, REV NEUROLOGIA, V42, P631, DOI 10.33588/rn.4210.2005804; Martin GG, 2008, REV ESP ANEST REANIM, V55, P323; Hahn AF, 1998, LANCET, V352, P635, DOI 10.1016/S0140-6736(97)12308-X; Hebl JR, 2006, ANESTH ANALG, V103, P1294, DOI 10.1213/01.ane.0000243384.75713.df; Hebl JR, 2006, ANESTH ANALG, V103, P223, DOI 10.1213/01.ane.0000220896.56427.53; Kocabas S, 2007, J CLIN ANESTH, V19, P299, DOI 10.1016/j.jclinane.2006.09.008; MCGRADY EM, 1987, ANAESTHESIA, V42, P899, DOI 10.1111/j.1365-2044.1987.tb04130.x; Maya IO, 2006, MED CLIN-BARCELONA, V127, P118, DOI 10.1157/13090271; PEREL A, 1977, ANAESTHESIA, V32, P257, DOI 10.1111/j.1365-2044.1977.tb11604.x; Rigg JRA, 2002, LANCET, V359, P1276, DOI 10.1016/S0140-6736(02)08266-1; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; ROPPER AH, 1992, NEW ENGL J MED, V326, P1130, DOI 10.1056/NEJM199204233261706; STEINER I, 1985, NEUROLOGY, V35, P1473, DOI 10.1212/WNL.35.10.1473; Urwin SC, 2000, BRIT J ANAESTH, V84, P450; Vassiliev DV, 2001, REGION ANESTH PAIN M, V26, P174, DOI 10.1053/rapm.2001.21090; Vercauteren M, 2007, ACTA ANAESTH SCAND, V51, P831, DOI 10.1111/j.1399-6576.2007.01325.x; Wiertlewski S, 2004, ANESTH ANALG, V98, P825	21	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	AUG	2013	25	5					409	412		10.1016/j.jclinane.2013.01.017			4	Anesthesiology	Anesthesiology	235PJ	WOS:000325732900012	23965204				2020-06-30	J	Harlos, MS; Stenekes, S; Lambert, D; Hohl, C; Chochinov, HM				Harlos, Michael S.; Stenekes, Simone; Lambert, David; Hohl, Chris; Chochinov, Harvey Max			Intranasal Fentanyl in the Palliative Care of Newborns and Infants	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Palliative care; newborn; neonatal; perinatal; infants; fentanyl; intranasal; dyspnea	POSTOPERATIVE PAIN MANAGEMENT; RANDOMIZED CONTROLLED-TRIAL; BREAKTHROUGH CANCER PAIN; DOUBLE-BLIND; OPEN-LABEL; INTRAVENOUS MORPHINE; CROSSOVER TRIAL; TUBE PLACEMENT; ORAL MORPHINE; CHILDREN	Context. Perinatal palliative care is an area of increasing focus among clinicians supporting newborns and their families. Although not every newborn will survive the neonatal period, assuring their comfort and quality of life remains an imperative for their care providers. It can be challenging to administer medications such as opioids in a minimally invasive yet effective manner. Objectives. To describe the experience using intranasal (IN) fentanyl in the management of distress in a case series of 11 dying neonates. Methods. A retrospective chart review was undertaken of 58 consecutive referrals of newborns and infants aged six months or younger between November 2006 and July 2010 to the Winnipeg Regional Health Authority Pediatric Palliative Care Service to determine how often IN fentanyl was used and review documented responses after the medication. Results. Of 58 referrals, IN fentanyl was used in 11 patients, in all cases for concerns regarding respiratory distress. Chart documentation indicated that fentanyl was tolerated well, with no circumstances of drug-related apnea and no occurrences of chest wall rigidity. In most cases, labored breathing and restlessness settled after medication administration. The average time from administration of the last dose of fentanyl until death was 61 minutes. Conclusion. We found IN fentanyl, which can be administered in a variety of care settings, to be a minimally invasive means of palliating distress in dying newborns and infants. No adverse events related to its use were noted. J Pain Symptom Manage 2013;46:265-274. (C) 2013 U. S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.	[Harlos, Michael S.] Univ Manitoba, Palliat Med Sect, Winnipeg, MB, Canada; [Harlos, Michael S.; Chochinov, Harvey Max] Univ Manitoba, Fac Med, Winnipeg, MB, Canada; [Lambert, David] Univ Manitoba, Dept Anesthesiol, Winnipeg, MB, Canada; [Harlos, Michael S.] Winnipeg Reg Hlth Author Palliat Care, Winnipeg, MB, Canada; [Harlos, Michael S.; Stenekes, Simone; Lambert, David; Hohl, Chris] Winnipeg Reg Hlth Author Pediat Palliat Care, Winnipeg, MB, Canada; [Lambert, David] Winnipeg Childrens Hosp, Dept Pediat Anesthesiol, Winnipeg, MB, Canada; [Hohl, Chris] Winnipeg Childrens Hosp, Dept Pediat, Winnipeg, MB, Canada; [Chochinov, Harvey Max] CancerCare Manitoba, Manitoba Palliat Care Res Unit, Winnipeg, MB, Canada	Harlos, MS (reprint author), St Boniface Gen Hosp, Room A8024,409 Tache Ave, Winnipeg, MB R2H 2A6, Canada.	mike@harlos.net			Manitoba Institute of Child Health; Canada Research Chair in Palliative Care, Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR)	This study was supported by a grant to Dr. Harlos from the Manitoba Institute of Child Health. The granting agency had no role in the study design, analysis and interpretation of data, writing of the report, or decision to submit the article for publication. Dr. Chochinov is supported by a Canada Research Chair in Palliative Care, Canadian Institutes of Health Research. The authors declare no conflicts of interest.	Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; Bendall JC, 2011, PREHOSP EMERG CARE, V15, P158, DOI 10.3109/10903127.2010.541980; Berlin CM, 1997, PEDIATRICS, V100, P143; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Chung S, 2010, PEDIATR RADIOL, V40, P1236, DOI 10.1007/s00247-009-1521-1; Cole J, 2009, EMERG MED AUSTRALAS, V21, P395, DOI 10.1111/j.1742-6723.2009.01216.x; Crellin D, 2010, EMERG MED AUSTRALAS, V22, P62, DOI 10.1111/j.1742-6723.2010.01257.x; Finn J, 2004, BURNS, V30, P262, DOI 10.1016/j.burns.2003.10.017; Finn M, 2010, EMERG MED J, V27, P300, DOI 10.1136/emj.2008.070474; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Holdgate A, 2010, ACAD EMERG MED, V17, P214, DOI 10.1111/j.1553-2712.2009.00636.x; Johnston S, 2011, EMERG MED J, V28, P57, DOI 10.1136/emj.2009.078717; Kaasa Stein, 2010, J Opioid Manag, V6, P17; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Leuthner SR, 2004, PEDIATR CLIN N AM, V51, P747, DOI 10.1016/j.pcl.2004.01.006; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; Manjushree R, 2002, CAN J ANAESTH, V49, P190; Mercadante S, 2009, EJC SUPPL, V7, P254, DOI 10.1016/S1359-6349(09)70871-7; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Mercadante S, 2009, EUR J PAIN S1, V13, pS198; Mudd S, 2011, J PEDIATR HEALTH CAR, V25, P316, DOI 10.1016/j.pedhc.2010.04.011; OSBORNE R, 1990, CLIN PHARMACOL THER, V47, P12, DOI 10.1038/clpt.1990.2; PANNUTI F, 1982, PHARMACOL RES COMMUN, V14, P369, DOI 10.1016/S0031-6989(82)80107-0; Reisfield GM, 2007, J PALLIAT MED, V10, P465, DOI 10.1089/jpm.2006.0150; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Saunders M, 2010, ACAD EMERG MED, V17, P1155, DOI 10.1111/j.1553-2712.2010.00905.x; Schwagmeier R, 1996, ANAESTHESIST, V45, P231, DOI 10.1007/s001010050257; Sitte Thomas, 2008, J Pain Symptom Manage, V36, pe3, DOI 10.1016/j.jpainsymman.2008.08.002; Striebel H W, 1993, Schmerz, V7, P122, DOI 10.1007/BF02527870; Striebel H W, 1993, Schmerz, V7, P174, DOI 10.1007/BF02530425; STRIEBEL HW, 1993, ANAESTHESIA, V48, P753, DOI 10.1111/j.1365-2044.1993.tb07583.x; STRIEBEL HW, 1992, ANESTHESIOLOGY, V77, P281, DOI 10.1097/00000542-199208000-00010; Striebel HW, 1996, J CLIN ANESTH, V8, P4, DOI 10.1016/0952-8180(95)00167-0; Toussaint S, 2000, CAN J ANAESTH, V47, P299, DOI 10.1007/BF03020941; Vissers D, 2010, CURR MED RES OPIN, V26, P1037, DOI 10.1185/03007991003694340; Voronov P, 2008, PEDIATR ANESTH, V18, P1196, DOI 10.1111/j.1460-9592.2008.02789.x; WEINBERG DS, 1988, CLIN PHARMACOL THER, V44, P335, DOI 10.1038/clpt.1988.159; Wolfe T, 2007, ANN EMERG MED, V49, P721, DOI 10.1016/j.annemergmed.2006.11.031; Wolfe TR, 2010, PEDIATRICS, V126, P532, DOI 10.1542/peds.2010-0616; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P253, DOI 10.1016/S0885-3924(00)00180-9	45	27	28	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	AUG	2013	46	2					265	274		10.1016/j.jpainsymman.2012.07.009			10	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	213AU	WOS:000324026100015	23017621	Bronze			2020-06-30	J	Bayazit, EG; Karaaslan, K; Ozturan, K; Serin, E; Kocoglu, H				Bayazit, Esra Gunnus; Karaaslan, Kazim; Ozturan, Kutay; Serin, Erdinc; Kocoglu, Hasan			Effect of epidural levobupivacaine and levobupivacaine with fentanyl on stress response and postoperative analgesia after total knee replacement	INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS			English	Article						adjuvants; anesthesia; fentanyl; analgesia; patient-controlled; anesthetics; local; levobupivacaine; arthroplasty; replacement; knee; pain; postoperative; surgery stress; response	ROPIVACAINE; BUPIVACAINE; ANESTHESIA; CLONIDINE; SURGERY	Background: Providing sufficient and convenient analgesia is crucial during the postoperative period after total-knee replacement (TKR) to enhance patient mobility and reduce stress response to surgery. The scope of this study is to compare the effects of levobupivacaine and levobupivacaine plus fentanyl on stress response and analgesic efficiency after TKR. Method: In this study, 40 ASA I - II patients scheduled to undergo TKR were subjected to combined spinal epidural anesthesia (CSEA) injecting of 15 mg levobupivacaine and randomly assigned to receive either levobupivacaine 0.125% (Group L) or levobupivacaine 0.125% plus fentanyl 4 mu g ml(-1) (Group F) during postoperative period via the epidural route. Patient controlled epidural analgesia (PCEA) was offered for 24 hours. Venous blood samples were assayed for ach-enocorticotropic hormone (ACTH), cortisol and prolactin levels before surgery and after analgesia administration. Analgesia was assessed using a visual analogue scale (VAS) at rest (VASR) and during movement (VASM). Results: There was no statistically significant difference between the groups in terms of total doses, bolus requests, bolus delivered and side effects (p > 0.05). The ACTH, cortisol and prolactin levels increased following the surgery and decreased during PCA infusion in both groups where the decline in Group F was significant (p < 0.05) at 24 hours after the analgesic treatment and 48 hours after the surgery. Conclusion: We have demonstrated that infusion of levobupivacaine (0.125%) in combination with fentanyl (4 jig ml-1) using PCEA suppressed stress response to surgery significantly and provided better pain relief than levobupivacaine (0.125%) alone after TKR.	[Bayazit, Esra Gunnus; Kocoglu, Hasan] Abant Izzet Baysal Univ Hosp, Dept Anesthesiol, Bolu, Turkey; [Karaaslan, Kazim] Bezmialem Vakif Univ, Fac Med, Dept Anesthesiol, Istanbul, Turkey; [Ozturan, Kutay] Abant Izzet Baysal Univ Hosp, Dept Orthoped & Traumatol, Bolu, Turkey; [Serin, Erdinc] Abant Izzet Baysal Univ Hosp, Fac Med, Dept Biochem, Bolu, Turkey; [Bayazit, Esra Gunnus] Princess Alexandra Hosp, Dept Anesthesiol, Essex, England	Karaaslan, K (reprint author), Bezmialem Vakif Univ, Fac Med, Dept Anesthesiol, Istanbul, Turkey.	kazimkaraaslan@gmail.com			Abant Izzet Baysal UniversityAbant Izzet Baysal University [2008.08.02.280]	This study was funded and supported by a project grant from Abant Izzet Baysal University (Scientific Project Number of 2008.08.02.280). The authors gratefully acknowledge the skillful statistical assistance of Dr. Mustafa Kemal Bayazit and Neslim Hancilar, MSc.	Akural EI, 2002, BRIT J ANAESTH, V88, P803, DOI 10.1093/bja/88.6.803; Burlacu CL, 2006, ANAESTHESIA, V61, P932, DOI 10.1111/j.1365-2044.2006.04793.x; Cinar SO, 2009, EUR J ANAESTH, V26, P430, DOI 10.1097/EJA.0b013e32832974fc; Collis RE, 1999, BRIT J ANAESTH, V82, P233, DOI 10.1093/bja/82.2.233; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; DESBOROUGH JP, 1989, BAILLIERE CLIN ANAES, V3, P317, DOI 10.1016/S0950-3501(89)80003-0; Forster JG, 2004, BRIT J ANAESTH, V93, P670, DOI 10.1093/bja/aeh259; Foster RH, 2000, DRUGS, V59, P551, DOI 10.2165/00003495-200059030-00013; Holte K, 2002, CLIN NUTR, V21, P199, DOI 10.1054/clnu.2001.0514; Howard R, 2008, PEDIATR ANESTH, V18, P64, DOI 10.1111/j.1155-5645.2008.02432.x; Kopacz DJ, 1999, ANESTH ANALG, V89, P1497, DOI 10.1097/00000539-199912000-00034; Kopacz DJ, 1998, ANESTHESIOLOGY, V89, pU785, DOI 10.1097/00000542-199809150-00037; Kouraklis G, 2000, INT SURG, V85, P353; LACOUMENTA S, 1987, BRIT J ANAESTH, V59, P713, DOI 10.1093/bja/59.6.713; Liu SS, 1998, ANESTHESIOLOGY, V88, P688, DOI 10.1097/00000542-199803000-00020; Lyons G, 2001, INT J OBSTET ANESTH, V10, P259, DOI 10.1054/ijoa.2001.0859; Pitimana-Aree S, 2005, REGION ANESTH PAIN M, V30, P446, DOI 10.1016/j.rapm.2005.05.010; Purdie NL, 2004, ANAESTHESIA, V59, P133, DOI 10.1111/j.1365-2044.2004.03582.x; Sanford M, 2010, DRUGS, V70, P761, DOI 10.2165/11203250-000000000-00000; Sezer OA, 2007, INT J OBSTET ANESTH, V16, P226, DOI 10.1016/j.ijoa.2007.02.007; Silvasti M, 2001, ACTA ANAESTH SCAND, V45, P471, DOI 10.1034/j.1399-6576.2001.045004471.x; Yardeni Israel Z, 2007, Int J Surg, V5, P239, DOI 10.1016/j.ijsu.2006.09.008	22	4	5	0	10	DUSTRI-VERLAG DR KARL FEISTLE	DEISENHOFEN-MUENCHEN	BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY	0946-1965			INT J CLIN PHARM TH	Int. J. Clin. Pharmacol. Ther.	AUG	2013	51	8					652	659		10.5414/CP201862			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	212NO	WOS:000323990300005	23782581				2020-06-30	J	Wuethrich, PY; Kessler, TM; Burkhard, FC				Wuethrich, Patrick Y.; Kessler, Thomas M.; Burkhard, Fiona C.			The Effects of Thoracic Epidurally Administered Drugs on Urethral Sphincter Function in Women: A Pooled Analysis	PAIN MEDICINE			English	Article						Urethral Sphincter Function; Epidural Analgesia	LOWER URINARY-TRACT; OPEN RENAL SURGERY; LOW-DOSE INFUSION; DOUBLE-BLIND; SPINAL-ANESTHESIA; BLADDER FUNCTION; MAJOR SURGERY; SYMPTOM INDEX; ANALGESIA; BUPIVACAINE	Objectives. Thoracic epidural analgesia (TEA) has been shown to inhibit detrusor activity in patients undergoing open renal surgery, resulting in clinically relevant post-void residuals. However, the impact of different epidural drug mixtures on urethral sphincter function is not completely elucidated. Design. Pooled analysis of an open observational study and a double-blind randomized trial. Setting. Single tertiary centre. Subjects. Twenty-eight women without lower urinary tract symptoms and post-void residual <100 mL, who underwent open renal surgery with TEA. Methods. Pooling results in three groups with different epidural regimens (7 with bupivacaine 0.125%, 8 with bupivacaine 0.125% and fentanyl 2 mg/mL, and 13 with bupivacaine 0.1% plus fentanyl 2 mg/mL and epinephrine 2 mg/mL). All women underwent urethral pressure measurements before TEA and during TEA 2-3 days postoperatively. All patients received a TEA placed at the insertion site interspace T 8-9. Results. Maximum urethral closure pressure at rest decreased significantly during TEA with bupivacaine alone (median 70 cm H2O [interquartile range 66-76] to 43 [43-65], P = 0.031) and with bupivacaine/fentanyl/epinephrine (75 cm H2O [68-78] to 56 [52-75], P = 0.028), whereas with bupivacaine/fentanyl, no significant change could be detected (74 [51-88] vs 67 [46-70], P = 0.156). In all groups, functional profile length at rest was not influenced during TEA. Conclusion. TEA with bupivacaine and the addition of fentanyl and epinephrine appears to decrease maximum urethral closure pressure at rest in women. The addition of fentanyl alone to bupivacaine may reduce this effect. Thus, the TEA effect on urethral sphincter function seems to depend on the drug mixture administered.	[Wuethrich, Patrick Y.] Univ Hosp Bern, Dept Anesthesiol & Pain Therapy, CH-3010 Bern, Switzerland; [Burkhard, Fiona C.] Univ Hosp Bern, Dept Urol, CH-3010 Bern, Switzerland; [Kessler, Thomas M.] Univ Zurich, Balgrist Univ Hosp, Spinal Cord Injury Ctr & Res, Zurich, Switzerland	Wuethrich, PY (reprint author), Univ Hosp Bern, Dept Anesthesiol & Pain Therapy, CH-3010 Bern, Switzerland.	patrick.wuethrich@insel.ch	Burkhard, Fiona/AAE-4524-2020				Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052; ANDERSSON KE, 1982, PROG NEUROBIOL, V19, P71, DOI 10.1016/0301-0082(82)90021-1; APPELL RA, 1980, J UROLOGY, V124, P410, DOI 10.1016/S0022-5347(17)55474-9; AXELSSON K, 1985, ACTA ANAESTH SCAND, V29, P315, DOI 10.1111/j.1399-6576.1985.tb02207.x; Baldini G, 2009, ANESTHESIOLOGY, V110, P1139, DOI 10.1097/ALN.0b013e31819f7aea; Brading AF, 1999, EXP PHYSIOL, V84, P215, DOI 10.1111/j.1469-445X.1999.tb00084.x; CHAI TC, 1993, J UROLOGY, V150, P1710, DOI 10.1016/S0022-5347(17)35874-3; CHANCELLOR MB, 1993, J UROLOGY, V150, P1706, DOI 10.1016/S0022-5347(17)35872-X; Chapple CR, 2008, EUR UROL, V54, P563, DOI 10.1016/j.eururo.2008.03.109; Crayton R, 2010, NEUROUROL URODYNAM, V29, P777, DOI 10.1002/nau.20822; de Groat WC, 2006, BRIT J PHARMACOL, V147, pS25, DOI 10.1038/sj.bjp.0706604; Freise H, 2008, ANESTHESIOLOGY, V109, P1107, DOI 10.1097/ALN.0b013e31818db16c; Ginosar Y, 2003, ANESTH ANALG, V97, P1439, DOI 10.1213/01.ANE.0000081792.84877.A2; Kamphuis ET, 1998, ANESTHESIOLOGY, V88, P310, DOI 10.1097/00000542-199802000-00007; Madersbacher S, 1999, NEUROUROL URODYNAM, V18, P3, DOI 10.1002/(SICI)1520-6777(1999)18:1<3::AID-NAU2>3.0.CO;2-4; Malinovsky JM, 1998, ANESTH ANALG, V87, P456, DOI 10.1097/00000539-199808000-00042; Manion SC, 2011, ANESTHESIOLOGY, V115, P181, DOI 10.1097/ALN.0b013e318220847c; Michel MC, 2006, BRIT J PHARMACOL, V147, pS88, DOI 10.1038/sj.bjp.0706619; Niemi G, 1998, ACTA ANAESTH SCAND, V42, P897, DOI 10.1111/j.1399-6576.1998.tb05348.x; Niemi G, 2002, ANESTH ANALG, V94, P1598, DOI 10.1097/00000539-200206000-00044; Niemi G, 2003, ACTA ANAESTH SCAND, V47, P439, DOI 10.1034/j.1399-6576.2003.00077.x; Niemi G, 2001, ACTA ANAESTH SCAND, V45, P221, DOI 10.1034/j.1399-6576.2001.450214.x; Niemi G, 2005, BEST PRACT RES-CLIN, V19, P229, DOI 10.1016/j.bpa.2004.12.004; RAWAL N, 1983, ANESTH ANALG, V62, P641; Wiseman OJ, 2002, J UROLOGY, V3, P51; Wuethrich PY, 2013, ANESTHESIOLOGY, V118, P70, DOI 10.1097/ALN.0b013e318271606a; Wuethrich PY, 2011, NEUROUROL URODYNAM, V30, P121, DOI 10.1002/nau.20950; Wuethrich PY, 2010, ANESTHESIOLOGY, V112, P1345, DOI 10.1097/ALN.0b013e3181d4f4fe	28	4	4	0	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1526-2375			PAIN MED	Pain Med.	AUG	2013	14	8					1248	1253		10.1111/pme.12128			6	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	202FP	WOS:000323199400017	23614971	Bronze			2020-06-30	J	Toyama, S; Kakumoto, M; Morioka, M; Matsuoka, K; Omatsu, H; Tagaito, Y; Numai, T; Shimoyama, M				Toyama, S.; Kakumoto, M.; Morioka, M.; Matsuoka, K.; Omatsu, H.; Tagaito, Y.; Numai, T.; Shimoyama, M.			Perfusion index derived from a pulse oximeter can predict the incidence of hypotension during spinal anaesthesia for Caesarean delivery	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthesia; obstetric; anaesthetic techniques; subarachnoid; complications; hypotension; equipment; pulse oximeters; measurement techniques; plethysmography	COLLOID PRELOAD; PREVENTING HYPOTENSION; PHENYLEPHRINE INFUSION; VENOUS DISTENSIBILITY; NORMAL-PREGNANCY; CARDIAC-OUTPUT; BLOOD-VOLUME; INDICATOR; PARTURIENTS; PRESSURE	Hypotension during spinal anaesthesia for Caesarean delivery is a result of decreased vascular resistance due to sympathetic blockade and decreased cardiac output due to blood pooling in blocked areas of the body. Change in baseline peripheral vascular tone due to pregnancy may affect the degree of such hypotension. The perfusion index (PI) derived from a pulse oximeter has been used for assessing peripheral perfusion dynamics due to changes in peripheral vascular tone. The aim of this study was to examine whether baseline PI could predict the incidence of spinal anaesthesia-induced hypotension during Caesarean delivery. Parturients undergoing elective Caesarean delivery under spinal anaesthesia with hyperbaric bupivacaine 10 mg and fentanyl 20 g were enrolled in this prospective study. The correlation between baseline PI and the degree of hypotension during spinal anaesthesia and also the predictability of spinal anaesthesia-induced hypotension during Caesarean delivery by PI were investigated. Baseline PI correlated with the degree of decreases in systolic and mean arterial pressure (r0.664, P0.0001 and r0.491, P0.0029, respectively). The cut-off PI value of 3.5 identified parturients at risk for spinal anaesthesia-induced hypotension with a sensitivity of 81 and a specificity of 86 (P0.001). The change of PI in parturients with baseline PI3.5 was not significant during the observational period, while PI in parturients with baseline PI3.5 demonstrated marked decreases after spinal injection. We demonstrated that higher baseline PI was associated with profound hypotension and that baseline PI could predict the incidence of spinal anaesthesia-induced hypotension during Caesarean delivery.	[Toyama, S.; Kakumoto, M.; Morioka, M.; Matsuoka, K.; Omatsu, H.; Tagaito, Y.; Numai, T.; Shimoyama, M.] Teikyo Univ, Chiba Med Ctr, Dept Anesthesiol, Ichihara, Chiba 2990111, Japan	Toyama, S (reprint author), Teikyo Univ, Chiba Med Ctr, Dept Anesthesiol, 3426-3 Anesaki, Ichihara, Chiba 2990111, Japan.	s-toyama@suite.plala.or.jp		Toyama, Satoshi/0000-0003-3640-1976			Adsumelli RSN, 2003, BRIT J ANAESTH, V91, P695, DOI 10.1093/bja/aeg248; Ajne G, 2005, AM J OBSTET GYNECOL, V193, P234, DOI 10.1016/j.ajog.2004.11.023; Aya AGM, 2003, ANESTH ANALG, V97, P867, DOI 10.1213/01.ANE.0000073610.23885.F2; Babchenko A, 2001, PHYSIOL MEAS, V22, P389, DOI 10.1088/0967-3334/22/2/310; BARWIN BN, 1976, AM J OBSTET GYNECOL, V125, P921, DOI 10.1016/0002-9378(76)90489-0; Berlac P A, 2005, Int J Obstet Anesth, V14, P26, DOI 10.1016/j.ijoa.2004.06.003; BONICA JJ, 1972, ANESTHESIOLOGY, V36, P219, DOI 10.1097/00000542-197203000-00006; Bowyer L, 2003, BJOG-INT J OBSTET GY, V110, P383, DOI 10.1016/S1470-0328(02)02930-0; Broch O, 2011, ACTA ANAESTH SCAND, V55, P686, DOI 10.1111/j.1399-6576.2011.02435.x; Clapp JF, 1997, AM J CARDIOL, V80, P1469, DOI 10.1016/S0002-9149(97)00738-8; Cyna AM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002251.pub2; Frolich MA, 2002, CAN J ANAESTH, V49, P185; Galvin EM, 2006, ANESTH ANALG, V102, P598, DOI 10.1213/01.ane.0000189556.49429.16; Ginosar Y, 2009, ACTA ANAESTH SCAND, V53, P1018, DOI 10.1111/j.1399-6576.2009.01968.x; HALES JRS, 1989, CLIN EXP PHARMACOL P, V16, P403, DOI 10.1111/j.1440-1681.1989.tb01578.x; Hanss R, 2007, ACTA ANAESTH SCAND, V51, P1297, DOI 10.1111/j.1399-6576.2007.01455.x; Hanss R, 2005, ANESTHESIOLOGY, V102, P1086, DOI 10.1097/00000542-200506000-00005; Harten JM, 2005, ANAESTHESIA, V60, P348, DOI 10.1111/j.1365-2044.2005.04113.x; Holmes F, 1959, ANAESTHESIA, V14, P204; Kee WDN, 2005, ANESTHESIOLOGY, V103, P744, DOI 10.1097/00000542-200510000-00012; Kee WDN, 2004, ANESTH ANALG, V98, P815; Kinsella S M, 1996, Int J Obstet Anesth, V5, P3, DOI 10.1016/S0959-289X(96)80067-7; Langesaeter E, 2008, ANESTHESIOLOGY, V109, P856, DOI 10.1097/ALN.0b013e31818a401f; Ledowski T, 2010, INT J OBSTET ANESTH, V19, P282, DOI 10.1016/j.ijoa.2010.01.001; Lima AP, 2002, CRIT CARE MED, V30, P1210; Mowafi HA, 2009, ANESTH ANALG, V108, P549, DOI 10.1213/ane.0b013e31818fc35b; Panni MK, 2006, BRIT J ANAESTH, V96, P106, DOI 10.1093/bja/aei284; ROUT CC, 1993, ANAESTHESIA, V48, P304, DOI 10.1111/j.1365-2044.1993.tb06948.x; SAKAI K, 1994, HYPERTENSION, V24, P461, DOI 10.1161/01.HYP.24.4.461; Sharwood-Smith G, 2006, BRIT J ANAESTH, V96, P100, DOI 10.1093/bja/aei266; Siddik-Sayyid SM, 2009, ANESTH ANALG, V109, P1219, DOI 10.1213/ane.0b013e3181b2bd6b; Takahashi S, 2010, J PERINATOL, V30, P265, DOI 10.1038/jp.2009.159; Tamilselvan P, 2009, ANESTH ANALG, V109, P1916, DOI 10.1213/ANE.0b013e3181bbfdf6; Teoh WHL, 2009, ANESTH ANALG, V108, P1592, DOI 10.1213/ane.0b013e31819e016d; Ueyama H, 1999, ANESTHESIOLOGY, V91, P1571, DOI 10.1097/00000542-199912000-00006; Zaramella Patrizia, 2005, J Perinatol, V25, P417, DOI 10.1038/sj.jp.7211328	36	32	35	0	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	AUG	2013	111	2					235	241		10.1093/bja/aet058			7	Anesthesiology	Anesthesiology	190KF	WOS:000322337900016	23518802	Bronze			2020-06-30	J	Kaufman, MJ; Janes, AC; Frederick, BD; Brimson-Theberge, M; Tong, YJ; McWilliams, SB; Bear, A; Gillis, TE; Schrode, KM; Renshaw, PF; Negus, SS				Kaufman, Marc J.; Janes, Amy C.; Frederick, Blaise deB; Brimson-Theberge, Melanie; Tong, Yunjie; McWilliams, Samuel B.; Bear, Ashley; Gillis, Timothy E.; Schrode, Katrina M.; Renshaw, Perry F.; Negus, S. Stevens			A Method for Conducting Functional MRI Studies in Alert Nonhuman Primates: Initial Results With Opioid Agonists in Male Cynomolgus Monkeys	EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY			English	Article						macaque; fMRI; fentanyl; U69,593; awake animal imaging	RECEPTOR-LIGAND BINDING; RHESUS-MONKEYS; MOTIVATIONAL PROPERTIES; ANALGESIC EFFICACY; HUMAN STRIATUM; KAPPA; MU; INVOLVEMENT; ACTIVATION; PEPTIDES	Functional MRI (fMRI) has emerged as a powerful technique for assessing neural effects of psychoactive drugs and other stimuli. Several experimental approaches have been developed to use fMRI in anesthetized and awake animal subjects, each of which has its advantages and complexities. We sought to assess whether one particular method to scan alert postanesthetized animals can be used to assess fMRI effects of opioid agonists. To date, the use of fMRI as a method to compare pharmacological effects of opioid drugs has been limited. Such studies are important because mu and kappa opioid receptor agonists produce distinct profiles of behavioral effects related both to clinically desirable endpoints (e.g., analgesia) and to undesirable effects (e.g., abuse potential). This study sought to determine whether we could use our fMRI approach to compare acute effects of behaviorally equipotent (3.2 mu g/kg) intravenous doses of fentanyl and U69,593 (doses that do not affect cardiorespiratory parameters). Scans were acquired in alert male cynomolgus macaques acclimated to undergo fMRI scans under restraint, absent excessive stress hormone increases. These opioid agonists activated bilateral striatal and nucleus accumbens regions of interest. At the dose tested, U69,593 induced greater left nucleus accumbens BOLD activation than fentanyl, while fentanyl activated left dorsal caudate nucleus more than U69,593. Our results suggest that our fMRI approach could be informative for comparing effects of opioid agonists.	[Kaufman, Marc J.; Janes, Amy C.; Frederick, Blaise deB; Brimson-Theberge, Melanie; Tong, Yunjie; Gillis, Timothy E.; Renshaw, Perry F.] McLean Hosp, McLean Imaging Ctr, Belmont, MA 02478 USA; [Kaufman, Marc J.; Janes, Amy C.; Frederick, Blaise deB; Brimson-Theberge, Melanie; Tong, Yunjie; McWilliams, Samuel B.; Bear, Ashley; Gillis, Timothy E.; Schrode, Katrina M.; Renshaw, Perry F.; Negus, S. Stevens] Harvard Univ, Sch Med, Dept Psychiat, Belmont, MA 02178 USA; [McWilliams, Samuel B.; Bear, Ashley; Schrode, Katrina M.; Negus, S. Stevens] McLean Hosp, Alcohol & Drug Abuse Res Ctr, Belmont, MA 02478 USA	Kaufman, MJ (reprint author), McLean Hosp, McLean Imaging Ctr, 115 Mill St, Belmont, MA 02478 USA.	kaufman@mclean.harvard.edu	Frederick, Blaise/G-6098-2012; Renshaw, Perry/O-1384-2018; Janes, Amy/A-5322-2013	Frederick, Blaise/0000-0001-5832-5279; Janes, Amy/0000-0002-3749-5006; Kaufman, Marc/0000-0002-4383-1264	NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA11460, K02 DA017324, K01 DA029645, K25 DA014013]; Counter-Drug Technology Assessment Center (CTAC), an office within the Office of National Drug Control Policy (ONDCP) [DABK39-03-C-0075]	This work was supported in part by NIDA Grants R01 DA11460 (SSN), K02 DA017324 (MJK), K01 DA029645 (ACJ), K25 DA014013 (BBF), and by a gift from John and Virginia B. Taplin. In addition, this project was supported in part by the Counter-Drug Technology Assessment Center (CTAC), an office within the Office of National Drug Control Policy (ONDCP), via Contract Number DABK39-03-C-0075 awarded by the Army Contracting Agency. The content of the information does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred. The sponsors had no role in this study other than providing financial support.	BALSKUBIK R, 1989, PSYCHOPHARMACOLOGY, V98, P203, DOI 10.1007/BF00444692; Becerra L, 2001, NEURON, V32, P927, DOI 10.1016/S0896-6273(01)00533-5; Beraha E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046931; BESSON C, 1995, NEUROSCIENCE, V68, P963, DOI 10.1016/0306-4522(95)00255-H; Butelman ER, 2008, PSYCHONEUROENDOCRINO, V33, P292, DOI 10.1016/j.psyneuen.2007.11.011; Butelman ER, 2012, J PHARMACOL EXP THER, V341, P802, DOI 10.1124/jpet.112.193227; Butelman ER, 2010, PSYCHOPHARMACOLOGY, V210, P253, DOI 10.1007/s00213-009-1771-5; Carlezon WA, 2009, NEUROPHARMACOLOGY, V56, P122, DOI 10.1016/j.neuropharm.2008.06.075; Cauda F, 2011, J COGNITIVE NEUROSCI, V23, P2864, DOI 10.1162/jocn.2011.21624; Chen G, 2012, MAGN RESON IMAGING, V30, P36, DOI 10.1016/j.mri.2011.09.010; Diaconescu AO, 2010, BRAIN RES, V1313, P143, DOI 10.1016/j.brainres.2009.11.064; DYKSTRA LA, 1988, J PHARMACOL EXP THER, V246, P813; Editorial, 2011, LANCET, V378, P1677, DOI [10.1016/S0140-6736(11)61723-6, DOI 10.1016/S0140-6736(11)61723-6]; Fechir M, 2010, NEUROIMAGE, V50, P847, DOI 10.1016/j.neuroimage.2009.12.004; FILE SE, 1986, BEHAV BRAIN RES, V21, P189, DOI 10.1016/0166-4328(86)90236-6; Ford CP, 2006, J NEUROSCI, V26, P2788, DOI 10.1523/JNEUROSCI.4331-05.2006; Gear R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0050169; GIUFFRA M, 1993, CLIN NEUROPHARMACOL, V16, P444, DOI 10.1097/00002826-199310000-00007; Gottfried JA, 2002, J NEUROSCI, V22, P10829; GUTSTEIN H, 2005, PHARMACOL BASIS THER, P547; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Ku SP, 2011, NEURON, V70, P352, DOI 10.1016/j.neuron.2011.02.048; Leppa M, 2006, NEUROIMAGE, V31, P661, DOI 10.1016/j.neuroimage.2005.12.019; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; Madsen K. H., 2006, P INT SOC MAGNETIC R, V14; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; MANSOUR A, 1994, J COMP NEUROL, V350, P412, DOI 10.1002/cne.903500307; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; MUCHA RF, 1985, PSYCHOPHARMACOLOGY, V86, P274, DOI 10.1007/BF00432213; Murnane KS, 2010, J NEUROSCI METH, V191, P11, DOI 10.1016/j.jneumeth.2010.06.001; Negus SS, 2008, EXP CLIN PSYCHOPHARM, V16, P386, DOI 10.1037/a0013088; NEGUS SS, 1993, J PHARMACOL EXP THER, V267, P896; Negus SS, 2004, J PAIN, V5, P92, DOI 10.1016/j.jpain.2003.11.006; NUSSMEIER NA, 1991, ANESTH ANALG, V72, P221, DOI 10.1213/00000539-199102000-00015; Oei NYL, 2012, SOC COGN AFFECT NEUR, V7, P403, DOI 10.1093/scan/nsr024; Ossewaarde L, 2011, NEUROIMAGE, V55, P345, DOI 10.1016/j.neuroimage.2010.11.068; Pande AC, 1996, CLIN NEUROPHARMACOL, V19, P451, DOI 10.1097/00002826-199619050-00009; Pande AC, 1996, CLIN NEUROPHARMACOL, V19, P92, DOI 10.1097/00002826-199619010-00009; PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896; Qin SZ, 2012, J NEUROSCI, V32, P4032, DOI 10.1523/JNEUROSCI.3101-11.2012; SHIPPENBERG TS, 1987, BRAIN RES, V436, P169, DOI 10.1016/0006-8993(87)91571-X; Sim-Selley LJ, 1999, NEUROSCIENCE, V94, P651, DOI 10.1016/S0306-4522(99)00344-9; SPANAGEL R, 1990, J NEUROCHEM, V55, P1734, DOI 10.1111/j.1471-4159.1990.tb04963.x; Todtenkopf MS, 2004, PSYCHOPHARMACOLOGY, V172, P463, DOI 10.1007/s00213-003-1680-y; Ur E, 1997, BRIT J PHARMACOL, V120, P781, DOI 10.1038/sj.bjp.0700971; Vivian JA, 1998, J PHARMACOL EXP THER, V286, P697; Vonkeman HE, 1996, J COMP NEUROL, V374, P223, DOI 10.1002/(SICI)1096-9861(19961014)374:2<223::AID-CNE5>3.0.CO;2-4; Voorn P, 1996, NEUROSCIENCE, V75, P777, DOI 10.1016/0306-4522(96)00271-0; WOODS JH, 1987, PSYCHOPHARMACOLOGY 3, P1555; Zald DH, 2002, NEUROIMAGE, V16, P746, DOI 10.1006/nimg.2002.1115; Zhang ZM, 2000, BRAIN RES, V852, P290, DOI 10.1016/S0006-8993(99)02243-X; Zhou Y, 2013, SYNAPSE, V67, P358, DOI 10.1002/syn.21638	52	2	2	0	2	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1064-1297			EXP CLIN PSYCHOPHARM	Exp. Clin. Psychopharmacol.	AUG	2013	21	4					323	331		10.1037/a0033062			9	Psychology, Biological; Psychology, Clinical; Pharmacology & Pharmacy; Psychiatry	Psychology; Pharmacology & Pharmacy; Psychiatry	198RC	WOS:000322939000007	23773004	Green Accepted			2020-06-30	J	Sawano, Y; Miyazaki, M; Shimada, H; Kadoi, Y				Sawano, Yukari; Miyazaki, Masumi; Shimada, Hitoshi; Kadoi, Yuji			Optimal fentanyl dosage for attenuating systemic hemodynamic changes, hormone release and cardiac output changes during the induction of anesthesia in patients with and without hypertension: a prospective, randomized, double-blinded study	JOURNAL OF ANESTHESIA			English	Article						Fentanyl dose; Cardiac output; Intubation; Hypertension	TRACHEAL INTUBATION; ENDOTRACHEAL INTUBATION; RESPONSES; LARYNGOSCOPY; ESMOLOL; REMIFENTANIL; ANAESTHESIA; ALFENTANIL; PROPOFOL; BLUNTS	The purpose of this study was to compare the dose-related effects of fentanyl on systemic hemodynamics, hormone release and cardiac output in response to endotracheal intubation in patients with and without hypertension. Forty-five patients without hypertension and 45 patients with hypertension (total 90 patients) undergoing elective general surgical, urological or gynecological procedures under general anesthesia were studied. The patients were randomly divided into three groups to receive either saline (control), 2.0 mu g/kg fentanyl or 4.0 mu g/kg fentanyl before tracheal intubation. Anesthesia was induced via intravenous target controlled infusion of propofol (plasma concentration, 4.0 mu g/mL) followed by administration of the three drugs. Heart rate, blood pressure, and cardiac output were continuously monitored using Flo Trac/Vigileo system (TM) and Bispectral index from before anesthetic induction until 10 min after tracheal intubation. In patients without hypertension, there was a significant difference in mean arterial pressure (MAP) among the three groups 2 min after intubation. Cardiac index (CI) in all three groups decreased before intubation compared with that in the awake period, returning to awake values after intubation in all three groups. There was a significant difference in CI between the 4 mu g/kg fentanyl group and the other two groups immediately and 1 min after intubation. In patients with hypertension, a differential time course of MAP changes was observed among the three groups after intubation. CI in the three groups decreased after the induction of anesthesia and increased after intubation in control and 2 mu g/kg fentanyl groups compared with that in the awake period. The present study shows that it is preferable to administer 2 mu g/kg fentanyl in patients without hypertension and 4 mu g/kg fentanyl in patients with hypertension in order to minimize the changes in heart rate, systolic blood pressure and cardiac output associated with tracheal intubation.	[Sawano, Yukari; Miyazaki, Masumi; Shimada, Hitoshi] Tomioka Gen Hosp, Dept Anesthesia, Maebashi, Gumma, Japan; [Kadoi, Yuji] Gunma Univ Hosp, Dept Anesthesiol, Maebashi, Gunma 3718511, Japan	Kadoi, Y (reprint author), Gunma Univ Hosp, Dept Anesthesiol, 3-39-22 Showa Machi, Maebashi, Gunma 3718511, Japan.	kadoi@med.gunma-u.ac.jp					Adachi YU, 2002, ANESTH ANALG, V95, P233, DOI 10.1097/00000539-200207000-00043; Alanoglu Z, 2006, J CLIN ANESTH, V18, P34, DOI 10.1016/j.jclinane.2005.06.006; Feng C K, 1996, Acta Anaesthesiol Sin, V34, P61; Figueredo E, 2001, ACTA ANAESTH SCAND, V45, P1011, DOI 10.1034/j.1399-6576.2001.450815.x; Fukuda I, 2011, J JAPAN SOC CLIN ANE, V31, P81; Guarracino F, 2005, Minerva Anestesiol, V71, P335; HELFMAN SM, 1991, ANESTH ANALG, V72, P482; Higuchi Tomoyasu, 2007, Masui, V56, P1339; Inomata S, 2010, BRIT J ANAESTH, V105, P361, DOI 10.1093/bja/aeq168; LOW JM, 1986, BRIT J ANAESTH, V58, P471, DOI 10.1093/bja/58.5.471; Maguire AM, 2001, BRIT J ANAESTH, V86, P90, DOI 10.1093/bja/86.1.90; MARTIN DE, 1982, ANESTH ANALG, V61, P680; MILLER DR, 1993, ANESTH ANALG, V76, P1040; Miyazaki M, 2008, J CLIN ANESTH, V20, P257, DOI 10.1016/j.jclinane.2007.11.006; Naito Aya, 2009, Masui, V58, P77; PRYSROBERTS C, 1971, BRIT J ANAESTH, V43, P531, DOI 10.1093/bja/43.6.531; PRYSROBERTS C, 1971, BRIT J ANAESTH, V43, P122, DOI 10.1093/bja/43.2.122; Reid JE, 2000, BRIT J ANAESTH, V84, P422; RUSSELL WJ, 1981, BRIT J ANAESTH, V53, P837, DOI 10.1093/bja/53.8.837; Sato Kenji, 2007, Masui, V56, P1274; Sharma S, 1996, CAN J ANAESTH, V43, P778, DOI 10.1007/BF03013028; VANAKEN H, 1988, ANESTHESIOLOGY, V68, P157; Wax DB, 2010, J CARDIOTHOR VASC AN, V24, P927, DOI 10.1053/j.jvca.2010.06.022	23	7	7	0	4	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668			J ANESTH	J. Anesth.	AUG	2013	27	4					505	511		10.1007/s00540-012-1552-x			7	Anesthesiology	Anesthesiology	202VQ	WOS:000323248700004	23314694				2020-06-30	J	Aydogan, MS; Ozturk, E; Erdogan, MA; Yucel, A; Durmus, M; Ersoy, MO; Colak, C				Aydogan, Mustafa Said; Ozturk, Erdogan; Erdogan, Mehmet Ali; Yucel, Aytac; Durmus, Mahmut; Ersoy, Mehmet Ozcan; Colak, Cemil			The effects of secondhand smoke on postoperative pain and fentanyl consumption	JOURNAL OF ANESTHESIA			English	Article						Secondhand smoke; Fentanyl consumption; Pain; Postoperative	NARCOTIC REQUIREMENTS; SERUM COTININE; MORPHINE; MISCLASSIFICATION; ANESTHESIA; SURGERY	Although the need for increased postoperative analgesia in smokers has been described, the effect of secondhand smoke on postoperative analgesia requirements has not been studied. We examined the effects of secondhand smoke on fentanyl consumption and postoperative pain. In this study, 101 patients (American Society of Anesthesiology physical status I and II) who underwent abdominal hysterectomy were divided into 3 groups according to history of exposure to cigarette smoke as per medical records which was retrospectively confirmed by measurement of serum cotinine: smokers (n = 28), nonsmokers (n = 31), and secondhand smokers (n = 32). All patients received propofol-remifentanil total intravenous anesthesia and used fentanyl patient controlled analgesia for postoperative pain. The fentanyl consumption visual analogue scale-pain intensity (VAS-PI) score and side effects were recorded in the postanesthesia care unit (PACU) and at 2, 4, 6, and 24 h after surgery. Fentanyl consumption at all the evaluation time points was significantly higher in secondhand smokers than in nonsmokers (P < 0.05). However, fentanyl consumption in secondhand smokers was lower than that in smokers in the PACU and at 24 h (P < 0.05). VAS-PI scores during movement and at rest in the PACU and at 4, 6, and 24 h after surgery were higher in secondhand smokers than in nonsmokers (P < 0.05). There were no statistically significant differences between the groups with regard to side effects such as nausea, vomiting, and dizziness (P > 0.05). Secondhand smoking was associated with increased postoperative fentanyl consumption, and increased VAS-PI scores. These findings may be beneficial for managing postoperative pain in secondhand smokers.	[Aydogan, Mustafa Said; Erdogan, Mehmet Ali; Yucel, Aytac; Durmus, Mahmut; Ersoy, Mehmet Ozcan] Inonu Univ, Fac Med, Dept Anesthesiol & Reanimat, Malatya, Turkey; [Ozturk, Erdogan] Bezm I Alem Univ, Fac Med, Dept Anesthesiol & Reanimat, Istanbul, Turkey; [Colak, Cemil] Inonu Univ, Fac Med, Dept Biostat & Med Informat, Malatya, Turkey	Aydogan, MS (reprint author), Inonu Univ, Fac Med, Dept Anesthesiol & Reanimat, Malatya, Turkey.	dr_mustafasaid@hotmail.com	Durmus, Mahmut/AAG-3377-2019				Apfel CC, 2002, ACTA ANAESTH SCAND, V46, P921, DOI 10.1034/j.1399-6576.2002.460801.x; BENOWITZ NL, 1983, CLIN PHARMACOL THER, V34, P604, DOI 10.1038/clpt.1983.222; Creekmore FM, 2004, ANN PHARMACOTHER, V38, P949, DOI 10.1345/aph.1D580; JARVIS MJ, 1984, [No title captured], V133, P68; LEE PN, 1986, LANCET, V2, P867; Macintyre PE, 1996, PAIN, V64, P357, DOI 10.1016/0304-3959(95)00128-X; Morin C, 2000, PAIN, V85, P79, DOI 10.1016/S0304-3959(99)00248-1; PATRICK DL, 1994, AM J PUBLIC HEALTH, V84, P1086, DOI 10.2105/AJPH.84.7.1086; Pavlin JD, 2008, CURR OPIN ANESTHESIO, V21, P729, DOI 10.1097/ACO.0b013e328316bb02; POMERLEAU OF, 1983, PSYCHOPHARMACOLOGY, V81, P61, DOI 10.1007/BF00439275; SCHEIN JR, 1995, ANN PHARMACOTHER, V29, P1139, DOI 10.1177/106002809502901113; Seccareccia F, 2003, EUR J EPIDEMIOL, V18, P487, DOI 10.1023/A:1024672522802; Shi Y, 2010, ANESTHESIOLOGY, V113, P977, DOI 10.1097/ALN.0b013e3181ebdaf9; SIVAM SP, 1984, PSYCHOPHARMACOLOGY, V84, P64, DOI 10.1007/BF00432026; STANLEY TH, 1984, CAN ANAESTH SOC J, V31, P368, DOI 10.1007/BF03015404; Steinmiller Caren L, 2012, J Opioid Manag, V8, P227, DOI 10.5055/jom.2012.0120; Tonnesen H, 2011, ANESTHESIOLOGY, V115, P1, DOI 10.1097/ALN.0b013e31822085f3; WAGENKNECHT LE, 1992, AM J PUBLIC HEALTH, V82, P33, DOI 10.2105/AJPH.82.1.33; Woodside JR, 2000, J ADDICT DIS, V19, P1, DOI 10.1300/J069v19n04_01; Yanagidate F, 2004, BRIT J ANAESTH, V93, P362, DOI 10.1093/bja/aeh218	20	11	12	0	3	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668			J ANESTH	J. Anesth.	AUG	2013	27	4					569	574		10.1007/s00540-013-1565-0			6	Anesthesiology	Anesthesiology	202VQ	WOS:000323248700013	23397133				2020-06-30	J	Kudo, T; Kimura, F; Kudo, T; Kudo, M; Hirota, K				Kudo, Tomoyuki; Kimura, Futoshi; Kudo, Tsuyoshi; Kudo, Mihoko; Hirota, Kazuyoshi			Quantitative measurement of blood remifentanil concentration: development of a new method and clinical application	JOURNAL OF ANESTHESIA			English	Article						Remifentanil; Fentanyl; Blood concentration; Gas chromatography-mass spectrometry	PHARMACOKINETICS	We have developed a new detection method of blood remifentanil concentration using a gas chromatography-mass spectrometry(GC-MS) with fentanyl as the internal standard(IS). The detection was performed at m/z 168 and 245 for remifentanil and fentanyl, respectively. In addition, the retention times of remifentanil and fentanyl were 5 min 45 s and 6 min 51 s, respectively. The standard curve of relationship between remifentanil concentration and the ratio of the peak area of remifentanil to fentanyl was satisfactorily fitted as linear regression (R (2) = 0.998, p < 0.01). Intra- and inter-assay CV was 10.5 and 11.5 %, respectively. In the clinical setting, 21 adult patients undergoing elective surgery under propofol-remifentanil TIVA were enrolled. To determine blood remifentanil concentrations, arterial blood was obtained at 0-30 min after cessation of remifentanil infusion at 0.2 mu g/kg/min. Blood samples were given into sample tubes(chilled on ice) containing citric acid 50 % 60 mu l which inactivates all esterase, and then stored at -20 A degrees C until assay. Measured blood remifentanil concentration was 3.59 +/- A 0.74 ng/ml at the end of remifentanil infusion, and the ime for a decrease in blood remifentanil concentration by half was similar to 2 min. Remifentanil concentration was below the detection limit 30 min after the cessation. Thus, we have confirmed that this new method is clinically applicable.	[Kudo, Tomoyuki; Kimura, Futoshi; Kudo, Tsuyoshi; Kudo, Mihoko; Hirota, Kazuyoshi] Hirosaki Univ, Grad Sch Med, Dept Anesthesiol, Hirosaki, Aomori 0368562, Japan	Hirota, K (reprint author), Hirosaki Univ, Grad Sch Med, Dept Anesthesiol, Hirosaki, Aomori 0368562, Japan.	hirotak@cc.hirosaki-u.ac.jp	Hirota, Kazuyoshi/S-3292-2019				Michelsen LG, 1996, J CLIN ANESTH, V8, P679, DOI 10.1016/S0952-8180(96)00179-1; Minto CF, 1997, ANESTHESIOLOGY, V86, P10, DOI 10.1097/00000542-199701000-00004	2	6	6	0	11	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668			J ANESTH	J. Anesth.	AUG	2013	27	4					615	617		10.1007/s00540-012-1549-5			3	Anesthesiology	Anesthesiology	202VQ	WOS:000323248700020	23291717				2020-06-30	J	Sung, TY; Kim, MS; Cho, CK; Park, DH; Kang, PS; Lee, SE; Kwon, WK; Woo, NS; Kim, SH				Sung, Tae-Yun; Kim, Min-Su; Cho, Choon-Kyu; Park, Dong-Ho; Kang, Po-Soon; Lee, Sang-Eok; Kwon, Won-Kyoung; Woo, Nam-Sik; Kim, Seong-Hyop			Clinical effects of intrathecal fentanyl on shoulder tip pain in laparoscopic total extraperitoneal inguinal hernia repair under spinal anaesthesia: A double-blind, prospective, randomized controlled trial	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						Laparoscopic total extraperitoneal inguinal hernia repair; spinal anaesthesia; intrathecal fentanyl	EPIDURAL-ANESTHESIA; MANAGEMENT; OPIOIDS; MESH	Objective The study evaluated the clinical intraoperative effects of intrathecal administration of fentanyl on shoulder tip pain in patients undergoing laparoscopic total extraperitoneal inguinal hernia repair (TEP) under spinal anaesthesia. Methods Patients undergoing TEP were allocated in a double-blinded, prospective, randomized manner to two groups. Spinal anaesthesia was induced by intrathecal administration of 2.8ml of 0.5% hyperbaric bupivacaine (14mg) in the control group and with 2.6ml of 0.5% hyperbaric bupivacaine (13mg) and 10 mu g fentanyl (0.2ml) in the experimental group. Results The quality of muscle relaxation, adequacy of operative space and incidence of pneumoperitoneum were similar in the two groups (n=36 per group). Compared with the control group, the experimental group had significantly fewer cases of hypotension (12 [33.3%]) versus 23 [63.9%]) and shoulder tip pain (nine [25%] versus 18 [50%]). Intraoperative shoulder tip pain was more severe in the control group than in the experimental group. Conclusions Addition of intrathecal fentanyl to local anaesthetic can relieve shoulder tip pain with no change in complications, especially hypotension, during TEP under spinal anaesthesia.	[Sung, Tae-Yun; Kim, Min-Su; Cho, Choon-Kyu; Park, Dong-Ho; Kang, Po-Soon] Konyang Univ, Coll Med, Konyang Univ Hosp, Dept Anaesthesiol & Pain Med, Taejon, South Korea; [Lee, Sang-Eok] Konyang Univ, Coll Med, Konyang Univ Hosp, Dept Surg, Taejon, South Korea; [Kwon, Won-Kyoung; Woo, Nam-Sik; Kim, Seong-Hyop] Konkuk Univ, Dept Anaesthesiol & Pain Med, Med Ctr, Sch Med, Seoul 143729, South Korea; [Kim, Seong-Hyop] Konkuk Univ, Sch Med, Res Inst Med Sci, Seoul, South Korea	Kim, SH (reprint author), Konkuk Univ, Dept Anaesthesiol & Pain Med, Med Ctr, Sch Med, 120-1 Neungdong Ro Hwayang Dong, Seoul 143729, South Korea.	yshkim75@daum.net			National Research Foundation of Korea (NRF)National Research Foundation of Korea; Ministry of Education, Science and TechnologyMinistry of Education, Science and Technology, Republic of Korea [2012R1A1A1001819]	This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Science and Technology (grant number 2012R1A1A1001819).	Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Azurin DJ, 1996, J LAPAROENDOSC SURG, V6, P369, DOI 10.1089/lps.1996.6.369; Ben-David B, 2000, ANESTHESIOLOGY, V92, P6, DOI 10.1097/00000542-200001000-00007; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; BROMAGE PR, 1964, BRIT J ANAESTH, V36, P342, DOI 10.1093/bja/36.6.342; Eisenach JC, 2001, REGION ANESTH PAIN M, V26, P296, DOI 10.1053/rapm.2001.22255; Hamber EA, 1999, REGION ANESTH PAIN M, V24, P255; HONET JE, 1992, ANESTH ANALG, V75, P734; Ismail M, 2009, HERNIA, V13, P115, DOI 10.1007/s10029-008-0442-5; Junger A, 2001, ANESTH ANALG, V92, P1203, DOI 10.1097/00000539-200105000-00023; Kararmaz A, 2003, ANAESTHESIA, V58, P526, DOI 10.1046/j.1365-2044.2003.03153.x; Knook MTT, 1999, SURG ENDOSC-ULTRAS, V13, P507, DOI 10.1007/s004649901023; Kohrs R, 1998, ANESTH ANALG, V87, P1186, DOI 10.1097/00000539-199811000-00039; Lal P, 2003, SURG ENDOSC, V17, P850, DOI 10.1007/s00464-002-8575-6; Lal P, 2007, SURG ENDOSC, V21, P595, DOI 10.1007/s00464-006-9050-6; Lau H, 2005, J LAPAROENDOSC ADV A, V15, P121, DOI 10.1089/lap.2005.15.121; Lau H, 2002, SURG ENDOSC, V16, P1474, DOI 10.1007/s00464-001-8299-z; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014; Memon MA, 2003, BRIT J SURG, V90, P1479, DOI 10.1002/bjs.4301; Miller RD, 2009, MILLERS ANESTHESIA, P774; Molinelli Bruce M, 2006, JSLS, V10, P341; Myles PS, 2000, BRIT J ANAESTH, V84, P6; Neumayer L, 2004, NEW ENGL J MED, V350, P1819, DOI 10.1056/NEJMoa040093; Ozgun H, 2002, EUR J SURG, V168, P455, DOI 10.1080/110241502321116442; Salihoglu Z, 2002, ANAESTH INTENS CARE, V30, P813; Spivak H, 1999, SURG ENDOSC-ULTRAS, V13, P1026, DOI 10.1007/s004649901161; Swanstrom LL, 1996, SURG CLIN N AM, V76, P483, DOI 10.1016/S0039-6109(05)70455-2; Swenson JD, 2001, REGION ANESTH PAIN M, V26, P306, DOI 10.1053/ramp.2001.25069; Zielmann S, 1997, ANAESTHESIST, V46, pS43, DOI 10.1007/PL00002464	29	7	8	0	1	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0300-0605	1473-2300		J INT MED RES	J. Int. Med. Res.	AUG	2013	41	4					1160	1170		10.1177/0300060513490083			11	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	192TB	WOS:000322507100026	23839277	DOAJ Gold			2020-06-30	J	Kim, WJ; Kang, H; Shin, HY; Baek, CW; Jung, YH; Woo, YC; Kim, JY; Koo, GH				Kim, Won Joong; Kang, Hyun; Shin, Hwa Yong; Baek, Chong Wha; Jung, Yong Hun; Woo, Young Cheol; Kim, Jin Yun; Koo, Gil Hoi			Ramosetron, midazolam, and combination of ramosetron and midazolam for prevention of postoperative nausea and vomiting: A prospective, randomized, double-blind study	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						Midazolam; ramosetron; thyroidectomy; postoperative nausea and vomiting; PONV	LAPAROSCOPIC CHOLECYSTECTOMY; ANTIEMETIC EFFICACY; ONDANSETRON; THYROIDECTOMY; PROPOFOL; TRIAL; ANESTHESIA; CHILDREN; PERIOD	Objective To compare the efficacy of ramosetron, midazolam, and the combination of ramosetron and midazolam in the prevention of postoperative nausea and vomiting (PONV) in female patients undergoing thyroidectomy. Methods Patients were randomized to receive 0.3mg ramosetron (Group R), 75 mu g/kg midazolam (Group M) or 0.3mg ramosetron combined with 75 mu g/kg midazolam (Group RM) before the induction of anaesthesia. PONV, use of rescue antiemetics, pain severity and fentanyl consumption were assessed for 24h after thyroidectomy. Results A total of 100 patients were enrolled; 94 patients completed the study. The severity of nausea was statistically significantly reduced at 0-2h in Group RM compared with Groups R and M, and at 2-6h in Group RM compared with Group M. The incidence of retching and vomiting was significantly lower at 0-2h, 2-6h, 6-12h in Group RM than in Group M, and lower in Group R than Group M at 6-12h. The requirement for rescue antiemetics was significantly lower at 0-2h in group RM than in group M. Conclusion The combination therapy of ramosetron and midazolam provided superior antiemetic efficacy compared with midazolam single therapy, but did not show any significant additional benefits compared with ramosetron single therapy.	[Kim, Won Joong; Kang, Hyun; Shin, Hwa Yong; Baek, Chong Wha; Jung, Yong Hun; Woo, Young Cheol; Kim, Jin Yun; Koo, Gil Hoi] Chung Ang Univ, Coll Med, Dept Anaesthesiol & Pain Med, Seoul 156755, South Korea	Kang, H (reprint author), Chung Ang Univ, Coll Med, Dept Anaesthesiol & Pain Med, 224-1 Heukseok Dong, Seoul 156755, South Korea.	roman00@cau.ac.kr	Kang, Hyun/AAE-7872-2020	Kang, Hyun/0000-0003-2844-5880	National Research Foundation of Korea (NRF)National Research Foundation of Korea; Ministry of Education, Science and TechnologyMinistry of Education, Science and Technology, Republic of Korea [2012R1A1A1003700]	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2012R1A1A1003700).	Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Apfel CC, 2004, NEW ENGL J MED, V350, P2441, DOI 10.1056/NEJMoa032196; Apfel CC, 2002, ACTA ANAESTH SCAND, V46, P921, DOI 10.1034/j.1399-6576.2002.460801.x; BENSHLOMO I, 1990, BRIT J ANAESTH, V64, P45, DOI 10.1093/bja/64.1.45; Byon HJ, 2012, EUR J ANAESTH, V29, P192, DOI 10.1097/EJA.0b013e32834fc1fb; DEJONCKHEERE M, 1990, EUR J ANAESTH, V7, P421; Ewalenko P, 1996, BRIT J ANAESTH, V77, P463, DOI 10.1093/bja/77.4.463; Fujii Y, 2003, CLIN THER, V25, P3100, DOI 10.1016/S0149-2918(03)90094-4; Fujii Y, 2002, CLIN THER, V24, P1148, DOI 10.1016/S0149-2918(02)80025-X; Fujii Y, 2011, CURR DRUG SAF, V6, P122, DOI 10.2174/157488611795684640; FUKUDA H, 1995, NEUROSCI LETT, V193, P117, DOI 10.1016/0304-3940(95)11682-M; Gan TJ, 2005, CNS DRUGS, V19, P225, DOI 10.2165/00023210-200519030-00004; Gan TJ, 2007, ANESTH ANALG, V105, P1615, DOI 10.1213/01.ane.0000295230.55439.f4; GRELOT L, 1990, BRAIN RES, V513, P101, DOI 10.1016/0006-8993(90)91094-W; Heidari Seied Morteza, 2004, Acta Anaesthesiol Taiwan, V42, P77; Jo YY, 2012, SURG ENDOSC, V26, P2306, DOI 10.1007/s00464-012-2180-0; Kang YK, 2002, J INT MED RES, V30, P220, DOI 10.1177/147323000203000302; Kim DS, 2012, KOREAN J ANESTHESIOL, V62, P343, DOI 10.4097/kjae.2012.62.4.343; Lee HS, 2009, CLIN EXP OTORHINOLAR, V2, P72, DOI 10.3342/ceo.2009.2.2.72; Lee Y, 2007, ANAESTHESIA, V62, P18, DOI 10.1111/j.1365-2044.2006.04895.x; Metaxari M, 2011, J ANESTH, V25, P356, DOI 10.1007/s00540-011-1119-2; Rabasseda X, 2002, DRUGS TODAY, V38, P75, DOI 10.1358/dot.2002.38.2.820104; RABEY PG, 1992, BRIT J ANAESTH, V69, pS40, DOI 10.1093/bja/69.supplement_1.40S; Ryu J, 2010, SURG ENDOSC, V24, P812, DOI 10.1007/s00464-009-0670-5; SPLINTER WM, 1995, CAN J ANAESTH, V42, P201, DOI 10.1007/BF03010676; Unlugenc H, 2004, EUR J ANAESTH, V21, P60, DOI 10.1017/S0265021504001103; Unlugenc H, 2003, EUR J ANAESTH, V20, P668, DOI 10.1097/00003643-200308000-00014; WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023; 곽경화, 2007, Korean Journal of Anesthesiology, V53, P344	29	6	6	0	2	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0300-0605	1473-2300		J INT MED RES	J. Int. Med. Res.	AUG	2013	41	4					1203	1213		10.1177/0300060513485864			11	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	192TB	WOS:000322507100030	23766412	DOAJ Gold			2020-06-30	J	Clivatti, J; Siddiqui, N; Goel, A; Shaw, M; Crisan, I; Carvalho, JCA				Clivatti, Jefferson; Siddiqui, Naveed; Goel, Akash; Shaw, Melissa; Crisan, Ioana; Carvalho, Jose C. A.			Quality of labour neuraxial analgesia and maternal satisfaction at a tertiary care teaching hospital: a prospective observational study	CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							EPIDURAL ANALGESIA; NULLIPAROUS WOMEN; PAIN RELIEF; BUPIVACAINE; FENTANYL; INFUSION; DELIVERY; INDEX; ANESTHETICS; SUFENTANIL	Current labour analgesia practices are evidence-based; however, such evidence often originates in controlled trials, the results of which may not be readily applicable in the context of day-to-day clinical practice. The objective of this study was to evaluate the effectiveness of and maternal satisfaction with the neuraxial labour analgesia regimen provided at a tertiary care teaching hospital. All women with a viable pregnancy who requested neuraxial analgesia for labour during November 2011 at our institution were approached to participate in this prospective study. Patients were managed as per departmental routine based on a patient-controlled epidural analgesia regimen with a maintenance solution of 0.0625% bupivacaine and fentanyl 2 mu g center dot mL(-1). Demographic and obstetric data, characteristics of the neuraxial analgesia, pain scores, side effects, and complications were recorded. After delivery, patients completed a satisfaction questionnaire. All 332 eligible women were approached, and 294 completed the study. Most women received epidural analgesia and considered its placement comfortable. A large number of women reported having experienced pain during the first or second stages of labour (38% and 26%, respectively). Although 24.4% of women required top-ups both by nurses and physicians, adjustment in the local anesthetic maintenance concentration was made in only 7.8% of the cases. Most women (92%) were satisfied with the quality of analgesia. Unintentional dural puncture occurred in three (1%) cases, and there were no cases of intravascular catheter insertion or systemic local anesthetic toxicity. Overweight women (body mass index 25-30 kg center dot m(-2)) (adjusted odds ratio [AOR] = 2.56; 95% confidence interval [CI]: 1.1 to 5.97), those undergoing induced labour (AOR = 2.4; 95% CI: 1.2 to 5.2), and those requiring top-ups by the anesthesiologist (AOR = 5.08; 95% CI: 2.31 to 11.11) were associated with more dissatisfaction with pain control during the first stage of labour. Although our technique with dilute local anesthetic-opioid infusion was considered effective in previous randomized clinical trials, it did not provide sufficient labour analgesia for a large proportion of women. Nevertheless, most women were satisfied with their pain management and childbirth experience. Strategies to individualize care for labour and delivery should be readily available while providing labour analgesia.	[Clivatti, Jefferson; Siddiqui, Naveed; Goel, Akash; Carvalho, Jose C. A.] Univ Toronto, Mt Sinai Hosp, Dept Anesthesia & Pain Management, Toronto, ON M5G 1X5, Canada; [Carvalho, Jose C. A.] Univ Toronto, Mt Sinai Hosp, Dept Obstet & Gynecol, Toronto, ON M5G 1X5, Canada; [Shaw, Melissa; Crisan, Ioana] Univ Toronto, Mt Sinai Hosp, Dept Nursing, Toronto, ON M5G 1X5, Canada	Carvalho, JCA (reprint author), Univ Toronto, Mt Sinai Hosp, Dept Anesthesia & Pain Management, 600 Univ Ave,Room 781, Toronto, ON M5G 1X5, Canada.	jose.carvalho@uhn.on.ca	Siddiqui, Naveed T/L-9437-2017	Siddiqui, Naveed T/0000-0001-6757-0057			Angle P, 2010, CAN J ANAESTH, V57, P468, DOI 10.1007/s12630-010-9289-1; Capogna G, 2001, ANESTHESIOLOGY, V94, P740, DOI 10.1097/00000542-200105000-00009; Carvalho B, 2005, INT J OBSTET ANESTH, V14, P223, DOI 10.1016/j.ijoa.2005.02.003; Carvalho B, 2010, INT J OBSTET ANESTH, V19, P10, DOI 10.1016/j.ijoa.2009.02.012; CHESTNUT DH, 1988, ANESTHESIOLOGY, V68, P754, DOI 10.1097/00000542-198805000-00013; COLUMB MO, 1995, ANESTH ANALG, V81, P833, DOI 10.1097/00000539-199510000-00030; de la Chapelle A, 2006, INT J OBSTET ANESTH, V15, P104, DOI 10.1016/j.ijoa.2005.07.002; Djulbegovic B, 2011, JAMA-J AM MED ASSOC, V305, P2005, DOI 10.1001/jama.2011.650; Dresner M, 2006, BJOG-INT J OBSTET GY, V113, P1178, DOI 10.1111/j.1471-0528.2006.01048.x; Ginosar Y, 2003, ANESTH ANALG, V97, P1439, DOI 10.1213/01.ANE.0000081792.84877.A2; Ginosar Y, 2010, INT J OBSTET ANESTH, V19, P171, DOI 10.1016/j.ijoa.2009.11.002; Hess PE, 2006, INT J OBSTET ANESTH, V15, P195, DOI 10.1016/j.ijoa.2005.12.006; Hodnett ED, 2002, AM J OBSTET GYNECOL, V186, pS160, DOI 10.1067/mob.2002.121141; Lilker S, 2009, J CLIN ANESTH, V21, P108, DOI 10.1016/j.jclinane.2008.06.027; LOMAS J, 1987, BIRTH-ISS PERINAT C, V14, P125, DOI 10.1111/j.1523-536X.1987.tb01472.x; Lyons G, 1997, BRIT J ANAESTH, V78, P493; Mhyre JM, 2010, CAN J ANAESTH, V57, P402, DOI 10.1007/s12630-010-9290-8; PAECH MJ, 1991, ANAESTH INTENS CARE, V19, P393, DOI 10.1177/0310057X9101900316; Pan PH, 2004, INT J OBSTET ANESTH, V13, P227, DOI 10.1016/j.ijoa.2004.04.008; Patel NP, 2012, ANAESTHESIA, V67, P584, DOI 10.1111/j.1365-2044.2011.07045.x; Reynolds F, 2003, INT J OBSTET ANESTH, V12, P156, DOI 10.1016/S0959-289X(03)00008-6; Russell R, 1995, Int J Obstet Anesth, V4, P82, DOI 10.1016/0959-289X(95)82997-O; Singh S, 2009, THESCIENTIFICWORLDJO, V9, P715, DOI 10.1100/tsw.2009.94; Vohra S, 2011, JAMA-J AM MED ASSOC, V306, P709, DOI 10.1001/jama.2011.1150	24	7	7	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANESTH	Can. J. Anesth.	AUG	2013	60	8					787	795		10.1007/s12630-013-9976-9			9	Anesthesiology	Anesthesiology	185ZG	WOS:000322009800007	23737258				2020-06-30	J	Lane, ME				Lane, Majella E.			The transdermal delivery of fentanyl	EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS			English	Review						Fentanyl; Transdermal patch; Reservoir; Matrix; Pharmacokinetics	CHROMATOGRAPHY-MASS-SPECTROMETRY; NARCOTIC ANALGESICS; POSTMORTEM REDISTRIBUTION; ELECTROCHEMICAL DEVICE; BALANCED ANESTHESIA; GAS-CHROMATOGRAPHY; IN-VITRO; PHARMACOKINETICS; METABOLITES; SUFENTANIL	The fentanyl patch is one of the great commercial successes in transdermal drug delivery. The suitability of this molecule for delivery through skin had been identified in the 1970s, and subsequently, a number of transdermal formulations became available on the market. This article reviews the development of fentanyl patch technology with particular emphasis on the pharmacokinetics and disposition of the drug when delivered through the skin. The various patch designs are considered as well as the bioequivalence of the different designs. The influence of heat on fentanyl permeation is highlighted. Post-mortem redistribution of fentanyl is discussed in light of the reported discrepancies in serum levels reported in patients after death compared with therapeutic levels in living subjects. Finally, alternatives to patch technology are considered, and recent novel transdermal formulations are highlighted. (C) 2013 Elsevier B.V. All rights reserved.	Univ London, Sch Pharm, Dept Pharmaceut, London WC1N 1AX, England	Lane, ME (reprint author), Univ London, Sch Pharm, Dept Pharmaceut, 29-39 Brunswick Sq, London WC1N 1AX, England.	majella.lane@btintemet.com					Andresen H, 2012, J ANAL TOXICOL, V36, P182, DOI 10.1093/jat/bks005; AROMAA U, 1980, ACTA ANAESTH SCAND, V24, P36, DOI 10.1111/j.1399-6576.1980.tb01501.x; Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; Barrer RM, 1939, T FARADAY SOC, V35, P0628, DOI 10.1039/tf9393500628; Boucaud A, 2001, INT J PHARMACEUT, V228, P69, DOI 10.1016/S0378-5173(01)00820-1; Cookson R.F., 1980, BRIT J ANAESTH, V52, P52; Daynes HA, 1920, P R SOC LOND A-CONTA, V97, P286, DOI 10.1098/rspa.1920.0034; DUTHIE DJR, 1988, BRIT J ANAESTH, V60, P614, DOI 10.1093/bja/60.6.614; FISET P, 1995, ANESTHESIOLOGY, V83, P459, DOI 10.1097/00000542-199509000-00004; GOROMARU T, 1984, ANESTHESIOLOGY, V61, P73, DOI 10.1097/00000542-198461010-00013; GUPTA SK, 1992, J PAIN SYMPTOM MANAG, V7, pS17, DOI 10.1016/0885-3924(92)90049-N; Hair PI, 2008, DRUGS, V68, P2001, DOI 10.2165/00003495-200868140-00005; HOLLEY FO, 1988, BRIT J ANAESTH, V60, P608, DOI 10.1093/bja/60.6.608; Hug CC, 1984, PHARMACOKINETICS ANA, P187; JANSSEN PAJ, 1962, BRIT J ANAESTH, V34, P260, DOI 10.1093/bja/34.4.260; Luckenbill K, 2008, J ANAL TOXICOL, V32, P639, DOI 10.1093/jat/32.8.639; Mather L.E., 1986, ACUTE PAIN MANAGEMEN, P77; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; MICHAELS AS, 1975, AICHE J, V21, P985, DOI 10.1002/aic.690210522; MIGUEL R, 1995, ANESTHESIOLOGY, V83, P470, DOI 10.1097/00000542-199509000-00005; Moffat A.C., 2004, CLARKES ANAL DRUGS P, P1029; Moore KT, 2012, J CLIN PHARMACOL, V52, P1174, DOI 10.1177/0091270011411710; Moore Kenneth Todd, 2011, J Opioid Manag, V7, P99; NILSSON E, 1963, ANESTHESIOLOGY, V24, P267, DOI 10.1097/00000542-196305000-00001; Oliveira G, 2012, TOXICOL IN VITRO, V26, P645, DOI 10.1016/j.tiv.2012.02.007; Olson KN, 2010, AM J CLIN PATHOL, V133, P447, DOI 10.1309/AJCP4X5VHFSOERFT; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; ROY SD, 1989, PHARM RES-DORDR, V6, P825, DOI 10.1023/A:1015944018555; Roy SD, 1996, J PHARM SCI, V85, P491, DOI 10.1021/js950415w; ROY SD, 1989, PHARMACEUT RES, V6, P147, DOI 10.1023/A:1015932610010; ROY SD, 1988, PHARMACEUT RES, V5, P580, DOI 10.1023/A:1015994030251; ROY SD, 1990, PHARMACEUT RES, V7, P842, DOI 10.1023/A:1015912932416; Santos P, 2011, INT J PHARMACEUT, V416, P155, DOI 10.1016/j.ijpharm.2011.06.024; Sathyan G, 2005, CURR MED RES OPIN, V21, P1961, DOI 10.1185/030079905X65259; Schroder B, 2012, J PHARM SCI-US, V101, P2262, DOI 10.1002/jps.23108; Schroder B, 2012, J PHARM SCI-US, V101, P245, DOI 10.1002/jps.22765; Shomaker TS, 2000, PAIN MED, V1, P225, DOI 10.1046/j.1526-4637.2000.00030.x; SILVERSTEIN JH, 1993, ANESTH ANALG, V76, P618; TAMMISTO T, 1980, ACTA ANAESTH SCAND, V24, P31, DOI 10.1111/j.1399-6576.1980.tb01500.x; Tateishi T., 1996, Anesthesia and Analgesia, V82, P167, DOI 10.1097/00000539-199601000-00031; VANROOY HH, 1981, J CHROMATOGR, V223, P85, DOI 10.1016/S0378-4347(00)80070-5; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; WHITE WD, 1979, BRIT MED J, V2, P166, DOI 10.1136/bmj.2.6183.166; WOLFE MJ, 1980, BRIT J ANAESTH, V52, P357, DOI 10.1093/bja/52.3.357-a	45	29	32	0	57	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0939-6411	1873-3441		EUR J PHARM BIOPHARM	Eur. J. Pharm. Biopharm.	AUG	2013	84	3					449	455		10.1016/j.ejpb.2013.01.018			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	181QE	WOS:000321682800002	23419814				2020-06-30	J	Nooh, N; Abdelhalim, AA; Abdullah, WA; Sheta, SA				Nooh, N.; Abdelhalim, A. A.; Abdullah, W. A.; Sheta, S. A.			Effect of remifentanil on the hemodynamic responses and recovery profile of patients undergoing single jaw orthognathic surgery	INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article						remifentanil; fentanyl; hemodynamic; stress response; jaw; orthognathic; surgery; Le Fort I osteotomy	CARDIAC-SURGERY; GENERAL-ANESTHESIA; NITROUS-OXIDE; FENTANYL; SEVOFLURANE; INDUCTION; INFUSION; BLOCK	The aim of this study was to compare fentanyl-based versus remifentanil-based anesthesia with regards to the intraoperative hemodynamic stress response and recovery profiles in patients undergoing Le Fort I osteotomy. Seventeen patients were randomly divided into two groups: patients in the F-group received 2 mu g/kg fentanyl intravenously followed by an infusion of 0.03-0.06 mu g/kg/min, while patients in the R-group received a 0.5 mu g/kg bolus of remifentanil followed by an infusion of 0.0625-0.250 mu g/kg/min. Mean arterial pressure and heart rate were recorded at the following points: before anesthetic induction, at endotracheal intubation, 5 min after intubation, at incision, just before the osteotomy, during the osteotomy, during the maxillary fracturing, at suturing, at extubation, 5 min after extubation, and then 15 and 30 min postoperatively. Heart rate and mean arterial pressure were significantly lower in the R-group in comparison to the F-group from t(1) to t(9) (P < 0.05). All measured recovery times were significantly shorter in the R-group (P < 0.05). The incidence of postoperative side effects was comparable between groups. Remifentanil-based anesthesia is an appropriate alternative to fentanyl during Le Fort I orthognathic surgery; it promotes hemodynamic stability, blunts the stress response to noxious stimuli, and provides a better recovery profile.	[Nooh, N.; Abdullah, W. A.; Sheta, S. A.] King Saud Univ, Dept Oral & Maxillofacial Surg, Riyadh, Saudi Arabia; [Abdelhalim, A. A.; Sheta, S. A.] Univ Alexandria, Fac Med, Dept Anesthesia, Alexandria, Egypt; [Abdullah, W. A.] Mansoura Univ, Dept Oral Surg, Mansoura, Egypt	Nooh, N (reprint author), King Saud Univ, Coll Dent, Dept Oral & Maxillofacial Surg, Riyadh, Saudi Arabia.	nassernoohomfs@gmail.com					ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Breslin DS, 2001, ANAESTHESIA, V56, P114, DOI 10.1046/j.1365-2044.2001.01795.x; Fukunaga AF, 2003, PAIN, V101, P129, DOI 10.1016/S0304-3959(02)00321-4; Gesztesi Z, 1999, ANESTH ANALG, V89, P1282, DOI 10.1213/00000539-199911000-00038; Glass PSA, 1999, ANESTH ANALG, V89, pS7; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Guy J, 1997, ANESTHESIOLOGY, V86, P514, DOI 10.1097/00000542-199703000-00002; Hall AP, 2000, BRIT J ANAESTH, V84, P100; KEATS AS, 1978, ANESTHESIOLOGY, V49, P233, DOI 10.1097/00000542-197810000-00001; Komatsu R, 2007, ANAESTHESIA, V62, P1266, DOI 10.1111/j.1365-2044.2007.05221.x; Koppert W, 2003, ANESTHESIOLOGY, V99, P152, DOI 10.1097/00000542-200307000-00025; Kovac AL, 2009, SIGNA VITAE, V4, P23, DOI 10.22514/SV42.102009.5; Kurdi O, 2001, BRIT J ANAESTH, V87, P943; LUNN JK, 1979, ANESTH ANALG, V58, P390; Mackey JJ, 2000, J CLIN ANESTH, V12, P427, DOI 10.1016/S0952-8180(00)00185-9; Michelsen LG, 2000, ANESTH ANALG, V91, P1563, DOI 10.1097/00000539-200012000-00059; Noma T, 1998, ORAL SURG ORAL MED O, V86, P511, DOI 10.1016/S1079-2104(98)90338-9; Prakash N, 2001, ANAESTHESIA, V56, P576, DOI 10.1111/j.1365-2044.2001.1913-3.x; Proffit W R, 1996, Int J Adult Orthodon Orthognath Surg, V11, P191; Reid JE, 2000, BRIT J ANAESTH, V84, P422; SCHINDLER I, 1994, ACTA ANAESTH SCAND, V38, P384, DOI 10.1111/j.1399-6576.1994.tb03912.x; Steinlechner B, 2007, BRIT J ANAESTH, V98, P598, DOI 10.1093/bja/aem069; Twersky RS, 2001, J CLIN ANESTH, V13, P407, DOI 10.1016/S0952-8180(01)00292-6; Wang JYY, 1999, ANAESTH INTENS CARE, V27, P363, DOI 10.1177/0310057X9902700405; Weale NK, 2004, BRIT J ANAESTH, V92, P187, DOI 10.1093/bja/aeh038; Wuesten R, 2001, ANESTHESIOLOGY, V94, P211, DOI 10.1097/00000542-200102000-00008; Yoo KY, 2011, ANESTH ANALG, V112, P191, DOI 10.1213/ANE.0b013e3181fc7139	27	5	6	0	2	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0901-5027			INT J ORAL MAX SURG	Int. J. Oral Maxillofac. Surg.	AUG	2013	42	8					988	993		10.1016/j.ijom.2013.02.001			6	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	178XX	WOS:000321481800011	23490474				2020-06-30	J	Samhan, YM; El-Sabae, HH; Khafagy, HF; Maher, MA				Samhan, Yasser M.; El-Sabae, Hossam H.; Khafagy, Hanan F.; Maher, Mohamed A.			A pilot study to compare epidural identification and catheterization using a saline-filled syringe versus a continuous hydrostatic pressure system	JOURNAL OF ANESTHESIA			English	Article						New technique; Epidural; Identification; Catheterization	SPACE; PARTURIENTS; ANESTHESIA; IDENTIFY; DEVICE	We are introducing a new continuous hydrostatic pressure system for identification and catheterization of epidural space in adults. One hundred and eight patients scheduled for elective endoscopic urological procedures were enrolled in this prospective randomized study. They were assigned to perform loss of resistance epidural technique by either the conventional saline-filled syringe (group C) or the new pressure technique (group P). The latter depends on observing passage of free flow of pressurized normal saline (50 mmHg) connected to epidural needle during its advancement, and then the epidural catheter was inserted to "float" easily while saline was flowing. Ten ml of bupivacaine 0.5 % with 50 mu g fentanyl were injected. Time to identify epidural space, number of attempts, ease of catheterization, sensory and motor block by Bromage scale after 20 min, quality of anesthesia and any side effects were recorded. Significant reduction was found in group P versus group C concerning time to identify epidural space [20 (6-40) vs. 60.5 (23-75) s with p = 0.001], number of attempts [1 (1-2) vs. 1 (1-4) with p = 0.02] and motor block [1 (0-3) vs. 2 (0-2) with p = 0.02], respectively. No significant difference in epidural catheterization, sensory block, quality of anesthesia and incidence of side effects. We concluded that this new technique is an easy way to identify epidural space using available tools in the operating room.	[Samhan, Yasser M.; El-Sabae, Hossam H.; Khafagy, Hanan F.; Maher, Mohamed A.] Minist Sci Res, Theodor Bilharz Res Inst, Dept Anesthesia, Giza 12411, Egypt	Khafagy, HF (reprint author), 164 El Haram St, Giza 12151, Egypt.	hanan_khafagy@yahoo.com	Samhan, Yasser M./AAN-6164-2020	Samhan, Yasser/0000-0002-6463-3769			Brown DL, 2010, MILLERS ANESTHESIA, P1611; Eappen S, 1998, INT J OBSTET ANESTH, V7, P220, DOI 10.1016/S0959-289X(98)80042-3; Ghelber O, 2008, REGION ANESTH PAIN M, V33, P346, DOI 10.1016/j.rapm.2008.01.012; Grau T, 2002, J CLIN ANESTH, V14, P169, DOI 10.1016/S0952-8180(01)00378-6; Habib AS, 2008, ANESTH ANALG, V106, P541, DOI 10.1213/ane.0b013e3181606c0a; Lechner TJ, 2003, ANESTH ANALG, V96, P1183, DOI 10.1213/01.ANE.0000052382.04446.42; Pan PH, 2004, INT J OBSTET ANESTH, V13, P227, DOI 10.1016/j.ijoa.2004.04.008; Riley ET, 2007, ANESTH ANALG, V105, P1164, DOI 10.1213/01.ane.0000281935.78144.82; Sawada A, 2012, J ANESTH, V26, P292, DOI 10.1007/s00540-011-1278-1; Tsui BCH, 1999, REGION ANESTH PAIN M, V24, P17, DOI 10.1016/S1098-7339(99)90160-8; YAMASHITA M, 1991, ANAESTHESIA, V46, P872, DOI 10.1111/j.1365-2044.1991.tb09607.x	11	5	5	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668			J ANESTH	J. Anesth.	AUG	2013	27	4					607	610		10.1007/s00540-013-1567-y			4	Anesthesiology	Anesthesiology	202VQ	WOS:000323248700018	23408046				2020-06-30	J	Matzo, M; Orwig, SR				Matzo, Marianne; Orwig, Steve R.			50 Shades of Gray	JOURNAL OF PALLIATIVE MEDICINE			English	Letter									[Matzo, Marianne] Univ Oklahoma, Dept Nursing, Oklahoma City, OK 73117 USA; [Orwig, Steve R.] Stephenson Canc Ctr, Oklahoma City, OK USA	Matzo, M (reprint author), Univ Oklahoma, Dept Nursing, 1100 N Stonewall Ave, Oklahoma City, OK 73117 USA.	mmatzo@ouhsc.edu					Billings JA, 2012, CRIT CARE MED, V40, P625, DOI 10.1097/CCM.0b013e318228235d; Campbell ML, 2007, AACN ADV CRIT CARE, V18, P397, DOI 10.1097/01.AACN.0000298631.53276.f7; Cheng KC, 2011, MINERVA ANESTESIOL, V77, P503; Gerstel E, 2008, AM J RESP CRIT CARE, V178, P798, DOI 10.1164/rccm.200711-1617OC; JONSEN AR, 1998, CLIN ETHICS PRACTICA	5	0	0	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1096-6218	1557-7740		J PALLIAT MED	J. Palliat. Med.	AUG	2013	16	8					833	835		10.1089/jpm.2013.0185			3	Health Care Sciences & Services	Health Care Sciences & Services	187JT	WOS:000322114600009	23758526				2020-06-30	J	Mercadante, S; Porzio, G; Aielli, F; Averna, L; Ficorella, C; Casuccio, A				Mercadante, Sebastiano; Porzio, Giampiero; Aielli, Federica; Averna, Lucilla; Ficorella, Corrado; Casuccio, Alessandra			The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting	SUPPORTIVE CARE IN CANCER			English	Article						Cancer pain; Breakthrough-episodic pain; Fentanyl buccal tablet; Opioids; Home care	CANCER PAIN; INTRAVENOUS MORPHINE; TRANSMUCOSAL FENTANYL; RECOMMENDATIONS; MANAGEMENT; TITRATION; UNIT	The dose of rapid onset opioids to be given for breakthrough cancer pain (BTcP) is controversial. Dose proportional to the basal opioid regimen seem to be safe and effective in hospital units. However, data in other less protected settings, like home care, are lacking. The aim of this open-label study was to assess the efficacy and safety in a group of patients with BTcP followed at home, after giving a dose of fentanyl buccal tablets (FBT) proportional to the opioid basal regimen, skipping the steps for dose titration. Consecutive patients admitted to a home care program presenting BTcP episodes and receiving stable doses of opioids for background pain were selected. Data from four consecutive episodes of BTcP were collected. For each episode, patients were instructed to routinely collect changes in pain intensity and severe adverse effects when pain got severe (T0) and to reassess the same items 15 min after FBT, given as a rescue medication in doses proportional to the daily opioid doses used for background pain (T15). One hundred twenty episodes of BTcP were recorded in 30 patients. One hundred eight episodes were defined as successfully treated, while 12 episodes required a further administration of opioids. Pain intensity significantly decreased at T15 (p < 0.001). In 95.5 and 90.8 % of episodes treated, there was a reduction in pain intensity of more than 33 and 50 %, respectively. No relevant adverse effects were recorded, even in older patients. This study suggests that FBT given in doses proportional to the basal opioid regimen for the management of BTcP is very effective and safe in clinical practice in the home care setting.	[Mercadante, Sebastiano] La Maddalena Canc Ctr, Anesthesia & Intens Care Unit, I-90145 Palermo, Italy; [Mercadante, Sebastiano] La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, I-90145 Palermo, Italy; [Mercadante, Sebastiano] Univ Palermo, Dept Anesthesiol Intens Care & Emergency, Palermo, Italy; [Porzio, Giampiero; Aielli, Federica; Averna, Lucilla; Ficorella, Corrado] Univ Aquila, Dept Oncol, I-67100 Laquila, Italy; [Casuccio, Alessandra] Univ Palermo, Dept Expt Biomedicine & Clin Neurosci, Palermo, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Anesthesia & Intens Care Unit, Via S Lorenzo 312, I-90145 Palermo, Italy.	terapiadeldolore@lamaddalenanet.it	casuccio, alessandra/B-1730-2013	casuccio, alessandra/0000-0002-5676-9535; AIELLI, Federica/0000-0003-2785-0702; Porzio, Giampiero/0000-0002-9875-9220			Aronoff GM, 2005, PAIN MED, V6, P305, DOI 10.1111/j.1526-4637.2005.00045.x; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Corli O, 2011, CAPIRE TRATTARE BREA; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Davies AN, 2008, J PAIN SYMPTOM MANAG, V35, P406, DOI 10.1016/j.jpainsymman.2007.05.010; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Hagen NA, 2007, J PALLIAT MED, V10, P47, DOI 10.1089/jpm.2006.0151; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Kleeberg UR, 2011, PAIN PRACT, V11, P185, DOI 10.1111/j.1533-2500.2010.00414.x; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V27, P352, DOI 10.1016/j.jpainsymman.2003.09.006; Mercadante S, 1998, CANCER TREAT REV, V24, P425, DOI 10.1016/S0305-7372(98)90005-6; Mercadante S, 2008, J PAIN SYMPTOM MANAG, V35, P307, DOI 10.1016/j.jpainsymman.2007.04.018; Mercadante S, 2012, CURR MED RES OPIN, V28, P963, DOI 10.1185/03007995.2012.683112; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; Mercadante S, 2011, CRIT REV ONCOL HEMAT, V80, P460, DOI 10.1016/j.critrevonc.2010.12.002; Mercadante S, 2011, J PAIN SYMPTOM MANAG, V42, P464, DOI 10.1016/j.jpainsymman.2010.12.010; Mercadante S, 2011, SUPPORT CARE CANCER, V19, P979, DOI 10.1007/s00520-010-0919-5; Mercadante S, 2010, LANCET ONCOL, V11, P484, DOI 10.1016/S1470-2045(09)70350-X; Mercadante S, 2010, CLIN J PAIN, V26, P306, DOI 10.1097/AJP.0b013e3181c4458a; Mercadante S, 2009, EUR J PAIN, V13, P329, DOI 10.1016/j.ejpain.2008.11.021; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012; Zeppetella G, 2010, PAIN PRACT, V10, P287, DOI 10.1111/j.1533-2500.2010.00359.x	26	16	16	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355			SUPPORT CARE CANCER	Support. Care Cancer	AUG	2013	21	8					2335	2339		10.1007/s00520-013-1799-2			5	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	179UG	WOS:000321546200031	23564072				2020-06-30	J	Nardi, GM; Bet, AC; Sordi, R; Fernandes, D; Assreuy, J				Nardi, Geisson Marcos; Bet, Angela Cristina; Sordi, Regina; Fernandes, Daniel; Assreuy, Jamil			Opioid analgesics in experimental sepsis: effects on physiological, biochemical, and haemodynamic parameters	FUNDAMENTAL & CLINICAL PHARMACOLOGY			English	Article						analgesia; cecal ligation and puncture; fentanyl; pain; sepsis; tramadol	CECAL LIGATION; SEPTIC SHOCK; ORGAN DYSFUNCTION; CRITICAL ILLNESS; MODEL; TRAMADOL; PUNCTURE; RATS; FAILURE	Cecal ligation and puncture (CLP) is the sepsis model that more closely resembles the human pathology, but it is likely to cause suffering to experimental animals. However, it is not clear whether the use of analgesia may affect some parameters evaluated in experimental sepsis research. Therefore, we investigated the effects of fentanyl and tramadol in experimental sepsis in the rat. The following parameters were evaluated: body temperature, body weight, water and food ingestion, mortality, analgesia, blood leukocytes, mean arterial blood pressure, vascular reactivity to phenylephrine, lung myeloperoxidase activity, and plasma levels of IL1-, glutamic-oxaloacetic, glutamic-pyruvic, lactate, creatinine and urea. While producing significant analgesia, the opioids modify minimally the parameters, with the exception of sepsis-induced hypotension and mortality. Although fentanyl and tramadol can minimize pain and the general suffering of animals submitted to CLP surgery, their effects on cardiovascular parameters as well as in the mortality indicate that their use in experimental sepsis must be done with caution and with all the proper control groups.	[Bet, Angela Cristina; Sordi, Regina; Assreuy, Jamil] Univ Fed Santa Catarina, Ctr Biol Sci, Dept Pharmacol, BR-88040900 Florianopolis, SC, Brazil	Assreuy, J (reprint author), Univ Fed Santa Catarina, Ctr Biol Sci, Dept Pharmacol, BR-88040900 Florianopolis, SC, Brazil.	jamil.assreuy@ufsc.br	Assreuy, Jamil/A-4205-2013; Fernandes, Daniel/B-7147-2012; Sordi, Regina/O-3377-2014; Nardi, Geisson Marcos/C-6640-2014	Fernandes, Daniel/0000-0002-8935-4176; Sordi, Regina/0000-0003-0264-7062; Nardi, Geisson Marcos/0000-0003-0484-8490	CNPqNational Council for Scientific and Technological Development (CNPq); CAPESCAPES; UNOESC; FAPESC; PRONEX, Brazil	The skillful technical assistance of Ms. Adriane Madeira is gratefully acknowledged. We also acknowledge Dr Ricardo Reinert Marques, MD; Dr Jussara Marcondes de Quadros, MD and Pharmacist Doralysa Nezello for the kind donation of fentanyl and tramadol. This work is supported by CNPq, CAPES, UNOESC, FAPESC, and PRONEX, Brazil.	Abraham E, 2007, CRIT CARE MED, V35, P2408, DOI 10.1097/01.CCM.0000282072.56245.91; Barichello T, 2005, CRIT CARE MED, V33, P221, DOI 10.1097/01.CCM.0000150741.12906.BD; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Brooks HF, 2007, METAB BRAIN DIS, V22, P353, DOI 10.1007/s11011-007-9058-1; Buras JA, 2005, NAT REV DRUG DISCOV, V4, P854, DOI 10.1038/nrd1854; Carvalho M, 2005, EUR J PHARMACOL, V525, P161, DOI 10.1016/j.ejphar.2005.09.049; Ellis CG, 2002, AM J PHYSIOL-HEART C, V282, pH156; Epstein J, 1999, CRIT CARE CLIN, V15, P17, DOI 10.1016/S0749-0704(05)70037-3; Fernandes D, 2009, J PHARMACOL EXP THER, V328, P991, DOI 10.1124/jpet.108.142034; Fernandez-Duenas V, 2011, PHARMACOL BIOCHEM BE, V98, P331, DOI 10.1016/j.pbb.2011.01.023; Fraser GL, 2000, PHARMACOTHERAPY, V20, P75, DOI 10.1592/phco.20.1.75.34663; Guneli E, 2007, PHARMACOL BIOCHEM BE, V88, P9, DOI 10.1016/j.pbb.2007.06.006; Hasselgren P O, 1999, Curr Opin Clin Nutr Metab Care, V2, P155, DOI 10.1097/00075197-199903000-00011; Hubbard WJ, 2005, SHOCK, V24, P52, DOI 10.1097/01.shk.0000191414.94461.7e; Hugunin KMS, 2010, SHOCK, V34, P250, DOI 10.1097/SHK.0b013e3181cdc412; LAM C, 1994, J CLIN INVEST, V94, P2077, DOI 10.1172/JCI117562; Merx MW, 2005, CIRCULATION, V112, P117, DOI 10.1161/CIRCULATIONAHA.104.502195; Minneci PC, 2007, AM J PHYSIOL-HEART C, V293, pH2487, DOI 10.1152/ajpheart.00589.2007; Molina PE, 2006, J INTERN MED, V259, P138, DOI 10.1111/j.1365-2796.2005.01569.x; Nakagawa NK, 2007, CLINICS, V62, P321, DOI 10.1590/S1807-59322007000300018; Romero A, 2010, PHARMACOL RES, V61, P511, DOI 10.1016/j.phrs.2010.02.011; Sessler CN, 2008, CRIT CARE, V12, DOI 10.1186/cc6147; Shih CC, 2008, CRIT CARE MED, V36, P1864, DOI 10.1097/CCM.0b013e318173f982; Tipps LB, 2000, NEUROSURGERY, V46, P596, DOI 10.1097/00006123-200003000-00015; Topcu I, 2006, ANESTH ANALG, V102, P876, DOI 10.1213/01.ane.0000196506.28780.94; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; Tuon L, 2007, INTENS CARE MED, V33, P2165, DOI 10.1007/s00134-007-0804-y; WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2; Yao LN, 2009, J SURG RES, V155, P25, DOI 10.1016/j.jss.2008.07.012; Zelcer S, 2005, BRAIN RES, V1040, P151, DOI 10.1016/j.brainres.2005.01.070	30	9	9	0	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0767-3981			FUND CLIN PHARMACOL	Fundam. Clin. Pharmacol.	AUG	2013	27	4					347	353		10.1111/j.1472-8206.2012.01041.x			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	169JD	WOS:000320775400001	22486445				2020-06-30	J	Graudins, A; Meek, R; Egerton-Warburton, D; Seith, R; Furness, T; Chapman, R				Graudins, Andis; Meek, Robert; Egerton-Warburton, Diana; Seith, Robert; Furness, Trentham; Chapman, Rose			The PICHFORK (Pain InCHildren Fentanyl OR Ketamine) trial comparing the efficacy of intranasal ketamine and fentanyl in the relief of moderate to severe pain in children with limb injuries: study protocol for a randomized controlled trial	TRIALS			English	Article						Intranasal ketamine; Fentanyl; Musculoskeletal injury; Children; Pain; Analgesia	INTRAVENOUS MORPHINE; DRUG-DELIVERY; ANALGESIA; SEDATION	Background: The effectiveness of intranasal (IN) fentanyl as an analgesic for painful pediatric limb injuries in the Emergency Department (ED) has been reported previously. However, efficacy of IN ketamine in sub-dissociative doses is not well studied in the ED setting. A non-blinded pilot study undertaken by this study group suggested that IN ketamine showed similar analgesic effectiveness to that reported with IN fentanyl in similar non-blinded studies. The aim of this randomized, controlled, equivalence trial is to compare the analgesic effect of sub-dissociative dose IN ketamine with IN fentanyl for children with isolated musculoskeletal limb injuries. Methods/Design: This is a prospective, randomized, controlled, double-blind equivalence trial of children agedthree to thirteen years and less than 50 kg body weight, with isolated musculoskeletal limb injury, presenting to the ED with moderate to severe pain, defined as a verbal response of at least six to a standard 11-point scale (0 = none, 10 = worst pain imaginable). Pain score, sedation, satisfaction with analgesic intervention, and adverse effects will be assessed over a 60 minute interval for each participant. Intranasal ketamine (1 mg/kg) or fentanyl (1.5 microgram/kg) will be administered via blinded syringe and mucosal atomization device in a standardized volume at 0.03 ml/kg, with a maximum volume of 1.5 ml divided equally to both nares. Participants will also receive 10 mg/kg ibuprofen orally. The primary outcome measure will be median change in pain score from pre-administration to 30 minutes post-administration. Non-parametric Mann-Whitney U tests will be computed to compare median change in the primary outcome measure for IN ketamine and fentanyl. A sample size of 36 participants per group is needed to detect the expected 40 mm reduction in pain rating with a 95% confidence interval (CI) no greater than +/- 10 mm at 30 minutes. Rescue analgesia will be given as IN fentanyl or intravenous morphine. Discussion: This is the first randomized-controlled trial comparing the efficacy of these two analgesic agents via the intranasal route. If IN ketamine is found to be equally effective to IN fentanyl for this indication, it will provide another analgesic agent that may be considered for the relief of acute pain in children in the ED.	[Seith, Robert] Monash Hlth, Monash Med Ctr, Pediat Emergency Dept, Clayton, Vic, Australia; [Graudins, Andis; Meek, Robert; Egerton-Warburton, Diana; Seith, Robert; Chapman, Rose] Monash Hlth, Monash Hlth Emergency Med Program, Clayton, Vic, Australia; [Furness, Trentham; Chapman, Rose] Australian Catholic Univ, Sch Nursing Midwifery & Paramed, Fitzroy, Vic, Australia; [Graudins, Andis; Egerton-Warburton, Diana] Monash Med Ctr, Dept Emergency Med, Clayton, Vic 3168, Australia	Graudins, A (reprint author), Monash Univ, Fac Med Nursing & Hlth Sci, Southern Clin Sch, Dept Med,Monash Hlth Emergency Med Res Grp, Clayton, Vic, Australia.	andis.graudins@monash.edu	Furness, Trentham/N-8563-2016	Furness, Trentham/0000-0002-3526-1687; Graudins, Andis/0000-0002-0310-3983; Egerton-Warburton, Diana/0000-0003-0262-1305	Jack Brockhoff Foundation	This trial is funded by the Jack Brockhoff Foundation.	ACEM, 2009, AUSTR COLL EM MED AU; Altman DG, 1999, BRIT MED J, V319, P703, DOI 10.1136/bmj.319.7211.703; Andrews C, 1983, CLIN ANAESTHESIOL, V1, P97; Bird SB, 2001, ANN EMERG MED, V38, P639, DOI 10.1067/mem.2001.118012; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Craven R, 2007, ANAESTHESIA, V62, P48, DOI 10.1111/j.1365-2044.2007.05298.x; Crellin D, 2010, EMERG MED AUSTRALAS, V22, P62, DOI 10.1111/j.1742-6723.2010.01257.x; Goldman RD, 2006, CURR DRUG THER, V1, P127, DOI 10.2174/157488506775268470; Grassin-Delyle S, 2012, PHARMACOL THERAPEUT, V134, P366, DOI 10.1016/j.pharmthera.2012.03.003; Helps Y, 2012, INJURY RES STAT SERI; Herd D, 2007, PEDIATR ANESTH, V17, P622, DOI 10.1111/j.1460-9592.2006.02145.x; Malviya S, 2002, BRIT J ANAESTH, V88, P241, DOI 10.1093/bja/88.2.241; National Institute of Clinical Studies, 2011, EM CAR AC PAIN MAN M; Reid C, 2011, EMERG MED J, V28, P328, DOI 10.1136/emj.2010.092825; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Wolfe TR, 2010, PEDIATRICS, V126, P532, DOI 10.1542/peds.2010-0616; Yeaman F, 2013, EMERG MED AUSTRALAS, V25, P161, DOI 10.1111/1742-6723.12059	17	5	5	1	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1745-6215			TRIALS	Trials	JUL 10	2013	14								208	10.1186/1745-6215-14-208			5	Medicine, Research & Experimental	Research & Experimental Medicine	184XL	WOS:000321927000001	23842536	DOAJ Gold, Green Published			2020-06-30	J	Ezhevskaya, AA; Mlyavykh, SG; Anderson, DG				Ezhevskaya, Anna A.; Mlyavykh, Sergey G.; Anderson, D. Greg			Effects of Continuous Epidural Anesthesia and Postoperative Epidural Analgesia on Pain Management and Stress Response in Patients Undergoing Major Spinal Surgery	SPINE			English	Article						spine surgery; epidural analgesia; surgical stress response; cytokines	UPPER ABDOMINAL-SURGERY; SURGICAL STRESS; INDUCED IMMUNOSUPPRESSION; INFLAMMATORY RESPONSE; LOCAL-ANESTHETICS; IMMUNE FUNCTION; FUSION SURGERY; TRIAL; HYPERGLYCEMIA; ROPIVACAINE	Study Design. A prospective, randomized study was used to compare 2 anesthesia/analgesia methods for reconstructive spine surgery. Objective. To assess the efficacy and influence of 2 anesthetic methods on clinical outcome and stress response during reconstructive spine surgery. Summary of Background Data. Pain control is an important goal of the postoperative care after spinal surgery. Some prior studies have suggested that epidural anesthesia with or without postoperative epidural analgesia may blunt the surgical stress response after major surgery. This treatment approach has not been fully investigated for patients undergoing major spinal surgery. We hypothesized that the stress response after major spine surgery would be attenuated by continuous epidural anesthesia/analgesia with ropivacaine, fentanyl, and epinephrine. Methods. Eighty-five patients were randomly allocated to 2 groups as follows: group E (n = 45) had epidural anesthesia and endotracheal anesthesia with sevoflurane during surgery and continuous epidural analgesia with ropivacaine, fentanyl, and epinephrine after surgery; group G (n = 40) had general anesthesia with sevoflurane and fentanyl and systemically administered opioids after surgery. Patient pain, nausea, mobility, and satisfaction were measured after surgery along with levels of cortisol, glucose, interleukin (IL)-1 beta, IL-6, and IL-10 during and after surgery. Results. In group E, there were significantly less pain, less nausea, earlier mobility, and higher satisfaction than those in group G. Group E also experienced significantly less introperative and postoperative blood loss. Group E demonstrated lower levels of glucose, cortisol, IL-1 beta, IL-6, and IL-10 during the postoperative period. Conclusion. Combined epidural/general anesthesia and postoperative epidural analgesia produced better pain control, less bleeding, and a lower surgical stress response than general anesthesia with postoperative systemically administered narcotic analgesia. This technique deserves further study in the setting of major spinal surgery.	[Ezhevskaya, Anna A.] Nizhny Novgorod Res Inst Traumatol & Orthoped, Dept Anesthesiol & Reanimat, Nizhnii Novgorod 603155, Russia; [Mlyavykh, Sergey G.] Nizhny Novgorod Res Inst Traumatol & Orthoped, Dept Neurosurg, Nizhnii Novgorod 603155, Russia; [Anderson, D. Greg] Thomas Jefferson Univ, Dept Orthopaed Surg & Neurol Surg, Philadelphia, PA 19107 USA	Ezhevskaya, AA (reprint author), Nizhny Novgorod Res Inst Traumatol & Orthoped, Dept Anesthesiol & Reanimat, 18 Verhne Voljskaya Naberejnaya, Nizhnii Novgorod 603155, Russia.	annaezhe@yandex.ru; greg.anderson@rothmaninstitute.com	Ezhevskaya, Anna/O-7316-2017; Mlyavykh, Sergey/M-5341-2017	Ezhevskaya, Anna/0000-0002-9286-4679; Mlyavykh, Sergey/0000-0002-6310-4961			Ahlers O, 2008, BRIT J ANAESTH, V101, P781, DOI 10.1093/bja/aen287; Armon C, 2007, NEUROLOGY, V68, P723, DOI 10.1212/01.wnl.0000256734.34238.e7; Bianconi M, 2004, ANESTH ANALG, V98, P166, DOI 10.1213/01.ANE.0000093310.47375.44; BONE RC, 1992, JAMA-J AM MED ASSOC, V268, P3452, DOI 10.1001/jama.268.24.3452; Cohen BE, 1997, SPINE, V22, P1892, DOI 10.1097/00007632-199708150-00016; Collier B, 2008, NUTR CLIN PRACT, V23, P3, DOI 10.1177/011542650802300103; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; Elder JB, 2008, SPINE, V33, P210, DOI 10.1097/BRS.0b013e318160447a; Esposito K, 2002, CIRCULATION, V106, P2067, DOI 10.1161/01.CIR.0000034509.14906.AE; Gagliese L, 2003, PAIN, V104, P597, DOI 10.1016/S0304-3959(03)00117-9; Gorobets E S, 2002, Anesteziol Reanimatol, P38; Gorobets E. S., 2003, Anesteziologiya i Reanimatologiya, P25; Guay Joanne, 2006, J Anesth, V20, P335, DOI 10.1007/s00540-006-0423-8; Hahnenkamp K, 2002, ANESTH ANALG, V94, P1441, DOI 10.1097/00000539-200206000-00011; Hollmann MW, 2004, MED HYPOTHESES, V63, P386, DOI 10.1016/j.mehy.2004.02.057; Holte K, 2002, Minerva Anestesiol, V68, P157; Hong JY, 2011, ACTA ANAESTH SCAND, V55, P282, DOI 10.1111/j.1399-6576.2010.02360.x; HOPF HW, 1994, ARCH SURG-CHICAGO, V129, P128; Jellish WS, 1996, ANESTH ANALG, V83, P559, DOI 10.1097/00000539-199609000-00021; Jin FL, 2001, J CLIN ANESTH, V13, P524, DOI 10.1016/S0952-8180(01)00320-8; Jirarattanaphochai K, 2007, SPINE, V32, P609, DOI 10.1097/01.brs.0000257541.91728.a1; Kawasaki T, 2007, BRIT J ANAESTH, V98, P196, DOI 10.1093/bja/ael334; Kehlet H, 2002, AM J SURG, V183, P630, DOI 10.1016/S0002-9610(02)00866-8; Kouraklis G, 2000, INT SURG, V85, P353; Marz P, 1998, P NATL ACAD SCI USA, V95, P3251, DOI 10.1073/pnas.95.6.3251; MEAKINS JL, 1991, ARCH SURG-CHICAGO, V126, P494; Melzack R, 2003, HDB PAIN MANAGEMENT; Norman JG, 1997, AM SURGEON, V63, P75; POLLOCK RE, 1991, ARCH SURG-CHICAGO, V126, P338; Qu Dong-Mei, 2003, Zhonghua Yi Xue Za Zhi, V83, P408; Raw DA, 2003, BRIT J ANAESTH, V91, P886, DOI 10.1093/bja/aeg253; Schenk MR, 2006, ANESTH ANALG, V103, P1311, DOI 10.1213/01.ane/0000247966.49492.72; Sekar C, 2004, Spine J, V4, P261; Sice PJA, 2005, BRIT J ANAESTH, V94, P378, DOI 10.1093/bja/aei061; SINATRA RS, 2002, J AM ACAD ORTHOP SUR, V10, P117; Solenkova A. V., 2000, Anesteziologiya i Reanimatologiya, P32; Solenkova AV, 2000, ANESTEZIOL REANIMAT, V4, P27; Tobias JD, 2004, ANESTH ANALG, V98, P956, DOI 10.1213/01.ANE.0000107938.80562.75; UDELSMAN R, 1987, J CLIN ENDOCR METAB, V64, P986, DOI 10.1210/jcem-64-5-986; Volk T, 2004, ANESTH ANALG, V98, P1086, DOI 10.1213/01.ANE.0000104586.12700.3A; Volk T, 2003, CYTOKINE, V24, P237, DOI 10.1016/S1043-4666(03)00090-5; Weekers F, 2003, ENDOCRINOLOGY, V144, P5329, DOI 10.1210/en.2003-0697; Yokoyama M, 2005, ANESTH ANALG, V101, P1521, DOI 10.1213/01.ANE.0000184287.15086.1E	43	26	29	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	JUL 1	2013	38	15					1324	1330		10.1097/BRS.0b013e318290ff26			7	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	298XR	WOS:000330358500023	23514874				2020-06-30	J	Diniz, MS; Kanashiro, GP; Bernardi, CA; Nicacio, GM; Cassu, RN				Diniz, Miriely Steim; Kanashiro, Glaucia Prada; Bernardi, Camila Angela; Nicacio, Gabriel Montoro; Cassu, Renata Navarro			Extradural anesthesia with lidocaine combined with fentanyl or methadone to ovariohisterectomy in dogs	ACTA CIRURGICA BRASILEIRA			English	Article						Anesthesia; Epidural; Analgesics; Opioid; Lidocaine; Fentanyl; Methadone; Dogs	EPIDURAL-ANESTHESIA; POSTOPERATIVE ANALGESIA; COMBINATION; MORPHINE; BUPIVACAINE; ROPIVACAINE; ISOFLURANE; PROPOFOL; SURGERY	PURPOSE: To compare the cardiopulmonary effects and the quality of anesthesia of the extradural lidocaine in combination with fentanyl or morphine in bitches undergoing ovariohysterectomy. METHODS: Sixteen female dogs, were sedated with intramuscular acepromazine (0.05mg kg(-1)), followed by anesthetic induction with intravenous propofol (4mg kg(-1)), to perform the lumbosacral puncture. The animals were randomly assigned to two treatments: T-F (n=8) extradural administration of fentanyl (5 mu g kg(-1)), T-M (n=8) extradural administration of methadone (0.3mg kg(-1)). In both treatment groups, opioids were combined with lidocaine, in order to make up a final volume of 0.4mL kg(-1). Heart rate (HR), respiratory rate (RR), systolic arterial blood pressure (SABP), intra-operative anesthetic supplementation, blood gases and adverse effects were investigated. RESULTS: HR, arterial pH and blood gases did not differ between treatments at any time point. RR and SABP decreased after epidural anesthesia, but the values were in terms of the physiological range of dogs. Intra-operative anesthetic supplementation was required in 50% and 62.5% of the fentanyl and methadone treated dogs, respectively. CONCLUSION: The extradural lidocaine in combination with fentanyl or morphine allowed cardiopulmonary stability, however sufficient sensitive blockade was not provided in 100% of the dogs.	[Diniz, Miriely Steim; Kanashiro, Glaucia Prada; Bernardi, Camila Angela; Nicacio, Gabriel Montoro; Cassu, Renata Navarro] Oeste Paulista Univ UNOESTE, Vet Hosp, Dept Vet Surg & Anestesiol, Fac Vet Med, Presidente Prudente, SP, Brazil	Cassu, RN (reprint author), Univ Oeste Paulista, Fac Med Vet, Dept Cirurgia & Anestesiol Vet, BR-19067175 Presidente Prudente, SP, Brazil.	navarro@unoeste.br	Cassu, Renata/M-1961-2018	Cassu, Renata/0000-0003-0681-0285			Almeida TF, 2007, JAVMA-J AM VET MED A, V230, P45, DOI 10.2460/javma.230.1.45; Aminkov BY, 1996, REV MED VET-TOULOUSE, V147, P819; Aprea F, 2012, JAVMA-J AM VET MED A, V241, P754, DOI 10.2460/javma.241.6.754; BAILEY CS, 1988, AM J VET RES, V49, P115; Bosmans T, 2011, VET ANAESTH ANALG, V38, P146, DOI 10.1111/j.1467-2995.2011.00595.x; BROCK N, 1994, CAN VET J, V35, P458; Cassu RN, 2008, ARQ BRAS MED VET ZOO, V60, P825, DOI 10.1590/S0102-09352008000400008; Cassu RN, 2010, CIENC RURAL, V40, P580, DOI 10.1590/S0103-84782010005000016; COUSINS MJ, 1984, ANESTHESIOLOGY, V61, P276; Cruz M. L., 1997, Journal of Veterinary Anaesthesia, V24, P30; Gasparini Simone Salata, 2007, Cienc. Rural, V37, P418, DOI 10.1590/S0103-84782007000200019; ILKIW JE, 1992, AM J VET RES, V53, P2323; ISHIY HM, 2002, [No title captured], V9, P134; Leibetseder EN, 2006, VET ANAESTH ANALG, V33, P128, DOI 10.1111/j.1467-2995.2005.00239.x; Monteiro ER, 2008, ARQ BRAS MED VET ZOO, V60, P1439, DOI 10.1590/S0102-09352008000600020; Tamanho RB, 2010, CIENC RURAL, V40, P115, DOI 10.1590/S0103-84782009005000252; TORDA TA, 1982, BRIT J ANAESTH, V54, P291, DOI 10.1093/bja/54.3.291; Torske KE, 2000, VET CLIN N AM-SMALL, V30, P860; Troncy E, 2002, J AM VET MED ASSOC, V221, P666, DOI 10.2460/javma.2002.221.666; VALVERDE A, 1989, VET COMP ORTHOPAED T, V2, P55	20	8	8	0	9	ACTA CIRURGICA BRASILEIRA	SAO PAULO	ALAMEDA RIO CLARO, 179-41, SAO PAULO, SP 01332-010, BRAZIL	0102-8650			ACTA CIR BRAS	Acta Cir. Bras.	JUL	2013	28	7					531	536		10.1590/S0102-86502013000700009			6	Surgery	Surgery	191IQ	WOS:000322407000009	23842935	DOAJ Gold			2020-06-30	J	Gupta, N; Rath, GP; Prabhakar, H; Dash, HH				Gupta, Nidhi; Rath, Girija P.; Prabhakar, Hemanshu; Dash, Hari H.			Effect of Intraoperative Dexmedetomidine on Postoperative Recovery Profile of Children Undergoing Surgery for Spinal Dysraphism	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						spinal dysraphism; children; dexmedetomidine infusion; intraoperative use; postoperative recovery	SEVOFLURANE ANESTHESIA; EMERGENCE DELIRIUM; REDUCES AGITATION; EVOKED POTENTIALS; MOTOR; ADENOIDECTOMY; TONSILLECTOMY; EXCITEMENT; ANALGESIA; PROVIDES	Background: Smooth recovery from anesthesia is desirable in children undergoing surgery for spinal dysraphism who are nursed in prone position during the postoperative period. Dexmedetomidine may be beneficial in these children owing to its sedative, anxiolytic, and opioid-sparing properties with minimal respiratory depression.Methods: Thirty-six children with spinal dysraphism at lumbosacral area, aged 8 to 12 years, undergoing corrective surgery were randomized to receive either dexmedetomidine or volume-matched saline (placebo) after positioned prone until beginning of skin closure. Inspired concentration of sevoflurane was changed to keep the bispectral index score between 45 and 55. Perioperative hemodynamics, intraoperative fentanyl and sevoflurane consumption, and postoperative recovery profile and fentanyl consumption was observed by blinded observers. Postoperative pain, emergence agitation (EA), and discharge readiness from postanesthesia care unit was evaluated using the modified objective pain score, agitation Cole score, and modified Aldrete score, respectively. Fentanyl 0.5-1 mu g/kg was administered for pain (objective pain score 4) or severe EA (agitation Cole score 4) lasting for >5 minutes.Results: The 2 groups did not differ significantly with respect to demographics, duration of anesthesia, emergence, and extubation times. The intraoperative consumption of sevoflurane and fentanyl was significantly less in dexmedetomidine group (0.2 +/- 0.1 vs. 0.3 +/- 0.1 mL/min, P<0.0001 and 2.3 +/- 0.5 vs. 3.1 +/- 0.6 g/kg, P=0.0001, respectively), along with a lower mean heart rate (P<0.001). The mean systolic blood pressure (P=0.98) and incidence of bradycardia and hypotension was comparable in between the 2 groups. Postoperatively, the children in dexmedetomidine group had significantly lower pain scores (P<0.0001), agitation scores (P<0.0001), and time to achieve full modified Aldrete score [0 (0 to 10) vs. 10 (0 to 20) min, P=0.001]. The postoperative consumption of fentanyl was significantly less in dexmedetomidine group [0 (0 to 1.04) vs. 0.88 (0 to 3) mu g/kg, P=0.003], along with a longer time of first analgesic requirement [600 (5 to 2100) vs. 5 (5 to 185) min, P=0.0001]. The mean heart rate and systolic blood pressure were higher in placebo group (P<0.001), whereas no difference was observed in respiratory rate (P=0.73) and arterial oxygen saturation (P=0.36). The number of patients with postoperative nausea and vomiting was significantly lower in dexmedetomidine group [2 (11.1%) vs. 9 (50%), P=0.03].Conclusions: Intraoperative use of dexmedetomidine in children undergoing spinal surgery results in a favorable recovery profile with reduced postoperative pain and EA, without adverse perioperative hemodynamic effects.	[Gupta, Nidhi; Rath, Girija P.; Prabhakar, Hemanshu; Dash, Hari H.] All India Inst Med Sci, Dept Neuroanaesthesiol, Ctr Neurosci, New Delhi 110029, India	Rath, GP (reprint author), All India Inst Med Sci, Dept Neuroanaesthesiol, Ctr Neurosci, New Delhi 110029, India.	girijarath@yahoo.co.in	Rath, Girija Prasad/J-4046-2019	Rath, Girija Prasad/0000-0002-3985-8202			Al-Zaben KR, 2010, EUR J ANAESTH, V27, P247, DOI 10.1097/EJA.0b013e32833522bf; ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Aono J, 1997, ANESTHESIOLOGY, V87, P1298, DOI 10.1097/00000542-199712000-00006; Bala E, 2008, ANESTHESIOLOGY, V109, P417, DOI 10.1097/ALN.0b013e318182a467; Blaudszun G, 2012, ANESTHESIOLOGY, V116, P1312, DOI 10.1097/ALN.0b013e31825681cb; Cole JW, 2002, PAEDIATR ANAESTH, V12, P442, DOI 10.1046/j.1460-9592.2002.00868.x; Easley RB, 2007, PEDIATR ANESTH, V17, P341, DOI 10.1111/j.1460-9592.2006.02100.x; ECKENHOFF J, 1961, ANESTHESIOLOGY, V22, P667, DOI 10.1097/00000542-196109000-00002; Fragen RJ, 1999, J CLIN ANESTH, V11, P466, DOI 10.1016/S0952-8180(99)00081-1; Guler G, 2005, PEDIATR ANESTH, V15, P762, DOI 10.1111/j.1460-9592.2004.01541.x; HANNALLAH RS, 1987, ANESTHESIOLOGY, V66, P832, DOI 10.1097/00000542-198706000-00023; HOLLIDAY MA, 1957, PEDIATRICS, V19, P823; Ibacache ME, 2004, ANESTH ANALG, V98, P60, DOI 10.1213/01.ANE.0000094947.20838.8E; Mahapatra AK, 2012, INDIAN J NEUROSURG, V1, P4, DOI 10.4103/2277-9167.94362; Mahmoud M, 2010, ANESTHESIOLOGY, V112, P1364, DOI 10.1097/ALN.0b013e3181d74f55; Mason KP, 2011, ANESTH ANALG, V113, P1129, DOI 10.1213/ANE.0b013e31822b8629; Olutoye OA, 2010, ANESTH ANALG, V111, P490, DOI 10.1213/ANE.0b013e3181e33429; Patel A, 2010, ANESTH ANALG, V111, P1004, DOI 10.1213/ANE.0b013e3181ee82fa; Petroz GC, 2006, ANESTHESIOLOGY, V105, P1098, DOI 10.1097/00000542-200612000-00009; Sato M, 2010, J ANESTH, V24, P675, DOI 10.1007/s00540-010-0976-4; Shukry M, 2005, PEDIATR ANESTH, V15, P1098, DOI 10.1111/j.1460-9592.2005.01660.x; Singh D, 2009, J NEUROSURG ANESTH, V21, P202, DOI 10.1097/ANA.0b013e31819f1ce0; Soundararajan N, 2007, BRIT J ANAESTH, V99, P86, DOI 10.1093/bja/aem120; Tobias JD, 2008, PEDIATR ANESTH, V18, P1082, DOI 10.1111/j.1460-9592.2008.02733.x; Tobias JD, 2007, PEDIATR CRIT CARE ME, V8, P115, DOI 10.1097/01.PCC.0000257100.31779.41; Wells LT, 1999, ANESTH ANALG, V88, P1308, DOI 10.1097/00000539-199906000-00020; Xu LL, 2012, J ANESTH, V26, P556, DOI 10.1007/s00540-012-1354-1	27	33	37	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JUL	2013	25	3					271	278		10.1097/ANA.0b013e31828cb6c0			8	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	202LJ	WOS:000323217100008	23519371				2020-06-30	J	Kreeger, TJ; Bjornlie, D; Thompson, D; Clapp, J; Clark, C; Hansen, C; Huizenga, M; Lockwood, S				Kreeger, Terry J.; Bjornlie, Dan; Thompson, Dan; Clapp, Justin; Clark, Colby; Hansen, Cole; Huizenga, Matt; Lockwood, Sam			Immobilization of Wyoming Bears Using Carfentanil and Xylazine	JOURNAL OF WILDLIFE DISEASES			English	Article						Black bear; carfentanil; grizzly bear; immobilization; Ursus americanus; Ursus arctos; Wyoming; xylazine	ANESTHESIA; HYDROCHLORIDE; HYPOXIA; BRAIN	Seven grizzly (Ursus arctos; four male, three female) and three black (Ursus americanus; two male, one female) bears caught in culvert traps or leg snares were immobilized in northwestern Wyoming with carfentanil and xylazine at doses, respectively, of 0.011 +/- 0.001 and 0.12 +/- 0.01 mg/kg for grizzly bears and 0.014 +/- 0.002 and 0.15 +/- 0.04 mg/kg for black bears. These drugs were antagonized with 1 mg/kg naltrexone and 2 mg/kg tolazoline. Induction and recovery times, respectively, were 4.3 +/- 0.5 and 7.1 +/- 0.8 min for grizzly bears and 5.2 +/- 0.4 and 9.1 +/- 2.2 mm for black bears. Inductions were smooth and uneventful. Recoveries were characterized initially by increased respiration followed by raising of the head, which quickly led to a full recovery, with the bears recognizing and avoiding humans and moving away, maneuvering around obstacles. All bears experienced respiratory depression, which did not significantly improve with supplemental oxygen on the basis of pulse oximetry (P=0.56). Rectal temperatures were normothermic. Carfentanil-xylazine immobilization of bears provided significant advantages over other drug regimens, including small drug volumes, predictable inductions, quick and complete recoveries, and lower costs. On the basis of these data, both grizzly and black bears can be immobilized effectively with 0.01 mg/kg carfentanil and 0.1 mg/kg xylazine.	[Kreeger, Terry J.; Hansen, Cole; Huizenga, Matt; Lockwood, Sam] Wyoming Game & Fish Dept, Wheatland, WY 82201 USA; [Bjornlie, Dan; Thompson, Dan; Clapp, Justin; Clark, Colby] Wyoming Game & Fish Dept, Lander, WY 82520 USA	Kreeger, TJ (reprint author), Wyoming Game & Fish Dept, 2362 Highway 34, Wheatland, WY 82201 USA.	tkreeg@gmail.com					Arnemo Jon M., 2001, P234; Cattet M, 2008, J MAMMAL, V89, P973, DOI 10.1644/08-MAMM-A-095.1; DECOURTENMYERS GM, 1985, STROKE, V16, P1016, DOI 10.1161/01.STR.16.6.1016; Fahlman A, 2010, J ZOO WILDLIFE MED, V41, P161, DOI 10.1638/2009-0036.1; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; HAIGH JC, 1983, J WILDLIFE DIS, V19, P140, DOI 10.7589/0090-3558-19.2.140; Kreeger T. J., 2012, HDB WILDLIFE CHEM IM; KREEGER TJ, 1986, J WILDLIFE DIS, V22, P600, DOI 10.7589/0090-3558-22.4.600; Mama KR, 2000, J AM VET MED ASSOC, V217, P546, DOI 10.2460/javma.2000.217.546; Mortenson J, 1996, P ANN M AM ASS ZOO V, P518; Paterson JM, 2009, J ZOO WILDLIFE MED, V40, P39, DOI 10.1638/2007-0107.1; Perry JL, 1977, 35 U MONT, V2; SCHMITT SM, 1987, ALCES, V23, P195; Schoch HJ, 2002, BRAIN, V125, P2549, DOI 10.1093/brain/awf257; TAYLOR WP, 1989, J WILDLIFE MANAGE, V53, P978, DOI 10.2307/3809598; VANBEVER WFM, 1976, ARZNEIMITTELFORSCH, V26, P1548; Wallach JD, 1968, MISSOURI VET, V19, P12; Wiesner H, 1984, J ZOO ANIM MED, V15, P18	18	2	2	0	13	WILDLIFE DISEASE ASSOC, INC	LAWRENCE	810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA	0090-3558			J WILDLIFE DIS	J. Wildl. Dis.	JUL	2013	49	3					674	678		10.7589/2012-10-269			5	Veterinary Sciences	Veterinary Sciences	183FA	WOS:000321798500026	23778620				2020-06-30	J	Sertoz, N; Kocaoglu, N; Ayanoglu, HO				Sertoz, Nezih; Kocaoglu, Nazan; Ayanoglu, Hilmi O.			Comparison of Lornoxicam and Fentanyl when added to Lidocaine in Intravenous Regional Anesthesia	REVISTA BRASILEIRA DE ANESTESIOLOGIA			English	Article						Anesthesia, Conduction; Anesthetics, Local; Fentanyl; Lidocaine; Piroxicam/lornoxicam	PRILOCAINE; ANALGESIA; KETOROLAC; MORPHINE; BLOCK; HAND	Background and objectives: In this study, our goal was to compare intraoperative and postoperative analgesic effects of lornoxicam and fentanyl when added to lidocaine Intravenous Regional Anesthesia (IVRA) in a group of outpatients who underwent hand surgery. Methods: This is a double blind randomized study. A total of 45 patients were included, randomized into three groups. Patients in Group I (L) received 3 mg.kg(-1) of 2% lidocaine 40 mL; patients in Group II (LL) received 3 mg.kg(-1) lidocaine 38 mL + 2 mL lornoxicam; patients in Group III (LF) received 3 mg.kg(-1) lidocaine 38 mL + 2 mL fentanyl. Our primary outcome was first analgesic requirement time at postoperative period. Results: Lornoxicam added to lidocaine IVRA increased the sensory block recovery time without increasing side effects and increased first analgesic requirement time at the postoperative period when compared to lidocaine IVRA (p < 0.001, p < 0.001 respectively) and fentanyl added to lidocaine IVRA (p < 0.001, p < 0.001 respectively). In addition, we also found that fentanyl decreased tourniquet pain (p < 0.01) when compared to lidocaine but showed similar analgesic effect with lornoxicam (p > 0.05) although VAS scores related to tourniquet pain were lower in fentanyl group. Lornoxicam added to lidocaine IVRA was not superior to lidocaine IVRA in decreasing tourniquet pain. Conclusions: Addition of fentanyl to lidocaine IVRA seems to be superior to lidocaine IVRA and lornoxicam added to lidocaine IVRA groups in decreasing tourniquet pain at the expense of increasing side effects. However, lornoxicam did not increase side effects while providing intraoperative and postoperative analgesia. Therefore, lornoxicam could be more appropriate for clinical use. (C) 2013 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. All rights reserved.	[Sertoz, Nezih] Ege Univ, Sch Med, Dept Anesthesiol & Reanimat, TR-35100 Izmir, Turkey; [Kocaoglu, Nazan] Kirsehir State Hosp, Dept Anesthesiol & Reanimat, Izmir, Turkey; [Ayanoglu, Hilmi O.] Marmara Univ, Sch Med, Dept Anesthesiol & Reanimat, Istanbul, Turkey	Sertoz, N (reprint author), Ege Univ, Tip Fak, Anestezi Anabilim Dali, TR-35100 Izmir, Turkey.	nezihsertoz@mynet.com					Aslan B, 2009, AGRI, V21, P22; Berg J, 1999, INFLAMM RES, V48, P369, DOI 10.1007/s000110050474; Brill S, 2004, ACTA ANAESTH SCAND, V48, P117, DOI 10.1111/j.1399-6576.2004.00280.x; BROWN EM, 1989, CAN J ANAESTH, V36, P307, DOI 10.1007/BF03010770; Candido KD, 2007, TXB REGIONAL ANESTHE, V2, P565; GUPTA A, 1993, REGION ANESTH, V18, P250; Jones NC, 1996, ANAESTHESIA, V51, P446, DOI 10.1111/j.1365-2044.1996.tb07789.x; Lauretti Gabriela Rocha, 2008, Rev. Bras. Anestesiol., V58, P280, DOI 10.1590/S0034-70942008000300011; Memis D, 2004, ANESTH ANALG, V98, P835; Reuben SS, 1996, REGION ANESTH, V21, P565; Sen H, 2009, ANESTH ANALG, V109, P1327, DOI 10.1213/ane.0b013e3181b0fedb; Sen S, 2006, BRIT J ANAESTH, V97, P408, DOI 10.1093/bja/ael170; Singh R, 2010, MINERVA ANESTESIOL, V76, P109; Stein C, 1997, PAIN, V71, P119, DOI 10.1097/00006396-199706000-00001; Turan A, 2002, ANESTH ANALG, V95, P1419, DOI 10.1097/00000539-200211000-00058; Viscomi CM, 2009, REGION ANESTH PAIN M, V34, P130, DOI 10.1097/AAP.0b013e31819bb006	16	2	2	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0034-7094			REV BRAS ANESTESIOL	Rev. Bras. Anestesiol.	JUL-AUG	2013	63	4					311	316		10.1016/j.bjane.2012.07.001			6	Anesthesiology	Anesthesiology	199SL	WOS:000323015700001	23931243	DOAJ Gold			2020-06-30	J	Turk, HS; Aydogmus, M; Unsal, O; Koksal, HM; Acik, ME; Oba, S				Turk, Hacer Sebnem; Aydogmus, Meltem; Unsal, Oya; Koksal, Hakan Mustafa; Acik, Mehmet Eren; Oba, Sibel			Sedation-Analgesia in Elective Colonoscopy: Propofol-Fentanyl versus Propofol-Alfentanil	REVISTA BRASILEIRA DE ANESTESIOLOGIA			English	Article						Alfentanil; Colonoscopy; Fentanyl; Propofol	ANESTHESIA; ENDOSCOPY	Background and objectives: Sedation-analgesia is recommended for comfortable colonoscopy procedures, which are invasive and can be painful. This study aimed to compare the combinations of propofol-alfentanil and propofol-fentanyl for sedation-analgesia in elective colonoscopy patients. Methods: This prospective and randomized study was planned in ASA I-II groups and included 80 patients between the ages of 18 and 65 years. Sedation-analgesia induction was performed as 1 mu g.kg(-1) fentanyl, 1 mg.kg(-1) propofol in the propofol-fentanyl group (Group PF) and 10 mu g.kg(-1) alfentanil, 1 mg.kg(-1) propofol in the propofol-alfentanil group (Group PA). Patients' scores were limited to 3-4 values on the Ramsey Sedation Scale (RSS) by 0.5 mg.kg(-1) bolus additional doses of propofol in sedation-analgesia maintenance. We recorded demographical data, heart rate, mean arterial pressure (MAP), oxygen saturation of hemoglobin (SpO2), RSS value, colonoscopy time, total dose of propofol, complications, recovery time, and discharge time, as well as colonoscopist and patient satisfaction scores. Results: MAP at the 15th minute in Group PA was significantly higher than in Group PF (p = 0.037). Group PA's beginning mean heart rate was higher than the mean heart rate at subsequent readings (p = 0.012, p = 0.002). The mean total propofol dose of Group PA was significantly higher than the total dose of Group PF (p = 0.028). The mean recovery time of Group PA was significantly longer than that of Group PF (p = 0.032). Conclusion: Fentanyl provides better operative conditions and reduces the need for additional propofol doses. These advantages cause a shorter recovery time. Therefore, propofol-fentanyl is superior to the propofol-alfentanil for sedation-analgesia in colonoscopy. (C) 2013 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. All rights reserved.	[Turk, Hacer Sebnem; Aydogmus, Meltem; Unsal, Oya; Koksal, Hakan Mustafa; Acik, Mehmet Eren; Oba, Sibel] Sisli Etfal Training & Res Hosp, Dept Anesthesiol & Intens Care Med, Istanbul, Turkey; [Koksal, Hakan Mustafa] Sisli Etfal Training & Res Hosp, Dept Gen Surg, Istanbul, Turkey		hacersebnem@yahoo.com.tr	FERAH, OYA/AAH-4973-2019	FERAH, OYA/0000-0001-5585-7368; TURK, HACER SEBNEM/0000-0003-0225-1965			Avramov MN, 1997, ANESTH ANALG, V85, P566, DOI 10.1097/00000539-199709000-00015; CHOKHAVATIA S, 1993, AM J GASTROENTEROL, V88, P393; Consales G, 2006, MINERVA ANESTESIOL, V72, P329; Dal H, 2011, J TURK ANESTH INT CA, V39, P134, DOI [10.5222/JTAICS.2011.134, DOI 10.5222/JTAICS.2011.134]; DEMIRARAN Y., 2009, ENDOSCOPY, V17, P18; DIPALMA JA, 1995, SOUTHERN MED J, V88, P630, DOI 10.1097/00007611-199506000-00006; Fanti L, 2011, DIGEST LIVER DIS, V43, P726, DOI 10.1016/j.dld.2011.04.012; Heiman DR, 1998, SOUTH MED J, V91, P560, DOI 10.1097/00007611-199806000-00010; HOLLOWAY AM, 1990, ANAESTH INTENS CARE, V18, P210, DOI 10.1177/0310057X9001800209; Jabbour-Khoury SI, 2003, CAN J ANAESTH, V50, P116, DOI 10.1007/BF03017841; Kulling D, 2001, GASTROINTEST ENDOSC, V54, P1, DOI 10.1067/mge.2001.116174; Lazzaroni M, 1999, ENDOSCOPY, V31, P2, DOI 10.1055/s-1999-13642; Lee D. W. H., 2004, Hong Kong Medical Journal, V10, P84; Madan A, 2004, SOUTH MED J, V97, P800, DOI 10.1097/01.SMJ.0000129794.97798.A5; Mondello Epifanio, 2002, J Clin Monit Comput, V17, P271, DOI 10.1023/A:1021250320103; Roseveare C, 1998, ENDOSCOPY, V30, P482, DOI 10.1055/s-2007-1001312; Runza M, 2009, MINERVA ANESTESIOL, V75, P673; Sporea Ioan, 2005, Rom J Gastroenterol, V14, P195; Toklu S, 2009, EUR J ANAESTH, V26, P370, DOI 10.1097/EJA.0b013e328318c666; Usta B, 2011, J CLIN GASTROENTEROL, V45, pE72, DOI 10.1097/MCG.0b013e318201fbce; Weatherburn C, 2007, ANAESTH INTENS CARE, V35, P204, DOI 10.1177/0310057X0703500208	21	9	12	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0034-7094	1806-907X		REV BRAS ANESTESIOL	Rev. Bras. Anestesiol.	JUL-AUG	2013	63	4					353	358		10.1016/j.bjane.2012.07.007			6	Anesthesiology	Anesthesiology	199SL	WOS:000323015700008	24565243	DOAJ Gold			2020-06-30	J	Kadam, VR; Van Wijk, RM; Moran, JL; Millers, D				Kadam, V. Rao; Van Wijk, R. M.; Moran, J. L.; Millers, D.			Epidural versus continuous transversus abdominis plane catheter technique for postoperative analgesia after abdominal surgery	ANAESTHESIA AND INTENSIVE CARE			English	Article						transversus abdominis plane; TAP blocks; postoperative analgesia; abdominal surgery	RANDOMIZED CONTROLLED-TRIAL; CESAREAN DELIVERY; TAP BLOCK; EFFICACY; ANESTHESIA	Transversus abdominis plane block is an effective postoperative analgesic technique after abdominal surgery, but no study has compared continuous transversus abdominis plane block with continuous epidural analgesia. We designed a randomised controlled trial comparing these techniques for major abdominal surgery. Patients in the epidural group received a bolus of 8 to 15 ml of ropivacaine 0.2% and an infusion of 5 to 15 ml/hour and the transversus abdominis plane block group a bolus dose of 20 ml of ropivacaine 0.375% bilaterally and an infusion of 0.2% ropivacaine 8 ml/hour bilaterally, for three days. Both groups received paracetamol and patient controlled analgesia with fentanyl for three days. Primary outcomes were numerical rating scores for pain (rest and dynamic over 72 hours) and total fentanyl use; complications and satisfaction scores were also noted. The study was terminated early after 42 patients had been randomised (epidural n=19; transversus abdominis plane block n=22; one excluded). No differences were found in regards to point pain scores or scores over time, either immediately postoperatively or in surgical wards; total fentanyl requirement and Likert satisfaction scores were also similar in both groups. In this underpowered study we found comparable results between continuous transversus abdominis plane technique and epidural analgesia in regard to pain, analgesic use and satisfaction after abdominal surgery. To confirm this finding, randomised trials with larger numbers of participants are needed.	[Kadam, V. Rao; Van Wijk, R. M.; Moran, J. L.; Millers, D.] Queen Elizabeth Hosp, Dept Anaesthesia, Woodville South, SA 5011, Australia	Van Wijk, RM (reprint author), Queen Elizabeth Hosp, Dept Anaesthesia, Woodville Rd, Woodville South, SA 5011, Australia.	roelof.vanwijk@health.sa.gov.au		Van Wijk, Roelof/0000-0001-8498-9861			Abdallah FW, 2012, REGION ANESTH PAIN M, V37, P193, DOI 10.1097/AAP.0b013e3182429531; Ahlers O, 2008, BRIT J ANAESTH, V101, P781, DOI 10.1093/bja/aen287; Auroy Y, 1997, ANESTHESIOLOGY, V87, P479, DOI 10.1097/00000542-199709000-00005; Belavy D, 2009, BRIT J ANAESTH, V103, P726, DOI 10.1093/bja/aep235; Borglum J, 2011, ACTA ANAESTH SCAND, V55, P658, DOI 10.1111/j.1399-6576.2011.02430.x; Carney J, 2008, ANESTH ANALG, V107, P2056, DOI 10.1213/ane.0b013e3181871313; El-Dawlatly AA, 2009, BRIT J ANAESTH, V102, P763, DOI 10.1093/bja/aep067; George MJ, 2006, ANAESTHESIA, V61, P659, DOI 10.1111/j.1365-2044.2006.04713.x; Guay Joanne, 2006, J Anesth, V20, P335, DOI 10.1007/s00540-006-0423-8; Hebbard P, 2007, ANAESTH INTENS CARE, V35, P616; Hebbard PD, 2010, REGION ANESTH PAIN M, V35, P436, DOI 10.1097/AAP.0b013e3181e66702; Kadam Rao V, 2011, J ANESTH, V25, P786; Kadam Rao V, 2011, J ANAESTHESIOL CLIN, V27, P333; Mallinckrodt CH, 2008, DRUG INF J, V42, P303, DOI 10.1177/009286150804200402; Mann C, 2000, ANESTHESIOLOGY, V92, P433, DOI 10.1097/00000542-200002000-00025; McDonnell JG, 2008, ANESTH ANALG, V106, P186, DOI 10.1213/01.ane.0000290294.64090.f3; McDonnell JG, 2007, ANESTH ANALG, V104, P193, DOI 10.1213/01.ane.0000250223.49963.0f; Niraj G, 2011, ANAESTHESIA, V66, P465, DOI 10.1111/j.1365-2044.2011.06700.x; Niraj G, 2009, BRIT J ANAESTH, V103, P601, DOI 10.1093/bja/aep175; O'Donnell BD, 2006, REGION ANESTH PAIN M, V31, P91, DOI 10.1016/j.rapm.2005.10.006; Petersen PL, 2010, ACTA ANAESTH SCAND, V54, P529, DOI 10.1111/j.1399-6576.2010.02215.x; Ralloc RP, 2000, STATA TECHNICAL B, V54, P49; Schricker T, 2002, ANESTHESIOLOGY, V97, P943, DOI 10.1097/00000542-200210000-00029; Wheatley RG, 2001, BRIT J ANAESTH, V87, P47, DOI 10.1093/bja/87.1.47	24	31	31	0	8	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2027, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	JUL	2013	41	4					476	481		10.1177/0310057X1304100407			6	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	176QV	WOS:000321320100007	23808506	Bronze			2020-06-30	J	Escobar, Y; Manas, A; Julia, J; Galvez, R; Zaragoza, F; Margarit, C; Lopez, R; Casas, A; Anton, A; Cruz, JJ				Escobar, Y.; Manas, A.; Julia, J.; Galvez, R.; Zaragoza, F.; Margarit, C.; Lopez, R.; Casas, A.; Anton, A.; Cruz, J. J.			Optimal management of breakthrough cancer pain (BCP)	CLINICAL & TRANSLATIONAL ONCOLOGY			English	Review						Breakthrough cancer pain (BCP); Management; Fentanyl; Intranasal administration	PECTIN NASAL SPRAY; TRANSMUCOSAL FENTANYL CITRATE; DOUBLE-BLIND; MORPHINE-SULFATE; BUCCAL TABLET; OPEN-LABEL; MU-G; EFFICACY; TOLERABILITY; PHARMACOKINETICS	Breakthrough cancer pain (BCP) is common in patients with cancer, causing a negative impairment in quality of life. Recent diagnostic criteria allow for differentiation of background chronic pain and BCP, for which proportion of unpredictable episodes is very high. Five characteristics define BCP: rapid onset, high intensity, maximum intensity (minutes), mean duration 30 min, and unpredictable onset. Fentanyl is a synthetic opioid characterized by rapid absorption and start of the analgesic effects. In addition to comparing some of the marked differences between the four pharmaceutical forms of fentanyl marketed in Spain, this paper discusses the data collected in a comprehensive clinical trial program with fentanyl pectin nasal spray (FPNS), a formulation that takes advantage of the intranasal route and the PecSys (TM) technology. The FPNS formulation achieves analgesic action 5 min after application and significant pain relief at 10 min. FPNS, therefore, has key features to be an optimal treatment for BCP.	[Escobar, Y.] Gregorio Maranon Gen Univ Hosp, Dept Med Oncol, Madrid, Spain; [Escobar, Y.] Hosp Gen Univ Gregorio Maranon, Serv Oncol Med, Madrid, Spain; [Manas, A.] Hosp Univ La Paz, Dept Oncol Radiotherapy, Madrid, Spain; [Julia, J.] Hosp Badalona Germans Trias & Pujol, Dept Integral Support & Palliat Care, Inst Catala Oncol ICO Badalona, Badalona, Spain; [Galvez, R.] Hosp Virgen de las Nieves, Unit Pain & Palliat Care, Granada, Spain; [Zaragoza, F.] Univ Alcala de Henares, Dept Pharmacol, Madrid, Spain; [Margarit, C.] Alicante Univ Gen Hosp, Pain Unit, Alicante, Spain; [Lopez, R.] Univ Hosp Complex, Dept Med Oncol, Santiago De Compostela, Spain; [Casas, A.] Hosp Virgen de la Macarena, Dept Med Oncol, Seville, Spain; [Anton, A.] Miguel Servet Hosp, Dept Med Oncol, Zaragoza, Spain; [Cruz, J. J.] Salamanca Univ Hosp, Dept Med Oncol, Salamanca, Spain	Escobar, Y (reprint author), Hosp Gen Univ Gregorio Maranon, Serv Oncol Med, Madrid, Spain.	yolandaesco@yahoo.es	Anton, Antonio/AAP-6563-2020				Actiq/Abstral/Effentora, INF COM FARM TER I C; American Pain Foundation, 2011, J Pain Palliat Care Pharmacother, V25, P252, DOI 10.3109/15360288.2011.599920; [Anonymous], 2010, ACT FICH TECN; [Anonymous], FICH TECN; [Anonymous], PRACTICE; [Anonymous], 2008, AV RES CAR PROD; [Anonymous], 2009, FICH TECN; Ashburn MA, 2011, ANESTH ANALG, V112, P693, DOI 10.1213/ANE.0b013e318209d320; Brennan F, 2007, ANESTH ANALG, V105, P205, DOI 10.1213/01.ane.0000268145.52345.55; Brooks D, 2010, ANN ONCOL, V21, P385; Cadime, 2011, BTA, V27, P13; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Castile, 2011, 2011 AM ASS PHARM SC; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Collins SL, 1998, J PAIN SYMPTOM MANAG, V16, P388, DOI 10.1016/S0885-3924(98)00094-3; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI [10.1586/ERN.11.63, 10.1586/ern.11.63]; Duragesic, 2009, DUR RES CAR PROD; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Fisher A, 2010, INT J CLIN PHARM TH, V48, P138; Fisher T, 2011, 12 RES C EUR ASS PAL; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Lennernas B, 2010, PALLIATIVE MED, V24, P286, DOI 10.1177/0269216309356138; Leppert W, 2009, INT J CLIN PRACT, V63, P1095, DOI 10.1111/j.1742-1241.2008.01990.x; Lyseng-Williamson KA, 2011, CNS DRUGS, V25, P511, DOI 10.2165/11207470-000000000-00000; McCarberg BH, 2007, PAIN MED, V8, pS8; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; MS Sevredol, MS SEVR FICH TECN; Mystakidou K, 2011, EXPERT OPIN PHARMACO, V12, P1653, DOI 10.1517/14656566.2011.585637; Nucynta&REG; ER, 2011, RES CAR PROD; Oxycontin&REG;, 2010, RES CAR PROD; Oxynorm, OX RES CAR PROD; Palexia, 2010, FICH TECN; Palexia, 2011, PAL FICH TECN; Porta-Sales J, 2010, MED CLIN-BARCELONA, V135, P280, DOI 10.1016/j.medcli.2010.02.008; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; POYHIA R, 1992, BRIT J CLIN PHARMACO, V33, P617, DOI 10.1111/j.1365-2125.1992.tb04090.x; Radbruch L, 2012, SUPPORT CARE CANCER, V20, P565, DOI 10.1007/s00520-011-1124-x; Taylor Donald, 2010, J Support Oncol, V8, P184; Taylor DR, 2012, FUTURE ONCOL, V8, P121, DOI [10.2217/FON.11.146, 10.2217/fon.11.146]; Torres L, 2011, EUR MULT CANC C 23 2; Watts P, 2009, EXPERT OPIN DRUG DEL, V6, P543, DOI [10.1517/17425240902939135, 10.1517/17425240902939135 ]; *WHO EXP COMM, 1986, CANC PAIN REL; Zeppetella G, 2009, GUIDELINES PRACTICE, V12, P1; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012	53	4	7	0	11	SPRINGER INTERNATIONAL PUBLISHING AG	CHAM	GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND	1699-048X	1699-3055		CLIN TRANSL ONCOL	Clin. Transl. Oncol.	JUL	2013	15	7					526	534		10.1007/s12094-012-0981-1			9	Oncology	Oncology	173WO	WOS:000321112900004	23263914				2020-06-30	J	Ryu, HR; Lee, J; Park, JH; Kang, SW; Jeong, JJ; Hong, JY; Chung, WY				Ryu, Haeng Rang; Lee, Jandee; Park, Jae-Hyun; Kang, Sang-Wook; Jeong, Jong Ju; Hong, Jeong-Youn; Chung, Woong Youn			A Comparison of Postoperative Pain After Conventional Open Thyroidectomy and Transaxillary Single-Incision Robotic Thyroidectomy: A Prospective Study	ANNALS OF SURGICAL ONCOLOGY			English	Article							ENDOSCOPIC THYROIDECTOMY; MANAGEMENT	The aim of this study was to compare conventional open thyroidectomy with robotic thyroidectomy in terms of postoperative pain. We compared the intensity of postoperative pain experienced by patients who received conventional open thyroidectomy (n = 45) versus those who underwent robotic thyroidectomy (n = 45). During surgery, we carefully controlled the anesthetic conditions. All the patients underwent a total thyroidectomy with ipsilateral central compartment node dissection. Postoperative pain in the 2 groups was compared using a visual analog scale and the amount of rescue analgesic at 30 min, 4 h, 1, 2, 3, and 10 days after surgery. The postoperative pain at 30 min and 4 h after surgery were 3.0 +/- A 0.9 and 2.6 +/- A 0.9 (p = .066) and 4.9 +/- A 1.3 and 4.4 +/- A 1.3 (p = .055) in the conventional open group and the robotic group, respectively. The mean pain scores at 1, 2, 3, and 10 days after surgery were 3.8 +/- A 1.3 and 3.0 +/- A 1.3 (p = .001), 2.6 +/- A 1.2 and 2.0 +/- A 0.9 (p = .005), 1.7 +/- A 0.9 and 1.3 +/- A 0.6 (p = .034), and 0.9 +/- A 0.7 and 1.2 +/- A 1.1 (p = .093), respectively. No significant differences were observed between the 2 groups in terms of postoperative rescue analgesic use (1.1 +/- A 1.1 and 0.8 +/- A 0.9, p = .264). Even though robotic thyroidectomy using the transaxillary technique requires a more extensive subcutaneous dissection than conventional open thyroidectomy, robotic thyroidectomy does not result in more postoperative pain or use of analgesic when compared with open thyroidectomy.	[Ryu, Haeng Rang; Kang, Sang-Wook; Jeong, Jong Ju; Chung, Woong Youn] Yonsei Univ, Coll Med, Dept Surg, Seoul, South Korea; [Lee, Jandee; Park, Jae-Hyun] Eulji Univ, Sch Med, Dept Surg, Seoul, South Korea; [Hong, Jeong-Youn] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Anesthesiol & Pain Med, Seoul, South Korea	Hong, JY (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Anesthesiol & Pain Med, Seoul, South Korea.	jenyhongg@gmail.com		Jeong, Jong Ju/0000-0002-4155-6035; Kang, Sang-Wook/0000-0001-5355-833X			Breivik H, 1998, EUR J ANAESTH, V15, P748, DOI 10.1097/00003643-199811000-00022; Breivik H, 2008, PAIN, V137, P233, DOI 10.1016/j.pain.2008.04.014; Carr DB, 1999, LANCET, V353, P2051, DOI 10.1016/S0140-6736(99)03313-9; Chung YS, 2007, WORLD J SURG, V31, P2302, DOI 10.1007/s00268-007-9117-0; Del Rio P, 2008, EUR SURG RES, V41, P33, DOI 10.1159/000127404; Del Rio P, 2008, LANGENBECK ARCH SURG, V393, P271, DOI 10.1007/s00423-007-0229-7; Ganger M., 1996, BRIT J SURG, V83, P875; GOZAL Y, 1994, ACTA ANAESTH SCAND, V38, P813, DOI 10.1111/j.1399-6576.1994.tb04010.x; Huscher CSG, 1997, SURG ENDOSC-ULTRAS, V11, P877, DOI 10.1007/s004649900476; Ikeda Y, 2003, J AM COLL SURGEONS, V196, P189, DOI 10.1016/S1072-7515(02)01665-4; Jeong JJ, 2009, J SURG ONCOL, V100, P477, DOI 10.1002/jso.21367; Kang SW, 2009, SURGERY, V146, P1048, DOI 10.1016/j.surg.2009.09.007; Kang SW, 2009, SURG ENDOSC, V23, P2399, DOI 10.1007/s00464-009-0366-x; Lee J, 2011, ANN SURG ONCOL, V18, P1439, DOI 10.1245/s10434-010-1486-1; Lee J, 2010, SURG ENDOSC, V24, P3186, DOI 10.1007/s00464-010-1113-z; Lee Kyu Eun, 2009, Surg Laparosc Endosc Percutan Tech, V19, pe71, DOI 10.1097/SLE.0b013e3181a4ccae; Miccoli P, 2010, SURG ENDOSC, V24, P2415, DOI 10.1007/s00464-010-0964-7; Palazzo FF, 2006, SURG ENDOSC, V20, P339, DOI 10.1007/s00464-005-0385-1; Rolke R, 2006, PAIN, V123, P231, DOI 10.1016/j.pain.2006.01.041; Ryu Haeng Rang, 2010, J Am Coll Surg, V211, pe13, DOI 10.1016/j.jamcollsurg.2010.05.021	20	40	40	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1068-9265			ANN SURG ONCOL	Ann. Surg. Oncol.	JUL	2013	20	7					2279	2284		10.1245/s10434-012-2557-2			6	Oncology; Surgery	Oncology; Surgery	159JC	WOS:000320040700028	23529779				2020-06-30	J	Merivirta, R; Aarimaa, V; Aantaa, R; Koivisto, M; Leino, K; Liukas, A; Kuusniemi, K				Merivirta, Riika; Aarimaa, Ville; Aantaa, Riku; Koivisto, Mari; Leino, Kari; Liukas, Antti; Kuusniemi, Kristiina			Postoperative Fentanyl Patch Versus Subacromial Bupivacaine Infusion in Arthroscopic Shoulder Surgery	ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY			English	Article							ACTIVE-CONTROLLED-TRIALS; PAIN PUMP USE; TRANSDERMAL FENTANYL; DOUBLE-BLIND; GLENOHUMERAL CHONDROLYSIS; AMBULATORY SURGERY; PLACEBO; MANAGEMENT; ANALGESIA; COMPLICATIONS	Purpose: The purpose of our study was to compare the effectiveness of subacromial bupivacaine infusion and a transdermal fentanyl patch in the treatment of postoperative pain after arthroscopic shoulder surgery. Methods: Sixty patients with rotator cuff disease scheduled for elective arthroscopic shoulder surgery were enrolled in the study. For the treatment of postoperative pain, 30 patients constituted group F and received a 12.0-mg/h fentanyl patch for 72 hours and saline solution infusion in a subacromial manner at the rate of 4 mL/h. The remaining 30 patients constituted group B and received a placebo patch and an infusion of 2.5-mg/mL bupivacaine in a subacromial manner for 72 hours. The primary outcome measure was the postoperative numerical rating scale pain score. The consumption of opioids, ibuprofen, and acetaminophen was also recorded. The Constant scores and general recovery were followed up until the 90th postoperative day. Results: There was no statistically significant difference in the numerical rating scale scores (P = .60) between the groups. No differences in the use of rescue analgesic were observed except that the patients receiving bupivacaine used more ibuprofen (median, 1,200 mg v 600 mg) during the day of surgery (P = .042). No difference was found in general recovery between the groups. Conclusions: A fentanyl patch delivering 12-mg/h fentanyl offers an easy and safe treatment option as a part of multimodal analgesia with few adverse effects in the treatment of postoperative pain in a carefully selected patient group after arthroscopic shoulder surgery. Level of Evidence: Level I, randomized controlled trial.	[Merivirta, Riika; Aantaa, Riku; Leino, Kari; Liukas, Antti; Kuusniemi, Kristiina] Univ Turku, Dept Anaesthesiol Intens Care Emergency Care & Pa, Turku, Finland; [Aarimaa, Ville] Univ Turku, Dept Orthopaed & Traumatol, Turku, Finland; [Koivisto, Mari] Univ Turku, Dept Biostat, Turku, Finland	Merivirta, R (reprint author), Turku Univ Hosp, PL 52, FI-20521 Turku, Finland.	riika.merivirta@tyks.fi					[Anonymous], 2012, SUMMARY PRODUCT CHAR; Barber FA, 2002, ARTHROSCOPY, V18, P76, DOI 10.1053/jars.2002.25976; Busfield BT, 2008, J SHOULDER ELB SURG, V17, P860, DOI 10.1016/j.jse.2008.03.011; Busfield BT, 2009, ARTHROSCOPY, V25, P647, DOI 10.1016/j.arthro.2009.01.019; CAPLAN RA, 1989, JAMA-J AM MED ASSOC, V261, P1036, DOI 10.1001/jama.261.7.1036; Coghlan JA, 2009, J BONE JOINT SURG AM, V91A, P1558, DOI 10.2106/JBJS.H.00948; CONSTANT CR, 1987, CLIN ORTHOP RELAT R, P160; Elvir-Lazo OL, 2010, CURR OPIN ANESTHESIO, V23, P697, DOI 10.1097/ACO.0b013e32833fad0a; Fredrickson MJ, 2010, ANAESTHESIA, V65, P608, DOI 10.1111/j.1365-2044.2009.06231.x; GOURLAY GK, 1989, PAIN, V37, P193, DOI 10.1016/0304-3959(89)90130-9; GOURLAY GK, 1990, PAIN, V40, P21, DOI 10.1016/0304-3959(90)91046-L; Howick J, 2009, AM J BIOETHICS, V9, P34, DOI 10.1080/15265160903090041; Joshi GP, 2005, INT ANESTHESIOL CLIN, V43, P197, DOI 10.1097/01.aia.0000166336.69251.dd; Lenters TR, 2007, J SHOULDER ELB SURG, V16, P379, DOI 10.1016/j.jse.2006.10.007; Merivirta R, 2012, ACTA ANAESTH SCAND, V56, P210, DOI 10.1111/j.1399-6576.2011.02606.x; Petrini C, 2009, AM J BIOETHICS, V9, P56, DOI 10.1080/15265160903098606; ROSENBERG P H, 1985, Anesthesiology (Hagerstown), V62, P178, DOI 10.1097/00000542-198502000-00015; SANDLER AN, 1994, ANESTHESIOLOGY, V81, P1169, DOI 10.1097/00000542-199411000-00010; Savoie FH, 2000, ARTHROSCOPY, V16, P339, DOI 10.1016/S0749-8063(00)90076-8; Schug SA, 2009, CURR OPIN ANESTHESIO, V22, P738, DOI 10.1097/ACO.0b013e32833020f4; Solomon DJ, 2009, ARTHROSCOPY, V25, P1329, DOI 10.1016/j.arthro.2009.06.001; Stiglitz Y, 2011, ORTHOP TRAUMATOL-SUR, V97, P260, DOI 10.1016/j.otsr.2011.02.003; VANBASTELAERE M, 1995, J CLIN ANESTH, V7, P26, DOI 10.1016/0952-8180(94)00000-T; Webb D, 2007, ARTHROSCOPY, V23, P1006, DOI 10.1016/j.arthro.2007.04.008	24	13	13	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0749-8063			ARTHROSCOPY	Arthroscopy	JUL	2013	29	7					1129	1134		10.1016/j.arthro.2013.04.018			6	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	173UC	WOS:000321105200004	23809446				2020-06-30	J	Lee, JR; Kim, MS; Moon, BE; Kim, H				Lee, J. -R.; Kim, M. -S.; Moon, B. -E.; Kim, H.			Comparison of propofol and fentanyl for preventing emergence agitation in children	BRITISH JOURNAL OF ANAESTHESIA			English	Letter							SEVOFLURANE ANESTHESIA; MIDAZOLAM				leejeongrim@gmail.com					Abu-Shahwan I, 2008, PEDIATR ANESTH, V18, P55, DOI 10.1111/j.1460-9592.2007.02376.x; Aouad MT, 2005, ACTA ANAESTH SCAND, V49, P300, DOI 10.1111/j.1399-6576.2005.00642.x; Burke CN, 2009, J PERIANESTH NURS, V24, P216, DOI 10.1016/j.jopan.2009.03.014; Chen JY, 2010, PEDIATR ANESTH, V20, P873, DOI 10.1111/j.1460-9592.2010.03375.x; Dahmani S, 2010, BRIT J ANAESTH, V104, P216, DOI 10.1093/bja/aep376; Hong JY, 2009, ANESTH ANALG, V109, P1073, DOI 10.1213/ane.0b013e3181b20c52; Kim MS, 2013, BRIT J ANAESTH, V110, P274, DOI 10.1093/bja/aes382; Koner O, 2011, EUR J ANAESTH, V28, P640, DOI 10.1097/EJA.0b013e328344db1a; Vlajkovic GP, 2007, ANESTH ANALG, V104, P84, DOI 10.1213/01.ane.0000250914.91881.a8	9	2	2	0	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	JUL	2013	111	1					121	122		10.1093/bja/aet182			2	Anesthesiology	Anesthesiology	173ES	WOS:000321061500020	23794654	Bronze			2020-06-30	J	Narayanasamy, AK; Ghori, A				Narayanasamy, A. K.; Ghori, A.			Emergence agitation after sevoflurane anaesthesia in children	BRITISH JOURNAL OF ANAESTHESIA			English	Letter							ANXIETY				nashok75@gmail.com					Aono J, 1999, ACTA ANAESTH SCAND, V43, P542, DOI 10.1034/j.1399-6576.1999.430509.x; Kim MS, 2013, BRIT J ANAESTH, V110, P274, DOI 10.1093/bja/aes382; Reduque LL, 2013, BJA EDUC, V13, P39, DOI 10.1093/bjaceaccp/mks051; Yoo JB, 2012, J KOREAN ACAD NURS, V42, P333, DOI 10.4040/jkan.2012.42.3.333	4	1	4	0	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	JUL	2013	111	1					121	121		10.1093/bja/aet183			1	Anesthesiology	Anesthesiology	173ES	WOS:000321061500019	23794655	Bronze			2020-06-30	J	Narita, M; Imai, S; Nakamura, A; Ozeki, A; Asato, M; Rahmadi, M; Sudo, Y; Hojo, M; Uezono, Y; Devi, LA; Kuzumaki, N; Suzuki, T				Narita, Minoru; Imai, Satoshi; Nakamura, Atsushi; Ozeki, Ayumi; Asato, Megumi; Rahmadi, Mahardian; Sudo, Yuka; Hojo, Minoru; Uezono, Yasuhito; Devi, Lakshmi A.; Kuzumaki, Naoko; Suzuki, Tsutomu			Possible involvement of prolonging spinal mu-opioid receptor desensitization in the development of antihyperalgesic tolerance to mu-opioids under a neuropathic pain-like state	ADDICTION BIOLOGY			English	Article						Fentanyl; mouse; neuropathic pain; opioid tolerance; -opioid receptor; spinal cord	ENDOGENOUS BETA-ENDORPHIN; PROTEIN-COUPLED RECEPTORS; SCIATIC-NERVE INJURY; MORPHINE; ENDOCYTOSIS; MODEL; MICE; ARRESTIN; NEURONS; ROLES	In the present study, we investigated the possible development of tolerance to the antihyperalgesic effect of mu-opioid receptor (MOR) agonists under a neuropathic pain-like state. Repeated treatment with fentanyl, but not morphine or oxycodone, produced a rapid development of tolerance to its antihyperalgesic effect in mice with sciatic nerve ligation. Like the behavioral study, G-protein activation induced by fentanyl was significantly reduced in membranes obtained from the spinal cord of nerve-ligated mice with in vivo repeated injection of fentanyl. In -endorphin-knockout mice with nerve ligation, developed tolerance to the antihyperalgesic effect of fentanyl was abolished, and reduced G-protein activation by fentanyl after nerve ligation with fentanyl was reversed to the normal level. The present findings indicate that released -endorphin within the spinal cord may be implicated in the rapid development of tolerance to fentanyl under a neuropathic pain-like state.	[Narita, Minoru; Imai, Satoshi; Nakamura, Atsushi; Ozeki, Ayumi; Asato, Megumi; Rahmadi, Mahardian; Kuzumaki, Naoko; Suzuki, Tsutomu] Hoshi Univ, Dept Toxicol, Sch Pharm & Pharmaceut Sci, Tokyo 1428501, Japan; [Sudo, Yuka; Uezono, Yasuhito] Nagasaki Univ, Dept Cellular & Mol Biol, Grad Sch Biomed Sci, Nagasaki, Japan; [Hojo, Minoru] Nagasaki Univ, Dept Anesthesiol, Grad Sch Biomed Sci, Nagasaki, Japan; [Uezono, Yasuhito] Natl Canc Ctr, Res Inst, Canc Pathophysiol Div, Kashiwa, Chiba, Japan; [Devi, Lakshmi A.] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY USA	Narita, M (reprint author), Hoshi Univ, Dept Toxicol, Sch Pharm & Pharmaceut Sci, Shinagawa Ku, 2-4-41 Ebara, Tokyo 1428501, Japan.	narita@hoshi.ac.jp; suzuki@hoshi.ac.jp	Kuzumaki, Naoko/L-1287-2013; Sudo, Yuka/G-3182-2013		NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K05 DA019521, R37 DA008863, R01 DA008863]; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS026880]		Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Debic HH, 2005, J NEUROSCI, V25, P7847, DOI 10.1523/JNEUROSCI.5045-04.2005; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; Imai Satoshi, 2006, JAPANESE JOURNAL OF NEUROPSYCHOPHARMACOLOGY, V26, P183; Kieffer BL, 2002, CELL, V108, P587, DOI 10.1016/S0092-8674(02)00666-9; Koch T, 2005, MOL PHARMACOL, V67, P280, DOI 10.1124/mol.104.004994; Malmberg AB, 1998, PAIN, V76, P215, DOI 10.1016/S0304-3959(98)00045-1; Minnis JG, 2003, NEUROSCIENCE, V119, P33, DOI 10.1016/S0306-4522(03)00135-0; Narita M, 2001, J BIOL CHEM, V276, P15409, DOI 10.1074/jbc.M009716200; Niikura K, 2008, NEUROSCI LETT, V435, P257, DOI 10.1016/j.neulet.2008.02.059; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; Rubinstein M, 1996, P NATL ACAD SCI USA, V93, P3995, DOI 10.1073/pnas.93.9.3995; Schulz S, 2004, EMBO J, V23, P3282, DOI 10.1038/sj.emboj.7600334; SELTZER Z, 1990, PAIN, V43, P205, DOI 10.1016/0304-3959(90)91074-S; Ventafridda V, 1981, Int Rehabil Med, V3, P149; Walwyn WM, 2004, NEUROSCIENCE, V123, P111, DOI 10.1016/j.neuroscience.2003.08.060; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; Zangen A, 1998, NEUROSCIENCE, V85, P659, DOI 10.1016/S0306-4522(98)00050-5; Zollner C, 2008, J CLIN INVEST, V118, P1065, DOI 10.1172/JCI25911; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	22	12	12	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1355-6215	1369-1600		ADDICT BIOL	Addict. Biol.	JUL	2013	18	4					614	622		10.1111/j.1369-1600.2011.00354.x			9	Biochemistry & Molecular Biology; Substance Abuse	Biochemistry & Molecular Biology; Substance Abuse	169IW	WOS:000320774700002	21812868	Green Accepted			2020-06-30	J	Benato, L; Chesnel, M; Eatwell, K; Meredith, A				Benato, L.; Chesnel, M.; Eatwell, K.; Meredith, A.			Arterial blood gas parameters in pet rabbits anaesthetized using a combination of fentanyl-fluanisone-midazolam-isoflurane	JOURNAL OF SMALL ANIMAL PRACTICE			English	Article							ANESTHESIA; SEVOFLURANE; HEMATOCRIT; PROPOFOL; TENSION	Objectives Blood gas analysis is a well-recognized method to monitor pulmonary function, blood oxygenation, ventilation and acid-base status during general anaesthesia. The aim of this study was to report blood gas analysis results in pet rabbits (Oryctolagus cuniculus) obtained during general anaesthesia using a portable clinical analyser. Methods Thirty-two rabbits were premedicated with 0 center dot 2 mL/kg fentanyl and fluanisone. Anaesthesia was induced with 0 center dot 2 mg/kg midazolam and maintained with 2% isoflurane in oxygen via endotracheal tube. Arterial blood samples were taken from the central ear artery 10 minutes after induction of anaesthesia. Results Respiratory acidaemia was observed during anaesthesia. Mean +/- sd (range) arterial blood pH was 7 center dot 33 +/- 0 center dot 08 (7 center dot 15 to 7 center dot 48). PaCO2 and PaO2 were, respectively, 55 center dot 02 +/- 10 center dot 5 (37 center dot 7 to 92 center dot 1) mmHg and 370 center dot 0 +/- 120 center dot 5 (67 to 561) mmHg. Base excess was 2 center dot 8 +/- 3 center dot 6 (-3 to 11) mmol/L, HCO3 was 28 center dot 73 +/- 3 center dot 07 (23 center dot 7 to 35 center dot 4) mmol/L and TCO2 was 30 center dot 4 +/- 3 center dot 2 (25 to 37) mmol/L. None of the rabbits developed haematoma during arterial blood collection or ischaemia of the pinna during the hospitalization period. Clinical Significance Arterial blood gas analysis is a safe and easy to perform diagnostic technique that can contribute to improved safety of rabbit anaesthesia, by providing information on the respiratory and metabolic status of the patient.	Univ Edinburgh, Hosp Small Anim, Easter Bush Vet Ctr, Royal Dick Sch Vet Studies, Roslin EH25 9RG, Midlothian, Scotland; Univ Edinburgh, Hosp Small Anim, Easter Bush Vet Ctr, Roslin Inst,Div Vet Clin Sci, Roslin EH25 9RG, Midlothian, Scotland	Benato, L (reprint author), Univ Glasgow, Sch Vet Med, Coll Med Vet Med & Life Sci MVLS, Glasgow G61 1QH, Lanark, Scotland.		Meredith, Anna/AAC-4311-2019	Meredith, Anna/0000-0002-3965-8737; benato, livia/0000-0003-2399-4194			AGOSTONI E, 1970, RESP PHYSIOL, V8, P332, DOI 10.1016/0034-5687(70)90040-X; Allweiler S, 2010, LAB ANIM-UK, V44, P113, DOI 10.1258/la.2009.009036; BARZAGO MM, 1992, LAB ANIM, V26, P73, DOI 10.1258/002367792780745904; Bateman L, 2005, VET ANAESTH ANALG, V32, P280, DOI 10.1111/j.1467-2995.2005.00169.x; Brodbelt DC, 2008, VET ANAESTH ANALG, V35, P365, DOI 10.1111/j.1467-2995.2008.00397.x; Cecen G, 2009, ANKARA UNIV VET FAK, V56, P255; DEEB BJ, 1990, J CLIN MICROBIOL, V28, P70, DOI 10.1128/JCM.28.1.70-75.1990; Dugdale A., 2010, VET ANAESTHESIA PRIN, P156; Geffre A, 2011, VET CLIN PATH, V40, P107, DOI 10.1111/j.1939-165X.2011.00287.x; GLEED RD, 1988, RES VET SCI, V44, P255, DOI 10.1016/S0034-5288(18)30851-8; Heard Darryl J., 2007, P83; Jin WZ, 2011, RESP PHYSIOL NEUROBI, V177, P183, DOI 10.1016/j.resp.2011.03.009; Martinez MA, 2009, VET REC, V164, P803, DOI 10.1136/vr.164.26.803; Martino P. A., 2003, 9 WORLD RABB C JUN 1; MOCK T, 1995, CLIN BIOCHEM, V28, P187, DOI 10.1016/0009-9120(95)90708-6; O'Malley B., 2005, CLIN ANATOMY PHYSL E, P173; Schroeder CA, 2011, J AM ASSOC LAB ANIM, V50, P205; Swenson J, 2008, J EXOT PET MED, V17, P175, DOI 10.1053/j.jepm.2008.05.004; Topal A, 2006, IRISH VET J, V59, P278, DOI 10.1186/2046-0481-59-5-278; Unoki Takeshi, 2003, Respir Care, V48, P754; VEGFORS M, 1992, ACTA ANAESTH SCAND, V36, P454, DOI 10.1111/j.1399-6576.1992.tb03496.x; WILLIS N, 1995, ACTA ANAESTH SCAND, V39, P45, DOI 10.1111/j.1399-6576.1995.tb04329.x	22	3	3	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-4510	1748-5827		J SMALL ANIM PRACT	J. Small Anim. Pract.	JUL	2013	54	7					343	346		10.1111/jsap.12081			4	Veterinary Sciences	Veterinary Sciences	169JT	WOS:000320777000004	23659374				2020-06-30	J	Ziesenitz, VC; Konig, SK; Mahlke, N; Jantos, R; Skopp, G; Weiss, J; Haefeli, WE; Mikus, G				Ziesenitz, Victoria C.; Koenig, Sonja K.; Mahlke, Nina; Jantos, Ricarda; Skopp, Gisela; Weiss, Johanna; Haefeli, Walter E.; Mikus, Gerd			Fentanyl Pharmacokinetics is not Dependent on Hepatic Uptake by Organic Anion-Transporting Polypeptide 1B1 in Human Beings	BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY			English	Article							HEALTHY-VOLUNTEERS; DRUG-INTERACTIONS; 521T-GREATER-THAN-C POLYMORPHISM; SLCO1B1 POLYMORPHISM; OATP TRANSPORTERS; PRAVASTATIN; DISPOSITION; ACID; 3A4; ATORVASTATIN	A recent study investigating the pharmacokinetics of fentanyl in Sprague-Dawley rats suggested fentanyl to be a substrate of rat organic anion-transporting polypeptide Oatp. In human beings, the most important OATP for the pharmacokinetics of many drugs is OATP1B1. Therefore, genetic variants of OATP1B1 (SLCO1B1) might modulate fentanyl pharmacokinetics and efficacy in human beings. Sixteen healthy male and female volunteers, homozygous for SLCO1B1*1a (genetic wild-type) (n=11) or *15 (deficient haplotype carrying the single-nucleotide polymorphisms rs2306283 and rs4149056 and exhibiting altered transport activity; n=5), were included in this randomized crossover study. The participants received fentanyl (5g/kg) intravenously alone or with the OATP inhibitor rifampicin (600mg single oral dose). The pharmacokinetics of fentanyl and norfentanyl were determined by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). In addition, fentanyl uptake in vitro was evaluated in OATP1B1 overexpressing HEK293 cells and compared to a mock-transfected cell line. In the clinical trial, fentanyl clearance was 18.8 +/- 8.2 mL/min.kg in SLCO1B1*1a and 19.5 +/- 1.8 mL/min/kg in SLCO1B1*15 carriers and not significantly different between the genotypes. During rifampicin, fentanyl clearance was 15.0 +/- 4.4 mL/min/kg in SLCO1B1*1a and 16.7 +/- 5.9 mL/min/kg in SLCO1B1*15 carriers (p>0.5). In addition, in vitro data also indicate that fentanyl is not transported by OATP1B1. In conclusion, our data indicate that OATP1B1 has no impact on fentanyl pharmacokinetics in human beings.	[Ziesenitz, Victoria C.; Koenig, Sonja K.; Weiss, Johanna; Haefeli, Walter E.; Mikus, Gerd] Univ Heidelberg Hosp, Dept Clin Pharmacol & Pharmacoepidemiol, D-69120 Heidelberg, Germany; [Mahlke, Nina; Jantos, Ricarda; Skopp, Gisela] Univ Heidelberg Hosp, Inst Legal & Traff Med, D-69120 Heidelberg, Germany	Mikus, G (reprint author), Univ Heidelberg Hosp, Dept Clin Pharmacol & Pharmacoepidemiol, Neuenheimer Feld 410, D-69120 Heidelberg, Germany.	gerd.mikus@med.uni-heidelberg.de	Ziesenitz, Victoria/J-2945-2019; Mikus, Gerd/D-4152-2013; Haefeli, Walter Emil/AAJ-3024-2020	Ziesenitz, Victoria/0000-0003-2836-4212; Mikus, Gerd/0000-0003-1783-133X; Haefeli, Walter Emil/0000-0003-0672-6876			Aklillu E, 2011, EUR J CLIN PHARMACOL, V67, P1139, DOI 10.1007/s00228-011-1065-9; Ariano RE, 2001, J CLIN PHARMACOL, V41, P757, DOI 10.1177/00912700122010663; BOWER S, 1982, BRIT J ANAESTH, V54, P871, DOI 10.1093/bja/54.8.871; Deng JW, 2008, PHARMACOGENET GENOM, V18, P424, DOI 10.1097/FPC.0b013e3282fb02a3; Deng S, 2009, CLIN THER, V31, P1256, DOI 10.1016/j.clinthera.2009.06.006; Elkiweri IA, 2009, ANESTH ANALG, V108, P149, DOI 10.1213/ane.0b013e31818e0bd1; Fahrmayr C, 2010, DRUG METAB REV, V42, P380, DOI 10.3109/03602530903491683; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Giacomini KM, 2010, NAT REV DRUG DISCOV, V9, P215, DOI 10.1038/nrd3028; Hagenbuch B, 2008, XENOBIOTICA, V38, P778, DOI [10.1080/00498250801986951, 10.1080/00498250801986951 ]; Hagenbuch B, 2002, NEWS PHYSIOL SCI, V17, P231, DOI 10.1152/nips.01402.2002; He YJ, 2009, CLIN CHIM ACTA, V405, P49, DOI 10.1016/j.cca.2009.04.003; Hirano M, 2006, DRUG METAB DISPOS, V34, P1229, DOI 10.1124/dmd.106.009290; Ho RH, 2007, PHARMACOGENET GENOM, V17, P647, DOI 10.1097/FPC.0b013e3280ef698f; Kalliokoski A, 2009, BRIT J PHARMACOL, V158, P693, DOI 10.1111/j.1476-5381.2009.00430.x; Konig J, 2012, BASIC CLIN PHARMACOL, V111, P81, DOI 10.1111/j.1742-7843.2012.00865.x; Konig J, 2006, N-S ARCH PHARMACOL, V372, P432, DOI 10.1007/s00210-006-0040-y; Konig J, 2000, J BIOL CHEM, V275, P23161, DOI 10.1074/jbc.M001448200; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lau YY, 2007, CLIN PHARMACOL THER, V81, P194, DOI 10.1038/sj.clpt.6100038; Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936; Matsushima S, 2008, DRUG METAB DISPOS, V36, P663, DOI 10.1124/dmd.107.017814; Michaud V, 2012, CLIN PHARMACOL THER, V91, P475, DOI 10.1038/clpt.2011.249; Niemi M, 2004, PHARMACOGENETICS, V14, P429, DOI 10.1097/01.fpc.0000114750.08559.32; Niemi M, 2011, PHARMACOL REV, V63, P157, DOI 10.1124/pr.110.002857; Ohno Y, 2008, CLIN PHARMACOKINET, V47, P669, DOI 10.2165/00003088-200847100-00004; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; Palkama VJ, 1998, BRIT J ANAESTH, V81, P598, DOI 10.1093/bja/81.4.598; Pasanen MK, 2008, PHARMACOGENOMICS, V9, P19, DOI 10.2217/14622416.9.1.19; Pasanen MK, 2006, PHARMACOGENET GENOM, V16, P873, DOI 10.1097/01.fpc.0000230416.82349.90; Schulz M, 2003, PHARMAZIE, V58, P447; Tateishi T., 1996, Anesthesia and Analgesia, V82, P167, DOI 10.1097/00000539-199601000-00031; van Giersbergen PLM, 2007, CLIN PHARMACOL THER, V81, P414, DOI 10.1038/sj.clpt.6100075; Vollmer K O, 1988, Fortschr Med, V106, P593; Weiss J, 2013, BIOCHEM PHARMACOL, V85, P265, DOI 10.1016/j.bcp.2012.11.020; Xiang XQ, 2009, PHARMACOGENET GENOM, V19, P447, DOI 10.1097/FPC.0b013e32832bcf7b	36	6	8	0	5	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-7835	1742-7843		BASIC CLIN PHARMACOL	Basic Clin. Pharmacol. Toxicol.	JUL	2013	113	1					43	48		10.1111/bcpt.12066			6	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	164ES	WOS:000320392300007	23480028				2020-06-30	J	Milonski, J; Zielinska-Blizniewska, H; Golusinski, W; Urbaniak, J; Sobanski, R; Olszewski, J				Milonski, Jaroslaw; Zielinska-Blizniewska, Hanna; Golusinski, Wojciech; Urbaniak, Joanna; Sobanski, Rafal; Olszewski, Jurek			Effects of three different types of anaesthesia on perioperative bleeding control in functional endoscopic sinus surgery	EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY			English	Article						Type of anaesthesia; Perioperative bleeding; Functional endoscopic sinus surgery (FESS)	BLOOD-LOSS; SURGICAL FIELD; SEVOFLURANE ANESTHESIA; PROPOFOL; REMIFENTANIL; HYPOTENSION	The aim of the study was to assess the effect of three different types of anaesthesia on perioperative bleeding control and to analyse the mean arterial blood pressure and heart rate in patients undergoing endoscopic paranasal sinus surgery. Ninety patients (30 women and 60 men, aged 18-85 years) scheduled to undergo functional endoscopic sinus surgery in the years 2008-2010 were identified as candidates for inclusion in the study. Patients were randomly assigned to one of three groups (30 patients each) according to the type of general anaesthesia to be administered. Groups I and II both received inhalation anaesthesia (sevoflurane for sedation) and intravenous anaesthesia (fentanyl in group I, remifentanil in group II). Anaesthesia was delivered solely via intravenous route (TIVA) in group III, with propofol used for sedation and remifentanil for analgesia. Blood pressure and heart rate were monitored during surgery and post-surgically for 4 h. Mean anaesthesia duration in groups I, II and III was 108.7 +/- A 20.8, 112.6 +/- A 22.2 and 103.7 +/- A 17.5 min and the surgery duration was 71.3 +/- A 16.7, 78.8 +/- A 24.2 and 66.5 +/- A 15.5 min, respectively. Mean blood loss during surgery was 365.0 +/- A 176.2, 340.0 +/- A 150.5 and 225.0 +/- A 91.7 ml, with a mean blood loss rate of 5.1 +/- A 2.4, 4.5 +/- A 2.2 and 3.4 +/- A 1.1 ml/min in groups I, II and III, respectively. Technologically advanced control of the drug dose with the TIVA technique allows for better control of perioperative bleeding.	[Milonski, Jaroslaw; Zielinska-Blizniewska, Hanna; Urbaniak, Joanna; Olszewski, Jurek] Med Univ Lodz, Chair Otolaryngol 2, Dept Otolaryngol & Laryngol Oncol, PL-90549 Lodz, Poland; [Golusinski, Wojciech] Med Univ Poznan, Dept Head & Neck Surg & Laryngol Oncol, Poznan, Poland; [Sobanski, Rafal] Med Univ Lodz, Dept Anaesthesiol & Intens Therapy, PL-90549 Lodz, Poland	Olszewski, J (reprint author), Med Univ Lodz, Chair Otolaryngol 2, Dept Otolaryngol & Laryngol Oncol, Zeromskiego 113, PL-90549 Lodz, Poland.	jurek.olszewski@umed.lodz.pl	Olszewski, Jurek/S-9907-2016; Milonski, Jaroslaw/AAG-2334-2019	Milonski, Jaroslaw/0000-0001-6890-6093; Olszewski, Jurek/0000-0002-8868-9679; GOLUSINSKI, WOJCIECH/0000-0002-6075-3464			Ahn HJ, 2008, BRIT J ANAESTH, V100, P50, DOI 10.1093/bja/aem304; Baker AR, 2010, ACTA ANAESTH SCAND, V54, P795, DOI 10.1111/j.1399-6576.2010.02259.x; BLACKWELL KE, 1993, AM J OTOLARYNG, V14, P262, DOI 10.1016/0196-0709(93)90072-F; BOEZAART AP, 1995, CAN J ANAESTH, V42, P373, DOI 10.1007/BF03015479; Cafiero T, 2007, EUR J ANAESTH, V24, P441, DOI 10.1017/S0265021506002080; Crawley BK, 2009, ARCH OTOLARYNGOL, V135, P994, DOI 10.1001/archoto.2009.139; Danielsen A, 2003, EUR ARCH OTO-RHINO-L, V260, P481, DOI 10.1007/s00405-003-0613-z; Eberhart LHJ, 2003, LARYNGOSCOPE, V113, P1369, DOI 10.1097/00005537-200308000-00019; Gorce BM, 2007, SAUDI MED J, V28, P358; Ko MT, 2008, LARYNGOSCOPE, V118, P1687, DOI 10.1097/MLG.0b013e31817c6b7c; Manola M, 2005, ORL-J OTO-RHIN-LARYN, V67, P83, DOI 10.1159/000084576; Momota Yoshihiro, 2010, Anesth Prog, V57, P13, DOI 10.2344/0003-3006-57.1.13; Nair S, 2004, LARYNGOSCOPE, V114, P1042, DOI 10.1097/00005537-200406000-00016; Nekhendzy V, 2007, ANESTH ANALG, V105, P1404, DOI 10.1213/01.ane.0000282781.56025.52; Sieskiewicz Andrzej, 2010, Otolaryngol Pol, V64, P225, DOI 10.1016/S0030-6657(10)70020-2; SIMPSON P, 1992, BRIT J ANAESTH, V69, P498, DOI 10.1093/bja/69.5.498; Sivaci R, 2004, SAUDI MED J, V25, P1995; Wormald PJ, 2005, AM J RHINOL, V19, P514, DOI 10.1177/194589240501900516	18	17	17	0	4	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0937-4477	1434-4726		EUR ARCH OTO-RHINO-L	Eur. Arch. Oto-Rhino-Laryn.	JUL	2013	270	7					2045	2050		10.1007/s00405-012-2311-1			6	Otorhinolaryngology	Otorhinolaryngology	155PU	WOS:000319761200012	23263204	Other Gold, Green Published			2020-06-30	J	Gramigni, E; Bracco, D; Carli, F				Gramigni, Elena; Bracco, David; Carli, Franco			Epidural analgesia and postoperative orthostatic haemodynamic changes Observational study	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article							BUPIVACAINE MORPHINE; ACUTE PAIN; SURGERY; HYPOTENSION; SAFETY; CARE; COMPLICATIONS; ANESTHESIA; EFFICACY	CONTEXTIn thoracic and abdominal surgery, epidural analgesia provides excellent pain relief, but associated postural hypotension can delay mobilisation.OBJECTIVESTo assess postoperative orthostatic haemodynamic changes in patients receiving epidural analgesia after major surgery.DESIGNProspective observational study. Physiological intervention.SETTINGSMontreal General Hospital tertiary teaching hospital.PATIENTS OR OTHER PARTICIPANTSPatients scheduled for thoracic or abdominal surgery with thoracic epidural analgesia using a mixture of bupivacaine 0.1% and fentanyl 3gml(-1).INTERVENTION(S)Arterial blood pressure and heart rate were measured in supine, sitting and standing position before surgery and daily for the first 3 postoperative days.MAIN OUTCOME MEASUREOrthostatic hypotension, defined as a drop in SBP of more than 20mmHg during the orthostatic tests, was investigated as a predictor of inability to mobilise during the postoperative period.RESULTSOne hundred and sixty-one patients were enrolled in the study. Hypotension was detected in 59 (37%) of the patients on postoperative day 1, 20 (12%) on day 2 and four (2.5%) on day 3. On day 1, 43% of the patients walked, 39% only sat and 17% were bedridden. Supine SBP less than 90mmHg, haemodynamic changes during the orthostatic tests, dizziness or nausea, did not predict inability to walk. Only blood loss more than 500ml and supine mean BP less than 70mmHg were negative predictors of mobilisation on day 1.CONCLUSIONEpidural analgesia is associated with arterial hypotension in the postoperative period. However, haemodynamic assessment does not predict inability to walk after thoracic and abdominal surgery. Early mobilisation should be tried irrespective of BP or orthostatic changes in postoperative patients with epidural analgesia.	[Gramigni, Elena; Bracco, David; Carli, Franco] McGill Univ, Ctr Hlth, Dept Anesthesia, Montreal, PQ H3G 1A4, Canada	Bracco, D (reprint author), McGill Univ, Ctr Hlth, Montreal Gen Hosp, Dept Anesthesia, 1650 Cedar Ave,Room D 10-141, Montreal, PQ H3G 1A4, Canada.	David.Bracco@McGill.Ca			Anesthesia Department of the Montreal General Hospital; Department of Anaesthesia, University of Florence, Italy	Financial support and sponsorship: the study was funded by internal funds of the Anesthesia Department of the Montreal General Hospital. EG is a recipient of a clinical research scholarship from the Department of Anaesthesia, University of Florence, Italy.	Bradshaw BGG, 1998, J AM COLL SURGEONS, V186, P501, DOI 10.1016/S1072-7515(98)00078-7; Carli F, 2002, ANESTHESIOLOGY, V97, P540, DOI 10.1097/00000542-200209000-00005; Cashman JN, 2004, BRIT J ANAESTH, V93, P212, DOI 10.1093/bja/aeh180; Cowie DA, 2004, ANESTH ANALG, V98, P40, DOI 10.1213/01.ANE.0000093388.17298.90; Crawford ME, 1996, ANESTH ANALG, V83, P1028, DOI 10.1097/00000539-199611000-00022; Flisberg P, 2003, ACTA ANAESTH SCAND, V47, P457, DOI 10.1034/j.1399-6576.2003.00104.x; Gehrking JA, 2005, CLIN AUTON RES, V15, P71, DOI 10.1007/s10286-005-0246-y; HARPER CM, 1988, J AM GERIATR SOC, V36, P1047, DOI 10.1111/j.1532-5415.1988.tb04375.x; Henriksen MG, 2002, NUTRITION, V18, P263, DOI 10.1016/S0899-9007(01)00749-3; Kehlet H, 2003, LANCET, V362, P1921, DOI 10.1016/S0140-6736(03)14966-5; Kehlet H, 2002, AM J SURG, V183, P630, DOI 10.1016/S0002-9610(02)00866-8; Leithauser DJ, 1941, ARCH SURG-CHICAGO, V42, P1086, DOI 10.1001/archsurg.1941.01210120121015; Licker M, 2003, BRIT J ANAESTH, V91, P525, DOI 10.1093/bja/aeg212; MOINICHE S, 1993, ACTA ANAESTH SCAND, V37, P65, DOI 10.1111/j.1399-6576.1993.tb03600.x; Newcombe RG, 1998, STAT MED, V17, P857, DOI 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E; Ready LB, 1999, REGION ANESTH PAIN M, V24, P499, DOI 10.1016/S1098-7339(99)90038-X; Taqi A, 2007, SURG ENDOSC, V21, P247, DOI 10.1007/s00464-006-0069-5; Tsui SL, 1997, ANAESTHESIA, V52, P1042, DOI 10.1111/j.1365-2044.1997.232-az0371.x; Wheatley RG, 2001, BRIT J ANAESTH, V87, P47, DOI 10.1093/bja/87.1.47; White PF, 2007, ANESTH ANALG, V104, P1380, DOI 10.1213/01.ane.0000263034.96885.e1; Wu CL, 2005, ANESTHESIOLOGY, V103, P1079, DOI 10.1097/00000542-200511000-00023	21	13	14	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	JUL	2013	30	7					398	404		10.1097/EJA.0b013e32835b162c			7	Anesthesiology	Anesthesiology	247GG	WOS:000326604100005	23435278				2020-06-30	J	Juba, KM; Wahler, RG; Daron, SM				Juba, Katherine M.; Wahler, Robert G.; Daron, Susan M.			Morphine and Hydromorphone-Induced Hyperalgesia in a Hospice Patient	JOURNAL OF PALLIATIVE MEDICINE			English	Editorial Material							ACID RECEPTORS; CANCER PAIN; TOLERANCE; MORPHINE-3-GLUCURONIDE; ANTAGONIST; MECHANISMS; ALLODYNIA; MK-801	Opioids including morphine and hydromorphone are widely used for control of moderate to severe pain and dyspnea in hospice and palliative care patients. Accumulation of the active morphine-3-glucuronide (M3G) and hydromorphone-3-glucuronide (H3G) metabolites is one proposed mechanism for the development of neuroexcitatory effects including allodynia and opioid-induced hyperalgesia (OIH). We report the case of a 43-year-old female hospice patient with metastatic non-small cell lung cancer who initially developed allodynia following morphine administration and again following administration of hydromorphone. The allodynia resolved both times following the discontinuation of the opioid and rotation to a different opioid regimen. Potential opioid-induced neuroexcitatory treatment options include opioid rotation to an agent with inactive metabolites, use of adjuvant pain medications for opioid-sparing effects, management of undesired symptoms (e. g., myoclonus), or increasing opioid clearance with intravenous (IV) fluids. Although the incidence is not well defined in the literature, hospice and palliative care clinicians should suspect OIH in patients with allodynia and/or hyperalgesia, especially when repeated dose escalations do not improve analgesia or pain escalates following opioid dose titration.	[Juba, Katherine M.] St John Fisher Coll, Wegmans Sch Pharm, Dept Pharm Practice, Rochester, NY 14618 USA; [Wahler, Robert G.] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Dept Pharm Practice, Buffalo, NY 14260 USA; [Daron, Susan M.] Med Letter, New Rochelle, NY USA	Juba, KM (reprint author), St John Fisher Coll, Wegmans Sch Pharm, 3690 East Ave, Rochester, NY 14618 USA.	kjuba@sjfc.edu	Wahler, Robert/H-6628-2016	Wahler, Robert/0000-0003-0593-3195			Bruera Eduardo, 2002, J Palliat Med, V5, P127, DOI 10.1089/10966210252785097; Chung Keun Sam, 2004, Conn Med, V68, P547; Dupen A, 2007, PAIN MANAG NURS, V8, P113, DOI 10.1016/j.pmn.2007.02.004; Fishbain DA, 2009, PAIN MED, V10, P829, DOI 10.1111/j.1526-4637.2009.00653.x; Forero M, 2012, PAIN PRACT, V12, P154, DOI 10.1111/j.1533-2500.2011.00475.x; Hemstapat K, 2003, ANESTH ANALG, V97, P494, DOI 10.1213/01.ANE.0000059225.40049.99; MACDONALD N, 1993, PAIN, V53, P353, DOI 10.1016/0304-3959(93)90232-E; MAO J, 1994, J NEUROSCI, V14, P2301; Mao JR, 2002, J NEUROSCI, V22, P8312; MAREK P, 1991, BRAIN RES, V547, P77; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; Nagar Swati, 2008, J Fam Pract, V57, pS25; Olesen AE, 2010, BRIT J CLIN PHARMACO, V70, P189, DOI 10.1111/j.1365-2125.2010.03700.x; Ossipov MH, 2005, BIOPOLYMERS, V80, P319, DOI 10.1002/bip.20254; Parisod E, 2003, ANESTH ANALG, V97, P183, DOI 10.1213/01.ANE.0000068482.67289.1A; Patel S, 2006, ANN PHARMACOTHER, V40, P2068, DOI 10.1345/aph.1H243; SJOGREN P, 1994, PAIN, V59, P313, DOI 10.1016/0304-3959(94)90084-1; Sjogren P, 1998, ACTA ANAESTH SCAND, V42, P1070, DOI 10.1111/j.1399-6576.1998.tb05378.x; SMITH MT, 1990, LIFE SCI, V47, P579, DOI 10.1016/0024-3205(90)90619-3; Smith MT, 1999, ANESTH ANALG, V88, P109, DOI 10.1097/00000539-199901000-00021; Smith MT, 2000, CLIN EXP PHARMACOL P, V27, P524, DOI 10.1046/j.1440-1681.2000.03290.x; Thwaites Daniel, 2004, J Palliat Med, V7, P545, DOI 10.1089/jpm.2004.7.545; TRUJILLO KA, 1991, SCIENCE, V251, P85, DOI 10.1126/science.1824728; Wright AWE, 2001, LIFE SCI, V69, P409, DOI 10.1016/S0024-3205(01)01133-X	24	7	7	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1096-6218			J PALLIAT MED	J. Palliat. Med.	JUL	2013	16	7					809	812		10.1089/jpm.2011.0502			4	Health Care Sciences & Services	Health Care Sciences & Services	169GV	WOS:000320768900026	22925158				2020-06-30	J	Melanson, SEF; Tanasijevic, MJ; Snyder, ML; Darragh, A; Quade, C; Jarolim, P				Melanson, Stacy E. F.; Tanasijevic, Milenko J.; Snyder, Marion L.; Darragh, Alicia; Quade, Cathleen; Jarolim, Petr			Significant cost savings achieved by in-sourcing urine drug testing for monitoring medication compliance in pain management	CLINICA CHIMICA ACTA			English	Article						Pain management; Toxicology; LC-MS/MS; Send out costs; In-sourcing	OPIOID THERAPY; UTILITY; PHYSICIANS	Introduction: Reference laboratory testing can represent a significant component of the laboratory budget. Therefore, most laboratories continually reassess the feasibility of in-sourcing various tests. We describe the transfer of urine drug testing performed for monitoring medication compliance in pain management from a reference laboratory into an academic clinical laboratory. Methods: The process of implementing of both screening immunoassays and confirmatory LC-MS/MS testing and the associated cost savings is outlined. Results: The initial proposal for in-sourcing this testing, which included the tests to be in-sourced, resources required, estimated cost savings and timeline for implementation, was approved in January 2009. All proposed testing was implemented by March 2011. Conclusions: Keys to the successful implementation included budgeting adequate resources and developing a realistic timeline, incorporating the changes with the highest budget impact first. We were able to in-source testing in 27 months and save the laboratory approximately $1 million in the first 3 year. (C) 2013 Elsevier B.V. All rights reserved.	[Melanson, Stacy E. F.; Tanasijevic, Milenko J.; Darragh, Alicia; Quade, Cathleen; Jarolim, Petr] Harvard Univ, Brigham & Womens Hosp, Dept Pathol, Sch Med, Boston, MA 02115 USA; [Snyder, Marion L.] Greenville Hosp Syst Univ Med Ctr, Dept Chem, Greenville, SC USA	Melanson, SEF (reprint author), Brigham & Womens Hosp, 75 Francis St,Amory 2, Boston, MA 02115 USA.	semelanson@partners.org					Bhamb B, 2006, CURR MED RES OPIN, V22, P1859, DOI 10.1185/030079906X132398; Cone EJ, 2008, J ANAL TOXICOL, V32, P530, DOI 10.1093/jat/32.8.530; Heit HA, 2004, J PAIN SYMPTOM MANAG, V27, P260, DOI 10.1016/j.jpainsymman.2003.07.008; Ives TJ, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-46; Katz N, 2002, CLIN J PAIN, V18, pS76, DOI 10.1097/00002508-200207001-00009; Katz NP, 2003, ANESTH ANALG, V97, P1097, DOI 10.1213/01.ANE.0000080159.83342.B5; Langman L, 2010, C43 A2 GAS CHROMATOG; Langman L, 2012, TIETZ TXB CLIN CHEM, P1109; Magnani B, 2012, CLIN LAB MED, V32, P379, DOI 10.1016/j.cll.2012.07.001; Manchikanti Laxmaiah, 2006, Pain Physician, V9, P215; Manchikanti Laxmaiah, 2006, Pain Physician, V9, P123; Manchikanti L, 2008, PAIN PHYSICIAN, V11, pS155; Melanson SEF, 2012, CLIN LAB MED, V32, P429, DOI 10.1016/j.cll.2012.06.004; Melanson SEF, 2012, J ANAL TOXICOL, V36, P201, DOI 10.1093/jat/bks003; Melanson SEF, 2009, CLIN CHEM LAB MED, V47, P971, DOI 10.1515/CCLM.2009.220; Michna E, 2007, CLIN J PAIN, V23, P173, DOI 10.1097/AJP.0b013e31802b4f95; Nafziger AN, 2009, CLIN J PAIN, V25, P73, DOI 10.1097/AJP.0b013e31817e13cc; Snyder ML, 2011, CLIN CHIM ACTA, V412, P946, DOI 10.1016/j.cca.2011.01.029; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS5; Trescot Andrea M, 2006, Pain Physician, V9, P1	20	9	9	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0009-8981			CLIN CHIM ACTA	Clin. Chim. Acta	JUN 25	2013	422						10	14		10.1016/j.cca.2013.03.010			5	Medical Laboratory Technology	Medical Laboratory Technology	170ZP	WOS:000320894400003	23545276				2020-06-30	J	dos Santos, MEL; Maluf, F; Chaves, DM; Matuguma, SE; Ide, E; Luz, GD; de Souza, TF; Pessorrusso, FCS; de Moura, EGH; Sakai, P				Lera dos Santos, Marcos Eduardo; Maluf-Filho, Fauze; Chaves, Dalton Marques; Matuguma, Sergio Eiji; Ide, Edson; Luz, Gustavo de Oliveira; de Souza, Thiago Ferreira; Simoes Pessorrusso, Fernanda C.; Hourneaux de Moura, Eduardo Guimaraes; Sakai, Paulo			Deep sedation during gastrointestinal endoscopy: Propofol-fentanyl and midazolam-fentanyl regimens	WORLD JOURNAL OF GASTROENTEROLOGY			English	Article						Endoscopy; Deep sedation; Anesthetic administration; Anesthetic dose; Adverse effects	RANDOMIZED CONTROLLED-TRIAL; GI ENDOSCOPY; NON-ANESTHESIOLOGISTS; CONSCIOUS SEDATION; COMPARING PROPOFOL; MODERATE SEDATION; NATIONWIDE SURVEY; GUIDELINES; NURSES; GASTROENTEROLOGIST	AIM: To compare deep sedation with propofol-fentanyl and midazolam-fentanyl regimens during upper gastrointestinal endoscopy. METHODS: After obtaining approval of the research ethics committee and informed consent, 200 patients were evaluated and referred for upper gastrointestinal endoscopy. Patients were randomized to receive propofol-fentanyl or midazolam-fentanyl (n = 100/group). We assessed the level of sedation using the observer's assessment of alertness/sedation (OAA/S) score and bispectral index (BIS). We evaluated patient and physician satisfaction, as well as the recovery time and complication rates. The statistical analysis was performed using SPSS statistical software and included the Mann-Whitney test, chi(2) test, measurement of analysis of variance, and the kappa statistic. RESULTS: The times to induction of sedation, recovery, and discharge were shorter in the propofol-fentanyl group than the midazolam-fentanyl group. According to the OAA/S score, deep sedation events occurred in 25% of the propofol-fentanyl group and 11% of the midazolam-fentanyl group (P = 0.014). Additionally, deep sedation events occurred in 19% of the propofol-fentanyl group and 7% of the midazolam-fentanyl group according to the BIS scale (P = 0.039). There was good concordance between the OAA/S score and BIS for both groups (kappa = 0.71 and kappa = 0.63, respectively). Oxygen supplementation was required in 42% of the propofol-fentanyl group and 26% of the midazolam-fentanyl group (P = 0.025). The mean time to recovery was 28.82 and 44.13 min in the propofol-fentanyl and midazolam-fentanyl groups, respectively (P < 0.001). There were no severe complications in either group. Although patients were equally satisfied with both drug combinations, physicians were more satisfied with the propofol-fentanyl combination. CONCLUSION: Deep sedation occurred with propofol-fentanyl and midazolam-fentanyl, but was more frequent in the former. Recovery was faster in the propofol-fentanyl group. (c) 2013 Baishideng. All rights reserved.	[Lera dos Santos, Marcos Eduardo; Maluf-Filho, Fauze; Chaves, Dalton Marques; Matuguma, Sergio Eiji; Ide, Edson; Luz, Gustavo de Oliveira; de Souza, Thiago Ferreira; Simoes Pessorrusso, Fernanda C.; Hourneaux de Moura, Eduardo Guimaraes; Sakai, Paulo] Univ Sao Paulo, Sch Med, Hosp Clin, Dept Gastroenterol, BR-05403900 Sao Paulo, Brazil; [Maluf-Filho, Fauze; Matuguma, Sergio Eiji] Canc Inst Sao Paulo State, BR-01246000 Sao Paulo, Brazil	dos Santos, MEL (reprint author), Univ Sao Paulo, Sch Med, Hosp Clin, Dept Gastroenterol,Endoscopy Div, Av Angelica,2163 Cj76, BR-05403900 Sao Paulo, Brazil.	marcoslera@gmail.com	Maluf-Filho, Fauze/D-5062-2013; de Moura, Eduardo Guimaraes Hourneaux/D-3885-2018	Maluf-Filho, Fauze/0000-0001-8875-420X; de Moura, Eduardo Guimaraes Hourneaux/0000-0002-8023-3722; Pessorrusso, Fernanda/0000-0002-6530-4940			Benson AA, 2008, GUT LIVER, V2, P105, DOI 10.5009/gnl.2008.2.2.105; Bower AL, 2000, GASTROINTEST ENDOSC, V52, P192, DOI 10.1067/mge.2000.107284; CARVALHO PHB, 2008, TRATADO ENDOSCOPIA D, V4, P37; Chen SC, 2004, ALIMENT PHARM THER, V19, P147, DOI 10.1111/j.0269-2813.2004.01833.x; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Cohen LB, 2010, ALIMENT PHARM THER, V32, P425, DOI 10.1111/j.1365-2036.2010.04352.x; Cohen LB, 2007, GASTROENTEROLOGY, V133, P675, DOI 10.1053/j.gastro.2007.06.002; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; Cohen Lawrence B, 2008, Gastrointest Endosc Clin N Am, V18, P651, DOI 10.1016/j.giec.2008.06.015; Cohen LB, 2004, GASTROINTEST ENDOSC, V59, P795, DOI 10.1016/S0016-5107(04)00349-9; Cohen LB, 2003, GASTROINTEST ENDOSC, V58, P725, DOI 10.1016/S0016-5107(03)02010-8; COHEN LB, 2008, GASTROINTEST ENCLOSE, V18, pR7, DOI DOI 10.1016/J.GIEC.2008.06.015]; Correia LM, 2011, GASTROINTEST ENDOSC, V73, P45, DOI 10.1016/j.gie.2010.09.025; DEAZEVEDO MP, 2005, MED PERIOPERATORIA, V81, P709; DeWitt JM, 2008, DIGEST DIS SCI, V53, P2739, DOI 10.1007/s10620-008-0198-x; Dinis-Ribeiro M, 2010, DIGESTION, V82, P100, DOI 10.1159/000287215; Drake LM, 2006, AM J GASTROENTEROL, V101, P2003, DOI 10.1111/j.1572-0241.2006.00806.x; Dumonceau JM, 2010, ENDOSCOPY, V42, P960, DOI 10.1055/s-0030-1255728; Faigel DO, 2002, GASTROINTEST ENDOSC, V56, P613; Fanti L, 2010, WORLD J GASTROENTERO, V16, P2451, DOI 10.3748/wjg.v16.i20.2451; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Heuss LT, 2008, GASTROINTEST ENDOSC, V18, pix, DOI DOI 10.1016/J.GIEC.2008.06.007; Heuss Ludwig T, 2008, Gastrointest Endosc Clin N Am, V18, P727, DOI 10.1016/j.giec.2008.06.007; Imagawa A, 2008, ENDOSCOPY, V40, P905, DOI 10.1055/s-2008-1077641; Lichtenstein DR, 2008, GASTROINTEST ENDOSC, V68, P815, DOI 10.1016/j.gie.2008.09.029; McQuaid KR, 2008, GASTROINTEST ENDOSC, V67, P910, DOI 10.1016/j.gie.2007.12.046; Meining A, 2007, ENDOSCOPY, V39, P345, DOI 10.1055/s-2006-945195; MOSES PL, 2004, GASTROINTEST E S1574, V59, P130, DOI DOI 10.1016/S0016-5107; Paspatis GA, 2009, ENDOSCOPY, V41, P1046, DOI 10.1055/s-0029-1215342; Patel S, 2005, AM J GASTROENTEROL, V100, P2689, DOI 10.1111/j.1572-0241.2005.00320.x; Qadeer MA, 2008, CLIN GASTROENTEROL H, V6, P102, DOI 10.1016/j.cgh.2007.10.005; Rex DK, 2006, ALIMENT PHARM THER, V24, P163, DOI 10.1111/j.1365-2036.2006.02986.x; Rex DK, 2002, AM J GASTROENTEROL, V97, P1159; Riphaus A, 2010, Z GASTROENTEROL, V48, P392, DOI 10.1055/s-0028-1109765; Sipe BW, 2002, GASTROINTEST ENDOSC, V55, P815, DOI 10.1067/mge.2002.124636; Tan Gang, 2010, F1000 Med Rep, V2, P79, DOI 10.3410/M2-79; Thomson A, 2010, J GASTROEN HEPATOL, V25, P469, DOI 10.1111/j.1440-1746.2009.06174.x; Vargo JJ, 2009, GASTROINTEST ENDOSC, V70, P1053, DOI 10.1016/j.gie.2009.07.020; Waring JP, 2003, GASTROINTEST ENDOSC, V58, P317, DOI 10.1067/S0016-5107(03)00001-4	39	24	25	1	6	BAISHIDENG PUBL GRP CO LTD	WANCHAI	ROOM 1701, 17-F, HENAN BUILDING, NO. 90, JAFFE RD, WANCHAI, HONG KONG 100025, PEOPLES R CHINA	1007-9327			WORLD J GASTROENTERO	World J. Gastroenterol.	JUN 14	2013	19	22					3439	3446		10.3748/wjg.v19.i22.3439			8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	163YU	WOS:000320375400009	23801836	Green Published, Other Gold			2020-06-30	J	Ishibashi, M; Akiyoshi, H; Iseri, T; Ohashi, F				Ishibashi, Maki; Akiyoshi, Hideo; Iseri, Toshie; Ohashi, Fumihito			Skin Conductance Reflects Drug-Induced Changes in Blood Levels of Cortisol, Adrenaline and Noradrenaline in Dogs	JOURNAL OF VETERINARY MEDICAL SCIENCE			English	Article						nervous system; skin conductance; stress	PERIOPERATIVE STRESS; FENTANYL; RATS; CATECHOLAMINE; MEDETOMIDINE; RESPONSES; OPIATES	To verify availability of skin conductance (SC) as an indicator for the sympathetic nervous system (SNS) activity in dogs, the changes in SC and blood levels of stress-related hormones induced by drugs were compared. SC and cortisol, adrenaline and noradrenaline levels were measured in 5 dogs on 4 occasions with or without drug-induced sedation at 7-day intervals (no treatment, intramuscular medetomidine 0.01 mg/kg, intramuscular acepromazine 0.1 mg/kg and intravenous fentanyl 0.02 mg/kg). The fentanyl treatment produced significantly higher levels of SC and plasma cortisol and adrenaline compared with the other 3 treatments. The plasma noradrenaline level also tended to be higher following the fentanyl treatment. These results indicate that SC may reflect changes in the SNS activities in dogs.	[Ishibashi, Maki; Akiyoshi, Hideo; Iseri, Toshie; Ohashi, Fumihito] Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Dept Vet Clin Med, Izumisano, Osaka 5988531, Japan	Ishibashi, M (reprint author), Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Dept Vet Clin Med, 1-58 Rinku Ohrai Kita, Izumisano, Osaka 5988531, Japan.	sq205004@edu.osakafu-u.ac.jp	Ishibashi, Maki/K-3313-2013				Allen DL, 2010, AM J PHYSIOL-REG I, V299, pR889, DOI 10.1152/ajpregu.00296.2010; Ambrisko TD, 2005, AM J VET RES, V66, P406, DOI 10.2460/ajvr.2005.66.406; Brunton PJ, 2008, J PHYSIOL-LONDON, V586, P369, DOI 10.1113/jphysiol.2007.146233; CAPOGNA M, 1993, J PHYSIOL-LONDON, V470, P539, DOI 10.1113/jphysiol.1993.sp019874; DEBOER SF, 1990, PHYSIOL BEHAV, V47, P1117, DOI 10.1016/0031-9384(90)90361-7; EDELBERG R, 1977, J INVEST DERMATOL, V69, P324, DOI 10.1111/1523-1747.ep12507771; Gjerstad AC, 2008, PEDIATRICS, V122, pE848, DOI 10.1542/peds.2007-2545; GRIMNES S, 1982, MED BIOL ENG COMPUT, V20, P734, DOI 10.1007/BF02442528; HOEHE M, 1993, PSYCHONEUROENDOCRINO, V18, P141, DOI 10.1016/0306-4530(93)90065-S; Kamata M, 2012, J VET MED SCI, V74, P231, DOI 10.1292/jvms.10-0565; Kim MS, 2006, J VET MED SCI, V68, P409, DOI 10.1292/jvms.68.409; Kinoshita C., 2004, B SCH AGR, V139, P41; LIU WS, 1977, CAN ANAESTH SOC J, V24, P371, DOI 10.1007/BF03005110; MIRKIN AM, 1980, BRIT J PSYCHIAT, V137, P93, DOI 10.1192/bjp.137.1.93; Molina PE, 2006, J INTERN MED, V259, P138, DOI 10.1111/j.1365-2796.2005.01569.x; Rasheed N, 2010, EUR J PHARMACOL, V643, P121, DOI 10.1016/j.ejphar.2010.06.032; Shirai K., 2003, J INT SOC LIFE INF S, V21, P235; Storm H, 2002, ACTA ANAESTH SCAND, V46, P887, DOI 10.1034/j.1399-6576.2002.460721.x; Takahashi Y., 1964, THESIS TOHOKU U JAPA; Tiller W. A., 1982, J HOLIST MED, V4; Vaisanen M, 2002, AM J VET RES, V63, P969, DOI 10.2460/ajvr.2002.63.969; Vlachopoulos C, 2006, PSYCHOSOM MED, V68, P231, DOI 10.1097/01.psy.0000203171.33348.72; YAMAMOTO K, 1994, SCHIZOPHR RES, V13, P145, DOI 10.1016/0920-9964(94)90095-7	23	8	8	0	9	JAPAN SOC VET SCI	TOKYO	UNIV TOKYO, 1-1-1 YAYOI, BUNKYO-KU, TOKYO, 103, JAPAN	0916-7250	1347-7439		J VET MED SCI	J. Vet. Med. Sci.	JUN	2013	75	6					809	813		10.1292/jvms.12-0478			5	Veterinary Sciences	Veterinary Sciences	297PV	WOS:000330268300021	23358494	Bronze, Green Published			2020-06-30	J	Meissner, W; Sabatowski, R				Meissner, W.; Sabatowski, R.			Fentanyl "Fast and furious?"	ANAESTHESIST			German	Editorial Material							BREAKTHROUGH PAIN; MANAGEMENT		[Meissner, W.] Univ Klinikum Jena, Klinikum Innere Med 2, Klin Anasthesiol & Intens Therapie, Sekt Schmerztherapie, D-07747 Jena, Germany; [Meissner, W.] Univ Klinikum Jena, Klinikum Innere Med 2, Abt Palliat Med, D-07747 Jena, Germany; [Sabatowski, R.] Univ Klinikum Carl Gustav Carus, Klin Anasthesiol & Intens Therapie, Dresden, Germany; [Sabatowski, R.] Univ Klinikum Carl Gustav Carus, Univ SchmerzCtr, Dresden, Germany	Meissner, W (reprint author), Univ Klinikum Jena, Klinikum Innere Med 2, Klin Anasthesiol & Intens Therapie, Sekt Schmerztherapie, Erlanger Allee 101, D-07747 Jena, Germany.	Winfried.Meissner@med.uni-jena.de	Sabatowski, Rainer/K-3475-2019	Sabatowski, Rainer/0000-0003-2228-3147			Ashburn MA, 2011, ANESTH ANALG, V112, P693, DOI 10.1213/ANE.0b013e318209d320; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Markman JD, 2008, PAIN, V136, P227, DOI 10.1016/j.pain.2008.03.011; SCHWAGMEIER R, 1995, J CLIN ANESTH, V7, P109, DOI 10.1016/0952-8180(94)00023-W	4	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0003-2417			ANAESTHESIST	Anaesthesist	JUN	2013	62	6					429	430		10.1007/s00101-013-2195-5			2	Anesthesiology	Anesthesiology	185IF	WOS:000321960300001	23748418	Bronze			2020-06-30	J	Beutlhauser, T; Oeltjenbruns, J; Schafer, M				Beutlhauser, T.; Oeltjenbruns, J.; Schaefer, M.			Breakthrough pain and short-acting opioids	ANAESTHESIST			German	Article						Tumors; Chronic pain; Fentanyl; Drug administration routes; Treatment outcome	PECTIN NASAL SPRAY; HEALTH-ORGANIZATION GUIDELINES; FENTANYL BUCCAL TABLET; CANCER PAIN; DOUBLE-BLIND; RELATIVE BIOAVAILABILITY; TOLERANT PATIENTS; ANALGESIC LADDER; MORPHINE-SULFATE; MU-G	Conventional opioid therapy consists of the regular administration of extended-release opioids following fixed time intervals and, as needed, the supplemental use of an immediate-release formulation. For the patient needs of such rescue medication, recent studies distinguished different scenarios, such as an inadequate daily opioid dose or time interval (end-of-dose failure) from so-called breakthrough pain where the attacks can suddenly occur either spontaneously (idiopathic pain) or due to certain provocations (incident pain) despite optimal dose adjustment. In line with this time course, a fast and short-lasting elevation of the opioid plasma concentration seems to be reasonable. Although in a recent European survey breakthrough pain attacks in the majority of cancer pain patients were sufficiently treated with immediate-release opioids, currently running clinical trials examine whether the application of transmucosal or intranasal fentanyl with their known reduced time to maximum plasma concentrations show a possible advantage in comparison to immediate-release opioids. In these clinical trials the pain intensity and number of pain episodes were significantly reduced following transmucosal or intranasal fentanyl; however, the magnitude of these effects does not convincingly appear to be clinically relevant. Among other reasons this may be related to the fact that those patients who would perhaps benefit from such treatment have not yet been identified.	[Beutlhauser, T.; Oeltjenbruns, J.; Schaefer, M.] Charite, Campus Virchow Klinikum, Klin Anasthesiol Schwerpunkt Intens Med, D-13353 Berlin, Germany	Schafer, M (reprint author), Charite, Campus Virchow Klinikum, Klin Anasthesiol Schwerpunkt Intens Med, Augustenburgerpl 1, D-13353 Berlin, Germany.	micha.schaefer@charite.de	Schafer, Michael/AAB-1395-2020				American Pain Society, 1992, PRINC AN US AC PAIN; Ashburn MA, 2011, ANESTH ANALG, V112, P693, DOI 10.1213/ANE.0b013e318209d320; Bertram L, 2010, SCHMERZ, V24, P605, DOI 10.1007/s00482-010-0989-9; Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Davies A, 2006, CANC RELATED BREAK P; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419; Felleiter P, 2005, SCHMERZ, V19, P265, DOI 10.1007/s00482-004-0338-y; Fine PG, 2010, J PAIN SYMPTOM MANAG, V40, P747, DOI 10.1016/j.jpainsymman.2010.02.009; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Guttler K, 2012, ANASTH INTENSIV NOTF, V47, P224, DOI 10.1055/s-0032-1310410; Haugen DF, 2010, PAIN, V149, P476, DOI 10.1016/j.pain.2010.02.035; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; JADAD AR, 1995, JAMA-J AM MED ASSOC, V274, P1870, DOI 10.1001/jama.274.23.1870; Kessler J, 2011, ANAESTHESIST, V60, P674, DOI 10.1007/s00101-011-1868-1; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Likar R, 2007, PRAXIS TRANSDERMALEN; Liukas A, 2008, CLIN PHARMACOL THER, V84, P462, DOI 10.1038/clpt.2008.64; Lotsch JR, 2005, J PAIN SYMPTOM MANAG, V29, pS90, DOI 10.1016/j.jpainsymman.2005.01.012; Manchikanti L, 2011, PAIN PHYSICIAN, V14, pE103; McNicol E, 2004, J CLIN ONCOL, V22, P1975, DOI 10.1200/JCO.2004.10.524; McNicol ED, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006332.pub2; Mercadante S, 2005, ANN ONCOL, V16, P132, DOI 10.1093/annonc/mdi922; Mercadante S, 2011, CRIT REV ONCOL HEMAT, V80, P460, DOI 10.1016/j.critrevonc.2010.12.002; Muller-Schwefe GH, 2011, PRAX REP, V3, P1; O'Brian CP, 2011, GOODMAN GILMANS PHAR, P599; Oeltjenbruns J, 2010, PHARM FOKUS SCHMERZT, V1, P7; Passik SD, 2011, J PAIN SYMPTOM MANAG, V41, P116, DOI 10.1016/j.jpainsymman.2010.03.012; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; Petzke F, 1999, J PAIN SYMPTOM MANAG, V17, P391, DOI 10.1016/S0885-3924(99)00023-8; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Portenoy Russell K, 2010, J Opioid Manag, V6, P97; Portenoy Russell K, 2010, J Opioid Manag, V6, P109; Radbruch L, 2012, SUPPORT CARE CANCER, V20, P565, DOI 10.1007/s00520-011-1124-x; Raffa RB, 2010, DRUGS, V70, P1657, DOI 10.2165/11537940-000000000-00000; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Rodriguez RF, 2007, J PALLIAT MED, V10, P56, DOI 10.1089/jpm.2006.0117; Sabatowski R, 2001, SCHMERZ, V15, P241, DOI 10.1007/s004820100054; Shibutani K, 2005, BRIT J ANAESTH, V95, P377, DOI 10.1093/bja/aei195; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; Tassinari D, 2011, PALLIATIVE MED, V25, P410, DOI 10.1177/0269216311405090; *WHO, 1990, WHO TECHN REP SER, V804; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M; Zeppetella G, 2009, GUIDELINES PRACTICE, V12, P1; Zeppetella G, 2011, PALLIATIVE MED, V25, P516, DOI 10.1177/0269216310385601	53	3	3	0	5	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0003-2417	1432-055X		ANAESTHESIST	Anaesthesist	JUN	2013	62	6					431	439		10.1007/s00101-013-2193-7			9	Anesthesiology	Anesthesiology	185IF	WOS:000321960300002	23754483				2020-06-30	J	Slavkovic, Z; Stamenkovic, DM; Geric, V; Veljovic, M; Ivanovic, N; Tomic, A; Randjelovic, T; Raskovic, J; Karanikolas, M				Slavkovic, Zoran; Stamenkovic, Dusica M.; Geric, Veselin; Veljovic, Milic; Ivanovic, Nebojsa; Tomic, Aleksandar; Randjelovic, Tomislav; Raskovic, Jelena; Karanikolas, Menelaos			Comparison of analgesic effect of intrathecal morphine alone or in combination with bupivacaine and fentanyl in patients undergoing total gastrectomy: A prospective randomized, double blind clinical trial	VOJNOSANITETSKI PREGLED			English	Article						anesthesia, epidural; anesthesia, spinal; methods; fentanyl; bupivacaine; morphine; analgesia; gastrectomy	SPINAL-EPIDURAL ANALGESIA; GENERAL-ANESTHESIA; POSTOPERATIVE PAIN; ABDOMINAL-SURGERY; LABOR PAIN; RECOVERY; RELIEF; DRUGS	Background/Aim. Combined spinal-epidural-general anesthesia has several advantages over general anesthesia alone. This study was designed to compare the efficacy of intrathecal (IT) morphine alone, or in combination with bupivacaine and fentanyl, as part of a combined spinal-epidural (CSE) analgesia, in patients undergoing elective total gastrectomy. Methods. This prospective, randomized double-blind study included 60 patients undergoing total gastrectomy under general anesthesia and CSE. We compared the analgesic effect of lumbar IT morphine 300 mg (the group M, n = 20) vs morphine 300 mu g + bupivacaine 2 mg (the group MB, n = 20) vs morphine 300 mu g + bupivacaine 2 mg + fentanyl 25 mu g (the group MBF, n = 20) given after thoracic epidural catheter placement (T6-7) but before general anesthesia induction. Pain visual analogue scale (VAS) at rest (R), with movement (M) and with cough (C), and the number of analgesia requests were assessed for 72 h and after epidural catheter removal. Results. Compared to other groups, the MBF group required significantly fewer additional intra-operative epidural bupivacaine doses (p < 0.001), whereas the M group required significantly more supplemental intraoperative intravenous fentanyl, compared with the MBF (p = 0.022) and MB groups (p = 0.005). Postoperative pain relief was satisfactory in all the groups at all the time. VAS-R and VAS-M did not differ significantly among the groups. Compared to the M group, VAS-C scores 30 min postoperatively were significantly lower in the MBF (p = 0.029) and MB groups = 0.002). Duration of analgesia was longer in the MBF and MB groups, but the difference reached no significance. The number of supplemental analgesia requests was similar in all the groups in the first 12 h and during 72 h. Additional analgesia requests after epidural catheter removal were similar in all the groups, and side effects were infrequent. Conclusion. Compared to IT morphine alone, triple IT combination administered as part of CSE provided better intraoperative analgesia, but conferred no benefit with regards to postoperative analgesia.	[Slavkovic, Zoran; Stamenkovic, Dusica M.; Veljovic, Milic] Mil Med Acad, Clin Anesthesiol & Intens Care, Belgrade 11002, Serbia; [Tomic, Aleksandar] Mil Med Acad, Clin Vasc Surg, Belgrade 11002, Serbia; [Slavkovic, Zoran; Veljovic, Milic; Tomic, Aleksandar] Univ Def, Mil Med Acad, Fac Med, Belgrade, Serbia; [Geric, Veselin] Univ Med Ctr Bezanijska Kosa, Dept Anaesthesia, Belgrade, Serbia; [Ivanovic, Nebojsa; Randjelovic, Tomislav] Univ Med Ctr Bezanijska Kosa, Dept Surg, Belgrade, Serbia; [Raskovic, Jelena] Univ Belgrade, Sch Econ, Dept Stat, Belgrade, Serbia; [Karanikolas, Menelaos] Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA	Slavkovic, Z (reprint author), Mil Med Acad, Clin Anesthesiol & Intens Care, Crnotravska 17, Belgrade 11002, Serbia.		Stamenkovic, Dusica M/A-3319-2008; Tomic, Aleksandar/Y-1199-2019; Karanikolas, Menelaos/O-5928-2017	Karanikolas, Menelaos/0000-0001-8541-7988; Stamenkovic, Dusica/0000-0003-4121-1966			Aida S, 2000, ANESTHESIOLOGY, V92, P1624, DOI 10.1097/00000542-200006000-00020; AKERMAN B, 1988, ANESTH ANALG, V67, P943; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; Benzon HT, 2007, SPINAL EPIDURAL ANES, P325; Camporesi E, 2005, MILLERS ANESTHESIA, P1458; Chrubasik J, 1993, POSTOPERATIVE EPIDUR, P45; ELDOR J, 1995, MED HYPOTHESES, V45, P86, DOI 10.1016/0306-9877(95)90209-0; Gong DJ, 2008, WORLD J GASTROENTERO, V14, P6560, DOI 10.3748/wjg.14.6560; Gwirtz KH, 1999, ANESTH ANALG, V88, P599, DOI 10.1097/00000539-199903000-00026; Hess PE, 2003, ANESTH ANALG, V97, P247, DOI 10.1213/01.ANE.0000066520.30763.B8; LIU SS, 1995, ANESTHESIOLOGY, V83, P757, DOI 10.1097/00000542-199510000-00015; Minty RG, 2007, CAN FAM PHYSICIAN, V53, P437; Rathmell JP, 2005, ANESTH ANALG, V101, pS30, DOI 10.1213/01.ANE.0000177101.99398.22; Scott NB, 1996, ACTA ANAESTH SCAND, V40, P691, DOI 10.1111/j.1399-6576.1996.tb04512.x; SOLOMON RE, 1994, ANESTH ANALG, V78, P1164; Stamenkovic D, 2009, ANAESTH INTENS CARE, V37, P552, DOI 10.1177/0310057X0903700410; Stamenkovic DM, 2008, INT J CLIN PRACT, V62, P255, DOI 10.1111/j.1742-1241.2007.01642.x; Stienstra R, 1996, ANESTH ANALG, V83, P382, DOI 10.1097/00000539-199608000-00031; Wang JJ, 1996, REGION ANESTH, V21, P281; Yeh HM, 2001, ANESTH ANALG, V92, P665, DOI 10.1097/00000539-200103000-00022	20	2	3	0	5	MILITARY MEDICAL ACAD-INI	BELGRADE	CRNOTRAVSKA 17, PO BOX 33-35, BELGRADE, 11040, SERBIA	0042-8450			VOJNOSANIT PREGL	Vojnosanit. Pregl.	JUN	2013	70	6					541	547		10.2298/VSP111011011S			7	Medicine, General & Internal	General & Internal Medicine	178WF	WOS:000321477400001	23885519	DOAJ Gold			2020-06-30	J	Plock, N; Facius, A; Hartmann, L; Baumann, S; Nave, R				Plock, Nele; Facius, Axel; Hartmann, Lene; Baumann, Sybille; Nave, Ruediger			An innovative Phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects	INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS			English	Article						breakthrough pain (BTP); intranasal fentanyl spray (INFS); population pharmacokinetics; clinical trial design	BREAKTHROUGH PAIN; ASSOCIATION; PREVALENCE	Background: Intranasal Fentanyl Spray (INFS) was developed for the treatment of breakthrough pain (BTP) in cancer patients using a new route of administration. Dose strengths of 50, 100, and 200 mu g INFS (Instanyl (R)) are currently on the market, however, some adult cancer patients with BTP may require higher doses up to 400 mu g INFS. Objective: As pharmacokinetic (PK) samples from cancer patients with BTP are hard to obtain, PK of 400 pig INFS was investigated in healthy volunteers. Using prior knowledge from an available population PK (PopPK) model, a PK trial design was derived which aimed for short study duration and reduced trial costs without jeopardizing trial readout. Methods: Different trial designs to investigate the systemic exposure of 400 mu g INFS were simulated using the available PopPK model. Parameters with strong influence on C-max and AUC, i.e., clearance (CL), absorption rate constant (KA), central volume (V2) and bioavailability (F1), were estimated, while other parameters were fixed to previous model estimates. The concentration-time data obtained from the applied trial design was subjected to a PopPK analysis. From the final individual parameter estimates, single-dose concentration-time profiles with wash-out were simulated, and AUC and C-max values were calculated as for a classical trial design. Results: The final trial design was a two-sequence, three period, and three-treatment cross-over design with no wash-out intervals between treatments. 20 subjects received three doses of INFS. Four hours after a single dose of 200 mu g INFS (Treatment A), subjects received either a single dose of 400 mu g INFS (Treatment B) or two single doses (10 minutes apart) of 400 mu g INFS (Treatment C). At t = 24 hours subjects received either Treatment B or Treatment C as cross-over. Plasma samples were taken up to 72 hours. The study duration per subject was less than 4 days. PopPK analysis and validation were performed successfully. The estimated primary PK parameters were F1 = 59%, CL=33.5 1/h, V2 = 68.8 1 and KA = 12.8 1/h. The ratio analysis of the least square geometric means of dose normalized AUC(infinity) values resulted in point estimates of 97-104%, indicating dose proportionality in the investigated dose range of 200 mu g 2 x 400 mu g. Conclusion: The implementation of a PopPK approach in the planning and analysis of this trial yielded an innovative, cost- and time-saving trial design that successfully delivered the required information about the PK of the 400 mu g dose strength within this small clinical study.	[Plock, Nele; Facius, Axel] Takeda Pharmaceut Int GmbH, Zurich, Switzerland; [Hartmann, Lene] Takeda Denmark, Roskilde, Denmark; [Baumann, Sybille] CRS Mannheim GmbH, Mannheim, Germany; [Nave, Ruediger] Takeda GmbH, Constance, Germany	Plock, N (reprint author), Care of Kaessner N, Takeda Pharmaceut Int GmbH, Thurgauerstr 130, CH-8152 Zurich, Switzerland.				Takeda Denmark	The study was funded by Nycomed Denmark (now: Takeda Denmark), and was conducted at CRS Mannheim GmbH.	[Anonymous], 2009, EUR J PAIN, V13, pS207; Bjorkman S, 2012, BLOOD, V119, P612, DOI 10.1182/blood-2011-07-360594; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI [10.1586/ERN.11.63, 10.1586/ern.11.63]; European Medical Agency, INST PROD INF; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Kaasa Stein, 2010, J Opioid Manag, V6, P17; Kaessner N, 2012, INT J CLIN PHARM TH, V50, P665, DOI 10.5414/CP201737; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Nave R, 2011, EUR J PAIN, V5, pS611; Nave R, 2012, INT J CLIN PHARM TH, V50, P751, DOI 10.5414/CP201729; Ogungbenro K, 2008, EUR J CLIN PHARMACOL, V64, P705, DOI 10.1007/s00228-008-0493-7; Patt RB, 1998, ONCOLOGY-NY, V12, P1035; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Smith H, 2012, CNS DRUGS, V26, P509, DOI 10.2165/11630580-000000000-00000; *WORLD MED ASS DEC, 1964, ETH PRINC MED RES IN; Zhang N, 2013, STAT MED, V32, P424, DOI 10.1002/sim.5567	19	4	4	0	8	DUSTRI-VERLAG DR KARL FEISTLE	DEISENHOFEN-MUENCHEN	BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY	0946-1965			INT J CLIN PHARM TH	Int. J. Clin. Pharmacol. Ther.	JUN	2013	51	6					495	508		10.5414/CP201867			14	Pharmacology & Pharmacy	Pharmacology & Pharmacy	170GZ	WOS:000320839700007	23611571				2020-06-30	J	Nave, R; Schmitt, H; Popper, L				Nave, Ruediger; Schmitt, Holger; Popper, Lars			Faster absorption and higher systemic bioavailability of intranasal fentanyl spray compared to oral transmucosal fentanyl citrate in healthy subjects	DRUG DELIVERY			English	Article						Breakthrough cancer pain; drug delivery system; incomplete consumption of oral transmucosal fentanyl citrate; pharmacokinetics; single-dose delivery system	BREAKTHROUGH CANCER PAIN; RELATIVE BIOAVAILABILITY; CROSSOVER TRIAL; DOUBLE-BLIND; OPEN-LABEL; MU-G; PHARMACOKINETICS; PREVALENCE; MANAGEMENT; TOLERABILITY	Context: Intranasal fentanyl spray (INFS) was developed for the treatment of breakthrough pain in cancer patients using an alternative route of administration. Objective: The aim of this clinical study was to investigate the pharmacokinetic (PK) profile and bioavailability of INFS in healthy subjects compared to oral transmucosal fentanyl citrate (OTFC). Materials and methods: In a randomized, single-center, open-label, two-way crossover PK study, 24 subjects (12 male, 12 female, mean age 25.2 years) received INFS (single-dose delivery system 200 mu g/100 mu l) and OTFC (buccal lozenge, 200 mu g). Naltrexone was given to prevent potential adverse reactions. Frequent plasma samples were taken up to 96 h and analyzed by LC-MS/MS with a lower limit of quantitation of 25 pg/ml. Primary PK parameter was the area under the fentanyl plasma concentration-time curve (AUC(0-inf)). Results: Compared to OTFC, a much faster absorption rate was observed for INFS which was supported by the much earlier appearance of detectable fentanyl plasma levels and a shorter T-max. At 15 min post-dose, the mean plasma fentanyl levels reached 602 pg/ml for INFS and 29 pg/ml for OTFC. Significantly higher C-max and AUC values were obtained with INFS compared to OTFC. Although administered for 15 min, consumption of OTFC was incomplete in many incidences (similar to 70%) upon visual inspection. No safety concerns were identified for fentanyl administration in combination with oral naltrexone. Discussion and conclusion: One dose of INFS gives significantly higher plasma fentanyl levels and significantly higher bioavailability than OTFC based on dose-normalized AUC.	[Nave, Ruediger; Schmitt, Holger] Nycomed, Constance, Germany; [Popper, Lars] Takeda Pharma AS, Clin Sci, DK-4000 Roskilde, Denmark	Popper, L (reprint author), Takeda Pharma AS, Clin Sci, Langebjerg 1, DK-4000 Roskilde, Denmark.	lars.popper@takeda.com			Hurley Consulting Associates LTD (Chatham, MA)	The authors thank Hurley Consulting Associates LTD (Chatham, MA) and Dr Evin H. Sides (AAI Pharma, Morrisville, Durham, NC) for supporting the study conduct.	Agu RU, 2008, DRUG ABSORPTION STUD, P216; [Anonymous], 2004, ETH PRINC MED RES IN; [Anonymous], 2009, EUR J PAIN, V13, pS207; BENNETT D, 2005, [No title captured], V30, P354; Chaushu G, 2000, CANCER, V88, P984, DOI 10.1002/(SICI)1097-0142(20000301)88:5<984::AID-CNCR6>3.3.CO;2-S; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Davies AN, 2005, J PAIN SYMPTOM MANAG, V30, P496, DOI 10.1016/j.jpainsymman.2005.11.006; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; *EUR MED AG, 2011, INST INST FENT SPRAY; *FDA, 2011, ACT APPR US PRESCR I; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Gomez-Batiste X, 2002, J PAIN SYMPTOM MANAG, V24, P45, DOI 10.1016/S0885-3924(02)00421-9; Hanks G., 2001, EUR J PALLIAT CARE, V8, P6; Kaasa Stein, 2010, J Opioid Manag, V6, P17; Kaessner N, 2012, INT J CLIN PHARM TH, V50, P665, DOI 10.5414/CP201737; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Nave R, 2011, EUR J PAIN, V5, pS611; Nave R, 2012, INT J CLIN PHARM TH, V50, P751, DOI 10.5414/CP201729; Patt RB, 1998, ONCOLOGY-NY, V12, P1035; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Simmonds MA, 1999, ONCOLOGY-NY, V13, P1103; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; Sweeney MP, 1998, ORAL ONCOL, V34, P123, DOI 10.1016/S1368-8375(97)00076-6; Walker G, 2003, PALLIATIVE MED, V17, P219, DOI 10.1191/0269216303pm755oa; Zeppetella G, 2003, EXPERT OPIN PHARMACO, V4, P493, DOI 10.1517/14656566.4.4.493; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5	34	14	14	0	9	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1071-7544			DRUG DELIV	Drug Deliv.	JUN-JUL	2013	20	5					216	223		10.3109/10717544.2012.762435			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	171MN	WOS:000320933600003	23650968				2020-06-30	J	Butt, WW				Butt, Warwick W.			Minimize Stress and Maximize Clinical Outcome!	PEDIATRIC CRITICAL CARE MEDICINE			English	Editorial Material						anesthesia; cardiac surgery; extubation; stress response	CARDIAC-SURGERY; EXTUBATION; INFANTS		[Butt, Warwick W.] Royal Childrens Hosp, Pediat Intens Care Unit, Melbourne, Vic, Australia; [Butt, Warwick W.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Butt, Warwick W.] Murdoch Childrens Res Inst, Crit Care & Neurosciences, Melbourne, Vic, Australia	Butt, WW (reprint author), Royal Childrens Hosp, Pediat Intens Care Unit, Melbourne, Vic, Australia.						Alghamdi AA, 2010, J CARDIAC SURG, V25, P586, DOI 10.1111/j.1540-8191.2010.01088.x; ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; Cuesta JM, 2012, CRIT CARE MED, V40, P3283, DOI 10.1097/CCM.0b013e31826567eb; Gruber EM, 2001, ANESTH ANALG, V92, P882; Hiesmayr M, 2005, EUR J ANAESTH, V22, P13; Kussman BD, 2001, PAEDIATR ANAESTH, V11, P663, DOI 10.1046/j.1460-9592.2001.00740.x; Laussen PC, 1996, ANESTH ANALG, V82, P988, DOI 10.1097/00000539-199605000-00017; Naguib AN, 2013, PEDIATR CRIT CARE ME, V14, P481, DOI 10.1097/PCC.0b013e31828a742c; Schwartz D, 2011, ROM ANEST TERAP INT, V18, P95; Shew S B, 1999, Semin Pediatr Surg, V8, P131; Shi SS, 2008, CHEST, V134, P768, DOI 10.1378/chest.07-2573; Tobias JD, 2007, PEDIATR CRIT CARE ME, V8, P115, DOI 10.1097/01.PCC.0000257100.31779.41	12	1	1	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1529-7535			PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JUN	2013	14	5					547	548		10.1097/PCC.0b013e31828a8319			2	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	157SV	WOS:000319920300025	23867435				2020-06-30	J	Jung, WS; Kim, YB; Park, HY; Choi, WJ; Yang, HS				Jung, Wol Seon; Kim, Yong Beom; Park, Hee Yeon; Choi, Woo Jong; Yang, Hong Seuk			Oral administration of aprepitant to prevent postoperative nausea in highly susceptible patients after gynecological laparoscopy	JOURNAL OF ANESTHESIA			English	Article						Aprepitant; Gynecological laparoscopy; Neurokinin-1 receptor antagonists; Postoperative nausea and vomiting	CONTROLLED ANALGESIA; RECEPTOR ANTAGONISTS; ONDANSETRON; SURGERY; EMESIS; DROPERIDOL; FERRETS; SCORE; PAIN; PCA	The use of opioids following surgery is associated with a high incidence of postoperative nausea and vomiting (PONV). We conducted a prospective, randomized, double-blind, placebo-controlled study to investigate the effect of orally administered aprepitant, a neurokinin-1 receptor antagonist, for reducing PONV in patients with fentanyl-based, patient-controlled analgesia (PCA) given intravenously after gynecological laparoscopy. One hundred and twenty female patients (ages 21-60) undergoing laparoscopic hysterectomy were randomly allocated to receive 80 mg (A80 group, n = 40) or 125 mg aprepitant (A125 group, n = 40) or placebo (control group, n = 40) orally 2 h before anesthesia induction. Anesthesia was maintained with isoflurane and remifentanil, and PCA IV using fentanyl and ketorolac were provided for 48 h after surgery. Incidences of nausea, vomiting/retching, and use of rescue antiemetics were recorded at 2, 24, and 48 h after surgery. Complete response was defined as no PONV and no need for rescue treatment. The incidence of complete response was significantly lower in the A80 and A125 groups than in controls, 56 % and 63 %, vs. 28 %, respectively, P = 0.007 and P = 0.003, respectively, during the first 48 h, and 65 % and 65 % vs. 38 %, respectively, both P = 0.025, during the first 2 h. However, there were no statistically significant differences between A80 and A125 groups in the incidences of complete response and PONV during the study period. Aprepitant 80 mg orally was effective in lowering the incidence of PONV in the first 48 h after anesthesia in patients receiving fentanyl-based PCA after gynecological laparoscopy.	[Jung, Wol Seon; Kim, Yong Beom; Park, Hee Yeon] Gachon Univ, Gil Med Ctr, Dept Anesthesiol & Pain Med, Inchon, South Korea; [Choi, Woo Jong; Yang, Hong Seuk] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Anesthesiol & Pain Med, Seoul 138736, South Korea	Yang, HS (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Anesthesiol & Pain Med, 388-1 Pungnap Dong, Seoul 138736, South Korea.	hsyang@amc.seoul.kr					ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Apfel CC, 2008, CURR OPIN ANESTHESIO, V21, P427, DOI 10.1097/ACO.0b013e328301831c; Ariumi H, 2000, NEUROSCI LETT, V286, P123, DOI 10.1016/S0304-3940(00)01113-7; Cherian VT, 2001, BRIT J ANAESTH, V87, P502, DOI 10.1093/bja/87.3.502; Choi YS, 2008, SPINE, V33, pE602, DOI 10.1097/BRS.0b013e31817c6bde; Chung Seunghyun, 2009, Korean J Anesthesiol, V57, P151, DOI 10.4097/kjae.2009.57.2.151; Diemunsch P, 2007, BRIT J ANAESTH, V99, P202, DOI 10.1093/bja/aem133; Diernunsch P, 2007, CURR MED RES OPIN, V23, P2559, DOI 10.1185/030079907X233115; Eriksson H, 1996, ANESTH ANALG, V82, P533, DOI 10.1097/00000539-199603000-00019; Gan TJ, 2001, ANESTH ANALG, V92, P393, DOI 10.1213/00000539-200102000-00022; Gan TJ, 2003, ANESTH ANALG, V97, P62, DOI 10.1213/01.ANE.0000068580.00245.95; Gan TJ, 2007, ANESTH ANALG, V104, P1082, DOI 10.1213/01.ane.0000263277.35140.a3; Kakuta N, 2011, J MED INVESTIG, V58, P246, DOI 10.2152/jmi.58.246; Kim JA, 2009, J KOREAN MED SCI, V24, P930, DOI 10.3346/jkms.2009.24.5.930; MADEJ TH, 1986, BRIT J ANAESTH, V58, P879, DOI 10.1093/bja/58.8.879; Millo J, 2001, ANAESTHESIA, V56, P60, DOI 10.1046/j.1365-2044.2001.01763-4.x; SINATRA R, 1989, ANESTHESIOLOGY, V71, P502, DOI 10.1097/00000542-198910000-00005; Tattersall FD, 1996, NEUROPHARMACOLOGY, V35, P1121, DOI 10.1016/S0028-3908(96)00020-2; TATTERSALL FD, 1994, NEUROPHARMACOLOGY, V33, P259, DOI 10.1016/0028-3908(94)90018-3; Tramer MR, 1997, ANESTHESIOLOGY, V87, P1277, DOI 10.1097/00000542-199712000-00004; van den Bosch JE, 2006, ANESTHESIOLOGY, V104, P1033, DOI 10.1097/00000542-200605000-00020; White H, 2007, BRIT J ANAESTH, V98, P470, DOI 10.1093/bja/aem001	23	17	18	0	9	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	JUN	2013	27	3					396	401		10.1007/s00540-012-1529-9			6	Anesthesiology	Anesthesiology	163KO	WOS:000320335100013	23224788				2020-06-30	J	Kim, SY; Chang, CH; Lee, JS; Kim, YJ; Kim, MD; Han, DW				Kim, So Yeon; Chang, Chul Ho; Lee, Jong Seok; Kim, Yoon Jae; Kim, Man Deuk; Han, Dong Woo			Comparison of the Efficacy of Dexmedetomidine plus Fentanyl Patient-controlled Analgesia with Fentanyl Patient-controlled Analgesia for Pain Control in Uterine Artery Embolization for Symptomatic Fibroid Tumors or Adenomyosis: A Prospective, Randomized Study	JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY			English	Article							ENDOTOXIN-INDUCED SHOCK; INFLAMMATORY RESPONSES; MORPHINE; LEIOMYOMATA; MANAGEMENT; MORTALITY; SURGERY; TRIAL; RATS	Purpose: To investigate whether dexmedetomidine infusion could reduce opioid consumption and opioid-related side effects after uterine artery embolization (UAE). Materials and Methods: Fifty patients undergoing UAE for symptomatic leiomyomas or adenomyosis were randomized into two groups. In 25 patients, dexmedetomidine infusion was started at 0.2 mu g/kg/h at 30 minutes before the procedure, followed by 0.4 mu g/kg/h for 6 hours after the procedure. In another 25 patients (control group), volume-matched normal saline solution was administered. Both groups received fentanyl-based intravenous patient-controlled analgesia (PCA; fentanyl 10 mu g/h with a bolus dose of 20 mu g) during the 24 hours after the procedure. Nonspherical polyvinyl alcohol particles were used. Pain scores, fentanyl consumption, need for additional analgesics, and side effects were assessed for 24 hours after UAE. Results: Compared with the Control group, patients in the dexmedetomidine group required 28%; less PCA fentanyl during the 24 hours after UAE (P = .006). Numeric rating scale scores for pain (5.0 +/- 2.4 vs 7.0 +/- 2.2; P = .026) and the need for additional analgesics (two of 25 vs 17 of 25; P < .001) were lower in the dexmedetomidine group than in the control group during the first 1 hour after UAE. The incidence and severity of nausea and vomiting, during the 24 hours after UAE were lower in the dexmedetomidine group than in the control group (P < .05). Conclusions: The addition of dexmedetomidine infusion to fentanyl PCA provides better analgesia, fentanyl-sparing effect, and less nausea and vomiting without significant hemodynamic instability.	[Kim, So Yeon; Chang, Chul Ho; Lee, Jong Seok; Kim, Yoon Jae; Han, Dong Woo] Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul 120752, South Korea; [Kim, So Yeon; Chang, Chul Ho; Lee, Jong Seok; Kim, Yoon Jae; Han, Dong Woo] Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Seoul 120752, South Korea; [Kim, Man Deuk] Yonsei Univ, Coll Med, Dept Radiol, Seoul 120752, South Korea; [Kim, Man Deuk] Yonsei Univ, Coll Med, Res Inst Radiol Sci, Seoul 120752, South Korea	Kim, MD (reprint author), Yonsei Univ, Coll Med, Dept Radiol, Res Inst Radiol Sci, 50 Yonsei Ro, Seoul 120752, South Korea.	mdkim@yuhs.ac; hanesth@yuhs.ac		Han, Dong Woo/0000-0002-8757-663X			Abdelmageed WM, 2011, SAUDI J ANAESTH, V5, P150, DOI 10.4103/1658-354X.82782; Bhana N, 2000, DRUGS, V59, P263, DOI 10.2165/00003495-200059020-00012; Can M, 2009, ACTA ANAESTH SCAND, V53, P1068, DOI 10.1111/j.1399-6576.2009.02019.x; Gerlach AT, 2007, ANN PHARMACOTHER, V41, P245, DOI 10.1345/aph.1H314; Goodwin SC, 2001, J VASC INTERV RADIOL, V12, P1011, DOI 10.1016/S1051-0443(07)61586-3; Hovsepian DM, 2006, J VASC INTERV RADIOL, V17, P665, DOI 10.1097/01.RVI.0000208986.80383.4C; HUTCHISON RW, 2006, [No title captured], V41, P659; Jensen LL, 2008, ACTA ANAESTH SCAND, V52, P479, DOI 10.1111/j.1399-6576.2008.01602.x; Keyoung JA, 2001, J VASC INTERV RADIOL, V12, P1065, DOI 10.1016/S1051-0443(07)61592-9; Kim H, 2008, CARDIOVASC INTER RAD, V31, P1100, DOI 10.1007/s00270-008-9430-5; Kim JC, 2011, SPINE, V36, P428, DOI 10.1097/BRS.0b013e3181d26708; Kim MD, 2011, J VASC INTERV RADIOL, V22, P497, DOI 10.1016/j.jvir.2011.01.426; Kim SY, 2008, THYROID, V18, P1285, DOI 10.1089/thy.2008.0007; Lampmann LE, 2007, CARDIOVASC INTER RAD, V30, P809, DOI 10.1007/s00270-007-9069-7; Lin TF, 2009, BRIT J ANAESTH, V102, P117, DOI 10.1093/bja/aen320; Lipszyc M, 2011, BRIT J ANAESTH, V106, P724, DOI 10.1093/bja/aer041; Marret E, 2005, ANESTHESIOLOGY, V102, P1249, DOI 10.1097/00000542-200506000-00027; Memis D, 2007, BRIT J ANAESTH, V98, P550, DOI 10.1093/bja/aem017; ORSINI LF, 1984, RADIOLOGY, V153, P113, DOI 10.1148/radiology.153.1.6473771; Pisco JM, 2008, J VASC INTERV RADIOL, V19, P1537, DOI 10.1016/j.jvir.2008.07.015; Pron G, 2003, J VASC INTERV RADIOL, V14, P1243, DOI 10.1097/01.RVI.0000092664.72261.F9; Pron G, 2003, FERTIL STERIL, V79, P120, DOI 10.1016/S0015-0282(02)04538-7; Roberts GW, 2005, ANESTH ANALG, V101, P1343, DOI 10.1213/01.ANE.0000180204.64588.EC; Roth AR, 2000, J VASC INTERV RADIOL, V11, P1047, DOI 10.1016/S1051-0443(07)61337-2; Ryan JM, 2002, RADIOLOGY, V224, P610, DOI 10.1148/radiol.2242011954; Sadhasivam S, 2009, J CLIN ANESTH, V21, P493, DOI 10.1016/j.jclinane.2008.12.017; Spies JB, 2005, OBSTET GYNECOL, V106, P933, DOI 10.1097/01.AOG.0000182582.64088.84; Spies JB, 2002, OBSTET GYNECOL, V100, P873, DOI 10.1016/S0029-7844(02)02341-4; Stall L, 2011, J VASC INTERV RADIOL, V22, P716, DOI 10.1016/j.jvir.2011.01.442; Taniguchi T, 2004, CRIT CARE MED, V32, P1322, DOI 10.1097/01.CCM.0000128579.84228.2A; Taniguchi T, 2008, J ANESTH, V22, P221, DOI 10.1007/s00540-008-0611-9; Wheeler M, 2002, J PAIN, V3, P159, DOI 10.1054/jpai.2002.123652; Williamson A, 2005, J CLIN NURS, V14, P798, DOI 10.1111/j.1365-2702.2005.01121.x	33	16	21	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1051-0443			J VASC INTERV RADIOL	J. Vasc. Interv. Radiol.	JUN	2013	24	6					779	786		10.1016/j.jvir.2013.02.034			8	Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease	Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology	158FY	WOS:000319956100003	23707085				2020-06-30	J	Abdi, R; Fallah-Arzpeima, S				Abdi, Roohollah; Fallah-Arzpeima, Sima			Pancreaticobiliary disorders: comparison between magnetic resonance cholangiopancreatography images before and after fentanyl injection	ABDOMINAL IMAGING			English	Article						ERCP (endoscopic retrograde cholangiopancreatography); MRCP (magnetic resonance cholangiopancreatography); MRI (magnetic resonance imaging); Pancreaticobiliary disorders	MR CHOLANGIOPANCREATOGRAPHY; SECRETIN; DISEASE	This study was designed to determine the effects of intravenous fentanyl on magnetic resonance cholangiopancreatography image quality in the treatment of pancreaticobiliary disorders. Forty consecutive patients referred for the evaluation of pancreaticobiliary disorders underwent magnetic resonance cholangiopancreatography in the coronal and oblique-coronal planes before and after fentanyl injection (every 2 up to 9 min). The images were analyzed qualitatively and quantitatively. Diameter and signal intensity were measured at the widest point and distal to the common bile duct and main pancreatic duct. The mean common bile duct diameters at the widest and distal points and mean pancreatic duct diameter were measured 7.53, 4.72, and 2.14 and 8.33, 5.35, and 2.57 before and after fentanyl injection, respectively. Mean signal intensity at the widest and distal point of the common bile duct and mean pancreatic duct signal intensity measured 278, 199, and 113 and 296, 218, and 121 before and after fentanyl injection, respectively. Minor improvements in image quality were detected qualitatively. Fentanyl injection improves images qualitatively and quantitatively. In agreement with previous studies, our results confirm the beneficial effects of fentanyl as a simple adjunct to traditional magnetic resonance cholangiopancreatography.	[Abdi, Roohollah; Fallah-Arzpeima, Sima] Mazandaran Univ Med Sci, Imam Khomeini Teaching Hosp, Dept Radiol, Fac Med, Sari, Iran	Abdi, R (reprint author), Mazandaran Univ Med Sci, Imam Khomeini Teaching Hosp, Dept Radiol, Fac Med, Sari, Iran.	amirhossein_pharma@yahoo.com	Abdi, Rohollah/J-6998-2017		Mazandaran University of Medical Sciences, Sari, Iran	This project was supported by a Grant from the Mazandaran University of Medical Sciences, Sari, Iran.	Agarwal S, 2006, ABDOM IMAGING, V31, P582, DOI 10.1007/s00261-005-0155-5; Chu ZQ, 2010, ABDOM IMAGING, V35, P367, DOI 10.1007/s00261-009-9514-y; Cohen SA, 1996, ABDOM IMAGING, V21, P385, DOI 10.1007/s002619900089; Czako Laszlo, 2004, Orvosi Hetilap, V145, P529; Duncan HD, 1997, EUR J GASTROEN HEPAT, V9, P905, DOI 10.1097/00042737-199709000-00015; Edelman R, 2006, CLIN MAGNETIC RESONA, P2483; FIG LM, 1990, RADIOLOGY, V175, P467, DOI 10.1148/radiology.175.2.2109335; Hellund JC, 2007, ACTA RADIOL, V48, P135, DOI 10.1080/02841850601128983; Kaltenthaler EC, 2006, BMC IMAGING, V14, P6; Lee NJ, 2006, ABDOM IMAGING, V31, P575, DOI 10.1007/s00261-005-0118-x; Manfredi R, 2000, RADIOLOGY, V214, P849, DOI 10.1148/radiology.214.3.r00mr24849; Matos C, 1997, RADIOLOGY, V203, P435, DOI 10.1148/radiology.203.2.9114101; MCCAMMON RL, 1984, ANESTH ANALG, V63, P139; Shanmugam V, 2005, BRIT J RADIOL, V78, P888, DOI 10.1259/bjr/51075444; Silva AC, 2004, RADIOGRAPHICS, V24, P677, DOI 10.1148/rg.243035087	15	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-8925	1432-0509		ABDOM IMAGING	Abdom. Imaging	JUN	2013	38	3					537	542		10.1007/s00261-012-9937-8			6	Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging	Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging	158QX	WOS:000319988500012	22782316				2020-06-30	J	Tan, PCS; Mohamad, NAN; Gan, SH				Tan, Peter Chee Seong; Mohamad, Nik Abdullah Nik; Gan, Siew Hua			Factors That Influence Pain Intensity and Fentanyl Requirements After a Gynecologic Laparotomy	PAIN MANAGEMENT NURSING			English	Article							PATIENT-CONTROLLED ANALGESIA; VISUAL ANALOG SCALE; POSTOPERATIVE PAIN; PREDICTORS; METABOLISM; INCISIONS; EFFICACY; MIDLINE	The association between pain intensity and its control by intravenous patient-controlled analgesia (IV-PCA) with fentanyl after a laparotomy for cystectomy/salphingoophorectomy, myomectomy, or hysterectomy was investigated. IV fentanyl infusion was administered to patients (n = 94) at 3 mu g/kg/h to provide intraoperative analgesia after induction of general anesthesia. Postoperative fentanyl requirements were quantified via IV-PCA, and the amounts of rescue fentanyl required both during and after surgery were recorded. Mean values for PCA use as well as the visual analog scores (VAS) for pain were documented for up to 24 hours. The association between postoperative fentanyl requirements and VAS were then analyzed by using Mann-Whitney or Kruskal-Wallis tests. Patients with lower midline incisions had greater degrees of pain (p < .05) during the first 16 hours after surgery but did not consume more fentanyl compared with patients with Pfannenstiel incisions. Subjects who underwent operations lasting > 4 hours required more rescue fentanyl during surgery (p < .05). However, this group consumed less fentanyl during the first 4 hours after surgery (p < .05). The demand at the fourth 4-hour period was lower among subjects undergoing myomectomy compared with cystectomy/salphingoophorectomy or hysterectomy (p = .045). Only a poor correlation was observed between pain intensity and analgesic usage. Postoperative pain intensity is influenced by the type of surgical incision but not the type of gynecologic surgery nor the duration of surgery. The relationship between subjective pain ratings with analgesic consumption is weak. Prolonged intraoperative administration of continuous IV fentanyl infusion may reduce fentanyl requirements in the immediate postoperative period. Crown Copyright (c) 2013 Published by Elsevier Inc. on behalf of the American Society for Pain Management Nursing	[Tan, Peter Chee Seong; Mohamad, Nik Abdullah Nik] Univ Sains Malaysia, Sch Med Sci, Dept Anesthesiol & Intens Care, Kubang Kerian 16150, Kelantan, Malaysia; [Gan, Siew Hua] Univ Sains Malaysia, Sch Med Sci, Dept Pharmacol, Kubang Kerian 16150, Kelantan, Malaysia	Gan, SH (reprint author), Univ Sains Malaysia, Sch Med Sci, Hlth Campus, Kubang Kerian 16150, Kelantan, Malaysia.	shgan@kck.usm.my	gan, siew hua/A-6266-2011	gan, siew hua/0000-0001-6470-3651	Research University grant [1001/PPSP/815022]	Supported by a Research University grant (no. 1001/PPSP/815022).	BLOCK RI, 1991, ANESTHESIOLOGY, V75, P746, DOI 10.1097/00000542-199111000-00005; Brown SR, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005199.pub2; Butkovic D, 2007, BRIT J ANAESTH, V98, P677, DOI 10.1093/bja/aem055; DeLoach LJ, 1998, ANESTH ANALG, V86, P102, DOI 10.1097/00000539-199801000-00020; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Fukuda K, 2010, MILLERS ANESTHESIA, P769; Grantcharov TP, 2001, EUR J SURG, V167, P260; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; GROSSI E, 1985, ADV PAIN RES THER, V9, P371; Guitton J, 1997, BIOCHEM PHARMACOL, V53, P1613, DOI 10.1016/S0006-2952(96)00893-3; Habib AS, 2009, CURR MED RES OPIN, V25, P1529, DOI 10.1185/03007990902959168; Ho K, 1996, ANN EMERG MED, V27, P427, DOI 10.1016/S0196-0644(96)70223-8; Ip HYV, 2009, ANESTHESIOLOGY, V111, P657, DOI 10.1097/ALN.0b013e3181aae87a; JAMISON RN, 1993, ANESTH ANALG, V77, P121; Jamison RN, 1993, POSTOPERATIVE PAIN M, P119; Karanikolas M, 2010, J CLIN PHARM THER, V35, P603, DOI 10.1111/j.1365-2710.2009.01114.x; Katz J, 2008, CAN J ANAESTH, V55, P88, DOI 10.1007/BF03016320; Li L, 2007, PAIN MED, V8, P223, DOI 10.1111/j.1526-4637.2007.00296.x; Pasero C, 2002, AM J NURS, V102, P73, DOI 10.1097/00000446-200204000-00027; REVILL SI, 1976, ANAESTHESIA, V31, P1191, DOI 10.1111/j.1365-2044.1976.tb11971.x; Ruggiero A, 2007, SUPPORT CARE CANCER, V15, P569, DOI 10.1007/s00520-006-0193-8; Seiler CM, 2009, ANN SURG, V249, P913, DOI 10.1097/SLA.0b013e3181a77c92; Stoelting RK, 2006, PHARM PHYSL ANESTHET, P87; TAENZER P, 1986, PAIN, V24, P331, DOI 10.1016/0304-3959(86)90119-3; Tateishi T, 1996, ANESTH ANALG, V82, P167; Yen CR, 2010, ANESTHESIOLOGY, V112, P688, DOI 10.1097/ALN.0b013e3181cbd1f3	26	2	2	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1524-9042	1532-8635		PAIN MANAG NURS	Pain Manag. Nurs.	JUN	2013	14	2					102	109		10.1016/j.pmn.2010.12.004			8	Nursing	Nursing	156TK	WOS:000319846600006	23688364				2020-06-30	J	Dzeletovic, I; Harrison, ME; Crowell, MD; Ramirez, FC; Yows, CR; Harris, LA; Pasha, SF; Gurudu, SR; Leighton, JA; Heigh, RI				Dzeletovic, Ivana; Harrison, M. Edwyn; Crowell, Michael D.; Ramirez, Francisco C.; Yows, Catherine R.; Harris, Lucinda A.; Pasha, Shabana F.; Gurudu, Suryakanth R.; Leighton, Jonathan A.; Heigh, Russell I.			Impact of fentanyl in lieu of meperidine on endoscopy unit efficiency: a prospective comparative study in patients undergoing EGD	GASTROINTESTINAL ENDOSCOPY			English	Article							SEDATION; TRIAL	Background: Turnaround time is an important component of endoscopy unit efficiency. Any reduction in the total time from patient arrival in the endoscopy room to departure from the recovery area may translate into better endoscopy unit efficiency. Objective: To evaluate the effects on endoscopy unit efficiency of a change in narcotic choice for moderate sedation in patients undergoing EGD at an ambulatory surgery center. Design: Prospective, comparative, quality-improvement project. Setting: Endoscopy unit of a tertiary-care academic medical center. Patients: We enrolled consecutive patients (n = 1963) who underwent outpatient EGD by 1 of 5 endoscopists between November 2008 and November 2010. Intervention: Moderate sedation with midazolam plus fentanyl versus meperidine. Main Outcome Measurements: Sedation-dependent endoscopy unit efficiency and total procedure time (induction-to-intubation, intubation-to-extubation, and extubation-to-discharge). Results: Fentanyl was associated with reduced total procedure time by 10.1 minutes resulting from both shorter induction-to-intubation time and extubation-to-discharge time (P < .001). The mean (+/- SD) sedation-dependent endoscopy unit efficiency was 3.2 (+/- 1.9) procedures per hour for the meperidine group and 3.9 (+/- 2.7) procedures per hour for the fentanyl group (P = .012); this would translate into possibly increasing the endoscopy suite efficiency by 22%. Based on dosage equivalency conversion, equal doses of fentanyl and meperidine were used. No sedation-related complications or need for reversal agents were recorded. Limitations: No randomization was performed. Conclusion: Compared with meperidine, fentanyl in combination with midazolam was associated with significantly shorter total procedure time. By improving the turnaround time, sedation-dependent endoscopy unit efficiency may be improved by 22%.	[Dzeletovic, Ivana; Harrison, M. Edwyn; Crowell, Michael D.; Ramirez, Francisco C.; Yows, Catherine R.; Harris, Lucinda A.; Pasha, Shabana F.; Gurudu, Suryakanth R.; Leighton, Jonathan A.; Heigh, Russell I.] Mayo Clin, Div Gastroenterol & Hepatol, Scottsdale, AZ 85259 USA	Harrison, ME (reprint author), Mayo Clin, Div Gastroenterol & Hepatol, 13400 East Shea Blvd, Scottsdale, AZ 85259 USA.	harrison.m@mayo.edu		Crowell, Michael/0000-0002-1162-3831			Benson AA, 2008, GUT LIVER, V2, P105, DOI 10.5009/gnl.2008.2.2.105; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; Hayee B, 2009, GASTROINTEST ENDOSC, V69, P681, DOI 10.1016/j.gie.2008.09.033; Horn Ed, 2004, Gastrointest Endosc Clin N Am, V14, P247, DOI 10.1016/j.giec.2004.01.001; Lichtenstein DR, 2008, GASTROINTEST ENDOSC, V68, P815, DOI 10.1016/j.gie.2008.09.029; McQuaid KR, 2008, GASTROINTEST ENDOSC, V67, P910, DOI 10.1016/j.gie.2007.12.046; Robertson DJ, 2009, ALIMENT PHARM THER, V29, P817, DOI 10.1111/j.1365-2036.2009.03943.x; Vargo JJ, 2012, GASTROINTEST ENDOSC, V76, pE1, DOI 10.1016/j.gie.2012.03.001; Zamir S, 2002, AM J GASTROENTEROL, V97, P1968	9	5	7	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107			GASTROINTEST ENDOSC	Gastrointest. Endosc.	JUN	2013	77	6					883	887		10.1016/j.gie.2013.01.013			5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	152CU	WOS:000319508400008	23472999				2020-06-30	J	Monkemuller, K; Wilcox, CM				Moenkemueller, Klaus; Wilcox, C. Mel			Positive domino effect, choice of conscious sedation, and endoscopic unit efficiency	GASTROINTESTINAL ENDOSCOPY			English	Editorial Material							GASTROINTESTINAL ENDOSCOPY; GI ENDOSCOPY; PROPOFOL; MIDAZOLAM; GASTROENTEROLOGY; COLONOSCOPY		[Moenkemueller, Klaus; Wilcox, C. Mel] Univ Alabama Birmingham, Basil Hirschowitz Endoscop Ctr Excellence, Div Gastroenterol & Hepatol, Birmingham, AL USA	Monkemuller, K (reprint author), Univ Alabama Birmingham, Basil Hirschowitz Endoscop Ctr Excellence, Div Gastroenterol & Hepatol, Birmingham, AL USA.						Al-Awabdy B, 2013, WORLD J GASTRO ENDOS, V5, P1, DOI 10.4253/wjge.v5.i1.1; Cohen LB, 2004, GASTROINTEST ENDOSC, V59, P795, DOI 10.1016/S0016-5107(04)00349-9; Dumonceau JM, 2010, ENDOSCOPY, V42, P960, DOI 10.1055/s-0030-1255728; Dzeletovic I, 2013, GASTROINTEST ENDOSC, V77, P883, DOI 10.1016/j.gie.2013.01.013; GINSBERG GG, 1992, GASTROINTEST ENDOSC, V38, P651, DOI 10.1016/S0016-5107(92)70559-8; Ginsberg Gregory G, 2004, Gastrointest Endosc Clin N Am, V14, P635, DOI 10.1016/j.giec.2004.05.001; Heuss LT, 2012, ENDOSCOPY, V44, P504, DOI 10.1055/s-0031-1291668; Inadomi JM, 2010, GASTROINTEST ENDOSC, V72, P580, DOI 10.1016/j.gie.2010.04.040; Lichtenstein DR, 2008, GASTROINTEST ENDOSC, V68, P815, DOI 10.1016/j.gie.2008.09.029; McQuaid KR, 2008, GASTROINTEST ENDOSC, V67, P910, DOI 10.1016/j.gie.2007.12.046; Robertson DJ, 2009, ALIMENT PHARM THER, V29, P817, DOI 10.1111/j.1365-2036.2009.03943.x; Seifert H, 2000, ALIMENT PHARM THERAP, V14, P1207; Vargo JJ, 2007, J CLIN GASTROENTEROL, V41, P591, DOI 10.1097/01.mcg.0000225634.52780.0e; Vargo JJ, 2012, GASTROENTEROLOGY, V143, DOI 10.1053/j.gastro.2012.05.001; Wilcox Charles M, 2004, Gastrointest Endosc Clin N Am, V14, P647, DOI 10.1016/j.giec.2004.04.004	15	1	2	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107			GASTROINTEST ENDOSC	Gastrointest. Endosc.	JUN	2013	77	6					888	890		10.1016/j.gie.2013.02.036			3	Gastroenterology & Hepatology	Gastroenterology & Hepatology	152CU	WOS:000319508400009	23684092				2020-06-30	J	Schmittner, MD; Dieterich, S; Gebhardt, V; Weiss, C; Burmeister, MA; Bussen, DG; Viergutz, T				Schmittner, Marc D.; Dieterich, Sven; Gebhardt, Volker; Weiss, Christel; Burmeister, Marc A.; Bussen, Dieter G.; Viergutz, Tim			Randomised clinical trial of pilonidal sinus operations performed in the prone position under spinal anaesthesia with hyperbaric bupivacaine 0.5 % versus total intravenous anaesthesia	INTERNATIONAL JOURNAL OF COLORECTAL DISEASE			English	Article						Pilonidal sinus; Spinal anaesthesia; General anaesthesia; Hyperbaric; Prone position	AMBULATORY SURGERY; LOCAL-ANESTHESIA; PATIENT; ANALGESIA; MIDAZOLAM; RECOVERY; HISTORY; DISEASE; AIRWAY	The aim of this randomised clinical trial was to determine whether spinal anaesthesia (SPA) is superior to total intravenous anaesthesia (TIVA) in patients undergoing pilonidal sinus (PS) operations in the prone position. After approval of the local ethics committee, suitable patients aged 19-49 years were randomised to SPA (7.5 mg hyperbaric bupivacaine) or TIVA (Propofol and Fentanyl). Cumulative consumption of analgesics, postoperative recovery, complications and patient satisfaction were evaluated. A total of 50 patients were randomised within a 24-month period. Median monitoring time in the recovery room was 0 (0-11) min for SPA versus 40 (5-145) min for TIVA (p < 0.0001). Patients in the SPA group were able to drink (40.5 (0-327) min versus TIVA 171 (72-280) min, p < 0.0001) and eat (55 (0-333) min versus TIVA 220 (85-358), p < 0.0001) earlier. More patients with a TIVA needed analgesics in the recovery room (SPA n = 0 versus TIVA n = 6, p = 0.0023) and suffered more frequently from a sore throat (SPA n = 0 versus TIVA n = 11, p = 0.0001). Two patients with a TIVA suffered from nausea and vomiting. Patients of both groups were equally satisfied with the anaesthesia technique offered. SPA with 7.5 mg hyperbaric bupivacaine is superior to TIVA in patients undergoing PS operations in the prone position in terms of analgesia consumption in the recovery room, recovery times and postoperative complications.	[Schmittner, Marc D.; Dieterich, Sven; Gebhardt, Volker; Viergutz, Tim] Univ Med Ctr Mannheim, Dept Anaesthesiol & Surg Intens Care Med, D-68167 Mannheim, Germany; [Weiss, Christel] Univ Med Ctr Mannheim, Dept Med Stat, Mannheim, Germany; [Burmeister, Marc A.] B Braun, Melsungen, Germany; [Burmeister, Marc A.] Univ Med Ctr Hamburg Eppendorf, Dept Anaesthesiol, Hamburg, Germany; [Bussen, Dieter G.] Ctr Coloproctol, Mannheim, Germany	Schmittner, MD (reprint author), Univ Med Ctr Mannheim, Dept Anaesthesiol & Surg Intens Care Med, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	marc.schmittner@umm.de	Kim, Sang Sub/A-4583-2016				ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Apfel CC, 2002, BRIT J ANAESTH, V88, P659, DOI 10.1093/bja/88.5.659; BACKOFEN JE, 1985, ANESTH ANALG, V64, P194; BAGSHAW ONT, 1995, ANAESTHESIA, V50, P890, DOI 10.1111/j.1365-2044.1995.tb05857.x; Borgeat A, 2003, ANESTHESIOLOGY, V98, P530, DOI 10.1097/00000542-200302000-00036; Bussen D, 2003, CHIRURG, V74, P839, DOI 10.1007/s00104-003-0670-2; CARPENTER RL, 1992, ANESTHESIOLOGY, V76, P906, DOI 10.1097/00000542-199206000-00006; Castellvi J, 2009, INT J COLORECTAL DIS, V24, P1011, DOI 10.1007/s00384-009-0715-1; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; CLOTHIER PR, 1984, ANN ROY COLL SURG, V66, P201; Deutsche Gesellschaft fur Anaesthesiologie und Intensivmedizin Berufsverband Deutscher Anaesthesisten, 2002, ANASTH INTENSIVMED, V43, P457; Eberhart LHJ, 2002, ANAESTHESIST, V51, P463, DOI 10.1007/s00101-002-0322-9; Edgcombe H, 2008, BRIT J ANAESTH, V100, P165, DOI 10.1093/bja/aem380; Empfehlung der Deutschen Gesellschaft fur Anasthesiologie und Intensivmedizin und des Berufsverbandes Deutscher Anasthesisten, 2009, UBERWACHUNG NACH S2, V50, pS486; Gupta A, 2007, CURR OPIN ANESTHESIO, V20, P520, DOI 10.1097/ACO.0b013e3282f021c9; Hernandez MR, 2012, ANESTH ANALG, V114, P349, DOI 10.1213/ANE.0b013e31823b6748; Higgins PP, 2002, BRIT J ANAESTH, V88, P582, DOI 10.1093/bja/88.4.582; Humphries AE, 2010, SURG CLIN N AM, V90, P113, DOI 10.1016/j.suc.2009.09.006; Liu SS, 2007, ANESTH ANALG, V105, P789, DOI 10.1213/01.ane.0000278089.16848.1e; Liu SS, 2001, ANESTHESIOLOGY, V94, P888, DOI 10.1097/00000542-200105000-00030; Lopez AM, 2011, BRIT J ANAESTH, V107, P265, DOI 10.1093/bja/aer104; Mhyre JM, 2007, ANESTHESIOLOGY, V106, P1096, DOI 10.1097/01.anes.0000267592.34626.6b; Naja MZ, 2003, ANAESTHESIA, V58, P1007, DOI 10.1046/j.1365-2044.2003.03401.x; Nessar G, 2004, AM J SURG, V187, P300, DOI 10.1016/j.amjsurg.2003.11.012; RITTOO DB, 1995, ANAESTHESIA, V50, P719, DOI 10.1111/j.1365-2044.1995.tb06102.x; Romsing J, 2002, BRIT J ANAESTH, V88, P215, DOI 10.1093/bja/88.2.215; Schmittner MD, 2010, BRIT J SURG, V97, P12, DOI 10.1002/bjs.6792; Schmittner MD, 2010, INT J COLORECTAL DIS, V25, P775, DOI 10.1007/s00384-010-0888-7; Schmittner MD, 2009, INT J COLORECTAL DIS, V24, P827, DOI 10.1007/s00384-009-0681-7; SONDENAA K, 1995, INT J COLORECTAL DIS, V10, P39, DOI 10.1007/BF00337585; Standl T, 1999, ANAESTHESIST, V48, P242, DOI 10.1007/s001010050697; Stevens WC, 2008, J CLIN ANESTH, V20, P487, DOI 10.1016/j.jclinane.2008.05.009; Sungurtekin H, 2003, J CLIN ANESTH, V15, P201, DOI 10.1016/S0952-8180(03)00032-1; TETZLAFF JE, 1995, REGION ANESTH, V20, P533; Vercauteren MP, 2000, ANESTH ANALG, V90, P324, DOI 10.1097/00000539-200002000-00016	35	5	5	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0179-1958	1432-1262		INT J COLORECTAL DIS	Int. J. Colorectal Dis.	JUN	2013	28	6					873	880		10.1007/s00384-012-1619-z			8	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	150ZY	WOS:000319431600017	23196892				2020-06-30	J	Petrov, RR; Lee, YS; Vardanyan, RS; Liu, L; Ma, SW; Davis, P; Lai, J; Porreca, F; Vanderah, TW; Hruby, VJ				Petrov, Ravil R.; Lee, Yeon Sun; Vardanyan, Ruben S.; Liu, Lu; Ma, Shou-Wu; Davis, Peg; Lai, Josephine; Porreca, Frank; Vanderah, Todd W.; Hruby, Victor J.			Effect of anchoring 4-anilidopiperidines to opioid peptides	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						Opioid peptide; Dynorphine analog; Bivalent ligand; Fentanyl; Analgesic	BRAIN-BARRIER PERMEABILITY; RECEPTOR SELECTIVITY; KAPPA-RECEPTOR; DYNORPHIN; FENTANYL; ANALOGS; RESIDUES; AFFINITY; PAIN	We report here the design, synthesis, and in vitro characterization of new opioid peptides featuring a 4-anilidopiperidine moiety. Despite the fact that the chemical structures of fentanyl surrogates have been found suboptimal per se for the opioid activity, the corresponding conjugates with opioid peptides displayed potent opioid activity. These studies shed an instructive light on the strategies and potential therapeutic values of anchoring the 4-anilidopiperidine scaffold to different classes of opioid peptides. (C) 2013 Elsevier Ltd. All rights reserved.	[Petrov, Ravil R.; Lee, Yeon Sun; Vardanyan, Ruben S.; Liu, Lu; Hruby, Victor J.] Univ Arizona, Dept Chem & Biochem, Tucson, AZ 85721 USA; [Ma, Shou-Wu; Davis, Peg; Lai, Josephine; Porreca, Frank; Vanderah, Todd W.] Univ Arizona, Dept Pharmacol, Tucson, AZ 85721 USA	Hruby, VJ (reprint author), Univ Arizona, Dept Chem & Biochem, Tucson, AZ 85721 USA.	hruby@email.arizona.edu	Vardanyan, Ruben S/G-8173-2016		USDHS; National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-12394, DA-06284]	The work was supported by Grants from the USDHS, National Institute on Drug Abuse (DA-12394 and DA-06284).	CHAVKIN C, 1981, P NATL ACAD SCI-BIOL, V78, P6543, DOI 10.1073/pnas.78.10.6543; Chen HR, 2009, SCI CHINA SER B, V52, P338, DOI 10.1007/s11426-008-0150-0; Colpaert FC, 2001, PAIN, V91, P33, DOI 10.1016/S0304-3959(00)00413-9; Decaillot FM, 2008, P NATL ACAD SCI USA, V105, P16045, DOI 10.1073/pnas.0804106105; Deguchi Y, 2004, J PHARMACOL EXP THER, V310, P177, DOI 10.1124/jpet.103.064006; EMMERSON PJ, 1994, J PHARMACOL EXP THER, V271, P1630; ERSPAMER V, 1989, P NATL ACAD SCI USA, V86, P5188, DOI 10.1073/pnas.86.13.5188; HORAN PJ, 1993, J PHARMACOL EXP THER, V265, P1446; Lee YS, 2007, J MED CHEM, V50, P5528, DOI 10.1021/jm061465o; Lee YM, 2010, J MED CHEM, V53, P4038, DOI 10.1021/jm1001106; Liu HM, 2006, J PHARMACOL EXP THER, V319, P308, DOI 10.1124/jpet.106.106484; Liu WX, 2012, MED RES REV, V32, P536, DOI 10.1002/med.20222; Lung FDT, 1996, J MED CHEM, V39, P2456, DOI 10.1021/jm950655o; Morse M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025643; Petrov RR, 2006, BIOORG MED CHEM LETT, V16, P4946, DOI 10.1016/j.bmcl.2006.06.040; Schafer M, 2000, CNS DRUGS, V13, P161; SNYDER KR, 1992, J MED CHEM, V35, P4330, DOI 10.1021/jm00101a010; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Tamura M, 2003, EUR J ANAESTH, V20, P482, DOI 10.1097/00003643-200306000-00011; Wade CL, 2008, EUR J PHARMACOL, V587, P135, DOI 10.1016/j.ejphar.2008.04.007; Wheeler M, 2004, ANESTH ANALG, V99, P1347, DOI 10.1213/01.ANE.0000132777.00967.A3; Yamamoto T, 2009, J MED CHEM, V52, P5164, DOI 10.1021/jm900473p; Ye Y, 2012, J PAIN, V13, P524, DOI 10.1016/j.jpain.2012.01.006	23	6	6	0	10	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	JUN 1	2013	23	11					3434	3437		10.1016/j.bmcl.2013.03.065			4	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	144XR	WOS:000318976100063	23623418	Green Accepted			2020-06-30	J	Nomura, M; Inoue, K; Matsushita, S; Takahari, D; Kondoh, C; Shitara, K; Ura, T; Hayashi, K; Kojima, H; Kamata, M; Tatematsu, M; Hosoda, R; Sawada, S; Oka, H; Muro, K				Nomura, Motoo; Inoue, Koichi; Matsushita, Shoko; Takahari, Daisuke; Kondoh, Chihiro; Shitara, Kohei; Ura, Takashi; Hayashi, Kenji; Kojima, Hiroyuki; Kamata, Minoru; Tatematsu, Michiko; Hosoda, Renko; Sawada, Satoshi; Oka, Hisao; Muro, Kei			Serum Concentration of Fentanyl During Conversion From Intravenous to Transdermal Administration to Patients With Chronic Cancer Pain	CLINICAL JOURNAL OF PAIN			English	Article						cancer pain; opioid; fentanyl; transdermal; serum concentration	RESERVOIR; DELIVERY	Background: To the best of our knowledge, there have been no reports on the pharmacokinetics and pharmacodynamics during the conversion from continuous intravenous infusion (CII) to transdermal fentanyl administration. The primary objective of the present study was to clarify the pharmacokinetic characteristics during this conversion. A secondary objective was to identify an association between serum albumin and the absorption of fentanyl from the transdermal patch. Methods: A prospective study was conducted from February 2010 to August 2011 that enrolled 19 patients with chronic cancer pain. Patients were classified into 2 study groups according to body mass index and albumin level. All patients received the conversion from CII to transdermal fentanyl using a 2-step taper of CII over 6 hours. Comparisons of efficacy, toxicity, and serum fentanyl concentrations between study groups were analyzed at baseline, 3, 6, 9, 12, 15, 18, and 24 hours after initiation of the conversion. Results: The dose-adjusted serum fentanyl concentrations for all patients were significantly decreased at 15 to 24 hours after conversion compared with baseline, although pain intensity and the number of rescue events remained stable during the conversion. The dose-adjusted serum fentanyl concentrations at 9 to 24 hours were significantly reduced in the low albumin group compared with the normal albumin group (P < 0.05). Conclusions: Our study demonstrated that the dose-adjusted serum fentanyl concentrations remained relatively stable, and pain intensity and the number of rescue events remained stable during conversion. Hypoalbuminemia was strongly associated with poor absorption of transdermally administered fentanyl.	[Nomura, Motoo; Takahari, Daisuke; Kondoh, Chihiro; Shitara, Kohei; Ura, Takashi; Muro, Kei] Aichi Canc Ctr Hosp, Dept Clin Oncol, Aichi, Japan; [Tatematsu, Michiko] Aichi Canc Ctr Hosp, Dept Pharm, Aichi, Japan; [Hosoda, Renko] Aichi Canc Ctr Hosp, Dept Palliat Care, Aichi, Japan; [Matsushita, Shoko; Oka, Hisao] Kinjo Gakuin Univ, Sch Pharm, Dept Phys & Analyt Chem, Nagoya, Aichi, Japan; [Nomura, Motoo; Hayashi, Kenji; Kojima, Hiroyuki; Kamata, Minoru; Sawada, Satoshi] Kansai Med Univ, Dept Radiol, Hirakata, Osaka, Japan; [Inoue, Koichi] Univ Shizuoka, Sch Pharmaceut Sci, Lab Analyt & Bioanalyt Chem, Shizuoka 4228526, Japan	Nomura, M (reprint author), 1-1 Kanokoden Chikusa Ku, Nagoya, Aichi 4648681, Japan.	excell@hkg.odn.ne.jp		Takahari, Daisuke/0000-0002-2492-6014			Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; DECONNO F, 1994, PAIN, V57, P161, DOI 10.1016/0304-3959(94)90219-4; FDA, 2001, GUID IND BIOAN METH; Freynhagen R, 2005, J PAIN SYMPTOM MANAG, V30, P289, DOI 10.1016/j.jpainsymman.2005.03.015; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Heiskanen T, 2009, PAIN, V144, P218, DOI 10.1016/j.pain.2009.04.012; Inoue K, 2011, JPN J PHARM PALLIAT, V4, P111; Kornick CA, 2001, CANCER, V92, P3056, DOI 10.1002/1097-0142(20011215)92:12<3056::AID-CNCR10166>3.0.CO;2-H; Kress HG, 2010, EUR J PHARM BIOPHARM, V75, P225, DOI 10.1016/j.ejpb.2010.02.005; Marier JF, 2007, BRIT J CLIN PHARMACO, V63, P121, DOI 10.1111/j.1365-2125.2006.02758.x; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Moore Kenneth Todd, 2011, J Opioid Manag, V7, P99; Moore KT, 2011, J CLIN PHAR IN PRESS; Morley JE, 2006, AM J CLIN NUTR, V83, P735; Nomura M, 2011, SUPPORT CARE CANCER, V19, P691, DOI 10.1007/s00520-010-0890-1; Paice JA, 1997, CANCER NURS, V20, P88, DOI 10.1097/00002820-199704000-00002; Tassinari D, 2008, J PALLIAT MED, V11, P492, DOI 10.1089/jpm.2007.0200	17	9	9	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-8047	1536-5409		CLIN J PAIN	Clin. J. Pain	JUN	2013	29	6					487	491		10.1097/AJP.0b013e318266f6a5			5	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	143XO	WOS:000318902700003	23328324				2020-06-30	J	Bastami, S; Norling, C; Trinks, C; Holmlund, B; Walz, TM; Ahlner, J; Uppugunduri, S				Bastami, Salumeh; Norling, Cecilia; Trinks, Cecilia; Holmlund, Birgitta; Walz, Thomas M.; Ahlner, Johan; Uppugunduri, Srinivas			Inhibitory effect of opiates on LPS mediated release of TNF and IL-8	ACTA ONCOLOGICA			English	Article							IMMUNE-RESPONSE; KAPPA-B; MORPHINE; TRAMADOL; FENTANYL; CELLS; MACROPHAGES; ACTIVATION; RECEPTORS; PATHWAY	Most patients with advanced cancer experience severe pain and are often treated with opiates. Cancer patients are especially susceptible to opportunistic infections due to treatment with immunosuppressive and cytostatic drugs. Since opiates have been demonstrated to have immunomodulatory effects, it is of clinical importance to evaluate potential differences between commonly used opiates with regard to their effect on the immune system. The aim of this study was to evaluate the effect of morphine, tramadol, fentanyl and ketobemidone on the functioning of the immune system with special reference to TNF and IL-8 release. Method. U-937 cells were preincubated with different concentrations of opioids followed by stimulation with LPS 100 mu g/ml for three hours. The effect of opioids on the levels of cytokine mRNA was studied using RT-PCR. Erk and Akt phosphorylation was also measured by Western blot. Results. All opioids with the exception of fentanyl were capable of inhibiting TNF release from U-937 cells. Morphine had no effect on IL-8 release but the effect of other opiates was almost the same as the effect on TNF. All opioids with the exception of fentanyl were capable of inhibiting production of mRNA for TNF and IL-8. The observed effects of opiates were not always reversible by naloxone, suggesting that the effects might be mediated by other receptors or through a non-receptor mediated direct effect. Although preliminary evidence suggests the involvement of Erk and Akt pathways, further studies are needed to unravel the intracellular pathways involved in mediating the effects of opiates. Our data suggests that the order of potency with regard to inhibition of cytokine release is as follows: tramadol > ketobemidone > morphine > fentanyl. Conclusion. Further studies are needed to understand the clinical implications of the observed immunosuppressive effects of tramadol and ketobemidone and to improve opioid treatment strategies in patients with cancer.	[Bastami, Salumeh; Ahlner, Johan] Linkopings Univ, Dept Med & Hlth Sci, Div Drug Res, Linkoping, Ostergotland, Sweden; [Norling, Cecilia] Linkopings Univ, Dept Clin & Expt Med, Div Cell Biol, Linkoping, Ostergotland, Sweden; [Trinks, Cecilia] Linkoping Univ Hosp, Cty Council Ostergotland, Dept Clin Genet, S-58185 Linkoping, Ostergotland, Sweden; [Trinks, Cecilia] Linkopings Univ, Fac Hlth Sci, Dept Clin & Expt Med, Div Clin Sci, Linkoping, Ostergotland, Sweden; [Holmlund, Birgitta] Linkoping Univ Hosp, Cty Council Ostergotland, Dept Oncol, S-58185 Linkoping, Ostergotland, Sweden; [Walz, Thomas M.] Karolinska Univ Hosp, Dept Oncol, Stockholm, Sweden; [Uppugunduri, Srinivas] Cty Council Ostergotland, Fac Hlth Sci, Dept Clin & Expt Med, Div Clin Chem,Dept Clin Chem, Linkoping, Ostergotland, Sweden	Bastami, S (reprint author), Linkopings Univ, Dept Med & Hlth Sci, Div Drug Res, Linkoping, Ostergotland, Sweden.	salumeh.bastami@liu.se			Swedish Academy of Pharmaceutical Sciences (SAPS); National Board of Health and Welfare in Sweden; County Council of Ostergotland; Hospital pharmacy in Linkoping (Apoteket Farmaci); local fund Ostgotaregionenes cancerfond	This work was financially supported by Swedish Academy of Pharmaceutical Sciences (SAPS), The National Board of Health and Welfare in Sweden, County Council of Ostergotland, the Hospital pharmacy in Linkoping (Apoteket Farmaci) and the local fund Ostgotaregionenes cancerfond.	Andersen S, 1996, PAIN, V67, P369, DOI 10.1016/0304-3959(96)03123-5; Beilin B, 2005, CAN J ANAESTH, V52, P1035, DOI 10.1007/BF03021601; Bilfinger TV, 1998, INT J CARDIOL, V64, pS61, DOI 10.1016/S0167-5273(98)00037-0; Boldyrev AA, 2012, BIOCHEMISTRY-MOSCOW+, V77, P128, DOI 10.1134/S0006297912020022; Budd K, 2004, ACUTE PAIN, P6; Demirjian L, 2006, BBA-MOL BASIS DIS, V1762, P592, DOI 10.1016/j.bbadis.2006.04.004; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Feghali Carol A., 1997, Frontiers in Bioscience (online), V2, pD12; HOUSE RV, 1995, IMMUNOL LETT, V46, P117, DOI 10.1016/0165-2478(95)00035-4; Idova GV, 2012, INT IMMUNOPHARMACOL, V12, P618, DOI 10.1016/j.intimp.2012.02.010; Kraus J, 2003, MOL PHARMACOL, V64, P876, DOI 10.1124/mol.64.4.876; Lazennec G, 2010, TRENDS MOL MED, V16, P133, DOI 10.1016/j.molmed.2010.01.003; Liu Zhihen, 2006, J Huazhong Univ Sci Technolog Med Sci, V26, P478, DOI 10.1007/s11596-006-0427-5; Mohamed MM, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-3; Rodriguez-Vita J, 2010, CYTOKINE GROWTH F R, V21, P61, DOI 10.1016/j.cytogfr.2009.11.006; Roy S, 1998, BIOCHEM BIOPH RES CO, V245, P392, DOI 10.1006/bbrc.1998.8415; Sacerdote P, 2006, PALLIATIVE MED, V20, pS9, DOI 10.1191/0269216306pm1124oa; Sacerdote P, 1997, PAIN, V72, P325, DOI 10.1016/S0304-3959(97)00055-9; Saklatvala J, 2002, ARTHRITIS RES, V4, P146, DOI 10.1186/ar398; Shirzad H, 2009, INT IMMUNOPHARMACOL, V9, P968, DOI 10.1016/j.intimp.2009.04.002; Thomson and Reuters, 2012, MICROMEDEX 2 0 MICRO; Tynan RJ, 2012, BRAIN BEHAV IMMUN, V26, P469, DOI 10.1016/j.bbi.2011.12.011; Walczak H, 2011, IMMUNOL REV, V244, P9, DOI 10.1111/j.1600-065X.2011.01066.x; Wang JH, 2005, J IMMUNOL, V174, P426, DOI 10.4049/jimmunol.174.1.426; Wang J, 2008, ARCH IMMUNOL THER EX, V56, P299, DOI 10.1007/s00005-008-0035-0; Yeager MP, 2002, ANESTH ANALG, V94, P94, DOI 10.1097/00000539-200201000-00018; Yokota T, 2000, CAN J ANAESTH, V47, P303, DOI 10.1007/BF03020942	27	13	15	0	13	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0284-186X			ACTA ONCOL	Acta Oncol.	JUN	2013	52	5					1022	1033		10.3109/0284186X.2012.737932			12	Oncology	Oncology	140LJ	WOS:000318655300020	23145506				2020-06-30	J	Ertmer, C; Kampmeier, T; Van Aken, H				Ertmer, Christian; Kampmeier, Tim; Van Aken, Hugo			Fluid therapy in critical illness: a special focus on indication, the use of hydroxyethyl starch and its different raw materials	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						acute kidney injury; fluid therapy; hydroxyethyl starch; transfusion	ACUTE KIDNEY INJURY; RANDOMIZED CONTROLLED-TRIAL; INTENSIVE-CARE-UNIT; ACUTE LUNG INJURY; OF-THE-LITERATURE; RENAL BLOOD-FLOW; SEVERE SEPSIS; ILL PATIENTS; SEPTIC SHOCK; 6-PERCENT HYDROXYETHYLSTARCH	Purpose of review Fluid therapy is a complex intervention with insufficient resuscitation, as well as overinfusion and fluid accumulation being associated with adverse outcomes. Early goal-directed therapy with later conservative fluid management (i.e. prevention of positive fluid balance and weight gain) appears to markedly improve the survival of patients with severe sepsis. The impact of colloids in resuscitation of patients with sepsis has been the topic of several recently published studies. The purpose of the present review is to outline the indication of fluid administration in critically ill patients, discuss the recent findings of trials involving hydroxyethyl starch (HES) solutions and highlight the impact of different raw materials for HES synthesis. Recent findings Pragmatic trials of modern HES solutions versus crystalloids in critically ill patients show either no difference or adverse outcomes associated with HES infusion. However, fluid therapy was not protocolized in most of these studies and probably associated with overinfusion and hemodilution. Data on the use of waxy maize-derived 6% HES 130/0.4 during early goal-directed therapy show no evidence for harm and an improvement in microvascular blood flow. In addition, experimental data suggest that waxy maize-derived 6% HES 130/0.4 may have different biological effects compared to potato-derived 6% HES 130/0.42 with potentially reduced pulmonary inflammation. Summary Adverse effects of fluid resuscitation in critically ill patients appear to be a consequence of dose and timing rather than the type of fluid itself. Modern waxy maize-derived 6% HES 130/0.4 may have advantages over crystalloids in the very early course of the disease. Clinical trials of early, goal-directed and protocolized therapy with innovative endpoints of resuscitation comparing balanced crystalloids and balanced, waxy maize-derived 6% HES 130/0.4 as the initial resuscitation fluid are warranted.	[Ertmer, Christian; Kampmeier, Tim; Van Aken, Hugo] Univ Hosp Muenster, Dept Anesthesiol Intens Care & Pain Med, D-48149 Munster, Germany	Ertmer, C (reprint author), Univ Hosp Muenster, Dept Anesthesiol Intens Care & Pain Therapy, Albert Schweitzer Campus 1,Bldg A1, D-48149 Munster, Germany.	ertmerc@uni-muenster.de			Fresenius Kabi Germany	H. Van Aken received honoraria and travel reimbursement from Vifor Pharma Ltd. Switzerland, Abbott Germany and Fresenius Kabi Germany. C. Ertmer and T. Kampmeier received research funding and travel reimbursement from Fresenius Kabi Germany.	Aksu U, 2012, RESUSCITATION, V83, P767, DOI 10.1016/j.resuscitation.2011.11.022; Bagchi A, 2013, ANESTHESIOLOGY, V118, P244, DOI 10.1097/ALN.0b013e31827e5582; Bellomo R, 2012, LANCET, V380, P756, DOI 10.1016/S0140-6736(11)61454-2; Bellomo R, 2012, CRIT CARE MED, V40, P1753, DOI 10.1097/CCM.0b013e318246b9c6; Blennow A, 2000, INT J BIOL MACROMOL, V27, P211, DOI 10.1016/S0141-8130(00)00121-5; Blennow A, 2001, INT J BIOL MACROMOL, V28, P409, DOI 10.1016/S0141-8130(01)00133-7; Bouchard J, 2009, KIDNEY INT, V76, P422, DOI 10.1038/ki.2009.159; Boyd JH, 2011, CRIT CARE MED, V39, P259, DOI 10.1097/CCM.0b013e3181feeb15; Bracco D, 2008, NEW ENGL J MED, V358, P2072; Bruegger D, 1999, AM J PHYSIOL-HEART C, V289, pH1993; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Chowdhury AH, 2012, ANN SURG, V256, P18, DOI 10.1097/SLA.0b013e318256be72; Dellinger RP, 2013, CRIT CARE MED, V41, P580, DOI 10.1097/CCM.0b013e31827e83af; Dolecek M, 2009, HEPATO-GASTROENTEROL, V56, P1622; Dubin A, 2010, J CRIT CARE, V25, p659e1; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Gattas DJ, 2012, ANESTH ANALG, V114, P159, DOI 10.1213/ANE.0b013e318236b4d6; Gattas DJ, INTENSIVE C IN PRESS; Godet MC, 1995, INT J BIOL MACROMOL, V17, P405, DOI 10.1016/0141-8130(96)81853-8; Guidet B, 2012, CRIT CARE, V16, DOI 10.1186/cc11358; Haase N, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f839; Hilton AK, 2012, CRIT CARE, V16, DOI 10.1186/cc11154; Hilton AK, 2011, CRIT CARE, V15, DOI 10.1186/cc10247; James MFM, 2011, BRIT J ANAESTH, V107, P693, DOI 10.1093/bja/aer229; Langanke C, EUR J ANAES IN PRESS; Latta T., 1831, LANCET, V2, P274, DOI DOI 10.1016/S0140-6736(02)80289-6; Lee CH, 2010, SHOCK, V33, P454, DOI 10.1097/SHK.0b013e3181c8af66; Lehmann G, 2007, Drugs R D, V8, P229, DOI 10.2165/00126839-200708040-00003; Lewins R, 1832, LANCET, V18, P243, DOI [DOI 10.1016/S0140-6736(02)82831-8, 10.1016/S0140-6736(02)82831-8]; LICHTWARCKASCHOFF M, 1992, INTENS CARE MED, V18, P142, DOI 10.1007/BF01709237; Lin SM, 2006, SHOCK, V26, P551, DOI 10.1097/01.shk.0000232271.09440.8f; Liu KD, 2011, CRIT CARE MED, V39, P2665, DOI 10.1097/CCM.0b013e318228234b; Lobo DN, 2010, CRIT CARE MED, V38, P464, DOI 10.1097/CCM.0b013e3181bc80f1; Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549; Marik PE, 2008, CHEST, V134, P172, DOI 10.1378/chest.07-2331; Marik PE, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-1; Marik PE, 2009, CRIT CARE MED, V37, P2642, DOI 10.1097/CCM.0b013e3181a590da; Martin C, 2013, ANESTHESIOLOGY, V118, P387, DOI 10.1097/ALN.0b013e31827e5569; McIlroy DR, 2003, ANESTH ANALG, V96, P1572, DOI 10.1213/01.ANE.0000061460.59320B0; Muller L, 2008, NEW ENGL J MED, V358, P2072; Myburgh JA, 2012, NEW ENGL J MED, V367, P1901, DOI 10.1056/NEJMoa1209759; Palevsky Paul M, 2002, Curr Opin Crit Care, V8, P515, DOI 10.1097/00075198-200212000-00006; Payen D, 2008, CRIT CARE, V12, DOI 10.1186/cc6916; Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242; Pranskunas A, 2012, INTENSIVE C IN PRESS; Prowle JR, 2010, CURR OPIN CRIT CARE, V16, P332, DOI 10.1097/MCC.0b013e32833be90b; Rehm M, 2001, ANESTHESIOLOGY, V95, P849, DOI 10.1097/00000542-200110000-00011; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Rivers EP, 2012, MINERVA ANESTESIOL, V78, P712; Russell JA, 1998, CRIT CARE MED, V26, P981, DOI 10.1097/00003246-199806000-00003; Sakr Y, 2007, BRIT J ANAESTH, V98, P216, DOI 10.1093/bja/ael333; Saotome T, 2010, INTENS CARE MED, V36, P533, DOI 10.1007/s00134-009-1740-9; Shum HP, 2011, J CRIT CARE, V26, P613, DOI 10.1016/j.jcrc.2011.02.008; Singh N, 2003, FOOD CHEM, V81, P219, DOI 10.1016/S0308-8146(02)00416-8; Sommermeyer K., 2007, Transfusion Alternatives in Transfusion Medicine, V9, P127, DOI 10.1111/j.1778-428X.2007.00071.x; Surgenor SD, 2009, ANESTH ANALG, V108, P1741, DOI 10.1213/ane.0b013e3181a2a696; SZEJTLI J, 1978, STARKE, V30, P85, DOI 10.1002/star.19780300305; TABATA S, 1971, STARKE, V23, P267, DOI 10.1002/star.19710230803; TAKEDA Y, 1986, CARBOHYD RES, V153, P295, DOI 10.1016/S0008-6215(00)90271-4; Vamvakas EC, 2009, BLOOD, V113, P3406, DOI 10.1182/blood-2008-10-167643; Van Der Linden P, 2013, ANESTH ANALG, V116, P35, DOI 10.1213/ANE.0b013e31827175da; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; von Heymann C, 2012, NEW ENGL J MED, V367, P1265, DOI 10.1056/NEJMc1209905; Westphal M, 2009, ANESTHESIOLOGY, V111, P187, DOI 10.1097/ALN.0b013e3181a7ec82; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564; WIEDERSHEIM M, 1957, ARCH INT PHARMACOD T, V111, P353; WILCOX CS, 1983, J CLIN INVEST, V71, P726, DOI 10.1172/JCI110820; Yunos NM, 2012, JAMA-J AM MED ASSOC, V308, P1566, DOI 10.1001/jama.2012.13356; Zarychanski R, 2013, JAMA-J AM MED ASSOC, V309, P678, DOI 10.1001/jama.2013.430	69	9	10	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	JUN	2013	26	3					253	260		10.1097/ACO.0b013e3283606b71			8	Anesthesiology	Anesthesiology	139WT	WOS:000318616400001	23492982				2020-06-30	J	Verbiest, T; Binst, D; Waelbers, T; Coppieters, E; Polis, I				Verbiest, Tom; Binst, Dominique; Waelbers, Tim; Coppieters, Eva; Polis, Ingeborgh			Perioperative changes in cardiac troponin I concentrations in dogs	RESEARCH IN VETERINARY SCIENCE			English	Article						Cardiac troponin I (cTnI); Dogs; Anesthesia	POSTOPERATIVE MYOCARDIAL-INFARCTION; SEVOFLURANE	This study determines the influence of general anesthesia on serum cardiac troponin I (cTnI) concentrations in dogs. All dogs showed no abnormalities on clinical and echocardiographic examination. Venous blood samples were drawn within 12 h of induction and 12 h after discontinuation of anesthesia. Each dog was premedicated with methadone IV and induced with diazepam IV and propofol IV. Anesthesia was maintained using isoflurane in oxygen in combination with a continuous rate infusion of fentanyl. The cTnI concentrations were measured using a third generation chemiluminescent microparticle immunoassay with a detection limit of 0.01 ng/mL (below this level '<0.01 ng/mL'). Ten dogs (55%) had a post-anesthetic increase of cTnI concentration relative to their pre-anesthetic cTnI concentration, whereas a decrease was observed in two dogs (11%). This study shows that cTnI can increase in healthy dog undergoing general anesthesia. (C) 2012 Elsevier Ltd. All rights reserved.	[Verbiest, Tom; Binst, Dominique; Waelbers, Tim; Polis, Ingeborgh] Univ Ghent, Fac Vet Med, Dept Small Anim Med & Clin Biol, B-9820 Merelbeke, Belgium; [Coppieters, Eva] Univ Ghent, Fac Vet Med, Dept Vet Med Imaging & Small Anim Orthoped, B-9820 Merelbeke, Belgium	Verbiest, T (reprint author), Univ Ghent, Fac Vet Med, Dept Small Anim Med & Clin Biol, B-9820 Merelbeke, Belgium.	verbiest_tom@hotmail.com					Alpert JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735-1097(00)00804-4; Barry JAW, 2008, BJA EDUC, V8, P62, DOI 10.1093/bjaceaccp/mkn001; BERNARD JM, 1990, ANESTHESIOLOGY, V72, P659, DOI 10.1097/00000542-199004000-00014; Boswood Adrian, 2009, J Vet Cardiol, V11 Suppl 1, pS23, DOI 10.1016/j.jvc.2009.01.003; CHARLSON ME, 1989, ANN SURG, V210, P637, DOI 10.1097/00000658-198911000-00012; Cilli F, 2010, VET ANAESTH ANALG, V37, P409, DOI 10.1111/j.1467-2995.2010.00554.x; Liu SS, 2012, REGION ANESTH PAIN M, V37, P45, DOI 10.1097/AAP.0b013e31823354f5; Lobetti R, 2002, J VET INTERN MED, V16, P63, DOI 10.1892/0891-6640(2002)016&lt;0063:CTICB&gt;2.3.CO;2; Saunders AB, 2009, VET ANAESTH ANALG, V36, P449, DOI 10.1111/j.1467-2995.2009.00483.x; Wu AHB, 2009, CLIN CHEM, V55, P52, DOI 10.1373/clinchem.2008.107391	10	8	8	0	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0034-5288			RES VET SCI	Res. Vet. Sci.	JUN	2013	94	3					446	448		10.1016/j.rvsc.2012.10.023			3	Veterinary Sciences	Veterinary Sciences	136RH	WOS:000318380600012	23178045				2020-06-30	J	Gusak, V; Turkovic, V; Nesek-Adam, V; Lerotic, I; Popovic, M; Brajenovic, N; Karaconji, IB; Vnuk, D				Gusak, V.; Turkovic, V.; Nesek-Adam, V.; Lerotic, I.; Popovic, M.; Brajenovic, N.; Karaconji, I. Brcic; Vnuk, D.			Lidocaine serum concentration after epidural administration in combination with morphine and fentanyl in rabbit - A preliminary study	RESEARCH IN VETERINARY SCIENCE			English	Article						Lidocaine; Concentration; Serum; Morphine; Fentanyl	INTRAVENOUS LIDOCAINE; ANESTHESIA; DOGS; ONSET; RAT	Morphine and fentanyl are often used as adjuvants in epidural anesthesia to prolong analgesia. The aim of this study was to evaluate the impact of addition of morphine or fentanyl to lidocaine on serum lidocaine concentrations in rabbits after epidural administration. During general anesthesia, rabbits of the group L received epidurally 2% lidocaine, rabbits of the group LM 2% lidocaine and morphine, and rabbits of the group LF 2% lidocaine and fentanyl. Blood for determination of serum lidocaine concentration was taken before anesthesia and in first 90 mm after epidural administration. After 5, 10, and 25 min in the group L the lidocaine serum concentrations were the lowest, while in the group LM the lidocaine serum concentrations were the highest. Morphine and fentanyl did not cause significant changes of serum lidocaine concentration in rabbits and may be used as adjuvant in epidural anesthesia without significant increase in lidocaine absorption from epidural space. (C) 2012 Elsevier Ltd. All rights reserved.	[Gusak, V.; Vnuk, D.] Univ Zagreb, Fac Vet Med, Clin Surg Orthoped & Ophthalmol, Zagreb 41000, Croatia; [Turkovic, V.] Univ Vet Med Vienna, Div Anaesthesiol & Perioperat Intens Care, Vienna, Austria; [Nesek-Adam, V.] Sveti Duh Gen Hosp, Dept Anesthesiol Resuscitat & Intens Care, Zagreb, Croatia; [Lerotic, I.] Gen Hosp Dr Ivo Pedisic Sisak, Sisak, Croatia; [Popovic, M.] Univ Zagreb, Fac Vet Med, Dept Biol, Zagreb 41000, Croatia; [Brajenovic, N.; Karaconji, I. Brcic] Inst Med Res & Occupat Hlth, Analyt Toxicol & Mineral Metab Unit, Zagreb 41000, Croatia	Vnuk, D (reprint author), Univ Zagreb, Fac Vet Med, Clin Surg Orthoped & Ophthalmol, Zagreb 41000, Croatia.	valentina.gusak@gmail.com; dvnuk@vef.hr	Karaconji, Irena Brcic/S-3610-2018; Vnuk, Drazen/AAG-8774-2020	Karaconji, Irena Brcic/0000-0002-1151-8839; 			Adetunji A, 2002, VET J, V163, P335, DOI 10.1053/tvjl.2001.0692; Almeida TF, 2007, JAVMA-J AM VET MED A, V230, P45, DOI 10.2460/javma.230.1.45; Auroy Y, 1997, ANESTHESIOLOGY, V87, P479, DOI 10.1097/00000542-199709000-00005; Beasley V.R., 1999, LOCAL ANESTHETICS SY, P870; Cherng CH, 2005, ANESTH ANALG, V101, P1834, DOI 10.1213/01.ANE.0000184131.06529.35; Cherng CH, 2002, ANESTH ANALG, V94, P1614, DOI 10.1097/00000539-200206000-00046; Forsyth S., 2001, WSAVA WORLD C VANC; Gold MS, 1998, J PHARMACOL EXP THER, V285, P413; Hall LW, 2000, VET ANAESTHESIA, P225; JOHNS RA, 1985, ANESTHESIOLOGY, V62, P141, DOI 10.1097/00000542-198502000-00008; Jones RS, 2001, VET J, V161, P123, DOI 10.1053/tvjl.2000.0528; KLEIN SW, 1968, CAN MED ASSOC J, V99, P472; Lamont L. A., 2007, LUMB JONES VET ANEST, V4, P241; Lemo N, 2007, VET REC, V160, P374, DOI 10.1136/vr.160.11.374; Liu P., 1980, ANESTHESIOLOGY, V53, P231; LUNNEY J., 1995, TXB VET INTERNAL MED, V1, P959; Meyer GA, 2001, EQUINE VET J, V33, P434, DOI 10.2746/042516401776254871; RIGLER ML, 1991, ANESTH ANALG, V72, P275; SKARDA RT, 1991, EQUINE ANESTHESIA MO, P199; Song JJ, 1994, KOREAN J ANESTHESIOL, V27, P782; Wallace MS, 1997, ANESTHESIOLOGY, V86, P1262, DOI 10.1097/00000542-199706000-00006; WILCKE JR, 1983, J VET PHARMACOL THER, V6, P105, DOI 10.1111/j.1365-2885.1983.tb00386.x	22	6	6	0	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0034-5288			RES VET SCI	Res. Vet. Sci.	JUN	2013	94	3					651	655		10.1016/j.rvsc.2012.10.001			5	Veterinary Sciences	Veterinary Sciences	136RH	WOS:000318380600048	23122811				2020-06-30	J	Cata, JP; Bauer, M; Sokari, T; Ramirez, MF; Mason, D; Plautz, G; Kurz, A				Cata, Juan P.; Bauer, Maria; Sokari, Telemate; Ramirez, Maria F.; Mason, David; Plautz, Gregory; Kurz, Andrea			Effects of surgery, general anesthesia, and perioperative epidural analgesia on the immune function of patients with non-small cell lung cancer	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Analgesia, epidural; Anesthesia; Innate immunity; Lung cancer; Natural killers non-small cell lung cancer	T-CELLS; HEPATOCELLULAR-CARCINOMA; CYTOKINE RESPONSE; STRESS-RESPONSE; BREAST-CANCER; LYMPHOCYTE; RECURRENCE; MONOCYTE; CYTOTOXICITY; SUPPRESSION	Study Objective: To assess preoperative and postoperative immune function in patients undergoing surgical resection of non-small cell lung cancer during general anesthesia and postoperative epidural analgesia. Design: Observational single-center study. Setting: University-affiliated academic center. Patients: 24 adult, ASA physical status 3 and 4 patients with stage 1, 2, or 3 non-small cell lung cancer. No study patient received preoperative chemotherapy or radiation. Interventions: Patients underwent thoracotomy with general anesthesia and postoperative epidural analgesia. Measurements: Bispectral index monitoring, sevoflurane requirements, and intraoperative transfusions were recorded. Total fentanyl consumption and pain (verbal numeric rating scale) were recorded 24 hours after surgery. Preoperative and 24-hour postoperative natural killer cell percentage and function and percentages of natural killer T cells, T helper cells (CD4+), and cytotoxic T lymphocytes (CD8+) were measured. Plasma concentrations of the T(H)1 cytokine interleukin-2 and interferon-gamma and the T(H)2 cytokines interleukin-4 were measured at the same time points. Results: The percentage (preoperative, 13.07 +/- 9.81% vs postoperative, 9.6 +/- 6.57%, P < 0.001) and function (preoperative, 31.61 +/- 21.96%; postoperative, 13.61 +/- 9.36%; P < 0.001) of natural killer cells was significantly decreased after surgery, but the percentage of natural killer T cells, T helper cells (CD4+), and cytotoxic T lymphocytes (CD8+) remained unchanged postoperatively; thus, the CD4/CD8 ratio remained unchanged. Postoperative plasma concentrations of the three cytokines were similar to preoperative levels; therefore, the T(H)1/T(H)2 ratio also remained unchanged. Conclusions: Innate immunity is depressed in patients with non-small cell lung cancer after surgical resection, and immunity is not preserved by the use of postoperative epidural analgesia. (c) 2013 Elsevier Inc. All rights reserved.	[Cata, Juan P.; Ramirez, Maria F.] Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Perioperat Med, Houston, TX 77030 USA; [Bauer, Maria] Weill Cornell Univ, Dept Anesthesiol, New York, NY 10065 USA; [Sokari, Telemate] Baylor Coll Med, Dept Emergency Med, Houston, TX 77030 USA; [Mason, David] Cleveland Clin, Dept Thorac & Cardiovasc Surg, Cleveland, OH 44195 USA; [Mason, David] Cleveland Clin, Transplantat Ctr, Cleveland, OH 44195 USA; [Plautz, Gregory] Cleveland Clin, Dept Pediat Hematol & Oncol, Cleveland, OH 44195 USA; [Kurz, Andrea] Cleveland Clin, Inst Anesthesiol, Dept Outcomes Res & Gen Anesthesiol, Cleveland, OH 44195 USA	Cata, JP (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Perioperat Med, Unit 409, 1515 Holcombe Blvd, Houston, TX 77030 USA.	jcata@mdanderson.org			Cancer Center Support Grant from the National Institutes of Health (NIH), Bethesda, MD, USA [CA016672]	Supported in part by a Cancer Center Support Grant (CA016672) from the National Institutes of Health (NIH), Bethesda, MD, USA.	Ahlers O, 2008, BRIT J ANAESTH, V101, P781, DOI 10.1093/bja/aen287; Bar-Yosef S, 2001, ANESTHESIOLOGY, V94, P1066, DOI 10.1097/00000542-200106000-00022; BAXEVANIS CN, 1994, CLIN IMMUNOL IMMUNOP, V71, P82, DOI 10.1006/clin.1994.1055; Beilin B, 1996, ANESTH ANALG, V82, P492, DOI 10.1097/00000539-199603000-00011; Bradley LM, 1996, J IMMUNOL, V157, P1350; Brand JM, 1997, CLIN IMMUNOL IMMUNOP, V83, P190, DOI 10.1006/clin.1997.4351; Cata JP, 2011, EUR J PAIN S, V5, P345, DOI DOI 10.1016/J.EUJPS.2011.08.017; Chechlinska M, 2004, CELL MOL BIOL LETT, V9, P69; Conrick-Martin I, 2012, J CLIN ANESTH, V24, P3, DOI 10.1016/j.jclinane.2011.09.001; Crane CA, 2010, NEURO-ONCOLOGY, V12, P7, DOI 10.1093/neuonc/nop009; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; DIPIRO JT, 1995, ARCH SURG-CHICAGO, V130, P1159; Ellyard JI, 2007, TISSUE ANTIGENS, V70, P1, DOI 10.1111/j.1399-0039.2007.00869.x; Exadaktylos AK, 2006, ANESTHESIOLOGY, V105, P660, DOI 10.1097/00000542-200610000-00008; Greenfeld K, 2007, BRAIN BEHAV IMMUN, V21, P503, DOI 10.1016/j.bbi.2006.12.006; Han YF, 2011, WORLD J GASTROENTERO, V17, P4258, DOI 10.3748/wjg.v17.i38.4258; Hong JY, 2008, REGION ANESTH PAIN M, V33, P44, DOI 10.1016/j.rapm.2007.07.010; Johnston SRD, 1998, BRIT J CANCER, V77, P1280, DOI 10.1038/bjc.1998.214; Kobayashi N, 2012, LUNG CANCER, V75, P223, DOI 10.1016/j.lungcan.2011.06.009; Le Cras AE, 1998, ANESTH ANALG, V87, P1421, DOI 10.1097/00000539-199812000-00041; Liao W, 2011, CURR OPIN IMMUNOL, V23, P598, DOI 10.1016/j.coi.2011.08.003; Liu SJ, 2011, ANESTH ANALG, V113, P572, DOI 10.1213/ANE.0b013e3182278237; Motohashi S, 2009, IMMUNOTHERAPY-UK, V1, P73, DOI 10.2217/1750743X.1.1.73; Mrakovcic-Sutic I, 2011, COLLEGIUM ANTROPOL, V35, P57; Neuner A, 2002, INT J CANCER, V101, P287, DOI 10.1002/ijc.10604; Ng CSH, 2005, J INVEST SURG, V18, P81, DOI 10.1080/08941930590926320; NORAZMI MN, 1994, IMMUNOL LETT, V43, P177, DOI 10.1016/0165-2478(94)90219-4; Ruffell B, 2010, CYTOKINE GROWTH F R, V21, P3, DOI 10.1016/j.cytogfr.2009.11.002; Sessler DI, 2008, CONTEMP CLIN TRIALS, V29, P517, DOI 10.1016/j.cct.2008.01.002; Sessler DI, 2008, EUR J CANCER PREV, V17, P269, DOI 10.1097/CEJ.0b013e3282f0c005; Sessler DI, 1999, AM SURGEON, V65, P1193; TONNESEN E, 1993, EUR J ANAESTH, V10, P189; Vanni G, 2010, ANN THORAC SURG, V90, P973, DOI 10.1016/j.athoracsur.2010.04.070; VITALE M, 1989, J IMMUNOL METHODS, V121, P115, DOI 10.1016/0022-1759(89)90426-2; Volk T, 2004, ANESTH ANALG, V98, P1086, DOI 10.1213/01.ANE.0000104586.12700.3A; Volk T, 2003, CYTOKINE, V24, P237, DOI 10.1016/S1043-4666(03)00090-5; Wada H, 2007, ANESTHESIOLOGY, V106, P499, DOI 10.1097/00000542-200703000-00014; Wang GN, 2005, J CLIN ANESTH, V17, P444, DOI 10.1016/j.jclinane.2004.10.008; Westerterp M, 2008, CANCER IMMUNOL IMMUN, V57, P1837, DOI 10.1007/s00262-008-0511-8; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Woo EY, 2001, CANCER RES, V61, P4766; Yokoyama M, 2005, ANESTH ANALG, V101, P1521, DOI 10.1213/01.ANE.0000184287.15086.1E; Yuen MF, 2001, CANCER, V92, P2136, DOI 10.1002/1097-0142(20011015)92:8<2136::AID-CNCR1555>3.0.CO;2-J; Zamarron BF, 2011, INT J BIOL SCI, V7, P651, DOI 10.7150/ijbs.7.651	44	44	55	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180			J CLIN ANESTH	J. Clin. Anesth.	JUN	2013	25	4					255	262		10.1016/j.jclinane.2012.12.007			8	Anesthesiology	Anesthesiology	198TF	WOS:000322944500002	23659826				2020-06-30	J	Naguib, AN; Tobias, JD; Hall, MW; Cismowski, MJ; Miao, YJ; Barry, N; Preston, T; Galantowicz, M; Hoffman, TM				Naguib, Aymen N.; Tobias, Joseph D.; Hall, Mark W.; Cismowski, Mary J.; Miao, Yongjie; Barry, N'Diris; Preston, Thomas; Galantowicz, Mark; Hoffman, Timothy M.			The Role of Different Anesthetic Techniques in Altering the Stress Response During Cardiac Surgery in Children: A Prospective, Double-Blinded, and Randomized Study	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						cytokines; early extubation after pediatric cardiac surgery; pediatric cardiac surgery; stress response after cardiopulmonary bypass	SYSTEMIC INFLAMMATORY RESPONSE; OPEN-HEART-SURGERY; VENTRICULAR SYSTOLIC FUNCTION; INTENSIVE-CARE-UNIT; CARDIOPULMONARY BYPASS; EARLY EXTUBATION; MODIFIED ULTRAFILTRATION; FENTANYL ANESTHESIA; CYTOKINE RATIOS; PRETERM BABIES	Objectives: Our goal was to evaluate the role of three anesthetic techniques in altering the stress response in children undergoing surgery for repair of congenital heart diseases utilizing cardiopulmonary bypass in the setting of fast tracking or early tracheal extubation. Furthermore, we wanted to evaluate the correlation between blunting the stress response and the perioperative clinical outcomes. Design: Prospective, randomized, double-blinded study. Setting: Single center from December 2008 to May of 2011. Patients: Forty-eight subjects (low-dose fentanyl plus placebo, n = 16; high-dose fentanyl plus placebo, n = 17; low-dose fentanyl plus dexmedetomidine, n = 15) were studied between ages 30 days to 3 years old who were scheduled to undergo repair for a ventricular septal defect, atrioventricular septal defect, or Tetralogy of Fallot. Methods: Children undergoing surgical repair of congenital heart disease were randomized to receive low-dose fentanyl (10 mcg/kg; low-dose fentanyl), high-dose fentanyl (25mcg/kg; high-dose fentanyl), or low-dose fentanyl plus dexmedetomidine (as a 1 mcg/kg loading dose followed by infusion at 0.5mcg/kg/hr until separation from cardiopulmonary bypass. In addition, patients received a volatile anesthetic agent as needed to maintain hemodynamic stability. Blood samples were tested for metabolic, hormonal and cytokine markers at baseline, after sternotomy, after the start of cardiopulmonary bypass, at the end of the procedure and at 24 hours postoperatively. Measurements and Main Results: Forty-eight subjects (low-dose fentanyl plus placebo, n = 16; high-dose fentanyl plus placebo, n = 17; low-dose fentanyl plus dexmedetomidine, n = 15) were studied. Subjects in the low-dose fentanyl plus placebo group had significantly higher levels of adrenocorticotropic hormone, cortisol, glucose, lactate, and epinephrine during the study period. The lowest levels of stress markers were seen in the high-dose fentanyl plus placebo group both over time (adrenocorticotropic hormone, p= 0.01; glucose, p = 0.007) and at individual time points (cortisol and lactate at the end of surgery, epinephrine poststernotomy; p < 0.05). Subjects in the low-dose fentanyl plus dexmedetomidine group had lower lactate levels at the end of surgery compared with the low-dose fentanyl plus placebo group (p < 0.05). Although there were no statistically significant differences in plasma cytokine levels between the three groups, the low-dose fentanyl plus placebo group had significantly higher interleukin-6:interleukin-10 ratio at 24 hours postoperatively (p < 0.0001). In addition, when compared with the low-dose fentanyl plus placebo group, the low-dose fentanyl plus dexmedetomidine group showed a lower norepinephrine level from baseline at poststernotomy, after the start of cardiopulmonary bypass, and at the end of surgery (p 0.05). Subjects in the low-dose fentanyl plus placebo group had more postoperative narcotic requirement (p = 0.004), higher prothrombin time (p 0.03), and more postoperative chest tube output (p < 0.05). Success of fast tracking was not significantly different between groups (low-dose fentanyl plus placebo 75%, high-dose fentanyl plus placebo 82%, low-dose fentanyl plus dexmedetomidine 93%; p = 0.39). Conclusions: The use of low-dose fentanyl was associated with the greatest stress response, most coagulopathy, and highest transfusion requirement among our cohorts. Higher dose fentanyl demonstrated more favorable blunting of the stress response. When compared with low-dose fentanyl alone, the addition of dexmedetomidine improved the blunting of the stress response, while achieving better postoperative pain control.	[Naguib, Aymen N.; Tobias, Joseph D.; Hall, Mark W.; Cismowski, Mary J.; Miao, Yongjie; Barry, N'Diris; Preston, Thomas; Galantowicz, Mark; Hoffman, Timothy M.] Nationwide Childrens Hosp, Sect Crit Care Med, Ctr Heart, Dept Anesthesiol, Columbus, OH USA; [Naguib, Aymen N.; Tobias, Joseph D.; Hall, Mark W.; Cismowski, Mary J.; Miao, Yongjie; Barry, N'Diris; Preston, Thomas; Galantowicz, Mark; Hoffman, Timothy M.] Nationwide Childrens Hosp, Sect Crit Care Med, Ctr Heart, Dept Pediat, Columbus, OH USA; [Naguib, Aymen N.; Tobias, Joseph D.; Hall, Mark W.; Cismowski, Mary J.; Miao, Yongjie; Barry, N'Diris; Preston, Thomas; Galantowicz, Mark; Hoffman, Timothy M.] Ohio State Univ, Coll Med, Columbus, OH 43210 USA	Naguib, AN (reprint author), Nationwide Childrens Hosp, Sect Crit Care Med, Ctr Heart, Dept Anesthesiol, Columbus, OH USA.	aymen.naguib@nationwidechildrens.org	Hoffman, Timothy/E-3253-2011; Hall, Mark/E-3193-2011; Cismowski, Mary/E-2897-2011	Hoffman, Timothy/0000-0001-7715-8197	Heart Center Translational Research Fund at Nationwide Children's Hospital [231708]	Supported, in part, by an intramural grant from Heart Center Translational Research Fund (grant #231708) at Nationwide Children's Hospital.	Alexander JC, 1997, CHEST, V112, P1153, DOI 10.1378/chest.112.5.1153-a; Allan CK, 2010, ANESTH ANALG, V111, P1244, DOI 10.1213/ANE.0b013e3181f333aa; ANAND B. K., 1954, INDIAN JOUR MED REIS, V42, P231; ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; ANAND KJS, 1987, LANCET, V1, P243; ANAND KJS, 1987, LANCET, V1, P62; Anand KJS, 2001, ANESTHESIOLOGY, V95, P823, DOI 10.1097/00000542-200110000-00006; ANAND KJS, 1986, PROG FOOD NUTR SCI, V10, P67; Bichel T, 2000, PAEDIATR ANAESTH, V10, P609, DOI 10.1111/j.1460-9592.2000.00557.x; Biswas Santanu, 2010, Korean Journal of Internal Medicine, V25, P44, DOI 10.3904/kjim.2010.25.1.44; Brix-Christensen V, 2001, ACTA ANAESTH SCAND, V45, P671, DOI 10.1034/j.1399-6576.2001.045006671.x; Can M, 2009, ACTA ANAESTH SCAND, V53, P1068, DOI 10.1111/j.1399-6576.2009.02019.x; Caputo M, 2009, J THORAC CARDIOV SUR, V138, P206, DOI 10.1016/j.jtcvs.2008.12.028; Chaturvedi RR, 1999, EUR J CARDIO-THORAC, V15, P742, DOI 10.1016/S1010-7940(99)00101-3; Chrysostomou C, 2011, ANN THORAC SURG, V92, P964, DOI 10.1016/j.athoracsur.2011.04.099; Chrysostomou C, 2009, PEDIATR CRIT CARE ME, V10, P654, DOI 10.1097/PCC.0b013e3181a00b7a; Cray SH, 2001, PAEDIATR ANAESTH, V11, P465, DOI 10.1046/j.1460-9592.2001.00706.x; Soares LCD, 2010, ARQ BRAS CARDIOL, V94, P127, DOI 10.1590/S0066-782X2010000100019; Davies MJ, 1998, J THORAC CARDIOV SUR, V115, P361, DOI 10.1016/S0022-5223(98)70280-6; Davis Steve, 2004, Pediatr Crit Care Med, V5, P63, DOI 10.1097/01.PCC.0000102386.96434.46; Friesen RH, 2003, PAEDIATR ANAESTH, V13, P122, DOI 10.1046/j.1460-9592.2003.00978.x; Gajarski RJ, 2010, PEDIATR CRIT CARE ME, V11, P44, DOI 10.1097/PCC.0b013e3181a64743; Gourlay T, 2010, PERFUSION-UK, V25, P427, DOI 10.1177/0267659110381453; Gruber EM, 2001, ANESTH ANALG, V92, P882; Hirai S, 2004, Kyobu Geka, V57, P455; Kilic T, 2006, HEART, V92, P1041, DOI 10.1136/hrt.2005.080382; Kloth RL, 2002, CRIT CARE MED, V30, P787, DOI 10.1097/00003246-200204000-00011; Kozik DJ, 2006, ANN THORAC SURG, V81, pS2347, DOI 10.1016/j.athoracsur.2006.02.073; Lespron Robles Ma. del Carmen, 2006, ARCHIVOS DE CARDIOLOGIA DE MEXICO, V76, pS92; Leyvi G, 2005, J CARDIOTHOR VASC AN, V19, P734, DOI 10.1053/j.jvca.2005.01.041; Meissner U, 2008, PEDIATR CARDIOL, V29, P317, DOI 10.1007/s00246-007-9023-0; Mukhtar AM, 2006, ANESTH ANALG, V103, P52, DOI 10.1213/01.ane.0000217204.92904.76; Naguib A, 2011, SAUDI J ANAESTH, V5, P426, DOI 10.4103/1658-354X.87276; Ootaki Y, 2002, SURG TODAY, V32, P203, DOI 10.1007/s005950200021; Peterson KL, 2000, ANESTH ANALG, V90, P1014, DOI 10.1097/00000539-200005000-00002; Prakanrattana Ungkab, 2002, Journal of the Medical Association of Thailand, V85, pS807; Preisman S, 2009, J CARDIOTHOR VASC AN, V23, P348, DOI 10.1053/j.jvca.2008.11.011; Raja Shahzad G, 2005, Asian Cardiovasc Thorac Ann, V13, P382; ROSEN KR, 1989, ANESTHESIOLOGY, V70, P418, DOI 10.1097/00000542-198903000-00009; Roth-Isigkeit A, 1998, J ENDOCRINOL INVEST, V21, P12, DOI 10.1007/BF03347280; Sendasgupta C, 2009, ANN CARD ANAESTH, V12, P27, DOI 10.4103/0971-9784.45010; Abuchaim DCS, 2010, REV BRAS CIR CARDIOV, V25, P103, DOI 10.1590/S0102-76382010000100020; Steppan J, 2009, INFECTION, V37, P14; Taniguchi T, 2008, J ANESTH, V22, P221, DOI 10.1007/s00540-008-0611-9; Tobias JD, 2011, PEDIATR CARDIOL, V32, P1075, DOI 10.1007/s00246-011-0092-8; Vida VL, 2006, ANN THORAC SURG, V81, P1460, DOI 10.1016/j.athoracsur.2005.11.050; Wernovsky G, 2007, CARDIOL YOUNG, V17, P652, DOI 10.1017/S1047951107001461; Winch PD, 2009, HEART LUNG CIRC, V18, P271, DOI 10.1016/j.hlc.2008.11.009	48	40	43	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JUN	2013	14	5					481	490		10.1097/PCC.0b013e31828a742c			10	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	157SV	WOS:000319920300014	23644384	Green Accepted			2020-06-30	J	Anselmi, L; Jaramillo, I; Palacios, M; Huynh, J; Sternini, C				Anselmi, Laura; Jaramillo, Ingrid; Palacios, Michelle; Huynh, Jennifer; Sternini, Catia			Ligand-induced opioid receptor internalization in enteric neurons following chronic treatment with the opiate fentanyl	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						G-protein-coupled receptors; endogenous opioids; tolerant and naive animals	PROTEIN-COUPLED RECEPTORS; GUINEA-PIG ILEUM; INDUCED BOWEL DYSFUNCTION; MYENTERIC PLEXUS; NERVOUS-SYSTEM; BETA-ARRESTIN; MU; DESENSITIZATION; ENDOCYTOSIS; MORPHINE	Morphine differs from most opiates its poor ability to internalize opioid receptors (ORs). However, chronic treatment with morphine produces adaptational changes at the dynamin level, which enhance the efficiency of acute morphine stimulation to promote OR internalization in enteric neurons. This study tested the effect of chronic treatment with fentanyl, a OR-internalizing agonist, on ligand-induced endocytosis and the expression of the intracellular trafficking proteins, dynamin and -arrestin, in enteric neurons using organotypic cultures of the guinea pig ileum. In enteric neurons from guinea pigs chronically treated with fentanyl, OR immunoreactivity was predominantly at the cell surface after acute exposure to morphine with a low level of OR translocation, slightly higher than in neurons from naive animals. This internalization was not due to morphine's direct effect, because it was also observed in neurons exposed to medium alone. By contrast, D-Ala2-N-Me-Phe4-Gly-ol5-enkephalin (DAMGO), a potent OR-internalizing agonist, induced pronounced and rapid OR endocytosis in enteric neurons from animals chronically treated with fentanyl or from naive animals. Chronic fentanyl treatment did not alter dynamin or -arrestin expression. These findings indicate that prolonged activation of ORs with an internalizing agonist such as fentanyl does not enhance the ability of acute morphine to trigger OR endocytosis or induce changes in intracellular trafficking proteins, as observed with prolonged activation of ORs with a poorly internalizing agonist such as morphine. Cellular adaptations induced by chronic opiate treatment might be ligand dependent and vary with the agonist efficiency to induce receptor internalization. (c) 2013 Wiley Periodicals, Inc.	[Anselmi, Laura; Palacios, Michelle; Huynh, Jennifer; Sternini, Catia] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Div Digest Dis, Los Angeles, CA 90095 USA; [Anselmi, Laura; Palacios, Michelle; Huynh, Jennifer; Sternini, Catia] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; [Jaramillo, Ingrid; Sternini, Catia] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA	Sternini, C (reprint author), VAGLAHS, CURE, Digest Dis Res Ctr, Bldg 115,Room 223,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	csternin@ucla.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DK54155, 41301]	Contract grant sponsor: National Institutes of Health; Contract grant numbers: DK54155 (to C.S.); contract grant number: 41301 (Morphology and Cell Imaging Core; to C.S.).	Alvarez VA, 2002, J NEUROSCI, V22, P5769; Arttamangkul S, 2008, MOL PHARMACOL, V74, P972, DOI 10.1124/mol.108.048512; Bagnol D, 1997, NEUROSCIENCE, V81, P579, DOI 10.1016/S0306-4522(97)00227-3; Bohm SK, 1997, BIOCHEM J, V322, P1; Bohn LM, 2004, MOL PHARMACOL, V66, P106, DOI 10.1124/mol.66.1.106; Borgland SL, 2003, J BIOL CHEM, V278, P18776, DOI 10.1074/jbc.M300525200; Brock C, 2012, DRUGS, V72, P1847, DOI 10.2165/11634970-000000000-00000; CHAVKIN C, 1984, P NATL ACAD SCI-BIOL, V81, P7253, DOI 10.1073/pnas.81.22.7253; Christie MJ, 2008, BRIT J PHARMACOL, V154, P384, DOI 10.1038/bjp.2008.100; Dang VC, 2012, BRIT J PHARMACOL, V165, P1704, DOI 10.1111/j.1476-5381.2011.01482.x; Debic HH, 2005, J NEUROSCI, V25, P7847, DOI 10.1523/JNEUROSCI.5045-04.2005; Ding YQ, 1996, J COMP NEUROL, V367, P375; DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018; Eisinger DA, 2002, J NEUROSCI, V22, P10192; Evans CJ, 2000, MOL PSYCHIATR, V5, P122, DOI 10.1038/sj.mp.4000739; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; Hashimoto T, 2006, ANESTHESIOLOGY, V105, P574, DOI 10.1097/00000542-200609000-00023; Ho A, 2003, J COMP NEUROL, V458, P404, DOI 10.1002/cne.10606; Keith DE, 1998, MOL PHARMACOL, V53, P377; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kieffer BL, 2002, PROG NEUROBIOL, V66, P285, DOI 10.1016/S0301-0082(02)00008-4; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; Koch T, 2005, MOL PHARMACOL, V67, P280, DOI 10.1124/mol.104.004994; Kovoor A, 1998, MOL PHARMACOL, V54, P704; KROMER W, 1988, PHARMACOL REV, V40, P121; Law PY, 1999, J PHARMACOL EXP THER, V289, P607; Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002; Martini L, 2007, CURR OPIN NEUROBIOL, V17, P556, DOI 10.1016/j.conb.2007.10.004; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; McConalogue K, 1999, NEUROSCIENCE, V90, P1051, DOI 10.1016/S0306-4522(98)00514-4; Minnis JG, 2003, NEUROSCIENCE, V119, P33, DOI 10.1016/S0306-4522(03)00135-0; Morgan MM, 2011, BRIT J PHARMACOL, V164, P1322, DOI 10.1111/j.1476-5381.2011.01335.x; Panchal SJ, 2007, INT J CLIN PRACT, V61, P1181, DOI 10.1111/j.1742-1241.2007.01415.x; PARONIS CA, 1992, J PHARMACOL EXP THER, V262, P1; PASTERNAK GW, 1988, OPIATE RECEPTORS; Patierno S, 2004, NEUROSCIENCE, V123, P101, DOI 10.1016/j.neuroscience.2003.08.052; Patierno S, 2011, GASTROENTEROLOGY, V140, P618, DOI 10.1053/j.gastro.2010.11.005; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; SCHULZ R, 1985, EUR J PHARMACOL, V110, P335, DOI 10.1016/0014-2999(85)90561-8; Sternini C, 2000, NEUROSCIENCE, V98, P233, DOI 10.1016/S0306-4522(00)00118-4; Sternini C, 2001, AM J PHYSIOL-GASTR L, V281, pG8; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; Trafton JA, 2004, NEUROSCIENCE, V125, P541, DOI 10.1016/j.neuroscience.2004.02.019; von Zastrow M, 2003, LIFE SCI, V74, P217, DOI 10.1016/j.lfs.2003.09.008; von Zastrow M, 2003, CURR OPIN NEUROBIOL, V13, P348, DOI 10.1016/S0959-4388(03)00069-2; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; Williams JT, 2001, PHYSIOL REV, V81, P299; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	52	7	7	2	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JUN	2013	91	6					854	860		10.1002/jnr.23214			7	Neurosciences	Neurosciences & Neurology	132DB	WOS:000318047000012	23553842	Green Accepted			2020-06-30	J	Wong, I; St John-Green, C; Walker, SM				Wong, Ivan; St John-Green, Celia; Walker, Suellen M.			Opioid-sparing effects of perioperative paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs) in children	PEDIATRIC ANESTHESIA			English	Article						pain; postoperative; child; analgesics; opioid; analgesics; non-narcotic; anti-inflammatory agents; nonsteroidal	PATIENT-CONTROLLED ANALGESIA; POSTOPERATIVE PAIN MANAGEMENT; MAJOR SURGERY; RECTAL ACETAMINOPHEN; MORPHINE REQUIREMENTS; CLINICAL-TRIALS; KETOPROFEN; KETOROLAC; EFFICACY; ADENOIDECTOMY	Background and Objectives Perioperative pain in children can be effectively managed with systemic opioids, but addition of paracetamol or nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce opioid requirements and potentially improve analgesia and/or reduce adverse effects. Methods A systematic literature search was conducted to identify trials evaluating postoperative opioid requirements in children and comparing NSAID and/or paracetamol with placebo. Studies were stratified according to design: continuous availability of intravenous opioid (PCA/NCA) vs intermittent as needed' bolus; and single vs multiple dose paracetamol/NSAIDs. Primary outcome data were extracted, and the percentage decrease in mean opioid consumption was calculated for statistically significant reductions compared with placebo. Secondary outcomes included differences in pain intensity, adverse effects (sedation, respiratory depression, postoperative nausea and vomiting, pruritus, urinary retention, bleeding), and patient/parent satisfaction. Results Thirty-one randomized controlled studies, with 48 active treatment arms compared with placebo, were included. Significant opioid sparing was reported in 38 of 48 active treatment arms, across 21 of the 31 studies. Benefit was most consistently reported when multiple doses of study drug were administered, and 24h PCA or NCA opioid requirements were assessed. The proportion of positive studies was less with paracetamol, but was influenced by dose and route of administration. Despite availability of opioid for titration, a reduction in pain intensity by NSAIDs and/or paracetamol was reported in 16 of 29 studies. Evidence for clinically significant reductions in opioid-related adverse effects was less robust. Conclusion This systematic review supports addition of NSAIDs and/or paracetamol to systemic opioid for perioperative pain management in children.	[Wong, Ivan; Walker, Suellen M.] Great Ormond St Hosp Children NHS Fdn Trust, Dept Anaesthesia, London WC1N 1EH, England; [Wong, Ivan; St John-Green, Celia] Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Cambridge CB2 2QQ, England; [Walker, Suellen M.] UCL Inst Child Hlth, Portex Unit Pain Res, London WC1N 1EH, England	Walker, SM (reprint author), UCL Inst Child Hlth, Portex Unit Pain Res, 30 Guilford St, London WC1N 1EH, England.	suellen.walker@ucl.ac.uk	Walker, Suellen M/I-6080-2012	Walker, Suellen/0000-0002-6086-9459	Royal College of Anaesthetists/British Journal of Anaesthesia project grant	This work was supported in part by funding from a Royal College of Anaesthetists/British Journal of Anaesthesia project grant (SMW).	Allegaert K, 2011, ARCH DIS CHILD, V96, P575, DOI 10.1136/adc.2010.204552; ANDERSON BJ, 1995, PAEDIATR ANAESTH, V5, P237; Anderson BJ, 2002, ANESTHESIOLOGY, V96, P1336, DOI 10.1097/00000542-200206000-00012; Anderson BJ, 2001, EUR J CLIN PHARMACOL, V57, P559, DOI 10.1007/s002280100367; Ansermino M, 2003, PAEDIATR ANAESTH, V13, P561, DOI 10.1046/j.1460-9592.2003.01048.x; Antila H, 2006, PEDIATR ANESTH, V16, P548, DOI 10.1111/j.1460-9592.2005.01819.x; BeanLijewski JD, 1996, J CLIN ANESTH, V8, P25, DOI 10.1016/0952-8180(95)00168-9; Berde CB, 2012, PEDIATRICS, V129, P354, DOI 10.1542/peds.2010-3591; Bouwmeester NJ, 2003, INTENS CARE MED, V29, P2009, DOI 10.1007/s00134-003-1899-4; Bremerich DH, 2001, ANESTH ANALG, V92, P907; Cardwell M, 2005, COCHRANE DATABASE SY, V18; Carr A. S., 2009, GUIDELINES PREVENTIO; Ceelie I, 2013, JAMA-J AM MED ASSOC, V309, P149, DOI 10.1001/jama.2012.148050; Dashti Gholam Ali, 2009, Middle East Journal of Anesthesiology, V20, P245; Elia N, 2005, ANESTHESIOLOGY, V103, P1296, DOI 10.1097/00000542-200512000-00025; Hamunen K, 2005, PAIN, V117, P40, DOI 10.1016/j.pain.2005.05.012; Hannam J, 2011, PEDIATR ANESTH, V21, P1234, DOI 10.1111/j.1460-9592.2011.03644.x; Duedahl TH, 2007, PEDIATR ANESTH, V17, P756, DOI 10.1111/j.1460-9592.2007.02213.x; Hong JY, 2010, ANESTHESIOLOGY, V113, P672, DOI 10.1097/ALN.0b013e3181e2c34b; Hong JY, 2010, J UROLOGY, V183, P1551, DOI 10.1016/j.juro.2009.12.043; Howard RF, 2010, PEDIATR ANESTH, V20, P126, DOI 10.1111/j.1460-9592.2009.03242.x; Howard RJ, 2012, PROG TRANSPLANT, V22, P6, DOI 10.7182/pit2012157; Hyllested M, 2002, BRIT J ANAESTH, V88, P199, DOI 10.1093/bja/88.2.199; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kokki H, 2000, BRIT J ANAESTH, V85, P836, DOI 10.1093/bja/85.6.836; Kokki H, 1999, ACTA ANAESTH SCAND, V43, P13, DOI 10.1034/j.1399-6576.1999.430104.x; Kokki H, 2002, PAEDIATR ANAESTH, V12, P162, DOI 10.1046/j.1460-9592.2002.00804.x; Kokki H, 1998, BRIT J ANAESTH, V81, P870; Korpela R, 2007, ACTA ANAESTH SCAND, V51, P726, DOI 10.1111/j.1399-6576.2007.01319.x; Korpela R, 1999, ANESTHESIOLOGY, V91, P442, DOI 10.1097/00000542-199908000-00019; Kovac Anthony L, 2007, Paediatr Drugs, V9, P47, DOI 10.2165/00148581-200709010-00005; Lonnqvist PA, 2005, BRIT J ANAESTH, V95, P59, DOI 10.1093/bja/aei065; Macintyre PE, 2009, ACUTE PAIN MANAGEMENT, P204, DOI 10.1017/CBO9780511576706.016; Maund E, 2011, BRIT J ANAESTH, V106, P292, DOI 10.1093/bja/aeq406; MAUNUKSELA EL, 1992, CAN J ANAESTH, V39, P226, DOI 10.1007/BF03008781; MAUNUKSELA EL, 1988, CAN J ANAESTH, V35, P123, DOI 10.1007/BF03010650; McDaid C, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14170; McGrath PJ, 2008, J PAIN, V9, P771, DOI 10.1016/j.jpain.2008.04.007; Michelet D, 2012, ANESTH ANALG, V114, P393, DOI 10.1213/ANE.0b013e31823d0b45; Mireskandari SM, 2011, J CRANIOFAC SURG, V22, P1955, DOI 10.1097/SCS.0b013e31822ea7fd; Moore RA, 2012, EUR J PAIN, V16, P585, DOI 10.1016/j.ejpain.2011.08.009; Morton NS, 2010, PEDIATR ANESTH, V20, P119, DOI 10.1111/j.1460-9592.2009.03187.x; Morton NS, 1999, BRIT J ANAESTH, V82, P715; Munro HM, 2002, CAN J ANAESTH, V49, P461, DOI 10.1007/BF03017921; Nikanne E, 1997, BRIT J ANAESTH, V78, P24; Ong CKS, 2010, ANESTH ANALG, V110, P1170, DOI 10.1213/ANE.0b013e3181cf9281; Oztekin S, 2002, PAEDIATR ANAESTH, V12, P694, DOI 10.1046/j.1460-9592.2002.00950.x; Power NM, 2012, ARCH DIS CHILD, V97, P879, DOI 10.1136/archdischild-2011-301378; Prins SA, 2008, PEDIATR ANESTH, V18, P582, DOI 10.1111/j.1460-9592.2008.02619.x; Remy C, 2005, BRIT J ANAESTH, V94, P505, DOI 10.1093/bja/aei085; Romsing J, 1998, ACTA ANAESTH SCAND, V42, P770, DOI 10.1111/j.1399-6576.1998.tb05320.x; Rugyte D, 2007, EUR J PAIN, V11, P694, DOI 10.1016/j.ejpain.2006.11.001; Sheeran PW, 2004, PEDIATR ANESTH, V14, P579, DOI 10.1111/j.1460-9592.2004.01263.x; SIMS C, 1994, ANAESTH INTENS CARE, V22, P272, DOI 10.1177/0310057X9402200304; Standing JF, 2009, BRIT J CLIN PHARMACO, V68, P243, DOI 10.1111/j.1365-2125.2009.03447.x; Stewart DW, 2012, PEDIATR ANESTH, V22, P136, DOI 10.1111/j.1460-9592.2011.03713.x; Sutters K A, 1999, Am J Orthop (Belle Mead NJ), V28, P351; SUTTERS KA, 1995, PAIN, V61, P145, DOI 10.1016/0304-3959(94)00166-C; Taylor J, 2013, PEDIATR ANESTH, V23, P40, DOI 10.1111/j.1460-9592.2012.03917.x; Tuomilehto H, 2000, BRIT J ANAESTH, V85, P224, DOI 10.1093/bja/85.2.224; Tuomilehto H, 2002, ACTA ANAESTH SCAND, V46, P184, DOI 10.1034/j.1399-6576.2002.460211.x; van der Marel CD, 2007, BRIT J ANAESTH, V98, P372, DOI 10.1093/bja/ael371; VETTER TR, 1994, J CLIN ANESTH, V6, P110, DOI 10.1016/0952-8180(94)90006-X; Viitanen H, 2003, BRIT J ANAESTH, V91, P363, DOI 10.1093/bja/aeg196; WATCHA MF, 1992, ANESTHESIOLOGY, V76, P368, DOI 10.1097/00000542-199203000-00008	65	79	82	3	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	JUN	2013	23	6					475	495		10.1111/pan.12163			21	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	137MV	WOS:000318440900003	23570544	Green Published			2020-06-30	J	Perelman, M; Fisher, AN; Smith, A; Knight, A				Perelman, Michael; Fisher, Anthony N.; Smith, Alan; Knight, Alastair			Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl	INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS			English	Article						breakthrough pain in cancer; fentanyl; intranasal; pharmacokinetics; allergic rhinitis	BREAKTHROUGH PAIN; DOUBLE-BLIND; SPRAY; TOLERABILITY; INTRANASAL; PECTIN; EFFICACY; ACCEPTABILITY; MORPHINE; OPIOIDS	Objectives: Fentanyl pectin nasal spray (FPNS, Lazanda (R) in the US and PecFent (R) in Europe and Australia) is a novel analgesic approved for the management of breakthrough pain in cancer patients. Given that the fentanyl is nasally administered, it is important to understand whether concomitant allergic rhinitis, or its treatment with a vasoconstrictor, would affect its absorption and, potentially, its efficacy or safety. Methods and subjects: Subjects with a history of allergic rhinitis were screened to identify subjects who developed at least moderate rhinitis symptoms on exposure to pollen allergen (either ragweed or tree) in an environmental exposure chamber (EEC). These were entered into a randomized, three-way cross-over study in which each subject received 100 mu g of FPNS under three exposure conditions; Control (no rhinitis), Rhinitis (symptomatic without decongestant), Treated (symptomatic with concomitant oxymetazoline). Blood samples for fentanyl were collected over a 24-hour period. Results: A total of 132 subjects was screened to identify 54 for inclusion in the study; 31 were evaluable for pharmacokinetics. Measures of fentanyl absorption (mean or median) were similar between Control and Rhinitis conditions: C-max 453.0 vs. 467.8 pg/ml; AUC(t) 1,292.3 vs. 1,325.4 pgxh/ml, AUC(0-infinity) 1,430.6 vs. 1,387 pgxh/ml and t(max) 20 vs. 17 minutes. When oxymetazoline was co-administered, overall fentanyl absorption was slightly reduced (AUC(0-infinity) 1,362.4 pgxh/ml); but, more clinically relevant were the delayed rate of absorption (t(max) 53 minutes) and reduced C-max (235.3 pg/ml). Conclusions: Patients treated with FPNS will be unaffected by the development of allergic rhinitis; but, if oxymetazoline is prescribed, the patient would benefit from added supervision when oxymetazoline is started and stopped.	[Perelman, Michael; Fisher, Anthony N.; Smith, Alan] Archimedes Dev Ltd, Albert Einstein Ctr, Nottingham NG7 2TN, England; [Knight, Alastair] Evicom Ltd, Teddington, Middx, England	Smith, A (reprint author), Archimedes Dev Ltd, Albert Einstein Ctr, Sci & Technol Pk,Univ Blvd, Nottingham NG7 2TN, England.	alansmith@archimedespharma.com			Archimedes Development Ltd., UK	The study was executed with the assistance of Allied Research International with a grant from Archimedes Development Ltd., UK. M. Perelman, A.N. Fisher and A. Smith are employees of Archimedes Development Ltd. Thanks to Suzan Leake (Archimedes Pharma Ltd.) for editorial assistance.	ARGENTI D, 1994, J CLIN PHARMACOL, V34, P854, DOI 10.1002/j.1552-4604.1994.tb02051.x; Capper SJ, 2010, EUR J ANAESTH, V27, P241, DOI 10.1097/EJA.0b013e328331a361; Castile J, 2012, DRUG DEV IND PHARM; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Davis GA, 2004, PHARMACOTHERAPY, V24, P26, DOI 10.1592/phco.24.1.26.34810; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Fisher A, 2010, INT J CLIN PHARM TH, V48, P138; Fisher A, 2010, J CLIN PHARMACOL, V48, P860; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Lister N, 2011, J CLIN PHARMACOL, V51, P1195, DOI 10.1177/0091270010379410; Nave R, 2009, 6 C EUR FED IASP CHA; Paech MJ, 2003, ANAESTHESIA, V58, P740, DOI 10.1046/j.1365-2044.2003.03286.x; Pires A, 2009, J PHARM PHARM SCI, V12, P288, DOI 10.18433/J3NC79; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Portenoy Russell K, 2010, J Opioid Manag, V6, P319; Prommer E, 2009, J PALLIAT MED, V12, P947, DOI 10.1089/jpm.2009.0051; Radbruch L, 2012, SUPPORT CARE CANCER, V20, P565, DOI 10.1007/s00520-011-1124-x; Taylor Donald, 2010, J Support Oncol, V8, P184; Trotti A, 2003, RADIOTHER ONCOL, V66, P253, DOI 10.1016/S0167-8140(02)00404-8; Watts P, 2009, EXPERT OPIN DRUG DEL, V6, P543, DOI [10.1517/17425240902939135, 10.1517/17425240902939135 ]; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012	25	9	11	0	7	DUSTRI-VERLAG DR KARL FEISTLE	DEISENHOFEN-MUENCHEN	BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY	0946-1965			INT J CLIN PHARM TH	Int. J. Clin. Pharmacol. Ther.	MAY	2013	51	5					349	356		10.5414/CP201825			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	170GY	WOS:000320839600001	23458227				2020-06-30	J	Kim, KM; Kim, HS; Lim, SH; Cheong, SH; Choi, EJ; Kang, H; Choi, HR; Jeon, JW; Yon, JH; Oh, M; Shin, JG				Kim, Kye-Min; Kim, Ho-Sook; Lim, Se Hun; Cheong, Soon Ho; Choi, Eun-Jung; Kang, Hyun; Choi, Hey-Ran; Jeon, Jin-Woo; Yon, Jun Heum; Oh, Minkyung; Shin, Jae-Gook			Effect of genetic polymorphisms of OPRM1, ABCB1, CYP3A4/5 on postoperative fentanyl consumption in Korean gynecological patients	INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS			English	Article						pharmacogenetics; fentanyl; analgesia; postoperative pain	MU-OPIOID-RECEPTOR; SINGLE NUCLEOTIDE POLYMORPHISMS; MORPHINE CONSUMPTION; JAPANESE POPULATION; P-GLYCOPROTEIN; A118G POLYMORPHISM; ANALGESIA; PAIN; ASSOCIATION; VARIANT	Objective: Fentanyl, a mu-opioid receptor agonist, is a substrate of P-glycoprotein. Its metabolism is catalyzed by CYP3A4 and CYP3A5. The aim of this study was to investigate the association between postoperative fentanyl consumption and genetic polymorphisms of mu-opioid receptor (OPRM1), ABCB1 (gene encoding P-glycoprotein), CYP3A4 and CYP3A5 in Korean patients. Methods: 196 female patients scheduled to undergo total abdominal hysterectomy or laparoscopic assisted vaginal hysterectomy under general anesthesia were enrolled in this study. Intravenous patient-controlled analgesia with fentanyl was provided postoperatively. Cumulative fentanyl consumption was measured during the first 48 hours postoperatively. The severity of pain at rest was assessed with the visual analogue scale. OPRM1 118A>G, ABCB1 2677G>A/T, ABCB1 3435C>T, CYP3A4*18 and CYP3A5*3 variant alleles were geno-typed. The effects of genetic and non-genetic factors on fentanyl requirements were evaluated with multiple linear regression analysis. Results: The 24-hour cumulative fentanyl doses were significantly associated with pain score, weight and type of surgery (p < 0.05). The 48-hour cumulative fentanyl doses were significantly associated with pain score, type of surgery and history of PONY or motion sickness (p < 0.05). Genetic polymorphisms were not associated with fentanyl requirements. Conclusion: In Korean gynecologic patients, no association was found between genetic factors and postoperative fentanyl consumption.	[Kim, Kye-Min; Lim, Se Hun; Cheong, Soon Ho; Kang, Hyun; Jeon, Jin-Woo; Yon, Jun Heum] Inje Univ Sanggye Paik Hosp, Dept Anesthesiol & Pain Med, Seoul 139707, South Korea; [Kim, Ho-Sook; Choi, Eun-Jung; Oh, Minkyung; Shin, Jae-Gook] Inje Univ, Dept Pharmacol, Coll Med, Seoul, South Korea; [Kim, Ho-Sook; Choi, Eun-Jung; Oh, Minkyung; Shin, Jae-Gook] Inje Univ, PharmacoGen Res Ctr, Coll Med, Seoul, South Korea; [Kim, Ho-Sook; Shin, Jae-Gook] Inje Univ Sanggye Paik Hosp, Dept Clin Pharmacol, Seoul 139707, South Korea; [Kang, Hyun] Chung Ang Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul 156756, South Korea	Kim, KM (reprint author), Inje Univ Sanggye Paik Hosp, Dept Anesthesiol & Pain Med, 1342 Dongil Ro, Seoul 139707, South Korea.	kyemin@paik.ac.kr; phshinjg@inje.ac.kr	Kang, Hyun/AAE-7872-2020	Kang, Hyun/0000-0003-2844-5880	Inje University; National Project for Personalized Genomic Medicine, Korea Health 21 R&D Project, Ministry for Health & Welfare, Republic of Korea [A111218-11-PG02]	Supported by grant from Inje University, 2007 and supported by grants A111218-11-PG02 from the National Project for Personalized Genomic Medicine, Korea Health 21 R&D Project, Ministry for Health & Welfare, Republic of Korea.	Befort K, 2001, J BIOL CHEM, V276, P3130, DOI 10.1074/jbc.M006352200; Beyer A, 2004, J NEUROCHEM, V89, P553, DOI 10.1111/j.1471-4159.2004.02340.x; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; Campa D, 2008, CLIN PHARMACOL THER, V83, P559, DOI 10.1038/sj.clpt.6100385; Chou WY, 2006, ACTA ANAESTH SCAND, V50, P787, DOI 10.1111/j.1399-6576.2006.01058.x; Chou WY, 2006, ANESTHESIOLOGY, V105, P334, DOI 10.1097/00000542-200608000-00016; Coulbault L, 2006, CLIN PHARMACOL THER, V79, P316, DOI 10.1016/j.clpt.2006.01.007; Dai D, 2001, J PHARMACOL EXP THER, V299, P825; Elens L, 2011, PHARMACOGENOMICS, V12, P1383, DOI [10.2217/PGS.11.90, 10.2217/pgs.11.90]; Fujii T, 2012, J PSYCHIATR RES, V46, P555, DOI 10.1016/j.jpsychires.2012.01.012; Fukuen S, 2002, PHARMACOGENETICS, V12, P331, DOI 10.1097/00008571-200206000-00009; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397; Hu YF, 2005, CLIN CHIM ACTA, V353, P187, DOI 10.1016/j.cccn.2004.11.005; Huang WL, 2004, DRUG METAB DISPOS, V32, P1434, DOI 10.1124/dmd.104.001313; Hustert E, 2001, PHARMACOGENETICS, V11, P773, DOI 10.1097/00008571-200112000-00005; Janicki PK, 2006, ANESTH ANALG, V103, P1011, DOI 10.1213/01.ane.0000231634.20341.88; Jin M, 2005, J ANAL TOXICOL, V29, P590, DOI 10.1093/jat/29.7.590; Kudzi W, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-111; Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Landau R, 2008, PAIN, V139, P5, DOI 10.1016/j.pain.2008.02.023; Lee SJ, 2007, DRUG METAB DISPOS, V35, P2095, DOI 10.1124/dmd.107.016733; Mahmoud S, 2011, ANESTHESIOLOGY, V115, P1054, DOI 10.1097/ALN.0b013e318231fc11; Ono T, 2009, BIOL PHARM BULL, V32, P721, DOI 10.1248/bpb.32.721; Ozdemir V, 2000, PHARMACOGENETICS, V10, P373, DOI 10.1097/00008571-200007000-00001; Park HJ, 2007, CLIN PHARMACOL THER, V81, P539, DOI 10.1038/sj.clpt.6100046; Shinn Helen Ki, 2007, Korean Journal of Anesthesiology, V52, P16; Sia AT, 2008, ANESTHESIOLOGY, V109, P520, DOI 10.1097/ALN.0b013e318182af21; Somogyi AA, 2007, CLIN PHARMACOL THER, V81, P429, DOI 10.1038/sj.clpt.6100095; Tan EC, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-32; Tan PCS, 2012, J CLIN PHARM THER, V37, P100, DOI 10.1111/j.1365-2710.2010.01232.x; Tang K, 2004, HUM MOL GENET, V13, P783, DOI 10.1093/hmg/ddh099; Thompson SJ, 2000, ANESTHESIOLOGY, V92, P1392, DOI 10.1097/00000542-200005000-00030; Van Schaik RHN, 2002, CLIN CHEM, V48, P1668; Wang D, 2011, PHARMACOGENOMICS J, V11, P274, DOI 10.1038/tpj.2010.28; Wong CA, 2010, INT J OBSTET ANESTH, V19, P246, DOI 10.1016/j.ijoa.2009.09.005; Yamamoto Takehito, 2003, Drug Metab Pharmacokinet, V18, P267, DOI 10.2133/dmpk.18.267; Yang JC, 2000, CLIN J PAIN, V16, P314, DOI 10.1097/00002508-200012000-00007; Zhang Y, 2005, J BIOL CHEM, V280, P32618, DOI 10.1074/jbc.M504942200	40	20	22	0	14	DUSTRI-VERLAG DR KARL FEISTLE	DEISENHOFEN-MUENCHEN	BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY	0946-1965			INT J CLIN PHARM TH	Int. J. Clin. Pharmacol. Ther.	MAY	2013	51	5					383	392		10.5414/CP201824			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	170GY	WOS:000320839600005	23557865				2020-06-30	J	Paparella, SF				Paparella, Susan F.			A SERIOUS THREAT TO PATIENT SAFETY: THE UNINTENDED MISUSE OF FENTANYL PATCHES	JOURNAL OF EMERGENCY NURSING			English	Editorial Material									ISMP, Horsham, PA USA	Paparella, SF (reprint author), ISMP, Horsham, PA USA.	spaparella@ismp.org					American Pharmacists Association, 2012, ACC FENT PATCH SER; [Anonymous], 2010, P & T, V35, P653; [Anonymous], 2008, DUR FENT PATCH EXT R; Food and Drug Administration, 2013, FENT PATCH CAN BE DE; Food and Drug Administration, FDA PUBL HLTH ADV IM; Institute for Safe Medication Practices, 2005, MED SAF ALERT, V10, P1; ISMP's National Medication Error Reporting Program (ISMP MERP), PRIV INT ACC ISMPS C; National Alert Network Alert, 2012, PROP DISP FENT PATCH; Paparella S, 2005, J EMERG NURS, V31, P278, DOI 10.1016/j.jen.2005.01.010; Pennsylvania Patient Safety Authority, 2007, PA PSRS PATIENT SAF, V4, P53; Pennsylvania Patient Safety Authority, 2004, PS PSRS PATIENT SAF, V1, P11	11	5	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0099-1767	1527-2966		J EMERG NURS	J. Emerg. Nurs.	MAY	2013	39	3					245	247		10.1016/j.jen.2013.01.007			3	Emergency Medicine; Nursing	Emergency Medicine; Nursing	162ZX	WOS:000320306200014	23537470				2020-06-30	J	Meng, WB; Yuan, JQ; Zhang, CL; Bai, ZT; Zhou, WC; Yan, J; Li, X				Meng, Wenbo; Yuan, Jinqiu; Zhang, Chuanlei; Bai, Zhongtian; Zhou, Wence; Yan, Jun; Li, Xun			Parenteral analgesics for pain relief in acute pancreatitis: A systematic review	PANCREATOLOGY			English	Review						Acute pancreatitis; Pain relief; Procaine; Buprenorphine; Pentazocine	TRANSDERMAL FENTANYL; INTRAVENOUS PROCAINE; MANAGEMENT; BUPRENORPHINE; EFFICACY; GUIDELINES; MORPHINE	Aim: To assess the efficiency and safety of parenteral analgesics for pain relief in acute pancreatitis. Materials and methods: We carried out an electronic search of PubMed, Cochrane Library, EMBASE, WEIPU, CNKI and CBM and a manual search for eligible studies. The methodological quality of included trials and quality of evidence were examined by the Cochrane Collaboration's tool for assessing risk of bias and GRADE, respectively. The data were mainly analyzed descriptively and some were pooled by Review manager 5. Results: Eight randomized controlled trials with a total of 356 patients were finally included in this systematic review. Compared with procaine, pentazocine led to lower pain severity: day 1, Mean Difference (MD), 95%CI: 40.0 [35.3, 44.7]; day 2, MD, 95%CI: 24.00 [20.88, 27.12]; day 3, MD, 95%CI: 5.00 [2.17, 7.83], and it decreased the requirement for additional analgesics, Relative Risk, 95%CI: 2.23 [1.63, 3.05]. The combination of fentanyl, atropine, droperidol and lidocaine rendered lower pain score: day 1, MD, 95%CI: -5.46 [-6.95, -3.97]; day 2, MD, 95%CI: -5.78 [-739, -4.17]. Patients treated with meta-mizole tended to had lower pain than those treated with morphine, MD, 95%CI: -2.60 [-2.95, 2.25]. Nausea, emesis and vomiting were the common adverse events reported and there was almost no significant difference between different agents on safety. Conclusions: The systemic review showed that the randomized controlled trials comparing different analgesics were of low quality and did not favor clearly any particular analgesic for pain relief in acute pancreatitis. Copyright (C) 2013, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. All rights reserved.	[Meng, Wenbo; Bai, Zhongtian; Zhou, Wence; Yan, Jun; Li, Xun] Lanzhou Univ, Clin Med Coll Canc Ctr, Hepatopancreatobiliary Surg Inst Gansu Prov, Dept Gen Surg 2,Hosp 1, Lanzhou 730000, Gansu, Peoples R China; [Yuan, Jinqiu] Chinese Univ Hong Kong, Sch Publ Hlth & Primary Care, Hong Kong, Hong Kong, Peoples R China; [Zhang, Chuanlei] Univ Arkansas Med Sci, Dept Biostat, Little Rock, AR 72205 USA	Li, X (reprint author), Lanzhou Univ, Clin Med Coll Canc Ctr, Hepatopancreatobiliary Surg Inst Gansu Prov, Dept Gen Surg 2,Hosp 1, Lanzhou 730000, Gansu, Peoples R China.	drlixun@163.com	Yuan, Jinqiu/A-4867-2018	Zhou, Wence/0000-0001-9180-6648			[Anonymous], 2001, Eur J Gastroenterol Hepatol, V13 Suppl 4, pS1; Banks PA, 1997, AM J GASTROENTEROL, V92, P377; Banks Peter A, 2010, Gastroenterol Hepatol (N Y), V6, P1; BLAMEY SL, 1984, BMJ-BRIT MED J, V288, P1494, DOI 10.1136/bmj.288.6429.1494-a; Bollen FL, 2008, BRIT J SURG, V95, P6, DOI 10.1002/bjs.6010; CAPLAN RA, 1989, JAMA-J AM MED ASSOC, V261, P1036, DOI 10.1001/jama.261.7.1036; Chai X, 1997, J HEPATOBILARY SURGE, V5, P239; Chen Y., 2000, HEILONGJIANG NURS J, V6, P23; Chunming XIAO, 2002, CHIN J BASES CLIN GE, V9, P427; COELHO JCU, 1986, ANN SURG, V204, P53, DOI 10.1097/00000658-198607000-00007; Dervenis C, 1999, INT J PANCREATOL, V25, P195; EBBEHOJ N, 1985, SCAND J GASTROENTERO, V20, P798, DOI 10.3109/00365528509088825; Fantini Lorenzo, 2006, World J Emerg Surg, V1, P16, DOI 10.1186/1749-7922-1-16; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE; He Zhaozhou, 2006, CHIN MAGAZINE CLIN M, V12, P2719; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Jakobs R, 2000, SCAND J GASTROENTERO, V35, P1319; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Kahl S, 2004, DIGESTION, V69, P5, DOI 10.1159/000076541; Kaufman M, 2010, J CLIN GASTROENTEROL, V44, P127, DOI 10.1097/MCG.0b013e3181bb854d; Keller J, 2009, GASTROENTEROLOGY, V136, pA76; Khaliq A, 2010, J PANCREAS, V11, P492; Kingsnorth A, 2006, BMJ-BRIT MED J, V332, P1072, DOI 10.1136/bmj.332.7549.1072; Koo HC, 2009, GASTROINTEST ENDOSC, V69, pAB270, DOI 10.1016/j.gie.2009.03.716; LANKISCH PG, 1984, DRUGS, V28, P554, DOI 10.2165/00003495-198428060-00004; Layer P, 2011, PANCREAS; LEHMANN KA, 1988, ANAESTHESIST, V37, P65; Lerch MM, 2004, DIGESTION, V69, P2, DOI 10.1159/000076540; Lowham A, 1999, INT J PANCREATOL, V25, P103, DOI 10.1385/IJGC:25:2:103; MCNALLY GP, 2002, [No title captured], P35; Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535; Peiro AM, 2008, PANCREATOLOGY, V8, P25, DOI 10.1159/000114852; Pezzilli R, 2010, PHARMACEUTICALS, V3, P558, DOI 10.3390/ph3030558; PUGH GC, 1987, BRIT J ANAESTH, V59, P1364, DOI 10.1093/bja/59.11.1364; ROSOW CE, 1987, DRUG ALCOHOL DEPEN, V20, P329, DOI 10.1016/0376-8716(87)90006-8; Runzi M, 2000, Z GASTROENTEROL, V38, P571, DOI 10.1055/s-2000-7447; Sekimoto M, 2006, J HEPATO-BILIARY-PAN, V13, P10, DOI 10.1007/s00534-005-1047-3; Spiegel B, 2001, AM FAM PHYSICIAN, V64, P219; STEINBERG W, 1994, NEW ENGL J MED, V330, P1198, DOI 10.1056/NEJM199404283301706; Stevens M, 2002, APPL NURS RES, V15, P102, DOI 10.1053/apnr.2002.29532; Takeda K, 2006, J HEPATO-BILIARY-PAN, V13, P42, DOI 10.1007/s00534-005-1050-8; Tao D, 2006, ZHEJIANG J TRADITION, V41, P334; WERESZCZYNSKASIEMIATKOWSKA U, 1987, RES EXP MED, V187, P211, DOI 10.1007/BF01852085; Wilms B, 2010, DEUT MED WOCHENSCHR, V135, P2290, DOI 10.1055/s-0030-1267512; Wu Weiguo, 2002, WORLD CHIN J DIGESTO, V10, P1994; Yadav D, 2006, PANCREAS, V33, P323, DOI 10.1097/01.mpa.0000236733.31617.52; Yousaf M, 2003, BRIT J SURG, V90, P407, DOI 10.1002/bjs.4179; Zurnic SS, 2009, INTENS CARE MED, V35, P278	48	20	22	0	19	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1424-3903	1424-3911		PANCREATOLOGY	Pancreatology	MAY-JUN	2013	13	3					201	206		10.1016/j.pan.2013.02.003			6	Gastroenterology & Hepatology	Gastroenterology & Hepatology	159VD	WOS:000320074500003	23719588				2020-06-30	J	Taylor, DR; Burton, AW; Gabrail, NY; Mayeur, D; Poulain, P; Serrie, A; Torres, LM				Taylor, Donald R.; Burton, Allen W.; Gabrail, Nashat Y.; Mayeur, Didier; Poulain, Philippe; Serrie, Alain; Torres, Luis M.			Letter to the Editor: Pharmacokinetics of Non-Intravenous Formulations of Fentanyl	CLINICAL PHARMACOKINETICS			English	Letter									[Taylor, Donald R.] Comprehens Pain Care PC, Marietta, GA USA; [Taylor, Donald R.] Taylor Res LLC, Marietta, GA USA; [Burton, Allen W.] Houston Pain Associates, Houston, TX USA; [Gabrail, Nashat Y.] Oncologist Gabrail Canc Ctr Res, Canton, OH USA; [Gabrail, Nashat Y.] Gabrail Canc Ctr, Canton, OH USA; [Mayeur, Didier] Ctr Hosp Versailles, Hop Andre Mignot, Serv Hematol Oncol, Le Chesnay, France; [Poulain, Philippe] Polyclin Ormeau, Tarbes, France; [Serrie, Alain] Hop Univ Lariboisiere, Ctr Traitement Douleur, Paris, France; [Torres, Luis M.] Hosp Puerta del Mar Cadiz, Serv Anestesia Reanimac & Tratamiento Dolor, Cadiz, Spain	Taylor, DR (reprint author), Comprehens Pain Care PC, Marietta, GA USA.	dtaylor@cpcnopain.com	Torres, Luis M/Q-6983-2019; Torres, Luis Miguel/O-1720-2015	Torres, Luis Miguel/0000-0002-0194-7875			Curtiss Carol P, 2011, Evid Based Nurs, V14, P90, DOI 10.1136/ebn1150; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028	3	0	0	0	7	ADIS INT LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND	0312-5963			CLIN PHARMACOKINET	Clin. Pharmacokinet.	MAY	2013	52	5					397	398		10.1007/s40262-013-0059-4			2	Pharmacology & Pharmacy	Pharmacology & Pharmacy	138RI	WOS:000318525700007	23553424				2020-06-30	J	Gart, MS; Ko, JH; Heyer, KS; Mustoe, TA				Gart, Michael S.; Ko, Jason H.; Heyer, Kamaldeep S.; Mustoe, Thomas A.			Breast Implant Procedures under Conscious Sedation: A 6-Year Experience in 461 Consecutive Patients	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article							PREDICTABLE 24-HOUR RETURN; REFINED SURGICAL TECHNIQUES; PLASTIC-SURGERY PROCEDURES; INTRAVENOUS SEDATION; AUGMENTATION-MASTOPEXY; POSTOPERATIVE NAUSEA; OUTPATIENT SURGERY; LOCAL-ANESTHESIA; PART II; OUTCOMES	Background: Breast implant procedures are commonly performed using general anesthesia; however, patient apprehension, the potential for improved safety, lower costs, and faster recovery times have increased interest in the use of conscious sedation in plastic surgery. The authors examined the safety and efficacy of breast implant procedures performed under conscious sedation over a 6-year period using their standardized institutional protocol. Methods: Between 2002 and 2008, 461 consecutive patients underwent breast implant procedures under conscious sedation using a protocol of preoperative intravenous diazepam along with intraoperative midazolam, fentanyl, and local anesthetic. All operative and follow-up data were recorded. Augmentation mammaplasty patients were further analyzed for conscious sedation medication dosing. Results: The study population was divided into two groups (years 1 to 3 and years 4 to 6 of the study period) to analyze changes to the authors' regimen over time. In years 4 to 6, higher preoperative doses of diazepam (p = 0.01) allowed more effective local anesthesia administration, thereby reducing intraoperative fentanyl requirements (p < 0.0001). Midazolam doses and operating times did not differ significantly between groups. No patient required conversion to a deeper method of anesthesia. The overall complication rate was 4.34 percent. Conclusions: The authors' study demonstrates the safety and efficacy of conscious sedation in breast implant procedures. Higher preoperative doses of diazepam have significantly reduced fentanyl requirements, resulting in shorter recovery times, decreased postoperative nausea/ vomiting, and elimination of unintended admissions. These benefits are obtained without increasing operative times or complications. The authors conclude that conscious sedation is the preferred method of anesthesia for most patients undergoing breast implant procedures.	NW Mem Hosp, Div Plast & Reconstruct Surg, Dept Surg, Chicago, IL USA; Univ Washington, Dept Surg, Div Plast Surg, Seattle, WA 98195 USA	Mustoe, TA (reprint author), Northwestern Univ, Div Plast & Reconstruct Surg, Feinberg Sch Med, 675 North St Clair St,Galter Suite 19-250, Chicago, IL 60611 USA.	tmustoe@nmh.org					American Society of Aesthetic Plastic Surgery, 2011, COSMETIC SURGERY NAT; BAKER TJ, 1988, PLAST RECONSTR SURG, V82, P244, DOI 10.1097/00006534-198808000-00005; Baxter Richard A, 2005, Aesthet Surg J, V25, P447, DOI 10.1016/j.asj.2005.07.006; Benito-Ruiz J, 2009, PLAST RECONSTR SURG, V123, p31E, DOI 10.1097/PRS.0b013e31819055b5; Bitar G, 2003, PLAST RECONSTR SURG, V111, P150, DOI 10.1097/01.PRS.0000037756.88297.BC; Brown T, 2012, AESTHET PLAST SURG, V36, P566, DOI 10.1007/s00266-011-9840-7; Bun MY, 1999, PLAST RECONSTR SURG, V103, P1260; Cinnella G, 2007, PLAST RECONSTR SURG, V119, P2263, DOI 10.1097/01.prs.0000260754.59310.38; Colque A, 2012, AESTHET SURG J, V32, P303, DOI 10.1177/1090820X12436601; Domino KB, 1999, ANESTH ANALG, V88, P1370, DOI 10.1097/00000539-199906000-00032; Tijerina VNE, 2010, AESTHET PLAST SURG, V34, P16, DOI 10.1007/s00266-009-9402-4; Glasberg SB, 2005, PLAST RECONSTR SURG, V116, P341, DOI 10.1097/01.PRS.0000173540.81212.98; Goes JCS, 2003, AESTHET PLAST SURG, V27, P178, DOI 10.1007/s00266-003-0004-2; Graf RM, 2003, PLAST RECONSTR SURG, V111, P904, DOI 10.1097/01.PRS.0000041601.59651.15; HANDEL N, 1995, PLAST RECONSTR SURG, V96, P1521, DOI 10.1097/00006534-199512000-00003; Hanemann MS, 2010, ANN PLAS SURG, V64, P537, DOI 10.1097/SAP.0b013e3181cdabf8; Hasen KV, 2003, PLAST RECONSTR SURG, V112, P1683, DOI 10.1097/01.PRS.0000086363.34535.A4; Hoka S, 1998, ANESTHESIOLOGY, V89, P1495, DOI 10.1097/00000542-199812000-00028; Hunstad JP, 2010, AESTHET PLAST SURG, V34, P365, DOI 10.1007/s00266-009-9466-1; Iverson RE, 1999, PLAST RECONSTR SURG, V104, P1559, DOI 10.1097/00006534-199910000-00055; KAPUR PA, 1991, ANESTH ANALG, V73, P243; KENNY GNC, 1994, ANAESTHESIA, V49, P6, DOI 10.1111/j.1365-2044.1994.tb03576.x; Keyes GR, 2008, PLAST RECONSTR SURG, V122, P245, DOI 10.1097/PRS.0b013e31817747fd; Keyes GR, 2012, AESTHET SURG J, V32, P308, DOI 10.1177/1090820X12436602; Keyes GR, 2004, PLAST RECONSTR SURG, V113, P1760, DOI 10.1097/01.PRS.0000124743.75839.11; Kryger ZB, 2004, PLAST RECONSTR SURG, V113, P1807, DOI 10.1097/01.PRS.0000117303.63028.7D; Lee JH, 2012, AESTHET PLAST SURG, V36, P115, DOI 10.1007/s00266-011-9761-5; Marcus JR, 1999, PLAST RECONSTR SURG, V104, P1338, DOI 10.1097/00006534-199910000-00015; Marcus JR, 2002, PLAST RECONSTR SURG, V109, P2487, DOI 10.1097/00006534-200206000-00049; MERIDY HW, 1982, ANESTH ANALG, V61, P921; Mustoe TA, 2010, PLAST RECONSTR SURG, V126, p165E, DOI 10.1097/PRS.0b013e3181ebe5e9; MUZI M, 1992, ANESTH ANALG, V74, P877; PRATT JM, 1985, CLIN PLAST SURG, V12, P73; Reinisch JF, 2001, PLAST RECONSTR SURG, V107, P1570, DOI 10.1097/00006534-200105000-00044; Rezai Allen, 2004, Aesthet Surg J, V24, P277, DOI 10.1016/j.asj.2004.02.006; Shapiro FE, 2008, CURR OPIN ANESTHESIO, V21, P704, DOI 10.1097/ACO.0b013e328318694f; Shestak KC, 2004, PLAST RECONSTR SURG, V113, P1818, DOI 10.1097/01.PRS.0000118267.35908.01; Siclovan HR, 2008, AESTHET PLAST SURG, V32, P426, DOI 10.1007/s00266-008-9141-y; Tebbetts JB, 2002, PLAST RECONSTR SURG, V109, P398, DOI 10.1097/00006534-200201000-00072; Tebbetts JB, 2002, PLAST RECONSTR SURG, V109, P273, DOI 10.1097/00006534-200201000-00044; Tebbetts JB, 2002, PLAST RECONSTR SURG, V109, P293, DOI 10.1097/00006534-200201000-00046; Tebbetts JB, 2006, PLAST RECONSTR SUR S, V118, p128S; Tebbetts JB, 2006, PLAST RECONSTR SURG, V118, p115S, DOI 10.1097/00006534-200612001-00016; White PF, 2003, PLAST RECONSTR SURG, V112, P1690, DOI 10.1097/01.PRS.0000086364.71178.AC	44	6	6	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0032-1052	1529-4242		PLAST RECONSTR SURG	Plast. Reconstr. Surg.	MAY	2013	131	5					1169	1178		10.1097/PRS.0b013e31828e2196			10	Surgery	Surgery	138WG	WOS:000318540700068	23629098				2020-06-30	J	Keating, SCJ; Kerr, CL; Valverde, A; Johnson, RJ; McDonell, WN				Keating, Stephanie C. J.; Kerr, Carolyn L.; Valverde, Alexander; Johnson, Ron J.; McDonell, Wayne N.			Cardiopulmonary effects of intravenous fentanyl infusion in dogs during isoflurane anesthesia and with concurrent acepromazine or dexmedetomidine administration during anesthetic recovery	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article							MINIMUM ALVEOLAR CONCENTRATION; PAIN MANAGEMENT; CONSCIOUS DOGS; CONSTANT RATE; URINE OUTPUT; MEDETOMIDINE; COMBINATION; MORPHINE; BUPRENORPHINE; BUTORPHANOL	Objective-To evaluate the cardiopulmonary effects of IV fentanyl administration in dogs during isoflurane anesthesia and during anesthetic recovery with or without dexmedetomidine or acepromazine. Animals-7 sexually intact male purpose-bred hound-type dogs aged 11 to 12 months. Procedures-Dogs received a loading dose of fentanyl (5 mu g/kg, IV) followed by an IV infusion (5 mu g/kg/h) for 120 minutes while anesthetized with isoflurane and for an additional 60 minutes after anesthesia was discontinued. Dogs were randomly assigned in a crossover design to receive dexmedetomidine (2.5 mu g/kg), acepromazine (0.05 mg/kg), or saline (0.9% NaCl) solution (1 mL).IV after anesthesia ceased. Cardiopulmonary data were obtained during anesthesia and for 90 minutes after treatment administration during anesthetic recovery. Results-Concurrent administration of fentanyl and isoflurane resulted in significant decreases in mean arterial blood pressure, heart rate, and cardiac index and a significant increase in Paco(2). All but Paco(2) returned to pretreatment values before isoflurane anesthesia was discontinued. During recovery, dexmedetomidine administration resulted in significant decreases in heart rate, cardiac index, and mixed venous oxygen tension and a significant increase in arterial blood pressure, compared with values for saline solution and acepromazine treatments. Acepromazine administration resulted in significantly lower blood pressure and higher cardiac index and Po-2 in mixed venous blood than did the other treatments. Dexmedetomidine treatment resulted in significantly lower values for Pao(2) and arterial pH and higher Paco(2) values than both other treatments. Conclusions and Clinical Relevance-Fentanyl resulted in transient pronounced cardiorespiratory effects when administered during isoflurane anesthesia. During anesthetic recovery, when administered concurrently with an IV fentanyl infusion, dexmedetomidine resulted in evidence of cardiopulmonary compromise and acepromazine transiently improved cardiopulmonary performance. (Am J Vet Res 2013;74:672-682)	[Keating, Stephanie C. J.; Kerr, Carolyn L.; Valverde, Alexander; McDonell, Wayne N.] Univ Guelph, Ontario Vet Coll, Dept Clin Studies, Guelph, ON N1G 2W1, Canada; [Johnson, Ron J.] Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada	Keating, SCJ (reprint author), Univ Guelph, Ontario Vet Coll, Dept Clin Studies, Guelph, ON N1G 2W1, Canada.	skeating@uoguelph.ca		Valverde, Alexander/0000-0002-8356-0104	Ontario Veterinary College Pet Trust Fund	Supported by the Ontario Veterinary College Pet Trust Fund.	Aguado D, 2011, VET J, V189, P63, DOI 10.1016/j.tvjl.2010.05.029; Anderson MK, 2008, VET ANAESTH ANALG, V35, P528, DOI 10.1111/j.1467-2995.2008.00413.x; ARNDT JO, 1984, ANESTHESIOLOGY, V61, P355, DOI 10.1097/00000542-198410000-00001; BEDNARSKI R. M., 2007, LUMB JONES VET ANEST, P705; BOYD CJ, 1991, CAN J VET RES, V55, P107; Brodbelt DC, 2008, VET ANAESTH ANALG, V35, P365, DOI 10.1111/j.1467-2995.2008.00397.x; Bufalari A, 2007, VET RES COMMUN, V31, P277, DOI 10.1007/s11259-007-0046-z; Carregaro AB, 2006, AM J VET RES, V67, P1675, DOI 10.2460/ajvr.67.10.1675; Clarke K. W., 1990, Journal of the Association of Veterinary Anaesthetists of Great Britain and Ireland, V17, P4; CORNICK JL, 1992, J AM VET MED ASSOC, V200, P1952; Coulter D B, 1981, Cornell Vet, V71, P75; Dyson DH, 1998, J AM ANIM HOSP ASSOC, V34, P325, DOI 10.5326/15473317-34-4-325; Enouri SS, 2008, AM J VET RES, V69, P586, DOI 10.2460/ajvr.69.5.586; FEIHL F, 1994, AM J RESP CRIT CARE, V150, P1722, DOI 10.1164/ajrccm.150.6.7952641; GAUMANN DM, 1988, NEUROSCI LETT, V91, P30, DOI 10.1016/0304-3940(88)90244-3; Grimm KA, 2005, AM J VET RES, V66, P1222, DOI 10.2460/ajvr.2005.66.1222; Haskins S, 2005, COMPARATIVE MED, V55, P156; ILKIW JE, 1994, CAN J VET RES, V58, P248; Ilkiw JE, 1999, CLIN TECH SMALL AN P, V14, P27, DOI 10.1016/S1096-2867(99)80024-3; JACOBSON JD, 1994, VET SURG, V23, P299, DOI 10.1111/j.1532-950X.1994.tb00488.x; Ko JCH, 2000, J AM VET MED ASSOC, V216, P1578, DOI 10.2460/javma.2000.216.1578; Kuusela E, 2000, J VET PHARMACOL THER, V23, P15, DOI 10.1046/j.1365-2885.2000.00245.x; Kuusela E, 2001, AM J VET RES, V62, P1073, DOI 10.2460/ajvr.2001.62.1073; Lerche P, 2006, AM J VET RES, V67, P782, DOI 10.2460/ajvr.67.5.782; Lerche P, 2004, AM J VET RES, V65, P720, DOI 10.2460/ajvr.2004.65.720; Lipkowski AW, 2004, PURE APPL CHEM, V76, P941, DOI 10.1351/pac200476050941; MACKENZI.AI, 1969, BMJ-BRIT MED J, V3, P619, DOI 10.1136/bmj.3.5671.619; MAZZE RI, 1974, ANESTHESIOLOGY, V40, P536, DOI 10.1097/00000542-197406000-00006; Monteiro ER, 2009, VET ANAESTH ANALG, V36, P25, DOI 10.1111/j.1467-2995.2008.00424.x; MUIR WW, 1978, AM J VET RES, V39, P1632; Mutoh T, 1997, AM J VET RES, V58, P885; Papich M. G, 2009, VET PHARM THERAPEUTI, P301; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P917, DOI 10.1016/S0195-5616(08)70015-9; POPOVIC NA, 1972, AM J VET RES, V33, P1819; Pypendop BH, 1998, VET SURG, V27, P612, DOI 10.1111/j.1532-950X.1998.tb00539.x; Raekallio MR, 2009, VET ANAESTH ANALG, V36, P158, DOI 10.1111/j.1467-2995.2008.00444.x; RIMOY GH, 1994, EUR J CLIN PHARMACOL, V46, P203; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; SALMENPERA MT, 1994, ANESTHESIOLOGY, V80, P837, DOI 10.1097/00000542-199404000-00017; Sinclair MD, 2003, VET ANAESTH ANALG, V30, P211, DOI 10.1046/j.1467-2995.2003.00122.x; Sinclair MD, 2003, CAN VET J, V44, P885; Steagall PVM, 2006, JAVMA-J AM VET MED A, V229, P522, DOI 10.2460/javma.229.4.522; STEFFEY EP, 1977, AM J VET RES, V38, P1833; STEPIEN RL, 1995, AM J VET RES, V56, P78; Szoke MO, 1998, AM J VET RES, V59, P1287	45	12	12	0	15	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0002-9645			AM J VET RES	Am. J. Vet. Res.	MAY	2013	74	5					672	682		10.2460/ajvr.74.5.672			11	Veterinary Sciences	Veterinary Sciences	134IL	WOS:000318203500002	23627379				2020-06-30	J	Fant, F; Tina, E; Sandblom, D; Andersson, SO; Magnuson, A; Hultgren-Hornkvist, E; Axelsson, K; Gupta, A				Fant, F.; Tina, E.; Sandblom, D.; Andersson, S. -O.; Magnuson, A.; Hultgren-Hornkvist, E.; Axelsson, K.; Gupta, A.			Thoracic epidural analgesia inhibits the neuro-hormonal but not the acute inflammatory stress response after radical retropubic prostatectomy	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthesia technique; epidural, physiological; surgery: stress response; urological	UPPER ABDOMINAL-SURGERY; SURGICAL STRESS; INDUCED IMMUNOSUPPRESSION; PERITONEAL INFLAMMATION; ANESTHESIA; PATIENT; TRIAL; CYTOKINES; RECOVERY; TRAUMA	Background. Epidural anaesthesia and analgesia has been shown to suppress the neurohormonal stress response, but its role in the inflammatory response is unclear. The primary aim was to assess whether the choice of analgesic technique influences these processes in patients undergoing radical retropubic prostatectomy. Methods. Twenty-six patients were randomized to Group P (systemic opioid-based analgesia) or Group E (thoracic epidural-based analgesia) perioperatively. Induction and maintenance of anaesthesia followed a standardized protocol. The following measurements were made perioperatively: plasma cortisol, glucose, insulin, C-reactive proteins, leucocyte count, plasma cytokines [interleukin (IL)-6, tumour necrosis factor (TNF)-alpha], and pokeweed mitogen-stimulated cytokines [interferon (IFN)-gamma, IL-2, IL-12p70, IL-10, IL-4, and IL-17]. Other parameters recorded were pain, morphine consumption, and perioperative complications. Results. Plasma concentration of cortisol and glucose were significantly higher in Group P compared with Group E at the end of surgery, the mean difference was 232 nmol litre(-1) [95% confidence interval (CI) 84-381] (P=0.004) and 1.6 mmol litre(-1) (95% CI 0.6-2.5) (P=0.003), respectively. No significant differences were seen in IL-6 and TNF-alpha at 24 h (P=0.953 and 0.368, respectively) and at 72 h (P=0.931 and 0.691, respectively). IL-17 was higher in Group P compared with Group E, both at 24 h (P=0.001) and 72 h (P=0.018) after operation. Pain intensity was significantly greater in Group P compared with Group E (P<0.05) up to 24 h. Conclusions. In this small prospective randomized study, thoracic epidural analgesia reduced the early postoperative stress response but not the acute inflammatory response after radical retrobupic prostatectomy, suggesting that other pathways are involved during the acute phase reaction.	[Fant, F.; Axelsson, K.; Gupta, A.] Univ Hosp, Dept Anesthesiol & Intens Care, SE-70185 Orebro, Sweden; [Tina, E.] Univ Orebro, Clin Res Ctr, Orebro, Sweden; [Sandblom, D.; Andersson, S. -O.] Univ Orebro, Dept Urol, Orebro, Sweden; [Sandblom, D.; Andersson, S. -O.] Univ Orebro, Hlth Acad, Orebro, Sweden; [Magnuson, A.] Univ Orebro, Clin Epidemiol & Biostat Unit, Orebro, Sweden; [Hultgren-Hornkvist, E.] Univ Orebro, Sch Hlth & Med Sci, Orebro Univ Hosp, Orebro, Sweden	Fant, F (reprint author), Univ Hosp, Dept Anesthesiol & Intens Care, SE-70185 Orebro, Sweden.	federica.fant@orebroll.se			Regional Research Committee; Orebro County Council, Orebro, Sweden; Nyckelfond, Orebro Sweden	This study was funded by the Regional Research Committee, Orebro County Council, Orebro, Sweden, and Nyckelfond, Orebro Sweden.	Ahlers O, 2008, BRIT J ANAESTH, V101, P781, DOI 10.1093/bja/aen287; Angele MK, 2002, CRIT CARE, V6, P298, DOI 10.1186/cc1514; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Beilin B, 2003, ANESTH ANALG, V97, P822, DOI 10.1213/01.ANE.0000078586.82810.3B; Carvalho B, 2008, J PAIN, V9, P650, DOI 10.1016/j.jpain.2008.02.004; Chalhoub V, 2011, ACTA ANAESTH SCAND, V55, P549, DOI 10.1111/j.1399-6576.2011.02419.x; CHAMBRIER C, 1992, ANN FR ANESTH, V11, P636, DOI 10.1016/S0750-7658(05)80783-X; Fant F, 2011, BRIT J ANAESTH, V107, P782, DOI 10.1093/bja/aer296; Gupta A, 2006, ANESTHESIOLOGY, V105, P784, DOI 10.1097/00000542-200610000-00025; Hong JY, 2011, ACTA ANAESTH SCAND, V55, P282, DOI 10.1111/j.1399-6576.2010.02360.x; Kahokehr A, 2011, ANN SURG, V254, P28, DOI 10.1097/SLA.0b013e318221f0cf; Kawasaki T, 2007, BRIT J ANAESTH, V98, P196, DOI 10.1093/bja/ael334; Kim TK, 2010, KOREAN J ANESTHESIOL, V59, P265, DOI 10.4097/kjae.2010.59.4.265; Konsman JP, 2002, TRENDS NEUROSCI, V25, P154, DOI 10.1016/S0166-2236(00)02088-9; Menger MD, 2004, LANGENBECK ARCH SURG, V389, P475, DOI 10.1007/s00423-004-0472-0; Moselli NM, 2011, ANN SURG ONCOL, V18, P2722, DOI 10.1245/s10434-011-1700-9; Norman JG, 1997, AM SURGEON, V63, P75; Paddison JS, 2008, PSYCHONEUROENDOCRINO, V33, P446, DOI 10.1016/j.psyneuen.2007.12.011; ROUMEN RMH, 1993, ANN SURG, V218, P769, DOI 10.1097/00000658-199312000-00011; Sammour T, 2012, J SURG RES, V173, P278, DOI 10.1016/j.jss.2010.10.009; Sammour T, 2010, WORLD J SURG, V34, P704, DOI 10.1007/s00268-009-0382-y; Schietroma M, 2004, HEPATO-GASTROENTEROL, V51, P1595; Schneemilch CE, 2005, EUR J ANAESTH, V22, P616, DOI 10.1017/S0265021505001031; Schneemilch Christine E, 2004, Best Pract Res Clin Anaesthesiol, V18, P493; Sheeran P, 1997, BRIT J ANAESTH, V78, P201; TONNESEN E, 1984, ACTA ANAESTH SCAND, V28, P654, DOI 10.1111/j.1399-6576.1984.tb02140.x; Tylman M, 2011, MINERVA ANESTESIOL, V77, P275; Volk T, 2003, CYTOKINE, V24, P237, DOI 10.1016/S1043-4666(03)00090-5; WALSH PC, 1980, UROL CLIN N AM, V7, P583; Wright CE, 2005, BRAIN BEHAV IMMUN, V19, P345, DOI 10.1016/j.bbi.2004.10.003; Yokoyama M, 2005, ANESTH ANALG, V101, P1521, DOI 10.1213/01.ANE.0000184287.15086.1E; Zargar-Shoshtari K, 2009, BRIT J SURG, V96, P1253, DOI 10.1002/bjs.6744; Zargar-Shoshtari K, 2009, WORLD J SURG, V33, P738, DOI 10.1007/s00268-008-9906-0	33	26	27	0	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	MAY	2013	110	5					747	757		10.1093/bja/aes491			11	Anesthesiology	Anesthesiology	133BH	WOS:000318111900011	23295713	Bronze			2020-06-30	J	Roxburgh, A; Burns, L; Drummer, OH; Pilgrim, J; Farrell, M; Degenhardt, L				Roxburgh, Amanda; Burns, Lucy; Drummer, Olaf H.; Pilgrim, Jennifer; Farrell, Michael; Degenhardt, Louisa			Trends in fentanyl prescriptions and fentanyl-related mortality in Australia	DRUG AND ALCOHOL REVIEW			English	Article						fentanyl; IDU; overdose; dependence; pharmaceutical opioid		Introduction and Aims The study aims to quantify trends in fentanyl prescribing and fentanyl mortality in Australia within the context of concern among health professionals concerning increasing accessibility of fentanyl, and the harms that may arise as a result. Design and Methods This paper presents data on prescribing patterns of fentanyl by 10 year age group adjusted by population rate, detailed analyses of fentanyl-related deaths from the National Coronial Information System and deaths adjusted for prescribing levels within Australia. Results Fentany prescriptions have increased and are most prevalent among Australians aged over 80 years. One hundred and thirty-six fentanyl-related deaths were recorded during 20002011; 54% of decedents had a history of injecting drug use and, among this group, 95% had injected fentanyl at the time of death; 62% of deaths recorded misuse (most notably injection) of fentanyl; 50% recorded a history of drug dependence and 40% a mental health problem; 37% recorded a history of chronic pain; and 36% recorded fentanyl as being prescribed at the time of death. Deaths were primarily among Australians under 47 years of age. Discussion and Conclusions There have been significant increases in fentanyl prescribing in Australia. It is unclear what proportion of this increase represents legitimate treatment of pain. Fentanyl deaths have also increased, although mortality is currently low in Australia. A large proportion of the deaths involved the injection of diverted fentanyl, highlighting the need for messages regarding safer injecting practices targeting people who inject drugs, and strategies to minimise the risks of diversion. [Roxburgh A, Burns L, Drummer OH, Pilgrim J, Farrell M, Degenhardt L. Trends in fentanyl prescriptions and fentanyl-related mortality in Australia. Drug Alcohol Rev 2013;32:269-275]	[Roxburgh, Amanda; Burns, Lucy; Farrell, Michael; Degenhardt, Louisa] Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia; [Degenhardt, Louisa] Univ Melbourne, Sch Populat Hlth, Ctr Hlth Policy Programs & Econ, Melbourne, Vic, Australia; [Drummer, Olaf H.] Victorian Inst Forens Med, Melbourne, Vic, Australia; [Drummer, Olaf H.; Pilgrim, Jennifer] Monash Univ, Dept Forens Med, Melbourne, Vic 3004, Australia	Roxburgh, A (reprint author), Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia.	a.roxburgh@unsw.edu.au	Drummer, Olaf/H-7094-2014; Burns, Lucy/M-7882-2013; Farrell, Michael P/A-4769-2012; Roxburgh, Amanda/T-1736-2018; Degenhardt, Louisa J/D-4515-2012	Drummer, Olaf/0000-0001-8953-0312; Burns, Lucy/0000-0003-3178-8091; Farrell, Michael P/0000-0001-7008-8130; Roxburgh, Amanda/0000-0001-8609-0075; Degenhardt, Louisa J/0000-0002-8513-2218; Schumann, Jennifer/0000-0002-8870-6272			Anex, 2012, HARM SPEC FOR FENT I; Australian Govermnent Department of Health and Ageing, 2011, AUSTR STAT MED 2009; Boddiger D, 2006, LANCET, V368, P569, DOI 10.1016/S0140-6736(06)69181-2; Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; Darke S, 2006, ADDICTION, V101, P1299, DOI 10.1111/j.1360-0443.2006.01495.x; European Monitoring Centre for Drugs and Drug Addiction, 2012, FENT EUR EMCDDA TREN; Fodale V, 2008, EXPERT OPIN DRUG SAF, V7, P213, DOI [10.1517/14740338.7.3.213, 10.1517/14740338.7.3.213 ]; GUTSTEIN HB, 2006, GOODMAN GILMANS PHAR, P547; IBM Corp, 2011, IBM SPSS STAT VERS 2; International Narcotics Control Board, 2011, NARC DRUGS EST WORLD; National Drug and Alcohol Research Centre, 2012, REV OP PRESCR TASM B; National Prescribing Service, 2012, FENT PATCH DUR CHRON; Roxburgh A, 2011, MED J AUSTRALIA, V195, P280, DOI 10.5694/mja10.11450; Royal Australasian College of Physicians, 2009, PRESCR OP POL IMPR M; STRANG J, 2010, BMJ-BRIT MED J, V341, P4851	15	48	48	1	22	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-5236			DRUG ALCOHOL REV	Drug Alcohol Rev.	MAY	2013	32	3					269	275		10.1111/dar.12033			7	Substance Abuse	Substance Abuse	131FL	WOS:000317978000007	23442164				2020-06-30	J	Reilly, S; Seddighi, R; Egger, CM; Rohrbach, BW; Doherty, TJ; Qu, W; Johnson, JR				Reilly, Sabrina; Seddighi, Reza; Egger, Christine M.; Rohrbach, Barton W.; Doherty, Thomas J.; Qu, Wen; Johnson, James R.			The effect of fentanyl on the end-tidal sevoflurane concentration needed to prevent motor movement in dogs	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						anesthesia; dogs; fentanyl; minimum alveolar concentration; sevoflurane	MINIMUM ALVEOLAR CONCENTRATION; ACUTE TOLERANCE; ISOFLURANE; REMIFENTANIL; COMBINATION; ANESTHESIA; REDUCTION	Objective The objectives of this study were to determine the effects of fentanyl on the end-tidal concentration of sevoflurane needed to prevent motor movement (MACNM) in response to noxious stimulation, and to evaluate if acute tolerance develops. Study design Randomized cross-over experimental study. Animals Six healthy, adult (23years old), intact male, mixed-breed dogs weighing 16.2 +/- 1.1kg. Methods Six dogs were randomly assigned to receive one of three separate treatments over a 3 week period. After baseline sevoflurane MACNM (MACNM-B) determination, fentanyl treatments (T) were administered as a loading dose (Ld) and constant rate infusion (CRI) as follows: T1-Ld of 7.5gkg1 and CRI at 3gkg1hour1; T2-Ld of 15gkg1 and CRI at 6.0gkg 1hour1; T3-Ld of 30gkg1 and CRI at 12gkg1hour1. The MACNM was defined as the minimum end-tidal sevoflurane concentration preventing motor movement. The first post-treatment MACNM (MACNM-I) determination was initiated 90minutes after the start of the CRI, and a second MACNM (MACNM-II) determination was initiated 3hours after MACNM-I was established. Results The overall least square mean MACNM-B for all groups was 2.66%. All treatments decreased (p<0.05) MACNM, and the decrease from baseline was 22%, 35% and 41% for T1, T2 and T3, respectively. Percentage change in T1 differed (p<0.05) from T2 and T3; however, T2 did not differ from T3. MACNM-I was not significantly different from MACNM-II within treatments. Conclusions and clinical relevance Fentanyl doses in the range of 312gkg1hour1 significantly decreased the sevoflurane MACNM. Clinically significant tolerance to fentanyl did not occur under the study conditions.	[Reilly, Sabrina; Egger, Christine M.] Univ Tennessee, Coll Vet Med, Dept Small Anim Clin Sci, Knoxville, TN 37996 USA; [Seddighi, Reza; Doherty, Thomas J.] Univ Tennessee, Coll Vet Med, Dept Large Anim Clin Sci, Knoxville, TN 37996 USA; [Rohrbach, Barton W.] Univ Tennessee, Coll Vet Med, Dept Comparat Med, Knoxville, TN 37996 USA; [Qu, Wen; Johnson, James R.] Univ Tennessee, Coll Pharm, Dept Pharmaceut Sci, Memphis, TN USA	Seddighi, R (reprint author), Univ Tennessee, Coll Vet Med, Dept Large Anim Clin Sci, POB 1071, Knoxville, TN 37996 USA.	mrsed@utk.edu		Seddighi, Reza/0000-0003-3537-4232; Doherty, Thomas J/0000-0002-5617-1138			Antognini JF, 2002, BRIT J ANAESTH, V89, P156, DOI 10.1093/bja/aef156; ASKITOPOULOU H, 1985, ANESTHESIOLOGY, V63, P255, DOI 10.1097/00000542-198509000-00003; Docquier MA, 2003, ANESTH ANALG, V97, P1033, DOI 10.1213/01.ANE.0000078587.51622.D0; de Segura IAG, 2009, ANESTHESIOLOGY, V110, P1133, DOI 10.1097/ALN.0b013e31819dadaf; HALL RI, 1988, ANESTHESIOLOGY, V68, P862, DOI 10.1097/00000542-198806000-00005; HALL RI, 1987, ANESTHESIOLOGY, V67, P518, DOI 10.1097/00000542-198710000-00013; Hayashida M, 2003, ANESTH ANALG, V97, P1347, DOI 10.1213/01.ANE.0000083370.80416.38; Hellyer PW, 2001, AM J VET RES, V62, P555, DOI 10.2460/ajvr.2001.62.555; Hug C.C., 1972, CHEM BIOL ASPECTS DR, P307; Ilkiw JE, 1993, CAN J VET RES, V57, P248; Martinez E, 2008, 14 INT VET EM CRIT C, P851; Mitra S, 2004, ANESTHESIOLOGY, V101, P212, DOI 10.1097/00000542-200407000-00032; MURPHY MR, 1982, ANESTHESIOLOGY, V57, P485, DOI 10.1097/00000542-198212000-00009; Qu W, 2007, AM ASS PHARM SCI ANN; Rang HP, 2001, PHARMACOLOGY, P572; Seddighi Reza, 2011, Vet Anaesth Analg, V38, P195, DOI 10.1111/j.1467-2995.2011.00615.x; Steagall PVM, 2006, JAVMA-J AM VET MED A, V229, P522, DOI 10.2460/javma.229.4.522; Ueyama Y, 2009, AM J VET RES, V70, P1459, DOI 10.2460/ajvr.70.12.1459; Valverde A, 2003, AM J VET RES, V64, P957, DOI 10.2460/ajvr.2003.64.957; Walker EA, 2001, PSYCHOPHARMACOLOGY, V154, P131, DOI 10.1007/s002130000620; Wilson J, 2008, 14 INT VET EM CRIT C, P847	21	15	15	0	14	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1467-2987			VET ANAESTH ANALG	Vet. Anaesth. Analg.	MAY	2013	40	3					290	296		10.1111/vaa.12013			7	Veterinary Sciences	Veterinary Sciences	132AF	WOS:000318039400009	23368842				2020-06-30	J	Palamalai, V; Olson, KN; Kloss, J; Middleton, O; Mills, K; Strobl, AQ; Thomas, LC; Apple, FS				Palamalai, Vikram; Olson, Kalen N.; Kloss, Julie; Middleton, Owen; Mills, Kelly; Strobl, A. Quinn; Thomas, Lindsey C.; Apple, Fred S.			Superiority of postmortem liver fentanyl concentrations over peripheral blood influenced by postmortem interval for determination of fentanyl toxicity	CLINICAL BIOCHEMISTRY			English	Article						Post-mortem redistribution; Liver; Blood; Fentanyl; Toxicity; Medical examiners	TRICYCLIC ANTIDEPRESSANT CONCENTRATIONS; DRUG REDISTRIBUTION; DEATHS; CIRCUMSTANCES; TOXICOLOGY	Objective: The current study was undertaken to determine the relationship between postmortem (PM) peripheral blood (PB) and liver fentanyl concentrations and the role of measuring liver fentanyl concentrations in cause of death investigations in medical examiner cases in which fentanyl was identified. Design and methods: FB and liver tissue were routinely collected at autopsy from 4 Minnesota medical examiners' offices in 2010-2011. Samples were analyzed by gas chromatography-mass spectrometry (GC-MS). Results: PB fentanyl ranged from <2-15 mu g/L in non-drug related deaths (n=5), <2-22 mu g/L from mixed drug toxicity (n=26) and 3.7-56 mu g/L from fentanyl toxicity (n=33). Liver fentanyl ranged from 11 to 104 mu g/kg, 6 to 235 mu g/kg, and 18 to 365 mu g/kg, respectively. PB and liver fentanyl showed a modest correlation (r=0.67). PM interval to the liver/blood ratio showed a decreasing ratio over increasing PM interval in cases from fentanyl and mixed drug toxicity. Liver fentanyl concentrations best define therapeutic use at <23 mu g/kg and fatal toxicity at >56 mu g/kg, without substantial overlap as found in blood fentanyl concentrations. Conclusion: Discriminatory liver fentanyl concentrations suggestive of therapeutic or toxic drug levels may better assist cause of death determination in cases of suspected fentanyl toxicity than postmortem PB concentrations. Peripheral blood fentanyl concentrations appear to undergo postmortem redistribution, associated with an increasing PM interval. (C) 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.	[Palamalai, Vikram; Apple, Fred S.] Univ Minnesota, Minneapolis, MN USA; [Olson, Kalen N.] HealthPartners, Minneapolis, MN USA; [Kloss, Julie; Apple, Fred S.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA	Apple, FS (reprint author), Hennepin Cty Med Ctr, Clin Labs P4, 701 Pk Ave, Minneapolis, MN 55415 USA.	apple004@umn.edu					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Andresen H, 2012, J ANAL TOXICOL, V36, P182, DOI 10.1093/jat/bks005; APPLE FS, 1988, AM J CLIN PATHOL, V89, P794, DOI 10.1093/ajcp/89.6.794; APPLE FS, 1989, J ANAL TOXICOL, V13, P197, DOI 10.1093/jat/13.4.197; BONNICHSEN R, 1970, Z RECHTSMED, V67, P19; Gill JR, 2012, J MED TOXICOL; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Hilberg T, 1999, J FORENSIC SCI, V44, P3; Hilberg T, 1999, J FORENSIC SCI, V44, P956; Krinsky CS, 2011, AM J FOREN MED PATH, V32, P347, DOI 10.1097/PAF.0b013e31822ad269; Luckenbill K, 2008, J ANAL TOXICOL, V32, P639, DOI 10.1093/jat/32.8.639; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Maruyama Y, 1969, Keio J Med, V18, P59; Moriya F, 1999, J FORENSIC SCI, V44, P10; Olson KN, 2010, AM J CLIN PATHOL, V133, P447, DOI 10.1309/AJCP4X5VHFSOERFT; PROUTY RW, 1990, J FORENSIC SCI, V35, P243; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; Yaksh TL, 2011, ANALGESIA PAIN MANAG; Yarema MC, 2005, CLIN TOXICOL, V43, P235, DOI 10.1081/CLT-200058950	19	14	14	1	18	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0009-9120	1873-2933		CLIN BIOCHEM	Clin. Biochem.	MAY	2013	46	7-8					598	602		10.1016/j.clinbiochem.2013.02.001			5	Medical Laboratory Technology	Medical Laboratory Technology	129XU	WOS:000317878100007	23485343				2020-06-30	J	Moustafa, MA				Moustafa, Moustafa A.			Nebulized lidocaine alone or combined with fentanyl as a premedication to general anesthesia in spontaneously breathing pediatric patients undergoing rigid bronchoscopy	PEDIATRIC ANESTHESIA			English	Article						nebulized lidocaine; fentanyl; pediatric; bronchoscopy	MORPHINE ANALGESIA; OPIOID RECEPTORS; PAIN	Introduction Pediatric bronchoscopy is an intensely stimulating procedure that requires a deep level of anesthesia to prevent hemodynamic overstimulation and straining. Topical anesthesia of the airway may be a beneficial component of the anesthetic technique to achieve adequate depth without residual sedation. Experimental evidence suggests that in addition to its central effects, locally applied opioids elicit potent analgesic effects. Methods Forty-five patients aged 16years scheduled for rigid bronchoscopy for foreign body removal were selected and subjected preoperatively to a nebulizer setting according to its components patients were divided into three groups. Group A: Nebulized solution contains 4mg center dot kg1 lidocaine 1%. Group B: Nebulized solution contains 4mg center dot kg1 lidocaine 1% plus 2g center dot kg1 fentanyl. Group C: Nebulized solution contains 0.9% normal saline. Anesthesia was induced with 8% sevoflurane in 100% oxygen and maintained with continuous infusion of propofol 200g center dot kg1. Increments of 500g center dot kg1 propofol were given to the patient in case of straining or coughing. Patients were followed for the hemodynamics, the intraoperative difficulties, postoperative sedation score, time to full wakefulness and the postoperative complications. Results The hemodynamic parameters were much more stable in the fentanyl group relative to the other two groups. Also, the incidence of intraoperative difficulties was less significantly evident among patients in the fentanyl group (As regards cough P1=0.003, P2=0.0001, As regards the need to manual ventilation P1=0.037, P2=0.001, As regards Propofol increments P1=0.001, P2=0.001 where P1 refers to the fentanyl group relative to the lidocaine group, and P2 refers to fentanyl group relative to the placebo group). The postoperative sedation score was significantly higher, and the time to full wakefulness was significantly prolonged among patients in the fentanyl group relative to the other groups (P=0.0001). Conclusion It is concluded that preoperative nebulized fentanyl reduces the hemodynamic response to bronchoscopy and decreases the intraoperative coughing in response to surgical manipulation without significant side effects except prolonged time to full wakefulness of patients.	Univ Alexandria, Fac Med, Alexandria, Egypt	Moustafa, MA (reprint author), Univ Alexandria, Fac Med, Alnasr St Albroug Bldg,Bldg 5, Alexandria, Egypt.	m.3abdelaziz@hotmail.com	Moustafa, Moustafa/H-2110-2019	Moustafa, Moustafa/0000-0001-8689-5025			Bertschy C, 1999, PROG UROL, V9, P474; Brunton L. L., 2006, GOODMAN GILMANS PHAR; Craft RM, 1995, J PHARMACOL EXP THER, V275, P1535; CRAWFORD M, 1993, BRIT J ANAESTH, V70, P419, DOI 10.1093/bja/70.4.419; Endres-Becker J, 2007, MOL PHARMACOL, V71, P12, DOI 10.1124/mol.106.026740; Farrell PT, 2004, PEDIATR ANESTH, V14, P84, DOI 10.1046/j.1460-9592.2003.01194.x; Fristad I, 2006, ARCH ORAL BIOL, V51, P273, DOI 10.1016/j.archoralbio.2005.08.007; Jongkamonwiwat N, 2003, HEARING RES, V181, P85, DOI 10.1016/S0378-5955(03)00175-8; LAWRENCE AJ, 1992, EUR J CLIN PHARMACOL, V43, P351, DOI 10.1007/BF02220608; Likar R, 1997, ANESTH ANALG, V84, P1313, DOI 10.1097/00000539-199706000-00025; Likar R, 1998, PAIN, V76, P145, DOI 10.1016/S0304-3959(98)00036-0; Matot I, 2000, ANESTH ANALG, V91, P828, DOI 10.1097/00000539-200010000-00011; Miner JR, 2007, ACAD EMERG MED, V14, P895, DOI 10.1197/j.aem.2007.06.036; Pinzoni F, 2007, INT J PEDIATR OTORHI, V71, P1897, DOI 10.1016/j.ijporl.2007.09.002; Puehler W, 2006, NEUROSCIENCE, V141, P989, DOI 10.1016/j.neuroscience.2006.03.078; Shaffer TH, 2004, PEDIATR ANESTH, V14, P3, DOI 10.1046/j.1460-9592.2003.01207.x; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; STEIN C, 1995, ANN MED, V27, P219, DOI 10.3109/07853899509031962; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; Twillman RK, 1999, J PAIN SYMPTOM MANAG, V17, P288, DOI 10.1016/S0885-3924(98)00140-7; Vayne-Bossert P, 2010, J PALLIAT MED, V13, P125, DOI 10.1089/jpm.2009.0195; Zollner C, 2008, CLIN J PAIN, V24, P690, DOI 10.1097/AJP.0b013e318175929e; Zur KB, 2009, PEDIATR ANESTH, V19, P109, DOI 10.1111/j.1460-9592.2009.03006.x	23	4	5	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	MAY	2013	23	5					429	434		10.1111/pan.12081			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	127CS	WOS:000317673600009	23190026				2020-06-30	J	Aydogan, MS; Korkmaz, MF; Ozgul, U; Erdogan, MA; Yucel, A; Karaman, A; Togal, T; Durmus, M; Colak, C				Aydogan, Mustafa S.; Korkmaz, Mehmet F.; Ozgul, Ulku; Erdogan, Mehmet A.; Yucel, Aytac; Karaman, Abdurrahman; Togal, Turkan; Durmus, Mahmut; Colak, Cemil			Pain, fentanyl consumption, and delirium in adolescents after scoliosis surgery: dexmedetomidine vs midazolam	PEDIATRIC ANESTHESIA			English	Article						scoliosis; sedation; adolescents; fentanyl consumption; pain; postoperative; delirium	CRITICALLY-ILL PATIENTS; MECHANICAL VENTILATION; GENERAL-ANESTHESIA; CHILDREN; SEVOFLURANE; SEDATION; INFUSIONS; ANALGESIA; MORPHINE; TRIAL	Background The study aim was to compare the efficacy of dexmedetomidine vs midazolam for sedation during the early postoperative period in adolescents who underwent scoliosis surgery. Methods We performed a prospective, randomized trial in an intensive care unit (ICU) in a tertiary care center. In this study, 42 patients (American Society of Anesthesiology physical status I and II) who underwent scoliosis surgery were divided into two groups according to sedation protocols: group dexmedetomidine (DEX) (n=22) and group midazolam (MDZ) (n=20). Adolescents (1218years) requiring mechanical ventilation underwent a continuous infusion of either dexmedetomidine (group DEX; starting dose, 0.4g center dot kg1 center dot h1) or midazolam (group MDZ; starting dose, 0.1mg center dot kg1 center dot h1) with intermittent fentanyl, as needed. The efficacy of sedation was assessed using the Richmond Agitation Sedation Scale (RASS). Quality of pain relief was measured using the Numeric Visual Analog Scale (NVAS). Delirium was determined in patients in the RASS range of 2 to +1 using the Confusion Assessment Method for the ICU (CAM-ICU). Fentanyl consumption, incidence of delirium, NVAS scores, and hemodynamics were recorded postoperatively at 2, 4, 6, and 24h in the ICU. Results The NVAS pain scores and fentanyl consumption at all the evaluation time points were significantly higher in group MDZ than those in group DEX (P<0.05). Further, total fentanyl consumption in group MDZ was significantly higher than that in group DEX (P<0.05). Delirium was significantly higher in the group MDZ than that in group DEX (31.3% vs 12.5%) when analyzed as the endpoint of CAM-ICU (P<0.05). The heart rate was significantly lower in group DEX compared with that in group MDZ at all the evaluation time points (P<0.05). Conclusion Dexmedetomidine was associated with the decreased postoperative fentanyl consumption, NVAS scores, and a decreased incidence of delirium. These findings may be beneficial for managing sedation protocols in adolescents who have undergone scoliosis surgery.	[Aydogan, Mustafa S.; Ozgul, Ulku; Erdogan, Mehmet A.; Yucel, Aytac; Togal, Turkan; Durmus, Mahmut] Inonu Univ, Fac Med, Dept Anesthesiol & Reanimat, Malatya, Turkey; [Korkmaz, Mehmet F.] Inonu Univ, Fac Med, Dept Orthoped Surg, Malatya, Turkey; [Karaman, Abdurrahman] Inonu Univ, Fac Med, Dept Pediat Surg, Malatya, Turkey; [Colak, Cemil] Inonu Univ, Fac Med, Dept Biostat & Med Informat, Malatya, Turkey	Aydogan, MS (reprint author), Inonu Univ, Sch Med, Dept Anesthesiol & Reanimat, Malatya, Turkey.	dr_mustafasaid@hotmail.com	Durmus, Mahmut/AAG-3377-2019; KARAMAN, Abdurrahman/G-7825-2016; korkmaz, mehmet/W-1966-2017	korkmaz, mehmet/0000-0001-7498-6763			Arain SR, 2004, ANESTH ANALG, V98, P153, DOI 10.1213/01.ANE.0000093225.39866.75; BLOOR BC, 1992, ANESTHESIOLOGY, V77, P1134, DOI 10.1097/00000542-199212000-00014; Chrysostomou C, 2006, PEDIATR CRIT CARE ME, V7, P126, DOI 10.1097/01.PCC.0000200967.76996.07; CORREASALES C, 1992, ANESTHESIOLOGY, V76, P948, DOI 10.1097/00000542-199206000-00013; Deutsch E, 2007, PEDIATR ANESTH, V17, P438, DOI 10.1111/j.1460-9592.2006.02139.x; Ely EW, 2001, SEMIN RESP CRIT CARE, V22, P115, DOI 10.1055/s-2001-13826; Gibson PRJ, 2004, ANAESTH INTENS CARE, V32, P548, DOI 10.1177/0310057X0403200413; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; Ibacache ME, 2004, ANESTH ANALG, V98, P60, DOI 10.1213/01.ANE.0000094947.20838.8E; Ingersoll-Weng E, 2004, ANESTHESIOLOGY, V100, P738, DOI 10.1097/00000542-200403000-00040; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Ouimet S, 2007, INTENS CARE MED, V33, P66, DOI 10.1007/s00134-006-0399-8; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Ruokonen E, 2009, INTENS CARE MED, V35, P282, DOI 10.1007/s00134-008-1296-0; Sadhasivam S, 2009, J CLIN ANESTH, V21, P493, DOI 10.1016/j.jclinane.2008.12.017; Shehabi Y, 2009, ANESTHESIOLOGY, V111, P1075, DOI 10.1097/ALN.0b013e3181b6a783; Shukry M, 2005, PEDIATR ANESTH, V15, P1098, DOI 10.1111/j.1460-9592.2005.01660.x; Tobias JD, 2004, SOUTH MED J, V97, P451, DOI 10.1097/00007611-200405000-00007; Tobias JD, 2002, PAEDIATR ANAESTH, V12, P171, DOI 10.1046/j.1460-9592.2002.00805.x; Tobias JD, 2007, PEDIATR CRIT CARE ME, V8, P115, DOI 10.1097/01.PCC.0000257100.31779.41; van Gool WA, 2010, LANCET, V375, P773, DOI 10.1016/S0140-6736(09)61158-2; Wong DL, 1999, WHALEY WONGS NURSING, P1153; Wu CL, 2005, REGION ANESTH PAIN M, V30, P516, DOI 10.1016/j.rapm.2005.07.190	23	29	31	0	24	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	MAY	2013	23	5					446	452		10.1111/pan.12128			7	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	127CS	WOS:000317673600012	23448434				2020-06-30	J	Mihara, T; Goto, T				Mihara, Takahiro; Goto, Takahisa			Is ramosetron superior to ondansetron?	PEDIATRIC ANESTHESIA			English	Letter									[Mihara, Takahiro; Goto, Takahisa] Yokohama City Univ, Grad Sch Med, Dept Anesthesiol & Crit Care Med, Yokohama, Kanagawa 232, Japan	Mihara, T (reprint author), Yokohama City Univ, Grad Sch Med, Dept Anesthesiol & Crit Care Med, Yokohama, Kanagawa 232, Japan.	miharaxxxtotoro@yahoo.co.jp		Mihara, Takahiro/0000-0003-0613-511X			Park YH, 2013, PEDIATR ANESTH, V23, P360, DOI 10.1111/pan.12103; Ryu J, 2010, SURG ENDOSC, V24, P812, DOI 10.1007/s00464-009-0670-5	2	0	0	0	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	MAY	2013	23	5					464	464		10.1111/pan.12153			1	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	127CS	WOS:000317673600017	23577824				2020-06-30	J	Ross, SB; Mangar, D; Karlnoski, R; Camporesi, E; Downes, K; Luberice, K; Haines, K; Rosemurgy, AS				Ross, Sharona B.; Mangar, Devanand; Karlnoski, Rachel; Camporesi, Enrico; Downes, Katheryne; Luberice, Kenneth; Haines, Krista; Rosemurgy, Alexander S.			Laparo-endoscopic single-site (LESS) cholecystectomy with epidural vs. general anesthesia	SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES			English	Article						Epidural anesthesia; General anesthesia; Laparo-endoscopic single-site (LESS) surgery; Cholecystectomy; Single-incision laparoscopy	SPINAL-ANESTHESIA; POSTOPERATIVE PAIN; URINARY RETENTION; HERNIA REPAIR; BUPIVACAINE; RECOVERY; SURGERY	Laparo-endoscopic single-site (LESS) surgery involves a single umbilical incision, lending itself to epidural anesthesia. This prospective, randomized study was undertaken to evaluate epidural anesthesia for patients undergoing LESS cholecystectomy, to assess the feasibility, and to analyze all intraoperative and postoperative complications. The secondary objectives were to determine differences in postoperative pain and time until PACU discharge-to-home readiness between patients. With institutional review board approval, 20 patients with chronic cholecystitis, cholelithiasis, and/or biliary dyskinesia were randomized to receive spinal epidural anesthesia (n = 10) or general anesthesia (n = 10). Postoperative pain at rest was recorded in the PACU every 10 min, and at rest and walking at discharge using the visual analog scale (VAS). Operative time and time until PACU discharge-to-home readiness were recorded. Results are expressed as mean +/- A SD. Patient age, American Society of Anesthesiologists class, and body mass index were similar. There were no additional ports/incisions, conversions to "open" operations, or conversions to general anesthesia. There were no differences in operative duration. Time until postanesthesia care unit discharge-to-home ready was not significantly different. The most common postoperative adverse event was urinary retention (1 epidural and 3 general anesthesia patients). Resting postoperative VAS pain score at discharge was 4.7 +/- A 2.5 vs. 2.2 +/- A 1.6 (p = 0.02, general versus epidural anesthesia respectively); the stressed VAS pain score at discharge was 6.1 +/- A 2.3 vs. 3.1 +/- A 2.8 (p = 0.02, general versus epidural anesthesia respectively). LESS cholecystectomy with epidural anesthesia was completed with no operative or anesthetic conversions, and less postoperative pain at discharge. Epidural anesthesia appears to be a preferable alternative to general anesthesia for patients undergoing LESS cholecystectomy.	[Ross, Sharona B.; Luberice, Kenneth; Rosemurgy, Alexander S.] Florida Hosp Tampa, Southeastern Ctr Digest Disorders & Pancreat Canc, Tampa, FL 33613 USA; [Mangar, Devanand; Karlnoski, Rachel; Camporesi, Enrico] Tampa Gen Hosp, Florida Gulf To Bay Anesthesiol, Tampa, FL 33606 USA; [Downes, Katheryne] Univ S Florida, Dept Res Biostat, Tampa, FL USA; [Haines, Krista] Univ S Florida, Dept Surg, Tampa, FL 33620 USA	Ross, SB (reprint author), Florida Hosp Tampa, Southeastern Ctr Digest Disorders & Pancreat Canc, 3000 Med Pk Dr,Suite 310, Tampa, FL 33613 USA.	sharona.ross@yahoo.com		Haines, Krista/0000-0002-2056-1820			Aldrete J A, 1998, J Perianesth Nurs, V13, P148, DOI 10.1016/S1089-9472(98)80044-0; Ali Yasser, 2008, Middle East Journal of Anesthesiology, V19, P1027; Alkhamesi NA, 2007, SURG ENDOSC, V21, P602, DOI 10.1007/s00464-006-9087-6; Aono H, 1998, J CLIN ANESTH, V10, P546, DOI 10.1016/S0952-8180(98)00079-8; Beattie WS, 2001, ANESTH ANALG, V93, P853, DOI 10.1097/00000539-200110000-00010; Chiu AW, 1996, UROL INT, V57, P80, DOI 10.1159/000282884; CIOFOLO MJ, 1990, ANESTH ANALG, V70, P357; Coventry D M, 1995, J R Coll Surg Edinb, V40, P151; Curtis LA, 2001, EMERG MED CLIN N AM, V19, P591, DOI 10.1016/S0733-8627(05)70205-4; Hernandez J, 2010, J AM COLL SURGEONS, V211, P652, DOI 10.1016/j.jamcollsurg.2010.07.008; Hernandez JM, 2009, AM SURGEON, V75, P681; Hodgett SE, 2009, J GASTROINTEST SURG, V13, P188, DOI 10.1007/s11605-008-0735-0; Imbelloni LE, 2010, REV BRAS ANESTESIOL, V60, P217, DOI [10.1590/S0034-70942010000300001, 10.1016/S0034-7094(10)70030-1]; Jackson SA, 1996, ANAESTHESIA, V51, P485, DOI 10.1111/j.1365-2044.1996.tb07798.x; Jensen P, 2002, REGION ANESTH PAIN M, V27, P612, DOI 10.1053/rapm.2002.37122; Kamphuis ET, 1998, ANESTHESIOLOGY, V88, P310, DOI 10.1097/00000542-199802000-00007; Kuramochi K, 2004, SURG ENDOSC, V18, P847, DOI 10.1007/s00464-003-8227-5; Lal P, 2007, SURG ENDOSC, V21, P595, DOI 10.1007/s00464-006-9050-6; Lee JH, 2010, KOREAN J ANESTHESIOL, V59, P383, DOI 10.4097/kjae.2010.59.6.383; McAuley DF, 2009, OPIOD NARCOTIC ANALG; Nishio I, 1993, Masui, V42, P862; Ooka T, 1993, Masui, V42, P398; Otton P E, 1966, Can Anaesth Soc J, V13, P541, DOI 10.1007/BF03002223; Park YH, 2011, J SURG RES, V171, P94, DOI 10.1016/j.jss.2010.03.024; Phelps P, 2008, OBSTET GYNECOL, V111, P1155, DOI 10.1097/AOG.0b013e31816e34b4; Pursnani KG, 1998, SURG ENDOSC, V12, P1082, DOI 10.1007/s004649900785; SHIR Y, 1994, ANESTHESIOLOGY, V80, P49, DOI 10.1097/00000542-199401000-00011; Sinha R, 2009, J LAPAROENDOSC ADV S, V19, P323, DOI 10.1089/lap.2008.0393; Song DJ, 2000, ANESTH ANALG, V91, P876, DOI 10.1097/00000539-200010000-00020; Teixeira J, 2009, SURG ENDOSC, V23, P1409, DOI 10.1007/s00464-009-0411-9; Tzovaras G, 2006, SURG ENDOSC, V20, P580, DOI 10.1007/s00464-005-0405-1; Tzovaras G, 2008, AM J SURG, V196, P191, DOI 10.1016/j.amjsurg.2007.07.028; van Zundert AAJ, 2007, BRIT J ANAESTH, V98, P682, DOI 10.1093/bja/aem058; van Zundert AAJ, 2006, BRIT J ANAESTH, V96, P464, DOI 10.1093/bja/ael036; Yuksek YN, 2008, AM J SURG, V195, P533, DOI 10.1016/j.amjsurg.2007.05.043; Zhang HW, 2012, AM SURGEON, V78, P107	36	10	11	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0930-2794	1432-2218		SURG ENDOSC	Surg. Endosc.	MAY	2013	27	5					1810	1819		10.1007/s00464-012-2667-8			10	Surgery	Surgery	129PG	WOS:000317853100050	23242490				2020-06-30	J	Guterstam, J; Jayaram-Lindstrom, N; Cervenka, S; Frost, JJ; Farde, L; Halldin, C; Franck, J				Guterstam, Joar; Jayaram-Lindstrom, Nitya; Cervenka, Simon; Frost, J. James; Farde, Lars; Halldin, Christer; Franck, Johan			Effects of amphetamine on the human brain opioid system - a positron emission tomography study	INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY			English	Article						Amphetamine; brain imaging; carfentanil; positron emission tomography.	INDUCED DOPAMINE RELEASE; CEREBRAL-CORTEX; IN-VIVO; NALTREXONE; QUANTIFICATION; COCAINE; PET; RECEPTORS; STRIATUM; NEUROTRANSMISSION	Studies in rodents have shown that psychostimulant drugs such as cocaine and amphetamine cause endorphin release in the brain reward system. There is also evidence for the involvement of the opioid system in human psychostimulant dependence. The acute effects of an i.v. psychostimulant drug on the brain opioid system, however, have not yet been investigated in humans. We hypothesized that an i.v. dose of amphetamine as compared to placebo would cause an opioid release in the human brain reward system, measurable as a reduction of the binding potential of the m-opioid receptor radioligand [C-11] carfentanil. Ten healthy young men were examined using positron emission tomography (PET) and [C-11] carfentanil in three sessions : at baseline; after placebo; after an i.v. amphetamine dose of 0.3 mg/kg bodyweight. The order of amphetamine and placebo was double-blinded and randomized. PET examinations were performed with a Siemens high resolution research tomograph. Data were analysed with the simplified reference tissue model, applying manually drawn regions of interest for every subject. Using repeated measures analysis of variance, we found no significant differences in [C-11] carfentanil binding potential between amphetamine and placebo conditions in any of the investigated brain regions. In contrast to data from rodent studies and a recent study of oral amphetamine administration in humans, an i.v. dose of amphetamine does not cause any acute opioid release in healthy human subjects. The postulated role of the opioid system in mediating the effects of amphetamine needs to be further investigated in animal models of the disease as well as in patient populations.	[Guterstam, Joar; Jayaram-Lindstrom, Nitya; Cervenka, Simon; Farde, Lars; Halldin, Christer; Franck, Johan] Karolinska Univ Hosp, Dept Clin Neurosci, Karolinska Inst, SE-17176 Stockholm, Sweden; [Frost, J. James] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD USA	Guterstam, J (reprint author), Karolinska Univ Hosp, Dept Clin Neurosci, Karolinska Inst, SE-17176 Stockholm, Sweden.	joar.guterstam@ki.se	Cervenka, Simon/Q-2155-2018	Cervenka, Simon/0000-0001-8103-6977; Jayaram-Lindstrom, Nitya/0000-0002-2678-3782	Swedish Research CouncilSwedish Research Council [30207123]; Swedish Brain Fund; Stockholm County CouncilStockholm County Council	The authors thank Per Stenkrona and Andrea Varrone, as well as other members of the Karolinska PET group, for assistance in planning and execution of the study. This study was supported by the Swedish Research Council (Grant 30207123), the Swedish Brain Fund and the Stockholm County Council.	Abi-Dargham A, 2002, J NEUROSCI, V22, P3708, DOI 10.1523/jneurosci.22-09-03708.2002; Ballmaier M, 2004, AM J PSYCHIAT, V161, P99, DOI 10.1176/appi.ajp.161.1.99; BERGER B, 1991, TRENDS NEUROSCI, V14, P21, DOI 10.1016/0166-2236(91)90179-X; Berridge KC, 2009, CURR OPIN PHARMACOL, V9, P65, DOI 10.1016/j.coph.2008.12.014; Boileau I, 2006, ARCH GEN PSYCHIAT, V63, P1386, DOI 10.1001/archpsyc.63.12.1386; BUTCHER SP, 1988, J NEUROCHEM, V50, P346, DOI 10.1111/j.1471-4159.1988.tb02919.x; Colasanti A, 2012, BIOL PSYCHIAT, V72, P371, DOI 10.1016/j.biopsych.2012.01.027; Crespo-Facorro B, 2000, PSYCHIAT RES-NEUROIM, V100, P97, DOI 10.1016/S0925-4927(00)00072-X; Dlugos AM, 2011, GENES BRAIN BEHAV, V10, P199, DOI 10.1111/j.1601-183X.2010.00655.x; Drevets WC, 2001, BIOL PSYCHIAT, V49, P81, DOI 10.1016/S0006-3223(00)01038-6; Endres CJ, 2003, NUCL MED BIOL, V30, P177, DOI 10.1016/S0969-8051(02)00411-0; FROST JJ, 1985, J COMPUT ASSIST TOMO, V9, P231, DOI 10.1097/00004728-198503000-00001; Ghitza UE, 2010, BIOL PSYCHIAT, V68, P697, DOI 10.1016/j.biopsych.2010.05.003; Gorelick DA, 2005, BIOL PSYCHIAT, V57, P1573, DOI 10.1016/j.biopsych.2005.02.026; Haggkvist J, 2011, ADDICT BIOL, V16, P20, DOI 10.1111/j.1369-1600.2009.00199.x; Haggkvist J, 2009, BEHAV BRAIN RES, V197, P219, DOI 10.1016/j.bbr.2008.08.021; Hirvonen J, 2009, EUR J NUCL MED MOL I, V36, P275, DOI 10.1007/s00259-008-0935-6; Innis RB, 2007, J CEREBR BLOOD F MET, V27, P1533, DOI 10.1038/sj.jcbfm.9600493; Jayaram-Lindstrom N, 2004, J CLIN PSYCHOPHARM, V24, P665, DOI 10.1097/01.jcp.0000144893.29987.e5; Jayaram-Lindstrom N, 2008, AM J PSYCHIAT, V165, P1442, DOI 10.1176/appi.ajp.2008.08020304; Jayaram-Lindstrom N, 2008, NEUROPSYCHOPHARMACOL, V33, P1856, DOI 10.1038/sj.npp.1301572; Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0; Mawlawi O, 2001, J CEREBR BLOOD F MET, V21, P1034, DOI 10.1097/00004647-200109000-00002; MELTZER CC, 1990, J COMPUT ASSIST TOMO, V14, P561, DOI 10.1097/00004728-199007000-00011; Mitchell JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002902; Montgomery AJ, 2006, J NUCL MED, V47, P1936; Olive MF, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-23-j0002.2001; Pruessner JC, 2000, CEREB CORTEX, V10, P433, DOI 10.1093/cercor/10.4.433; Roth-Deri I, 2003, J NEUROCHEM, V84, P930, DOI 10.1046/j.1471-4159.2003.01584.x; Schain M, 2012, NEUROIMAGE, V60, P800, DOI 10.1016/j.neuroimage.2011.12.047; Scott DJ, 2008, ARCH GEN PSYCHIAT, V65, P220, DOI 10.1001/archgenpsychiatry.2007.34; Scott DJ, 2007, NEUROPSYCHOPHARMACOL, V32, P450, DOI 10.1038/sj.npp.1301238; SEITZ RJ, 1990, J CEREBR BLOOD F MET, V10, P443, DOI 10.1038/jcbfm.1990.87; Soderman AR, 2009, BRAIN RES, V1296, P63, DOI 10.1016/j.brainres.2009.08.035; Spreckelmeyer KN, 2011, BIOL PSYCHIAT, V70, P770, DOI 10.1016/j.biopsych.2011.05.035; Varrone A, 2009, EUR J NUCL MED MOL I, V36, P1639, DOI 10.1007/s00259-009-1156-3; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	37	14	14	0	20	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1461-1457	1469-5111		INT J NEUROPSYCHOPH	Int. J. Neuropsychopharmacol.	MAY	2013	16	4					763	769		10.1017/S1461145712000818			7	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	117ZJ	WOS:000316991800006	22932428	Green Published, Bronze			2020-06-30	J	Bornemann-Cimenti, H; Wejbora, M; Szilagyi, IS; Sandner-Kiesling, A				Bornemann-Cimenti, Helmar; Wejbora, Mischa; Szilagyi, Istvan S.; Sandner-Kiesling, Andreas			Fentanyl for the Treatment of Tumor-Related Breakthrough Pain	DEUTSCHES ARZTEBLATT INTERNATIONAL			English	Review							BUCCAL SOLUBLE FILM; OPIOID-TOLERANT PATIENTS; PECTIN NASAL SPRAY; CANCER PAIN; TRANSMUCOSAL FENTANYL; INTRANASAL FENTANYL; DOSE-TITRATION; OPEN-LABEL; MORPHINE-SULFATE; CITRATE	Background: Breakthrough cancer pain (BTCP) is common among cancer patients and markedly lowers their quality of life. The treatment for BTCP episodes that is recommended in current guidelines involves extended-release formulations in combination with rapid-onset and short-acting opioids. In the past few years, several new preparations of fentanyl, an opioid with a very rapid onset, have been approved for this indication. Treating physicians need to be aware of the clinical differences between the newer fentanyl preparations and immediate-release opioids. Methods: We searched the PubMed and Embase databases for randomized controlled trials (RCTs) of fentanyl for buccal, sublingual or intranasal administration in comparison with other opioids or a different fentanyl preparation for the treatment of BTCP. Results: In 6 trials of buccal, sublingual or intranasal fentanyl versus oral immediate-release opioids for the treatment of BTCP episodes, the use of fentanyl was associated with significantly less intense pain. In particular, fentanyl more often lowered the intensity of pain by at least 33% (range between studies: 13% to 57%) or by at least 50% (range between studies: 9% to 38%) within 15 minutes. Please change to "versus" if you agree.] Dose titration should begin at the lowest dose. When one fentanyl preparation is exchanged for another, the effective dose will probably differ. Conclusion: The newer fentanyl preparations extend the treatment options for BTCP. They relieve pain within a short time better than conventional, immediate-release oral opioids do and may therefore be very helpful for patients with suddenly arising, intense, and short-lasting BTCP episodes. Further comparative trials are urgently needed.	[Bornemann-Cimenti, Helmar; Wejbora, Mischa; Szilagyi, Istvan S.; Sandner-Kiesling, Andreas] Med Univ Graz, Dept Anesthesiol & Intens Care Med, A-8036 Graz, Austria	Sandner-Kiesling, A (reprint author), Med Univ Graz, Univ Klin Anasthesiol & Intensivmed, Auenbruggerpl 29, A-8036 Graz, Austria.	andreas.sandner@medunigraz.at	Bornemann-Cimenti, Helmar/C-1252-2009	Bornemann-Cimenti, Helmar/0000-0002-1201-3752	PfizerPfizer; Mundipharma; Cephalon; Grunenthal; Fresenius	Professor Sandner-Kiesling has had conference attendance fees and travel expenses reimbursed by Pfizer, Mundipharma, Cephalon, Grunenthal, and Fresenius. He has received lecture fees from Cephalon and Grunenthal.	Arzneimittelkommission der deutschen Arzteschaft, 2012, DTSCH ARZTEBL, V109, pA724; Ashburn MA, 2011, ANESTH ANALG, V112, P693, DOI 10.1213/ANE.0b013e318209d320; Burton AW, 2004, CLIN J PAIN, V20, P195, DOI 10.1097/00002508-200405000-00011; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Caraceni A, 2012, J PAIN SYMPTOM MANAG, V43, P833, DOI 10.1016/j.jpainsymman.2011.05.018; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI [10.1586/ERN.11.63, 10.1586/ern.11.63]; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Fine PG, 2010, PAIN MED, V11, P1024, DOI 10.1111/j.1526-4637.2010.00891.x; Finn AL, 2012, CLIN DRUG INVEST, V32, P63, DOI 10.2165/11594670-000000000-00000; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; Joppich R, 2001, REFRESHER COURSE 37, P277; Kleeberg UR, 2011, PAIN PRACT, V11, P185, DOI 10.1111/j.1533-2500.2010.00414.x; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Leppert Wojciech, 2010, Cancer Manag Res, V2, P225, DOI 10.2147/CMR.S7926; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; Manchikanti L, 2011, PAIN PHYSICIAN, V14, pE103; Mandel L, 2011, J AM DENT ASSOC, V142, P406, DOI 10.14219/jada.archive.2011.0195; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; Mercadante S, 2011, CRIT REV ONCOL HEMAT, V80, P460, DOI 10.1016/j.critrevonc.2010.12.002; Nunez-Olarte JM, 2011, J PAIN SYMPTOM MANAG, V42, pE6, DOI 10.1016/j.jpainsymman.2011.07.006; Passik SD, 2011, J PAIN SYMPTOM MANAG, V41, P116, DOI 10.1016/j.jpainsymman.2010.03.012; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Prommer E, 2011, PATIENT PREFER ADHER, V5, P157, DOI 10.2147/PPA.S7665; Prommer E, 2009, J PALLIAT MED, V12, P947, DOI 10.1089/jpm.2009.0051; Radbruch L, 2012, SUPPORT CARE CANCER, V20, P565, DOI 10.1007/s00520-011-1124-x; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Stanley TH, 2005, J PAIN SYMPTOM MANAG, V29, pS67, DOI 10.1016/j.jpainsymman.2005.01.009; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Tennant Forest, 2002, J Pain Palliat Care Pharmacother, V16, P37; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; Vasisht N, 2010, PAIN MED, V11, P1017, DOI 10.1111/j.1526-4637.2010.00875.x; Vasisht N, 2009, CLIN DRUG INVEST, V29, P647, DOI 10.2165/11315300-000000000-00000; Vissers D, 2010, CURR MED RES OPIN, V26, P1037, DOI 10.1185/03007991003694340; Vissers DCJ, 2011, VALUE HEALTH, V14, P274, DOI 10.1016/j.jval.2010.09.007; Watts P, 2009, EXPERT OPIN DRUG DEL, V6, P543, DOI [10.1517/17425240902939135, 10.1517/17425240902939135 ]; Zeppetela G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub2; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012; Zeppetella G, 2011, PALLIATIVE MED, V25, P516, DOI 10.1177/0269216310385601	55	7	8	0	5	DEUTSCHER AERZTE-VERLAG GMBH	COLOGNE	DIESELSTRABE 2, POSTFACH 400265, D-50859 COLOGNE, GERMANY	1866-0452			DTSCH ARZTEBL INT	Dtsch. Arztebl. Int.	APR 19	2013	110	16					271	U23		10.3238/arztebl.2013.0271			8	Medicine, General & Internal	General & Internal Medicine	136BS	WOS:000318335000001	23671467	Green Published			2020-06-30	J	Canan, U; Ornek, D; Kilci, O; Donmez, F; Gamli, M; Dikmen, B				Canan, Un; Ornek, D.; Kilci, O.; Donmez, F.; Gamli, M.; Dikmen, B.			Comparison of the maternal and neonatal effects of bupivacaine plus fentanyl and ropivacaine plus fentanyl during cesarean delivery	NIGERIAN JOURNAL OF CLINICAL PRACTICE			English	Article						Bupivacaine; cesarean; opioid; ropivacaine	EPIDURAL ROPIVACAINE; SPINAL-ANESTHESIA; PLAIN SOLUTIONS; SECTION; LEVOBUPIVACAINE; SUFENTANIL; ANALGESIA; LABOR; MG	Purpose: The aim of the present study was to compare the anesthetic efficacy, and fetal and maternal effects of 7.5 mg (1 ml) intrathecal 0.75% hyperbaric ropivacaine 25 g (0.5 ml) fentanyl versus 5 mg (l ml) intrathecal 0.5% hyperbaric bupivacaine 25 g (0.5 ml) fentanyl in elective cesarean delivery. Materials and Methods: The study included 40 ASA I-II cases scheduled for cesarean delivery that were randomized into two groups of 20 cases each. Cases in the RF group were administered 0.75% hyperbaric ropivacaine 25 g (0.5 ml) fentanyl and those in the BF group were administered 5 mg (l ml) hyperbaric bupivacaine 25 g (0.5 ml) fentanyl into the spinal space. The time until spinal anesthesia in the T4 dermatome, overall duration of analgesia, hemodynamic parameters, Apgar score of newborns at 1-5 min, fetal blood gas values (pH, PO2, PCO2, HCO3, and BE), maternal side effects, the degree of motor block, maternal need for ephedrine, objective pain scale score, and patient satisfaction were recorded in each group. Results: There were no significant differences between the groups in terms of the parameters evaluated (P > 0.05). Conclusion: In elective cesarean delivery, the combinations of bupivacaine fentanyl or ropivacaine fentanyl exhibited similar anesthetic efficacy, and fetal and maternal effects.	[Canan, Un; Ornek, D.; Kilci, O.; Donmez, F.; Gamli, M.; Dikmen, B.] Ankara Numune Training & Res Hosp, Dept Anesthesiol, Ankara, Turkey	Canan, U (reprint author), Ankara Numune Training & Res Hosp, Dept Anesthesiol, Ankara, Turkey.	cananun@yahoo.com		Ornek, Dilsen/0000-0002-3300-4839			ALAHUHTA S, 1995, ANESTHESIOLOGY, V83, P23, DOI 10.1097/00000542-199507000-00004; Balki M, 2005, INT J OBSTET ANESTH, V14, P230, DOI 10.1016/j.ijoa.2004.12.004; Ben-David B, 2000, REGION ANESTH PAIN M, V25, P235, DOI 10.1016/S1098-7339(00)90004-X; Bjornestad E, 1999, ACTA ANAESTH SCAND, V43, P603, DOI 10.1034/j.1399-6576.1999.430602.x; BOGRA J, 2005, BMC ANESTHESIOL, V5, DOI DOI 10.1186/1471-2253-5-5); Celleno D, 2005, Minerva Anestesiol, V71, P521; CHEN XZ, 2006, J ZHEJIANG UNIV-SC B, V712, P992; Chestnut DC, 1999, ANESTHESIA CAESAREAN, P470; Christelis N, 2005, INT J OBSTET ANESTH, V14, P212, DOI 10.1016/j.ijoa.2005.01.002; DATTA S, 1995, ANESTHESIOLOGY, V82, P1346, DOI 10.1097/00000542-199506000-00004; DeBalli P, 2003, CNS DRUGS, V17, P889, DOI 10.2165/00023210-200317120-00003; Gaffud PG, 1986, ANESTHESIOLOGY, V65, P331; Garry M, 2002, INT J OBSTET ANESTH, V11, P9, DOI 10.1054/ijoa.2001.0903; Geng ZY, 2011, CHINESE MED J-PEKING, V124, P509, DOI 10.3760/cma.j.issn.0366-6999.2011.04.005; Glosten B., 2000, ANESTHESIA, P2049; Gogarten W, 2004, EUR J ANAESTH, V21, P38, DOI 10.1017/S0265021504001073; Kallio H, 2004, ANESTH ANALG, V99, P713, DOI 10.1213/01.ANE.0000129976.26455.32; Khaw KS, 2002, ANESTH ANALG, V94, P680, DOI 10.1097/00000539-200203000-00037; Knudsen K, 1997, BRIT J ANAESTH, V78, P507; Koinig H, 1999, ANESTHESIOLOGY, V90, P1331; McLeod GA, 2004, BRIT J ANAESTH, V92, P547, DOI 10.1093/bja/aeh094; Mercier F J, 1996, Cah Anesthesiol, V44, P173; Ogun CO, 2003, BRIT J ANAESTH, V90, P659, DOI 10.1093/bja/aeg123; Parpaglioni R, 2009, ACTA ANAESTH SCAND, V53, P1214, DOI 10.1111/j.1399-6576.2009.02033.x; Roofthooft E, 2008, CURR OPIN ANESTHESIO, V21, P259, DOI 10.1097/ACO.0b013e3282ff5e41; RUTTEN AJ, 1989, ANESTH ANALG, V69, P291; Shibli KU, 2000, INT J OBSTET ANESTH, V9, P160, DOI 10.1054/ijoa.1999.0382; Veneziani A, 2000, MONTR WORLD C AN	28	3	3	0	4	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	1119-3077			NIGER J CLIN PRACT	Niger. J. Clin. Pract.	APR-JUN	2013	16	2					195	200		10.4103/1119-3077.110154			6	Medicine, General & Internal	General & Internal Medicine	248XY	WOS:000326740600013	23563461				2020-06-30	J	Orge, FH; Lee, TJ; Walsh, M; Gordon, K				Oerge, Faruk H.; Lee, Tamara J.; Walsh, Michele; Gordon, Kimberly			Comparison of fentanyl and morphine in laser surgery for retinopathy of prematurity	JOURNAL OF AAPOS			English	Article							THRESHOLD RETINOPATHY; ANESTHESIA; PHOTOCOAGULATION; CRYOTHERAPY; ANALGESIA; SEDATION; EFFICACY; NEWBORN; PAIN	PURPOSE To compare complication rates of the analgesics fentanyl and morphine in preterm infants undergoing laser therapy for retinopathy of prematurity (ROP). METHODS In this observational study, the medical records of consecutive preterm neonates undergoing laser treatment of ROP from June 2007 through September 2010 were retrospectively reviewed. Because a fentanyl-based infusion protocol was initiated in November 2009, there was approximately the same number of treatment sessions with morphine and with fentanyl. In both groups, midazolam was used additionally on a case-by-case basis. Analgesia type, complications, and vital signs were documented at 5-minute intervals for all surgeries. The primary outcome was change in ventilation status. Secondary complications included change in temperature and incidence of apneic, bradycardic, and desaturation events. RESULTS A total of 35 patients were included, with 17 in the morphine group (mean gestational age, 24.8 weeks; mean birth weight, 661 g) and 18 in the fentanyl group (mean gestational age, 24.4 weeks; mean birth weight, 681 g). Overall worsening of ventilation status was noted in 29% of patients in the morphine group and 6% of patients in the fentanyl group (P = 0.08; 95% confidence interval, -2% to 48%). Temperature instability (outside of 36.5 degrees to 37.4 degrees C range) was noted in 6% of patients in the morphine group and no patients in the fentanyl group. Apneic events were 3.2 times more common and bradycardic events 1.5 times more common in the morphine group. CONCLUSIONS We found no difference in safety parameters for fentanyl infusion or morphine for analgesia in preterm infants undergoing ROP laser therapy in the neonatal intensive care unit setting. Although estimates of complication rates suggest that fentanyl may be safer, further study is needed to confirm this premise.	[Oerge, Faruk H.] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA; [Oerge, Faruk H.; Walsh, Michele; Gordon, Kimberly] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Lee, Tamara J.] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH 44106 USA; [Walsh, Michele; Gordon, Kimberly] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA	Orge, FH (reprint author), Rainbow Babies & Childrens Hosp, 11100 Euclid Ave,Suite 1200, Cleveland, OH 44106 USA.	Faruk.Orge@uhhospitals.org					Anand KJS, 1999, ARCH PEDIAT ADOL MED, V153, P331; Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; Calenda E, 2009, J CLIN ANESTH, V21, P311, DOI 10.1016/j.jclinane.2008.11.006; Chen SDM, 2007, EYE, V21, P1033, DOI 10.1038/sj.eye.6702499; Connolly BP, 2002, OPHTHALMOLOGY, V109, P936, DOI 10.1016/S0161-6420(01)01015-6; Jackson JK, 2003, PEDIATRICS, V111; Kirwan C, 2007, ACTA OPHTHALMOL SCAN, V85, P644, DOI 10.1111/j.1600-0420.2007.00900.x; Lago P, 2009, ACTA PAEDIATR, V98, P932, DOI 10.1111/j.1651-2227.2009.01291.x; Lyon F, 2008, EYE, V22, P684, DOI 10.1038/sj.eye.6702717; Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374; National Eye Institute, 2011, HLTH INF FACTS RET P; Ng EYJ, 2002, OPHTHALMOLOGY, V109, P928, DOI 10.1016/S0161-6420(01)01017-X; RUBIN AP, 1995, BRIT J ANAESTH, V75, P93, DOI 10.1093/bja/75.1.93; Sammartino M, 2003, PAEDIATR ANAESTH, V13, P596, DOI 10.1046/j.1460-9592.2003.01101.x; Suarez Amanda, 2010, J Pediatr Pharmacol Ther, V15, P142; Sullivan T J, 1995, Eur J Ophthalmol, V5, P187	16	8	9	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	1091-8531			J AAPOS	J. AAPOS	APR	2013	17	2					135	139		10.1016/j.jaapos.2012.11.020			5	Ophthalmology; Pediatrics	Ophthalmology; Pediatrics	145OY	WOS:000319027700004	23622445				2020-06-30	J	Vujovic, KRS; Vuckovic, S; Srebro, D; Ivanovic, M; Dosen-Micovic, L; Vucetic, C; Dzoljic, E; Prostran, M				Vujovic, Katarina R. Savic; Vuckovic, Sonja; Srebro, Dragana; Ivanovic, Milovan; Dosen-Micovic, Ljiljana; Vucetic, Cedomir; Dzoljic, Eleonora; Prostran, Milica			A comparison of the antinociceptive and temperature responses to morphine and fentanyl derivatives in rats	ARCHIVES OF PHARMACAL RESEARCH			English	Article						Fentanyl; Morphine; Derivatives; Temperature; Antinociception; Rats	OPIOID RECEPTOR SUBTYPES; BODY-TEMPERATURE; AGONIST; ANALOGS	In addition to producing antinociception, opioids exert profound effects on body temperature. This study aimed at comparing antinociceptive and hyperthermic responses between two groups of mu-opioid receptor agonists: fentanyl (4-anilinopiperidine-type) and morphine (phenanthrene-type) derivatives in rats. Analgesic activity was assessed by tail immersion test and the body temperature by insertion of a thermometer probe into the colon. Fentanyl (F), (+/-)-cis-3-methyl fentanyl (CM), (+/-)-cis-3-carbomethoxy fentanyl (C), (+/-)trans-3-carbomethoxy fentanyl (T) and (+/-)-cis-3 butyl fentanyl (B) produced dose-dependent increase in antinociception and hyperthermia. The relative order of analgesic potency was: CM(11.27)> F(1)> C(0.35)a parts per thousand yenT(0.11)a parts per thousand yenB(0.056). Similar to this, the relative order of hyperthermic potency was: CM(8.43)> F(1)> C(0.46)a parts per thousand yenT(0.11)a parts per thousand yenB(0.076). Morphine (M), oxycodone (O), thebacon (T) and 6,14-ethenomorphinan-7-methanol, 4,5-epoxy-6-fluoro-3-hydroxy-alpha,alpha,17-trimethyl-, (5 alpha,7 alpha) (E) also produced dose-dependent increase in antinociception and hyperthermia. Among morphine derivatives the relative order of analgesic potency was: E(56)> O(5)a parts per thousand yenT(2.6)> M(1), and similar to this, the relative order of hyperthermic potency was: E(37)> O(3)a parts per thousand yenT(2.3)> M(1). Morphine (phenanthrene-type) and fentanyl (4-anilinopiperidine-type) derivatives produced hyperthermia in rats at doses about 2 times lower, and 6-11 times higher, than their median antinociceptive doses, respectively. This study is first to identify difference between these two classes of opioid drugs in their potencies in producing hyperthermia. Further studies are needed to clarify the significance of these findings.	[Vujovic, Katarina R. Savic; Vuckovic, Sonja; Srebro, Dragana; Prostran, Milica] Univ Belgrade, Fac Med, Dept Pharmacol Clin Pharmacol & Toxicol, Belgrade, Serbia; [Ivanovic, Milovan; Dosen-Micovic, Ljiljana] Univ Belgrade, Fac Chem, Belgrade, Serbia; [Vucetic, Cedomir] Univ Belgrade, Inst Orthopaed Surg & Traumatol, Clin Ctr Serbia, Fac Med, Belgrade, Serbia; [Dzoljic, Eleonora] Univ Belgrade, Fac Med, Clin Ctr Serbia, Neurol Clin, Belgrade, Serbia	Vujovic, KRS (reprint author), Univ Belgrade, Fac Med, Dept Pharmacol Clin Pharmacol & Toxicol, Belgrade, Serbia.	katrins79@yahoo.com	Ivanovic, Milovan/R-5245-2016	Ivanovic, Milovan/0000-0002-2534-4673; Srebro, Dragana/0000-0002-9680-0840	Ministry of Education, Science and Technological Development of Serbia [175023]	This work was supported by Ministry of Education, Science and Technological Development of Serbia (Grant No. 175023). The author would like to convey thanks to Alkaloid (Skopje, Macedonia) and University of Debrecen, Hungary, who gifted us some of the compounds tested.	Adler M W, 1989, NIDA Res Monogr, V95, P180; Baker AK, 2002, J PHARMACOL EXP THER, V302, P1253, DOI 10.1124/jpet.102.037655; Benamar K, 2007, J PHARMACOL EXP THER, V323, P990, DOI 10.1124/jpet.107.129973; Berenyi Sandor, 1995, Medicinal Chemistry Research, V5, P26; Bourne H., 2007, BASIC CLIN PHARM, P11; Cao W. H., 2005, AM J PHYSIOL, V288, P723; Chen XH, 2005, LIFE SCI, V78, P329, DOI 10.1016/j.lfs.2005.04.084; Davis MP, 2012, EXPERT OPIN DRUG DIS, V7, P165, DOI 10.1517/17460441.2012.648611; Dietis N, 2011, BRIT J ANAESTH, V107, P8, DOI 10.1093/bja/aer115; Dosen-Micovic L, 2006, BIOORGAN MED CHEM, V14, P2887, DOI 10.1016/j.bmc.2005.12.010; Fraga D, 2008, AM J PHYSIOL-REG I, V294, pR411, DOI 10.1152/ajpregu.00465.2007; Groer CE, 2011, J BIOL CHEM, V286, P31731, DOI 10.1074/jbc.M111.248310; Ivanovic MD, 2004, J SERB CHEM SOC, V69, P511, DOI 10.2298/JSC0407511I; JANSSEN PAJ, 1963, ARZNEIMITTEL-FORSCH, V13, P502; KISSIN I, 1983, CAN ANAESTH SOC J, V30, P623, DOI 10.1007/BF03015233; Lu YF, 1998, SYNAPSE, V28, P117, DOI 10.1002/(SICI)1098-2396(199802)28:2<117::AID-SYN2>3.3.CO;2-8; Micovic IV, 1998, HETEROCYCL COMMUN, V4, P171; Nozaki C, 2012, J PHARMACOL EXP THER, V342, P799, DOI 10.1124/jpet.111.188987; Pradhan AA, 2012, BRIT J PHARMACOL, V167, P960, DOI 10.1111/j.1476-5381.2012.02075.x; Rawls Scott M, 2011, Front Biosci (Schol Ed), V3, P822; Rivero G, 2012, MOL PHARMACOL, V82, P178, DOI 10.1124/mol.112.078659; Rives ML, 2012, J BIOL CHEM, V287, P27050, DOI 10.1074/jbc.C112.387332; Tallarida R. J., 1986, MANUAL PHARMACOLOGIC; Tomic MA, 2010, ANESTH ANALG, V110, P1198, DOI 10.1213/ANE.0b013e3181cbd8da; Vuckovic S, 2000, JPN J PHARMACOL, V84, P188, DOI 10.1254/jjp.84.188; Vuckovic S, 1998, JPN J PHARMACOL, V78, P523, DOI 10.1254/jjp.78.523; Vuckovic S, 2009, CURR MED CHEM, V16, P2468, DOI 10.2174/092986709788682074; YANG PK, 1992, ANESTHESIOLOGY, V77, P153, DOI 10.1097/00000542-199207000-00022	28	8	8	0	7	PHARMACEUTICAL SOC KOREA	SEOUL	1489-3 SUHCHO-DONG, SUHCHO-KU, SEOUL 137-071, SOUTH KOREA	0253-6269	1976-3786		ARCH PHARM RES	Arch. Pharm. Res.	APR	2013	36	4					501	508		10.1007/s12272-013-0072-z			8	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	131CO	WOS:000317969800014	23440583				2020-06-30	J	Helin-Tanninen, M; Lehtonen, M; Naaranlahti, T; Venalainen, T; Pentikainen, J; Laatikainen, A; Kokki, H				Helin-Tanninen, M.; Lehtonen, M.; Naaranlahti, T.; Venalainen, T.; Pentikainen, J.; Laatikainen, A.; Kokki, H.			Stability of an epidural analgesic admixture of levobupivacaine, fentanyl and epinephrine	JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS			English	Article						adrenaline; epidural; epinephrine; fentanyl; levobupivacaine; pain	BUPIVACAINE; INFUSION; METAANALYSIS; ADRENALINE; EFFICACY	What is known and Objective: Admixtures of levobupivacaine, fentanyl and epinephrine are increasingly used in epidural pain management. Neither the compatibility nor the stability of levobupivacaine with fentanyl and epinephrine is known and therefore we examined the chemical, physical and microbiological stability of levobupivacaine-fentanyl-epinephrine and levobupivacaine-fentanyl admixtures prepared in the hospital pharmacy. Methods: Fentanyl and epinephrine were added into commercial levobupivacaine infusion bags. The components were analysed by HPLC and assays were performed up to 60 days of storage of the bags both protected and exposed to light at room temperature and stored in the refrigerator. In addition, sterility, bacterial endotoxins, organoleptic properties, pH and mass of the admixture were determined. Results and Discussion: Levobupivacaine, fentanyl and epinephrine concentrations remained within the +/- 10% specification limit during 60 days storage in the refrigerator in tightly closed secondary packing material and protected from light and for at least 40 days at room temperature. The degradation of epinephrine exceeded 10% within 60 hours when exposed to light. The solutions were microbiologically and physically stable. What is new and Conclusion: Epidural analgesic admixtures of levobupivacaine and fentanyl with or without epinephrine have to be stored in a tightly closed secondary package protected from light. The extended stability, up to 60 days, in a refrigerator enables the centralized preparation in the hospital pharmacy.	[Helin-Tanninen, M.; Naaranlahti, T.] Kuopio Univ Hosp, Dept Pharm, FI-70211 Kuopio, Finland; [Lehtonen, M.; Venalainen, T.] Univ Eastern Finland, Sch Pharm, Kuopio, Finland; [Pentikainen, J.; Laatikainen, A.] Eastern Finland Lab Ctr Joint Author Enterprise, Kuopio, Finland; [Kokki, H.] Kuopio Univ Hosp, Dept Anaesthesiol & Intens Care, FI-70211 Kuopio, Finland; [Kokki, H.] Univ Eastern Finland, Kuopio, Finland	Helin-Tanninen, M (reprint author), Kuopio Univ Hosp, Dept Pharm, POB 1777, FI-70211 Kuopio, Finland.	minna.helin-tanninen@kuh.fi	Sallinen, Taisa/N-1969-2019	Sallinen, Taisa/0000-0003-2769-6338			ALBRIGHT GA, 1979, ANESTHESIOLOGY, V51, P285, DOI 10.1097/00000542-197910000-00001; ALLEN LV, 1993, AM J HOSP PHARM, V50, P714, DOI 10.1093/ajhp/50.4.714; [Anonymous], 2005, ICH HARM TROP GUID V; [Anonymous], 2008, EUDRALEX, V4; Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; Cameron CM, 2007, ANESTHESIOLOGY, V106, P997, DOI 10.1097/01.anes.0000265160.32309.10; Christie IW, 2007, ANAESTHESIA, V62, P335, DOI 10.1111/j.1365-2044.2007.04992.x; Council of Europe, 2007, EUR PHARM ONL 5 2; DAWSON PJ, 1992, BRIT J ANAESTH, V68, P414, DOI 10.1093/bja/68.4.414; Foster RH, 2000, DRUGS, V59, P551, DOI 10.2165/00003495-200059030-00013; Halpern SH, 1998, JAMA-J AM MED ASSOC, V280, P2105, DOI 10.1001/jama.280.24.2105; ICH, 2003, ICH HARM TRIP GUID S; International Conference on Harmonisation (ICH), 2003, ICH HARM TRIP GUID E; Jappinen A, 2003, EUR J PHARM SCI, V19, P31, DOI 10.1016/S0928-0987(03)00041-1; Kedlaya Divakara, 2002, Best Pract Res Clin Anaesthesiol, V16, P651, DOI 10.1053/bean.2002.0253; Kjonniksen I, 2000, ACTA ANAESTH SCAND, V44, P864, DOI 10.1034/j.1399-6576.2000.440713.x; Niemi G, 2001, ACTA ANAESTH SCAND, V45, P221, DOI 10.1034/j.1399-6576.2001.450214.x; Priston MJ, 2004, ANAESTHESIA, V59, P979, DOI 10.1111/j.1365-2044.2004.03803.x; Wu CL, 2005, ANESTHESIOLOGY, V103, P1079, DOI 10.1097/00000542-200511000-00023	19	2	2	0	7	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0269-4727			J CLIN PHARM THER	J. Clin. Pharm. Ther.	APR	2013	38	2					104	108		10.1111/jcpt.12035			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	133TY	WOS:000318164700006	23442020				2020-06-30	J	Coruh, B; Tonelli, MR; Park, DR				Coruh, Basak; Tonelli, Mark R.; Park, David R.			Fentanyl-Induced Chest Wall Rigidity	CHEST			English	Editorial Material							LOW-DOSE FENTANYL; MUSCLE RIGIDITY; PRETERM INFANT; ANESTHESIA	Fentanyl and other opiates used in procedural sedation and analgesia are associated with several well-known complications. We report the case of a man who developed the uncommon complication of chest wall rigidity and ineffective spontaneous ventilation following the administration of fentanyl during an elective bronchoscopy. His ventilation was assisted and the condition was reversed with naloxone. Although this complication is better described in pediatric patients and with anesthetic doses, chest wall rigidity can occur with analgesic doses of fentanyl and related compounds. Management includes ventilatory support and reversal with either naloxone or a short-acting neuromuscular blocking agent. This reaction does not appear to be a contraindication to future use of fentanyl or related compounds. Chest wall rigidity causing respiratory compromise should be readily recognized and treated by bronchoscopists. CHEST 2013; 143(4):1145-1146	[Coruh, Basak; Tonelli, Mark R.; Park, David R.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA	Coruh, B (reprint author), Univ Washington, Div Pulm & Crit Care Med, Box 356522,1959 NE Pacific St, Seattle, WA 98195 USA.	bcoruh@u.washington.edu					Ackerman W E, 1990, Anesth Prog, V37, P46; Bennett JA, 1997, ANESTHESIOLOGY, V87, P1070, DOI 10.1097/00000542-199711000-00010; Carvalho B, 2004, INT J OBSTET ANESTH, V13, P53, DOI 10.1016/j.ijoa.2003.09.001; Dewhirst E, 2012, PEDIATR EMERG CARE, V28, P465, DOI 10.1097/PEC.0b013e3182535a2a; Elakkumanan LB, 2008, PEDIATR ANESTH, V18, P1115, DOI 10.1111/j.1460-9592.2008.02602.x; Eventov-Friedman S, 2010, J PERINATOL, V30, P149, DOI 10.1038/jp.2009.66; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; FREYE E, 1976, PHARMACOLOGY, V14, P1, DOI 10.1159/000136573; HAMILTON WK, 1953, ANESTHESIOLOGY, V14, P550, DOI 10.1097/00000542-195311000-00002; JAFFE TB, 1983, ANESTHESIOLOGY, V58, P562, DOI 10.1097/00000542-198306000-00015; KLAUSNER JM, 1988, ARCH SURG-CHICAGO, V123, P66; Lindemann R, 1998, EUR J PEDIATR, V157, P1012, DOI 10.1007/s004310050988; Mao C C, 1997, Acta Anaesthesiol Sin, V35, P187; Muller P, 2000, AM J PERINAT, V17, P23, DOI 10.1055/s-2000-7289; NEIDHART P, 1989, ACTA ANAESTH SCAND, V33, P1, DOI 10.1111/j.1399-6576.1989.tb02849.x; SOKOLL MD, 1972, ANESTH ANAL CURR RES, V51, P16; Vaughn R L, 1981, Anesth Prog, V28, P50; Viscomi CM, 1997, OBSTET GYNECOL, V89, P822, DOI 10.1016/S0029-7844(97)81423-8; Wahidi MM, 2011, CHEST, V140, P1342, DOI 10.1378/chest.10-3361; WELLS S, 1994, HEART LUNG, V23, P196	20	41	43	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0012-3692	1931-3543		CHEST	Chest	APR	2013	143	4					1145	1146		10.1378/chest.12-2131			2	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	129VG	WOS:000317871500040	23546488				2020-06-30	J	Miyakoshi, K; Tanaka, M; Morisaki, H; Kim, SH; Hosokawa, Y; Matsumoto, T; Minegishi, K; Yoshimura, Y				Miyakoshi, Kei; Tanaka, Mamoru; Morisaki, Hiroshi; Kim, Seon-Hye; Hosokawa, Yuki; Matsumoto, Tadashi; Minegishi, Kazuhiro; Yoshimura, Yasunori			Perinatal outcomes: Intravenous patient-controlled fentanyl versus no analgesia in labor	JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH			English	Article						cesarean section; fentanyl; intravenous patient-controlled analgesia; labor pain relief; prolonged labor	MEPERIDINE; OPIOIDS	Aim To investigate perinatal outcomes, the analgesic efficacy and maternal satisfaction in nulliparous women receiving fentanyl intravenous patient-controlled analgesia (i.v.-PCA). Material and Methods A total of 1401 nulliparous women with a singleton pregnancy who received fentanyl i.v.-PCA (i.v.-PCA group, n=290) or no analgesia (control group, n=1111) in labor between 2005 and 2010 were reviewed. Fentanyl i.v.-PCA was implemented on maternal request during the first stage of labor over 35 weeks of gestation, and discontinued at full cervical dilatation. Perinatal outcomes were compared between the i.v.-PCA and the control groups. The numerical rating scale (NRS) levels during labor were also examined in the i.v.-PCA group. Additionally, parturients received fentanyl i.v.-PCA in 2010 (n=73) were asked about overall satisfaction using a scale poor, moderate, good and excellent on postpartum day 03. Results Women receiving i.v.-PCA showed significantly longer labor and more need of oxytocin augmentation, compared with the control. Cesarean section was significantly less frequent in the i.v.-PCA group compared with the control (11.0% v.s. 24.1%, respectively), with the vacuum-assisted delivery rate comparable between groups. Neonatal outcomes (i.e. Apgar score <7 at 1min or 5min, umbilical artery pH <7.20) were comparable between groups, irrespective of mode of delivery. Significant reduction of NRS levels was noted until 3h after induction of i.v.-PCA, compared to the baseline. Of the women who expressed their satisfaction, 72% (48/67) exhibited excellent' or good' for pain relief by i.v.-PCA. Conclusion Fentanyl i.v.-PCA could be a useful approach for labor pain relief in nulliparas when regional blocks are unavailable.	[Miyakoshi, Kei; Tanaka, Mamoru; Kim, Seon-Hye; Matsumoto, Tadashi; Minegishi, Kazuhiro; Yoshimura, Yasunori] Keio Univ, Sch Med, Dept Obstet & Gynecol, Tokyo 1608582, Japan; [Morisaki, Hiroshi] Keio Univ, Sch Med, Dept Anesthesiol, Tokyo 1608582, Japan; [Hosokawa, Yuki] Aiiku Hosp, Div Anesthesiol, Tokyo, Japan	Miyakoshi, K (reprint author), Keio Univ, Sch Med, Dept Obstet & Gynecol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	kei@z7.keio.jp	Morisaki, Hiroshi/J-5960-2013				Beilin Y, 2003, ANESTH ANALG, V96, P1794, DOI 10.1213/01.ANE.0000061581.23351.29; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; Conell-Price J, 2008, ANESTH ANALG, V106, P1509, DOI 10.1213/ane.0b013e31816d14f3; Cunningham F, 2010, NEWBORN INFANT WILLI, P594; Cunningham FG, 2010, ABNORMAL LABOR WILLI, P464; Davis JJ, 2003, ANESTH ANALG, V97, P1661, DOI 10.1213/01.ANE.0000090151.13573.42; Douma MR, 2011, INT J OBSTET ANESTH, V20, P118, DOI 10.1016/j.ijoa.2010.11.009; Douma MR, 2010, BRIT J ANAESTH, V104, P209, DOI 10.1093/bja/aep359; Evron S, 2007, CURR OPIN ANESTHESIO, V20, P181, DOI 10.1097/ACO.0b013e328136c1d1; Halpern SH, 2004, ANESTH ANALG, V99, P1532, DOI 10.1213/01.ANE.0000136850.08972.07; Hawkins JL, 2010, NEW ENGL J MED, V362, P1503, DOI 10.1056/NEJMct0909254; Hosokawa Y, 2012, J ANESTH, V26, P219, DOI 10.1007/s00540-011-1292-3; Kayacan N, 2007, ADV THER, V24, P368, DOI 10.1007/BF02849906; Macones GA, 2008, OBSTET GYNECOL, V112, P661, DOI 10.1097/AOG.0b013e3181841395; Marwah R, 2012, CAN J ANESTH, V59, P246, DOI 10.1007/s12630-011-9625-0; Morley-Forster PK, 1998, INT J OBSTET ANESTH, V7, P103, DOI 10.1016/S0959-289X(98)90005-X; Morley-Forster PK, 2000, CAN J ANAESTH, V47, P113, DOI 10.1007/BF03018845; Nikkola EM, 1997, CAN J ANAESTH, V44, P1248, DOI 10.1007/BF03012771; RAYBURN W, 1989, AM J OBSTET GYNECOL, V161, P202, DOI 10.1016/0002-9378(89)90266-4; RAYBURN WF, 1989, OBSTET GYNECOL, V74, P604; Saravanakumar K, 2007, INT J OBSTET ANESTH, V16, P221, DOI 10.1016/j.ijoa.2007.01.010; SHNIDER SM, 1979, ANESTHESIOLOGY, V50, P524; Tveit TO, 2009, ACTA ANAESTH SCAND, V53, P794, DOI 10.1111/j.1399-6576.2009.01988.x; Yoo KY, 2001, ANESTH ANALG, V92, P1006	24	7	7	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1341-8076	1447-0756		J OBSTET GYNAECOL RE	J. Obstet. Gynaecol. Res.	APR	2013	39	4					783	789		10.1111/j.1447-0756.2012.02044.x			7	Obstetrics & Gynecology	Obstetrics & Gynecology	122GV	WOS:000317307400005	23167696				2020-06-30	J	Pergolizzi, JV; Gharibo, CG; Gudin, JA; Nalamachu, SR				Pergolizzi, Joseph V.; Gharibo, Christopher G.; Gudin, Jeffrey A.; Nalamachu, Srinivas R.			Development of Federally Mandated Risk Evaluation and Mitigation Strategies (REMS) for Transmucosal Immediate-Release Fentanyl Products	PAIN PRACTICE			English	Editorial Material							UNITED-STATES; OPIOID ANALGESICS; DIVERSION; PAIN; DEATHS; OVERDOSE; ABUSE		[Pergolizzi, Joseph V.] Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19122 USA; [Pergolizzi, Joseph V.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Pergolizzi, Joseph V.] Georgetown Univ, Sch Med, Dept Anesthesiol, Washington, DC USA; [Pergolizzi, Joseph V.] Naples Anesthesia & Pain Associates, Naples, FL USA; [Gharibo, Christopher G.] NYU Langone Hosp Joint Dis, Dept Anesthesiol & Orthoped, New York, NY USA; [Gudin, Jeffrey A.] Englewood Hosp & Med Ctr, Englewood, NJ USA; [Nalamachu, Srinivas R.] Int Clin Res Inst, Overland Pk, KS USA	Pergolizzi, JV (reprint author), Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19122 USA.						[Anonymous], 2012, ABSTR FENT SUBL TABL; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; Inciardi JA, 2006, SUBST USE MISUSE, V41, P255, DOI 10.1080/10826080500391829; Inciardi JA, 2007, PAIN MED, V8, P171, DOI 10.1111/j.1526-4637.2006.00255.x; Joranson DE, 2007, PAIN MED, V8, P128, DOI 10.1111/j.1526-4637.2007.00274.x; Joranson DE, 2005, J PAIN SYMPTOM MANAG, V30, P299, DOI 10.1016/j.jpainsymman.2005.09.001; Keller KH, 2010, PAINWEEK SEPT 8 11 2; Kuehn BM, 2010, JAMA-J AM MED ASSOC, V303, P495, DOI 10.1001/jama.2010.71; Nelson LS, 2012, JAMA-J AM MED ASSOC, V308, P457, DOI 10.1001/jama.2012.8165; Office of National Drug Control Policy, 2010, NATL DRUG CONTROL ST; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; Paulozzi LJ, 2006, PHARMACOEPIDEM DR S, V15, P618, DOI 10.1002/pds.1276; Peppin JF, 2011, ISSUES LAW MED, V27, P91; Substance Abuse and Mental Health Services Administration Office of Applied Studies, 2009, NSDUH SERIES H, VH-36; U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2009, GUID IND FORM CONT P; US Food and Drug Administration, FDA APPR SHAR SYST R; Volkow ND, 2011, JAMA-J AM MED ASSOC, V305, P1346, DOI 10.1001/jama.2011.369; White J, 2010, WASHINGTON POST; 2009, FED REG, V74, P17967	20	3	4	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1530-7085	1533-2500		PAIN PRACT	Pain Pract.	APR	2013	13	4					259	263		10.1111/papr.12040			5	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	122CP	WOS:000317293600001	23464790	Green Published			2020-06-30	J	Becker, WM; Mama, KR; Rao, S; Palmer, RH; Egger, EL				Becker, Willem M.; Mama, Khursheed R.; Rao, Sangeeta; Palmer, Ross H.; Egger, Erick L.			Prevalence of Dysphoria after Fentanyl in Dogs Undergoing Stifle Surgery	VETERINARY SURGERY			English	Article							EAR CANAL ABLATION; ANALGESIA; MORPHINE; PAIN; PREMEDICATION; ISOFLURANE; INJECTION; INFUSION	Objective To describe the prevalence of dysphoria after intraoperative administration of fentanyl by infusion and identify other risk factors influencing this in dogs undergoing stifle surgery. Study Design Prospective, randomized clinical study. Animals Dogs (n = 92) that had tibial plateau leveling osteotomy (TPLO) or tibial tuberosity advancement (TTA). Methods Dogs were anesthetized using a standardized anesthetic protocol, and randomly assigned to receive a loading dose followed by 1 of 3 infusions of fentanyl perioperatively: 2 g/kg/h, 10 g/kg/h, or 20 g/kg/h. Dog characteristics and all additional medications were recorded and included as part of the statistical analysis. Dog behavior was scored before anesthesia and during recovery using a scale of 14 (Appendices A and B). If no improvement in behavior was seen in 35 minutes postextubation, dogs with a score of 3 or 4 during recovery were administered fentanyl (2 g/kg intravenously [IV]) in the event that the behaviors associated with the higher scores were related to pain. If they did not respond favorably to the administration of additional fentanyl and wound palpation did not elicit a response, but the untoward behaviors continued, dogs were administered either a tranquilizer, sedative, or opioid antagonist, and were considered dysphoric. Results Of 92 dogs, 22 (23.9%) were considered dysphoric using aforementioned criteria. Conclusions About one-fourth of dogs enrolled in this study were dysphoric based on study criteria.	[Becker, Willem M.; Mama, Khursheed R.; Rao, Sangeeta; Palmer, Ross H.; Egger, Erick L.] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Clin Sci, Ft Collins, CO 80523 USA	Mama, KR (reprint author), Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Clin Sci, Ft Collins, CO 80523 USA.	kmama@colostate.edu			Center for Companion Animal Studies PVM Student Grant Program at Colorado State University	Funded in part by the Center for Companion Animal Studies PVM Student Grant Program at Colorado State University.	Becker WM, 2008, 9 ANN CSU CVMBS RES; Buback JL, 1996, VET SURG, V25, P380, DOI 10.1111/j.1532-950X.1996.tb01431.x; Fox SM, 2000, RES VET SCI, V68, P265, DOI 10.1053/rvsc.2000.0375; Hall LW, 2001, VET ANAESTHESIA, P93; Hellyer PW, 2001, AM J VET RES, V62, P555, DOI 10.2460/ajvr.2001.62.555; Hofmeister EH, 2006, J VET EMERG CRIT CAR, V16, P44, DOI 10.1111/j.1476-4431.2005.04022.x; Jones RS, 2001, VET J, V161, P123, DOI 10.1053/tvjl.2000.0528; Kona-Boun JJ, 2006, JAVMA-J AM VET MED A, V229, P1103, DOI 10.2460/javma.229.7.1103; Lamont L., 2002, HDB VET PAIN MANAGEM, P199; Lemke KA, 2007, LUMB JONES VET ANEST, P210; LIGHT GS, 1993, APPL ANIM BEHAV SCI, V37, P331, DOI 10.1016/0168-1591(93)90122-6; Lucas AN, 2001, J AM VET MED ASSOC, V218, P884, DOI 10.2460/javma.2001.218.884; Mahler SP, 2008, VET ANAESTH ANALG, V35, P80, DOI 10.1111/j.1467-2995.2007.00356.x; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6; Plumb DC, 2005, PLUMBS VET DRUG HDB, P390; Riviere PJM, 2004, BRIT J PHARMACOL, V141, P1331, DOI 10.1038/sj.bjp.0705763; Ross JR, 2008, CANCER-AM CANCER SOC, V112, P1390, DOI 10.1002/cncr.23292; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; Starcevic V, 2007, AUSTRALAS PSYCHIATRY, V15, P9, DOI 10.1080/10398560601083035; Steagall PVM, 2006, JAVMA-J AM VET MED A, V229, P522, DOI 10.2460/javma.229.4.522; Vaisanen M, 2004, VET REC, V155, P729; Wagner AE, 2002, HDB VET PAIN MANAGEM, P177; Wolfe TM, 2006, VET ANAESTH ANALG, V33, P328, DOI 10.1111/j.1467-2995.2005.00272.x; Zackny JP, 1992, PSYCHOPHARMACOLOGY, V107, P319	24	18	18	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0161-3499	1532-950X		VET SURG	Vet. Surg.	APR	2013	42	3					302	307		10.1111/j.1532-950X.2012.01080.x			6	Veterinary Sciences	Veterinary Sciences	118IO	WOS:000317019300013	23231071				2020-06-30	J	Bruins, B; Kilbaugh, TJ; Margulies, SS; Friess, SH				Bruins, Benjamin; Kilbaugh, Todd J.; Margulies, Susan S.; Friess, Stuart H.			The Anesthetic Effects on Vasopressor Modulation of Cerebral Blood Flow in an Immature Swine Model	ANESTHESIA AND ANALGESIA			English	Article							TRAUMATIC BRAIN-INJURY; ISOFLURANE ANESTHESIA; OXYGEN-CONSUMPTION; NITROUS-OXIDE; MIDAZOLAM; AUTOREGULATION; PROPOFOL; VELOCITY; METABOLISM; PERFUSION	BACKGROUND: The effect of various sedatives and anesthetics on vasopressor modulation of cerebral blood flow (CBF) in children is unclear. In adults, isoflurane has been described to decrease CBF to a lesser extent than fentanyl and midazolam. Most large-animal models of neurocritical care use inhaled anesthetics for anesthesia. Investigations involving modulations. CBF would have improved translatability within a model that more closely approximates the current practice in the pediatric intensive care unit. METHODS: Fifteen 4-week-old piglets were given 1 of 2 anesthetic protocols: total IV anesthesia (TIVA) (midazolam 1 mg/kg/h and fentanyl 100 mu g/kg/h, n = 8) or ISO (isoflurane 1.5%-2% and fentanyl 100 mu g/kg/h, n = 7). Mean arterial blood pressure, intracranial pressure (ICP), CBF, and brain tissue oxygen tension were measured continuously as piglets were exposed to escalating doses of arginine vasopressin, norepinephrine (NE), and phenylephrine (PE). RESULTS: Baseline CBF was similar in the 2 groups (ISO 38 +/- 10 vs TIVA 35 +/- 26 mL/100 g/min) despite lower baseline cerebral perfusion pressure in the ISO group (45 +/- 11 vs 71 +/- 11 mm Hg; P < 0.0005). Piglets in the ISO group displayed increases in ICP with PE and NE (11 +/- 4 vs 16 +/- 4 mm Hg, and 11 +/- 8 vs 18 +/- 5 mm Fig; P < 0.05), but in the TIVA group, only exposure to PE resulted in increases in ICP when comparing maximal dose values with baseline data (11 +/- 4 vs 15 +/- 5 mm Hg; P < 0.05). Normalized CBF displayed statistically significant increases regarding anesthetic group and vasopressor dose when piglets were exposed to NE and PE (P < 0.05), suggesting an impairment of autoregulation within ISO, but not TIVA. CONCLUSION: The vasopressor effect on CBF was limited when using a narcotic-benzodiazepine based anesthetic protocol compared with volatile anesthetics, consistent with a preservation of autoregulation. Selection of anesthetic drugs is critical to investigate mechanisms of cerebrovascular hemodynamics, and in translating critical care investigations between the laboratory and bedside. (Anesth Analg 2013;116:838-44)	[Bruins, Benjamin; Kilbaugh, Todd J.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Margulies, Susan S.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Friess, Stuart H.] Washington Univ, Dept Pediat, St Louis Sch Med, St Louis, MO 63110 USA	Friess, SH (reprint author), Washington Univ, Dept Pediat, St Louis Sch Med, Campus Box 8028,5th Floor MPRB,660 S Euclid Ave, St Louis, MO 63110 USA.	Friess_S@kids.wustl.edu		Kilbaugh, Todd/0000-0002-4959-3092	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K08NS064051, U01NS069545, R01NS39679]	Supported by NIH grants K08NS064051, U01NS069545, and R01NS39679.	Brady KM, 2009, ANESTH ANALG, V108, P1278, DOI 10.1213/ane.0b013e3181964848; CHENG MA, 1993, J NEUROSURG ANESTH, V5, P232; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; CHI OZ, 1992, ANESTHESIOLOGY, V76, P426, DOI 10.1097/00000542-199203000-00016; Clausen T, 2004, BRAIN RES, V1019, P113, DOI 10.1016/j.brainres.2004.05.099; CUCCHIARA RF, 1974, ANESTHESIOLOGY, V40, P571, DOI 10.1097/00000542-197406000-00011; Di Gennaro JL, 2010, DEV NEUROSCI-BASEL, V32, P420, DOI 10.1159/000322083; Dudkiewicz M, 2008, CRIT CARE MED, V36, P2641, DOI 10.1097/CCM.0b013e3181847af3; Feinstein AJ, 2005, J AM COLL SURGEONS, V201, P536, DOI 10.1016/j.jamcollsurg.2005.05.031; FORSTER A, 1982, ANESTHESIOLOGY, V56, P453, DOI 10.1097/00000542-198206000-00009; Friess SH, 2011, NEUROSURGERY, V69, P1139, DOI 10.1227/NEU.0b013e3182284aa1; GELMAN S, 1984, ANESTH ANALG, V63, P557; HOFFMAN WE, 1986, ANESTH ANALG, V65, P729; KNUDSEN L, 1990, ANAESTHESIA, V45, P1016, DOI 10.1111/j.1365-2044.1990.tb14877.x; KOCHS E, 1993, ANESTH ANALG, V76, P1222, DOI 10.1213/00000539-199376060-00007; Missios S, 2009, J NEUROTRAUM, V26, P1943, DOI [10.1089/neu.2009.0956, 10.1089/neu.2009-0956]; Muller S, 2008, CRIT CARE, V12, DOI 10.1186/cc6794; Myburgh JA, 2002, ANAESTH INTENS CARE, V30, P725, DOI 10.1177/0310057X0203000602; Nachar RA, 2011, PEDIATR RES, V70, P473, DOI 10.1203/PDR.0b013e31822e178e; Nouira S, 2005, CRIT CARE MED, V33, P2339, DOI 10.1097/01.CCM.0000182801.48137.13; NUGENT M, 1982, ANESTHESIOLOGY, V56, P172, DOI 10.1097/00000542-198203000-00003; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; Ogawa Y, 2010, ANESTH ANALG, V111, P1279, DOI 10.1213/ANE.0b013e3181f42fc0; OLSEN KS, 1992, BRIT J ANAESTH, V69, P263, DOI 10.1093/bja/69.3.263; Pfister D, 2008, EUR J ANAESTH, V25, P98, DOI 10.1017/S0265021507003407; Rosengarten B, 2012, CRIT CARE, V16, DOI 10.1186/cc11310; Rosenthal G, 2011, J NEUROSURG, V114, P62, DOI 10.3171/2010.6.JNS091360; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schramm P, 2012, CRIT CARE, V16, DOI 10.1186/cc11665; Semmler A, 2013, J NEUROL NEUROSUR PS, V84, P62, DOI 10.1136/jnnp-2012-302883; Simon F, 2009, CRIT CARE, V13, DOI 10.1186/cc7959; Smith JH, 2005, ACTA ANAESTH SCAND, V49, P23, DOI 10.1111/j.1399-6576.2004.00535.x; Sookplung P, 2011, NEUROCRIT CARE, V15, P46, DOI 10.1007/s12028-010-9448-9; Steiner LA, 2004, CRIT CARE MED, V32, P1049, DOI 10.1097/01.CCM.0000120054.32845.A6; Swindle M. M., 2007, SWINE LAB SURG ANEST; Todd MM, 1996, J NEUROSURG ANESTH, V8, P296, DOI 10.1097/00008506-199610000-00007; Tsuneyoshi I, 2001, CRIT CARE MED, V29, P487, DOI 10.1097/00003246-200103000-00004; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Vajkoczy P, 2000, J NEUROSURG, V93, P265, DOI 10.3171/jns.2000.93.2.0265; Vavilala MS, 2005, PEDIATR RES, V58, P574, DOI 10.1203/01.PDR.0000179405.30737.0F; Wintermark M, 2004, PEDIATRICS, V113, P1642, DOI 10.1542/peds.113.6.1642; WOLFF J, 1990, ACTA ANAESTH SCAND, V34, P75, DOI 10.1111/j.1399-6576.1990.tb03189.x	42	16	16	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	APR	2013	116	4					838	844		10.1213/ANE.0b013e3182860fe7			7	Anesthesiology	Anesthesiology	113EA	WOS:000316648100014	23460561	Green Accepted			2020-06-30	J	Vereecke, HEM; Proost, JH; Heyse, B; Eleveld, DJ; Katoh, T; Luginbuhl, M; Struys, MMRF				Vereecke, Hugo E. M.; Proost, Johannes H.; Heyse, Bjorn; Eleveld, Douglas J.; Katoh, Takasumi; Luginbuehl, Martin; Struys, Michel M. R. F.			Interaction between Nitrous Oxide, Sevoflurane, and Opioids A Response Surface Approach	ANESTHESIOLOGY			English	Article							MINIMUM ALVEOLAR CONCENTRATION; ISOFLURANE; REQUIREMENTS; PROPOFOL; FENTANYL; MAC	Background: The interaction of sevoflurane and opioids can be described by response surface modeling using the hierarchical model. We expanded this for combined administration of sevoflurane, opioids, and 66 vol.% nitrous oxide (N2O), using historical data on the motor and hemodynamic responsiveness to incision, the minimal alveolar concentration, and minimal alveolar concentration to block autonomic reflexes to nociceptive stimuli, respectively. Methods: Four potential actions of 66 vol.% N2O were postulated: (1) N2O is equivalent to A ng/ml of fentanyl (additive); (2) N2O reduces C50 of fentanyl by factor B; (3) N2O is equivalent to X vol.% of sevoflurane (additive); (4) N2O reduces C50 of sevoflurane by factor Y. These four actions, and all combinations, were fitted on the data using NON-MEM (version VI, Icon Development Solutions, Ellicott City, MD), assuming identical interaction parameters (A, B, X, Y) for movement and sympathetic responses. Results: Sixty-six volume percentage nitrous oxide evokes an additive effect corresponding to 0.27 ng/ml fentanyl (A) with an additive effect corresponding to 0.54 vol.% sevoflurane (X). Parameters B and Y did not improve the fit. Conclusion: The effect of nitrous oxide can be incorporated into the hierarchical interaction model with a simple extension. The model can be used to predict the probability of movement and sympathetic responses during sevoflurane anesthesia taking into account interactions with opioids and 66 vol.% N2O.	[Vereecke, Hugo E. M.; Proost, Johannes H.; Heyse, Bjorn; Eleveld, Douglas J.; Katoh, Takasumi; Luginbuehl, Martin; Struys, Michel M. R. F.] Univ Med Ctr Groningen, Dept Anesthesiol, NL-9700 RB Groningen, Netherlands; [Vereecke, Hugo E. M.; Proost, Johannes H.; Eleveld, Douglas J.; Struys, Michel M. R. F.] Univ Groningen, Univ Med Ctr Groningen, Dept Anesthesiol, Groningen, Netherlands	Vereecke, HEM (reprint author), Univ Med Ctr Groningen, Dept Anesthesiol, Hanzepl 1,POB 30 001,Huispostcode EB32, NL-9700 RB Groningen, Netherlands.	h.e.m.vereecke@umcg.nl	Proost, Johannes/F-5629-2014; Vereecke, Hugo/K-9429-2019	Vereecke, Hugo/0000-0002-3688-785X	Drager Medical, Lubeck, Germany	Received from the Department of Anesthesiology, University Medical Center Groningen, Groningen, The Netherlands. Submitted for publication January 18, 2012. Accepted for publication January 3, 2013. Support was provided solely from institutional and/or departmental sources. The Department of Anesthesiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, received a nonrestrictive educational grant from Drager Medical, Lubeck, Germany, to support the research on drug interaction modeling. Drs. Vereecke and Proost contributed equally to this article.	Bouillon T, 2008, HDB EXPT PHARM, P471; CHORTKOFF BS, 1993, ANESTHESIOLOGY, V79, P724, DOI 10.1097/00000542-199310000-00014; DWYER R, 1992, ANESTHESIOLOGY, V77, P888, DOI 10.1097/00000542-199211000-00009; Eger EJ, 2008, ANESTH ANALG, V107, P479, DOI 10.1213/01.ane.0000295805.70887.65; Ezri T, 2007, ANESTHESIOLOGY, V107, P9, DOI 10.1097/01.anes.0000267534.31668.62; Fragen RJ, 1996, J CLIN ANESTH, V8, P352, DOI 10.1016/0952-8180(96)00082-7; GRECO WR, 1995, PHARMACOL REV, V47, P331; Heyse B, 2012, ANESTHESIOLOGY, V116, P311, DOI 10.1097/ALN.0b013e318242a2ec; Katoh T, 1996, BRIT J ANAESTH, V77, P265, DOI 10.1093/bja/77.2.265; Katoh T, 1999, ANESTHESIOLOGY, V90, P398, DOI 10.1097/00000542-199902000-00012; Katoh T, 1997, BRIT J ANAESTH, V79, P465, DOI 10.1093/bja/79.4.465; Ozcan MS, 2010, J NEUROSURG ANESTH, V22, P309, DOI 10.1097/ANA.0b013e3181e4b7c8; RAMPIL IJ, 1991, ANESTHESIOLOGY, V74, P429, DOI 10.1097/00000542-199103000-00007; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; STEVENS WC, 1975, ANESTHESIOLOGY, V42, P197, DOI 10.1097/00000542-197502000-00014; Struys MMRF, 2011, BRIT J ANAESTH, V107, P38, DOI 10.1093/bja/aer108; Vuyk J, 1997, ANESTHESIOLOGY, V87, P1549, DOI 10.1097/00000542-199712000-00033	17	8	8	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	APR	2013	118	4					894	902		10.1097/ALN.0b013e3182860486			9	Anesthesiology	Anesthesiology	109GR	WOS:000316355000019	23360899	Bronze			2020-06-30	J	Fraser, GL; Worby, CP; Riker, RR				Fraser, Gilles L.; Worby, Craig P.; Riker, Richard R.			Dissecting Sedation-Induced Delirium	CRITICAL CARE MEDICINE			English	Editorial Material						critical care; benzodiazepine; delirium; delirium assessment; intensive care; sedation; sedation-induced delirium	MECHANICALLY VENTILATED PATIENTS; INTENSIVE-CARE-UNIT; CRITICALLY-ILL; DEXMEDETOMIDINE; MIDAZOLAM		[Fraser, Gilles L.] Maine Med Ctr, Dept Pharm, Dept Crit Care Med, Portland, ME 04102 USA; [Worby, Craig P.] Maine Med Ctr, Dept Pharm, Portland, ME 04102 USA; [Riker, Richard R.] Maine Med Ctr, Dept Crit Care Med, Inst Neurosci, Portland, ME 04102 USA	Fraser, GL (reprint author), Maine Med Ctr, Dept Pharm, Dept Crit Care Med, Portland, ME 04102 USA.			fraser, gilles/0000-0003-0841-7946			Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Bergeron N, 2005, INTENS CARE MED, V31, P887, DOI 10.1007/s00134-005-2642-0; Bigatello LM, 2012, CRIT CARE MED, V40, P319, DOI 10.1097/CCM.0b013e318232d2cc; de Rooij SE, 2005, INT J GERIATR PSYCH, V20, P609, DOI 10.1002/gps.1343; Deans KJ, 2010, ANESTH ANALG, V111, P444, DOI 10.1213/ane.0b013e3181aa8903; Devlin JW, 2007, INTENS CARE MED, V33, P929, DOI 10.1007/s00134-007-0603-5; Dubois MJ, 2001, INTENS CARE MED, V27, P1297, DOI 10.1007/s001340101017; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Jakob SM, 2012, JAMA-J AM MED ASSOC, V307, P1151, DOI 10.1001/jama.2012.304; Jakob SM, 2009, LANCET, V373, P1824, DOI 10.1016/S0140-6736(09)60866-7; MacLullich AMJ, 2009, INT REV PSYCHIATR, V21, P30, DOI 10.1080/09540260802675031; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; Poston J, 2010, AM J RESP CRIT CARE, V181; Reade MC, 2012, CRIT CARE RESUSC, V14, P236; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Roberts DJ, 2012, DRUGS, V72, P1881, DOI 10.2165/11636220-000000000-00000; Skrobik Y, 2013, CRIT CARE MED, V41, P999, DOI 10.1097/CCM.0b013e318275d014; Weinert CR, 2007, CRIT CARE MED, V35, P393, DOI 10.1097/01.CCM.0000254339.18639.1D	19	4	4	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2013	41	4					1144	1146		10.1097/CCM.0b013e31827c02f0			4	Critical Care Medicine	General & Internal Medicine	114HN	WOS:000316731800038	23528763				2020-06-30	J	Mousa, SA; Shaqura, M; Khalefa, BI; Zollner, C; Schaad, L; Schneider, J; Shippenberg, TS; Richter, JF; Hellweg, R; Shakibaei, M; Schafer, M				Mousa, Shaaban A.; Shaqura, Mohammed; Khalefa, Baled I.; Zoellner, Christian; Schaad, Laura; Schneider, Jonas; Shippenberg, Toni S.; Richter, Jan F.; Hellweg, Rainer; Shakibaei, Mehdi; Schaefer, Michael			Rab7 Silencing Prevents mu-Opioid Receptor Lysosomal Targeting and Rescues Opioid Responsiveness to Strengthen Diabetic Neuropathic Pain Therapy	DIABETES			English	Article							NERVE GROWTH-FACTOR; INFLAMMATORY PAIN; SPINAL-CORD; SENSORY NEURONS; ENDOCYTIC TRAFFICKING; DOWN-REGULATION; RATS; BIOGENESIS; ACTIVATION; MORPHINE	Painful diabetic neuropathy is poorly controlled by analgesics and requires high doses of opioids, triggering side effects and reducing patient quality of life. This study investigated whether enhanced Rab7-mediated lysosomal targeting of peripheral sensory neuron mu-opioid receptors (MORs) is responsible for diminished opioid responsiveness in rats with streptozotocin-induced diabetes. In diabetic animals, significantly impaired peripheral opioid analgesia was associated with a loss in sensory neuron MOR and a reduction in functional MOR G-protein-coupling. In control animals, MORs were retained mainly on the neuronal cell membrane. In contrast, in diabetic rats, they were colocalized with upregulated Rab7 in LampI-positive perinuclear lysosome compartments. Silencing endogenous Rab7 with intrathecal Rab7-siRNA or, indirectly, by reversing nerve growth factor deprivation in peripheral sensory neurons not only prevented MOR targeting to lysosomes, restoring their plasma membrane density, but also rescued opioid responsiveness toward better pain relief. These findings elucidate in vivo the mechanisms by which enhanced Rab7 lysosomal targeting of MORs leads to a loss in opioid antinociception in diabetic neuropathic pain. This is in contrast to peripheral sensory neuron MOR upregulation and antinociception in inflammatory pain, and provides intriguing evidence that regulation of opioid responsiveness varies as a function of pain pathogenesis. Diabetes 62:1308-1319, 2013	[Mousa, Shaaban A.; Shaqura, Mohammed; Khalefa, Baled I.; Schaad, Laura; Schneider, Jonas; Schaefer, Michael] Charite, Dept Anaesthesiol & Intens Care Med, D-13353 Berlin, Germany; [Zoellner, Christian] Univ Klinikum Hamburg Eppendorf, Dept Anaesthesiol, Hamburg, Germany; [Shippenberg, Toni S.] NIDA, Integrat Neurosci Sect, NIH, Baltimore, MD USA; [Richter, Jan F.] Charite, Dept Clin Physiol, D-13353 Berlin, Germany; [Hellweg, Rainer] Charite, Dept Psychiat & Psychotherapy, D-13353 Berlin, Germany; [Shakibaei, Mehdi] Univ Munich, Dept Anat, Munich, Germany	Schafer, M (reprint author), Charite, Dept Anaesthesiol & Intens Care Med, Campus Virchow Klinikum & Campus Charite Mitre, D-13353 Berlin, Germany.	micha.schaefer@charite.de	Schafer, Michael/AAB-1395-2020; Shakibaei, Mehdi/AAA-7004-2020		Deutsche Forschungsgemeinschaft (DFG, Bonn, Germany)German Research Foundation (DFG) [KFO100, MO 1006/1-4, SCHA 820/3-2]; European Society of Anesthesiology	This work was supported by the Deutsche Forschungsgemeinschaft (DFG, Bonn, Germany) grants KFO100, MO 1006/1-4, and SCHA 820/3-2 and by a grant of the European Society of Anesthesiology (C.Z.).	Annemans L, 2011, CLIN DRUG INVEST, V31, P73, DOI 10.2165/11536290-000000000-00000; Apfel SC, 2002, INT REV NEUROBIOL, V50, P393; Balut CM, 2010, AM J PHYSIOL-CELL PH, V299, pC1015, DOI 10.1152/ajpcell.00120.2010; Boulton AJM, 2005, DIABETES CARE, V28, P956, DOI 10.2337/diacare.28.4.956; Brack A, 2004, PAIN, V112, P229, DOI 10.1016/j.pain.2004.08.029; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; Cahill CM, 2003, NEUROPHARMACOLOGY, V45, P543, DOI 10.1016/S0028-3908(03)00192-8; Cattaneo A, 2010, CURR OPIN MOL THER, V12, P94; Ceresa BP, 2006, J BIOL CHEM, V281, P1099, DOI 10.1074/jbc.M504175200; Chen SR, 2003, ANESTHESIOLOGY, V99, P1409, DOI 10.1097/00000542-200312000-00026; Chen SR, 2002, ANESTHESIOLOGY, V97, P1602, DOI 10.1097/00000542-200212000-00037; Courteix C, 1998, J PHARMACOL EXP THER, V285, P63; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Davidson E, 2009, EXP DIABETES RES; Dworkin RH, 2010, MAYO CLIN PROC, V85, pS3, DOI 10.4065/mcp.2009.0649; Endres-Becker J, 2007, MOL PHARMACOL, V71, P12, DOI 10.1124/mol.106.026740; Gaveriaux-Ruff C, 2011, PAIN, V152, P1238, DOI 10.1016/j.pain.2010.12.031; Hanyaloglu AC, 2008, ANN REV PHARM TOXICO, V48, P537; Harati Y, 2000, J DIABETES COMPLICAT, V14, P65, DOI 10.1016/S1056-8727(00)00060-X; Hellweg R, 2006, LEARN MEMORY, V13, P63, DOI 10.1101/lm.2606; Kanbayashi H, 2002, J INT MED RES, V30, P512, DOI 10.1177/147323000203000507; Leterrier C, 2004, J BIOL CHEM, V279, P36013, DOI 10.1074/jbc.M403990200; Li J, 2001, MOL PHARMACOL, V60, P1064; Luo MC, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-29; Martini L, 2007, FASEB J, V21, P802, DOI 10.1096/fj.06-7132com; Mousa SA, 2004, ENDOCRINOLOGY, V145, P1331, DOI 10.1210/en.2003-1287; Mousa SA, 2007, BRAIN, V130, P502, DOI 10.1093/brain/awl330; Mousa SA, 2010, J COMP NEUROL, V518, P3836, DOI 10.1002/cne.22427; Ohsawa M, 2005, J PHARMACOL SCI, V98, P25, DOI 10.1254/jphs.FP0040621; Piper RC, 2007, ANNU REV CELL DEV BI, V23, P519, DOI 10.1146/annurev.cellbio.23.090506.123319; Rosales KR, 2009, MOL BIOL CELL, V20, P2831, DOI 10.1091/mbc.E08-09-0911; Sasaki K, 2002, J UROLOGY, V168, P1259, DOI 10.1016/S0022-5347(05)64636-8; Shaqura MA, 2004, J PHARMACOL EXP THER, V308, P712, DOI 10.1124/jpet.103.057257; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; Thibault D, 2011, J BIOL CHEM, V286, P9174, DOI 10.1074/jbc.M110.166454; Truong W, 2003, ANN NEUROL, V53, P366, DOI 10.1002/ana.10465; Vanlandingham PA, 2009, J BIOL CHEM, V284, P12110, DOI 10.1074/jbc.M809277200; Watson CPN, 2003, PAIN, V105, P71, DOI 10.1016/S0304-3959(03)00160-X; Yamdeu RS, 2011, ANESTHESIOLOGY, V114, P150, DOI 10.1097/ALN.0b013e318201c88c; Yao XL, 2007, BRAIN RES, V1182, P116, DOI 10.1016/j.brainres.2007.08.076; Yu SG, 2003, J NEUROCHEM, V86, P1006, DOI 10.1046/j.1471-4159.2003.01912.x; Yuyama K, 2009, J NEUROCHEM, V109, P1250, DOI 10.1111/j.1471-4159.2009.06046.x; Zhao HB, 2001, J BIOL CHEM, V276, P39295, DOI 10.1074/jbc.M010999200; Zochodne DW, 2001, BRAIN, V124, P2319, DOI 10.1093/brain/124.11.2319; Zollner C, 2008, J CLIN INVEST, V118, P1065, DOI 10.1172/JCI25911; Zurek JR, 2001, PAIN, V90, P57, DOI 10.1016/S0304-3959(00)00386-9	46	30	30	0	7	AMER DIABETES ASSOC	ALEXANDRIA	1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA	0012-1797	1939-327X		DIABETES	Diabetes	APR	2013	62	4					1308	1319		10.2337/db12-0590			12	Endocrinology & Metabolism	Endocrinology & Metabolism	111MS	WOS:000316526000041	23230081	Green Published, Other Gold			2020-06-30	J	Bradley, AM; Valgus, JM; Bernard, S				Bradley, Amber M.; Valgus, John M.; Bernard, Stephen			Converting to Transdermal Fentanyl: Avoidance of Underdosing	JOURNAL OF PALLIATIVE MEDICINE			English	Article							CANCER PAIN; OPIOID ROTATION; ORAL MORPHINE; CONVERSION	Background: Converting between the various opioid agents continues to be challenge for many practitioners. Specifically, variable recommendations for converting to the transdermal fentanyl patch may lead to confusion among clinicians and errors in dosing. Objective: Our aim was to describe the inconsistencies among available opioid conversions with regard to transdermal fentanyl and to provide recommendations for safe and effective utilization of this product in patients with chronic pain. Results: Available reports support the use of the morphine intravenous to oral ratio of 1:3 during the conversion to transdermal fentanyl product. Conclusions: Underdosing is an often overlooked complication of switching to transdermal fentanyl. Current recommendations for converting to transdermal fentanyl do not reflect contemporary clinical practice and should be reevaluated.	[Bradley, Amber M.] Univ Georgia, Coll Pharm, Augusta, GA 30912 USA; [Valgus, John M.] Univ N Carolina Hosp & Clin, UNC Eshelman Sch Pharm, Chapel Hill, NC USA; [Bernard, Stephen] Univ N Carolina, Sch Med, Chapel Hill, NC USA	Bradley, AM (reprint author), Univ Georgia, Coll Pharm, 1120 15th St,HM 1201, Augusta, GA 30912 USA.	abradley@gru.edu	Bernard, Stephen/E-9705-2013	Bernard, Stephen/0000-0002-6501-9576			Anderson R, 2001, J PAIN SYMPTOM MANAG, V21, P397, DOI 10.1016/S0885-3924(01)00271-8; ASHBURN MA, 1993, ANESTH ANALG, V76, P402; Astolfi J, 2011, PHARMACOTHERAPY PATH, P147; Clemens KE, 2007, JPN J CLIN ONCOL, V37, P302, DOI 10.1093/jjco/hym017; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Gammaitoni AR, 2003, CLIN J PAIN, V19, P286, DOI 10.1097/00002508-200309000-00002; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; HANKS GW, 1995, J PAIN SYMPTOM MANAG, V10, P87, DOI 10.1016/S0885-3924(08)80004-8; Hui D, 2011, APPROACH INTERNAL ME; Janssen Pharmaceutica Products, DUR FENT TRANSD SYST; Ketchum K, 2005, OREGON DUR BOARD NOV, V7; Knotkova H, 2009, J PAIN SYMPTOM MANAG, V38, P426, DOI 10.1016/j.jpainsymman.2009.06.001; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; Mcpherson M., 2010, DEMYSTIFYING OPIOID; Mercadante S, 2011, PALLIATIVE MED, V25, P504, DOI 10.1177/0269216311406577; PAYNE R, 1992, J PAIN SYMPTOM MANAG, V7, pS40, DOI 10.1016/0885-3924(92)90052-J; SIMMONDS MA, 1992, J PAIN SYMPTOM MANAG, V7, pS36, DOI 10.1016/0885-3924(92)90051-I; Sinatra R. S., 2010, ESSENCE ANALGESIA AN; Slatkin NE, 2009, CURR MED RES OPIN, V25, P2133, DOI 10.1185/03007990903120158; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; Webster LR, 2012, PAIN MED, V13, P562, DOI 10.1111/j.1526-4637.2012.01357.x; Webster LR, 2012, PAIN MED, V13, P571, DOI 10.1111/j.1526-4637.2012.01356.x	22	5	5	1	7	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1096-6218			J PALLIAT MED	J. Palliat. Med.	APR	2013	16	4					409	411		10.1089/jpm.2012.0424			3	Health Care Sciences & Services	Health Care Sciences & Services	116BJ	WOS:000316857000017	23477303				2020-06-30	J	Spahn, V; Fischer, O; Endres-Becker, J; Schafer, M; Stein, C; Zollner, C				Spahn, Viola; Fischer, Oliver; Endres-Becker, Jeannette; Schaefer, Michael; Stein, Christoph; Zoellner, Christian			Opioid withdrawal increases transient receptor potential vanilloid 1 activity in a protein kinase A-dependent manner	PAIN			English	Article						Opioids; Withdrawal; TRPV1; Hyperalgesia; cAMP	RAT SENSORY NEURONS; MOLECULAR-MECHANISMS; CAPSAICIN RECEPTOR; POTASSIUM CURRENTS; ADENYLATE-CYCLASE; PEPTIDE RELEASE; MORPHINE; TRPV1; SENSITIZATION; PAIN	Hyperalgesia is a cardinal symptom of opioid withdrawal. The transient receptor potential vanilloid 1 (TRPV1) is a ligand-gated ion channel expressed on sensory neurons responding to noxious heat, protons, and chemical stimuli such as capsaicin. TRPV1 can be inhibited via mu-opioid receptor (MOR)-mediated reduced activity of adenylyl cyclases (ACs) and decreased cyclic adenosine monophosphate (cAMP) levels. In contrast, opioid withdrawal following chronic activation of MOR uncovers AC superactivation and subsequent increases in cAMP and protein kinase A (PKA) activity. Here we investigated (1) whether an increase in cAMP during opioid withdrawal increases the activity of TRPV1 and (2) how opioid withdrawal modulates capsaicin-induced nocifensive behavior in rats. We applied whole-cell patch clamp, microfluorimetry, cAMP assays, radioligand binding, site-directed mutagenesis, and behavioral experiments. Opioid withdrawal significantly increased cAMP levels and capsaicin-induced TRPV1 activity in both transfected human embryonic kidney 293 cells and dissociated dorsal root ganglion (DRG) neurons. Inhibition of AC and PKA, as well as mutations of the PKA phosphorylation sites threonine 144 and serine 774, prevented the enhanced TRPV1 activity. Finally, capsaicin-induced nocifensive behavior was increased during opioid withdrawal in vivo. In summary, our results demonstrate an increased activity of TRPV1 in DRG neurons as a new mechanism contributing to opioid withdrawal-induced hyperalgesia. (c) 2013 International Association for the Study of Pain. Published by Elsevier B. V. All rights reserved.	[Spahn, Viola; Fischer, Oliver; Endres-Becker, Jeannette; Schaefer, Michael; Stein, Christoph; Zoellner, Christian] Charite, Klin Anaesthesiol & Operat Intensivmed, D-12203 Berlin, Germany; [Zoellner, Christian] Univ Klinikum Hamburg Eppendorf, Anasthesiol Klin, D-20251 Hamburg, Germany	Spahn, V (reprint author), Charite, Klin Anaesthesiol & Operat Intensivmed, Campus Benjamin Franklin,Hindenburgdamm 30, D-12203 Berlin, Germany.	viola.spahn@charite.de	Schafer, Michael/AAB-1395-2020	Seitz (nee Spahn), Viola/0000-0002-8086-8090; Stein, Christoph/0000-0001-5240-6836	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [KFO 100/2]; Bundesministerium fur Bildung und ForschungFederal Ministry of Education & Research (BMBF) [MedSys 0101-31P5783]; European Society of Anaesthesiology	This work was supported by Deutsche Forschungsgemeinschaft (Grant KFO 100/2); Bundesministerium fur Bildung und Forschung (Grant MedSys 0101-31P5783) and a Grant by the European Society of Anaesthesiology (C.Z.). We thank Nicole Vogel for technical assistance.	AKINS PT, 1993, NEUROSCIENCE, V56, P759, DOI 10.1016/0306-4522(93)90372-M; Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; ANTONIJEVIC I, 1995, J NEUROSCI, V15, P165; Bagley EE, 2005, NEURON, V45, P433, DOI 10.1016/j.neuron.2004.12.049; Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Bie BH, 2005, J NEUROSCI, V25, P3824, DOI 10.1523/JNEUROSCI.5010-04.2005; Bolyard LA, 2000, PAIN, V88, P277, DOI 10.1016/S0304-3959(00)00341-9; Borgland SL, 2001, J PHYSIOL-LONDON, V536, P35, DOI 10.1111/j.1469-7793.2001.t01-1-00035.x; Bujedo Borja Mugabure, 2012, J Opioid Manag, V8, P177, DOI 10.5055/jom.2012.0114; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Christie MJ, 2008, BRIT J PHARMACOL, V154, P384, DOI 10.1038/bjp.2008.100; Crandall M, 2002, PAIN, V98, P109, DOI 10.1016/S0304-3959(02)00034-9; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Diem R, 2001, J NEUROSCI, V21, P2058, DOI 10.1523/JNEUROSCI.21-06-02058.2001; Duarte PC, 2012, EXP NEUROL, V234, P466, DOI 10.1016/j.expneurol.2012.01.021; Endres-Becker J, 2007, MODULATION TRANSIENT; Endres-Becker J, 2007, MOL PHARMACOL, V71, P12, DOI 10.1124/mol.106.026740; Gold MS, 1998, J NEUROSCI, V18, P10345; Hackel D, 2012, P NATL ACAD SCI USA, V109, pE2018, DOI 10.1073/pnas.1120800109; Herz A., 1971, ADV DRUG RES, V6, P79; Huang JJ, 2006, SEMIN CELL DEV BIOL, V17, P638, DOI 10.1016/j.semcdb.2006.11.002; Irnaten M, 2003, NEUROSCIENCE, V116, P573, DOI 10.1016/S0306-4522(02)00657-7; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Lee CWS, 2011, NEUROCHEM RES, V36, P2008, DOI 10.1007/s11064-011-0525-z; Maione S, 2009, J NEUROPHYSIOL, V101, P2411, DOI 10.1152/jn.91225.2008; Matsumoto S, 2007, NEUROPHARMACOLOGY, V52, P904, DOI 10.1016/j.neuropharm.2006.10.008; Mert T, 2009, N-S ARCH PHARMACOL, V380, P415, DOI 10.1007/s00210-009-0447-3; Mohapatra DP, 2005, J BIOL CHEM, V280, P13424, DOI 10.1074/jbc.M410917200; Mohapatra DP, 2003, J BIOL CHEM, V278, P50080, DOI 10.1074/jbc.M306619200; Mohapatra DP, 2003, MOL CELL NEUROSCI, V23, P314, DOI 10.1016/S1044-7431(03)00054-X; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Phelps CB, 2010, J BIOL CHEM, V285, P731, DOI 10.1074/jbc.M109.052548; Rathee PK, 2002, J NEUROSCI, V22, P4740, DOI 10.1523/JNEUROSCI.22-11-04740.2002; Rittner HL, 2009, BRAIN BEHAV IMMUN, V23, P548, DOI 10.1016/j.bbi.2009.02.007; Ross GR, 2012, AM J PHYSIOL-CELL PH, V302, pC1152, DOI 10.1152/ajpcell.00171.2011; SCHROEDER JE, 1993, J NEUROSCI, V13, P867; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; Sugiura T, 2002, J NEUROPHYSIOL, V88, P544, DOI 10.1152/jn.2002.88.1.544; Szallasi A, 1999, MOL PHARMACOL, V56, P581; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Tumati S, 2010, EUR J PHARMACOL, V648, P95, DOI 10.1016/j.ejphar.2010.08.042; Tumati S, 2009, J PHARMACOL EXP THER, V330, P810, DOI 10.1124/jpet.109.151704; Vardanyan A, 2009, J PAIN, V10, P243, DOI 10.1016/j.jpain.2008.07.004; Vellani V, 2001, J PHYSIOL-LONDON, V534, P813, DOI 10.1111/j.1469-7793.2001.00813.x; Vetter I, 2006, MOL PAIN, V2, DOI 10.1186/1744-8069-2-22; Vetter I, 2008, J BIOL CHEM, V283, P19540, DOI 10.1074/jbc.M707865200; Watts VJ, 2002, J PHARMACOL EXP THER, V302, P1, DOI 10.1124/jpet.302.1.1; Watts VJ, 2005, PHARMACOL THERAPEUT, V106, P405, DOI 10.1016/j.pharmthera.2004.12.005; Xia MH, 2011, CELL MOL NEUROBIOL, V31, P901, DOI 10.1007/s10571-011-9689-y; YAKSH TL, 1986, ANESTHESIOLOGY, V64, P54, DOI 10.1097/00000542-198601000-00009; Yue X, 2006, EUR J PHARMACOL, V540, P57, DOI 10.1016/j.ejphar.2006.04.033; Zaki PA, 2000, J PHARMACOL EXP THER, V292, P1127; Zhang JM, 2002, J NEUROPHYSIOL, V88, P1387, DOI 10.1152/jn.2002.88.3.1387; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4; Zollner C, 2010, ANAESTHESIST, V59, P983, DOI 10.1007/s00101-010-1803-x	57	41	41	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	APR	2013	154	4					598	608		10.1016/j.pain.2012.12.026			11	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	113HW	WOS:000316658200012	23398938				2020-06-30	J	Margarido, CB; Dlacic, A; Balki, M; Furtado, L; Carvalho, JCA				Margarido, Clarita B.; Dlacic, Aleksandra; Balki, Mrinalini; Furtado, Louis; Carvalho, Jose C. A.			The epidural electric stimulation test does not predict local anesthetic spread or consumption in labour epidural analgesia	CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							NERVE-STIMULATION; CATHETER; CONFIRMATION	The epidural electrical stimulation test (EEST) is a highly specific and sensitive test for confirming placement of the epidural catheter in the epidural space. The purpose of this study was to investigate if the EEST could predict the spread and consumption of local anesthetic solutions during labour epidural analgesia. This observational study was conducted in labouring parturients requesting epidural analgesia. The EEST was performed after the epidural catheter placement (T0) and repeated five minutes after a test dose with 2% lidocaine 3 mL (T1). The minimum current required to elicit the motor response at each time point was recorded. A loading dose of 0.125% bupivacaine 10 mL and fentanyl 50 mu g was administered and followed by patient-controlled epidural analgesia with 0.0625% bupivacaine and fentanyl 2 mu g center dot mL(-1) (baseline infusion 10 mL center dot hr(-1), bolus dose 5 mL, lockout interval ten minutes, maximum dose 20 mL center dot hr(-1)). The primary outcome was the correlation between the current required to elicit motor responses at T0 and T1 and the consumption of bupivacaine in the first two hours of epidural administration. The secondary outcomes included the muscle contraction patterns determined by the EEST and the incidence of failed, inadequate, or asymmetric blocks. The study was conducted in 102 parturients. The mean electric current required to elicit muscle response was 4.43 mA (range 1-10 mA) at T0, 5.97 mA (range 1-14 mA) at T1, and the mean Delta (T1-T0) current was 1.54 mA (range 0-8 mA). There was no correlation between either the mean baseline current required or the Delta (T1-T0) current and the total bupivacaine consumption at two hours. The incidence of inadequate blocks at two hours was 18%; however, none of the catheters required replacement. Unilateral left (34%) or right (31%) leg contraction was the most frequent pattern elicited by the EEST. The EEST shows a wide range of electrical current requirements and elicits a variety of muscle twitch patterns on the lower limbs. Although it confirms the epidural placement of the catheter, the EEST cannot be used to predict the spread or consumption of the local anesthetic solution during labour epidural analgesia.	[Margarido, Clarita B.; Dlacic, Aleksandra; Balki, Mrinalini] Univ Toronto, Mt Sinai Hosp, Dept Anesthesia & Pain Management, Toronto, ON M5G 1X5, Canada; [Furtado, Louis] Queens Univ, Kingston, ON, Canada; [Carvalho, Jose C. A.] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada; [Carvalho, Jose C. A.] Univ Toronto, Dept Obstet & Gynecol, Toronto, ON, Canada; [Margarido, Clarita B.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Anesthesia, Div Obstet Anaesthesia, Toronto, ON M4N 3M5, Canada	Margarido, CB (reprint author), Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Anesthesia, Div Obstet Anaesthesia, M5-318,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	claritamargarido@hotmail.com	Balki, Mrinalini/A-2669-2015				de Medicis E, 2005, ANESTH ANALG, V101, P1830, DOI 10.1213/01.ANE.0000184130.73634.BE; Eappen S, 1998, INT J OBSTET ANESTH, V7, P220, DOI 10.1016/S0959-289X(98)80042-3; GIELEN MJM, 1991, ACTA ANAESTH SCAND, V35, P81, DOI 10.1111/j.1399-6576.1991.tb03246.x; Goobie SM, 2003, ANESTH ANALG, V97, P984, DOI 10.1213/01.ANE.0000080609.05942.38; Hermanides J, 2012, BRIT J ANAESTH, V109, P144, DOI 10.1093/bja/aes214; Pan PH, 2004, INT J OBSTET ANESTH, V13, P227, DOI 10.1016/j.ijoa.2004.04.008; Ready LB, 1999, REGION ANESTH PAIN M, V24, P499, DOI 10.1016/S1098-7339(99)90038-X; Tsui BCH, 2004, ANESTHESIOLOGY, V100, P683, DOI 10.1097/00000542-200403000-00032; Tsui BCH, 1998, CAN J ANAESTH, V45, P640, DOI 10.1007/BF03012093; Tsui BCH, 2001, ANAESTHESIA, V56, P816; Tsui BCH, 1999, REGION ANESTH PAIN M, V24, P17, DOI 10.1016/S1098-7339(99)90160-8; Tsui BCH, 2000, REGION ANESTH PAIN M, V25, P306, DOI 10.1016/S1098-7339(00)90017-8	12	7	7	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANESTH	Can. J. Anesth.	APR	2013	60	4					393	398		10.1007/s12630-013-9887-9			6	Anesthesiology	Anesthesiology	108LF	WOS:000316293900008	23341165	Bronze			2020-06-30	J	Berg, T; Jorgenrud, B; Strand, DH				Berg, Thomas; Jorgenrud, Benedicte; Strand, Dag Helge			Determination of Buprenorphine, Fentanyl and LSD in Whole Blood by UPLCMS-MS	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; MASS-SPECTROMETRY METHOD; PH MOBILE-PHASE; ACID DIETHYLAMIDE LSD; O-H-LSD; ORAL FLUID; ISO-LSD; PHARMACEUTICAL ANALYSIS; CYTOCHROME-P450 3A4; ION SUPPRESSION	A sensitive ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS-MS) method has been developed and validated for the quantification of buprenorphine, fentanyl and lysergic acid diethylamide (LSD) in whole blood. Sample preparation was performed by liquid-liquid extraction (LLE) with methyl tert-butyl ether. UPLC-MS-MS analysis was performed with a mobile phase consisting of ammonium formate (pH 10.2) and methanol. Positive electrospray ionization MS-MS detection was performed with two multiple reaction monitoring transitions for each of the analytes and the deuterium labeled internal standards. Limit of detection values of buprenorphine, fentanyl and LSD were 0.28, 0.044 and 0.0097 ng/mL and limit of quantification values were 0.94, 0.14 and 0.036 ng/mL, respectively. Most phospholipids were removed during LLE. No or only minor matrix effects were observed. The method has been routinely used at the Norwegian Institute of Public Health since September 2011 for qualitative and quantitative detections of buprenorphine, fentanyl and/or LSD in more than 400 whole blood samples with two replicates per sample.	[Berg, Thomas; Strand, Dag Helge] Norwegian Inst Publ Hlth, Div Forens Med & Drug Abuse Res, Oslo, Norway; [Jorgenrud, Benedicte] Aker Sykehus, Oslo Univ Hosp, Hormone Lab, Oslo, Norway	Berg, T (reprint author), Norwegian Inst Publ Hlth, Div Forens Med & Drug Abuse Res, Oslo, Norway.	thomas.berg@fhi.no		Berg, Thomas/0000-0002-7675-2095; Jorgenrud, Benedicte/0000-0001-5917-8776			Annesley TM, 2003, CLIN CHEM, V49, P1041, DOI 10.1373/49.7.1041; Badawi N, 2009, CLIN CHEM, V55, P2004, DOI 10.1373/clinchem.2008.122341; Berg T, 2009, J CHROMATOGR B, V877, P421, DOI 10.1016/j.jchromb.2008.12.052; Bjork MK, 2010, ANAL BIOANAL CHEM, V396, P2393, DOI 10.1007/s00216-009-3268-9; Canezin J, 2001, J CHROMATOGR B, V765, P15, DOI 10.1016/S0378-4347(01)00386-3; Ceccato A, 2003, J PHARMACEUT BIOMED, V32, P619, DOI 10.1016/S0731-7085(03)00169-9; Chambers E, 2007, J CHROMATOGR B, V852, P22, DOI 10.1016/j.jchromb.2006.12.030; CHRUBASIK J, 1988, ANESTHESIOLOGY, V68, P929, DOI 10.1097/00000542-198806000-00016; Chung A, 2009, J ANAL TOXICOL, V33, P253, DOI 10.1093/jat/33.5.253; CONE EJ, 1984, DRUG METAB DISPOS, V12, P577; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Cooreman S, 2010, J SEP SCI, V33, P2654, DOI 10.1002/jssc.201000330; Favretto D, 2007, INT J LEGAL MED, V121, P259, DOI 10.1007/s00414-006-0078-x; Ghassabian S, 2012, J CHROMATOGR B, V903, P126, DOI 10.1016/j.jchromb.2012.07.005; Giacomelli S, 1998, LIFE SCI, V63, P215, DOI 10.1016/S0024-3205(98)00262-8; Gray N, 2011, J CHROMATOGR A, V1218, P2098, DOI 10.1016/j.chroma.2010.10.104; Guillarme D, 2008, EUR J PHARM BIOPHARM, V68, P430, DOI 10.1016/j.ejpb.2007.06.018; Guillarme D, 2007, EUR J PHARM BIOPHARM, V66, P475, DOI 10.1016/j.ejpb.2006.11.027; Hopfgartner G, 2003, MASS SPECTROM REV, V22, P195, DOI 10.1002/mas.10050; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Iribarne C, 1997, LIFE SCI, V60, P1953, DOI 10.1016/S0024-3205(97)00160-4; JASINSKI DR, 1978, ARCH GEN PSYCHIAT, V35, P501; Johansen SS, 2005, J CHROMATOGR B, V825, P21, DOI 10.1016/j.jchromb.2004.12.040; Klette KL, 2000, J ANAL TOXICOL, V24, P550, DOI 10.1093/jat/24.7.550; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Little JL, 2006, J CHROMATOGR B, V833, P219, DOI 10.1016/j.jchromb.2006.02.011; Lund HME, 2011, J CHROMATOGR B, V879, P3367, DOI 10.1016/j.jchromb.2011.09.002; Matuszewski BK, 2003, ANAL CHEM, V75, P3019, DOI 10.1021/ac020361s; Mess JN, 2009, BIOANALYSIS, V1, P1419, DOI 10.4155/BIO.09.133; Muller C, 2002, J CHROMATOGR B, V773, P47, DOI 10.1016/S1570-0232(02)00142-3; Novakova L, 2009, ANAL CHIM ACTA, V656, P8, DOI 10.1016/j.aca.2009.10.004; Oiestad EL, 2007, CLIN CHEM, V53, P300, DOI 10.1373/clinchem.2006.074237; Oiestad EL, 2011, J ANAL TOXICOL, V35, P280, DOI 10.1093/anatox/35.5.280; Pang LQ, 2008, J CHROMATOGR B, V869, P118, DOI 10.1016/j.jchromb.2008.05.027; Passie T, 2008, CNS NEUROSCI THER, V14, P295, DOI 10.1111/j.1755-5949.2008.00059.x; Peng L, 2008, J CHROMATOGR A, V1179, P131, DOI 10.1016/j.chroma.2007.11.048; Polettini A, 2001, J CHROMATOGR B, V754, P447, DOI 10.1016/S0378-4347(01)00029-9; Selden T, 2011, FORENSIC SCI INT, V209, P113, DOI 10.1016/j.forsciint.2011.01.011; Sporer KA, 2004, ANN EMERG MED, V43, P580, DOI 10.1016/j.annemergmed.2003.11.006; Verplaetse R, 2012, J CHROMATOGR A, V1249, P147, DOI 10.1016/j.chroma.2012.06.023; Verplaetse R, 2012, FORENSIC SCI INT, V215, P136, DOI 10.1016/j.forsciint.2011.01.047; Verplaetse R, 2010, J CHROMATOGR B, V878, P1987, DOI 10.1016/j.jchromb.2010.05.033; Vindenes V, 2012, FORENSIC SCI INT, V219, P1, DOI [10.1016/j.forsciint.2011.11.004, 10.1016/j.forsciint.2012.01.001]; WALSH SL, 1995, J PHARMACOL EXP THER, V274, P361; Wren SAC, 2006, J CHROMATOGR A, V1119, P140, DOI 10.1016/j.chroma.2006.02.052; Xia YQ, 2009, RAPID COMMUN MASS SP, V23, P2125, DOI 10.1002/rcm.4121	47	15	15	2	35	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	APR	2013	37	3					159	165		10.1093/jat/bkt005			7	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	108KD	WOS:000316290800004	23423312	Green Published, Bronze			2020-06-30	J	Drummond, JC; Blake, JL; Patel, PM; Clopton, P; Schulteis, G				Drummond, John C.; Blake, Jacob L.; Patel, Piyush M.; Clopton, Paul; Schulteis, Gery			An Observational Study of the Influence of "White-coat Hypertension" on Day-of-Surgery Blood Pressure Determinations	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						baseline blood pressure; preoperative evaluation; white-coat hypertension	INTRAOPERATIVE HYPOTENSION; PROGNOSTIC VALUE; HOME; PREVALENCE; PREDICTORS; MORTALITY	Background: Because decisions as to what range of intraoperative blood pressure (BP) is consistent with cerebral well-being are often made in reference to "baseline BP," we sought to determine whether day-of-surgery BPs accurately reflect baseline BP, as defined by ambulatory clinic BPs over the preceding 7 months. Methods: Consecutive patients (n = 101) who were severely hypertensive (Severe-HTN), systolic (S) > 160mm Hg, or diastolic (D)> 100 at first operating room BP (1st OR-BP) were identified retrospectively. Two additional groups were formed from patients whose 1st OR-BP was moderately hypertensive (Mod-HTN, systolic BP = 140 to 159 and/ or diastolic BP = 90 to 99; and normotensive, SBP = 110 to 139 and DBP < 89). 1st OR-BP was compared with: (1) BP before transfer to the OR (Pre-OR-BP); (2) BP during ambulatory evaluation 1 to 30 days preoperatively (Preop-Eval-BP); and (3) Baseline-BP (average of at least 3 ambulatory clinic BPs during the preceding 7 months). Comorbidity data were collected. Results: For Severe-HTNs, 1st OR-BP, and Pre-OR-BP (expressed as mean arterial pressure) exceeded Baseline-BP by 16.4 +/- 11.6 (SD) and 5.2 +/- 11.6 (SD), respectively (P < 0.05). Preop-Eval-BP was not different from Baseline-BP. For Mod-HTNs, 1st OR-BP exceeded Baseline-BP by 7.4 +/- 8.1 (SD) (P < 0.05). But, Pre-OR-BP and Preop-Eval-BP did not differ from Baseline-BP. Among normotensives, 1st OR-BP was not different from Preop-Eval-BP or Baseline-BP. Hypertension, number of antihypertensive medications, vascular diagnoses (peripheral, coronary, cerebral), diabetes, and renal disease were more common in the hypertensive groups. The number of an-tihypertensive medications, a history of coronary disease, and insulin administration were predictors of an increase in 1st OR-BP over Baseline-BP. Conclusions: For most patients whose 1st OR-BP is hypertensive, that BP is greater than ambulatory clinic BPs recorded during the preceding 7 months. For most patients with SevereHTN at 1st OR-BP, day-of-surgery BPs overestimate Baseline-BP and reference to prehospitalization BPs is advisable. When 1st OR-BP is normotensive, that BP usually reflects Baseline-BP.	[Drummond, John C.; Patel, Piyush M.; Schulteis, Gery] Univ Calif San Diego, Dept Anesthesiol, San Diego, CA 92103 USA; [Drummond, John C.; Patel, Piyush M.; Schulteis, Gery] VA San Diego Healthcare Syst, San Diego, CA USA; [Clopton, Paul] VA San Diego Healthcare Syst, Res & Dev Serv, San Diego, CA USA; [Blake, Jacob L.] Southwest Intervent Pain Clin, Vancouver, WA USA	Drummond, JC (reprint author), VA Med Ctr, Anesthesia Serv 125, La Jolla Village Dr, San Diego, CA 92161 USA.	jdrummond@ucsd.edu			Department of Veterans AffairsUS Department of Veterans Affairs; Department of Anesthesiology, The University of California, San Diego; Research Career Scientist Award from Biomedical Laboratory Research & Development Program, Veterans Health Administration	Salary support for J.C.D. and P.M.P.: The Department of Veterans Affairs and the Department of Anesthesiology, The University of California, San Diego; Salary support for P.C.: The Department of Veterans Affairs; Salary support for G.S.: Research Career Scientist Award from Biomedical Laboratory Research & Development Program, Veterans Health Administration.	ARMITAGE P, 1966, CLIN SCI, V30, P325; Ben-Dov IZ, 2007, HYPERTENSION, V49, P1235, DOI 10.1161/HYPERTENSIONAHA.107.087262; Bergese SD, 2010, ASA NEWS LETT, V74, P22; Bijker JB, 2012, ANESTHESIOLOGY, V116, P658, DOI 10.1097/ALN.0b013e3182472320; Bijker JB, 2009, ANESTHESIOLOGY, V111, P1217, DOI 10.1097/ALN.0b013e3181c14930; Chobanian AV, 2003, JAMA-J AM MED ASSOC, V289, P2560, DOI 10.1001/jama.289.19.2560; de la Sierra A, 2009, HYPERTENSION, V53, P466, DOI 10.1161/HYPERTENSIONAHA.108.124008; Eguchi K, 2011, BLOOD PRESS MONIT, V16, P142, DOI 10.1097/MBP.0b013e328346d669; Fagard RH, 2008, HYPERTENSION, V51, P55, DOI 10.1161/HYPERTENSIONAHA.107.100727; Henskens LH, 2008, J HYPERTENS, V26, P691, DOI 10.1097/HJH.0b013e3282f4225f; JYOTHINAGARAM SG, 1990, J HUM HYPERTENS, V4, P269; Ohkubo T, 2002, J HYPERTENS, V20, P2183, DOI 10.1097/00004872-200211000-00017; Owens P, 1999, HYPERTENSION, V34, P267, DOI 10.1161/01.HYP.34.2.267; Parati G, 2008, J HYPERTENS, V26, P1505, DOI 10.1097/HJH.0b013e328308da66; Pickering TG, 2005, HYPERTENSION, V45, P142, DOI 10.1161/01.HYP.0000150859.47929.8e; Pool JL, 2007, CLIN THER, V29, P61, DOI 10.1016/j.clinthera.2007.01.007; Sanders RD, 2011, ANAESTHESIA, V66, P968, DOI 10.1111/j.1365-2044.2011.06915.x; Sega R, 2005, CIRCULATION, V111, P1777, DOI 10.1161/01.CIR.0000160923.04524.5B; Soo JCL, 2011, ANAESTHESIA, V66, P354, DOI 10.1111/j.1365-2044.2011.06657.x; Staessen JA, 1999, JAMA-J AM MED ASSOC, V282, P539, DOI 10.1001/jama.282.6.539; Staessen JA, 1997, HYPERTENSION, V29, P30, DOI 10.1161/01.HYP.29.1.30; Verdecchia P, 2000, HYPERTENSION, V35, P844, DOI 10.1161/01.HYP.35.3.844; Yocum GT, 2009, ANESTHESIOLOGY, V110, P254, DOI 10.1097/ALN.0b013e3181942c7a	23	16	17	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	APR	2013	25	2					154	161		10.1097/ANA.0b013e31827a0151			8	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	103XN	WOS:000315952900006	23211641				2020-06-30	J	Zhang, CY; Wang, MH; Wang, RR; Wang, WJ				Zhang, Chunyan; Wang, Maohua; Wang, Rurong; Wang, Wenjian			Accuracy of End-tidal CO2 Measurement Through the Nose and Pharynx in Nonintubated Patients During Digital Subtraction Cerebral Angiography	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						end-tidal CO2; accuracy; spontaneously breathing; Smart CapnoLine; digital subtraction angiography; non-intubated anesthesia	PROCEDURAL SEDATION; CARBON-DIOXIDE; RESPIRATORY EVENTS; OBESE-PATIENTS; CAPNOGRAPHY; ANESTHESIA; CAPNOMETRY; ANALGESIA; PCO2	Objective: To determine the accuracy of end-tidal CO2 (PETCO2) obtained in the nose through the Smart CapnoLine and in the pharynx through the modified Filterline H Set with supplemental oxygen at 5 L/min in nonintubated patients undergoing digital subtraction cerebral angiography (DSA). Type of Study: Prospective, observational. Patients: Twenty patients with disturbance of consciousness because of brain disease, who will receive DSA. Methods: PETCO2 was measured in the nose through the Smart CapnoLine and in the pharynx using the modified Filterline H Set that was inserted through the nasopharyngeal airway. Oxygen was administered through the Smart CapnoLine at a rate of 5 L/min. Five minutes after a constant and normally shaped capnography waveform, arterial blood was drawn from an indwelling femoral catheter for analyzing arterial CO2 partial pressure (PaCO2), and PETCO2 that was measured through the nose and the pharynx were simultaneously recorded. After the DSA procedure, PaCO2 was analyzed again. Data were analyzed with Pearson correlation and Bland-Altman analysis. Results: PETCO2 sampled from both the nose and the pharynx was significantly correlated with PaCO2, and the correlation coefficients had approximate values, 0.832 (P < 0.0001) for PaCO2 with PETCO2 through the nose and 0.836 (P < 0.0001) for PaCO2 with PETCO2 through the pharynx. The mean bias +/- SD for PETCO2 and PaCO2 was 4.53 +/- 2.76 mm Hg (nose) and 3.22 +/- 2.86 mm Hg (pharynx). The 95% level of agreement for PETCO2 and PaCO2 ranged from -0.90 to 9.95 mm Hg (nose) and from -2.39 to 8.82 mm Hg (pharynx). End-tidal CO2 measurements through the nose and the pharynx had comparable performance. The correlation of PETCO2 measured through the nose and the pharynx was 0.971 (P < 0.001). The difference between PETCO2 measured through the nose and the pharynx was 1.31 +/- 1.25 mm Hg, and t test results showed that arterial to end-tidal CO2 pressure difference (Pa-ETCO2) in sampling through the nose was significantly greater than Pa-ETCO2 sampling through the pharynx (P < 0.05). Conclusions: In a clinical setting, end-tidal CO2 measurements sampled from the nose and the pharynx were accurate and reliable in nonintubated patients with a nasopharynx airway in place during DSA.	[Zhang, Chunyan; Wang, Maohua; Wang, Rurong; Wang, Wenjian] Sichuan Univ, West China Hosp, Peoples Hosp Henan Prov, Chengdu 610041, Sichuan, Peoples R China	Wang, RR (reprint author), Sichuan Univ, West China Hosp, Dept Anesthesiol, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China.	66zhangchunyan@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81170077]	Supported by National Natural Science Foundation of China (81170077).	Ab Rahman NHN, 2010, INT J EMERG MED, V3, P315, DOI 10.1007/s12245-010-0233-5; Abramo TJ, 1997, CRIT CARE MED, V25, P1242, DOI 10.1097/00003246-199707000-00029; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Burton JH, 2006, ACAD EMERG MED, V13, P500, DOI 10.1197/j.aem.2005.12.017; Cacho G, 2010, REV ESP ENFERM DIG, V102, P86, DOI 10.4321/s1130-01082010000200003; Chudnofsky CR, 2006, ROSENS EMERGENCY MED, P2938; Deitch K, 2010, ANN EMERG MED, V55, P258, DOI 10.1016/j.annemergmed.2009.07.030; Eichhorn V, 2010, CURR OPIN ANESTHESIO, V23, P494, DOI 10.1097/ACO.0b013e32833b9c9f; FLETCHER R, 1984, BRIT J ANAESTH, V56, P109, DOI 10.1093/bja/56.2.109; Gravenstein N, 1985, J Clin Monit, V1, P6, DOI 10.1007/BF02832683; Green SM, 2010, ANN EMERG MED, V55, P265, DOI 10.1016/j.annemergmed.2009.08.019; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Hou Wen-Yeong, 1993, Journal of the Formosan Medical Association, V92, P553; Kasuya Y, 2009, ANESTHESIOLOGY, V111, P609, DOI 10.1097/ALN.0b013e3181b060b6; Krauss B, 2007, ANN EMERG MED, V50, P172, DOI 10.1016/j.annemergmed.2006.10.016; Lightdale JR, 2006, PEDIATRICS, V117, pE1170, DOI 10.1542/peds.2005-1709; McCarter T, 2008, AM HEALTH DRUG BENEF, V1, P28; Miller R. D., 2009, MILLERS ANESTHESIA; Miner JR, 2002, ACAD EMERG MED, V9, P275, DOI 10.1197/aemj.9.4.275; Qadeer MA, 2009, GASTROENTEROLOGY, V136, P1568, DOI 10.1053/j.gastro.2009.02.004; RICH GF, 1990, ANESTHESIOLOGY, V73, P265, DOI 10.1097/00000542-199008000-00013; Sandlin Debbie, 2002, J Perianesth Nurs, V17, P277, DOI 10.1053/jpan.2002.34336; Soto RG, 2004, ANESTH ANALG, V99, P379; Takano Y, 2003, RESP MED, V97, P476, DOI 10.1053/rmed.2002.1468; Waugh JB, 2011, J CLIN ANESTH, V23, P189, DOI 10.1016/j.jclinane.2010.08.012; Willinsky RA, 2003, RADIOLOGY, V227, P522, DOI 10.1148/radiol.2272012071; Yamamori Shinji, 2008, J Clin Monit Comput, V22, P209, DOI 10.1007/s10877-008-9126-z; Yazigi Alexandre, 2007, Middle East Journal of Anesthesiology, V19, P483	28	6	8	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	APR	2013	25	2					191	196		10.1097/ANA.0b013e31827c9d5a			6	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	103XN	WOS:000315952900011	23269088				2020-06-30	J	Haldar, R; Gyanesh, P; Bettaswamy, G				Haldar, Rudrashish; Gyanesh, Prakhar; Bettaswamy, Guruprasad			Isolated Bradycardia Due to Skull Pin Fixation: An Unusual Occurrence	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Letter							HYPERTENSION		[Haldar, Rudrashish; Gyanesh, Prakhar] Sanjay Gandhi Post Grad Inst Med Sci, Dept Anaesthesiol, Lucknow, Uttar Pradesh, India; [Bettaswamy, Guruprasad] Sanjay Gandhi Post Grad Inst Med Sci, Dept Neurosurg, Lucknow, Uttar Pradesh, India	Haldar, R (reprint author), Sanjay Gandhi Post Grad Inst Med Sci, Dept Anaesthesiol, Lucknow, Uttar Pradesh, India.						BEDFORD RF, 1980, ANESTH ANALG, V59, P435; Chowdhury T, 2012, SAUDI J ANAESTH, V6, P308, DOI 10.4103/1658-354X.101234; HILLMAN DR, 1987, ANESTHESIOLOGY, V67, P1001, DOI 10.1097/00000542-198712000-00026; SHAPIRO HM, 1972, ANESTHESIOLOGY, V37, P399, DOI 10.1097/00000542-197210000-00008	4	3	3	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	APR	2013	25	2					206	207		10.1097/ANA.0b013e31827d1cac			2	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	103XN	WOS:000315952900012	23242253				2020-06-30	J	Chowdhury, T; Cappellani, RB				Chowdhury, Tumul; Cappellani, Ronald B.			Role of Fentanyl in Supratentorial Tumor: Can it Change the Requirement of Propofol?	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Letter							INDUCTION		[Chowdhury, Tumul; Cappellani, Ronald B.] Univ Manitoba, Hlth Sci Ctr, Dept Anesthesiol, Winnipeg, MB, Canada	Chowdhury, T (reprint author), Univ Manitoba, Hlth Sci Ctr, Dept Anesthesiol, Winnipeg, MB, Canada.						Bansal S, 2012, J NEUROSURG ANESTH, V24, P345, DOI 10.1097/ANA.0b013e318262282f; Ferreira DA, 2008, J CLIN ANESTH, V20, P116, DOI 10.1016/j.jclinane.2007.09.011; Firestone LL, 1996, ANESTH ANALG, V82, P1247, DOI 10.1097/00000539-199606000-00025; Kolbitsch C, 1997, J NEUROSURG ANESTH, V9, P313, DOI 10.1097/00008506-199710000-00004	4	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	APR	2013	25	2					208	208		10.1097/ANA.0b013e31827de29f			1	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	103XN	WOS:000315952900015	23269089				2020-06-30	J	Park, YH; Jang, YE; Byon, HJ; Kim, JT; Kim, HS				Park, Yong-Hee; Jang, Young-Eun; Byon, Hyo-Jin; Kim, Jin-Tae; Kim, Hee-Soo			Comparison of the efficacy of ramosetron and ondansetron in the prophylaxis of postoperative vomiting in children receiving fentanyl by patient-controlled analgesia after orthopedic surgery: a randomized controlled trial	PEDIATRIC ANESTHESIA			English	Article						postoperative vomiting; children; antiemetics	DOUBLE-BLIND; NAUSEA; PREVENTION; MIDAZOLAM; PAIN; PCA	Background This study was designed to compare the efficacy of prophylactic ramosetron and ondansetron in preventing postoperative vomiting in children who received fentanyl by patient-controlled analgesia after orthopedic surgery. Methods Two hundred and eighteen children, 215years old, ASA physical status 1 or 2, scheduled for elective orthopedic surgeries, were randomly divided into the ramosetron group (n=109) or ondansetron group (n=109). Patients in ondansetron group received ondansetron 100g center dot kg1 and patients in ramosetron group received ramosetron 6g center dot kg1 after surgery. Intravenous patient-controlled analgesia with fentanyl was used in both groups. The incidence of postoperative vomiting and side effects were assessed during the 48h after surgery. Results There was significantly less vomiting during the first 24-h and 624-h period after surgery in ramosetron group than in ondansetron group (P<0.01). There were no significant differences in side effect of 5-HT3 antagonist between the two groups. Conclusion Ramosetron was more effective during the first 24-h period after surgery than ondansetron in children using fentanyl patient-controlled analgesia after general anesthesia.	[Park, Yong-Hee; Jang, Young-Eun; Byon, Hyo-Jin; Kim, Jin-Tae; Kim, Hee-Soo] Seoul Natl Univ Hosp, Dept Anesthesiol & Pain Med, Seoul 110744, South Korea	Kim, HS (reprint author), Seoul Natl Univ Hosp, Dept Anesthesiol & Pain Med, 101 Daehang Ro, Seoul 110744, South Korea.	dami0605@snu.ac.kr	Kim, Jin-Tae/T-7983-2019; KIM, JIN TAE/D-5734-2012	Kim, Jin-Tae/0000-0002-3738-0081; KIM, JIN TAE/0000-0002-3738-0081; Jang, Young-Eun/0000-0002-7511-4104			Butkovic D, 2007, BRIT J ANAESTH, V98, P677, DOI 10.1093/bja/aem055; Byon HJ, 2012, EUR J ANAESTH, V29, P192, DOI 10.1097/EJA.0b013e32834fc1fb; Chiaretti A, 2008, CHILD NERV SYST, V24, P119, DOI 10.1007/s00381-007-0429-z; Choi YS, 2008, SPINE, V33, pE602, DOI 10.1097/BRS.0b013e31817c6bde; Davis PJ, 2008, ANESTH ANALG, V106, P1117, DOI 10.1213/ane.0b013e318167cc3a; DOYLE E, 1994, BRIT J ANAESTH, V72, P72, DOI 10.1093/bja/72.1.72; Endo T, 1999, RES COMMUN MOL PATH, V104, P145; Engelman E, 2008, ANESTHESIOLOGY, V109, P1023, DOI 10.1097/ALN.0b013e31818d6b26; Jellish WS, 2006, OTOLARYNG HEAD NECK, V135, P175, DOI 10.1016/j.otohns.2006.02.027; Kadokura T, 2008, EUR J CLIN PHARMACOL, V64, P605, DOI 10.1007/s00228-008-0472-z; Kokinsky E, 1999, ACTA ANAESTH SCAND, V43, P191, DOI 10.1034/j.1399-6576.1999.430212.x; Neufeld Susan M, 2009, Can J Neurosci Nurs, V31, P30; Sakellaris G, 2008, ACTA PAEDIATR, V97, P801, DOI 10.1111/j.1651-2227.2008.00804.x; Shi YK, 2007, CHEMOTHERAPY, V53, P44, DOI 10.1159/000098418; Wax D, 2007, J CLIN ANESTH, V19, P356, DOI 10.1016/j.jclinane.2007.02.008; Yeh CH, 1999, J ADV NURS, V30, P193, DOI 10.1046/j.1365-2648.1999.01064.x	16	13	13	0	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	APR	2013	23	4					360	364		10.1111/pan.12103			5	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	103OG	WOS:000315927000010	23281658				2020-06-30	J	Skrobik, Y; Leger, C; Cossette, M; Michaud, V; Turgeon, J				Skrobik, Yoanna; Leger, Caroline; Cossette, Marieve; Michaud, Veronique; Turgeon, Jacques			Factors Predisposing to Coma and Delirium: Fentanyl and Midazolam Exposure; CYP3A5, ABCB1, and ABCG2 Genetic Polymorphisms; and Inflammatory Factors	CRITICAL CARE MEDICINE			English	Article						coma; CYP3A4; delirium; inflammatory mediators; midazolam	MECHANICALLY VENTILATED PATIENTS; POSTTRAUMATIC-STRESS-DISORDER; ACUTE BRAIN-DYSFUNCTION; CRITICALLY-ILL PATIENTS; P-GLYCOPROTEIN; COGNITIVE IMPAIRMENT; SEDATION; METABOLISM; DEXMEDETOMIDINE; PHARMACOKINETICS	Background: Delirium and sedative-induced coma are described as incremental manifestations of cerebral dysfunction. Both may be associated with sedative or opiate doses and pharmacokinetic or pharmacogenetic variables, such as drug plasma levels (exposure), drug metabolism, and/or their transport across the blood-brain barrier. Objectives: To compare biological and drug treatment characteristics in patients with coma and/or delirium while in the ICU. Patients and Measurements: In 99 patients receiving IV fentanyl, midazolam, or both, we evaluated drug doses, covariates likely to influence drug effects (age, body mass index, and renal and hepatic dysfunction); delirium risk factors; concomitant administration of CYP3A and P-glycoprotein substrates/inhibitors; ABCB1, ABCG2, and CYP3A5 genetic polymorphisms; and fentanyl and midazolam plasma levels. Delirium and coma were evaluated daily. In patients with only coma (n = 15), only delirium (n = 7), and neither ever (n = 14), we measured plasma levels of tumor necrosis factor-alpha, interleukin (IL)-1 beta, IL-1RA, IL-6, IL-8, IL-10, IL-17, macrophage inflammatory protein-1 beta, and monocyte chemotactic protein-1. Results: Time to first coma was associated with fentanyl and midazolam doses (p = 0.03 and p = 0.01, respectively). The number of days in coma was associated with the number of days of coadministration of CYP3A inhibitors (r = 0.30; p = 0.006). Plasma levels of fentanyl were higher in patients with clinical coma (3.7 +/- 4.7 vs. 2.0 +/- 1.8 ng/mL, p = 0.0001) as were midazolam plasma levels (1050 +/- 2232 vs. 168 +/- 249 ng/mL, p = 0.0001). Delirium occurrence was unrelated to midazolam administration, cumulative doses, or serum levels. Days with delirium were associated with days of coadministration of P-glycoprotein inhibitor (r = 0.35; p = 0.0004). Delirious patients had higher levels of the inflammatory mediator IL-6 than comatose patients (129.3 vs. 35.0 pg/mL, p = 0.05). Conclusions: Coma is associated with fentanyl and midazolam exposure; delirium is unrelated to midazolam and may be linked to inflammatory status. These data suggest that iatrogenic coma and delirium are not mechanistically linked. (Crit Care Med 2013; 41: 999-1008)	[Skrobik, Yoanna] Hop Maison Neuve Rosemont, Montreal, PQ H1T 2M4, Canada; [Skrobik, Yoanna] Univ Montreal, Intens Care Unit, Montreal, PQ, Canada; [Leger, Caroline] Univ Calgary, Fac Med, Dept Physiol & Pharmacol, Calgary, AB, Canada; [Cossette, Marieve] Montreal Heart Inst, Coordinating Ctr, Montreal, PQ H1T 1C8, Canada; [Michaud, Veronique; Turgeon, Jacques] Ctr Hosp Univ Montreal, CRCHUM, Montreal, PQ, Canada; [Michaud, Veronique; Turgeon, Jacques] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada	Turgeon, J (reprint author), Ctr Hosp Univ Montreal, CRCHUM, Montreal, PQ, Canada.	jacques.turgeon.chum@ssss.gouv.qc.ca	Skrobik, Yoanna/J-6393-2013; Skrobik, Yoanna/K-8165-2014	Skrobik, Yoanna/0000-0002-5315-6020	CHUM Foundation; Canadian Institutes for Health Research (CIHR)Canadian Institutes of Health Research (CIHR); CIHR fellowshipCanadian Institutes of Health Research (CIHR)	Supported, in part, by the unrestricted research funds obtained from the CHUM Foundation and by the Canadian Institutes for Health Research (CIHR). Veronique Michaud was the recipient of a CIHR fellowship during this work.	Agarwal V, 2010, J BURN CARE RES, V31, P706, DOI 10.1097/BCR.0b013e3181eebee9; BAUER TM, 1995, LANCET, V346, P145, DOI 10.1016/S0140-6736(95)91209-6; BENSHLOMO I, 1990, BRIT J ANAESTH, V64, P45, DOI 10.1093/bja/64.1.45; Bergeron N, 2001, INTENS CARE MED, V27, P859, DOI 10.1007/s001340100909; Bienvenu OJ, 2011, CURR PSYCHIAT REP, V13, P3, DOI 10.1007/s11920-010-0166-y; CALLAGHAN R, 1993, J BIOL CHEM, V268, P16059; Cascorbi I, 2001, CLIN PHARMACOL THER, V69, P169, DOI 10.1067/mcp.2001.114164; de Rooij SE, 2007, J PSYCHOSOM RES, V62, P521, DOI 10.1016/j.jpsychores.2006.11.013; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Dugan LL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005518; Eap CB, 2004, PHARMACOGENETICS, V14, P255, DOI 10.1097/00008571-200404000-00005; Ely EW, 2012, CHEST, V142, P281, DOI 10.1378/chest.12-1189; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Fukasawa T, 2007, J CLIN PHARM THER, V32, P333, DOI 10.1111/j.1365-2710.2007.00829.x; Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1; GORSKI JC, 1994, BIOCHEM PHARMACOL, V47, P1643; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Hopkins RO, 2010, GEN HOSP PSYCHIAT, V32, P147, DOI 10.1016/j.genhosppsych.2009.11.003; Huppert J, 2010, FASEB J, V24, P1023, DOI 10.1096/fj.09-141978; Iacobone Emanuele, 2009, Crit Care Med, V37, pS331, DOI 10.1097/CCM.0b013e3181b6ed58; Kapfhammer HP, 2004, AM J PSYCHIAT, V161, P45, DOI 10.1176/appi.ajp.161.1.45; Kastin AJ, 2003, MOL BRAIN RES, V114, P168, DOI 10.1016/S0169-328X(03)00167-0; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Martin Jorg, 2010, Ger Med Sci, V8, pDoc02, DOI 10.3205/000091; Mehta S, 2006, CRIT CARE MED, V34, P374, DOI 10.1097/01.CCM.0000196830.61965.F1; Milbrandt EB, 2004, CRIT CARE MED, V32, P955, DOI 10.1097/01.CCM.0000119429.16055.92; Ouimet S, 2007, INTENS CARE MED, V33, P66, DOI 10.1007/s00134-006-0399-8; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; Park GR, 1996, BRIT J ANAESTH, V77, P32; Park HJ, 2007, CLIN PHARMACOL THER, V81, P539, DOI 10.1038/sj.clpt.6100046; Patanella AK, 2010, J NEUROSCI RES, V88, P1106, DOI 10.1002/jnr.22276; Paulussen A, 2000, PHARMACOGENETICS, V10, P415, DOI 10.1097/00008571-200007000-00005; Pisani MA, 2009, CRIT CARE MED, V37, P177, DOI 10.1097/CCM.0b013e318192fcf9; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Rivest S, 2010, PROG BRAIN RES, V181, P43, DOI 10.1016/S0079-6123(08)81004-7; Roberts DJ, 2009, CRIT CARE MED, V37, P2767, DOI 10.1097/CCM.0b013e3181b755d5; Saari TI, 2008, EUR J CLIN PHARMACOL, V64, P25, DOI 10.1007/s00228-007-0398-x; Sadeque AJM, 2000, CLIN PHARMACOL THER, V68, P231, DOI 10.1067/mcp.2000.109156; SAIJA A, 1995, LIFE SCI, V56, P775, DOI 10.1016/0024-3205(95)00008-T; Shehabi Y, 2009, ANESTHESIOLOGY, V111, P1075, DOI 10.1097/ALN.0b013e3181b6a783; Skrobik Y, 2012, CHEST, V142, P284, DOI 10.1378/chest.12-1191; Skrobik Y, 2010, ANESTH ANALG, V111, P451, DOI 10.1213/ANE.0b013e3181d7e1b8; Thompson SJ, 2000, ANESTHESIOLOGY, V92, P1392, DOI 10.1097/00000542-200005000-00030; van den Boogaard M, 2011, CRIT CARE, V15, DOI 10.1186/cc10598; Vasilevskis EE, 2010, CRIT CARE MED, V38, pS683, DOI 10.1097/CCM.0b013e3181f245d3; Wilson JRA, 2012, CRIT CARE MED, V40, P835, DOI 10.1097/CCM.0b013e318236f62d; Yang GY, 1999, MOL BRAIN RES, V72, P129, DOI 10.1016/S0169-328X(99)00205-3; Young B, 2011, J POPUL THERAP CLIN, V18, pe176	52	58	59	0	30	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2013	41	4					999	1008		10.1097/CCM.0b013e318275d014			10	Critical Care Medicine	General & Internal Medicine	114HN	WOS:000316731800018	23385102				2020-06-30	J	Zheng, H; Zhang, Y; Li, W; Loh, HH; Law, PY				Zheng, Hui; Zhang, Yue; Li, Wen; Loh, Horace H.; Law, Ping-Yee			NeuroD Modulates Opioid Agonist-Selective Regulation of Adult Neurogenesis and Contextual Memory Extinction	NEUROPSYCHOPHARMACOLOGY			English	Article						agonist-selective signaling; NeuroD activity; adult neurogenesis; contextual memory	CONDITIONED PLACE PREFERENCE; HIPPOCAMPAL NEUROGENESIS; DENTATE GYRUS; EXPRESSION PATTERNS; COCAINE SEEKING; GRANULE CELLS; MORPHINE; REINSTATEMENT; DOUBLECORTIN; NEUROBIOLOGY	Addictive drugs, including opioids, modulate adult neurogenesis. In order to delineate the probable implications of neurogenesis on contextual memory associated with addiction, we investigated opioid agonist-selective regulation of neurogenic differentiation 1 (NeuroD) activities under the conditioned place preference (CPP) paradigm. Training mice with equivalent doses of morphine and fentanyl produced different CPP extinction rates without measurable differences in the CPP acquisition rate or magnitude. Fentanyl-induced CPP required much longer time for extinction than morphine-induced CPP. We observed a parallel decrease in NeuroD activities and neurogenesis after morphine-induced CPP, but not after fentanyl-induced CPP. Increasing NeuroD activities with NeuroD-lentivirus (nd-vir) injection at the dentate gyrus before CPP training reversed morphine-induced decreases in NeuroD activities and neurogenesis, and prolonged the time required for extinction of morphine-induced CPP. On the other hand, decreasing NeuroD activities via injection of miRNA-190-virus (190-vir) reversed the fentanyl effect on NeuroD and neurogenesis and shortened the time required for extinction of fentanyl-induced CPP. Another contextual memory task, the Morris Water Maze (MWM), was affected similarly by alteration of NeuroD activities. The reduction in NeuroD activities either by morphine treatment or 190-vir injection decreased MWM task retention, while the increase in NeuroD activities by nd-vir prolonged MWM task retention. Thus, by controlling NeuroD activities, opioid agonists differentially regulate adult neurogenesis and subsequent contextual memory retention. Such drug-related memory regulation could have implications in eventual context-associated relapse. Neuropsychopharmacology (2013) 38, 770-777; doi:10.1038/npp.2012.242; published online 16 January 2013	[Zheng, Hui; Li, Wen] Chinese Acad Sci, Key Lab Regenerat Biol CAS, Guangdong Prov Key Lab Stem Cell & Regenerat Med, South China Inst Stem Cell Biol & Regenerat Med,G, Sci City, Guangzhou, Peoples R China; [Zheng, Hui; Zhang, Yue; Loh, Horace H.; Law, Ping-Yee] Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	Zheng, H (reprint author), Guangzhou Inst Biomed & Hlth, A-131,190 Kaiyuan Ave, Sci City 510530, Guangzhou, Peoples R China.	zheng_hui@gibh.ac.cn		Zheng, Hui/0000-0001-6801-0529; Law, Ping-Yee/0000-0002-5364-1093	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [31100773]; Bureau of Science and Information Technology of Guangzhou Municipal Government [2012J5100007]; Guangdong Natural Science FoundationNational Natural Science Foundation of Guangdong Province [S2012010010087]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA031442, DA023905, DA011806]	This research was supported by the National Natural Science Foundation of China (31100773), the 'Guangzhou International Science and Technology Cooperation Projects from Bureau of Science and Information Technology of Guangzhou Municipal Government (2012J5100007)', the 'Guangdong Natural Science Foundation (S2012010010087)', and the NIH grants DA031442, DA023905 and DA011806.	Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; Aguilar MA, 2009, BRAIN RES REV, V59, P253, DOI 10.1016/j.brainresrev.2008.08.002; Aimone JB, 2011, NEURON, V70, P589, DOI 10.1016/j.neuron.2011.05.010; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Cetin A, 2006, NAT PROTOC, V1, P3166, DOI 10.1038/nprot.2006.450; Chao J, 2004, ANNU REV MED, V55, P113, DOI 10.1146/annurev.med.55.091902.103730; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Cunningham CL, 2006, NAT PROTOC, V1, P1662, DOI 10.1038/nprot.2006.279; Eisch AJ, 2006, HIPPOCAMPUS, V16, P271, DOI 10.1002/hipo.20161; Fan GH, 1999, MOL PHARMACOL, V56, P39; Fischer SJ, 2008, NEUROSCIENCE, V151, P1217, DOI 10.1016/j.neuroscience.2007.11.035; Fuchs RA, 2005, NEUROPSYCHOPHARMACOL, V30, P296, DOI 10.1038/sj.npp.1300579; Gaudilliere B, 2004, NEURON, V41, P229, DOI 10.1016/S0896-6273(03)00841-9; Hernandez-Rabaza V, 2008, NEUROBIOL LEARN MEM, V90, P553, DOI 10.1016/j.nlm.2008.06.008; Hodge RD, 2008, J NEUROSCI, V28, P3707, DOI 10.1523/JNEUROSCI.4280-07.2008; Kamath SG, 2004, GENE EXPRESSION, V12, P123; Kee N, 2007, NAT NEUROSCI, V10, P355, DOI 10.1038/nn1847; Lansink CS, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000173; Lee I, 2004, HIPPOCAMPUS, V14, P301, DOI 10.1002/hipo.10177; Lee JK, 2000, DEV DYNAM, V217, P361, DOI 10.1002/(SICI)1097-0177(200004)217:4<361::AID-DVDY3>3.0.CO;2-8; Lee JLC, 2008, NAT NEUROSCI, V11, P1264, DOI 10.1038/nn.2205; Liu K, 2010, NUCLEIC ACIDS RES, V39, P2859; McCormick MB, 1996, MOL CELL BIOL, V16, P5792; Milekic MH, 2006, J NEUROSCI, V26, P3010, DOI 10.1523/JNEUROSCI.4818-05.2006; Nakashiba T, 2012, CELL, V149, P188, DOI 10.1016/j.cell.2012.01.046; Noonan MA, 2010, J NEUROSCI, V30, P304, DOI 10.1523/JNEUROSCI.4256-09.2010; Restivo L, 2009, J NEUROSCI, V29, P8206, DOI 10.1523/JNEUROSCI.0966-09.2009; Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237; Rothwell PE, 2010, NEUROPSYCHOPHARMACOL, V35, P2579, DOI 10.1038/npp.2010.134; Seo S, 2007, EMBO J, V26, P5093, DOI 10.1038/sj.emboj.7601923; Shaham Y, 2003, PSYCHOPHARMACOLOGIA, V150, P337; Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1; Singer AC, 2009, NEURON, V64, P910, DOI 10.1016/j.neuron.2009.11.016; Snyder JS, 2009, J NEUROSCI, V29, P14484, DOI 10.1523/JNEUROSCI.1768-09.2009; Snyder JS, 2005, NEUROSCIENCE, V130, P843, DOI 10.1016/j.neuroscience.2004.10.009; Tashiro A, 2007, J NEUROSCI, V27, P3252, DOI 10.1523/JNEUROSCI.4941-06.2007; Thomas JL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029128; Trouche S, 2009, P NATL ACAD SCI USA, V106, P5919, DOI 10.1073/pnas.0811054106; Tzschentke TM, 2007, ADDICT BIOL, V12, P227, DOI 10.1111/j.1369-1600.2007.00070.x; Uittenbogaard M, 2000, NEUROSCI LETT, V280, P95, DOI 10.1016/S0304-3940(00)00761-8; von Bohlen und Halbach O, 2007, CELL TISSUE RES, V329, P409, DOI 10.1007/s00441-007-0432-4; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Weed MR, 2006, PHARMACOL BIOCHEM BE, V84, P487, DOI 10.1016/j.pbb.2006.06.012; Zhang ZW, 2011, FEBS LETT, V585, P2592, DOI 10.1016/j.febslet.2011.06.039; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zheng B, 1999, TRENDS BIOCHEM SCI, V24, P411, DOI 10.1016/S0968-0004(99)01474-7; Zheng H, 2008, MOL PHARMACOL, V73, P178, DOI 10.1124/mol.107.039842; Zheng H, 2010, J NEUROSCI, V30, P8102, DOI 10.1523/JNEUROSCI.6069-09.2010; Zheng H, 2010, MOL PHARMACOL, V77, P102, DOI 10.1124/mol.109.060848	50	21	22	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	APR	2013	38	5					770	777		10.1038/npp.2012.242			8	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	106RB	WOS:000316161300007	23303051	Bronze, Green Published			2020-06-30	J	Grassin-Delyle, S; Naline, E; Devillier, P				Grassin-Delyle, Stanislas; Naline, Emmanuel; Devillier, Philippe			Comment: Intranasal Fentanyl Spray: A Novel Dosage Form for the Treatment of Breakthrough Cancer Pain	ANNALS OF PHARMACOTHERAPY			English	Letter							DOUBLE-BLIND; CROSSOVER TRIAL; OPEN-LABEL; MU-G; PHARMACOKINETICS; TOLERABILITY; EFFICACY; PECTIN; SURGERY; OPIOIDS		[Grassin-Delyle, Stanislas; Naline, Emmanuel; Devillier, Philippe] UPRES, EA220, Lab Pharmacol, Suresnes, France; [Grassin-Delyle, Stanislas; Naline, Emmanuel; Devillier, Philippe] Univ Versailles St Quentin, Suresnes, France	Grassin-Delyle, S (reprint author), UPRES, EA220, Lab Pharmacol, Suresnes, France.	s.grassindelyle@hopital-foch.org					Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Dietrich E, 2012, ANN PHARMACOTHER, V46, P1382, DOI 10.1345/aph.1R069; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Fisher A, 2010, INT J CLIN PHARM TH, V48, P138; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Grassin-Delyle S, 2012, PHARMACOL THERAPEUT, V134, P366, DOI 10.1016/j.pharmthera.2012.03.003; Kaasa Stein, 2010, J Opioid Manag, V6, P17; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Veldhorst-Janssen NML, 2010, CLIN THER, V32, P1427, DOI 10.1016/j.clinthera.2010.07.001; Vissers D, 2010, CURR MED RES OPIN, V26, P1037, DOI 10.1185/03007991003694340	13	0	0	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1060-0280	1542-6270		ANN PHARMACOTHER	Ann. Pharmacother.	MAR	2013	47	3					427	428		10.1345/aph.1R069a			3	Pharmacology & Pharmacy	Pharmacology & Pharmacy	225TZ	WOS:000324987200021	23463741				2020-06-30	J	Perelman, M; Leake, S				Perelman, Michael; Leake, Suzan			Comment: Intranasal Fentanyl Spray: A Novel Dosage Form for the Treatment of Breakthrough Cancer Pain	ANNALS OF PHARMACOTHERAPY			English	Letter									[Perelman, Michael; Leake, Suzan] Archimedes Pharma, Bedminster, NJ USA	Perelman, M (reprint author), Archimedes Pharma, Bedminster, NJ USA.	suzanleake@archimedespharma.com					Dietrich E, 2012, ANN PHARMACOTHER, V46, P1382, DOI 10.1345/aph.1R069; European Medicines Agency, EMEA2903642009; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Kaasa Stein, 2010, J Opioid Manag, V6, P17; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028	5	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1060-0280			ANN PHARMACOTHER	Ann. Pharmacother.	MAR	2013	47	3					428	428		10.1345/aph.1R069b			1	Pharmacology & Pharmacy	Pharmacology & Pharmacy	225TZ	WOS:000324987200022	23463744				2020-06-30	J	Dietrich, E; Gums, JG				Dietrich, Eric; Gums, John G.			Comment: Intranasal Fentanyl Spray: A Novel Dosage Form for the Treatment of Breakthrough Cancer Pain REPLY	ANNALS OF PHARMACOTHERAPY			English	Letter									[Dietrich, Eric] Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL 32611 USA; [Dietrich, Eric] Univ Florida, Coll Pharm, Dept Community Hlth & Family Med, Gainesville, FL 32611 USA; [Dietrich, Eric] Univ Florida, Coll Med, Dept Pharmacotherapy & Translat Res, Gainesville, FL 32611 USA; [Dietrich, Eric] Univ Florida, Coll Pharm, Dept Community Hlth & Family Med, Gainesville, FL 32611 USA; [Gums, John G.] Univ Florida, Dept Pharmacotherapy & Translat Res, Gainesville, FL 32611 USA; [Gums, John G.] Univ Florida, Dept Community Hlth & Family Med, Gainesville, FL 32611 USA	Dietrich, E (reprint author), Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL 32611 USA.						[Anonymous], EMEA2903642009; [Anonymous], 2011, MORPH SULF TABL; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028	4	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1060-0280			ANN PHARMACOTHER	Ann. Pharmacother.	MAR	2013	47	3					429	429		10.1345/aph.1R069c			1	Pharmacology & Pharmacy	Pharmacology & Pharmacy	225TZ	WOS:000324987200023	23463745				2020-06-30	J	Parikh, N; Goskonda, V; Chavan, A; Dillaha, L				Parikh, Neha; Goskonda, Venkat; Chavan, Ashok; Dillaha, Larry			Single-Dose Pharmacokinetics of Fentanyl Sublingual Spray and Oral Transmucosal Fentanyl Citrate in Healthy Volunteers: A Randomized Crossover Study	CLINICAL THERAPEUTICS			English	Article						breakthrough pain; cancer pain; fentanyl; fentanyl sublingual spray; oral transmucosal fentanyl citrate	BUCCAL SOLUBLE FILM; BREAKTHROUGH PAIN; CANCER-PATIENTS; RELATIVE BIOAVAILABILITY; ADULT VOLUNTEERS; DOUBLE-BLIND; OPEN-LABEL; MU-G; TABLET; XEROSTOMIA	Background: Fentanyl sublingual spray (FSS) is a novel fentanyl formulation recently developed for the treatment of breakthrough cancer pain, which is characterized by a fast onset and a relatively short duration. Objective: To compare rate of absorption and systemic bioavailability between FSS and oral transmucosal fentanyl citrate (OTFC) in healthy volunteers. Methods: This randomized 3-way crossover study involved 29 healthy volunteers (25 men and 4 women; mean age, 35 years) who received single doses of FSS (400 mu g), OTFC (400 mu g), and intravenous fentanyl citrate (100 p,g) separated by washout periods of >= 7 days. Oral naltrexone was given to minimize potential adverse effects of fentanyl. Plasma fentanyl concentrations were measured for 36 hours after each dose for the calculation of pharmacokinetic parameters. Results: Mean C-max values of fentanyl were higher with FSS versus OTFC (0.81 ng/mL vs 0.61 ng/mL) and were attained more quickly; the median T-max was 1.5 hours with FSS and 2.0 hours with OTFC (P < 0.05). Furthermore, potentially effective fentanyl concentrations were achieved more quickly with FSS than with OTFC. Five and 10 minutes after administration, mean plasma concentrations were 19.0% and 53.7% of C-max with FSS, respectively, compared with levels below the lower limit of assay quantification and 6.1%, respectively, with OTFC. Plasma concentrations of fentanyl at 10 minutes with FSS were equivalent to those with OTFC at 60 minutes. The C-max and AUCs were approximately 33% to 36% greater with FSS than with OTFC, and the 90% CIs of the geometric mean ratios for each parameter fell outside the bioequivalence range of 80% to 125%. Systemic bioavailability was also greater with FSS than with OTFC (approximately 76% vs 51%). All 3 fentanyl treatments were well tolerated. All reported adverse events were mild and consistent with those previously reported in healthy volunteers receiving transmucosal fentanyl with naltrexone, and none occurred in >2 participants during any treatment period. Conclusions: Absorption of fentanyl in this study was faster and bioavailability was greater with FSS than with OTFC. The pharmacokinetic profile of the sublingual spray closely matches the duration of onset to pain intensity in a breakthrough cancer pain episode. These findings suggest that FSS is appropriate for the treatment of breakthrough cancer pain. ClinicalTrials.gov identifier: NCT01780233. (Clin Ther. 2013;35:236-243) (C) 2013 Elsevier HS Journals, Inc. All rights reserved.	[Parikh, Neha; Goskonda, Venkat; Chavan, Ashok; Dillaha, Larry] INSYS Therapeut Inc, Chandler, AZ 85224 USA	Parikh, N (reprint author), INSYS Therapeut Inc, 444 S Ellis Rd, Chandler, AZ 85224 USA.	nparikh@insysrx.com			Insys Therapeutics Inc.	Technical editorial and medical writing support was provided by Michael Shaw, PhD, for Synchrony Medical Communications, LLC. Funding for this support was provided by Insys Therapeutics Inc. Neha Parikh was responsible for study design, data collection, data analysis, critical review and revisions, decision to publish, and final approval. Drs. Goskonda, Chavan, and Dillaha were responsible for data analysis, critical review and revisions, decision to publish, and final approval.	[Anonymous], 2012, SUBS FENT SUBL SPRAY; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; *CTR DRUG EV RES, 2001, [No title captured]; *CTR DRUG EV RES, 2003, [No title captured]; Darwish M, 2006, CLIN THER, V28, P707, DOI 10.1016/j.clinthera.2006.05.015; Darwish M, 2006, CLIN THER, V28, P715, DOI 10.1016/j.clinthera.2006.05.016; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Davies AN, 2005, J PAIN SYMPTOM MANAG, V30, P496, DOI 10.1016/j.jpainsymman.2005.11.006; Davies AN, 2001, J PAIN SYMPTOM MANAG, V22, P820, DOI 10.1016/S0885-3924(01)00318-9; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Jacobsen Ramune, 2008, J Opioid Manag, V4, P383; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Malkawi AH, 2008, AAPS J, V10, P261, DOI 10.1208/s12248-008-9031-x; Narang N, 2011, INT J PHARM PHARM S2, V3, P18; Pather SI, 2001, DRUG DELIV TECH, V1, P54; Porta-Sales J, 2010, EUR J PALLIAT CAR S3, V17, P20; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy Russell K, 2010, J Opioid Manag, V6, P97; Prommer E, 2009, J PALLIAT MED, V12, P947, DOI 10.1089/jpm.2009.0051; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Rauck R, 2012, CURR MED RES OPIN, V28, P859, DOI 10.1185/03007995.2012.683111; Shojaei A H, 1998, J Pharm Pharm Sci, V1, P15; Shojaei AH, 1999, INT J PHARMACEUT, V192, P139, DOI 10.1016/S0378-5173(99)00301-4; Vasisht N, 2010, PAIN MED, V11, P1017, DOI 10.1111/j.1526-4637.2010.00875.x; Vasisht N, 2010, J CLIN PHARMACOL, V50, P785, DOI 10.1177/0091270010361354; WEINBERG DS, 1988, CLIN PHARMACOL THER, V44, P335, DOI 10.1038/clpt.1988.159; William L, 2008, DRUGS, V68, P913, DOI 10.2165/00003495-200868070-00003	30	15	15	0	8	ELSEVIER	BRIDGEWATER	685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA	0149-2918			CLIN THER	Clin. Ther.	MAR	2013	35	3					236	243		10.1016/j.clinthera.2013.02.017			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	134GC	WOS:000318197400006	23497761				2020-06-30	